{"meta":{"query_hash":"b1cf7d12156a","filters":{"topic":"HER2/EGFR in Cancer Research"},"cohort_total":1303,"direct_labels_cover":3,"predictions_cover":1303,"exported":1303,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/b1cf7d12156a","api":"https://metacan.xera.ac/api/v1/cohort?topic=HER2%2FEGFR+in+Cancer+Research"},"results":[{"id":"W121131437","doi":"10.1007/978-3-642-02112-1_7","title":"Epidermal Growth Factor (EGF) Receptor Signaling and Cancer","year":2009,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"ErbB; Epidermal growth factor; Receptor; Signal transduction; Epidermal growth factor receptor; Growth factor receptor; Receptor tyrosine kinase; Cancer research; Growth factor receptor inhibitor; Phosphorylation; Biology; Cell biology; Tyrosine phosphorylation; Tyrosine kinase; Cell surface receptor; Biochemistry","score_opus":0.0813281919803595,"score_gpt":0.36011725495210806,"score_spread":0.27878906297174855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W121131437","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00081134035,0.14868473,0.0052224477,0.004191937,0.0043504112,0.000035141944,0.00017693995,0.00014931758,0.83637786],"genre_scores_gemma":[0.004508358,0.0786891,0.0038329754,0.0017394725,0.0006718894,0.000035148194,0.00013091385,0.00005948533,0.9103327],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99993515,0.000008270101,0.0000021318967,0.000009196537,0.000038285372,0.000006996803],"domain_scores_gemma":[0.99996436,0.00001753495,0.000001704073,0.0000025563313,0.00000909605,0.000004819634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014484138,0.0005418055,0.00033132505,0.00054205756,0.00042230915,0.0013569386,0.00047011892,0.0007037001,0.02739387],"category_scores_gemma":[0.0001859504,0.00014679645,0.00019044545,0.00065737136,0.00048554744,0.001363665,0.0005017971,0.0013606882,0.012846205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023886563,0.000059267262,0.000054350247,0.00033438538,0.0000055952887,0.00011422572,0.00020912933,0.0004368975,0.0025717043,0.17416613,0.48009974,0.3419246],"study_design_scores_gemma":[0.0000017678992,0.000004979881,0.000055022178,0.00007265491,0.0000016755638,0.00009814987,0.000028114748,0.00007693732,0.00023049928,0.013817953,0.98561007,0.00000223503],"about_ca_topic_score_codex":0.0013021859,"about_ca_topic_score_gemma":0.0037948291,"teacher_disagreement_score":0.02739387,"about_ca_system_score_codex":0.00088373147,"about_ca_system_score_gemma":0.00067765487,"threshold_uncertainty_score":0.091641665},"labels":[],"label_agreement":null},{"id":"W1259037943","doi":"","title":"Multiplexed in situ analysis of protein expression to predict response to trastuzumab","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Institute","funders":"","keywords":"Trastuzumab; Oncology; Breast cancer; Internal medicine; Multivariate analysis; Cohort; Estrogen receptor; Survival analysis; Cancer; Hierarchical clustering; Medicine; Tissue microarray; Biology; Cancer research; Cluster analysis; Artificial intelligence; Computer science","score_opus":0.12425819423436822,"score_gpt":0.5046287916801975,"score_spread":0.38037059744582924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1259037943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98538995,0.0005346403,0.01263769,0.00004240906,0.000016891698,0.000052655156,0.00040072584,0.00011946493,0.0008055263],"genre_scores_gemma":[0.98387754,0.00018502215,0.014245433,0.000036536014,0.000010955234,0.000099166864,0.00040104118,0.000014981141,0.0011293066],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9995585,0.00010912875,0.0000303827,0.00012719737,0.00011415575,0.000060571372],"domain_scores_gemma":[0.99966145,0.00013454723,0.00007708681,0.000033474367,0.000067816014,0.000025574576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007292208,0.0002670244,0.0002482999,0.00081379956,0.00016215832,0.00040894732,0.00021296428,0.00032351946,0.0007356937],"category_scores_gemma":[0.0007435796,0.00016253899,0.00014185987,0.00038017493,0.000187487,0.0001868866,0.00022469235,0.0003347863,0.0002903158],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085665256,0.00018169516,0.080794714,0.000053680717,0.00008428668,0.000072469484,0.00023304725,0.0018495843,0.8930221,0.00018365012,0.00022580325,0.022442216],"study_design_scores_gemma":[0.000053510892,0.00096270884,0.34610012,0.000020809448,0.00013585962,0.00060440466,0.00039580278,0.062924795,0.5859584,0.00060191663,0.0021953862,0.000046326688],"about_ca_topic_score_codex":0.0007471745,"about_ca_topic_score_gemma":0.0010998537,"teacher_disagreement_score":0.00081379956,"about_ca_system_score_codex":0.00030792475,"about_ca_system_score_gemma":0.0001140769,"threshold_uncertainty_score":0.0038565397},"labels":[],"label_agreement":null},{"id":"W136595265","doi":"10.3390/curroncol13010001","title":"Does HER2/neu Overexpression in Breast Cancer Influence Adjuvant Chemotherapy and Hormonal Therapy Choices by Ontario Physicians? A Physician Survey","year":2006,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Hormonal therapy; Tyrosine kinase; Breast cancer; Adjuvant; Hormone; Oncology; HER2/neu; Chemotherapy; Internal medicine; Cancer research; Transmembrane protein; Glycoprotein; Cancer; Receptor; Biology; Genetics","score_opus":0.04944875264955394,"score_gpt":0.40636161428073864,"score_spread":0.3569128616311847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W136595265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887177,0.00082952913,0.000038414746,0.0033027998,0.00001625443,0.000022529237,0.001939863,0.0000042574707,0.005128694],"genre_scores_gemma":[0.9965371,0.0009887888,0.00005643082,0.00063211913,0.000018475297,0.000011982203,0.0005004181,0.0000029913458,0.0012517464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931145,0.000107709944,0.00006140295,0.00006378627,0.00026928706,0.00018654019],"domain_scores_gemma":[0.9948303,0.0005669787,0.0020546892,0.000087017404,0.001442458,0.0010184961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006163057,0.00009134728,0.00016810688,0.0007503608,0.0013734997,0.0006052491,0.00044473936,0.00046302666,0.0031181003],"category_scores_gemma":[0.004768347,0.00025666042,0.00026243893,0.0027529201,0.00044100417,0.00049428956,0.00050737243,0.00039569513,0.00034182597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037470552,0.000027053116,0.9948212,0.000023077433,0.0000117087775,0.0000584125,0.0012580742,0.000017975071,0.000085668435,0.000025320716,0.0012576472,0.0023763906],"study_design_scores_gemma":[0.0000037560778,0.000016187947,0.9971343,0.00001712412,0.000008268933,0.000036842983,0.0014888012,0.0000470619,0.0000210568,0.000006485688,0.0012162111,0.0000038249104],"about_ca_topic_score_codex":0.8874326,"about_ca_topic_score_gemma":0.9503014,"teacher_disagreement_score":0.8874326,"about_ca_system_score_codex":0.008359707,"about_ca_system_score_gemma":0.009869855,"threshold_uncertainty_score":0.2264607},"labels":[],"label_agreement":null},{"id":"W1481580402","doi":"10.1111/j.1476-5381.2010.00742.x","title":"Kinetic analysis of novel mono‐ and multivalent VHH‐fragments and their application for molecular imaging of brain tumours","year":2010,"lang":"en","type":"article","venue":"British Journal of Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Institute for Biodiagnostics; McGill University; University of Calgary; Biotechnology Research Institute; University of Ottawa; Institute for Biological Sciences","funders":"Canadian Institutes of Health Research","keywords":"Biodistribution; In vivo; Surface plasmon resonance; Molecular imaging; Chemistry; Epidermal growth factor receptor; Biophysics; Single-domain antibody; Preclinical imaging; Pharmacokinetics; Affinities; Molecular biology; In vitro; Antibody; Receptor; Materials science; Biology; Stereochemistry; Biochemistry; Nanotechnology; Pharmacology","score_opus":0.0174384845330435,"score_gpt":0.3774108267549451,"score_spread":0.3599723422219016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1481580402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801987,0.0013847853,0.017277936,0.000040891082,0.000009891254,0.000032827462,0.00019593118,0.000088708235,0.000770248],"genre_scores_gemma":[0.98822904,0.0005811565,0.009672087,0.000028860535,0.0000034490633,0.00003103275,0.0003478192,0.000027617554,0.0010789633],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998869,0.000015225781,0.000005971914,0.000024145114,0.000042409232,0.0000253441],"domain_scores_gemma":[0.9998752,0.000033313863,0.000029612336,0.000008195756,0.000036649304,0.000017109367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024087472,0.00024370989,0.00018199261,0.00017773717,0.00007999962,0.0002548149,0.00028129315,0.00024731492,0.0006841736],"category_scores_gemma":[0.0003382318,0.000102009275,0.00017982676,0.00016090873,0.00011323286,0.00020561767,0.00009119592,0.00039773126,0.00023582374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002036395,0.000035048193,0.00065927533,0.000051481995,0.00001606243,0.00002450111,0.000020357746,0.0008055262,0.99369204,0.00008998601,0.000049181224,0.004352803],"study_design_scores_gemma":[0.000006341775,0.00016689602,0.0016585919,0.000002911923,0.000015325648,0.0001253362,0.0000117368745,0.0065536364,0.9908049,0.000028164857,0.00062051986,0.000005666317],"about_ca_topic_score_codex":0.0018113332,"about_ca_topic_score_gemma":0.0011940673,"teacher_disagreement_score":0.0018113332,"about_ca_system_score_codex":0.0005810795,"about_ca_system_score_gemma":0.00018168606,"threshold_uncertainty_score":0.004216075},"labels":[],"label_agreement":null},{"id":"W1482906151","doi":"10.5539/cco.v1n2p49","title":"Influence of Alternative Tubulin Inhibitors on the Potency of Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate","year":2012,"lang":"en","type":"article","venue":"Cancer and Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Epirubicin; Chemistry; Potency; Biochemistry; In vitro; Internal medicine; Medicine; Chemotherapy","score_opus":0.07410527420465987,"score_gpt":0.4440767310897255,"score_spread":0.3699714568850656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1482906151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963058,0.0015763859,0.0004539002,0.000027410453,0.000015090299,0.000017305454,0.00014578192,0.000019867404,0.0014385312],"genre_scores_gemma":[0.99658006,0.0012051656,0.0007989429,0.000022710146,0.000005989095,0.000020723961,0.0002630408,0.000010896894,0.0010925297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998585,0.0000355126,0.000016775763,0.000026633546,0.000033747034,0.000028778677],"domain_scores_gemma":[0.9998369,0.00005546533,0.00003952581,0.000012233694,0.0000234909,0.00003225511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020724405,0.00027544922,0.0002333004,0.00015628994,0.00008915494,0.00024176422,0.00022389958,0.00020049329,0.0011501259],"category_scores_gemma":[0.00022374168,0.000094896524,0.0000991881,0.00020827056,0.000121003344,0.00015766926,0.000089134206,0.00037674847,0.00018411994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003088501,0.00008837689,0.00014266552,0.00004278582,0.000008199512,0.000029188666,0.000017739734,0.0002056671,0.996942,0.00007163835,0.000035673525,0.002107185],"study_design_scores_gemma":[0.000018012493,0.00079308235,0.00079816463,0.000003763498,0.00001664827,0.000055828554,0.00000802203,0.00043826122,0.99700636,0.000009653049,0.0008497082,0.0000024559524],"about_ca_topic_score_codex":0.00084030547,"about_ca_topic_score_gemma":0.001643785,"teacher_disagreement_score":0.0011501259,"about_ca_system_score_codex":0.0002500904,"about_ca_system_score_gemma":0.00022371308,"threshold_uncertainty_score":0.003847599},"labels":[],"label_agreement":null},{"id":"W1487295350","doi":"10.18433/j3v59v","title":"Targeting the Calmodulin-Regulated ErbB/Grb7 Signaling Axis in Cancer Therapy","year":2013,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Signal transduction; ErbB; Epidermal growth factor receptor; Signal transducing adaptor protein; Receptor; Calmodulin; Cell biology; Biology; Cancer research; Epidermal growth factor; Biochemistry","score_opus":0.3828448787525353,"score_gpt":0.5710487369877085,"score_spread":0.18820385823517322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1487295350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033455933,0.99789536,0.00018716656,0.00017399568,0.00014818567,0.000008893158,0.000014441589,0.00001024267,0.0012271247],"genre_scores_gemma":[0.0013922075,0.99732864,0.0002753594,0.00012334097,0.000101255784,0.0000098326855,0.00002774017,0.000001219483,0.0007402717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989784,0.000014188004,0.000013518264,0.000015713196,0.000046103607,0.000012620636],"domain_scores_gemma":[0.9998952,0.00004058144,0.000018591712,0.0000030236224,0.000029775194,0.000012793652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031255532,0.0005866077,0.0010148165,0.0017184732,0.00021984371,0.00060588104,0.000658394,0.00091112626,0.002905642],"category_scores_gemma":[0.00025763942,0.0002344423,0.000416674,0.0013067444,0.0002750784,0.0007595446,0.00047880085,0.0015526665,0.0018773254],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009260005,0.00019631363,0.00016983518,0.014469939,0.00009652906,0.000297257,0.000053382893,0.00052637403,0.00880086,0.00365857,0.018935358,0.9527029],"study_design_scores_gemma":[0.0000430155,0.00022634429,0.0009828691,0.0016500005,0.00012683657,0.001856177,0.000047809608,0.00024401126,0.0025771805,0.001411697,0.9908132,0.000020939964],"about_ca_topic_score_codex":0.0005390797,"about_ca_topic_score_gemma":0.0014756598,"teacher_disagreement_score":0.002905642,"about_ca_system_score_codex":0.00045483463,"about_ca_system_score_gemma":0.0005437528,"threshold_uncertainty_score":0.0097203255},"labels":[],"label_agreement":null},{"id":"W1505224726","doi":"10.1111/cbdd.12043","title":"Biological Effects of AL622, a Molecule Rationally Designed to Release an EGFR and a c‐Src Kinase Inhibitor","year":2012,"lang":"en","type":"article","venue":"Chemical Biology & Drug Design","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Royal Victoria Regional Health Centre","funders":"Canadian Institutes of Health Research; Cytokinetics","keywords":"Proto-oncogene tyrosine-protein kinase Src; Chemistry; Linker; Transfection; Cancer research; Kinase; Cancer cell; Cell biology; Cancer; Biochemistry; Biology; Gene","score_opus":0.03622846146117841,"score_gpt":0.33662829650147064,"score_spread":0.3003998350402922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1505224726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954093,0.0006759892,0.002069765,0.00004448668,0.000015243706,0.000047270452,0.000104708495,0.00004012078,0.0015931635],"genre_scores_gemma":[0.9959371,0.0003497533,0.0022315045,0.000047145022,0.0000055219834,0.000025199968,0.00013588082,0.000007593974,0.0012602567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999286,0.000016708598,0.0000061858805,0.000016534394,0.00001731364,0.000014640224],"domain_scores_gemma":[0.99996257,0.0000076872975,0.000010961975,0.0000041681074,0.0000055811356,0.000009054136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112161775,0.00031155362,0.00016987807,0.00017007435,0.00008780198,0.00019601063,0.00013425195,0.00029378454,0.0006077888],"category_scores_gemma":[0.000115149596,0.00011207784,0.00015767889,0.00011398491,0.00017333114,0.00021160452,0.00010754505,0.00023934203,0.00018270129],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021590226,0.000084209685,0.000097311335,0.000049196988,0.000007164372,0.00005433269,0.00001298367,0.00063849415,0.99635565,0.00012435288,0.00003559927,0.0023248189],"study_design_scores_gemma":[0.000086838634,0.0014495822,0.0005443424,0.0000027064536,0.000011364675,0.000103626706,0.000007787265,0.0014333951,0.99515057,0.00003229431,0.0011712933,0.0000061197943],"about_ca_topic_score_codex":0.00025338773,"about_ca_topic_score_gemma":0.00043399853,"teacher_disagreement_score":0.0006077888,"about_ca_system_score_codex":0.00015221405,"about_ca_system_score_gemma":0.00011209302,"threshold_uncertainty_score":0.0020332336},"labels":[],"label_agreement":null},{"id":"W1507298324","doi":"10.1186/1471-2202-7-19","title":"Deficits in spatial learning and motor coordination in ADAM11-deficient mice","year":2006,"lang":"en","type":"article","venue":"BMC Neuroscience","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai; University of Toronto","keywords":"Neuroscience; Motor coordination; Cerebellum; Water maze; Hippocampus; Cell adhesion molecule; Synapse; Morris water navigation task; Motor learning; Biology; Spinal cord; Psychology; Cell biology","score_opus":0.03698199649797151,"score_gpt":0.33560298458090276,"score_spread":0.29862098808293125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1507298324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98165685,0.0013348996,0.008630361,0.0003428577,0.000092138114,0.00010877053,0.0038129285,0.0014211477,0.0026001022],"genre_scores_gemma":[0.95457464,0.0019661596,0.01804777,0.00021424778,0.00007399772,0.00030225219,0.004606882,0.00063102815,0.019583156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99949396,0.00004876777,0.0000982271,0.0001854098,0.00010386422,0.00006978962],"domain_scores_gemma":[0.9984958,0.00021875097,0.0006935601,0.000094188836,0.000081680635,0.0004160188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033421995,0.0033661104,0.00091690186,0.0021161716,0.00045776626,0.00068979856,0.0008768414,0.0016614192,0.008071229],"category_scores_gemma":[0.00045935056,0.0006064403,0.0007506254,0.0004715343,0.0010614849,0.00056945614,0.00077339594,0.0018056553,0.0017990385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060719444,0.00023882893,0.00076275365,0.00018369929,0.000059957325,0.0013769198,0.000096650336,0.0006689772,0.99128413,0.00038403642,0.00025964619,0.0040773316],"study_design_scores_gemma":[0.00035396175,0.0018219713,0.022346038,0.00015627261,0.00031440004,0.009434854,0.00013494337,0.0040457123,0.9541301,0.0006933606,0.0064964727,0.00007184096],"about_ca_topic_score_codex":0.000852351,"about_ca_topic_score_gemma":0.00092779106,"teacher_disagreement_score":0.008071229,"about_ca_system_score_codex":0.00064942177,"about_ca_system_score_gemma":0.00044096005,"threshold_uncertainty_score":0.027000904},"labels":[],"label_agreement":null},{"id":"W1525771749","doi":"10.18632/oncotarget.3036","title":"Predicting response to HER2 kinase inhibition","year":2014,"lang":"en","type":"letter","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Kinase; Cancer research; Medicine; Lapatinib; Cancer; Oncology; Internal medicine; Biology; Trastuzumab; Breast cancer; Cell biology","score_opus":0.041065228260144644,"score_gpt":0.35670946421454974,"score_spread":0.3156442359544051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1525771749","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014457229,0.0020458857,0.00036981428,0.9575259,0.033857856,0.000038184702,0.00028270646,0.00009329749,0.0043405765],"genre_scores_gemma":[0.017368227,0.0027963645,0.00074086775,0.8593415,0.11033352,0.00008273068,0.00025817822,0.00004376229,0.009034914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984125,0.00046792434,0.00028852187,0.00021459616,0.0004612484,0.00015526338],"domain_scores_gemma":[0.99541783,0.0023960047,0.00025464882,0.00017566052,0.0013464038,0.0004095494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001806416,0.0007846372,0.001343685,0.00074841944,0.0010704517,0.0012549333,0.0012250335,0.01231595,0.004297488],"category_scores_gemma":[0.015453444,0.00038277585,0.0011242449,0.00051116996,0.0009642315,0.0013795241,0.0005354679,0.0133364685,0.006939299],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015531642,0.000042072774,0.002809857,0.00006767294,0.000021934491,0.0033166544,0.000039284037,0.00018332872,0.00039917615,0.00074034143,0.9682773,0.023947103],"study_design_scores_gemma":[0.0005496489,0.0005298434,0.012916893,0.00092085043,0.00023812523,0.020579727,0.0004571854,0.0045944583,0.0031534033,0.01578108,0.940084,0.00019475663],"about_ca_topic_score_codex":0.003716341,"about_ca_topic_score_gemma":0.0041665607,"teacher_disagreement_score":0.01231595,"about_ca_system_score_codex":0.0029778855,"about_ca_system_score_gemma":0.001054253,"threshold_uncertainty_score":0.021606207},"labels":[],"label_agreement":null},{"id":"W1535415765","doi":"10.1038/modpathol.2011.206","title":"‘Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases","year":2012,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Fluorescence in situ hybridization; Biology; Breast carcinoma; Genetic heterogeneity; In situ; Fish <Actinopterygii>; Pathology; Molecular biology; Chromosome; Breast cancer; Phenotype; Genetics; Gene; Cancer; Medicine; Chemistry","score_opus":0.09402426994475052,"score_gpt":0.3758515445733378,"score_spread":0.28182727462858725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1535415765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99935144,0.00020135977,0.00011932584,0.000014479,0.0000016436103,0.00001730348,0.00005844494,0.0000020257976,0.00023403362],"genre_scores_gemma":[0.99948645,0.000102721555,0.00011875488,0.00001851694,0.000006492165,0.000016631562,0.00016267294,0.0000022493523,0.00008557249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983688,0.00031140298,0.0002777415,0.00049350515,0.0003422641,0.00020622207],"domain_scores_gemma":[0.99812037,0.0005604486,0.0006273059,0.000251452,0.00018936621,0.00025095802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013512373,0.0003511506,0.00041419352,0.0018878,0.0006009807,0.00059418764,0.00052491395,0.0006206095,0.0012354844],"category_scores_gemma":[0.0041713556,0.0005322133,0.00038166158,0.0012900622,0.0007823283,0.000568509,0.0008417869,0.00034192947,0.00046205535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012093733,0.000046629404,0.99315417,0.000015915546,0.000020890986,0.0034566517,0.000275979,0.00004511278,0.0009286503,0.000026796482,0.00006519614,0.0018430395],"study_design_scores_gemma":[0.000013004209,0.00023091503,0.97840047,0.000015380856,0.00003607491,0.018886486,0.0009730474,0.0003177987,0.0004983207,0.000033661006,0.0005813192,0.0000134871425],"about_ca_topic_score_codex":0.002487469,"about_ca_topic_score_gemma":0.0022500535,"teacher_disagreement_score":0.002487469,"about_ca_system_score_codex":0.0005147228,"about_ca_system_score_gemma":0.00028057027,"threshold_uncertainty_score":0.00714612},"labels":[],"label_agreement":null},{"id":"W1538972651","doi":"10.1158/0008-5472.can-03-3013","title":"Suppression of Ovarian Cancer Cell Tumorigenicity and Evasion of Cisplatin Resistance Using a Truncated Epidermal Growth Factor Receptor in a Rat Model","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute","keywords":"Epidermal growth factor receptor; Cisplatin; Epidermal growth factor; Ovarian cancer; Cancer research; Biology; MAPK/ERK pathway; Signal transduction; Tyrosine kinase; Cancer; Cell growth; Internal medicine; Endocrinology; Medicine; Receptor; Cell biology; Chemotherapy","score_opus":0.1587982255810195,"score_gpt":0.44702963869025175,"score_spread":0.2882314131092323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1538972651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960775,0.00053291366,0.0020946984,0.00012864677,0.000043605873,0.00007472307,0.00033177473,0.000108552245,0.0006076131],"genre_scores_gemma":[0.9921278,0.0010746196,0.0026299772,0.00004445913,0.000011253901,0.00013540746,0.00058712927,0.00002631824,0.0033632054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999767,0.000035002995,0.000024991143,0.000045562563,0.00006798358,0.000059508096],"domain_scores_gemma":[0.9998148,0.000019569996,0.00005563628,0.0000420976,0.000019539859,0.000048293496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023052297,0.0006305721,0.0004896923,0.00070662814,0.00021385717,0.00029161156,0.0003744531,0.00042067707,0.0013029813],"category_scores_gemma":[0.00016031894,0.00027636017,0.00053442304,0.00027946875,0.0004069337,0.00034192228,0.00028821902,0.001141564,0.00037252138],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038859068,0.00032029042,0.0003491867,0.000038095273,0.00001098243,0.000113424176,0.000027573697,0.00013960569,0.9966235,0.0002060519,0.00006037302,0.0017223688],"study_design_scores_gemma":[0.00008592468,0.0039132736,0.0031174796,0.00000795819,0.000045746194,0.0006107036,0.0000547668,0.0015114475,0.9884526,0.000066405875,0.002123256,0.000010481093],"about_ca_topic_score_codex":0.0011025844,"about_ca_topic_score_gemma":0.0015087576,"teacher_disagreement_score":0.0013029813,"about_ca_system_score_codex":0.0004148795,"about_ca_system_score_gemma":0.00049554964,"threshold_uncertainty_score":0.0043589473},"labels":[],"label_agreement":null},{"id":"W1539015594","doi":"10.1186/bcr1028","title":"Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells","year":2005,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Susan G. Komen; AstraZeneca","keywords":"Gefitinib; Surgical oncology; Cancer research; Breast cancer; Insulin-like growth factor; Epidermal growth factor receptor; Growth factor receptor inhibitor; Medicine; Oncology; Inhibitory postsynaptic potential; Internal medicine; Growth factor; Receptor; Cancer","score_opus":0.037751638025765595,"score_gpt":0.367743655658585,"score_spread":0.32999201763281943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1539015594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879374,0.0058310395,0.0012351247,0.0002134451,0.00014184487,0.000088281195,0.00088871026,0.00023855185,0.0034256333],"genre_scores_gemma":[0.99009234,0.0026466022,0.0029268283,0.00008517028,0.00004172192,0.00011313571,0.002246033,0.000021731896,0.0018265117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996,0.00007205225,0.00005862641,0.00007029295,0.00011498961,0.00008405249],"domain_scores_gemma":[0.99991703,0.00002203277,0.000013343761,0.00001405129,0.000014295083,0.000019267274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032335357,0.00059212215,0.0008622109,0.00044891494,0.0002462413,0.00037493624,0.00027707277,0.00033764658,0.0016042596],"category_scores_gemma":[0.00014777786,0.00020148061,0.0005295219,0.00050168857,0.00017865299,0.000182578,0.00013994919,0.0006315506,0.000760725],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087232474,0.00041813048,0.00045073114,0.0001502271,0.00003351393,0.00011754857,0.000047003672,0.00017609248,0.9928403,0.00005360815,0.0003941248,0.004446451],"study_design_scores_gemma":[0.00018496848,0.0021408775,0.006947513,0.000011830515,0.00005067943,0.000677307,0.00002724624,0.0014000401,0.9849279,0.000017837381,0.0036044703,0.000009402472],"about_ca_topic_score_codex":0.0013280046,"about_ca_topic_score_gemma":0.0016518042,"teacher_disagreement_score":0.0016042596,"about_ca_system_score_codex":0.00044438522,"about_ca_system_score_gemma":0.00034699432,"threshold_uncertainty_score":0.005366802},"labels":[],"label_agreement":null},{"id":"W1549851394","doi":"10.1093/annonc/mdu364","title":"Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Roche","keywords":"Medicine; Trastuzumab; Adjuvant; Breast cancer; Cohort; Oncology; Cohort study; Cancer; Internal medicine; Surgery","score_opus":0.08889308378065346,"score_gpt":0.4284548250882904,"score_spread":0.33956174130763694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1549851394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991774,0.00024831446,0.0001201909,0.00005106832,0.00001280526,0.000037567363,0.0001660054,0.0000031003094,0.00018343519],"genre_scores_gemma":[0.99920505,0.00009669508,0.00011378025,0.00008823184,0.000019042314,0.000035584755,0.00027972952,0.0000031175862,0.00015876506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99773043,0.001515084,0.00009294301,0.000275643,0.00016396133,0.00022198568],"domain_scores_gemma":[0.99612856,0.0023993761,0.0007149656,0.0003586177,0.000059500147,0.0003389397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034019558,0.00073503883,0.0014866019,0.00016846086,0.00031663486,0.0009058401,0.0007154455,0.0009663012,0.0026124923],"category_scores_gemma":[0.004507002,0.00041787152,0.0023773974,0.00034078327,0.00083021354,0.00090931414,0.00033953754,0.0016314066,0.00028611772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83690035,0.0036322721,0.12436541,0.00019873108,0.0047637005,0.0002500663,0.00029690375,0.0022119656,0.0033618393,0.00030494513,0.0010742077,0.022639485],"study_design_scores_gemma":[0.30560422,0.1272689,0.5305236,0.00011109284,0.011324739,0.00089220545,0.001177928,0.014150941,0.003725556,0.002563138,0.0023745382,0.00028310512],"about_ca_topic_score_codex":0.000703198,"about_ca_topic_score_gemma":0.0010778327,"teacher_disagreement_score":0.0034019558,"about_ca_system_score_codex":0.00048877386,"about_ca_system_score_gemma":0.00043748392,"threshold_uncertainty_score":0.017991424},"labels":[],"label_agreement":null},{"id":"W1558260067","doi":"10.1096/fasebj.28.1_supplement.802.13","title":"The EGF receptor is activated during mitosis and its cell signaling is mediated differently than in interphase (802.13)","year":2014,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Interphase; Phosphorylation; Cell biology; Mitosis; Nocodazole; Epidermal growth factor; Signal transduction; Chemistry; Cell cycle; Protein kinase B; Epidermal growth factor receptor; MAPK/ERK pathway; Receptor; Biology; Cell; Biochemistry; Cytoskeleton","score_opus":0.025972254779987897,"score_gpt":0.3005262758537149,"score_spread":0.274554021073727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1558260067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970722,0.012809093,0.0071664965,0.00019967214,0.00008778284,0.000052838976,0.00072545477,0.00008770033,0.008148986],"genre_scores_gemma":[0.9823073,0.006878598,0.0024784228,0.00012432337,0.0000293688,0.000056230187,0.0009921759,0.00001601616,0.007117455],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999156,0.000010935368,0.000006225119,0.000019415807,0.000023652516,0.000024256246],"domain_scores_gemma":[0.9999467,0.0000074869354,0.000016854314,0.000005518767,0.000008885548,0.000014569233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074807904,0.00026454966,0.00017444602,0.00030046335,0.00017731704,0.0003096989,0.00018003109,0.00025156763,0.0021708906],"category_scores_gemma":[0.00008154452,0.00010841946,0.00015661605,0.00019430039,0.00014070896,0.00029577827,0.0001621036,0.00033350792,0.0006536968],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018164745,0.000015705105,0.00030643088,0.0000738045,0.0000040860036,0.00009147861,0.000011101636,0.000010363585,0.99616665,0.00020064744,0.00004070208,0.0028972905],"study_design_scores_gemma":[0.000024128365,0.00033458034,0.035170972,0.000015658428,0.000023611365,0.0010300244,0.000089100206,0.00027508786,0.9546086,0.00020786872,0.008211519,0.00000887],"about_ca_topic_score_codex":0.0006067343,"about_ca_topic_score_gemma":0.0008895344,"teacher_disagreement_score":0.0021708906,"about_ca_system_score_codex":0.00025466504,"about_ca_system_score_gemma":0.00018384328,"threshold_uncertainty_score":0.007262349},"labels":[],"label_agreement":null},{"id":"W1565037297","doi":"10.1002/path.4202","title":"Dasatinib inhibits mammary tumour development in a genetically engineered mouse model","year":2013,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Cancer Research UK","keywords":"Dasatinib; Proto-oncogene tyrosine-protein kinase Src; Cancer research; Breast cancer; Cancer; ErbB; PTEN; Biology; Kinase; Medicine; Cre recombinase; Internal medicine; Genetically modified mouse; Tyrosine kinase; Transgene; Receptor; Signal transduction; PI3K/AKT/mTOR pathway; Gene; Cell biology; Genetics","score_opus":0.04213517269409412,"score_gpt":0.3176747396598824,"score_spread":0.2755395669657883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1565037297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783222,0.0027514691,0.009226724,0.00073848077,0.00024688354,0.0004453734,0.0024761346,0.0006393432,0.005153392],"genre_scores_gemma":[0.9672637,0.0028806946,0.007891207,0.00021196522,0.000045134046,0.00043022053,0.0022268882,0.00010410201,0.018946145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995023,0.000071201175,0.000054401204,0.00011218163,0.00016041576,0.00009952399],"domain_scores_gemma":[0.9997322,0.00004572665,0.00008913875,0.000042210053,0.000020027197,0.00007072697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036640244,0.0007651031,0.00065265043,0.00081420946,0.00025174805,0.0004987595,0.0006341095,0.00093119714,0.002134964],"category_scores_gemma":[0.00017261617,0.00039885537,0.00070312025,0.0003733761,0.00039939658,0.00041938917,0.00028425115,0.0020055643,0.0008939548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039065848,0.00021911666,0.0001360224,0.000051368228,0.000013747657,0.00012902965,0.00002640294,0.00013471452,0.9969652,0.00027591374,0.00012395615,0.0015337248],"study_design_scores_gemma":[0.00015739376,0.0026997663,0.0019777867,0.00001549445,0.000036013105,0.0008530262,0.000049022256,0.0018404064,0.98661196,0.00013053828,0.005615897,0.000012703957],"about_ca_topic_score_codex":0.0006810913,"about_ca_topic_score_gemma":0.0015395912,"teacher_disagreement_score":0.002134964,"about_ca_system_score_codex":0.0006560145,"about_ca_system_score_gemma":0.00041106303,"threshold_uncertainty_score":0.007142186},"labels":[],"label_agreement":null},{"id":"W1593299612","doi":"10.1158/1538-7445.am2014-753","title":"Abstract 753: Enhanced anti-tumor activity of erlotinib in combination with FAK tyrosine kinase inhibitors in non-small cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Erlotinib; T790M; Cancer research; Tyrosine kinase; Epidermal growth factor receptor; Medicine; Erlotinib Hydrochloride; EGFR inhibitors; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-kinase inhibitor; Gefitinib; Cancer; Internal medicine; Receptor","score_opus":0.04532424740537488,"score_gpt":0.3983098243007043,"score_spread":0.3529855768953294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1593299612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896492,0.004552826,0.00047611364,0.0002478731,0.00014748864,0.00014805332,0.0007581009,0.00014532865,0.0038749813],"genre_scores_gemma":[0.9943768,0.0017070828,0.00068905816,0.00010395388,0.000039285675,0.000063420644,0.00084950705,0.000015838856,0.0021551887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988055,0.00002811843,0.000010229667,0.000015006667,0.000025687477,0.000040259936],"domain_scores_gemma":[0.9999405,0.00001112458,0.000008914479,0.000005838953,0.0000069927246,0.000026559785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000207566,0.00043414417,0.0006843455,0.00037949038,0.00018709789,0.00038838384,0.00038209732,0.000357948,0.0027412274],"category_scores_gemma":[0.00013260421,0.00015189464,0.00045212792,0.00034342,0.00014127739,0.00018892098,0.00015920219,0.0006589517,0.0005852498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012571958,0.0041196174,0.00086480775,0.00055503886,0.00020173445,0.00050476607,0.00006916558,0.0011275869,0.92805874,0.0002973704,0.0029105458,0.04871879],"study_design_scores_gemma":[0.0068815793,0.05508414,0.027556298,0.00007637588,0.0005271358,0.002022161,0.000084067404,0.0057529006,0.8847895,0.00013399258,0.01701616,0.00007562903],"about_ca_topic_score_codex":0.001846437,"about_ca_topic_score_gemma":0.0040097237,"teacher_disagreement_score":0.0027412274,"about_ca_system_score_codex":0.0003108789,"about_ca_system_score_gemma":0.0004868393,"threshold_uncertainty_score":0.009170294},"labels":[],"label_agreement":null},{"id":"W1606941281","doi":"10.3390/curroncol13050019","title":"Receptor tyrosine kinases: role in cancer progression.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Cancer; Gerontology; Tyrosine kinase; Library science; Oncology; Cancer research; Internal medicine; Receptor","score_opus":0.03675221050722706,"score_gpt":0.34455889534348677,"score_spread":0.3078066848362597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606941281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044502516,0.96407664,0.00043779655,0.014955637,0.011583988,0.000010125711,0.0000745601,0.00003073898,0.008385585],"genre_scores_gemma":[0.010389073,0.9091231,0.0010412753,0.0038407415,0.022342678,0.000022713837,0.00017829357,0.00001132801,0.053050704],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99967885,0.000046949714,0.000034036948,0.000044657936,0.00016574013,0.000029744573],"domain_scores_gemma":[0.9993575,0.00017372894,0.000089076115,0.000016204789,0.0002249635,0.00013857354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010479994,0.0008413847,0.0006533842,0.001164874,0.00030824577,0.0013145875,0.00064831425,0.0009682383,0.005935701],"category_scores_gemma":[0.0010622805,0.00031172417,0.00023922934,0.00079619297,0.00063899043,0.0011441152,0.00034802366,0.0018567196,0.0037813096],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019053141,0.000038255097,0.00073280325,0.0012031889,0.000031093816,0.00030471364,0.00010812879,0.00016991477,0.0034025388,0.00987356,0.5424302,0.44151506],"study_design_scores_gemma":[0.000044419434,0.0001036733,0.0018387648,0.0003579795,0.000025572312,0.001524777,0.00008747001,0.00012205685,0.0009298885,0.0036175966,0.9913374,0.000010425277],"about_ca_topic_score_codex":0.0010780889,"about_ca_topic_score_gemma":0.0044518188,"teacher_disagreement_score":0.005935701,"about_ca_system_score_codex":0.00075554784,"about_ca_system_score_gemma":0.00073216064,"threshold_uncertainty_score":0.01985687},"labels":[],"label_agreement":null},{"id":"W1607152800","doi":"10.3747/co.v13i1.91","title":"Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead","year":2006,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Trastuzumab; Medicine; Adjuvant; Breast cancer; Oncology; Clinical trial; Internal medicine; Cancer","score_opus":0.09057353432679374,"score_gpt":0.44662414739111606,"score_spread":0.3560506130643223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1607152800","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010421056,0.68209845,0.0005810988,0.31168547,0.0030797534,0.000011103264,0.000037881233,0.000023081016,0.0014410086],"genre_scores_gemma":[0.01921792,0.8644606,0.0024988062,0.09427636,0.017592581,0.000037303005,0.00007893357,0.000037252237,0.0018002791],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697125,0.0012189375,0.00052923465,0.0002087105,0.00076664076,0.00030516303],"domain_scores_gemma":[0.9810193,0.013000348,0.0010713933,0.00043193504,0.0030529583,0.0014240263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020037336,0.0007959165,0.0015292729,0.0010752579,0.0011188851,0.0044911234,0.0014936747,0.0053286306,0.0029918274],"category_scores_gemma":[0.023042953,0.00029754514,0.0007339022,0.001719648,0.0037822563,0.00906517,0.0021504867,0.0114693,0.0011223316],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010598155,0.00019454389,0.0015071752,0.002958641,0.00013527436,0.00034499104,0.00036529684,0.00046718257,0.0008778843,0.035765126,0.12570633,0.83061785],"study_design_scores_gemma":[0.00026938264,0.0005998059,0.0021348349,0.0058754366,0.00027661113,0.0008119957,0.00145608,0.00042019653,0.00097642775,0.07884779,0.9082442,0.00008732357],"about_ca_topic_score_codex":0.002725597,"about_ca_topic_score_gemma":0.0064458326,"teacher_disagreement_score":0.020037336,"about_ca_system_score_codex":0.0032575363,"about_ca_system_score_gemma":0.006077188,"threshold_uncertainty_score":0.10596883},"labels":[],"label_agreement":null},{"id":"W1633933096","doi":"10.1016/j.anndiagpath.2015.08.001","title":"Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks","year":2015,"lang":"en","type":"article","venue":"Annals of Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"American Society of Clinical Oncology","keywords":"Medicine; Breast cancer; Immunohistochemistry; Pathology; Breast carcinoma; Biomarker; Genetic heterogeneity; Cancer; Oncology; Phenotype; Internal medicine; Biology; Gene","score_opus":0.26251326692040067,"score_gpt":0.4016394002811805,"score_spread":0.13912613336077984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1633933096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719757,0.005316839,0.016546907,0.0008305683,0.000086494154,0.0001253356,0.00024471045,0.00030528105,0.004568196],"genre_scores_gemma":[0.99051917,0.00043565923,0.008233106,0.00020567194,0.000054576332,0.000029237606,0.00012941369,0.000048664395,0.0003445778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99314135,0.0028500005,0.0005844378,0.0008032504,0.002175079,0.00044590284],"domain_scores_gemma":[0.9738864,0.020112403,0.0014337108,0.0018393978,0.0021385853,0.0005895373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009880653,0.00073008373,0.0007322493,0.0022518977,0.0003444387,0.0012519957,0.0010508307,0.0013009984,0.0017290876],"category_scores_gemma":[0.03253046,0.0006507309,0.00056008826,0.0006546196,0.00082255213,0.0011855961,0.0008075163,0.00073723844,0.0008973753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035035291,0.00021354806,0.8114607,0.00032345107,0.00031197947,0.0036463141,0.00046522194,0.001548162,0.08837803,0.00047061223,0.0011003505,0.088578135],"study_design_scores_gemma":[0.00011296807,0.0023461343,0.7297706,0.00020788414,0.0010196139,0.041831277,0.0008959815,0.032480527,0.18111381,0.0030882487,0.007052655,0.000080310434],"about_ca_topic_score_codex":0.0013818258,"about_ca_topic_score_gemma":0.0026928126,"teacher_disagreement_score":0.009880653,"about_ca_system_score_codex":0.0005485122,"about_ca_system_score_gemma":0.00044296947,"threshold_uncertainty_score":0.052254498},"labels":[],"label_agreement":null},{"id":"W1664877704","doi":"10.1016/j.ejca.2015.06.004","title":"Duration of Trastuzumab. In matters of the heart, one size may not fit all?","year":2015,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Clinical trial; Oncology; Internal medicine; Intensive care medicine; Cancer","score_opus":0.11603175485353937,"score_gpt":0.3744749291052125,"score_spread":0.2584431742516732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1664877704","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059582596,0.0018888029,0.00005600668,0.9892743,0.0055490923,0.00000353145,0.000031625314,0.000007914061,0.0025928689],"genre_scores_gemma":[0.011078692,0.0031686104,0.00015952517,0.93643916,0.04315258,0.000015520336,0.000034092307,0.000014516462,0.0059373616],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987601,0.00041296642,0.00018109713,0.00017204192,0.0002900038,0.00018372004],"domain_scores_gemma":[0.99684936,0.0017906968,0.00024122451,0.0000903484,0.0003417797,0.00068662065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014256849,0.00038781072,0.0011807521,0.00036700148,0.0022354599,0.0020468018,0.00082737714,0.023508025,0.006867774],"category_scores_gemma":[0.015702287,0.00027710685,0.0007489985,0.00035962966,0.001302057,0.003169692,0.0006627537,0.019173881,0.0031618911],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028936483,0.000085961714,0.004232482,0.000108771135,0.00004562246,0.0097110355,0.00020640939,0.00014847783,0.00045685918,0.009595368,0.9356776,0.03944202],"study_design_scores_gemma":[0.0005053346,0.00028865406,0.00518582,0.0009974618,0.00009159179,0.017360948,0.0008087512,0.0007467321,0.0003392533,0.03295652,0.9406173,0.000101613245],"about_ca_topic_score_codex":0.0033268046,"about_ca_topic_score_gemma":0.0076814047,"teacher_disagreement_score":0.023508025,"about_ca_system_score_codex":0.002660069,"about_ca_system_score_gemma":0.0016438694,"threshold_uncertainty_score":0.022974968},"labels":[],"label_agreement":null},{"id":"W1679330090","doi":"10.1158/1538-7445.sabcs14-p6-09-07","title":"Abstract P6-09-07: The development of a prediction tool for moderate to severe diarrhea in HER-2/hormone positive metastatic breast cancer (MBC) patients receiving lapatinib in combination with letrozole (L-L)","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Lapatinib; Letrozole; Diarrhea; Discontinuation; Internal medicine; Gee; Metastatic breast cancer; Receiver operating characteristic; Cancer; Oncology; Breast cancer; Generalized estimating equation; Statistics; Mathematics","score_opus":0.09324568005919245,"score_gpt":0.40662034562188604,"score_spread":0.31337466556269356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1679330090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9421021,0.0004714199,0.04941268,0.0005572317,0.000064524786,0.00076900003,0.0036244655,0.0009676821,0.0020308488],"genre_scores_gemma":[0.96907544,0.00014264834,0.027902503,0.00011004355,0.000031389398,0.00028734253,0.0018435613,0.000037951995,0.0005690967],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99802953,0.0011340642,0.00018776725,0.00017745332,0.00040741367,0.00006379522],"domain_scores_gemma":[0.9933822,0.0041823066,0.0010954973,0.00026018036,0.00087131007,0.00020844443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050474256,0.00070043374,0.00071847095,0.0014261046,0.00018221296,0.0011203662,0.00057383534,0.00062017754,0.001926432],"category_scores_gemma":[0.014637455,0.00027151394,0.0010886712,0.0006211595,0.00021945022,0.0004734288,0.00057570596,0.0007311734,0.00079461414],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046746903,0.0019677493,0.77907807,0.0003187701,0.00076454895,0.00037049386,0.00013928291,0.027103068,0.0052622855,0.00027279597,0.0038759296,0.17617223],"study_design_scores_gemma":[0.0007473861,0.0073421653,0.41464955,0.00012768489,0.0007177233,0.0018035813,0.00016845278,0.5607573,0.009106338,0.0007327682,0.00373692,0.00011012911],"about_ca_topic_score_codex":0.0012335911,"about_ca_topic_score_gemma":0.0012381367,"teacher_disagreement_score":0.0050474256,"about_ca_system_score_codex":0.0003822797,"about_ca_system_score_gemma":0.00086790574,"threshold_uncertainty_score":0.026693642},"labels":[],"label_agreement":null},{"id":"W1724585481","doi":"","title":"Closing the personalized medicine information gap: HER2 test documentation practice.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Toronto; Alberta Bone and Joint Health Institute; Western University; McMaster University; Ontario Institute for Cancer Research; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Internal medicine; Stage (stratigraphy); Breast cancer; Cancer; Immunohistochemistry; Fluorescence in situ hybridization; Adjuvant therapy; Disease; Companion diagnostic; Gene","score_opus":0.056645168947227396,"score_gpt":0.3604705696905919,"score_spread":0.3038254007433645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1724585481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.749636,0.032446522,0.0051528206,0.17941114,0.0002395474,0.00018177496,0.006335803,0.00040436813,0.026191978],"genre_scores_gemma":[0.988199,0.0045685223,0.0018895247,0.0036093572,0.00011422754,0.000026861477,0.0010084847,0.000017260094,0.00056662905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99541926,0.001536339,0.00033169435,0.000452066,0.0017729582,0.00048769097],"domain_scores_gemma":[0.9610919,0.013833623,0.014710896,0.0017028399,0.005166017,0.0034946539],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006442511,0.00013323821,0.00023446063,0.0011572383,0.0010528213,0.001821711,0.0011797076,0.00063619396,0.0027852352],"category_scores_gemma":[0.042017855,0.00015074726,0.00026176422,0.0029753763,0.0011964451,0.0016837472,0.0016618534,0.0008905729,0.00021940502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009577457,0.00006998943,0.77566105,0.00053890416,0.000052617546,0.0003389903,0.0027226806,0.0006190932,0.00022094036,0.0015388853,0.028004747,0.19013643],"study_design_scores_gemma":[0.00003041867,0.0000883373,0.9682869,0.0013747666,0.00006643174,0.0008694259,0.0031493807,0.002261286,0.00035547465,0.0025261894,0.020955713,0.00003569534],"about_ca_topic_score_codex":0.5820497,"about_ca_topic_score_gemma":0.5494569,"teacher_disagreement_score":0.9935575,"about_ca_system_score_codex":0.015321029,"about_ca_system_score_gemma":0.03313324,"threshold_uncertainty_score":0.8408233},"labels":[],"label_agreement":null},{"id":"W1748137726","doi":"10.1200/jco.2014.32.18_suppl.lba4","title":"First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Hazard ratio; Regimen; Clinical endpoint; Oncology; Anthracycline; Gastroenterology; Breast cancer; Cancer; Confidence interval; Clinical trial","score_opus":0.27672095696187204,"score_gpt":0.4792496435740614,"score_spread":0.20252868661218937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1748137726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83414996,0.0638864,0.0050012893,0.014370627,0.0030788595,0.008859541,0.038809083,0.0007165485,0.031127825],"genre_scores_gemma":[0.8786948,0.016863192,0.010202143,0.018401181,0.0019157939,0.010423881,0.04673278,0.0002585175,0.016507775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99846494,0.0011607184,0.000044780976,0.00012468807,0.000111231384,0.0000935764],"domain_scores_gemma":[0.9973315,0.0009092894,0.0006047076,0.00022149943,0.00014342627,0.00078968494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046774694,0.0013434433,0.001986733,0.00033797746,0.00043577532,0.0011963272,0.0010414682,0.0016655546,0.00717229],"category_scores_gemma":[0.0048906473,0.00041729867,0.0026679682,0.00046743744,0.0008084417,0.0010496911,0.00066706137,0.0038195923,0.0013107469],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85306656,0.0070586354,0.0031144354,0.002565056,0.0041324184,0.00010746205,0.00017295108,0.002979862,0.0027858003,0.0005833608,0.039302852,0.08413065],"study_design_scores_gemma":[0.87517303,0.0937442,0.008842706,0.0003525657,0.0028205796,0.00026695858,0.00005306359,0.00092857913,0.0008404075,0.0007838657,0.016131755,0.00006232702],"about_ca_topic_score_codex":0.0013894665,"about_ca_topic_score_gemma":0.005112308,"teacher_disagreement_score":0.00717229,"about_ca_system_score_codex":0.0011808999,"about_ca_system_score_gemma":0.0016179142,"threshold_uncertainty_score":0.02473712},"labels":[],"label_agreement":null},{"id":"W1766320810","doi":"10.1111/j.1365-2559.2010.03602.x","title":"A novel method of cell embedding for tissue microarrays","year":2010,"lang":"en","type":"letter","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Embedding; Computer science; Content (measure theory); Information retrieval; DNA microarray; Tissue microarray; Computational biology; Artificial intelligence; Biology; Pathology; Medicine; Mathematics; Genetics; Gene expression; Gene; Immunohistochemistry","score_opus":0.05416591762640351,"score_gpt":0.40508664235903413,"score_spread":0.35092072473263064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1766320810","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036698014,0.0046384544,0.91354334,0.0041294615,0.00702226,0.0023863856,0.0019378877,0.0044961968,0.025147926],"genre_scores_gemma":[0.06998587,0.0034674702,0.8878748,0.0012981206,0.00054336555,0.0037473526,0.0017743105,0.0006370739,0.030671649],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99911374,0.00019346779,0.000097342585,0.00019991811,0.00031787727,0.000077653065],"domain_scores_gemma":[0.9989347,0.0004911817,0.00007821883,0.00028407839,0.00015662688,0.000055260865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011490269,0.0010569366,0.00034824136,0.00081690156,0.00068095495,0.0005037409,0.0010669418,0.00127655,0.013690496],"category_scores_gemma":[0.0014120162,0.000999795,0.0006443955,0.00043273479,0.00045540227,0.0007240566,0.0006272718,0.0022164835,0.0100477],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053013835,0.00005592706,0.00018452154,0.00032812468,0.000021703989,0.00063446775,0.00009543601,0.00021445045,0.96626127,0.0014227785,0.0075907903,0.023137601],"study_design_scores_gemma":[0.000102725215,0.00050856767,0.0046919216,0.000115332296,0.000089199515,0.01094806,0.00012254015,0.009889556,0.6314063,0.0027796328,0.33921772,0.00012838376],"about_ca_topic_score_codex":0.00032958164,"about_ca_topic_score_gemma":0.0019467218,"teacher_disagreement_score":0.013690496,"about_ca_system_score_codex":0.00029039028,"about_ca_system_score_gemma":0.00039830475,"threshold_uncertainty_score":0.045799315},"labels":[],"label_agreement":null},{"id":"W1782943140","doi":"10.1309/ajcpt41tcbuevdqc","title":"Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1","year":2015,"lang":"en","type":"review","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Lapatinib; Trastuzumab; Breast cancer; Medicine; Human Epidermal Growth Factor Receptor 2; Standardization; Medical physics; Oncology; Cancer; Internal medicine; Computer science","score_opus":0.24146479820065314,"score_gpt":0.5770063516071183,"score_spread":0.3355415534064652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1782943140","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042787532,0.99203193,0.0015414252,0.0009236595,0.0004945009,0.000048093,0.00019272292,0.000041053667,0.004298657],"genre_scores_gemma":[0.0033648238,0.9878071,0.0050811297,0.000724141,0.00039575878,0.000088509114,0.00036269464,0.000017430208,0.0021582756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998372,0.00033633795,0.0002868219,0.00023435676,0.00068813586,0.00008233328],"domain_scores_gemma":[0.99643576,0.0023735932,0.00034665572,0.000108552675,0.0006782557,0.000057265243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025171523,0.0011241966,0.0014150174,0.0043933145,0.0003493072,0.0014919541,0.0012990042,0.0015780891,0.006452515],"category_scores_gemma":[0.004087592,0.0004879755,0.0012295177,0.002854902,0.00066437165,0.0020485236,0.000776266,0.0017250002,0.0038647912],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010323824,0.000051184725,0.0008059298,0.03339085,0.000173351,0.00034211128,0.000108658365,0.0002493328,0.004836043,0.0041382485,0.025540894,0.9302602],"study_design_scores_gemma":[0.00002036179,0.00014264366,0.0020427967,0.00869121,0.00035946592,0.003969251,0.000121409736,0.00014096366,0.0048960876,0.0026124618,0.9769495,0.000053873242],"about_ca_topic_score_codex":0.0007071573,"about_ca_topic_score_gemma":0.0013626849,"teacher_disagreement_score":0.006452515,"about_ca_system_score_codex":0.0005281385,"about_ca_system_score_gemma":0.0012214285,"threshold_uncertainty_score":0.021585763},"labels":[],"label_agreement":null},{"id":"W1797772724","doi":"10.1200/jco.2006.24.18_suppl.514","title":"ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Breast cancer; Gefitinib; Tissue microarray; Cancer; Internal medicine; Oncology; Estrogen receptor; Microarray; Cancer research; Immunohistochemistry; Epidermal growth factor receptor; Fulvestrant; Pathology; Gene expression; Biology; Gene","score_opus":0.11404282470768969,"score_gpt":0.4747955722268884,"score_spread":0.3607527475191987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1797772724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933013,0.0016793613,0.00084645004,0.00013630929,0.00001944421,0.000057750236,0.0008580971,0.000024429519,0.0030769594],"genre_scores_gemma":[0.99364674,0.0012336194,0.001146964,0.00018104444,0.00007353627,0.000066502565,0.001842514,0.000014619252,0.0017944642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998067,0.00003537589,0.000014054416,0.00005019237,0.000046928413,0.000046740774],"domain_scores_gemma":[0.99979573,0.000030114245,0.00010547837,0.000014059303,0.000020007834,0.000034594475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020746232,0.00026215333,0.0005760086,0.00042150173,0.00034023225,0.00032844552,0.00026406004,0.00030017848,0.0031809744],"category_scores_gemma":[0.0002519536,0.0000887985,0.0002225935,0.0005951537,0.0003270831,0.00018024957,0.0002912648,0.00030975943,0.0006631602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032239892,0.0006214935,0.6715217,0.0005011526,0.00013101893,0.0074578268,0.00025906344,0.00040735962,0.24548522,0.0010291515,0.0039811865,0.06538079],"study_design_scores_gemma":[0.00011026212,0.0026477047,0.8886841,0.000040242438,0.0001294371,0.0536008,0.0005033396,0.0007448591,0.025649896,0.00065630575,0.027206842,0.000026325297],"about_ca_topic_score_codex":0.0006062467,"about_ca_topic_score_gemma":0.0011486833,"teacher_disagreement_score":0.0031809744,"about_ca_system_score_codex":0.00020363014,"about_ca_system_score_gemma":0.00016823516,"threshold_uncertainty_score":0.010641456},"labels":[],"label_agreement":null},{"id":"W1813373450","doi":"","title":"ST6GAL1, COX-2 AND HB-EGF MRNA EXPRESSION IN BREAST CANCER SAMPLES FROM KASHAN, IRAN","year":2015,"lang":"en","type":"article","venue":"Middle East journal of cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Breast cancer; Proportional hazards model; Correlation; Histology; Immunohistochemistry; Metastasis; Cancer; Pathology; Reverse transcriptase; Internal medicine; Oncology; Gene; Biology; Polymerase chain reaction; Genetics","score_opus":0.16282187968548853,"score_gpt":0.3785528154159658,"score_spread":0.21573093573047727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1813373450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982476,0.00087593426,0.00023770465,0.000028986231,0.000010075646,0.000018086159,0.0002819043,0.0000097647935,0.00028995896],"genre_scores_gemma":[0.99618196,0.0009310747,0.0012674177,0.000052872667,0.00002023368,0.00004936897,0.00088218984,0.0000037058733,0.0006112377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998653,0.000012036309,0.000013504553,0.000025070993,0.000058785092,0.000025358371],"domain_scores_gemma":[0.9998858,0.000024175502,0.000028289161,0.000007766895,0.000041415955,0.0000126826935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029488036,0.00018604757,0.00017718284,0.0010416062,0.00028962578,0.00022057333,0.00015746524,0.00015753356,0.0006308273],"category_scores_gemma":[0.0002578938,0.00014007243,0.00020029802,0.00071486476,0.00024364973,0.000074400545,0.0001336905,0.00021086959,0.00012960067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001372194,0.000299632,0.7352252,0.0005011932,0.00021077019,0.0026753577,0.002126349,0.00045211727,0.21114072,0.00020173208,0.00086021755,0.04493441],"study_design_scores_gemma":[0.000048592432,0.00048412613,0.9685166,0.000019475985,0.00015361093,0.005147636,0.0010405255,0.00035047563,0.02121114,0.000082872255,0.0029321958,0.000012761193],"about_ca_topic_score_codex":0.0036288577,"about_ca_topic_score_gemma":0.005095308,"teacher_disagreement_score":0.0036288577,"about_ca_system_score_codex":0.00025343578,"about_ca_system_score_gemma":0.0003874329,"threshold_uncertainty_score":0.0072154403},"labels":[],"label_agreement":null},{"id":"W1857349325","doi":"10.14740/wjon919w","title":"Trastuzumab Exposure in Early Pregnancy for a Young Lady With Locally Invasive Breast Cancer","year":2015,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Pregnancy; Breast cancer; Adjuvant; Oncology; Obstetrics; Cancer; Internal medicine; Gynecology","score_opus":0.061963999291913215,"score_gpt":0.3812725102733918,"score_spread":0.3193085109814786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1857349325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97258943,0.011444105,0.0005215493,0.010015529,0.0002237287,0.00004118807,0.000101076774,0.000032785418,0.0050306446],"genre_scores_gemma":[0.99299836,0.004618983,0.00025069492,0.0009991862,0.00018571952,0.0000072023636,0.000040581064,0.000005282711,0.0008940219],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99989676,0.000019807574,0.000013087651,0.000014450791,0.000017655317,0.000038202204],"domain_scores_gemma":[0.9998068,0.00006585964,0.000035939527,0.0000049889027,0.0000075400976,0.00007879038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001391362,0.00020247992,0.00033575544,0.00045337173,0.0006833441,0.00040089394,0.00019818137,0.0010809731,0.0010662437],"category_scores_gemma":[0.001089015,0.00019336153,0.0003009711,0.00029423754,0.00027395194,0.0003691954,0.0002863524,0.0011541047,0.00016212014],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067606143,0.0001328013,0.09754571,0.00006597203,0.000022755617,0.8800262,0.00045796612,0.00015989254,0.0024634663,0.00022888959,0.0011908467,0.017029358],"study_design_scores_gemma":[0.00006623603,0.0010587685,0.08092112,0.00015024823,0.00010483007,0.90930593,0.0010079948,0.00066204777,0.0019172825,0.0005988143,0.0041741333,0.00003252682],"about_ca_topic_score_codex":0.0020626218,"about_ca_topic_score_gemma":0.003626865,"teacher_disagreement_score":0.0020626218,"about_ca_system_score_codex":0.0005950071,"about_ca_system_score_gemma":0.00053934596,"threshold_uncertainty_score":0.004317045},"labels":[],"label_agreement":null},{"id":"W1859048196","doi":"","title":"À la recherche des patientes présentant un cancer HER2/neu positif : analyse rétrospective","year":2006,"lang":"fr","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Gynecology; Trastuzumab; Cancer; Breast cancer; Internal medicine","score_opus":0.20681717962571394,"score_gpt":0.46654891486572586,"score_spread":0.2597317352400119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1859048196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775476,0.0064500514,0.0009023837,0.00014684566,0.000018253108,0.00037205708,0.0019582177,0.000013530256,0.0023839646],"genre_scores_gemma":[0.991295,0.0036921136,0.0008341627,0.00022588599,0.0000322421,0.00051040796,0.00226252,0.000007136185,0.0011405007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978484,0.00086470495,0.00035351023,0.0003132859,0.00047562335,0.00014450091],"domain_scores_gemma":[0.99242365,0.0032821984,0.002284275,0.00043991074,0.0013224592,0.00024754845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003100298,0.00023269438,0.00030932855,0.0019140334,0.0004621287,0.00087416655,0.00037439316,0.0004357778,0.0033815198],"category_scores_gemma":[0.009237921,0.00042770014,0.0006074104,0.0023118695,0.00042896386,0.00041366337,0.0005013066,0.00027669503,0.0006322469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093206647,0.00011006479,0.9807169,0.0005645554,0.00015000823,0.0005506062,0.0007251434,0.000108563,0.0009036332,0.00012813385,0.0005499494,0.014560291],"study_design_scores_gemma":[0.00012144858,0.0011669772,0.97925675,0.0005458168,0.00033953035,0.0048586805,0.0024569451,0.0003236909,0.0013436858,0.0000716779,0.009487991,0.000026898344],"about_ca_topic_score_codex":0.007252189,"about_ca_topic_score_gemma":0.0061306874,"teacher_disagreement_score":0.007252189,"about_ca_system_score_codex":0.00089678384,"about_ca_system_score_gemma":0.001515777,"threshold_uncertainty_score":0.016396105},"labels":[],"label_agreement":null},{"id":"W1861748936","doi":"10.1158/1078-0432.ccr-15-0468","title":"Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Takeda Pharmaceuticals International","keywords":"Breast cancer; Medicine; Antibody-drug conjugate; Cancer; Cancer research; Tissue microarray; Antibody; Immunohistochemistry; Cytotoxic T cell; Pharmacology; Pathology; Internal medicine; Monoclonal antibody; Immunology; In vitro; Biology","score_opus":0.3735274212817079,"score_gpt":0.6302471702096378,"score_spread":0.2567197489279299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1861748936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954052,0.0009957169,0.0018662118,0.00007696208,0.000021926202,0.0003347478,0.00022751738,0.000049311704,0.001022333],"genre_scores_gemma":[0.99588674,0.00085873104,0.0017225972,0.00003569059,0.000019982172,0.00014423953,0.00035067444,0.000011951111,0.0009693019],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981564,0.000057799574,0.000011469627,0.000025918887,0.000056237743,0.00003293776],"domain_scores_gemma":[0.9997559,0.0000416986,0.0000817385,0.000025772115,0.000057907626,0.000036950732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005635784,0.00046912694,0.00037307898,0.00037178112,0.00019522576,0.0003074431,0.0003706805,0.00039994027,0.0011152453],"category_scores_gemma":[0.00040969616,0.00015346198,0.0002579695,0.00021862735,0.00025895497,0.00026876535,0.00013062287,0.0005080611,0.00029405527],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025885138,0.0024728822,0.0013611731,0.0001773525,0.000057459332,0.000096966,0.000063757754,0.0018999812,0.97315466,0.00013286839,0.00027221098,0.017722258],"study_design_scores_gemma":[0.00050199754,0.052628614,0.0036503149,0.000015749145,0.000117595955,0.00034236163,0.000031021624,0.0031912178,0.93695974,0.000047155583,0.002504646,0.000009592937],"about_ca_topic_score_codex":0.0006749359,"about_ca_topic_score_gemma":0.00087827083,"teacher_disagreement_score":0.0011152453,"about_ca_system_score_codex":0.0005832207,"about_ca_system_score_gemma":0.0006408173,"threshold_uncertainty_score":0.004231572},"labels":[],"label_agreement":null},{"id":"W1867789233","doi":"10.1200/jco.2012.30.15_suppl.lba1","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lapatinib; Capecitabine; Medicine; Trastuzumab emtansine; Trastuzumab; Oncology; Internal medicine; Metastatic breast cancer; Breast cancer; Cancer; Gynecology; Colorectal cancer","score_opus":0.12002997400766796,"score_gpt":0.48375085071599894,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1867789233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7795911,0.066999316,0.003186059,0.005679206,0.0030475263,0.018301822,0.06385134,0.0007486811,0.058595005],"genre_scores_gemma":[0.86266005,0.025321843,0.0055012824,0.011209667,0.0019238817,0.008064967,0.04932524,0.0002938454,0.035699222],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99931264,0.0003878341,0.00004390616,0.00008096839,0.000064600004,0.00011004363],"domain_scores_gemma":[0.99851114,0.0004750416,0.00025662806,0.00013150161,0.00012406374,0.000501628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031634772,0.0015292852,0.0023875977,0.0004424829,0.00051569607,0.0011442134,0.0012054467,0.00141332,0.013416852],"category_scores_gemma":[0.0028889421,0.0005880497,0.0023180589,0.00050555076,0.0004433949,0.00076567597,0.00031653346,0.0038559057,0.0029936314],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7873456,0.033567153,0.0032707795,0.0031066847,0.004562411,0.00030577285,0.00017469021,0.0023073838,0.017051209,0.0003394422,0.0477806,0.10018831],"study_design_scores_gemma":[0.74785024,0.19878069,0.024858179,0.00027698942,0.004438878,0.00040708444,0.000071829556,0.00063955144,0.004205987,0.00034006656,0.018080102,0.0000503469],"about_ca_topic_score_codex":0.0011473037,"about_ca_topic_score_gemma":0.0042443955,"teacher_disagreement_score":0.013416852,"about_ca_system_score_codex":0.0008636374,"about_ca_system_score_gemma":0.0012148913,"threshold_uncertainty_score":0.044883847},"labels":[],"label_agreement":null},{"id":"W1889879569","doi":"10.14740/wjon934w","title":"FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?","year":2015,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Genotype; Oncology; Internal medicine; Single-nucleotide polymorphism; Allele; Cancer; Gene; Genetics; Biology","score_opus":0.02091081476966107,"score_gpt":0.33976451593695634,"score_spread":0.3188537011672953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1889879569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991848,0.000406919,0.00006305283,0.00008643487,0.000007694222,0.0000018237737,0.000046236008,0.000001980951,0.00020091784],"genre_scores_gemma":[0.9997416,0.000055645898,0.000047805537,0.000029747462,0.000015094874,0.0000014052503,0.000052453062,9.591304e-7,0.000055329456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996717,0.00012679923,0.000033814882,0.0000617075,0.000064621614,0.0000413628],"domain_scores_gemma":[0.9984112,0.0009739681,0.00030350013,0.000074691925,0.00008087754,0.00015565635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009042266,0.00026076235,0.00032868734,0.00035035776,0.00017011068,0.00035647702,0.00024542026,0.00056351366,0.001229574],"category_scores_gemma":[0.0022083204,0.000102987935,0.00031794558,0.00040222213,0.00033993606,0.00019587387,0.00014238527,0.0005444779,0.00018150998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007222576,0.00003225055,0.99527043,0.00000810882,0.00006442128,0.00010877455,0.00003193257,0.00012157961,0.0010661365,0.000016109128,0.000047965645,0.0025101155],"study_design_scores_gemma":[0.000033338594,0.00029427314,0.99692184,0.000009405098,0.00012801203,0.0007046184,0.00008946504,0.0008078143,0.00063519,0.000101104895,0.0002707173,0.0000042362476],"about_ca_topic_score_codex":0.00056809135,"about_ca_topic_score_gemma":0.0006783812,"teacher_disagreement_score":0.001229574,"about_ca_system_score_codex":0.00014281891,"about_ca_system_score_gemma":0.00016887514,"threshold_uncertainty_score":0.0047820807},"labels":[],"label_agreement":null},{"id":"W1900170853","doi":"10.1038/sj.bjc.6603295","title":"Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours","year":2006,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Medical Research and Materiel Command; Canadian Institutes of Health Research; Strong; CancerCare Manitoba Foundation; Manitoba Health Research Council","keywords":"Oestrogen receptor; Phenotype; Estrogen receptor; Basal (medicine); Receptor; Progesterone receptor; Internal medicine; Breast cancer; Tissue microarray; Biology; Mammary gland; Gene isoform; Estrogen receptor alpha; Endocrinology; Estrogen; Cancer research; Immunohistochemistry; Medicine; Gene; Cancer; Genetics","score_opus":0.018497775031478175,"score_gpt":0.3388497727771877,"score_spread":0.32035199774570955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1900170853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955271,0.0023020674,0.00047490376,0.00001950429,0.000006727087,0.0000074303875,0.0002715546,0.0000115094745,0.0013791035],"genre_scores_gemma":[0.99489224,0.0014913166,0.00054000394,0.000027133288,0.0000058404667,0.00001967529,0.0008144533,0.0000044818053,0.0022049448],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99993527,0.000009245467,0.000007885775,0.000012889125,0.000022623923,0.000012048453],"domain_scores_gemma":[0.9999285,0.000017755077,0.00001656585,0.000008359802,0.000016303948,0.0000124668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010894479,0.00009557846,0.00010101698,0.00045892494,0.00011612678,0.00025284593,0.000063427884,0.0001375292,0.000902288],"category_scores_gemma":[0.00018043512,0.00012467903,0.00008437335,0.00034567362,0.0001031514,0.000107579726,0.00008367315,0.00010495231,0.00044589903],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033955552,0.000021339729,0.028080598,0.000092614086,0.00002323716,0.00037442107,0.00014679728,0.000083667306,0.9660994,0.000069934125,0.00009167855,0.004576742],"study_design_scores_gemma":[0.000034370198,0.00066389906,0.7900259,0.000043104126,0.00009971187,0.008776858,0.0006055795,0.0010346255,0.1904967,0.00017589342,0.00802834,0.00001499974],"about_ca_topic_score_codex":0.00065622275,"about_ca_topic_score_gemma":0.00081626925,"teacher_disagreement_score":0.000902288,"about_ca_system_score_codex":0.000111458634,"about_ca_system_score_gemma":0.00009074821,"threshold_uncertainty_score":0.0030184984},"labels":[],"label_agreement":null},{"id":"W1915169570","doi":"10.1186/1472-6890-6-2","title":"Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer","year":2006,"lang":"en","type":"article","venue":"BMC Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"Manitoba Medical Service Foundation","keywords":"Medicine; Breast cancer; Immunohistochemistry; Oncology; Cancer; Internal medicine; Pathology","score_opus":0.09186309284021754,"score_gpt":0.4781727390351837,"score_spread":0.38630964619496616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1915169570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8330596,0.016925247,0.14126107,0.00064866705,0.00039681102,0.0006495755,0.00044538165,0.000663511,0.0059500514],"genre_scores_gemma":[0.88156086,0.0038163995,0.11053527,0.00031688568,0.00013206711,0.0005087302,0.00050839817,0.00009858803,0.0025227312],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9928351,0.0036377711,0.0005016918,0.00095718546,0.0018048204,0.00026345128],"domain_scores_gemma":[0.9901918,0.0066297,0.0011526109,0.00063524896,0.0012246321,0.00016595893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008444162,0.0006838419,0.00056752877,0.0012562901,0.00023558016,0.000985174,0.0006883952,0.00079647906,0.0015099361],"category_scores_gemma":[0.008875004,0.00053167413,0.0003609792,0.000540079,0.0012551934,0.00096130447,0.0004953709,0.0007307224,0.0010290449],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024247481,0.00050819956,0.053886298,0.00071776996,0.000104662686,0.00080856774,0.0006712058,0.0016165426,0.87475824,0.00062918285,0.00037723998,0.06349728],"study_design_scores_gemma":[0.00013126784,0.004492724,0.10121628,0.00019436685,0.00032939855,0.007946068,0.0007582249,0.02355664,0.8503424,0.0013818202,0.009493358,0.00015743265],"about_ca_topic_score_codex":0.00050757587,"about_ca_topic_score_gemma":0.0012568041,"teacher_disagreement_score":0.008444162,"about_ca_system_score_codex":0.0003981548,"about_ca_system_score_gemma":0.00058295915,"threshold_uncertainty_score":0.04465753},"labels":[],"label_agreement":null},{"id":"W1930155869","doi":"","title":"Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Epidermal growth factor; Epidermal growth factor receptor; Toxicity; Breast cancer; Cancer; Medicine; Internal medicine; Endocrinology; Cancer research; Pathology; Receptor","score_opus":0.033976140266475524,"score_gpt":0.31475742855074706,"score_spread":0.2807812882842715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1930155869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952716,0.0019977372,0.0013873474,0.000048308393,0.000018659623,0.000033484877,0.00013332196,0.000075119075,0.0010344962],"genre_scores_gemma":[0.99447757,0.0010588624,0.0020719504,0.000031881766,0.000012562388,0.000036435922,0.00030673365,0.000023191846,0.0019806942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989736,0.000029769522,0.0000049613504,0.000018867915,0.000022241233,0.000026683549],"domain_scores_gemma":[0.99987817,0.000031065534,0.000040910494,0.000011965243,0.000012150759,0.000025713127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016156751,0.00039751918,0.00023796313,0.00020758757,0.0000920411,0.00015806727,0.00018706362,0.0003688508,0.0010053555],"category_scores_gemma":[0.000103987295,0.00011747487,0.00014381885,0.00009901884,0.00026425472,0.00021486582,0.00008099768,0.00046383528,0.00017449491],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005556597,0.00014002113,0.00035491542,0.00003262484,0.0000062499344,0.000044300563,0.000014608539,0.00011075094,0.9966698,0.000048583017,0.00003951327,0.0019829054],"study_design_scores_gemma":[0.00004867226,0.0046103997,0.0025464774,0.000004884387,0.000022136557,0.00027848105,0.000008729994,0.0005510025,0.9910573,0.000019725534,0.00084956514,0.0000026493062],"about_ca_topic_score_codex":0.00039446805,"about_ca_topic_score_gemma":0.0004906055,"teacher_disagreement_score":0.0010053555,"about_ca_system_score_codex":0.00025532974,"about_ca_system_score_gemma":0.00014569396,"threshold_uncertainty_score":0.0033632517},"labels":[],"label_agreement":null},{"id":"W1932286144","doi":"10.1111/his.12723","title":"Impact of the 2013 <scp>A</scp>merican <scp>S</scp>ociety of <scp>C</scp>linical <scp>O</scp>ncology/<scp>C</scp>ollege of <scp>A</scp>merican <scp>P</scp>athologists guideline recommendations for human epidermal growth factor receptor 2 (<scp>HER</scp>2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for <scp>HER</scp>2 gene amplification by fluorescence <i>in‐situ</i> hybridization","year":2015,"lang":"en","type":"article","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Pathological; Oncology; Cancer","score_opus":0.07644435501988396,"score_gpt":0.36364471400517234,"score_spread":0.2872003589852884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1932286144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9004696,0.018574977,0.0020507493,0.032741304,0.0010659478,0.0003075936,0.006098494,0.00008827655,0.038603067],"genre_scores_gemma":[0.97199655,0.0093964115,0.0035040793,0.008237072,0.0003856721,0.00011710569,0.0036467721,0.00006253694,0.002653927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921292,0.001564963,0.001408595,0.00066875183,0.0036697297,0.0005587923],"domain_scores_gemma":[0.97931826,0.004690212,0.0038631114,0.00079292356,0.010439437,0.0008960784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00781397,0.00018061516,0.00023814698,0.0010662469,0.0004580735,0.001654903,0.0007437447,0.0006671924,0.0015554915],"category_scores_gemma":[0.019656189,0.00023819762,0.00025138157,0.0013835357,0.000649866,0.0005248889,0.0010355863,0.00071720436,0.00025732938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025449038,0.00018961854,0.8042099,0.0006019437,0.000112581765,0.00096953585,0.00064988004,0.0010525452,0.004044037,0.0010874941,0.041185495,0.14564247],"study_design_scores_gemma":[0.000022453602,0.00021998037,0.9117443,0.0006315623,0.00015600238,0.0017922327,0.0015076166,0.0008921958,0.0038447613,0.00015700626,0.07899966,0.000032266584],"about_ca_topic_score_codex":0.08051539,"about_ca_topic_score_gemma":0.13435988,"teacher_disagreement_score":0.08051539,"about_ca_system_score_codex":0.004169268,"about_ca_system_score_gemma":0.0076209106,"threshold_uncertainty_score":0.16009349},"labels":[],"label_agreement":null},{"id":"W1941265576","doi":"10.1007/s00280-015-2761-4","title":"A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"Symphogen; Merck KGaA","keywords":"Medicine; Tolerability; Cetuximab; Internal medicine; Epidermal growth factor receptor; Adverse effect; Oncology; Head and neck cancer; Antibody; Head and neck squamous-cell carcinoma; Monoclonal antibody; Gastroenterology; Cancer; Immunology","score_opus":0.0269664643091963,"score_gpt":0.35541487793565163,"score_spread":0.3284484136264553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1941265576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99066985,0.0015796479,0.0007380165,0.0009378354,0.0004892718,0.0018819994,0.0006081626,0.00012650572,0.0029687444],"genre_scores_gemma":[0.9867203,0.0020848345,0.0016726119,0.00084552966,0.0002741446,0.0014649078,0.0010492719,0.000025423467,0.0058628735],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996307,0.00019293666,0.00001455713,0.000050429364,0.000029607356,0.000081870785],"domain_scores_gemma":[0.99958676,0.00013078883,0.00004595553,0.000035076006,0.000026186395,0.00017512198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012192351,0.0011024441,0.0017015752,0.00042260738,0.0003632838,0.0008707867,0.0009301131,0.001411387,0.008989709],"category_scores_gemma":[0.0010141582,0.00043803555,0.0014615156,0.00031487233,0.00082413334,0.00094092276,0.0004101979,0.0032329378,0.0011346585],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86470485,0.027248338,0.0014081845,0.0006427395,0.0007545099,0.00019478097,0.000109188884,0.0013543024,0.017164119,0.00053064205,0.0022547513,0.08363355],"study_design_scores_gemma":[0.5477577,0.44117743,0.0040814923,0.000035095385,0.00042648605,0.00011783672,0.00007608067,0.00079271756,0.0024600446,0.00025726104,0.0027923798,0.000025475303],"about_ca_topic_score_codex":0.001002225,"about_ca_topic_score_gemma":0.0031522557,"teacher_disagreement_score":0.008989709,"about_ca_system_score_codex":0.0011479056,"about_ca_system_score_gemma":0.0018602906,"threshold_uncertainty_score":0.030073643},"labels":[],"label_agreement":null},{"id":"W1941925635","doi":"10.1158/1538-7445.sabcs14-ot3-1-10","title":"Abstract OT3-1-10: HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Vinorelbine; Capecitabine; Internal medicine; Anthracycline; Oncology; Metastatic breast cancer; Taxane; Trastuzumab emtansine; Chemotherapy; Breast cancer; Lapatinib; Cancer; Colorectal cancer","score_opus":0.14428242805559724,"score_gpt":0.4836444026667105,"score_spread":0.3393619746111133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1941925635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833174,0.0023546692,0.0005939234,0.000986818,0.0006084638,0.0056723184,0.0019583881,0.00019749087,0.004310439],"genre_scores_gemma":[0.9726054,0.0020391757,0.002412477,0.0019478131,0.00071249396,0.008459631,0.0028241104,0.000039276798,0.008959632],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996124,0.0001958363,0.000017880846,0.00008514317,0.000025388299,0.00006335068],"domain_scores_gemma":[0.99933845,0.000174965,0.00014491721,0.000040546933,0.0000299468,0.0002712786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016293841,0.0020667277,0.0017263629,0.00042584824,0.0003282943,0.0010300399,0.0010804875,0.001714653,0.009246685],"category_scores_gemma":[0.0013624935,0.00054988783,0.0013670946,0.00029496782,0.0012202691,0.0011923925,0.00042838583,0.0033806616,0.0012916249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96747255,0.0122142155,0.00043905634,0.0004531739,0.00036842248,0.00005145994,0.000055805463,0.00045679635,0.0044396203,0.00022564664,0.0015869534,0.012236373],"study_design_scores_gemma":[0.9218074,0.07573878,0.0008474126,0.000025366266,0.00013869847,0.000024581606,0.000015630354,0.00033248335,0.0003506778,0.00011189485,0.00059596886,0.000011179229],"about_ca_topic_score_codex":0.0008657549,"about_ca_topic_score_gemma":0.0023355747,"teacher_disagreement_score":0.009246685,"about_ca_system_score_codex":0.00076496636,"about_ca_system_score_gemma":0.0012605649,"threshold_uncertainty_score":0.030933201},"labels":[],"label_agreement":null},{"id":"W1963526316","doi":"10.1371/journal.pone.0064817","title":"Odin (ANKS1A) Modulates EGF Receptor Recycling and Stability","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto; Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"HEK 293 cells; Endosome; Cell biology; Internalization; Epidermal growth factor receptor; Receptor; Endocytic cycle; Epidermal growth factor; Gene knockdown; Phosphorylation; Receptor tyrosine kinase; Biology; MAPK/ERK pathway; Tyrosine kinase; Signal transduction; Chemistry; Cell culture; Endocytosis; Biochemistry; Intracellular","score_opus":0.1547145327569723,"score_gpt":0.32065561314635765,"score_spread":0.16594108038938535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963526316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737823,0.0009281579,0.00073505554,0.000059166785,0.000014115803,0.000006539608,0.00014811284,0.000030233708,0.000700453],"genre_scores_gemma":[0.9978058,0.00048247437,0.00046610413,0.00002750064,0.0000032555092,0.0000073492324,0.00016809162,0.000010665409,0.0010287554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991214,0.000010735415,0.000008487805,0.000018565486,0.000018220868,0.000031796157],"domain_scores_gemma":[0.999931,0.000007400596,0.000027217236,0.000004824918,0.0000064933797,0.000023217744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117554664,0.00019859373,0.00019472679,0.00016542626,0.00019294678,0.00032166246,0.00018054269,0.00021537406,0.0009885009],"category_scores_gemma":[0.00011087401,0.000098172204,0.000174882,0.00012973706,0.00024070255,0.00028905584,0.00023434129,0.0004262989,0.000213335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022965591,0.000022819917,0.0004134398,0.0000291581,0.0000039536612,0.000043965527,0.0000081777425,0.00007795532,0.99722856,0.0001013257,0.00004085251,0.0018001591],"study_design_scores_gemma":[0.000024633679,0.0001992374,0.011440882,0.0000054508146,0.00001619227,0.0002168135,0.00003870092,0.0011711189,0.98492175,0.00009029808,0.0018680717,0.0000068694862],"about_ca_topic_score_codex":0.0003827678,"about_ca_topic_score_gemma":0.00062589464,"teacher_disagreement_score":0.0009885009,"about_ca_system_score_codex":0.00041628114,"about_ca_system_score_gemma":0.0001624519,"threshold_uncertainty_score":0.0033069253},"labels":[],"label_agreement":null},{"id":"W1963612017","doi":"10.1097/00129039-200409000-00011","title":"Her2 Amplification","year":2004,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Sept Iles","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Immunohistochemistry; Concordance; Fish <Actinopterygii>; Fluorescence in situ hybridization; Gene duplication; Biology; Molecular biology; In situ hybridization; Pathology; Medicine; Gene; Bioinformatics; Genetics; Gene expression; Chromosome; Fishery","score_opus":0.013604345253688015,"score_gpt":0.3185765279131056,"score_spread":0.30497218265941756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963612017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64515483,0.0358636,0.040599085,0.0014350758,0.00081391446,0.0010597855,0.0061646868,0.0022058715,0.2667031],"genre_scores_gemma":[0.9029863,0.010123783,0.016775334,0.0009131319,0.00013717529,0.000323192,0.00511141,0.00018937288,0.06344027],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999556,0.00006861878,0.00003042815,0.000093082876,0.00017908533,0.000072849376],"domain_scores_gemma":[0.99976903,0.000058517224,0.000033493812,0.000034533496,0.00007240543,0.000031952033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005236918,0.0003691486,0.00032171767,0.001628245,0.00022370902,0.00039836246,0.00031603864,0.00041830871,0.012065721],"category_scores_gemma":[0.0008479588,0.00012566817,0.00028014314,0.0007780841,0.00025463445,0.00032968784,0.0004443524,0.00031863808,0.003560514],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093323376,0.00012832266,0.088928744,0.00091550074,0.00013743635,0.007909979,0.0003284311,0.0003977772,0.5043548,0.0027499776,0.021979887,0.37123597],"study_design_scores_gemma":[0.00011623263,0.00087196595,0.30088434,0.00028085453,0.00022694579,0.09309778,0.00040041795,0.0031942588,0.26772362,0.0028795206,0.33024454,0.000079438134],"about_ca_topic_score_codex":0.00067471084,"about_ca_topic_score_gemma":0.0012137821,"teacher_disagreement_score":0.012065721,"about_ca_system_score_codex":0.00030249805,"about_ca_system_score_gemma":0.00013333722,"threshold_uncertainty_score":0.04036379},"labels":[],"label_agreement":null},{"id":"W1964407943","doi":"10.1007/s10549-012-2369-x","title":"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer","year":2012,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Center for Research Resources; GlaxoSmithKline","keywords":"Lapatinib; Pazopanib; Medicine; Clinical endpoint; Internal medicine; Cohort; Adverse effect; Breast cancer; Oncology; Cancer; Pharmacology; Randomized controlled trial; Trastuzumab; Sunitinib","score_opus":0.07212824753998884,"score_gpt":0.4215965446262711,"score_spread":0.34946829708628224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964407943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698953,0.004244644,0.0019760467,0.0012726977,0.00097265036,0.016762896,0.0017264728,0.00019825864,0.0029511394],"genre_scores_gemma":[0.9622519,0.003527656,0.00484586,0.0024072472,0.00079324737,0.019883176,0.0018772887,0.000050060124,0.004363682],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99883085,0.00073871406,0.00005482167,0.00016598358,0.00007899411,0.00013078893],"domain_scores_gemma":[0.9986162,0.00033963125,0.00034453615,0.000111079455,0.00008388348,0.00050462503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002980293,0.002024104,0.003068432,0.0006507334,0.0004736902,0.0010164672,0.0009231102,0.001618854,0.0048508435],"category_scores_gemma":[0.0023805029,0.0010109537,0.0019957104,0.00056220545,0.0009933548,0.0011054856,0.0005477246,0.0036575033,0.0009618234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9492108,0.021039246,0.0008743967,0.00039944894,0.0008223501,0.000049510883,0.000058129433,0.0007100343,0.0052900854,0.00014530701,0.0010883978,0.020312263],"study_design_scores_gemma":[0.90266436,0.09498002,0.00081924244,0.000012042054,0.00020977546,0.000027088605,0.000009714397,0.00038100674,0.00028685405,0.00011633616,0.0004826393,0.000010901097],"about_ca_topic_score_codex":0.0005942199,"about_ca_topic_score_gemma":0.0019829292,"teacher_disagreement_score":0.0048508435,"about_ca_system_score_codex":0.000842868,"about_ca_system_score_gemma":0.0017462025,"threshold_uncertainty_score":0.016227663},"labels":[],"label_agreement":null},{"id":"W1964525628","doi":"10.1016/s1470-2045(14)70181-0","title":"When is downstream pathway inhibition important?","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Lapatinib; Oncology; Internal medicine; Trastuzumab emtansine; Breast cancer; Vinorelbine; Taxane; Cancer; Everolimus; Metastatic breast cancer; Context (archaeology); Neratinib; Clinical trial; Chemotherapy","score_opus":0.0997091515519647,"score_gpt":0.3847506483452985,"score_spread":0.2850414967933338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964525628","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007943455,0.0016414983,0.000036175592,0.9866219,0.010423416,0.000003980619,0.000020587186,0.00000853379,0.0011644408],"genre_scores_gemma":[0.0012344081,0.0016582106,0.00009462766,0.9610264,0.033406544,0.000018911964,0.000015673546,0.000010386152,0.0025348586],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99225813,0.0023544133,0.0008437982,0.00092430675,0.002357008,0.0012623497],"domain_scores_gemma":[0.97755367,0.013860117,0.0014243674,0.00053687405,0.0026417577,0.003983085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073482855,0.0012126068,0.0028850646,0.001054028,0.0046167825,0.0069784317,0.002567769,0.098251395,0.0116196405],"category_scores_gemma":[0.048997115,0.0013088619,0.0024326053,0.0010123686,0.006551615,0.006961702,0.0036419753,0.09040751,0.008794937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092174894,0.000033393437,0.00031916203,0.00007746338,0.000028819522,0.000627305,0.00005634468,0.000068014204,0.00014882014,0.004614852,0.98035973,0.013573898],"study_design_scores_gemma":[0.00047769796,0.00015570292,0.0007102182,0.0007589353,0.00009147394,0.001244214,0.00032123073,0.0004081492,0.00036201667,0.031776432,0.9635894,0.00010440367],"about_ca_topic_score_codex":0.004120746,"about_ca_topic_score_gemma":0.009374036,"teacher_disagreement_score":0.098251395,"about_ca_system_score_codex":0.0071864147,"about_ca_system_score_gemma":0.007167242,"threshold_uncertainty_score":0.05214131},"labels":[],"label_agreement":null},{"id":"W1964775486","doi":"10.1371/journal.pone.0031723","title":"Specific and Sensitive Hydrolysis Probe-Based Real-Time PCR Detection of Epidermal Growth Factor Receptor Variant III in Oral Squamous Cell Carcinoma","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"Health Research Board; University of Calgary; Cancer Research Institute","keywords":"Epidermal growth factor receptor; Basal cell; Epidermal growth factor; Cancer research; Receptor; Chemistry; Biology; Molecular biology; Medicine; Pathology; Biochemistry","score_opus":0.050617691737500504,"score_gpt":0.2618416511089167,"score_spread":0.21122395937141622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964775486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8688614,0.0022975723,0.12480748,0.00014080458,0.00008705167,0.00026146192,0.0010782831,0.0005487019,0.0019172793],"genre_scores_gemma":[0.87587345,0.0010621167,0.11792162,0.00023960063,0.000053163425,0.0005810439,0.0017862038,0.000058436282,0.0024243167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854666,0.00025375446,0.00011665388,0.00060207536,0.00037144366,0.0001094362],"domain_scores_gemma":[0.99927837,0.00032317257,0.0001746982,0.000052659667,0.00013930081,0.000031815965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008142515,0.00059740996,0.00039280474,0.00072089984,0.00011469513,0.00040669518,0.0004039605,0.00063948694,0.0009617795],"category_scores_gemma":[0.0013343387,0.0003119867,0.0002962061,0.00031753816,0.00043211054,0.0002564755,0.0002319251,0.00053743925,0.00062944775],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000148667,0.000055338805,0.0056785517,0.00009066138,0.000015044016,0.000088108995,0.0000887749,0.00018561729,0.98427504,0.00007342956,0.00008961788,0.009211162],"study_design_scores_gemma":[0.000030885487,0.0013767295,0.048645947,0.00004336817,0.00010331878,0.0029323208,0.00020616407,0.009845722,0.9328808,0.00032629556,0.0035650132,0.00004338728],"about_ca_topic_score_codex":0.00018469755,"about_ca_topic_score_gemma":0.00043293988,"teacher_disagreement_score":0.0009617795,"about_ca_system_score_codex":0.00025337032,"about_ca_system_score_gemma":0.00023857424,"threshold_uncertainty_score":0.004306197},"labels":[],"label_agreement":null},{"id":"W1964896818","doi":"10.1159/000055406","title":"Role of Herceptin&lt;sup&gt;®&lt;/sup&gt; in Primary Breast Cancer: Views from North America and Europe","year":2001,"lang":"en","type":"review","venue":"Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Oncology; Tamoxifen; Internal medicine; Population; Adjuvant; Regimen; Clinical trial; Adjuvant therapy; Asymptomatic; Trastuzumab; Antiestrogen; Cancer; Metastatic breast cancer","score_opus":0.06729062533461543,"score_gpt":0.40555167360208066,"score_spread":0.3382610482674652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964896818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005505639,0.9987412,0.00002314039,0.0005300971,0.00014406112,0.0000016261815,0.000005352913,0.0000021053927,0.0004973506],"genre_scores_gemma":[0.00038416483,0.99867356,0.00007017678,0.0003568753,0.000111859656,0.0000027063804,0.000006874672,9.0251615e-7,0.00039293032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969697,0.000079333004,0.00004539725,0.000051808463,0.0001035747,0.000022993176],"domain_scores_gemma":[0.9992405,0.0003564825,0.00012372436,0.000021485186,0.0001919602,0.00006578349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018329185,0.0007361005,0.0015161559,0.0016491596,0.00021011315,0.0009708663,0.00083637837,0.0013416448,0.0028487837],"category_scores_gemma":[0.0014260474,0.00021045079,0.0005920302,0.0028799141,0.00044524705,0.0015991848,0.00048709993,0.0015297505,0.0014069818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017971639,0.00004056282,0.00014977095,0.014613155,0.00011332972,0.00014226056,0.00004969467,0.0002743622,0.00083745795,0.0018491183,0.047753807,0.9339968],"study_design_scores_gemma":[0.00009447804,0.00016805436,0.0014551738,0.01017114,0.0002727901,0.0010940264,0.00007879525,0.00008569792,0.00039261547,0.001469415,0.9847023,0.000015532094],"about_ca_topic_score_codex":0.0021711148,"about_ca_topic_score_gemma":0.005717801,"teacher_disagreement_score":0.0028487837,"about_ca_system_score_codex":0.0009819004,"about_ca_system_score_gemma":0.0014881301,"threshold_uncertainty_score":0.009693503},"labels":[],"label_agreement":null},{"id":"W1965229389","doi":"10.1038/sj.onc.1209574","title":"Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4","year":2006,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal University Hospital","funders":"Medical Research and Materiel Command; U.S. Army Materiel Command; National Cancer Institute; U.S. Army Medical Command; U.S. Army","keywords":"ERBB4; Biology; ERBB3; ErbB; Carcinogenesis; Receptor tyrosine kinase; Mammary gland; Cancer research; Epidermal growth factor receptor; Internal medicine; Breast cancer; Receptor; Cancer; Medicine; Genetics","score_opus":0.023243280609411266,"score_gpt":0.32484009203234593,"score_spread":0.30159681142293465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965229389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915371,0.0010145623,0.0014745999,0.00022878333,0.000058149642,0.00002432873,0.0010208413,0.00026916034,0.004372486],"genre_scores_gemma":[0.9839829,0.00046640658,0.0010726595,0.000072215946,0.000010574645,0.000034773526,0.0014182789,0.00009916274,0.012842939],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999554,0.000060165446,0.0000357256,0.00007223972,0.00012751282,0.00015032952],"domain_scores_gemma":[0.99949384,0.000091098875,0.00012497448,0.00008544427,0.000036323512,0.0001683206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026737215,0.00061081,0.00043061186,0.0010086889,0.000319287,0.00077288755,0.00058162416,0.00053416844,0.004178488],"category_scores_gemma":[0.00025981982,0.00045948764,0.0004463315,0.00033450653,0.0006258192,0.0004970277,0.0004612012,0.0012005046,0.0011443753],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030445447,0.000068019064,0.0001463826,0.000012362469,0.000007259035,0.00008366496,0.00000998982,0.000066208675,0.99842846,0.00020156575,0.000053988908,0.00061768206],"study_design_scores_gemma":[0.00002175348,0.00011450238,0.0028737236,0.0000035559804,0.000011927007,0.00041141876,0.000034011504,0.0006802681,0.9936488,0.00007707227,0.0021178802,0.000004983974],"about_ca_topic_score_codex":0.0025415993,"about_ca_topic_score_gemma":0.002386049,"teacher_disagreement_score":0.004178488,"about_ca_system_score_codex":0.00078936445,"about_ca_system_score_gemma":0.0006458354,"threshold_uncertainty_score":0.013978481},"labels":[],"label_agreement":null},{"id":"W1966524957","doi":"10.1016/j.febslet.2014.09.017","title":"Amphiregulin induces human ovarian cancer cell invasion by down‐regulating E‐cadherin expression","year":2014,"lang":"en","type":"article","venue":"FEBS Letters","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; China Scholarship Council","keywords":"Amphiregulin; Cadherin; Epidermal growth factor receptor; Epidermal growth factor; Cancer research; Ovarian cancer; Biology; Cell biology; Slug; Cell growth; Cell; Cancer; Receptor","score_opus":0.03545871640016448,"score_gpt":0.32488384708821466,"score_spread":0.2894251306880502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966524957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781406,0.00080555445,0.00026159297,0.000051639527,0.000010522599,0.000014507192,0.00006850703,0.000019015155,0.00095463963],"genre_scores_gemma":[0.9974923,0.0005570833,0.0004276168,0.00005158247,0.000004783872,0.00001937304,0.0002939441,0.0000046359764,0.0011486195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999465,0.000012975528,0.0000048757265,0.0000049883056,0.000014827933,0.000015939333],"domain_scores_gemma":[0.9999722,0.0000086437385,0.0000054461643,0.0000039231736,0.0000029650153,0.0000067476903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057305348,0.00014975927,0.00011651444,0.00014829845,0.00007927475,0.0001052009,0.000054038752,0.00011598867,0.0008323546],"category_scores_gemma":[0.000051386367,0.000057455934,0.00011819467,0.000092093156,0.00008164754,0.00006853231,0.00010069086,0.00030278225,0.00012841444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012628493,0.000056879562,0.00031545578,0.00003098877,0.0000047632443,0.00007221697,0.000012200883,0.000027044227,0.9972191,0.000042751166,0.00006710787,0.0020252177],"study_design_scores_gemma":[0.00005049353,0.00078585633,0.014782458,0.000005525139,0.000014320545,0.000451113,0.00003657057,0.00054021005,0.9793115,0.000037653946,0.003981313,0.0000029715916],"about_ca_topic_score_codex":0.00031214228,"about_ca_topic_score_gemma":0.00066883944,"teacher_disagreement_score":0.0008323546,"about_ca_system_score_codex":0.00010166317,"about_ca_system_score_gemma":0.00008970303,"threshold_uncertainty_score":0.0027844906},"labels":[],"label_agreement":null},{"id":"W1966679991","doi":"10.1016/j.clon.2013.08.011","title":"Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial","year":2013,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Taxane; Breast cancer; Metastatic breast cancer; Adjuvant; Docetaxel; Adjuvant therapy; Cancer","score_opus":0.12712808958940675,"score_gpt":0.45457163262624756,"score_spread":0.3274435430368408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966679991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448484,0.0032072843,0.00011570258,0.00040816018,0.00011203856,0.00015064579,0.00031885479,0.000019675863,0.0011827357],"genre_scores_gemma":[0.9934343,0.0021958216,0.00026010367,0.00071092555,0.00016814069,0.00015569481,0.0012640009,0.000015140211,0.0017958678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994362,0.00025223556,0.000029065392,0.00007271488,0.000068297915,0.00014143669],"domain_scores_gemma":[0.9994229,0.00016967482,0.00012542123,0.000057881767,0.000034059012,0.00019002862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018216617,0.00076530874,0.0016118706,0.0002520966,0.00029874808,0.00078887533,0.00052370876,0.0007434839,0.001072923],"category_scores_gemma":[0.0016820504,0.00021055216,0.0014182532,0.00032202824,0.0004948954,0.00075092487,0.00032138627,0.0021765293,0.000227937],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66922176,0.01402804,0.026319802,0.00059587235,0.0030505373,0.00046109184,0.0004677022,0.0041035768,0.011223397,0.00029451933,0.006377514,0.26385617],"study_design_scores_gemma":[0.403911,0.3607894,0.20604283,0.00020789342,0.005743114,0.0010857843,0.00032499182,0.004427409,0.005714614,0.0007115689,0.010960108,0.00008129958],"about_ca_topic_score_codex":0.0017358648,"about_ca_topic_score_gemma":0.004022579,"teacher_disagreement_score":0.0018216617,"about_ca_system_score_codex":0.0008814394,"about_ca_system_score_gemma":0.0007637445,"threshold_uncertainty_score":0.009634018},"labels":[],"label_agreement":null},{"id":"W1966937303","doi":"10.1073/pnas.1014835108","title":"Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 <sup>+</sup> breast cancer patients","year":2011,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":332,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba","funders":"National Cancer Institute; Instituto de Salud Carlos III; Breast Cancer Research Foundation","keywords":"Trastuzumab; Cancer research; Cyclin D; Cyclin E; Breast cancer; Cyclin E1; Cyclin D1; Cyclin A; Cyclin; Cyclin B; Cyclin A2; Cell cycle; Cancer; Biology; Medicine; Internal medicine","score_opus":0.0794277388188846,"score_gpt":0.3594816967174915,"score_spread":0.2800539578986069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966937303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982167,0.0007896591,0.0001625199,0.00006269789,0.0000022592956,0.000006707882,0.000066760134,0.000007992997,0.00068474666],"genre_scores_gemma":[0.99927336,0.00023385091,0.00011315864,0.000032370197,0.0000061232695,0.0000034204563,0.00009492008,0.000002005847,0.00024090787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999249,0.000016149343,0.000008548336,0.000016953474,0.000016989667,0.00001630885],"domain_scores_gemma":[0.99988663,0.000024141611,0.000049797345,0.000008816425,0.000011352646,0.000019282608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015021263,0.000092523595,0.00020408965,0.00021200033,0.000119697834,0.00034156928,0.00009067866,0.000138298,0.0009947105],"category_scores_gemma":[0.00031637534,0.00010404106,0.00010940484,0.000282536,0.00011299599,0.00012327427,0.000106821535,0.00021691395,0.00017475616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026585315,0.00018282128,0.7931931,0.000068150825,0.000093431736,0.0026672154,0.00016083424,0.00047699627,0.15628402,0.0003099356,0.00072606147,0.04317886],"study_design_scores_gemma":[0.000088497996,0.00088617636,0.9442764,0.0000114007025,0.00010404427,0.014816197,0.00017215492,0.0018247371,0.032892823,0.0002591168,0.004657448,0.000011014064],"about_ca_topic_score_codex":0.00039016863,"about_ca_topic_score_gemma":0.0004776521,"teacher_disagreement_score":0.0009947105,"about_ca_system_score_codex":0.00019688574,"about_ca_system_score_gemma":0.00010688216,"threshold_uncertainty_score":0.0033276677},"labels":[],"label_agreement":null},{"id":"W1967993118","doi":"10.5114/wo.2010.974","title":"New targeted therapies in the treatment of patients with metastatic melanoma","year":2010,"lang":"pl","type":"article","venue":"Współczesna Onkologia","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic melanoma; Melanoma; Oncology; Internal medicine; Targeted therapy; Cancer research; Cancer","score_opus":0.03216117638503764,"score_gpt":0.32580088293654336,"score_spread":0.29363970655150573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967993118","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010640611,0.8061639,0.0017085352,0.07799325,0.008989033,0.00018601514,0.0009702436,0.0003300938,0.093018316],"genre_scores_gemma":[0.08050387,0.80052644,0.0057335566,0.027690222,0.008618271,0.00025634436,0.0016393253,0.00011414811,0.07491784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994417,0.0001706644,0.00004277957,0.000041521078,0.0002572916,0.00004599533],"domain_scores_gemma":[0.9993272,0.00018992164,0.00012499404,0.00003425745,0.00018759964,0.00013610822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012335153,0.00023048276,0.00043256575,0.0009613118,0.00032643857,0.0009812827,0.00032522867,0.00068141555,0.013716403],"category_scores_gemma":[0.002873289,0.00012224451,0.000517919,0.0006188066,0.00019315534,0.0009867953,0.0005842653,0.0012065403,0.0058832183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002135468,0.000109361914,0.0023164982,0.0010489142,0.000041466923,0.00027922416,0.00011377437,0.00008010891,0.0009886656,0.0011717485,0.29260337,0.7010333],"study_design_scores_gemma":[0.00011760421,0.00032942867,0.007110758,0.001432143,0.00009630558,0.0016625044,0.00013332022,0.00014548867,0.0006684926,0.0013913807,0.9868989,0.000013825818],"about_ca_topic_score_codex":0.0009484387,"about_ca_topic_score_gemma":0.0031702602,"teacher_disagreement_score":0.013716403,"about_ca_system_score_codex":0.00054399285,"about_ca_system_score_gemma":0.0007738412,"threshold_uncertainty_score":0.04588592},"labels":[],"label_agreement":null},{"id":"W1968993470","doi":"10.1089/cbr.2008.0553","title":"<sup>111</sup> In-Labeled Immunoconjugates (ICs) Bispecific for the Epidermal Growth Factor Receptor (EGFR) and Cyclin-Dependent Kinase Inhibitor, p27 <sup>Kip1</sup>","year":2009,"lang":"en","type":"article","venue":"Cancer Biotherapy and Radiopharmaceuticals","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Internalization; Epidermal growth factor receptor; Molecular biology; Chemistry; Kinase; Epidermal growth factor; Trastuzumab; Cancer research; Receptor; Biology; Biochemistry; Cancer","score_opus":0.057479573944970046,"score_gpt":0.38831058519363243,"score_spread":0.3308310112486624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968993470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734115,0.0020895244,0.014381472,0.00020580838,0.00005856137,0.000072279305,0.00024549023,0.00021872218,0.009316732],"genre_scores_gemma":[0.9698855,0.0015241503,0.018611591,0.00015257492,0.000024100282,0.00008816374,0.00091089925,0.00009578419,0.008707277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998603,0.000025696365,0.00000871069,0.00003309115,0.0000398694,0.000032349508],"domain_scores_gemma":[0.9999223,0.000013689953,0.00002728738,0.0000068547197,0.000014872667,0.000014939094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014783128,0.0005767316,0.00022455808,0.0001646057,0.0001324383,0.00029307455,0.00020679281,0.0003009992,0.0016602491],"category_scores_gemma":[0.000099366174,0.0001731681,0.00012501738,0.00018039349,0.00025255705,0.000205582,0.00020493242,0.00031392576,0.0006835017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010619468,0.000016843269,0.00023355024,0.000068929425,0.000005593263,0.000053911415,0.000011825184,0.00016328288,0.9973187,0.00027253747,0.00013167417,0.001617004],"study_design_scores_gemma":[0.000006045593,0.00010988152,0.0005794445,0.0000028093714,0.000012062871,0.00019982831,0.0000072593275,0.00042833388,0.9957273,0.000015547059,0.0029093667,0.0000020631212],"about_ca_topic_score_codex":0.0002867275,"about_ca_topic_score_gemma":0.00034877995,"teacher_disagreement_score":0.0016602491,"about_ca_system_score_codex":0.0005068308,"about_ca_system_score_gemma":0.00019399439,"threshold_uncertainty_score":0.0055541396},"labels":[],"label_agreement":null},{"id":"W1969115197","doi":"10.1309/ajcpdyz1xmf4hjwk","title":"Canadian Association of Pathologists–Association canadienne des pathologistes National Standards Committee/Immunohistochemistry","year":2010,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University Health Network; Canadian Cancer Society; Jewish General Hospital; London Health Sciences Centre; Vancouver Hospital and Health Sciences Centre; McMaster University; Mount Sinai Hospital; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan","funders":"","keywords":"Immunohistochemistry; Medicine; Pathology; Anatomical pathology","score_opus":0.03934688866447082,"score_gpt":0.4371159760607226,"score_spread":0.3977690873962518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969115197","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012504294,0.048664354,0.075854406,0.18840863,0.028183227,0.011982412,0.021073192,0.0037603914,0.6095691],"genre_scores_gemma":[0.08651411,0.06691847,0.26710278,0.06552845,0.0051000575,0.0074773673,0.043151684,0.0018279481,0.45637912],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.949834,0.0059000463,0.0040087267,0.0020960274,0.035163812,0.002997368],"domain_scores_gemma":[0.7102364,0.010133045,0.004945653,0.007955756,0.25990683,0.0068223528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03484578,0.0010503578,0.0014823893,0.007157006,0.009045539,0.006396153,0.0060954066,0.0040235654,0.020572303],"category_scores_gemma":[0.055829383,0.0013070774,0.0017572547,0.008135371,0.0053196913,0.001652465,0.002456253,0.00724223,0.010575048],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016050253,0.000107933294,0.006819529,0.0012988467,0.000078998375,0.00037675872,0.0005263016,0.0004927821,0.0031130416,0.015060379,0.8434957,0.1284692],"study_design_scores_gemma":[0.000025892004,0.000026995827,0.013612196,0.00077466806,0.00004595987,0.00032336084,0.00024325645,0.000412129,0.0009834174,0.0018472077,0.98163855,0.000066295164],"about_ca_topic_score_codex":0.7297968,"about_ca_topic_score_gemma":0.8373802,"teacher_disagreement_score":0.7297968,"about_ca_system_score_codex":0.031671766,"about_ca_system_score_gemma":0.20228595,"threshold_uncertainty_score":0.5435889},"labels":[],"label_agreement":null},{"id":"W1969175190","doi":"10.1073/pnas.1220763110","title":"Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Alberta; Università degli Studi di Milano; European Commission; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Israel Cancer Research Fund","keywords":"Cetuximab; Epidermal growth factor receptor; Panitumumab; Monoclonal antibody; Triple-negative breast cancer; Cancer research; Antibody; EGFR inhibitors; Growth inhibition; Epidermal growth factor; Receptor; Chemistry; Breast cancer; Cell growth; Biology; Medicine; Cancer; Immunology; Internal medicine; Biochemistry","score_opus":0.073597400590453,"score_gpt":0.38499940610813116,"score_spread":0.31140200551767816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969175190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981369,0.0031825854,0.010908348,0.00020432386,0.000090178786,0.00025143413,0.00031925362,0.0001986606,0.0034762048],"genre_scores_gemma":[0.98431396,0.00201728,0.010074462,0.00008791565,0.000022239221,0.00013995111,0.00035812723,0.00003336354,0.0029526064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998097,0.00004266362,0.000016941147,0.00002761854,0.000060529765,0.00004256105],"domain_scores_gemma":[0.99992716,0.000015898113,0.000016184009,0.000010038946,0.000008437234,0.00002221584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034564,0.0006155956,0.00041506012,0.00032393457,0.00015394254,0.00027473114,0.00031083773,0.00027154994,0.0007970686],"category_scores_gemma":[0.000099966535,0.0001441614,0.00031781892,0.000122971,0.00014912714,0.00019641024,0.00015355785,0.0006118865,0.000184973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017080273,0.00014622412,0.000087478926,0.00004777814,0.000013890142,0.00003894595,0.000013008982,0.00015945545,0.9971163,0.00016194303,0.00009644751,0.0019476737],"study_design_scores_gemma":[0.000021769267,0.00067873305,0.00039544585,0.0000033658891,0.000022790337,0.0001347005,0.0000049253254,0.00061564316,0.9968291,0.000021428965,0.0012691927,0.0000029240007],"about_ca_topic_score_codex":0.00092641794,"about_ca_topic_score_gemma":0.0029046834,"teacher_disagreement_score":0.00092641794,"about_ca_system_score_codex":0.0003137615,"about_ca_system_score_gemma":0.00033774914,"threshold_uncertainty_score":0.0026664138},"labels":[],"label_agreement":null},{"id":"W1969915666","doi":"10.1182/blood-2010-10-313940","title":"Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Terry Fox Foundation; Cancer Research Institute","keywords":"ADAM10; Cyclin D1; Cell growth; Cancer research; Cell cycle; Cell biology; Biology; Cell culture; Mantle cell lymphoma; Disintegrin; Chemistry; Cell; Metalloproteinase; Immunology; Matrix metalloproteinase; Lymphoma; Biochemistry","score_opus":0.032896522401532104,"score_gpt":0.25513160406285285,"score_spread":0.22223508166132075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969915666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963921,0.00143209,0.0010110298,0.00007926493,0.000008819948,0.0000069581088,0.00009089745,0.000049858398,0.0009291278],"genre_scores_gemma":[0.9983835,0.00035195012,0.00035560993,0.000017228065,0.0000058797614,0.000007612061,0.0001427973,0.000003903926,0.00073148374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988484,0.000034181736,0.000008718957,0.000012427345,0.000027312446,0.000032546748],"domain_scores_gemma":[0.99992,0.000020783582,0.000017847431,0.000015974505,0.000007341131,0.000017910894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001605625,0.00019098973,0.00015959068,0.00018972448,0.00010953051,0.00029519372,0.000080516365,0.00014651299,0.0014864397],"category_scores_gemma":[0.00013777544,0.000091362526,0.0001408573,0.00012309068,0.00017251233,0.00014249326,0.00014536272,0.00043328523,0.00039537443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001183492,0.000030525684,0.0011240863,0.000026402517,0.000005030289,0.00021263582,0.000018374307,0.00003251036,0.9964341,0.000096288175,0.000079044745,0.0018227295],"study_design_scores_gemma":[0.000050575636,0.00046079434,0.021488829,0.000007617393,0.000028251565,0.0029657732,0.00007616903,0.0013040035,0.9681817,0.00013778848,0.0052945376,0.000003948547],"about_ca_topic_score_codex":0.00032672938,"about_ca_topic_score_gemma":0.00053036265,"teacher_disagreement_score":0.0014864397,"about_ca_system_score_codex":0.00024908452,"about_ca_system_score_gemma":0.00013265025,"threshold_uncertainty_score":0.0049726963},"labels":[],"label_agreement":null},{"id":"W1969929253","doi":"10.1016/j.cancergencyto.2007.05.030","title":"Molecular cytogenetic characterization of human breast cancer cell line MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic metastasis","year":2008,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Western University; London Health Sciences Centre","funders":"Canadian Breast Cancer Research Alliance; London Health Sciences Centre; Canada Research Chairs; Breast Cancer Alliance","keywords":"Biology; Karyotype; Fluorescence in situ hybridization; Breakpoint; Cell culture; Metastasis; Molecular biology; Chromosome; Aneuploidy; Cytogenetics; Cancer; Cancer research; Genetics; Gene","score_opus":0.04032510654948662,"score_gpt":0.32920249004575153,"score_spread":0.2888773834962649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969929253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319434,0.00056888675,0.0016950569,0.00010443117,0.000011826511,0.000020742458,0.0017447731,0.000056815126,0.0026030536],"genre_scores_gemma":[0.99194735,0.00036394887,0.0013365349,0.000028923798,0.000003613043,0.000023341947,0.0038622557,0.000019988936,0.0024139239],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99993885,0.000008630041,0.000008318193,0.000013591676,0.000018229313,0.0000123880445],"domain_scores_gemma":[0.9998896,0.000027345675,0.000015926711,0.000025428397,0.000024254066,0.000017484066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008109699,0.00013563714,0.00014558341,0.00033323557,0.00017558814,0.00020758779,0.00014751291,0.00017339413,0.0023922543],"category_scores_gemma":[0.00017701247,0.0001070868,0.00013187299,0.0002719222,0.00011096689,0.00013895602,0.00015678235,0.00022986958,0.0006676424],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001249443,0.000013369145,0.0015725181,0.00001696539,0.0000049428113,0.00019699903,0.00005405088,0.00007223446,0.9964128,0.00018413483,0.000080815014,0.001266192],"study_design_scores_gemma":[0.000059622125,0.00064213265,0.17195497,0.000010451876,0.00008445348,0.0065878155,0.0004875655,0.0020260466,0.7993998,0.00032609186,0.01840169,0.000019387286],"about_ca_topic_score_codex":0.0035581582,"about_ca_topic_score_gemma":0.002549057,"teacher_disagreement_score":0.0035581582,"about_ca_system_score_codex":0.00020111747,"about_ca_system_score_gemma":0.00012707998,"threshold_uncertainty_score":0.008002937},"labels":[],"label_agreement":null},{"id":"W1971160611","doi":"10.1021/jm0600390","title":"The Combi-Targeting Concept:  Synthesis of Stable Nitrosoureas Designed to Inhibit the Epidermal Growth Factor Receptor (EGFR)","year":2006,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Royal Victoria Regional Health Centre","funders":"","keywords":"Chemistry; Potency; Epidermal growth factor receptor; Tyrosine kinase; Epidermal growth factor; EGFR inhibitors; IC50; Moiety; Stereochemistry; Receptor; Biochemistry; In vitro","score_opus":0.018175125596438173,"score_gpt":0.29717429876118195,"score_spread":0.27899917316474376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971160611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9394126,0.0073419805,0.045292713,0.00014945059,0.00009104888,0.00027541543,0.00064626074,0.00027813914,0.006512313],"genre_scores_gemma":[0.9676289,0.0032210718,0.025204593,0.00009976697,0.000018686258,0.00013587173,0.00036896238,0.000025218642,0.0032969983],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999367,0.000010003195,0.0000035737012,0.000017067103,0.000022070133,0.0000105862555],"domain_scores_gemma":[0.99994814,0.000007922133,0.000020244293,0.0000047240205,0.000009565636,0.000009355801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013489535,0.00022049007,0.00019151274,0.00020897432,0.00006772955,0.00017733428,0.00027229244,0.00020870988,0.00072854874],"category_scores_gemma":[0.00016064919,0.00009573244,0.00014786018,0.00015737953,0.00013928315,0.00020069929,0.00016212834,0.0002755564,0.00026095807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009263114,0.000058561352,0.00021326517,0.000118985554,0.000012233615,0.0000721421,0.000036016172,0.00075697596,0.9813461,0.0013851501,0.00013533547,0.015772559],"study_design_scores_gemma":[0.00008292951,0.001715511,0.0020132328,0.000011240073,0.000024633413,0.0004498957,0.000017869785,0.0038655137,0.97758955,0.0002660599,0.0139429495,0.000020622147],"about_ca_topic_score_codex":0.00033742952,"about_ca_topic_score_gemma":0.000527216,"teacher_disagreement_score":0.00072854874,"about_ca_system_score_codex":0.00018647559,"about_ca_system_score_gemma":0.00014973515,"threshold_uncertainty_score":0.002437234},"labels":[],"label_agreement":null},{"id":"W1971209307","doi":"10.1016/j.ctrv.2013.09.001","title":"HER2 testing: Current status and future directions","year":2013,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Genentech","keywords":"Medicine; Clinical Oncology; Human Epidermal Growth Factor Receptor 2; Medical physics; Breast cancer; Oncology; Intensive care medicine; Gynecology; Cancer; Internal medicine","score_opus":0.33526958615058944,"score_gpt":0.5178544713757319,"score_spread":0.1825848852251425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971209307","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003967669,0.9992003,0.000040120587,0.00032624602,0.00010190611,0.0000020723876,0.0000122747615,0.0000031958639,0.00027425264],"genre_scores_gemma":[0.00037620898,0.99890554,0.00009897197,0.0003015363,0.00013675322,0.0000028541665,0.00001838792,8.981094e-7,0.00015883255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995828,0.0001029057,0.000067019515,0.00007062664,0.00013668866,0.00004000457],"domain_scores_gemma":[0.9984107,0.0010444933,0.00018222307,0.00002215082,0.00025679174,0.000083534156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015280078,0.0009428172,0.0022709277,0.0025143619,0.00022747564,0.0013372661,0.0010518187,0.0012539261,0.005734592],"category_scores_gemma":[0.0023915423,0.00033501908,0.00088431645,0.002666291,0.0005573797,0.0017947528,0.00078724313,0.001893826,0.0012599342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011484117,0.00005093908,0.00027752115,0.016806755,0.00012766989,0.00010176033,0.000029223469,0.0002602112,0.0003961739,0.0013598474,0.03534853,0.9451265],"study_design_scores_gemma":[0.00009241051,0.00015810126,0.0015791907,0.019080438,0.00082165946,0.0011200875,0.00013578233,0.00022255509,0.00031132207,0.0026112956,0.9738313,0.000035826746],"about_ca_topic_score_codex":0.0017018846,"about_ca_topic_score_gemma":0.005505594,"teacher_disagreement_score":0.005734592,"about_ca_system_score_codex":0.00088588387,"about_ca_system_score_gemma":0.0018197802,"threshold_uncertainty_score":0.019184113},"labels":[],"label_agreement":null},{"id":"W1973729526","doi":"10.1007/s10549-008-0267-z","title":"Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays of ERα positive human breast carcinomas","year":2008,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation; National Cancer Institute; University of Manitoba; Manitoba Health Research Council","keywords":"Immunohistochemistry; Estrogen receptor; Breast cancer; Tissue microarray; Cancer research; Estrogen receptor alpha; Estrogen receptor beta; Antibody; Phosphorylation; Estrogen; Biology; Epitope; Cancer; Internal medicine; Pathology; Medicine; Immunology; Cell biology","score_opus":0.0845461179765854,"score_gpt":0.39014807308163685,"score_spread":0.30560195510505145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973729526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96204334,0.0038088176,0.027895425,0.00025933434,0.00010295892,0.00014895413,0.0006825936,0.00019874886,0.0048599252],"genre_scores_gemma":[0.94228244,0.0032759504,0.04440844,0.00019367595,0.00006484159,0.00043102395,0.0025184853,0.00007371095,0.006751538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965405,0.00006202045,0.000041467603,0.000080987644,0.00007361179,0.00008778358],"domain_scores_gemma":[0.99965453,0.00008782029,0.000042479147,0.000050540002,0.0001300292,0.000034615594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000565949,0.00046692215,0.00037338145,0.000622606,0.00045187544,0.00034132937,0.00040986214,0.00042255037,0.0022725717],"category_scores_gemma":[0.00041821742,0.0004708823,0.00033619508,0.0005144292,0.00021109972,0.00037477986,0.00027453134,0.00045486234,0.0006383644],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012216019,0.000025120886,0.0004701023,0.00006564799,0.000015258849,0.000041771607,0.000031194086,0.000055805132,0.9980186,0.0000861689,0.000038861042,0.0010292964],"study_design_scores_gemma":[0.00005428588,0.00041783776,0.034973938,0.000026681522,0.00017771141,0.0013117134,0.00021921338,0.0035982635,0.95396715,0.00019974077,0.0050397185,0.00001378507],"about_ca_topic_score_codex":0.00071600924,"about_ca_topic_score_gemma":0.0014629944,"teacher_disagreement_score":0.0022725717,"about_ca_system_score_codex":0.0002530724,"about_ca_system_score_gemma":0.00023069557,"threshold_uncertainty_score":0.007602513},"labels":[],"label_agreement":null},{"id":"W1974449499","doi":"10.2144/000113354","title":"A Proximity Ligation Assay Using Transiently Transfected, Epitope-Tagged Proteins: Application for in Situ Detection of Dimerized Receptor Tyrosine Kinases","year":2010,"lang":"en","type":"article","venue":"BioTechniques","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Toronto Western Hospital; Hospital for Sick Children","funders":"National Cancer Institute; Sick Kids Foundation","keywords":"Proximity ligation assay; Epitope; Epidermal growth factor receptor; Immunoprecipitation; Receptor tyrosine kinase; Tyrosine kinase; Receptor; Transfection; Molecular biology; Biology; Cell biology; Target protein; Ligand (biochemistry); Chemistry; Computational biology; Antibody; Biochemistry; Immunology; Gene","score_opus":0.03177015599344328,"score_gpt":0.3461302312628107,"score_spread":0.3143600752693674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974449499","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26381254,0.0030713277,0.72759336,0.0005502414,0.0001693419,0.00033264328,0.00039145368,0.0013110393,0.0027680702],"genre_scores_gemma":[0.53569025,0.004431673,0.44940427,0.00030233533,0.00012232612,0.00082681,0.0009902252,0.00014758205,0.0080845235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865925,0.00049671583,0.00008817616,0.0003807211,0.00028606917,0.00008899741],"domain_scores_gemma":[0.99920315,0.00039361755,0.00015286353,0.000097462405,0.00007880892,0.00007415722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011070089,0.0010874221,0.0009555557,0.00066535024,0.0006287013,0.0008410961,0.00070314243,0.0011151965,0.0016355414],"category_scores_gemma":[0.00073152955,0.00053683226,0.00064722734,0.0005586871,0.00060623256,0.00085036637,0.00074258854,0.0020754535,0.0011308516],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033429587,0.000024981695,0.000038556227,0.00005220076,0.0000064936867,0.000027501912,0.000024683844,0.00003637596,0.9985164,0.000112411784,0.00003818128,0.0010887166],"study_design_scores_gemma":[0.000008441256,0.00016365916,0.00038590908,0.000004385769,0.00001965093,0.00029909203,0.000018043991,0.0019911213,0.99541134,0.00006731911,0.0016223751,0.000008693327],"about_ca_topic_score_codex":0.00025950762,"about_ca_topic_score_gemma":0.00036490874,"teacher_disagreement_score":0.0016355414,"about_ca_system_score_codex":0.0004582572,"about_ca_system_score_gemma":0.00034560345,"threshold_uncertainty_score":0.0058544874},"labels":[],"label_agreement":null},{"id":"W1974685860","doi":"10.5858/arpa.2013-0953-sa","title":"Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update","year":2013,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1793,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Clinical Oncology; Guideline; Human Epidermal Growth Factor Receptor 2; Medicine; Breast cancer; Clinical Practice; Oncology; Internal medicine; Cancer; Gynecology; Pathology; Family medicine","score_opus":0.1532947712403345,"score_gpt":0.5152501178346831,"score_spread":0.3619553465943486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974685860","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040283017,0.20815283,0.027123144,0.5902852,0.023341212,0.010856937,0.015838018,0.001609104,0.118765295],"genre_scores_gemma":[0.021005478,0.34752473,0.22611207,0.28462234,0.010160166,0.01824526,0.05271911,0.00066820066,0.038942695],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98036,0.007558757,0.0047329175,0.00063371647,0.0060391766,0.0006754574],"domain_scores_gemma":[0.9310493,0.012037473,0.0064127278,0.0012048332,0.047258697,0.0020370018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016177945,0.0013072821,0.0021903599,0.0073550325,0.0012568106,0.0029469302,0.005365675,0.008037216,0.00864321],"category_scores_gemma":[0.054183662,0.0009883808,0.004075865,0.0059880367,0.0010691687,0.0030191476,0.0025422075,0.0078123175,0.0081736995],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039468505,0.00016264318,0.0012157706,0.0035791788,0.00007451632,0.00031526494,0.00021675201,0.00042968764,0.0002964507,0.0017226323,0.82464606,0.16730157],"study_design_scores_gemma":[0.00026801229,0.00010353488,0.0045800717,0.030785106,0.00036194068,0.001420836,0.00033532575,0.00067426945,0.0003395779,0.004134624,0.95689875,0.00009788539],"about_ca_topic_score_codex":0.024078073,"about_ca_topic_score_gemma":0.042498942,"teacher_disagreement_score":0.024078073,"about_ca_system_score_codex":0.004510709,"about_ca_system_score_gemma":0.021755137,"threshold_uncertainty_score":0.08555812},"labels":[],"label_agreement":null},{"id":"W1974840376","doi":"10.1186/1471-2407-14-166","title":"Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study","year":2014,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Santé et de Services Sociaux de Chicoutimi; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Medicine; Trastuzumab; Tolerability; Sunitinib; Internal medicine; Adverse effect; Lapatinib; Breast cancer; Oncology; Clinical endpoint; Metastatic breast cancer; Cancer; Surgery; Clinical trial","score_opus":0.055248083394234544,"score_gpt":0.40422131192543503,"score_spread":0.3489732285312005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974840376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919863,0.005125322,0.0005915852,0.00022566615,0.00005167799,0.00083643454,0.00035691532,0.000069436755,0.000756733],"genre_scores_gemma":[0.9920912,0.0034428393,0.0011016172,0.00041024006,0.00014462645,0.00080830377,0.0012758713,0.000026028256,0.0006993515],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99938524,0.00030917296,0.00005195363,0.000082131155,0.000085658605,0.00008581903],"domain_scores_gemma":[0.9991366,0.00016866114,0.00022921445,0.000065344175,0.000068570625,0.0003316528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029040028,0.0010543654,0.0020816668,0.00038767877,0.0003309131,0.0008033258,0.0006269105,0.0007889031,0.00203128],"category_scores_gemma":[0.0008961393,0.00036911923,0.001303443,0.0003858728,0.0005698511,0.0005402407,0.0002201164,0.0017447294,0.00040767298],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4874099,0.09861149,0.023024252,0.0028603163,0.0068570417,0.0008022231,0.0006060908,0.0051324405,0.099903286,0.00023728679,0.0050642015,0.2694914],"study_design_scores_gemma":[0.40967092,0.5380172,0.035205323,0.00010636791,0.0019501211,0.0010558852,0.00006779667,0.001890362,0.007764511,0.00012462784,0.0040995562,0.000047251186],"about_ca_topic_score_codex":0.00044511762,"about_ca_topic_score_gemma":0.0010218716,"teacher_disagreement_score":0.0029040028,"about_ca_system_score_codex":0.0006269326,"about_ca_system_score_gemma":0.0011862201,"threshold_uncertainty_score":0.015357971},"labels":[],"label_agreement":null},{"id":"W1975577601","doi":"10.1097/pas.0b013e3181b72865","title":"HER2 Intermediate Breast Cancers","year":2009,"lang":"en","type":"letter","venue":"The American Journal of Surgical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.0248011963571624,"score_gpt":0.3455573383850037,"score_spread":0.3207561420278413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975577601","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055927513,0.006395927,0.000217132,0.92477316,0.024150664,0.000041254996,0.00017405,0.000060177554,0.03859486],"genre_scores_gemma":[0.059520107,0.014838358,0.0006273051,0.79779845,0.07749211,0.000059189995,0.00025578137,0.000049348146,0.04935933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940956,0.00013957231,0.000058819183,0.000074473355,0.00017383328,0.00014367003],"domain_scores_gemma":[0.99907196,0.00037646224,0.00005270681,0.000044063356,0.00023633293,0.00021845115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006820201,0.00044708612,0.00071106973,0.00050369743,0.0014918455,0.0009745627,0.00050662557,0.007722658,0.005832928],"category_scores_gemma":[0.0048052673,0.0002685197,0.00058538676,0.00034214728,0.0005374257,0.00095479994,0.0004016621,0.006211094,0.0046143136],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006084417,0.00004439783,0.0036735104,0.000047746256,0.00001125984,0.021110767,0.000075082455,0.00007065638,0.0005125438,0.0020688921,0.94627,0.026054263],"study_design_scores_gemma":[0.00018968913,0.00016614044,0.0118426,0.00076190126,0.00004931123,0.098276,0.00047928575,0.00073860795,0.0006577371,0.008692685,0.87809765,0.000048395897],"about_ca_topic_score_codex":0.003011656,"about_ca_topic_score_gemma":0.0076594534,"teacher_disagreement_score":0.007722658,"about_ca_system_score_codex":0.0012329168,"about_ca_system_score_gemma":0.0011535177,"threshold_uncertainty_score":0.01951313},"labels":[],"label_agreement":null},{"id":"W1976545696","doi":"10.1097/01.pai.0000213138.01536.2e","title":"PGDS, A Novel Technique Combining Chromogenic In Situ Hybridization and Immunohistochemistry for the Assessment of ErbB2 (HER2/neu) Status in Breast Cancer","year":2007,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Immunohistochemistry; Fluorescence in situ hybridization; Breast cancer; Gene duplication; Concordance; Tissue microarray; In situ hybridization; Pathology; HER2/neu; SKBR3; Cancer; Biology; Cancer research; Molecular biology; Gene; Medicine; Oncology; Internal medicine; Gene expression; Genetics","score_opus":0.012150194241980812,"score_gpt":0.3499342812423337,"score_spread":0.3377840870003529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976545696","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60525835,0.0067171184,0.37845197,0.0003330572,0.00023327519,0.0005077777,0.00051574426,0.0018133209,0.006169296],"genre_scores_gemma":[0.78152686,0.002834634,0.21084365,0.00016178898,0.00009899266,0.00030111766,0.0006450391,0.00005309216,0.003534816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900013,0.00025148623,0.000054426113,0.0002862269,0.0003205415,0.00008710574],"domain_scores_gemma":[0.9995584,0.00017721843,0.00008077927,0.0000771499,0.000058291367,0.000048153186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008684174,0.0007208432,0.00047313466,0.0016949655,0.00022182253,0.00042212865,0.0005821921,0.00035367353,0.0008427596],"category_scores_gemma":[0.0005964851,0.00037579684,0.00040129735,0.00069655984,0.0011215237,0.0005031701,0.000998595,0.00048292085,0.00029350628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010864628,0.00003513068,0.00432636,0.00014486385,0.00004429738,0.00019961548,0.00005256838,0.00032513292,0.9630717,0.00033630946,0.00017341488,0.031181937],"study_design_scores_gemma":[0.000057823247,0.0013127761,0.039236538,0.000020825104,0.0001503778,0.0054404447,0.00013553035,0.009295932,0.934127,0.00050219696,0.009659794,0.000060850325],"about_ca_topic_score_codex":0.0007404662,"about_ca_topic_score_gemma":0.001804803,"teacher_disagreement_score":0.0016949655,"about_ca_system_score_codex":0.00037177847,"about_ca_system_score_gemma":0.00047446627,"threshold_uncertainty_score":0.0045927167},"labels":[],"label_agreement":null},{"id":"W1976913414","doi":"10.1067/mob.2003.347","title":"Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer","year":2003,"lang":"en","type":"article","venue":"American Journal of Obstetrics and Gynecology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Medicine; Monoclonal antibody; Antibody; Immune system; Antigen; Immunology; Ovarian cancer; Internal medicine; Cancer; Adverse effect; Gastroenterology","score_opus":0.021191614882539463,"score_gpt":0.32938766422337024,"score_spread":0.3081960493408308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976913414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99883765,0.00030379253,0.000049950708,0.0000701317,0.000015148657,0.000004968941,0.000060422783,0.000005693829,0.0006522264],"genre_scores_gemma":[0.99919814,0.00010415243,0.000025079366,0.00006017209,0.000021582231,0.000007005562,0.000086942724,0.0000021197143,0.0004949222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998802,0.000034065368,0.0000068838185,0.000015874866,0.00001698949,0.00004595048],"domain_scores_gemma":[0.9992879,0.00021401349,0.00025239305,0.00004406842,0.000048766742,0.00015286599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022653326,0.00016980601,0.00021131501,0.00033611513,0.00019405416,0.00020112589,0.00013524105,0.00044191003,0.0021414969],"category_scores_gemma":[0.0014058287,0.00013500088,0.00015886084,0.00022323283,0.00019082899,0.00014418065,0.0001652612,0.00043727062,0.00029856217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002412419,0.00034662208,0.95137095,0.0000382753,0.00009770968,0.000683846,0.00020606382,0.00017389953,0.03136794,0.000054777865,0.00046442225,0.012783062],"study_design_scores_gemma":[0.000031422078,0.0010640089,0.99532866,0.000005572592,0.00004446,0.0012930427,0.00010231815,0.00013920563,0.0012825538,0.00003678598,0.0006687113,0.0000032220848],"about_ca_topic_score_codex":0.0006433023,"about_ca_topic_score_gemma":0.0006158935,"teacher_disagreement_score":0.0021414969,"about_ca_system_score_codex":0.0001286056,"about_ca_system_score_gemma":0.00014034247,"threshold_uncertainty_score":0.007164061},"labels":[],"label_agreement":null},{"id":"W1977290575","doi":"10.1016/j.nucmedbio.2013.03.005","title":"Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments","year":2013,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Nuclear medicine; Pharmacokinetics; Breast carcinoma; Spleen; Ductal carcinoma; Carcinoma; Radiology; Pathology; Breast cancer; Internal medicine; Cancer","score_opus":0.02024150232607888,"score_gpt":0.3179105145745654,"score_spread":0.2976690122484865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977290575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959561,0.0008340941,0.00043206566,0.00044349578,0.0001360773,0.00067569624,0.0003107607,0.000059902253,0.0011517256],"genre_scores_gemma":[0.99430496,0.0009202321,0.0007327059,0.00038180462,0.00014833052,0.0010090265,0.0007411563,0.000031244606,0.0017306247],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996112,0.00016889226,0.000011568931,0.00007128292,0.000019856701,0.00011719851],"domain_scores_gemma":[0.99909997,0.00024111888,0.00017017251,0.000094040945,0.000034975572,0.00035964695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012312838,0.0019157175,0.0021618681,0.0003230248,0.00048053075,0.0013233942,0.0009236187,0.0016918007,0.0024912152],"category_scores_gemma":[0.0012602115,0.0007943783,0.0012623792,0.00039614618,0.0014578153,0.0010636001,0.0003293115,0.004597921,0.000756943],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.903859,0.033939637,0.003032929,0.0002344418,0.0005174893,0.00014046393,0.00029139488,0.0025448005,0.02184804,0.00024203054,0.0014834611,0.031866323],"study_design_scores_gemma":[0.47400153,0.5101185,0.0068023144,0.000022047141,0.0004170501,0.00016038114,0.00012258058,0.0019238819,0.005017569,0.00019206709,0.0011914986,0.000030588235],"about_ca_topic_score_codex":0.0022282475,"about_ca_topic_score_gemma":0.0032225149,"teacher_disagreement_score":0.0024912152,"about_ca_system_score_codex":0.001059483,"about_ca_system_score_gemma":0.0015736596,"threshold_uncertainty_score":0.008333921},"labels":[],"label_agreement":null},{"id":"W1977874955","doi":"10.1097/pai.0b013e318169fc1c","title":"Systematic Review of HER2 Breast Cancer Testing","year":2008,"lang":"en","type":"review","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Commission","keywords":"Concordance; Breast cancer; Medicine; Trastuzumab; Cochrane Library; Critical appraisal; Fish <Actinopterygii>; Oncology; MEDLINE; Internal medicine; Cancer; Meta-analysis; Pathology; Alternative medicine; Biology","score_opus":0.03304839716079931,"score_gpt":0.3771348958789459,"score_spread":0.34408649871814656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977874955","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010157501,0.99641883,0.00018735146,0.00033284948,0.0001402867,0.00053222437,0.00090572756,0.000010858732,0.00045603557],"genre_scores_gemma":[0.015214641,0.9809475,0.0009608207,0.0006942773,0.0001204746,0.0011783976,0.00062837586,0.000010315756,0.00024526194],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98822594,0.0042228727,0.004317399,0.00078525115,0.0021509412,0.00029775198],"domain_scores_gemma":[0.95687735,0.030340673,0.007259364,0.0006044669,0.0045407666,0.00037740308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010852078,0.0019277941,0.009633084,0.016075918,0.00064885017,0.002649548,0.0025008973,0.0018081013,0.0073995357],"category_scores_gemma":[0.04992948,0.0010521038,0.007560811,0.016282372,0.0009519455,0.0021842956,0.0016313787,0.0010801917,0.00053087424],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001285361,0.000008953414,0.0003566119,0.975774,0.0055775377,0.000092452094,0.00008246741,0.000073480296,0.000087408676,0.00013523655,0.0012584238,0.016424928],"study_design_scores_gemma":[0.00020310497,0.00016914927,0.0027544345,0.93341696,0.046845675,0.00034325535,0.00017003849,0.00007497933,0.00014311522,0.00024307254,0.015607017,0.000029287963],"about_ca_topic_score_codex":0.0102393525,"about_ca_topic_score_gemma":0.025104055,"teacher_disagreement_score":0.016075918,"about_ca_system_score_codex":0.0056572035,"about_ca_system_score_gemma":0.013929521,"threshold_uncertainty_score":0.057392},"labels":[],"label_agreement":null},{"id":"W1978986213","doi":"10.5539/cco.v2n1p17","title":"Improved Survival of HER2-Positive Metastatic Breast Cancer in Routine Care","year":2012,"lang":"en","type":"article","venue":"Cancer and Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Radiation therapy; Metastasis; Chemotherapy; Cancer; Hormonal therapy","score_opus":0.11095570523052116,"score_gpt":0.5247413960935513,"score_spread":0.41378569086303013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978986213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776256,0.00164047,0.00007002429,0.000089398076,0.0000065683785,0.000006868886,0.000060445014,0.0000070027127,0.0003567496],"genre_scores_gemma":[0.9993236,0.00030475305,0.00008233053,0.00004614512,0.00001699398,0.000005075704,0.0001315243,8.6110674e-7,0.00008875122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998055,0.0000746068,0.0000119182405,0.00003543865,0.000042965672,0.000029581313],"domain_scores_gemma":[0.99949765,0.00012268472,0.00020026402,0.000017697383,0.000047474605,0.00011426697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003815459,0.000115010225,0.00026989158,0.00017838523,0.00019637671,0.0002304443,0.00014237565,0.00023182164,0.0012991762],"category_scores_gemma":[0.0017511992,0.000051610656,0.00015394122,0.00026230782,0.00014831882,0.00017967045,0.00023104646,0.00022846834,0.00010800609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022911748,0.00040848053,0.922058,0.00019186607,0.00015944558,0.0004905896,0.00022826089,0.00040450972,0.006235523,0.000054605218,0.0010693492,0.06640816],"study_design_scores_gemma":[0.00015164785,0.0030181813,0.9910025,0.0000347358,0.00011031574,0.0023683752,0.000089289315,0.00045689623,0.0012189281,0.000048023398,0.0014954573,0.000005622597],"about_ca_topic_score_codex":0.0008390888,"about_ca_topic_score_gemma":0.0015226556,"teacher_disagreement_score":0.0012991762,"about_ca_system_score_codex":0.00031508104,"about_ca_system_score_gemma":0.00024423606,"threshold_uncertainty_score":0.004346192},"labels":[],"label_agreement":null},{"id":"W1979488703","doi":"10.1002/ijc.11599","title":"HER‐2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors","year":2003,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Response Biomedical (Canada)","funders":"National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Colorectal Cancer Alliance","keywords":"Biology; Cytoplasm; Oncogene; Immunohistochemistry; Molecular biology; Cell culture; Immunoelectron microscopy; Cell; Colorectal cancer; Pathology; Cancer; Cell cycle; Cancer research; Cell biology; Immunology; Medicine; Biochemistry","score_opus":0.023545232991041953,"score_gpt":0.3872312312991643,"score_spread":0.36368599830812237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979488703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99205315,0.0043763416,0.0012130395,0.00005212677,0.000012189624,0.000020956855,0.0008049823,0.000040891675,0.0014264046],"genre_scores_gemma":[0.9951036,0.0017373458,0.0008958681,0.000024365647,0.000006664298,0.00003260049,0.0012154629,0.00000584198,0.0009783471],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983597,0.000031768304,0.000014062685,0.000032372238,0.00005347592,0.000032260246],"domain_scores_gemma":[0.9998882,0.000026558851,0.00002022843,0.000020491329,0.000024281757,0.000020117099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017570604,0.00012351583,0.000108668915,0.0003530774,0.00011147426,0.00022793395,0.00007613122,0.00013192683,0.00092907774],"category_scores_gemma":[0.00025551094,0.00010650116,0.00008096988,0.00040902084,0.000098061806,0.00009977816,0.00008979657,0.00014208636,0.00022041838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059246743,0.000065434135,0.024909524,0.00012003325,0.000029223125,0.0004407873,0.00010471773,0.00012675718,0.96636534,0.00013704071,0.00034154562,0.006767007],"study_design_scores_gemma":[0.00010510767,0.0011397015,0.5060611,0.0000314132,0.000089085035,0.009265305,0.00028859725,0.0015127164,0.46669948,0.00012897751,0.014655347,0.00002314396],"about_ca_topic_score_codex":0.0020036383,"about_ca_topic_score_gemma":0.0023809988,"teacher_disagreement_score":0.0020036383,"about_ca_system_score_codex":0.00022080775,"about_ca_system_score_gemma":0.00014528401,"threshold_uncertainty_score":0.003983915},"labels":[],"label_agreement":null},{"id":"W1979791033","doi":"10.1038/bjc.2011.355","title":"Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform","year":2011,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; McGill University; Université du Québec","funders":"National Institute of General Medical Sciences; Winship Cancer Institute; National Cancer Institute; National Institutes of Health; Georgia Research Alliance; Emory University","keywords":"Breast cancer; Bead; Pathology; Medicine; Cancer; Biology; Materials science; Internal medicine","score_opus":0.05657751986548907,"score_gpt":0.3345027286124366,"score_spread":0.2779252087469475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979791033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9009459,0.0011412011,0.08113962,0.0001858456,0.000053219763,0.00036275684,0.01120826,0.0008713328,0.004091866],"genre_scores_gemma":[0.824471,0.0010673144,0.13672711,0.00049831707,0.000035236713,0.0014620981,0.028763892,0.0002185738,0.006756422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99955934,0.00004239663,0.000035691945,0.00018046488,0.00013416307,0.00004791786],"domain_scores_gemma":[0.999782,0.000060167295,0.000036804195,0.000049332473,0.00005312192,0.000018509507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040675915,0.00028139135,0.0002585632,0.00047117932,0.00019239602,0.0004088388,0.0002599395,0.00030749087,0.0018951287],"category_scores_gemma":[0.000522889,0.00016655667,0.00024008917,0.00044759866,0.00019436654,0.00014386397,0.00023870688,0.0002801984,0.0014344881],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016924414,0.00002491668,0.0048219147,0.00009150251,0.00001694251,0.00004265993,0.00004042934,0.0005984094,0.98774916,0.00009355539,0.00035501816,0.005996282],"study_design_scores_gemma":[0.00004700896,0.0005651859,0.11061652,0.000030529045,0.00009473386,0.0010040832,0.0000750211,0.009601835,0.8638756,0.00029430466,0.013759824,0.000035370365],"about_ca_topic_score_codex":0.00036120816,"about_ca_topic_score_gemma":0.00088949455,"teacher_disagreement_score":0.0018951287,"about_ca_system_score_codex":0.00023292078,"about_ca_system_score_gemma":0.00025590928,"threshold_uncertainty_score":0.006339848},"labels":[],"label_agreement":null},{"id":"W1979836319","doi":"10.1158/0008-5472.sabcs-09-5111","title":"A Phase 1 Study To Assess the Safety, Tolerability and Pharmacokinetics of ARRY-380 – An Oral Inhibitor of HER2.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; Dosing; Nausea; Rash; Adverse effect; Pharmacology; Internal medicine; Cancer; Toxicity; Pharmacodynamics; Breast cancer; Oncology; Gastroenterology","score_opus":0.2830463335743338,"score_gpt":0.5830860017591729,"score_spread":0.3000396681848391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979836319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98667914,0.0017869344,0.0018088856,0.0005333102,0.00015937127,0.0046529165,0.001883884,0.000119832344,0.002375675],"genre_scores_gemma":[0.97313267,0.0021572958,0.005258999,0.0014639074,0.0002707488,0.005986951,0.005389821,0.00007033919,0.0062691686],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999509,0.00022931192,0.000017555272,0.00009587628,0.0000702174,0.00007817303],"domain_scores_gemma":[0.99919266,0.00014474471,0.0001764747,0.00007908274,0.00006541239,0.0003415985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018598372,0.0014819553,0.0017054854,0.0003954234,0.00045510044,0.00071483996,0.00091881107,0.0010565374,0.0049658394],"category_scores_gemma":[0.0009851856,0.0006798736,0.00073259056,0.0003365897,0.0008380561,0.0010782373,0.00027944503,0.0032766354,0.0010228222],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47375077,0.22441441,0.007924658,0.0012335104,0.001417848,0.0010620229,0.00050759956,0.0043106005,0.15931378,0.0009961142,0.014612748,0.11045596],"study_design_scores_gemma":[0.26494282,0.7092909,0.009253485,0.000030948344,0.00027011769,0.0009059314,0.000059279628,0.001812754,0.0074826577,0.00048510302,0.005427912,0.00003810118],"about_ca_topic_score_codex":0.0008594082,"about_ca_topic_score_gemma":0.001590969,"teacher_disagreement_score":0.0049658394,"about_ca_system_score_codex":0.00101008,"about_ca_system_score_gemma":0.0019632538,"threshold_uncertainty_score":0.01661241},"labels":[],"label_agreement":null},{"id":"W1980168308","doi":"10.1007/s10549-007-9656-y","title":"HER2/neu in systemic therapy for women with breast cancer: a systematic review","year":2007,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Cancer Care Ontario; McMaster University; Mount Sinai Hospital; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Taxane; Oncology; Internal medicine; Anthracycline; Breast cancer; Hazard ratio; Meta-analysis; Adjuvant therapy; Confidence interval; Regimen; Relative risk; Cochrane Library; Clinical trial; Randomized controlled trial; Cancer; Gynecology","score_opus":0.17333335732310998,"score_gpt":0.5007484195405519,"score_spread":0.327415062217442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980168308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008035183,0.99845016,0.00006880929,0.00016738551,0.000064812506,0.00010504339,0.00016802638,0.0000052401965,0.00016693835],"genre_scores_gemma":[0.016162869,0.9826199,0.0004028287,0.0004219924,0.000051135106,0.0001492237,0.000082972765,0.0000030273425,0.00010619465],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99773324,0.00090754527,0.00070799445,0.00023524593,0.0003289445,0.00008690233],"domain_scores_gemma":[0.9915175,0.005875717,0.0018615193,0.00010462847,0.00048681427,0.00015373567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003614519,0.0010666766,0.008476938,0.004000103,0.00031445656,0.0011475392,0.0010299496,0.0013238468,0.0045672082],"category_scores_gemma":[0.013709386,0.00088358327,0.005769443,0.0049153147,0.0005114424,0.0012379698,0.00091346103,0.0010136613,0.00021440208],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008768121,0.000039048948,0.0010670172,0.8973447,0.024298776,0.000187431,0.00014020434,0.00018955594,0.00032721125,0.0001496361,0.003108652,0.0722709],"study_design_scores_gemma":[0.003047304,0.0012222378,0.0108747175,0.5425907,0.39981598,0.0010426252,0.00035201135,0.00022731541,0.0005357502,0.00039181608,0.03982483,0.00007474415],"about_ca_topic_score_codex":0.0067820614,"about_ca_topic_score_gemma":0.028425232,"teacher_disagreement_score":0.008476938,"about_ca_system_score_codex":0.00220687,"about_ca_system_score_gemma":0.004500612,"threshold_uncertainty_score":0.019115627},"labels":[],"label_agreement":null},{"id":"W1980356205","doi":"10.1016/j.radonc.2009.06.017","title":"The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment","year":2009,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"KWF Kankerbestrijding","keywords":"In vivo; Cancer research; Clonogenic assay; Cell culture; In vitro; Epidermal growth factor receptor; Cell growth; Biology; Mutant; Tumor microenvironment; Chemistry; Receptor; Gene; Genetics; Tumor cells","score_opus":0.021359013602000293,"score_gpt":0.3457004025610288,"score_spread":0.32434138895902853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980356205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733716,0.00047374182,0.00096989743,0.00007504854,0.000024724342,0.0000075548655,0.00017227345,0.000037116093,0.0009023358],"genre_scores_gemma":[0.99835783,0.00017989316,0.00023532519,0.000021679078,0.000007062904,0.0000041818153,0.00022683597,0.000021649017,0.0009455457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998932,0.000020183634,0.000008700615,0.000021997394,0.000023841902,0.00003213579],"domain_scores_gemma":[0.99986875,0.000028393168,0.000029410663,0.000025798976,0.000009288331,0.00003834326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009333069,0.00034878094,0.00025867933,0.00017171474,0.00015294236,0.00030342868,0.00018317539,0.00027595763,0.0023721152],"category_scores_gemma":[0.00014099693,0.00013834864,0.0002621211,0.0001046545,0.00027500998,0.00015657934,0.00021764048,0.0006185772,0.00048851885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013416776,0.00002411474,0.00058495696,0.0000084377325,0.000006503474,0.0001685253,0.0000061787478,0.000035252462,0.99807113,0.00009862352,0.000046252884,0.0008158072],"study_design_scores_gemma":[0.000018262723,0.00041979153,0.019902918,0.0000044139347,0.000045542285,0.0051575173,0.000051546405,0.00057530584,0.9703966,0.0001757357,0.003242818,0.000009521968],"about_ca_topic_score_codex":0.00037062008,"about_ca_topic_score_gemma":0.00023287591,"teacher_disagreement_score":0.0023721152,"about_ca_system_score_codex":0.00011405385,"about_ca_system_score_gemma":0.00012278868,"threshold_uncertainty_score":0.007935524},"labels":[],"label_agreement":null},{"id":"W1980543089","doi":"10.1016/j.nucmedbio.2014.09.011","title":"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab","year":2014,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University Health Network; McMaster University; Ontario Institute for Cancer Research; University of Toronto","funders":"Ontario Institute for Cancer Research","keywords":"Biodistribution; Clinical trial; Pharmacokinetics; Dosimetry; Medicine; Pharmacology; Regulatory authority; Medical physics; Toxicity; Oncology; Nuclear medicine; Internal medicine; In vivo; Biotechnology; Biology","score_opus":0.3390109953650138,"score_gpt":0.5810161384611477,"score_spread":0.24200514309613397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980543089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83117753,0.0060012885,0.09710697,0.0043895817,0.00064225314,0.020461611,0.009841614,0.0008598379,0.02951927],"genre_scores_gemma":[0.9319638,0.0014804183,0.03228497,0.0025447095,0.00029024697,0.0085331565,0.013185591,0.00048715415,0.009229885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99659437,0.0019416398,0.00016616566,0.0001895385,0.0006740763,0.00043411044],"domain_scores_gemma":[0.9966665,0.0007688486,0.00059227645,0.000596733,0.00062421465,0.00075136777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01087436,0.0007722298,0.0014706657,0.00051045103,0.0011059885,0.0023372842,0.0010008896,0.001798231,0.0052804197],"category_scores_gemma":[0.006998975,0.0007781361,0.0011801015,0.00071648124,0.0011494703,0.0013461604,0.00045979634,0.0029270896,0.002404518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06486793,0.018300448,0.013639064,0.0006591157,0.0004450892,0.0010996256,0.00081998354,0.013084475,0.770342,0.0061521707,0.021857513,0.088732526],"study_design_scores_gemma":[0.020991633,0.22878596,0.071819,0.00026619932,0.0016342322,0.006268776,0.00078620453,0.01451246,0.45682195,0.009291585,0.18860424,0.00021774886],"about_ca_topic_score_codex":0.0015481095,"about_ca_topic_score_gemma":0.0022367747,"teacher_disagreement_score":0.01087436,"about_ca_system_score_codex":0.001421177,"about_ca_system_score_gemma":0.0052739317,"threshold_uncertainty_score":0.05750978},"labels":[],"label_agreement":null},{"id":"W1981249718","doi":"10.1074/jbc.275.9.6600","title":"Characterization of a Repressor Element and a Juxtaposed Tissue-restricted Activator Element Located on the Distal neu Gene Promoter","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Occupational Cancer Research Centre; Cancer Care Ontario; Ontario Institute for Cancer Research","funders":"","keywords":"Repressor; Molecular biology; Biology; Promoter; Gene; Transcription (linguistics); DNA; Reporter gene; Base pair; Response element; Activator (genetics); Transcription factor; Genetics; Gene expression","score_opus":0.043327417591045324,"score_gpt":0.32051227406763716,"score_spread":0.27718485647659186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981249718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95363885,0.0018562106,0.041195247,0.00017211672,0.00004160913,0.0000888494,0.00087232253,0.00014896909,0.0019858135],"genre_scores_gemma":[0.9587226,0.0008212471,0.030520024,0.00010424852,0.000023206794,0.00006364421,0.0043166853,0.000091068454,0.005337318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998567,0.000018112445,0.000010353361,0.000040923118,0.00004705243,0.000026794893],"domain_scores_gemma":[0.99971,0.00009201005,0.00005581123,0.000030418269,0.000039723942,0.00007203909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020936404,0.00027821976,0.0002851985,0.00021112387,0.00011788221,0.00025985794,0.000419345,0.0002567456,0.0013812049],"category_scores_gemma":[0.0003895359,0.00018734334,0.00038806425,0.00012907689,0.00021913763,0.00016507678,0.00021881901,0.0007443722,0.0011728142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054963693,0.000014074401,0.0001335039,0.000022827651,0.0000015747729,0.000036354257,0.000009708545,0.000043172116,0.9988127,0.00008630312,0.0000068391187,0.00077804516],"study_design_scores_gemma":[0.000024446832,0.00016704769,0.005304484,0.000018796129,0.00002005533,0.00074521423,0.000034858604,0.0025016638,0.98648816,0.000080984704,0.004604914,0.000009270816],"about_ca_topic_score_codex":0.00083266915,"about_ca_topic_score_gemma":0.0008156578,"teacher_disagreement_score":0.0013812049,"about_ca_system_score_codex":0.00023974308,"about_ca_system_score_gemma":0.00037088816,"threshold_uncertainty_score":0.0046206117},"labels":[],"label_agreement":null},{"id":"W1982624212","doi":"10.1016/j.semcancer.2005.01.003","title":"ETV6–NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages","year":2005,"lang":"en","type":"review","venue":"Seminars in Cancer Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Research (Canada); University of British Columbia","funders":"","keywords":"Transformation (genetics); Tyrosine kinase; Cell biology; Receptor tyrosine kinase; Chimeric gene; Biology; Gene; Signal transduction; Genetics; Gene expression","score_opus":0.08058589550381658,"score_gpt":0.4234648176214793,"score_spread":0.34287892211766274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982624212","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005271691,0.98013866,0.005034326,0.00064927095,0.00082085637,0.000043642707,0.00014324422,0.00017136733,0.007726764],"genre_scores_gemma":[0.0129920915,0.97530794,0.0021852243,0.00040385113,0.00017068737,0.000046914545,0.00035551106,0.000014127038,0.00852357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99991393,0.0000085852025,0.000010682593,0.000015997184,0.000035990335,0.000014722253],"domain_scores_gemma":[0.9999356,0.000022815011,0.000013302662,0.0000047230515,0.0000136437875,0.000009914232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038021477,0.0008097358,0.0009380271,0.0007366086,0.00012115656,0.00048652524,0.00081162,0.00068231265,0.0018007914],"category_scores_gemma":[0.00016842649,0.00018257416,0.00026150004,0.0007980795,0.00028448566,0.0008321853,0.00034014013,0.0009255917,0.0022226865],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002686012,0.00010627513,0.00018314182,0.0037617474,0.000060941198,0.0007145049,0.000027127477,0.0010327698,0.051130775,0.00321271,0.020152317,0.91934896],"study_design_scores_gemma":[0.00007051372,0.00018157871,0.00067564734,0.00024522093,0.00010800226,0.0038391359,0.000021225047,0.00030222352,0.027692039,0.0006373958,0.96620965,0.000017425298],"about_ca_topic_score_codex":0.00048130073,"about_ca_topic_score_gemma":0.00076332974,"teacher_disagreement_score":0.0018007914,"about_ca_system_score_codex":0.00057967304,"about_ca_system_score_gemma":0.00040795407,"threshold_uncertainty_score":0.006024301},"labels":[],"label_agreement":null},{"id":"W1983589811","doi":"10.1016/j.neuroscience.2007.04.066","title":"Developmental profile of neuregulin receptor ErbB4 in postnatal rat cerebral cortex and hippocampus","year":2007,"lang":"en","type":"article","venue":"Neuroscience","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Douglas Mental Health University Institute","funders":"Canadian Institutes of Health Research","keywords":"Biology; Hippocampal formation; Neuroscience; Dendritic spine; ERBB4; Glial fibrillary acidic protein; Hippocampus; Cerebral cortex; Astrocyte; Immunocytochemistry; Cell biology; Receptor tyrosine kinase; Central nervous system; Endocrinology; Immunohistochemistry; Kinase; Immunology","score_opus":0.029569792642449317,"score_gpt":0.32988400967044784,"score_spread":0.30031421702799854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983589811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97313935,0.010709979,0.004902121,0.00023268202,0.0000826567,0.000030507532,0.0016824466,0.00014052361,0.0090796305],"genre_scores_gemma":[0.9756766,0.006793476,0.0022910975,0.00010010511,0.00002122278,0.00007639104,0.0010070808,0.00010853143,0.013925502],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998878,0.0000060365032,0.000007494052,0.000023404948,0.000038691047,0.000036415953],"domain_scores_gemma":[0.99966764,0.000044064192,0.000087302455,0.00001629685,0.00009527765,0.00008934057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017273554,0.0003648691,0.00045440276,0.0013118521,0.0003821438,0.0006039419,0.00033984985,0.00021654282,0.0016906381],"category_scores_gemma":[0.00028420426,0.00042475562,0.00026350626,0.00044894402,0.00043255126,0.00072049873,0.00034587175,0.0007861568,0.00044326895],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006095822,0.000038310554,0.0036474788,0.00015674839,0.000040539482,0.000595507,0.00014211175,0.0001372235,0.984772,0.0011649679,0.00021338505,0.0084820865],"study_design_scores_gemma":[0.000025271349,0.00021806914,0.13156995,0.000054831955,0.00011378644,0.0012071271,0.00070194376,0.0005535223,0.8600577,0.0008305607,0.004644652,0.000022616072],"about_ca_topic_score_codex":0.005899978,"about_ca_topic_score_gemma":0.009998073,"teacher_disagreement_score":0.005899978,"about_ca_system_score_codex":0.0008607419,"about_ca_system_score_gemma":0.0008022648,"threshold_uncertainty_score":0.011731267},"labels":[],"label_agreement":null},{"id":"W1984634863","doi":"10.1002/pros.22475","title":"“Combi‐targeting” mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer","year":2012,"lang":"en","type":"article","venue":"The Prostate","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"Canadian Institutes of Health Research; China Scholarship Council; Prostate Cancer Canada","keywords":"DU145; In vivo; LNCaP; Cancer research; Epidermal growth factor receptor; DNA damage; Comet assay; Cytotoxicity; Prostate cancer; Pharmacology; Apoptosis; Biology; Cancer; Molecular biology; In vitro; Medicine; Biochemistry; Internal medicine; DNA","score_opus":0.08884745670678014,"score_gpt":0.36372449310603977,"score_spread":0.27487703639925964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984634863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945104,0.0033199948,0.0013533602,0.000054084918,0.000020533525,0.00004665578,0.00011617825,0.000042534288,0.000536296],"genre_scores_gemma":[0.9938864,0.0019344001,0.0028165749,0.000027819082,0.000016484022,0.000026721298,0.0002582221,0.00000717103,0.001026182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995124,0.0000069567877,0.0000040899577,0.00001076215,0.000014496356,0.00001247723],"domain_scores_gemma":[0.9999714,0.0000025660268,0.000009798741,0.0000026032162,0.00000404111,0.0000096478925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011080584,0.00027511356,0.00025794344,0.00019156733,0.00006647254,0.00019554264,0.00019067932,0.00016293654,0.00047428178],"category_scores_gemma":[0.00006346637,0.00006132757,0.00014318393,0.00013304586,0.00012448589,0.00011675957,0.000082521474,0.0002423294,0.000100829886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042598756,0.00016038005,0.0004153706,0.00009015383,0.000015487147,0.000068195586,0.000013517641,0.00019562145,0.9855678,0.00010313167,0.000102130885,0.012842156],"study_design_scores_gemma":[0.00017085283,0.0035369825,0.0061266846,0.000007886499,0.00008649842,0.0008743402,0.0000127558405,0.0013519736,0.98084575,0.000022853532,0.0069538644,0.000009625537],"about_ca_topic_score_codex":0.0004547882,"about_ca_topic_score_gemma":0.0013788523,"teacher_disagreement_score":0.00047428178,"about_ca_system_score_codex":0.00018385434,"about_ca_system_score_gemma":0.00011777424,"threshold_uncertainty_score":0.001586616},"labels":[],"label_agreement":null},{"id":"W1984729575","doi":"10.1016/s1470-2045(09)70295-5","title":"Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Progesterone receptor; Oncology; Concordance; Biopsy; Internal medicine; Hormone receptor; Cancer; Estrogen receptor; Gynecology","score_opus":0.16106710979578487,"score_gpt":0.44171524985814115,"score_spread":0.2806481400623563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984729575","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045532934,0.0012331615,0.000052089108,0.9870582,0.009679939,0.0000057632074,0.00003350835,0.000008891497,0.0014730205],"genre_scores_gemma":[0.006453504,0.0017430153,0.0003536272,0.9399488,0.049486667,0.000023819126,0.000052439198,0.0000147533165,0.0019233256],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662244,0.0009929239,0.0005783185,0.00041408732,0.0008472602,0.00054500584],"domain_scores_gemma":[0.98445964,0.00775876,0.0013198227,0.0005100499,0.0030279113,0.0029239007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034842587,0.0006678607,0.0017311604,0.0010819115,0.0029639418,0.0027230682,0.0018787438,0.069111705,0.007823258],"category_scores_gemma":[0.041614905,0.000938839,0.0015079301,0.00096168736,0.0029055758,0.003999754,0.0013361011,0.04473715,0.006122105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016870392,0.00004756448,0.0058266167,0.00014310781,0.000048361453,0.0038625367,0.00014053364,0.00012446307,0.00039053863,0.0019744497,0.96401954,0.023253614],"study_design_scores_gemma":[0.00072755123,0.0003486421,0.014020167,0.0022164276,0.00024580336,0.02114407,0.0017147792,0.0014156586,0.00065015914,0.025498934,0.931805,0.00021284012],"about_ca_topic_score_codex":0.0095914705,"about_ca_topic_score_gemma":0.020992137,"teacher_disagreement_score":0.069111705,"about_ca_system_score_codex":0.004665304,"about_ca_system_score_gemma":0.004175543,"threshold_uncertainty_score":0.0338493},"labels":[],"label_agreement":null},{"id":"W1985285674","doi":"10.1016/j.annpat.2011.10.013","title":"Détermination de l’amplification de l’oncogène HER-2 dans le cancer du sein invasif par hybridation chromogénique in situ double couleur (dc-CISH) : étude comparative avec l’hybridation fluorescente in situ (FISH)","year":2011,"lang":"fr","type":"review","venue":"Annales de Pathologie","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Biology; Molecular biology; Medicine","score_opus":0.19465328660041734,"score_gpt":0.4239853753041589,"score_spread":0.22933208870374158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985285674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005877661,0.9975249,0.0007184007,0.000106905245,0.00007248667,0.0000044088383,0.000011225407,0.000008959658,0.0009649407],"genre_scores_gemma":[0.003350836,0.99430346,0.0007593823,0.00012159359,0.0000732034,0.000008148952,0.00003890392,0.0000037341367,0.0013408215],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996991,0.000041336807,0.00003376142,0.00008861927,0.00010998954,0.000027230708],"domain_scores_gemma":[0.99952567,0.00031204612,0.0000466559,0.000015317552,0.00008373144,0.000016567088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001063258,0.00091168896,0.0013475964,0.002546868,0.00017150088,0.00086867856,0.0009400473,0.0009293128,0.0017344276],"category_scores_gemma":[0.000707585,0.00048305807,0.0005339674,0.0017511677,0.00079068984,0.0013271164,0.00038604517,0.0010040681,0.0013071501],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103478524,0.000048102025,0.0006311827,0.0109294895,0.00014076488,0.00064314046,0.00010033854,0.00033220666,0.020882068,0.0024957263,0.006206956,0.95748657],"study_design_scores_gemma":[0.000045234698,0.00020392833,0.0048371516,0.0021940414,0.00054021535,0.011103253,0.00018263253,0.00028717995,0.029602801,0.0014526146,0.94948167,0.000069187074],"about_ca_topic_score_codex":0.0017605133,"about_ca_topic_score_gemma":0.0022791515,"teacher_disagreement_score":0.002546868,"about_ca_system_score_codex":0.00077415246,"about_ca_system_score_gemma":0.0006172242,"threshold_uncertainty_score":0.0058022738},"labels":[],"label_agreement":null},{"id":"W1985328983","doi":"10.1200/jco.2007.12.8033","title":"Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service; American Society of Clinical Oncology","keywords":"Medicine; Tissue microarray; Oncology; Internal medicine; Human Epidermal Growth Factor Receptor 2; Biomarker; Clinical Oncology; Trastuzumab; Epidermal growth factor receptor; Estrogen receptor; Immunohistochemistry; Pathology; Cancer; Breast cancer; Biology","score_opus":0.6171535550304519,"score_gpt":0.662183900523995,"score_spread":0.04503034549354312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985328983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58245605,0.021710278,0.3406898,0.014957847,0.007936153,0.004407784,0.0025276819,0.0016920442,0.023622269],"genre_scores_gemma":[0.72738695,0.0010726071,0.2606123,0.003835992,0.00072142034,0.0025863938,0.0011540739,0.0004561485,0.0021740978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.91903925,0.0526603,0.009515534,0.003305734,0.014794586,0.00068454305],"domain_scores_gemma":[0.9321131,0.035430036,0.0071700234,0.006415233,0.017785069,0.0010865226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.076897785,0.0011389962,0.0011113918,0.002526156,0.0013752681,0.0018183638,0.0024363906,0.001818151,0.0011196252],"category_scores_gemma":[0.08064017,0.000517449,0.0010399395,0.0020318301,0.0034113214,0.00087254506,0.001632712,0.0026937977,0.0006168034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008312652,0.0014456236,0.42102063,0.004646651,0.00265017,0.0011676867,0.0034739631,0.0072670598,0.13698813,0.015961643,0.06601559,0.33105016],"study_design_scores_gemma":[0.0018562097,0.007347455,0.63840127,0.0025697637,0.0014908153,0.005732921,0.0025546532,0.08122478,0.11286293,0.025360677,0.1199502,0.0006483794],"about_ca_topic_score_codex":0.0015009536,"about_ca_topic_score_gemma":0.0034540636,"teacher_disagreement_score":0.076897785,"about_ca_system_score_codex":0.0015043933,"about_ca_system_score_gemma":0.0013050727,"threshold_uncertainty_score":0.4066792},"labels":[],"label_agreement":null},{"id":"W1986004507","doi":"10.1158/0008-5472.sabcs-4115","title":"Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Tolerability; Medicine; Metastatic breast cancer; Trastuzumab; Taxane; Internal medicine; Sunitinib; Dosing; Breast cancer; Clinical endpoint; Lapatinib; Placebo; Oncology; Pharmacology; Adverse effect; Cancer; Clinical trial; Pathology","score_opus":0.1784208525827542,"score_gpt":0.5111586758417982,"score_spread":0.332737823259044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986004507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897648,0.005477169,0.00054527284,0.00028971586,0.00008257593,0.0014991214,0.00078074925,0.00008854779,0.0014720478],"genre_scores_gemma":[0.99040776,0.0033039288,0.00096477946,0.00047004712,0.00020617725,0.0012683843,0.0018122907,0.000040162588,0.001526623],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991887,0.00043214927,0.00005312321,0.00011165905,0.00008418201,0.00013008469],"domain_scores_gemma":[0.99903095,0.00020914807,0.0002446901,0.000068919086,0.00006337974,0.0003828829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029305972,0.0015075317,0.003039352,0.0004475449,0.00041789757,0.0010246871,0.0009421549,0.0012322693,0.004123412],"category_scores_gemma":[0.0012521865,0.0005867464,0.0015835153,0.0005107847,0.0008194365,0.0009685608,0.00027703922,0.002084242,0.0008504081],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7052094,0.07453036,0.009249967,0.0017368275,0.0029464017,0.00048519543,0.00039071357,0.0023991077,0.054206084,0.00015248785,0.0038440381,0.14484952],"study_design_scores_gemma":[0.36974755,0.6002105,0.021201774,0.000069958885,0.0010011833,0.00054811867,0.000059965198,0.0008941535,0.0035379957,0.000119051285,0.0025760462,0.00003366952],"about_ca_topic_score_codex":0.00083659636,"about_ca_topic_score_gemma":0.0019098788,"teacher_disagreement_score":0.004123412,"about_ca_system_score_codex":0.0009618721,"about_ca_system_score_gemma":0.001359501,"threshold_uncertainty_score":0.015498638},"labels":[],"label_agreement":null},{"id":"W1986396848","doi":"10.1016/j.drup.2008.04.001","title":"Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents","year":2008,"lang":"en","type":"review","venue":"Drug Resistance Updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Fondation de France; American Association for Cancer Research","keywords":"Medicine; Biomarker; Biomarker discovery; Trastuzumab; Imatinib; Drug; Clinical trial; Breast cancer; Druggability; Personalized medicine; Sunitinib; Oncology; Cancer; Pharmacology; Bioinformatics; Cancer research; Internal medicine; Biology; Proteomics","score_opus":0.1392766723441191,"score_gpt":0.4201719401740726,"score_spread":0.2808952678299535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986396848","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013720979,0.99741673,0.0004568161,0.0011450932,0.00024743384,0.000004415627,0.000010998248,0.000010330756,0.0005708976],"genre_scores_gemma":[0.0009124487,0.99616075,0.00097611774,0.0007520724,0.00048167366,0.000009258033,0.000029898556,0.0000031915158,0.0006745807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992949,0.00015668276,0.000108034685,0.000106958156,0.00028263291,0.00005071443],"domain_scores_gemma":[0.99760604,0.0014504134,0.0001872551,0.000053052117,0.00060857314,0.00009462001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036771616,0.0009995464,0.0031073329,0.0022413405,0.00030815793,0.002197026,0.0014734833,0.0021549165,0.0026604636],"category_scores_gemma":[0.0029815147,0.00045505166,0.00075468,0.0022176367,0.0009402516,0.0037437628,0.0009906122,0.0034097265,0.0021861691],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011283127,0.000085705404,0.0002934376,0.006619154,0.000069012385,0.00025855232,0.000066768705,0.00040995193,0.0019990213,0.005090586,0.028795315,0.9561997],"study_design_scores_gemma":[0.000049937935,0.00018912437,0.0009052514,0.0024868883,0.00014804787,0.0018793012,0.00011798149,0.00041809966,0.0012207103,0.003689669,0.98886466,0.000030291949],"about_ca_topic_score_codex":0.001271373,"about_ca_topic_score_gemma":0.0027560256,"teacher_disagreement_score":0.0036771616,"about_ca_system_score_codex":0.0010401793,"about_ca_system_score_gemma":0.0016767995,"threshold_uncertainty_score":0.01944691},"labels":[],"label_agreement":null},{"id":"W1986405458","doi":"10.1179/joc.2011.23.1.32","title":"Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Chemotherapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Vinorelbine; Trastuzumab; Oncology; Medicine; Breast cancer; Internal medicine; Chemotherapy; Cancer; Cisplatin","score_opus":0.027853901849152547,"score_gpt":0.3377025580965879,"score_spread":0.30984865624743535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986405458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392235,0.0052791443,0.00013494607,0.0000923632,0.0000105764575,0.000016244097,0.000023100953,0.0000035713915,0.000517808],"genre_scores_gemma":[0.9983181,0.001090357,0.00018862428,0.00005680795,0.000022807233,0.000010680354,0.00006031785,0.0000010713176,0.0002511933],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997423,0.00016042033,0.0000118839835,0.000014976387,0.000034647965,0.00003571544],"domain_scores_gemma":[0.9997862,0.00009540471,0.00004277824,0.0000088480265,0.000008996246,0.00005783978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062519265,0.00013543347,0.0003603318,0.00011313583,0.00009237902,0.00014963836,0.00011923681,0.00015394534,0.0003890707],"category_scores_gemma":[0.0007837065,0.00007616179,0.00013864921,0.00012350605,0.00010757172,0.00012300654,0.00010783618,0.00030408174,0.00006002532],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081639305,0.0039319494,0.22035415,0.0004946022,0.0004987006,0.002636377,0.00029327697,0.003444283,0.056598708,0.00032496656,0.0016890311,0.6280947],"study_design_scores_gemma":[0.013930362,0.16958408,0.7530131,0.00014813761,0.00069708395,0.008711538,0.00018428253,0.004405578,0.028850676,0.00067109487,0.019760866,0.000043143813],"about_ca_topic_score_codex":0.00034048143,"about_ca_topic_score_gemma":0.0017244042,"teacher_disagreement_score":0.00062519265,"about_ca_system_score_codex":0.00024643436,"about_ca_system_score_gemma":0.00020553221,"threshold_uncertainty_score":0.0033063889},"labels":[],"label_agreement":null},{"id":"W1987039060","doi":"10.1016/j.molimm.2011.05.016","title":"Novel method for differentiation between Trastuzumab and host adaptive response","year":2011,"lang":"en","type":"article","venue":"Molecular Immunology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University","funders":"Canadian Breast Cancer Research Alliance","keywords":"Trastuzumab; Epitope; Monoclonal antibody; Epidermal growth factor receptor; Antibody; SKBR3; Atezolizumab; Cancer research; Mutant; Biology; Pertuzumab; Cancer; Immune system; Cancer cell; Breast cancer; Immunology; Immunotherapy; Biochemistry; Human breast; Genetics; Gene","score_opus":0.08670512800503326,"score_gpt":0.3691413584816509,"score_spread":0.28243623047661764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987039060","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.352866,0.0077569233,0.6225225,0.00087798346,0.0007571405,0.00048565873,0.00086967176,0.0016293577,0.0122348],"genre_scores_gemma":[0.6315253,0.0035474913,0.34190768,0.00066638674,0.0001955677,0.00079968345,0.001136308,0.0001966048,0.02002499],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996648,0.0000768969,0.000022837366,0.00009917697,0.00008399944,0.00005220899],"domain_scores_gemma":[0.99977285,0.00006994037,0.000029832714,0.000037628808,0.000058008154,0.000031718802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050072157,0.0007390319,0.0004565961,0.0008710191,0.0003076938,0.00055319874,0.00050600106,0.0007759657,0.0019393446],"category_scores_gemma":[0.00038492805,0.00030050403,0.00037413643,0.00030254072,0.00029697406,0.00058636593,0.00057299505,0.0014646051,0.0008730765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104863,0.0000405611,0.00036447556,0.000094879855,0.000014791219,0.000047744044,0.00003564474,0.000058932867,0.98615813,0.0008773718,0.00023941058,0.0119632315],"study_design_scores_gemma":[0.0000401563,0.00019105904,0.0013162382,0.000016866135,0.00005403348,0.00046079274,0.00003295261,0.0045454544,0.98479617,0.0006857926,0.007842456,0.000018043782],"about_ca_topic_score_codex":0.00026323154,"about_ca_topic_score_gemma":0.00059397897,"teacher_disagreement_score":0.0019393446,"about_ca_system_score_codex":0.0004257679,"about_ca_system_score_gemma":0.00029669845,"threshold_uncertainty_score":0.006487787},"labels":[],"label_agreement":null},{"id":"W1987122879","doi":"10.1016/s1368-7646(03)00024-4","title":"The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery","year":2003,"lang":"en","type":"review","venue":"Drug Resistance Updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Breast Cancer Society of Canada; Cancer Research Society","keywords":"ErbB; Biology; Receptor tyrosine kinase; Receptor; Drug discovery; Signal transduction; Cancer research; Context (archaeology); Cell signaling; Bioinformatics; Cell biology; Genetics","score_opus":0.1794879031040422,"score_gpt":0.4597632419439453,"score_spread":0.2802753388399031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987122879","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000115448835,0.99828655,0.00016037535,0.00049195846,0.0002922211,0.0000029569107,0.000008563615,0.000004839647,0.00063700316],"genre_scores_gemma":[0.00056724926,0.99757034,0.0002894896,0.00040348477,0.00028781095,0.000005142615,0.000016546825,0.0000011573991,0.00085879705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997583,0.000050652037,0.000030996176,0.00004375299,0.000092560265,0.00002365351],"domain_scores_gemma":[0.99961424,0.00021324305,0.00003619941,0.000010144753,0.00009763825,0.000028477478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012147317,0.0009599724,0.001990723,0.0016662888,0.00031311065,0.0016596004,0.0010100328,0.0018579052,0.0024806692],"category_scores_gemma":[0.0008593181,0.00034440617,0.0005329395,0.0022636016,0.0008086606,0.002510792,0.00060469523,0.0025431714,0.0016803298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022574082,0.00009800812,0.00023259675,0.008433335,0.00007789677,0.0005328307,0.000105270876,0.00040089487,0.0031539518,0.0052583236,0.04970132,0.93177986],"study_design_scores_gemma":[0.000050997878,0.000119461896,0.000610081,0.0016244069,0.00009964153,0.0016090671,0.000118101096,0.00011919117,0.0005977947,0.0024066847,0.99262553,0.00001901614],"about_ca_topic_score_codex":0.001584614,"about_ca_topic_score_gemma":0.0042618476,"teacher_disagreement_score":0.0024806692,"about_ca_system_score_codex":0.0010799237,"about_ca_system_score_gemma":0.0013595904,"threshold_uncertainty_score":0.0082986355},"labels":[],"label_agreement":null},{"id":"W1987951388","doi":"10.1089/dna.2005.24.351","title":"HER2-Mediated Internalization of a Targeted Prodrug Cytotoxic Conjugate Is Dependent on the Valency of the Targeting Ligand","year":2005,"lang":"en","type":"article","venue":"DNA and Cell Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Susan G. Komen; Susan G. Komen for the Cure","keywords":"Internalization; Prodrug; Biology; Cytotoxicity; Cytotoxic T cell; Downregulation and upregulation; Ligand (biochemistry); Cancer research; Conjugate; Receptor; Biochemistry; Cell biology; Pharmacology; In vitro","score_opus":0.01696157687622419,"score_gpt":0.2839249945242098,"score_spread":0.2669634176479856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987951388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99292207,0.00059981504,0.0043218513,0.00003658033,0.000008949814,0.000052278418,0.00005493097,0.000048978145,0.0019544968],"genre_scores_gemma":[0.9940228,0.00046365993,0.0026498789,0.000034185632,0.0000039892016,0.000041378382,0.00014075916,0.000015257006,0.0026281457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999126,0.000016098156,0.0000071823,0.000018887575,0.000025203963,0.000020112353],"domain_scores_gemma":[0.9999541,0.000011151765,0.000012323048,0.000006442862,0.000007804373,0.000008273271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011220243,0.00029667863,0.00021116757,0.00013319857,0.00009832904,0.00021320565,0.0001470942,0.00019945072,0.00076221727],"category_scores_gemma":[0.00010490219,0.00013458688,0.00011798894,0.00011843419,0.0001531864,0.00015824598,0.000138365,0.00029930772,0.00020365286],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068112466,0.000029253684,0.00008803386,0.000029941846,0.000004070994,0.000042810396,0.000013324211,0.00024010209,0.9973786,0.0002114989,0.000024608054,0.0018697814],"study_design_scores_gemma":[0.000012448397,0.00031065068,0.0005278574,0.0000028925162,0.000006273287,0.0001293231,0.000004053666,0.00055364764,0.9977214,0.000020511568,0.0007088866,0.000002074058],"about_ca_topic_score_codex":0.0003519063,"about_ca_topic_score_gemma":0.0004159481,"teacher_disagreement_score":0.00076221727,"about_ca_system_score_codex":0.00038546656,"about_ca_system_score_gemma":0.00019017253,"threshold_uncertainty_score":0.0027967691},"labels":[],"label_agreement":null},{"id":"W1988187875","doi":"10.1042/bj20110921","title":"The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist","year":2012,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"ErbB; ERBB4; Neuregulin; Tyrosine phosphorylation; Receptor tyrosine kinase; ERBB3; Cell biology; Phosphorylation; Cancer research; Biology; Neuregulin 1; Tyrosine kinase; Platelet-derived growth factor receptor; Chemistry; Receptor; Signal transduction; Biochemistry; Growth factor","score_opus":0.03743538225188499,"score_gpt":0.36104776715802245,"score_spread":0.3236123849061375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988187875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784913,0.0023056094,0.010552371,0.0004361958,0.0001527811,0.0001682056,0.0015031372,0.00027385703,0.006116561],"genre_scores_gemma":[0.9737235,0.002086234,0.009888423,0.00038647154,0.000022302236,0.00017234385,0.002292365,0.000120883094,0.011307573],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997985,0.000041031013,0.000021705227,0.00003233283,0.000071932256,0.000034477354],"domain_scores_gemma":[0.9999337,0.000008371932,0.000018836095,0.000008595942,0.000008220503,0.000022275432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027188123,0.0005990612,0.0003964922,0.00020709848,0.00020844102,0.00021662355,0.00047457666,0.00046337416,0.004091772],"category_scores_gemma":[0.0001296715,0.0002880682,0.00047633811,0.00019259774,0.00026091182,0.00021569838,0.0002386821,0.0008070659,0.0019538584],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102652484,0.000046706497,0.00016062152,0.000030325009,0.000018353834,0.00022973263,0.000008982145,0.00013075933,0.9963408,0.00031282927,0.0001509167,0.0024672346],"study_design_scores_gemma":[0.0003477923,0.0012765629,0.0059896642,0.000019259069,0.00006353369,0.0069579296,0.000045565896,0.0031862468,0.9430649,0.00034270703,0.038674563,0.000031139632],"about_ca_topic_score_codex":0.00078283943,"about_ca_topic_score_gemma":0.0007319654,"teacher_disagreement_score":0.004091772,"about_ca_system_score_codex":0.00030495183,"about_ca_system_score_gemma":0.00031294415,"threshold_uncertainty_score":0.013688326},"labels":[],"label_agreement":null},{"id":"W1988557714","doi":"10.1016/j.ctrv.2003.10.002","title":"Epidermal growth factor receptor: a promising target in solid tumours","year":2003,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Monoclonal antibody; Tyrosine kinase; Cancer research; Cancer; Receptor tyrosine kinase; Signal transduction; Targeted therapy; EGFR inhibitors; Cetuximab; Blockade; Pharmacology; Receptor; Immunology; Antibody; Internal medicine; Biology; Cell biology","score_opus":0.2218575342477881,"score_gpt":0.48518779668646167,"score_spread":0.2633302624386736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988557714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012104163,0.9971686,0.00017860343,0.00040426245,0.0005117049,0.0000074236063,0.000026766445,0.000012050897,0.0015696236],"genre_scores_gemma":[0.0004926945,0.9971521,0.00023401415,0.00037068178,0.00030456737,0.000008307701,0.000041574098,0.0000018843577,0.0013941863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977,0.000037183505,0.000029430961,0.00003576421,0.00010455488,0.000023127164],"domain_scores_gemma":[0.99970967,0.00012858553,0.00004406911,0.0000083354535,0.000075219825,0.000034151868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008243148,0.0013023783,0.0021006872,0.0022341656,0.00032492832,0.001255317,0.00079270225,0.0014558356,0.0050712386],"category_scores_gemma":[0.00064334495,0.00030136819,0.0005050566,0.0027920126,0.00044522184,0.0016465135,0.00053046376,0.0018169043,0.0036554725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015520329,0.0000891942,0.00011907761,0.010524842,0.00008729262,0.00036706938,0.000035741312,0.0003236285,0.00305092,0.001829484,0.08130823,0.9021094],"study_design_scores_gemma":[0.000051477433,0.0001439147,0.00044153622,0.0015540838,0.00016509974,0.0013915971,0.000042020027,0.00007168593,0.0005234434,0.00074654975,0.99485564,0.000012910601],"about_ca_topic_score_codex":0.00116896,"about_ca_topic_score_gemma":0.0031895298,"teacher_disagreement_score":0.0050712386,"about_ca_system_score_codex":0.0008262415,"about_ca_system_score_gemma":0.0012746948,"threshold_uncertainty_score":0.016965032},"labels":[],"label_agreement":null},{"id":"W1988717588","doi":"10.3390/cancers4030725","title":"Automated Quantitative Analysis of p53, Cyclin D1, Ki67 and pERK Expression in Breast Carcinoma Does Not Differ from Expert Pathologist Scoring and Correlates with Clinico-Pathological Characteristics","year":2012,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Pathological; Pathology; Biomarker; Kappa; Immunohistochemistry; Lymph node; Oncology; Cancer; Internal medicine; Biology","score_opus":0.059697679766819174,"score_gpt":0.37771644454020675,"score_spread":0.3180187647733876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988717588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97801036,0.0005233299,0.019496232,0.00004191401,0.000013735835,0.00003127077,0.00023919526,0.00020192922,0.0014420988],"genre_scores_gemma":[0.99093086,0.00010894304,0.008233231,0.000021346157,0.00001286655,0.00002032419,0.0002427455,0.000020253972,0.0004095067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735767,0.0009184176,0.00020078926,0.00045060483,0.0009800309,0.00009243827],"domain_scores_gemma":[0.99444675,0.0024067156,0.0010198877,0.00088923017,0.0010990847,0.00013832407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033206728,0.00024778344,0.00034344158,0.0014294173,0.00014912472,0.00066610693,0.0002770432,0.00027808,0.0009652389],"category_scores_gemma":[0.0058228304,0.00022113431,0.00020236163,0.0006900774,0.00041921972,0.0004451675,0.00032846993,0.00018019922,0.00050193444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007135123,0.0000992974,0.7931599,0.0001491542,0.00034075935,0.00010073923,0.00024768698,0.002003818,0.12481714,0.00017889547,0.00044671714,0.07774232],"study_design_scores_gemma":[0.000017330363,0.00036777556,0.957245,0.000013677439,0.00008012394,0.00074293057,0.00013783522,0.015169397,0.02514497,0.00039394217,0.00066323427,0.000023869829],"about_ca_topic_score_codex":0.0006210906,"about_ca_topic_score_gemma":0.0013741401,"teacher_disagreement_score":0.0033206728,"about_ca_system_score_codex":0.00022295373,"about_ca_system_score_gemma":0.00015136157,"threshold_uncertainty_score":0.017561615},"labels":[],"label_agreement":null},{"id":"W1988936433","doi":"10.1002/cncr.20970","title":"Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival","year":2005,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; St. Paul's Hospital; University of British Columbia; BC Cancer Agency","funders":"Michael Smith Health Research BC","keywords":"Medicine; Oncology; Internal medicine; Breast carcinoma; Univariate analysis; Breast cancer; Tissue microarray; Proportional hazards model; Survival analysis; Multivariate analysis; Lymph node; Log-rank test; Immunohistochemistry; Carcinoma; Pathology; Cancer","score_opus":0.045872047031467245,"score_gpt":0.3330101099408247,"score_spread":0.28713806290935745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988936433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99926454,0.00038939255,0.0001086448,0.000016326409,0.0000020033974,0.0000012413187,0.000022220735,0.0000037186028,0.00019183558],"genre_scores_gemma":[0.99961436,0.000121527504,0.00014436882,0.0000063377843,0.0000041608464,0.0000018203622,0.00004251931,0.0000011478778,0.0000637152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975854,0.00006821129,0.000018864863,0.00004058309,0.00005928396,0.000054592398],"domain_scores_gemma":[0.9991522,0.00035412845,0.00025148471,0.0000692264,0.000048593738,0.00012443734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040689606,0.00018089179,0.00023043969,0.00031339767,0.00015551144,0.00023094295,0.00012402651,0.00014075231,0.00126583],"category_scores_gemma":[0.0007910655,0.0000898753,0.0002592309,0.00021652754,0.00022289295,0.00012973681,0.0002293302,0.00022602345,0.00016249793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024133157,0.00012978913,0.80322826,0.00006382638,0.00024861106,0.0003894831,0.000046393914,0.00058161264,0.17655191,0.000058391182,0.00017985872,0.01610864],"study_design_scores_gemma":[0.000020411087,0.00073398574,0.9690323,0.000008509564,0.00021558149,0.0023585868,0.00007882414,0.0012212043,0.025746962,0.00006210861,0.00051563134,0.000006026341],"about_ca_topic_score_codex":0.00028660477,"about_ca_topic_score_gemma":0.0006687186,"teacher_disagreement_score":0.00126583,"about_ca_system_score_codex":0.00017650532,"about_ca_system_score_gemma":0.00019542205,"threshold_uncertainty_score":0.004234612},"labels":[],"label_agreement":null},{"id":"W1989502045","doi":"10.4137/cmt.s3783","title":"Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside","year":2011,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Lapatinib; Trastuzumab; Breast cancer; Cancer research; Medicine; Tyrosine kinase; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Metastatic breast cancer; Cancer; Targeted therapy; Pertuzumab; Letrozole; Oncology; Internal medicine; Receptor; Tamoxifen","score_opus":0.18813864389023785,"score_gpt":0.4205964844946525,"score_spread":0.23245784060441463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989502045","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057740666,0.9065737,0.0061784224,0.011393613,0.0009187723,0.00008223692,0.000075614036,0.00016477756,0.016872212],"genre_scores_gemma":[0.32526556,0.6409555,0.00881838,0.0050871572,0.0023859392,0.000102232036,0.00023386956,0.000027291931,0.017124115],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988484,0.000040460374,0.000009618837,0.000012479864,0.00003361975,0.000018885969],"domain_scores_gemma":[0.9999368,0.000023225897,0.000010257078,0.0000019586266,0.00001049266,0.000017267792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005209575,0.0002636867,0.00035078137,0.00028139562,0.00012407513,0.0004870361,0.0002903806,0.0006442088,0.0010507171],"category_scores_gemma":[0.00027774772,0.000088027075,0.00017139234,0.00024787465,0.00020703272,0.00064851384,0.00027271072,0.0008231355,0.000418749],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010553853,0.00060039695,0.0012805292,0.0012603273,0.00004207518,0.0018348165,0.00014046625,0.00075523707,0.068114065,0.005163334,0.021295644,0.8984578],"study_design_scores_gemma":[0.002317633,0.011415652,0.010834665,0.00058291375,0.00032715278,0.031981893,0.0003027174,0.0045403955,0.12617745,0.006713665,0.80471003,0.00009573004],"about_ca_topic_score_codex":0.00014346505,"about_ca_topic_score_gemma":0.00063382095,"teacher_disagreement_score":0.0010507171,"about_ca_system_score_codex":0.00034099078,"about_ca_system_score_gemma":0.0002516528,"threshold_uncertainty_score":0.003515005},"labels":[],"label_agreement":null},{"id":"W1989558595","doi":"10.1097/01.pgp.0000152026.39268.57","title":"Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma","year":2005,"lang":"en","type":"article","venue":"International Journal of Gynecological Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Tissue microarray; Immunohistochemistry; Pathology; Ovarian carcinoma; Fluorescence in situ hybridization; Serous fluid; Biology; Carcinoma; Ovarian cancer; Stage (stratigraphy); Cancer; Medicine; Chromosome; Gene","score_opus":0.04215770612288521,"score_gpt":0.40388880445555314,"score_spread":0.3617310983326679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989558595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99933845,0.00022710879,0.0001884909,0.00000546758,0.0000011905171,0.0000054217726,0.000020165626,0.0000025847546,0.00021124337],"genre_scores_gemma":[0.99946696,0.00012885625,0.00020385797,0.000007521716,0.0000019205825,0.0000061014393,0.00006638635,0.000001034263,0.00011731792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981517,0.000037630616,0.00001736593,0.000027037502,0.00006200034,0.000040787312],"domain_scores_gemma":[0.99974257,0.000093548275,0.000045861372,0.000025369725,0.000042604806,0.000050080376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003996047,0.00013639093,0.00020348672,0.00072447496,0.00018658515,0.000259032,0.00012154769,0.00031031837,0.00059196446],"category_scores_gemma":[0.00048772414,0.00016375314,0.00013556551,0.0003557551,0.00024484858,0.00017272976,0.00019702001,0.00020309653,0.000109290355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011374876,0.00013399702,0.7041143,0.000054252625,0.000037668142,0.00154247,0.00035037365,0.00038117106,0.28289315,0.000052887768,0.0000896632,0.009212617],"study_design_scores_gemma":[0.000022968516,0.00053549616,0.9805244,0.0000042996758,0.000027464033,0.0034422397,0.00021888544,0.00084240345,0.013741803,0.00004575438,0.00058856735,0.000005632618],"about_ca_topic_score_codex":0.0010855452,"about_ca_topic_score_gemma":0.0017939319,"teacher_disagreement_score":0.0010855452,"about_ca_system_score_codex":0.0002082098,"about_ca_system_score_gemma":0.00011153008,"threshold_uncertainty_score":0.0021584034},"labels":[],"label_agreement":null},{"id":"W1990275745","doi":"10.1158/1078-0432.ccr-09-0931","title":"Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; National Institutes of Health","keywords":"Trastuzumab; Medicine; Cyclophosphamide; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.31175981025520483,"score_gpt":0.6359241077453549,"score_spread":0.3241642974901501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990275745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973062,0.0013382945,0.00028249042,0.000031081458,0.000030154126,0.000026385083,0.00015437859,0.00001345625,0.0008174922],"genre_scores_gemma":[0.9972921,0.00076002965,0.0004493953,0.000027296754,0.000013937379,0.00003591583,0.00039839285,0.000010666691,0.0010123041],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997967,0.00006904977,0.000013095429,0.000028270217,0.00004763568,0.000045186145],"domain_scores_gemma":[0.99984384,0.000052230294,0.000024659095,0.00001826036,0.000017032446,0.000043899596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002329403,0.00031624778,0.00043504252,0.00013392758,0.0001001799,0.00026318285,0.00017898531,0.00020087906,0.0009277871],"category_scores_gemma":[0.0001843745,0.000091635535,0.00018434778,0.00013164082,0.00017938526,0.00022391453,0.000105961735,0.00042657144,0.00013820584],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003032658,0.0007272568,0.0007211982,0.00008458876,0.000032800606,0.00006924202,0.000029141573,0.00070513,0.9903238,0.00011846349,0.00015051375,0.0040051746],"study_design_scores_gemma":[0.000256243,0.01722355,0.008228058,0.000012125662,0.00005732716,0.0002290158,0.000043568678,0.0022055164,0.96997863,0.000036234454,0.0017226005,0.0000072153894],"about_ca_topic_score_codex":0.0013051777,"about_ca_topic_score_gemma":0.0019761717,"teacher_disagreement_score":0.0013051777,"about_ca_system_score_codex":0.00033809931,"about_ca_system_score_gemma":0.00027258205,"threshold_uncertainty_score":0.003103733},"labels":[],"label_agreement":null},{"id":"W1990719422","doi":"10.1007/s10549-012-2157-7","title":"Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis","year":2012,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pertuzumab; Medicine; Rash; Internal medicine; Oncology; Trastuzumab; Incidence (geometry); Breast cancer; Docetaxel; Clinical trial; Cancer","score_opus":0.271116512031164,"score_gpt":0.5036414260120149,"score_spread":0.2325249139808509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990719422","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03332068,0.9635773,0.0013751764,0.00023027508,0.0002677435,0.00008266542,0.0006880825,0.00004232554,0.0004157886],"genre_scores_gemma":[0.55472225,0.43973643,0.0021251212,0.0009002076,0.00040031172,0.00021933838,0.00083606876,0.00005719293,0.0010030457],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968556,0.0014614511,0.0006361398,0.0005922812,0.00029783064,0.00015669865],"domain_scores_gemma":[0.99346536,0.0047121937,0.0009175192,0.00036771485,0.00041699037,0.000120282566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004829545,0.0024312956,0.008779495,0.0016221806,0.00033581755,0.0015063665,0.0014343351,0.0017948638,0.0034416397],"category_scores_gemma":[0.010689022,0.001323826,0.03126746,0.0027608199,0.00033918748,0.00094945176,0.00096878596,0.00207253,0.00028803304],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009263736,0.00004040058,0.012110521,0.043290973,0.9222466,0.00018705553,0.000042005347,0.0008060075,0.00036542054,0.00010020078,0.00072477787,0.010822371],"study_design_scores_gemma":[0.0007748349,0.00023210756,0.006331849,0.0011410699,0.9900774,0.00011293285,0.000023029414,0.00023133057,0.00011603756,0.00015530194,0.00078456115,0.000019562824],"about_ca_topic_score_codex":0.0048861126,"about_ca_topic_score_gemma":0.008307474,"teacher_disagreement_score":0.008779495,"about_ca_system_score_codex":0.0009860769,"about_ca_system_score_gemma":0.00093615305,"threshold_uncertainty_score":0.025541365},"labels":[],"label_agreement":null},{"id":"W1990829939","doi":"10.1038/modpathol.3800118","title":"Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas","year":2004,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Epidermal growth factor receptor; Epidermal growth factor; Biology; Growth factor receptor; Growth factor receptor inhibitor; Internal medicine; Endocrinology; TGF alpha; Cancer research; Receptor expression; Receptor; Medicine","score_opus":0.03998788086667816,"score_gpt":0.31347896644590045,"score_spread":0.2734910855792223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990829939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463934,0.0017913197,0.0007418709,0.000039645747,0.000016529675,0.000015205909,0.00024670103,0.000021564805,0.0024879584],"genre_scores_gemma":[0.99726784,0.00062742946,0.00045679908,0.000017498078,0.000012995421,0.0000115753655,0.00033273906,0.000008301276,0.0012649536],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999856,0.000016155254,0.000012307605,0.000019530939,0.00004547719,0.000050491984],"domain_scores_gemma":[0.99978,0.00008973239,0.000019260116,0.000013877383,0.000043849766,0.00005323907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002032329,0.00014850109,0.00020458474,0.0010733155,0.0002785566,0.00033275905,0.00016302652,0.00018277082,0.0013461848],"category_scores_gemma":[0.0003517116,0.0001614642,0.00017812058,0.00053519994,0.0003610059,0.00019974283,0.00019294936,0.000263001,0.00025193536],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029571645,0.000035943052,0.016313432,0.00010401617,0.00003479407,0.0018606189,0.00024011824,0.0000822383,0.97299623,0.00029600944,0.000088636916,0.0049908767],"study_design_scores_gemma":[0.00011694895,0.001296514,0.48502824,0.000018137842,0.00021422032,0.013376689,0.0014568204,0.0013058255,0.4859043,0.00045257597,0.010794278,0.000035540088],"about_ca_topic_score_codex":0.0042597856,"about_ca_topic_score_gemma":0.00282979,"teacher_disagreement_score":0.0042597856,"about_ca_system_score_codex":0.00027524502,"about_ca_system_score_gemma":0.00028327908,"threshold_uncertainty_score":0.008469999},"labels":[],"label_agreement":null},{"id":"W1991720804","doi":"10.13034/cysj-2013-008","title":"SLAK-1, a proposed antibody-conjugated illudin analogue that selectively targets breast cancer<sup>1</sup>","year":2013,"lang":"en","type":"article","venue":"Journal of Student Science and Technology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Conjugated system; Breast cancer; Antibody; Cancer; Chemistry; Molecular biology; Biology; Genetics; Organic chemistry","score_opus":0.024877469565184114,"score_gpt":0.3624262542020876,"score_spread":0.3375487846369035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991720804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97292894,0.006078283,0.013791204,0.00040034245,0.0000986019,0.000087080545,0.00019265992,0.00015328111,0.006269665],"genre_scores_gemma":[0.9893,0.0011193245,0.006147323,0.0001329505,0.0000092123,0.00002215751,0.00018319474,0.0000093786175,0.0030763934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999591,0.0000067832493,0.0000024678652,0.000008490033,0.0000120670575,0.000011038214],"domain_scores_gemma":[0.999979,0.0000022634267,0.000007659608,0.0000016647465,0.0000036864235,0.000005709465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005906496,0.0001861741,0.00014043538,0.00008088946,0.00008896352,0.00018106485,0.00028676138,0.00031377104,0.0010101108],"category_scores_gemma":[0.000064118,0.00006184209,0.00013558826,0.00009949987,0.0001315437,0.00018547369,0.00010849258,0.00026845187,0.00027531246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001853823,0.00003814072,0.00027925207,0.00017789098,0.000008696738,0.00012699602,0.000021211468,0.00089453,0.9892273,0.0009388618,0.00019343501,0.007908314],"study_design_scores_gemma":[0.00002789626,0.00048698872,0.00050414726,0.0000037765149,0.000013593658,0.00025467374,0.0000116053925,0.0016237455,0.9893085,0.000057540317,0.0077004363,0.000007057868],"about_ca_topic_score_codex":0.00031325905,"about_ca_topic_score_gemma":0.0003632189,"teacher_disagreement_score":0.0010101108,"about_ca_system_score_codex":0.000240636,"about_ca_system_score_gemma":0.00013733434,"threshold_uncertainty_score":0.0033791661},"labels":[],"label_agreement":null},{"id":"W1991836995","doi":"10.1038/sj.bjc.6602098","title":"Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line","year":2004,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Canada; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Epidermal growth factor receptor; A431 cells; Biology; Epidermal growth factor; Tyrosine kinase; Epidermoid carcinoma; Cancer research; Autophosphorylation; DNA synthesis; Molecular biology; Biochemistry; DNA; Kinase; Receptor; Cell cycle; Cancer; Cell; Protein kinase A; Oncogene","score_opus":0.018930168018259818,"score_gpt":0.2920890244876561,"score_spread":0.2731588564693963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991836995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616903,0.0017235456,0.0011429003,0.0000307922,0.000012901424,0.000017808004,0.000083424056,0.000047783076,0.0007717687],"genre_scores_gemma":[0.9953892,0.000832764,0.0014464466,0.000013668657,0.0000055166206,0.000027647518,0.00014729875,0.000008168297,0.0021293135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999087,0.000013480149,0.000007582924,0.000019257855,0.000029172405,0.000021725327],"domain_scores_gemma":[0.9999604,0.0000055120418,0.000013024134,0.0000073797687,0.0000067495225,0.0000068719737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091263784,0.0003389557,0.00022193887,0.0001743868,0.00010164689,0.00023150315,0.00018668854,0.00021143291,0.00086952647],"category_scores_gemma":[0.00006664098,0.00010953742,0.0002751196,0.000096808064,0.00011031918,0.0001581971,0.00012754118,0.00036358854,0.00022150042],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050434242,0.000015399628,0.000047308968,0.000013692012,0.0000033921146,0.000024530767,0.000007815636,0.000056023433,0.9988716,0.00003534941,0.000009507434,0.00086483255],"study_design_scores_gemma":[0.0000058772252,0.00034330675,0.0007436474,0.0000011997494,0.000008068732,0.00010670019,0.0000074188456,0.00021010003,0.9977597,0.000007198922,0.00080553285,0.0000012750078],"about_ca_topic_score_codex":0.00049152784,"about_ca_topic_score_gemma":0.0007389368,"teacher_disagreement_score":0.00086952647,"about_ca_system_score_codex":0.0001626759,"about_ca_system_score_gemma":0.0001691246,"threshold_uncertainty_score":0.0029088259},"labels":[],"label_agreement":null},{"id":"W1992301100","doi":"10.1158/0008-5472.can-06-1595","title":"Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Ottawa","funders":"","keywords":"Autocrine signalling; Cancer research; Carcinogenesis; Cancer; Gene silencing; Cancer cell; Biology; Epidermal growth factor receptor; Paracrine signalling; Receptor","score_opus":0.08061258326414547,"score_gpt":0.4013514787068154,"score_spread":0.32073889544267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992301100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935341,0.0007483191,0.0030484197,0.00007815834,0.00003564385,0.000026485404,0.0004585792,0.00018862612,0.00188179],"genre_scores_gemma":[0.9946725,0.00039656996,0.0012655449,0.0000190741,0.0000053012436,0.000019614969,0.0004223265,0.000037645714,0.0031614269],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999819,0.000025805124,0.000021405116,0.000028776934,0.00006528494,0.00003963593],"domain_scores_gemma":[0.9997249,0.000057538386,0.000066681816,0.00006224783,0.000022487617,0.000066016975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013065539,0.00038074324,0.0003477668,0.0002853348,0.00012625552,0.00033546396,0.0001977444,0.00020078197,0.0019970073],"category_scores_gemma":[0.00014656049,0.00014944273,0.00028456055,0.00012648724,0.0002958657,0.00018022518,0.0001917552,0.0007147112,0.0005246621],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000569308,0.000020409949,0.00010500837,0.000015589907,0.0000060367424,0.00017233027,0.000010493864,0.00006654247,0.9985286,0.00019592512,0.000024005121,0.0007981012],"study_design_scores_gemma":[0.000009331687,0.00012710298,0.0012441454,0.000002030966,0.000010416207,0.00074654893,0.000012297427,0.00064528495,0.99583876,0.00004179381,0.0013199148,0.000002387082],"about_ca_topic_score_codex":0.0007780059,"about_ca_topic_score_gemma":0.00083632383,"teacher_disagreement_score":0.0019970073,"about_ca_system_score_codex":0.00028254947,"about_ca_system_score_gemma":0.00034020207,"threshold_uncertainty_score":0.006680608},"labels":[],"label_agreement":null},{"id":"W1992381279","doi":"10.1016/j.bbamcr.2011.03.006","title":"Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling","year":2011,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University; University of British Columbia","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Epidermal growth factor; Epidermal growth factor receptor; Somatostatin receptor; Somatostatin receptor 1; Signal transduction; Cell biology; Cyclin-dependent kinase 8; ERBB3; Cancer research; ErbB; Phosphorylation; EGFR inhibitors; HEK 293 cells; Somatostatin receptor 2; Somatostatin; Biology; Receptor; Endocrinology; Receptor tyrosine kinase; Biochemistry; Notch signaling pathway","score_opus":0.06273415189932313,"score_gpt":0.3378670819149432,"score_spread":0.27513293001562006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992381279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95020294,0.031707216,0.0015148032,0.0006816783,0.00012551842,0.000029951936,0.000187923,0.00004093593,0.015509075],"genre_scores_gemma":[0.99191767,0.0045439806,0.0006512801,0.00014488399,0.000035417896,0.000008188338,0.0001319619,0.000002960333,0.0025635397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998579,0.00004287885,0.000008765352,0.00001088301,0.000020640846,0.00005891503],"domain_scores_gemma":[0.99991536,0.00002932725,0.000017836084,0.000006194736,0.000007391311,0.000023840248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035475192,0.0002669944,0.00016750781,0.00031097347,0.00015029272,0.00062306726,0.0002647662,0.00045014842,0.0021322314],"category_scores_gemma":[0.00022659462,0.000108924745,0.00031500804,0.000077631994,0.0002856647,0.0004307024,0.00024951808,0.00029429307,0.00029985665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003534636,0.00016180798,0.0040960773,0.00033393656,0.000074789255,0.0018144175,0.00012332827,0.0012429834,0.93501836,0.009940331,0.0005757753,0.043083604],"study_design_scores_gemma":[0.00036762646,0.0034870328,0.086920105,0.00020023983,0.00020936679,0.0038403682,0.0008360356,0.0071016676,0.86478215,0.004465952,0.027716689,0.00007278445],"about_ca_topic_score_codex":0.0006687852,"about_ca_topic_score_gemma":0.00086375844,"teacher_disagreement_score":0.0021322314,"about_ca_system_score_codex":0.0004350595,"about_ca_system_score_gemma":0.0002612578,"threshold_uncertainty_score":0.0071330667},"labels":[],"label_agreement":null},{"id":"W1992785655","doi":"10.1006/bbrc.2000.3731","title":"Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3","year":2000,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre; University of Alberta","funders":"","keywords":"ERBB3; Receptor; Drug resistance; Chemistry; Pharmacology; Biology; Biochemistry; Epidermal growth factor receptor; Microbiology","score_opus":0.08551839111255723,"score_gpt":0.41578677843615414,"score_spread":0.3302683873235969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992785655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959241,0.00085938384,0.0011235366,0.00010774165,0.00004663654,0.000025130159,0.00050238165,0.000096111224,0.0013149581],"genre_scores_gemma":[0.9959791,0.000284303,0.00065886934,0.00003426696,0.0000069374446,0.000019960082,0.00050413667,0.00003318266,0.002479263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997154,0.000056475663,0.00002680437,0.000040002702,0.000083123414,0.00007824049],"domain_scores_gemma":[0.9998078,0.000055386336,0.00002399689,0.000046382793,0.000032891578,0.000033600976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018406358,0.0003525273,0.00066527457,0.00023272567,0.00020801018,0.00057959295,0.00024779807,0.00040638924,0.0025738042],"category_scores_gemma":[0.0002245694,0.00023532823,0.00045041885,0.00034991847,0.00022361157,0.00031642843,0.00025656307,0.0007197686,0.00085841253],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019711455,0.00003819513,0.00014223054,0.000013176817,0.000008688273,0.000043818796,0.000016530174,0.00007083223,0.99862146,0.000077548146,0.000056807006,0.00071360957],"study_design_scores_gemma":[0.00002121688,0.00029097122,0.003182144,0.000002416074,0.000013794755,0.00030948332,0.00002811252,0.0009612871,0.9938717,0.000024562467,0.0012890634,0.0000052945875],"about_ca_topic_score_codex":0.0015934426,"about_ca_topic_score_gemma":0.0009497097,"teacher_disagreement_score":0.0025738042,"about_ca_system_score_codex":0.0003456423,"about_ca_system_score_gemma":0.00021540734,"threshold_uncertainty_score":0.008610308},"labels":[],"label_agreement":null},{"id":"W1992809873","doi":"10.1245/s10434-007-9771-3","title":"EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases","year":2008,"lang":"en","type":"article","venue":"Annals of Surgical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancerfonden; National Natural Science Foundation of China; Cancer Research Society","keywords":"Medicine; Epidermal growth factor receptor; Surgical oncology; Lymph node; Primary tumor; Immunohistochemistry; Carcinoma; Targeted therapy; Laryngeal Neoplasm; Pathology; Oncology; Cancer research; Metastasis; Receptor; Cancer; Internal medicine","score_opus":0.1372243667815465,"score_gpt":0.42939965239453903,"score_spread":0.29217528561299255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992809873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985745,0.00026058152,0.000042345408,0.000012718254,0.0000026087864,0.0000037278548,0.0001268951,0.000003447436,0.0009731367],"genre_scores_gemma":[0.99919766,0.00012044681,0.00004604387,0.0000072557164,0.0000045069473,0.0000044406124,0.000113107344,0.0000014875551,0.0005050869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999064,0.000010891627,0.000007977937,0.000014814138,0.000023577237,0.00003630224],"domain_scores_gemma":[0.99985385,0.000057453028,0.000022625834,0.000008601183,0.000024257108,0.000033138815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018174533,0.00009639427,0.00019256891,0.00044668373,0.00020955974,0.00024789802,0.00012065735,0.00020094763,0.0024739855],"category_scores_gemma":[0.00061309343,0.0001226623,0.0001433521,0.0002893953,0.00019266551,0.00018468592,0.00018259733,0.0001633494,0.00024731044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042541614,0.00009690337,0.89310247,0.00007212573,0.000058600075,0.004638456,0.0004450767,0.00028159356,0.08342611,0.00019966318,0.00046602936,0.012958927],"study_design_scores_gemma":[0.000015972104,0.00019348055,0.9871171,0.0000046870746,0.000052446136,0.004217364,0.0003596319,0.00050181977,0.006887971,0.000065419204,0.00057955337,0.0000046423843],"about_ca_topic_score_codex":0.004578104,"about_ca_topic_score_gemma":0.0065298886,"teacher_disagreement_score":0.004578104,"about_ca_system_score_codex":0.0003984322,"about_ca_system_score_gemma":0.00023507439,"threshold_uncertainty_score":0.009102941},"labels":[],"label_agreement":null},{"id":"W1992844744","doi":"10.1074/jbc.m106239200","title":"Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins","year":2001,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; McMaster University","funders":"","keywords":"Effector; Phosphorylation; ErbB; Transformation (genetics); Cell biology; Biology; Cancer research; Computational biology; Signal transduction; Genetics; Gene","score_opus":0.06143622664116654,"score_gpt":0.341590139487884,"score_spread":0.2801539128467175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992844744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989761,0.00021626128,0.00042723224,0.000011272957,0.0000019792744,0.0000046838095,0.000021528249,0.000013218507,0.00032778192],"genre_scores_gemma":[0.99817204,0.0002596107,0.0005791494,0.000011375235,0.0000021393705,0.00001007175,0.00014050849,0.0000042418314,0.0008207622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998765,0.000018690902,0.000008986709,0.000023401091,0.000036232672,0.000036244626],"domain_scores_gemma":[0.99993455,0.000011575466,0.00002216881,0.0000075030484,0.0000035103858,0.000020792568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012788642,0.00037186034,0.000120690034,0.00014625072,0.0001195305,0.00029765491,0.00019377883,0.00017425217,0.00068532606],"category_scores_gemma":[0.00010712317,0.00013310855,0.000207938,0.00008561615,0.00016830607,0.00017498276,0.00030349466,0.0002871414,0.00033155287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055084303,0.000024324125,0.0004923405,0.00001196161,0.0000026661771,0.000056841596,0.000007262435,0.00004071466,0.9985065,0.00008612251,0.0000107343285,0.0007054551],"study_design_scores_gemma":[0.000017409397,0.00022794514,0.011391609,0.000003533023,0.000017958691,0.00090921466,0.00002669926,0.0013454397,0.9848059,0.00006602857,0.0011851036,0.000003196984],"about_ca_topic_score_codex":0.00015989241,"about_ca_topic_score_gemma":0.00029621652,"teacher_disagreement_score":0.00068532606,"about_ca_system_score_codex":0.00021937826,"about_ca_system_score_gemma":0.0001051669,"threshold_uncertainty_score":0.0022926927},"labels":[],"label_agreement":null},{"id":"W1993832282","doi":"10.1007/s10911-008-9082-8","title":"The Role of NRG3 in Mammary Development","year":2008,"lang":"en","type":"review","venue":"Journal of Mammary Gland Biology and Neoplasia","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Breakthrough Cancer Research","keywords":"Biology; ERBB4; Morphogenesis; ErbB; Mammary gland; Neuregulin; Receptor tyrosine kinase; Cell biology; Cancer research; Kinase; Gene; Signal transduction; Cancer; Breast cancer; Genetics","score_opus":0.033215898353138006,"score_gpt":0.35856208930900224,"score_spread":0.32534619095586426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993832282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041146253,0.9956713,0.0003548677,0.000570553,0.00037910772,0.0000075109006,0.000041854302,0.000020146808,0.0025432678],"genre_scores_gemma":[0.002197419,0.9947555,0.0004813939,0.00038147674,0.00020938895,0.000009116786,0.00009393844,0.0000033184194,0.0018684716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998186,0.000022455733,0.00002274294,0.00003802331,0.00007373935,0.000024421353],"domain_scores_gemma":[0.99979216,0.000072989555,0.000032272434,0.000011837915,0.00006703292,0.000023796243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007676163,0.00094441616,0.0015134607,0.0013039731,0.00025451893,0.0010322045,0.0014450806,0.0013466354,0.0033253646],"category_scores_gemma":[0.0005699304,0.0003130835,0.0005280318,0.0015022755,0.00073783554,0.0011524699,0.0006925717,0.0018292292,0.0028609599],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019884498,0.000059763897,0.00034913857,0.0058279545,0.00009842169,0.00062562514,0.0000451039,0.000839331,0.008212527,0.00440299,0.025084047,0.95425624],"study_design_scores_gemma":[0.000037705944,0.00006552608,0.00092007045,0.0009155295,0.00009829099,0.0012459289,0.000047444548,0.00014836756,0.001999339,0.0020967813,0.9924044,0.00002063148],"about_ca_topic_score_codex":0.002014925,"about_ca_topic_score_gemma":0.0035831034,"teacher_disagreement_score":0.0033253646,"about_ca_system_score_codex":0.0011841469,"about_ca_system_score_gemma":0.0013779872,"threshold_uncertainty_score":0.011124492},"labels":[],"label_agreement":null},{"id":"W1994749565","doi":"10.1038/sj.cgt.7700117","title":"Tetracycline-induced expression of an anti-c-Myb single-chain antibody and its inhibitory effect on proliferation of the human leukemia cell line K562","year":2000,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; Lymphoma Research Foundation","keywords":"K562 cells; MYB; Leukemia; Molecular biology; Biology; Cell culture; Chronic myelogenous leukemia; Gene silencing; Cancer research; Chemistry; Gene expression; Gene; Biochemistry; Immunology; Genetics","score_opus":0.048304029365198474,"score_gpt":0.37605356969522835,"score_spread":0.3277495403300299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994749565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535394,0.0012142243,0.00085694744,0.00012981538,0.000052374828,0.00002121034,0.00030149723,0.000047358924,0.0020226662],"genre_scores_gemma":[0.9954919,0.0006117844,0.00081441324,0.00003820649,0.000011273908,0.000025905529,0.0006504268,0.000020434492,0.0023355358],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998418,0.000026437587,0.000017207287,0.000023551154,0.000042037434,0.000048949623],"domain_scores_gemma":[0.99987996,0.0000452357,0.000019497238,0.000019046422,0.000011399307,0.000024783052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013840024,0.00024696407,0.0003195315,0.00017582285,0.00018930236,0.0002634972,0.00022674353,0.0003165383,0.0015425275],"category_scores_gemma":[0.00017156417,0.00014579763,0.00023908408,0.00021919384,0.00021141575,0.00014305115,0.00015517519,0.0007726288,0.0003446816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020579353,0.00007483219,0.000088157394,0.000021994938,0.000003838677,0.000036860976,0.000016088357,0.000073953524,0.99864286,0.00014483748,0.000064513624,0.00062616385],"study_design_scores_gemma":[0.00004562723,0.00035384088,0.0024540108,0.0000053256176,0.00001138048,0.000110091365,0.00002201416,0.0011512055,0.9942135,0.000021583446,0.0016082765,0.000003164244],"about_ca_topic_score_codex":0.002093198,"about_ca_topic_score_gemma":0.0033151158,"teacher_disagreement_score":0.002093198,"about_ca_system_score_codex":0.00036997264,"about_ca_system_score_gemma":0.00030106207,"threshold_uncertainty_score":0.0051603317},"labels":[],"label_agreement":null},{"id":"W1995492023","doi":"10.1186/s12916-014-0129-y","title":"Advances in treating HER2-positive breast cancer: an interview with Sunil Verma","year":2014,"lang":"en","type":"article","venue":"BMC Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Internal medicine","score_opus":0.04296304446602,"score_gpt":0.39898249484147136,"score_spread":0.35601945037545135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995492023","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015632448,0.024148984,0.0004300104,0.9282431,0.03684283,0.00009297987,0.00014789533,0.00010476004,0.008426139],"genre_scores_gemma":[0.01782849,0.01765823,0.001306649,0.9040814,0.018815968,0.00028623175,0.00011023795,0.00019685089,0.03971595],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940433,0.00360338,0.00019406852,0.0004620266,0.0010050246,0.00069217494],"domain_scores_gemma":[0.9910033,0.0039135097,0.00045036702,0.00013046456,0.0012414361,0.0032610681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008466501,0.0009168286,0.0016430676,0.0007644719,0.006058501,0.003943078,0.0016784534,0.008933094,0.010618798],"category_scores_gemma":[0.020762717,0.0009422936,0.0012157706,0.0005683142,0.0034498875,0.0065564243,0.004458301,0.028798508,0.0042718],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059312064,0.00007063871,0.00017337651,0.00012455074,0.000008930809,0.00030518498,0.0025146534,0.0000854286,0.00021284833,0.0014114607,0.984117,0.010916606],"study_design_scores_gemma":[0.000054246593,0.00017369656,0.00063977204,0.00069819577,0.000013295526,0.0016417571,0.008186895,0.00017685912,0.00016972872,0.0017596117,0.9863927,0.000093189934],"about_ca_topic_score_codex":0.0073667425,"about_ca_topic_score_gemma":0.0112657705,"teacher_disagreement_score":0.010618798,"about_ca_system_score_codex":0.006231625,"about_ca_system_score_gemma":0.00493112,"threshold_uncertainty_score":0.04521376},"labels":[],"label_agreement":null},{"id":"W1995517580","doi":"10.1007/s10549-011-1896-1","title":"TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients","year":2011,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Adjuvant; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.056476571669289696,"score_gpt":0.3589421221986461,"score_spread":0.30246555052935636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995517580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154484,0.006145463,0.0002314513,0.00051778887,0.0001374438,0.000024089664,0.00036580738,0.000029982357,0.0010030696],"genre_scores_gemma":[0.9974324,0.0010384861,0.0003757129,0.00009918755,0.00014403186,0.000018084611,0.00040553958,0.0000048307957,0.0004817576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996138,0.00015243464,0.000041157295,0.00005642299,0.00007826201,0.00005800656],"domain_scores_gemma":[0.9988539,0.0004879819,0.00021084436,0.000049461418,0.000069635535,0.00032807232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011565941,0.00086942455,0.0018866621,0.0006824258,0.00023430755,0.00087293884,0.00044295614,0.000615782,0.0012511791],"category_scores_gemma":[0.002205858,0.00031935913,0.0007372016,0.0005717177,0.00021840548,0.0005416173,0.00028063555,0.0010674325,0.0003376358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13793974,0.0018078269,0.7489717,0.00030388072,0.0025502823,0.00060940423,0.00014191717,0.004809976,0.014057439,0.00018401703,0.0022062247,0.08641767],"study_design_scores_gemma":[0.0057995627,0.018564627,0.92692274,0.00020833891,0.005445551,0.0014849484,0.00028036078,0.029494246,0.0069145486,0.0010057879,0.0037608112,0.000118551354],"about_ca_topic_score_codex":0.0008520246,"about_ca_topic_score_gemma":0.0027196826,"teacher_disagreement_score":0.0018866621,"about_ca_system_score_codex":0.00051247375,"about_ca_system_score_gemma":0.0005637237,"threshold_uncertainty_score":0.006116748},"labels":[],"label_agreement":null},{"id":"W1995674745","doi":"10.1177/1078155213506478","title":"Trastuzumab therapy in breast cancer: To reload or not to reload?","year":2013,"lang":"en","type":"editorial","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.10153406861746643,"score_gpt":0.5481237729204406,"score_spread":0.4465897043029741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995674745","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058975755,0.013154421,0.00009286483,0.090186834,0.8953042,0.000017544546,0.00003479434,0.000030231111,0.0011201797],"genre_scores_gemma":[0.00047391033,0.0069758766,0.00008654346,0.037503555,0.952476,0.000016460657,0.000013320359,0.00001499512,0.0024392812],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99288696,0.0017191159,0.0013170289,0.0007236043,0.0027423804,0.0006108856],"domain_scores_gemma":[0.96796083,0.015317364,0.0027086767,0.00063097116,0.008682745,0.0046994374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011403116,0.0031372805,0.0049174516,0.003214007,0.003304812,0.007574312,0.0042942306,0.030305777,0.006762201],"category_scores_gemma":[0.04550127,0.0013538019,0.003119068,0.0021170508,0.0029350787,0.0045613134,0.0017013354,0.0334405,0.004996333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000612627,0.000024535982,0.000055844408,0.0003765856,0.000045925713,0.00017739211,0.000014627482,0.00002961561,0.00003458412,0.0002655682,0.98987216,0.009042054],"study_design_scores_gemma":[0.00039714528,0.00011023153,0.0007620802,0.0021344458,0.00036279368,0.0008061547,0.00010298812,0.0003772479,0.00018647531,0.0013152693,0.99339193,0.000053145915],"about_ca_topic_score_codex":0.0031911207,"about_ca_topic_score_gemma":0.009810247,"teacher_disagreement_score":0.030305777,"about_ca_system_score_codex":0.00605291,"about_ca_system_score_gemma":0.005501956,"threshold_uncertainty_score":0.06030613},"labels":[],"label_agreement":null},{"id":"W1996149704","doi":"10.1097/pas.0b013e31820e6237","title":"The Effect of Prolonged Fixation on the Immunohistochemical Evaluation of Estrogen Receptor, Progesterone Receptor, and HER2 Expression in Invasive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Progesterone receptor; Breast cancer; Medicine; Immunohistochemistry; Estrogen receptor; Internal medicine; Fixation (population genetics); Estrogen; Receptor; Oncology; Gynecology; Endocrinology; Urology; Cancer; Population","score_opus":0.04011181376275936,"score_gpt":0.3518738265315343,"score_spread":0.31176201276877497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996149704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944722,0.004150355,0.00086130644,0.00003321671,0.000024236664,0.000023961014,0.00003753633,0.000008054459,0.00038921562],"genre_scores_gemma":[0.997489,0.0008443312,0.0011168654,0.000034975597,0.000028659264,0.00003495026,0.0001136493,0.000009389392,0.0003281769],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986626,0.00056996,0.00015819175,0.00018909687,0.00023402067,0.00018603509],"domain_scores_gemma":[0.9959604,0.002216461,0.0010237494,0.00031893406,0.00023001092,0.00025048896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026133596,0.0003560399,0.00034671277,0.0003549307,0.000314313,0.00042253063,0.00027253397,0.0003073118,0.0012802387],"category_scores_gemma":[0.0034714495,0.00023060894,0.0003503479,0.0002959969,0.00044080394,0.00044801377,0.00044672334,0.00037873047,0.00016000938],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03135564,0.00044702413,0.15657698,0.00055174244,0.00040412523,0.0012426156,0.0005856544,0.0010477452,0.7628703,0.0001490983,0.0002486075,0.04452043],"study_design_scores_gemma":[0.000118420496,0.020414636,0.82083535,0.00006489608,0.00039703125,0.0031138728,0.000512297,0.0015137325,0.15064906,0.000118376025,0.0022160436,0.00004627641],"about_ca_topic_score_codex":0.0010554674,"about_ca_topic_score_gemma":0.0022148315,"teacher_disagreement_score":0.0026133596,"about_ca_system_score_codex":0.0004630977,"about_ca_system_score_gemma":0.00031225657,"threshold_uncertainty_score":0.013820946},"labels":[],"label_agreement":null},{"id":"W1996494247","doi":"10.1038/onc.2010.365","title":"The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells","year":2010,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Michael Smith Health Research BC; Child and Family Research Institute; Breast Cancer Alliance","keywords":"Trastuzumab; CD44; Biology; Cancer research; Cell culture; Cancer cell; Cancer; Population; Cell; Molecular biology; Breast cancer; Medicine; Biochemistry","score_opus":0.013583241705343727,"score_gpt":0.30749476806958176,"score_spread":0.293911526364238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996494247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682343,0.00048499883,0.00088967814,0.00014465097,0.00002641054,0.000015216846,0.00011514909,0.000056886172,0.0014436881],"genre_scores_gemma":[0.9944846,0.00026343088,0.000874772,0.00004407017,0.000011282345,0.000020129803,0.00033997727,0.000012950689,0.00394873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987304,0.000025056153,0.000009724229,0.000014677491,0.000026745647,0.000050700764],"domain_scores_gemma":[0.9999436,0.000014572441,0.00000962299,0.000010413381,0.0000063892676,0.000015248239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010587032,0.00017012154,0.00018224475,0.00012648785,0.00014644678,0.00027427732,0.00015140761,0.00022017935,0.0031904276],"category_scores_gemma":[0.00010414816,0.00013197867,0.00015419406,0.00013500874,0.000112648726,0.00019970456,0.00014233084,0.0005527249,0.00068786426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016878374,0.000056379213,0.00016584179,0.000010949338,0.0000020528453,0.000029174016,0.0000088029,0.000036135316,0.9983012,0.00010412346,0.00007631091,0.0010402773],"study_design_scores_gemma":[0.00003123173,0.0002830876,0.0029760546,0.0000018538605,0.000005573871,0.00014515095,0.000020983194,0.0013168023,0.99368757,0.000034582805,0.0014950982,0.0000020191515],"about_ca_topic_score_codex":0.00046000016,"about_ca_topic_score_gemma":0.0005830992,"teacher_disagreement_score":0.0031904276,"about_ca_system_score_codex":0.00026637298,"about_ca_system_score_gemma":0.00016604354,"threshold_uncertainty_score":0.010673046},"labels":[],"label_agreement":null},{"id":"W1996750641","doi":"10.1309/ajcpzsv2w1cpgrjw","title":"HER2 Testing of Multifocal Invasive Breast Carcinoma","year":2013,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast carcinoma; Carcinoma; Pathology; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.1217815960190142,"score_gpt":0.4510944160237823,"score_spread":0.32931282000476814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996750641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986743,0.00058205525,0.0002035052,0.000040457817,0.000003593401,0.0000060971406,0.00003948964,0.000007512074,0.0004430626],"genre_scores_gemma":[0.9994305,0.00012390825,0.00034011476,0.000011565318,0.000007522969,0.0000026243483,0.000035633744,0.0000017436923,0.000046344332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991221,0.00028576158,0.000101382255,0.00010626412,0.0002651479,0.0001194272],"domain_scores_gemma":[0.9961582,0.0018384855,0.0010078538,0.0002006955,0.0004746339,0.00032013445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017084464,0.00035585838,0.00023125298,0.0016305487,0.00022013107,0.00043370738,0.0004955733,0.0004404024,0.0015615849],"category_scores_gemma":[0.010774164,0.00024384842,0.00016007715,0.00041534452,0.00043724023,0.00056382496,0.00055406755,0.00025006992,0.00029408693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041396462,0.000024361512,0.984968,0.000039593466,0.000021189338,0.002569887,0.00010213621,0.00014203611,0.0047462345,0.000019900643,0.00009152812,0.0068610883],"study_design_scores_gemma":[0.0000321355,0.00036756895,0.9441917,0.000056316196,0.00005700873,0.044635024,0.00039018277,0.0017849634,0.007662254,0.00010789907,0.000700407,0.000014412469],"about_ca_topic_score_codex":0.000978447,"about_ca_topic_score_gemma":0.0013932481,"teacher_disagreement_score":0.0017084464,"about_ca_system_score_codex":0.0002979326,"about_ca_system_score_gemma":0.00022943933,"threshold_uncertainty_score":0.00903523},"labels":[],"label_agreement":null},{"id":"W1997043452","doi":"10.1200/jco.2014.59.7559","title":"Reply to E.A. Rakha et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine","score_opus":0.4547363669323985,"score_gpt":0.6349800255671316,"score_spread":0.18024365863473313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997043452","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017992717,0.0010317988,0.00003228837,0.98671085,0.011114504,0.000005373211,0.000037232156,0.00001801929,0.0008700357],"genre_scores_gemma":[0.0029372084,0.0008148376,0.00009160527,0.9717604,0.021484513,0.000020855463,0.000026090149,0.000014721139,0.002849771],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974516,0.00086152763,0.00029558834,0.00033409818,0.00067281915,0.00038441777],"domain_scores_gemma":[0.9931961,0.0034475054,0.0006040646,0.00019560965,0.0014428037,0.0011138484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031726467,0.0008256414,0.0015087841,0.0009037929,0.0033798332,0.0035236594,0.002071489,0.049897045,0.008312362],"category_scores_gemma":[0.030853944,0.0008700279,0.0011429911,0.00075857644,0.0030177329,0.0039865295,0.0016497461,0.033163812,0.007949395],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044069267,0.000014398576,0.00038349454,0.000031134638,0.000008851278,0.0011613508,0.00008854913,0.000026875057,0.0000529252,0.0009438947,0.9946197,0.0026246915],"study_design_scores_gemma":[0.00019600584,0.00011522303,0.0016056125,0.00041642127,0.00005885225,0.008247418,0.00084556226,0.0005458114,0.0004455734,0.009390487,0.97801226,0.000120597106],"about_ca_topic_score_codex":0.0038640206,"about_ca_topic_score_gemma":0.0047904793,"teacher_disagreement_score":0.049897045,"about_ca_system_score_codex":0.0034012434,"about_ca_system_score_gemma":0.0031969398,"threshold_uncertainty_score":0.027807653},"labels":[],"label_agreement":null},{"id":"W1997091177","doi":"10.1073/pnas.1505649112","title":"iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling","year":2015,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute of General Medical Sciences; National Cancer Institute; Biotechnology and Biological Sciences Research Council; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Upstream (networking); Biology; Computational biology; Cell biology; Computer science; Telecommunications","score_opus":0.09462102397983845,"score_gpt":0.3813311216611781,"score_spread":0.28671009768133965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997091177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98591983,0.0038652052,0.0052873758,0.00021439343,0.000059288435,0.000058278925,0.0014746903,0.0005430305,0.0025780753],"genre_scores_gemma":[0.98371464,0.0019534144,0.005879719,0.00011046969,0.00004165019,0.00007780368,0.0020238808,0.00010638062,0.006092085],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996481,0.000048841852,0.000043207405,0.000087956345,0.0001005183,0.0000713133],"domain_scores_gemma":[0.99959415,0.000032704684,0.00022440645,0.000037870865,0.000017326462,0.00009361425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018373376,0.00064549665,0.00037059354,0.0005928786,0.0003290529,0.00049417606,0.00042838525,0.0005460097,0.0019952783],"category_scores_gemma":[0.00016919589,0.00030830866,0.00038044975,0.0001604621,0.0003956876,0.0003180147,0.00051913015,0.0008478739,0.0010082691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011481654,0.000016438342,0.00055136177,0.000051710675,0.000004833846,0.0003818468,0.000018910352,0.000056595876,0.9969682,0.00022950949,0.0000798037,0.0015259169],"study_design_scores_gemma":[0.0000286854,0.00016941997,0.018201547,0.000015304526,0.000023662647,0.002857158,0.000055018823,0.0004920911,0.9711415,0.00011520463,0.0068870806,0.000013323472],"about_ca_topic_score_codex":0.00016591344,"about_ca_topic_score_gemma":0.00029048775,"teacher_disagreement_score":0.0019952783,"about_ca_system_score_codex":0.0003118014,"about_ca_system_score_gemma":0.00022757435,"threshold_uncertainty_score":0.006674826},"labels":[],"label_agreement":null},{"id":"W1997519635","doi":"10.1038/sj.clpt.6100096","title":"Molecular Imaging as a Tool for Personalized and Targeted Anticancer Therapy","year":2007,"lang":"en","type":"review","venue":"Clinical Pharmacology & Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Library science; Citation; Psychology; Sociology; Computer science","score_opus":0.32858627950061575,"score_gpt":0.6135134024562962,"score_spread":0.2849271229556804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997519635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015533417,0.9933466,0.0014282473,0.0008079874,0.0005703941,0.000013188918,0.00002330298,0.00003426692,0.003620732],"genre_scores_gemma":[0.0014488222,0.9921193,0.0012925674,0.00082424434,0.00071170443,0.000022100761,0.000041363477,0.0000063775237,0.0035334707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997451,0.00004852576,0.00002183561,0.00004064029,0.00011976785,0.000024168805],"domain_scores_gemma":[0.9996458,0.00016973469,0.00004264479,0.000014915337,0.00009879579,0.000028030607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094630045,0.0015622266,0.0020004525,0.0027297826,0.00031254697,0.0015399152,0.0012936564,0.0021180091,0.0049819266],"category_scores_gemma":[0.00066864816,0.00050204183,0.0005142356,0.0023392309,0.0010867086,0.002073355,0.00084195816,0.0027749622,0.003963996],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082627106,0.00014364964,0.0000936369,0.004847975,0.00006714685,0.00024191721,0.00003232871,0.0004728439,0.0060066544,0.007853775,0.051691562,0.92846584],"study_design_scores_gemma":[0.000035371013,0.000113100374,0.0003133317,0.0008949673,0.00008457491,0.0017301965,0.000025176272,0.00034957493,0.0025691825,0.002998859,0.99086165,0.00002401528],"about_ca_topic_score_codex":0.0010185417,"about_ca_topic_score_gemma":0.0018826455,"teacher_disagreement_score":0.0049819266,"about_ca_system_score_codex":0.0010696107,"about_ca_system_score_gemma":0.0010666406,"threshold_uncertainty_score":0.016666234},"labels":[],"label_agreement":null},{"id":"W1997955685","doi":"10.3816/cbc.2006.n.038","title":"Molecular Predictive Factors in Patients Receiving Trastuzumab-Based Chemotherapy for Metastatic Disease","year":2006,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Michael Smith Health Research BC","keywords":"Medicine; Trastuzumab; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Chemotherapy; Disease; Cancer","score_opus":0.04488971125718346,"score_gpt":0.41535157853292376,"score_spread":0.3704618672757403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997955685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967894,0.0010713377,0.00007835342,0.00030722364,0.000044066444,0.000008162909,0.00020067314,0.00000684313,0.0014938733],"genre_scores_gemma":[0.99897695,0.000264105,0.000056667253,0.00007240771,0.00007636606,0.000006455795,0.00020934688,0.0000030333401,0.00033481274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998036,0.00004790818,0.000019871966,0.00003114019,0.00004150586,0.000055978086],"domain_scores_gemma":[0.9986904,0.00051029393,0.00034132003,0.00005006094,0.000085337735,0.0003225792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003299312,0.00028385385,0.00044653838,0.0004221174,0.00040779056,0.00069120084,0.00034522227,0.000729827,0.0025069737],"category_scores_gemma":[0.0030285993,0.00018837972,0.00038705912,0.00086145906,0.00024304555,0.0004276235,0.00020235081,0.0010695257,0.00027165376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092007616,0.00007747918,0.9947149,0.000010854822,0.000052089134,0.00031406217,0.000027871974,0.00013302783,0.0005634765,0.000049538125,0.0003059858,0.002830771],"study_design_scores_gemma":[0.000048113532,0.00027462505,0.99681026,0.000008147959,0.000119582415,0.00096231286,0.000112768466,0.0006648535,0.00024676157,0.00011514098,0.0006307755,0.000006669021],"about_ca_topic_score_codex":0.0020914127,"about_ca_topic_score_gemma":0.0028638057,"teacher_disagreement_score":0.0025069737,"about_ca_system_score_codex":0.00034746487,"about_ca_system_score_gemma":0.00049713335,"threshold_uncertainty_score":0.008386672},"labels":[],"label_agreement":null},{"id":"W1998071315","doi":"10.1007/s12154-009-0023-9","title":"Measuring and interpreting the selectivity of protein kinase inhibitors","year":2009,"lang":"en","type":"article","venue":"Journal of Chemical Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"Selectivity; Kinase; Protein kinase inhibitor; Protein kinase A; Small molecule; Chemistry; Computational biology; Chemical biology; Biochemistry; Biology","score_opus":0.03466070349873216,"score_gpt":0.33809482695497317,"score_spread":0.303434123456241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998071315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8958287,0.0071394066,0.07509098,0.00079151004,0.00023895527,0.00011556709,0.0009601222,0.00082134304,0.01901346],"genre_scores_gemma":[0.9828249,0.0016732871,0.013055912,0.0004069418,0.00006253652,0.00003701214,0.00031835717,0.00007076921,0.0015502342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988003,0.00019876775,0.00005198694,0.00024503894,0.00056664046,0.00013725553],"domain_scores_gemma":[0.9983346,0.00091321755,0.00023975327,0.0001357811,0.00029369333,0.00008296444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016593199,0.00052668137,0.00063936843,0.0008102248,0.00040459025,0.0012783221,0.00077505043,0.0010838597,0.0016949235],"category_scores_gemma":[0.0030066948,0.00035898245,0.00026424162,0.0005020495,0.0004993684,0.0010057224,0.00034634557,0.0009999602,0.0007226859],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056970236,0.000067821304,0.007796197,0.0001333922,0.00006229001,0.00008101549,0.00003234162,0.0021339008,0.96351254,0.0012791421,0.0005717944,0.02375982],"study_design_scores_gemma":[0.000020758485,0.00024265946,0.0037801706,0.0000051988004,0.00006156076,0.00022481446,0.00003972626,0.01072314,0.9828015,0.0005129789,0.0015759794,0.000011603793],"about_ca_topic_score_codex":0.0012402182,"about_ca_topic_score_gemma":0.0016761331,"teacher_disagreement_score":0.0016949235,"about_ca_system_score_codex":0.0011175462,"about_ca_system_score_gemma":0.0004902334,"threshold_uncertainty_score":0.008775413},"labels":[],"label_agreement":null},{"id":"W1998331864","doi":"10.4161/cc.3.9.1127","title":"Developmental Timing of Activated erbB2 Expression Plays a Critical Role in the Induction of Mammary Tumors","year":2004,"lang":"en","type":"article","venue":"Cell Cycle","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; Germline; Carcinogenesis; Mammary gland; Allele; Genetically modified mouse; Penetrance; Cancer research; Endogeny; Oncogene; Transgene; Mammary tumor; Regulation of gene expression; Gene; Genetics; Cancer; Phenotype; Cell cycle; Endocrinology; Breast cancer","score_opus":0.03732561836379729,"score_gpt":0.3324290827669174,"score_spread":0.29510346440312013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998331864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722592,0.0076992307,0.0132515235,0.00021038823,0.00006804702,0.00010292515,0.0006986376,0.00022881114,0.0054812697],"genre_scores_gemma":[0.9919171,0.0026632287,0.0025461563,0.000045343288,0.000014690335,0.000049974984,0.0002479105,0.0000332376,0.002482433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982786,0.000028767312,0.000018810013,0.000038293387,0.00004537614,0.00004076815],"domain_scores_gemma":[0.99974257,0.00006554457,0.000079811216,0.000022277396,0.000034149085,0.000055532397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002700079,0.00026301254,0.00023987936,0.0002693235,0.00013798357,0.00051103014,0.00018979612,0.00024200455,0.0013723609],"category_scores_gemma":[0.0003304355,0.00019825394,0.00012084953,0.00013919816,0.00014933206,0.00030297224,0.00025813116,0.0004665273,0.00039817172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010744156,0.000016132173,0.00070916815,0.000019779976,0.0000017780515,0.000078719124,0.000013898382,0.000049564078,0.99711716,0.00023483536,0.000027494718,0.0016240577],"study_design_scores_gemma":[0.000013737878,0.00034423577,0.035856955,0.000016428748,0.000019796755,0.00055059395,0.0000736995,0.00051062106,0.9580326,0.00019642312,0.004375632,0.0000093171775],"about_ca_topic_score_codex":0.0004780689,"about_ca_topic_score_gemma":0.00079796533,"teacher_disagreement_score":0.0013723609,"about_ca_system_score_codex":0.0003334749,"about_ca_system_score_gemma":0.00032112963,"threshold_uncertainty_score":0.0045910478},"labels":[],"label_agreement":null},{"id":"W1998655933","doi":"10.1074/jbc.275.14.9946","title":"Genuine Monovalent Ligands of TrkA Nerve Growth Factor Receptors Reveal a Novel Pharmacological Mechanism of Action","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Tropomyosin receptor kinase A; Receptor; Internalization; Tyrosine kinase; Cell biology; Receptor tyrosine kinase; Chemistry; Allosteric regulation; Low-affinity nerve growth factor receptor; Biochemistry; Biology; Nerve growth factor","score_opus":0.11230203858458988,"score_gpt":0.37958071790451814,"score_spread":0.26727867931992827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998655933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975023,0.0066022626,0.012908075,0.0003308241,0.000084931315,0.00008402953,0.00009701218,0.00008982758,0.004780078],"genre_scores_gemma":[0.98797613,0.002018507,0.0061339033,0.00026191457,0.000020869056,0.000041403135,0.00010483913,0.000013831673,0.0034286734],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998541,0.00002715018,0.000010231582,0.000023274351,0.000046258992,0.000038963153],"domain_scores_gemma":[0.9999497,0.000012920065,0.000009025158,0.0000060557495,0.000007592179,0.000014648341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017098589,0.00027842727,0.00023641877,0.00011096805,0.00014095014,0.000488898,0.00033347105,0.00034755666,0.0012974087],"category_scores_gemma":[0.0001341272,0.00011882853,0.00016615949,0.000071372924,0.00020839114,0.0002937479,0.0002099049,0.0006066672,0.00037241448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005686726,0.0000139077865,0.000046768808,0.000037014255,0.0000050689873,0.00003353185,0.000008676701,0.000074881886,0.9972211,0.000503145,0.00003544102,0.0019635004],"study_design_scores_gemma":[0.000038189148,0.00048323165,0.0008533236,0.0000093016,0.000024742885,0.0003613125,0.000028850993,0.0009277282,0.992698,0.000187832,0.004380099,0.000007343029],"about_ca_topic_score_codex":0.00025423177,"about_ca_topic_score_gemma":0.00081430847,"teacher_disagreement_score":0.0012974087,"about_ca_system_score_codex":0.0003784443,"about_ca_system_score_gemma":0.00016470997,"threshold_uncertainty_score":0.004340291},"labels":[],"label_agreement":null},{"id":"W1998827682","doi":"10.1186/1471-2407-11-420","title":"The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity","year":2011,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Gefitinib; Trastuzumab; In vivo; Cytostasis; Medicine; Cancer research; Everolimus; Breast cancer; SKBR3; PI3K/AKT/mTOR pathway; Pharmacology; Cell growth; Growth inhibition; Surgical oncology; Vinorelbine; Cancer; Oncology; Signal transduction; Internal medicine; Cytotoxicity; Epidermal growth factor receptor; In vitro; Biology; Chemotherapy; Cisplatin","score_opus":0.044814712231167134,"score_gpt":0.32160145844209626,"score_spread":0.27678674621092914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998827682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933575,0.0026430227,0.00092503394,0.00008664076,0.000039472496,0.000045916895,0.00018291504,0.00010049516,0.0026190442],"genre_scores_gemma":[0.9960335,0.0009047671,0.0011834014,0.000028081282,0.0000193102,0.000039269176,0.0002676395,0.000009300122,0.0015146066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998578,0.000029084225,0.00001579276,0.000023114577,0.000043964017,0.000030254925],"domain_scores_gemma":[0.9999393,0.00001248309,0.000016227386,0.000008831558,0.0000069409857,0.000016188249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012882886,0.00029713212,0.00041659852,0.00026853787,0.00009021077,0.00022832504,0.00019954276,0.00019944806,0.0011069804],"category_scores_gemma":[0.000106321655,0.00009880907,0.00021667108,0.0001760965,0.0001367853,0.00010464093,0.0001199905,0.00034977822,0.00032427444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008714966,0.00035408372,0.00083785475,0.00010477916,0.000043405093,0.00007823259,0.000016989268,0.00040237862,0.98570234,0.00009778,0.00025015522,0.01124046],"study_design_scores_gemma":[0.00015480514,0.004773496,0.008342407,0.000007936328,0.000070492344,0.00073415594,0.000015349156,0.0011989895,0.9803962,0.000023619523,0.0042722854,0.00001020777],"about_ca_topic_score_codex":0.0003116704,"about_ca_topic_score_gemma":0.0009422344,"teacher_disagreement_score":0.0011069804,"about_ca_system_score_codex":0.00020302509,"about_ca_system_score_gemma":0.00022812224,"threshold_uncertainty_score":0.0037032366},"labels":[],"label_agreement":null},{"id":"W1999442391","doi":"10.1016/s1470-2045(08)70177-3","title":"Part II: Milestones in personalised medicine—trastuzumab","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Trastuzumab; Oncology; Medicine; Imatinib; Breast cancer; Internal medicine; Oncogene; Cancer; Ovarian cancer; Cancer research; Bioinformatics; Myeloid leukemia; Biology; Cell cycle","score_opus":0.269792299096941,"score_gpt":0.452685699643005,"score_spread":0.18289340054606396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999442391","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00177736,0.56318533,0.003193898,0.3442625,0.052733015,0.00012550295,0.00017975237,0.00011051213,0.03443211],"genre_scores_gemma":[0.04742504,0.53036,0.004825184,0.23580687,0.10803721,0.00037749202,0.00039956483,0.00019579957,0.0725729],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967849,0.0012246709,0.00023903733,0.00031293381,0.0009333546,0.0005049815],"domain_scores_gemma":[0.9933216,0.0037105482,0.0005965672,0.00047818976,0.00093270803,0.00096032594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071514207,0.0012229885,0.0010328916,0.0012670622,0.0007365068,0.0049234307,0.0013141788,0.008739082,0.007877147],"category_scores_gemma":[0.011498368,0.00053398265,0.0007269702,0.001286483,0.003935893,0.006552847,0.0025639797,0.008978892,0.0033092347],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022277846,0.00011988795,0.00030119455,0.0012679234,0.0000457741,0.00017385234,0.0002418371,0.0006793644,0.0014038387,0.09344388,0.6751105,0.22698914],"study_design_scores_gemma":[0.00007652391,0.0001510077,0.0014269709,0.0013599019,0.000025176882,0.00040462622,0.000121873665,0.00034639763,0.0008741585,0.034931757,0.96024996,0.00003158599],"about_ca_topic_score_codex":0.0018486232,"about_ca_topic_score_gemma":0.002532695,"teacher_disagreement_score":0.008739082,"about_ca_system_score_codex":0.005217556,"about_ca_system_score_gemma":0.004135242,"threshold_uncertainty_score":0.03785616},"labels":[],"label_agreement":null},{"id":"W1999461982","doi":"10.1007/s10549-008-0033-2","title":"Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer","year":2008,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Calgary; Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Metastatic breast cancer; Multivariate analysis; Oncology; Univariate analysis; Cancer; Proportional hazards model; Prognostic variable","score_opus":0.11164049616071636,"score_gpt":0.4002757301324612,"score_spread":0.28863523397174484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999461982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801195,0.0008126657,0.00019358055,0.000061125924,0.000020282374,0.000004122784,0.00032331204,0.0000106846355,0.00056230533],"genre_scores_gemma":[0.9991391,0.00016549842,0.00008698503,0.000019644962,0.000022362346,0.000004278524,0.0002623058,0.0000017631332,0.00029797672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99983203,0.000039177212,0.000021572705,0.000038651862,0.00003210243,0.000036505753],"domain_scores_gemma":[0.99892384,0.0003475097,0.0003789652,0.00007104151,0.00012858644,0.00015008624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048628345,0.00021881527,0.00033892336,0.0007613675,0.00022133006,0.0005676275,0.00018453067,0.0004580336,0.0010689645],"category_scores_gemma":[0.0020538666,0.00011433914,0.00026205936,0.00090496265,0.00020348789,0.0004642896,0.0001825277,0.0003973161,0.0002982043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003285222,0.000084684936,0.97971493,0.000021749802,0.00009058547,0.00027144133,0.00007040736,0.00023292679,0.0056304648,0.000043891963,0.00018965984,0.010364122],"study_design_scores_gemma":[0.000011659441,0.00031370908,0.9959198,0.0000046993755,0.000061380066,0.0006395415,0.00008448456,0.00080831256,0.001566818,0.000087481516,0.0004950152,0.00000699286],"about_ca_topic_score_codex":0.0011727298,"about_ca_topic_score_gemma":0.0011622483,"teacher_disagreement_score":0.0011727298,"about_ca_system_score_codex":0.00024736326,"about_ca_system_score_gemma":0.00013703047,"threshold_uncertainty_score":0.0035759807},"labels":[],"label_agreement":null},{"id":"W1999612798","doi":"10.1074/jbc.m113.475301","title":"Mutation of the Salt Bridge-forming Residues in the ETV6-SAM Domain Interface Blocks ETV6-NTRK3-induced Cellular Transformation","year":2013,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; British Columbia Knowledge Development Fund; Michael Smith Health Research BC; Conquer Cancer Foundation","keywords":"Salt bridge; Chemistry; Tyrosine; Receptor tyrosine kinase; Protein kinase B; Tyrosine kinase; Cell biology; Phosphorylation; Signal transduction; Biology; Molecular biology; Biochemistry; Gene; Mutant","score_opus":0.05373030542084133,"score_gpt":0.33754060868248587,"score_spread":0.2838103032616445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999612798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790907,0.00011589764,0.0013432271,0.000025171532,0.000010113829,0.000015330452,0.0000692611,0.000034753608,0.00047710424],"genre_scores_gemma":[0.9985135,0.00008179988,0.00068211474,0.000013608879,0.0000026068737,0.000012064942,0.00012984252,0.000017524011,0.00054696796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998265,0.000042917552,0.000028040728,0.000024361347,0.0000458934,0.000032383854],"domain_scores_gemma":[0.99981016,0.00004863891,0.000068839705,0.00002273017,0.000008667653,0.0000409291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013269998,0.0003497207,0.00023023873,0.00012494599,0.000130943,0.00020090779,0.0002821731,0.00031077728,0.0009441098],"category_scores_gemma":[0.00016771894,0.0001234546,0.0002605347,0.00010776988,0.00031181067,0.00018424532,0.00023213949,0.00045390122,0.0003293646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093874754,0.00003998266,0.00008179106,0.000007909772,0.0000049472033,0.00003541447,0.000006664838,0.00013438758,0.9991498,0.000107281565,0.0000070075153,0.00033089702],"study_design_scores_gemma":[0.000012152235,0.00013177654,0.0006606987,0.0000012497942,0.000005158935,0.00008804478,0.000006185553,0.000857665,0.9978162,0.000016022834,0.00040264768,0.000002154678],"about_ca_topic_score_codex":0.00044034468,"about_ca_topic_score_gemma":0.000414343,"teacher_disagreement_score":0.0009441098,"about_ca_system_score_codex":0.0002857407,"about_ca_system_score_gemma":0.00014037715,"threshold_uncertainty_score":0.003158331},"labels":[],"label_agreement":null},{"id":"W2000042618","doi":"10.1136/jcp.2008.056291","title":"Expression of epidermal growth factor receptor in relation to <i>BRCA1</i> status, basal-like markers and prognosis in breast cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University; McGill University Health Centre; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Breast cancer; Epidermal growth factor receptor; Cytokeratin; Immunohistochemistry; Oncology; Progesterone receptor; Internal medicine; Tissue microarray; Basal (medicine); Pathology; Univariate analysis; Biology; Cancer; Medicine; Multivariate analysis; Cancer research; Estrogen receptor","score_opus":0.09197521465323369,"score_gpt":0.4300134908668419,"score_spread":0.33803827621360816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000042618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99941146,0.00039273177,0.000038774026,0.000018247783,0.0000014665337,0.000001535553,0.00003713488,0.0000023136329,0.00009641806],"genre_scores_gemma":[0.99959415,0.00013561365,0.000056172332,0.0000066678404,0.000004692262,0.0000016350486,0.00010719864,6.717071e-7,0.000093328206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998838,0.000037377602,0.000011683486,0.000021446103,0.000021819676,0.000023841267],"domain_scores_gemma":[0.99954176,0.00014103297,0.00015295063,0.0000260133,0.000059639093,0.000078581914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046187767,0.00015423978,0.00014555815,0.00044943282,0.00016280841,0.00033910063,0.00014380952,0.00026298445,0.0007577091],"category_scores_gemma":[0.0010251733,0.00010448997,0.00013626795,0.00035041603,0.00022111576,0.00016899161,0.00011673809,0.0002036284,0.00019376924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022614974,0.000016489934,0.9958456,0.000007889706,0.000027076814,0.000108593136,0.000020761228,0.00006739327,0.001135411,0.00000381215,0.00004132034,0.0024995913],"study_design_scores_gemma":[0.0000040750056,0.00009991737,0.9986338,0.0000036716922,0.000028038894,0.0006703882,0.000037470945,0.00019785357,0.00022763708,0.000010637006,0.000084852494,0.0000015900664],"about_ca_topic_score_codex":0.0027566575,"about_ca_topic_score_gemma":0.0034388248,"teacher_disagreement_score":0.0027566575,"about_ca_system_score_codex":0.00023855195,"about_ca_system_score_gemma":0.00017398786,"threshold_uncertainty_score":0.005481243},"labels":[],"label_agreement":null},{"id":"W2000193382","doi":"10.1158/0008-5472.sabcs11-p1-06-07","title":"P1-06-07: TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Mount Sinai Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Anthracycline; Oncology; Internal medicine; Adjuvant; Immunohistochemistry; Biomarker; Cancer; Clinical trial; Biology","score_opus":0.07569601257387051,"score_gpt":0.39045621716267986,"score_spread":0.3147602045888094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000193382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743074,0.0013285725,0.0000998008,0.00026439302,0.000020241278,0.00008106749,0.000280457,0.000011943846,0.00048283284],"genre_scores_gemma":[0.998632,0.00019133535,0.00023762003,0.00012039689,0.000054226053,0.00006862252,0.00040475768,0.000002350152,0.00028850933],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9995141,0.00030739198,0.000027071203,0.00006669281,0.000042979456,0.000041753647],"domain_scores_gemma":[0.99896896,0.00037507535,0.0002230856,0.00005368186,0.000040130773,0.0003390757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012707483,0.0005556113,0.00087311974,0.00036487554,0.00015797807,0.0005744209,0.00040662542,0.0005947086,0.001772039],"category_scores_gemma":[0.0014664911,0.00019678158,0.0006744109,0.00028727445,0.00029039168,0.00031937467,0.00026000838,0.00090035226,0.00029655534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6329196,0.002631014,0.27472767,0.00027314157,0.001994567,0.00018305,0.000079020756,0.0018085624,0.01325923,0.00013504562,0.0018664085,0.07012256],"study_design_scores_gemma":[0.124671794,0.18629134,0.6547824,0.00018061782,0.0043672575,0.0008562238,0.00010532491,0.015763262,0.008091522,0.00065669743,0.0041672923,0.00006640573],"about_ca_topic_score_codex":0.0006587565,"about_ca_topic_score_gemma":0.0015616636,"teacher_disagreement_score":0.001772039,"about_ca_system_score_codex":0.00047487282,"about_ca_system_score_gemma":0.00055621105,"threshold_uncertainty_score":0.0067204237},"labels":[],"label_agreement":null},{"id":"W2000474546","doi":"10.1371/journal.pone.0069325","title":"Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Universitat de Barcelona; Generalitat de Catalunya; Universitat de Girona","keywords":"Epidermal growth factor receptor; EGFR inhibitors; Internalization; Epidermal growth factor; Cancer research; Cancer cell; Cell growth; Cell biology; Phosphorylation; Growth factor; Biology; Chemistry; Receptor; Cancer; Pharmacology; Biochemistry","score_opus":0.13600609727588403,"score_gpt":0.32604322474359304,"score_spread":0.190037127467709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000474546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785507,0.002851742,0.015475721,0.00014033995,0.000062159175,0.00013298985,0.00035411728,0.00011257624,0.002319579],"genre_scores_gemma":[0.97836816,0.002064761,0.014881896,0.000084354906,0.000017770042,0.00006659367,0.0006979446,0.000027201535,0.0037913292],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999391,0.0000059933936,0.0000062906142,0.000013657269,0.000021658818,0.000013282223],"domain_scores_gemma":[0.9999491,0.0000062692125,0.00001442782,0.000004193597,0.00000818894,0.000017834442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000841901,0.0003084439,0.00022578136,0.00013113304,0.000074706826,0.00019608109,0.00024406545,0.0002942406,0.00078065344],"category_scores_gemma":[0.00009310127,0.00012412021,0.00028057027,0.00012267938,0.00009283717,0.00015629338,0.00010397916,0.0005299675,0.00029515827],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049761093,0.000034557965,0.00003712386,0.000018886083,0.000004427783,0.00004343921,0.0000036226918,0.0001200851,0.99804735,0.00005419048,0.000017342534,0.0015693147],"study_design_scores_gemma":[0.000035031913,0.00055865396,0.00061057013,0.000003116627,0.000024936573,0.00035955766,0.0000036620688,0.00080833654,0.99450535,0.0000152400635,0.0030712422,0.000004401714],"about_ca_topic_score_codex":0.00045076053,"about_ca_topic_score_gemma":0.0003517,"teacher_disagreement_score":0.00078065344,"about_ca_system_score_codex":0.00021638762,"about_ca_system_score_gemma":0.00018491199,"threshold_uncertainty_score":0.002611518},"labels":[],"label_agreement":null},{"id":"W2000570160","doi":"10.1155/2012/135819","title":"The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy: An Observational Study","year":2012,"lang":"en","type":"article","venue":"Cardiology Research and Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Trastuzumab; Ejection fraction; Breast cancer; Stage (stratigraphy); Cardiotoxicity; Internal medicine; Algorithm; Observational study; Cancer; Chemotherapy; Heart failure","score_opus":0.4389692035418175,"score_gpt":0.5643795326448076,"score_spread":0.12541032910299005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000570160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991585,0.00022285192,0.000047745998,0.00011142366,0.000006661522,0.000022724584,0.00011278344,0.000001421067,0.00031582007],"genre_scores_gemma":[0.9993249,0.00018890727,0.000088689485,0.0001434555,0.000016914193,0.000028200477,0.00013851761,0.0000017204895,0.00006868389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981164,0.0008071241,0.00018710236,0.0002594448,0.0003129382,0.00031713987],"domain_scores_gemma":[0.9919625,0.001464537,0.004092567,0.00017681581,0.00059096084,0.0017126509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015186027,0.00020318775,0.0004106917,0.0007235518,0.001206303,0.0011840154,0.0006049472,0.00078704616,0.0015100281],"category_scores_gemma":[0.0062655807,0.00036126928,0.00040521225,0.0010185281,0.00038642497,0.0008580793,0.0010336018,0.0011568085,0.00021287233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010402548,0.00029252368,0.9967751,0.00002128442,0.00003327642,0.00019459667,0.0007892741,0.000018363444,0.00009737199,0.000013930233,0.00020758313,0.0014526874],"study_design_scores_gemma":[0.00004064947,0.00063769624,0.99271715,0.000050835875,0.00004383731,0.00079506164,0.0048316866,0.00019257428,0.000043573804,0.000024695506,0.0006080287,0.00001424005],"about_ca_topic_score_codex":0.01072076,"about_ca_topic_score_gemma":0.017969288,"teacher_disagreement_score":0.01072076,"about_ca_system_score_codex":0.0010603514,"about_ca_system_score_gemma":0.0014404182,"threshold_uncertainty_score":0.021316707},"labels":[],"label_agreement":null},{"id":"W2000786845","doi":"10.1158/0008-5472.can-06-1898","title":"ErbB-2 Induces the <i>Cyclin D1</i> Gene in Prostate Epithelial Cells <i>In vitro</i> and <i>In vivo</i>","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Cancer research; Cyclin D1; ErbB; LNCaP; Biology; Prostate cancer; DU145; Cyclin D; Cyclin B; Carcinogenesis; Prostate; Cell cycle; Cancer; Signal transduction; Cell biology","score_opus":0.06950052905009499,"score_gpt":0.41905375034486486,"score_spread":0.34955322129476984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000786845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775488,0.0036999676,0.0069445386,0.00033857473,0.00015034022,0.00009581073,0.00204988,0.0004186581,0.008753414],"genre_scores_gemma":[0.9792403,0.0017100637,0.0030265832,0.00020269555,0.000023235003,0.000098217875,0.002635305,0.00010637237,0.012957282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997987,0.000026663363,0.000017551922,0.000043222568,0.000060039903,0.000053789405],"domain_scores_gemma":[0.9998615,0.000022882828,0.0000288471,0.000024677081,0.000012527818,0.00004955926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015183585,0.0003734868,0.0001918858,0.0003544078,0.00020923631,0.00046604307,0.00020888787,0.0001950146,0.0023390139],"category_scores_gemma":[0.00008444378,0.00033282916,0.00040344635,0.00022011115,0.00026493685,0.00015257938,0.00021612429,0.0008631114,0.00077646645],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004881881,0.000032965272,0.00009043409,0.000032223412,0.000004181865,0.000018768611,0.000011529862,0.00003884558,0.99909353,0.00014005891,0.00009129996,0.00039730823],"study_design_scores_gemma":[0.000014146848,0.00017687214,0.0023202987,0.000004712876,0.0000076038355,0.00010787701,0.000019910076,0.00045790072,0.99305,0.00003666087,0.003800912,0.0000031268876],"about_ca_topic_score_codex":0.0024754945,"about_ca_topic_score_gemma":0.0029531887,"teacher_disagreement_score":0.0024754945,"about_ca_system_score_codex":0.0006250109,"about_ca_system_score_gemma":0.00036226338,"threshold_uncertainty_score":0.007824779},"labels":[],"label_agreement":null},{"id":"W2000828606","doi":"10.1016/j.jval.2012.08.2198","title":"PCN158 Adherence to Human Epidermal Growth Factor Receptor-2 (HER2) Testing &amp; Adjuvant Trastuzumab Treatment Guidelines in a Canadian Province","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Bone and Joint Health Institute; Princess Margaret Cancer Centre; McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Cohort; Breast cancer; Oncology; Odds ratio; Cancer registry; Cancer","score_opus":0.33491114660301574,"score_gpt":0.46467707360967625,"score_spread":0.1297659270066605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000828606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38684744,0.012009687,0.0023753443,0.32957333,0.0018217929,0.0022057018,0.012431193,0.0003128804,0.25242266],"genre_scores_gemma":[0.80019546,0.010588029,0.017117828,0.07020425,0.00040469537,0.0007040037,0.003997428,0.00018531627,0.09660304],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99618006,0.00035968123,0.00037625298,0.00021593648,0.0015835954,0.0012845646],"domain_scores_gemma":[0.98007536,0.0015000413,0.0011896966,0.0001942467,0.009989237,0.0070513953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032512732,0.00024178381,0.0003079723,0.0017062122,0.006988315,0.0023473597,0.0022444692,0.0019209794,0.0055060172],"category_scores_gemma":[0.009408428,0.00048937945,0.00056109164,0.0032474524,0.0013797613,0.0004929023,0.0012157874,0.0019734078,0.00037542108],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023003397,0.0006732407,0.28574923,0.0010098389,0.00010076412,0.004994012,0.012705894,0.0021385304,0.0032516385,0.024962787,0.5001319,0.1640522],"study_design_scores_gemma":[0.00019119456,0.00016343751,0.50339836,0.001850303,0.000090083086,0.0016174621,0.014176851,0.0022177415,0.0008341846,0.001408101,0.47384846,0.00020377708],"about_ca_topic_score_codex":0.99595815,"about_ca_topic_score_gemma":0.9985506,"teacher_disagreement_score":0.10179653,"about_ca_system_score_codex":0.10179653,"about_ca_system_score_gemma":0.4099479,"threshold_uncertainty_score":0.738589},"labels":[],"label_agreement":null},{"id":"W2001633715","doi":"10.1002/cncr.24114","title":"Adjuvant targeted therapy in early breast cancer","year":2009,"lang":"en","type":"review","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency; McGill University; Alberta Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Oncology; Breast cancer; Internal medicine; Adjuvant; Cancer; Adjuvant therapy; Clinical trial; Chemotherapy","score_opus":0.12475098361661355,"score_gpt":0.472917085885185,"score_spread":0.3481661022685715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001633715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007433374,0.9992841,0.000035689227,0.00007552117,0.00008984378,0.000013757809,0.000012015852,0.0000018711395,0.00041296953],"genre_scores_gemma":[0.0009133906,0.9982262,0.00015405707,0.00021388114,0.000059464855,0.00001645278,0.000028001,7.4558676e-7,0.00038777175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99956864,0.00014031433,0.00009169355,0.00003797521,0.00013206403,0.000029265793],"domain_scores_gemma":[0.999571,0.00023606524,0.00009901118,0.000010576613,0.00006869641,0.000014548406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007304971,0.0007009295,0.0019671454,0.0029643732,0.00018008104,0.00082824286,0.00062587974,0.0009550251,0.0050723883],"category_scores_gemma":[0.0017003128,0.0002492192,0.0012238695,0.0026248654,0.00023848553,0.00078267656,0.0005100928,0.0008099469,0.0010231682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016118633,0.00004799222,0.00018405159,0.12732911,0.0005839105,0.00022533748,0.00007013474,0.0003066462,0.0007022887,0.001291947,0.01952922,0.84956825],"study_design_scores_gemma":[0.0001983969,0.00022214337,0.0020339028,0.10340375,0.002035989,0.0025235813,0.00011956156,0.00011755648,0.0004580117,0.0016007941,0.8872649,0.00002148641],"about_ca_topic_score_codex":0.0014762003,"about_ca_topic_score_gemma":0.0039806757,"teacher_disagreement_score":0.0050723883,"about_ca_system_score_codex":0.00080683985,"about_ca_system_score_gemma":0.0012247255,"threshold_uncertainty_score":0.016968846},"labels":[],"label_agreement":null},{"id":"W2001948214","doi":"10.1016/j.ctrv.2012.05.004","title":"The evolving landscape of protein kinases in breast cancer: Clinical implications","year":2012,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Druggability; Medicine; Kinase; Breast cancer; Carcinogenesis; Cancer; Drug discovery; Bioinformatics; Cancer research; Internal medicine; Biology; Gene","score_opus":0.3287504679105725,"score_gpt":0.5473864501181303,"score_spread":0.21863598220755776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001948214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058648257,0.998966,0.00005209329,0.0004766542,0.00014003114,0.0000012361512,0.00001041688,0.0000033784036,0.0002915562],"genre_scores_gemma":[0.00034375873,0.99883455,0.00009711244,0.0003131135,0.00020336558,0.0000022181523,0.0000136352255,7.9866516e-7,0.00019140755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997236,0.000054090757,0.000039610197,0.0000521925,0.000098563025,0.000031934313],"domain_scores_gemma":[0.99911815,0.00052410684,0.000094300056,0.000016328797,0.00018891595,0.000058195783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011130569,0.00090115087,0.0018407983,0.001806718,0.00027446513,0.0014799146,0.0009052391,0.0014802966,0.0033466916],"category_scores_gemma":[0.0014047045,0.00028223527,0.0006051744,0.002496324,0.0006471811,0.002086582,0.0007646322,0.0024118102,0.0015600489],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012349921,0.000059806946,0.00028932517,0.018015316,0.00012267868,0.00018593733,0.000052162257,0.00037066976,0.001238014,0.004093121,0.04885656,0.9265928],"study_design_scores_gemma":[0.000041830343,0.00010363046,0.0011195106,0.0051536397,0.0002264497,0.0010425481,0.00011488899,0.00012543591,0.0003215376,0.003261714,0.9884643,0.000024606788],"about_ca_topic_score_codex":0.0010366658,"about_ca_topic_score_gemma":0.0032958102,"teacher_disagreement_score":0.0033466916,"about_ca_system_score_codex":0.00091325614,"about_ca_system_score_gemma":0.0013443737,"threshold_uncertainty_score":0.011195779},"labels":[],"label_agreement":null},{"id":"W2002083419","doi":"10.1039/c4ib00062e","title":"The EGFR demonstrates linear signal transmission","year":2014,"lang":"en","type":"article","venue":"Integrative Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"Cancer Research UK","keywords":"Transmission (telecommunications); SIGNAL (programming language); Computational biology; Biology; Chemistry; Biophysics; Computer science; Telecommunications","score_opus":0.03196739022355707,"score_gpt":0.3882039810596925,"score_spread":0.35623659083613546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002083419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69325,0.0014032755,0.25263688,0.001413858,0.00013333793,0.00009983844,0.0006231792,0.0011832474,0.04925647],"genre_scores_gemma":[0.9768192,0.00042190592,0.01376617,0.000100174664,0.00001185095,0.00003298269,0.00008936354,0.000032705422,0.008725519],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998846,0.000010163244,0.0000047928493,0.000037950354,0.00004284145,0.000019692046],"domain_scores_gemma":[0.99993145,0.000020786001,0.000014267478,0.000010186165,0.000012640791,0.000010576674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011200092,0.00028926812,0.00025276278,0.00010515888,0.00014129678,0.00061460666,0.0003235978,0.0005344618,0.0020543104],"category_scores_gemma":[0.00030858335,0.00021086114,0.0002212446,0.00012894649,0.000471867,0.00084326527,0.00036265247,0.00039914288,0.0006687199],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009674394,0.00004482689,0.00037335444,0.00017424258,0.000015648187,0.00036451357,0.00006662977,0.021364989,0.92648965,0.04254332,0.00051852356,0.007947416],"study_design_scores_gemma":[0.000080742124,0.00041494917,0.002777987,0.000025084719,0.00003847415,0.0012414125,0.00006249052,0.3744587,0.5756184,0.031585228,0.013621893,0.00007456133],"about_ca_topic_score_codex":0.0012957767,"about_ca_topic_score_gemma":0.0006450428,"teacher_disagreement_score":0.0020543104,"about_ca_system_score_codex":0.0005118501,"about_ca_system_score_gemma":0.0002837148,"threshold_uncertainty_score":0.006872356},"labels":[],"label_agreement":null},{"id":"W2002914543","doi":"10.1371/journal.pone.0063458","title":"Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency","keywords":"Immunohistochemistry; Cancer; Metastasis; Medicine; Pathology; Gastroenterology; Adenocarcinoma; Internal medicine","score_opus":0.09346606272102356,"score_gpt":0.29512173842365824,"score_spread":0.20165567570263468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002914543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995389,0.00021970116,0.000065604385,0.000013741829,0.0000023392663,0.0000017006828,0.00005925715,0.0000023440007,0.00009642566],"genre_scores_gemma":[0.9997749,0.000043274867,0.000065874316,0.000007786604,0.0000029537687,0.0000017928656,0.000061696155,5.067872e-7,0.000041247706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99983394,0.000047485326,0.000024214998,0.000034619432,0.00003169298,0.000028004562],"domain_scores_gemma":[0.9991549,0.00029102984,0.00030902744,0.00003470275,0.00007370003,0.00013656267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031921972,0.00019821594,0.00024894587,0.00048883515,0.00015865255,0.00034698934,0.000121512814,0.00034422634,0.0010697785],"category_scores_gemma":[0.0016543336,0.00019873164,0.00016049379,0.0004195637,0.00023667408,0.00018566036,0.00022945792,0.0002922305,0.00020377757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024786545,0.0000145633185,0.99622715,0.000009860154,0.000021318356,0.00017797475,0.000016109367,0.00006167077,0.002274008,0.000005782147,0.000039725513,0.0009038687],"study_design_scores_gemma":[0.00001082328,0.00014233631,0.99693775,0.000003137271,0.000035971887,0.0015374103,0.000059394217,0.00045138868,0.0006581376,0.000019866358,0.00013984577,0.0000038148755],"about_ca_topic_score_codex":0.00061484886,"about_ca_topic_score_gemma":0.0009420962,"teacher_disagreement_score":0.0010697785,"about_ca_system_score_codex":0.00015435896,"about_ca_system_score_gemma":0.000110850655,"threshold_uncertainty_score":0.003578782},"labels":[],"label_agreement":null},{"id":"W2003433778","doi":"10.1200/jco.2002.99.002","title":"HER-2/<i>neu</i> Serum Levels Vis-à-Vis Hormonal Response in Metastatic Breast Cancer","year":2002,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Internal medicine; Citation; Clinical Oncology; Multivariate analysis; Oncology; Hormone; Cancer; Gastroenterology; Library science","score_opus":0.33728410643388906,"score_gpt":0.5535752643029328,"score_spread":0.21629115786904374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003433778","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008196968,0.008740217,0.0005147702,0.9441985,0.03319828,0.000064586275,0.00049628725,0.00013210272,0.004458261],"genre_scores_gemma":[0.09469315,0.02039683,0.003989116,0.7637928,0.072854735,0.0002515906,0.00071139616,0.00019791974,0.043112405],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99911314,0.00027321014,0.00014262227,0.00012338505,0.00022612471,0.00012151014],"domain_scores_gemma":[0.9945714,0.0023495923,0.00039474346,0.00036027905,0.0020465734,0.0002773979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026192265,0.00042732683,0.0006103893,0.00084866275,0.0009841752,0.0013192295,0.0012313841,0.0061997403,0.011445645],"category_scores_gemma":[0.010548697,0.00027872235,0.0007587434,0.0010321391,0.00127494,0.001467124,0.0004987895,0.0060261856,0.0080303],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033643644,0.00005924402,0.016784944,0.00014670295,0.000031735304,0.0011031943,0.00020519977,0.0000772869,0.00066849735,0.00039672724,0.94232845,0.037861567],"study_design_scores_gemma":[0.0002964065,0.0005386966,0.05651077,0.00084703945,0.00032595685,0.021930104,0.0034778,0.0009438339,0.005566085,0.0066589178,0.9026485,0.00025588856],"about_ca_topic_score_codex":0.002657952,"about_ca_topic_score_gemma":0.004724874,"teacher_disagreement_score":0.011445645,"about_ca_system_score_codex":0.00077677175,"about_ca_system_score_gemma":0.00062693766,"threshold_uncertainty_score":0.038289487},"labels":[],"label_agreement":null},{"id":"W2003852222","doi":"10.1158/1078-0432.ccr-05-2242","title":"Expression and Nuclear Localization of ErbB3 in Prostate Cancer","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal; University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"Institut Du Cancer de Montréal","keywords":"DU145; LNCaP; Prostate cancer; Prostate; Cancer; Tissue microarray; Pathology; Biology; Cancer research; PCA3; Immunohistochemistry; Medicine; Internal medicine","score_opus":0.22629727301224037,"score_gpt":0.5769018912532754,"score_spread":0.35060461824103506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003852222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894533,0.007887273,0.0010251892,0.00006628395,0.000006945819,0.000008300556,0.00033137048,0.00004517277,0.0011760956],"genre_scores_gemma":[0.9969451,0.0015618567,0.00064949883,0.000032513446,0.0000048486836,0.000007873508,0.00041716886,0.0000051298825,0.00037604594],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99988484,0.000015797797,0.000007746057,0.000026195026,0.000042973097,0.00002236536],"domain_scores_gemma":[0.9998901,0.000019098197,0.000037967973,0.00001234761,0.00002197644,0.000018528659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017219745,0.00017328157,0.00013157117,0.00035172753,0.00022290462,0.00027639998,0.00014395632,0.00014390815,0.0011309825],"category_scores_gemma":[0.00014864035,0.00010979382,0.00016482733,0.0004542945,0.00022476456,0.000107000655,0.00017036943,0.00022219573,0.00027964063],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004536907,0.000035911475,0.053495128,0.00028544877,0.00005837486,0.0003353115,0.00009351452,0.00016416067,0.9355825,0.00015663021,0.00021748045,0.009121794],"study_design_scores_gemma":[0.000058471065,0.0006772928,0.71338785,0.000055127486,0.00019160629,0.010449723,0.00033131757,0.0013994788,0.26500756,0.0002901974,0.0081293555,0.00002198553],"about_ca_topic_score_codex":0.0018960589,"about_ca_topic_score_gemma":0.0027518624,"teacher_disagreement_score":0.0018960589,"about_ca_system_score_codex":0.00035208766,"about_ca_system_score_gemma":0.00031629213,"threshold_uncertainty_score":0.0037834644},"labels":[],"label_agreement":null},{"id":"W2003885794","doi":"10.1158/0008-5472.can-12-1339-t","title":"Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; University of Pennsylvania","keywords":"Trastuzumab; Cancer research; Tumor microenvironment; Cytotoxic T cell; CD8; PTEN; Medicine; PI3K/AKT/mTOR pathway; Breast cancer; T cell; Protein kinase B; Mammary tumor; Antibody; Cancer; Immunology; Antigen; Immune system; Biology; Internal medicine; Signal transduction; In vitro; Cell biology; Tumor cells","score_opus":0.05514960438187381,"score_gpt":0.39744508346180224,"score_spread":0.3422954790799284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003885794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924763,0.0021418347,0.0025133186,0.0000835343,0.00003316835,0.000074162235,0.00008210154,0.00010741925,0.0024881735],"genre_scores_gemma":[0.9963787,0.0007737343,0.001635421,0.000035822824,0.000018755924,0.000036581834,0.00009413885,0.000010008178,0.0010168742],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998466,0.000036702124,0.000011570574,0.000023858895,0.000034818066,0.000046429202],"domain_scores_gemma":[0.99995565,0.0000079711035,0.000010458052,0.000008175462,0.0000038375406,0.000013944409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013798449,0.0003323282,0.00036387148,0.00021932156,0.00007410266,0.00021244066,0.00015251101,0.00016299514,0.0007955021],"category_scores_gemma":[0.00009263766,0.00010106486,0.00016118606,0.0001511131,0.00013233277,0.00013174592,0.00018011764,0.00044226466,0.00022230293],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037942769,0.0002667023,0.00028217345,0.000051372997,0.000016686356,0.00005899174,0.000011996608,0.00044803586,0.98841596,0.00014395389,0.00013129844,0.0097933505],"study_design_scores_gemma":[0.0001460212,0.0023420544,0.002431172,0.000004603583,0.000051033934,0.00046940584,0.000010228624,0.0019433134,0.9884022,0.000056280078,0.00413982,0.0000039837155],"about_ca_topic_score_codex":0.00018215702,"about_ca_topic_score_gemma":0.0006486981,"teacher_disagreement_score":0.0007955021,"about_ca_system_score_codex":0.00016145526,"about_ca_system_score_gemma":0.00020391286,"threshold_uncertainty_score":0.0026612282},"labels":[],"label_agreement":null},{"id":"W2004714285","doi":"10.1038/sj.onc.1208230","title":"Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth","year":2004,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; McMaster University","funders":"Canadian Institutes of Health Research; U.S. Department of Defense","keywords":"Biology; Mammary gland; Morphogenesis; Genetically modified mouse; Receptor tyrosine kinase; Endocrinology; Internal medicine; Tyrosine kinase; Cancer research; Epithelium; Mammary tumor; Cancer; Receptor; Transgene; Breast cancer; Cell biology; Kinase; Signal transduction; Gene; Genetics; Medicine","score_opus":0.03604846698600035,"score_gpt":0.3439230656669381,"score_spread":0.30787459868093775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004714285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914136,0.0013550421,0.0031765902,0.00017816006,0.00005810005,0.000015633988,0.0009683925,0.00024888475,0.0025855636],"genre_scores_gemma":[0.9895845,0.0005333893,0.0012530215,0.00006216833,0.0000047983526,0.000009800211,0.0005114825,0.00007268269,0.007968021],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974424,0.000022327502,0.00002111437,0.000051233335,0.0000906049,0.00007051823],"domain_scores_gemma":[0.99977416,0.000036982925,0.000060297618,0.000038476628,0.00001137992,0.000078780664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016518448,0.00046282585,0.00032487878,0.0003834835,0.0002659469,0.0006210411,0.00026639606,0.00052234676,0.0018858128],"category_scores_gemma":[0.0001271275,0.00033768069,0.00035121987,0.00022261748,0.00042899064,0.0002742313,0.0003989177,0.0009923602,0.00092952885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011732022,0.000021526539,0.00009913111,0.000011171049,0.0000050596345,0.00010542293,0.000008995995,0.00011406918,0.9988158,0.00016523752,0.000038779675,0.0004975742],"study_design_scores_gemma":[0.00001061657,0.00006591126,0.002588531,0.0000032092194,0.0000130082635,0.00055279187,0.000041724536,0.0005767958,0.9944384,0.00008159806,0.0016235732,0.0000038008354],"about_ca_topic_score_codex":0.0011466614,"about_ca_topic_score_gemma":0.001945941,"teacher_disagreement_score":0.0018858128,"about_ca_system_score_codex":0.0005364852,"about_ca_system_score_gemma":0.00038038753,"threshold_uncertainty_score":0.006308615},"labels":[],"label_agreement":null},{"id":"W2006035341","doi":"10.1080/01635581.2013.756921","title":"Dietary Flaxseed–Trastuzumab Interactive Effects on the Growth of HER2-Overexpressing Human Breast Tumors (BT-474)","year":2013,"lang":"en","type":"article","venue":"Nutrition and Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nutrition Society","funders":"","keywords":"Medicine; Protein kinase A; Trastuzumab; Apoptosis; Internal medicine; Endocrinology; MAPK/ERK pathway; Mammary tumor; Cancer research; Estrogen receptor; AKT2; Basal (medicine); Kinase; AKT1; Protein kinase B; Breast cancer; Biology; Cancer; Cell biology; Biochemistry","score_opus":0.02676153708598555,"score_gpt":0.33925665738997374,"score_spread":0.3124951203039882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006035341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798775,0.0006189762,0.00028821873,0.0000697526,0.000022401493,0.000014469423,0.00050052034,0.000041783263,0.0004560842],"genre_scores_gemma":[0.9934882,0.0007067654,0.0008612066,0.00008221238,0.000010606254,0.00004731462,0.0009583058,0.00002035827,0.003824985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999182,0.000012957751,0.000007113688,0.000019198444,0.000017309434,0.000025163732],"domain_scores_gemma":[0.99993896,0.000008437833,0.000016972252,0.000004550315,0.0000071523177,0.00002390579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008875813,0.00040049406,0.00034974937,0.0003224239,0.00014992431,0.0001647992,0.00016267714,0.00023060718,0.001686245],"category_scores_gemma":[0.0000706886,0.0001156859,0.00033354835,0.00017356765,0.00015226762,0.00016250582,0.00017796118,0.00048485975,0.00018624193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003651936,0.0003801023,0.00023323925,0.00007263877,0.000023005205,0.000040907464,0.00001850171,0.000071724346,0.9931765,0.00003838527,0.000078296536,0.0022148094],"study_design_scores_gemma":[0.00025082604,0.008269716,0.011016392,0.00001663631,0.00013505742,0.00014602549,0.00005654568,0.0007111214,0.9758616,0.000064088636,0.0034589556,0.000013004277],"about_ca_topic_score_codex":0.0020863952,"about_ca_topic_score_gemma":0.002955776,"teacher_disagreement_score":0.0020863952,"about_ca_system_score_codex":0.00033164615,"about_ca_system_score_gemma":0.00019014899,"threshold_uncertainty_score":0.005641043},"labels":[],"label_agreement":null},{"id":"W2006069672","doi":"10.1016/j.aanat.2010.12.002","title":"Complex patterns of ADAM12 mRNA and protein splice variants in the human placenta","year":2011,"lang":"en","type":"article","venue":"Annals of Anatomy - Anatomischer Anzeiger","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"RWTH Aachen University; Deutsche Forschungsgemeinschaft","keywords":"Cytotrophoblast; Syncytium; Placenta; Syncytiotrophoblast; Blot; Immunohistochemistry; Trophoblast; Biology; In situ hybridization; Molecular biology; Virology; Messenger RNA; Immunology; Gene; Pregnancy; Genetics; Virus; Fetus","score_opus":0.19892840454113753,"score_gpt":0.4124213046702093,"score_spread":0.2134929001290718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006069672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961265,0.0017017295,0.0009937882,0.00006059526,0.0000106190455,0.000005738048,0.00034567754,0.00002302869,0.00073248736],"genre_scores_gemma":[0.9965148,0.0009493219,0.0009209888,0.000024442075,0.000016255868,0.000010396851,0.00046743243,0.000025083607,0.0010711089],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998349,0.000042259748,0.000023677732,0.000040089788,0.000034607085,0.00002449317],"domain_scores_gemma":[0.99955136,0.00017986105,0.00007836654,0.00005914367,0.00008231019,0.000048845046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000246258,0.00013225293,0.0002569986,0.0013613513,0.00021545317,0.0005769075,0.00017149565,0.00024715086,0.0015988888],"category_scores_gemma":[0.0007784294,0.00027690956,0.00027467587,0.0005073294,0.00039103715,0.00022285343,0.00019617422,0.00037576052,0.00039920412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002643345,0.000029997385,0.04899205,0.00011542836,0.00010651724,0.0027827418,0.00083207473,0.0002429092,0.9298614,0.0007205358,0.00019765562,0.0134752495],"study_design_scores_gemma":[0.0000877911,0.0006451096,0.7108138,0.000045137574,0.00032439633,0.022159014,0.0022187226,0.0018924776,0.25200582,0.0015785972,0.008168762,0.000060436418],"about_ca_topic_score_codex":0.0009699672,"about_ca_topic_score_gemma":0.00074521045,"teacher_disagreement_score":0.0015988888,"about_ca_system_score_codex":0.00019707279,"about_ca_system_score_gemma":0.00015949817,"threshold_uncertainty_score":0.005348861},"labels":[],"label_agreement":null},{"id":"W2006371959","doi":"10.1158/0008-5472.sabcs12-p5-15-02","title":"Abstract P5-15-02: The benefit of targeted therapeutics in medical oncology since the development of trastuzumab","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Cancer","score_opus":0.23133876086043306,"score_gpt":0.5183204141789531,"score_spread":0.2869816533185201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006371959","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027476144,0.98155516,0.00040387546,0.0040618707,0.0018661098,0.00078052055,0.004406439,0.000023975072,0.0041542747],"genre_scores_gemma":[0.04326311,0.9399067,0.0021072133,0.0047812057,0.003020953,0.0011100981,0.0035655783,0.000031408672,0.0022136837],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99015594,0.0026968874,0.004121304,0.0005392645,0.0022986194,0.00018789101],"domain_scores_gemma":[0.93261904,0.044500925,0.012233713,0.0006751714,0.009348469,0.0006227752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012320893,0.0010087505,0.0034006936,0.01585384,0.0004381828,0.0041383086,0.0010924768,0.0017007831,0.016202757],"category_scores_gemma":[0.059106305,0.00043429856,0.003957591,0.021377934,0.0008734355,0.0029089511,0.0012626131,0.0009604192,0.0013551571],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007177435,0.000024767889,0.002768713,0.8614279,0.0047685914,0.0002709542,0.0001847206,0.00015709197,0.0005999114,0.0015082251,0.02740213,0.10016925],"study_design_scores_gemma":[0.00066224334,0.00027732938,0.019142535,0.8325002,0.024979101,0.0007559263,0.0004036173,0.00021942324,0.00063664693,0.002738119,0.11763876,0.0000460443],"about_ca_topic_score_codex":0.003518886,"about_ca_topic_score_gemma":0.006434736,"teacher_disagreement_score":0.016202757,"about_ca_system_score_codex":0.0044287774,"about_ca_system_score_gemma":0.008709017,"threshold_uncertainty_score":0.06515986},"labels":[],"label_agreement":null},{"id":"W2006937919","doi":"10.3389/fgene.2015.00017","title":"ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics","year":2015,"lang":"en","type":"review","venue":"Frontiers in Genetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fondation du cancer du sein du Québec","keywords":"ErbB; ERBB4; ERBB3; Biology; Receptor tyrosine kinase; Single-nucleotide polymorphism; Cancer research; Neuregulin; Computational biology; Genetics; Gene; Receptor; Genotype","score_opus":0.13994944969110415,"score_gpt":0.450494039254615,"score_spread":0.31054458956351083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006937919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0074015683,0.98272103,0.0017683308,0.004026163,0.00035171615,0.000013596038,0.0005325758,0.00003661103,0.0031484007],"genre_scores_gemma":[0.05462441,0.938428,0.001849951,0.0018652271,0.00080135703,0.000040564173,0.0005924232,0.00001644422,0.0017815604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959904,0.00012971806,0.000051926352,0.000074000825,0.000109451285,0.000035744968],"domain_scores_gemma":[0.9994086,0.0003565545,0.00008710197,0.000018609499,0.00010529394,0.000023778994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010575963,0.00030606883,0.0008036504,0.0008038875,0.00009722223,0.0009570545,0.00038839123,0.0006595951,0.0025644493],"category_scores_gemma":[0.0019081569,0.00013093263,0.0005793102,0.0007816878,0.00027201115,0.0005962776,0.0003661308,0.0011410705,0.0007201864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007893904,0.0001033462,0.011826992,0.008173986,0.0005844351,0.0008131181,0.00018324434,0.0022800232,0.012588285,0.0135927545,0.017655453,0.93140894],"study_design_scores_gemma":[0.00015590544,0.0010791548,0.06131366,0.0072068633,0.0016076585,0.007988602,0.00045355214,0.0031428323,0.011046767,0.03222478,0.8736276,0.00015273897],"about_ca_topic_score_codex":0.0005617044,"about_ca_topic_score_gemma":0.0008700918,"teacher_disagreement_score":0.0025644493,"about_ca_system_score_codex":0.00060111994,"about_ca_system_score_gemma":0.0005516704,"threshold_uncertainty_score":0.008578956},"labels":[],"label_agreement":null},{"id":"W2006951838","doi":"10.4161/cbt.7.4.5533","title":"Differential sensitivity of A549 non small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors","year":2008,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Epidermal growth factor receptor; A549 cell; Motility; Epidermal growth factor; Cancer research; Cell growth; Biology; EGFR inhibitors; Cell biology; Growth factor receptor; Apoptosis; Cell; Receptor; Signal transduction; Biochemistry","score_opus":0.0625310769672316,"score_gpt":0.3354780181004788,"score_spread":0.2729469411332472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006951838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914213,0.0038556582,0.0014482442,0.000071536706,0.000035533303,0.000041925316,0.0006519454,0.00006396097,0.0024098232],"genre_scores_gemma":[0.9939022,0.0019490089,0.0011477558,0.000069459034,0.00001004561,0.000067780304,0.0009247679,0.000014502835,0.0019145771],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965775,0.00007532962,0.00004149078,0.00005074296,0.00011036598,0.00006440366],"domain_scores_gemma":[0.99982196,0.00006127405,0.00002791682,0.000024422345,0.0000364987,0.000028066792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017296677,0.00031070114,0.00047546867,0.00035112517,0.00016156412,0.00035976648,0.00013715544,0.0003320093,0.0011581674],"category_scores_gemma":[0.00024618473,0.00017713859,0.00030706284,0.00023540904,0.00012515073,0.00017720177,0.00017527014,0.0004170831,0.00041505616],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099928264,0.000034433688,0.00032017386,0.000028258273,0.000009388408,0.000025717774,0.000014507959,0.00006712508,0.9983656,0.000024559597,0.000031670286,0.0009786361],"study_design_scores_gemma":[0.000013322629,0.00075352046,0.01381254,0.0000044486014,0.00002105012,0.00026303405,0.000040816416,0.00074043585,0.9834305,0.000023868908,0.0008899618,0.000006363188],"about_ca_topic_score_codex":0.0016964063,"about_ca_topic_score_gemma":0.0018263385,"teacher_disagreement_score":0.0016964063,"about_ca_system_score_codex":0.00025167703,"about_ca_system_score_gemma":0.0001640734,"threshold_uncertainty_score":0.0038744807},"labels":[],"label_agreement":null},{"id":"W2007855317","doi":"10.1016/s0009-9236(03)90662-x","title":"Pharmacokinetics of Trastuzumab in Combination With Paclitaxel Given Every 3 Weeks in Women With HER2 Positive Metastatic Breast Cancer","year":2003,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Paclitaxel; Medicine; Metastatic breast cancer; Pharmacokinetics; Oncology; Breast cancer; Internal medicine; Cancer","score_opus":0.07312905217516238,"score_gpt":0.44980259319497,"score_spread":0.37667354101980766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007855317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940584,0.0027445818,0.00049477554,0.0005844296,0.0001140711,0.000089083514,0.00023463443,0.000079552636,0.0016005134],"genre_scores_gemma":[0.9966378,0.0010689556,0.00037569585,0.00017980121,0.00011073672,0.00007296126,0.00019992006,0.00003170398,0.0013222884],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995976,0.00021626295,0.000012900387,0.000069456946,0.00005010364,0.000053731474],"domain_scores_gemma":[0.99915695,0.00034601483,0.00016728976,0.00005916128,0.000039363516,0.00023123974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062702666,0.00058028556,0.001400371,0.00040848818,0.00034425157,0.0007118654,0.0004092716,0.0010580311,0.0024954122],"category_scores_gemma":[0.0039709285,0.0007656523,0.00048609526,0.00049131404,0.00045249463,0.0008661436,0.0002131262,0.0018510371,0.0005648712],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67109805,0.0072927135,0.041506797,0.00029302863,0.0010232684,0.0017299658,0.00072415534,0.007886119,0.07267993,0.00054800353,0.0044487305,0.19076924],"study_design_scores_gemma":[0.07882109,0.46968573,0.3629435,0.00017196631,0.0031414207,0.0058952556,0.000993219,0.02437359,0.034607127,0.0013160555,0.01782112,0.00022988494],"about_ca_topic_score_codex":0.0016456344,"about_ca_topic_score_gemma":0.0028811782,"teacher_disagreement_score":0.0024954122,"about_ca_system_score_codex":0.00090142916,"about_ca_system_score_gemma":0.00075250835,"threshold_uncertainty_score":0.008347988},"labels":[],"label_agreement":null},{"id":"W2008691121","doi":"10.5858/arpa.2013-0604-oa","title":"HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation","year":2014,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; University Health Network; BC Cancer Agency","funders":"","keywords":"Immunohistochemistry; Medicine; Trastuzumab; HER2/neu; Tissue microarray; Cancer; External quality assessment; Pathology; Internal medicine; Oncology; Companion diagnostic; Breast cancer","score_opus":0.019046056051971363,"score_gpt":0.3665332145124135,"score_spread":0.34748715846044215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008691121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700851,0.0021633923,0.025552412,0.00009270909,0.00006620793,0.0002482406,0.0001980506,0.00010428286,0.001489477],"genre_scores_gemma":[0.9908215,0.00017273771,0.008477915,0.00006511867,0.000029709758,0.000100973535,0.00020254936,0.000026659862,0.000102786405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9218158,0.044887744,0.00763116,0.008222614,0.01658429,0.0008583765],"domain_scores_gemma":[0.87705415,0.077896394,0.0181019,0.011432931,0.0147186695,0.00079595315],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.07877172,0.0005972827,0.0006231314,0.0020999408,0.0005305586,0.0011185654,0.0010946196,0.0007626012,0.00038876577],"category_scores_gemma":[0.08289227,0.00036678233,0.0006260301,0.0016750364,0.0016417189,0.00060283253,0.0018475051,0.0005086772,0.00017665011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005614196,0.00012711668,0.9458123,0.00038304442,0.0011083704,0.0001714563,0.0023467515,0.0020990013,0.01752148,0.00021799689,0.0003080547,0.029343076],"study_design_scores_gemma":[0.00003340069,0.0010878191,0.97088224,0.00011358492,0.00045473242,0.001212514,0.0007763109,0.0074602077,0.01552095,0.0006049898,0.0017891091,0.00006413639],"about_ca_topic_score_codex":0.0013610233,"about_ca_topic_score_gemma":0.0018222973,"teacher_disagreement_score":0.9212283,"about_ca_system_score_codex":0.0008331295,"about_ca_system_score_gemma":0.0005348633,"threshold_uncertainty_score":0.41658962},"labels":[],"label_agreement":null},{"id":"W2008692957","doi":"10.1016/j.mpdhp.2014.10.002","title":"ER, PR and HER2 testing in breast cancer","year":2014,"lang":"en","type":"article","venue":"Diagnostic histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Breast cancer; Estrogen receptor; Oncology; Biomarker; Medicine; Cancer; Human Epidermal Growth Factor Receptor 2; Internal medicine; Targeted therapy; Bioinformatics; Biology","score_opus":0.029263649304944607,"score_gpt":0.3369614672014343,"score_spread":0.30769781789648964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008692957","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7645717,0.15732272,0.0019772698,0.016905814,0.0011355177,0.00003561133,0.0006122788,0.00010245607,0.0573366],"genre_scores_gemma":[0.976533,0.018560708,0.0010410103,0.00072319794,0.0008229385,0.000009181042,0.00013908745,0.000013194148,0.0021576912],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990392,0.00040000965,0.00010922163,0.00006041878,0.00025362772,0.00013759312],"domain_scores_gemma":[0.9976184,0.0014037532,0.00026850056,0.000088115674,0.00038372359,0.00023739038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023186477,0.00027147614,0.0003196144,0.0022776502,0.00031962228,0.0011850388,0.0005420031,0.0007226797,0.0023927393],"category_scores_gemma":[0.00760674,0.00022850189,0.00020720335,0.0013084443,0.0007270867,0.0009894803,0.00040099066,0.00068373233,0.00047248747],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010971021,0.00019007307,0.7784273,0.00027279733,0.000095402,0.004877388,0.00019105172,0.00054311915,0.003388957,0.002140089,0.0071484633,0.20162833],"study_design_scores_gemma":[0.00003788515,0.0005631394,0.9092954,0.00043064405,0.0003034116,0.038034666,0.0018645653,0.003136186,0.0047680507,0.008488413,0.033035714,0.000041980617],"about_ca_topic_score_codex":0.002088639,"about_ca_topic_score_gemma":0.0040401705,"teacher_disagreement_score":0.0023927393,"about_ca_system_score_codex":0.00060113164,"about_ca_system_score_gemma":0.0007279079,"threshold_uncertainty_score":0.012262344},"labels":[],"label_agreement":null},{"id":"W2010059199","doi":"10.1016/j.ctrv.2013.01.002","title":"HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials","year":2013,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lapatinib; Pertuzumab; Trastuzumab; Oncology; Breast cancer; Internal medicine; Neoadjuvant therapy; Clinical trial; Targeted therapy; Chemotherapy; Cancer","score_opus":0.30647694075076715,"score_gpt":0.523487102194639,"score_spread":0.21701016144387186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010059199","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049918564,0.99888855,0.00007789246,0.00009132999,0.000052912066,0.00010626765,0.00015206874,0.000004567759,0.00012736257],"genre_scores_gemma":[0.007420563,0.9914341,0.00038611447,0.00038806992,0.00004200979,0.00012843109,0.00009988382,0.0000036042272,0.00009716201],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9972646,0.0009342006,0.0010504266,0.00025140587,0.0003998099,0.00009951818],"domain_scores_gemma":[0.9930774,0.0045489725,0.0017279806,0.00010036551,0.0004291311,0.00011617292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004784888,0.0015501664,0.008863924,0.0040152273,0.00031869247,0.0017523776,0.0014880954,0.0012688368,0.0044877687],"category_scores_gemma":[0.013561507,0.000837514,0.0076646814,0.00536148,0.0005639505,0.0015226565,0.0011482359,0.0013420505,0.00025846585],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079597125,0.000025445876,0.00045064834,0.92572224,0.02346248,0.00007006682,0.00008608656,0.00018132295,0.00033324497,0.00014133842,0.0018353112,0.04689589],"study_design_scores_gemma":[0.002141318,0.0007586224,0.005897217,0.54374343,0.40364614,0.00051040837,0.00024386588,0.00018345135,0.00038654942,0.0005394967,0.041874293,0.000075273245],"about_ca_topic_score_codex":0.004178512,"about_ca_topic_score_gemma":0.020681186,"teacher_disagreement_score":0.008863924,"about_ca_system_score_codex":0.0020075333,"about_ca_system_score_gemma":0.0038178603,"threshold_uncertainty_score":0.025305152},"labels":[],"label_agreement":null},{"id":"W2010208199","doi":"10.1158/0008-5472.sabcs13-p4-12-16","title":"Abstract P4-12-16: Safety profile and costs of related adverse events of trastuzumab emtansine compared to other regimens in the Canadian health care system","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Trastuzumab emtansine; Medicine; Trastuzumab; Taxane; Lapatinib; Internal medicine; Capecitabine; Docetaxel; Adverse effect; Oncology; Breast cancer; Cancer","score_opus":0.08097982633674465,"score_gpt":0.42649058274963975,"score_spread":0.3455107564128951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010208199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9374922,0.021677108,0.0004821846,0.0047060126,0.00010043865,0.00059873104,0.016762124,0.000079945734,0.018101152],"genre_scores_gemma":[0.98965085,0.0036389355,0.00044848054,0.00054405356,0.000056923498,0.00009070674,0.0035659971,0.000010536519,0.0019934578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794537,0.00043385694,0.00015316621,0.00019574178,0.0010311431,0.00024069671],"domain_scores_gemma":[0.99435437,0.00067003217,0.0018591861,0.00013732494,0.0019479941,0.0010310053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001325437,0.00025893448,0.0004929761,0.0010861875,0.0008094007,0.0010662209,0.0009120048,0.00039312767,0.0056036026],"category_scores_gemma":[0.008874555,0.00014275778,0.0010014814,0.0022510772,0.0003002406,0.00035753037,0.0005786882,0.0006975905,0.00018649107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020591786,0.0010225235,0.5376472,0.0018281081,0.0019695414,0.00040329993,0.00033455758,0.0054749525,0.0016948726,0.0015858797,0.033439938,0.39400735],"study_design_scores_gemma":[0.0017286255,0.003258386,0.9730334,0.00042863385,0.00061718037,0.00029125804,0.0002693352,0.004357692,0.0007276512,0.00023089304,0.015011121,0.000045776833],"about_ca_topic_score_codex":0.73433304,"about_ca_topic_score_gemma":0.7924813,"teacher_disagreement_score":0.26566696,"about_ca_system_score_codex":0.02914511,"about_ca_system_score_gemma":0.02383505,"threshold_uncertainty_score":0.53446305},"labels":[],"label_agreement":null},{"id":"W2012258371","doi":"10.1159/000326671","title":"Assessment of Thin-Layer Breast Aspirates for Immunocytochemical Evaluation of HER2 Status","year":2003,"lang":"en","type":"article","venue":"Acta Cytologica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Immunostaining; Medicine; Pathology; Immunohistochemistry; Immunocytochemistry; Staining; Fluorescence in situ hybridization; Biology; Gene","score_opus":0.14559067214893495,"score_gpt":0.4630585170960219,"score_spread":0.31746784494708696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012258371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426174,0.0011903482,0.0029681525,0.000024010107,0.000015243655,0.000084727486,0.0000837015,0.000046721223,0.0013252056],"genre_scores_gemma":[0.9916483,0.0008521786,0.0066451873,0.00004655462,0.000021362997,0.00007077115,0.00028923395,0.0000130436665,0.00041329884],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99960834,0.00010296959,0.0000771952,0.000047627527,0.00012527329,0.00003863113],"domain_scores_gemma":[0.99866366,0.00038754765,0.00017700998,0.00009636071,0.0005403267,0.00013498006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012699503,0.00043090756,0.00023466416,0.0011088918,0.00023197751,0.0002806096,0.00017122312,0.00027842887,0.0014690364],"category_scores_gemma":[0.0022995227,0.00016855291,0.00013596579,0.00031604344,0.0002732987,0.00023929958,0.00022824995,0.00017142617,0.0004612566],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006019829,0.00010744013,0.27050945,0.00023533149,0.000064608925,0.0017686697,0.00019718116,0.000099221754,0.7150944,0.00004055558,0.00017813459,0.011102998],"study_design_scores_gemma":[0.000081694605,0.0020084667,0.7589271,0.00009439362,0.00020624953,0.014269434,0.0007679176,0.0030650923,0.21790501,0.000084639396,0.0025699376,0.00002010385],"about_ca_topic_score_codex":0.00095560896,"about_ca_topic_score_gemma":0.0014699594,"teacher_disagreement_score":0.0014690364,"about_ca_system_score_codex":0.00015607355,"about_ca_system_score_gemma":0.0002184367,"threshold_uncertainty_score":0.0067162514},"labels":[],"label_agreement":null},{"id":"W2012505736","doi":"10.1038/modpathol.2013.103","title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","year":2013,"lang":"en","type":"review","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":282,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Polysomy; Trastuzumab; Breast cancer; Genetic heterogeneity; Fluorescence in situ hybridization; Chromosome 17 (human); Cancer; Biology; Oncology; Pathology; Internal medicine; Chromosome; Medicine; Genetics; Phenotype; Gene","score_opus":0.14856773862352984,"score_gpt":0.48226546491079003,"score_spread":0.3336977262872602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012505736","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001305571,0.9990374,0.000110294015,0.00024277125,0.000096025986,0.000001457826,0.000012631705,0.0000036868985,0.00036530526],"genre_scores_gemma":[0.0010453513,0.99812895,0.00019221407,0.00021797624,0.00019240279,0.00000209333,0.000026495949,0.0000013301905,0.00019316965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997222,0.00004612233,0.000042779255,0.000065084794,0.00010028866,0.000023458093],"domain_scores_gemma":[0.99929535,0.00042399263,0.00009378794,0.000014020769,0.00013264922,0.000040113806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008543452,0.00067639415,0.0012754763,0.0026670063,0.00013786652,0.0007774675,0.0009147104,0.0008190056,0.001551864],"category_scores_gemma":[0.0012779813,0.00024422817,0.00039778036,0.0025105497,0.00055011536,0.0011949565,0.0006614314,0.0010275327,0.00066625356],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050918825,0.000018089491,0.00076902955,0.00800597,0.000092468275,0.00057984993,0.000041096504,0.00020611154,0.0012491662,0.0014042563,0.016492935,0.97109014],"study_design_scores_gemma":[0.000028598097,0.00008339829,0.0048325243,0.0072365194,0.00057128374,0.010170642,0.00025510116,0.00018931783,0.0009409307,0.0036570774,0.97197986,0.000054727327],"about_ca_topic_score_codex":0.0011861009,"about_ca_topic_score_gemma":0.0024845034,"teacher_disagreement_score":0.0026670063,"about_ca_system_score_codex":0.00057065394,"about_ca_system_score_gemma":0.0010914308,"threshold_uncertainty_score":0.005191505},"labels":[],"label_agreement":null},{"id":"W2013058114","doi":"10.1038/ncb1134","title":"Memo mediates ErbB2-driven cell motility","year":2004,"lang":"en","type":"article","venue":"Nature Cell Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Roche Diagnostics; Krebsliga Schweiz","keywords":"Motility; Cell biology; Lamellipodium; Cell migration; Biology; Actin; Actin cytoskeleton; Signal transducing adaptor protein; Kinase; Cytoskeleton; Phosphorylation; Cell; Biochemistry","score_opus":0.01527616212539192,"score_gpt":0.3427650390801068,"score_spread":0.3274888769547149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013058114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98108095,0.0019123909,0.0036529158,0.00050889235,0.00013438128,0.000036017296,0.00076150405,0.00013763142,0.011775282],"genre_scores_gemma":[0.9877152,0.0006141211,0.00096017384,0.00013298231,0.00002130885,0.00003620777,0.0005061749,0.000024597333,0.009989134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999082,0.0000105761055,0.0000047008766,0.000014573995,0.000014662381,0.00004738015],"domain_scores_gemma":[0.9999224,0.00001570025,0.000012935296,0.00001238777,0.000007380487,0.000029176923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000160553,0.0003239534,0.0001597417,0.00016046608,0.00028428342,0.00050918903,0.00025463567,0.0003771006,0.004279257],"category_scores_gemma":[0.00016774981,0.00014378443,0.00022347964,0.0000814978,0.00020659575,0.00037017942,0.0005063938,0.0005314048,0.001020046],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024799837,0.000029310144,0.00019935706,0.000050494273,0.000004893407,0.00013112664,0.000020163192,0.000050560677,0.9951438,0.0017686432,0.00024714888,0.002106501],"study_design_scores_gemma":[0.000026096424,0.00010014435,0.0026164493,0.00000875342,0.0000051768307,0.00020683314,0.00005067533,0.00078250014,0.9893801,0.0002493628,0.006569954,0.00000397291],"about_ca_topic_score_codex":0.0004165165,"about_ca_topic_score_gemma":0.0005977531,"teacher_disagreement_score":0.004279257,"about_ca_system_score_codex":0.00036159108,"about_ca_system_score_gemma":0.00014460609,"threshold_uncertainty_score":0.014315546},"labels":[],"label_agreement":null},{"id":"W2013797830","doi":"10.1186/bcr2904","title":"Luminal-B breast cancer and novel therapeutic targets","year":2011,"lang":"en","type":"review","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Breast cancer; Surgical oncology; Estrogen receptor; Medicine; Cancer research; Gene expression profiling; Bioinformatics; Pathological; Endocrine system; Oncology; Cancer; Internal medicine; Gene; Gene expression; Biology; Hormone; Genetics","score_opus":0.289696687158721,"score_gpt":0.5148012716975511,"score_spread":0.2251045845388301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013797830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011255053,0.99813217,0.00011280542,0.0003593969,0.00014504712,0.00000423812,0.000012751937,0.000007197023,0.0011137591],"genre_scores_gemma":[0.0006964637,0.9979395,0.00018448256,0.0002516257,0.00013466817,0.0000069145444,0.000027733295,0.000001362313,0.0007571233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984086,0.000033946242,0.000019004037,0.000026611342,0.00006157972,0.000017943601],"domain_scores_gemma":[0.9998561,0.000057135912,0.000019853422,0.000005621157,0.00004522125,0.000015984684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048771183,0.00071509817,0.0013357392,0.0019602682,0.00024137176,0.00079579325,0.0007726479,0.00092559826,0.00341066],"category_scores_gemma":[0.0005121461,0.00025275748,0.00038960107,0.0016243499,0.0003995548,0.0011190824,0.00049001776,0.0020029787,0.0023193385],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007100823,0.00013251088,0.00012357828,0.007489764,0.000059341364,0.0004254004,0.000043462962,0.00047307747,0.0023103026,0.0039830813,0.039074294,0.94581413],"study_design_scores_gemma":[0.000032914253,0.00009872568,0.00063920725,0.002665962,0.000056623085,0.0023191986,0.000050308434,0.00012474407,0.0005435383,0.0021753618,0.991277,0.00001647678],"about_ca_topic_score_codex":0.0006823653,"about_ca_topic_score_gemma":0.0016570898,"teacher_disagreement_score":0.00341066,"about_ca_system_score_codex":0.0006920245,"about_ca_system_score_gemma":0.00064937107,"threshold_uncertainty_score":0.011409819},"labels":[],"label_agreement":null},{"id":"W2014836885","doi":"10.1111/tbj.12284","title":"Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression-Free Survival on First-Line Therapy Predicts Overall Survival Impact","year":2014,"lang":"en","type":"article","venue":"The Breast Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Cancer Care Nova Scotia; Queen Elizabeth II Health Sciences Centre","funders":"Roche Canada","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Docetaxel; Breast cancer; Chemotherapy; Retrospective cohort study; Paclitaxel; Cohort; Cancer","score_opus":0.03977329334124006,"score_gpt":0.3970839875597167,"score_spread":0.3573106942184766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014836885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98465294,0.013377702,0.00024534,0.00018722223,0.000012354134,0.000010106381,0.00042698372,0.000006194851,0.0010811965],"genre_scores_gemma":[0.9982907,0.0011786262,0.00008455931,0.000033622156,0.00003964829,0.0000035927164,0.00026035696,0.000002006521,0.00010687443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99936646,0.00026689874,0.00007833575,0.000089729336,0.00013555419,0.000062958956],"domain_scores_gemma":[0.9955361,0.002091018,0.0016829014,0.00015968262,0.00028018415,0.00025004294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001681434,0.0001402665,0.00039728693,0.00062531064,0.00012302179,0.0006341197,0.00027295342,0.0002496435,0.0009819611],"category_scores_gemma":[0.005375589,0.000098738055,0.0006348808,0.0006666064,0.00018814963,0.0005016018,0.00024661253,0.0004363683,0.00018460829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050499564,0.000014223672,0.9841263,0.00005601449,0.000117658965,0.00014306788,0.000029661758,0.00012509726,0.00031437722,0.000023022329,0.00014799513,0.014397645],"study_design_scores_gemma":[0.000015328544,0.00019759398,0.99739873,0.000031850177,0.00021037743,0.0008873463,0.00004353706,0.00039596588,0.0001857839,0.000045089335,0.0005846669,0.000003744004],"about_ca_topic_score_codex":0.0009899226,"about_ca_topic_score_gemma":0.0024562224,"teacher_disagreement_score":0.001681434,"about_ca_system_score_codex":0.00037186246,"about_ca_system_score_gemma":0.00026027203,"threshold_uncertainty_score":0.008892357},"labels":[],"label_agreement":null},{"id":"W2015918488","doi":"10.1038/modpathol.2011.198","title":"HER2 testing in gastric cancer: a practical approach","year":2012,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":596,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Immunohistochemistry; Cancer; Breast cancer; Medicine; Fluorescence in situ hybridization; Pathology; Capecitabine; Oncology; CISH; In situ hybridization; Stomach cancer; Adenocarcinoma; Metastatic breast cancer; Companion diagnostic; Internal medicine; Biology; Colorectal cancer","score_opus":0.2028628030829037,"score_gpt":0.4404619443020513,"score_spread":0.23759914121914763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015918488","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030055294,0.11107101,0.40957525,0.36693683,0.00834401,0.0008610864,0.00042780547,0.0016441201,0.0710846],"genre_scores_gemma":[0.4208995,0.09478989,0.36614534,0.06267371,0.037951753,0.0009295467,0.0005412481,0.0004092387,0.015659746],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966485,0.0014655155,0.00040095006,0.00036242444,0.0009275916,0.00019505258],"domain_scores_gemma":[0.9924759,0.00409334,0.00024092688,0.00058037665,0.0019078499,0.00070157467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009706363,0.001897181,0.0019349654,0.0045527173,0.0015788955,0.005199819,0.004295495,0.007306153,0.0076318737],"category_scores_gemma":[0.013737579,0.0011030576,0.0013758228,0.0010688346,0.004396329,0.007911969,0.0044207033,0.008933453,0.0028449206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010311651,0.0011813407,0.042351365,0.0014723398,0.00030361046,0.02891732,0.00092647196,0.0038670334,0.010782315,0.053718634,0.11180326,0.7436451],"study_design_scores_gemma":[0.00089221855,0.0017548255,0.036739137,0.0052330787,0.0010364989,0.12593664,0.008113743,0.031993087,0.009722082,0.51091504,0.26712474,0.00053890835],"about_ca_topic_score_codex":0.0012779471,"about_ca_topic_score_gemma":0.0022343444,"teacher_disagreement_score":0.009706363,"about_ca_system_score_codex":0.00203646,"about_ca_system_score_gemma":0.0024123646,"threshold_uncertainty_score":0.05133277},"labels":[],"label_agreement":null},{"id":"W2016074317","doi":"10.3747/co.19.960","title":"Outcomes of Women with Early-Stage Breast Cancer Receiving Adjuvant Trastuzumab","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Stage (stratigraphy); Cancer; Hazard ratio; Population; Adjuvant; Cohort; Retrospective cohort study; Confidence interval; Gynecology","score_opus":0.12985228809018168,"score_gpt":0.46645928155331545,"score_spread":0.3366069934631338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016074317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962096,0.0017390149,0.000040760624,0.00020240006,0.000009705635,0.000033879256,0.000839988,0.0000032072794,0.0009214547],"genre_scores_gemma":[0.99834096,0.00054011185,0.000027826225,0.00009405503,0.000013610745,0.000024727544,0.0007278356,6.111558e-7,0.00023031831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996524,0.00010082817,0.00002689219,0.00005285248,0.000095812335,0.00007113971],"domain_scores_gemma":[0.99913377,0.00018788988,0.0003802933,0.000032962387,0.00012507,0.0001400962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000698423,0.00015694824,0.00036893663,0.00033390053,0.00027363346,0.0004005895,0.00023501189,0.0003097659,0.0011601731],"category_scores_gemma":[0.0021743919,0.00009694312,0.00032160972,0.0005970297,0.00025927613,0.0001439032,0.0001777631,0.00036759078,0.00015069755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026850062,0.00015240899,0.9845035,0.00008594831,0.000180873,0.00010080193,0.000072435876,0.0001399643,0.0002035065,0.000024045527,0.00053522,0.0113163255],"study_design_scores_gemma":[0.000273594,0.00074697984,0.99778014,0.000031230382,0.00014310254,0.00018072958,0.00006866233,0.00012206718,0.00009044053,0.0000453929,0.000512819,0.0000048269944],"about_ca_topic_score_codex":0.026470408,"about_ca_topic_score_gemma":0.034098893,"teacher_disagreement_score":0.026470408,"about_ca_system_score_codex":0.0011027692,"about_ca_system_score_gemma":0.001103066,"threshold_uncertainty_score":0.05263269},"labels":[],"label_agreement":null},{"id":"W2016827479","doi":"10.3747/co.v17i4.700","title":"Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Toronto; Université de Sherbrooke; University of Ottawa; Centre hospitalier universitaire de Québec; Hôpital du Saint-Sacrement; Health Sciences Centre; Ottawa Hospital; Santé Montérégie; University of Alberta; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Anthracycline; Population; Stage (stratigraphy); Disease; Clinical trial; Cancer; Adjuvant; Gynecology","score_opus":0.2447587637129754,"score_gpt":0.5587603142850097,"score_spread":0.3140015505720343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016827479","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024772354,0.29482272,0.0020017633,0.6940759,0.0030978383,0.00001998008,0.000027197353,0.000017329088,0.0034601127],"genre_scores_gemma":[0.091875724,0.66513234,0.02170154,0.18513711,0.032853704,0.000086865,0.000085234766,0.000041283605,0.0030862072],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942789,0.002338605,0.00059734716,0.00037018288,0.0020138284,0.000401103],"domain_scores_gemma":[0.9830104,0.006890609,0.001514608,0.00032180798,0.0063138534,0.0019486699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016346551,0.0004964248,0.0011113648,0.0011486214,0.0016203098,0.0047264597,0.0020311184,0.006359787,0.0016407634],"category_scores_gemma":[0.017341519,0.00022457606,0.0005264324,0.0012080674,0.0041662245,0.0047598192,0.0018685253,0.007859443,0.000498983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028791404,0.00025223344,0.0037430725,0.0048511145,0.00011057538,0.00084399956,0.0015214473,0.0011682732,0.0022252167,0.0226976,0.17085926,0.79143924],"study_design_scores_gemma":[0.00018875592,0.0008627482,0.008537311,0.008761649,0.0002326494,0.0024656395,0.008524001,0.0012020189,0.0012898388,0.061513763,0.90625715,0.00016446746],"about_ca_topic_score_codex":0.007101645,"about_ca_topic_score_gemma":0.020109141,"teacher_disagreement_score":0.016346551,"about_ca_system_score_codex":0.0056348937,"about_ca_system_score_gemma":0.012353133,"threshold_uncertainty_score":0.08644992},"labels":[],"label_agreement":null},{"id":"W2016909614","doi":"10.3747/co.22.2363","title":"Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature","year":2015,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Targeted therapy; Oncology; Human Epidermal Growth Factor Receptor 2; Clinical trial; Internal medicine; Cancer; Disease; Trastuzumab; Natural history","score_opus":0.265833073951816,"score_gpt":0.5634664620124306,"score_spread":0.29763338806061457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016909614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006256217,0.9994282,0.000033981036,0.0000962108,0.00006493331,0.0000032326852,0.00001577714,0.000002450845,0.00029262813],"genre_scores_gemma":[0.00024874942,0.9994778,0.000057751233,0.00006441148,0.000046880097,0.0000025680056,0.000012638382,3.9820256e-7,0.00008881784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998155,0.00003182694,0.000044270848,0.000031999625,0.00006452198,0.000012004485],"domain_scores_gemma":[0.9995425,0.00026000856,0.000078148514,0.000008643097,0.000084180654,0.000026596703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005310142,0.0007551731,0.0015512406,0.0030594263,0.00024984684,0.00078309025,0.0008075251,0.00077259226,0.00397454],"category_scores_gemma":[0.0010210634,0.0002530244,0.0006444087,0.0035148673,0.00031546337,0.0010994263,0.00049445545,0.0010255293,0.0012514633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007781174,0.00007020024,0.0002089944,0.06308502,0.0001753436,0.00025881722,0.00007434704,0.00033610006,0.0009537545,0.0013699757,0.02961618,0.9037734],"study_design_scores_gemma":[0.000034432218,0.0001665279,0.0017078861,0.027811052,0.00067169353,0.0030303898,0.00012627208,0.00012829616,0.0003770755,0.0016616817,0.96425116,0.000033537934],"about_ca_topic_score_codex":0.0010357003,"about_ca_topic_score_gemma":0.0024053643,"teacher_disagreement_score":0.00397454,"about_ca_system_score_codex":0.00045551732,"about_ca_system_score_gemma":0.0010346619,"threshold_uncertainty_score":0.013296127},"labels":[],"label_agreement":null},{"id":"W2017265537","doi":"10.3389/fonc.2013.00023","title":"Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?","year":2013,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Canadian Institutes of Health Research; Susan G. Komen for the Cure","keywords":"Medicine; Tyrosine kinase; Immune system; Cancer research; Receptor tyrosine kinase; Oncology; Receptor; Breast cancer; Internal medicine; Immunology; Cancer","score_opus":0.02863190148130483,"score_gpt":0.3510033395204924,"score_spread":0.32237143803918755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017265537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5770834,0.31096426,0.0063462886,0.055865575,0.0036242004,0.0005131273,0.0010066187,0.0006003605,0.043996174],"genre_scores_gemma":[0.8668137,0.11241522,0.00207327,0.0085114185,0.0012513002,0.00017985699,0.00043079702,0.00004589838,0.008278556],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99983776,0.00004974009,0.00001233457,0.000020891202,0.00002501268,0.00005423041],"domain_scores_gemma":[0.9997274,0.00011164171,0.000058506754,0.000031408767,0.000034650948,0.00003628633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082485145,0.0002768676,0.00082234165,0.00029197015,0.00014649887,0.0007847426,0.00040056984,0.00070840144,0.003938468],"category_scores_gemma":[0.00088426046,0.00011785422,0.00038058538,0.00024190627,0.0005124066,0.0007396459,0.00024549844,0.0013876006,0.0011139706],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061101937,0.004028349,0.009935837,0.0023613023,0.00040562844,0.0012491759,0.000310149,0.0019210273,0.14225352,0.014128831,0.03522862,0.7820675],"study_design_scores_gemma":[0.0084106615,0.058080435,0.07789811,0.0016767588,0.0016915237,0.013143142,0.0013719058,0.0037005215,0.23057622,0.03711871,0.5660854,0.00024657793],"about_ca_topic_score_codex":0.00012899027,"about_ca_topic_score_gemma":0.00066246535,"teacher_disagreement_score":0.003938468,"about_ca_system_score_codex":0.00030881702,"about_ca_system_score_gemma":0.00024750576,"threshold_uncertainty_score":0.0131754875},"labels":[],"label_agreement":null},{"id":"W2017526027","doi":"10.1016/j.bbrc.2015.03.180","title":"Transforming growth factor-α induces human ovarian cancer cell invasion by down-regulating E-cadherin in a Snail-independent manner","year":2015,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Child and Family Research Institute","funders":"Canadian Institutes of Health Research; China Scholarship Council","keywords":"Amphiregulin; Snail; Cadherin; Transforming growth factor; Epidermal growth factor; Biology; Transcription factor; Cancer research; Cell biology; Growth factor; Epidermal growth factor receptor; Receptor; Cell; Gene; Genetics","score_opus":0.20629836130672247,"score_gpt":0.4363558832850915,"score_spread":0.23005752197836904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017526027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611133,0.0006049783,0.00054485054,0.00010565916,0.00004986989,0.000026946256,0.00022223307,0.000047957343,0.002286246],"genre_scores_gemma":[0.995577,0.00058010564,0.00026899244,0.00005537426,0.000012140526,0.000026467551,0.000551027,0.0000070663614,0.0029219522],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999895,0.000016723723,0.000008339321,0.000007352767,0.000024689205,0.000047971404],"domain_scores_gemma":[0.99994016,0.000013393461,0.000008206222,0.000012292054,0.0000068329773,0.000019176172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010410358,0.0002506595,0.00014711692,0.00024977158,0.00014137778,0.000193227,0.00009118366,0.000113336246,0.0015392693],"category_scores_gemma":[0.00010669774,0.00014440561,0.0003259901,0.00019885864,0.00018483268,0.000103999104,0.00014133951,0.00053053454,0.00037730235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006320948,0.00018647774,0.0007688108,0.000046563142,0.000011208049,0.00017945298,0.000036294514,0.00007338052,0.9961714,0.0001325186,0.00022778742,0.0015339996],"study_design_scores_gemma":[0.00012236516,0.00079364417,0.018490704,0.000007305102,0.000033877426,0.00045031236,0.00010711995,0.0012409008,0.97456205,0.000097449774,0.004088846,0.0000054280076],"about_ca_topic_score_codex":0.0012097798,"about_ca_topic_score_gemma":0.0018806591,"teacher_disagreement_score":0.0015392693,"about_ca_system_score_codex":0.0001690227,"about_ca_system_score_gemma":0.0002940104,"threshold_uncertainty_score":0.0051493645},"labels":[],"label_agreement":null},{"id":"W2018630641","doi":"10.1074/jbc.m500313200","title":"Human Tumorous Imaginal Disc 1 (TID1) Associates with Trk Receptor Tyrosine Kinases and Regulates Neurite Outgrowth in nnr5-TrkA Cells","year":2005,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Robarts Clinical Trials","funders":"","keywords":"Tropomyosin receptor kinase A; Trk receptor; Receptor tyrosine kinase; Neurite; Low-affinity nerve growth factor receptor; Imaginal disc; Kinase; Cell biology; Receptor Protein-Tyrosine Kinases; Tyrosine kinase; Mitogen-activated protein kinase; Receptor; Signal transduction; Biology; Chemistry; Neurotrophin; Gene; In vitro; Drosophila melanogaster; Biochemistry","score_opus":0.02441895128307746,"score_gpt":0.31010602066520454,"score_spread":0.28568706938212707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018630641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949694,0.0026979423,0.0010505739,0.000067449386,0.000020558686,0.00001260525,0.00044264883,0.000045277637,0.00069359137],"genre_scores_gemma":[0.9936242,0.0012020783,0.0013261732,0.000045291556,0.000007461866,0.000018902654,0.0016222378,0.00001096037,0.0021426254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999163,0.000008305996,0.0000072679877,0.000023491082,0.00002008343,0.000024527493],"domain_scores_gemma":[0.99993813,0.0000062649365,0.000025614392,0.000005271904,0.0000046361392,0.000020074272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006318773,0.0003408208,0.00024279147,0.0002074651,0.00029264484,0.0002814225,0.00015773198,0.0002187827,0.00092204614],"category_scores_gemma":[0.00007485608,0.00015695437,0.0004475871,0.00016543259,0.0001366565,0.00015689032,0.00023616599,0.00038096146,0.0006919839],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092406226,0.000016194806,0.0007436185,0.000048959566,0.0000070311385,0.000119743796,0.000020618105,0.000044942524,0.99799746,0.000040303355,0.00006251731,0.00080614904],"study_design_scores_gemma":[0.000038467162,0.0004449226,0.05877016,0.000018503506,0.000052127936,0.0020921917,0.0001271421,0.0023388972,0.9286822,0.000059611506,0.0073600807,0.0000157147],"about_ca_topic_score_codex":0.0009658456,"about_ca_topic_score_gemma":0.0013092465,"teacher_disagreement_score":0.0009658456,"about_ca_system_score_codex":0.00060273893,"about_ca_system_score_gemma":0.00013616482,"threshold_uncertainty_score":0.004373193},"labels":[],"label_agreement":null},{"id":"W2018650005","doi":"10.1158/1078-0432.ccr-09-1192","title":"Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Tamoxifen; Medicine; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Cancer; Metastasis","score_opus":0.1474246640642809,"score_gpt":0.5366681232496262,"score_spread":0.3892434591853453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018650005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997449,0.0011242621,0.00018986755,0.00010406265,0.000015434878,0.00054394646,0.00017483332,0.000014502714,0.00038411716],"genre_scores_gemma":[0.9936312,0.001442211,0.0012112572,0.00030820747,0.00007761022,0.0010710894,0.0012650553,0.000009342728,0.0009840813],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999729,0.00011314752,0.000015866988,0.000037086218,0.00005286691,0.00005203349],"domain_scores_gemma":[0.99977595,0.000037790902,0.000037612816,0.000023054457,0.000026125492,0.00009944335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009792486,0.000936558,0.0013580971,0.00036991728,0.00029692057,0.0005135958,0.00038515008,0.00068157533,0.0017709008],"category_scores_gemma":[0.00053855457,0.00032442968,0.00058301835,0.00028906303,0.00047267732,0.00038559444,0.00021469686,0.0010602317,0.00030882348],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27954844,0.07813829,0.02432561,0.0009030391,0.0013716032,0.0007059075,0.00036878622,0.0022821273,0.4565141,0.00017904892,0.0019132788,0.1537498],"study_design_scores_gemma":[0.17327908,0.6924964,0.076634996,0.000051423885,0.001111513,0.0014725619,0.00010981146,0.0028535987,0.048598036,0.00014310796,0.0032008232,0.000048589973],"about_ca_topic_score_codex":0.00042944707,"about_ca_topic_score_gemma":0.0010422072,"teacher_disagreement_score":0.0017709008,"about_ca_system_score_codex":0.00060445815,"about_ca_system_score_gemma":0.00066019606,"threshold_uncertainty_score":0.0059242845},"labels":[],"label_agreement":null},{"id":"W2018698872","doi":"10.1200/jco.2006.10.0651","title":"Trastuzumab-Associated Peripheral Vascular Toxicity","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Toxicity; Peripheral; Cardiotoxicity; Oncology; Internal medicine; Breast cancer; Pharmacology; Cancer","score_opus":0.22312135106304717,"score_gpt":0.5646926958525449,"score_spread":0.3415713447894977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018698872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694211,0.011863828,0.0019130181,0.0010079406,0.00007722634,0.00006587854,0.00025279753,0.0001047893,0.015293559],"genre_scores_gemma":[0.99662554,0.0012963627,0.00012864356,0.0003674478,0.00006704951,0.000010645187,0.00011156225,0.000009979859,0.0013827552],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9997367,0.00012329814,0.000025591067,0.000023837034,0.000032543318,0.00005799029],"domain_scores_gemma":[0.99889475,0.000520717,0.00026092198,0.000104263585,0.000071931274,0.00014752318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051794515,0.00023950684,0.00038868273,0.0001908148,0.00027014362,0.0003285251,0.00027977664,0.000432515,0.0022363171],"category_scores_gemma":[0.0022136213,0.00009942256,0.0003747454,0.00037675299,0.00021832448,0.00016689784,0.00023276515,0.00082235463,0.00023423787],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021296948,0.0015680667,0.2137924,0.0012754336,0.0010222715,0.15683883,0.0003675756,0.0041491226,0.030402653,0.0031813532,0.008826371,0.55727893],"study_design_scores_gemma":[0.0023734665,0.013460891,0.55744416,0.00026116276,0.0014490264,0.366939,0.00017589325,0.0062062517,0.01702461,0.0026397014,0.03197636,0.0000494902],"about_ca_topic_score_codex":0.00082920626,"about_ca_topic_score_gemma":0.001561272,"teacher_disagreement_score":0.0022363171,"about_ca_system_score_codex":0.0007451973,"about_ca_system_score_gemma":0.0003329558,"threshold_uncertainty_score":0.0074812174},"labels":[],"label_agreement":null},{"id":"W2019089983","doi":"10.1158/0008-5472.sabcs-09-5114","title":"Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; BC Cancer Agency; Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Oncology; Internal medicine; Cohort; Metastatic breast cancer; Breast cancer; Cancer; Pharmacology","score_opus":0.22807095443971398,"score_gpt":0.4791410790961227,"score_spread":0.2510701246564087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019089983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375606,0.0046250294,0.00021599424,0.00021692297,0.000046330173,0.00009210973,0.00010336403,0.00001600899,0.00092816807],"genre_scores_gemma":[0.99692863,0.0011298881,0.0004245146,0.00024740168,0.0001598261,0.000077046214,0.00045651002,0.0000039879114,0.0005721901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916697,0.00036423918,0.00009475369,0.00012461875,0.00016385701,0.000085433516],"domain_scores_gemma":[0.99877256,0.0004505374,0.00031010757,0.00009694698,0.00012655368,0.00024317931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016913756,0.00032860306,0.00058327074,0.00025110153,0.0002169032,0.00048686296,0.00037049272,0.00069252425,0.0007944665],"category_scores_gemma":[0.0026307092,0.0001384426,0.0006164393,0.00022238221,0.00022000057,0.00046628836,0.00023150469,0.00079588726,0.00019817628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119045675,0.0045368774,0.46207732,0.00058271573,0.0012740337,0.003605944,0.0006461077,0.0007181214,0.036884975,0.00020995259,0.0036872807,0.36673108],"study_design_scores_gemma":[0.009260694,0.115616776,0.81179804,0.0001262358,0.0014181776,0.015118046,0.00025701392,0.00201633,0.025656397,0.0002000176,0.018453093,0.00007903984],"about_ca_topic_score_codex":0.00027100704,"about_ca_topic_score_gemma":0.00042934515,"teacher_disagreement_score":0.0016913756,"about_ca_system_score_codex":0.00056359824,"about_ca_system_score_gemma":0.00028636333,"threshold_uncertainty_score":0.008944929},"labels":[],"label_agreement":null},{"id":"W2019184486","doi":"10.1016/s0896-6273(00)81176-9","title":"Regulation of Neuregulin Signaling by PSD-95 Interacting with ErbB4 at CNS Synapses","year":2000,"lang":"en","type":"article","venue":"Neuron","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":382,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Neuregulin; ERBB4; Neuregulin 1; Postsynaptic density; Long-term potentiation; Synaptic plasticity; Neuroscience; Postsynaptic potential; ErbB; Cell biology; Neurotransmission; Receptor tyrosine kinase; Biology; Signal transduction; Kinase; Chemistry; Receptor; Biochemistry","score_opus":0.025219585103816167,"score_gpt":0.31733038654952317,"score_spread":0.292110801445707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019184486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904082,0.0032353655,0.0022575078,0.00020044528,0.00003551788,0.0000090291815,0.00011284911,0.00004591878,0.0036951287],"genre_scores_gemma":[0.9957709,0.0008691241,0.0007325123,0.000026468111,0.0000061019286,0.000007957975,0.000093917195,0.000008503282,0.0024845598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998253,0.000019527843,0.000008858258,0.000025809764,0.00004727413,0.000073265845],"domain_scores_gemma":[0.9999392,0.000007746552,0.000015068398,0.000007690183,0.0000124019025,0.000017988032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012326769,0.00033788953,0.0002383178,0.00032616514,0.0004468096,0.0006602977,0.0005980862,0.00028912228,0.0015998313],"category_scores_gemma":[0.0002028171,0.0001894049,0.00035033186,0.00017285827,0.00030151044,0.0005290686,0.00054716156,0.0005982669,0.00059466495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030614188,0.0000380587,0.00063156313,0.000053111427,0.000026876189,0.00026906337,0.000034216933,0.000189928,0.99220216,0.0009449332,0.00014402554,0.005159948],"study_design_scores_gemma":[0.000051361363,0.00009569484,0.03125547,0.0000151432305,0.000044238528,0.0006370157,0.00020033083,0.0036462992,0.9613484,0.00084521034,0.0018485516,0.000012313908],"about_ca_topic_score_codex":0.0014421702,"about_ca_topic_score_gemma":0.0020458046,"teacher_disagreement_score":0.0015998313,"about_ca_system_score_codex":0.0010425698,"about_ca_system_score_gemma":0.00029774348,"threshold_uncertainty_score":0.0075644255},"labels":[],"label_agreement":null},{"id":"W2019669516","doi":"10.4137/cmo.s6460","title":"Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations","year":2012,"lang":"en","type":"article","venue":"Clinical Medicine Insights Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.2429678331864455,"score_gpt":0.5547950459468237,"score_spread":0.3118272127603782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019669516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008038702,0.49283502,0.004751987,0.45942628,0.0017291276,0.00011378553,0.00018930365,0.00003865776,0.032877196],"genre_scores_gemma":[0.17885137,0.72274417,0.009829286,0.06185924,0.014547053,0.00027850224,0.00024488082,0.0000438157,0.011601794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976839,0.0011428333,0.00016307946,0.00010676954,0.0007871353,0.00011639724],"domain_scores_gemma":[0.9927527,0.004728697,0.0007599139,0.000110325345,0.0010209355,0.00062742183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005741366,0.0004581864,0.00088340737,0.0009619174,0.00041002687,0.0032249603,0.0009160963,0.0038694332,0.008585145],"category_scores_gemma":[0.012841314,0.00016155074,0.00042210994,0.0010904819,0.0013362481,0.0027667827,0.0008818397,0.0035725827,0.0012525419],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083978125,0.0002410853,0.0016724187,0.0028127902,0.00014222841,0.002106298,0.00014011766,0.0037517908,0.0021957152,0.08507012,0.095000185,0.80602753],"study_design_scores_gemma":[0.0007504464,0.0013400103,0.0070466097,0.008973295,0.0002763654,0.009858926,0.00076731725,0.0046930932,0.0014599806,0.13860038,0.82610905,0.00012448049],"about_ca_topic_score_codex":0.001042675,"about_ca_topic_score_gemma":0.0023934257,"teacher_disagreement_score":0.008585145,"about_ca_system_score_codex":0.0018644441,"about_ca_system_score_gemma":0.003829299,"threshold_uncertainty_score":0.03036362},"labels":[],"label_agreement":null},{"id":"W2019887943","doi":"10.1186/1471-2407-9-165","title":"Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situhybridization (FISH): pathologist assessment compared to quantitative image analysis","year":2009,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre for Advancing Health Outcomes; University of British Columbia","funders":"Canadian Institutes of Health Research; Sanofi","keywords":"Kappa; Concordance; Medicine; Immunohistochemistry; Fish <Actinopterygii>; Pathology; Breast cancer; Cohen's kappa; Internal medicine; Tissue microarray; Reproducibility; Surgical oncology; Cancer; Biology","score_opus":0.06874392968058383,"score_gpt":0.4566391556024249,"score_spread":0.38789522592184106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019887943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92045146,0.001604632,0.07213291,0.00011497031,0.00017778714,0.00028820845,0.00039096837,0.00042176212,0.0044173384],"genre_scores_gemma":[0.98806787,0.000093861316,0.010737081,0.000051912266,0.000037600155,0.00012594336,0.00021518205,0.000095759315,0.0005747611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.949039,0.029611245,0.0044788118,0.0074282624,0.008721163,0.00072157045],"domain_scores_gemma":[0.91677034,0.052078165,0.0073282677,0.0090798475,0.014025748,0.000717628],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.035115793,0.00054499606,0.0006624767,0.0018673545,0.00056994375,0.0012680775,0.0007436235,0.000779359,0.0010455531],"category_scores_gemma":[0.060929466,0.00047109867,0.0008237095,0.0007595182,0.001093695,0.00075193093,0.0016686599,0.0004413461,0.0005573935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004187672,0.00018212889,0.8744752,0.0005356919,0.0026569213,0.00022501736,0.0045842207,0.003882051,0.034953006,0.0004957523,0.00091225945,0.07291013],"study_design_scores_gemma":[0.00016667279,0.0013916759,0.92168975,0.0001288343,0.0010329509,0.0016870592,0.0010521534,0.035499785,0.033001527,0.0013723021,0.0028135101,0.0001637486],"about_ca_topic_score_codex":0.0014675327,"about_ca_topic_score_gemma":0.0025413928,"teacher_disagreement_score":0.9648842,"about_ca_system_score_codex":0.0005716942,"about_ca_system_score_gemma":0.00040283435,"threshold_uncertainty_score":0.18571228},"labels":[],"label_agreement":null},{"id":"W2020124426","doi":"10.1159/000055398","title":"Testing for HER2 Status","year":2001,"lang":"en","type":"review","venue":"Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"American Society of Clinical Oncology","keywords":"Concordance; Medicine; Oncology; Breast cancer; Internal medicine; Immunohistochemistry; Gold standard (test); Pathology; Cancer","score_opus":0.4448169212812722,"score_gpt":0.5934718822558205,"score_spread":0.14865496097454828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020124426","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008765218,0.9868563,0.00080272695,0.00057916297,0.00029645846,0.00002310705,0.00009383585,0.000031297008,0.010440663],"genre_scores_gemma":[0.0079874005,0.98428947,0.0009884267,0.0005954721,0.00021363187,0.00002499176,0.00021399399,0.0000044331955,0.005682183],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972516,0.000059442475,0.000027105729,0.000052907362,0.00011616228,0.000019261815],"domain_scores_gemma":[0.99973124,0.00013594475,0.000032062788,0.000016839535,0.00007116474,0.000012784139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006559798,0.0005530429,0.0010254185,0.0024641696,0.00014169764,0.00051554595,0.0006804561,0.0007078076,0.004838441],"category_scores_gemma":[0.0010908825,0.00012742411,0.00034416758,0.0015508323,0.00031154443,0.00070196664,0.00032826583,0.0005570615,0.0044779037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043860266,0.000025257936,0.0010207144,0.0023882475,0.000046171215,0.0004166532,0.00002959357,0.00006943705,0.0018086522,0.00083999475,0.020837173,0.97247416],"study_design_scores_gemma":[0.000026875827,0.00013449376,0.0061219055,0.003346155,0.00014794737,0.011660275,0.00009023475,0.00011100122,0.0033425952,0.0020142365,0.97298145,0.000022897879],"about_ca_topic_score_codex":0.0010394983,"about_ca_topic_score_gemma":0.0012040982,"teacher_disagreement_score":0.004838441,"about_ca_system_score_codex":0.00026989312,"about_ca_system_score_gemma":0.00038065706,"threshold_uncertainty_score":0.016186178},"labels":[],"label_agreement":null},{"id":"W2020371671","doi":"10.1007/s00280-013-2229-3","title":"Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Gefitinib; Paclitaxel; Epidermal growth factor receptor; Cancer research; Chemotherapy; Medicine; Pharmacology; Cell cycle; Cancer; Oncology; Biology; Internal medicine","score_opus":0.0884284157506157,"score_gpt":0.4195852517613815,"score_spread":0.3311568360107658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020371671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96285814,0.003281766,0.021319678,0.00064186426,0.00081279466,0.00077276776,0.0008762379,0.00080080645,0.008635915],"genre_scores_gemma":[0.98424685,0.0006675245,0.0107510425,0.00017092172,0.00008544419,0.00027550964,0.00060247356,0.00011313472,0.0030871173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981254,0.000023724513,0.000014147328,0.00003981221,0.000044297656,0.00006543137],"domain_scores_gemma":[0.99986553,0.000023175831,0.00002617869,0.000016824555,0.000021407583,0.000046820976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021179143,0.0003886685,0.0006656925,0.00042463237,0.00040787397,0.00040394414,0.0003797243,0.00028578864,0.0037588582],"category_scores_gemma":[0.00045322414,0.00021749256,0.00039233227,0.0004191172,0.00018338232,0.00037843437,0.00017469985,0.0006538355,0.0007081952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022749951,0.0032639743,0.0040968396,0.00022102385,0.00010958411,0.00021557153,0.00011721416,0.0154640535,0.8222279,0.0020163897,0.007207443,0.12231007],"study_design_scores_gemma":[0.0012069298,0.0110957995,0.016150814,0.000017189219,0.00022110256,0.000512928,0.00012364417,0.027479906,0.92151874,0.0012425525,0.020345606,0.00008481479],"about_ca_topic_score_codex":0.0013870529,"about_ca_topic_score_gemma":0.0042784093,"teacher_disagreement_score":0.0037588582,"about_ca_system_score_codex":0.0009729258,"about_ca_system_score_gemma":0.0013609651,"threshold_uncertainty_score":0.012574613},"labels":[],"label_agreement":null},{"id":"W2022055121","doi":"10.1186/1471-2407-7-110","title":"External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer","year":2007,"lang":"en","type":"review","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"Cancer Care Ontario","keywords":"Trastuzumab; Medicine; Breast cancer; Vinorelbine; Oncology; Docetaxel; Internal medicine; Adjuvant; Cancer; Pharmacy; Surgical oncology; Clinical trial; Family medicine; Cisplatin; Chemotherapy","score_opus":0.20780236134818136,"score_gpt":0.5198323342998467,"score_spread":0.3120299729516653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022055121","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714655,0.0030451706,0.0005880463,0.009096503,0.00007942476,0.00011879894,0.00017392258,0.000016210772,0.0154163595],"genre_scores_gemma":[0.99315614,0.0032453404,0.00061244855,0.0010168611,0.00010565932,0.000030373141,0.000070395625,0.000018704572,0.0017441047],"study_design_codex":"case_report","study_design_gemma":"qualitative","domain_scores_codex":[0.99626005,0.0016835841,0.00029801598,0.00021685941,0.0008122769,0.00072934723],"domain_scores_gemma":[0.9775883,0.01232651,0.0062178527,0.00054000696,0.0013592985,0.001968059],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027673733,0.00044017032,0.00034814014,0.0019577676,0.0063915118,0.0025242358,0.001040661,0.0021878623,0.0028915051],"category_scores_gemma":[0.022138778,0.00041988742,0.00046537627,0.0035640546,0.0030009456,0.0013877103,0.0016173965,0.0022411647,0.00023437345],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002943678,0.00038551466,0.30731934,0.0008712137,0.00012602688,0.3493274,0.27949572,0.00038952313,0.0010639717,0.00573698,0.011071944,0.04391802],"study_design_scores_gemma":[0.00008553772,0.0003346947,0.21417686,0.0019171797,0.00029399488,0.2519984,0.43490365,0.002171804,0.0013792298,0.003025624,0.08947249,0.0002405376],"about_ca_topic_score_codex":0.2776755,"about_ca_topic_score_gemma":0.3894149,"teacher_disagreement_score":0.9972326,"about_ca_system_score_codex":0.012397299,"about_ca_system_score_gemma":0.008670041,"threshold_uncertainty_score":0.55211854},"labels":[],"label_agreement":null},{"id":"W2022184484","doi":"10.2174/1381612053382205","title":"Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions","year":2005,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib; Medicine; Trastuzumab; Myeloid leukemia; Targeted therapy; Bevacizumab; Chronic myelogenous leukemia; Clinical trial; Cancer; Bioinformatics; Breast cancer; Cancer research; Leukemia; Immunology; Biology; Internal medicine; Chemotherapy","score_opus":0.2605662726175213,"score_gpt":0.5193172596919667,"score_spread":0.25875098707444544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022184484","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007301158,0.9961649,0.0005290939,0.0008315687,0.00011839421,0.000009448545,0.000012179957,0.000011256328,0.0015929767],"genre_scores_gemma":[0.0027365333,0.99445665,0.0009954902,0.00051485107,0.00019065115,0.000014535552,0.00001769919,0.0000037347618,0.0010698049],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996061,0.000098371056,0.000057889505,0.000061733816,0.00014007038,0.00003587181],"domain_scores_gemma":[0.9994276,0.00028389343,0.00008175858,0.000023395114,0.0001346609,0.00004873329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020773793,0.00076880853,0.0013790592,0.0015698501,0.00026471165,0.0012532854,0.0010381215,0.0012127986,0.0029955364],"category_scores_gemma":[0.0010709113,0.00025303065,0.00038797458,0.001418308,0.00065956713,0.002384929,0.00048709067,0.0016238681,0.0015548051],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016487893,0.00020215767,0.00018094754,0.0057912683,0.00005555218,0.00031644636,0.00009100844,0.00065576186,0.004866321,0.00784751,0.010219964,0.9696082],"study_design_scores_gemma":[0.00013360594,0.0008430966,0.0009482029,0.002721562,0.00013748572,0.0024349857,0.00015473142,0.0004743391,0.005211288,0.0054497775,0.9814585,0.0000324464],"about_ca_topic_score_codex":0.00054685393,"about_ca_topic_score_gemma":0.00148985,"teacher_disagreement_score":0.0029955364,"about_ca_system_score_codex":0.00088732585,"about_ca_system_score_gemma":0.00084131816,"threshold_uncertainty_score":0.010986388},"labels":[],"label_agreement":null},{"id":"W2022706281","doi":"10.1158/1535-7163.targ-11-a143","title":"Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Kingston General Hospital","funders":"","keywords":"Pharmacokinetics; Pharmacology; Kinase; Drug; Potency; Metastatic breast cancer; Tyrosine-kinase inhibitor; Medicine; Cancer; Chemistry; Breast cancer; Cancer research; Internal medicine; In vitro; Biochemistry","score_opus":0.23610018967859558,"score_gpt":0.45589901344279576,"score_spread":0.21979882376420018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022706281","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3343767,0.481229,0.016010588,0.021356331,0.0073584393,0.0032936388,0.0060094674,0.0020737327,0.12829207],"genre_scores_gemma":[0.65124714,0.19143684,0.016560296,0.014085354,0.0038122889,0.0009572844,0.006985922,0.000244576,0.11467025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998198,0.000030263558,0.000016206053,0.000027300668,0.00007633419,0.000030114164],"domain_scores_gemma":[0.99985754,0.000013654984,0.000025203464,0.0000060217676,0.00003868847,0.000058899055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077403814,0.00088148436,0.00057901954,0.0004022447,0.0002098725,0.00069240044,0.00067315006,0.00078935653,0.010116569],"category_scores_gemma":[0.00031703842,0.0002146852,0.00030663368,0.0003015274,0.00029878767,0.00054846436,0.00032750124,0.0014563287,0.003646498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011829155,0.0022114282,0.0012693915,0.002601049,0.00014748423,0.001868326,0.00011821128,0.001043304,0.16150597,0.005398604,0.07968744,0.73231965],"study_design_scores_gemma":[0.020597374,0.06957703,0.014113915,0.0010891621,0.00056312076,0.011377837,0.00009026289,0.0045487136,0.18354967,0.0039901664,0.6903493,0.00015338445],"about_ca_topic_score_codex":0.0008722305,"about_ca_topic_score_gemma":0.0016609281,"teacher_disagreement_score":0.010116569,"about_ca_system_score_codex":0.00060064456,"about_ca_system_score_gemma":0.0010398424,"threshold_uncertainty_score":0.03384334},"labels":[],"label_agreement":null},{"id":"W2023063845","doi":"10.1191/1078155202jp089oa","title":"Clinical effectiveness of trastuzumab: early experience","year":2002,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Alberta; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Cardiotoxicity; Clinical trial; Oncology; Breast cancer; Metastatic breast cancer; Adverse effect; Cancer; Incidence (geometry); Surgery; Chemotherapy","score_opus":0.25688355352266745,"score_gpt":0.5927217133347364,"score_spread":0.335838159812069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023063845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8461299,0.13812815,0.0009557775,0.0028200517,0.0000807398,0.00009842516,0.00016922054,0.000029922028,0.011587937],"genre_scores_gemma":[0.98589885,0.0124234995,0.00044761613,0.000646381,0.00013894809,0.000013904055,0.00012962482,0.000004723728,0.000296385],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978345,0.0010374968,0.00012821516,0.00012061735,0.0007090552,0.00017010178],"domain_scores_gemma":[0.99256,0.0039874036,0.0010587652,0.00025362297,0.0015864895,0.00055376097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056756935,0.00018343111,0.0003222506,0.00027359044,0.00019905459,0.0009823219,0.00042091412,0.00035352923,0.00051112636],"category_scores_gemma":[0.013213904,0.00006823319,0.0001283312,0.0005908089,0.00068399304,0.00041376948,0.00031715847,0.00045510998,0.00008274124],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006532611,0.0005594836,0.26742342,0.00081712863,0.00022277699,0.0011657383,0.0014685821,0.00084518275,0.0051883864,0.0015158515,0.0043503605,0.70991045],"study_design_scores_gemma":[0.0018842599,0.025315188,0.8384495,0.0012075058,0.00071362115,0.009598941,0.0013969719,0.001519795,0.011141067,0.0012055233,0.10750063,0.000066924826],"about_ca_topic_score_codex":0.0046257004,"about_ca_topic_score_gemma":0.0051007937,"teacher_disagreement_score":0.0056756935,"about_ca_system_score_codex":0.0022524002,"about_ca_system_score_gemma":0.0013281609,"threshold_uncertainty_score":0.030016243},"labels":[],"label_agreement":null},{"id":"W2023431277","doi":"10.1158/1535-7163.mct-15-0067","title":"AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Antibody-drug conjugate; Pharmacology; Medicine; Drug; Conjugate; Antibody; Immunology; Monoclonal antibody","score_opus":0.05551429481243274,"score_gpt":0.3826702077750343,"score_spread":0.32715591296260155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023431277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96022654,0.02365246,0.008139794,0.0005953451,0.00012479957,0.00014755764,0.00019384641,0.00016373333,0.0067560077],"genre_scores_gemma":[0.98545146,0.007118938,0.003549034,0.0002108673,0.000031280844,0.000031943404,0.00027167227,0.000015187051,0.0033195876],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993753,0.000011074351,0.00000419332,0.000010991651,0.000018945015,0.000017231217],"domain_scores_gemma":[0.99998033,0.0000023168757,0.0000034716268,0.0000024722638,0.000003855382,0.0000075595235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009783885,0.00023221808,0.00017377132,0.00024179257,0.000084999934,0.00024025954,0.00012841432,0.00026630238,0.0007626263],"category_scores_gemma":[0.000059955528,0.00011166459,0.00015881253,0.00012432881,0.00012578027,0.00021489554,0.00017368418,0.00033672465,0.00025622325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022734539,0.000111112924,0.0004194812,0.00013063192,0.000015462285,0.00022179825,0.000028608014,0.00043485838,0.9614942,0.0009975085,0.00053378777,0.035385307],"study_design_scores_gemma":[0.00015829528,0.0019096497,0.0026914112,0.000013883598,0.00004182053,0.0014391558,0.0000151755285,0.0023447229,0.9605694,0.00017658019,0.03062873,0.000011221931],"about_ca_topic_score_codex":0.0003364708,"about_ca_topic_score_gemma":0.0005847488,"teacher_disagreement_score":0.0007626263,"about_ca_system_score_codex":0.00027353724,"about_ca_system_score_gemma":0.00019028937,"threshold_uncertainty_score":0.002551198},"labels":[],"label_agreement":null},{"id":"W2023764867","doi":"10.1016/j.clbc.2012.01.001","title":"Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial","year":2012,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service; Genentech; National Institutes of Health; Mayo Clinic","keywords":"Vinorelbine; Capecitabine; Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Cancer; Phases of clinical research; Chemotherapy; Colorectal cancer","score_opus":0.10161322086899631,"score_gpt":0.4580827344753126,"score_spread":0.3564695136063163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023764867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875683,0.002982839,0.000556266,0.0014796974,0.00029612173,0.0020517209,0.0015120804,0.00016191257,0.0033909734],"genre_scores_gemma":[0.9744966,0.0032036402,0.002552482,0.002721783,0.00044902693,0.0034080218,0.0037535091,0.00009657046,0.0093183825],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993894,0.00033404597,0.000015028907,0.00010620541,0.00003946414,0.0001158305],"domain_scores_gemma":[0.9990421,0.00016024895,0.00017613622,0.00008839852,0.000050462626,0.00048261354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021798739,0.0020489986,0.002667344,0.00049101224,0.0005346924,0.001053892,0.0014076252,0.0015502771,0.006602717],"category_scores_gemma":[0.001093781,0.00083891896,0.0016160797,0.0005247126,0.0016162827,0.0009531974,0.00041409323,0.003670716,0.001559979],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9105669,0.024694683,0.0026592647,0.00045234952,0.0011607057,0.00014710349,0.00020747173,0.0012571497,0.010283122,0.00035407968,0.0065846224,0.041632537],"study_design_scores_gemma":[0.91131145,0.08018943,0.0052102683,0.000023938439,0.00032369824,0.00010602826,0.00003164473,0.00048030537,0.00058858714,0.00013381145,0.0015837364,0.000017075154],"about_ca_topic_score_codex":0.005029526,"about_ca_topic_score_gemma":0.01781867,"teacher_disagreement_score":0.006602717,"about_ca_system_score_codex":0.0020788636,"about_ca_system_score_gemma":0.0032881955,"threshold_uncertainty_score":0.02208823},"labels":[],"label_agreement":null},{"id":"W2023982632","doi":"10.1016/s0399-8320(04)94872-5","title":"Nouvelles approches pharmacologiques de traitement des cancers","year":2004,"lang":"fr","type":"review","venue":"Gastroentérologie Clinique et Biologique","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Gynecology","score_opus":0.14535946250255677,"score_gpt":0.4674084473057148,"score_spread":0.322048984803158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023982632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002925317,0.99795246,0.00027281107,0.0004192662,0.00012705126,0.000006428812,0.0000121840685,0.0000075018784,0.00090972235],"genre_scores_gemma":[0.0023395477,0.99548113,0.00045686387,0.00052859285,0.0003007801,0.000010410669,0.000025456096,0.0000017963364,0.00085542543],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997366,0.00007176233,0.000032936634,0.000049454964,0.0000829111,0.000026270345],"domain_scores_gemma":[0.99951553,0.00033789992,0.000058098347,0.000015659894,0.000054457927,0.000018351098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081328256,0.00088327687,0.0017085668,0.0016974015,0.00029424034,0.0007486113,0.0006281521,0.0012508174,0.0039626127],"category_scores_gemma":[0.0012154175,0.00032113362,0.001084634,0.0010708582,0.00045173414,0.0010029916,0.00036483468,0.0020663727,0.0011513156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003252185,0.00012365714,0.0002329078,0.01193055,0.0003177155,0.00044571495,0.000051757514,0.0003759031,0.0031410488,0.0015021785,0.012561098,0.9689924],"study_design_scores_gemma":[0.00072494725,0.0010797156,0.0036459002,0.0062623825,0.0015528026,0.0043767514,0.00009265415,0.00030188786,0.004102956,0.0021928204,0.975615,0.00005220765],"about_ca_topic_score_codex":0.0013674846,"about_ca_topic_score_gemma":0.0031817395,"teacher_disagreement_score":0.0039626127,"about_ca_system_score_codex":0.0005796346,"about_ca_system_score_gemma":0.00068597664,"threshold_uncertainty_score":0.013256252},"labels":[],"label_agreement":null},{"id":"W2024076573","doi":"10.1016/j.jconrel.2015.02.001","title":"Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models","year":2015,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Nebraska Department of Health and Human Services; Foundation for the National Institutes of Health; U.S. Department of Defense","keywords":"Doxorubicin; Nanocarriers; In vivo; Breast cancer; Trastuzumab; Chemistry; Pharmacology; Cytotoxicity; Cancer research; Drug delivery; Chemotherapy; Drug; Cancer; In vitro; Medicine; Biology; Internal medicine; Biochemistry","score_opus":0.03961456749424253,"score_gpt":0.33281772068589316,"score_spread":0.29320315319165063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024076573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598145,0.0010784568,0.0019598778,0.000043258442,0.000037438884,0.00002194825,0.00010545473,0.000044664015,0.0007274426],"genre_scores_gemma":[0.99518174,0.00067037257,0.002158842,0.000025223659,0.000007963482,0.000027057113,0.00012560362,0.000015296515,0.0017879577],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999312,0.000010268247,0.0000068010218,0.000017246202,0.0000149950965,0.000019488942],"domain_scores_gemma":[0.99994993,0.000009480502,0.000013735829,0.000004164284,0.000006506347,0.000016116852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014853904,0.00027811687,0.00021069996,0.00011982301,0.00007249147,0.00012453551,0.000100596706,0.00019869072,0.00063100073],"category_scores_gemma":[0.00007305456,0.00011017159,0.00017613327,0.00007540545,0.00012761648,0.00018662626,0.00009195715,0.00025386966,0.00016210022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085373176,0.000016738282,0.000032907985,0.0000216193,0.0000035939713,0.000012804358,0.0000061810397,0.00006929996,0.9990852,0.000021573145,0.000021986118,0.0006226623],"study_design_scores_gemma":[0.000010216465,0.00026930295,0.00046818572,0.0000022903619,0.000014355121,0.000043961238,0.0000050287945,0.00036833316,0.9980636,0.000005736337,0.00074650976,0.0000024034812],"about_ca_topic_score_codex":0.00038442342,"about_ca_topic_score_gemma":0.00077420595,"teacher_disagreement_score":0.00063100073,"about_ca_system_score_codex":0.00015093554,"about_ca_system_score_gemma":0.00013633085,"threshold_uncertainty_score":0.0021108985},"labels":[],"label_agreement":null},{"id":"W2024170532","doi":"10.1038/modpathol.3800555","title":"Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm","year":2006,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Concordance; Immunohistochemistry; Fluorescence in situ hybridization; Gene duplication; Biology; In situ hybridization; Human Epidermal Growth Factor Receptor 2; Pathology; Molecular biology; Medicine; Cancer; Bioinformatics; Gene; Breast cancer; Genetics; Gene expression","score_opus":0.03722846614933295,"score_gpt":0.32165529426484235,"score_spread":0.2844268281155094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024170532","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008501405,0.002071148,0.9796586,0.0013668443,0.00046769882,0.00011976704,0.000084103965,0.0009770745,0.006753361],"genre_scores_gemma":[0.113895714,0.003336671,0.8751151,0.0006872293,0.0002969623,0.00023380594,0.00014516829,0.00024234559,0.006047058],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977271,0.0011429623,0.00008639944,0.00029291393,0.0006163949,0.00013430788],"domain_scores_gemma":[0.99729747,0.001473267,0.00014708514,0.00039155394,0.0005481072,0.00014254595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040378952,0.0010727057,0.0010733713,0.002882839,0.00073669315,0.0022317744,0.0024116095,0.0014806582,0.008889351],"category_scores_gemma":[0.0042889714,0.00065705535,0.0008517644,0.0010967604,0.0017937919,0.0015834798,0.0011856745,0.0025308223,0.0022373314],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013628684,0.00027428792,0.011012478,0.0008882522,0.00026822038,0.0021678612,0.00035946662,0.004880713,0.24659173,0.11886051,0.009249359,0.6040842],"study_design_scores_gemma":[0.0003488238,0.0015791389,0.011955468,0.00041862772,0.00077194534,0.03879684,0.00072562037,0.21263233,0.39671922,0.17434724,0.1613155,0.00038930366],"about_ca_topic_score_codex":0.0007990558,"about_ca_topic_score_gemma":0.0016773742,"teacher_disagreement_score":0.008889351,"about_ca_system_score_codex":0.00069017435,"about_ca_system_score_gemma":0.0009402945,"threshold_uncertainty_score":0.02973783},"labels":[],"label_agreement":null},{"id":"W2024823531","doi":"10.1158/0008-5472.sabcs13-p4-12-11","title":"Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Cohort; Crossover study; Breast cancer; Clinical endpoint; Randomization; Randomized controlled trial; Internal medicine; Oncology; Cancer; Pathology","score_opus":0.08074014626197955,"score_gpt":0.3842851056611099,"score_spread":0.30354495939913034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024823531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876034,0.00013064044,0.00016746834,0.00006027406,0.000015991747,0.00019270636,0.0004193392,0.0000030242547,0.00025026707],"genre_scores_gemma":[0.9981535,0.000074662676,0.00027524412,0.0001668803,0.000041425104,0.00028654313,0.00060392194,0.0000029040978,0.00039480854],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9984571,0.0009821493,0.00008117799,0.00020632017,0.0001499403,0.00012327745],"domain_scores_gemma":[0.99784696,0.00079757924,0.00065670174,0.0002277575,0.000115951785,0.00035494173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031645799,0.00059067126,0.0007327924,0.0001784259,0.0003301562,0.000548457,0.000403621,0.0006314357,0.0043401886],"category_scores_gemma":[0.004022757,0.00022056744,0.0014331336,0.00021495433,0.00038403663,0.0005345721,0.00031882557,0.0012356979,0.0004891873],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5825485,0.01901671,0.34493166,0.00031119137,0.0038899016,0.00042691524,0.0008512937,0.0007598954,0.00890235,0.00023936883,0.0038254734,0.034296807],"study_design_scores_gemma":[0.06906865,0.22849725,0.6829434,0.00009000144,0.003225796,0.00078195025,0.0009036974,0.004284977,0.004868902,0.00074319,0.0044150646,0.00017719554],"about_ca_topic_score_codex":0.00082950265,"about_ca_topic_score_gemma":0.0011983076,"teacher_disagreement_score":0.0043401886,"about_ca_system_score_codex":0.00040184922,"about_ca_system_score_gemma":0.0005850203,"threshold_uncertainty_score":0.01673609},"labels":[],"label_agreement":null},{"id":"W2024903800","doi":"10.1016/s1470-2045(13)70383-8","title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Clinical endpoint; Breast cancer; Internal medicine; Population; Surgery; Oncology; Clinical trial; Cancer","score_opus":0.11089225089377973,"score_gpt":0.41324273047037563,"score_spread":0.3023504795765959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024903800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987204,0.0025997988,0.0010327556,0.0005287073,0.0007452136,0.0025241792,0.00076232443,0.00006713687,0.001867988],"genre_scores_gemma":[0.9926318,0.0012255267,0.0010367789,0.00067359593,0.0005382432,0.0017169195,0.000435056,0.000020186315,0.00172197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979176,0.0012656789,0.00013545736,0.00031848773,0.000114606286,0.00024817552],"domain_scores_gemma":[0.9967957,0.0017068097,0.0005475562,0.00030336785,0.00010691495,0.00053962006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026598233,0.0019248748,0.0039978814,0.00040950323,0.00044961987,0.0013220657,0.0010179641,0.002410488,0.013324238],"category_scores_gemma":[0.00397851,0.0010420182,0.0031741625,0.0005573138,0.0021013562,0.002009904,0.00071234856,0.004056325,0.0015722727],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99081403,0.0026198141,0.00026243427,0.00021544578,0.0002863348,0.000016356546,0.00003070487,0.000118063326,0.0005112535,0.00005812192,0.00014490924,0.0049226005],"study_design_scores_gemma":[0.91384566,0.08357419,0.0009955157,0.00002920196,0.00044782038,0.000018309218,0.000030340805,0.00037156077,0.00015245342,0.00019511086,0.00031655488,0.00002328463],"about_ca_topic_score_codex":0.000899806,"about_ca_topic_score_gemma":0.0012121635,"teacher_disagreement_score":0.013324238,"about_ca_system_score_codex":0.0010280135,"about_ca_system_score_gemma":0.00094568846,"threshold_uncertainty_score":0.044574022},"labels":[],"label_agreement":null},{"id":"W2025510375","doi":"10.1073/pnas.0306802101","title":"Germ-line expression of an oncogenic <i>erbB2</i> allele confers resistance to <i>erbB2</i> -induced mammary tumorigenesis","year":2004,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University; Royal University Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; U.S. Department of Defense","keywords":"Carcinogenesis; Biology; Allele; Mammary tumor; Mammary gland; Genetically modified mouse; Oncogene; Cancer research; Population; Germline; Transgene; Gene; Cancer; Genetics; Medicine; Cell cycle","score_opus":0.08221381654363341,"score_gpt":0.3839007725629311,"score_spread":0.3016869560192977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025510375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969308,0.00025944467,0.0012347228,0.000044327673,0.000011159892,0.000015224567,0.00016631179,0.000110820205,0.00122714],"genre_scores_gemma":[0.99640393,0.00024030912,0.00095539837,0.00003267666,0.0000073246856,0.0000139462045,0.00042849928,0.00005026361,0.0018675304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998253,0.00003005864,0.000019579722,0.00002816693,0.000045228055,0.000051828658],"domain_scores_gemma":[0.9997595,0.000036929094,0.00008828316,0.00003600132,0.000012259116,0.000067045556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015427936,0.00033635763,0.00022221796,0.00033840502,0.00010605009,0.0002993628,0.00018912896,0.00028151047,0.0013644237],"category_scores_gemma":[0.00015580235,0.00020543582,0.000209522,0.00014626968,0.00022444205,0.00012414792,0.0001984003,0.0006035805,0.0004657948],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041687956,0.00002256616,0.00020128656,0.000005710763,0.0000031792033,0.000038209153,0.00000610132,0.000026721034,0.9992187,0.00006458365,0.000021127134,0.00035009114],"study_design_scores_gemma":[0.00003416599,0.0005363613,0.009630603,0.000006868741,0.000025938234,0.001458641,0.000036983383,0.0012260191,0.9847172,0.00007376864,0.002245512,0.000007995365],"about_ca_topic_score_codex":0.0003400544,"about_ca_topic_score_gemma":0.0005259061,"teacher_disagreement_score":0.0013644237,"about_ca_system_score_codex":0.0001894134,"about_ca_system_score_gemma":0.000112750386,"threshold_uncertainty_score":0.0045644045},"labels":[],"label_agreement":null},{"id":"W2027515445","doi":"10.1097/sla.0b013e3181dbb77e","title":"HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival","year":2010,"lang":"en","type":"article","venue":"Annals of Surgery","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; St. Paul's Hospital; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"","keywords":"Medicine; Breast cancer; Tissue microarray; Cancer; Oncology; Immunohistochemistry; Internal medicine; Lymphovascular invasion; Estrogen receptor; Univariate analysis; Pathology; Multivariate analysis; Metastasis","score_opus":0.3353829394354498,"score_gpt":0.4594446625524266,"score_spread":0.12406172311697683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027515445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99809784,0.00089431315,0.00023792569,0.00006641286,0.000011598619,0.000003107172,0.00036461346,0.000011201657,0.00031300494],"genre_scores_gemma":[0.99928266,0.0001776846,0.00008967203,0.000012640615,0.000018257215,0.0000022882855,0.00030147328,0.000002044507,0.00011329749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998641,0.000032752258,0.000014435141,0.000037767066,0.000026467642,0.000024516112],"domain_scores_gemma":[0.9991554,0.00027282126,0.00030694777,0.000078673445,0.000067048764,0.000119139506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038490252,0.00016787526,0.00024296652,0.00034872943,0.00013656597,0.00035186202,0.00014787666,0.0002432514,0.0019072235],"category_scores_gemma":[0.0010714118,0.00011315256,0.00025056297,0.00035333264,0.00015540693,0.00015596986,0.00019028083,0.00024145783,0.0002615018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009857377,0.000019519235,0.98525006,0.000026402824,0.00007985168,0.00016835069,0.000024957266,0.00019321738,0.0069172895,0.000017966979,0.00031331816,0.0060032867],"study_design_scores_gemma":[0.0000081933185,0.00008424764,0.9966127,0.0000054680963,0.000081801125,0.0010286643,0.000033892644,0.00045311218,0.0011991174,0.000070603586,0.0004179127,0.0000042224888],"about_ca_topic_score_codex":0.00047865073,"about_ca_topic_score_gemma":0.000642971,"teacher_disagreement_score":0.0019072235,"about_ca_system_score_codex":0.00015699313,"about_ca_system_score_gemma":0.00013689164,"threshold_uncertainty_score":0.0063803196},"labels":[],"label_agreement":null},{"id":"W2028678591","doi":"10.1097/00128360-200301000-00011","title":"Demonstration of Her-2 Protein in Cervical Carcinomas","year":2003,"lang":"en","type":"article","venue":"Journal of Lower Genital Tract Disease","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Staining; Immunohistochemistry; Pathology; Cervix; Lymph node; Breast cancer; Cervical cancer; Cancer; Oncology; Internal medicine","score_opus":0.034484311770550016,"score_gpt":0.32984190846087963,"score_spread":0.2953575966903296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028678591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994848,0.0020500363,0.00037495748,0.00006798334,0.000010517186,0.000020422132,0.00010786537,0.000016322227,0.0025038512],"genre_scores_gemma":[0.99807835,0.0006640931,0.00057989784,0.00003347469,0.000007747266,0.000012952917,0.00009442236,0.0000027592741,0.000526388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979407,0.000021737304,0.000021218091,0.000033132215,0.000071952934,0.000057863075],"domain_scores_gemma":[0.99978775,0.000039761067,0.000047447054,0.000020784953,0.00006573383,0.00003847811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034027704,0.00021491459,0.00013295417,0.00091881753,0.00029617333,0.00031227505,0.00021889913,0.0003813935,0.0021526783],"category_scores_gemma":[0.0008038181,0.00014249474,0.00013112855,0.00036029797,0.00029762654,0.00021101581,0.00031549402,0.00015009078,0.00043337196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086045294,0.000074440264,0.39723608,0.00038076733,0.00006262188,0.009184098,0.00045403652,0.00017518895,0.5682431,0.00020959477,0.00062343216,0.022496242],"study_design_scores_gemma":[0.000097842974,0.0007272781,0.778522,0.00013542268,0.00015986331,0.06138482,0.0009874253,0.0008794957,0.14675681,0.00034443487,0.0099784555,0.00002614101],"about_ca_topic_score_codex":0.0021179677,"about_ca_topic_score_gemma":0.0031060155,"teacher_disagreement_score":0.0021526783,"about_ca_system_score_codex":0.00040583833,"about_ca_system_score_gemma":0.00035060634,"threshold_uncertainty_score":0.007201433},"labels":[],"label_agreement":null},{"id":"W2029678186","doi":"10.1007/s10120-011-0118-1","title":"Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study","year":2011,"lang":"en","type":"article","venue":"Gastric Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Research Foundation","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Medicine; Hazard ratio; Trastuzumab; Internal medicine; Capecitabine; Oncology; Confidence interval; Chemotherapy; Regimen; Cancer; Population; Breast cancer; Colorectal cancer","score_opus":0.03215206981824119,"score_gpt":0.3282366159019147,"score_spread":0.2960845460836735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029678186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592125,0.0034463669,0.00015105585,0.000059471884,0.000033724056,0.00005500271,0.0001822556,0.0000029299033,0.00014789916],"genre_scores_gemma":[0.99872917,0.000483555,0.000100903504,0.00009384239,0.000047852318,0.00005471028,0.00040665336,0.0000033097797,0.00007997478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844366,0.0006025745,0.00030199878,0.00030993123,0.00015916266,0.00018280331],"domain_scores_gemma":[0.9987575,0.00030554598,0.00036515953,0.00027107514,0.00012897975,0.00017184569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026978694,0.0010053761,0.0029139083,0.00075294264,0.00043295475,0.0009583183,0.00045735648,0.00072592386,0.0005434699],"category_scores_gemma":[0.0029034463,0.0003907372,0.0067738243,0.0010252539,0.00032972934,0.00041463895,0.0006355492,0.00054647226,0.00008564065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08019687,0.00049434084,0.8365897,0.00086680125,0.04884815,0.0010015296,0.0007361637,0.0011345529,0.0069393218,0.00009895165,0.00076317985,0.022330299],"study_design_scores_gemma":[0.009443878,0.005181665,0.92081743,0.000118266624,0.057914965,0.0007843984,0.00070318277,0.0020207388,0.0010714422,0.00031471276,0.0015485374,0.00008081005],"about_ca_topic_score_codex":0.0029403176,"about_ca_topic_score_gemma":0.00646821,"teacher_disagreement_score":0.0029403176,"about_ca_system_score_codex":0.00063246104,"about_ca_system_score_gemma":0.00071814645,"threshold_uncertainty_score":0.014267862},"labels":[],"label_agreement":null},{"id":"W2030031549","doi":"10.3747/co.v18i1.623","title":"Immune Therapy for Breast Cancer in 2010—Hype or Hope?","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Toronto; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Immune system; Cancer; Bioinformatics; Immunology; Internal medicine; Biology","score_opus":0.38223391733961404,"score_gpt":0.5307872293519582,"score_spread":0.14855331201234417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030031549","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001093992,0.91639245,0.00025837345,0.07507501,0.004458758,0.000005259084,0.000018233459,0.000013942969,0.0026840046],"genre_scores_gemma":[0.021320565,0.90757334,0.0009601547,0.0520291,0.011010968,0.000019511172,0.000051010502,0.000013479917,0.0070219394],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99944943,0.00024532498,0.000072795505,0.000040250292,0.00013243557,0.000059739174],"domain_scores_gemma":[0.99894625,0.0006062061,0.00012807788,0.000024797577,0.00019562704,0.000098962315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030523934,0.00038948076,0.0006899212,0.00061202206,0.00048120136,0.0016788472,0.00038180844,0.00236149,0.0024879621],"category_scores_gemma":[0.0023571656,0.00013375936,0.0003849128,0.0006491582,0.0010559285,0.003474507,0.0007295927,0.0030560917,0.00084403617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000462423,0.00016872092,0.0010582448,0.002768468,0.0000668154,0.0006968037,0.00038235346,0.00041304177,0.0023327873,0.035358462,0.15157144,0.8047204],"study_design_scores_gemma":[0.00009526746,0.0006840026,0.0012892539,0.0019765166,0.000051048075,0.0019927064,0.00065486704,0.00024566744,0.0007404145,0.01679927,0.9754436,0.000027332095],"about_ca_topic_score_codex":0.00069838343,"about_ca_topic_score_gemma":0.0030816875,"teacher_disagreement_score":0.0030523934,"about_ca_system_score_codex":0.0011718743,"about_ca_system_score_gemma":0.0011536649,"threshold_uncertainty_score":0.016142845},"labels":[],"label_agreement":null},{"id":"W2030287014","doi":"10.1038/87310","title":"Ewing tumor cells activate distinct signaling pathways in monolayer versus anchorage-independent cultures","year":2001,"lang":"en","type":"article","venue":"Nature Genetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Institute of Indigenous Peoples' Health; Children's & Women's Health Centre of British Columbia","funders":"","keywords":"Biology; Signal transduction; Cell biology; Monolayer; Cancer research; Tumor cells; Cell culture; Genetics; Biochemistry","score_opus":0.04396581008631634,"score_gpt":0.35316148163552935,"score_spread":0.309195671549213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030287014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97909945,0.0037782935,0.008125266,0.00018673085,0.00011137222,0.00009902911,0.0019655123,0.00022223528,0.006411969],"genre_scores_gemma":[0.97580296,0.0036731132,0.0060735894,0.00013932984,0.000044961707,0.00016353189,0.00346854,0.00009912431,0.010534822],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99960846,0.000056719087,0.00004374501,0.00005777735,0.000105329564,0.00012802596],"domain_scores_gemma":[0.99973065,0.00009498208,0.000028511397,0.0000613489,0.00003630638,0.00004818684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028292686,0.00046696715,0.0005131349,0.0006635256,0.00030110253,0.0007921321,0.00032573412,0.00029011714,0.0018931996],"category_scores_gemma":[0.00020567003,0.00031097705,0.00056610524,0.0005880046,0.00016510228,0.0007270101,0.00038808887,0.0011118429,0.0010228135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001685248,0.0000681543,0.00014179618,0.000029836005,0.000007896101,0.000027984688,0.000033633038,0.00004584377,0.9976295,0.000170745,0.00014390831,0.001532219],"study_design_scores_gemma":[0.00002569632,0.000162149,0.0059676124,0.0000068657973,0.000023219738,0.00010804831,0.00007419511,0.00086425507,0.9906481,0.000098099066,0.0020152393,0.0000064548653],"about_ca_topic_score_codex":0.0009851247,"about_ca_topic_score_gemma":0.0020453006,"teacher_disagreement_score":0.0018931996,"about_ca_system_score_codex":0.00041446523,"about_ca_system_score_gemma":0.00022229721,"threshold_uncertainty_score":0.006333351},"labels":[],"label_agreement":null},{"id":"W2030789072","doi":"10.1093/emboj/20.13.3342","title":"N‐arginine dibasic convertase is a specific receptor for heparin‐binding EGF‐like growth factor that mediates cell migration","year":2001,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Medical Research Council; Bayer Yakuhin; National Institutes of Health; National Institute of General Medical Sciences; Medical Research Council Canada","keywords":"Biology; Epidermal growth factor; Receptor; Biochemistry; Cell biology; Growth factor; Cell migration; Cell; Molecular biology","score_opus":0.0788249204008761,"score_gpt":0.3347640994761005,"score_spread":0.25593917907522434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030789072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96096075,0.01680811,0.0069535687,0.0006620003,0.00021034754,0.000085784726,0.0005486064,0.00019074602,0.013580198],"genre_scores_gemma":[0.9651438,0.006545774,0.003754934,0.00018707423,0.0001024027,0.00002203734,0.0013927144,0.000016081569,0.0228353],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992216,0.000009224709,0.0000050762837,0.000014087281,0.000025446958,0.000023998904],"domain_scores_gemma":[0.99992657,0.000009490376,0.00001744933,0.00000555177,0.000011181968,0.000029772436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013877581,0.00034691097,0.00016493518,0.00022863635,0.00018162164,0.00036315256,0.00024453175,0.00030244672,0.0017858053],"category_scores_gemma":[0.00015383954,0.000109461595,0.00015037916,0.00011751039,0.00017620971,0.00023353832,0.00017695037,0.0003564167,0.00094880065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002969918,0.00004320952,0.0005270522,0.000067228706,0.000007849924,0.00067846215,0.000014545024,0.00005768045,0.9854548,0.00061134575,0.000516247,0.01172452],"study_design_scores_gemma":[0.00008334721,0.00045256468,0.020196201,0.000015610227,0.000037504815,0.0068182475,0.000053173386,0.0014294441,0.93791705,0.0005345126,0.03244487,0.000017597577],"about_ca_topic_score_codex":0.0006318399,"about_ca_topic_score_gemma":0.00074105023,"teacher_disagreement_score":0.0017858053,"about_ca_system_score_codex":0.00035923457,"about_ca_system_score_gemma":0.00017158219,"threshold_uncertainty_score":0.0059741735},"labels":[],"label_agreement":null},{"id":"W2032037224","doi":"10.1038/sj.onc.1203685","title":"Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis","year":2000,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal; Université de Montréal; McGill University; Jewish General Hospital","funders":"Medical Research Council","keywords":"Autocrine signalling; Neuregulin; Paracrine signalling; Biology; Angiogenesis; Cancer research; Receptor tyrosine kinase; ErbB; Neuregulin 1; Vascular endothelial growth factor; ERBB3; Cancer cell; Growth factor; Endocrinology; Internal medicine; Receptor; Cell biology; Cancer; Signal transduction; Medicine","score_opus":0.02377665788304897,"score_gpt":0.3135931693418926,"score_spread":0.28981651145884363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032037224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920676,0.0033619269,0.0008941721,0.00034053437,0.00017465306,0.00003670086,0.0003338485,0.00014258616,0.00264796],"genre_scores_gemma":[0.99458414,0.0014586147,0.0011050344,0.00015373128,0.00007744616,0.000049088165,0.0005858364,0.00002174422,0.0019645186],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997702,0.000062553925,0.000019322259,0.000026792703,0.00003321403,0.000087852146],"domain_scores_gemma":[0.9999126,0.000027569618,0.000011481312,0.000015126367,0.0000072654802,0.000025948704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013558114,0.00041860828,0.0004766058,0.0005071909,0.00023381972,0.00042406318,0.00018697162,0.00041347355,0.0016414274],"category_scores_gemma":[0.00020066675,0.00017328553,0.00033722582,0.0003994097,0.00023101454,0.0003946723,0.00022129629,0.00074810354,0.00041975634],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064314454,0.00015645435,0.00021688521,0.000042150743,0.000011792153,0.0001706734,0.00002141558,0.00006359063,0.9958484,0.000118678385,0.00026547897,0.0024412635],"study_design_scores_gemma":[0.000082048704,0.0006064024,0.003891985,0.0000035029932,0.000024570563,0.0003842757,0.000034705346,0.00034401094,0.99190277,0.000046738438,0.0026736888,0.000005307821],"about_ca_topic_score_codex":0.00060701655,"about_ca_topic_score_gemma":0.0012629197,"teacher_disagreement_score":0.0016414274,"about_ca_system_score_codex":0.00057348213,"about_ca_system_score_gemma":0.00022965534,"threshold_uncertainty_score":0.005491078},"labels":[],"label_agreement":null},{"id":"W2032199025","doi":"10.2174/1568009023333926","title":"Mutant Epidermal Growth Factor Receptors as Targets for Cancer Therapy","year":2002,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Receptor; Epidermal growth factor receptor; Epidermal growth factor; Cancer research; Extracellular; Biology; Tyrosine kinase; Epitope; Cancer; Receptor tyrosine kinase; Cancer cell; Mutant; Growth factor receptor; Mutation; Growth factor receptor inhibitor; Antibody; Cell biology; Immunology; Biochemistry; Genetics; Gene","score_opus":0.1673419595737975,"score_gpt":0.45933838070023336,"score_spread":0.29199642112643587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032199025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025817787,0.99615365,0.00023466014,0.0003415685,0.00025536717,0.000009021206,0.000012619675,0.0000126308005,0.0027222335],"genre_scores_gemma":[0.0011912232,0.9955896,0.00033258394,0.00034526328,0.00015703695,0.000012454561,0.00002723101,0.0000023143575,0.002342205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977463,0.000045736702,0.000018730072,0.000028282213,0.00011318626,0.000019403464],"domain_scores_gemma":[0.9998739,0.000052104104,0.00001533394,0.0000057815814,0.000036532703,0.0000163583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006299525,0.00071725284,0.0012889735,0.0020252224,0.0002791617,0.0008301669,0.00088535936,0.0011918321,0.004005027],"category_scores_gemma":[0.00040261168,0.00022989171,0.00039314266,0.001745811,0.00046274607,0.0011856717,0.0004508458,0.0016696857,0.003575687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012977987,0.0001691361,0.0001559286,0.0068298858,0.0000686452,0.0004931891,0.00008326564,0.00059250236,0.0055548977,0.0080571165,0.04197028,0.93589526],"study_design_scores_gemma":[0.00003933404,0.00010186316,0.00037679778,0.0008640452,0.000036168964,0.001297172,0.000031855805,0.00009203702,0.0008212007,0.0020249314,0.99430484,0.000009677078],"about_ca_topic_score_codex":0.0006383507,"about_ca_topic_score_gemma":0.001320694,"teacher_disagreement_score":0.004005027,"about_ca_system_score_codex":0.0008157654,"about_ca_system_score_gemma":0.00055996655,"threshold_uncertainty_score":0.013398111},"labels":[],"label_agreement":null},{"id":"W2032699899","doi":"10.1158/0008-5472.sabcs-4058","title":"Combination effects of herceptin, pertuzumab and bevacizumab in a HER2-overexpressing breast cancer xenograft model.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Bevacizumab; Breast cancer; Metastatic breast cancer; Combination therapy; Metastasis; Internal medicine; Chemotherapy; Oncology; Cancer; Pharmacology; Cancer research","score_opus":0.06386456340538994,"score_gpt":0.4504525453210939,"score_spread":0.386587981915704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032699899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259394,0.0020099191,0.0010148144,0.00019662113,0.00015048617,0.000120629935,0.00097418606,0.00014744158,0.0027920841],"genre_scores_gemma":[0.99071,0.0013198339,0.0024388607,0.000072374816,0.000029612904,0.00013356884,0.0012544013,0.000030773877,0.00401052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998648,0.000031366264,0.000012625792,0.000023944764,0.000035756486,0.000031434065],"domain_scores_gemma":[0.9998919,0.000018465575,0.000026015563,0.000011590492,0.000012143916,0.00003986385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027469682,0.0005596576,0.0004624431,0.00023559091,0.00011859692,0.00017973145,0.0003090883,0.00032044304,0.0010762792],"category_scores_gemma":[0.000072771356,0.00017609414,0.00034684152,0.00021566835,0.00009971937,0.00024148799,0.00009224811,0.0005739863,0.0002789233],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001531568,0.0012635799,0.00023929725,0.00010662579,0.000033036296,0.00008647939,0.000023757602,0.00039669292,0.9925964,0.00008575536,0.0004772124,0.0031595584],"study_design_scores_gemma":[0.0005518756,0.017846946,0.005173388,0.000013518612,0.000095087795,0.0004109566,0.000034798773,0.003101911,0.9685448,0.00004888906,0.004165317,0.000012472757],"about_ca_topic_score_codex":0.001905255,"about_ca_topic_score_gemma":0.0028530646,"teacher_disagreement_score":0.001905255,"about_ca_system_score_codex":0.00028147103,"about_ca_system_score_gemma":0.00030694375,"threshold_uncertainty_score":0.003788352},"labels":[],"label_agreement":null},{"id":"W2033053403","doi":"10.1038/sj.onc.1208898","title":"The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation","year":2005,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Biology; ErbB; Proto-oncogene tyrosine-protein kinase Src; Tyrosine kinase; Transformation (genetics); Receptor tyrosine kinase; Cancer research; Protein kinase domain; Signal transduction; Cell biology; Tyrosine; Genetics; Biochemistry; Gene; Mutant","score_opus":0.02874161291172162,"score_gpt":0.33401668820393904,"score_spread":0.3052750752922174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033053403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96690315,0.019057374,0.0030343034,0.0016901043,0.00011093402,0.000014014249,0.000113134294,0.00004787626,0.009029183],"genre_scores_gemma":[0.99208903,0.0043950286,0.0006217796,0.000096707314,0.00007914202,0.000005859565,0.00012924675,0.000008392615,0.0025748846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998344,0.000022026456,0.000006853163,0.000023313523,0.00005397272,0.00005943208],"domain_scores_gemma":[0.9999051,0.00001910384,0.000023443441,0.000010646038,0.00001766321,0.000024027555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032187812,0.0003626817,0.0002405417,0.00034121436,0.0004232097,0.0009897,0.00040391102,0.0005022426,0.0010958043],"category_scores_gemma":[0.00038627177,0.00022737827,0.00019633834,0.00034300968,0.00055897544,0.00083843025,0.00036467088,0.0006675075,0.0005295307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007849177,0.00013104499,0.0036968407,0.00013966586,0.000022844184,0.0018721353,0.00013124598,0.0006198377,0.9634415,0.014725912,0.0010589748,0.013375159],"study_design_scores_gemma":[0.00013732104,0.00041905022,0.045500662,0.00004203476,0.0001017073,0.012885868,0.00054710044,0.006697863,0.88984644,0.011331591,0.032445442,0.000044794957],"about_ca_topic_score_codex":0.000616467,"about_ca_topic_score_gemma":0.0006169004,"teacher_disagreement_score":0.0010958043,"about_ca_system_score_codex":0.00079116056,"about_ca_system_score_gemma":0.00033336712,"threshold_uncertainty_score":0.005740285},"labels":[],"label_agreement":null},{"id":"W2033475362","doi":"10.1158/0008-5472.sabcs12-s5-6","title":"Abstract S5-6: Activating HER2 mutations in HER2 gene amplification negative breast cancers.","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lapatinib; Biology; Breast cancer; Mutation; Germline mutation; Somatic cell; Cancer research; Genetics; Trastuzumab; Cancer; COLD-PCR; Exon; Gefitinib; Gene; Point mutation; Molecular biology; Epidermal growth factor receptor","score_opus":0.20732919088547383,"score_gpt":0.5058111658886728,"score_spread":0.29848197500319895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033475362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870101,0.0020533344,0.0006429383,0.00035634465,0.000099283476,0.00010522439,0.0034811154,0.00006295405,0.0061886907],"genre_scores_gemma":[0.9922272,0.0005403983,0.0010545912,0.00016695813,0.000034170964,0.000016306029,0.0034447222,0.00001315929,0.0025025334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998745,0.000016389353,0.000018486644,0.000024246623,0.000049180606,0.00001719123],"domain_scores_gemma":[0.9998832,0.00002606518,0.000028033679,0.000006059159,0.00002201896,0.000034627672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018687555,0.00039838106,0.00020414784,0.00037044418,0.00021291476,0.00022598446,0.00023623602,0.00035966703,0.0038015042],"category_scores_gemma":[0.00030348657,0.000068425215,0.00024706556,0.00028415926,0.00015226995,0.00009477453,0.00013478825,0.00024756405,0.0010095816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055844863,0.0005978628,0.19867487,0.0011941365,0.00018561064,0.0403166,0.0003250866,0.0022178097,0.65317357,0.0005922798,0.012672533,0.08446514],"study_design_scores_gemma":[0.0004502542,0.0032772517,0.4281658,0.00013881065,0.0003388315,0.112032,0.00028185165,0.0034824153,0.41487655,0.00053041027,0.03639128,0.00003453893],"about_ca_topic_score_codex":0.0011328317,"about_ca_topic_score_gemma":0.0014493654,"teacher_disagreement_score":0.0038015042,"about_ca_system_score_codex":0.0003113268,"about_ca_system_score_gemma":0.00022147488,"threshold_uncertainty_score":0.012717247},"labels":[],"label_agreement":null},{"id":"W2034014431","doi":"10.2165/11588350-000000000-00000","title":"Adjuvant Trastuzumab for Breast Cancer","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Atlantic School of Theology; Cancer Care Nova Scotia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Breast cancer; Adjuvant; Quality of Life Research; Medicine; Oncology; Health economics; Internal medicine; Public health; Cancer; Pathology","score_opus":0.1428086307434459,"score_gpt":0.43489554137371356,"score_spread":0.29208691063026765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034014431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5330793,0.2163814,0.0035019137,0.15994008,0.0019507803,0.0002761466,0.0021639233,0.00011624249,0.08259017],"genre_scores_gemma":[0.9566142,0.027055752,0.00078601285,0.008429543,0.0021643275,0.000082028,0.0005189776,0.000011244026,0.0043378538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990689,0.00055892987,0.000060644794,0.000043275624,0.00016937873,0.000098942386],"domain_scores_gemma":[0.99755967,0.0016783836,0.00033258423,0.00007129222,0.00011832875,0.0002396803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013278807,0.000107629596,0.00025421384,0.00031488374,0.0001373443,0.00042126878,0.00017168316,0.0004780181,0.004169399],"category_scores_gemma":[0.006795987,0.00005054677,0.00028844277,0.0005266146,0.0001274703,0.00028582325,0.00021289932,0.00076166796,0.00019470505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0144395735,0.0007416878,0.021224786,0.000832696,0.00045853673,0.0005684253,0.0000673944,0.0036415663,0.0022910633,0.0057389135,0.027616864,0.9223785],"study_design_scores_gemma":[0.012804866,0.010654566,0.36621097,0.0041068257,0.0047731423,0.005102387,0.00055014837,0.021970298,0.009854874,0.03709656,0.5267997,0.00007583273],"about_ca_topic_score_codex":0.0016317695,"about_ca_topic_score_gemma":0.004619338,"teacher_disagreement_score":0.004169399,"about_ca_system_score_codex":0.0015566858,"about_ca_system_score_gemma":0.0015271446,"threshold_uncertainty_score":0.013948023},"labels":[],"label_agreement":null},{"id":"W2034281669","doi":"10.1038/sj.onc.1206983","title":"Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression","year":2003,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University","funders":"Natural Sciences and Engineering Research Council of Canada; U.S. Army","keywords":"Biology; Cancer research; Amphiregulin; Epidermal growth factor receptor; Mammary tumor; Carcinogenesis; ErbB; Oncogene; Tumor progression; Genetically modified mouse; Epidermal growth factor; Metastasis; Transgene; Cancer; Signal transduction; Breast cancer; Receptor; Cell biology; Gene; Cell cycle","score_opus":0.05198894877530207,"score_gpt":0.3542389475828333,"score_spread":0.30224999880753123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034281669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841309,0.009798823,0.0022172092,0.00030880535,0.00005627057,0.00003512987,0.0005812673,0.00013192795,0.0027395894],"genre_scores_gemma":[0.9919171,0.001969802,0.0011262569,0.00004295633,0.000007714047,0.000024697074,0.00051366095,0.000017230785,0.0043806513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989176,0.000019266805,0.0000063373545,0.000012124787,0.00002509132,0.000045350964],"domain_scores_gemma":[0.9999201,0.000008406092,0.000021859501,0.000011027872,0.000015757456,0.000022824865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001667984,0.0005549637,0.00018781998,0.000444766,0.00029864925,0.0005867833,0.00031461008,0.00027252332,0.0012696263],"category_scores_gemma":[0.00017011068,0.00025512316,0.0003345432,0.00019592395,0.00020385745,0.00039476657,0.00036618282,0.00071489514,0.00047269827],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004055359,0.000022088263,0.0005661629,0.00007362537,0.000011306677,0.00015883481,0.0000248641,0.00012772086,0.99560815,0.0009685809,0.00014455346,0.0018886015],"study_design_scores_gemma":[0.0000323054,0.000103775055,0.017989032,0.000017622782,0.000036206566,0.00064814213,0.00009366224,0.001545778,0.9726284,0.0003234145,0.0065735765,0.000008092077],"about_ca_topic_score_codex":0.0024390589,"about_ca_topic_score_gemma":0.0042626467,"teacher_disagreement_score":0.0024390589,"about_ca_system_score_codex":0.00078039465,"about_ca_system_score_gemma":0.00036810295,"threshold_uncertainty_score":0.005662143},"labels":[],"label_agreement":null},{"id":"W2034398380","doi":"10.1038/modpathol.3800774","title":"Standardization of HER2 testing: results of an international proficiency-testing ring study","year":2007,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immunohistochemistry; Medicine; Breast cancer; Pathology; Fish <Actinopterygii>; Anatomical pathology; Cancer; Internal medicine; Oncology; Biology","score_opus":0.13295152696789742,"score_gpt":0.4354257715679868,"score_spread":0.30247424460008937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034398380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95914024,0.0013825552,0.022794016,0.00044590482,0.00018752241,0.0010300159,0.00087003206,0.00033396698,0.013815767],"genre_scores_gemma":[0.9887792,0.00018495174,0.008542685,0.00015056632,0.00003141061,0.00020639294,0.0008426539,0.00013524483,0.0011269549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9543407,0.027690182,0.004391015,0.0054751183,0.0067325463,0.0013703405],"domain_scores_gemma":[0.90369797,0.036163945,0.005215443,0.025590919,0.02749368,0.001837989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05272387,0.0011704374,0.0008899321,0.0021574444,0.0012220051,0.0014441643,0.0014360634,0.0009783803,0.0018485738],"category_scores_gemma":[0.06320847,0.00048917095,0.0012819305,0.0016460622,0.0019480971,0.0011916091,0.0022342158,0.0012192717,0.0010193659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009904532,0.0026105582,0.67701757,0.0006934949,0.0014123389,0.00058512413,0.020610895,0.003859093,0.09710277,0.003566393,0.0050449534,0.17759223],"study_design_scores_gemma":[0.0006302551,0.010253517,0.80707836,0.00023740382,0.0016831337,0.0019872952,0.0041810335,0.006364229,0.14332713,0.0014247624,0.022614868,0.00021802004],"about_ca_topic_score_codex":0.0024904334,"about_ca_topic_score_gemma":0.0015184046,"teacher_disagreement_score":0.05272387,"about_ca_system_score_codex":0.0012122061,"about_ca_system_score_gemma":0.0013849015,"threshold_uncertainty_score":0.2788338},"labels":[],"label_agreement":null},{"id":"W2034827497","doi":"10.3747/co.19.1049","title":"Future of Personalized Medicine in Non-Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Personalized medicine; Clinical trial; Targeted therapy; Bioinformatics; ErbB; Precision medicine; Cancer research; Computational biology; Cancer; Oncology; Pathology; Internal medicine; Biology","score_opus":0.14506551953330715,"score_gpt":0.49732441473731803,"score_spread":0.3522588952040109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034827497","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029193992,0.64692855,0.014972989,0.30682334,0.003814545,0.000046968547,0.00019736818,0.00022022422,0.024076661],"genre_scores_gemma":[0.08367237,0.81229013,0.020055413,0.05539659,0.020685283,0.00020757095,0.00030004542,0.00005543992,0.0073371134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988617,0.0007106226,0.000043674747,0.00009985586,0.00021264871,0.000071450864],"domain_scores_gemma":[0.9969279,0.0021159686,0.00014336276,0.00013997234,0.00040883038,0.00026404078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050893314,0.0005299157,0.0012548717,0.00089679233,0.0006216061,0.0023547458,0.00087139267,0.0030356566,0.0111301085],"category_scores_gemma":[0.00385894,0.00017359048,0.0007467613,0.0006099781,0.0023860387,0.0040050745,0.0014696101,0.005080615,0.0018924527],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003410973,0.00026083353,0.0017496437,0.0024776564,0.00020424364,0.0005703696,0.0002661564,0.0026759913,0.0018335909,0.13442254,0.11276647,0.7424313],"study_design_scores_gemma":[0.0001869701,0.00052665337,0.004357634,0.0024837968,0.00018719168,0.0019446365,0.0006665641,0.003453424,0.00096250186,0.32826886,0.65686095,0.00010089569],"about_ca_topic_score_codex":0.00058783597,"about_ca_topic_score_gemma":0.00163662,"teacher_disagreement_score":0.0111301085,"about_ca_system_score_codex":0.00193305,"about_ca_system_score_gemma":0.0025934388,"threshold_uncertainty_score":0.03723389},"labels":[],"label_agreement":null},{"id":"W2034917939","doi":"10.1111/his.12336","title":"Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma <i>in situ</i>","year":2013,"lang":"en","type":"article","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Government of Ontario","keywords":"Tissue microarray; Ductal carcinoma; Biomarker; In situ; Breast cancer; Biomarker discovery; DNA microarray; Immunohistochemistry; Computational biology; Cancer; Oncology; Pathology; Biology; Computer science; Medicine; Internal medicine; Chemistry; Proteomics","score_opus":0.08097265473608932,"score_gpt":0.35776919644008653,"score_spread":0.2767965417039972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034917939","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035006158,0.0008180598,0.95697737,0.00024278752,0.00013690375,0.00024433446,0.0006703098,0.003954523,0.0019495451],"genre_scores_gemma":[0.12619013,0.0006269413,0.8700593,0.00016160158,0.00006429005,0.00057181704,0.00073061296,0.00034717665,0.0012481482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979119,0.0006756862,0.00012003478,0.0004277883,0.00077037665,0.000094182964],"domain_scores_gemma":[0.9985275,0.00058920984,0.00025638274,0.00032853862,0.00023419573,0.00006413898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002409534,0.0011009722,0.0009780718,0.0009792704,0.00035837156,0.0018427101,0.0013210947,0.0006538146,0.0027178843],"category_scores_gemma":[0.0042847684,0.0008168692,0.0008222735,0.0008622943,0.00048705447,0.0012395309,0.0013632383,0.0007739087,0.0013202074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045880923,0.00018052754,0.005217651,0.0005146973,0.00025063934,0.00021275866,0.00013929096,0.085173376,0.6146337,0.008118202,0.004349569,0.2807508],"study_design_scores_gemma":[0.00008560718,0.0010065568,0.0066857566,0.00006680345,0.00022218477,0.0012992921,0.00013783548,0.49266806,0.44952232,0.0134785725,0.034664895,0.00016205852],"about_ca_topic_score_codex":0.00057652267,"about_ca_topic_score_gemma":0.001286578,"teacher_disagreement_score":0.0027178843,"about_ca_system_score_codex":0.0005752559,"about_ca_system_score_gemma":0.0006475016,"threshold_uncertainty_score":0.012742996},"labels":[],"label_agreement":null},{"id":"W2035064666","doi":"10.1038/onc.2012.283","title":"Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs","year":2012,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institutes of Health; Canadian Institutes of Health Research; Fondation du cancer du sein du Québec","keywords":"In vivo; Trastuzumab; Cytotoxicity; Doxorubicin; Pharmacology; Cancer research; Monoclonal antibody; Metastasis; Antibody-drug conjugate; Metastatic breast cancer; Biology; Cancer; Breast cancer; In vitro; Chemotherapy; Antibody; Immunology","score_opus":0.030106146075399257,"score_gpt":0.35764700341101024,"score_spread":0.327540857335611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035064666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509853,0.0009518578,0.0011858178,0.00012261017,0.000073201314,0.000028706481,0.00042616666,0.00008747884,0.0020255884],"genre_scores_gemma":[0.99255615,0.00045045433,0.0008281932,0.000042177795,0.000014852212,0.000040528266,0.000804975,0.000024964647,0.0052375975],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999798,0.000041173906,0.0000109143075,0.0000328794,0.000044774697,0.00007218848],"domain_scores_gemma":[0.9998964,0.000030854957,0.00001383622,0.000015577072,0.000016489093,0.000026814849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014653617,0.00040463536,0.00046039672,0.00024249071,0.00018801026,0.00023328705,0.00029535303,0.000455396,0.002624582],"category_scores_gemma":[0.00014806617,0.00025450267,0.00028794107,0.00022745221,0.00020210168,0.00022530225,0.000116788644,0.0006785613,0.00049604254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040038896,0.00012885687,0.000080458354,0.000026530275,0.000007862914,0.00002872045,0.000013927137,0.00009437652,0.9983876,0.00006268284,0.00007416887,0.0006945353],"study_design_scores_gemma":[0.000032541306,0.0004975288,0.0017659169,0.0000019223507,0.000015560467,0.000068805704,0.000010803715,0.0011219386,0.9958572,0.00001567228,0.0006093724,0.0000028104264],"about_ca_topic_score_codex":0.002565994,"about_ca_topic_score_gemma":0.002105074,"teacher_disagreement_score":0.002624582,"about_ca_system_score_codex":0.0003753069,"about_ca_system_score_gemma":0.0002777009,"threshold_uncertainty_score":0.008780062},"labels":[],"label_agreement":null},{"id":"W2035214881","doi":"10.3111/13696998.2014.979938","title":"Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; Roche (Canada)","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Neoadjuvant therapy; Inflammatory breast cancer; Cancer","score_opus":0.024272920471406934,"score_gpt":0.34425611307015447,"score_spread":0.3199831925987475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035214881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96745837,0.003519513,0.0044832635,0.0023388544,0.000050976116,0.0012387055,0.008675855,0.00008711115,0.012147399],"genre_scores_gemma":[0.9949675,0.0006137897,0.0014714743,0.00015487174,0.000007687862,0.000150048,0.0015146639,0.000009458181,0.0011105804],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99728286,0.0011689025,0.00008040766,0.00018960869,0.00049784256,0.0007803213],"domain_scores_gemma":[0.9941981,0.00342251,0.00052437605,0.00013205883,0.0011902793,0.0005327296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004155928,0.0010928712,0.0011786154,0.0017012124,0.0010123816,0.0019613851,0.0020287673,0.0009746068,0.0028254515],"category_scores_gemma":[0.013237638,0.0007270274,0.0024773874,0.0022348494,0.00094407244,0.0006309836,0.0010343194,0.0013156001,0.00010820959],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004366669,0.00054664543,0.04233965,0.0006261228,0.0014041173,0.0004556935,0.00014750683,0.9215412,0.0005983169,0.008359242,0.0032233114,0.016391462],"study_design_scores_gemma":[0.0011975266,0.0011364567,0.065061495,0.00017580522,0.001314576,0.00020916527,0.0005165678,0.92328334,0.00059370685,0.0031032267,0.003275704,0.000132353],"about_ca_topic_score_codex":0.9509151,"about_ca_topic_score_gemma":0.9095958,"teacher_disagreement_score":0.10062197,"about_ca_system_score_codex":0.10062197,"about_ca_system_score_gemma":0.049493205,"threshold_uncertainty_score":0.7300669},"labels":[],"label_agreement":null},{"id":"W2035360235","doi":"10.1016/j.ctrv.2006.01.005","title":"Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence","year":2006,"lang":"en","type":"article","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Adjuvant; Internal medicine; Chemotherapy; Stage (stratigraphy); Metastatic breast cancer; Monoclonal antibody; Cancer; Antibody; Immunology","score_opus":0.06632819832425466,"score_gpt":0.4043932864000384,"score_spread":0.3380650880757837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035360235","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7213358,0.26299486,0.0007073399,0.0035213914,0.0009273031,0.00007791484,0.00020372563,0.0001513142,0.0100803245],"genre_scores_gemma":[0.9313498,0.058439646,0.0004810924,0.00089755864,0.00069257716,0.00003923535,0.00022782071,0.000028156299,0.007844206],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998522,0.00005670382,0.000010114175,0.000013446057,0.000035542595,0.000031995427],"domain_scores_gemma":[0.99966776,0.00014567468,0.00008536693,0.00001813408,0.000032132255,0.000050882936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035331785,0.0002147458,0.0009942903,0.00023950115,0.00012430451,0.00027199456,0.00023467556,0.00029814374,0.0033894388],"category_scores_gemma":[0.0014683924,0.000086129745,0.00033324797,0.0002244155,0.00008035713,0.00019970837,0.00010450173,0.0005584863,0.00033784108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017259689,0.001718164,0.009024145,0.00098039,0.00063872023,0.00036079195,0.00014923303,0.00054029323,0.010681368,0.0002970195,0.015432059,0.942918],"study_design_scores_gemma":[0.01792747,0.096310325,0.67733204,0.0011255379,0.0064813085,0.0070105228,0.0004897955,0.002425812,0.030477133,0.0015692975,0.15877202,0.00007875214],"about_ca_topic_score_codex":0.0007756127,"about_ca_topic_score_gemma":0.0025759279,"teacher_disagreement_score":0.0033894388,"about_ca_system_score_codex":0.00030412173,"about_ca_system_score_gemma":0.00026891194,"threshold_uncertainty_score":0.01133883},"labels":[],"label_agreement":null},{"id":"W2035903801","doi":"10.1007/s10549-007-9887-y","title":"New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up","year":2008,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Breast Cancer Research Alliance; Sanofi; Breast Cancer Alliance","keywords":"Breast cancer; Immunohistochemistry; Internal medicine; Oncology; Fluorescence in situ hybridization; Population; Cancer; Medicine; Cohort; Trastuzumab; Fish <Actinopterygii>; Pathology; Biology; Gene; Genetics","score_opus":0.05632076209097779,"score_gpt":0.43925768052665604,"score_spread":0.38293691843567823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035903801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749833,0.00027475672,0.0012834511,0.00005571846,0.000020222005,0.000026828255,0.000572836,0.000018424464,0.00024930594],"genre_scores_gemma":[0.9974022,0.00008125061,0.0010500776,0.000047784633,0.000023537441,0.00007086818,0.0009626135,0.000013607895,0.00034796403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989077,0.00034219061,0.00009798223,0.00035270778,0.00017989546,0.00011953259],"domain_scores_gemma":[0.99780995,0.0009714753,0.00039411825,0.0003593371,0.00026073933,0.00020450192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024943335,0.0007640633,0.001064016,0.0011048212,0.0007013632,0.0013702498,0.0009796689,0.0012091865,0.0013215522],"category_scores_gemma":[0.0057333605,0.00038251645,0.0009274389,0.0010258416,0.00044903284,0.0006868303,0.000636955,0.0011419528,0.0002981116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017903211,0.00015153385,0.9866564,0.000015632577,0.00040671774,0.00030658266,0.00017677368,0.00041469204,0.0030578044,0.00009098462,0.0004592795,0.006473282],"study_design_scores_gemma":[0.00012241448,0.0003704942,0.9953101,0.0000068042646,0.00026843807,0.00083367596,0.00014939262,0.0016388438,0.0005408097,0.00020195384,0.000539677,0.00001743301],"about_ca_topic_score_codex":0.002539736,"about_ca_topic_score_gemma":0.0028784398,"teacher_disagreement_score":0.002539736,"about_ca_system_score_codex":0.00036268774,"about_ca_system_score_gemma":0.0003955043,"threshold_uncertainty_score":0.013191462},"labels":[],"label_agreement":null},{"id":"W2037737356","doi":"10.1158/0008-5472.can-11-3513","title":"Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Mammary gland; Carcinogenesis; ERBB3; Cancer; PI3K/AKT/mTOR pathway; Internal medicine; Cancer research; Biology; Endocrinology; Medicine; Breast cancer; Cell biology; Signal transduction; Epidermal growth factor receptor","score_opus":0.13422335716945008,"score_gpt":0.4469408649623257,"score_spread":0.31271750779287566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037737356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970393,0.0005280026,0.00069763546,0.00010289378,0.000019367086,0.0000135237315,0.00043908312,0.000097401695,0.0010628682],"genre_scores_gemma":[0.99547845,0.00043993723,0.00076559285,0.000051300132,0.0000053582903,0.000023112354,0.00053269684,0.000037418904,0.0026662098],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997688,0.000029189556,0.000024761588,0.0000308809,0.00007492107,0.00007135687],"domain_scores_gemma":[0.9997484,0.00003902735,0.00006617107,0.000030869905,0.000010412798,0.000105179366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001508846,0.00046530575,0.00034106377,0.0003294679,0.00015584336,0.00031383836,0.00030355368,0.0003449242,0.0018476397],"category_scores_gemma":[0.00015209465,0.00021776772,0.00034263494,0.00020778958,0.00035163548,0.0002248293,0.00026077675,0.00080515054,0.000514657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002589838,0.00009042644,0.00022982144,0.000021627158,0.000009044675,0.000077244695,0.000010597697,0.00010745719,0.99772173,0.00015180465,0.00004811598,0.0012731843],"study_design_scores_gemma":[0.000051957442,0.0006687737,0.0066054496,0.000010267955,0.000025351927,0.00052106037,0.000045829023,0.0014503434,0.9885006,0.00012825517,0.0019830472,0.000008972592],"about_ca_topic_score_codex":0.0013453362,"about_ca_topic_score_gemma":0.002459226,"teacher_disagreement_score":0.0018476397,"about_ca_system_score_codex":0.00039264394,"about_ca_system_score_gemma":0.00053169945,"threshold_uncertainty_score":0.0061810017},"labels":[],"label_agreement":null},{"id":"W2038780142","doi":"10.1016/j.ejca.2015.02.005","title":"Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Minimal clinically important difference; Quality of life (healthcare); Lapatinib; Placebo; Breast cancer; Discontinuation; SF-36; Randomized controlled trial; Internal medicine; Physical therapy; Adverse effect; Cancer; Health related quality of life; Disease; Alternative medicine","score_opus":0.09232333326504484,"score_gpt":0.4008121555903717,"score_spread":0.3084888223253269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038780142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944336,0.002235593,0.00014073947,0.0004072239,0.00032296643,0.00081048964,0.0006055046,0.000029526433,0.0010144367],"genre_scores_gemma":[0.994086,0.0010000088,0.00027664396,0.00053585425,0.0002477506,0.0011431698,0.0006085984,0.0000057522266,0.0020961363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996458,0.00016124302,0.000023030514,0.000060216444,0.000022384507,0.00008731154],"domain_scores_gemma":[0.99958485,0.00008439572,0.00008816702,0.000033769087,0.000029976216,0.00017874021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006976699,0.0011382543,0.00235869,0.00028415603,0.00046256738,0.00067716837,0.00050534745,0.0015116401,0.005452291],"category_scores_gemma":[0.0012521114,0.00054947,0.0016821561,0.0002822132,0.0008295722,0.00061352336,0.0005083125,0.0024172303,0.00057975453],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98676664,0.004457327,0.00094645505,0.00026121573,0.00038410802,0.000022453452,0.00002643411,0.00010876005,0.0015347179,0.00002850312,0.0002431429,0.0052201934],"study_design_scores_gemma":[0.88459396,0.10478523,0.008444895,0.000035345587,0.0008447646,0.000022872202,0.000042239357,0.00022463006,0.00036260113,0.00008950723,0.0005385508,0.000015277757],"about_ca_topic_score_codex":0.0018838187,"about_ca_topic_score_gemma":0.0030640939,"teacher_disagreement_score":0.005452291,"about_ca_system_score_codex":0.00061268243,"about_ca_system_score_gemma":0.000756762,"threshold_uncertainty_score":0.018239796},"labels":[],"label_agreement":null},{"id":"W2040371382","doi":"10.2967/jnumed.109.069716","title":"Methotrexate, Paclitaxel, and Doxorubicin Radiosensitize <i>HER2</i>-Amplified Human Breast Cancer Cells to the Auger Electron–Emitting Radiotherapeutic Agent <sup>111</sup>In-NLS-Trastuzumab","year":2010,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; McMaster University; University of Toronto","funders":"Cancer Research UK; Canadian Breast Cancer Research Alliance","keywords":"Trastuzumab; Doxorubicin; Chemistry; Methotrexate; Cancer research; Molecular biology; Cancer; Breast cancer; Chemotherapy; Medicine; Internal medicine; Biology","score_opus":0.025095790872974363,"score_gpt":0.3553990813217046,"score_spread":0.33030329044873025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040371382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684405,0.0010413128,0.0008280942,0.000031797725,0.000008884153,0.000021201697,0.00004676905,0.000025083162,0.0011528087],"genre_scores_gemma":[0.99643505,0.00078632165,0.00096088793,0.000027619535,0.000008327935,0.00002124318,0.00012195636,0.0000097430475,0.0016289452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998735,0.000032007738,0.000011570743,0.000020501115,0.000033912795,0.000028447024],"domain_scores_gemma":[0.99993336,0.000017588203,0.000020068952,0.000012045856,0.00000875876,0.000008259131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112205846,0.00025989363,0.00024514197,0.000095361516,0.00009434604,0.00019888878,0.00013400844,0.00019951252,0.0009084858],"category_scores_gemma":[0.00012517258,0.00011002041,0.00014893517,0.00010107315,0.00014328596,0.00010813615,0.00011202496,0.0001797455,0.0002325877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012270917,0.000021094187,0.000366074,0.000025126292,0.000007984095,0.000038224043,0.00001666064,0.00010234592,0.9979031,0.00003410368,0.000033995933,0.0013285903],"study_design_scores_gemma":[0.000015215265,0.000312484,0.0037191294,0.0000025239901,0.000013182177,0.0002104184,0.000013080278,0.0002989961,0.9943815,0.0000066274033,0.0010254547,0.0000014030486],"about_ca_topic_score_codex":0.0007098138,"about_ca_topic_score_gemma":0.0012251566,"teacher_disagreement_score":0.0009084858,"about_ca_system_score_codex":0.00029437503,"about_ca_system_score_gemma":0.00010666468,"threshold_uncertainty_score":0.0030392408},"labels":[],"label_agreement":null},{"id":"W2041576667","doi":"10.1073/pnas.97.7.3444","title":"Amplification of the <i>neu/erbB-2</i> oncogene in a mouse model of mammary tumorigenesis","year":2000,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Mammary gland; Carcinogenesis; Biology; Genetically modified mouse; Mouse mammary tumor virus; Endogeny; Mammary tumor; Cancer research; ErbB; Oncogene; HER2/neu; Transgene; Gene; Breast cancer; Endocrinology; Cancer; Cell cycle; Genetics","score_opus":0.09758280350511378,"score_gpt":0.36622042648022635,"score_spread":0.26863762297511257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041576667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719088,0.002734909,0.0136015415,0.000935826,0.00020085419,0.00053117925,0.0019643668,0.00096824556,0.0071542673],"genre_scores_gemma":[0.9494752,0.003763317,0.017042255,0.00043493917,0.00008480211,0.0008653577,0.003441041,0.0002221808,0.024670891],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993765,0.00011803053,0.000075072516,0.0001074713,0.0001785355,0.00014441075],"domain_scores_gemma":[0.99953127,0.00006970575,0.00011050577,0.000068554284,0.000032603788,0.00018738616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073669245,0.0011705133,0.0005394498,0.0017062097,0.00051333715,0.00066282466,0.00072507415,0.0012316932,0.0028756151],"category_scores_gemma":[0.00017304726,0.0006496509,0.00066379574,0.00054614607,0.00066221727,0.0005900456,0.00050184474,0.002325542,0.0011114008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005452336,0.0005869609,0.00042283433,0.00005955427,0.000017719132,0.00029858237,0.000056420133,0.00017617301,0.9940515,0.0012866139,0.00030688275,0.0021915094],"study_design_scores_gemma":[0.00033293405,0.0030856496,0.0030558,0.000055376353,0.00007589202,0.0022110473,0.0000705834,0.0021599792,0.97701436,0.00058859156,0.011325601,0.000024109982],"about_ca_topic_score_codex":0.000736144,"about_ca_topic_score_gemma":0.0012136295,"teacher_disagreement_score":0.0028756151,"about_ca_system_score_codex":0.0007909103,"about_ca_system_score_gemma":0.0005503603,"threshold_uncertainty_score":0.009619951},"labels":[],"label_agreement":null},{"id":"W2041762805","doi":"10.1371/journal.pone.0071987","title":"Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Alberta","funders":"Alberta Innovates; Terry Fox Research Institute","keywords":"Epithelial–mesenchymal transition; Trastuzumab; CD44; Mesenchymal stem cell; Cancer research; Lapatinib; Breast cancer; Phenotype; Biology; Cancer cell; Cancer; Immunology; Cell; Metastasis; Cell biology; Genetics; Gene","score_opus":0.025350801212130927,"score_gpt":0.2765852262329153,"score_spread":0.2512344250207844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041762805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981585,0.0005927441,0.0006536067,0.000029573057,0.0000035620428,0.000017315773,0.00008494478,0.000023810027,0.00043582462],"genre_scores_gemma":[0.9989323,0.00021187484,0.00024553688,0.000029415893,0.00000254283,0.000018081138,0.00018223673,0.000004083515,0.0003739952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998814,0.000030836578,0.000011412354,0.0000140368875,0.00003382101,0.000028390574],"domain_scores_gemma":[0.9998603,0.000036727553,0.000034762306,0.000021926591,0.000014868597,0.000031290652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016952145,0.000106548185,0.00016981005,0.00017785297,0.00015708298,0.00029732735,0.00011396524,0.00023228143,0.00060695],"category_scores_gemma":[0.00019986076,0.00011597805,0.00016415758,0.00012283109,0.00013814562,0.00012383306,0.00018948529,0.00035610577,0.00017292901],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021056153,0.00011279019,0.006823694,0.000027065644,0.000010573878,0.00029746513,0.00006149743,0.0001936621,0.9891634,0.00015660845,0.000089217916,0.0028533442],"study_design_scores_gemma":[0.00004016088,0.0022500334,0.16069245,0.000009994756,0.0000424122,0.0048923474,0.00025079664,0.003884229,0.82457626,0.00020172092,0.0031462184,0.000013317302],"about_ca_topic_score_codex":0.0005211671,"about_ca_topic_score_gemma":0.00088741846,"teacher_disagreement_score":0.00060695,"about_ca_system_score_codex":0.00018736941,"about_ca_system_score_gemma":0.00013046018,"threshold_uncertainty_score":0.0020304918},"labels":[],"label_agreement":null},{"id":"W2042012206","doi":"10.1007/s12282-015-0587-x","title":"HER2-directed therapy: current treatment options for HER2-positive breast cancer","year":2015,"lang":"en","type":"review","venue":"Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Surgical oncology; Oncology; Targeted therapy; Cancer; Internal medicine; Metastatic breast cancer","score_opus":0.17407789079844727,"score_gpt":0.4954471902524908,"score_spread":0.3213692994540435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042012206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008784001,0.99898976,0.000076324075,0.00023087762,0.000104621744,0.000003181911,0.000023030923,0.0000053283475,0.0004790474],"genre_scores_gemma":[0.0005605567,0.9986518,0.00012438072,0.0002442061,0.00009305305,0.0000032765013,0.000034711647,0.000001038888,0.0002869696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986625,0.000022924023,0.000021177673,0.000026212034,0.000047849724,0.00001563897],"domain_scores_gemma":[0.99976236,0.00012666872,0.000039217994,0.0000056439094,0.000044134358,0.000022046554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044733568,0.00065878656,0.0013749027,0.0014617904,0.00018743,0.00083902525,0.0007865105,0.00074727164,0.004398724],"category_scores_gemma":[0.0006848051,0.00019392504,0.00056956796,0.0016274174,0.0002711311,0.0010149437,0.000551107,0.0015098354,0.0013235436],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086580396,0.000056317185,0.00015829258,0.016897855,0.00011307354,0.00011283634,0.000025395428,0.00029702287,0.0010706742,0.0013831868,0.032099225,0.94769955],"study_design_scores_gemma":[0.00005420907,0.00013988299,0.0009800589,0.0072236247,0.00047417553,0.0011938344,0.000058782138,0.0001678034,0.00045517788,0.0018747925,0.98735493,0.000022741602],"about_ca_topic_score_codex":0.00076648674,"about_ca_topic_score_gemma":0.0025704023,"teacher_disagreement_score":0.004398724,"about_ca_system_score_codex":0.00043010197,"about_ca_system_score_gemma":0.00073290104,"threshold_uncertainty_score":0.014715254},"labels":[],"label_agreement":null},{"id":"W2042147906","doi":"10.1097/01.pap.0000184177.65919.5e","title":"Prognostic and Predictive Molecular Markers in DCIS","year":2005,"lang":"en","type":"review","venue":"Advances in Anatomic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Ductal carcinoma; Medicine; Breast cancer; Oncology; Mammography; Angiogenesis; Extracellular matrix; Cancer; Internal medicine; Pathology; Bioinformatics; Biology","score_opus":0.027658947053845168,"score_gpt":0.4261770229758327,"score_spread":0.3985180759219875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042147906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047034293,0.9982834,0.00016166043,0.00019374826,0.00006921456,0.0000033450528,0.0000148817035,0.00000522242,0.00079826603],"genre_scores_gemma":[0.0033289199,0.99563026,0.0003355032,0.00010461295,0.000104767096,0.000005530737,0.000031494757,8.916951e-7,0.00045798282],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983585,0.000036043923,0.000026724281,0.000026633019,0.00006189546,0.0000128353095],"domain_scores_gemma":[0.9997558,0.00013352562,0.00004070671,0.000007283667,0.00005301905,0.000009631142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047521768,0.0004900159,0.0010228242,0.0018554775,0.00012996873,0.0005342514,0.0005403084,0.00048677408,0.0013805592],"category_scores_gemma":[0.00093410956,0.00016314331,0.00035597544,0.0017311473,0.00027114505,0.00059795287,0.00026426706,0.00073830993,0.00078390026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007623955,0.000053353375,0.001840279,0.006276147,0.00009027246,0.00050906505,0.000047022037,0.00030599564,0.0016441968,0.0011406922,0.008014704,0.98000216],"study_design_scores_gemma":[0.000056286906,0.0003098107,0.022960505,0.01055879,0.00076721905,0.014711086,0.00019930792,0.0006314132,0.0049962904,0.0040478334,0.9407013,0.00006021572],"about_ca_topic_score_codex":0.00092088414,"about_ca_topic_score_gemma":0.0013212916,"teacher_disagreement_score":0.0018554775,"about_ca_system_score_codex":0.00040547887,"about_ca_system_score_gemma":0.0005177455,"threshold_uncertainty_score":0.004618466},"labels":[],"label_agreement":null},{"id":"W2042702856","doi":"10.1002/cncr.20418","title":"The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma","year":2004,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Breast cancer; Odds ratio; Retrospective cohort study; Breast carcinoma; Confidence interval; Lymph node; Metastatic breast cancer; Cancer","score_opus":0.011740488913623292,"score_gpt":0.27161435400797174,"score_spread":0.25987386509434846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042702856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986444,0.0008198044,0.00003578795,0.00007364903,0.000007801424,0.0000040781047,0.000073143376,0.000002161309,0.0003391377],"genre_scores_gemma":[0.9996276,0.00019221155,0.00001946386,0.000020986225,0.000016766995,0.0000028474858,0.00007294456,9.733442e-7,0.00004619174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954814,0.00014459032,0.000043337528,0.00008145027,0.00010257205,0.00007987123],"domain_scores_gemma":[0.99643916,0.0010840842,0.0016755329,0.00013852905,0.00020329408,0.00045933752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006454404,0.00018571525,0.00046065022,0.00045535623,0.00032692132,0.000539851,0.00031508974,0.00053415087,0.001117396],"category_scores_gemma":[0.0042787143,0.00016661354,0.00049363205,0.0007913241,0.00023972295,0.0003005086,0.0002802604,0.0007873376,0.00013684388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049065205,0.0000303508,0.9971179,0.000009669757,0.000056081717,0.00029955767,0.000026588776,0.00007618091,0.00017771171,0.000008678303,0.000079384496,0.0016272315],"study_design_scores_gemma":[0.000029634064,0.00027459182,0.9974267,0.000008174579,0.000073190735,0.0015018344,0.00006958685,0.00030425665,0.00013006586,0.00003073865,0.0001456231,0.000005554504],"about_ca_topic_score_codex":0.0022748713,"about_ca_topic_score_gemma":0.0020033172,"teacher_disagreement_score":0.0022748713,"about_ca_system_score_codex":0.00039178063,"about_ca_system_score_gemma":0.0003732293,"threshold_uncertainty_score":0.0045232773},"labels":[],"label_agreement":null},{"id":"W2043070875","doi":"10.3747/co.v15i3.249","title":"The Cost Burden of Trastuzumab and Bevacizumab Therapy for Solid Tumours in Canada","year":2008,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Medicine; Bevacizumab; Breast cancer; Oncology; Metastatic breast cancer; Context (archaeology); Colorectal cancer; Internal medicine; Targeted therapy; Lung cancer; Cancer; Intensive care medicine; Chemotherapy","score_opus":0.17774581717795576,"score_gpt":0.46265116577872767,"score_spread":0.2849053486007719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043070875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7923097,0.041463677,0.004012573,0.041679505,0.00047454957,0.0006693826,0.031151714,0.00019430653,0.08804462],"genre_scores_gemma":[0.9726563,0.012926272,0.0024274257,0.0010361111,0.000058828275,0.000069943904,0.003992462,0.000025390922,0.0068072313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845994,0.00021355962,0.00006793298,0.000073717914,0.0008245129,0.00036039494],"domain_scores_gemma":[0.99790585,0.00019530015,0.00029984245,0.00002383394,0.0011702542,0.00040490835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000728871,0.00043522773,0.00025621252,0.0013948805,0.0012784828,0.0020587484,0.0009401606,0.00056267314,0.0029495321],"category_scores_gemma":[0.0038157862,0.00024723948,0.0007957822,0.0028467758,0.0004799137,0.00042889966,0.00079149,0.0006975051,0.00015040411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012809781,0.0002656112,0.4214006,0.002227157,0.0015096453,0.0019805534,0.0010555157,0.111995,0.0024875368,0.047040217,0.08411215,0.32464492],"study_design_scores_gemma":[0.00047486022,0.00044560985,0.72775674,0.0019992439,0.0012891382,0.001535991,0.0035621722,0.096534014,0.0017296172,0.0055541196,0.15887433,0.00024415075],"about_ca_topic_score_codex":0.9919516,"about_ca_topic_score_gemma":0.99298817,"teacher_disagreement_score":0.121094316,"about_ca_system_score_codex":0.121094316,"about_ca_system_score_gemma":0.13766736,"threshold_uncertainty_score":0.8786049},"labels":[],"label_agreement":null},{"id":"W2043605505","doi":"10.1038/bjc.2013.609","title":"Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial","year":2013,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Cancer Research UK; Government of Ontario; Ontario Institute for Cancer Research; Pfizer","keywords":"Tamoxifen; Exemestane; Hazard ratio; Internal medicine; Oncology; Medicine; Breast cancer; Subgroup analysis; Tissue microarray; Confidence interval; Estrogen receptor; Prospective cohort study; Cancer","score_opus":0.0407244504869702,"score_gpt":0.3703711812747373,"score_spread":0.3296467307877671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043605505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893902,0.0028588597,0.0013160679,0.0011300266,0.0002893213,0.00056843966,0.0026522144,0.000045630608,0.0017494109],"genre_scores_gemma":[0.99428743,0.00056420255,0.0011344049,0.00058269274,0.00022333518,0.00061603455,0.0017622667,0.000030459545,0.00079917803],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9841277,0.013314915,0.0005220502,0.0010501565,0.00035235364,0.0006328195],"domain_scores_gemma":[0.9681846,0.018215518,0.007224908,0.004191457,0.0006376585,0.0015458218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01082221,0.0012869867,0.0035513225,0.00026059532,0.00062036375,0.0018362453,0.001042675,0.0025599955,0.006387613],"category_scores_gemma":[0.0257535,0.00059577404,0.005057195,0.00087032386,0.0012439834,0.002197183,0.0007423826,0.0033134618,0.0010487405],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94494313,0.0013738137,0.026190653,0.00054004864,0.008581981,0.0001283977,0.00016503736,0.0014703309,0.00073983346,0.0007009283,0.002463836,0.012701951],"study_design_scores_gemma":[0.63527673,0.19055341,0.10270924,0.00066714274,0.04264762,0.0006106917,0.00054704107,0.00914783,0.0021508713,0.008606997,0.006729423,0.00035299288],"about_ca_topic_score_codex":0.0009911073,"about_ca_topic_score_gemma":0.0015211008,"teacher_disagreement_score":0.01082221,"about_ca_system_score_codex":0.0009694268,"about_ca_system_score_gemma":0.0020058632,"threshold_uncertainty_score":0.05723399},"labels":[],"label_agreement":null},{"id":"W2044083199","doi":"10.1016/s1470-2045(12)70013-x","title":"Don't pick the loser: lessons from the GeparQuinto trial","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Taxane; Trastuzumab; Medicine; Lapatinib; Anthracycline; Oncology; Internal medicine; Epirubicin; Breast cancer; Docetaxel; Regimen; Chemotherapy; Cancer","score_opus":0.253008395605485,"score_gpt":0.4743445344544751,"score_spread":0.22133613884899012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044083199","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051255635,0.005063939,0.000087044005,0.98548895,0.0058998787,0.0000055656515,0.00009509946,0.000018463566,0.002828588],"genre_scores_gemma":[0.0053825937,0.0026418425,0.00017836374,0.9670282,0.0222916,0.000026814296,0.000048880567,0.00003937257,0.002362207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99134094,0.0045416523,0.0004899017,0.0007898267,0.0018855081,0.00095226767],"domain_scores_gemma":[0.9677844,0.02360709,0.0013636053,0.00079801097,0.0017437278,0.0047032074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014094451,0.0008941776,0.002455975,0.00055392843,0.0028398419,0.005291401,0.0027218706,0.049273107,0.0111227],"category_scores_gemma":[0.054657906,0.0005548034,0.0016271732,0.0008802049,0.004214437,0.0056715184,0.002494539,0.043905117,0.006522017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007226285,0.00006323713,0.00069186446,0.00015951073,0.000109554545,0.0007649545,0.000114820505,0.00014938686,0.00021488579,0.0077659846,0.9527448,0.03649842],"study_design_scores_gemma":[0.003309497,0.0004470926,0.0020543667,0.0012706963,0.000283452,0.0014210443,0.00039986696,0.00064298895,0.0004556256,0.060008485,0.9295627,0.00014416747],"about_ca_topic_score_codex":0.004068155,"about_ca_topic_score_gemma":0.009738334,"teacher_disagreement_score":0.049273107,"about_ca_system_score_codex":0.0040450566,"about_ca_system_score_gemma":0.0046373163,"threshold_uncertainty_score":0.07453948},"labels":[],"label_agreement":null},{"id":"W2045058534","doi":"10.1158/0008-5472.sabcs10-p3-14-07","title":"Abstract P3-14-07: A Phase 1 Study To Assess the Safety, Tolerability and PK of ARRY-380 — An Oral HER2 Inhibitor","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cmax; Nausea; Tolerability; Rash; Dosing; Adverse effect; Lapatinib; Trastuzumab; Internal medicine; Pharmacokinetics; Gastroenterology; Pharmacology; Cancer; Breast cancer","score_opus":0.2525772356432266,"score_gpt":0.5622187609640096,"score_spread":0.309641525320783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045058534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175644,0.0009997524,0.0009723352,0.00040226793,0.000064412576,0.002343007,0.0014058572,0.0002084815,0.0018474517],"genre_scores_gemma":[0.9791702,0.001341117,0.0044649574,0.0012483167,0.00014356169,0.0035604043,0.005393052,0.00011429396,0.0045640874],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995208,0.00018815635,0.000022013688,0.000089984176,0.00007145936,0.00010749892],"domain_scores_gemma":[0.9993767,0.00008027536,0.00009242387,0.000060742557,0.000045789275,0.00034412148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018001162,0.0017084773,0.0020544191,0.0004054433,0.0005400667,0.000941887,0.001271728,0.0013317956,0.0043002106],"category_scores_gemma":[0.0007549609,0.0006596882,0.000861739,0.00042602385,0.0011649921,0.0010417427,0.00037774575,0.0047589745,0.001520691],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3552044,0.2075588,0.0105808405,0.0011502065,0.0014493344,0.0013399041,0.0006207704,0.005017422,0.2422313,0.0007085372,0.018182542,0.15595596],"study_design_scores_gemma":[0.27093095,0.6925709,0.012442722,0.00003432007,0.0003188996,0.0013334426,0.00007188423,0.002581347,0.014368663,0.0003570525,0.0049417038,0.000048047514],"about_ca_topic_score_codex":0.0014582006,"about_ca_topic_score_gemma":0.0024014784,"teacher_disagreement_score":0.0043002106,"about_ca_system_score_codex":0.0012757642,"about_ca_system_score_gemma":0.0028901473,"threshold_uncertainty_score":0.014385641},"labels":[],"label_agreement":null},{"id":"W2045324973","doi":"10.1016/s0140-6736(07)60028-2","title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1511,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Institute of Cancer Research","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Clinical trial; Chemotherapy; Adjuvant; Cancer; Surgery; Confidence interval","score_opus":0.02317066928127298,"score_gpt":0.34360082901363015,"score_spread":0.32043015973235717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045324973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653976,0.019023664,0.001247847,0.0019800453,0.004116011,0.0038525425,0.0015036487,0.00018109662,0.0026975947],"genre_scores_gemma":[0.98303866,0.004301418,0.00091429934,0.0014946031,0.0012988823,0.003722663,0.001128432,0.000031482723,0.00406957],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686426,0.0016722049,0.00021733432,0.0005664721,0.00017429944,0.0005053386],"domain_scores_gemma":[0.99650455,0.0014320476,0.00074964546,0.00041914845,0.00020811662,0.0006864309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00456464,0.0030517522,0.007672349,0.0006691964,0.0008425119,0.0021740226,0.0018650362,0.005768951,0.009408829],"category_scores_gemma":[0.006243457,0.0016082849,0.005529016,0.0009433581,0.002274588,0.0025597299,0.0011091116,0.006683202,0.0014462108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99631774,0.0006488695,0.00021093027,0.00027081324,0.00081847527,0.000019691626,0.000017598833,0.000086189815,0.00019204359,0.00003269824,0.0001455711,0.001239384],"study_design_scores_gemma":[0.9807087,0.01593056,0.0011221555,0.000057636717,0.0014695997,0.000016302454,0.000018117044,0.0001930418,0.0000847381,0.00012811004,0.00025487007,0.000016121749],"about_ca_topic_score_codex":0.003384917,"about_ca_topic_score_gemma":0.00354606,"teacher_disagreement_score":0.009408829,"about_ca_system_score_codex":0.0018660253,"about_ca_system_score_gemma":0.0016755133,"threshold_uncertainty_score":0.031475663},"labels":[],"label_agreement":null},{"id":"W2045375334","doi":"10.12968/bjon.2012.21.sup4.s18","title":"An overview of drug development for metastatic breast cancer","year":2012,"lang":"en","type":"review","venue":"British Journal of Nursing","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Breast cancer; Multidisciplinary approach; Disease; Intensive care medicine; Metastatic breast cancer; Drug development; Radiation therapy; Cancer; Clinical trial; Drug; Oncology; Internal medicine; Pharmacology","score_opus":0.36923911357679706,"score_gpt":0.5368313989316446,"score_spread":0.1675922853548475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045375334","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000100136516,0.99742436,0.00014917937,0.00022170373,0.00017300801,0.000013540725,0.000029881405,0.000011049616,0.0018771284],"genre_scores_gemma":[0.00055783946,0.99774003,0.0003701161,0.00021009748,0.00009030477,0.000015124234,0.000036689573,0.0000018757089,0.000978015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996511,0.00007184493,0.000057955305,0.00004800532,0.0001428111,0.000028408871],"domain_scores_gemma":[0.99956125,0.0002343452,0.000062879524,0.000012674853,0.000098094126,0.000030698884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006874406,0.0010913486,0.0014953812,0.003921499,0.0004310425,0.0009529206,0.00087227736,0.0012390735,0.007108218],"category_scores_gemma":[0.0008842456,0.00041514877,0.00092839944,0.003384124,0.00043431987,0.0014209503,0.00057965756,0.0021127537,0.003500287],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008800917,0.00013191407,0.00011123289,0.02762979,0.000103047314,0.00027572448,0.00006034205,0.0003893188,0.001642611,0.0035090104,0.04127441,0.9247848],"study_design_scores_gemma":[0.00003075897,0.00014114044,0.00048074182,0.0048253597,0.000088285786,0.0011614065,0.00003052207,0.00008191548,0.0003950238,0.0011808019,0.99157,0.000014041498],"about_ca_topic_score_codex":0.001585639,"about_ca_topic_score_gemma":0.0036587145,"teacher_disagreement_score":0.007108218,"about_ca_system_score_codex":0.0008611735,"about_ca_system_score_gemma":0.0011113881,"threshold_uncertainty_score":0.023779333},"labels":[],"label_agreement":null},{"id":"W2045950562","doi":"10.1016/s1470-2045(09)70087-7","title":"Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Internal medicine; Breast cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Inflammatory breast cancer; Trastuzumab; Anthracycline; Cohort; Progressive disease; Metastatic breast cancer; Cancer; Refractory (planetary science); Taxane; Gastroenterology; Chemotherapy","score_opus":0.0591464160017507,"score_gpt":0.4011642093019165,"score_spread":0.3420177933001658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045950562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975005,0.0011188827,0.00009838455,0.00012926475,0.000021897675,0.000076945704,0.00035295213,0.000020432826,0.00068076566],"genre_scores_gemma":[0.99547774,0.0013127666,0.0003544387,0.00026873153,0.00007269053,0.0001222589,0.0015419279,0.00001438351,0.0008351294],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996965,0.00013760409,0.000015876794,0.000044599656,0.000036296697,0.00006917875],"domain_scores_gemma":[0.99957114,0.000090515125,0.000079848396,0.000051327792,0.000018563685,0.0001885319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011293982,0.000983396,0.0019991058,0.0002305441,0.00023828982,0.0007972957,0.0005682329,0.0005301456,0.0011797638],"category_scores_gemma":[0.0005742859,0.00034876348,0.0011056246,0.00038696357,0.0004792193,0.00086787844,0.00028058497,0.0018122861,0.00033835066],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.727372,0.012132927,0.05953685,0.00042208025,0.002668259,0.0007472242,0.00025023936,0.0048317057,0.027765915,0.00018109179,0.003481392,0.16061038],"study_design_scores_gemma":[0.43912265,0.27737248,0.26301,0.0000892429,0.0032507083,0.0017192139,0.00029850908,0.0056219506,0.004550726,0.0005632799,0.004271751,0.00012948533],"about_ca_topic_score_codex":0.0010169797,"about_ca_topic_score_gemma":0.0035486526,"teacher_disagreement_score":0.0019991058,"about_ca_system_score_codex":0.00071795995,"about_ca_system_score_gemma":0.0006449171,"threshold_uncertainty_score":0.005972922},"labels":[],"label_agreement":null},{"id":"W2046583400","doi":"10.1016/s1470-2045(02)00676-9","title":"Trastuzumab: hopes and realities","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital; McGill University; Montreal General Hospital; Royal Victoria Hospital","funders":"","keywords":"Trastuzumab; Political science; Medicine; Internal medicine; Breast cancer; Cancer","score_opus":0.39974076953613047,"score_gpt":0.5236081176257247,"score_spread":0.12386734808959421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046583400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031787506,0.9962121,0.00003260367,0.0026416583,0.0007671164,9.52395e-7,0.000006374403,0.0000031077145,0.00030433078],"genre_scores_gemma":[0.0005398067,0.9945387,0.00011421584,0.0029493673,0.0012994685,0.000004275448,0.00001163112,0.0000018022561,0.000540706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991872,0.00022531202,0.00010135107,0.00009169334,0.00031993014,0.00007454808],"domain_scores_gemma":[0.9962136,0.0026050135,0.00031637444,0.00006247869,0.00058642577,0.0002160486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037124008,0.0015890495,0.0032295543,0.0026843615,0.00068601256,0.003803036,0.0013503953,0.0045688064,0.0039141304],"category_scores_gemma":[0.00609621,0.0004721887,0.00077206385,0.004458551,0.0019775643,0.0062743784,0.0015461242,0.0053235656,0.0016717615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040806836,0.000070395385,0.00030969185,0.016926873,0.00026370454,0.0003223329,0.00019566996,0.00065132725,0.0007321369,0.019927533,0.19955036,0.760642],"study_design_scores_gemma":[0.00010584294,0.000058243022,0.0004153933,0.007174137,0.00016552824,0.00048441126,0.00019853219,0.00013946852,0.000084733074,0.00855489,0.9825921,0.000026740265],"about_ca_topic_score_codex":0.0023864238,"about_ca_topic_score_gemma":0.007519853,"teacher_disagreement_score":0.0045688064,"about_ca_system_score_codex":0.0028807714,"about_ca_system_score_gemma":0.0030210556,"threshold_uncertainty_score":0.020901501},"labels":[],"label_agreement":null},{"id":"W2047034979","doi":"10.1097/01.mp.0000038462.62634.b1","title":"The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma In Situ to Invasive Carcinoma of the Breast","year":2002,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Ductal carcinoma; Pathology; Invasive ductal carcinoma; In situ; HER2/neu; Carcinoma in situ; Medicine; Breast carcinoma; Immunohistochemistry; Carcinoma; Biology; Breast cancer; Internal medicine; Cancer; Chemistry","score_opus":0.03184448073635069,"score_gpt":0.3110719908158152,"score_spread":0.2792275100794645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047034979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979715,0.001185378,0.00014971312,0.000021321597,0.0000033927572,0.000009176368,0.00003085756,0.000005702939,0.00062292686],"genre_scores_gemma":[0.9987276,0.00073831936,0.00021121655,0.000012836363,0.00001918945,0.000008528099,0.00008145586,0.0000022668614,0.00019863316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994867,0.00020528462,0.00005063074,0.000050955292,0.00012619761,0.00008023628],"domain_scores_gemma":[0.9983215,0.0007156252,0.00052576966,0.00008035917,0.00020143423,0.00015531259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011905291,0.00024326392,0.00017857533,0.0012050442,0.00028105674,0.0006169043,0.0002922818,0.0002561947,0.0008361541],"category_scores_gemma":[0.0028945534,0.0003054124,0.00013195488,0.000620527,0.00049913855,0.00041174737,0.00027254486,0.00023088416,0.00023369332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004909579,0.00008249404,0.97043467,0.00007371004,0.00002968664,0.0019802726,0.00029280753,0.00019655358,0.010792827,0.000063457795,0.00014907101,0.015413425],"study_design_scores_gemma":[0.00001283078,0.00017347641,0.98918205,0.000016197211,0.000030278532,0.0071285446,0.00027476618,0.0004706915,0.0021203745,0.000095704876,0.000484799,0.000010294582],"about_ca_topic_score_codex":0.0013731675,"about_ca_topic_score_gemma":0.001745477,"teacher_disagreement_score":0.0013731675,"about_ca_system_score_codex":0.00029353146,"about_ca_system_score_gemma":0.0002463202,"threshold_uncertainty_score":0.0062962174},"labels":[],"label_agreement":null},{"id":"W2047065833","doi":"10.1073/pnas.1302553110","title":"iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; National Institutes of Health; Alexander von Humboldt-Stiftung","keywords":"Ectodomain; Cell biology; Disintegrin; Biology; Receptor; Metalloproteinase; Chemistry; Matrix metalloproteinase; Biochemistry","score_opus":0.06677136800725088,"score_gpt":0.37229593489883434,"score_spread":0.30552456689158347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047065833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593204,0.0008414928,0.0010188571,0.00008984127,0.00003206534,0.000017880475,0.0005397104,0.000109032815,0.0014191628],"genre_scores_gemma":[0.99621445,0.00037524986,0.00074073847,0.0000485945,0.0000106670095,0.000031181582,0.0006068942,0.000051782325,0.0019203128],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997577,0.00004034119,0.00003334647,0.000062605905,0.000044545086,0.000061386614],"domain_scores_gemma":[0.99971837,0.0000411971,0.000089426336,0.000040129486,0.000018349574,0.00009259824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019684988,0.0002836764,0.0003007898,0.00022741297,0.0001980193,0.0004926928,0.00027959267,0.00034043373,0.0027039677],"category_scores_gemma":[0.0001644664,0.00025507767,0.00028071232,0.00013706759,0.0002929005,0.00024523406,0.00038679285,0.0006086827,0.00084791833],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001734636,0.000023014856,0.0002072165,0.000025816129,0.0000032718892,0.00007085107,0.000010710825,0.00002773782,0.9989642,0.00005517908,0.00004522963,0.0003932621],"study_design_scores_gemma":[0.000030420424,0.00012098591,0.0062381527,0.000005489629,0.000012405094,0.00036796572,0.00004063151,0.0006661175,0.9900006,0.000032976906,0.0024769043,0.0000072784887],"about_ca_topic_score_codex":0.0003143028,"about_ca_topic_score_gemma":0.00040277792,"teacher_disagreement_score":0.0027039677,"about_ca_system_score_codex":0.00024228019,"about_ca_system_score_gemma":0.00014668058,"threshold_uncertainty_score":0.0090456605},"labels":[],"label_agreement":null},{"id":"W2047560376","doi":"10.1074/jbc.m800073200","title":"ErbB4-Neuregulin Signaling Modulates Synapse Development and Dendritic Arborization through Distinct Mechanisms","year":2008,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Mental Health","keywords":"ERBB4; Neuregulin 1; Receptor tyrosine kinase; Cell biology; Synapse; Excitatory synapse; Glutamatergic; Biology; Neuroscience; Postsynaptic potential; Neuregulin; Excitatory postsynaptic potential; Inhibitory postsynaptic potential; Signal transduction; Chemistry; Receptor; Glutamate receptor; Biochemistry","score_opus":0.06885269894920246,"score_gpt":0.3139734565449161,"score_spread":0.24512075759571364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047560376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971597,0.00092114107,0.00061948947,0.000030320658,0.0000048529473,0.00000656942,0.00008002856,0.00002229135,0.001155567],"genre_scores_gemma":[0.99703026,0.0008749303,0.000525188,0.000013957525,0.000002252424,0.000010418392,0.00009003533,0.000004074706,0.0014488114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988127,0.000021555956,0.000007047495,0.000018027242,0.000030141991,0.000042004947],"domain_scores_gemma":[0.9999614,0.0000043959203,0.000014019747,0.0000037235816,0.000005436111,0.000011008308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009469359,0.00033619953,0.00019053699,0.00019826359,0.00013708026,0.0002784355,0.00015872745,0.0002202705,0.0008448831],"category_scores_gemma":[0.00010199011,0.00011528967,0.0001644308,0.00012295436,0.00018112427,0.00018950336,0.00026060155,0.0002721764,0.00020920378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007952612,0.000014926877,0.0007629045,0.000019675255,0.000007925411,0.00005362298,0.000008539767,0.00008238976,0.9970419,0.000109860084,0.000013042109,0.001805646],"study_design_scores_gemma":[0.000033560733,0.00026184216,0.071498245,0.000008513349,0.000057615103,0.0005178115,0.00007037251,0.0017144128,0.9240278,0.00023458868,0.001566885,0.000008401135],"about_ca_topic_score_codex":0.00073411444,"about_ca_topic_score_gemma":0.0014510716,"teacher_disagreement_score":0.0008448831,"about_ca_system_score_codex":0.0004359347,"about_ca_system_score_gemma":0.00018336537,"threshold_uncertainty_score":0.0031629205},"labels":[],"label_agreement":null},{"id":"W2048180653","doi":"10.1007/s00702-013-1091-0","title":"NRG3 gene is associated with the risk and age at onset of Alzheimer disease","year":2013,"lang":"en","type":"article","venue":"Journal of Neural Transmission","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health","keywords":"Single-nucleotide polymorphism; Haplotype; Biology; SNP; Genetics; Alzheimer's disease; Gene; Disease; Allele; Genotype; Medicine; Internal medicine","score_opus":0.049461132406249324,"score_gpt":0.3302373574795915,"score_spread":0.28077622507334216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048180653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759066,0.0005474752,0.00036584874,0.00016118292,0.00003541536,0.000005306018,0.00033714547,0.000020421505,0.0009365799],"genre_scores_gemma":[0.9983444,0.00017782989,0.00022367534,0.000040045565,0.000023592998,0.000004540287,0.00017742992,0.00001210301,0.0009963901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997564,0.00007018484,0.000034705532,0.00006411254,0.000037016496,0.000037538513],"domain_scores_gemma":[0.9991185,0.00026550065,0.0003218314,0.00006967331,0.00006930928,0.00015518199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035032953,0.0005464598,0.00044465833,0.0006998505,0.00048854866,0.00045530396,0.0004583382,0.0008725022,0.0046422556],"category_scores_gemma":[0.0013583759,0.00028419777,0.0011012245,0.0009017053,0.0003571366,0.0002826373,0.00023545326,0.00086867687,0.00046878099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004862062,0.00026601154,0.93689096,0.00007966674,0.0006846554,0.007398168,0.00037282705,0.00028988515,0.03952089,0.00049372914,0.0006389122,0.008502203],"study_design_scores_gemma":[0.00004451815,0.00017754505,0.98917353,0.00002180336,0.0003195229,0.0063056583,0.00015875774,0.00086688786,0.0015784191,0.0004248395,0.0009086896,0.000019818155],"about_ca_topic_score_codex":0.003742829,"about_ca_topic_score_gemma":0.0021615596,"teacher_disagreement_score":0.0046422556,"about_ca_system_score_codex":0.0002395964,"about_ca_system_score_gemma":0.0002749211,"threshold_uncertainty_score":0.015529871},"labels":[],"label_agreement":null},{"id":"W2048250189","doi":"10.1007/s10549-011-1840-4","title":"Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial","year":2011,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; BC Cancer Agency; University of British Columbia; McMaster University; Queen's University; St. Michael's Hospital; Hamilton Health Sciences; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Gene duplication; Oncology; Internal medicine; Anthracycline; Medicine; Breast cancer; Biology; Chromosome; Genetics; Cancer; Gene","score_opus":0.4511763596314084,"score_gpt":0.5504747129697497,"score_spread":0.0992983533383413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048250189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95131314,0.040230174,0.0002814685,0.0022453964,0.00033023293,0.00015790925,0.0017911961,0.000037571277,0.0036128159],"genre_scores_gemma":[0.988064,0.007169996,0.0003500365,0.0010875078,0.0003728224,0.00012304277,0.0016361875,0.000012155843,0.0011842628],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9989932,0.0007129918,0.000056082805,0.000103410915,0.00007162326,0.00006267298],"domain_scores_gemma":[0.9946684,0.0032495302,0.0011174208,0.00028017152,0.00017494753,0.00050951034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023525984,0.00060018105,0.0014855921,0.00021195144,0.00023926835,0.00064791983,0.00054760923,0.00091530196,0.0035798247],"category_scores_gemma":[0.006312247,0.00018983702,0.0013433485,0.00046321427,0.00043280862,0.00053795124,0.0002852714,0.0018117082,0.0003511186],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7811393,0.00125256,0.08892507,0.0021886893,0.015427615,0.00022501883,0.00014278588,0.0019934631,0.0023509993,0.00051905925,0.0072603063,0.09857525],"study_design_scores_gemma":[0.3404046,0.07358587,0.5114152,0.0016959541,0.04492896,0.0009373235,0.00022925378,0.0039143297,0.0021017175,0.0020371787,0.018639613,0.00010992454],"about_ca_topic_score_codex":0.0017287353,"about_ca_topic_score_gemma":0.0038649184,"teacher_disagreement_score":0.0035798247,"about_ca_system_score_codex":0.00045200833,"about_ca_system_score_gemma":0.0006179205,"threshold_uncertainty_score":0.012441874},"labels":[],"label_agreement":null},{"id":"W2048272960","doi":"10.1016/j.bbrc.2004.11.053","title":"ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter","year":2004,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Susan G. Komen; Susan G. Komen for the Cure; U.S. Department of Defense","keywords":"VEGF receptors; Core (optical fiber); Cell biology; Chemistry; Promoter; Molecular biology; Cancer research; Biology; Gene; Biochemistry; Gene expression; Computer science; Telecommunications","score_opus":0.15905167231891118,"score_gpt":0.443353538389809,"score_spread":0.2843018660708978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048272960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317074,0.0013488474,0.0022345893,0.0001487412,0.000041457297,0.00002177171,0.00031344756,0.00010864976,0.0026117954],"genre_scores_gemma":[0.99464697,0.0005319086,0.0013907827,0.000055269695,0.000012487443,0.000021185411,0.00045125387,0.000023261679,0.0028669112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983263,0.000027003522,0.000012385676,0.00002209418,0.000036457346,0.00006941679],"domain_scores_gemma":[0.99987614,0.000027321794,0.000024766987,0.000018796718,0.000015668966,0.00003727658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019273808,0.0003040174,0.00019786038,0.00024961683,0.000129766,0.00034299167,0.00012415738,0.00018653605,0.0010077107],"category_scores_gemma":[0.00013548991,0.00016717974,0.00026400693,0.0001812948,0.0001790616,0.00021310283,0.00027703738,0.0005537582,0.00037891793],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011855112,0.000023016839,0.00011093355,0.0000093726,0.0000015776386,0.0000178289,0.0000076106826,0.000036958514,0.99897504,0.00010852045,0.00003783052,0.0005528344],"study_design_scores_gemma":[0.0000125835595,0.00012210388,0.0017025371,0.000002629101,0.0000055798114,0.000073842595,0.000016213533,0.00063824106,0.9960129,0.000041971125,0.0013695757,0.0000018274458],"about_ca_topic_score_codex":0.0013401634,"about_ca_topic_score_gemma":0.0017186514,"teacher_disagreement_score":0.0013401634,"about_ca_system_score_codex":0.0006805255,"about_ca_system_score_gemma":0.0003064601,"threshold_uncertainty_score":0.0049375296},"labels":[],"label_agreement":null},{"id":"W2048623699","doi":"10.1186/1471-2407-9-433","title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","year":2009,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Eli Lilly Canada; Michael Smith Health Research BC; Sanofi; BC Cancer Agency; Eli Lilly and Company","keywords":"Trastuzumab; Medicine; Mucinous carcinoma; Oncology; Carboplatin; Mucinous Tumor; Surgical oncology; Ovarian cancer; Chemotherapy; Internal medicine; Targeted therapy; Paclitaxel; Immunohistochemistry; Cancer; Pathology; Adenocarcinoma; Breast cancer; Cisplatin","score_opus":0.06060265793451496,"score_gpt":0.3509393049700187,"score_spread":0.2903366470355037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048623699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99896014,0.000564879,0.00016656805,0.00002002284,8.282956e-7,0.000004655323,0.000016199627,0.000006564576,0.00026004028],"genre_scores_gemma":[0.99951386,0.00024471313,0.00013457214,0.000008393275,0.000004206717,0.0000031122509,0.000038003887,0.0000011978605,0.00005209662],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999835,0.000031543277,0.000015614398,0.000018665545,0.000058670626,0.000040537183],"domain_scores_gemma":[0.99950826,0.0001236695,0.00025555093,0.000033557,0.00003697535,0.00004197018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035391687,0.00016741217,0.00021753987,0.00039316365,0.00014578874,0.00020838914,0.00015970804,0.00017726817,0.00061165006],"category_scores_gemma":[0.0012139815,0.00011086567,0.00013587209,0.0003171095,0.00021824247,0.00015083986,0.00019496719,0.00015950107,0.00011071502],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005056358,0.000046772257,0.87548006,0.000090976566,0.000056103105,0.0066598714,0.00020479414,0.00031202027,0.07735056,0.00007157517,0.00020389867,0.039017793],"study_design_scores_gemma":[0.00003413129,0.0005308498,0.91122746,0.00002121454,0.00010881829,0.061136093,0.00023834856,0.0008073454,0.023547774,0.00018329413,0.002157908,0.000006734888],"about_ca_topic_score_codex":0.00050769415,"about_ca_topic_score_gemma":0.00078111887,"teacher_disagreement_score":0.00061165006,"about_ca_system_score_codex":0.00017202563,"about_ca_system_score_gemma":0.00012557008,"threshold_uncertainty_score":0.0020462275},"labels":[],"label_agreement":null},{"id":"W2048686497","doi":"10.1200/jco.2003.12.109","title":"Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":296,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Pharmacokinetics; Internal medicine; Adverse effect; Oncology; Metastatic breast cancer; Pharmacology; Breast cancer; Cancer","score_opus":0.17231465087547926,"score_gpt":0.5133159105305432,"score_spread":0.3410012596550639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048686497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985166,0.00073780306,0.00029535728,0.00003614428,0.000009674838,0.00006122354,0.000024203027,0.000024453833,0.000294493],"genre_scores_gemma":[0.9988776,0.000250128,0.00035648863,0.000042407366,0.00002134112,0.00008006688,0.000105748564,0.000009411793,0.00025681555],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99969244,0.00014305244,0.000013223621,0.00004353343,0.000060688777,0.00004706045],"domain_scores_gemma":[0.99965787,0.00009150613,0.000114697694,0.000025321144,0.000016639366,0.00009395465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041224697,0.00035073824,0.00058830733,0.0002302721,0.00016903415,0.00038046823,0.00033209415,0.00029203613,0.00060548563],"category_scores_gemma":[0.0009250679,0.0002558061,0.00025778363,0.00023137649,0.00034570857,0.0002124042,0.00008848491,0.00076559465,0.00023035161],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2122714,0.025487177,0.053499516,0.0003100711,0.0005864855,0.00079724524,0.0004591885,0.009196633,0.3696864,0.00016657785,0.0016036229,0.3259357],"study_design_scores_gemma":[0.101295196,0.56414336,0.17695454,0.00009805046,0.00083456305,0.0036415735,0.00018646676,0.020451732,0.123860024,0.00033479606,0.008104836,0.00009490444],"about_ca_topic_score_codex":0.00042292173,"about_ca_topic_score_gemma":0.00047052716,"teacher_disagreement_score":0.00060548563,"about_ca_system_score_codex":0.00043120605,"about_ca_system_score_gemma":0.00041480674,"threshold_uncertainty_score":0.0031286478},"labels":[],"label_agreement":null},{"id":"W2048798052","doi":"10.1097/00006231-200505000-00006","title":"Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments","year":2005,"lang":"en","type":"article","venue":"Nuclear Medicine Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; University Health Network","funders":"","keywords":"Trastuzumab; Biodistribution; HER2/neu; Antibody; Breast cancer; Medicine; Chemistry; Molecular biology; Cancer; Internal medicine; Immunology; Biology; Biochemistry; In vitro","score_opus":0.08266441590882018,"score_gpt":0.43228369902485714,"score_spread":0.34961928311603696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048798052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845685,0.0030151631,0.005126963,0.00013239202,0.000019988473,0.000053398602,0.00043728514,0.00022890152,0.0025291063],"genre_scores_gemma":[0.982928,0.0028598013,0.008146097,0.000081028345,0.000015962842,0.00007587513,0.00071927067,0.000060065573,0.0051139146],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987817,0.000021854958,0.000005528508,0.000032186406,0.000030230622,0.00003206652],"domain_scores_gemma":[0.99994814,0.000008810092,0.000017161965,0.000005188351,0.000007897918,0.000012871676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022411914,0.00054496905,0.000292189,0.00029388402,0.00010113717,0.00028583276,0.00026203014,0.00042888822,0.0012485493],"category_scores_gemma":[0.00007425241,0.00021783667,0.00019175594,0.00018369978,0.00021524885,0.000204926,0.00014280407,0.0004097229,0.00033563047],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009129241,0.000010422147,0.00007019981,0.000018598847,0.0000032094588,0.000019279723,0.0000063881603,0.000062232684,0.99929094,0.000022798868,0.000022122636,0.00038243327],"study_design_scores_gemma":[0.000025789623,0.00043800884,0.0019902496,0.0000050457893,0.00002401101,0.0002742111,0.000010218196,0.0010842338,0.99488825,0.000015466007,0.0012415115,0.0000031751365],"about_ca_topic_score_codex":0.0013738686,"about_ca_topic_score_gemma":0.0011092452,"teacher_disagreement_score":0.0013738686,"about_ca_system_score_codex":0.00041701176,"about_ca_system_score_gemma":0.00017085616,"threshold_uncertainty_score":0.0041767955},"labels":[],"label_agreement":null},{"id":"W2048901403","doi":"10.1016/j.nucmedbio.2009.05.003","title":"In vivo monitoring of intranuclear p27kip1 protein expression in breast cancer cells during trastuzumab (Herceptin) therapy","year":2009,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Cancer Research UK","keywords":"Trastuzumab; SKBR3; In vivo; Chemistry; Molecular biology; Cancer research; Antibody; Monoclonal antibody; Cancer cell; Breast cancer; Cancer; Biology; Medicine; Immunology; Internal medicine; Human breast","score_opus":0.046645326687403066,"score_gpt":0.3696165900322034,"score_spread":0.3229712633448003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048901403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872477,0.0018838008,0.0049881227,0.00012711466,0.00004662785,0.00003099196,0.0004512726,0.000097417585,0.0036498255],"genre_scores_gemma":[0.99194443,0.00072219013,0.0026826528,0.000040065865,0.000012210591,0.000053116626,0.00037412383,0.000027377162,0.0041439612],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998721,0.000022679653,0.0000064049277,0.000029185696,0.000035447505,0.000034202887],"domain_scores_gemma":[0.99988425,0.000042153475,0.000019130586,0.000015103882,0.000022198305,0.000017224027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019501423,0.00022091978,0.00036875537,0.00017243867,0.0003189216,0.00038736736,0.00021596528,0.0003501781,0.0010389448],"category_scores_gemma":[0.00015183499,0.000162561,0.00015701499,0.0003181745,0.00027821524,0.00032404327,0.00017615226,0.0005782132,0.00031177944],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034174972,0.000047034955,0.00031577187,0.000025134828,0.0000057780344,0.00004619248,0.000055873825,0.00016433572,0.9977435,0.000087406486,0.000047669833,0.0011196805],"study_design_scores_gemma":[0.000027417682,0.00027538976,0.006344601,0.000002278906,0.000015387763,0.00010834022,0.00008407311,0.0023597234,0.98981804,0.000056988145,0.0009036531,0.000004200217],"about_ca_topic_score_codex":0.0029958654,"about_ca_topic_score_gemma":0.0028007845,"teacher_disagreement_score":0.0029958654,"about_ca_system_score_codex":0.00051110855,"about_ca_system_score_gemma":0.00027679343,"threshold_uncertainty_score":0.005956888},"labels":[],"label_agreement":null},{"id":"W2049479627","doi":"10.1200/jco.2003.11.038","title":"<i>neu</i>/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Citation; Breast cancer; Oncology; Hormonal therapy; Clinical Oncology; Internal medicine; Cancer; Adjuvant; Clinical trial; Adjuvant therapy; Gynecology; Library science","score_opus":0.12406823849787108,"score_gpt":0.49276206234913544,"score_spread":0.36869382385126437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049479627","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6015967,0.3022018,0.00057834183,0.025373278,0.0020184775,0.00024036868,0.0037059775,0.000053604046,0.064231485],"genre_scores_gemma":[0.91010666,0.06841139,0.00056782743,0.0028767383,0.0018883822,0.00012707638,0.0021059758,0.000022685495,0.013893226],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998136,0.00008389513,0.000011631506,0.000015938827,0.0000480064,0.000026847374],"domain_scores_gemma":[0.99918383,0.0003871386,0.00020407735,0.000028854201,0.00008496354,0.00011121767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008055934,0.00015537995,0.00037902486,0.00052621344,0.00016058977,0.0007694139,0.0001698031,0.0003719518,0.009345523],"category_scores_gemma":[0.0023294883,0.0001374322,0.0002132018,0.0006578135,0.00028870386,0.0003851872,0.00028690195,0.0005003308,0.0010195912],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056113843,0.00025603359,0.6233775,0.0007166878,0.00027952253,0.00071175606,0.00031728894,0.00031058342,0.0029629478,0.0006809336,0.092106335,0.27266893],"study_design_scores_gemma":[0.00015725814,0.00039799383,0.9726537,0.0005531729,0.000169179,0.0012693218,0.00032688724,0.00032813224,0.0004523231,0.000544114,0.02313484,0.000013236598],"about_ca_topic_score_codex":0.001656004,"about_ca_topic_score_gemma":0.0032402987,"teacher_disagreement_score":0.009345523,"about_ca_system_score_codex":0.0003831495,"about_ca_system_score_gemma":0.00039378894,"threshold_uncertainty_score":0.031263888},"labels":[],"label_agreement":null},{"id":"W2049589423","doi":"10.1007/s12609-013-0121-0","title":"Novel Therapies for Metastatic HER2 Positive Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Current Breast Cancer Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Lapatinib; Metastatic breast cancer; Docetaxel; Oncology; Trastuzumab emtansine; Internal medicine; Breast cancer; Cancer","score_opus":0.06508384817084498,"score_gpt":0.4015346760583286,"score_spread":0.3364508278874836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049589423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10189801,0.8318316,0.004890043,0.009965878,0.002695958,0.0002685702,0.00056964805,0.0002652249,0.04761514],"genre_scores_gemma":[0.35635367,0.58495957,0.006494881,0.0048170784,0.002359536,0.00037936456,0.0011782101,0.00006518112,0.043392565],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999137,0.000018845547,0.0000058806245,0.000013649189,0.000023177874,0.00002480872],"domain_scores_gemma":[0.9999343,0.00002125793,0.000015514504,0.0000052421683,0.000010350166,0.000013287532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032545291,0.0004174419,0.00062835624,0.0005512964,0.0002446607,0.00063508836,0.0005187997,0.0004747253,0.00911819],"category_scores_gemma":[0.0002127875,0.00012858342,0.0005129781,0.0003584973,0.0002822089,0.0007980281,0.0003861497,0.0012646135,0.0014936045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012906252,0.0011393785,0.0008304692,0.0021135362,0.0001583354,0.00081767153,0.00014529425,0.00069261127,0.06063717,0.0066564917,0.020743813,0.90477455],"study_design_scores_gemma":[0.003374144,0.009875502,0.008939257,0.0014114719,0.00073882594,0.006530257,0.00033708586,0.0018828126,0.050076902,0.008979895,0.90778846,0.00006538017],"about_ca_topic_score_codex":0.00025833034,"about_ca_topic_score_gemma":0.0016391682,"teacher_disagreement_score":0.00911819,"about_ca_system_score_codex":0.000433398,"about_ca_system_score_gemma":0.00025605818,"threshold_uncertainty_score":0.030503392},"labels":[],"label_agreement":null},{"id":"W2049693836","doi":"10.1007/s12020-011-9524-8","title":"Cross-talk and modulation of signaling between somatostatin and growth factor receptors","year":2011,"lang":"en","type":"review","venue":"Endocrine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"G protein-coupled receptor; Signal transduction; Biology; Receptor; Receptor tyrosine kinase; Cell biology; Rhodopsin-like receptors; Somatostatin receptor; Growth factor receptor; Epidermal growth factor; Epidermal growth factor receptor; Metabotropic receptor; Genetics","score_opus":0.13315848609970424,"score_gpt":0.4335789883210327,"score_spread":0.30042050222132843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049693836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035160064,0.9984138,0.00016278792,0.00013978367,0.00010060197,0.000003684028,0.000016826023,0.0000051239053,0.0008057485],"genre_scores_gemma":[0.0012801277,0.9976803,0.0002062045,0.00012405381,0.00011541823,0.000005433915,0.000032845102,9.006113e-7,0.0005546445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984276,0.000024647594,0.000020102896,0.000028358603,0.000062266095,0.000021848931],"domain_scores_gemma":[0.9998579,0.000070146656,0.000026330597,0.000005252061,0.000027232772,0.000013148014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004913852,0.0008703202,0.001428547,0.0014599249,0.00014884926,0.0008886669,0.00079557486,0.0008032187,0.002131513],"category_scores_gemma":[0.00043116068,0.00025661784,0.00036969746,0.0016738487,0.00038986508,0.0010378174,0.0005599964,0.0011422853,0.0014816469],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015894516,0.00008598974,0.0002501701,0.010684032,0.00014926078,0.00046391884,0.000046340938,0.0004745475,0.013428745,0.0028044737,0.01300254,0.95845115],"study_design_scores_gemma":[0.00005352914,0.0002050888,0.0024764303,0.0022472825,0.00024966508,0.002339626,0.00010204097,0.00021470443,0.004503195,0.0025354763,0.9850364,0.000036657093],"about_ca_topic_score_codex":0.0005180274,"about_ca_topic_score_gemma":0.0011230535,"teacher_disagreement_score":0.002131513,"about_ca_system_score_codex":0.00051902083,"about_ca_system_score_gemma":0.0005105024,"threshold_uncertainty_score":0.007130623},"labels":[],"label_agreement":null},{"id":"W2049978627","doi":"10.1097/jto.0b013e31817c6094","title":"Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"University of Toronto","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Univariate analysis; Immunohistochemistry; Radiation therapy; Internal medicine; Oncology; Cancer; MAPK/ERK pathway; Prospective cohort study; Epidermal growth factor; Pathology; Cancer research; Receptor; Kinase; Biology; Multivariate analysis","score_opus":0.016138289761563358,"score_gpt":0.3563431171994241,"score_spread":0.34020482743786074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049978627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990357,0.00041739794,0.00003512377,0.000057433834,0.000009536077,0.0000020533448,0.000102905404,0.0000034605896,0.00033639802],"genre_scores_gemma":[0.99967194,0.00007387366,0.000014061504,0.000018452783,0.000011254805,0.0000019413474,0.00009453281,9.714437e-7,0.000113100075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998666,0.00003436746,0.00001444279,0.000026534051,0.000021687649,0.000036317],"domain_scores_gemma":[0.9992611,0.00024212124,0.00025215937,0.00003439214,0.00006106565,0.00014914182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023157246,0.0001672885,0.00035972823,0.00040923886,0.00029491071,0.00042593738,0.0002305177,0.0004508802,0.0014347661],"category_scores_gemma":[0.001193555,0.00015339907,0.00045018233,0.00068014907,0.0002542713,0.00034827276,0.00018569666,0.00053683564,0.00015032467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011836074,0.00004567913,0.9956007,0.000012238196,0.00008824865,0.00019996302,0.00004252179,0.00012038566,0.0009496327,0.0000128542715,0.00009161131,0.0016525451],"study_design_scores_gemma":[0.000022565519,0.00028188355,0.9986425,0.0000027561382,0.00009014791,0.00041978882,0.00007346945,0.00021540209,0.0001144305,0.000022088178,0.000111056754,0.0000039007846],"about_ca_topic_score_codex":0.0022340105,"about_ca_topic_score_gemma":0.0027869097,"teacher_disagreement_score":0.0022340105,"about_ca_system_score_codex":0.0003036854,"about_ca_system_score_gemma":0.0002816976,"threshold_uncertainty_score":0.004799783},"labels":[],"label_agreement":null},{"id":"W2051210210","doi":"10.1007/s10585-006-9034-x","title":"Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents","year":2006,"lang":"en","type":"article","venue":"Clinical & Experimental Metastasis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; NOSM University; University of Calgary; Lakehead University; Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Bone marrow; Medicine; Chemotherapy; Cisplatin; Paclitaxel; Chemosensitivity assay; Cancer; Cancer cell; Ascites; Doxorubicin; Pleural effusion; Peripheral blood mononuclear cell; Hematology; Cancer research; Internal medicine; Oncology; Pathology; Biology; In vitro","score_opus":0.0984071611901411,"score_gpt":0.46769499226900446,"score_spread":0.36928783107886337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051210210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995249,0.0012813723,0.0017699876,0.00009433201,0.00003298732,0.000037086415,0.0002716266,0.00003839478,0.0012252812],"genre_scores_gemma":[0.99708635,0.00029425265,0.00059945503,0.000047453435,0.00002129911,0.000033720582,0.00047921768,0.000009807954,0.0014285241],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99966335,0.0001258359,0.000023893319,0.000052170493,0.000059423386,0.000075354255],"domain_scores_gemma":[0.9997471,0.000113477116,0.000025754025,0.00004428593,0.000030128982,0.000039190807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035795057,0.0001589804,0.00026571675,0.00019758796,0.00020307349,0.0003372882,0.00031188322,0.0003221084,0.0053231763],"category_scores_gemma":[0.0005236025,0.00013362832,0.00016492196,0.00013991196,0.0002017255,0.00016349713,0.00020710914,0.0005927348,0.00068330765],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019088576,0.00031029357,0.0013248222,0.000060221973,0.000021569986,0.0002686927,0.00009514293,0.00015014807,0.99016273,0.00069204427,0.00030327938,0.004702162],"study_design_scores_gemma":[0.00039762107,0.0056866356,0.024930788,0.000025062429,0.00007673726,0.006593672,0.0003988963,0.002110859,0.950389,0.0008624763,0.008508213,0.000019984902],"about_ca_topic_score_codex":0.00043233176,"about_ca_topic_score_gemma":0.0004467555,"teacher_disagreement_score":0.0053231763,"about_ca_system_score_codex":0.00015258694,"about_ca_system_score_gemma":0.00019067348,"threshold_uncertainty_score":0.017807782},"labels":[],"label_agreement":null},{"id":"W2051827896","doi":"10.1158/0008-5472.sabcs11-ot1-02-02","title":"OT1-02-02: HALT MBC: HER2 Suppression with the Addition of Lapatinib to Trastuzumab in HER2−Positive Metastatic Breast Cancer (LPT112515).","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lapatinib; Trastuzumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Discontinuation; Paclitaxel; Cancer; Chemotherapy","score_opus":0.13753868251921628,"score_gpt":0.4509132527718353,"score_spread":0.31337457025261906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051827896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99425226,0.0015386257,0.0001837685,0.0003868575,0.00012251106,0.00090235693,0.00073525944,0.00008230361,0.0017960244],"genre_scores_gemma":[0.99162465,0.0013547102,0.0006774113,0.00038050118,0.000119409866,0.0009835688,0.0017191765,0.000017980083,0.0031225486],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99977976,0.000069570844,0.000015537484,0.000032715157,0.000026516393,0.00007602426],"domain_scores_gemma":[0.99978703,0.000025897982,0.000044588807,0.000016382137,0.000009838788,0.00011619827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000664146,0.0007947486,0.001216191,0.00033168218,0.00025007204,0.00068122364,0.0007555226,0.00089586695,0.0048867664],"category_scores_gemma":[0.0003629778,0.0002914712,0.00067205715,0.0003636658,0.00066288974,0.0005857953,0.00027322888,0.0022147254,0.00065409666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52518934,0.08593714,0.0054801367,0.0016606387,0.0008003297,0.0007575354,0.00024248425,0.002264278,0.19899316,0.001030583,0.008163336,0.16948108],"study_design_scores_gemma":[0.3317225,0.6190565,0.01238678,0.000075587115,0.00048368302,0.00074958574,0.0000750648,0.0014272189,0.027329683,0.00021941125,0.006433781,0.000040291216],"about_ca_topic_score_codex":0.0011972067,"about_ca_topic_score_gemma":0.0030518784,"teacher_disagreement_score":0.0048867664,"about_ca_system_score_codex":0.0006228609,"about_ca_system_score_gemma":0.0011168699,"threshold_uncertainty_score":0.016347885},"labels":[],"label_agreement":null},{"id":"W2052080762","doi":"10.1158/0008-5472.sabcs12-p5-18-08","title":"Abstract P5-18-08: Identification of ErbB2 function in the heart: implication for anti-ErbB2 therapy in breast cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Trastuzumab; Cardiotoxicity; Medicine; Cancer; Breast cancer; Cardiac function curve; Heart development; Pressure overload; Receptor tyrosine kinase; Lapatinib; Internal medicine; Endocrinology; Heart failure; Receptor; Biology; Chemotherapy; Embryonic stem cell","score_opus":0.2143064985937281,"score_gpt":0.5200085182150096,"score_spread":0.3057020196212815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052080762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8780256,0.060684945,0.014723735,0.0044473,0.00066242524,0.00045174704,0.01212878,0.00048547264,0.028390054],"genre_scores_gemma":[0.9341555,0.022970362,0.010056602,0.0010460557,0.0002271194,0.0002993425,0.009575863,0.00007297856,0.021596124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998882,0.000016650582,0.0000074440795,0.00001658173,0.000039751598,0.000031525826],"domain_scores_gemma":[0.9999249,0.000010147838,0.000014900517,0.0000063330094,0.000019311135,0.00002443392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028209834,0.00027329402,0.0002930589,0.0003013317,0.00018008258,0.00047884014,0.00023630787,0.00038303828,0.004547083],"category_scores_gemma":[0.00011972843,0.000098941164,0.00023579046,0.0003089401,0.00013817514,0.00019516713,0.00017505886,0.0006050728,0.0013672346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008356776,0.00020335609,0.0028991273,0.0003682252,0.000020539705,0.00032854988,0.000027842585,0.00023448012,0.9521734,0.00086904585,0.003411324,0.03862847],"study_design_scores_gemma":[0.00021007631,0.0022961386,0.06149754,0.00012415381,0.0001342469,0.003268847,0.00015607495,0.0027910168,0.8284228,0.00072226994,0.100357115,0.000019864288],"about_ca_topic_score_codex":0.00047145964,"about_ca_topic_score_gemma":0.00046781317,"teacher_disagreement_score":0.004547083,"about_ca_system_score_codex":0.0004313175,"about_ca_system_score_gemma":0.00037797232,"threshold_uncertainty_score":0.015211523},"labels":[],"label_agreement":null},{"id":"W2052249651","doi":"10.1016/j.ctrv.2014.08.003","title":"Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis","year":2014,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Receptor tyrosine kinase; Odds ratio; Oncology; Breast cancer; Internal medicine; Meta-analysis; Confidence interval; Cancer; Fibroblast growth factor receptor; Epidermal growth factor receptor; Receptor; Tyrosine kinase; Cancer research; Fibroblast growth factor","score_opus":0.23622312007243446,"score_gpt":0.4790153302447197,"score_spread":0.24279221017228525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052249651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005772183,0.99283147,0.00040959058,0.00016072542,0.00013278889,0.000031026684,0.0004432081,0.000016562737,0.00020242963],"genre_scores_gemma":[0.21486993,0.78077614,0.0014688743,0.0009007891,0.00033232287,0.00013508984,0.0009629485,0.00003321337,0.00052074],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99702185,0.0013091157,0.00065153756,0.0005076462,0.00035859403,0.0001512482],"domain_scores_gemma":[0.99563533,0.0030966713,0.00067158893,0.0001945522,0.00030665967,0.00009523367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047710566,0.001860496,0.008444816,0.0023371475,0.00026730463,0.0014912892,0.0011909611,0.0011309254,0.0030683414],"category_scores_gemma":[0.00819343,0.000971093,0.022008162,0.004363834,0.0003236913,0.0010129575,0.0010223965,0.0015299997,0.0002991491],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031238159,0.00003339678,0.013955356,0.12006411,0.8325856,0.00015744612,0.000061284416,0.00093147065,0.00050438906,0.00016447957,0.0019255424,0.026493056],"study_design_scores_gemma":[0.00045708395,0.00013181366,0.008700934,0.004538458,0.98301214,0.00009601508,0.00003454216,0.00018697121,0.00010510585,0.00023433761,0.0024774978,0.00002505109],"about_ca_topic_score_codex":0.004331718,"about_ca_topic_score_gemma":0.011577805,"teacher_disagreement_score":0.008444816,"about_ca_system_score_codex":0.0010243806,"about_ca_system_score_gemma":0.0012804039,"threshold_uncertainty_score":0.025232017},"labels":[],"label_agreement":null},{"id":"W2052627379","doi":"10.4236/jct.2012.36149","title":"Breast Cancer Therapies Present and Future","year":2012,"lang":"en","type":"article","venue":"Journal of Cancer Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Langara College; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Disease; Metastatic breast cancer; Anticipation (artificial intelligence); Acknowledgement; Oncology; Cancer; Metastasis; Internal medicine","score_opus":0.043276471542809336,"score_gpt":0.40893733565084156,"score_spread":0.3656608641080322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052627379","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017701341,0.8900732,0.0021729958,0.06988296,0.004262455,0.000032443502,0.00015531751,0.000121801124,0.03152865],"genre_scores_gemma":[0.02086676,0.9135242,0.0057822154,0.021863619,0.0073114685,0.00010685771,0.00027678083,0.00005041241,0.030217653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993742,0.00016602052,0.00004894484,0.00008709665,0.0002099779,0.00011368312],"domain_scores_gemma":[0.9989324,0.00035569977,0.00009969688,0.000068031666,0.00025766005,0.00028651388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028103776,0.0005358022,0.0006687951,0.0008980835,0.00061570125,0.0028210054,0.00076152757,0.0030059617,0.019629123],"category_scores_gemma":[0.0016541115,0.00023363273,0.00057271874,0.0005402417,0.0012283752,0.0038690341,0.001068549,0.0034659225,0.005202073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002574895,0.0003019128,0.0004383768,0.0016403215,0.000030517847,0.00035392694,0.00019643508,0.0005068215,0.0038651987,0.04777515,0.12846178,0.8161721],"study_design_scores_gemma":[0.0000285386,0.00021139118,0.00034619932,0.0009116824,0.000021137897,0.0007591511,0.00016437873,0.000263309,0.00054695277,0.011839766,0.98489225,0.000015138506],"about_ca_topic_score_codex":0.00079973025,"about_ca_topic_score_gemma":0.0028139092,"teacher_disagreement_score":0.019629123,"about_ca_system_score_codex":0.0016721745,"about_ca_system_score_gemma":0.0025283042,"threshold_uncertainty_score":0.06566596},"labels":[],"label_agreement":null},{"id":"W2052707876","doi":"10.1158/0008-5472.sabcs13-p1-08-09","title":"Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Adjuvant; Cancer; Pathological; Randomized controlled trial","score_opus":0.13457686107845843,"score_gpt":0.4477739577996906,"score_spread":0.3131970967212322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052707876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377644,0.0009664034,0.0002342225,0.0006726003,0.00007244501,0.00023890981,0.0007346024,0.00003329886,0.0032709674],"genre_scores_gemma":[0.99439186,0.00028941856,0.00037268622,0.0008696118,0.000105660816,0.0002575323,0.0015157335,0.000016639107,0.0021808832],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.999676,0.0001666561,0.000023205715,0.00005765674,0.000046624216,0.000029835484],"domain_scores_gemma":[0.999286,0.00020582516,0.00019551934,0.00006523434,0.000045788875,0.00020175736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011532524,0.00042720383,0.000792745,0.00012466477,0.0001302952,0.0006093802,0.00024531918,0.00055353553,0.0026230873],"category_scores_gemma":[0.0008660863,0.00012108437,0.0005574774,0.00012242416,0.00040959346,0.00048981135,0.00027789158,0.0012112637,0.0003505778],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8414803,0.0046407217,0.037427645,0.00069154566,0.0016112473,0.00023738715,0.00012942766,0.0018036701,0.053206094,0.00052940135,0.007131671,0.051110834],"study_design_scores_gemma":[0.4157046,0.24303657,0.28840142,0.00018926211,0.003494561,0.0016340866,0.00016505294,0.006864439,0.020330561,0.0021814548,0.017880082,0.000117821866],"about_ca_topic_score_codex":0.000135376,"about_ca_topic_score_gemma":0.0005707091,"teacher_disagreement_score":0.0026230873,"about_ca_system_score_codex":0.0003088591,"about_ca_system_score_gemma":0.00029868344,"threshold_uncertainty_score":0.008775055},"labels":[],"label_agreement":null},{"id":"W2052815331","doi":"10.1016/s0140-6736(09)62069-9","title":"Challenging the dogma on trastuzumab: a matter of the heart","year":2010,"lang":"en","type":"letter","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Regimen; Chemotherapy; Clinical endpoint; Neoadjuvant therapy; Hazard ratio; Chemotherapy regimen; Cancer; Clinical trial","score_opus":0.07993825610166451,"score_gpt":0.3581730562135883,"score_spread":0.2782348001119238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052815331","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008147566,0.0025914425,0.00004944402,0.9877435,0.008882831,0.000002046911,0.000009706891,0.0000056944273,0.00063395355],"genre_scores_gemma":[0.0015881626,0.0018752933,0.00014053658,0.95142806,0.043353956,0.000011146505,0.000008470761,0.000015486079,0.001578864],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9871443,0.005132222,0.0010189746,0.0015558471,0.0039241174,0.0012245256],"domain_scores_gemma":[0.9530826,0.033070054,0.0016988547,0.001073094,0.0050168387,0.0060584787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0143405,0.0013658941,0.0036198879,0.0010401134,0.006400803,0.009194506,0.0034780884,0.11723174,0.010199662],"category_scores_gemma":[0.062155303,0.0010561283,0.0015863472,0.0011335814,0.011958855,0.014953715,0.0042473045,0.102124535,0.0074643805],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001375794,0.000048677262,0.0002729692,0.00012053957,0.00004244751,0.00070716813,0.00015867564,0.00006825095,0.00018282747,0.010338712,0.97636783,0.011554353],"study_design_scores_gemma":[0.00039772096,0.00010575808,0.00056059303,0.0006919806,0.00006607987,0.0009859086,0.0007902505,0.0004501623,0.00020143084,0.055163827,0.9404625,0.00012373514],"about_ca_topic_score_codex":0.0045433673,"about_ca_topic_score_gemma":0.009494924,"teacher_disagreement_score":0.11723174,"about_ca_system_score_codex":0.007658536,"about_ca_system_score_gemma":0.007172952,"threshold_uncertainty_score":0.07584077},"labels":[],"label_agreement":null},{"id":"W2052953726","doi":"10.1158/1538-7445.am2013-lb-63","title":"Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab emtansine; Lapatinib; Medicine; Trastuzumab; Hazard ratio; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Cancer; Antibody-drug conjugate; Progression-free survival; Capecitabine; Proportional hazards model; Chemotherapy; Antibody; Confidence interval; Monoclonal antibody; Immunology","score_opus":0.15458355897690865,"score_gpt":0.48886552015526247,"score_spread":0.33428196117835385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052953726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99392265,0.0025197791,0.00030533673,0.0003003519,0.000034331944,0.0005177677,0.0006859814,0.00006668585,0.001647008],"genre_scores_gemma":[0.9942543,0.00085117505,0.0007628491,0.00060361496,0.0000931139,0.00044678073,0.0015057626,0.000018140503,0.0014642602],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9995059,0.0002759442,0.000031144842,0.000057015543,0.000060486385,0.000069542635],"domain_scores_gemma":[0.9991032,0.00020285904,0.0002635182,0.000058214722,0.000050699335,0.00032148414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020573393,0.00085944624,0.0010917599,0.0005056368,0.0002102354,0.0006705377,0.0006951089,0.0008751633,0.0020822207],"category_scores_gemma":[0.0012171633,0.00030301558,0.00078414794,0.00045239128,0.00044959888,0.0004259883,0.00032757837,0.0021482878,0.0005992948],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64675117,0.050720245,0.04365137,0.0009974008,0.0028495868,0.00026810024,0.00022586944,0.002895142,0.07736951,0.00018251038,0.004417274,0.16967179],"study_design_scores_gemma":[0.2128488,0.59117216,0.16882321,0.00008948328,0.0021212532,0.00048792167,0.00006499358,0.0027969154,0.017117653,0.00012719473,0.004287526,0.00006282068],"about_ca_topic_score_codex":0.00057835545,"about_ca_topic_score_gemma":0.0014525861,"teacher_disagreement_score":0.0020822207,"about_ca_system_score_codex":0.00068361347,"about_ca_system_score_gemma":0.0006121099,"threshold_uncertainty_score":0.010880411},"labels":[],"label_agreement":null},{"id":"W2053128405","doi":"10.1007/s00044-014-1237-0","title":"A review of new approaches in Her-2 targeting and 1H MRI application","year":2014,"lang":"en","type":"review","venue":"Medicinal Chemistry Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Breast cancer; Trastuzumab; Magnetic resonance imaging; Biomarker; Cancer research; Cancer; Chemistry; Medical physics; Medicine; Radiology; Internal medicine; Biochemistry","score_opus":0.3666462089674463,"score_gpt":0.5315942859567334,"score_spread":0.1649480769892871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053128405","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003176646,0.9970162,0.0006925486,0.00016012392,0.00015740872,0.000011062426,0.00003859299,0.000018208477,0.0015882255],"genre_scores_gemma":[0.0013166294,0.9967933,0.00069859374,0.00019104427,0.00013372382,0.000010328533,0.00004161319,0.0000025866163,0.00081207365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986696,0.000019153953,0.000018759047,0.000029047624,0.000049573002,0.000016550568],"domain_scores_gemma":[0.9998271,0.0000895231,0.000030259911,0.0000059495806,0.000034444292,0.000012741228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044805475,0.00083392335,0.001223366,0.002447919,0.00025635742,0.0007125051,0.00080527674,0.0007628498,0.0032482692],"category_scores_gemma":[0.00050437945,0.0004397991,0.00056697376,0.002327747,0.00036842978,0.00121835,0.00047270575,0.0013993931,0.0015794097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010935442,0.00016168736,0.00014408941,0.02715291,0.00010009483,0.00032484587,0.00006220366,0.00063701463,0.014436183,0.0033644512,0.024102964,0.9294042],"study_design_scores_gemma":[0.000033868586,0.00029395262,0.0010165782,0.002284393,0.00021602357,0.0022930505,0.00005267918,0.00042260162,0.00709466,0.002133853,0.9841037,0.000054706474],"about_ca_topic_score_codex":0.00074953894,"about_ca_topic_score_gemma":0.0015848684,"teacher_disagreement_score":0.0032482692,"about_ca_system_score_codex":0.00046425196,"about_ca_system_score_gemma":0.0006995208,"threshold_uncertainty_score":0.010866582},"labels":[],"label_agreement":null},{"id":"W2053311062","doi":"10.1158/0008-5472.sabcs-09-5044","title":"Prospective Evaluation of Joint Symptoms in Postmenopausal Women Initiating Aromatase Inhibitors for Early Stage Breast Cancer.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Brief Pain Inventory; Grip strength; Internal medicine; Discontinuation; Joint pain; Physical therapy; Cancer; Stage (stratigraphy); Chronic pain","score_opus":0.13473932912777978,"score_gpt":0.48232960110874196,"score_spread":0.34759027198096215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053311062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982126,0.0006875324,0.00004274021,0.00002208962,0.00000649438,0.000068060224,0.0005625716,0.0000045544875,0.00039331906],"genre_scores_gemma":[0.9987956,0.00018790817,0.00009924878,0.000030994695,0.000011068417,0.000055017506,0.00054953794,0.0000011157307,0.00026949684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99964654,0.00011950551,0.00003958562,0.000051016785,0.000086602,0.000056774286],"domain_scores_gemma":[0.9991315,0.00010961826,0.00034880143,0.00003798102,0.00014626357,0.00022583533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008428307,0.0003542232,0.00042089488,0.00049327995,0.00041557496,0.0003783321,0.00018614535,0.00037803358,0.0010102469],"category_scores_gemma":[0.0014532917,0.00025269552,0.0003913161,0.00065854774,0.00013583283,0.00023548762,0.00025772737,0.00045758844,0.00030530003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009631915,0.00018422845,0.9960129,0.00002921544,0.00004541876,0.0001208489,0.00004824894,0.000018960205,0.00045906767,0.00000251385,0.00008431714,0.0020311181],"study_design_scores_gemma":[0.000055548277,0.0012506275,0.99807906,0.0000043364116,0.00003629985,0.0002578879,0.00004922506,0.000028735516,0.00007553679,0.000003094953,0.00015695515,0.0000026521457],"about_ca_topic_score_codex":0.0020932984,"about_ca_topic_score_gemma":0.0036406121,"teacher_disagreement_score":0.0020932984,"about_ca_system_score_codex":0.00023670182,"about_ca_system_score_gemma":0.00033279776,"threshold_uncertainty_score":0.0044573545},"labels":[],"label_agreement":null},{"id":"W2053744053","doi":"10.1016/j.yexcr.2008.10.034","title":"ErbB receptors and cell polarity: New pathways and paradigms for understanding cell migration and invasion","year":2008,"lang":"en","type":"review","venue":"Experimental Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Biology; ErbB; Receptor tyrosine kinase; Signal transduction; Cell polarity; Cell migration; Carcinogenesis; Cell biology; Cancer research; Cell; Cancer; Genetics","score_opus":0.46247054392137305,"score_gpt":0.4763953289026991,"score_spread":0.013924784981326044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053744053","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008720309,0.9970197,0.0004285006,0.000737325,0.0004254345,0.0000041757407,0.000015188435,0.000011620881,0.0012708417],"genre_scores_gemma":[0.00044028024,0.99784684,0.00035789065,0.00035850488,0.00032228028,0.0000071200243,0.000021842363,0.0000014392512,0.00064376136],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997973,0.000034084573,0.000020698968,0.000033346612,0.00009356125,0.00002104786],"domain_scores_gemma":[0.999521,0.0002538381,0.000036883583,0.000017144035,0.00012504488,0.00004609085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010418231,0.0012762509,0.0019241926,0.0020655105,0.0003844315,0.001465288,0.0014024255,0.0019701885,0.0030614515],"category_scores_gemma":[0.00082239305,0.00034617985,0.0004901448,0.0028791025,0.0014572187,0.0027816868,0.0008052901,0.003332834,0.0023969077],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105116815,0.00008265173,0.00014861528,0.007509355,0.00006931841,0.00025902086,0.00008395082,0.00050255243,0.0033857098,0.013468625,0.06229451,0.91209066],"study_design_scores_gemma":[0.000023554898,0.000039442664,0.0003399726,0.0010118736,0.000055404053,0.0008027812,0.000087639164,0.00008334021,0.00054811995,0.005429425,0.99155843,0.000020135527],"about_ca_topic_score_codex":0.001224094,"about_ca_topic_score_gemma":0.0022759961,"teacher_disagreement_score":0.0030614515,"about_ca_system_score_codex":0.0012221856,"about_ca_system_score_gemma":0.001327913,"threshold_uncertainty_score":0.010241568},"labels":[],"label_agreement":null},{"id":"W2054350484","doi":"10.1007/s10549-013-2490-5","title":"MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using 111In-labeled bispecific radioimmunoconjugates","year":2013,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Cancer research; Chimera (genetics); Pathology; Biology; Gene","score_opus":0.0593012011594051,"score_gpt":0.39596892794450966,"score_spread":0.3366677267851046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054350484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94607556,0.0029369295,0.04023004,0.00040424013,0.00007622619,0.00023220966,0.0014495286,0.0005139918,0.008081253],"genre_scores_gemma":[0.94473296,0.0016979594,0.04033718,0.00018151112,0.000038546932,0.0002554844,0.0017508788,0.00030608234,0.010699388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998005,0.000042197324,0.000008680333,0.00004923971,0.00004038927,0.00005892446],"domain_scores_gemma":[0.99983144,0.000059050326,0.00003597028,0.00002059319,0.000020615966,0.00003229082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006137825,0.00070213224,0.0004024442,0.00055965415,0.0002834736,0.00037464293,0.0005083961,0.0006609569,0.0019714797],"category_scores_gemma":[0.00016476086,0.00040060957,0.00033374203,0.0003484647,0.00034997237,0.0005572546,0.00024778084,0.0012853972,0.00037954916],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000355364,0.00005842011,0.00012834561,0.00003792442,0.000009072836,0.000077772536,0.000026642225,0.00041199697,0.9976265,0.00023838328,0.00013474796,0.00089495577],"study_design_scores_gemma":[0.000070434915,0.00036327893,0.002479068,0.000005799741,0.00003405097,0.00041658277,0.00003358232,0.0072141653,0.9880434,0.000059250066,0.0012712409,0.000009093868],"about_ca_topic_score_codex":0.005274625,"about_ca_topic_score_gemma":0.004339008,"teacher_disagreement_score":0.005274625,"about_ca_system_score_codex":0.0006149283,"about_ca_system_score_gemma":0.0005410162,"threshold_uncertainty_score":0.0104878545},"labels":[],"label_agreement":null},{"id":"W2054706573","doi":"10.2967/jnumed.109.062224","title":"Micro-SPECT/CT with <sup>111</sup>In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated <i>HER2</i> Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts","year":2009,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Pertuzumab; Trastuzumab; Biodistribution; Chemistry; Molecular biology; In vivo; Downregulation and upregulation; Pathology; Nuclear medicine; Medicine; In vitro; Breast cancer; Cancer; Internal medicine; Biochemistry; Biology","score_opus":0.015957895086321016,"score_gpt":0.29818524253828493,"score_spread":0.28222734745196393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054706573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98076874,0.0040453174,0.0102138985,0.00019408313,0.000023315786,0.00005920872,0.00057929644,0.00053363165,0.0035825414],"genre_scores_gemma":[0.9810823,0.0022921404,0.011357745,0.00010318813,0.000026374913,0.000079210244,0.0011646835,0.00007351526,0.0038207185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987054,0.00002250647,0.0000057369853,0.000028913215,0.00003288383,0.000039424704],"domain_scores_gemma":[0.9999105,0.000018440242,0.00002950218,0.0000059796803,0.000013625657,0.000021896554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020578047,0.0005281206,0.00039417803,0.00032817823,0.00011650523,0.00038236298,0.00034946375,0.00044856998,0.0020291063],"category_scores_gemma":[0.00014073928,0.00024916694,0.00016546555,0.00022387525,0.0003864165,0.0002249618,0.00014566854,0.00054519606,0.0005291934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001466845,0.000011952971,0.00026052364,0.000017023076,0.0000036614986,0.000026030297,0.0000041656576,0.000056653236,0.9988689,0.000013391047,0.000045907327,0.00054515555],"study_design_scores_gemma":[0.00002263189,0.00034399008,0.0077220206,0.0000037460843,0.000028232858,0.0005406553,0.000014039251,0.0016217384,0.98881847,0.000015021352,0.00086426333,0.000005100406],"about_ca_topic_score_codex":0.001964696,"about_ca_topic_score_gemma":0.0018167115,"teacher_disagreement_score":0.0020291063,"about_ca_system_score_codex":0.0005612589,"about_ca_system_score_gemma":0.00021538968,"threshold_uncertainty_score":0.006788075},"labels":[],"label_agreement":null},{"id":"W2055235037","doi":"10.1016/s1470-2045(13)70411-x","title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Oncology; Population; Pertuzumab; Cyclophosphamide; Chemotherapy; Surgery; Clinical trial; Cancer","score_opus":0.18881223491172663,"score_gpt":0.5311267806640083,"score_spread":0.3423145457522817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055235037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94517523,0.0059107,0.0024976595,0.0027175054,0.0015644614,0.027366683,0.005631763,0.0005317992,0.008604182],"genre_scores_gemma":[0.93205345,0.004234921,0.005419084,0.0034954364,0.0006994734,0.037912846,0.004591351,0.00012980014,0.0114637185],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99866354,0.00080989726,0.000059445305,0.00017827291,0.00007525535,0.00021368242],"domain_scores_gemma":[0.9986437,0.00037212597,0.00024558112,0.00013117035,0.000058187004,0.0005492497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029027532,0.003012743,0.0034662588,0.0005485357,0.0006642403,0.0016182269,0.0012148017,0.0026382843,0.01573076],"category_scores_gemma":[0.0027742933,0.0011239573,0.0029714718,0.0006260817,0.0021110415,0.001891475,0.0008813391,0.005380075,0.0026269173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9881521,0.0025604384,0.00015912876,0.00040016908,0.00038142182,0.000018289069,0.0000370339,0.00031367215,0.0008986545,0.00008954766,0.00088542904,0.006104088],"study_design_scores_gemma":[0.9770733,0.021685317,0.0003179987,0.000021340313,0.00012735515,0.000013334738,0.000010169137,0.0001528336,0.00009225088,0.00013733601,0.00036003435,0.0000087557],"about_ca_topic_score_codex":0.0016455866,"about_ca_topic_score_gemma":0.0035874883,"teacher_disagreement_score":0.01573076,"about_ca_system_score_codex":0.0015047853,"about_ca_system_score_gemma":0.0023893644,"threshold_uncertainty_score":0.052624643},"labels":[],"label_agreement":null},{"id":"W2055644704","doi":"10.1016/j.jss.2008.11.232","title":"192. HER-3 Expression Shows Prognostic Utility for Breast Cancer Survival: A Study of 4046 Patients","year":2009,"lang":"en","type":"article","venue":"Journal of Surgical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Breast cancer; Medicine; Oncology; Cancer; Internal medicine; Protein expression; Breast carcinoma; Bioinformatics; Biology; Gene; Genetics","score_opus":0.25494562783494623,"score_gpt":0.5222534090486812,"score_spread":0.267307781213735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055644704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99869543,0.00036233163,0.00006243551,0.000025768308,0.000004544509,0.000006031433,0.0005150247,0.000002517135,0.000325946],"genre_scores_gemma":[0.99828786,0.00016901195,0.000054026317,0.00004112905,0.00001824927,0.000010685613,0.0010440989,0.0000035116375,0.0003714042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99966276,0.00007729185,0.00003206059,0.000112547714,0.000039724408,0.00007564524],"domain_scores_gemma":[0.99944466,0.00017389758,0.00013599795,0.000087476736,0.00005059743,0.00010733687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045233007,0.00033616717,0.0005730677,0.00045938935,0.00070964306,0.00063082454,0.0002524764,0.000417,0.0021645227],"category_scores_gemma":[0.0009906872,0.0004207198,0.00045571255,0.0010416926,0.00052571815,0.0003992614,0.00030843803,0.00042041752,0.0007581291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002743238,0.00009756507,0.9900629,0.000018740047,0.00017302655,0.00040461644,0.00021411557,0.00010745266,0.0019847555,0.00002910826,0.00025227922,0.0039121513],"study_design_scores_gemma":[0.00014959148,0.0007296975,0.99512863,0.000006559691,0.00018175573,0.0016761465,0.00023250103,0.00015625736,0.0005202383,0.00004617144,0.001159498,0.000012955295],"about_ca_topic_score_codex":0.0025318868,"about_ca_topic_score_gemma":0.002911673,"teacher_disagreement_score":0.0025318868,"about_ca_system_score_codex":0.00027349524,"about_ca_system_score_gemma":0.00021108321,"threshold_uncertainty_score":0.0072410107},"labels":[],"label_agreement":null},{"id":"W2056264529","doi":"10.1016/j.semradonc.2007.10.006","title":"Tissue Microarrays in Clinical Oncology","year":2008,"lang":"en","type":"review","venue":"Seminars in Radiation Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Tissue microarray; Medicine; Precision oncology; Clinical Oncology; Biomarker; Oncology; Molecular biomarkers; Biomarker discovery; Internal medicine; Computational biology; Pathology; Bioinformatics; Immunohistochemistry; Cancer; Proteomics; Biology; Gene","score_opus":0.1738491061078373,"score_gpt":0.5683243816508772,"score_spread":0.39447527554303985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056264529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006458676,0.9959247,0.000563987,0.0008917922,0.0012200949,0.000010479933,0.000025531153,0.000022160664,0.0012767111],"genre_scores_gemma":[0.00064090296,0.99421763,0.00075624284,0.0012461322,0.0010058947,0.000023877856,0.00006912543,0.000004630669,0.0020355885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992878,0.00019602285,0.000089948706,0.000115506446,0.00026010373,0.000050747498],"domain_scores_gemma":[0.9987717,0.00066802994,0.00015260822,0.00007964982,0.0002561888,0.000071709626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001733608,0.0013203783,0.0024203288,0.0037308198,0.00038565238,0.0016028495,0.0016149168,0.0020191013,0.008064783],"category_scores_gemma":[0.0028672607,0.0006394105,0.0005554169,0.0038102583,0.0011552266,0.0031984202,0.0015810318,0.0023047503,0.0059319716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053960866,0.00003488091,0.00015891108,0.008825986,0.00005410912,0.00022417922,0.000040060022,0.00017037163,0.002170822,0.0032588593,0.09801708,0.8869908],"study_design_scores_gemma":[0.000016534947,0.000049353355,0.0005508144,0.0025954233,0.00008672835,0.0016835185,0.000046821344,0.000072354036,0.00063479564,0.0019764542,0.992273,0.0000142179015],"about_ca_topic_score_codex":0.0008565623,"about_ca_topic_score_gemma":0.0017549477,"teacher_disagreement_score":0.008064783,"about_ca_system_score_codex":0.0011433286,"about_ca_system_score_gemma":0.0015949704,"threshold_uncertainty_score":0.026979387},"labels":[],"label_agreement":null},{"id":"W2056274073","doi":"10.1093/annonc/mdt081.2","title":"Trastuzumab Beyond Progression for Metastatic HER2+ Breast Cancer (MBC): Survival Outcomes in a Canadian Population","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; Dalhousie University","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Cohort; Oncology; Population; Cancer; Hazard ratio; Breast cancer; Surgery; Confidence interval","score_opus":0.13781537271264574,"score_gpt":0.5099880635076068,"score_spread":0.37217269079496107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056274073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925229,0.0012833076,0.000045957047,0.0010327637,0.000017699462,0.000022447008,0.0021100512,0.0000067748583,0.0029581196],"genre_scores_gemma":[0.99638295,0.0011773474,0.00007561409,0.00025613533,0.000019135601,0.000009303313,0.0012015227,0.0000051078296,0.0008729151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993461,0.000028660806,0.000022680953,0.00009881073,0.0001443751,0.0003593837],"domain_scores_gemma":[0.9990858,0.000036380014,0.0001677157,0.000022698068,0.00034939422,0.0003380063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043666415,0.0004366756,0.00047080015,0.00082842604,0.0027598224,0.0012973469,0.0010451783,0.0007335788,0.0024195611],"category_scores_gemma":[0.0013405476,0.00028446506,0.0008285689,0.00312455,0.00065198645,0.00053804484,0.0006541955,0.0011611616,0.0002469563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005462013,0.00014360771,0.98310953,0.00004603015,0.00009111788,0.00049577537,0.00090884906,0.00028208934,0.00047749278,0.00040224305,0.002714813,0.01078229],"study_design_scores_gemma":[0.00006822612,0.00017353203,0.9938259,0.00004255251,0.00010567523,0.0004885231,0.0020100018,0.00043585777,0.00007552318,0.00014072821,0.0025994095,0.00003407842],"about_ca_topic_score_codex":0.98399734,"about_ca_topic_score_gemma":0.9860217,"teacher_disagreement_score":0.026692381,"about_ca_system_score_codex":0.026692381,"about_ca_system_score_gemma":0.029823605,"threshold_uncertainty_score":0.19366771},"labels":[],"label_agreement":null},{"id":"W2056793446","doi":"10.1038/labinvest.3780396","title":"EGFR and ErbB2 Differentially Regulate Raf-1 Translocation and Activation","year":2002,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre","funders":"","keywords":"Endocytosis; SKBR3; Epidermal growth factor; ERBB3; Transfection; Cell biology; Epidermal growth factor receptor; Signal transduction; Biology; Cell surface receptor; Receptor; Cancer research; Cell culture; Chemistry; Cancer cell; Receptor tyrosine kinase; Cancer; Biochemistry","score_opus":0.039409676281349414,"score_gpt":0.2768893961973752,"score_spread":0.23747971991602576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056793446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924499,0.0016301743,0.0016011919,0.00021668887,0.00003673742,0.00002288419,0.0002182131,0.000062724896,0.0037615276],"genre_scores_gemma":[0.99292976,0.000525274,0.0009004084,0.000052020503,0.000018313933,0.00004544727,0.00036986166,0.000020035235,0.00513892],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99963725,0.00006847112,0.000012778086,0.000038141334,0.00005726992,0.00018600686],"domain_scores_gemma":[0.9998646,0.00004302545,0.000018676477,0.000016541677,0.000020803805,0.000036294558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026470658,0.00032650738,0.00021326034,0.00050279323,0.00041446407,0.0007172778,0.00031402605,0.0003712927,0.0040535103],"category_scores_gemma":[0.00040020436,0.00027252178,0.0003290275,0.00025009757,0.00034503045,0.00054894073,0.0003835239,0.00071597646,0.00092549995],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080841465,0.000066678534,0.00030027798,0.000019094141,0.0000041892367,0.00008132304,0.00004027449,0.000039708637,0.9961307,0.0007012244,0.00010929727,0.0016987944],"study_design_scores_gemma":[0.00009279235,0.00023886577,0.017455257,0.0000046644036,0.000015376094,0.00067074376,0.00017627762,0.0010388975,0.9767171,0.00041711942,0.0031630665,0.000009838043],"about_ca_topic_score_codex":0.0006641146,"about_ca_topic_score_gemma":0.0011071317,"teacher_disagreement_score":0.0040535103,"about_ca_system_score_codex":0.0006637859,"about_ca_system_score_gemma":0.00025447234,"threshold_uncertainty_score":0.013560295},"labels":[],"label_agreement":null},{"id":"W2057194480","doi":"10.3747/co.v16i4.469","title":"The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Santé Montérégie; Cancer Care Nova Scotia; Hôpital du Saint-Sacrement; Ottawa Hospital; Health Sciences Centre; University of Alberta; University of Toronto; Université de Sherbrooke; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Ottawa","funders":"","keywords":"Trastuzumab; Medicine; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Targeted therapy; Pertuzumab; Clinical trial; Adjuvant; Cancer; Disease","score_opus":0.07348489514262137,"score_gpt":0.4417653748954514,"score_spread":0.36828047975283007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057194480","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002075776,0.90708,0.0004218311,0.07949701,0.0015577186,0.000029250177,0.000116910145,0.000025955873,0.009195524],"genre_scores_gemma":[0.038843192,0.93213093,0.0018800133,0.020799479,0.0034478465,0.000041933883,0.00015214476,0.000021065904,0.002683423],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987564,0.000544538,0.00010755776,0.000099873716,0.00038557645,0.0001061767],"domain_scores_gemma":[0.99710506,0.0013433011,0.0004253233,0.00005824898,0.00071725756,0.00035083803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034668664,0.00025051017,0.00082445855,0.0008061581,0.0006678311,0.0013437637,0.00080411695,0.001213648,0.0026103773],"category_scores_gemma":[0.007338803,0.00013622534,0.00057124026,0.001147723,0.0010279533,0.0010281472,0.00080485473,0.002380856,0.00058926415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004959219,0.00006015813,0.005569072,0.0031275775,0.000096444914,0.00045007488,0.00041630561,0.0001978421,0.0007646039,0.0032086847,0.08458602,0.90102726],"study_design_scores_gemma":[0.00014098386,0.00039634964,0.013960226,0.006900141,0.0003162504,0.0015523472,0.0006300278,0.00016685645,0.00066064886,0.0041489066,0.97108096,0.00004637397],"about_ca_topic_score_codex":0.02786,"about_ca_topic_score_gemma":0.07975039,"teacher_disagreement_score":0.02786,"about_ca_system_score_codex":0.0031558701,"about_ca_system_score_gemma":0.007085635,"threshold_uncertainty_score":0.055395663},"labels":[],"label_agreement":null},{"id":"W2057655573","doi":"10.1093/ajh/hpu094","title":"Vascular Induction of a Disintegrin and Metalloprotease 17 by Angiotensin II Through Hypoxia Inducible Factor 1α","year":2014,"lang":"en","type":"article","venue":"American Journal of Hypertension","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; American Heart Association","keywords":"Angiotensin II; Metalloproteinase; Renin–angiotensin system; Endocrinology; Disintegrin; Internal medicine; Hypoxia (environmental); Downregulation and upregulation; Medicine; Hypoxia-inducible factors; Vascular smooth muscle; Biology; Matrix metalloproteinase; Receptor; Chemistry; Biochemistry; Gene","score_opus":0.04220785733757095,"score_gpt":0.29871163519001437,"score_spread":0.25650377785244344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057655573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455863,0.0013281181,0.002439333,0.00011839645,0.000046129942,0.000022807902,0.0002052915,0.00006375599,0.0012175188],"genre_scores_gemma":[0.99643135,0.0008622842,0.0013088245,0.0000463685,0.000027968517,0.00002203328,0.00018495276,0.0000075568996,0.0011085942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991417,0.000020011634,0.0000058109686,0.000012487826,0.000019591773,0.000027983984],"domain_scores_gemma":[0.99987745,0.000019303166,0.000042644137,0.0000114215645,0.000012886794,0.00003624183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012220255,0.00021573169,0.00012843784,0.00015583444,0.00007246514,0.00017317651,0.000082068276,0.000114302195,0.0011691923],"category_scores_gemma":[0.00008740684,0.00009327018,0.00020650418,0.000073541174,0.00020519365,0.000120066616,0.00010516179,0.00037583895,0.00019683393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001318471,0.000025680625,0.00045977643,0.000038460075,0.000004990999,0.00013821582,0.000009340675,0.00003288896,0.9982077,0.00009090482,0.00004450971,0.0008157803],"study_design_scores_gemma":[0.00002886458,0.00071495044,0.017997477,0.000009866028,0.00002682228,0.00068128895,0.00004721052,0.0006695314,0.9775917,0.0001239747,0.0021046514,0.0000037016878],"about_ca_topic_score_codex":0.00018461919,"about_ca_topic_score_gemma":0.00025129793,"teacher_disagreement_score":0.0011691923,"about_ca_system_score_codex":0.00017721376,"about_ca_system_score_gemma":0.000120118486,"threshold_uncertainty_score":0.003911376},"labels":[],"label_agreement":null},{"id":"W2058595915","doi":"10.1097/00001813-200112004-00003","title":"Maximizing the response to Herceptin® therapy through optimal use and patient selection","year":2001,"lang":"en","type":"review","venue":"Anti-Cancer Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Immunohistochemistry; Medicine; Concordance; Oncology; Breast cancer; Trastuzumab; Metastatic breast cancer; Internal medicine; Targeted therapy; Cancer; Disease; Fluorescence in situ hybridization; Gene; Biology","score_opus":0.17277203939993846,"score_gpt":0.44606148375622434,"score_spread":0.2732894443562859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058595915","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8035395,0.026602237,0.08432328,0.019638931,0.0006086049,0.004123423,0.0007455393,0.0009129048,0.059505504],"genre_scores_gemma":[0.9490957,0.00675072,0.032510903,0.0041121533,0.0011054389,0.00142533,0.00074579206,0.00013399079,0.004120028],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895006,0.0005360066,0.000107485284,0.00009994187,0.00021140449,0.00009509546],"domain_scores_gemma":[0.99922585,0.00028520208,0.0001581518,0.000055687462,0.0000615182,0.00021356552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022888363,0.00039378705,0.00082597625,0.0006193887,0.0002959749,0.0009022695,0.00033968713,0.0006217992,0.0021591298],"category_scores_gemma":[0.002924737,0.0001525353,0.00044030417,0.00037266983,0.00019195258,0.0006746276,0.00062213984,0.00067690125,0.0010366756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056447024,0.001366627,0.09847193,0.00020807973,0.00011923413,0.0016149502,0.00023135485,0.005994491,0.013935756,0.0015894237,0.01440602,0.8564174],"study_design_scores_gemma":[0.0054702493,0.033283345,0.5262808,0.0013686244,0.0010944082,0.03242407,0.0008624601,0.054508056,0.047603965,0.021182846,0.27555445,0.00036675675],"about_ca_topic_score_codex":0.000108351865,"about_ca_topic_score_gemma":0.00018954926,"teacher_disagreement_score":0.0022888363,"about_ca_system_score_codex":0.0003520026,"about_ca_system_score_gemma":0.00056415156,"threshold_uncertainty_score":0.0121046305},"labels":[],"label_agreement":null},{"id":"W2058901727","doi":"10.1111/j.1524-4733.2009.00511.x","title":"The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial","year":2009,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Economic evaluation; Relative risk; Demography; Cancer; Confidence interval","score_opus":0.057001828599170044,"score_gpt":0.3867357524686461,"score_spread":0.3297339238694761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058901727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854214,0.008491076,0.0010266821,0.00081318425,0.00009683042,0.00013915352,0.0029827934,0.000020426434,0.0010084311],"genre_scores_gemma":[0.9951573,0.0015517096,0.00039725998,0.0002126552,0.0000715797,0.00006435312,0.0022342114,0.000011622914,0.00029932527],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99707365,0.0019322737,0.00017466223,0.00026095446,0.00033095258,0.00022756992],"domain_scores_gemma":[0.99364156,0.0042864396,0.0010633877,0.00040320345,0.00022331935,0.0003821803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047139847,0.0010858818,0.0023831755,0.00079201895,0.00016157153,0.0010380984,0.00084006245,0.00075579045,0.0015920177],"category_scores_gemma":[0.0108664185,0.00047657106,0.0048184586,0.0015725992,0.00043194313,0.0010914973,0.00059496827,0.001679375,0.00013385034],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6099126,0.0012094104,0.18468775,0.0017974471,0.03152993,0.0005804923,0.00015850854,0.0667023,0.002090722,0.0016383495,0.00437638,0.09531613],"study_design_scores_gemma":[0.107314244,0.040452752,0.6192367,0.0005830105,0.09415687,0.0016209973,0.00039981928,0.1176258,0.0027355936,0.006893753,0.0087097725,0.0002707065],"about_ca_topic_score_codex":0.004979358,"about_ca_topic_score_gemma":0.0050679506,"teacher_disagreement_score":0.004979358,"about_ca_system_score_codex":0.001820696,"about_ca_system_score_gemma":0.0009951859,"threshold_uncertainty_score":0.024930239},"labels":[],"label_agreement":null},{"id":"W2059162955","doi":"10.1016/j.ygyno.2005.11.043","title":"Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy","year":2006,"lang":"en","type":"letter","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Cetuximab; Bevacizumab; Oncology; HER2/neu; Internal medicine; Ovarian cancer; Fluorescence in situ hybridization; Targeted therapy; Cancer; Chemotherapy; Colorectal cancer; Breast cancer","score_opus":0.06132552669997006,"score_gpt":0.3740022859081994,"score_spread":0.31267675920822935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059162955","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3808454,0.0072847623,0.002213611,0.5462916,0.012069052,0.0002251181,0.00046068494,0.00017038517,0.050439518],"genre_scores_gemma":[0.79009706,0.005408885,0.0015097639,0.1599659,0.019633187,0.000087219865,0.00040099106,0.000054325046,0.022842724],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99965096,0.00009943471,0.00003669396,0.00004459022,0.000059370424,0.00010892932],"domain_scores_gemma":[0.9991339,0.00045905742,0.00008223542,0.000041255007,0.00004412395,0.00023953346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003820595,0.0004131034,0.0008200067,0.0003049806,0.0014128091,0.0006459767,0.0006432508,0.0099936,0.0020396158],"category_scores_gemma":[0.0033213513,0.00029320928,0.0007990702,0.00032300077,0.00068364275,0.0007156623,0.00044207816,0.0059496677,0.00054036017],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018521501,0.00035231517,0.016496075,0.00013664369,0.00008292777,0.8773333,0.0004506596,0.0009808294,0.0045923064,0.0037405544,0.068290845,0.025691455],"study_design_scores_gemma":[0.0017748099,0.0023913446,0.040941734,0.00028377955,0.00024080198,0.8013628,0.0007678418,0.007637298,0.0041769976,0.010217793,0.13010865,0.00009609934],"about_ca_topic_score_codex":0.0018665307,"about_ca_topic_score_gemma":0.0040182564,"teacher_disagreement_score":0.0099936,"about_ca_system_score_codex":0.0016688084,"about_ca_system_score_gemma":0.00079313864,"threshold_uncertainty_score":0.012108147},"labels":[],"label_agreement":null},{"id":"W2059170159","doi":"10.1002/cncr.22806","title":"Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer","year":2007,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Cost-effectiveness analysis; Internal medicine; Life expectancy; Cost effectiveness; Clinical trial; Quality-adjusted life year; Cancer; Population","score_opus":0.07170571895907751,"score_gpt":0.4652865692052998,"score_spread":0.3935808502462223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059170159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9193371,0.034145404,0.026516981,0.0035714586,0.00026959603,0.0018751081,0.0029574241,0.00013276025,0.011194237],"genre_scores_gemma":[0.9922736,0.0029682948,0.0032495982,0.00016159483,0.000043554257,0.00032648657,0.00043038253,0.00000920144,0.0005372991],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99684143,0.0024768587,0.00010462559,0.000119901226,0.0002807742,0.0001764913],"domain_scores_gemma":[0.9930097,0.005784925,0.00057147455,0.00011407711,0.00030568414,0.000214144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067458395,0.001485213,0.001518044,0.0016780333,0.0002549471,0.0017002772,0.0010041905,0.0010179111,0.0027228415],"category_scores_gemma":[0.016377326,0.00065497524,0.0044210996,0.001205213,0.00043741305,0.0012147693,0.00078484986,0.0014377054,0.00013776796],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016431704,0.0006846678,0.011570661,0.002305195,0.0076091457,0.0004936638,0.00007408627,0.9095266,0.0010419972,0.0054911207,0.0015800083,0.043191154],"study_design_scores_gemma":[0.0046120817,0.005782274,0.01676151,0.0011915321,0.01432865,0.0007094823,0.00014832012,0.9439552,0.001368261,0.0079326015,0.0030768525,0.00013326049],"about_ca_topic_score_codex":0.009999531,"about_ca_topic_score_gemma":0.005994193,"teacher_disagreement_score":0.009999531,"about_ca_system_score_codex":0.007545863,"about_ca_system_score_gemma":0.003782826,"threshold_uncertainty_score":0.05474931},"labels":[],"label_agreement":null},{"id":"W2059715478","doi":"10.1016/j.cell.2012.12.030","title":"Architecture and Membrane Interactions of the EGF Receptor","year":2013,"lang":"en","type":"article","venue":"Cell","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":525,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Howard Hughes Medical Institute","keywords":"Extracellular; Transmembrane protein; Biology; Transmembrane domain; Biophysics; Cell biology; Intracellular; Cell membrane; Kinase; Membrane; Biochemistry; Receptor","score_opus":0.019523464147139107,"score_gpt":0.3043025665013322,"score_spread":0.28477910235419307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059715478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900686,0.0017829299,0.0027800635,0.0002892845,0.000015042408,0.000004322062,0.0000622417,0.000026641535,0.004970926],"genre_scores_gemma":[0.99632865,0.000843374,0.00064808683,0.000053292202,0.000007507507,0.0000028486668,0.00010313607,0.000006922297,0.0020061769],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996066,0.0000076719325,0.0000015873019,0.0000066722255,0.000009113392,0.000014403131],"domain_scores_gemma":[0.99996436,0.000006036142,0.0000070764954,0.0000024288458,0.000009402106,0.000010703262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000061201725,0.00015834092,0.00010033527,0.00018644147,0.00041651138,0.00055581785,0.00025242992,0.00027757196,0.0012039951],"category_scores_gemma":[0.00012973817,0.00014015818,0.00009832398,0.00013874364,0.00021193325,0.000569264,0.00022891775,0.00038586895,0.0004419829],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018709475,0.000022467617,0.0014507358,0.00007043037,0.000012772967,0.00020822046,0.00011325631,0.0012066856,0.9799668,0.011650196,0.00032419912,0.0047871415],"study_design_scores_gemma":[0.000058278725,0.00046244328,0.069384456,0.00009948929,0.00010895255,0.002269836,0.0018947093,0.066312544,0.7987333,0.024526285,0.0360506,0.0000990915],"about_ca_topic_score_codex":0.0013263734,"about_ca_topic_score_gemma":0.0014504914,"teacher_disagreement_score":0.0013263734,"about_ca_system_score_codex":0.00046905872,"about_ca_system_score_gemma":0.00021553616,"threshold_uncertainty_score":0.0040277243},"labels":[],"label_agreement":null},{"id":"W2060062311","doi":"10.3892/or.17.2.465","title":"Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor","year":2007,"lang":"en","type":"article","venue":"Oncology Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Lapatinib; Cancer research; Tyrosine-kinase inhibitor; ErbB; MCF-7; Epidermal growth factor receptor; Cancer; Apoptosis; Biology; Breast cancer; Receptor tyrosine kinase; Cell culture; Kinase; Trastuzumab; Medicine; Internal medicine; Cell biology; Biochemistry","score_opus":0.01930924732753868,"score_gpt":0.3442483565456914,"score_spread":0.3249391092181527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060062311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847552,0.006710289,0.0028755027,0.00020619521,0.00018661704,0.00018248208,0.0005619276,0.0001423368,0.00437929],"genre_scores_gemma":[0.9855009,0.003613842,0.0055652363,0.00012737792,0.00004291024,0.0002151298,0.0009221182,0.000019014064,0.0039934805],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999665,0.00007246843,0.000032440996,0.00004887814,0.00011150344,0.00006966038],"domain_scores_gemma":[0.9999014,0.000025261314,0.000013766545,0.000015508402,0.000017461794,0.000026641064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002626394,0.0006044273,0.0008211765,0.00040163816,0.00014513145,0.00030736043,0.00034964853,0.00028643294,0.0014238484],"category_scores_gemma":[0.00010847096,0.00020758125,0.0005179763,0.00039352063,0.00013358219,0.00023803984,0.0002625946,0.00066096697,0.00035087284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001020025,0.00086340716,0.00045875614,0.0002504289,0.00008906065,0.00010347486,0.000048470043,0.0003900688,0.9856595,0.00018225535,0.00045230414,0.010482242],"study_design_scores_gemma":[0.00021818776,0.0038102572,0.0031120055,0.000013329316,0.00011163768,0.00037659687,0.000034514713,0.0017444771,0.9856241,0.000031121763,0.0049132435,0.000010575687],"about_ca_topic_score_codex":0.000556755,"about_ca_topic_score_gemma":0.0021666463,"teacher_disagreement_score":0.0014238484,"about_ca_system_score_codex":0.00026112658,"about_ca_system_score_gemma":0.00037622056,"threshold_uncertainty_score":0.004763186},"labels":[],"label_agreement":null},{"id":"W2060234566","doi":"10.1158/1538-7445.am2012-770","title":"Abstract 770: Overcoming Trastuzumab resistance with the novel pan-erbb inhibitor AZD8931","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; Jewish General Hospital","funders":"","keywords":"Trastuzumab; SKBR3; Medicine; Cancer research; Breast cancer; Monoclonal antibody; Tyrosine-kinase inhibitor; ErbB; Tyrosine kinase; Cancer; Internal medicine; Oncology; Pharmacology; Antibody; Immunology; Receptor","score_opus":0.14736024053927196,"score_gpt":0.4481766815643935,"score_spread":0.3008164410251215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060234566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817059,0.009062088,0.0020641244,0.00021123684,0.000086246946,0.00013633871,0.00071642624,0.00025761625,0.0057599773],"genre_scores_gemma":[0.98958975,0.004183618,0.001973489,0.00010510744,0.00002684221,0.000044427856,0.0013141433,0.000016302469,0.0027461925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999051,0.00001254508,0.000009723215,0.000017087426,0.000031049163,0.000024514475],"domain_scores_gemma":[0.9999757,0.0000034420723,0.000005935842,0.0000032188334,0.0000050543536,0.0000067420656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010003022,0.00028673213,0.00032008337,0.0001942602,0.00008940524,0.00020892333,0.00034455088,0.00019246555,0.001472709],"category_scores_gemma":[0.00010002765,0.000103086786,0.00012217285,0.00023898858,0.00009764824,0.00016168032,0.00015718711,0.00037285252,0.00062553264],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005754296,0.00027460055,0.0006128613,0.00012299638,0.000026080419,0.00014109486,0.000020300413,0.0008240621,0.9670574,0.00023221096,0.000914573,0.02919843],"study_design_scores_gemma":[0.0005495617,0.00521577,0.01053713,0.000023418721,0.00009044859,0.0014732217,0.00002223758,0.0054065012,0.9578803,0.000096858734,0.018684564,0.000019916917],"about_ca_topic_score_codex":0.0007436448,"about_ca_topic_score_gemma":0.0013850256,"teacher_disagreement_score":0.001472709,"about_ca_system_score_codex":0.00029082247,"about_ca_system_score_gemma":0.00020164915,"threshold_uncertainty_score":0.0049266815},"labels":[],"label_agreement":null},{"id":"W2061961124","doi":"10.3747/co.v17i2.422","title":"One Year of Complete Clinical Response in a Metastatic Breast Cancer Patient Treated with a Combination of Lapatinib and Gemcitabine","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lapatinib; Medicine; Capecitabine; Gemcitabine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Tyrosine-kinase inhibitor; Chemotherapy; Cancer; Combination therapy; Epidermal growth factor receptor; Trastuzumab; Colorectal cancer","score_opus":0.21236500145766643,"score_gpt":0.4999086760678354,"score_spread":0.28754367461016894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061961124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96252453,0.0035928716,0.002984137,0.013461358,0.0007712622,0.00031613276,0.00061624474,0.00021669481,0.015516774],"genre_scores_gemma":[0.9918085,0.0008827953,0.00075416645,0.0025856118,0.00041948294,0.000040920986,0.00029996294,0.000023088742,0.0031854291],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99967194,0.00006046443,0.000034648958,0.000061723935,0.000052330393,0.00011888957],"domain_scores_gemma":[0.99871624,0.00037106161,0.00019102766,0.00008021558,0.00008718585,0.00055430515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003919478,0.0007098896,0.0009945953,0.0008455411,0.0011093566,0.00058282976,0.0007730069,0.0045776237,0.0011592286],"category_scores_gemma":[0.0020257968,0.00039386514,0.0012667303,0.00046687454,0.00063291786,0.00074688223,0.00056818716,0.0036742296,0.0005158746],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058957614,0.00032551566,0.010864559,0.000051994513,0.00004607039,0.9778025,0.00027661378,0.00036531844,0.0022990818,0.00026981413,0.0012982072,0.005810795],"study_design_scores_gemma":[0.00016561241,0.0022183931,0.036156084,0.000034339504,0.00007593352,0.95357066,0.00018923184,0.0015502278,0.0025111283,0.00023588113,0.0032460208,0.000046581445],"about_ca_topic_score_codex":0.0021098566,"about_ca_topic_score_gemma":0.0035864403,"teacher_disagreement_score":0.0045776237,"about_ca_system_score_codex":0.00091206905,"about_ca_system_score_gemma":0.0005158596,"threshold_uncertainty_score":0.006617546},"labels":[],"label_agreement":null},{"id":"W2062151299","doi":"10.1038/onc.2009.312","title":"Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity","year":2009,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McGill University","funders":"National Cancer Institute; U.S. Department of Defense","keywords":"Biology; Cell biology; Apoptosis; Cell growth; MAPK/ERK pathway; Signal transduction; Protein kinase B; Cancer research; Paclitaxel; Gene knockdown; Cancer; Biochemistry; Genetics","score_opus":0.06726552474081585,"score_gpt":0.36744907643768554,"score_spread":0.3001835516968697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062151299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989565,0.0020016723,0.002160962,0.00034700305,0.00008037252,0.000027001235,0.0014899039,0.00019442798,0.0041336124],"genre_scores_gemma":[0.99395037,0.0002843255,0.000775269,0.00008346027,0.000014401572,0.000026740327,0.0016933456,0.000062431165,0.0031096525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99954164,0.00004332022,0.00004098692,0.00006566665,0.00016676231,0.000141577],"domain_scores_gemma":[0.999138,0.00018160572,0.00018616769,0.0001326692,0.0001016005,0.00025999657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027255007,0.00048305272,0.00048481417,0.0007176501,0.00064564124,0.0009210649,0.0005676037,0.00057236623,0.0029317986],"category_scores_gemma":[0.00039389895,0.00045572149,0.00040168202,0.00040557628,0.0007473101,0.00050356326,0.00070266513,0.0010437652,0.0012383879],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001951306,0.0000296335,0.0005325427,0.000030874442,0.000011265835,0.00021419628,0.000009671552,0.00008027214,0.99747807,0.0002576041,0.00016967767,0.0009910131],"study_design_scores_gemma":[0.000039368362,0.000053754473,0.016705185,0.000008210078,0.000019831446,0.0007787012,0.00007232937,0.0019137982,0.97681797,0.00014021335,0.0034386595,0.0000120982],"about_ca_topic_score_codex":0.0031325999,"about_ca_topic_score_gemma":0.004796102,"teacher_disagreement_score":0.0031325999,"about_ca_system_score_codex":0.0011375616,"about_ca_system_score_gemma":0.0008169599,"threshold_uncertainty_score":0.009807885},"labels":[],"label_agreement":null},{"id":"W2063273481","doi":"10.1007/s00702-008-0182-9","title":"Neuregulin 1 and age of onset in the major psychoses","year":2009,"lang":"en","type":"article","venue":"Journal of Neural Transmission","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Centre for Addiction and Mental Health","funders":"Canadian Institutes of Health Research; National Alliance for Research on Schizophrenia and Depression","keywords":"Proband; Haplotype; Schizophrenia (object-oriented programming); Bipolar disorder; Psychosis; Age of onset; Neuregulin 1; Psychiatry; Psychology; Mania; Medicine; Genetics; Allele; Disease; Biology; Internal medicine; Mood; Gene; Mutation","score_opus":0.05868095437224368,"score_gpt":0.39548942485298677,"score_spread":0.3368084704807431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063273481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590224,0.0024341475,0.000045049685,0.000107965054,0.000029686285,0.00000839334,0.00043391425,0.0000059203167,0.0010327018],"genre_scores_gemma":[0.99854857,0.0006709079,0.00003641407,0.00002547232,0.000027808663,0.0000030639965,0.00024534354,0.0000017764925,0.00044055012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99984777,0.000036651934,0.000018894456,0.000025040948,0.000026911917,0.000044608867],"domain_scores_gemma":[0.9984068,0.00031498534,0.0007422348,0.000044114975,0.00008335152,0.00040856897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041237118,0.00035679238,0.0004999042,0.0009921305,0.0004915536,0.0005920895,0.00025411107,0.00058063876,0.002367563],"category_scores_gemma":[0.0024347086,0.0002483267,0.000391464,0.0006497781,0.00018868408,0.00040652035,0.0005132121,0.00086043443,0.0002498897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019625262,0.0001855244,0.9904474,0.00003828162,0.00011123107,0.0009665896,0.00013995837,0.00007221996,0.0019796302,0.000077124336,0.00012511594,0.0038944941],"study_design_scores_gemma":[0.000004559681,0.000111956106,0.9992354,0.000006327074,0.000019168268,0.00035299393,0.00005859821,0.000041473133,0.00005062651,0.000033331144,0.00008209566,0.0000035731505],"about_ca_topic_score_codex":0.0050275787,"about_ca_topic_score_gemma":0.005282564,"teacher_disagreement_score":0.0050275787,"about_ca_system_score_codex":0.0005174606,"about_ca_system_score_gemma":0.00033909484,"threshold_uncertainty_score":0.009996653},"labels":[],"label_agreement":null},{"id":"W2064047759","doi":"10.1016/s1470-2045(10)70297-7","title":"Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Genentech","keywords":"Medicine; Breast cancer; Internal medicine; Discontinuation; Trastuzumab; Oncology; Human Epidermal Growth Factor Receptor 2; Clinical trial; Cancer","score_opus":0.1137773007743218,"score_gpt":0.37204568943079974,"score_spread":0.25826838865647794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064047759","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006514391,0.092991844,0.0007081883,0.8743296,0.019760827,0.000014096206,0.0002958645,0.00005957617,0.0053254925],"genre_scores_gemma":[0.22208169,0.17871623,0.0025888656,0.4758249,0.10541094,0.000055107383,0.0005970495,0.00015019106,0.014575035],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9968274,0.0012350758,0.00047675325,0.00031099338,0.00090758776,0.00024209196],"domain_scores_gemma":[0.9769364,0.011481493,0.0014897807,0.0013407348,0.006356281,0.002395315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039607272,0.00067269476,0.0015081356,0.0013762022,0.0008785005,0.0023070988,0.00087111536,0.0065810527,0.0025590896],"category_scores_gemma":[0.046506446,0.00064318976,0.00070763426,0.0009402722,0.0018264358,0.003645005,0.0013611595,0.010216468,0.001332664],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006772232,0.00007447608,0.021609867,0.00030503815,0.00014114313,0.0015628687,0.00034064337,0.00020022983,0.0005408439,0.0043350756,0.76667327,0.20353922],"study_design_scores_gemma":[0.0009574108,0.00094242545,0.060414895,0.0070728716,0.0006810332,0.020228786,0.0039173714,0.0031323493,0.0018981744,0.05531602,0.844834,0.00060464675],"about_ca_topic_score_codex":0.0037527531,"about_ca_topic_score_gemma":0.0049707447,"teacher_disagreement_score":0.0065810527,"about_ca_system_score_codex":0.0013057585,"about_ca_system_score_gemma":0.0020382002,"threshold_uncertainty_score":0.020946562},"labels":[],"label_agreement":null},{"id":"W2064282349","doi":"10.4137/bcbcr.s6374","title":"Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Breast Cancer Basic and Clinical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Lapatinib; Breast cancer; Medicine; Oncology; Cancer; Internal medicine; Trastuzumab; Adverse effect","score_opus":0.21577710336506944,"score_gpt":0.5485440153192331,"score_spread":0.3327669119541637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064282349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5941808,0.38388035,0.0019297585,0.0021876916,0.0003271733,0.00023970788,0.0006979534,0.0001049393,0.01645165],"genre_scores_gemma":[0.9549543,0.040527187,0.00058207265,0.00083816063,0.00029354126,0.00008019586,0.00045517815,0.000030947464,0.0022382669],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99961627,0.00019661103,0.000036333226,0.0000271141,0.00008988711,0.000033789285],"domain_scores_gemma":[0.99966407,0.00012110292,0.00010618882,0.000016098315,0.000043589193,0.000048924965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009238014,0.00016507473,0.00063597265,0.00019170016,0.00011837626,0.00034893095,0.00019052265,0.00022880384,0.0015353404],"category_scores_gemma":[0.0011156168,0.00006873809,0.00041788226,0.00028946373,0.00011928173,0.00029575796,0.000120339304,0.0008680827,0.0002652356],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03405348,0.002285206,0.01098794,0.0028975827,0.0007836298,0.0010400048,0.00026360896,0.0023747138,0.05913766,0.00052526244,0.0048513417,0.88079965],"study_design_scores_gemma":[0.021748424,0.32212797,0.3320768,0.002132727,0.004043781,0.01574135,0.0008795026,0.0076156785,0.093795136,0.0024423557,0.19719654,0.00019973564],"about_ca_topic_score_codex":0.00027753066,"about_ca_topic_score_gemma":0.00082163484,"teacher_disagreement_score":0.0015353404,"about_ca_system_score_codex":0.00029382936,"about_ca_system_score_gemma":0.00022186124,"threshold_uncertainty_score":0.005136192},"labels":[],"label_agreement":null},{"id":"W2064695567","doi":"10.1016/j.jbi.2015.03.009","title":"Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles","year":2015,"lang":"en","type":"article","venue":"Journal of Biomedical Informatics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Intertek (Canada)","funders":"National Center for Advancing Translational Sciences; National Center for Chronic Disease Prevention and Health Promotion; National Center for Research Resources; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute","keywords":"Drug; Side effect (computer science); Medicine; Erlotinib; Anticancer drug; Imatinib; Pharmacology; Cancer; Bioinformatics; Oncology; Internal medicine; Computer science; Epidermal growth factor receptor; Biology","score_opus":0.029976354621585793,"score_gpt":0.3485802429429896,"score_spread":0.31860388832140385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064695567","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47746405,0.049804397,0.11108584,0.0022439845,0.0015671693,0.0017825011,0.32265526,0.024222234,0.009174633],"genre_scores_gemma":[0.52005017,0.009732779,0.19603443,0.0006896759,0.0013433697,0.0010357517,0.26463053,0.0009792283,0.0055041765],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.999203,0.00010202969,0.00016937433,0.00020732534,0.00025508093,0.00006320871],"domain_scores_gemma":[0.99375546,0.0036978887,0.00085422234,0.0003099714,0.0011701083,0.00021238094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011631437,0.0014113003,0.0010582055,0.009763966,0.0004964884,0.0009823546,0.0007477187,0.0010639552,0.0024661066],"category_scores_gemma":[0.0052515827,0.00028157624,0.0015295699,0.004158125,0.000247718,0.00081516325,0.00073196815,0.0006479427,0.001976629],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036069243,0.00067959045,0.054156415,0.009739796,0.0014193067,0.005498948,0.00033027655,0.0064071747,0.102780946,0.0006844938,0.06055378,0.7541424],"study_design_scores_gemma":[0.0009526959,0.001941236,0.37821707,0.0018735486,0.0075831558,0.014031898,0.0012262041,0.21833332,0.17920792,0.007865597,0.18826166,0.00050571415],"about_ca_topic_score_codex":0.0029140662,"about_ca_topic_score_gemma":0.0061686467,"teacher_disagreement_score":0.009763966,"about_ca_system_score_codex":0.00039260052,"about_ca_system_score_gemma":0.0015954853,"threshold_uncertainty_score":0.0082499385},"labels":[],"label_agreement":null},{"id":"W2064731204","doi":"10.1074/jbc.m002172200","title":"ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg; University of Manitoba","funders":"","keywords":"Disintegrin; Metalloproteinase; Immunoprecipitation; Proteases; Proteolysis; Biology; Growth factor; Molecular biology; Biochemistry; Chemistry; Matrix metalloproteinase; Receptor; Gene","score_opus":0.05014929115601866,"score_gpt":0.3165801696925174,"score_spread":0.2664308785364987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064731204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97275984,0.007611933,0.0140219815,0.00046475575,0.00017012637,0.00006408429,0.00073190394,0.00029016018,0.003885256],"genre_scores_gemma":[0.9742279,0.005211062,0.008474818,0.00020913057,0.00006869082,0.00005048547,0.0021512795,0.00004807343,0.009558666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997229,0.000047159963,0.000028870953,0.000048724545,0.00008287439,0.00006951927],"domain_scores_gemma":[0.99983895,0.000024721254,0.000045903256,0.000014501351,0.000030926218,0.000045063513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018162806,0.0007516078,0.00051248085,0.00035021518,0.00035974145,0.0005378415,0.00024410686,0.0003490013,0.0017240545],"category_scores_gemma":[0.00033943218,0.00032480352,0.00076350657,0.00027785925,0.00022949358,0.00032594506,0.00050031795,0.0006560001,0.0012254787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017932977,0.000024656962,0.0021732114,0.000118482276,0.000032575794,0.0011921305,0.00005748272,0.00007931776,0.992474,0.00018176857,0.00029271582,0.003194287],"study_design_scores_gemma":[0.00006132321,0.00033164007,0.053288184,0.00004005582,0.00011933293,0.010815316,0.00024786658,0.0037152555,0.9062552,0.0003679217,0.024730647,0.00002719006],"about_ca_topic_score_codex":0.0006376271,"about_ca_topic_score_gemma":0.0006666724,"teacher_disagreement_score":0.0017240545,"about_ca_system_score_codex":0.000343977,"about_ca_system_score_gemma":0.0002424119,"threshold_uncertainty_score":0.005767584},"labels":[],"label_agreement":null},{"id":"W2065683374","doi":"10.1158/1535-7163.mct-06-0389","title":"C35 (<i>C17orf37</i>) is a novel tumor biomarker abundantly expressed in breast cancer","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"Cancer Institute, University of Pittsburgh; Tufts University School of Medicine; National Cancer Institute; Ludwig Institute for Cancer Research","keywords":"Biology; Biomarker; Breast cancer; Gene; Immunohistochemistry; Cancer; Oncogene; Cancer research; Complementary DNA; Open reading frame; Pathology; Gene expression; Medicine; Immunology; Genetics; Cell cycle; Peptide sequence","score_opus":0.04298584457033967,"score_gpt":0.3514532504766201,"score_spread":0.30846740590628047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065683374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883394,0.0036181335,0.002709681,0.00022058497,0.000080227364,0.00004300134,0.0036802627,0.0001550648,0.0011535335],"genre_scores_gemma":[0.9894456,0.0007643061,0.0042890836,0.00019226814,0.00004823998,0.00003476266,0.004264132,0.000037270034,0.0009242399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998227,0.000015450158,0.000014724728,0.00007161461,0.00004118702,0.00003430838],"domain_scores_gemma":[0.9997719,0.000036565438,0.00011706107,0.000012208657,0.000021537202,0.00004069269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020935526,0.0006023027,0.0003663649,0.0007455635,0.00030614762,0.00039727878,0.0002479737,0.00068576745,0.0020454193],"category_scores_gemma":[0.00034341522,0.00009939051,0.00043243504,0.000710775,0.00045887876,0.00014215587,0.00020783019,0.00029296614,0.0006523979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071473815,0.000028389812,0.01701533,0.00018981393,0.0000596977,0.002396509,0.00007030353,0.00034823272,0.96428263,0.0004036143,0.0011598695,0.013330806],"study_design_scores_gemma":[0.0001245874,0.0010376067,0.24474277,0.000102628714,0.0002580637,0.028625071,0.00016926507,0.004257144,0.68087196,0.0008671773,0.03884412,0.00009966792],"about_ca_topic_score_codex":0.0016387376,"about_ca_topic_score_gemma":0.0017648604,"teacher_disagreement_score":0.0020454193,"about_ca_system_score_codex":0.0005804235,"about_ca_system_score_gemma":0.00031302022,"threshold_uncertainty_score":0.006842613},"labels":[],"label_agreement":null},{"id":"W2066998622","doi":"10.1038/onc.2014.340","title":"Amplified Ras-MAPK signal states correlate with accelerated EGFR internalization, cytostasis and delayed HER2 tumor onset in Fer-deficient model systems","year":2014,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University of Waterloo; Ontario Institute for Cancer Research","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Health Canada; Cancer Research Institute","keywords":"Cytostasis; Biology; Internalization; Cancer research; Carcinogenesis; MAPK/ERK pathway; ATRX; Signal transduction; Immunology; Genetics; Cancer; Mutation; Receptor","score_opus":0.038493480504389735,"score_gpt":0.3192166501895523,"score_spread":0.2807231696851626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066998622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911713,0.0004391296,0.0050878776,0.00010528867,0.00003443121,0.00004730902,0.0010855421,0.0002810476,0.0017479883],"genre_scores_gemma":[0.99266535,0.0002448865,0.0024675236,0.000031867337,0.00000579046,0.00005039874,0.000758496,0.0000850729,0.003690459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997458,0.000025627178,0.00002127335,0.00005304153,0.00006365396,0.00009066322],"domain_scores_gemma":[0.9996737,0.000052975323,0.00010534447,0.000052291878,0.000034632074,0.000080953636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001690804,0.00064754236,0.00044023286,0.0004944873,0.0002603929,0.00049335614,0.00034705768,0.00050168857,0.0023067016],"category_scores_gemma":[0.0001972166,0.0002925338,0.0004278019,0.0002012197,0.00037864278,0.000566418,0.00034539,0.0012983785,0.0006547999],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015341508,0.00003318748,0.00008432854,0.000010701802,0.0000041365106,0.0000435515,0.000015685584,0.000060272003,0.9991788,0.00015230337,0.000026680094,0.00023678891],"study_design_scores_gemma":[0.000004688131,0.00010450145,0.0012497964,0.000001263137,0.0000049908226,0.00013949313,0.000017874152,0.0007052506,0.99726176,0.000043968248,0.0004617967,0.0000046563255],"about_ca_topic_score_codex":0.0018055403,"about_ca_topic_score_gemma":0.0021568974,"teacher_disagreement_score":0.0023067016,"about_ca_system_score_codex":0.0006840511,"about_ca_system_score_gemma":0.00024542774,"threshold_uncertainty_score":0.0077166557},"labels":[],"label_agreement":null},{"id":"W2067395077","doi":"10.2147/ijwh.s47357","title":"Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations","year":2014,"lang":"en","type":"review","venue":"International Journal of Women s Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Disease; Clinical trial; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Cancer; Targeted therapy","score_opus":0.11594759933645989,"score_gpt":0.5152411216543599,"score_spread":0.3992935223179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067395077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008918338,0.99903345,0.00003737721,0.00035647882,0.000076919016,0.0000030305334,0.00000589801,0.0000016366207,0.00039603922],"genre_scores_gemma":[0.0005296286,0.9988562,0.00008309595,0.00019155706,0.00008873264,0.000004424434,0.000006928034,5.270739e-7,0.0002390019],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970263,0.00007539489,0.00004710242,0.000035690864,0.00011698689,0.000022121392],"domain_scores_gemma":[0.99959236,0.00023244406,0.000057799567,0.0000083960795,0.00008650658,0.000022475631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009464506,0.0004621084,0.001402913,0.001675707,0.00022458954,0.0010428345,0.00088336994,0.00136318,0.0025343108],"category_scores_gemma":[0.0012215065,0.00022115771,0.0005536162,0.0021700324,0.00037175365,0.0012312094,0.00043412411,0.001415729,0.00093761744],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079795114,0.00005539637,0.00010411712,0.02083321,0.00009515823,0.00028922333,0.00005189615,0.00028750347,0.000780963,0.0030265374,0.0226358,0.9517604],"study_design_scores_gemma":[0.000052126616,0.00015280067,0.0008604039,0.008171167,0.00019962652,0.0019993728,0.000084114494,0.000115516006,0.0003687752,0.002538705,0.98543835,0.00001906186],"about_ca_topic_score_codex":0.0011888994,"about_ca_topic_score_gemma":0.0028020847,"teacher_disagreement_score":0.0025343108,"about_ca_system_score_codex":0.00062590686,"about_ca_system_score_gemma":0.0012948397,"threshold_uncertainty_score":0.008478105},"labels":[],"label_agreement":null},{"id":"W2069824527","doi":"10.1038/onc.2011.617","title":"MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition","year":2012,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Trastuzumab; Biology; Chromatin immunoprecipitation; Kinase; Molecular biology; Cancer research; Small interfering RNA; Phosphorylation; Cell culture; Gene; Gene expression; Cell biology; Transfection; Genetics; Cancer; Promoter; Breast cancer","score_opus":0.05093400353462508,"score_gpt":0.3643168706496098,"score_spread":0.31338286711498475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069824527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98360646,0.0039941617,0.0038784302,0.00067345874,0.00014963117,0.00004620832,0.0008208903,0.00042762107,0.006403162],"genre_scores_gemma":[0.9922402,0.0011906323,0.0017405181,0.00006993542,0.000019848983,0.000024424422,0.00085147115,0.000055964814,0.003807],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979657,0.000028044837,0.000024418581,0.000034445045,0.000068158086,0.000048307724],"domain_scores_gemma":[0.99988735,0.00001974547,0.000049839284,0.000012728394,0.000010447161,0.000019820709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024573845,0.00045568278,0.0003714416,0.0003280062,0.000283153,0.00039344412,0.00040159604,0.00025236906,0.0031526017],"category_scores_gemma":[0.00031985153,0.00020164184,0.00032194902,0.00024996357,0.00040393087,0.00025443715,0.0002456,0.0009619926,0.001112013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051702705,0.00007248386,0.0005643556,0.00011370701,0.000031612897,0.00023562122,0.00002093542,0.0004294154,0.9901543,0.00067861145,0.0004895984,0.006692371],"study_design_scores_gemma":[0.000068524496,0.00016022538,0.0026687488,0.000009283915,0.000039750346,0.0010058795,0.000018601728,0.001228896,0.9877632,0.00013198117,0.0068965,0.0000083533205],"about_ca_topic_score_codex":0.0008407375,"about_ca_topic_score_gemma":0.00132287,"teacher_disagreement_score":0.0031526017,"about_ca_system_score_codex":0.0009540388,"about_ca_system_score_gemma":0.00043443273,"threshold_uncertainty_score":0.010546505},"labels":[],"label_agreement":null},{"id":"W2071102398","doi":"10.1023/a:1017938608460","title":"Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers","year":2001,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada; Health Sciences Centre; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Medical Research Council","keywords":"Androgen receptor; Cancer research; Biology; Transactivation; Breast cancer; Endocrinology; Internal medicine; Cancer; Gene expression; Medicine; Prostate cancer; Gene","score_opus":0.052325602305618654,"score_gpt":0.3874648457897417,"score_spread":0.33513924348412305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071102398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99907196,0.00025523655,0.000093156945,0.000023399527,0.0000030804845,0.0000028941538,0.000076831144,0.000008035668,0.00046548966],"genre_scores_gemma":[0.9994004,0.00012619814,0.000049509104,0.0000124868975,0.0000065330923,0.0000027168894,0.00010829015,0.000002585726,0.000291231],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999248,0.000008600924,0.0000051857423,0.000009417635,0.000023577177,0.000028304405],"domain_scores_gemma":[0.99987674,0.000021921596,0.00003070878,0.0000145555205,0.00001970275,0.000036388752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095068885,0.00011113812,0.00020717629,0.000500221,0.00019751319,0.0003410799,0.00017277738,0.00015867676,0.000903715],"category_scores_gemma":[0.00031767925,0.00008447245,0.00012577498,0.0002793238,0.00015377368,0.00012886684,0.00014985926,0.00017716223,0.00023036281],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001555568,0.00015216075,0.16337898,0.00004653533,0.00006268412,0.003093336,0.00018549274,0.00024634475,0.80894184,0.00028270375,0.00058804377,0.021466311],"study_design_scores_gemma":[0.000029733888,0.0004773583,0.93457025,0.0000044556255,0.00006267876,0.018597115,0.00036128968,0.0006773058,0.042615775,0.00021056544,0.0023820722,0.000011456571],"about_ca_topic_score_codex":0.0007220539,"about_ca_topic_score_gemma":0.0006331843,"teacher_disagreement_score":0.000903715,"about_ca_system_score_codex":0.0001242532,"about_ca_system_score_gemma":0.00011146033,"threshold_uncertainty_score":0.0030232668},"labels":[],"label_agreement":null},{"id":"W2071130163","doi":"10.1097/01.mp.0000052102.90815.82","title":"Current Perspectives on HER2 Testing: A Review of National Testing Guidelines","year":2003,"lang":"en","type":"review","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Medical physics; Quality assurance; Trastuzumab; Pathology; Test (biology); Fish <Actinopterygii>; External quality assessment; Intensive care medicine; Internal medicine; Breast cancer; Cancer; Biology","score_opus":0.5663146011887417,"score_gpt":0.5638883755037888,"score_spread":0.0024262256849528763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071130163","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006233329,0.99749506,0.00011720498,0.0015302836,0.00021762289,0.0000034932993,0.000029148623,0.000006004263,0.00053893187],"genre_scores_gemma":[0.0003551501,0.9979996,0.0002971981,0.0009103681,0.00023499792,0.000006591245,0.000040249513,0.0000014413768,0.00015439122],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989135,0.0002545903,0.00026761182,0.00014403556,0.00036454707,0.000055749166],"domain_scores_gemma":[0.99313736,0.0044837664,0.0006971428,0.00009711698,0.0013614878,0.0002232286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039791088,0.00093268085,0.0029926866,0.00433495,0.000413497,0.0016450213,0.0018973732,0.0021289617,0.0041470747],"category_scores_gemma":[0.006944489,0.0004122167,0.000965645,0.005973506,0.00081956375,0.00265899,0.00094824453,0.0024474452,0.0015555781],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001308507,0.000059519774,0.00049052545,0.020256747,0.00013126378,0.00033976117,0.00008194826,0.0002807969,0.00040510052,0.0022020233,0.08894155,0.8866799],"study_design_scores_gemma":[0.00006979429,0.00009488692,0.002559843,0.02919381,0.0006072806,0.0018599558,0.00022493675,0.00016350177,0.00028176716,0.0023973037,0.96250486,0.000042130196],"about_ca_topic_score_codex":0.0052380734,"about_ca_topic_score_gemma":0.014060375,"teacher_disagreement_score":0.0052380734,"about_ca_system_score_codex":0.0019858265,"about_ca_system_score_gemma":0.0047639296,"threshold_uncertainty_score":0.021043777},"labels":[],"label_agreement":null},{"id":"W2071275412","doi":"10.1158/0008-5472.can-05-4045","title":"Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor–Positive, HER-2/<i>neu</i>-Positive Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Fulvestrant; Endocrinology; Internal medicine; Estrogen receptor; Estrogen; Gefitinib; Protein kinase B; Breast cancer; Medicine; Cancer research; Tamoxifen; Epidermal growth factor receptor; Cancer; Biology; Phosphorylation","score_opus":0.04513150536202543,"score_gpt":0.38115746349442364,"score_spread":0.3360259581323982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071275412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563736,0.0016274207,0.001236717,0.00017038567,0.000030551408,0.000055820576,0.00023321409,0.00008555902,0.0009230352],"genre_scores_gemma":[0.99522614,0.0010163854,0.0010253299,0.000059502116,0.000012011489,0.000068160654,0.00045175847,0.000015842803,0.0021248024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998536,0.000023503098,0.000009993248,0.000022480433,0.00003599723,0.000054427124],"domain_scores_gemma":[0.9999088,0.000014699056,0.000028264623,0.000014693423,0.000008917537,0.000024569941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017756694,0.00047051575,0.0003791474,0.00033834245,0.0001363527,0.00024670942,0.00033474737,0.00037324318,0.00078307453],"category_scores_gemma":[0.00010192643,0.00019185962,0.0004228284,0.00015283783,0.00022082838,0.00034556817,0.00012290126,0.00084758434,0.00023252869],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040436,0.00022042163,0.0002634481,0.000028059569,0.000010301316,0.000065647495,0.000022252052,0.00018214561,0.9963649,0.00016515478,0.000086673055,0.0021867554],"study_design_scores_gemma":[0.0001023236,0.0030872778,0.004721328,0.0000053992194,0.000024091036,0.0005574996,0.000032092248,0.0018139412,0.98783815,0.000094310155,0.0017151242,0.000008469162],"about_ca_topic_score_codex":0.0007190881,"about_ca_topic_score_gemma":0.0007047189,"teacher_disagreement_score":0.00078307453,"about_ca_system_score_codex":0.00039647182,"about_ca_system_score_gemma":0.00017562462,"threshold_uncertainty_score":0.0028766394},"labels":[],"label_agreement":null},{"id":"W2072485456","doi":"10.1021/pr500987r","title":"Glycoproteomic Comparison of Clinical Triple-Negative and Luminal Breast Tumors","year":2015,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; National Research Council Canada","funders":"Fonds de Recherche du Québec - Santé; Fondation du cancer du sein du Québec","keywords":"Breast cancer; Estrogen receptor; Cancer research; Immunohistochemistry; Biology; Tissue microarray; Western blot; Internal medicine; Oncology; Cancer; Medicine; Gene","score_opus":0.4559443937309339,"score_gpt":0.5997107197676118,"score_spread":0.14376632603667794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072485456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99879575,0.00022692702,0.00021961844,0.00002650485,0.000005293579,0.000007366718,0.0004907613,0.000007251276,0.00022061936],"genre_scores_gemma":[0.99669975,0.0002707048,0.00066348084,0.000052552485,0.000007477143,0.000015263002,0.0019289711,0.0000059821537,0.00035588138],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986947,0.000018321392,0.00001127681,0.000032420103,0.000042634525,0.000025811692],"domain_scores_gemma":[0.9998685,0.000023733104,0.000033333756,0.000008128154,0.00003517964,0.00003103349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020273474,0.00023600772,0.00030207672,0.00063535623,0.00014588205,0.00035225,0.000090188754,0.00023216715,0.0005540438],"category_scores_gemma":[0.0004352611,0.000081870596,0.00013124286,0.00041728077,0.00016529288,0.0001228927,0.00024410081,0.00020217492,0.00015623258],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022334913,0.00010791116,0.16746607,0.00012406374,0.000139555,0.0006053397,0.00025248347,0.0003401143,0.8174239,0.00009875229,0.0004322959,0.010776039],"study_design_scores_gemma":[0.000028116594,0.0005853659,0.9201845,0.00001562574,0.00012536903,0.0020124211,0.00042197766,0.0029234947,0.071787894,0.00012774822,0.001772797,0.000014656376],"about_ca_topic_score_codex":0.00072908076,"about_ca_topic_score_gemma":0.0007750841,"teacher_disagreement_score":0.00072908076,"about_ca_system_score_codex":0.00015641637,"about_ca_system_score_gemma":0.00010704108,"threshold_uncertainty_score":0.0018535256},"labels":[],"label_agreement":null},{"id":"W2072648072","doi":"10.1038/modpathol.3880440","title":"HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization","year":2001,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Immunohistochemistry; Breast cancer; Stain; Concordance; Fluorescence in situ hybridization; Pathology; Medicine; Polyclonal antibodies; Trastuzumab; Monoclonal antibody; Staining; Cancer; Antibody; Biology; Internal medicine; Immunology; Gene","score_opus":0.019161283652451934,"score_gpt":0.2999954879935629,"score_spread":0.28083420434111095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072648072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97408336,0.0015912273,0.021339517,0.000074133175,0.00008654195,0.00006485613,0.000102517566,0.00018178877,0.0024760908],"genre_scores_gemma":[0.99398106,0.0001702064,0.0052555418,0.000039201794,0.000029169885,0.00004235096,0.00010942385,0.00007478415,0.00029823676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9715318,0.016998071,0.0031116435,0.003530047,0.0040232185,0.00080527784],"domain_scores_gemma":[0.9160454,0.06366161,0.005142019,0.0073431307,0.0071952175,0.0006125126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.039126553,0.00065702904,0.000730099,0.0023880238,0.0006862427,0.0011473835,0.0008738755,0.0011906509,0.0005137532],"category_scores_gemma":[0.048079867,0.0006919232,0.00090675015,0.0010175756,0.0013610447,0.001240725,0.0012295464,0.0007990295,0.0002873043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065444615,0.00021728082,0.8149066,0.0004265913,0.0027897295,0.0005034299,0.004245015,0.005924439,0.096234396,0.0006879791,0.00056647556,0.066953525],"study_design_scores_gemma":[0.00010903766,0.0009735118,0.92539257,0.0000670981,0.0012405157,0.0021883857,0.00093328697,0.0286416,0.037807923,0.0010297779,0.0015110448,0.000105366424],"about_ca_topic_score_codex":0.0018263818,"about_ca_topic_score_gemma":0.003968619,"teacher_disagreement_score":0.039126553,"about_ca_system_score_codex":0.0008134727,"about_ca_system_score_gemma":0.00031873223,"threshold_uncertainty_score":0.20692348},"labels":[],"label_agreement":null},{"id":"W2072990829","doi":"10.1158/1078-0432.ccr-08-0121","title":"Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; Genentech","keywords":"Trastuzumab; Gene knockdown; Cancer research; Apoptosis; Molecular biology; Cell culture; Small interfering RNA; Biology; Cancer cell; Cancer; Medicine; Internal medicine; Breast cancer; Transfection; Biochemistry","score_opus":0.2929450628927039,"score_gpt":0.5554410195244822,"score_spread":0.2624959566317783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072990829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942721,0.0027301859,0.0015717781,0.00007994732,0.000017122058,0.00003730974,0.00030949287,0.000042294894,0.000939753],"genre_scores_gemma":[0.9943356,0.001819794,0.0014446985,0.00004436679,0.000008430782,0.000039207327,0.00091055536,0.0000147236815,0.0013826385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998425,0.000026449283,0.000016522472,0.000028044653,0.00005219587,0.000034149372],"domain_scores_gemma":[0.9998863,0.00002378342,0.000030181003,0.000017376871,0.000024725938,0.000017668335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012129064,0.00023936987,0.0002644241,0.00011784579,0.00013156577,0.00042511756,0.00016559103,0.00023010906,0.0009828139],"category_scores_gemma":[0.0001676852,0.000115662304,0.00025982872,0.00023778214,0.00015470966,0.00016418498,0.0001715192,0.0005020122,0.0006620412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067869085,0.00003650124,0.00038423183,0.00003865457,0.0000069019343,0.00009578618,0.000023413317,0.00005623509,0.9982079,0.000048823054,0.000044299974,0.000989363],"study_design_scores_gemma":[0.000034450095,0.00042998127,0.00938013,0.000009682193,0.00003003103,0.0014822156,0.000059006983,0.0012238915,0.9829516,0.00003391777,0.004359438,0.0000057746465],"about_ca_topic_score_codex":0.00047580825,"about_ca_topic_score_gemma":0.00036932755,"teacher_disagreement_score":0.0009828139,"about_ca_system_score_codex":0.00021936862,"about_ca_system_score_gemma":0.00014219126,"threshold_uncertainty_score":0.0032878518},"labels":[],"label_agreement":null},{"id":"W2073149046","doi":"10.1158/1538-7445.am2011-1352","title":"Abstract 1352: Mechanism of action of AL622, a molecule rationally designed to release an EGFR and a Src kinase inhibitor","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Gefitinib; Transfection; EGFR inhibitors; Proto-oncogene tyrosine-protein kinase Src; Chemistry; Cancer research; Epidermal growth factor receptor; Cell growth; Western blot; Kinase; Pharmacology; Receptor; Biology; Biochemistry; Gene","score_opus":0.23121162410328822,"score_gpt":0.4647197616200853,"score_spread":0.2335081375167971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073149046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97841966,0.0033925388,0.009367811,0.00024137743,0.000098152224,0.00027053675,0.00056701445,0.00015076202,0.0074920827],"genre_scores_gemma":[0.99283534,0.0005924779,0.0030439845,0.00009791995,0.000012276356,0.000038480997,0.0002729291,0.000010415103,0.0030962077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999304,0.000014724264,0.000005131738,0.000015592523,0.000017963734,0.000016211063],"domain_scores_gemma":[0.99997866,0.0000030445876,0.00000596339,0.0000021036053,0.000004758825,0.0000054432708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011039022,0.0003300819,0.00017573887,0.00012388479,0.000095694646,0.0002144665,0.00022050626,0.00032650272,0.00175609],"category_scores_gemma":[0.00007545357,0.00008590583,0.00020570122,0.000087165216,0.00014692836,0.00022194756,0.00012081427,0.00022673445,0.0005807193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041851163,0.00012603647,0.00015340839,0.00016160979,0.000014618861,0.00019126627,0.0000215113,0.0009526393,0.9900665,0.0006452393,0.0002883205,0.006960263],"study_design_scores_gemma":[0.00024661754,0.0022997402,0.0010184317,0.000009010927,0.0000213069,0.000343114,0.000013657707,0.003815025,0.9853631,0.00014797652,0.0067069824,0.00001503602],"about_ca_topic_score_codex":0.00040199055,"about_ca_topic_score_gemma":0.00036649505,"teacher_disagreement_score":0.00175609,"about_ca_system_score_codex":0.0002161818,"about_ca_system_score_gemma":0.0001282693,"threshold_uncertainty_score":0.005874753},"labels":[],"label_agreement":null},{"id":"W2073871328","doi":"10.1159/000055399","title":"Dose Scheduling – Herceptin&lt;sup&gt;®&lt;/sup&gt;","year":2001,"lang":"en","type":"review","venue":"Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pharmacokinetics; Taxane; Paclitaxel; Pharmacology; Regimen; Capecitabine; Trastuzumab; Metastatic breast cancer; Docetaxel; Oncology; Oral administration; Internal medicine; Breast cancer; Chemotherapy; Cancer; Colorectal cancer","score_opus":0.1837246228174495,"score_gpt":0.4974194244479117,"score_spread":0.3136948016304622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073871328","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3153823,0.01032592,0.33220774,0.0046363394,0.0029426736,0.019511407,0.017870095,0.020897178,0.2762264],"genre_scores_gemma":[0.68038017,0.0026321325,0.16321631,0.004523107,0.00072877336,0.0076134345,0.012907811,0.0042281128,0.12377016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995166,0.00010875588,0.000037227863,0.0001458332,0.00012563614,0.00006601953],"domain_scores_gemma":[0.9997019,0.00004795002,0.00006444841,0.000075898235,0.000043134223,0.00006654605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056792056,0.00081130484,0.0006146708,0.00047825006,0.00024070573,0.00049551966,0.0008577184,0.0006009953,0.044755742],"category_scores_gemma":[0.00075352914,0.0004316179,0.000577821,0.0005040728,0.00020391673,0.00044279784,0.00036168247,0.0017253606,0.02116147],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017686307,0.0041288175,0.004055548,0.00068749604,0.00019616491,0.0001762042,0.0001366901,0.013795834,0.27791053,0.0040484862,0.07293268,0.6042453],"study_design_scores_gemma":[0.009943413,0.024820741,0.02542603,0.0001344776,0.00027133917,0.0024611978,0.000061759216,0.026706407,0.18849182,0.005072666,0.71643806,0.00017209396],"about_ca_topic_score_codex":0.0014975787,"about_ca_topic_score_gemma":0.0015327586,"teacher_disagreement_score":0.044755742,"about_ca_system_score_codex":0.0008767804,"about_ca_system_score_gemma":0.000892681,"threshold_uncertainty_score":0.14972281},"labels":[],"label_agreement":null},{"id":"W2074695616","doi":"10.1007/s10549-012-2236-9","title":"Management of small HER2 overexpressing tumours","year":2012,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Odds ratio; Chemotherapy; Cancer; Gynecology; Confidence interval","score_opus":0.29971512262007144,"score_gpt":0.4988222990774509,"score_spread":0.19910717645737946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074695616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021263835,0.9989236,0.0001822652,0.00015751191,0.00009712749,0.0000042750075,0.000009718637,0.0000051309535,0.00040770185],"genre_scores_gemma":[0.0022752387,0.99627787,0.00036459492,0.0003235879,0.00021711182,0.000007815903,0.000046805388,0.0000023110154,0.00048462892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998466,0.000033746925,0.000022633527,0.00002610308,0.00005163331,0.000019306657],"domain_scores_gemma":[0.9997807,0.00012083221,0.000042740656,0.00000567317,0.000030611624,0.00001943336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003958426,0.0007547292,0.0015673588,0.0014977354,0.00015923954,0.0007107009,0.0008741936,0.00076267717,0.0017532053],"category_scores_gemma":[0.00081304385,0.00017642052,0.0008021447,0.00081419747,0.0003481866,0.00078849914,0.0004891034,0.0014145647,0.0007245751],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117085205,0.000051682466,0.00021426057,0.012649177,0.00011378815,0.0004907744,0.000026403946,0.00034581797,0.0014301069,0.00065008044,0.014786778,0.9691241],"study_design_scores_gemma":[0.00022886817,0.00045228904,0.0050127255,0.013301408,0.00085471524,0.013324102,0.00017142024,0.00048425084,0.0017992435,0.0031864066,0.9611212,0.000063367566],"about_ca_topic_score_codex":0.00064469245,"about_ca_topic_score_gemma":0.0019625318,"teacher_disagreement_score":0.0017532053,"about_ca_system_score_codex":0.0003725979,"about_ca_system_score_gemma":0.00042476677,"threshold_uncertainty_score":0.005865097},"labels":[],"label_agreement":null},{"id":"W2075638718","doi":"10.1016/j.jval.2014.08.2164","title":"Overall Survival in Patients with HER2+ Early Stage Breast Cancer Patients Treated with Trastuzumab in the US Department of Defense Practice Setting","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Trastuzumab; Medicine; Adjuvant; Internal medicine; Breast cancer; Oncology; Stage (stratigraphy); Adjuvant therapy; Cancer; Clinical trial; Clinical Practice; Surgery; Physical therapy","score_opus":0.026365130467483195,"score_gpt":0.33172896818348613,"score_spread":0.30536383771600295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075638718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971316,0.0007609697,0.00002415243,0.00063667836,0.000013009901,0.0000049935034,0.00025122878,0.0000024325811,0.0011749219],"genre_scores_gemma":[0.99913603,0.00025381465,0.000017719347,0.00020042922,0.000014561212,0.00000317985,0.00017561254,8.0141376e-7,0.00019794684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996481,0.000105276784,0.000026827165,0.00006535201,0.000042170494,0.00011225621],"domain_scores_gemma":[0.9993037,0.00013798571,0.00022844222,0.000015950187,0.00006487076,0.00024897547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027100006,0.00011154688,0.0002588145,0.00032386786,0.00037752758,0.00060031924,0.00021562024,0.0003585243,0.0013307007],"category_scores_gemma":[0.0017697302,0.00010955099,0.00024016152,0.00061417423,0.00018798321,0.0003703451,0.00043666043,0.0005761849,0.00011083048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024492148,0.00008499681,0.9943488,0.000009560036,0.00004092998,0.00014825052,0.000095897994,0.00008109238,0.00010081097,0.000034814297,0.00060724624,0.0042026206],"study_design_scores_gemma":[0.000052471634,0.00033207686,0.99735534,0.00001955109,0.00005791073,0.0003908566,0.0006922066,0.00027445753,0.00006804816,0.00009146827,0.0006602241,0.0000053738636],"about_ca_topic_score_codex":0.014106112,"about_ca_topic_score_gemma":0.03251724,"teacher_disagreement_score":0.014106112,"about_ca_system_score_codex":0.0010126643,"about_ca_system_score_gemma":0.00083461136,"threshold_uncertainty_score":0.028048038},"labels":[],"label_agreement":null},{"id":"W2075966869","doi":"10.1007/s12012-012-9183-x","title":"The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin","year":2012,"lang":"en","type":"article","venue":"Cardiovascular Toxicology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Apotex (Canada)","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Lapatinib; Cardiotoxicity; Doxorubicin; Tyrosine-kinase inhibitor; Pharmacology; Tyrosine kinase; Myocyte; Medicine; Trastuzumab; Chemistry; Internal medicine; Receptor; Cancer; Chemotherapy; Breast cancer","score_opus":0.014463149592621903,"score_gpt":0.2814317603408668,"score_spread":0.2669686107482449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075966869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114335,0.0033339995,0.0016624068,0.00026335678,0.00006330105,0.000028966799,0.00019616084,0.000080569225,0.0032278611],"genre_scores_gemma":[0.99682283,0.0010903291,0.0005336908,0.00005631387,0.000014434103,0.000012778545,0.00015781526,0.000006413181,0.0013054293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999161,0.000019759222,0.0000056106323,0.000010121161,0.00001734767,0.00003100432],"domain_scores_gemma":[0.999946,0.000014011031,0.000010404888,0.0000054622815,0.000005251577,0.000018879704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014621655,0.00026802477,0.00031481922,0.00011874516,0.00013490256,0.00016290718,0.00012457898,0.00020528917,0.0020079997],"category_scores_gemma":[0.0001267768,0.00010980377,0.00017134659,0.00006963616,0.00014975727,0.00019934727,0.00015804016,0.0005608187,0.0002337388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005099524,0.00008345416,0.00018751399,0.00005972743,0.0000134538095,0.000059676815,0.000013191364,0.00012292097,0.9940501,0.00009390988,0.00023683495,0.0045692925],"study_design_scores_gemma":[0.00019045598,0.0031496212,0.011740543,0.000019727764,0.000048144982,0.0005180278,0.00003955199,0.0013340303,0.97982925,0.000095054005,0.0030236605,0.000011963019],"about_ca_topic_score_codex":0.0004899407,"about_ca_topic_score_gemma":0.0021007904,"teacher_disagreement_score":0.0020079997,"about_ca_system_score_codex":0.00018368787,"about_ca_system_score_gemma":0.00022404522,"threshold_uncertainty_score":0.006717384},"labels":[],"label_agreement":null},{"id":"W2076363741","doi":"10.1016/j.radonc.2009.06.021","title":"Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells","year":2009,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"KWF Kankerbestrijding","keywords":"Cetuximab; Internalization; Glioma; Flow cytometry; Cancer research; Epidermal growth factor receptor; Chemistry; Radiosensitivity; Clonogenic assay; Cell culture; Downregulation and upregulation; Cell; Biology; Molecular biology; Receptor; Antibody; Monoclonal antibody; Immunology; Medicine; Radiation therapy; Internal medicine; Biochemistry; Genetics","score_opus":0.05783316915741105,"score_gpt":0.38166028477161335,"score_spread":0.3238271156142023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076363741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694556,0.0007555119,0.00030831972,0.00010232614,0.000029283457,0.00001237119,0.0003049114,0.000018543853,0.0015232309],"genre_scores_gemma":[0.99633825,0.0003138732,0.00026989527,0.00004305506,0.000006100802,0.000012012463,0.0006962981,0.000007377874,0.002313234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996107,0.0000916273,0.000024234334,0.000033194134,0.0001075131,0.00013279781],"domain_scores_gemma":[0.9998816,0.000045949626,0.000009764392,0.000019721305,0.000020833902,0.000022071401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023004193,0.00024481333,0.00047317686,0.0003073285,0.00037245336,0.00033973926,0.00040152064,0.00059466664,0.002563258],"category_scores_gemma":[0.00026632522,0.00032798742,0.0004286528,0.0004050601,0.00024644,0.0002233744,0.00014614714,0.00057575584,0.0005087684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014789131,0.00021299851,0.000562488,0.00006398376,0.000029990417,0.00029635016,0.000080826685,0.0006719156,0.9947365,0.00023128443,0.00024291975,0.0013917251],"study_design_scores_gemma":[0.0000893414,0.0011640575,0.022310179,0.000007912459,0.000038300648,0.0007159568,0.00018119269,0.0042219865,0.9691263,0.00007618577,0.0020497371,0.000018896077],"about_ca_topic_score_codex":0.01570786,"about_ca_topic_score_gemma":0.0096905995,"teacher_disagreement_score":0.01570786,"about_ca_system_score_codex":0.0006540377,"about_ca_system_score_gemma":0.00038866236,"threshold_uncertainty_score":0.031232834},"labels":[],"label_agreement":null},{"id":"W2076365212","doi":"10.1016/j.bmc.2009.09.038","title":"Synthesis and radiopharmacological investigation of 3-[4′-[18F]fluorobenzylidene]indolin-2-one as possible tyrosine kinase inhibitor","year":2009,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Tyrosine-kinase inhibitor; Enzyme inhibitor; Tyrosine kinase; Chemical synthesis; Stereochemistry; Kinase; Biochemistry; Enzyme; In vitro; Signal transduction","score_opus":0.034886476533503435,"score_gpt":0.31876738183386943,"score_spread":0.283880905300366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076365212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9351531,0.011764456,0.030593991,0.00058012136,0.00012782999,0.00025158128,0.0009662251,0.0003338732,0.020228729],"genre_scores_gemma":[0.9815066,0.0029929418,0.009384296,0.0000968018,0.00002250133,0.0000662266,0.0005155584,0.000030359872,0.0053848373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994254,0.000013106735,0.0000034380673,0.0000122560195,0.000008550754,0.000020045802],"domain_scores_gemma":[0.9999645,0.00000946187,0.000007961496,0.0000039663687,0.0000055755013,0.000008447033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016903045,0.00023750798,0.00023398674,0.00028847717,0.00023850305,0.00017162375,0.00047724543,0.0002968034,0.0013132723],"category_scores_gemma":[0.00011161955,0.00017403481,0.0001881089,0.00016650077,0.00016155181,0.00023496774,0.000114232564,0.00022178466,0.00046011197],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003858298,0.00008943548,0.00011661795,0.00017179795,0.000010025325,0.00038185623,0.000057080782,0.0007567708,0.9889577,0.0012497279,0.00026594757,0.007557232],"study_design_scores_gemma":[0.00006240834,0.00066519465,0.00064908643,0.0000074028276,0.000032204203,0.0004899419,0.000011463155,0.000988141,0.9870063,0.00012145257,0.009951852,0.000014564409],"about_ca_topic_score_codex":0.0011265739,"about_ca_topic_score_gemma":0.0013867287,"teacher_disagreement_score":0.0013132723,"about_ca_system_score_codex":0.00025119112,"about_ca_system_score_gemma":0.00030934508,"threshold_uncertainty_score":0.004393339},"labels":[],"label_agreement":null},{"id":"W2078864821","doi":"10.1503/cmaj.090574","title":"Ranibizumab and the eye","year":2011,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Epidermal growth factor receptor; Medicine; Immunohistochemistry; Cancer research; Sanger sequencing; Oncology; Internal medicine; Druggability; Copy-number variation; Cancer; Biology; Gene; Mutation","score_opus":0.051965385983189935,"score_gpt":0.3803389735490467,"score_spread":0.3283735875658568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078864821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.439381,0.48070896,0.0025550204,0.012450002,0.00057585957,0.00007999373,0.000385611,0.0002377888,0.063625716],"genre_scores_gemma":[0.9621805,0.027438074,0.0013730826,0.0020352667,0.00043947992,0.000034717166,0.00025456815,0.000017049182,0.006227263],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998715,0.00003984738,0.000012049522,0.000021801978,0.000031273434,0.000023519484],"domain_scores_gemma":[0.999824,0.00005912878,0.000072194,0.000011432134,0.0000136798635,0.000019525918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003498429,0.0002212826,0.00031856395,0.00023447271,0.00019827341,0.0005226329,0.0001861798,0.0004561874,0.0032323014],"category_scores_gemma":[0.0004731951,0.000054594377,0.0003036382,0.0002180033,0.00018563718,0.00018091852,0.00015974915,0.0006502542,0.00057195994],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010988506,0.0006711887,0.07091995,0.0011901865,0.00094483315,0.015403986,0.00009013378,0.0008582342,0.047828045,0.010242851,0.014968029,0.8258941],"study_design_scores_gemma":[0.0029768285,0.006982427,0.3348632,0.0014674502,0.0019078893,0.17830189,0.00028024276,0.0073828115,0.035648704,0.013318456,0.4167353,0.00013484487],"about_ca_topic_score_codex":0.0009834835,"about_ca_topic_score_gemma":0.0011436364,"teacher_disagreement_score":0.0032323014,"about_ca_system_score_codex":0.0006088272,"about_ca_system_score_gemma":0.00028686938,"threshold_uncertainty_score":0.010813117},"labels":[],"label_agreement":null},{"id":"W2078881615","doi":"10.1056/nejmoa054504","title":"<i>HER2</i> and Responsiveness of Breast Cancer to Adjuvant Chemotherapy","year":2006,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":508,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Lunenfeld-Tanenbaum Research Institute; McMaster University; Queen's University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anthracycline; Oncology; Breast cancer; Internal medicine; Chemotherapy; Adjuvant; Adjuvant chemotherapy; Cancer; Cancer research; Human Epidermal Growth Factor Receptor 2","score_opus":0.01893375892135406,"score_gpt":0.3470915491465274,"score_spread":0.32815779022517333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078881615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459165,0.0041683633,0.00012070499,0.00018466797,0.000029461873,0.000117981865,0.00020040148,0.000007519045,0.00057934533],"genre_scores_gemma":[0.99829525,0.0006943407,0.00019197365,0.00016266729,0.00008094646,0.00010401734,0.00033721165,0.000002132541,0.00013150176],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9991647,0.00052980304,0.00005973446,0.00008664077,0.00008396014,0.00007516413],"domain_scores_gemma":[0.99649256,0.0021577147,0.00084520696,0.00011459695,0.00008521257,0.0003047955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030272577,0.00027571223,0.00058801443,0.00030496373,0.00013276984,0.0003924013,0.00034691676,0.0006049411,0.0015299437],"category_scores_gemma":[0.0037432236,0.00015303676,0.000517616,0.000295435,0.00048121653,0.00019676487,0.0001579838,0.0005298432,0.00013576394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.558068,0.0028947336,0.36883375,0.0009340928,0.0024655454,0.00017248586,0.00007092131,0.0015289537,0.007447302,0.00011662689,0.0011791262,0.056288425],"study_design_scores_gemma":[0.08850518,0.13479023,0.7556041,0.00033174836,0.005064578,0.0014984083,0.000077193814,0.002676424,0.0069397325,0.00048242044,0.0039931573,0.000036874324],"about_ca_topic_score_codex":0.000475219,"about_ca_topic_score_gemma":0.0005345891,"teacher_disagreement_score":0.0030272577,"about_ca_system_score_codex":0.0003276121,"about_ca_system_score_gemma":0.00038447604,"threshold_uncertainty_score":0.016009867},"labels":[],"label_agreement":null},{"id":"W2079324061","doi":"10.1002/1097-4652(200002)186:2<233::aid-jcp1017>3.0.co;2-l","title":"Regulation of heparin-binding EGF-like growth factor expression in Ha-ras transformed human Mammary epithelial cells","year":2001,"lang":"en","type":"article","venue":"Journal of Cellular Physiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Epidermal growth factor; Heparin-binding EGF-like growth factor; Biology; MAPK/ERK pathway; Tyrosine kinase; Molecular biology; Growth factor; Cell culture; Transfection; Monoclonal antibody; Cell biology; Signal transduction; Epidermal growth factor receptor; Receptor; Antibody; Immunology; Biochemistry","score_opus":0.032947315627009956,"score_gpt":0.3177514584656081,"score_spread":0.2848041428385981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079324061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98677456,0.0048165442,0.002859148,0.00017527454,0.00004937306,0.00003934689,0.001369412,0.0001846835,0.0037316415],"genre_scores_gemma":[0.98127985,0.0027267053,0.0036279021,0.00007988954,0.000016125507,0.000050379746,0.0030804218,0.000037417416,0.009101273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998423,0.000022603339,0.000012852492,0.000023868282,0.00006701096,0.00003134463],"domain_scores_gemma":[0.9999318,0.000010384854,0.000010869376,0.000010975247,0.000019828643,0.000016215725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102057136,0.00020404918,0.00020579029,0.00021,0.0001716334,0.00041512796,0.00012424041,0.0001839499,0.0011826808],"category_scores_gemma":[0.0000836036,0.00014580098,0.00018969011,0.00023848146,0.00017068404,0.00014206562,0.00013740455,0.00038194237,0.0012446649],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006868494,0.000017175164,0.00011706343,0.000021503443,0.0000025283794,0.000039784256,0.000015789221,0.000016528098,0.9983809,0.000068656314,0.00004786511,0.0012035915],"study_design_scores_gemma":[0.000016305512,0.00018189862,0.010820913,0.0000062389972,0.000010661697,0.00037631192,0.000054270702,0.0011178846,0.98191285,0.000051704883,0.0054452,0.000005874403],"about_ca_topic_score_codex":0.0013452581,"about_ca_topic_score_gemma":0.0017111761,"teacher_disagreement_score":0.0013452581,"about_ca_system_score_codex":0.00039882018,"about_ca_system_score_gemma":0.00018248681,"threshold_uncertainty_score":0.003956437},"labels":[],"label_agreement":null},{"id":"W2079349186","doi":"10.1016/j.bbrc.2013.03.062","title":"HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells","year":2013,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Child and Family Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Cadherin; Cancer research; Ovarian cancer; Biology; Epidermal growth factor; Gene knockdown; Slug; Cancer; Cancer cell; Tyrosine kinase; Receptor tyrosine kinase; Epidermal growth factor receptor; Receptor; Signal transduction; Cell biology; Cell; Cell culture; Genetics","score_opus":0.13816716400308032,"score_gpt":0.4295027855072308,"score_spread":0.2913356215041505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079349186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446917,0.0011200426,0.0005776283,0.00010912683,0.000032922675,0.000031424417,0.0005219513,0.000039298844,0.0030984103],"genre_scores_gemma":[0.9941322,0.00049503177,0.00027212876,0.00007291978,0.0000098268165,0.000032226824,0.00096159603,0.000009327146,0.0040147016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998307,0.000034580946,0.000010346439,0.000014141622,0.000028433762,0.00008171469],"domain_scores_gemma":[0.999951,0.000013931795,0.000004769766,0.000010609694,0.0000087749495,0.000010918852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014318789,0.00023758544,0.00027882785,0.00020264043,0.0002486536,0.0003621104,0.00020800444,0.00025264086,0.0027805176],"category_scores_gemma":[0.00014163063,0.00018289094,0.00040790663,0.0002476573,0.00014592503,0.00023317497,0.00024217764,0.0004516556,0.0007036596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029026275,0.00009706705,0.00034546363,0.000051758136,0.000012003413,0.00021321289,0.00004239741,0.00006691839,0.9975949,0.0001589972,0.00020757344,0.0009194117],"study_design_scores_gemma":[0.000048655147,0.00024006068,0.017755356,0.000004840275,0.000019185807,0.00035039973,0.00011158611,0.0012213083,0.9759149,0.000044350345,0.004283875,0.0000055370488],"about_ca_topic_score_codex":0.003431107,"about_ca_topic_score_gemma":0.0035293668,"teacher_disagreement_score":0.003431107,"about_ca_system_score_codex":0.0003169526,"about_ca_system_score_gemma":0.00024499407,"threshold_uncertainty_score":0.009301782},"labels":[],"label_agreement":null},{"id":"W2079374922","doi":"10.1186/1475-2867-8-18","title":"Ebp1 expression in benign and malignant prostate","year":2008,"lang":"en","type":"article","venue":"Cancer Cell International","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Saint-Luc; Centre Hospitalier de l’Université de Montréal","funders":"Université de Montréal; Canadian Urological Oncology Group; AstraZeneca","keywords":"Prostate; Medicine; Expression (computer science); Pathology; Computer science; Internal medicine; Cancer","score_opus":0.04630524633137489,"score_gpt":0.3573188501169256,"score_spread":0.3110136037855507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079374922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657464,0.0021687753,0.0003170558,0.000018130044,0.000004203673,0.00000949973,0.00021226198,0.000020863632,0.00067459897],"genre_scores_gemma":[0.998395,0.000522759,0.00026757162,0.000012643824,0.0000098472265,0.000013378837,0.0003028496,0.000004354571,0.0004714251],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998715,0.000013315352,0.0000073661895,0.000029717297,0.000050699146,0.000027389942],"domain_scores_gemma":[0.9998136,0.000039054506,0.00006294916,0.00000901617,0.000028830593,0.00004659143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001494855,0.0001489373,0.00013984795,0.0008095684,0.00018017688,0.00023627859,0.0001395606,0.00016294075,0.0016389678],"category_scores_gemma":[0.0002976765,0.00012485738,0.00009358593,0.00035827624,0.0002029529,0.00011446438,0.0001907302,0.00018962573,0.00019111123],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022883012,0.00009000582,0.22084735,0.00047403577,0.00010085818,0.0016510703,0.00034464872,0.00025786375,0.7535705,0.00021386873,0.00045909666,0.019702436],"study_design_scores_gemma":[0.000029926452,0.0006018767,0.8563635,0.00002030595,0.00011231238,0.010686931,0.00024409483,0.00069637847,0.12754634,0.00020500344,0.003481602,0.0000118416],"about_ca_topic_score_codex":0.0005076107,"about_ca_topic_score_gemma":0.0005476267,"teacher_disagreement_score":0.0016389678,"about_ca_system_score_codex":0.00022330819,"about_ca_system_score_gemma":0.00012506197,"threshold_uncertainty_score":0.005482912},"labels":[],"label_agreement":null},{"id":"W2079556349","doi":"10.1007/s00403-003-0391-x","title":"Proliferation?differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes","year":2003,"lang":"en","type":"article","venue":"Archives of Dermatological Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cascades (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health","keywords":"Neuregulin; Epidermal growth factor; Biology; Colocalization; Epidermis (zoology); ERBB3; Cell biology; ErbB; Epidermal growth factor receptor; Epiregulin; ERBB4; Endocrinology; Internal medicine; Receptor; Cancer research; Amphiregulin; Signal transduction; Anatomy; Receptor tyrosine kinase; Medicine; Biochemistry","score_opus":0.10116434887944394,"score_gpt":0.3737964244524777,"score_spread":0.27263207557303376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079556349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969036,0.0012737802,0.00021519297,0.00003219046,0.000008023642,0.000008267074,0.00010652784,0.000007950375,0.0014444218],"genre_scores_gemma":[0.99693596,0.0007323779,0.0002107086,0.000023353376,0.000009464157,0.000013897951,0.00022187493,0.0000032859448,0.0018490194],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998405,0.000040539144,0.000021109056,0.000014351248,0.000038928898,0.000044548007],"domain_scores_gemma":[0.9997651,0.000086341424,0.000016718188,0.000023193446,0.000062415056,0.000046265377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002529385,0.00009918924,0.00014294303,0.00045747048,0.00023077699,0.00038239654,0.00009238024,0.00021199528,0.0018589603],"category_scores_gemma":[0.0003186663,0.00018336989,0.00017620869,0.00027677655,0.00021907392,0.00034618762,0.00018542225,0.00037743564,0.00042323367],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012048346,0.00012296019,0.007609327,0.00005839497,0.000010843081,0.00030953367,0.00024588153,0.000097667624,0.9843038,0.00062130037,0.00012399124,0.005291524],"study_design_scores_gemma":[0.00009431944,0.0013621257,0.174725,0.000020319492,0.000056015866,0.0025309576,0.0011682517,0.001779511,0.8118758,0.00055355637,0.0058155535,0.000018459637],"about_ca_topic_score_codex":0.0007836344,"about_ca_topic_score_gemma":0.0006921125,"teacher_disagreement_score":0.0018589603,"about_ca_system_score_codex":0.00022957433,"about_ca_system_score_gemma":0.00016942514,"threshold_uncertainty_score":0.006218791},"labels":[],"label_agreement":null},{"id":"W2079698093","doi":"10.1016/j.jprot.2013.06.034","title":"Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification","year":2013,"lang":"en","type":"article","venue":"Journal of Proteomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Canadian Cancer Society; Alberta Cancer Foundation","keywords":"Biology; Breast cancer; Cancer; Cancer research; Epidermal growth factor receptor; Transfection; Gene; Proteomics; Effector; Cancer cell; Biomarker; Molecular biology; Cell biology; Genetics","score_opus":0.037396852642592654,"score_gpt":0.33723612929447366,"score_spread":0.29983927665188104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079698093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832895,0.002466654,0.0059712897,0.00026575103,0.00015042655,0.00006103729,0.0033328822,0.00013821949,0.0043243365],"genre_scores_gemma":[0.97580886,0.0022431212,0.010176323,0.00033501114,0.00003852431,0.00013083515,0.0046439357,0.000049203947,0.0065742517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998503,0.000012839033,0.000012238794,0.00002873122,0.000058361744,0.000037402344],"domain_scores_gemma":[0.9999052,0.000026238818,0.00001245351,0.0000092617975,0.00003094414,0.00001583367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016371257,0.00042434607,0.0002979323,0.0003564814,0.00027106673,0.00030692705,0.00018041671,0.0002538953,0.0009903258],"category_scores_gemma":[0.00014654093,0.00014341527,0.00024504543,0.00047719883,0.0001976025,0.00019294106,0.00013975942,0.00044624964,0.000340692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009322116,0.000014686496,0.00021618705,0.000024444285,0.000005699101,0.000051390816,0.000018843504,0.000010493362,0.999041,0.000028883745,0.000037077985,0.000457947],"study_design_scores_gemma":[0.000009175683,0.00018017317,0.027363146,0.000004821771,0.000037413207,0.00059391273,0.00011706082,0.0005415832,0.9688798,0.000054122105,0.0022104732,0.000008355902],"about_ca_topic_score_codex":0.0016488761,"about_ca_topic_score_gemma":0.0024024395,"teacher_disagreement_score":0.0016488761,"about_ca_system_score_codex":0.0002960878,"about_ca_system_score_gemma":0.00021359755,"threshold_uncertainty_score":0.003313005},"labels":[],"label_agreement":null},{"id":"W2080119134","doi":"10.3747/co.v17i1.517","title":"Pathology Re-Review as an Essential Component of Breast Cancer Management","year":2010,"lang":"en","type":"letter","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Cancer; Pathology; Oncology; Bioinformatics; Internal medicine; Biology","score_opus":0.14138602076453471,"score_gpt":0.5111257768656063,"score_spread":0.3697397561010716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080119134","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016387375,0.0036523566,0.0005935012,0.9546625,0.026052354,0.000029315552,0.000039658942,0.00015154608,0.013179926],"genre_scores_gemma":[0.024469549,0.009499111,0.0017996498,0.82343554,0.11213766,0.00005250162,0.00010015509,0.00008553142,0.028420405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99699485,0.0008958237,0.00036744025,0.00024086866,0.001197176,0.00030383965],"domain_scores_gemma":[0.98799765,0.004600945,0.0010945677,0.00071343407,0.0032711257,0.0023223192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002294961,0.00062137446,0.00078914827,0.00086860487,0.0022521238,0.002007004,0.0018154564,0.023772292,0.008574161],"category_scores_gemma":[0.01709291,0.00058386446,0.00093802216,0.00071983924,0.0017368161,0.0033820309,0.0011231124,0.01918167,0.009171525],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026101055,0.000042765714,0.0014785774,0.00008748184,0.000010139099,0.010635382,0.000090743,0.00011892732,0.0004573529,0.0011438011,0.96064633,0.025262507],"study_design_scores_gemma":[0.000047828085,0.00010101643,0.0035435292,0.00056959444,0.000028278215,0.050893065,0.0003978489,0.0006059697,0.00044342276,0.0048479107,0.9384715,0.000050037772],"about_ca_topic_score_codex":0.0028647112,"about_ca_topic_score_gemma":0.009827522,"teacher_disagreement_score":0.023772292,"about_ca_system_score_codex":0.0031984202,"about_ca_system_score_gemma":0.0033272267,"threshold_uncertainty_score":0.028683424},"labels":[],"label_agreement":null},{"id":"W2080518844","doi":"10.1158/1078-0432.ccr-07-0701","title":"Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>In vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":506,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Trastuzumab; Gefitinib; Lapatinib; Erlotinib; Cancer research; Epidermal growth factor receptor; ErbB; In vivo; Epidermal growth factor; Growth factor receptor; Biology; Cancer; Receptor; Medicine; Breast cancer; Internal medicine","score_opus":0.12656251714838357,"score_gpt":0.4760326595411657,"score_spread":0.3494701423927821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080518844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931774,0.0016954265,0.0014810914,0.000088272434,0.000024423374,0.00009057586,0.0009949676,0.000078311175,0.0023696104],"genre_scores_gemma":[0.9860838,0.001551487,0.0032001531,0.00010016809,0.000018557777,0.000104318984,0.0045377566,0.00003288213,0.004370875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997923,0.000028266155,0.000024719724,0.000037837824,0.000068860005,0.000048029597],"domain_scores_gemma":[0.99987984,0.000027029144,0.000027434613,0.00002875981,0.000020065752,0.000016976477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022937218,0.00032608927,0.0003554881,0.00016801376,0.00016647713,0.0003453982,0.00021724471,0.0002286686,0.0025151],"category_scores_gemma":[0.0001608868,0.00017115375,0.00024434927,0.00033817443,0.0001601712,0.00014962709,0.00015300377,0.0005305874,0.0011294801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029969143,0.00017817075,0.0036650477,0.00006351378,0.000025261867,0.0001976912,0.000045237535,0.00009048021,0.99119616,0.00014220776,0.0003031469,0.0037934221],"study_design_scores_gemma":[0.000115697316,0.0016339411,0.03108315,0.0000110038345,0.00008805179,0.0032266853,0.000075908574,0.00088349864,0.9548295,0.000048011192,0.007994322,0.00001023055],"about_ca_topic_score_codex":0.0016451041,"about_ca_topic_score_gemma":0.0013686391,"teacher_disagreement_score":0.0025151,"about_ca_system_score_codex":0.00032065637,"about_ca_system_score_gemma":0.0002297458,"threshold_uncertainty_score":0.008413851},"labels":[],"label_agreement":null},{"id":"W2081516478","doi":"10.1158/0008-5472.can-12-3925","title":"β-Catenin Signaling Is a Critical Event in ErbB2-Mediated Mammary Tumor Progression","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institute of Cancer Research; McGill University Health Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Cancer research; Tumor progression; Mammary tumor; Cancer; Catenin; Breast cancer; Wnt signaling pathway; Metastasis; Biology; Tumor initiation; Genetically modified mouse; Signal transduction; Transgene; Cell biology; Gene; Genetics","score_opus":0.13100631178326783,"score_gpt":0.5175240876879034,"score_spread":0.38651777590463554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081516478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264926,0.0033469878,0.0018802127,0.000112329544,0.000010245103,0.000025148222,0.00031882856,0.000072687086,0.0015842478],"genre_scores_gemma":[0.9960193,0.0016458314,0.0007244376,0.000022726674,0.0000040102263,0.000018710165,0.00031976736,0.0000044841695,0.0012407769],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988747,0.00001300375,0.000008257003,0.000022891172,0.000041326693,0.00002701515],"domain_scores_gemma":[0.9999418,0.000005211149,0.000022667784,0.00000507561,0.00000801594,0.000017219563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016011989,0.00039658108,0.00021298035,0.00034206934,0.00017933687,0.0004643465,0.00011892635,0.00022660024,0.0007807107],"category_scores_gemma":[0.00009580413,0.00018072748,0.00016042462,0.0002494905,0.00019945091,0.0002532778,0.00019551617,0.00051636086,0.0002260916],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009699152,0.00002046604,0.0007155087,0.000022405766,0.000002968753,0.00005982237,0.000008751451,0.0000580568,0.9977964,0.0001443518,0.000024562712,0.0010498357],"study_design_scores_gemma":[0.000021338317,0.00034079564,0.031240987,0.000011958667,0.000019482975,0.000712589,0.00006150117,0.0009840727,0.96330863,0.00022293915,0.0030675763,0.000008003777],"about_ca_topic_score_codex":0.0009767277,"about_ca_topic_score_gemma":0.0015039028,"teacher_disagreement_score":0.0009767277,"about_ca_system_score_codex":0.00046658266,"about_ca_system_score_gemma":0.00031979787,"threshold_uncertainty_score":0.0033853054},"labels":[],"label_agreement":null},{"id":"W2081555496","doi":"10.1158/0008-5472.sabcs12-ot1-1-07","title":"Abstract OT1-1-07: Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515)","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab; Metastatic breast cancer; Tolerability; Internal medicine; Discontinuation; Oncology; Breast cancer; Chemotherapy; Adverse effect; Cancer","score_opus":0.10302319983605311,"score_gpt":0.44882617489008764,"score_spread":0.3458029750540345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081555496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979115,0.00047236567,0.0001512612,0.0001232249,0.0000507565,0.0001982862,0.00038267442,0.000041643867,0.00066820905],"genre_scores_gemma":[0.9962084,0.0005098344,0.0004205406,0.00014777626,0.000048752772,0.00027917404,0.0012149983,0.000010505387,0.0011599074],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997787,0.000055387944,0.000021868755,0.000039484665,0.000033042503,0.0000716465],"domain_scores_gemma":[0.99977475,0.000026617554,0.000050009396,0.000021155047,0.000011179034,0.00011625582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040472162,0.00062317745,0.0011073168,0.00034888388,0.00025922272,0.00050293823,0.0006947397,0.0005723002,0.0031193008],"category_scores_gemma":[0.0002857952,0.00021368696,0.00060922076,0.0003747488,0.00062840927,0.0004867015,0.00030675737,0.0019228415,0.00046825845],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30818027,0.08089214,0.00675376,0.00095729827,0.00065918086,0.000565339,0.00017446154,0.0027570834,0.47916213,0.00054512866,0.0053606704,0.113992594],"study_design_scores_gemma":[0.13349566,0.7203919,0.018727124,0.000045715442,0.0005842694,0.0010261721,0.00009101822,0.00219168,0.119055554,0.00022320347,0.0041166,0.000051179388],"about_ca_topic_score_codex":0.00087863795,"about_ca_topic_score_gemma":0.0015437477,"teacher_disagreement_score":0.0031193008,"about_ca_system_score_codex":0.0004374695,"about_ca_system_score_gemma":0.0009181922,"threshold_uncertainty_score":0.010435045},"labels":[],"label_agreement":null},{"id":"W2081649373","doi":"10.1007/s10637-005-5860-y","title":"A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Hamilton Regional Laboratory Medicine Program; Ottawa Regional Cancer Foundation","funders":"","keywords":"Cancer; Medicine; Investigational Drugs; Drug; Cancer drugs; Family medicine; Gerontology; Internal medicine; Clinical trial; Pharmacology","score_opus":0.14092656980953736,"score_gpt":0.45770799104479143,"score_spread":0.3167814212352541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081649373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852186,0.0023980455,0.0006780874,0.0011164579,0.0002923056,0.0024957638,0.003641396,0.0002765887,0.0038827984],"genre_scores_gemma":[0.9722748,0.004432375,0.00255535,0.0016519015,0.00044048458,0.0027429145,0.0071385326,0.000116897034,0.008646777],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99953485,0.0002394167,0.000018061564,0.00006392996,0.00004398676,0.00009976823],"domain_scores_gemma":[0.9989473,0.00020599159,0.00014339227,0.000087296896,0.000059321843,0.0005567085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017077114,0.0029067488,0.0043728948,0.00084533246,0.0006848984,0.0013093817,0.0011480472,0.0017421029,0.005540175],"category_scores_gemma":[0.0014942167,0.0010239795,0.0020904588,0.0007576622,0.0013407794,0.0010724242,0.00037415285,0.0048358794,0.001690491],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8218663,0.06527223,0.0035283528,0.00088697317,0.0011980884,0.00028952994,0.0002526314,0.0024122298,0.025569694,0.00037963112,0.009664354,0.06867995],"study_design_scores_gemma":[0.77003026,0.22024819,0.0052389945,0.000018069391,0.00031909771,0.00017677575,0.000043692813,0.00088149065,0.0012191689,0.00012660575,0.0016622833,0.00003538436],"about_ca_topic_score_codex":0.0020146852,"about_ca_topic_score_gemma":0.004770187,"teacher_disagreement_score":0.005540175,"about_ca_system_score_codex":0.0009713415,"about_ca_system_score_gemma":0.002042409,"threshold_uncertainty_score":0.018533707},"labels":[],"label_agreement":null},{"id":"W2082207901","doi":"10.1002/ijc.24884","title":"The effects of gefitinib in tamoxifen‐resistant and hormone‐insensitive breast cancer: A phase II study","year":2009,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; World Health Organization","keywords":"Gefitinib; Tamoxifen; Breast cancer; Medicine; Epidermal growth factor receptor; Internal medicine; Estrogen receptor; Oncology; EGFR inhibitors; Cancer; Cancer research; Endocrinology","score_opus":0.014515962207241582,"score_gpt":0.4154056267011625,"score_spread":0.4008896644939209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082207901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673885,0.0017006764,0.00021780348,0.000098790544,0.000043506676,0.0005141848,0.0002580033,0.000037138427,0.00039117772],"genre_scores_gemma":[0.9930488,0.0019804072,0.00068582554,0.00030941708,0.000118572265,0.0011360461,0.0013684748,0.000024756799,0.0013276229],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994796,0.00025863032,0.000031402422,0.00007070209,0.00004959715,0.00011004323],"domain_scores_gemma":[0.999416,0.00010181658,0.00010778708,0.00007097497,0.000034159973,0.00026921535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014410348,0.0016835931,0.002858356,0.00049957266,0.00036757605,0.0006796158,0.0007124093,0.0012022771,0.0016183701],"category_scores_gemma":[0.00067277846,0.00055550324,0.0012562213,0.0003783415,0.0006858792,0.0006962888,0.0002174424,0.0019334079,0.0004840354],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5804806,0.11959601,0.012071963,0.0010160625,0.0018861857,0.00081634626,0.0005013414,0.002895941,0.17265734,0.00024397922,0.0027409904,0.10509332],"study_design_scores_gemma":[0.28984994,0.6597603,0.035685234,0.000032737833,0.00059759436,0.00094860786,0.00011131144,0.0014432727,0.009330567,0.000118246135,0.0020609456,0.0000612947],"about_ca_topic_score_codex":0.0006672878,"about_ca_topic_score_gemma":0.0022513578,"teacher_disagreement_score":0.002858356,"about_ca_system_score_codex":0.00064178725,"about_ca_system_score_gemma":0.00080038863,"threshold_uncertainty_score":0.0076209903},"labels":[],"label_agreement":null},{"id":"W2082211942","doi":"10.1186/1471-2407-10-255","title":"The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors","year":2010,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Cetuximab; Trastuzumab; Monoclonal antibody; Medicine; Immunohistochemistry; Distribution (mathematics); Cancer research; Surgical oncology; Carcinoma; Antibody; Pathology; Internal medicine; Cancer; Immunology; Breast cancer","score_opus":0.03490997489727181,"score_gpt":0.366115816217177,"score_spread":0.33120584131990516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082211942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98628867,0.004140452,0.007206165,0.00006810366,0.000011060384,0.000022626664,0.00015417313,0.000053873406,0.0020550138],"genre_scores_gemma":[0.99389887,0.0012117752,0.0031620935,0.00004109587,0.000009805499,0.000026102105,0.00018219557,0.000016976543,0.001451093],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997892,0.000027034119,0.000010814333,0.000051822582,0.00006511113,0.000056115125],"domain_scores_gemma":[0.9998265,0.000042818865,0.00005563136,0.000011552237,0.00003401345,0.000029567804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020214081,0.00016826596,0.00018290384,0.0002301843,0.00014447764,0.00037099727,0.00015310389,0.00032988217,0.0009117563],"category_scores_gemma":[0.00017474717,0.00015238469,0.00013387625,0.00016205323,0.00020924151,0.00027959637,0.00015997629,0.00031824035,0.00027243653],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009869748,0.000017562415,0.0018842818,0.00004753552,0.000010984169,0.000038120386,0.000018652441,0.0001901225,0.9948137,0.00009615295,0.000037626934,0.0027465874],"study_design_scores_gemma":[0.000020649517,0.0005358343,0.04215394,0.000013392657,0.000045849843,0.0005294094,0.000048535832,0.002264855,0.95092934,0.000087086,0.0033646412,0.000006513684],"about_ca_topic_score_codex":0.0014447495,"about_ca_topic_score_gemma":0.0010148243,"teacher_disagreement_score":0.0014447495,"about_ca_system_score_codex":0.0006095245,"about_ca_system_score_gemma":0.0003286112,"threshold_uncertainty_score":0.0044223666},"labels":[],"label_agreement":null},{"id":"W2082991733","doi":"10.1006/gyno.2002.6682","title":"General Keynote: Expression of Epidermal Growth Factor Receptor Family in Transgenic Mouse Models of Human Breast Cancer","year":2003,"lang":"en","type":"review","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Breast cancer; Genetically modified mouse; Human Epidermal Growth Factor Receptor 2; Cancer research; Transgene; Epidermal growth factor receptor; Expression (computer science); Cancer; Oncology; Internal medicine; Genetics; Gene; Biology","score_opus":0.16879511054871607,"score_gpt":0.4461844866397767,"score_spread":0.2773893760910606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082991733","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024887413,0.94985473,0.00074835814,0.0046515763,0.026807897,0.00007199856,0.0003463526,0.00011496013,0.017155234],"genre_scores_gemma":[0.0010246974,0.9406091,0.00062592456,0.006552196,0.011818882,0.00006521935,0.0006156762,0.000028463815,0.0386598],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982846,0.000019182227,0.000019437699,0.000032503285,0.00007943323,0.000021017424],"domain_scores_gemma":[0.99969697,0.00009247227,0.000045741395,0.000011950087,0.000098625176,0.000054226086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047181977,0.0013203934,0.0013340767,0.0024288914,0.00026030454,0.0007607612,0.0013236892,0.0018501362,0.019082077],"category_scores_gemma":[0.0006154748,0.00028015353,0.00058849127,0.0023670122,0.00040093414,0.0016062052,0.0007656975,0.0024516329,0.013694148],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015540564,0.00007221474,0.00007952868,0.0052387496,0.000025656547,0.00028892866,0.000019234787,0.00014911972,0.0039055434,0.0021087802,0.6682047,0.3197522],"study_design_scores_gemma":[0.000028360515,0.00005682431,0.00028624263,0.0006630554,0.000030182357,0.00060013344,0.000009390521,0.000025997017,0.0004894756,0.0006942863,0.99710864,0.000007447638],"about_ca_topic_score_codex":0.0016378197,"about_ca_topic_score_gemma":0.004182125,"teacher_disagreement_score":0.019082077,"about_ca_system_score_codex":0.00069250073,"about_ca_system_score_gemma":0.0008581942,"threshold_uncertainty_score":0.06383586},"labels":[],"label_agreement":null},{"id":"W2083053655","doi":"10.1038/sj.bjc.6601881","title":"HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review","year":2004,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Research Society","keywords":"Medicine; Lymph node; Trastuzumab; Breast cancer; Immunohistochemistry; Oncology; Cancer; CISH; Pathology; Cancer research; Internal medicine; Gene expression; Biology; Gene; In situ hybridization","score_opus":0.05765193668666164,"score_gpt":0.4376919582824539,"score_spread":0.38004002159579225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083053655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026766787,0.99894935,0.000029849502,0.00004475355,0.000049127742,0.0000043225796,0.000057912635,0.0000029846242,0.00059404166],"genre_scores_gemma":[0.0017550905,0.997497,0.00011310301,0.00007205897,0.0000578012,0.000007611281,0.00011227015,0.0000013460589,0.000383706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964416,0.000043926255,0.00009936579,0.00006126438,0.00012735443,0.00002381488],"domain_scores_gemma":[0.99925464,0.00035778055,0.00015398947,0.000022650263,0.000183224,0.000027674561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005944978,0.0007522688,0.002030388,0.004988931,0.00018410133,0.0009097518,0.00074748317,0.00065060286,0.0054182764],"category_scores_gemma":[0.0013744994,0.00030750287,0.0005953954,0.006892092,0.00034481473,0.0010442054,0.00035085494,0.00046107813,0.0017128941],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022528911,0.000049573577,0.0011473949,0.08366677,0.00020885692,0.0014232899,0.00011546545,0.00019238562,0.0029217566,0.00053531525,0.017163714,0.89235014],"study_design_scores_gemma":[0.00007556513,0.0003265804,0.018643588,0.043414827,0.001988547,0.029743992,0.00033325245,0.00013932568,0.0030689677,0.0009658151,0.90124255,0.000056960896],"about_ca_topic_score_codex":0.002576521,"about_ca_topic_score_gemma":0.0043791067,"teacher_disagreement_score":0.0054182764,"about_ca_system_score_codex":0.0005547157,"about_ca_system_score_gemma":0.0013269958,"threshold_uncertainty_score":0.018125951},"labels":[],"label_agreement":null},{"id":"W2084312945","doi":"10.1007/s10549-010-0733-2","title":"Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes","year":2010,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"School of Medicine, Indiana University; Eli Lilly and Company","keywords":"Breast cancer; Protein kinase C; Tissue microarray; Estrogen receptor; Cancer research; Cancer; Immunohistochemistry; Medicine; Internal medicine; Pathology; Biology; Oncology; Endocrinology; Kinase; Cell biology","score_opus":0.031178596612747553,"score_gpt":0.35196370857803233,"score_spread":0.32078511196528475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084312945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591726,0.0018713156,0.0003062572,0.000053097137,0.0000132111645,0.0000057078432,0.0003980173,0.000015024689,0.0014201924],"genre_scores_gemma":[0.99788886,0.0005149917,0.0001851334,0.000016070553,0.000011799469,0.000008701046,0.00044406048,0.0000073433007,0.0009231435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99983406,0.000021917254,0.000017314496,0.000038591865,0.000029176015,0.000058942172],"domain_scores_gemma":[0.99958163,0.00007087391,0.00011259687,0.00004724959,0.000095496136,0.00009223869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002186459,0.0001786707,0.0002401709,0.00089346606,0.0003467425,0.0005064544,0.000247297,0.0002509644,0.0020279796],"category_scores_gemma":[0.00053072046,0.00019452452,0.00023643115,0.0006434528,0.0002445861,0.00022590668,0.00021909837,0.00035323764,0.0005578867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060908766,0.00012728057,0.4997945,0.00012843123,0.0002178414,0.00049327186,0.00021663959,0.000232008,0.47623786,0.00034207117,0.0005928835,0.015526375],"study_design_scores_gemma":[0.00003162545,0.00014008496,0.9694635,0.000006188695,0.000064548905,0.0019650552,0.00032299082,0.0005544501,0.026166458,0.00015101579,0.001125163,0.000008859951],"about_ca_topic_score_codex":0.0016637945,"about_ca_topic_score_gemma":0.001275975,"teacher_disagreement_score":0.0020279796,"about_ca_system_score_codex":0.00035859662,"about_ca_system_score_gemma":0.00019823863,"threshold_uncertainty_score":0.00678432},"labels":[],"label_agreement":null},{"id":"W2085093059","doi":"10.3747/co.v16i5.510","title":"The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Santé Montérégie; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; Centre hospitalier universitaire de Québec; Sunnybrook Health Science Centre; Hôpital du Saint-Sacrement","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Targeted therapy; Neoadjuvant therapy; Human Epidermal Growth Factor Receptor 2; Adjuvant; Pertuzumab; Internal medicine; Stage (stratigraphy); Clinical trial; Cancer","score_opus":0.06684936890207013,"score_gpt":0.4379933897950619,"score_spread":0.3711440208929918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085093059","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063558854,0.82390314,0.0018228542,0.07896673,0.0010683844,0.00006342364,0.00009904351,0.000056426994,0.030461056],"genre_scores_gemma":[0.5018357,0.47312832,0.0053002886,0.011001878,0.0029290412,0.00008486566,0.00012001167,0.000034122197,0.005565812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995191,0.0002942373,0.000027622049,0.000024954537,0.00008602434,0.00004808044],"domain_scores_gemma":[0.9986076,0.0007793125,0.0001462463,0.000040851883,0.00023891599,0.00018704953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002833032,0.00018249881,0.0006257962,0.0002957481,0.0003256773,0.001084042,0.00039724662,0.00058356096,0.0014504141],"category_scores_gemma":[0.00351371,0.00010578707,0.00026655334,0.0002679461,0.0009023061,0.0007068012,0.00026241114,0.0010546307,0.00020158054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029698194,0.00020899376,0.01597053,0.0015850242,0.00008735343,0.001045537,0.0002877586,0.0017965148,0.00980436,0.005434525,0.026389021,0.9344205],"study_design_scores_gemma":[0.0008731761,0.004615935,0.09481153,0.0042269323,0.0006243094,0.008408448,0.001981141,0.0029393209,0.014426952,0.012242202,0.85468554,0.00016445137],"about_ca_topic_score_codex":0.0048993668,"about_ca_topic_score_gemma":0.028969387,"teacher_disagreement_score":0.0048993668,"about_ca_system_score_codex":0.0019147304,"about_ca_system_score_gemma":0.003354762,"threshold_uncertainty_score":0.0149827},"labels":[],"label_agreement":null},{"id":"W2085770486","doi":"10.1016/j.jsbmb.2005.02.001","title":"Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway","year":2005,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Estrogen receptor; ERBB3; Estrogen receptor alpha; Signal transduction; Estrogen receptor beta; ErbB; Phosphorylation; Biology; Neuregulin; Fulvestrant; Tyrosine phosphorylation; Cell biology; MAPK/ERK pathway; Cancer research; Chemistry; Receptor tyrosine kinase; Cancer; Breast cancer","score_opus":0.010584261150853662,"score_gpt":0.30548024091043136,"score_spread":0.2948959797595777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085770486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99159193,0.0019049504,0.0011013447,0.00016491096,0.00004020125,0.000019314284,0.000365517,0.000075169024,0.0047366465],"genre_scores_gemma":[0.995682,0.0006355818,0.00042781045,0.00003548466,0.000009454733,0.000019016497,0.00026579536,0.000011251945,0.0029134837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990785,0.000010720034,0.000004563846,0.000011296942,0.000014875828,0.000050728606],"domain_scores_gemma":[0.9999492,0.00000997358,0.000011100895,0.000010234809,0.000005026283,0.0000145295035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114792194,0.00032101394,0.00013521795,0.0001524187,0.00020634652,0.0002669483,0.0001789358,0.00009367825,0.0026995852],"category_scores_gemma":[0.000103566425,0.00014635535,0.00021936362,0.00010908472,0.00019471806,0.00015514072,0.00026152123,0.00032864945,0.0005070751],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029207303,0.00003138506,0.00012637992,0.000021026111,0.000004194152,0.00009032939,0.00001428961,0.000047666887,0.9970626,0.00030499694,0.000106766056,0.0018982507],"study_design_scores_gemma":[0.00005631303,0.00026899826,0.009183489,0.0000063197017,0.000009997833,0.0005335085,0.000049225142,0.0005500511,0.98586965,0.00022501488,0.0032425036,0.000004916783],"about_ca_topic_score_codex":0.0007585435,"about_ca_topic_score_gemma":0.0018128467,"teacher_disagreement_score":0.0026995852,"about_ca_system_score_codex":0.00035165407,"about_ca_system_score_gemma":0.00029467716,"threshold_uncertainty_score":0.009030998},"labels":[],"label_agreement":null},{"id":"W2086553369","doi":"10.1016/j.cellsig.2008.11.012","title":"Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: Agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells","year":2008,"lang":"en","type":"article","venue":"Cellular Signalling","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; University of British Columbia; McGill University","funders":"","keywords":"Somatostatin receptor; Epidermal growth factor; GRB2; Somatostatin receptor 1; Biology; Somatostatin receptor 2; Cell biology; MAPK/ERK pathway; Epidermal growth factor receptor; Cancer research; Signal transduction; Receptor; Somatostatin; Agonist; Signal transducing adaptor protein; Endocrinology; Biochemistry","score_opus":0.026069455954734814,"score_gpt":0.2526054131560498,"score_spread":0.22653595720131497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086553369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441034,0.0024235237,0.00045362703,0.0001830354,0.000047769503,0.000011197649,0.00012678686,0.00001527542,0.0023283707],"genre_scores_gemma":[0.99618584,0.0010682921,0.0003042879,0.00008483075,0.000015294932,0.000014864207,0.00036860647,0.000005546139,0.0019524401],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99972624,0.00008423066,0.00001826821,0.00002409714,0.000057422687,0.00008979682],"domain_scores_gemma":[0.99994373,0.00001653737,0.000012610182,0.0000063768866,0.000004842012,0.00001578701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002087903,0.00021250406,0.0001875646,0.00016820533,0.00017005212,0.00033299706,0.00015176811,0.00024703587,0.0016516682],"category_scores_gemma":[0.00018093699,0.00014749082,0.00026753,0.00017173095,0.000121933896,0.00019500678,0.00022175485,0.00029782383,0.0004706431],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032231427,0.000034512017,0.0004037377,0.00003056152,0.000010087708,0.00012432251,0.000021144371,0.000061740444,0.99753535,0.00016657065,0.00011445613,0.0011752723],"study_design_scores_gemma":[0.00010247915,0.00074996194,0.026293963,0.000013831505,0.000065410255,0.0020345564,0.00031082405,0.0017684668,0.9599157,0.00017497147,0.008554582,0.000015254639],"about_ca_topic_score_codex":0.00043902942,"about_ca_topic_score_gemma":0.00079959043,"teacher_disagreement_score":0.0016516682,"about_ca_system_score_codex":0.0002411599,"about_ca_system_score_gemma":0.00016265667,"threshold_uncertainty_score":0.00552541},"labels":[],"label_agreement":null},{"id":"W2086661954","doi":"10.1186/bcr1776","title":"Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study","year":2007,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Concordance; Breast cancer; Medicine; Immunohistochemistry; Oncology; Fish <Actinopterygii>; Internal medicine; Pathology; Cancer; Biology; In situ hybridization; Fishery; Gene; Genetics","score_opus":0.1242535920657148,"score_gpt":0.526977088041126,"score_spread":0.4027234959754112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086661954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9205972,0.006069006,0.053261556,0.000616407,0.00014285013,0.0019181272,0.0003973406,0.0003468776,0.01665065],"genre_scores_gemma":[0.9530094,0.00102232,0.04153844,0.00030362484,0.000090829126,0.0010197813,0.0015018557,0.00008154568,0.0014322957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9773942,0.015097108,0.0018351559,0.0021852371,0.0027861572,0.000702091],"domain_scores_gemma":[0.9789767,0.008172493,0.00203686,0.004822266,0.0049648136,0.0010268694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.049652953,0.0010140946,0.0005981193,0.0018379225,0.0006397771,0.0008609224,0.0013864449,0.00080938835,0.0016761698],"category_scores_gemma":[0.017038,0.00037617626,0.0006930953,0.00092707435,0.0021439614,0.00073917623,0.001810666,0.0007739655,0.00077856885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008752316,0.0023925563,0.5255832,0.0012677797,0.0011507297,0.0016091411,0.0057350667,0.0028985154,0.25387785,0.003810717,0.0025511582,0.19037095],"study_design_scores_gemma":[0.001657676,0.035770006,0.62593704,0.0005393637,0.0016041591,0.0142999645,0.0022026731,0.0061668777,0.2601353,0.0013204783,0.050153214,0.00021325404],"about_ca_topic_score_codex":0.0010319282,"about_ca_topic_score_gemma":0.00080221967,"teacher_disagreement_score":0.049652953,"about_ca_system_score_codex":0.0007909977,"about_ca_system_score_gemma":0.0010110051,"threshold_uncertainty_score":0.26259303},"labels":[],"label_agreement":null},{"id":"W2088169167","doi":"10.1097/cad.0b013e328331178f","title":"Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status","year":2009,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Docetaxel; Medicine; Internal medicine; Oncology; Hazard ratio; Breast cancer; Chemotherapy; Metastatic breast cancer; Trastuzumab; Univariate analysis; Cancer; Proportional hazards model; Confidence interval; Multivariate analysis","score_opus":0.014285805433521878,"score_gpt":0.33397448165097277,"score_spread":0.3196886762174509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088169167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99948716,0.00018883907,0.000051666506,0.000014316081,0.000004152457,0.000008599185,0.00014085995,0.000001249821,0.0001030923],"genre_scores_gemma":[0.99918264,0.00016627276,0.00006736234,0.00002605519,0.00001451298,0.00001276117,0.00038884522,0.0000022051165,0.00013939379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996581,0.00007012508,0.00003303811,0.000100858655,0.00006290337,0.00007498639],"domain_scores_gemma":[0.9990233,0.00019334366,0.00032131284,0.0001519834,0.00008253634,0.00022749644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000505604,0.00029286058,0.00049982726,0.00050916936,0.00059767906,0.0008408565,0.0002529947,0.00043178463,0.0008396687],"category_scores_gemma":[0.0015828484,0.00043652908,0.0005932395,0.0007394923,0.0002595576,0.00050322764,0.00032556494,0.00073924917,0.00029332278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004040744,0.00012011218,0.99742836,0.0000061041173,0.000058435868,0.00034498525,0.00009510358,0.000037150938,0.0003059404,0.00001078024,0.00007221422,0.00111677],"study_design_scores_gemma":[0.00007852085,0.0011959762,0.9948655,0.000009835161,0.000084368,0.0023317744,0.00031113817,0.00034306847,0.00020011666,0.000030011815,0.0005366307,0.000013156659],"about_ca_topic_score_codex":0.00374837,"about_ca_topic_score_gemma":0.0037212525,"teacher_disagreement_score":0.00374837,"about_ca_system_score_codex":0.00037847008,"about_ca_system_score_gemma":0.0004488146,"threshold_uncertainty_score":0.007453084},"labels":[],"label_agreement":null},{"id":"W2088605318","doi":"10.1007/s00280-007-0579-4","title":"Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Pharmacokinetics; Dosing; Medicine; Adverse effect; Toxicity; Internal medicine; Tyrosine-kinase inhibitor; Incidence (geometry); Pharmacology; Clinical trial; Gastroenterology; Oncology; Cancer","score_opus":0.018120891819779165,"score_gpt":0.380221315198652,"score_spread":0.3621004233788728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088605318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968125,0.0013771493,0.0004858131,0.0001775494,0.0000214626,0.00003943505,0.00026901564,0.00005918361,0.00075785513],"genre_scores_gemma":[0.9984617,0.0004020992,0.00027460064,0.00009659736,0.00003823366,0.00002203724,0.00029536977,0.000018249402,0.0003911503],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996331,0.00016824824,0.000022975182,0.00005480368,0.00006777491,0.000053084837],"domain_scores_gemma":[0.9990189,0.0003315704,0.00026621678,0.00005912964,0.00006205261,0.00026221797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000576673,0.00047519617,0.0013397876,0.00036784878,0.00028107522,0.0006493946,0.00028083497,0.00046998655,0.00095945393],"category_scores_gemma":[0.0026941448,0.00042388475,0.0005278871,0.0005138686,0.0002907019,0.00070750545,0.00015656871,0.0017507893,0.00026500484],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42337278,0.0061151744,0.19491026,0.0003226754,0.0020695212,0.0014532121,0.0005454633,0.013072213,0.13339521,0.0005599977,0.003601016,0.22058247],"study_design_scores_gemma":[0.02662511,0.16548423,0.7290282,0.000053871554,0.0021072316,0.005074981,0.00031042032,0.022690233,0.040458713,0.0006098747,0.0073786364,0.00017842591],"about_ca_topic_score_codex":0.0015101619,"about_ca_topic_score_gemma":0.0020052532,"teacher_disagreement_score":0.0015101619,"about_ca_system_score_codex":0.0008203549,"about_ca_system_score_gemma":0.00082323706,"threshold_uncertainty_score":0.00595212},"labels":[],"label_agreement":null},{"id":"W2089842133","doi":"10.1158/1535-7163.targ-09-c49","title":"Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non-toxic in a preclinical model of advanced triple negative breast cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nimotuzumab; Medicine; Metastatic breast cancer; Panitumumab; Cetuximab; Triple-negative breast cancer; Cyclophosphamide; Breast cancer; Cancer; Bevacizumab; Docetaxel; Trastuzumab; Oncology; Combination therapy; Cancer research; Targeted therapy; Pharmacology; Monoclonal antibody; Chemotherapy; Epidermal growth factor receptor; Internal medicine; Immunology; Antibody; Colorectal cancer","score_opus":0.03126555443784302,"score_gpt":0.3740643119938047,"score_spread":0.3427987575559617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089842133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955382,0.00078995107,0.00078134076,0.00013505308,0.00010661085,0.00018928095,0.00058041397,0.00008810973,0.0017910535],"genre_scores_gemma":[0.99293786,0.0006712183,0.0017219894,0.00006919339,0.000039622264,0.000191967,0.0009869884,0.000024072442,0.0033571657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982774,0.00002439618,0.000010943337,0.000028455433,0.000052761825,0.000055631484],"domain_scores_gemma":[0.99989676,0.000010978966,0.000019816662,0.000010480339,0.000013368404,0.00004858753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016506812,0.0004597258,0.0006375888,0.00035093172,0.00017643717,0.00025535582,0.0003313892,0.0003958968,0.0016082994],"category_scores_gemma":[0.00011352347,0.00012578662,0.00026590913,0.00017953002,0.00019289416,0.0001675698,0.00011382644,0.0007611042,0.00034871843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033450273,0.0028727762,0.00026830885,0.00006638564,0.00003596234,0.000096948614,0.000021960623,0.00046416261,0.98549575,0.00013284317,0.00065998215,0.006539877],"study_design_scores_gemma":[0.0009950541,0.038418654,0.0049357833,0.000012516992,0.00009182416,0.00041174283,0.000023398274,0.002666214,0.9475146,0.000047921716,0.004866667,0.000015679057],"about_ca_topic_score_codex":0.0017671603,"about_ca_topic_score_gemma":0.0035417008,"teacher_disagreement_score":0.0017671603,"about_ca_system_score_codex":0.000426023,"about_ca_system_score_gemma":0.00057264674,"threshold_uncertainty_score":0.0053803325},"labels":[],"label_agreement":null},{"id":"W2091242368","doi":"10.1172/jci57100","title":"Breast cancer — one term, many entities?","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University Health Centre; McGill University","keywords":"Breast cancer; Cancer; Breast tumor; Disease; Computational biology; Bioinformatics; Medicine; Tumor heterogeneity; Biology; Cancer research; Pathology; Internal medicine","score_opus":0.4923396356444193,"score_gpt":0.5576649504711761,"score_spread":0.06532531482675685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091242368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007903194,0.99377316,0.00013288936,0.0033401863,0.0012202115,0.00000232542,0.00001030551,0.000008753808,0.0014330925],"genre_scores_gemma":[0.0012983074,0.99243647,0.00034639693,0.0024058062,0.0018882939,0.0000055496307,0.000028428947,0.000003738182,0.0015869896],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996124,0.00011746632,0.000049049082,0.000053957236,0.00013204875,0.00003506373],"domain_scores_gemma":[0.99942964,0.00024589067,0.00006079005,0.000031553856,0.00015637619,0.00007571506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077117124,0.00086083706,0.0017913781,0.0021030917,0.00044372937,0.0017246085,0.00097386335,0.0013278307,0.0025379707],"category_scores_gemma":[0.0014156508,0.00024659277,0.00033171757,0.0028787847,0.0014908051,0.0040028915,0.0010825435,0.0028015797,0.0025189754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060486353,0.000039153536,0.0004154319,0.004423095,0.00006138792,0.00037363186,0.00015889957,0.00014375107,0.0007731897,0.01081153,0.17679776,0.80594164],"study_design_scores_gemma":[0.000006586939,0.000021539941,0.00040961106,0.0019239149,0.000028663897,0.0025799882,0.00021484826,0.000030823485,0.00007646936,0.0050315033,0.9896646,0.000011458765],"about_ca_topic_score_codex":0.0013639267,"about_ca_topic_score_gemma":0.002458247,"teacher_disagreement_score":0.0025379707,"about_ca_system_score_codex":0.0010667853,"about_ca_system_score_gemma":0.0015751348,"threshold_uncertainty_score":0.008490324},"labels":[],"label_agreement":null},{"id":"W2091805528","doi":"10.1002/cncr.23350","title":"Prognostic significance of HER‐2 status in women with inflammatory breast cancer","year":2008,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Defence Research and Development Canada","funders":"National Cancer Institute; Susan G. Komen for the Cure","keywords":"Medicine; Internal medicine; Trastuzumab; Breast cancer; Proportional hazards model; Univariate analysis; Anthracycline; Disease; Multivariate analysis; Oncology; Survival analysis; Inflammatory breast cancer; Regimen; Cancer; Chemotherapy; Surgery; Gastroenterology","score_opus":0.02885500294830198,"score_gpt":0.3240925398947564,"score_spread":0.29523753694645444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091805528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874556,0.0007515664,0.000024880781,0.00005770738,0.0000058832734,0.0000029975292,0.00010409106,0.0000012921457,0.00030614523],"genre_scores_gemma":[0.9996716,0.00013494182,0.000021911459,0.000012975598,0.000011869642,0.0000028580582,0.00009964789,5.11695e-7,0.000043567205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981874,0.000058077465,0.000018035023,0.000026001384,0.000030256282,0.000048977443],"domain_scores_gemma":[0.9987192,0.00037916625,0.0006139404,0.000032363358,0.00007030888,0.00018498642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005110793,0.00016986576,0.00017798138,0.00045666663,0.00023605996,0.0003682911,0.00018135498,0.0003225463,0.0011252782],"category_scores_gemma":[0.0024962872,0.000098067605,0.00018083263,0.00057260797,0.000288252,0.00028432297,0.0002495095,0.0002798823,0.00016914363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016350922,0.000006082112,0.9986859,0.0000050202443,0.000008547431,0.00008872623,0.000015320687,0.000035548972,0.000079722384,0.000006021266,0.00003749925,0.00086801173],"study_design_scores_gemma":[0.0000145163685,0.00010909748,0.9981996,0.000008859354,0.000031303967,0.0009920743,0.00009336542,0.00018652181,0.0000772671,0.000036740304,0.0002473816,0.0000032601813],"about_ca_topic_score_codex":0.0009114732,"about_ca_topic_score_gemma":0.0014834413,"teacher_disagreement_score":0.0011252782,"about_ca_system_score_codex":0.00020655616,"about_ca_system_score_gemma":0.00023569136,"threshold_uncertainty_score":0.0037644506},"labels":[],"label_agreement":null},{"id":"W2092014058","doi":"10.1016/j.apradiso.2014.10.011","title":"Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)","year":2014,"lang":"en","type":"article","venue":"Applied Radiation and Isotopes","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University Health Network; McMaster University; University of Toronto","funders":"Genentech","keywords":"Pertuzumab; Trastuzumab; Medicine; Breast cancer; Nuclear medicine; Cancer; Internal medicine","score_opus":0.014629073940783582,"score_gpt":0.3476201015675357,"score_spread":0.33299102762675215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092014058","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20066775,0.008341729,0.7090778,0.0013688746,0.0011678896,0.0072436086,0.008321324,0.018627724,0.045183282],"genre_scores_gemma":[0.1977895,0.0045250985,0.6269849,0.0012782032,0.0003445297,0.008724169,0.028311444,0.0026967914,0.12934537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990872,0.0002026603,0.000079406294,0.00023436165,0.00025943105,0.00013687428],"domain_scores_gemma":[0.9990243,0.00030101126,0.00009894542,0.00013562491,0.00024789834,0.00019220365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010978067,0.001565551,0.00086051313,0.002330086,0.0007671016,0.0007137014,0.0013950691,0.0013356488,0.03910714],"category_scores_gemma":[0.0017146082,0.0014890713,0.00069973985,0.00074705447,0.00037131304,0.00064736744,0.00077740004,0.0014626023,0.018824747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007913679,0.00025536775,0.00066877366,0.00062229374,0.00009247538,0.0003992748,0.00012646396,0.00040870748,0.95306844,0.0021987054,0.007100209,0.034267977],"study_design_scores_gemma":[0.000626376,0.0018465419,0.004685147,0.00020285381,0.0003022588,0.0039773043,0.0000565339,0.009247774,0.83843213,0.0010879113,0.13938086,0.00015433422],"about_ca_topic_score_codex":0.0005417996,"about_ca_topic_score_gemma":0.00145678,"teacher_disagreement_score":0.03910714,"about_ca_system_score_codex":0.00055341254,"about_ca_system_score_gemma":0.00091350335,"threshold_uncertainty_score":0.13082641},"labels":[],"label_agreement":null},{"id":"W2092796790","doi":"10.1007/s11095-005-4586-z","title":"Trastuzumab and Liposomal Doxorubicin in the Treatment of MCF-7 Xenograft Tumor-Bearing Mice: Combination Does Not Affect Drug Serum Levels","year":2005,"lang":"en","type":"article","venue":"Pharmaceutical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Doxorubicin; Trastuzumab; Pharmacology; Medicine; Liposome; Chemotherapy; Drug; Cancer; Breast cancer; Internal medicine; Chemistry","score_opus":0.22241735679233038,"score_gpt":0.5189544992396271,"score_spread":0.29653714244729673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092796790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946391,0.002456927,0.0007419684,0.00023726837,0.00010557113,0.000040098497,0.00017644787,0.0000842709,0.0015183921],"genre_scores_gemma":[0.9955148,0.0008447252,0.00081932277,0.00005092103,0.000040502768,0.000031942665,0.0003620543,0.000020008585,0.00231566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978215,0.00005866534,0.000015589869,0.000033511184,0.000049147693,0.00006097258],"domain_scores_gemma":[0.99982554,0.00004423002,0.00003362908,0.000025605743,0.0000137145535,0.00005738131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025401346,0.00038015604,0.00078581943,0.00029480614,0.00015177405,0.0003035447,0.00030412813,0.00040579017,0.0014630342],"category_scores_gemma":[0.0003047815,0.00024637752,0.000231796,0.00023048562,0.0002875397,0.00048459592,0.00016874139,0.0007716038,0.00029787893],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016636554,0.001057986,0.0011133389,0.000107886226,0.00011341412,0.00016526146,0.000054221553,0.0006116019,0.96192497,0.00020398002,0.00062019797,0.017390572],"study_design_scores_gemma":[0.0012819648,0.014468138,0.0047797365,0.000010018847,0.00020800823,0.0005121667,0.00004054964,0.002527615,0.97149974,0.00008254514,0.0045658676,0.000023646397],"about_ca_topic_score_codex":0.00081170036,"about_ca_topic_score_gemma":0.0019242376,"teacher_disagreement_score":0.0014630342,"about_ca_system_score_codex":0.00037853,"about_ca_system_score_gemma":0.00040939593,"threshold_uncertainty_score":0.004894316},"labels":[],"label_agreement":null},{"id":"W2095720296","doi":"10.1200/jco.2008.16.3972","title":"Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Receptor; Cancer research; Pharmacology; Internal medicine","score_opus":0.20157290432113878,"score_gpt":0.49655173568329786,"score_spread":0.2949788313621591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095720296","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034489978,0.3607402,0.018078601,0.36557668,0.1843478,0.000516644,0.00029338888,0.0010844376,0.034872256],"genre_scores_gemma":[0.16319123,0.27196872,0.0214973,0.31887987,0.09796551,0.0003792708,0.00067244796,0.0004662604,0.12497942],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914396,0.00017229281,0.000068682515,0.00010780019,0.00039449238,0.000112768466],"domain_scores_gemma":[0.9990946,0.0003117631,0.00008660801,0.000059179536,0.00024860355,0.00019932279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019409751,0.00071477355,0.0011204766,0.00064707565,0.00076074095,0.0030184775,0.0013272568,0.003488793,0.0049792826],"category_scores_gemma":[0.0018046965,0.00039642758,0.0010159812,0.00035446745,0.0010317429,0.0031042576,0.0008468041,0.0054768273,0.0023727526],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027362276,0.00059175043,0.0012782997,0.001071304,0.00026982723,0.00084133976,0.00013161633,0.00028781968,0.012511916,0.009535115,0.57324654,0.39749822],"study_design_scores_gemma":[0.00096876326,0.0012312655,0.0009992882,0.00029557952,0.00022769823,0.002177488,0.0002069139,0.0008887167,0.0047532325,0.004885528,0.98331046,0.000055047723],"about_ca_topic_score_codex":0.000513059,"about_ca_topic_score_gemma":0.0019720981,"teacher_disagreement_score":0.0049792826,"about_ca_system_score_codex":0.0008711561,"about_ca_system_score_gemma":0.0007627015,"threshold_uncertainty_score":0.016657352},"labels":[],"label_agreement":null},{"id":"W2095851238","doi":"10.1002/cncr.24574","title":"Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients","year":2009,"lang":"en","type":"letter","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"National Cancer Institute","keywords":"Medicine; Trastuzumab; Breast cancer; Concordance; Human Epidermal Growth Factor Receptor 2; Test (biology); Cancer; Documentation; Oncology; Test strategy; Gynecology; Intensive care medicine; Internal medicine","score_opus":0.10021456395726112,"score_gpt":0.465394555760633,"score_spread":0.36517999180337185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095851238","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9350935,0.02846806,0.00092828146,0.020584758,0.00010932536,0.00023410274,0.0014659091,0.00002254585,0.013093533],"genre_scores_gemma":[0.9942167,0.0032902127,0.0008100888,0.0010673229,0.00003781315,0.00007417787,0.00029361484,0.0000069318294,0.00020319186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9829511,0.010061443,0.002623053,0.001127341,0.0023908042,0.0008463851],"domain_scores_gemma":[0.91799814,0.047232997,0.026188029,0.0010126799,0.0052819047,0.002286185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0094982935,0.00014448867,0.00040858533,0.0015297491,0.00042596884,0.0018096253,0.0007184268,0.0008938965,0.0027760207],"category_scores_gemma":[0.09339612,0.00020932492,0.00077316316,0.0032071874,0.0005602548,0.0015652559,0.0011102876,0.0008146224,0.00019663115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057935633,0.00026417928,0.87592953,0.0010105749,0.0007344839,0.0003166409,0.0014081951,0.0023400644,0.00006761406,0.0019781424,0.004130107,0.11124111],"study_design_scores_gemma":[0.00040372455,0.0010664007,0.9552307,0.003989961,0.00078405684,0.0019501788,0.0085613495,0.008607059,0.00035209215,0.007558269,0.011391115,0.00010497079],"about_ca_topic_score_codex":0.012129536,"about_ca_topic_score_gemma":0.016984936,"teacher_disagreement_score":0.012129536,"about_ca_system_score_codex":0.004332481,"about_ca_system_score_gemma":0.004101088,"threshold_uncertainty_score":0.05023241},"labels":[],"label_agreement":null},{"id":"W2096365365","doi":"10.1007/s40261-015-0302-x","title":"Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System","year":2015,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); Santé Montérégie; Thornhill Medical (Canada)","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab emtansine; Capecitabine; Trastuzumab; Adverse effect; Oncology; Internal medicine; Breast cancer; Clinical trial; Metastatic breast cancer; Taxane; Cancer; Colorectal cancer","score_opus":0.08230834484887428,"score_gpt":0.41124979316270993,"score_spread":0.32894144831383565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096365365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730652,0.015492222,0.00023708332,0.0024646525,0.000051104296,0.000087531975,0.002749824,0.000009562069,0.0058427267],"genre_scores_gemma":[0.99736744,0.0014254262,0.00008978382,0.00020520305,0.00003277827,0.000008382897,0.0005575282,0.0000020411376,0.0003114629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985967,0.00041547325,0.00011679375,0.00009434112,0.00053457567,0.00024206506],"domain_scores_gemma":[0.99642,0.0010125745,0.0013312118,0.00007588854,0.0007020434,0.00045828972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001291123,0.00022563072,0.0005565958,0.0006912012,0.00040313974,0.0011654716,0.0005005567,0.00044098968,0.0021847403],"category_scores_gemma":[0.0068046954,0.0001517085,0.0018484831,0.0010885964,0.00028518413,0.00037176308,0.00032438082,0.0010035516,0.00009193189],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06861283,0.0010778109,0.6650617,0.0013677428,0.006753197,0.0014961539,0.00039272007,0.020425748,0.004067893,0.003005144,0.007580639,0.22015846],"study_design_scores_gemma":[0.0016411814,0.0052754213,0.9733018,0.00024327284,0.0032746918,0.0010012612,0.00044397262,0.009231546,0.00079720357,0.0005330322,0.004185885,0.00007085906],"about_ca_topic_score_codex":0.20074634,"about_ca_topic_score_gemma":0.3257331,"teacher_disagreement_score":0.9880109,"about_ca_system_score_codex":0.011989092,"about_ca_system_score_gemma":0.0063926894,"threshold_uncertainty_score":0.3991558},"labels":[],"label_agreement":null},{"id":"W2096433824","doi":"10.1186/bcr3690","title":"Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study","year":2014,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; PTEN; Pertuzumab; Tensin; Oncology; Medicine; Internal medicine; Biomarker; Breast cancer; Immunohistochemistry; Anthracycline; Epidermal growth factor receptor; Surgical oncology; Cancer; Biology; PI3K/AKT/mTOR pathway; Signal transduction; Genetics","score_opus":0.184716968103055,"score_gpt":0.5171683837353311,"score_spread":0.33245141563227615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096433824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964037,0.0016119224,0.00075354177,0.000052769115,0.000011026861,0.000079531026,0.00052478816,0.000008827725,0.0005539155],"genre_scores_gemma":[0.9988507,0.00010237455,0.00033991714,0.000030188587,0.000025728947,0.000067120054,0.0004810409,0.0000050099134,0.00009788791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996231,0.0023200056,0.00024580574,0.000457651,0.00055372244,0.00019174596],"domain_scores_gemma":[0.9918039,0.004772941,0.0017198891,0.0007722278,0.0004358843,0.00049512304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008392559,0.0006413739,0.00108186,0.0008694685,0.00021893464,0.0009793969,0.00053034443,0.0005262385,0.0011169576],"category_scores_gemma":[0.007849692,0.00020494123,0.0022779678,0.000746572,0.000384674,0.00046067484,0.000780688,0.00055749627,0.00018102293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04301911,0.00024910385,0.9203485,0.00023295508,0.012241424,0.00026885324,0.00020573629,0.0013554131,0.006214443,0.00011297343,0.0003349702,0.0154165],"study_design_scores_gemma":[0.0013362032,0.011932374,0.9731972,0.000040912426,0.0068001105,0.00049977284,0.0001435012,0.002341505,0.0021167626,0.0002733462,0.0012773141,0.000040920542],"about_ca_topic_score_codex":0.0003628501,"about_ca_topic_score_gemma":0.0005068806,"teacher_disagreement_score":0.008392559,"about_ca_system_score_codex":0.0002399297,"about_ca_system_score_gemma":0.00040498498,"threshold_uncertainty_score":0.0443846},"labels":[],"label_agreement":null},{"id":"W2097111905","doi":"10.1093/annonc/mdu438.2","title":"Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Trastuzumab; Hazard ratio; Adjuvant; Oncology; Clinical endpoint; Breast cancer; Surgery; Cancer; Clinical trial; Confidence interval","score_opus":0.1481050724017683,"score_gpt":0.4505014088418088,"score_spread":0.3023963364400405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097111905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810476,0.0094989985,0.0003900642,0.0013674776,0.00026213087,0.00013535935,0.0026141524,0.000039949467,0.0046443553],"genre_scores_gemma":[0.99046224,0.0019008096,0.00050162955,0.0009703318,0.00037556878,0.00016155017,0.003774847,0.0000165979,0.0018364222],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993567,0.00032481737,0.000026843141,0.000095626274,0.00005188714,0.00014409794],"domain_scores_gemma":[0.9992895,0.00023607328,0.00012610607,0.00007080848,0.00003634571,0.00024107011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026198744,0.0005490889,0.001186001,0.0002643961,0.00020673842,0.00075168343,0.00037566343,0.0007061377,0.0028867905],"category_scores_gemma":[0.0015229965,0.00015046263,0.0014782618,0.00030597372,0.0004089364,0.0011647663,0.0004738051,0.0019887695,0.00027242355],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7857189,0.0041686334,0.026199182,0.0007535857,0.002559328,0.00018275199,0.00013384684,0.006389957,0.010727971,0.00065861124,0.009221989,0.1532852],"study_design_scores_gemma":[0.34675443,0.3116906,0.2795865,0.00047778708,0.012918053,0.0012055713,0.00035952346,0.009782219,0.0061826855,0.0063681435,0.024533326,0.00014118713],"about_ca_topic_score_codex":0.000622517,"about_ca_topic_score_gemma":0.0028124913,"teacher_disagreement_score":0.0028867905,"about_ca_system_score_codex":0.00049173454,"about_ca_system_score_gemma":0.0006352055,"threshold_uncertainty_score":0.013855398},"labels":[],"label_agreement":null},{"id":"W2097261126","doi":"10.1158/0008-5472.can-04-3468","title":"An Identity Crisis for <i>fps/fes</i>: Oncogene or Tumor Suppressor?","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Queen's University","funders":"","keywords":"Cancer research; Mutation; Mdm2; Suppressor; Biology; Oncogene; Cancer; Somatic cell; Genetically modified mouse; Tyrosine kinase; Transgene; Gene; Genetics; Signal transduction; Cell cycle","score_opus":0.24452441533077324,"score_gpt":0.5695611574949402,"score_spread":0.32503674216416695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097261126","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840614,0.00084977574,0.007269093,0.0012254206,0.000054228844,0.000016109509,0.00009009273,0.00010416511,0.0063297725],"genre_scores_gemma":[0.9939621,0.00028208765,0.001679691,0.00015014733,0.000014007213,0.0000043162067,0.00014185235,0.000021104766,0.0037447233],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989545,0.000007794024,0.0000057318125,0.00002817737,0.000033231907,0.000029573257],"domain_scores_gemma":[0.99981815,0.000029410687,0.00004795706,0.000022616612,0.000030786676,0.000051191113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020213405,0.00019144134,0.00015187249,0.00019431095,0.0003415206,0.00037878036,0.00026028024,0.00042632042,0.0013686481],"category_scores_gemma":[0.00026062067,0.000072115225,0.00014748533,0.000079452155,0.000579725,0.00040049118,0.00023289146,0.0004578317,0.0005099798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000925872,0.000019069224,0.0013605675,0.000016115611,0.000002325869,0.0006033128,0.00006274809,0.00005421913,0.9867822,0.0058859563,0.0002365682,0.0048842733],"study_design_scores_gemma":[0.00002398235,0.00031171247,0.012385811,0.000012469223,0.000018149292,0.00739134,0.0003593034,0.0016068706,0.9495396,0.004846578,0.023490045,0.000014070784],"about_ca_topic_score_codex":0.0004268509,"about_ca_topic_score_gemma":0.0004509709,"teacher_disagreement_score":0.0013686481,"about_ca_system_score_codex":0.0004353205,"about_ca_system_score_gemma":0.00029780567,"threshold_uncertainty_score":0.0045785904},"labels":[],"label_agreement":null},{"id":"W2097591523","doi":"10.1158/1055-9965.epi-09-1023","title":"Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies","year":2010,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; National Institutes of Health; Cancer Research UK","keywords":"Tissue microarray; Breast cancer; Medicine; DNA microarray; Pathology; Cancer; Oncology; Computational biology; Internal medicine; Biology; Genetics; Gene expression; Gene","score_opus":0.12960050648887747,"score_gpt":0.5566568023448623,"score_spread":0.4270562958559848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097591523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52242094,0.004390333,0.45021653,0.00064661086,0.00034090006,0.002825425,0.0055224653,0.003490227,0.010146572],"genre_scores_gemma":[0.69590664,0.000545822,0.29685217,0.00022336091,0.00012070396,0.0024438275,0.002630772,0.00026528988,0.0010114228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9678084,0.016460877,0.0029556653,0.0022035735,0.010100178,0.00047120068],"domain_scores_gemma":[0.913155,0.03651464,0.0113085015,0.006442573,0.032039303,0.0005399702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.037668575,0.00086515094,0.000773731,0.006719691,0.0006977225,0.0019888103,0.0013231422,0.0007745266,0.0027069757],"category_scores_gemma":[0.069744095,0.0004540293,0.000862263,0.0030418194,0.0005101748,0.0009933828,0.0012900592,0.00051939645,0.0008427367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020241693,0.00046580337,0.5556853,0.00198164,0.0018529191,0.00037159934,0.0012612736,0.016161805,0.06845223,0.0026474178,0.008492146,0.34060386],"study_design_scores_gemma":[0.00014639452,0.0010905435,0.76841336,0.0003296067,0.0005449702,0.001679705,0.00088779605,0.16508396,0.041128572,0.004801099,0.015710033,0.00018401133],"about_ca_topic_score_codex":0.0012842915,"about_ca_topic_score_gemma":0.002027037,"teacher_disagreement_score":0.037668575,"about_ca_system_score_codex":0.0010436698,"about_ca_system_score_gemma":0.000884552,"threshold_uncertainty_score":0.19921285},"labels":[],"label_agreement":null},{"id":"W2097680149","doi":"10.1093/annonc/mdf295","title":"Trastuzumab therapy for the metastatic patient: does the primary match?","year":2002,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; Primary tumor; Internal medicine; Cancer; Metastasis","score_opus":0.21853642125591463,"score_gpt":0.4468525590948695,"score_spread":0.22831613783895485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097680149","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004399424,0.0033895385,0.00033147784,0.97843814,0.0069188573,0.000011492431,0.000029088207,0.000010994145,0.0064710253],"genre_scores_gemma":[0.08759345,0.013838047,0.001001516,0.7478014,0.13783602,0.00004270688,0.00009394111,0.000043110605,0.011749771],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979311,0.00070164446,0.00026640564,0.00023767323,0.00047445993,0.00038878949],"domain_scores_gemma":[0.9949704,0.002523257,0.00048400028,0.00014725531,0.0006063901,0.0012687431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025698545,0.000440483,0.0017615895,0.00067979336,0.0023417596,0.002984815,0.0012424575,0.03250569,0.006757319],"category_scores_gemma":[0.016396647,0.00041134353,0.0011878314,0.0007725621,0.0015356423,0.005373213,0.0010898059,0.020100527,0.00253474],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079241244,0.00031843095,0.026983114,0.00028381616,0.00018028225,0.095056064,0.0008683227,0.00071941724,0.0011663481,0.027181113,0.7611671,0.0852836],"study_design_scores_gemma":[0.0009825953,0.0010677766,0.015627326,0.0020358602,0.0003972301,0.20704362,0.0060218154,0.004652954,0.0010895028,0.11116404,0.64966744,0.00024984436],"about_ca_topic_score_codex":0.0020833297,"about_ca_topic_score_gemma":0.0061027287,"teacher_disagreement_score":0.03250569,"about_ca_system_score_codex":0.0034682108,"about_ca_system_score_gemma":0.002726048,"threshold_uncertainty_score":0.02516377},"labels":[],"label_agreement":null},{"id":"W2097934619","doi":"10.1093/annonc/mdp447","title":"Activity of fulvestrant in HER2-overexpressing advanced breast cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Trastuzumab; Cancer; Breast cancer; Metastatic breast cancer; Population; Hormone receptor; Endocrine system; Tamoxifen; Gynecology; Hormone","score_opus":0.13496576755862585,"score_gpt":0.5092962090046241,"score_spread":0.37433044144599825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097934619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934396,0.004669829,0.00018423767,0.0001924182,0.00005725194,0.00003077118,0.00018324534,0.00004300102,0.0011997146],"genre_scores_gemma":[0.9973418,0.0015249689,0.00012818973,0.000044195185,0.000034194672,0.000016297778,0.0003195623,0.000004845111,0.0005859293],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998807,0.000039252864,0.000007211171,0.000010412606,0.000013474528,0.00004905724],"domain_scores_gemma":[0.9998802,0.000044765915,0.000012455479,0.000017439155,0.000008056163,0.000037043894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000487047,0.00038030505,0.0006144345,0.00038399908,0.0001688819,0.00037324888,0.00027379396,0.00028018188,0.0015373424],"category_scores_gemma":[0.000478248,0.00010049968,0.00039965843,0.0003269157,0.00024046443,0.00035056556,0.00019218167,0.00071739237,0.00021257074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05569998,0.0050288574,0.009107613,0.0005581819,0.00037731614,0.00094423175,0.00042371443,0.0061715594,0.68258303,0.0011013262,0.0029208008,0.2350835],"study_design_scores_gemma":[0.018219523,0.17585269,0.08370306,0.0001295302,0.0010325478,0.0036792478,0.0003713395,0.011589362,0.6851551,0.00095312274,0.019230405,0.000084094216],"about_ca_topic_score_codex":0.0010625058,"about_ca_topic_score_gemma":0.0015993112,"teacher_disagreement_score":0.0015373424,"about_ca_system_score_codex":0.0003689899,"about_ca_system_score_gemma":0.00033467717,"threshold_uncertainty_score":0.005142987},"labels":[],"label_agreement":null},{"id":"W2098010907","doi":"10.1200/jco.2009.22.8361","title":"Are <i>HER2</i> and <i>TOP2A</i> Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Anthracycline; Oncology; Breast cancer; Internal medicine; Adjuvant; Adjuvant chemotherapy; Chemotherapy; Cancer; Trastuzumab; Predictive value","score_opus":0.16127825424187406,"score_gpt":0.5170535328735052,"score_spread":0.35577527863163116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098010907","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030170477,0.62115633,0.0008428692,0.073096395,0.2990573,0.00007948627,0.00039581148,0.00005986564,0.0022949162],"genre_scores_gemma":[0.020554468,0.30497444,0.0011241948,0.05916672,0.61159295,0.00011854566,0.00036177752,0.00008575049,0.0020210685],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9944213,0.002213439,0.0009459247,0.0008036454,0.0013315629,0.0002840257],"domain_scores_gemma":[0.9176092,0.05945582,0.0069502783,0.0013551498,0.013405222,0.0012243447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017080626,0.0009833617,0.0045464896,0.0020424293,0.0004304976,0.0055862973,0.0020153672,0.0048541017,0.001810523],"category_scores_gemma":[0.062238924,0.0005013587,0.002260474,0.0015103868,0.0021218543,0.0038897272,0.0004792566,0.006098605,0.0013063574],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008304692,0.000225138,0.014540338,0.040666405,0.007034198,0.00043026282,0.00045781583,0.00035618115,0.0020246753,0.0052379486,0.64689726,0.27382508],"study_design_scores_gemma":[0.0018747587,0.0018933781,0.026481148,0.02333904,0.01531073,0.0009616499,0.0009772087,0.0016383728,0.002525224,0.022609323,0.90194905,0.00044000658],"about_ca_topic_score_codex":0.000540936,"about_ca_topic_score_gemma":0.00070728944,"teacher_disagreement_score":0.017080626,"about_ca_system_score_codex":0.00090909365,"about_ca_system_score_gemma":0.001783129,"threshold_uncertainty_score":0.09033203},"labels":[],"label_agreement":null},{"id":"W2098544382","doi":"10.1093/jnci/93.24.1852","title":"Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)","year":2001,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":889,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Trastuzumab; SKBR3; Cell growth; Cancer research; Growth inhibition; Insulin-like growth factor; Receptor; Growth factor; Growth factor receptor; Biology; Endocrinology; Internal medicine; Chemistry; Cancer cell; Breast cancer; Medicine; Cancer; Biochemistry","score_opus":0.09529036687241335,"score_gpt":0.38763124921505876,"score_spread":0.29234088234264544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098544382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96695656,0.02604662,0.0012817552,0.0006327011,0.00007962648,0.000053513373,0.00021710877,0.00008272638,0.0046494626],"genre_scores_gemma":[0.99238527,0.0049018427,0.0006115899,0.00020155558,0.000050407638,0.00002535615,0.00027166246,0.000007699302,0.0015446679],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984455,0.000033354805,0.000014414401,0.00003424454,0.000038348408,0.000035017525],"domain_scores_gemma":[0.99979764,0.00004571482,0.00009809328,0.0000096496215,0.000017271912,0.000031616484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034282493,0.0003036014,0.00023955893,0.00018046764,0.00007208965,0.0003134906,0.00019586603,0.00038170305,0.0017020686],"category_scores_gemma":[0.00041319634,0.000113284485,0.0001826217,0.00023879361,0.00021286725,0.00016195359,0.000124275,0.00046616592,0.00033040554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004448667,0.0006450502,0.07420441,0.0005697167,0.00018485165,0.0030319341,0.00012295434,0.0006935277,0.8341857,0.0007806839,0.0029038764,0.07822859],"study_design_scores_gemma":[0.0008692359,0.008984662,0.38160944,0.0001541457,0.00046368554,0.0521029,0.00021469798,0.0043288185,0.50660354,0.001050178,0.04357514,0.00004362316],"about_ca_topic_score_codex":0.0003627358,"about_ca_topic_score_gemma":0.00020292019,"teacher_disagreement_score":0.0017020686,"about_ca_system_score_codex":0.00036801747,"about_ca_system_score_gemma":0.00013642735,"threshold_uncertainty_score":0.005693972},"labels":[],"label_agreement":null},{"id":"W2098749503","doi":"10.1158/1078-0432.ccr-15-0156","title":"An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"In vivo; Cancer research; Antigen; Monoclonal antibody; Antibody; Biology; Immunohistochemistry; Cytotoxic T cell; In vitro; Immunology","score_opus":0.32669273389124903,"score_gpt":0.5304941585481654,"score_spread":0.20380142465691636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098749503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968493,0.003981056,0.025039202,0.00013152121,0.000022348338,0.00010897389,0.0003228768,0.00016263593,0.0017382802],"genre_scores_gemma":[0.9841539,0.0014124111,0.012321295,0.0000565975,0.000006674118,0.000036434532,0.00048579354,0.000017002178,0.0015098656],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984515,0.000024932271,0.00000995426,0.00003428534,0.00006859446,0.000016956554],"domain_scores_gemma":[0.9999143,0.00001851773,0.00003117029,0.00000870182,0.00001331577,0.00001398557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027976732,0.00033804966,0.00028593338,0.00028727116,0.000104656,0.00033982345,0.00017190495,0.00034214972,0.0008379598],"category_scores_gemma":[0.00019319826,0.00010740834,0.00023127414,0.00019094275,0.00020370085,0.00020118862,0.0002098639,0.00034811324,0.00044169798],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008466045,0.000041699583,0.0003783169,0.00004949785,0.0000062473687,0.000026405072,0.0000042876977,0.00048261404,0.99615616,0.00006738143,0.000025979713,0.0026766276],"study_design_scores_gemma":[0.000014837895,0.00028708339,0.00078927114,0.0000026584619,0.000011426996,0.00017887756,0.0000031765778,0.0017570601,0.9955924,0.000016791777,0.0013446489,0.0000017218802],"about_ca_topic_score_codex":0.00015027566,"about_ca_topic_score_gemma":0.00020876066,"teacher_disagreement_score":0.0008379598,"about_ca_system_score_codex":0.00029206258,"about_ca_system_score_gemma":0.0001472525,"threshold_uncertainty_score":0.0028032064},"labels":[],"label_agreement":null},{"id":"W2098775844","doi":"10.1056/nejmoa0910383","title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2775,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"U.S. Army Medical Research and Development Command; National Cancer Institute; Genentech; Sanofi; Eli Lilly and Company; California Breast Cancer Research Program; GlaxoSmithKline; Amgen","keywords":"Trastuzumab; Medicine; Anthracycline; Internal medicine; Regimen; Docetaxel; Carboplatin; Breast cancer; Oncology; Cardiotoxicity; Adjuvant; Cancer; Chemotherapy; Surgery; Cisplatin","score_opus":0.0562133101311759,"score_gpt":0.35611518970783484,"score_spread":0.2999018795766589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098775844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98413014,0.013072009,0.0004073814,0.00032228857,0.000071654424,0.00020027258,0.00008855273,0.000009574655,0.0016981731],"genre_scores_gemma":[0.9940895,0.0042754454,0.00042300762,0.00019625406,0.000104297564,0.00018469607,0.00019572885,0.0000020227885,0.0005290947],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996189,0.00022931547,0.000029245724,0.00002741294,0.00005624786,0.00003886163],"domain_scores_gemma":[0.99967134,0.00015387351,0.00006510439,0.0000216371,0.000021135656,0.000067051726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011633071,0.00018136846,0.00042948904,0.00015408397,0.00013348134,0.00021039962,0.00020096335,0.00024730078,0.00083603535],"category_scores_gemma":[0.0013078519,0.00006882218,0.00016900129,0.0002810704,0.00017896583,0.000109069006,0.00017945934,0.00037392788,0.000099681536],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17661947,0.0059502716,0.12329354,0.0019559315,0.00060704834,0.0024301277,0.00024760768,0.0060260585,0.024440257,0.0009064924,0.0043205465,0.6532027],"study_design_scores_gemma":[0.14333662,0.3184141,0.3670387,0.0012194549,0.0034995559,0.0128575,0.00026598055,0.014814792,0.036152102,0.0040377276,0.09830144,0.000062050836],"about_ca_topic_score_codex":0.00025862458,"about_ca_topic_score_gemma":0.0005661273,"teacher_disagreement_score":0.0011633071,"about_ca_system_score_codex":0.0003495507,"about_ca_system_score_gemma":0.00041556527,"threshold_uncertainty_score":0.0061522126},"labels":[],"label_agreement":null},{"id":"W2098898117","doi":"10.1016/s1470-2045(11)70231-5","title":"HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Amis de l'Institut Bordet; Cancer Research UK; Strategiske Forskningsråd","keywords":"Anthracycline; Internal medicine; Oncology; Medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Adjuvant; Chemotherapy; Methotrexate; Cancer; Confidence interval","score_opus":0.43518734685932126,"score_gpt":0.5262071644404532,"score_spread":0.09101981758113198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098898117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20203827,0.7808526,0.00932365,0.0010718098,0.00094815285,0.00027204957,0.004114072,0.0002528568,0.0011265136],"genre_scores_gemma":[0.95407075,0.038918708,0.003185535,0.0006974616,0.0003677763,0.0003065203,0.0019082384,0.00011565677,0.0004291809],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9761741,0.01698446,0.0019791368,0.0030978115,0.0013168838,0.00044768813],"domain_scores_gemma":[0.9548918,0.035458785,0.0044231773,0.003609851,0.0009612907,0.0006550666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030305972,0.0028846902,0.0127013065,0.0034343335,0.00048540282,0.003233368,0.0020187814,0.0020335615,0.0018976515],"category_scores_gemma":[0.02930318,0.0015123377,0.052683648,0.004300284,0.0007341506,0.0013450711,0.0015243647,0.002431186,0.00026704324],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067331353,0.000018432065,0.025855238,0.0053939205,0.95589894,0.000074345924,0.00002168986,0.002271237,0.00033257186,0.00006923718,0.0002576333,0.0030735654],"study_design_scores_gemma":[0.00083275494,0.00041156227,0.017533902,0.00053369126,0.97781664,0.00009251046,0.000019968778,0.0014797284,0.00022466636,0.0002821871,0.0007489272,0.000023422472],"about_ca_topic_score_codex":0.0039240387,"about_ca_topic_score_gemma":0.0046259225,"teacher_disagreement_score":0.030305972,"about_ca_system_score_codex":0.001252795,"about_ca_system_score_gemma":0.00096980605,"threshold_uncertainty_score":0.16027516},"labels":[],"label_agreement":null},{"id":"W2099461930","doi":"10.1016/j.ygyno.2009.10.004","title":"HER2 Overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","year":2010,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Carboplatin; Ovarian cancer; Targeted therapy; Oncology; Ovarian carcinomas; Cancer research; Internal medicine; Ovarian carcinoma; Cancer; Chemotherapy; Breast cancer; Cisplatin","score_opus":0.04329109243936597,"score_gpt":0.34701284403533467,"score_spread":0.3037217515959687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099461930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925073,0.0024294152,0.00052401325,0.0002177644,0.000011691618,0.000015835121,0.00008975204,0.000033352953,0.004170772],"genre_scores_gemma":[0.9985897,0.0005223241,0.0001625465,0.00003093964,0.00001291026,0.000006004996,0.00010113796,0.000003040614,0.0005713652],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998745,0.00002142264,0.00000929854,0.000013916269,0.000040656327,0.00004026994],"domain_scores_gemma":[0.9998784,0.000037574828,0.00003670388,0.000010899292,0.00001832722,0.00001807915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002428306,0.00021644392,0.00026767593,0.00053245155,0.00016309727,0.00037295098,0.00013853305,0.00023278936,0.001000209],"category_scores_gemma":[0.0006522214,0.000120620425,0.0001602705,0.000444991,0.00020885801,0.00026342864,0.00022470007,0.00017621237,0.00016427487],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019832144,0.00014572579,0.40537363,0.00020545635,0.00011775805,0.019922296,0.00028982142,0.0010315386,0.44156078,0.00051956397,0.0013944488,0.12745585],"study_design_scores_gemma":[0.00010308207,0.00085079385,0.80358166,0.00003143406,0.00023861889,0.06448916,0.0005606819,0.003318891,0.10754439,0.00063280645,0.018630639,0.000017827988],"about_ca_topic_score_codex":0.0007752809,"about_ca_topic_score_gemma":0.0015131263,"teacher_disagreement_score":0.001000209,"about_ca_system_score_codex":0.00027118332,"about_ca_system_score_gemma":0.00014184446,"threshold_uncertainty_score":0.0033459663},"labels":[],"label_agreement":null},{"id":"W2099688742","doi":"10.5858/2008-132-61-htiaps","title":"HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Trastuzumab; Concordance; Immunohistochemistry; Medicine; Breast cancer; Oncology; Internal medicine; Context (archaeology); Metastatic breast cancer; Cancer; Fish <Actinopterygii>; Population; Fluorescence in situ hybridization; Pathology; Biology","score_opus":0.06859739418384475,"score_gpt":0.3079721304124999,"score_spread":0.23937473622865513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099688742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999342,0.00010271808,0.00004283621,0.000042650336,0.000002038099,0.000012407031,0.00014077558,0.000003228571,0.0003114373],"genre_scores_gemma":[0.9995906,0.000051500847,0.00004770314,0.000049598213,0.000003963948,0.0000077142195,0.00015528996,0.0000012503294,0.00009240803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994992,0.00008974553,0.000025545392,0.0001055164,0.00016537456,0.00011461717],"domain_scores_gemma":[0.99909973,0.0001421771,0.00022777697,0.000047514033,0.00022448805,0.0002584019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043849368,0.0002519889,0.0003569053,0.00062815804,0.0010742598,0.00055658596,0.0004023918,0.00045626416,0.0010130787],"category_scores_gemma":[0.0023150248,0.0003059291,0.00021592554,0.00095374254,0.0006554211,0.00023563449,0.0003473125,0.0005927724,0.00021208303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042047763,0.000019237124,0.9989675,0.0000032414946,0.000008730328,0.00015324124,0.00007419306,0.000015392443,0.00013508205,0.0000033810907,0.00006722783,0.0005106478],"study_design_scores_gemma":[0.000012611202,0.000119554345,0.99833894,0.0000038144049,0.000016335913,0.00085154205,0.00027291672,0.00012737981,0.00006523837,0.000008323993,0.00017973747,0.000003669908],"about_ca_topic_score_codex":0.33395395,"about_ca_topic_score_gemma":0.32671252,"teacher_disagreement_score":0.33395395,"about_ca_system_score_codex":0.0029063108,"about_ca_system_score_gemma":0.0026229476,"threshold_uncertainty_score":0.66402024},"labels":[],"label_agreement":null},{"id":"W2099718130","doi":"10.1371/journal.pone.0012766","title":"Deficiency of the Metalloproteinase-Disintegrin ADAM8 Is Associated with Thymic Hyper-Cellularity","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Disintegrin; Metalloproteinase; Biology; Medicine; Matrix metalloproteinase; Internal medicine","score_opus":0.0682251485582779,"score_gpt":0.2739221455789857,"score_spread":0.20569699702070782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099718130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543285,0.0012574013,0.0022915867,0.000050467243,0.000018378301,0.000017978113,0.00039815312,0.00013088471,0.00040226846],"genre_scores_gemma":[0.9965724,0.0006411769,0.0012846789,0.000022526776,0.000021248987,0.000020965626,0.00044149216,0.00003621855,0.0009593538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997422,0.000037155743,0.000042150135,0.00008335666,0.00006557781,0.000029500026],"domain_scores_gemma":[0.9991505,0.00012249517,0.00044809032,0.000052286145,0.000042953416,0.00018360211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014866331,0.0007518815,0.00038386407,0.00061313057,0.00013658211,0.00036166486,0.00026554608,0.00046621144,0.0027070441],"category_scores_gemma":[0.0003598867,0.00016066435,0.00026260762,0.00020284862,0.00048157352,0.00018993026,0.00037047258,0.00067585445,0.00046698962],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021787506,0.000022141281,0.002105585,0.00007794801,0.00001550772,0.0014048557,0.000019564617,0.000038005786,0.99482024,0.000041209278,0.000035086476,0.0012018684],"study_design_scores_gemma":[0.000062250176,0.00075681624,0.10761841,0.000044805958,0.00017034709,0.049260177,0.00012393652,0.0010442171,0.8377166,0.00027392665,0.0029066429,0.00002197108],"about_ca_topic_score_codex":0.00010715209,"about_ca_topic_score_gemma":0.000104251594,"teacher_disagreement_score":0.0027070441,"about_ca_system_score_codex":0.00015478344,"about_ca_system_score_gemma":0.00012714144,"threshold_uncertainty_score":0.0090559125},"labels":[],"label_agreement":null},{"id":"W2099988058","doi":"10.1186/1471-2407-11-313","title":"Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study","year":2011,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer; Amgen; American Heart Association","keywords":"Erlotinib; Gemcitabine; Medicine; Pharmacokinetics; Pharmacology; Nausea; Adverse effect; Internal medicine; Phases of clinical research; Oncology; Tolerability; Epidermal growth factor receptor; Gastroenterology; Toxicity; Chemotherapy; Cancer","score_opus":0.11214556829817944,"score_gpt":0.42831665357852666,"score_spread":0.3161710852803472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099988058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941606,0.0027840151,0.00048607087,0.00035471603,0.00005660008,0.00084456906,0.00047584705,0.00006515052,0.000772358],"genre_scores_gemma":[0.99140817,0.002097659,0.0015748746,0.00065947097,0.000110952395,0.0010640064,0.0019438103,0.000038919068,0.0011020398],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99950993,0.00022637163,0.000029147648,0.00008031623,0.000085815416,0.00006843779],"domain_scores_gemma":[0.9992187,0.00010552734,0.00026178663,0.00004862739,0.00006227003,0.00030297198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016396124,0.0012212575,0.0017772991,0.0003870842,0.00041637203,0.00080788805,0.000772146,0.0010595265,0.0024136007],"category_scores_gemma":[0.0009188955,0.0006183072,0.0010736013,0.00039015245,0.00065770943,0.00068943383,0.00029016472,0.0029378305,0.0007990238],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42595002,0.13424748,0.018429814,0.0017650168,0.0023875972,0.0006060881,0.0004591741,0.006755684,0.19715412,0.0002925955,0.0076912376,0.20426115],"study_design_scores_gemma":[0.3117635,0.62412494,0.03593587,0.00008546573,0.0007653106,0.0011844304,0.00006233277,0.0033856905,0.015686346,0.00016985319,0.0067679402,0.00006833842],"about_ca_topic_score_codex":0.00052369456,"about_ca_topic_score_gemma":0.0014378026,"teacher_disagreement_score":0.0024136007,"about_ca_system_score_codex":0.0011210503,"about_ca_system_score_gemma":0.0016135151,"threshold_uncertainty_score":0.008671224},"labels":[],"label_agreement":null},{"id":"W2100723992","doi":"10.1038/modpathol.3880372","title":"Defining a Test for HER-2/neu Evaluation in Breast Cancer in the Diagnostic Setting","year":2001,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Concordance; Immunohistochemistry; Breast cancer; Medicine; HER2/neu; Cancer; Gene duplication; Pathology; Oncology; Internal medicine; Gene; Biology","score_opus":0.06017018288462389,"score_gpt":0.4127420588739982,"score_spread":0.3525718759893743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100723992","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6334453,0.059975006,0.16148654,0.068846345,0.003817259,0.00078629487,0.000490593,0.0006284752,0.07052424],"genre_scores_gemma":[0.89278436,0.00682158,0.08679481,0.008862214,0.0019526355,0.0002173737,0.00027293857,0.0001186853,0.00217542],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99576795,0.0017026451,0.0006463177,0.00027859694,0.0010274067,0.00057706813],"domain_scores_gemma":[0.99194664,0.0037232225,0.00074195577,0.00026085577,0.0023898752,0.00093744916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006905375,0.00094928994,0.0012836374,0.003064987,0.0012747452,0.0041556675,0.0018110229,0.0035703087,0.0015720624],"category_scores_gemma":[0.017332746,0.00048815974,0.0007654298,0.0010096461,0.0031490612,0.0030281418,0.001347019,0.0031992001,0.0010045843],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014528444,0.0011473101,0.61835784,0.0009096966,0.00013641799,0.019618347,0.001435999,0.0016718499,0.047255162,0.024274513,0.015322625,0.26841736],"study_design_scores_gemma":[0.00032267446,0.0069231447,0.35417172,0.004798988,0.0012500427,0.24819559,0.016443314,0.03153949,0.13047291,0.06429007,0.14116654,0.0004255306],"about_ca_topic_score_codex":0.0015075984,"about_ca_topic_score_gemma":0.0015952605,"teacher_disagreement_score":0.006905375,"about_ca_system_score_codex":0.0012404071,"about_ca_system_score_gemma":0.003001298,"threshold_uncertainty_score":0.036519587},"labels":[],"label_agreement":null},{"id":"W2100784179","doi":"10.1007/s00428-002-0752-4","title":"Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray","year":2003,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Vimentin; Adenocarcinoma; Pathology; Carcinoembryonic antigen; Tissue microarray; Immunostaining; Carcinoma; Biopsy; Medicine; Immunohistochemistry; Biology; Cancer; Internal medicine","score_opus":0.07062212850741136,"score_gpt":0.4187798839344638,"score_spread":0.34815775542705246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100784179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422413,0.00077631464,0.0019524144,0.00009646721,0.000017956727,0.000028821534,0.001135911,0.00005812939,0.0017098162],"genre_scores_gemma":[0.9917807,0.000535431,0.0030516405,0.00008758895,0.00001820284,0.00008143597,0.002259761,0.000013544912,0.0021716207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997389,0.000034867084,0.000029343557,0.00006164052,0.000078276506,0.00005693819],"domain_scores_gemma":[0.99980587,0.00005856192,0.000026480997,0.000023328337,0.00006097112,0.00002480018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026103124,0.0001455719,0.00022175888,0.0009374567,0.0003064411,0.00032718698,0.00013746168,0.0002749911,0.001195396],"category_scores_gemma":[0.0003606545,0.00014369698,0.00016713879,0.00061615126,0.000098631994,0.00021694435,0.00020462902,0.00018482968,0.0004521044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004031053,0.000034641333,0.03139147,0.00005320835,0.000031369018,0.00020572412,0.00008783725,0.000099024786,0.96167517,0.0000526302,0.00022725722,0.005738543],"study_design_scores_gemma":[0.000021104996,0.0005824413,0.63945156,0.000015288255,0.00016364883,0.003715943,0.0005195982,0.0027908096,0.3448551,0.00011138913,0.0077575413,0.00001559037],"about_ca_topic_score_codex":0.00062580727,"about_ca_topic_score_gemma":0.0010991556,"teacher_disagreement_score":0.001195396,"about_ca_system_score_codex":0.000149912,"about_ca_system_score_gemma":0.00015814808,"threshold_uncertainty_score":0.003998995},"labels":[],"label_agreement":null},{"id":"W2100891604","doi":"10.1016/j.ctrv.2008.03.013","title":"Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review","year":2008,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre; Kingston General Hospital","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Internal medicine; Adjuvant; Cochrane Library; Adjuvant therapy; Randomized controlled trial; Clinical trial; Neoadjuvant therapy; Cancer","score_opus":0.11580775246216311,"score_gpt":0.432500353013039,"score_spread":0.3166926005508759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100891604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010158683,0.99827826,0.000077860765,0.00011914371,0.000076028686,0.00011356711,0.00013775857,0.000004876523,0.00017673457],"genre_scores_gemma":[0.01424122,0.9845828,0.0003745458,0.0003826688,0.000044730987,0.00014956671,0.00008167826,0.0000029142825,0.00013995169],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99846447,0.0005562036,0.0005320267,0.00015964606,0.00021770208,0.00006994516],"domain_scores_gemma":[0.99612504,0.0024340665,0.0010680488,0.000050422932,0.00024187338,0.00008060351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025774327,0.0011129094,0.006744814,0.0028425679,0.00025999796,0.001089827,0.0009378555,0.0010264653,0.0036282954],"category_scores_gemma":[0.0083978,0.0008194092,0.0054612583,0.003709474,0.00041251213,0.0009871202,0.0007679182,0.0010142825,0.00020043844],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011674598,0.00004700635,0.0009056223,0.897938,0.025085427,0.00015229927,0.00012450878,0.00024369544,0.00050222664,0.00014654735,0.002786138,0.07090104],"study_design_scores_gemma":[0.003404118,0.0013464228,0.009007438,0.52096325,0.41978484,0.00079261797,0.0002882999,0.0002213653,0.00056465215,0.0003734539,0.04318225,0.00007132657],"about_ca_topic_score_codex":0.0059521357,"about_ca_topic_score_gemma":0.02504888,"teacher_disagreement_score":0.006744814,"about_ca_system_score_codex":0.0019585553,"about_ca_system_score_gemma":0.0033338147,"threshold_uncertainty_score":0.014210343},"labels":[],"label_agreement":null},{"id":"W2101299592","doi":"10.1200/jco.2009.24.2024","title":"Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Pertuzumab; Trastuzumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Breast cancer; Cancer; Clinical trial; Phases of clinical research; Loading dose","score_opus":0.11767038809995356,"score_gpt":0.4940915774878471,"score_spread":0.37642118938789354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101299592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945775,0.0013184173,0.0003202251,0.00041529463,0.00013466719,0.0016040402,0.0003197512,0.00006175071,0.0012482001],"genre_scores_gemma":[0.99031925,0.00097410905,0.001110808,0.0007543782,0.00037130644,0.0027220377,0.0018051845,0.000019235596,0.0019237065],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993185,0.00039506378,0.000033807355,0.00008045247,0.000055404547,0.00011679471],"domain_scores_gemma":[0.9990004,0.00017375365,0.00017215917,0.00006527953,0.000053208867,0.00053518516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018334063,0.0020315845,0.0022034736,0.00044914117,0.00040457153,0.00094599166,0.0008882415,0.0014906134,0.00300769],"category_scores_gemma":[0.0014497857,0.00068289455,0.0011821549,0.00042166433,0.0010687858,0.0008702534,0.00043510724,0.002585803,0.0006822603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88223565,0.042732526,0.00639107,0.00035838483,0.00095717,0.00037666011,0.00027433073,0.0020525944,0.015962299,0.00024017695,0.002109523,0.046309635],"study_design_scores_gemma":[0.7327421,0.25712234,0.005967911,0.000017433766,0.00018846935,0.00020884367,0.000031425192,0.0010771328,0.0012189694,0.00008532775,0.0013241443,0.00001587918],"about_ca_topic_score_codex":0.0008363509,"about_ca_topic_score_gemma":0.0013130883,"teacher_disagreement_score":0.00300769,"about_ca_system_score_codex":0.0009642903,"about_ca_system_score_gemma":0.0017708678,"threshold_uncertainty_score":0.010061681},"labels":[],"label_agreement":null},{"id":"W2101687615","doi":"10.1016/j.jss.2005.02.006","title":"Expression of ZER6 in ERα-Positive Breast Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Surgical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Petroleum Technology Research Centre","keywords":"Estrogen receptor; Breast cancer; Estrogen receptor alpha; Biology; Cancer research; Western blot; Estrogen; Gene isoform; Transfection; Estrogen receptor beta; Breast carcinoma; Cancer; Cell culture; Endocrinology; Gene; Genetics","score_opus":0.11655404637524946,"score_gpt":0.5118174318911838,"score_spread":0.3952633855159343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101687615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996068,0.0015866309,0.0003473463,0.00006684229,0.000015025959,0.000005075183,0.00025662177,0.000013766599,0.0016406876],"genre_scores_gemma":[0.99623436,0.00057820213,0.00033167136,0.000015551817,0.000009378906,0.000003683598,0.00039781514,0.000003129119,0.0024261626],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990106,0.000015384423,0.000009270028,0.000011787325,0.000023875125,0.000038585582],"domain_scores_gemma":[0.99988973,0.000020088872,0.000021888292,0.000011064185,0.000024067986,0.000033056986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015034116,0.00010394229,0.00016739221,0.00062024937,0.00023641516,0.00031856788,0.00012133786,0.00021389918,0.0027570913],"category_scores_gemma":[0.00023314651,0.00011405918,0.00016942706,0.00028418587,0.00018556496,0.00019166053,0.0001644087,0.00020490373,0.0005549957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014924994,0.00004756838,0.011293484,0.000079009405,0.000020451553,0.0005156642,0.000112616326,0.00012380992,0.9805164,0.00026992924,0.00015187371,0.005376655],"study_design_scores_gemma":[0.00011680985,0.0013351311,0.2628563,0.00002062902,0.00010672898,0.009062909,0.0010431731,0.0028318348,0.70909745,0.0006222312,0.012885543,0.00002116714],"about_ca_topic_score_codex":0.00064882915,"about_ca_topic_score_gemma":0.00067819306,"teacher_disagreement_score":0.0027570913,"about_ca_system_score_codex":0.0002167471,"about_ca_system_score_gemma":0.00014350309,"threshold_uncertainty_score":0.009223402},"labels":[],"label_agreement":null},{"id":"W2102299301","doi":"10.1023/b:brea.0000036783.88387.47","title":"HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel","year":2004,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"Amis de l'Institut Bordet","keywords":"Docetaxel; Medicine; Internal medicine; Breast cancer; Oncology; Doxorubicin; Population; Odds ratio; Cancer; Cohort; Chemotherapy","score_opus":0.049143343182379784,"score_gpt":0.3644664732989722,"score_spread":0.3153231301165924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102299301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996973,0.00010480574,0.000027900112,0.00001624535,0.0000091668835,0.000008023233,0.000028834416,0.0000012263739,0.00010652168],"genre_scores_gemma":[0.9996737,0.00005485925,0.000027704762,0.00002721392,0.000022264563,0.000008666478,0.0000589538,8.682878e-7,0.00012574017],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999635,0.000135565,0.000021080397,0.00010797605,0.000045694484,0.000054761676],"domain_scores_gemma":[0.9991984,0.00035784097,0.00013064603,0.000052639585,0.00004553908,0.00021504035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006489519,0.0003204058,0.00080483523,0.00036802347,0.00033056183,0.00055018795,0.0002163738,0.0005781802,0.0008571322],"category_scores_gemma":[0.0021059166,0.0002906171,0.0005439812,0.00030462726,0.00047773862,0.0005011578,0.00025500666,0.0007726416,0.0001700484],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18254052,0.0022339947,0.78508794,0.000042146337,0.0006064548,0.00063387945,0.0003157616,0.0012331749,0.011525086,0.00011283991,0.00032319833,0.0153450705],"study_design_scores_gemma":[0.0046871896,0.0406067,0.9445513,0.00001051554,0.0010724827,0.0011038951,0.0003968654,0.004891263,0.0016447856,0.0002846474,0.0007052956,0.000045024964],"about_ca_topic_score_codex":0.001235828,"about_ca_topic_score_gemma":0.001006413,"teacher_disagreement_score":0.001235828,"about_ca_system_score_codex":0.00033582363,"about_ca_system_score_gemma":0.00029221465,"threshold_uncertainty_score":0.0034319758},"labels":[],"label_agreement":null},{"id":"W2103114638","doi":"10.1158/1078-0432.ccr-14-2993","title":"PTEN Loss Is Associated with Worse Outcome in <i>HER2</i> -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"National Cancer Institute","keywords":"PTEN; Trastuzumab; Breast cancer; Medicine; Immunohistochemistry; Population; Cancer; Oncology; Internal medicine; Cancer research; Pathology; Biology; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.332316024989978,"score_gpt":0.5229535913488315,"score_spread":0.19063756635885348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103114638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99941087,0.00018366275,0.00005197895,0.00003433961,0.000003070684,0.000007251723,0.000047250254,0.0000030293545,0.00025847522],"genre_scores_gemma":[0.9996811,0.000052757914,0.00003879536,0.00003172996,0.000011051722,0.0000061753553,0.000113307746,0.0000013115166,0.00006379679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997011,0.00007460456,0.000032770942,0.00007786331,0.000060446877,0.00005316926],"domain_scores_gemma":[0.9987043,0.00026432317,0.0006711287,0.00006452116,0.000050897146,0.00024471697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072790857,0.00023868254,0.00046450453,0.00043133515,0.00020413715,0.0004229806,0.00023101608,0.00038421387,0.0012179364],"category_scores_gemma":[0.0014027875,0.00013283682,0.00028845403,0.0003868424,0.00039502367,0.00023028791,0.00024072455,0.00049881847,0.00014757283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006343775,0.00025926993,0.9751383,0.00003748165,0.00013489298,0.0004322676,0.000035272962,0.00014620725,0.011499774,0.0000318062,0.00014761108,0.0057933126],"study_design_scores_gemma":[0.00020834387,0.0017787411,0.9940182,0.00000705912,0.00014360347,0.0015364909,0.000038058246,0.0003261803,0.0015469248,0.00006614506,0.00032391984,0.0000062426766],"about_ca_topic_score_codex":0.0003632078,"about_ca_topic_score_gemma":0.00044519358,"teacher_disagreement_score":0.0012179364,"about_ca_system_score_codex":0.00019726681,"about_ca_system_score_gemma":0.00023244247,"threshold_uncertainty_score":0.0040743947},"labels":[],"label_agreement":null},{"id":"W2103495720","doi":"10.1111/j.1365-2559.2011.03974.x","title":"Effect of prolonged formalin fixation on immunohistochemical staining for the proliferation marker Ki67","year":2011,"lang":"en","type":"letter","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Medicine; Clinical pharmacology; Gerontology; Pharmacology","score_opus":0.03643296119477207,"score_gpt":0.3493574119247354,"score_spread":0.31292445072996333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103495720","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92297554,0.035263363,0.007170147,0.012406088,0.00565316,0.0003314715,0.00031157339,0.00018652758,0.015702145],"genre_scores_gemma":[0.9656043,0.009792545,0.009104847,0.0039051867,0.00119828,0.00017272789,0.00037708823,0.000086337226,0.009758582],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995359,0.00017480107,0.000042521082,0.0000545422,0.000087000655,0.000105224426],"domain_scores_gemma":[0.99835724,0.0011225456,0.000118592885,0.00022064596,0.0001280396,0.000052944222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017391971,0.00046761814,0.00046675216,0.00030664363,0.00053736445,0.0003708786,0.0005229608,0.0015365295,0.0031317484],"category_scores_gemma":[0.0018301228,0.00038144898,0.00061922666,0.00030643964,0.0007835675,0.00041710102,0.0003227585,0.001627301,0.0007907384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008776369,0.00040510538,0.00295442,0.0004281827,0.00016142087,0.010515996,0.00032491572,0.0002876272,0.9401709,0.00062044465,0.0032281254,0.032126572],"study_design_scores_gemma":[0.0010069374,0.013246979,0.04242594,0.00016582118,0.0007390773,0.03493434,0.00043039935,0.0023047333,0.84783703,0.0011411998,0.055690095,0.0000774213],"about_ca_topic_score_codex":0.0013888382,"about_ca_topic_score_gemma":0.00546288,"teacher_disagreement_score":0.0031317484,"about_ca_system_score_codex":0.00055101456,"about_ca_system_score_gemma":0.00024425052,"threshold_uncertainty_score":0.010476768},"labels":[],"label_agreement":null},{"id":"W2103707992","doi":"10.3816/cbc.2009.n.019","title":"Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Doxorubicin; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.037202716011297425,"score_gpt":0.43187942971137866,"score_spread":0.3946767137000812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103707992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940904,0.0013647965,0.0005290977,0.0004544946,0.00014020054,0.0014034149,0.00046379142,0.00007267047,0.0014812176],"genre_scores_gemma":[0.9928687,0.0015353325,0.0008144056,0.00040959794,0.00013023757,0.0012567707,0.0008591996,0.000026039788,0.0020996698],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99968386,0.00012899774,0.000011387164,0.000060159666,0.00002178043,0.000093721545],"domain_scores_gemma":[0.9995116,0.00009813847,0.00006484838,0.00005090566,0.000026578286,0.0002479722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009597369,0.0014148456,0.0021721686,0.0003620526,0.0004035021,0.0008954812,0.0008902429,0.0009555148,0.0032479635],"category_scores_gemma":[0.0008118559,0.0006176093,0.0008958396,0.00042017087,0.0010566964,0.0008512865,0.0003372491,0.0027634245,0.00082410075],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7805521,0.07637088,0.00382308,0.0007223137,0.001099524,0.00028356406,0.00039550866,0.0031799055,0.04231743,0.00046372061,0.003454903,0.087337136],"study_design_scores_gemma":[0.59472734,0.39251477,0.005564243,0.000020313113,0.00036613658,0.00016061266,0.00007314795,0.0010879474,0.0034466702,0.00014480975,0.0018705403,0.000023498384],"about_ca_topic_score_codex":0.0018683181,"about_ca_topic_score_gemma":0.003366312,"teacher_disagreement_score":0.0032479635,"about_ca_system_score_codex":0.0010664328,"about_ca_system_score_gemma":0.0016296679,"threshold_uncertainty_score":0.010865569},"labels":[],"label_agreement":null},{"id":"W2103722534","doi":"","title":"SERUM LEVEL OF HER-2 EXTRACELLULAR DOMAIN IN IRANIAN PATIENTS WITH BREAST CANCER: A FOLLOW-UP STUDY","year":2005,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Metastasis; Internal medicine; Cancer; Oncology; Distant metastasis; Gastroenterology; CA 15-3; Metastatic breast cancer; CA15-3; Pathology","score_opus":0.06205799042741082,"score_gpt":0.34321852772474626,"score_spread":0.2811605372973354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103722534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999398,0.00019480604,0.000044736345,0.000018644723,0.0000053298845,0.0000050302815,0.00008385034,0.0000034852515,0.0002461215],"genre_scores_gemma":[0.9995246,0.000090975795,0.000049309612,0.000021553116,0.00001062639,0.0000051878656,0.00017435606,7.244049e-7,0.00012278424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99987984,0.000018159632,0.000008992362,0.000029411438,0.000030024348,0.00003365763],"domain_scores_gemma":[0.99962556,0.000054222575,0.00012607632,0.000024194256,0.00007202084,0.00009791323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018218812,0.00026351528,0.0003186244,0.0005558366,0.00036303367,0.00032093865,0.00015382325,0.00032397345,0.00082501495],"category_scores_gemma":[0.00069662154,0.00016357681,0.00028181527,0.00047888735,0.00017954578,0.00026502504,0.00013949833,0.00042911436,0.00018043477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013742513,0.00004499686,0.996855,0.0000067715177,0.000024180665,0.00039241553,0.000074026844,0.000031264426,0.0006830198,0.000006450757,0.000069307076,0.0016750336],"study_design_scores_gemma":[0.000009303781,0.00035115366,0.99739516,0.000002696222,0.0000379623,0.0014863665,0.00012662877,0.000105515726,0.00021850671,0.000009799162,0.00025323327,0.0000036941378],"about_ca_topic_score_codex":0.0022767119,"about_ca_topic_score_gemma":0.0015709692,"teacher_disagreement_score":0.0022767119,"about_ca_system_score_codex":0.00021389776,"about_ca_system_score_gemma":0.00020981867,"threshold_uncertainty_score":0.004526913},"labels":[],"label_agreement":null},{"id":"W2103725500","doi":"10.1159/000119747","title":"Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer","year":2008,"lang":"en","type":"article","venue":"Breast Care","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lapatinib; Adjuvant; Oncology; Breast cancer; Neoadjuvant therapy; Internal medicine; Trastuzumab; Adjuvant therapy; Cancer","score_opus":0.030207635558624314,"score_gpt":0.31920669491883774,"score_spread":0.2889990593602134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103725500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9252282,0.056202635,0.0009514464,0.0019305516,0.0005448456,0.0004045344,0.00064283056,0.0000644235,0.014030524],"genre_scores_gemma":[0.98464346,0.009328436,0.0012127981,0.00062081515,0.00016653113,0.00026354892,0.00092486857,0.000008309651,0.0028311978],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99985397,0.00006361212,0.0000150190535,0.000016302656,0.000020414695,0.000030673546],"domain_scores_gemma":[0.99986005,0.000032884076,0.000024083987,0.000014337002,0.000009628308,0.000058969286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004948485,0.00021298804,0.00041263425,0.00020858277,0.00014651915,0.00028580445,0.00013762602,0.0002391778,0.0021248702],"category_scores_gemma":[0.00047670488,0.000093862815,0.00030018674,0.0002218716,0.00014645433,0.0002405291,0.0001592769,0.00059197686,0.00027002644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10865645,0.007877277,0.03872009,0.0018367494,0.00063834403,0.0011498414,0.00022538955,0.004323,0.06269465,0.0010516286,0.00867011,0.7641564],"study_design_scores_gemma":[0.049621794,0.2611784,0.38028604,0.0018944712,0.003114582,0.008979401,0.000499821,0.011607741,0.058993172,0.0041771303,0.21952543,0.000122011996],"about_ca_topic_score_codex":0.0008142568,"about_ca_topic_score_gemma":0.0070020445,"teacher_disagreement_score":0.0021248702,"about_ca_system_score_codex":0.00047208383,"about_ca_system_score_gemma":0.0005395686,"threshold_uncertainty_score":0.0071083903},"labels":[],"label_agreement":null},{"id":"W2103735100","doi":"10.4161/cc.6.23.4949","title":"ErbB-2 Receptor Cooperates with E6/E7 Oncoproteins of HPV Type 16 in Breast Tumorigenesis","year":2007,"lang":"en","type":"article","venue":"Cell Cycle","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"ErbB; Cancer research; Carcinogenesis; Biology; Genetically modified mouse; Transgene; Breast cancer; Mammary gland; Cancer; Gene; Genetics","score_opus":0.015359304325813313,"score_gpt":0.3021665776746916,"score_spread":0.2868072733488783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103735100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974253,0.0013037212,0.00045474514,0.000029221761,0.000010276563,0.000010737196,0.00007160257,0.000018013961,0.00067647384],"genre_scores_gemma":[0.9961636,0.0009796662,0.0009253767,0.00002053348,0.000006257188,0.000019102219,0.00023651896,0.00000835908,0.0016406011],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99967825,0.000069212794,0.000028239301,0.00004511707,0.00009093219,0.000088293156],"domain_scores_gemma":[0.99985087,0.000022771583,0.000028634346,0.000023163317,0.000010525472,0.000064024505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030657815,0.00046642747,0.0003312259,0.0003974864,0.00015900648,0.0002846433,0.00019766127,0.00032376414,0.0009788194],"category_scores_gemma":[0.0001325275,0.0002537073,0.00036058782,0.00016519062,0.00020723122,0.00024727412,0.00041506585,0.00036075714,0.0003930216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016895756,0.000058793546,0.0007496871,0.000017794651,0.000005372317,0.000079055855,0.000008119921,0.000027514934,0.9983177,0.000052963438,0.000012899643,0.00050109735],"study_design_scores_gemma":[0.000031640047,0.0010618423,0.016101597,0.000008098317,0.000044833054,0.0013701447,0.000050858063,0.00090301316,0.9779302,0.00005059938,0.0024402456,0.0000069223343],"about_ca_topic_score_codex":0.0004104817,"about_ca_topic_score_gemma":0.00062199804,"teacher_disagreement_score":0.0009788194,"about_ca_system_score_codex":0.000184997,"about_ca_system_score_gemma":0.00016691835,"threshold_uncertainty_score":0.0032745004},"labels":[],"label_agreement":null},{"id":"W2105398998","doi":"10.1158/1078-0432.ccr-08-2635","title":"Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Biomedical Imaging and Bioengineering; National Cancer Institute","keywords":"Trastuzumab; Medicine; Apoptosis; Breast cancer; Positron emission tomography; Cancer; Cancer research; Immunohistochemistry; Annexin; Annexin A5; Pathology; Oncology; Internal medicine; Nuclear medicine; Biology","score_opus":0.3413549984427097,"score_gpt":0.6007117179825404,"score_spread":0.2593567195398307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105398998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986289,0.0067621316,0.004981029,0.00015999218,0.00003135931,0.00011957062,0.0005905325,0.00019420114,0.0008722228],"genre_scores_gemma":[0.9903066,0.0023718015,0.0044362843,0.00010947485,0.000033031643,0.00016536878,0.0008500032,0.000021914271,0.001705452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997018,0.000055715263,0.000017106533,0.00005218947,0.00013178619,0.000041332423],"domain_scores_gemma":[0.99967885,0.000057755635,0.00015035404,0.00001933472,0.00005819785,0.000035523557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062318513,0.00074771687,0.0005619442,0.00059825694,0.00007644943,0.00048678502,0.0002401638,0.0005600642,0.0007934357],"category_scores_gemma":[0.00061900716,0.00021314203,0.00016061595,0.00030826105,0.00017690632,0.00035354708,0.00015455749,0.00063721155,0.00035973697],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020956162,0.00084971014,0.0277309,0.00023267894,0.00008488382,0.00008414947,0.000036300706,0.0016035299,0.93972003,0.00006325102,0.00039229207,0.027106617],"study_design_scores_gemma":[0.00020002454,0.007326072,0.14100283,0.000043780197,0.00030713764,0.0008265615,0.00010984822,0.014719926,0.83152205,0.00016305922,0.0037464728,0.000032315376],"about_ca_topic_score_codex":0.0004139468,"about_ca_topic_score_gemma":0.00072179735,"teacher_disagreement_score":0.0007934357,"about_ca_system_score_codex":0.00042300622,"about_ca_system_score_gemma":0.00023858744,"threshold_uncertainty_score":0.0032957196},"labels":[],"label_agreement":null},{"id":"W2105662969","doi":"10.2174/138945009788488378","title":"Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer","year":2009,"lang":"en","type":"article","venue":"Current Drug Targets","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tyrosine kinase; Cancer; Cancer research; Medicine; Protein-Tyrosine Kinases; Internal medicine; Receptor","score_opus":0.05965188982531681,"score_gpt":0.403468311836028,"score_spread":0.34381642201071116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105662969","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057172207,0.95787823,0.0017407926,0.0052229012,0.0017631563,0.00006401695,0.0006632756,0.000112250964,0.026838087],"genre_scores_gemma":[0.044527277,0.90531194,0.0028129602,0.0021753171,0.0018631457,0.000088982466,0.0012246467,0.000025428079,0.0419702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987423,0.000022367916,0.000008937611,0.000016209007,0.000049826085,0.00002843999],"domain_scores_gemma":[0.99989855,0.000031257016,0.00001669373,0.0000048833053,0.00001909297,0.000029595494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041325562,0.0004978352,0.00092159037,0.00074698153,0.00023648144,0.00072138954,0.0006163888,0.0007803337,0.0253719],"category_scores_gemma":[0.0002937812,0.00017099585,0.0004369679,0.00055676483,0.00024334164,0.0008065366,0.0004216197,0.0014485844,0.0058967792],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011719645,0.00037544424,0.00038931795,0.003388848,0.00011090906,0.0007244649,0.00004353035,0.0007805001,0.017357185,0.008424788,0.08269276,0.8845403],"study_design_scores_gemma":[0.00079796894,0.0012185549,0.0032753374,0.000997738,0.00023006744,0.0028339252,0.00005137387,0.0007421514,0.008222271,0.0043591755,0.977234,0.00003739222],"about_ca_topic_score_codex":0.00079662475,"about_ca_topic_score_gemma":0.003945982,"teacher_disagreement_score":0.0253719,"about_ca_system_score_codex":0.0007370348,"about_ca_system_score_gemma":0.0006526943,"threshold_uncertainty_score":0.08487749},"labels":[],"label_agreement":null},{"id":"W2105730286","doi":"10.1136/jcp.2011.089847","title":"HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"In situ hybridisation; Medicine; Pathology; In situ hybridization; Immunohistochemistry; Medical physics; Biology","score_opus":0.5332641908238643,"score_gpt":0.5904470552369654,"score_spread":0.05718286441310105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105730286","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010973553,0.109643824,0.10609222,0.6043092,0.03084505,0.0044458215,0.007362066,0.0046991836,0.121629104],"genre_scores_gemma":[0.04999201,0.10242609,0.45524687,0.24314214,0.009439909,0.010461031,0.012019713,0.0019065435,0.115365684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97304326,0.009471283,0.007295572,0.0009448161,0.0079934085,0.0012516644],"domain_scores_gemma":[0.93280894,0.022503922,0.0059741335,0.002507118,0.033001874,0.003204068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025406152,0.0014906817,0.0020255742,0.006722906,0.0013964868,0.0031114034,0.0057319906,0.0147405965,0.009117406],"category_scores_gemma":[0.054192647,0.0015168223,0.0031509583,0.0040865326,0.0031694495,0.0031536391,0.002966193,0.0072207623,0.008370596],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001599161,0.00022980443,0.0030655528,0.0021984535,0.000044283188,0.0014496205,0.0006808098,0.0009176176,0.0027973775,0.003587934,0.7668588,0.21800984],"study_design_scores_gemma":[0.00019564271,0.0003070744,0.019221028,0.006617312,0.00012788027,0.002926487,0.0008540663,0.0012979126,0.0018054357,0.0044439007,0.96202314,0.00018015203],"about_ca_topic_score_codex":0.028579338,"about_ca_topic_score_gemma":0.045514464,"teacher_disagreement_score":0.028579338,"about_ca_system_score_codex":0.0028924937,"about_ca_system_score_gemma":0.007849733,"threshold_uncertainty_score":0.13436216},"labels":[],"label_agreement":null},{"id":"W2105980005","doi":"10.1158/1055-9965.epi-08-0713","title":"Sampling Strategies for Tissue Microarrays to Evaluate Biomarkers in Ovarian Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"National Cancer Institute","keywords":"Tissue microarray; Immunohistochemistry; Ovarian cancer; Cancer; Sampling (signal processing); Pathology; DNA microarray; Medicine; Biology; Oncology; Cancer research; Internal medicine; Gene expression; Gene; Computer science; Genetics","score_opus":0.18471134206552095,"score_gpt":0.5129714561115281,"score_spread":0.3282601140460071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105980005","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24597073,0.00851424,0.7370187,0.0005184611,0.00021122409,0.0026010028,0.00092672295,0.0010526193,0.0031863134],"genre_scores_gemma":[0.30638835,0.0026819394,0.68306226,0.00040362976,0.00010180547,0.004542442,0.0012586251,0.00017332697,0.001387729],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99635017,0.0018021215,0.00028791215,0.000482848,0.00091527187,0.000161644],"domain_scores_gemma":[0.9976265,0.0008472984,0.0005489253,0.00033032702,0.00058496353,0.00006192712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050145723,0.00073642854,0.0006432894,0.0014431861,0.00049557304,0.00085120543,0.00070995186,0.0006666048,0.0014693891],"category_scores_gemma":[0.0042865733,0.00068140385,0.00052192324,0.0011740274,0.00045357097,0.0005191485,0.00070389494,0.00063040835,0.0012151847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060922536,0.0001769118,0.025049124,0.0006448958,0.00014972757,0.0001801834,0.00030714556,0.0021305445,0.91236264,0.0012543454,0.00084807794,0.056287102],"study_design_scores_gemma":[0.00013603926,0.002598178,0.0863961,0.00022101661,0.00046238728,0.0022515913,0.0004894572,0.024577659,0.85287565,0.0031952406,0.026696816,0.00009981],"about_ca_topic_score_codex":0.00074408285,"about_ca_topic_score_gemma":0.0017369557,"teacher_disagreement_score":0.0050145723,"about_ca_system_score_codex":0.00045108353,"about_ca_system_score_gemma":0.00042918778,"threshold_uncertainty_score":0.026519895},"labels":[],"label_agreement":null},{"id":"W2106198994","doi":"10.1200/jco.2004.09.128","title":"The Combination of <i>p53</i> Mutation and <i>neu/erb</i>B-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; North York General Hospital; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Mutation; Disease; Cancer; Cancer research; Gene; Biology; Genetics","score_opus":0.13034729828871386,"score_gpt":0.4943392522767907,"score_spread":0.3639919539880768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106198994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994795,0.00027652862,0.0000645316,0.000033954755,0.0000031558577,0.0000014893985,0.000030945124,0.0000045989063,0.00010543304],"genre_scores_gemma":[0.99975175,0.00007284704,0.000047828184,0.000009679057,0.000013491858,0.0000015065708,0.000049785594,0.0000013720702,0.000051752886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99973696,0.00008357002,0.00002436079,0.000058950784,0.000050908297,0.00004535778],"domain_scores_gemma":[0.99804246,0.0004945636,0.0009833017,0.000090868445,0.00007289032,0.00031579542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049762364,0.00033803307,0.00029330823,0.0007864655,0.00027645135,0.0003354144,0.00031009183,0.00049101835,0.0016238117],"category_scores_gemma":[0.001826003,0.00020332671,0.00030065933,0.000450439,0.00046380368,0.0002209619,0.00028095974,0.00044827885,0.00024576212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003121411,0.000020162024,0.99648595,0.000007685421,0.00005831227,0.0002164224,0.0000144009055,0.000053575248,0.0016354853,0.0000044842564,0.00004057423,0.0011508645],"study_design_scores_gemma":[0.000011002425,0.00013396669,0.99659157,0.000004490445,0.000075734075,0.0024078707,0.000033919605,0.000287528,0.0003272344,0.000026269998,0.00009727657,0.0000029805972],"about_ca_topic_score_codex":0.0008528405,"about_ca_topic_score_gemma":0.0011144935,"teacher_disagreement_score":0.0016238117,"about_ca_system_score_codex":0.00014049056,"about_ca_system_score_gemma":0.0001659348,"threshold_uncertainty_score":0.0054321885},"labels":[],"label_agreement":null},{"id":"W2106635812","doi":"10.1369/jhc.6a7017.2006","title":"Direct Detection of Herceptin/Trastuzumab Binding on Breast Tissue Sections","year":2006,"lang":"en","type":"article","venue":"Journal of Histochemistry & Cytochemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"Barbara Ann Karmanos Cancer Institute","keywords":"Trastuzumab; Immunohistochemistry; Polyclonal antibodies; Humanized antibody; Antibody; Tissue microarray; Staining; Breast cancer; Monoclonal antibody; HER2/neu; Primary and secondary antibodies; Monoclonal; Medicine; Molecular biology; Pathology; Cancer; Cancer research; Biology; Immunology; Internal medicine","score_opus":0.013305496391511278,"score_gpt":0.30601956472144026,"score_spread":0.29271406832992897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106635812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95459384,0.004845245,0.03193769,0.00006483531,0.00007015993,0.00029594373,0.0004750866,0.00030901562,0.0074081575],"genre_scores_gemma":[0.9206648,0.0041548773,0.06632354,0.00011539871,0.000040707313,0.0005966837,0.0012862753,0.00007368457,0.006743915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99970144,0.000056528166,0.000033210003,0.00007389367,0.00008446297,0.000050402254],"domain_scores_gemma":[0.9997212,0.00008350338,0.00004463659,0.000046678204,0.00007831246,0.000025551508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074369967,0.00038820767,0.000231087,0.0008274351,0.00019560287,0.00017893377,0.00025977398,0.00036107437,0.0028125192],"category_scores_gemma":[0.0003662818,0.00030008086,0.00018296401,0.000468613,0.00023829687,0.00023224774,0.00024320504,0.00032609983,0.0005895737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011131541,0.000026954776,0.0018735839,0.00009844501,0.000015799254,0.00009627328,0.000040512485,0.000049668804,0.99419373,0.00009649019,0.000038059014,0.0033592181],"study_design_scores_gemma":[0.00008230129,0.0010476767,0.09165309,0.000053931282,0.0001551904,0.0018517377,0.00017221906,0.0034338187,0.89537156,0.0002999552,0.0058658156,0.000012786369],"about_ca_topic_score_codex":0.0006580346,"about_ca_topic_score_gemma":0.0017477142,"teacher_disagreement_score":0.0028125192,"about_ca_system_score_codex":0.0001972766,"about_ca_system_score_gemma":0.00020387281,"threshold_uncertainty_score":0.009408772},"labels":[],"label_agreement":null},{"id":"W2106837862","doi":"10.3747/co.19.1173","title":"Testing for HER2 in Breast Cancer: Current Pathology Challenges Faced in Canada","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University; McGill University; University of Manitoba; University of British Columbia; Saskatoon City Hospital; Vancouver General Hospital; Mount Sinai Hospital; Toronto General Hospital; University Health Network; University of Toronto; Dalhousie University; Queen Elizabeth II Health Sciences Centre; Juravinski Hospital; Women's College Hospital; Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Breast cancer; Human Epidermal Growth Factor Receptor 2; Clinical Oncology; MEDLINE; Core biopsy; Pathology; Medical physics; Family medicine; Cancer; Internal medicine","score_opus":0.3436562265670484,"score_gpt":0.5002725317108598,"score_spread":0.15661630514381142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106837862","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02497899,0.8498731,0.00078309537,0.09716292,0.0008594819,0.00010807545,0.0014510163,0.000056403565,0.024726825],"genre_scores_gemma":[0.1204475,0.8640075,0.0029008873,0.00797285,0.0004380616,0.00003416278,0.0010117108,0.000022596441,0.0031648125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932313,0.0006451599,0.000775149,0.0003914296,0.004290603,0.0006664471],"domain_scores_gemma":[0.9699799,0.004576,0.0021979914,0.00018281546,0.021493036,0.0015702174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005886011,0.00037750258,0.0008840136,0.0055149538,0.0026783731,0.004443557,0.0017557591,0.0010158403,0.0029967655],"category_scores_gemma":[0.017825073,0.00029983724,0.0005205014,0.014739799,0.0016287992,0.0020514862,0.001231129,0.0009786577,0.00037128542],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026681463,0.00008041602,0.051139966,0.014719442,0.00016520481,0.002705656,0.0036058095,0.00082400476,0.0013229657,0.0063324557,0.08192793,0.8369093],"study_design_scores_gemma":[0.00009650027,0.00022449356,0.22983976,0.01850027,0.00066176173,0.0049134498,0.017660525,0.0010115732,0.0014185129,0.0036195924,0.72178876,0.00026482146],"about_ca_topic_score_codex":0.9695077,"about_ca_topic_score_gemma":0.9871163,"teacher_disagreement_score":0.9471467,"about_ca_system_score_codex":0.052853286,"about_ca_system_score_gemma":0.1911614,"threshold_uncertainty_score":0.38347924},"labels":[],"label_agreement":null},{"id":"W2107337979","doi":"10.1128/mcb.24.11.4636-4650.2004","title":"Mutations in the SAM Domain of the ETV6-NTRK3 Chimeric Tyrosine Kinase Block Polymerization and Transformation Activity","year":2004,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Children’s Health Research Institute","funders":"","keywords":"Fusion protein; Biology; ETV6; Chimeric gene; Fusion gene; Mutant; Tyrosine kinase; Molecular biology; Tyrosine; Protein kinase domain; Transformation (genetics); Cell biology; Gene; Signal transduction; Biochemistry; Chromosomal translocation; Recombinant DNA; Gene expression","score_opus":0.010897383421098703,"score_gpt":0.2835636639335447,"score_spread":0.272666280512446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107337979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964729,0.00025550337,0.0019633644,0.000032589167,0.000014120244,0.00002483887,0.00018543133,0.000053855012,0.0009973175],"genre_scores_gemma":[0.996847,0.0001445234,0.001447423,0.000013797024,0.000002700351,0.000022023645,0.00024247287,0.000022080932,0.0012579244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998299,0.000038028884,0.000022987375,0.00002525965,0.000045053177,0.000038755497],"domain_scores_gemma":[0.99987376,0.000037180627,0.000039510913,0.0000145987115,0.000005372871,0.000029611505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012396196,0.00043398567,0.0002166308,0.00015767873,0.00013445642,0.00017228663,0.00028842353,0.00030564048,0.0016263005],"category_scores_gemma":[0.00013484199,0.00015303529,0.000310337,0.00014771335,0.0002602398,0.00014750446,0.00022367746,0.0005229115,0.0004741627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011481576,0.000035224424,0.00014604964,0.000012717305,0.0000047023127,0.00007995193,0.0000098301625,0.0001339648,0.99854195,0.00020449529,0.000016413216,0.00069981115],"study_design_scores_gemma":[0.00001879975,0.00015070905,0.0019184242,0.0000027182843,0.000007077566,0.00032303276,0.000008456386,0.0011644346,0.9946786,0.000030425044,0.0016940823,0.0000032418975],"about_ca_topic_score_codex":0.00047083717,"about_ca_topic_score_gemma":0.0007066352,"teacher_disagreement_score":0.0016263005,"about_ca_system_score_codex":0.0003877732,"about_ca_system_score_gemma":0.00020941175,"threshold_uncertainty_score":0.005440533},"labels":[],"label_agreement":null},{"id":"W2107723446","doi":"10.1007/s10549-012-2076-7","title":"Expression of activated type I receptor tyrosine kinases in early breast cancer","year":2012,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"AstraZeneca","keywords":"Breast cancer; Medicine; Tissue microarray; Immunohistochemistry; Internal medicine; Oncology; Cancer; Cohort; Receptor","score_opus":0.09947066223487866,"score_gpt":0.42730410465319474,"score_spread":0.3278334424183161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107723446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799241,0.0120835565,0.0007602594,0.0002255914,0.000033659002,0.000019711993,0.000374587,0.00003537425,0.0065430827],"genre_scores_gemma":[0.98653215,0.006196038,0.00085933314,0.00006471488,0.0000545361,0.000021456452,0.00051302114,0.000010997097,0.005747776],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999826,0.000027673965,0.000012855923,0.000016899081,0.000041968357,0.00007459205],"domain_scores_gemma":[0.9998375,0.00003046384,0.000035214936,0.000012011459,0.000047973175,0.000036899306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029575403,0.0001405451,0.00018398253,0.0009290379,0.00023460755,0.000708149,0.00020243725,0.00028634394,0.0019640015],"category_scores_gemma":[0.00042326856,0.00014981555,0.00015913647,0.0005755087,0.00020866591,0.00037273575,0.00020113683,0.0004183534,0.00042055076],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027023696,0.00025178408,0.05127314,0.00024819298,0.00003515549,0.001404391,0.0003737097,0.00026379977,0.89769715,0.0018632457,0.001162589,0.04272438],"study_design_scores_gemma":[0.00009707482,0.00112029,0.5419253,0.00010147676,0.00015343868,0.0096141705,0.0014726876,0.0015969491,0.40939143,0.001602484,0.03288822,0.00003649963],"about_ca_topic_score_codex":0.0011211637,"about_ca_topic_score_gemma":0.0012586124,"teacher_disagreement_score":0.0019640015,"about_ca_system_score_codex":0.00063956494,"about_ca_system_score_gemma":0.00034133898,"threshold_uncertainty_score":0.00657022},"labels":[],"label_agreement":null},{"id":"W2108422856","doi":"10.1016/j.schres.2008.03.025","title":"Neuregulin-1 and the P300 waveform—A preliminary association study using a psychosis endophenotype","year":2008,"lang":"en","type":"article","venue":"Schizophrenia Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"Psychiatry Research Trust; Wellcome Trust; National Institute for Health and Care Research; Schizophrenia Research Fund","keywords":"Endophenotype; Psychosis; Neuregulin 1; Psychology; Schizoaffective disorder; Schizophrenia (object-oriented programming); Latency (audio); Single-nucleotide polymorphism; Audiology; Mismatch negativity; Cognition; Neuroscience; Electroencephalography; Medicine; Psychiatry; Biology; Genetics; Genotype; Gene; Computer science","score_opus":0.13449240926788908,"score_gpt":0.41660735057205006,"score_spread":0.282114941304161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108422856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994518,0.00006516891,0.00014463913,0.00002103605,0.0000035296737,0.000010192841,0.000080117636,0.000001976142,0.00022148188],"genre_scores_gemma":[0.9990576,0.00005238529,0.00023024439,0.00002520584,0.000004739678,0.000016333413,0.00010290854,0.000004085266,0.0005065459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995821,0.00015774762,0.000021783035,0.00009802763,0.0000794817,0.000060887174],"domain_scores_gemma":[0.99929667,0.00026497172,0.00015806833,0.000087706925,0.00006495975,0.00012761088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061794784,0.00073912204,0.00037600167,0.00080714276,0.0008107616,0.0005458018,0.0005278579,0.0005257309,0.0017766072],"category_scores_gemma":[0.0017561619,0.00024790346,0.00034390631,0.0005827042,0.0004545795,0.0003296756,0.000567821,0.00079263275,0.00024989306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011407536,0.0017557351,0.82963467,0.00006230682,0.0004676034,0.003296089,0.00096393464,0.00020170321,0.13484901,0.0004770146,0.00027618426,0.016608182],"study_design_scores_gemma":[0.00010293248,0.0010931112,0.99080455,0.000005204257,0.0001545854,0.002448558,0.00038921944,0.00041188506,0.0040157307,0.00021423775,0.00034454904,0.00001551461],"about_ca_topic_score_codex":0.004450268,"about_ca_topic_score_gemma":0.0046844827,"teacher_disagreement_score":0.004450268,"about_ca_system_score_codex":0.0004625632,"about_ca_system_score_gemma":0.00034126558,"threshold_uncertainty_score":0.008848727},"labels":[],"label_agreement":null},{"id":"W2108572537","doi":"10.1002/ijc.10647","title":"Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibody","year":2002,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; McMaster University","funders":"","keywords":"Cancer research; In vivo; Oncogene; A431 cells; Apoptosis; Epidermal growth factor receptor; Monoclonal antibody; Epidermal growth factor; Cell culture; In vitro; Cytotoxic T cell; Cell growth; Antibody; Biology; Cell cycle; Cancer; Immunology; Medicine; Receptor; Internal medicine; Biochemistry","score_opus":0.05122474526373232,"score_gpt":0.42221908015241655,"score_spread":0.3709943348886842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108572537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991042,0.0037184455,0.0023388152,0.00015097928,0.000039656967,0.000056793742,0.00038996743,0.00016863286,0.0020945868],"genre_scores_gemma":[0.99359095,0.001630688,0.002527741,0.00008125561,0.000028542205,0.000039093014,0.00067256775,0.000019232488,0.0014099433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999912,0.000018802559,0.0000064264887,0.00001458082,0.00001924973,0.000028942968],"domain_scores_gemma":[0.9999441,0.00000957297,0.000011188576,0.0000071861505,0.000009331908,0.000018585939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017452486,0.00041555852,0.00025585198,0.00024938514,0.00010637732,0.00016960537,0.00025193344,0.0002558022,0.0009325574],"category_scores_gemma":[0.00007587385,0.00012075381,0.00026605418,0.00012878158,0.00014301461,0.000119860706,0.00008854433,0.0005802147,0.0002825651],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047064773,0.000182286,0.00016387094,0.000059729646,0.000012154932,0.0000562011,0.000012851372,0.00009676337,0.9930607,0.000109704364,0.0001401248,0.005634966],"study_design_scores_gemma":[0.00022565348,0.0033373635,0.0047054878,0.0000056184726,0.00004123305,0.0006710709,0.000008345767,0.00066999084,0.9863517,0.000043485332,0.0039332546,0.00000665893],"about_ca_topic_score_codex":0.00066278933,"about_ca_topic_score_gemma":0.0008614295,"teacher_disagreement_score":0.0009325574,"about_ca_system_score_codex":0.00019090688,"about_ca_system_score_gemma":0.0002829266,"threshold_uncertainty_score":0.0031196475},"labels":[],"label_agreement":null},{"id":"W2109765959","doi":"10.1158/0008-5472.can-05-0755","title":"Copy Number Aberrations in Mouse Breast Tumors Reveal Loci and Genes Important in Tumorigenic Receptor Tyrosine Kinase Signaling","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Biology; Amplicon; Receptor tyrosine kinase; Carcinogenesis; Cancer research; Locus (genetics); Genetics; Copy-number variation; Gene; Signal transduction; Genome","score_opus":0.06851699653895069,"score_gpt":0.4221883660174637,"score_spread":0.35367136947851296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109765959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397546,0.00058504083,0.0038622417,0.000055316774,0.000005917931,0.000013256617,0.000600342,0.00015665412,0.0007457428],"genre_scores_gemma":[0.99416876,0.00033258917,0.002548451,0.000028888997,0.0000031753102,0.000024005936,0.00079403695,0.000028199393,0.0020719136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997378,0.00003148248,0.000019774587,0.00007468162,0.0000757715,0.00006043526],"domain_scores_gemma":[0.99975806,0.00004198888,0.00010784156,0.000029434761,0.000014487945,0.000048084006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013582519,0.0003858723,0.00014671165,0.0012017717,0.0001569858,0.0002996932,0.00020324667,0.0004041891,0.0015079359],"category_scores_gemma":[0.00016792136,0.00026692566,0.00027417354,0.00042863176,0.00023287084,0.00014996948,0.00025217375,0.00039583925,0.00026449116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007406489,0.000008991082,0.0006548158,0.0000069406306,0.000005879033,0.000035952464,0.000009631002,0.000069583555,0.9982912,0.00006849882,0.000011436182,0.0007631204],"study_design_scores_gemma":[0.000026950096,0.0003384772,0.035567682,0.000007811865,0.000057474404,0.0010805322,0.00003728158,0.0016136183,0.95954585,0.00024197652,0.0014731088,0.00000932476],"about_ca_topic_score_codex":0.0009070047,"about_ca_topic_score_gemma":0.0016571924,"teacher_disagreement_score":0.0015079359,"about_ca_system_score_codex":0.0004882791,"about_ca_system_score_gemma":0.00013338287,"threshold_uncertainty_score":0.0050445795},"labels":[],"label_agreement":null},{"id":"W2110827195","doi":"10.1309/pef8-gl6f-ywmc-ag56","title":"Assessment of Interlaboratory Variation in the Immunohistochemical Determination of Estrogen Receptor Status Using a Breast Cancer Tissue Microarray","year":2002,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; Royal Columbian Hospital; Kelowna General Hospital; University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Kappa; Concordance; Tissue microarray; Breast cancer; Grading (engineering); Medicine; Reproducibility; Pathology; Immunohistochemistry; Estrogen receptor; Cohen's kappa; Cancer; Internal medicine; Biology; Mathematics; Statistics","score_opus":0.06939456895177747,"score_gpt":0.4871054210943099,"score_spread":0.4177108521425324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110827195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8030816,0.0032447889,0.18636778,0.00026141613,0.00035700764,0.0010414975,0.00062069483,0.0008243434,0.004200833],"genre_scores_gemma":[0.93714994,0.00027226136,0.05878004,0.00026198506,0.00010926975,0.0009645813,0.0011502759,0.00024691314,0.0010648286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.89468634,0.054243762,0.009104567,0.014402756,0.026131555,0.0014310448],"domain_scores_gemma":[0.8718,0.076198,0.009544995,0.02099157,0.020387052,0.0010782646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06817213,0.0009480651,0.0010451444,0.001955881,0.0011488425,0.0016389077,0.0009796931,0.000993847,0.0006294502],"category_scores_gemma":[0.08465,0.0006798847,0.00073086336,0.001735768,0.0016257796,0.00058505737,0.00201423,0.00070741546,0.00047366667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003804238,0.0012647911,0.51301295,0.0012074905,0.0034689321,0.0007083558,0.010726402,0.009290096,0.31787086,0.0019879653,0.0025777882,0.13408022],"study_design_scores_gemma":[0.00024513807,0.004988237,0.8163851,0.00018967637,0.001583307,0.0018925412,0.0011766974,0.028563,0.12874998,0.0023716528,0.013565051,0.00028961414],"about_ca_topic_score_codex":0.0019222137,"about_ca_topic_score_gemma":0.0032542339,"teacher_disagreement_score":0.06817213,"about_ca_system_score_codex":0.0009382442,"about_ca_system_score_gemma":0.0008490191,"threshold_uncertainty_score":0.360533},"labels":[],"label_agreement":null},{"id":"W2111347432","doi":"10.1200/jco.2009.23.1910","title":"Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"GlaxoSmithKline","keywords":"Trastuzumab; Medicine; Regimen; Loading dose; Cardiotoxicity; Metastatic breast cancer; Internal medicine; Pharmacokinetics; Chemotherapy; Adverse effect; Breast cancer; Phases of clinical research; Oncology; Cancer; Pharmacology; Gastroenterology","score_opus":0.17936158971020888,"score_gpt":0.5111639668432632,"score_spread":0.33180237713305427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111347432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921101,0.0015284683,0.0035275305,0.00010045573,0.000026319074,0.00046711776,0.00014647785,0.00018676417,0.001906763],"genre_scores_gemma":[0.9948953,0.0005545106,0.0027734402,0.0001525585,0.000096117285,0.00033536667,0.00040103294,0.000031969492,0.00075979077],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99979514,0.000048351536,0.000018159115,0.000040409894,0.00004963879,0.000048461683],"domain_scores_gemma":[0.99975365,0.000040000683,0.00007758011,0.000039361832,0.00001762937,0.0000717379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002879092,0.00047460245,0.0009204548,0.00020455041,0.00015201331,0.00029463024,0.00027106388,0.0003042972,0.0014856842],"category_scores_gemma":[0.00045762074,0.00013871057,0.00021328963,0.00022693796,0.0002989626,0.0003487196,0.00020314148,0.00092074904,0.00042764755],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013523964,0.008461058,0.0068979873,0.00020112142,0.00009700882,0.00024077763,0.00008890754,0.0019165489,0.8095504,0.00025998172,0.0010301685,0.15773213],"study_design_scores_gemma":[0.024713552,0.35712862,0.16141436,0.00013779747,0.0004006498,0.0043280167,0.00010988688,0.009115302,0.41296458,0.0008910294,0.028715847,0.00008041159],"about_ca_topic_score_codex":0.00017989965,"about_ca_topic_score_gemma":0.0003113167,"teacher_disagreement_score":0.0014856842,"about_ca_system_score_codex":0.00027088303,"about_ca_system_score_gemma":0.00024051555,"threshold_uncertainty_score":0.0049700737},"labels":[],"label_agreement":null},{"id":"W2111973486","doi":"10.1158/0008-5472.can-05-1829","title":"Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Gefitinib; Epidermal growth factor receptor; Cancer research; Growth factor receptor inhibitor; Epidermal growth factor; Transformation (genetics); Mutant; Cancer; Biology; Cell biology; Chemistry; Internal medicine; Receptor; Medicine; Genetics; Gene","score_opus":0.08131793499971414,"score_gpt":0.40494700614049417,"score_spread":0.32362907114078004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111973486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867964,0.0024947235,0.0049321065,0.0002760769,0.00011194872,0.00010392788,0.0013087926,0.0003979065,0.0035780726],"genre_scores_gemma":[0.9897327,0.001077158,0.0035734857,0.00009635276,0.00001898846,0.00012194868,0.00233627,0.00006968574,0.0029735202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996568,0.00005913829,0.000034495522,0.00005193634,0.000096527394,0.0001011066],"domain_scores_gemma":[0.99984634,0.000031806314,0.000031855492,0.00003678618,0.000020169795,0.000033119733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019900051,0.00059577887,0.00046861963,0.00039020993,0.00039446657,0.00036756293,0.000345725,0.000346019,0.0016781866],"category_scores_gemma":[0.00015643622,0.00018012073,0.00056807644,0.0004446702,0.00029151398,0.00020219517,0.00019825318,0.000956149,0.0006980354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014239333,0.00008384742,0.00009253153,0.000020385361,0.000008282313,0.000040869196,0.00001219143,0.00005157401,0.99850684,0.00011871647,0.00011314153,0.00080920313],"study_design_scores_gemma":[0.000036559744,0.00017762091,0.0019240561,0.0000029970483,0.000010924778,0.00022106564,0.000010883764,0.0009807011,0.99405116,0.000032555978,0.0025475493,0.0000039066886],"about_ca_topic_score_codex":0.0051374855,"about_ca_topic_score_gemma":0.0074787047,"teacher_disagreement_score":0.0051374855,"about_ca_system_score_codex":0.00073312345,"about_ca_system_score_gemma":0.0005307923,"threshold_uncertainty_score":0.010215163},"labels":[],"label_agreement":null},{"id":"W2112168902","doi":"10.1158/0008-5472.can-10-2840","title":"Transcriptional Control of the <i>ERBB2</i> Amplicon by ERRα and PGC-1β Promotes Mammary Gland Tumorigenesis","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Biology; Carcinogenesis; Amplicon; Coactivator; Cancer research; Promoter; Estrogen receptor; Gene; Transcriptional regulation; Genetics; Cancer; Breast cancer; Transcription factor; Gene expression; Polymerase chain reaction","score_opus":0.049304997911372044,"score_gpt":0.3891240746085691,"score_spread":0.3398190766971971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112168902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922943,0.0016950874,0.0034446034,0.00016077884,0.000028302287,0.000017292034,0.00041232165,0.00026159277,0.0016858024],"genre_scores_gemma":[0.99489874,0.0010467151,0.0013062818,0.000063872685,0.000012070111,0.000020750014,0.00041117135,0.000041677296,0.0021987732],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998852,0.000013794604,0.000007651136,0.000032225857,0.000029036244,0.000032077725],"domain_scores_gemma":[0.99987936,0.000009410358,0.000056019762,0.0000152295015,0.000011825102,0.000028139642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012906913,0.0002548268,0.0001928927,0.00018220722,0.00009052237,0.0002355231,0.00012757693,0.00014457632,0.000965973],"category_scores_gemma":[0.00008601377,0.00017124646,0.00023953107,0.00009751917,0.00021183002,0.00007374976,0.00025943242,0.00036528206,0.00035284137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000677331,0.000012199093,0.00060244533,0.000018079314,0.0000037133777,0.000027868293,0.0000092008795,0.00003997347,0.99820113,0.000053481537,0.000038857877,0.000925348],"study_design_scores_gemma":[0.000030435669,0.00031767006,0.05801841,0.000016779442,0.000033737895,0.00048894197,0.00006960572,0.0009489078,0.9332566,0.00009986146,0.0067124525,0.0000065127037],"about_ca_topic_score_codex":0.000504694,"about_ca_topic_score_gemma":0.0007471905,"teacher_disagreement_score":0.000965973,"about_ca_system_score_codex":0.00023068547,"about_ca_system_score_gemma":0.00014429481,"threshold_uncertainty_score":0.0032315254},"labels":[],"label_agreement":null},{"id":"W2112324274","doi":"10.1053/j.seminoncol.2004.07.019","title":"Optimizing treatment of HER2-positive metastatic breast cancer","year":2004,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Trastuzumab; Tolerability; Metastatic breast cancer; Breast cancer; Dosing; Oncology; Internal medicine; Regimen; Adverse effect; Clinical trial; Cancer","score_opus":0.044490724554963196,"score_gpt":0.42812279568189776,"score_spread":0.38363207112693454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112324274","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7772238,0.118045665,0.034811314,0.019354643,0.0007592545,0.00023029672,0.00046052012,0.0004538431,0.04866064],"genre_scores_gemma":[0.9561371,0.02506407,0.010956598,0.0016294005,0.00047782916,0.000098947574,0.00023756443,0.00007039409,0.0053281505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998591,0.00005207909,0.000006951571,0.000016036907,0.000038069404,0.000027778427],"domain_scores_gemma":[0.9999249,0.000026664848,0.000019294972,0.0000046896444,0.000012273721,0.000012145928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002611913,0.0002449151,0.000373822,0.00018235546,0.00016129322,0.0003929377,0.00025757408,0.00025727466,0.0025200944],"category_scores_gemma":[0.000612686,0.000074919204,0.00020326178,0.00018647773,0.00009579481,0.0002677331,0.00017044222,0.0005198457,0.0003131617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019364469,0.0010320217,0.009204524,0.0005035739,0.00015437492,0.0002763376,0.00013767864,0.012583935,0.081212245,0.0030884277,0.014240591,0.8756298],"study_design_scores_gemma":[0.0025070002,0.016408509,0.19224523,0.0008568234,0.0021150054,0.008113044,0.0013178114,0.06118818,0.2558658,0.02708503,0.43218634,0.00011135748],"about_ca_topic_score_codex":0.0009059069,"about_ca_topic_score_gemma":0.0023194498,"teacher_disagreement_score":0.0025200944,"about_ca_system_score_codex":0.00045599285,"about_ca_system_score_gemma":0.00044537443,"threshold_uncertainty_score":0.008430541},"labels":[],"label_agreement":null},{"id":"W2113167936","doi":"10.1634/theoncologist.2011-0379","title":"Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ministry of Health; Canadian Centre for Applied Research in Cancer Control; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Genentech; Canadian Cancer Society","keywords":"Medicine; Trastuzumab; Breast cancer; Regimen; Cost effectiveness; Oncology; Adjuvant; Quality of life (healthcare); Internal medicine; Quality-adjusted life year; Cancer","score_opus":0.1251169310672112,"score_gpt":0.4951463378981687,"score_spread":0.37002940683095753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113167936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715641,0.016059276,0.006524399,0.0016988014,0.00007331504,0.0005013864,0.0018364368,0.000031945474,0.001710313],"genre_scores_gemma":[0.99577737,0.0018902883,0.0015294465,0.00010545001,0.000018325813,0.00013770297,0.00046457004,0.0000048284683,0.00007202975],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9912277,0.007324899,0.00045616904,0.0003029418,0.00042577332,0.0002626007],"domain_scores_gemma":[0.95677805,0.0374368,0.0040556206,0.00053861196,0.00082593935,0.00036497417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015332401,0.00093811733,0.0012029754,0.0015574041,0.00020097043,0.0015950591,0.0009994559,0.0013865683,0.0013384427],"category_scores_gemma":[0.0618186,0.0007366419,0.0029452383,0.0014520059,0.00055173907,0.0015252422,0.00090564927,0.001088034,0.00009335089],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013075756,0.0013487621,0.11274723,0.0042421585,0.014800975,0.0002922718,0.00014186566,0.7995326,0.00051523646,0.0029633092,0.0011430165,0.04919682],"study_design_scores_gemma":[0.00412565,0.010716057,0.1036947,0.002481035,0.015280274,0.0006953843,0.00045558007,0.8455587,0.0015917581,0.0125447735,0.002632704,0.00022334489],"about_ca_topic_score_codex":0.012969973,"about_ca_topic_score_gemma":0.008580839,"teacher_disagreement_score":0.015332401,"about_ca_system_score_codex":0.005598222,"about_ca_system_score_gemma":0.0031354318,"threshold_uncertainty_score":0.08108646},"labels":[],"label_agreement":null},{"id":"W2113538442","doi":"10.1309/ajcp1iu7btsaqgyz","title":"Tissue Microarray for Routine Clinical Breast Biomarker Analysis","year":2010,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tissue microarray; Biomarker; Estrogen receptor; Immunohistochemistry; Breast cancer; Breast tissue; Pathology; Medicine; Oestrogen receptor; Oncology; Internal medicine; Bioinformatics; Biology; Cancer; Genetics","score_opus":0.09791513455714052,"score_gpt":0.539994501317924,"score_spread":0.4420793667607835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113538442","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0696395,0.023413561,0.7908809,0.0033937332,0.003032243,0.0072444743,0.04994008,0.014195156,0.038260274],"genre_scores_gemma":[0.096137345,0.009489261,0.81522155,0.0018572835,0.00057549187,0.0112206545,0.046448555,0.0005776721,0.018472247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99705315,0.00084836956,0.00029623546,0.00045614422,0.0011464935,0.00019965731],"domain_scores_gemma":[0.9988133,0.00021018031,0.000075074655,0.00044369113,0.0003473008,0.000110402805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024101394,0.00074058713,0.001251848,0.0023699948,0.00059812213,0.00094310916,0.0012564565,0.000805032,0.015313479],"category_scores_gemma":[0.0020296355,0.0005491501,0.00070849154,0.001553321,0.00020694609,0.00067620975,0.00075611897,0.0011990098,0.017636465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007679724,0.00027622207,0.003134291,0.00069088617,0.000114972565,0.0004428394,0.00006448909,0.00050901185,0.84492815,0.0021188348,0.032894433,0.11405791],"study_design_scores_gemma":[0.0002854168,0.0019910478,0.037855748,0.00031147662,0.00029382747,0.0076495763,0.00013011138,0.014883,0.47529027,0.0040565426,0.45711616,0.00013690713],"about_ca_topic_score_codex":0.0004028115,"about_ca_topic_score_gemma":0.00089432334,"teacher_disagreement_score":0.015313479,"about_ca_system_score_codex":0.00041829454,"about_ca_system_score_gemma":0.00074660184,"threshold_uncertainty_score":0.051228702},"labels":[],"label_agreement":null},{"id":"W2114163915","doi":"10.1158/0008-5472.can-09-1591","title":"β1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trastuzumab; Cancer research; Breast cancer; Metastatic breast cancer; Medicine; Protein kinase B; Integrin; Epidermal growth factor receptor; Cancer; Growth factor receptor; Internal medicine; Oncology; Signal transduction; Biology; Receptor; Cell biology","score_opus":0.06515304618792937,"score_gpt":0.4467056461121283,"score_spread":0.38155259992419893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114163915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238414,0.004574451,0.00067819847,0.00014554124,0.00005068988,0.000017480756,0.00007876875,0.000048577567,0.0020222894],"genre_scores_gemma":[0.99604094,0.0017720729,0.0004608181,0.00008617022,0.00001543595,0.00001397604,0.00023713848,0.000009841168,0.0013635625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990416,0.000019288336,0.0000067657625,0.000012957246,0.000022278235,0.00003451505],"domain_scores_gemma":[0.99997747,0.0000043921896,0.000006400461,0.0000041511666,0.0000028138686,0.0000046620735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098471384,0.00021306404,0.00023062235,0.00011324993,0.000103404294,0.00033539283,0.00014528666,0.00023594676,0.00048314666],"category_scores_gemma":[0.00010156889,0.00010291265,0.00017986003,0.00015312388,0.000089088826,0.00013031434,0.000120444216,0.0003451808,0.00018735208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009122849,0.00007913652,0.0002540227,0.000045714864,0.0000086116,0.000072662486,0.000014061383,0.00012385026,0.99456066,0.0001636622,0.00016595377,0.0044203806],"study_design_scores_gemma":[0.00007431431,0.0011589426,0.0100584235,0.000012753876,0.00006306565,0.0011323678,0.000031836484,0.002228425,0.9715385,0.00011459577,0.013579598,0.0000071408613],"about_ca_topic_score_codex":0.00034062023,"about_ca_topic_score_gemma":0.0007146346,"teacher_disagreement_score":0.00048314666,"about_ca_system_score_codex":0.00019224729,"about_ca_system_score_gemma":0.00011501144,"threshold_uncertainty_score":0.0016162992},"labels":[],"label_agreement":null},{"id":"W2114536437","doi":"10.1128/mcb.22.4.1073-1078.2002","title":"The Catalytic Activity of the ErbB-2 Receptor Tyrosine Kinase Is Essential for Embryonic Development","year":2002,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Biology; ErbB; Receptor tyrosine kinase; ROR1; Tropomyosin receptor kinase C; Tyrosine kinase; Receptor Protein-Tyrosine Kinases; Epidermal growth factor receptor; Epidermal growth factor; Cell biology; Cancer research; Signal transduction; Receptor; Molecular biology; Genetics; Platelet-derived growth factor receptor; Growth factor","score_opus":0.023360079035843306,"score_gpt":0.2937013517597644,"score_spread":0.2703412727239211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114536437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94718367,0.026669152,0.010968174,0.00056111143,0.00020388089,0.000052791755,0.0021387585,0.0005480824,0.01167433],"genre_scores_gemma":[0.9795378,0.008182201,0.0032118263,0.000087446344,0.000037083337,0.000023869414,0.0013868818,0.000042604457,0.007490248],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998536,0.000015888607,0.000014332753,0.000026253556,0.00006419831,0.000025672825],"domain_scores_gemma":[0.99987173,0.000016001071,0.00003426484,0.000014931759,0.00001588341,0.00004723392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014701314,0.00037869258,0.00018463751,0.00019249144,0.00016551415,0.000396923,0.0002345429,0.0002508826,0.0012362789],"category_scores_gemma":[0.00019309494,0.00016892958,0.00011011424,0.00013377161,0.00023172794,0.00020113665,0.00031467187,0.00030236426,0.00097121473],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107278545,0.000022225122,0.0011914423,0.000089025205,0.0000064385545,0.00040922762,0.00001704087,0.0001351779,0.9844482,0.0009247297,0.0003666621,0.012282534],"study_design_scores_gemma":[0.00005266061,0.0003491034,0.061097287,0.000057562553,0.00005047739,0.0043115425,0.00007717868,0.0009703057,0.8582778,0.00085737207,0.07387552,0.000023210354],"about_ca_topic_score_codex":0.0004351172,"about_ca_topic_score_gemma":0.0005203918,"teacher_disagreement_score":0.0012362789,"about_ca_system_score_codex":0.00024995024,"about_ca_system_score_gemma":0.00029684018,"threshold_uncertainty_score":0.0041357875},"labels":[],"label_agreement":null},{"id":"W2114882691","doi":"10.1158/0008-5472.can-06-4724","title":"Distinct ErbB-2–Coupled Signaling Pathways Promote Mammary Tumors with Unique Pathologic and Transcriptional Profiles","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"ErbB; Cancer research; Biology; HER2/neu; Receptor tyrosine kinase; Signal transduction; Metastasis; Mammary tumor; Proto-oncogene tyrosine-protein kinase Src; Carcinogenesis; Cancer; Breast cancer; Cell biology; Genetics","score_opus":0.11648727915294524,"score_gpt":0.40277159034118404,"score_spread":0.2862843111882388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114882691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99814224,0.00058070116,0.00055855926,0.000029907902,0.000002555687,0.000009422056,0.00011985383,0.00002936461,0.0005273521],"genre_scores_gemma":[0.9973574,0.00048198723,0.0007611378,0.000022768905,0.0000041792905,0.000017636059,0.00031886162,0.0000065543372,0.0010293465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998741,0.000016089738,0.0000071932236,0.00001975485,0.000040265553,0.000042532953],"domain_scores_gemma":[0.9999089,0.000008888399,0.000034609413,0.000009469252,0.0000085876,0.000029525861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012630368,0.00035978586,0.00016878065,0.00036977904,0.000098629076,0.0002454839,0.000079122496,0.00018141342,0.00053739524],"category_scores_gemma":[0.00007725012,0.00014505727,0.00018327725,0.00017375244,0.00017223111,0.00013782168,0.00021647697,0.00033414955,0.00019032529],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006918971,0.000021584723,0.0014039648,0.000010486188,0.0000029838618,0.0000647274,0.000009332197,0.00003415344,0.997491,0.00008221318,0.000015947482,0.0007943742],"study_design_scores_gemma":[0.000028281393,0.0005420249,0.08399109,0.0000073850615,0.000038830665,0.00292439,0.00011331085,0.0009911729,0.9095785,0.00018276679,0.0015936041,0.0000085263855],"about_ca_topic_score_codex":0.00018617464,"about_ca_topic_score_gemma":0.00050988817,"teacher_disagreement_score":0.00053739524,"about_ca_system_score_codex":0.00020918665,"about_ca_system_score_gemma":0.00014321478,"threshold_uncertainty_score":0.0017977953},"labels":[],"label_agreement":null},{"id":"W2115369621","doi":"10.1158/1055-9965.epi-08-1101","title":"HER-2/neu Overexpression as a Predictor for the Transition from <i>In situ</i> to Invasive Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institutes of Health","keywords":"Ductal carcinoma; Progesterone receptor; Breast cancer; Estrogen receptor; Oncology; Pathology; Immunohistochemistry; Medicine; Internal medicine; Univariate analysis; Cancer; Biology; Multivariate analysis","score_opus":0.06706633794037227,"score_gpt":0.42468656363259105,"score_spread":0.3576202256922188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115369621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99913055,0.00030683068,0.00009535223,0.00007835819,0.000008734684,0.0000063231405,0.000035351528,0.0000047595026,0.0003338394],"genre_scores_gemma":[0.9997137,0.00006953899,0.00007172347,0.00001235384,0.000010868229,0.0000024422832,0.000038281458,9.314063e-7,0.00008020722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997017,0.00014447288,0.000029651223,0.000028699895,0.000049746224,0.000045701145],"domain_scores_gemma":[0.998094,0.0007630384,0.0005405054,0.000082709696,0.00013321484,0.00038646522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071386714,0.00022555307,0.00021848921,0.0006775784,0.00021605715,0.00045930347,0.00019717806,0.00039231658,0.0011831073],"category_scores_gemma":[0.0028467174,0.00016789095,0.00025858096,0.000434528,0.00031090353,0.00023892616,0.0002659885,0.0008356188,0.0001824374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027677827,0.000046396148,0.99734503,0.0000073818514,0.000018965424,0.00017511894,0.000018299257,0.00006304871,0.00045928292,0.000012678632,0.000063065905,0.0015141008],"study_design_scores_gemma":[0.00001618039,0.00026859876,0.99671257,0.000010085271,0.0000645121,0.0012879517,0.00016391343,0.0008192101,0.000375484,0.00006526683,0.0002114972,0.000004750013],"about_ca_topic_score_codex":0.0009053456,"about_ca_topic_score_gemma":0.00096943096,"teacher_disagreement_score":0.0011831073,"about_ca_system_score_codex":0.000121560544,"about_ca_system_score_gemma":0.00023624414,"threshold_uncertainty_score":0.0039578676},"labels":[],"label_agreement":null},{"id":"W2115509290","doi":"10.1128/mcb.21.5.1540-1551.2001","title":"Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer","year":2001,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto; McMaster University","funders":"National Cancer Institute; Medical Research Council; Natural Sciences and Engineering Research Council of Canada; Cancer Research Society","keywords":"ErbB; Biology; Cancer research; Carcinogenesis; Receptor tyrosine kinase; HER2/neu; Signal transduction; Cell biology; Breast cancer; Cancer; Genetics","score_opus":0.0338421572962207,"score_gpt":0.34101334699826424,"score_spread":0.30717118970204355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115509290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513924,0.0030788719,0.0008144776,0.00013220994,0.00000792075,0.0000129379005,0.0001230478,0.000020774398,0.00067052105],"genre_scores_gemma":[0.99604577,0.0021730762,0.00060004875,0.00004475721,0.0000089069645,0.000017764283,0.00018909591,0.0000035051673,0.0009170136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999056,0.000019993606,0.000006911451,0.000014187315,0.000024680829,0.000028664273],"domain_scores_gemma":[0.9999465,0.000008109895,0.000016651742,0.0000055540195,0.0000049852233,0.000018158262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020711882,0.00032412176,0.0002245602,0.00028092734,0.00014440507,0.00034725625,0.00015032224,0.00028090135,0.0008239085],"category_scores_gemma":[0.00010216016,0.00013460279,0.00018967003,0.00019940146,0.00023000201,0.00018425798,0.0002941677,0.00028960174,0.0001498264],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011065602,0.0000976156,0.006315013,0.000080687205,0.000019236762,0.00036117603,0.000051657833,0.00021270981,0.9841999,0.0006437554,0.00006929268,0.0068424293],"study_design_scores_gemma":[0.00024471153,0.0018000602,0.16412967,0.00004271886,0.00014675783,0.006400095,0.00036474326,0.0026894317,0.81569785,0.00067663804,0.0077789966,0.000028313238],"about_ca_topic_score_codex":0.00038200282,"about_ca_topic_score_gemma":0.00058213185,"teacher_disagreement_score":0.0008239085,"about_ca_system_score_codex":0.00021894631,"about_ca_system_score_gemma":0.00019472641,"threshold_uncertainty_score":0.0027562976},"labels":[],"label_agreement":null},{"id":"W2117274017","doi":"10.3747/co.2007.131","title":"Updated Recommendations from the Canadian National Consensus Meeting on HER2/neu Testing in Breast Cancer","year":2007,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; HER2/neu; Breast cancer; Clinical Oncology; Family medicine; Test (biology); Medical physics; Gynecology; Cancer; Internal medicine","score_opus":0.3046895607523,"score_gpt":0.5141459403054996,"score_spread":0.20945637955319962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117274017","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030470372,0.24520077,0.013256595,0.5639066,0.05276735,0.0061449525,0.02559783,0.00067242683,0.08940648],"genre_scores_gemma":[0.036646497,0.3624582,0.21282712,0.20231918,0.0108378455,0.013508372,0.069483966,0.0004500904,0.09146878],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9871559,0.0032416012,0.002060446,0.0003500682,0.006263026,0.00092891057],"domain_scores_gemma":[0.94809264,0.0035973487,0.0014641435,0.00033026462,0.04353733,0.0029782723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019159319,0.001640461,0.0020410945,0.0077337045,0.0028782606,0.002801837,0.008316592,0.0061226883,0.008837137],"category_scores_gemma":[0.040431283,0.0008999505,0.0030943055,0.0073675127,0.0016277551,0.0017218523,0.0018388834,0.0080729695,0.0044745444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004257358,0.000055819866,0.0010226038,0.0010610013,0.000035189572,0.00023742221,0.0002368753,0.00033143046,0.000096689466,0.0012189222,0.9209552,0.07470631],"study_design_scores_gemma":[0.00023561847,0.00005037461,0.009925416,0.008422073,0.0003086399,0.0006089312,0.0007290879,0.00046289316,0.00021585902,0.0029069898,0.97599196,0.00014220695],"about_ca_topic_score_codex":0.64111304,"about_ca_topic_score_gemma":0.7345992,"teacher_disagreement_score":0.9701578,"about_ca_system_score_codex":0.029842196,"about_ca_system_score_gemma":0.10600285,"threshold_uncertainty_score":0.722001},"labels":[],"label_agreement":null},{"id":"W2117342082","doi":"10.1158/1055-9965.epi-08-1202","title":"Heritable Variation of<i>ERBB2</i>and Breast Cancer Risk","year":2009,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institute on Drug Abuse","keywords":"Breast cancer; Linkage disequilibrium; Haplotype; Biology; Single-nucleotide polymorphism; Odds ratio; Genetics; Oncology; Internal medicine; Locus (genetics); Cancer; Allele; Genotype; Gene; Medicine","score_opus":0.05187997438453702,"score_gpt":0.41210538428016175,"score_spread":0.36022540989562474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117342082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995158,0.0001534431,0.00011586713,0.0000145568865,0.0000026458963,0.0000026416606,0.000056226985,0.0000050082317,0.00013397835],"genre_scores_gemma":[0.9997516,0.000050554023,0.00007073841,0.0000063360685,0.0000066409657,0.0000019402673,0.00006350021,0.0000013499122,0.00004735123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942786,0.00022433081,0.00004075425,0.00014043257,0.00009787846,0.00006871973],"domain_scores_gemma":[0.99909985,0.00024166559,0.0003577922,0.00013690355,0.000055748453,0.00010805749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063047087,0.00028185477,0.0002134931,0.000668508,0.00023857263,0.000307463,0.00020332399,0.00028556856,0.00072455785],"category_scores_gemma":[0.0016421902,0.000229052,0.00030866367,0.0005716321,0.00037422669,0.00010666753,0.0002600808,0.0003160109,0.00009609252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001322788,0.000016738177,0.99615896,0.0000063976495,0.0001797954,0.00012860763,0.0000521755,0.00009110536,0.0017570005,0.000037109003,0.000030434689,0.0014093466],"study_design_scores_gemma":[0.0000045855395,0.00007515201,0.99907047,0.0000019170761,0.00005995053,0.00029626297,0.000020460731,0.0001531701,0.00023171774,0.000035071134,0.000049132344,0.0000021040491],"about_ca_topic_score_codex":0.0040293075,"about_ca_topic_score_gemma":0.0044522523,"teacher_disagreement_score":0.0040293075,"about_ca_system_score_codex":0.00016459786,"about_ca_system_score_gemma":0.00015805854,"threshold_uncertainty_score":0.008011699},"labels":[],"label_agreement":null},{"id":"W2118056343","doi":"10.1038/sj.embor.7400491","title":"Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation","year":2005,"lang":"en","type":"article","venue":"EMBO Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale; Ariad Pharmaceuticals","keywords":"Endocytosis; Cell biology; Epidermal growth factor receptor; Receptor; Enzyme-linked receptor; Receptor-mediated endocytosis; Growth factor receptor; Insulin-like growth factor 1 receptor; Tropomyosin receptor kinase C; ERBB3; Biology; Epidermal growth factor; Co-receptor; Chemistry; Platelet-derived growth factor receptor; Signal transduction; Biochemistry; Growth factor","score_opus":0.020544255728969736,"score_gpt":0.30299625935480295,"score_spread":0.2824520036258332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118056343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593627,0.012203658,0.0138543155,0.001913508,0.00041297334,0.000054454806,0.00034370643,0.00033883887,0.01151576],"genre_scores_gemma":[0.99160624,0.0014533261,0.0017514466,0.00026840495,0.000046094174,0.000015080159,0.00019730975,0.000029043023,0.004633027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99954,0.00009076401,0.000031244344,0.000092165465,0.000085779706,0.0001600778],"domain_scores_gemma":[0.9998253,0.000035546112,0.000040510316,0.0000305138,0.000022172962,0.000045931043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005342369,0.00028359497,0.0003116861,0.00014130541,0.00032190944,0.00089004694,0.00030645015,0.00043500125,0.002142662],"category_scores_gemma":[0.00033075854,0.0001831569,0.000333841,0.00013870634,0.00030315775,0.0007403871,0.00037855055,0.0007573972,0.00082420954],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003005991,0.000042261952,0.0001740778,0.000057348298,0.000010511378,0.000080057194,0.000029065473,0.00013156934,0.9929455,0.0024085052,0.0004647195,0.003355759],"study_design_scores_gemma":[0.000057679044,0.000089801186,0.0030774348,0.000008169042,0.00001101912,0.00052619015,0.00007292344,0.0031986686,0.98514426,0.00089022715,0.00691172,0.000011826098],"about_ca_topic_score_codex":0.0002649389,"about_ca_topic_score_gemma":0.0005043417,"teacher_disagreement_score":0.002142662,"about_ca_system_score_codex":0.00052080513,"about_ca_system_score_gemma":0.00021279076,"threshold_uncertainty_score":0.0071679354},"labels":[],"label_agreement":null},{"id":"W2118143278","doi":"10.1073/pnas.1201105109","title":"Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2 <sup>+</sup> :ERα <sup>−</sup> breast cancer","year":2012,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; University Health Network","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Trastuzumab; Oncology; Breast cancer; Internal medicine; Medicine; Gene signature; Lymph node; Chemotherapy; Cancer; Estrogen receptor; Cancer research; Hazard ratio; Lapatinib; Biology; Gene expression; Gene; Confidence interval","score_opus":0.11283602596926387,"score_gpt":0.417958517329261,"score_spread":0.30512249135999714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118143278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783117,0.00017596854,0.00024647024,0.000021125279,0.00000405492,0.000009788266,0.0014471881,0.000018037694,0.00024619047],"genre_scores_gemma":[0.9940765,0.0001543575,0.0006852134,0.000032215736,0.000006090024,0.000018563385,0.004601112,0.0000050829394,0.00042093304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99991846,0.000008334794,0.000006519409,0.000022106045,0.00002116192,0.000023331186],"domain_scores_gemma":[0.9998462,0.000029978479,0.000049123944,0.000010470279,0.000020116926,0.000044104483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012094993,0.00021006307,0.00027164546,0.00043653496,0.00011324744,0.00029032992,0.00008739059,0.0001449023,0.000863598],"category_scores_gemma":[0.00022857661,0.00005018137,0.00021221573,0.0005205339,0.00010910604,0.000078061734,0.00019652188,0.00023183491,0.00020789282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015444835,0.00022108738,0.60362387,0.00009907537,0.00012709608,0.00018923612,0.0000709191,0.0013835729,0.36698434,0.00007916148,0.000730171,0.024947006],"study_design_scores_gemma":[0.000023508435,0.00060635793,0.94827604,0.000008423525,0.0001253173,0.00048273476,0.00010021637,0.004894965,0.044159938,0.0001080246,0.0012034506,0.000010953947],"about_ca_topic_score_codex":0.0006422376,"about_ca_topic_score_gemma":0.0013305842,"teacher_disagreement_score":0.000863598,"about_ca_system_score_codex":0.00017665348,"about_ca_system_score_gemma":0.000204792,"threshold_uncertainty_score":0.0028890967},"labels":[],"label_agreement":null},{"id":"W2118430013","doi":"10.1128/mcb.25.9.3831-3841.2005","title":"Dok-R Mediates Attenuation of Epidermal Growth Factor-Dependent Mitogen-Activated Protein Kinase and Akt Activation through Processive Recruitment of c-Src and Csk","year":2005,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Proto-oncogene tyrosine-protein kinase Src; Tyrosine-protein kinase CSK; Protein kinase B; Biology; Cell biology; Epidermal growth factor; SH3 domain; Tyrosine kinase; MAPK/ERK pathway; Src family kinase; Phosphorylation; Cancer research; Molecular biology; Signal transduction; Biochemistry; Receptor","score_opus":0.05038912150552269,"score_gpt":0.3366343023050747,"score_spread":0.28624518079955197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118430013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972723,0.00053975504,0.0009396054,0.000050388175,0.000012355668,0.000013494526,0.000081887745,0.000041380168,0.0010487835],"genre_scores_gemma":[0.99778557,0.00026405734,0.0005008424,0.000018561335,0.0000051352354,0.000015098291,0.00016044613,0.000007847426,0.0012424155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997695,0.000049953935,0.000025646636,0.000027110369,0.00004480892,0.00008298598],"domain_scores_gemma":[0.99985147,0.000019298708,0.000051960866,0.000022791237,0.000011873386,0.00004250705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019639543,0.0003736998,0.00019561294,0.00013584968,0.0001697916,0.00031566524,0.00029864785,0.00019645314,0.0011220328],"category_scores_gemma":[0.0001658856,0.00015389573,0.00033411226,0.00006309927,0.00024800986,0.00018337218,0.00028427527,0.0005729637,0.0004471453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013542344,0.0000385899,0.0001370752,0.00003203187,0.0000046803257,0.000054246015,0.000009221641,0.000045072084,0.9989844,0.00011699297,0.000020025236,0.00042225412],"study_design_scores_gemma":[0.000025044796,0.00024977853,0.004429815,0.000004986862,0.000017491657,0.00033578795,0.00001977618,0.0006596679,0.9929482,0.000024855892,0.0012804935,0.0000040566533],"about_ca_topic_score_codex":0.00042359595,"about_ca_topic_score_gemma":0.000611342,"teacher_disagreement_score":0.0011220328,"about_ca_system_score_codex":0.0003241085,"about_ca_system_score_gemma":0.00025853683,"threshold_uncertainty_score":0.003753543},"labels":[],"label_agreement":null},{"id":"W2119416636","doi":"10.1200/jco.2007.15.4716","title":"HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Chemotherapy; Topoisomerase; Oncology; Internal medicine; Pharmacology; Genetics; DNA; Biology","score_opus":0.2872185641950503,"score_gpt":0.6115991896106241,"score_spread":0.3243806254155738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119416636","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75669116,0.23424542,0.0007991971,0.0016864031,0.0003567733,0.00010734254,0.002556424,0.000034624285,0.0035226725],"genre_scores_gemma":[0.9902678,0.0075758584,0.00025823992,0.00027439182,0.0003728395,0.0000478288,0.0006519189,0.00000739162,0.00054372475],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726486,0.0017813576,0.0002345125,0.0002577724,0.00032113018,0.00014033033],"domain_scores_gemma":[0.98587245,0.010184253,0.0024121874,0.00029041796,0.00050624105,0.00073435646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005271326,0.00041056803,0.0012476958,0.0009330937,0.00013743508,0.0008207682,0.00044361412,0.0007752026,0.0025459356],"category_scores_gemma":[0.014521099,0.00021096773,0.0025910742,0.0014965395,0.0002493,0.0005408811,0.0002527558,0.0011591348,0.00020603137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02963336,0.0003378336,0.9024819,0.002407535,0.020939788,0.0001926975,0.00009398477,0.002839101,0.0008367764,0.00024565708,0.001455167,0.038536213],"study_design_scores_gemma":[0.0014610495,0.0021188238,0.97704893,0.0004575376,0.0117577175,0.00019087025,0.00008174642,0.0029649201,0.00042190336,0.00066732557,0.0027914033,0.000037806676],"about_ca_topic_score_codex":0.0016957265,"about_ca_topic_score_gemma":0.0021538762,"teacher_disagreement_score":0.005271326,"about_ca_system_score_codex":0.000551525,"about_ca_system_score_gemma":0.0004360774,"threshold_uncertainty_score":0.027877808},"labels":[],"label_agreement":null},{"id":"W2119525612","doi":"10.1158/0008-5472.sabcs11-ot1-02-13","title":"OT1-02-13: Cardiac Biomarkers on Trastuzumab (Cabot Trial): Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Internal medicine; Breast cancer; Ejection fraction; Cardiology; Biomarker; Heart failure; Troponin; Brain natriuretic peptide; Oncology; Cancer; Natriuretic peptide; Chemotherapy; Myocardial infarction","score_opus":0.1620393432808645,"score_gpt":0.4198216100360337,"score_spread":0.2577822667551692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119525612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911527,0.0036791996,0.00012443653,0.000675965,0.00015817364,0.00078622263,0.0016557757,0.0000351595,0.0017322575],"genre_scores_gemma":[0.9866742,0.0021607545,0.00066983287,0.0012821003,0.00040786393,0.0013125859,0.0049074935,0.000020696252,0.0025644843],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997073,0.00013128888,0.0000139673875,0.000053682048,0.000028810458,0.00006498831],"domain_scores_gemma":[0.99953127,0.00007584708,0.000086541564,0.000026225802,0.000037668033,0.00024246496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009363305,0.00096782146,0.0014088113,0.0002217339,0.00022468099,0.0009639996,0.0004980979,0.0009448999,0.002843457],"category_scores_gemma":[0.0007522621,0.00022337164,0.0007187178,0.0004931782,0.0004923435,0.00049054937,0.00032978406,0.0014469492,0.0004526803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9147369,0.007048498,0.026956728,0.00079739,0.0010624027,0.00016964127,0.00007133209,0.0007106026,0.006986024,0.0002059057,0.0041823285,0.037072208],"study_design_scores_gemma":[0.7263757,0.15175855,0.1084515,0.00018787244,0.0025890705,0.00034736822,0.000080038895,0.0021698168,0.0020717187,0.0005708348,0.0053355377,0.0000620657],"about_ca_topic_score_codex":0.0013160607,"about_ca_topic_score_gemma":0.002791865,"teacher_disagreement_score":0.002843457,"about_ca_system_score_codex":0.00066548097,"about_ca_system_score_gemma":0.0009389257,"threshold_uncertainty_score":0.009512365},"labels":[],"label_agreement":null},{"id":"W2120171585","doi":"10.1016/j.ejca.2013.02.012","title":"Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital","funders":"","keywords":"Medicine; Erlotinib; Rash; T790M; Pharmacodynamics; Pharmacokinetics; Adverse effect; Pharmacology; Internal medicine; Epidermal growth factor receptor; Cohort; Discontinuation; Oncology; Cancer; Gefitinib","score_opus":0.03850557109698171,"score_gpt":0.38690989731739417,"score_spread":0.34840432622041245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120171585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843627,0.0038956455,0.0009971772,0.0010159287,0.00032529674,0.0026208307,0.0019073351,0.00021084938,0.004664227],"genre_scores_gemma":[0.9781861,0.004487767,0.0021065609,0.0016342419,0.00031473825,0.0022736122,0.0046813,0.00007521887,0.006240492],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954516,0.00018554505,0.000020657722,0.00007624004,0.00003990502,0.00013251837],"domain_scores_gemma":[0.9994437,0.000072986106,0.0000796844,0.000040184856,0.000034645112,0.00032869115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015177976,0.0021261699,0.0031320774,0.00066865166,0.00054980244,0.0013211815,0.0011039254,0.0014857966,0.0040643606],"category_scores_gemma":[0.0008054589,0.0009366896,0.002042865,0.0006608964,0.0014417616,0.0010424327,0.00041661877,0.0039326698,0.0013562823],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80426353,0.047886245,0.0046216864,0.0009538211,0.0024626693,0.00030722524,0.0003441001,0.004560751,0.045751337,0.00074015977,0.007957369,0.08015112],"study_design_scores_gemma":[0.66338784,0.31488085,0.011839279,0.00004325681,0.0008402045,0.00030541033,0.00008721314,0.0015495897,0.0026101924,0.00042905877,0.0039762934,0.000050930343],"about_ca_topic_score_codex":0.0026817305,"about_ca_topic_score_gemma":0.0071259956,"teacher_disagreement_score":0.0040643606,"about_ca_system_score_codex":0.0012359386,"about_ca_system_score_gemma":0.0020280126,"threshold_uncertainty_score":0.013596594},"labels":[],"label_agreement":null},{"id":"W2120746859","doi":"10.1093/jnci/djt360","title":"Validated or Not Validated? That Is the Question","year":2014,"lang":"en","type":"letter","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Epirubicin; Cyclophosphamide; Medicine; Oncology; Chemotherapy; Internal medicine; Doxorubicin; Fluorouracil","score_opus":0.251135481940737,"score_gpt":0.4613854406328746,"score_spread":0.21024995869213764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120746859","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015264116,0.066261664,0.11032773,0.73224247,0.044887964,0.0006724411,0.004040819,0.00062176643,0.025681002],"genre_scores_gemma":[0.36633974,0.027762065,0.12469636,0.42136392,0.04424785,0.002097404,0.0048055956,0.0018143817,0.00687274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.6636427,0.20280857,0.04127819,0.037097592,0.04888064,0.0062923627],"domain_scores_gemma":[0.16296731,0.5919052,0.035878543,0.073551014,0.13094887,0.0047490792],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.45438832,0.0013649273,0.004132241,0.0040973057,0.003371198,0.017272465,0.0065835034,0.012077408,0.008557551],"category_scores_gemma":[0.72946554,0.0015606625,0.002581458,0.005066539,0.026001308,0.023031715,0.005768568,0.01260923,0.0053351806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082624133,0.00022538408,0.06385222,0.007866901,0.002424255,0.00062351435,0.006454399,0.0022240032,0.0014907205,0.25858223,0.22632954,0.4291006],"study_design_scores_gemma":[0.00025235108,0.00034209326,0.020198423,0.022333669,0.0006827213,0.0015074342,0.0052946433,0.005166585,0.0028162713,0.37802702,0.5628707,0.00050819706],"about_ca_topic_score_codex":0.006943072,"about_ca_topic_score_gemma":0.003377105,"teacher_disagreement_score":0.45438832,"about_ca_system_score_codex":0.005434686,"about_ca_system_score_gemma":0.011979003,"threshold_uncertainty_score":0.67283636},"labels":[],"label_agreement":null},{"id":"W2121378565","doi":"10.2478/s11535-006-0014-6","title":"Targeting of solid tumors and blood malignancies by antibody-based therapies — EGFR-pathway as an example","year":2006,"lang":"en","type":"article","venue":"Open Life Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation; Manitoba Medical Service Foundation","keywords":"ERBB3; ErbB; Epidermal growth factor receptor; Cancer research; Receptor tyrosine kinase; MAPK/ERK pathway; Epidermal growth factor; PI3K/AKT/mTOR pathway; Tyrosine kinase; Protein kinase B; Signal transduction; Biology; ERBB4; Receptor; Cell biology; Biochemistry","score_opus":0.06080071927829519,"score_gpt":0.3812281827530076,"score_spread":0.32042746347471246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121378565","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22863494,0.66590947,0.02321268,0.0056976555,0.0017882456,0.00037859543,0.00031786365,0.0003493314,0.07371126],"genre_scores_gemma":[0.59565187,0.35200202,0.016951354,0.0018910747,0.0005859662,0.00016874778,0.00034479942,0.000031456126,0.03237279],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999536,0.000012533299,0.0000028045322,0.0000052841665,0.000015336493,0.000010356162],"domain_scores_gemma":[0.9999794,0.000006014351,0.0000020681748,0.0000015083905,0.0000053997505,0.0000056816234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014813578,0.00029388207,0.00026515065,0.00031909894,0.00011286021,0.0003129895,0.0001944429,0.0004996896,0.0013428528],"category_scores_gemma":[0.00007512847,0.000050478942,0.00018978507,0.00020410893,0.00011665352,0.000243308,0.00017247697,0.00046675594,0.00043096545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009696131,0.0016138686,0.001153238,0.0024382593,0.000100873236,0.0033398545,0.00010789513,0.002380183,0.47276527,0.02274076,0.01733874,0.4750514],"study_design_scores_gemma":[0.0005899037,0.0054205237,0.0061329775,0.0002939241,0.000265415,0.014782478,0.00007856857,0.005147484,0.42810506,0.0071917973,0.53195286,0.000038962797],"about_ca_topic_score_codex":0.00022875737,"about_ca_topic_score_gemma":0.00049981155,"teacher_disagreement_score":0.0013428528,"about_ca_system_score_codex":0.00019322036,"about_ca_system_score_gemma":0.00009336238,"threshold_uncertainty_score":0.0044923425},"labels":[],"label_agreement":null},{"id":"W2121576318","doi":"10.1016/j.ctrv.2009.12.012","title":"Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer","year":2010,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lapatinib; Medicine; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Hazard ratio; Randomized controlled trial; Adverse effect; Cancer; Clinical trial; Discontinuation; Trastuzumab; Confidence interval","score_opus":0.46909519296310337,"score_gpt":0.5766936765117843,"score_spread":0.1075984835486809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121576318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01047013,0.9879313,0.0005279866,0.00019330582,0.0001529268,0.00010863616,0.0003412885,0.000027927064,0.00024644716],"genre_scores_gemma":[0.24792491,0.74670565,0.002533108,0.0010128592,0.0002622239,0.0002682859,0.0007469676,0.000052906846,0.000493028],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99574775,0.0025567673,0.0007156881,0.00046474923,0.00037663613,0.00013850107],"domain_scores_gemma":[0.9919275,0.006274042,0.00111879,0.00023382308,0.0003166491,0.00012921498],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0086111305,0.002219849,0.011907787,0.0013864203,0.00028422053,0.0016663587,0.0013675765,0.0011397743,0.0027141501],"category_scores_gemma":[0.015805872,0.0010773573,0.017371692,0.0027117378,0.00045291707,0.0009346945,0.00083763374,0.0018113046,0.00020871186],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019225286,0.00006142598,0.0039931443,0.17781118,0.7588266,0.00013845805,0.0000744488,0.0011353792,0.0006219428,0.00016222421,0.0019338435,0.036016148],"study_design_scores_gemma":[0.0048495554,0.0004622635,0.0043421206,0.005051247,0.98188204,0.00012150307,0.000035778194,0.00020926504,0.00018130653,0.00028671284,0.0025526143,0.000025537136],"about_ca_topic_score_codex":0.0039833104,"about_ca_topic_score_gemma":0.011617456,"teacher_disagreement_score":0.9880922,"about_ca_system_score_codex":0.0016457668,"about_ca_system_score_gemma":0.0016688695,"threshold_uncertainty_score":0.04554051},"labels":[],"label_agreement":null},{"id":"W2121601348","doi":"10.1200/jco.2011.36.6385","title":"Testing for Discordance at Metastatic Relapse: Does It Matter?","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.379901934180019,"score_gpt":0.5724041181961178,"score_spread":0.1925021840160988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121601348","genre_codex":"editorial","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005254516,0.059026256,0.0007310928,0.18186824,0.75611275,0.000052305055,0.00012256215,0.00007629431,0.0014850587],"genre_scores_gemma":[0.003369753,0.030003684,0.00048471414,0.091238335,0.8735763,0.000045729463,0.00006603752,0.00005702228,0.0011584095],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.98988336,0.0032256737,0.0023097037,0.0014734862,0.0025278816,0.000579919],"domain_scores_gemma":[0.86318356,0.09297763,0.005557882,0.001606574,0.03316595,0.003508366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017499143,0.0012896389,0.0041256137,0.0029380121,0.002023238,0.0058029694,0.0036732976,0.01366299,0.0046229903],"category_scores_gemma":[0.13369541,0.0007782273,0.0014104478,0.0017572464,0.003686471,0.0047138706,0.0010358746,0.011579,0.00239791],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041978539,0.000041408854,0.0017379903,0.0019219746,0.00019678098,0.00048382572,0.00018005859,0.00007697035,0.00010260936,0.0016722189,0.922302,0.07086428],"study_design_scores_gemma":[0.00050772185,0.0005148515,0.009085441,0.014182587,0.0011591706,0.002771802,0.00093994837,0.0011718217,0.0006949929,0.012420044,0.9562777,0.00027382022],"about_ca_topic_score_codex":0.002707667,"about_ca_topic_score_gemma":0.0040568397,"teacher_disagreement_score":0.017499143,"about_ca_system_score_codex":0.0025947788,"about_ca_system_score_gemma":0.0030515492,"threshold_uncertainty_score":0.09254545},"labels":[],"label_agreement":null},{"id":"W2121850323","doi":"10.1038/sj.onc.1208892","title":"NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis","year":2005,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of British Columbia; BC Cancer Agency; Vancouver General Hospital","funders":"","keywords":"Amplicon; Biology; Carcinogenesis; Fluorescence in situ hybridization; Locus (genetics); Gene duplication; Estrogen receptor; Comparative genomic hybridization; Breast cancer; Genetics; Gene; Cancer research; Molecular biology; Cancer; Chromosome; Polymerase chain reaction","score_opus":0.09046705075895692,"score_gpt":0.4284531646079335,"score_spread":0.3379861138489766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121850323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998871,0.00010507283,0.0001226726,0.00005710401,0.0000033275694,0.000004474891,0.000076215365,0.000008189728,0.0007519651],"genre_scores_gemma":[0.9995308,0.000027393538,0.00014679054,0.000018943596,0.0000046437626,0.0000036188362,0.00006688105,0.000002711748,0.0001983006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982554,0.000027623113,0.000015806445,0.000039176877,0.00004139028,0.000050505474],"domain_scores_gemma":[0.99949825,0.00018788941,0.00013044268,0.000046060093,0.000041305684,0.000095972944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023705506,0.00025459877,0.00023693258,0.0008082541,0.00029051266,0.00027606706,0.00029182294,0.00048317295,0.0026989703],"category_scores_gemma":[0.0010173939,0.0001265425,0.0001360968,0.000395813,0.0004365237,0.00013621937,0.00026283078,0.0002961338,0.00038741904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051340703,0.0002173358,0.5054566,0.00009291796,0.00008179596,0.022963239,0.0004674836,0.0007847277,0.4455844,0.0004142785,0.00060736487,0.01819579],"study_design_scores_gemma":[0.000088560606,0.00050204253,0.9234069,0.000015064758,0.00012648187,0.04190459,0.0002723216,0.0012902289,0.0306011,0.00026971812,0.0015101712,0.000012776786],"about_ca_topic_score_codex":0.001003351,"about_ca_topic_score_gemma":0.0016562823,"teacher_disagreement_score":0.0026989703,"about_ca_system_score_codex":0.00024778178,"about_ca_system_score_gemma":0.00020003023,"threshold_uncertainty_score":0.009028912},"labels":[],"label_agreement":null},{"id":"W2121944733","doi":"10.1093/annonc/mds594","title":"An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital; London Health Sciences Centre","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Lapatinib; Medicine; Breast cancer; Internal medicine; Oncology; Clinical endpoint; Estrogen receptor; Cancer; Biomarker; Adverse effect; Clinical trial; Trastuzumab","score_opus":0.19327971489460452,"score_gpt":0.5173170746045165,"score_spread":0.324037359709912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121944733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322903,0.0022236889,0.00035813317,0.00044191835,0.0001680609,0.000714438,0.0012598662,0.00004745455,0.0015574081],"genre_scores_gemma":[0.9895238,0.0023245704,0.0007304213,0.00096659624,0.00047346312,0.0009908056,0.002198695,0.000024904,0.0027667843],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994868,0.0002960562,0.000018691888,0.00007321205,0.000039019444,0.00008626653],"domain_scores_gemma":[0.9988557,0.00030433654,0.00019536061,0.00008631317,0.000056898636,0.00050128874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011952417,0.0016963425,0.0024154799,0.0004116954,0.0004117154,0.0010864261,0.0007535277,0.0015338389,0.005035196],"category_scores_gemma":[0.0013035081,0.0006982903,0.0021649657,0.00039790454,0.001108284,0.0013717115,0.0005671016,0.0034548629,0.00087378186],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9554836,0.013467346,0.0044037537,0.0003353816,0.0009197838,0.00011491493,0.00007888172,0.00043041268,0.003832036,0.00008047266,0.0009386926,0.01991484],"study_design_scores_gemma":[0.8113392,0.17177121,0.013219225,0.000030006322,0.0008499776,0.00012266378,0.00009891388,0.00044272223,0.00055194,0.0001588555,0.0013765956,0.000038692],"about_ca_topic_score_codex":0.0012553834,"about_ca_topic_score_gemma":0.0035084598,"teacher_disagreement_score":0.005035196,"about_ca_system_score_codex":0.0007164853,"about_ca_system_score_gemma":0.0012417601,"threshold_uncertainty_score":0.016844392},"labels":[],"label_agreement":null},{"id":"W2123591186","doi":"10.1016/s1470-2045(11)70336-9","title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2358,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Pertuzumab; Trastuzumab; Docetaxel; Medicine; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Population; Chemotherapy; Clinical trial; Cancer","score_opus":0.06039123479763487,"score_gpt":0.3881995916148677,"score_spread":0.32780835681723286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123591186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950448,0.0018324394,0.0002065504,0.000617025,0.00020457101,0.000618451,0.0004117519,0.000040048148,0.0010243286],"genre_scores_gemma":[0.9911761,0.0015872855,0.0006657872,0.00089476357,0.00032557914,0.0013366247,0.0010836257,0.000023794619,0.0029064915],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993394,0.0003898284,0.00002745304,0.000104374085,0.000042910557,0.000096056945],"domain_scores_gemma":[0.99897814,0.00033716246,0.00019516164,0.000086987435,0.000039816106,0.0003627707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017531526,0.0017814697,0.0022799398,0.0003637272,0.00033057507,0.0009581393,0.00083788,0.0020711462,0.005738767],"category_scores_gemma":[0.0021602632,0.0008675606,0.0015842317,0.00037449776,0.0015818909,0.0015237862,0.00050987164,0.0031336856,0.0010143699],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9806631,0.003770045,0.0006735985,0.00017910359,0.00036971908,0.000027587683,0.000055384262,0.00031061727,0.0025330395,0.00006034163,0.0003911775,0.010966199],"study_design_scores_gemma":[0.875684,0.119945124,0.0023486847,0.000018444402,0.0003468345,0.00005716455,0.000030920037,0.0003720478,0.0004540383,0.00018646457,0.00053929747,0.000017002996],"about_ca_topic_score_codex":0.00070918293,"about_ca_topic_score_gemma":0.0016115828,"teacher_disagreement_score":0.005738767,"about_ca_system_score_codex":0.0010717179,"about_ca_system_score_gemma":0.0009633532,"threshold_uncertainty_score":0.01919806},"labels":[],"label_agreement":null},{"id":"W2123895170","doi":"10.3747/co.22.2322","title":"Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline","year":2015,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa; Cancer Care Ontario; McMaster University; Sunnybrook Health Science Centre; Regional Municipality of Durham; Ottawa Hospital; Kingston General Hospital","funders":"","keywords":"Trastuzumab; Medicine; Pertuzumab; Lapatinib; Neratinib; Oncology; Internal medicine; Breast cancer; Targeted therapy; Cancer; Clinical trial; Adjuvant therapy; Guideline; Neoadjuvant therapy; Pathology","score_opus":0.36218816961786476,"score_gpt":0.5593257468535162,"score_spread":0.19713757723565145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123895170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071977853,0.9959974,0.0001384506,0.0011040766,0.00014562663,0.0004974511,0.0008505192,0.000009222688,0.0005373919],"genre_scores_gemma":[0.010320794,0.9854236,0.0010320281,0.0014883005,0.000078417346,0.0007937739,0.00062422315,0.0000055709484,0.00023319377],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9901932,0.0032563494,0.0033160402,0.00061577983,0.0023182158,0.00030047024],"domain_scores_gemma":[0.978954,0.010638794,0.0058784555,0.00029112582,0.0038785213,0.00035908894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011234689,0.0012787721,0.0071254927,0.010663532,0.0006723051,0.002012354,0.0021243566,0.0016976432,0.004346926],"category_scores_gemma":[0.039748568,0.0009986522,0.0069401995,0.01192208,0.0008988981,0.0017874261,0.0014108521,0.0011325496,0.00033794573],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016883337,0.000012156965,0.0008491002,0.93623054,0.006459999,0.000074305215,0.00016838072,0.000103831175,0.00015069719,0.0002671733,0.007975775,0.047539126],"study_design_scores_gemma":[0.00037434112,0.00011915112,0.0050989953,0.92633724,0.039524384,0.00014656075,0.00016956475,0.00007661689,0.00009002322,0.0002361594,0.02779375,0.00003328506],"about_ca_topic_score_codex":0.055791985,"about_ca_topic_score_gemma":0.19751255,"teacher_disagreement_score":0.055791985,"about_ca_system_score_codex":0.008918635,"about_ca_system_score_gemma":0.031355496,"threshold_uncertainty_score":0.11093444},"labels":[],"label_agreement":null},{"id":"W2124076816","doi":"10.1124/jpet.109.160085","title":"The Combi-Targeting Concept: Selective Targeting of the Epidermal Growth Factor Receptor- and Her2-Expressing Cancer Cells by the Complex Combi-Molecule RB24","year":2010,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Canadian Institutes of Health Research","keywords":"Cancer research; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Epidermal growth factor; Cancer; Receptor; Cancer cell; Growth factor receptor inhibitor; Chemistry; Cell biology; Biology; Medicine; Internal medicine; Breast cancer; Biochemistry","score_opus":0.036086851710191145,"score_gpt":0.39376324219632186,"score_spread":0.3576763904861307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124076816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93962294,0.0045239893,0.039853785,0.00090866233,0.00015528768,0.00026588605,0.00043675082,0.00040261378,0.01383006],"genre_scores_gemma":[0.97517407,0.0013902703,0.014589233,0.000217857,0.000032732212,0.00013354214,0.00014487514,0.000032345564,0.008285074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999232,0.000012240352,0.0000033849578,0.000019826752,0.000025029733,0.000016334865],"domain_scores_gemma":[0.9999585,0.0000060986795,0.000013637882,0.0000043849122,0.0000052906366,0.000012152825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014791447,0.0002772062,0.00027652385,0.00018333792,0.00012364192,0.00042091412,0.00036078467,0.00046438255,0.0015145788],"category_scores_gemma":[0.00012424194,0.00015332273,0.00013799396,0.0001217205,0.00018148766,0.0004407882,0.000250323,0.00041747015,0.00054540945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017973325,0.000054129923,0.00006273574,0.00004417775,0.000008137501,0.00012650373,0.000034072575,0.00025420598,0.986426,0.0023877984,0.000537798,0.009884736],"study_design_scores_gemma":[0.00009971615,0.0005218712,0.00057626644,0.0000043730774,0.000017631472,0.0006642081,0.00001297039,0.0043411283,0.97917664,0.00031545985,0.014249624,0.000020084144],"about_ca_topic_score_codex":0.00018330173,"about_ca_topic_score_gemma":0.00023547413,"teacher_disagreement_score":0.0015145788,"about_ca_system_score_codex":0.0002923119,"about_ca_system_score_gemma":0.00013452003,"threshold_uncertainty_score":0.005066812},"labels":[],"label_agreement":null},{"id":"W2124824379","doi":"10.1111/j.1524-4741.2007.00396.x","title":"Intratumoral Heterogeneity of HER2/neu in Breast Cancer?A Rare Event","year":2007,"lang":"en","type":"article","venue":"The Breast Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; HER2/neu; Fluorescence in situ hybridization; Immunohistochemistry; Concordance; Breast carcinoma; Chromogenic in situ hybridization; Cancer research; Ductal carcinoma; clone (Java method); Oncology; In situ hybridization; Gene duplication; Cancer; Trastuzumab; Pathology; Gene; Internal medicine; Gene expression; Biology; Chromosome; Genetics","score_opus":0.031158404634053304,"score_gpt":0.3798291547736526,"score_spread":0.3486707501395993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124824379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928001,0.0030065314,0.0020305926,0.00016356425,0.000023628969,0.0000343907,0.00007378988,0.00004633922,0.0018209876],"genre_scores_gemma":[0.99892694,0.0004034463,0.00031640584,0.000039933202,0.000058433598,0.000009934615,0.00006778035,0.000010185893,0.0001668977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991617,0.0002454364,0.00008848789,0.00015138615,0.00017367204,0.0001792713],"domain_scores_gemma":[0.99618584,0.0013828763,0.0012686041,0.0006530806,0.00021428305,0.0002953352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077700464,0.00022564363,0.0005335507,0.0009913964,0.00046183844,0.00065770943,0.00037672423,0.0006337916,0.0010088956],"category_scores_gemma":[0.0029839394,0.00026832317,0.00024022358,0.00080763403,0.000758541,0.0006035848,0.00070221664,0.00039985942,0.0003898502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019457557,0.0002124471,0.6863934,0.00054016174,0.00024522434,0.13859937,0.0017482484,0.0005388572,0.10396101,0.0017146418,0.0012532666,0.06284752],"study_design_scores_gemma":[0.00007302248,0.0007439986,0.3658014,0.00006204747,0.00034972624,0.57378083,0.0012800868,0.0015593207,0.045804467,0.0022719344,0.008221629,0.000051529503],"about_ca_topic_score_codex":0.0003395953,"about_ca_topic_score_gemma":0.00043325944,"teacher_disagreement_score":0.0010088956,"about_ca_system_score_codex":0.00024295914,"about_ca_system_score_gemma":0.000114708484,"threshold_uncertainty_score":0.0041092634},"labels":[],"label_agreement":null},{"id":"W2125219284","doi":"10.1136/jclinpath-2013-201819","title":"HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Turnaround time; Clinical trial; Human Epidermal Growth Factor Receptor 2; Oncology; Adjuvant; Disease; Internal medicine; Adjuvant therapy; Intensive care medicine; Medical physics; Cancer; Computer science","score_opus":0.3399490467106761,"score_gpt":0.5409334627099476,"score_spread":0.20098441599927147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125219284","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047434377,0.010347321,0.04772164,0.8947523,0.00510142,0.0044682794,0.00096089026,0.0018135707,0.030091133],"genre_scores_gemma":[0.050605524,0.042613532,0.759114,0.11512906,0.0034219602,0.010797574,0.0029148401,0.000534885,0.014868505],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.94346833,0.03217411,0.010389574,0.0015271261,0.010015787,0.002425126],"domain_scores_gemma":[0.794464,0.07492571,0.018820783,0.006917615,0.080618255,0.02425366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.073805764,0.0014351904,0.0012848942,0.0049526435,0.0027745822,0.0074619744,0.0060890834,0.01065876,0.008896446],"category_scores_gemma":[0.14895019,0.00094730215,0.0019382392,0.003798017,0.0024282536,0.0057464885,0.006275092,0.011341988,0.006883605],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012125278,0.0007776247,0.00880334,0.0029678207,0.000059198916,0.0012684608,0.0017130681,0.0041480456,0.00093263574,0.011844877,0.640727,0.32663667],"study_design_scores_gemma":[0.00054584455,0.0008583439,0.030336646,0.025059296,0.00027892005,0.0020007822,0.011213636,0.009500357,0.0020061703,0.04765978,0.8701138,0.0004263085],"about_ca_topic_score_codex":0.013080367,"about_ca_topic_score_gemma":0.026045386,"teacher_disagreement_score":0.073805764,"about_ca_system_score_codex":0.00782545,"about_ca_system_score_gemma":0.059842993,"threshold_uncertainty_score":0.39032686},"labels":[],"label_agreement":null},{"id":"W2125620887","doi":"10.1016/s1470-2045(11)70033-x","title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":611,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Interim analysis; Breast cancer; Oncology; Clinical endpoint; Population; Adjuvant; Surgery; Clinical trial; Hazard ratio; Cancer; Confidence interval","score_opus":0.0317431920055709,"score_gpt":0.327746268557953,"score_spread":0.2960030765523821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125620887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98250455,0.010841863,0.00056459854,0.0009606966,0.0013364499,0.0016900096,0.00085122697,0.00007874102,0.0011718496],"genre_scores_gemma":[0.98910576,0.003408131,0.0005484837,0.000983514,0.0006963568,0.0016645148,0.0010664796,0.00001954929,0.0025071357],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973013,0.0014150047,0.00019053539,0.00043545742,0.00015022465,0.000507383],"domain_scores_gemma":[0.9969304,0.0010331678,0.0008012664,0.00037073263,0.00020876524,0.0006556513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004106796,0.002524831,0.006905101,0.0006524436,0.00082866644,0.0019649186,0.0016061983,0.0042994106,0.0056308396],"category_scores_gemma":[0.0052081896,0.0012261156,0.006060629,0.0009387553,0.0020167774,0.0023832142,0.0008949673,0.005769826,0.0009304335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99391717,0.0012141968,0.00047785105,0.0002282359,0.0010697274,0.000021136946,0.000027919054,0.00011644916,0.00027824735,0.00002247117,0.00016622659,0.0024604504],"study_design_scores_gemma":[0.9484632,0.04538711,0.0033381346,0.0000619971,0.0019064692,0.000022428461,0.000032222717,0.00020810393,0.00013779974,0.00010673369,0.00031434535,0.000021368165],"about_ca_topic_score_codex":0.003359125,"about_ca_topic_score_gemma":0.0039498075,"teacher_disagreement_score":0.006905101,"about_ca_system_score_codex":0.0018690652,"about_ca_system_score_gemma":0.0016235914,"threshold_uncertainty_score":0.021719038},"labels":[],"label_agreement":null},{"id":"W2125819588","doi":"10.1074/mcp.m112.019919","title":"Temporal Profiling of Lapatinib-suppressed Phosphorylation Signals in EGFR/HER2 Pathways","year":2012,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lapatinib; Phosphorylation; Profiling (computer programming); Chemistry; Computational biology; Cancer research; Pharmacology; Biology; Medicine; Computer science; Internal medicine; Biochemistry; Trastuzumab; Breast cancer; Cancer","score_opus":0.03578254199293283,"score_gpt":0.30133680016272824,"score_spread":0.2655542581697954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125819588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99106723,0.0022258884,0.0029479568,0.0000600618,0.000016636463,0.00002786899,0.0022887152,0.000087678156,0.00127798],"genre_scores_gemma":[0.98995006,0.0021236686,0.003427424,0.000064849286,0.000011258086,0.00008993966,0.0027890468,0.000030207202,0.0015135987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999354,0.0000039985966,0.000003372066,0.000017978116,0.00002187631,0.000017347456],"domain_scores_gemma":[0.99995255,0.00000564241,0.00001579278,0.0000027114957,0.000011367543,0.00001208612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007725712,0.00020025084,0.00024884762,0.0003254231,0.00012672483,0.00027325962,0.0001254779,0.00014683354,0.0009578587],"category_scores_gemma":[0.00007976979,0.00010290391,0.00020448252,0.00034889864,0.00009741387,0.00020425962,0.00016439019,0.00034992915,0.00019940412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032121586,0.000031202042,0.0014637213,0.0000900517,0.00001863088,0.00005640506,0.000018496723,0.00022739654,0.9949809,0.000058838712,0.00011175885,0.0026214186],"study_design_scores_gemma":[0.000036583886,0.00041771407,0.13143986,0.000017316524,0.000066155786,0.0004146609,0.00012114279,0.010342324,0.8537975,0.00022425549,0.003097231,0.000025255245],"about_ca_topic_score_codex":0.0005202028,"about_ca_topic_score_gemma":0.0008974172,"teacher_disagreement_score":0.0009578587,"about_ca_system_score_codex":0.00020227654,"about_ca_system_score_gemma":0.00012188544,"threshold_uncertainty_score":0.0032043457},"labels":[],"label_agreement":null},{"id":"W2127154017","doi":"10.1016/j.ctrv.2009.08.001","title":"Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions","year":2009,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Pfizer","keywords":"Lapatinib; Medicine; Trastuzumab; Tyrosine kinase; Receptor tyrosine kinase; Breast cancer; Tyrosine-kinase inhibitor; ErbB; Monoclonal antibody; Cancer research; Cancer; Pharmacology; Internal medicine; Receptor; Immunology; Antibody","score_opus":0.08835437902740187,"score_gpt":0.4363174976594466,"score_spread":0.34796311863204477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127154017","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001505793,0.9987791,0.000117996664,0.00016597135,0.00010978315,0.000004205726,0.000014766775,0.000008091524,0.0006495715],"genre_scores_gemma":[0.00070425466,0.9983205,0.00018265407,0.0001481123,0.00009195615,0.0000048627962,0.000023666957,0.0000011986574,0.0005226942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998338,0.000026304562,0.0000232183,0.000030446592,0.00006452783,0.000021671805],"domain_scores_gemma":[0.999731,0.00013852965,0.000052489537,0.000007327832,0.000049603048,0.00002107233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066524406,0.00095347356,0.0021441844,0.0013433804,0.0002128577,0.00094166264,0.0009034623,0.00091912446,0.0056383037],"category_scores_gemma":[0.0005895989,0.000288382,0.00054487603,0.001808344,0.0004057281,0.0013967361,0.00047071738,0.0015813044,0.0021708678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017418683,0.00011455012,0.00013306255,0.010118981,0.000089866924,0.0001458299,0.000026450678,0.0004312173,0.0016993354,0.0017551281,0.026385522,0.9589259],"study_design_scores_gemma":[0.000115892304,0.00032956232,0.0010300251,0.0029614056,0.00037432084,0.0013921208,0.000060753602,0.00026048528,0.0008972411,0.0016477038,0.9909044,0.000026063944],"about_ca_topic_score_codex":0.00091110286,"about_ca_topic_score_gemma":0.0033717537,"teacher_disagreement_score":0.0056383037,"about_ca_system_score_codex":0.00053665426,"about_ca_system_score_gemma":0.00093160715,"threshold_uncertainty_score":0.018862009},"labels":[],"label_agreement":null},{"id":"W2127376103","doi":"10.1158/1078-0432.ccr-05-0754","title":"Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Research Manitoba","keywords":"Apoptosis; Trastuzumab; Etoposide; Cancer research; Cell culture; Medicine; Chemistry; Breast cancer; Biology; Cancer; Chemotherapy; Internal medicine","score_opus":0.19438652816364593,"score_gpt":0.5409689330364883,"score_spread":0.34658240487284236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127376103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937854,0.0028327387,0.001771421,0.00013599505,0.000037460646,0.000033053104,0.000173668,0.00007302388,0.0011572099],"genre_scores_gemma":[0.9946636,0.0014918108,0.0018036149,0.0000847838,0.000016042875,0.000024427589,0.00033237538,0.000008917682,0.0015743903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999081,0.000015254126,0.000007681911,0.00001913369,0.000028727234,0.000021202952],"domain_scores_gemma":[0.99995136,0.000009619054,0.000015008432,0.000007262997,0.0000063363545,0.000010439693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001499509,0.0003053693,0.00018104656,0.00015605584,0.00009598069,0.0002027672,0.0001239441,0.0001866419,0.0013753381],"category_scores_gemma":[0.00009351314,0.00010605737,0.00017587298,0.00010275938,0.0001469816,0.00015070099,0.00010852301,0.0003943577,0.00023366458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059551905,0.000035327143,0.00014978631,0.000036610676,0.000006071786,0.000017031782,0.0000057047146,0.000065042834,0.99864227,0.000038602186,0.00003308117,0.00091093],"study_design_scores_gemma":[0.000040801428,0.00041395138,0.0020330776,0.0000062783574,0.000013754332,0.00027750025,0.000007630132,0.00049822143,0.9940374,0.00002237564,0.0026462483,0.000002850604],"about_ca_topic_score_codex":0.00029426898,"about_ca_topic_score_gemma":0.00049384264,"teacher_disagreement_score":0.0013753381,"about_ca_system_score_codex":0.00031754817,"about_ca_system_score_gemma":0.00014065168,"threshold_uncertainty_score":0.0046010017},"labels":[],"label_agreement":null},{"id":"W2127462608","doi":"10.1053/j.seminoncol.2004.07.020","title":"Maximizing clinical benefit with trastuzumab","year":2004,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Vinorelbine; Oncology; Metastatic breast cancer; Internal medicine; Taxane; Capecitabine; Breast cancer; Chemotherapy; Gemcitabine; Clinical trial; Cancer; Colorectal cancer","score_opus":0.17623130803002254,"score_gpt":0.5363274342574647,"score_spread":0.36009612622744214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127462608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021099776,0.9972108,0.00019884208,0.0007265542,0.00020094647,0.0000055671467,0.00001387,0.000008864787,0.0014235914],"genre_scores_gemma":[0.0021304965,0.9954755,0.00021748156,0.0006765762,0.00037193333,0.000011768911,0.000022906961,0.000002230723,0.0010911174],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997851,0.000062004685,0.000032188538,0.000033137072,0.0000623674,0.00002527206],"domain_scores_gemma":[0.99962914,0.00025140398,0.000060078,0.000011055257,0.000033011358,0.000015291755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078056974,0.0010765207,0.002016573,0.0013463713,0.00017542312,0.0008587321,0.0007462128,0.0009830606,0.0045897947],"category_scores_gemma":[0.0012106409,0.00026158657,0.00041287072,0.0014119496,0.0004275874,0.0012241062,0.0005522033,0.0015847349,0.001279965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002263628,0.00006397857,0.00009368095,0.007417385,0.00013100899,0.00015856231,0.000021006425,0.0004883896,0.00095748866,0.0027697743,0.031857125,0.9558152],"study_design_scores_gemma":[0.00033045563,0.0002979087,0.0011439967,0.005455143,0.00056855544,0.0017011755,0.00003720804,0.00027962722,0.0014452076,0.0044748723,0.9842444,0.000021397513],"about_ca_topic_score_codex":0.0005150911,"about_ca_topic_score_gemma":0.0017029608,"teacher_disagreement_score":0.0045897947,"about_ca_system_score_codex":0.0009720682,"about_ca_system_score_gemma":0.00072632247,"threshold_uncertainty_score":0.015354395},"labels":[],"label_agreement":null},{"id":"W2128338277","doi":"10.1186/1471-2407-12-500","title":"Identification of PADI2 as a potential breast cancer biomarker and therapeutic target","year":2012,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; U.S. Army Medical Research Acquisition Activity; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Office of Science; National Cancer Institute; National Institutes of Health; U.S. Department of Energy; U.S. Department of Defense","keywords":"Breast cancer; Cancer research; Cancer; Cell cycle; Surgical oncology; Biology; Medicine; Oncology; Internal medicine","score_opus":0.05164357233437762,"score_gpt":0.396314670605598,"score_spread":0.3446710982712204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128338277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74201804,0.182241,0.035022378,0.007808608,0.0010954381,0.0005161605,0.00886989,0.0010817026,0.021346793],"genre_scores_gemma":[0.94045556,0.023034206,0.019648708,0.0015134226,0.00040541033,0.00029679723,0.007144346,0.000052855685,0.007448694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998598,0.000020522546,0.000006885188,0.000040275958,0.0000474033,0.000025016046],"domain_scores_gemma":[0.9998299,0.00003637001,0.000044301047,0.000012756487,0.000040250256,0.000036287973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000479025,0.0004941186,0.0005177055,0.0004512975,0.00014289288,0.00083864806,0.00038159624,0.00056123047,0.0024916679],"category_scores_gemma":[0.00035825936,0.00014407319,0.0003559525,0.00042125976,0.00021839651,0.00030121568,0.00030248016,0.00093052123,0.0008809554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015366137,0.00032529165,0.026636248,0.0014718524,0.00021203863,0.00085268077,0.0000763457,0.0017524448,0.81532055,0.0018384721,0.007435537,0.14254189],"study_design_scores_gemma":[0.0002462389,0.0025436964,0.04850961,0.00024091678,0.0005234603,0.005087195,0.00021810958,0.01567016,0.8006652,0.0020112016,0.124222465,0.00006176943],"about_ca_topic_score_codex":0.0002103894,"about_ca_topic_score_gemma":0.00034880856,"teacher_disagreement_score":0.0024916679,"about_ca_system_score_codex":0.0005247129,"about_ca_system_score_gemma":0.00036270916,"threshold_uncertainty_score":0.008335531},"labels":[],"label_agreement":null},{"id":"W2128639169","doi":"10.1093/annonc/12.suppl_1.s43","title":"Pharmacologic insights into the future of trastuzumab","year":2001,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Clinical trial; Regimen; Breast cancer; Pharmacokinetics; Metastatic breast cancer; Pharmacodynamics; Pharmacology; Internal medicine; Cancer","score_opus":0.31034816364364753,"score_gpt":0.5674658620510857,"score_spread":0.2571176984074382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128639169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013650136,0.99746895,0.00013833711,0.0008278195,0.0003419639,0.0000044592775,0.000013921318,0.0000070710043,0.001060985],"genre_scores_gemma":[0.0005531475,0.9977977,0.00017157842,0.0004976521,0.00028637983,0.0000054962507,0.000019261455,9.571021e-7,0.00066788273],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997763,0.00004988858,0.000032021577,0.00003512018,0.00008299557,0.000023641735],"domain_scores_gemma":[0.99961567,0.00019971051,0.000048110545,0.000013464458,0.00008514231,0.000037739326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009614158,0.0010741017,0.0017695694,0.0017719268,0.00035324035,0.0014373537,0.0012016784,0.0014022285,0.0045254966],"category_scores_gemma":[0.0010113631,0.00035488466,0.0005072757,0.0017952695,0.0007266519,0.0022558759,0.0007079668,0.0030318708,0.0021747716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002851712,0.00018459227,0.00016507859,0.006292486,0.00008784742,0.00047119224,0.00005957361,0.00057306036,0.0027535688,0.007201496,0.052201293,0.9297246],"study_design_scores_gemma":[0.00011780243,0.00016783597,0.00053326203,0.001525249,0.000105752115,0.0008782133,0.000045985693,0.00015387869,0.0006277729,0.0026925441,0.993133,0.000018829487],"about_ca_topic_score_codex":0.0010862718,"about_ca_topic_score_gemma":0.0038557923,"teacher_disagreement_score":0.0045254966,"about_ca_system_score_codex":0.0011318539,"about_ca_system_score_gemma":0.0012895414,"threshold_uncertainty_score":0.015139222},"labels":[],"label_agreement":null},{"id":"W2128958667","doi":"10.1503/cmaj.061011","title":"Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis","year":2007,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Fonds de Recherche du Québec - Santé; McGill University; McGill University Health Centre","funders":"","keywords":"Concordance; Breast cancer; Medicine; Immunohistochemistry; Trastuzumab; Fluorescence in situ hybridization; Gold standard (test); Internal medicine; In situ hybridization; Oncology; Cancer; Pathology; Biology","score_opus":0.07575837233168622,"score_gpt":0.4433496187504585,"score_spread":0.3675912464187723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128958667","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032199835,0.9930246,0.00061060896,0.00050356315,0.00010804661,0.00044172586,0.0016185298,0.000019276154,0.00045365826],"genre_scores_gemma":[0.12285034,0.86988753,0.0031021286,0.0010468566,0.00018452926,0.0014164888,0.0012615614,0.000023547727,0.00022699825],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98447335,0.008513607,0.003493869,0.0010347816,0.0021112321,0.00037304574],"domain_scores_gemma":[0.9472719,0.04237406,0.006236139,0.0006042354,0.0031304553,0.00038318927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015687708,0.0020027547,0.011878879,0.008850722,0.0004612566,0.0024366376,0.002062346,0.0017742147,0.0044167573],"category_scores_gemma":[0.058005963,0.0012180123,0.020868747,0.010354779,0.000635253,0.0016293166,0.0010881274,0.0016321595,0.0002760347],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001099311,0.000038973238,0.0042967307,0.77225333,0.1922647,0.00019721228,0.000066786495,0.0014462855,0.00013459077,0.00043757295,0.0020123662,0.025752168],"study_design_scores_gemma":[0.0014095167,0.00049017847,0.010144958,0.26208058,0.7141405,0.00064138777,0.00011582272,0.0012438917,0.00020899426,0.0011172967,0.008339796,0.00006707851],"about_ca_topic_score_codex":0.012677853,"about_ca_topic_score_gemma":0.025982246,"teacher_disagreement_score":0.015687708,"about_ca_system_score_codex":0.0059687872,"about_ca_system_score_gemma":0.0063947313,"threshold_uncertainty_score":0.08296549},"labels":[],"label_agreement":null},{"id":"W2128964123","doi":"10.1093/annonc/mdq027","title":"Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Refractory (planetary science); Follicular lymphoma; Gastroenterology; Neutropenia; Adverse effect; Lymphoma; Cohort; Pharmacokinetics; CD20; Toxicity; Phases of clinical research; Oncology; Surgery","score_opus":0.06645319039979994,"score_gpt":0.4201120801170726,"score_spread":0.35365888971727266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128964123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913912,0.00391269,0.00056576845,0.00057533005,0.00011121185,0.0008008681,0.0008752746,0.000059158476,0.0017085226],"genre_scores_gemma":[0.9924374,0.001657427,0.001164809,0.000950262,0.00017535852,0.00054123905,0.002044198,0.00003534017,0.0009940082],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993493,0.00031916526,0.000042145148,0.0000927222,0.00005380811,0.00014274295],"domain_scores_gemma":[0.99880683,0.00033725833,0.0001270776,0.00013523032,0.00007538497,0.0005182707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026714467,0.0012645051,0.0023355903,0.00035307638,0.0004828242,0.000891475,0.0006183373,0.00095862604,0.0014078759],"category_scores_gemma":[0.0014467707,0.0004742567,0.0015858761,0.00036951707,0.001015419,0.00087832403,0.00024250991,0.0028234073,0.00045114802],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6140706,0.054464903,0.02803032,0.0009518718,0.0031272466,0.00084995746,0.00074607687,0.0044785785,0.07886374,0.00036913247,0.00520854,0.20883913],"study_design_scores_gemma":[0.42238948,0.5116622,0.04812859,0.000052394666,0.002289948,0.0009645299,0.00017821688,0.0014839069,0.006632444,0.00034672054,0.005816924,0.00005469319],"about_ca_topic_score_codex":0.0014549147,"about_ca_topic_score_gemma":0.0025830911,"teacher_disagreement_score":0.0026714467,"about_ca_system_score_codex":0.0008989285,"about_ca_system_score_gemma":0.0010778604,"threshold_uncertainty_score":0.014128149},"labels":[],"label_agreement":null},{"id":"W2129172826","doi":"10.1161/circulationaha.105.571414","title":"Altered Expression of Disintegrin Metalloproteinases and Their Inhibitor in Human Dilated Cardiomyopathy","year":2006,"lang":"en","type":"article","venue":"Circulation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; St. Michael's Hospital","funders":"","keywords":"Disintegrin; ADAM10; Integrin; Matrix metalloproteinase; Medicine; Dilated cardiomyopathy; Cell biology; Metalloproteinase; Internal medicine; Receptor; Pathology; Biology; Heart failure","score_opus":0.029393268866539014,"score_gpt":0.3083434272021627,"score_spread":0.27895015833562364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129172826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886584,0.0006798109,0.00016923726,0.000014401391,0.0000040756104,0.000005470955,0.000051980733,0.0000033632912,0.00020589976],"genre_scores_gemma":[0.99919254,0.0002744308,0.0002298264,0.00001459461,0.000009457497,0.000008797224,0.000117172785,0.0000013080346,0.00015199726],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99992573,0.00001560986,0.000011162972,0.00001883063,0.00001486913,0.000013696908],"domain_scores_gemma":[0.9998621,0.000031078845,0.00005399661,0.000008137362,0.00001637929,0.000028374083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026550432,0.00015345466,0.00013838137,0.00038392207,0.00011548861,0.00015710275,0.000060715403,0.0001848362,0.0006912078],"category_scores_gemma":[0.000258874,0.00006150532,0.00009170424,0.00018600482,0.00017364843,0.00008807644,0.00010841833,0.00014334226,0.0001269464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030140013,0.00018055919,0.3841184,0.00025271278,0.000056184614,0.0055422965,0.00038729896,0.00024814747,0.5864796,0.00017539175,0.00038055753,0.019164857],"study_design_scores_gemma":[0.000048718935,0.0006426311,0.94787025,0.000020974885,0.00006347915,0.010095626,0.00015273174,0.00049686583,0.038983915,0.00012604342,0.0014917658,0.00000700126],"about_ca_topic_score_codex":0.00011848728,"about_ca_topic_score_gemma":0.00013443669,"teacher_disagreement_score":0.0006912078,"about_ca_system_score_codex":0.00014126916,"about_ca_system_score_gemma":0.000067278495,"threshold_uncertainty_score":0.0023123026},"labels":[],"label_agreement":null},{"id":"W2129233814","doi":"10.1371/journal.pone.0010789","title":"Epistatic and Functional Interactions of Catechol-O-Methyltransferase (COMT) and AKT1 on Neuregulin1-ErbB Signaling in Cell Models","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health; Medical Research Council; National Institutes of Health; School of Medicine, New York University; University College, Oxford; York University","keywords":"Catechol-O-methyl transferase; Phosphorylation; Neuregulin; Signal transduction; AKT1; ErbB; Cell biology; Chemistry; MAPK/ERK pathway; HEK 293 cells; Cancer research; Biology; Endocrinology; Protein kinase B; Receptor; Biochemistry; Genotype; Gene","score_opus":0.11362211924003425,"score_gpt":0.3115481540192685,"score_spread":0.19792603477923426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129233814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682045,0.00030917223,0.0013395697,0.000063765714,0.0000112318985,0.000016716402,0.0009837841,0.000030244852,0.0004249793],"genre_scores_gemma":[0.99689996,0.0002295334,0.0014113975,0.000040731884,0.0000048541824,0.000041848125,0.00078322104,0.000019065597,0.00056938257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996124,0.0001358468,0.00003279151,0.0000812118,0.00009380337,0.000044040586],"domain_scores_gemma":[0.9996568,0.00011854336,0.00011929254,0.0000337875,0.000021358217,0.00005025841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037148618,0.0005867304,0.00039017736,0.0006975978,0.0002390533,0.00033464623,0.00032823393,0.00029059744,0.0021157074],"category_scores_gemma":[0.00033951504,0.00016472818,0.0006525721,0.00053185323,0.00021506072,0.0000972559,0.00043074592,0.00040585725,0.00017297898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012667276,0.00010040513,0.0078811785,0.000069805355,0.00017827378,0.00032824013,0.00003403472,0.0006635728,0.9867323,0.0002770242,0.000119359065,0.0023490826],"study_design_scores_gemma":[0.00035051443,0.0030961696,0.37961286,0.000033981265,0.0013195723,0.0035468724,0.00032878233,0.043315347,0.56130683,0.0011934037,0.0057889097,0.000106781845],"about_ca_topic_score_codex":0.0026611278,"about_ca_topic_score_gemma":0.004675647,"teacher_disagreement_score":0.0026611278,"about_ca_system_score_codex":0.0005177726,"about_ca_system_score_gemma":0.000236021,"threshold_uncertainty_score":0.007077694},"labels":[],"label_agreement":null},{"id":"W2129508275","doi":"10.14694/edbook_am.2015.35.e41","title":"Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease","year":2015,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Clinical trial; Disease; Chemotherapy; Adjuvant; Metastatic breast cancer; Pertuzumab; Adjuvant therapy; Cancer; Targeted therapy","score_opus":0.30777071585932586,"score_gpt":0.6224921145437846,"score_spread":0.31472139868445875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129508275","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009326173,0.99876404,0.000056307377,0.00014513009,0.00021860117,0.0000034714938,0.000013984423,0.0000043619466,0.0007007843],"genre_scores_gemma":[0.00081421726,0.9975701,0.000110271285,0.0003637046,0.00023418841,0.0000063499897,0.000040953968,0.0000014187212,0.00085890293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989605,0.000020572672,0.0000140010625,0.000018835888,0.00004212367,0.000008492292],"domain_scores_gemma":[0.9998871,0.00005217784,0.000023711375,0.000003969702,0.00002236155,0.000010554038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002739219,0.0005791277,0.00086074934,0.0013122663,0.00015095685,0.00037953016,0.00047607275,0.0004694365,0.0030921341],"category_scores_gemma":[0.0004761254,0.00016636049,0.00036562435,0.001320911,0.0002651221,0.0005690685,0.00042254914,0.0013686462,0.0018296108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007524156,0.00005198462,0.0001187558,0.009062814,0.00006251042,0.00011571865,0.000024102304,0.00021409852,0.0009264262,0.0010805454,0.04486355,0.94340426],"study_design_scores_gemma":[0.000041294374,0.00012621228,0.0014154429,0.004760693,0.00009948419,0.0021845412,0.000030554238,0.00008172349,0.00038681185,0.001248357,0.9896102,0.000014787357],"about_ca_topic_score_codex":0.0007129228,"about_ca_topic_score_gemma":0.0021488043,"teacher_disagreement_score":0.0030921341,"about_ca_system_score_codex":0.0003480862,"about_ca_system_score_gemma":0.0004501145,"threshold_uncertainty_score":0.010344267},"labels":[],"label_agreement":null},{"id":"W2129726505","doi":"10.1158/1078-0432.ccr-05-1109","title":"Strategies for Delaying or Treating<i>In vivo</i>Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Oncosuisse; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Trastuzumab; In vivo; Breast cancer; Medicine; Acquired resistance; Human breast; Oncology; Cancer; Internal medicine; Cancer research; Biology; Biotechnology","score_opus":0.276028954774144,"score_gpt":0.5780301207621373,"score_spread":0.3020011659879933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129726505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684079,0.009591966,0.014616143,0.0006798677,0.0001645764,0.00056172354,0.000627894,0.00036035536,0.0049894904],"genre_scores_gemma":[0.9804869,0.004872733,0.010679967,0.00021381269,0.00004093042,0.00024165618,0.0008933604,0.0000405325,0.002530215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999075,0.000018745644,0.000008554516,0.000019689418,0.000019413892,0.000026026988],"domain_scores_gemma":[0.99993443,0.000009714862,0.000020287656,0.000010196653,0.000009437705,0.000015991396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018840111,0.00038923448,0.00030062956,0.00016064229,0.00011871743,0.000379211,0.00039760084,0.00028470735,0.0008810309],"category_scores_gemma":[0.00011339462,0.000117506024,0.00024777162,0.00011460942,0.0001277888,0.00017416196,0.00015121486,0.000678906,0.0003327197],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002279413,0.00042262065,0.00035312606,0.00013850928,0.000016928248,0.00005378186,0.000021591846,0.0005486442,0.986167,0.00022382475,0.0003728199,0.011453129],"study_design_scores_gemma":[0.00026328216,0.004735666,0.0029466692,0.000030671017,0.000084482526,0.00056886324,0.000031406504,0.0023024895,0.97605056,0.00007306948,0.012901381,0.000011456365],"about_ca_topic_score_codex":0.00044530927,"about_ca_topic_score_gemma":0.00090710097,"teacher_disagreement_score":0.0008810309,"about_ca_system_score_codex":0.0002798025,"about_ca_system_score_gemma":0.00024074614,"threshold_uncertainty_score":0.0029472709},"labels":[],"label_agreement":null},{"id":"W2131178461","doi":"10.1634/theoncologist.2010-0137","title":"Treatment Beyond Progression: Is It Moving from Belief to Evidence?","year":2010,"lang":"en","type":"letter","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; MEDLINE; Internal medicine; Family medicine; Cancer","score_opus":0.17719670831203707,"score_gpt":0.4723174421791335,"score_spread":0.2951207338670965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131178461","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005763855,0.0006052558,0.00003240969,0.98447984,0.014298545,0.0000027225628,0.000012175119,0.0000055641376,0.00050601264],"genre_scores_gemma":[0.0011925375,0.0010439961,0.0001434354,0.9474936,0.04845286,0.000011319001,0.000009214489,0.0000110856,0.0016419902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98777884,0.005475547,0.0015332969,0.0010585515,0.0031656686,0.0009881522],"domain_scores_gemma":[0.94567966,0.03864334,0.0030615919,0.0008991167,0.0076665273,0.004049672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013415368,0.0009588502,0.0022023146,0.0009788162,0.004538044,0.0057072625,0.0031568261,0.05537018,0.0074257012],"category_scores_gemma":[0.0847985,0.0009684275,0.0020099566,0.0009679976,0.0047490587,0.008268301,0.0022506842,0.06909161,0.0047142194],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046450525,0.00001872914,0.00020155667,0.00006759923,0.00001880447,0.00043927124,0.000112747344,0.000025910751,0.0000367701,0.0017918353,0.9921475,0.005092852],"study_design_scores_gemma":[0.00041595387,0.00017436079,0.00097505096,0.0013394821,0.00011069082,0.0029088398,0.0008394189,0.00050181313,0.00030567258,0.020582443,0.9717106,0.00013559431],"about_ca_topic_score_codex":0.0052137114,"about_ca_topic_score_gemma":0.0117930155,"teacher_disagreement_score":0.05537018,"about_ca_system_score_codex":0.005863059,"about_ca_system_score_gemma":0.007422855,"threshold_uncertainty_score":0.070948064},"labels":[],"label_agreement":null},{"id":"W2131281105","doi":"10.18632/oncotarget.1170","title":"A Tumor initiating cell-enriched prognostic signature for HER2+:ERα− breast cancer; rationale, new features, controversies and future directions","year":2013,"lang":"en","type":"article","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University Health Network","funders":"Government of Ontario","keywords":"Medicine; Breast cancer; Cancer research; Oncology; Cancer; Internal medicine","score_opus":0.014213901404842072,"score_gpt":0.2996179213194829,"score_spread":0.2854040199146408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131281105","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1335712,0.6958046,0.018432338,0.13297625,0.004581109,0.0006810371,0.0017715791,0.00037404514,0.011807814],"genre_scores_gemma":[0.68115044,0.22834486,0.040039394,0.029408358,0.011855054,0.0011393091,0.0029243168,0.00022624689,0.0049121017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840313,0.0005757726,0.00018279537,0.000290073,0.00036677194,0.00018138651],"domain_scores_gemma":[0.9923447,0.0026853187,0.00052913505,0.00073647336,0.002866083,0.0008382946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015106877,0.00085230154,0.0018451167,0.0016633581,0.000734146,0.0044297026,0.0027023698,0.0014121467,0.0022866314],"category_scores_gemma":[0.009914193,0.0004652419,0.0006129555,0.002040543,0.002493271,0.004651574,0.0013195989,0.00443419,0.0013978273],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038169285,0.0013384401,0.110773355,0.0057585877,0.00034925353,0.0008145433,0.0010546272,0.0010599772,0.032969374,0.032161467,0.042028278,0.7678752],"study_design_scores_gemma":[0.0009493394,0.012217188,0.14907765,0.010602688,0.0034756288,0.007887294,0.007581794,0.019136399,0.046441298,0.097011425,0.6449626,0.00065675157],"about_ca_topic_score_codex":0.0011749079,"about_ca_topic_score_gemma":0.0016542698,"teacher_disagreement_score":0.015106877,"about_ca_system_score_codex":0.001555927,"about_ca_system_score_gemma":0.0034988571,"threshold_uncertainty_score":0.07989371},"labels":[],"label_agreement":null},{"id":"W2131551233","doi":"10.3747/co.20.1523","title":"Outcomes of her2-positive Early-Stage Breast Cancer in the Trastuzumab Era: A Population-Based Study of Canadian Patients","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Trastuzumab; Hazard ratio; Internal medicine; Breast cancer; Oncology; Confidence interval; Progesterone receptor; Human Epidermal Growth Factor Receptor 2; Estrogen receptor; Hormone receptor; Proportional hazards model; Stage (stratigraphy); Cancer; Population; Gynecology","score_opus":0.08963955385321012,"score_gpt":0.43641089297444924,"score_spread":0.34677133912123914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131551233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981579,0.00020740538,0.000028781147,0.0000856843,0.0000030727952,0.000013048031,0.001010522,0.0000036777278,0.0004898232],"genre_scores_gemma":[0.99884653,0.00018371508,0.00003529237,0.000042941043,0.000004006817,0.0000072166054,0.000760398,0.0000018620177,0.00011801926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939,0.000048003865,0.00003356039,0.00012856207,0.00020061004,0.00019919813],"domain_scores_gemma":[0.9988732,0.0000933562,0.0003566387,0.00004409906,0.00034414366,0.00028862938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004981955,0.0004471743,0.00044828438,0.0011900981,0.0018056701,0.0008154033,0.00091159996,0.00057616155,0.0015740013],"category_scores_gemma":[0.0014584215,0.00035242617,0.0005218959,0.0028721266,0.0007447337,0.0004210733,0.0006493234,0.0006276907,0.00019302516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004104341,0.000021602837,0.9986205,0.000009078258,0.000024188472,0.000065450346,0.00018013727,0.000045887995,0.000087486485,0.000016696007,0.00018640072,0.0007014441],"study_design_scores_gemma":[0.000008510057,0.000036471625,0.9989698,0.000007687287,0.000015731299,0.00015460514,0.00039505662,0.00014065753,0.00002668848,0.000011368584,0.00022608278,0.000007374497],"about_ca_topic_score_codex":0.88819,"about_ca_topic_score_gemma":0.8791623,"teacher_disagreement_score":0.11181003,"about_ca_system_score_codex":0.009293337,"about_ca_system_score_gemma":0.0068948893,"threshold_uncertainty_score":0.22493696},"labels":[],"label_agreement":null},{"id":"W2131849559","doi":"10.6000/1929-2279.2012.01.01.14","title":"Present and Emerging Targeted Therapy for Metastatic Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lapatinib; Trastuzumab; Targeted therapy; Metastatic breast cancer; Bevacizumab; Medicine; Breast cancer; Cancer research; Cancer; Epidermal growth factor receptor; Vascular endothelial growth factor; Estrogen receptor; Clinical trial; Oncology; Internal medicine; Chemotherapy; VEGF receptors","score_opus":0.1362072820073554,"score_gpt":0.5161103061489057,"score_spread":0.3799030241415503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131849559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003240285,0.9809341,0.0021093404,0.0040967036,0.0009388069,0.000029078928,0.00006770913,0.00004490344,0.008538943],"genre_scores_gemma":[0.018878821,0.96648806,0.003453014,0.0025840087,0.0016276977,0.000046073368,0.0001723314,0.00001637972,0.0067336513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982136,0.000046488552,0.00001560683,0.000028505146,0.000066056105,0.000022000931],"domain_scores_gemma":[0.9998596,0.00004193847,0.00002236663,0.0000087822855,0.000043659213,0.000023630582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074269756,0.0003966582,0.00056807644,0.00065603387,0.00019235567,0.00075725536,0.0005817755,0.0007083977,0.004373537],"category_scores_gemma":[0.00040047307,0.00011484672,0.00033888558,0.00062333426,0.0003552892,0.0012503475,0.00043811512,0.0014494357,0.0016531551],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025203114,0.00023522938,0.00037579137,0.0030160963,0.00003701491,0.00042230333,0.00008396678,0.0003118965,0.012607071,0.0097089065,0.020310048,0.9526397],"study_design_scores_gemma":[0.00016593112,0.0009555677,0.0014690346,0.0011972378,0.00012783604,0.002653173,0.000093349074,0.00058482663,0.0050948276,0.0068484363,0.98079175,0.000018135],"about_ca_topic_score_codex":0.0002653669,"about_ca_topic_score_gemma":0.0010246377,"teacher_disagreement_score":0.004373537,"about_ca_system_score_codex":0.00058817666,"about_ca_system_score_gemma":0.00048794132,"threshold_uncertainty_score":0.014630973},"labels":[],"label_agreement":null},{"id":"W2132557004","doi":"10.1158/1078-0432.ccr-06-1539","title":"First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Rash; Pharmacokinetics; Adverse effect; Gastroenterology; Internal medicine; Nausea; Dosing; Pharmacodynamics; Cmax; Toxicity; Pharmacology","score_opus":0.14627582029163708,"score_gpt":0.5347873946819192,"score_spread":0.38851157439028206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132557004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975926,0.0008650619,0.00033751913,0.00012246419,0.000020012123,0.0003314009,0.00015166013,0.000026577649,0.0005527678],"genre_scores_gemma":[0.9967411,0.0005375294,0.0008499935,0.00029340916,0.00014280228,0.0002905262,0.00063237303,0.000011013924,0.00050123606],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99945146,0.00029989245,0.00003350937,0.00007161677,0.000072595016,0.00007102124],"domain_scores_gemma":[0.99896336,0.00031779637,0.00023948756,0.00012240461,0.00006390487,0.00029305238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012218754,0.0011640382,0.001487161,0.00014287203,0.0003845662,0.00045419837,0.0005206907,0.00068369816,0.0017535641],"category_scores_gemma":[0.0014582375,0.0003457049,0.0006007548,0.00017616586,0.00086424133,0.0005734373,0.00018614552,0.0016329071,0.0004667751],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40408012,0.060617685,0.08368391,0.0015685556,0.0015581222,0.0024470976,0.0008237358,0.0046302015,0.21529636,0.00040826952,0.003314022,0.22157194],"study_design_scores_gemma":[0.10263824,0.8366916,0.03937814,0.00003153032,0.00039640034,0.0015249756,0.00007500268,0.0011976305,0.0152289895,0.00009580884,0.0027089848,0.00003266092],"about_ca_topic_score_codex":0.0005423224,"about_ca_topic_score_gemma":0.0007744716,"teacher_disagreement_score":0.0017535641,"about_ca_system_score_codex":0.0006206547,"about_ca_system_score_gemma":0.001030033,"threshold_uncertainty_score":0.006461978},"labels":[],"label_agreement":null},{"id":"W2132628497","doi":"10.1093/jnci/djp334","title":"A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment","year":2009,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Biomarker; Drug development; Food and drug administration; Biomarker discovery; Medicine; Risk analysis (engineering); Drug; Computer science; Computational biology; Biology; Pharmacology; Proteomics","score_opus":0.13847322546901603,"score_gpt":0.4302700547783281,"score_spread":0.29179682930931206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132628497","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003209951,0.03384796,0.003379947,0.9540939,0.0063216165,0.000031676427,0.00002083671,0.00003447644,0.0019486476],"genre_scores_gemma":[0.037450615,0.13562159,0.05067887,0.7203541,0.043537896,0.00055160315,0.0001524806,0.00018623468,0.01146664],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.93227077,0.041063227,0.004154371,0.004029151,0.014187577,0.0042949463],"domain_scores_gemma":[0.81409305,0.11936941,0.0049155774,0.004231913,0.033815004,0.023575056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.14867218,0.002432935,0.00341962,0.0040886695,0.009427798,0.021390636,0.009046215,0.054546405,0.009681726],"category_scores_gemma":[0.084012754,0.00180526,0.0038025554,0.0034858766,0.024528032,0.033663698,0.012274176,0.049089525,0.0024834895],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036228486,0.00077988155,0.0017554918,0.0029080259,0.00014230478,0.0026133636,0.0056018527,0.002601258,0.0014272606,0.24101855,0.5506352,0.19015442],"study_design_scores_gemma":[0.00016421027,0.00059629336,0.001124155,0.0026913688,0.000060401853,0.002045673,0.010639933,0.0020140072,0.000541734,0.21160816,0.7682273,0.00028679473],"about_ca_topic_score_codex":0.008382423,"about_ca_topic_score_gemma":0.013474081,"teacher_disagreement_score":0.14867218,"about_ca_system_score_codex":0.012777574,"about_ca_system_score_gemma":0.04646776,"threshold_uncertainty_score":0.78626305},"labels":[],"label_agreement":null},{"id":"W2133154503","doi":"10.1007/s10549-009-0364-7","title":"Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers","year":2009,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Trastuzumab; Breast cancer; Cancer research; Gene silencing; Medicine; Oncology; Cancer; Internal medicine; Biology; Gene; Genetics","score_opus":0.047857390762481605,"score_gpt":0.3666355244360162,"score_spread":0.3187781336735346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133154503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883918,0.004962633,0.0031505208,0.0004140229,0.00007788874,0.00005957221,0.00052643986,0.00014746598,0.0022695954],"genre_scores_gemma":[0.9948043,0.0012528141,0.0010066319,0.000073192234,0.00001809397,0.000041453473,0.0005948759,0.00003689509,0.0021716142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99954057,0.000105806546,0.00003739386,0.00006123718,0.00014097123,0.00011404423],"domain_scores_gemma":[0.99964917,0.00008013476,0.0000901097,0.00006918201,0.00004939554,0.000062000276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031278338,0.00034364004,0.00051902456,0.00041339197,0.00025184455,0.00045824278,0.0002024525,0.00057392044,0.0019364606],"category_scores_gemma":[0.0006220378,0.00029677906,0.000440609,0.00053501123,0.00028437583,0.0003012487,0.00030828928,0.000870873,0.0008365123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016204649,0.000048148435,0.00063150324,0.000046812158,0.000023317018,0.00062927074,0.000026833806,0.00013707008,0.99536777,0.00012187951,0.00032697094,0.00247833],"study_design_scores_gemma":[0.000066483844,0.0003663399,0.010312158,0.000007906096,0.000046706486,0.0070008505,0.000055815006,0.0013129594,0.97297734,0.00018044232,0.007662486,0.000010486369],"about_ca_topic_score_codex":0.0007061465,"about_ca_topic_score_gemma":0.0004326785,"teacher_disagreement_score":0.0019364606,"about_ca_system_score_codex":0.00033739288,"about_ca_system_score_gemma":0.00019424557,"threshold_uncertainty_score":0.006478131},"labels":[],"label_agreement":null},{"id":"W2133208325","doi":"10.1093/annonc/mdh031","title":"Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Trastuzumab; Medicine; Internal medicine; Oncology; Chemotherapy; Cisplatin; Lung cancer; Breast cancer; Cancer","score_opus":0.09359131375202594,"score_gpt":0.46961814393279155,"score_spread":0.3760268301807656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133208325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835777,0.003551341,0.00095403404,0.0016450882,0.0014233094,0.0040820697,0.0013704565,0.00016754099,0.0032284453],"genre_scores_gemma":[0.98259443,0.0022131715,0.0017469816,0.0016883574,0.000461312,0.0037195229,0.0017416808,0.00005551811,0.0057792226],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992867,0.00036866372,0.000034892317,0.00015490955,0.000036542813,0.00011824277],"domain_scores_gemma":[0.9989077,0.0003001065,0.00015576644,0.00012280564,0.000053642543,0.00046000603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018426927,0.0021170448,0.0044382485,0.00055645686,0.00061750045,0.0017212172,0.0014540995,0.0021003895,0.010361515],"category_scores_gemma":[0.0018974881,0.0011190802,0.002086005,0.00061867334,0.0020167734,0.0017648537,0.00072252477,0.0054388675,0.0018306229],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9803662,0.0055779135,0.0003770733,0.00029656425,0.00067765516,0.000031179075,0.000047189667,0.0005851289,0.0015548662,0.00013066479,0.000788043,0.009567631],"study_design_scores_gemma":[0.9717866,0.026513759,0.00053688645,0.000011919499,0.00022849106,0.000015757389,0.000016604485,0.00023731365,0.00017192395,0.00010772444,0.0003655604,0.000007479276],"about_ca_topic_score_codex":0.0020001573,"about_ca_topic_score_gemma":0.0045150965,"teacher_disagreement_score":0.010361515,"about_ca_system_score_codex":0.001614388,"about_ca_system_score_gemma":0.0017380468,"threshold_uncertainty_score":0.034662724},"labels":[],"label_agreement":null},{"id":"W2133432676","doi":"10.3747/co.v15i3.300","title":"Trastuzumab: A Cardiologist’s Perspective","year":2008,"lang":"en","type":"editorial","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Human Epidermal Growth Factor Receptor 2; Oncology; Breast cancer; Internal medicine; Monoclonal antibody; Clinical trial; Adjuvant; Perspective (graphical); Cancer; Antibody; Chemotherapy; Immunology; Artificial intelligence","score_opus":0.22241149420100934,"score_gpt":0.5407209232273045,"score_spread":0.3183094290262951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133432676","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007026217,0.073766,0.00029115446,0.14530389,0.77926165,0.000018176774,0.000054157823,0.00006905579,0.0011657196],"genre_scores_gemma":[0.0006007155,0.038470708,0.00022138894,0.09644704,0.8617489,0.000020404788,0.000024089444,0.000022456188,0.0024442563],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99638677,0.0009741076,0.000604963,0.0003980813,0.0014682721,0.00016795009],"domain_scores_gemma":[0.97013086,0.016368702,0.00112184,0.00045854232,0.009268598,0.0026515753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012306592,0.0029111884,0.004323331,0.0026174842,0.0014972534,0.0047564753,0.003264545,0.014785054,0.0037444439],"category_scores_gemma":[0.027598428,0.00077949645,0.0022376166,0.0014992958,0.002380871,0.005950801,0.001012793,0.028137702,0.0033863718],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006922554,0.000015819136,0.00003071179,0.0003670366,0.00003805617,0.00012509413,0.000013957556,0.000052839438,0.000053520496,0.00093181577,0.9821629,0.016139118],"study_design_scores_gemma":[0.00015603757,0.00012042203,0.00024117171,0.0012550473,0.00013010598,0.000498162,0.000043526838,0.00022856468,0.00009470106,0.0024163423,0.99478614,0.000029614524],"about_ca_topic_score_codex":0.0018461804,"about_ca_topic_score_gemma":0.003686292,"teacher_disagreement_score":0.014785054,"about_ca_system_score_codex":0.0025190446,"about_ca_system_score_gemma":0.0029739055,"threshold_uncertainty_score":0.06508422},"labels":[],"label_agreement":null},{"id":"W2133441588","doi":"10.1186/1746-1596-8-17","title":"Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens","year":2013,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Breast cancer; Classifier (UML); Fluorescence in situ hybridization; Gene duplication; Enumeration; Software; Biology; Computer science; Artificial intelligence; Pathology; Pattern recognition (psychology); Computational biology; Gene; Cancer; Medicine; Mathematics; Genetics","score_opus":0.0668948548099688,"score_gpt":0.3769452753394337,"score_spread":0.3100504205294649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133441588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8599641,0.0007635082,0.13404347,0.00014246775,0.00022251184,0.0004616547,0.0012281728,0.0018085747,0.0013654624],"genre_scores_gemma":[0.848341,0.0002174708,0.14609367,0.00009818521,0.00004559335,0.0004894241,0.003141988,0.00012934777,0.0014432698],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966504,0.0006653849,0.0003121694,0.00082154595,0.0013234173,0.00022711608],"domain_scores_gemma":[0.9919716,0.0038350243,0.0004078597,0.000445056,0.0030607819,0.00027964378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005057387,0.000599068,0.0009525638,0.0022296442,0.0005081994,0.0010082873,0.0009677763,0.0012987723,0.00090072723],"category_scores_gemma":[0.010733543,0.00024313453,0.00045921703,0.00066618086,0.0003584474,0.00083905685,0.0007311232,0.0005363587,0.0007750017],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031096798,0.0007661756,0.34281105,0.00049061567,0.0004885697,0.0004978235,0.00041905916,0.024359869,0.21607305,0.00060055684,0.0046600956,0.40572345],"study_design_scores_gemma":[0.00011342473,0.0016351077,0.15514831,0.000090229885,0.00029315025,0.0015459777,0.00025836666,0.6967175,0.13916908,0.00031287363,0.0046307663,0.00008519102],"about_ca_topic_score_codex":0.002664371,"about_ca_topic_score_gemma":0.0024713944,"teacher_disagreement_score":0.005057387,"about_ca_system_score_codex":0.0007124833,"about_ca_system_score_gemma":0.0008563947,"threshold_uncertainty_score":0.026746273},"labels":[],"label_agreement":null},{"id":"W2133999831","doi":"10.1158/1078-0432.ccr-03-0785","title":"Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development","year":2004,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Drug development; Mechanism (biology); Surrogate endpoint; Medicine; Drug; Oncology; Intensive care medicine; Pharmacology; Internal medicine","score_opus":0.5913131394625564,"score_gpt":0.6546057634251068,"score_spread":0.06329262396255042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133999831","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005855785,0.92514294,0.04182143,0.022899246,0.002179031,0.0003059262,0.00018825957,0.00008311278,0.006794468],"genre_scores_gemma":[0.01822981,0.90076905,0.05411916,0.017287923,0.0025029606,0.0015573795,0.0002460937,0.000042870433,0.005244827],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563223,0.0022376194,0.00056303956,0.00046960008,0.0009889978,0.000108435146],"domain_scores_gemma":[0.9931833,0.0052814335,0.0004531321,0.00025974552,0.0007029427,0.00011950794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017333217,0.0024949103,0.004506362,0.0033478322,0.0006111128,0.0037426974,0.0038360057,0.0058619,0.0027720872],"category_scores_gemma":[0.010324308,0.0010926453,0.0018591707,0.002032301,0.0069510792,0.006317447,0.0022502067,0.010949596,0.0024220704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003311377,0.00021922713,0.00056383834,0.009826492,0.00017870398,0.0007418021,0.00015309485,0.0041947826,0.0020013114,0.5269316,0.02137023,0.43348774],"study_design_scores_gemma":[0.0003402945,0.00051717804,0.0006754591,0.012129557,0.00025357827,0.0026026673,0.0001322179,0.002621646,0.0030610154,0.34864616,0.62889004,0.00013010151],"about_ca_topic_score_codex":0.0008476643,"about_ca_topic_score_gemma":0.00090057665,"teacher_disagreement_score":0.017333217,"about_ca_system_score_codex":0.0040286495,"about_ca_system_score_gemma":0.0045612855,"threshold_uncertainty_score":0.09166795},"labels":[],"label_agreement":null},{"id":"W2134169490","doi":"10.5539/gjhs.v7n1p98","title":"Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer","year":2014,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Regimen; Oncology; Adjuvant; Internal medicine; Cost effectiveness; Cost-effectiveness analysis; Randomized controlled trial; Clinical trial; Adjuvant therapy; Cohort; Cancer; Gynecology","score_opus":0.11303152186607289,"score_gpt":0.5009627399978569,"score_spread":0.387931218131784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134169490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7214513,0.158642,0.07897867,0.010632991,0.0007847831,0.0036284009,0.0069959993,0.00016863518,0.018717138],"genre_scores_gemma":[0.9848215,0.007894218,0.005090216,0.00027338308,0.000085233965,0.0004869397,0.00074239064,0.00001210041,0.00059387286],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9948521,0.0041130604,0.00017336234,0.00019919773,0.00043593784,0.00022629977],"domain_scores_gemma":[0.9874542,0.010807417,0.0009334496,0.00017018302,0.00046572485,0.00016902959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009388829,0.0010562239,0.0020503073,0.0016700777,0.00019057642,0.0013807741,0.00095161406,0.00095652585,0.0032816397],"category_scores_gemma":[0.023811188,0.00044201704,0.0051003555,0.0013070811,0.00035825744,0.0011614457,0.0007165758,0.0013969763,0.00010191768],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007083812,0.00038038008,0.0134819355,0.0048318254,0.008743078,0.0003668053,0.000068552334,0.9000747,0.00048146583,0.010311172,0.0016240781,0.052552156],"study_design_scores_gemma":[0.0033527159,0.005230332,0.024008049,0.003686785,0.022276692,0.0007941995,0.00021884919,0.90320784,0.0012487187,0.029303275,0.0065389564,0.00013343568],"about_ca_topic_score_codex":0.007319746,"about_ca_topic_score_gemma":0.0044705397,"teacher_disagreement_score":0.009388829,"about_ca_system_score_codex":0.0059958547,"about_ca_system_score_gemma":0.003995516,"threshold_uncertainty_score":0.04965347},"labels":[],"label_agreement":null},{"id":"W2134496677","doi":"10.1053/s0046-8177(03)00411-8","title":"Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer","year":2003,"lang":"en","type":"article","venue":"Human Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Tissue microarray; Synaptophysin; Neuroendocrine differentiation; Breast cancer; Pathology; Enolase; Progesterone receptor; Immunohistochemistry; Biology; Immunostaining; Chromogranin A; Breast carcinoma; Estrogen receptor; Univariate analysis; Carcinoma; Cancer; Oncology; Internal medicine; Medicine; Multivariate analysis","score_opus":0.036436739262175305,"score_gpt":0.36019780607332796,"score_spread":0.3237610668111527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134496677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991204,0.0021390358,0.0026316615,0.00026363926,0.000065418295,0.0000271544,0.0014966539,0.00006050238,0.002111932],"genre_scores_gemma":[0.9930354,0.00076375104,0.0027246089,0.000062974446,0.00002874233,0.0000579187,0.0015507085,0.000007980018,0.0017679965],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9996086,0.000109442626,0.000040996583,0.00006751457,0.00009589186,0.0000775267],"domain_scores_gemma":[0.9997104,0.000121576624,0.000037836096,0.000045549383,0.000056387395,0.000028308428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046470293,0.00013839165,0.00028033898,0.0007035653,0.0003039962,0.0004329927,0.00017076137,0.00023945868,0.0018642081],"category_scores_gemma":[0.0006718647,0.00015514088,0.00013670888,0.00076071883,0.00012448124,0.00019102996,0.00016586267,0.00028238707,0.00044034445],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018703403,0.0001456794,0.12704267,0.00016217495,0.00015609812,0.00047798676,0.00012543387,0.00045113367,0.8427436,0.00032304853,0.0013008314,0.025201095],"study_design_scores_gemma":[0.000040596668,0.00065419864,0.76629347,0.000020709214,0.0002920175,0.0030964105,0.0003492688,0.0041723284,0.21378447,0.00030839417,0.010966532,0.000021569282],"about_ca_topic_score_codex":0.0007122247,"about_ca_topic_score_gemma":0.0016942524,"teacher_disagreement_score":0.0018642081,"about_ca_system_score_codex":0.00022327858,"about_ca_system_score_gemma":0.00022503432,"threshold_uncertainty_score":0.0062363744},"labels":[],"label_agreement":null},{"id":"W2135530224","doi":"10.1200/jco.2014.57.1513","title":"Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Ramucirumab; Docetaxel; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Hazard ratio; Clinical endpoint; Taxane; Breast cancer; Placebo; Chemotherapy; Progression-free survival; Cancer; Randomized controlled trial; Pathology; Confidence interval","score_opus":0.1991386133547665,"score_gpt":0.5626661216359241,"score_spread":0.3635275082811576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135530224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9141552,0.028374536,0.0018798943,0.0029027846,0.0014251908,0.021626554,0.010892696,0.00078680133,0.017956398],"genre_scores_gemma":[0.95634633,0.00859712,0.0043113343,0.0029544318,0.0011651425,0.01156464,0.0065064323,0.000112833724,0.008441722],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987999,0.0006981143,0.0000749915,0.00020483135,0.00011079844,0.000111313486],"domain_scores_gemma":[0.998473,0.00038771468,0.00043067907,0.00011907993,0.0001276036,0.00046197983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036558078,0.002324747,0.0038157606,0.0004702456,0.0005237994,0.0012315548,0.0012071817,0.0017543288,0.012563446],"category_scores_gemma":[0.0031493308,0.0006877119,0.0019020449,0.00039541497,0.0015060926,0.0009920312,0.00030941996,0.0043755216,0.0021643012],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96686167,0.006448132,0.00058985513,0.001341898,0.00097339466,0.000050612372,0.000037837173,0.00029636873,0.0034073389,0.00017329457,0.0030358306,0.016783815],"study_design_scores_gemma":[0.9565931,0.03917356,0.0012492868,0.0000565954,0.00062384893,0.00004878456,0.0000056533872,0.00016287253,0.0008419366,0.000102390564,0.0011324111,0.00000955861],"about_ca_topic_score_codex":0.0005488636,"about_ca_topic_score_gemma":0.0014527404,"teacher_disagreement_score":0.012563446,"about_ca_system_score_codex":0.0007878494,"about_ca_system_score_gemma":0.0016434516,"threshold_uncertainty_score":0.042028904},"labels":[],"label_agreement":null},{"id":"W2135655765","doi":"10.1158/0008-5472.can-10-2229","title":"Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Immune system; Cancer research; Biology; Tumor progression; Signal transduction; Syk; Breast cancer; Carcinogenesis; Acquired immune system; Receptor tyrosine kinase; Mammary tumor; Tyrosine kinase; Cancer; Immunology; Cell biology","score_opus":0.05529221576837432,"score_gpt":0.4000468603426212,"score_spread":0.34475464457424687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135655765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99799,0.00059880764,0.00044794203,0.000050500472,0.0000056514036,0.0000046366044,0.00005317234,0.00003911361,0.00081007194],"genre_scores_gemma":[0.9988255,0.00020100943,0.00025762783,0.000020001879,0.000005049811,0.000005532651,0.000071601135,0.0000034479046,0.0006101796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991703,0.00001146834,0.0000046380314,0.000015016134,0.000021329126,0.000030456851],"domain_scores_gemma":[0.9999503,0.00000824984,0.000014787771,0.0000065551217,0.000004992703,0.000015158359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009519054,0.00017934763,0.000116014446,0.00016783267,0.000100473895,0.00027339984,0.000077216544,0.00013268023,0.0010885182],"category_scores_gemma":[0.00007029541,0.00006272515,0.0000818059,0.00008813014,0.00020969508,0.000120058605,0.00012530704,0.00031313783,0.00020207527],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057748402,0.000011753163,0.0004990564,0.00000893662,0.0000020049577,0.000030483234,0.000005282763,0.000026384638,0.9984609,0.00009610183,0.000025867454,0.0007754341],"study_design_scores_gemma":[0.00002830212,0.00030104746,0.010668663,0.0000036655838,0.00001577612,0.0005480775,0.000027795128,0.0008312528,0.9855735,0.00011495222,0.0018843581,0.0000026832463],"about_ca_topic_score_codex":0.00018940851,"about_ca_topic_score_gemma":0.00042206046,"teacher_disagreement_score":0.0010885182,"about_ca_system_score_codex":0.00016187238,"about_ca_system_score_gemma":0.00011812087,"threshold_uncertainty_score":0.0036414862},"labels":[],"label_agreement":null},{"id":"W2135995176","doi":"10.1200/jop.2011.000315","title":"Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?","year":2011,"lang":"en","type":"article","venue":"Journal of Oncology Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; University Health Network; University of Toronto; St. Joseph’s Healthcare Hamilton; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Targeted therapy; MEDLINE; Cancer; Internal medicine","score_opus":0.2166946998944679,"score_gpt":0.5339195624607045,"score_spread":0.3172248625662366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135995176","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023416698,0.6453698,0.06045517,0.22241904,0.005858236,0.0013905696,0.0049690334,0.00025987744,0.03586152],"genre_scores_gemma":[0.6049054,0.26888913,0.07293565,0.040970106,0.005425363,0.0033680256,0.0019721254,0.0002928683,0.001241281],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.5845882,0.34317973,0.032541018,0.0064958297,0.030820088,0.002375046],"domain_scores_gemma":[0.18337768,0.7468904,0.033496294,0.011490668,0.023730027,0.0010149326],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.26584652,0.00204937,0.0061376095,0.008959438,0.001032871,0.015709694,0.0038539057,0.0066324994,0.00653872],"category_scores_gemma":[0.7599527,0.0018621881,0.0050294856,0.009803237,0.004949317,0.021638235,0.0039187376,0.0071255905,0.0014569549],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024652868,0.00023209096,0.010981629,0.11851448,0.011196727,0.0003592303,0.0031099452,0.011483794,0.0002856415,0.08924402,0.04706272,0.70506454],"study_design_scores_gemma":[0.0017930833,0.0006145476,0.011717326,0.4370842,0.0098126335,0.00064239604,0.0041058455,0.013822866,0.0017350924,0.36211982,0.15599516,0.0005570774],"about_ca_topic_score_codex":0.002688204,"about_ca_topic_score_gemma":0.0033852935,"teacher_disagreement_score":0.26584652,"about_ca_system_score_codex":0.008585319,"about_ca_system_score_gemma":0.010855557,"threshold_uncertainty_score":0.9053419},"labels":[],"label_agreement":null},{"id":"W2136094622","doi":"10.1111/j.1464-410x.2007.06992.x","title":"Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer","year":2007,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Université de Montréal; Sanofi","keywords":"Biochemical recurrence; Prostate cancer; Proportional hazards model; Medicine; breakpoint cluster region; Oncology; Prostatectomy; Urology; Internal medicine; Univariate analysis; Cancer; Multivariate analysis; Receptor","score_opus":0.011159341666500316,"score_gpt":0.2947671631631771,"score_spread":0.28360782149667674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136094622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986265,0.0008719906,0.00009011054,0.00005669569,0.000006968852,0.0000023415685,0.00006810599,0.000004652747,0.00027264873],"genre_scores_gemma":[0.99972457,0.000079525256,0.000040560044,0.000009174069,0.0000072573416,0.0000013201459,0.00006202429,7.163244e-7,0.00007482964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998522,0.00004726436,0.000012910443,0.000022290189,0.0000365401,0.000028761044],"domain_scores_gemma":[0.99916863,0.00023522315,0.00033695414,0.000026761976,0.00007539443,0.00015707692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003891755,0.00022697885,0.0002375945,0.00033975707,0.00021442356,0.00033899528,0.00020086124,0.0004274293,0.0017191276],"category_scores_gemma":[0.0018121412,0.00012524695,0.00023079832,0.0004298474,0.0002501238,0.00022873077,0.00023285927,0.00041785953,0.0002272465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020214202,0.000015370022,0.9978188,0.000014649027,0.000024426634,0.00006648198,0.000019637067,0.00005782812,0.00032842226,0.000005990978,0.00005403267,0.0013922243],"study_design_scores_gemma":[0.000009654175,0.00011484243,0.9986205,0.0000051501897,0.000036329275,0.0007115525,0.000047625635,0.0002371455,0.00008756654,0.000015767891,0.00011111119,0.0000028174861],"about_ca_topic_score_codex":0.0021296295,"about_ca_topic_score_gemma":0.0031735383,"teacher_disagreement_score":0.0021296295,"about_ca_system_score_codex":0.00015144545,"about_ca_system_score_gemma":0.00024192334,"threshold_uncertainty_score":0.0057510138},"labels":[],"label_agreement":null},{"id":"W2136765170","doi":"10.1186/2193-1801-3-236","title":"Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis","year":2014,"lang":"en","type":"article","venue":"SpringerPlus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab; Discontinuation; Hazard ratio; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Proportional hazards model; Cancer; Confidence interval","score_opus":0.07301305932988728,"score_gpt":0.417565083098142,"score_spread":0.3445520237682547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136765170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99859446,0.00044489157,0.00008632607,0.000018942861,0.0000024665126,0.000012278814,0.00063205016,0.0000014431178,0.00020701103],"genre_scores_gemma":[0.99870205,0.00023389091,0.00007613579,0.000016652239,0.000006747383,0.000016407175,0.0009048176,0.0000020446723,0.000041187417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983531,0.0005150476,0.00038565975,0.00029640002,0.0002841286,0.0001657617],"domain_scores_gemma":[0.9955433,0.00093255704,0.0025358824,0.00028622043,0.00038167855,0.00032039458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016025474,0.00021481584,0.0005523004,0.0017185581,0.00027234177,0.00076101825,0.0003951813,0.00032991552,0.00070488406],"category_scores_gemma":[0.0046577686,0.0003064744,0.0010920095,0.003109848,0.00025496387,0.0005071855,0.00049680914,0.00039993855,0.00013438861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016586867,0.00001593619,0.99898106,0.000009226932,0.00014525343,0.000033515767,0.00001954443,0.000047775775,0.000021480653,0.000010672107,0.000038559087,0.00051110954],"study_design_scores_gemma":[0.0000124061535,0.00010898198,0.99891305,0.000008268647,0.000084048406,0.00024637443,0.000106045,0.00032460756,0.000037100363,0.000018454852,0.00013602804,0.0000046213004],"about_ca_topic_score_codex":0.0045756274,"about_ca_topic_score_gemma":0.0035574737,"teacher_disagreement_score":0.0045756274,"about_ca_system_score_codex":0.00062164606,"about_ca_system_score_gemma":0.00044016066,"threshold_uncertainty_score":0.009097993},"labels":[],"label_agreement":null},{"id":"W2137204308","doi":"10.1128/mcb.00034-09","title":"Tyrosine Phosphorylation of Grb2: Role in Prolactin/Epidermal Growth Factor Cross Talk in Mammary Epithelial Cell Growth and Differentiation","year":2009,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; McGill University Health Centre; McGill University","keywords":"Biology; GRB2; Epidermal growth factor; Cell biology; MAPK/ERK pathway; Tyrosine phosphorylation; Phosphorylation; Cell growth; Growth factor; Signal transduction; Cellular differentiation; Anti-apoptotic Ras signalling cascade; Tyrosine kinase; Cancer research; Receptor; Biochemistry","score_opus":0.009672646828723545,"score_gpt":0.2723362416139576,"score_spread":0.26266359478523404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137204308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096256,0.0060332585,0.0014825702,0.00016474973,0.000022702603,0.000010246772,0.00006470226,0.000037842132,0.0012213713],"genre_scores_gemma":[0.99719054,0.0011367075,0.0006801181,0.000041738025,0.000011204716,0.0000083170435,0.00010468919,0.0000041605463,0.0008226185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998568,0.000029878129,0.000012239213,0.00002199697,0.000037285703,0.000041739575],"domain_scores_gemma":[0.99993837,0.00001153455,0.0000190566,0.00000704574,0.000005721327,0.000018309382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023318299,0.0004602785,0.00020373773,0.00023583813,0.0001834227,0.00038300344,0.0002117573,0.00031751455,0.0010410601],"category_scores_gemma":[0.00012716012,0.000136501,0.00019576447,0.00016872675,0.00023621442,0.00030876283,0.00027556927,0.0004687195,0.00026489998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038069155,0.000065276945,0.0011131573,0.00009438975,0.00001476159,0.00029935729,0.000021361633,0.00017575598,0.993335,0.00037186613,0.00005834532,0.0040698946],"study_design_scores_gemma":[0.00009823889,0.00048191083,0.029345365,0.000019598654,0.00006278535,0.0026600044,0.00007314663,0.0031275703,0.96031785,0.0003705652,0.0034297542,0.000013240565],"about_ca_topic_score_codex":0.00022797612,"about_ca_topic_score_gemma":0.0003782232,"teacher_disagreement_score":0.0010410601,"about_ca_system_score_codex":0.00027068914,"about_ca_system_score_gemma":0.0001524043,"threshold_uncertainty_score":0.0034826994},"labels":[],"label_agreement":null},{"id":"W2138282377","doi":"10.1242/dev.01425","title":"Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development","year":2004,"lang":"en","type":"article","venue":"Development","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Biology; Mutant; Allele; Receptor; Cell biology; Signal transduction; Gene knockin; Knockout mouse; Null allele; Genetics; Gene","score_opus":0.2179819336539109,"score_gpt":0.3744139215533196,"score_spread":0.1564319878994087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138282377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913079,0.0011648772,0.005178012,0.00011360631,0.000014956777,0.000028902175,0.00036273463,0.00009072302,0.0017382187],"genre_scores_gemma":[0.99221367,0.0007504567,0.0044077504,0.00005078103,0.000005196804,0.000049442027,0.0003389671,0.00003465622,0.002149084],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987614,0.000014709319,0.0000127619205,0.000024366367,0.000039463594,0.00003259352],"domain_scores_gemma":[0.9998443,0.000032227246,0.000041553176,0.000018054343,0.000014495954,0.000049270566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014490217,0.0003256543,0.00029065536,0.00018777164,0.00017857055,0.00038043957,0.00024001686,0.00031213963,0.0016049157],"category_scores_gemma":[0.00015840676,0.00019772668,0.00016619053,0.00011964785,0.00025967715,0.00034266515,0.00027743488,0.00080490735,0.0003934437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027420238,0.0000056677272,0.00013572974,0.00001011826,6.2011003e-7,0.000022679451,0.0000032859177,0.000021768617,0.99936074,0.000047416615,0.0000068074887,0.0003578467],"study_design_scores_gemma":[0.000009572974,0.000121083285,0.005729148,0.000004497224,0.00000653529,0.00022794714,0.00001567929,0.0003845418,0.99244857,0.00004330376,0.0010059954,0.0000031819793],"about_ca_topic_score_codex":0.00042244425,"about_ca_topic_score_gemma":0.0008876235,"teacher_disagreement_score":0.0016049157,"about_ca_system_score_codex":0.00037422116,"about_ca_system_score_gemma":0.00023062235,"threshold_uncertainty_score":0.005368948},"labels":[],"label_agreement":null},{"id":"W2138501761","doi":"10.1158/1078-0432.ccr-03-0463","title":"Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Metastatic breast cancer; Celecoxib; Breast cancer; Internal medicine; Oncology; Regimen; Rash; Cancer","score_opus":0.1846703249882754,"score_gpt":0.5588671635938909,"score_spread":0.3741968386056155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138501761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918001,0.00173686,0.0005738836,0.00044465755,0.00015601715,0.0035036718,0.00047237225,0.000054043077,0.0012583596],"genre_scores_gemma":[0.9847178,0.0017832905,0.0016608761,0.0011091753,0.00033592063,0.0055577657,0.001889414,0.000024544868,0.0029212025],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99933773,0.0003265094,0.000031498912,0.000086216496,0.00006876873,0.00014935624],"domain_scores_gemma":[0.9990947,0.000119630255,0.000121666744,0.0000770354,0.000066769935,0.00052003976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018503317,0.0015722092,0.0027367065,0.00047388414,0.00059626286,0.0010083517,0.0009174992,0.0016116981,0.0029969793],"category_scores_gemma":[0.0011394786,0.00072695327,0.00114626,0.0004388378,0.00101457,0.0007055488,0.0004032512,0.0037518512,0.0008065846],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6458616,0.19557829,0.01322802,0.00061231246,0.0012399121,0.0005832939,0.00036078217,0.002534293,0.05418788,0.000310719,0.0033772856,0.08212563],"study_design_scores_gemma":[0.5009121,0.48237613,0.00961347,0.00002364902,0.0002286933,0.00028411538,0.00004333502,0.001015133,0.0032290134,0.00009636601,0.002161869,0.000016160038],"about_ca_topic_score_codex":0.00084486295,"about_ca_topic_score_gemma":0.001762394,"teacher_disagreement_score":0.0029969793,"about_ca_system_score_codex":0.0007959536,"about_ca_system_score_gemma":0.0018923716,"threshold_uncertainty_score":0.0100259185},"labels":[],"label_agreement":null},{"id":"W2138694026","doi":"10.1309/vp4w-5c55-7m09-6tx3","title":"Comparison of HER2/<i>neu</i>Status Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry","year":2001,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Immunohistochemistry; Concordance; Polymerase chain reaction; Medicine; Pathology; Real-time polymerase chain reaction; Biology; Molecular biology; Internal medicine; Gene; Genetics","score_opus":0.10119660765092921,"score_gpt":0.5448628036480689,"score_spread":0.44366619599713975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138694026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624336,0.0006694286,0.0022485368,0.00001584264,0.000004437857,0.000032845095,0.00016610665,0.000024588531,0.0005948865],"genre_scores_gemma":[0.99760854,0.00015570858,0.001531552,0.000018568826,0.0000056839267,0.000057927366,0.00026731446,0.000009899463,0.0003448137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998987,0.00029240578,0.00008683595,0.00019495895,0.00030848235,0.00013033868],"domain_scores_gemma":[0.99788946,0.0011320423,0.0003770012,0.00017293524,0.00035095468,0.00007769761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016655927,0.00022436182,0.00032105923,0.0007800099,0.00015581453,0.0004212987,0.0001900395,0.00020513829,0.0010432797],"category_scores_gemma":[0.00326664,0.00022538388,0.00015381137,0.00030518186,0.0004461095,0.00024579305,0.00014701119,0.00020085051,0.00025507231],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026313926,0.0002554564,0.76451737,0.00010443236,0.00014134859,0.00080325943,0.00042979966,0.00065637607,0.20568873,0.00018392605,0.00023012584,0.024357796],"study_design_scores_gemma":[0.000113287766,0.002800528,0.85717255,0.00001996397,0.00015104681,0.0047549373,0.00029448222,0.004377478,0.12779713,0.0002230389,0.002257694,0.000037806785],"about_ca_topic_score_codex":0.0007594628,"about_ca_topic_score_gemma":0.00062140793,"teacher_disagreement_score":0.0016655927,"about_ca_system_score_codex":0.00035240233,"about_ca_system_score_gemma":0.00014587425,"threshold_uncertainty_score":0.008808613},"labels":[],"label_agreement":null},{"id":"W2139479159","doi":"10.1186/1746-1596-2-8","title":"Quantitative image analysis of immunohistochemical stains using a CMYK color model","year":2007,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Magenta; H&E stain; Hue; RGB color model; Immunohistochemistry; Cyan; Artificial intelligence; Pathology; Computer science; Medicine; Physics","score_opus":0.07958119339257745,"score_gpt":0.45928764611825873,"score_spread":0.37970645272568126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139479159","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043357123,0.00029651076,0.9475483,0.00010914411,0.00009151296,0.00049005105,0.0008212856,0.005062415,0.0022236889],"genre_scores_gemma":[0.111037426,0.0003942813,0.88274676,0.000060733786,0.000023152588,0.0016696728,0.0009044675,0.0012227003,0.0019408343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99712497,0.0007862357,0.0003237235,0.0005259534,0.0010798175,0.00015937656],"domain_scores_gemma":[0.9951147,0.002178902,0.0007645399,0.0005231433,0.001302894,0.00011587041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004205911,0.0013760731,0.0006435329,0.0037162213,0.00042963747,0.001656977,0.0012416875,0.0006894722,0.0120119555],"category_scores_gemma":[0.005307181,0.00055697444,0.0011810609,0.0023536372,0.0009958821,0.0015011238,0.00079627836,0.0012094992,0.0028216506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001333795,0.0003129939,0.010130839,0.0022640384,0.0002911054,0.00024844226,0.00058891677,0.015753575,0.7598113,0.010229565,0.0060995976,0.19293591],"study_design_scores_gemma":[0.000091963986,0.000668091,0.033811443,0.00021059297,0.0002526246,0.001698914,0.00029970944,0.35502273,0.5781232,0.004415808,0.025139613,0.0002652831],"about_ca_topic_score_codex":0.0012227509,"about_ca_topic_score_gemma":0.0018278518,"teacher_disagreement_score":0.0120119555,"about_ca_system_score_codex":0.0014348507,"about_ca_system_score_gemma":0.0011757436,"threshold_uncertainty_score":0.04018396},"labels":[],"label_agreement":null},{"id":"W2140055441","doi":"10.1200/jco.2008.20.6847","title":"Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"F. Hoffmann-La Roche; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Anastrozole; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Hazard ratio; Oncology; Breast cancer; Aromatase inhibitor; Gynecology; Cancer; Tamoxifen; Confidence interval","score_opus":0.11580627615224622,"score_gpt":0.47668609962928,"score_spread":0.3608798234770338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140055441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926042,0.0043612625,0.0002917815,0.00046191263,0.00027731876,0.0006853466,0.0004237318,0.00004437041,0.0008500769],"genre_scores_gemma":[0.992008,0.0029763116,0.0008936708,0.0007247285,0.00039524594,0.0008696443,0.0007243585,0.000014979791,0.0013931823],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994779,0.00033432065,0.00003107004,0.00005809145,0.000045883837,0.000052741707],"domain_scores_gemma":[0.9992142,0.00024631972,0.00020994149,0.000048536724,0.000039124854,0.00024187287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018393664,0.0010064533,0.0020093904,0.0003585457,0.00020182248,0.00074298,0.00056981394,0.0009476272,0.0025674321],"category_scores_gemma":[0.0016220926,0.00045033792,0.0016116021,0.00032551278,0.00061890215,0.0007335606,0.00027277027,0.0018452967,0.00044121043],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.969017,0.0046928227,0.0009208847,0.00022870739,0.0010797939,0.000023127877,0.000034250195,0.00044854108,0.0030584007,0.000053128133,0.00063955266,0.019803667],"study_design_scores_gemma":[0.8267493,0.16511655,0.0042320737,0.000039464026,0.0013349903,0.000059272978,0.000025331463,0.0007587024,0.00076840055,0.00016075598,0.0007412158,0.000013963093],"about_ca_topic_score_codex":0.0006622195,"about_ca_topic_score_gemma":0.002029365,"teacher_disagreement_score":0.0025674321,"about_ca_system_score_codex":0.00069217023,"about_ca_system_score_gemma":0.0009386999,"threshold_uncertainty_score":0.009727657},"labels":[],"label_agreement":null},{"id":"W2140243420","doi":"10.1128/mcb.22.13.4714-4722.2002","title":"ErbB2 Is Required for Muscle Spindle and Myoblast Cell Survival","year":2002,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Lunenfeld-Tanenbaum Research Institute","funders":"Medical Research Council","keywords":"Biology; Myocyte; Regeneration (biology); Cell biology; Skeletal muscle; Anatomy","score_opus":0.04059659643877128,"score_gpt":0.30595585026725386,"score_spread":0.2653592538284826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140243420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930709,0.0019483818,0.0015683841,0.00010120211,0.000021907183,0.000009030752,0.0005412806,0.00012396243,0.0026148837],"genre_scores_gemma":[0.992987,0.0006576563,0.0008623579,0.00003127365,0.0000062061554,0.000011011174,0.0008083279,0.000024197005,0.0046120407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985576,0.000014270085,0.000013001415,0.000025352205,0.000053220258,0.000038381728],"domain_scores_gemma":[0.9998754,0.000010657709,0.000038342056,0.000013455042,0.00001738537,0.00004466702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110835645,0.00024430407,0.00022582356,0.00021964134,0.0001954938,0.00031510086,0.00014479678,0.0002615519,0.0017797651],"category_scores_gemma":[0.00014139248,0.00018459685,0.000146057,0.000130697,0.00014003717,0.00014818663,0.00023539716,0.00023666077,0.0008509856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066898414,0.000009177444,0.00056716515,0.000022616023,0.0000034240402,0.00016847844,0.000008318311,0.000037807622,0.9979849,0.00008022031,0.000057571393,0.0009934925],"study_design_scores_gemma":[0.000051686835,0.00027049414,0.066742614,0.00001568473,0.000028291568,0.0030929327,0.00012193115,0.0017070896,0.91753656,0.00014728702,0.010275028,0.00001030231],"about_ca_topic_score_codex":0.0010918758,"about_ca_topic_score_gemma":0.002387501,"teacher_disagreement_score":0.0017797651,"about_ca_system_score_codex":0.00025384253,"about_ca_system_score_gemma":0.00020036526,"threshold_uncertainty_score":0.005953908},"labels":[],"label_agreement":null},{"id":"W2140405230","doi":"10.1002/mc.20766","title":"Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells","year":2011,"lang":"en","type":"article","venue":"Molecular Carcinogenesis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Urological Oncology Group","keywords":"Biology; ERBB3; Prostate cancer; Cancer; Cancer research; Cell biology; Prostate; Cancer cell; Pinocytosis; Endocytosis; Cell; Signal transduction; Genetics","score_opus":0.028259815987639977,"score_gpt":0.27550411101191624,"score_spread":0.24724429502427625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140405230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98768497,0.005244459,0.0021926877,0.0002093816,0.00005214277,0.00003774982,0.0005382816,0.00025711991,0.003783169],"genre_scores_gemma":[0.994189,0.0016700585,0.0009834237,0.00007840851,0.000011240485,0.000039916213,0.00048829097,0.000029056284,0.0025105358],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998965,0.000016054433,0.0000072683983,0.000013864211,0.000031141237,0.000035205132],"domain_scores_gemma":[0.999925,0.000017932229,0.000017784283,0.000008487356,0.000011399407,0.000019393376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010563829,0.00024225202,0.00033846084,0.00019552231,0.0002218771,0.00042873024,0.00020186423,0.00021067605,0.0013456078],"category_scores_gemma":[0.00010712133,0.00013047585,0.00033161958,0.00016239741,0.00018140391,0.00017121267,0.00022617758,0.00045801417,0.00057578273],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038436084,0.00009576512,0.00018630992,0.000056408495,0.000008681491,0.000067331,0.00002754752,0.00012508292,0.99626344,0.0002367135,0.00018611884,0.0023622348],"study_design_scores_gemma":[0.00003581895,0.0003795372,0.005212477,0.0000052823434,0.000015629199,0.00022188514,0.000044610402,0.0019584638,0.98810697,0.00007451469,0.0039377995,0.0000069949783],"about_ca_topic_score_codex":0.0012306331,"about_ca_topic_score_gemma":0.0018275072,"teacher_disagreement_score":0.0013456078,"about_ca_system_score_codex":0.00033439748,"about_ca_system_score_gemma":0.00027290345,"threshold_uncertainty_score":0.0045015216},"labels":[],"label_agreement":null},{"id":"W2140841327","doi":"10.1158/0008-5472.can-08-4766","title":"Src Stimulates Fibroblast Growth Factor Receptor-2 Shedding by an ADAM15 Splice Variant Linked to Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Biotechnology and Biological Sciences Research Council; University of California, San Francisco; Wellcome Trust","keywords":"Proto-oncogene tyrosine-protein kinase Src; Cancer research; Biology; Breast cancer; Cancer; Src family kinase; splice; Cell biology; Kinase; Biochemistry; Gene; Genetics","score_opus":0.08792739972269824,"score_gpt":0.4507606643172731,"score_spread":0.3628332645945748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140841327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986552,0.00037754496,0.0002132157,0.000086750086,0.000023264229,0.0000081281605,0.00008355366,0.000012874933,0.0005394949],"genre_scores_gemma":[0.9982613,0.00028310873,0.00037806915,0.000049976905,0.000013255689,0.000010830292,0.00032682158,0.000008020468,0.0006687493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998029,0.00006061138,0.000019328529,0.000017021763,0.000051267525,0.000048933623],"domain_scores_gemma":[0.9998878,0.000032895405,0.000020734153,0.000018633733,0.000008315341,0.0000315829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022146346,0.00024137611,0.0002430247,0.00013397943,0.00012424396,0.0002545012,0.00012472578,0.00025744102,0.0017109523],"category_scores_gemma":[0.0002664113,0.00013063508,0.00030294133,0.000109926346,0.00018996812,0.000096942385,0.00020816037,0.00048993324,0.00055035535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034723995,0.000104630686,0.00057744345,0.000023273637,0.000010321558,0.00032870565,0.000015894233,0.00005859066,0.9971866,0.0001027165,0.00014991342,0.0010947142],"study_design_scores_gemma":[0.00016127952,0.0012035163,0.017285837,0.000010150922,0.000029132474,0.0046454263,0.00007323044,0.002697306,0.9702523,0.00018101283,0.003449777,0.000011088771],"about_ca_topic_score_codex":0.0003963552,"about_ca_topic_score_gemma":0.0006255804,"teacher_disagreement_score":0.0017109523,"about_ca_system_score_codex":0.00022002155,"about_ca_system_score_gemma":0.0001227077,"threshold_uncertainty_score":0.005723715},"labels":[],"label_agreement":null},{"id":"W2140914212","doi":"10.5966/sctm.2011-0016","title":"Functional Impairment of Human Resident Cardiac Stem Cells by the Cardiotoxic Antineoplastic Agent Trastuzumab","year":2012,"lang":"en","type":"article","venue":"Stem Cells Translational Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Heart Rhythm Society; Canadian Institutes of Health Research; National Institutes of Health; Deutsche Forschungsgemeinschaft; National Heart, Lung, and Blood Institute; Heart and Stroke Foundation of Canada","keywords":"Cardiotoxicity; In vivo; Stem cell; In vitro; Apoptosis; Trastuzumab; Medicine; Pharmacology; Ejection fraction; Cancer research; Internal medicine; Cancer; Chemotherapy; Cell biology; Heart failure; Biology; Breast cancer; Biotechnology; Biochemistry","score_opus":0.04812689393510634,"score_gpt":0.3156046184696444,"score_spread":0.26747772453453805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140914212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996831,0.0010554418,0.0009908497,0.00003708969,0.000011547321,0.000020756219,0.0001861503,0.00002681013,0.00084032957],"genre_scores_gemma":[0.9980868,0.00053356035,0.0003918521,0.000029806839,0.000004121733,0.000024347872,0.00027619622,0.000003945153,0.00064932276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989784,0.00001896726,0.00001125489,0.000015241406,0.000030495095,0.000026254116],"domain_scores_gemma":[0.99996233,0.000008669707,0.000008876767,0.000007279546,0.000005615528,0.0000073216056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012500951,0.00022496675,0.0001855312,0.00011146841,0.00007912537,0.00018194663,0.00009015143,0.00013349242,0.00081760355],"category_scores_gemma":[0.0000909068,0.00007564456,0.00014064148,0.00007219594,0.0001070961,0.00009292804,0.000103430924,0.00029572865,0.00018451325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104868304,0.000053488544,0.0003353375,0.000031403593,0.000005609901,0.000042604097,0.00002083282,0.000119755256,0.99694663,0.00006129195,0.000042520274,0.0022357358],"study_design_scores_gemma":[0.000036451704,0.0010861913,0.010972831,0.000007638783,0.000024021841,0.00031583,0.000046142417,0.0012716381,0.9836838,0.000030356377,0.0025219205,0.00000312507],"about_ca_topic_score_codex":0.000498243,"about_ca_topic_score_gemma":0.0005655821,"teacher_disagreement_score":0.00081760355,"about_ca_system_score_codex":0.00015414113,"about_ca_system_score_gemma":0.00012503575,"threshold_uncertainty_score":0.002735138},"labels":[],"label_agreement":null},{"id":"W2141506913","doi":"10.1586/14737167.8.5.433","title":"Is trastuzumab a cost-effective treatment for breast cancer?","year":2008,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Cost effectiveness; Internal medicine; Cancer; Intensive care medicine; Risk analysis (engineering)","score_opus":0.14571005024597344,"score_gpt":0.6090204262930101,"score_spread":0.4633103760470367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141506913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045775026,0.5414797,0.0017113999,0.43109336,0.003921287,0.00003017086,0.00020100438,0.000024031564,0.016961481],"genre_scores_gemma":[0.118444964,0.7720255,0.0024454661,0.08496517,0.015391257,0.00008299932,0.0002052927,0.00003379803,0.0064055305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738246,0.0010664475,0.00014656922,0.00017160566,0.0010843972,0.00014846942],"domain_scores_gemma":[0.99313873,0.0043654423,0.0008517888,0.00014709444,0.0011928937,0.00030397257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003972368,0.00039528357,0.0013986443,0.0011741483,0.00031896235,0.002994813,0.0007200632,0.0029365988,0.009914077],"category_scores_gemma":[0.021267317,0.00018319723,0.0005881083,0.0017208741,0.0014895244,0.0029668405,0.00045016772,0.0022888146,0.001546382],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009063222,0.00017936445,0.0030321449,0.0038147238,0.0006561229,0.0005061557,0.000092831106,0.001246857,0.0009159734,0.057952426,0.14558718,0.7851099],"study_design_scores_gemma":[0.0006746868,0.0006182843,0.011245055,0.00971702,0.0009908075,0.002285128,0.00066448847,0.0016992678,0.0010167469,0.12865552,0.84232384,0.00010911627],"about_ca_topic_score_codex":0.0024405315,"about_ca_topic_score_gemma":0.0022206954,"teacher_disagreement_score":0.009914077,"about_ca_system_score_codex":0.0026134667,"about_ca_system_score_gemma":0.0019862584,"threshold_uncertainty_score":0.033165872},"labels":[],"label_agreement":null},{"id":"W2141917836","doi":"10.2967/jnumed.106.037937","title":"111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Connaught Fund; Cancer Research UK; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Trastuzumab; HER2/neu; NLS; Breast cancer; Cancer research; Medicine; Chemistry; Nuclear localization sequence; Oncology; Cancer; Internal medicine; Gene","score_opus":0.05070695068423739,"score_gpt":0.38856828936995635,"score_spread":0.337861338685719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141917836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904208,0.0026327197,0.0048788167,0.00010277807,0.000021472422,0.000031714393,0.00007739872,0.00006760565,0.0017666904],"genre_scores_gemma":[0.99040234,0.0014444416,0.0052469103,0.0000523829,0.000014413737,0.00002447773,0.00025835406,0.000015543508,0.0025410682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989164,0.000025901507,0.000006101716,0.00002114098,0.00003118992,0.00002397054],"domain_scores_gemma":[0.9999281,0.0000136780145,0.000025825593,0.000008031456,0.000012763849,0.000011495754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016317178,0.0003311176,0.00022455635,0.000114825794,0.00007733032,0.00018924623,0.00023969372,0.000355772,0.0006464919],"category_scores_gemma":[0.00014195933,0.000106472624,0.000107473905,0.00013779542,0.00022666442,0.00016588766,0.00016738758,0.00016948636,0.00021702421],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103670835,0.000014219389,0.00025381136,0.000048111928,0.000002943533,0.0000391845,0.000007101587,0.0001357179,0.9981725,0.00006625442,0.000030935207,0.0011254515],"study_design_scores_gemma":[0.000023320967,0.00026749313,0.0017607182,0.00000541269,0.000012096243,0.00041697067,0.000008192208,0.00071501295,0.99459684,0.000014607004,0.002176068,0.000003117678],"about_ca_topic_score_codex":0.0003369292,"about_ca_topic_score_gemma":0.00042466112,"teacher_disagreement_score":0.0006464919,"about_ca_system_score_codex":0.00040751658,"about_ca_system_score_gemma":0.00018407482,"threshold_uncertainty_score":0.002956748},"labels":[],"label_agreement":null},{"id":"W2142716729","doi":"10.1007/s12253-015-9927-6","title":"Computer Aided Semi-Automated Evaluation of HER2 Immunodetection—A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy","year":2015,"lang":"en","type":"article","venue":"Pathology & Oncology Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Kappa; Tissue microarray; Medicine; Immunohistochemistry; Immunostaining; Quality assurance; Pathology; Medical physics; Mathematics; External quality assessment","score_opus":0.41795412429575285,"score_gpt":0.5636507555172239,"score_spread":0.14569663122147103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142716729","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.095491536,0.001118898,0.8876646,0.00018260964,0.000095835625,0.00017662409,0.001012833,0.011504598,0.002752522],"genre_scores_gemma":[0.48785987,0.00055544474,0.5054928,0.00029179006,0.000068499554,0.00018183069,0.0013474369,0.0005531906,0.0036491277],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99897563,0.0002464371,0.00007816991,0.00020483085,0.0004226277,0.00007241617],"domain_scores_gemma":[0.9974956,0.00096263294,0.00022709375,0.00031699368,0.0009337319,0.0000639164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012721458,0.0008320989,0.00095315155,0.0017010366,0.00031078054,0.0012805455,0.0011499582,0.0009810574,0.0028177854],"category_scores_gemma":[0.002904026,0.0004915136,0.00044568084,0.0007267015,0.00030731206,0.0004944413,0.00085296156,0.000552088,0.0018522243],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012982622,0.00021759087,0.011671859,0.0005657469,0.00018512332,0.00035739734,0.00017806533,0.024536816,0.32632846,0.0012186917,0.009151868,0.62429017],"study_design_scores_gemma":[0.000049780854,0.00027850087,0.018858662,0.00005906342,0.00011344476,0.0009889541,0.00011807283,0.7489109,0.21904375,0.0018406399,0.009633884,0.000104320214],"about_ca_topic_score_codex":0.002444247,"about_ca_topic_score_gemma":0.004318945,"teacher_disagreement_score":0.0028177854,"about_ca_system_score_codex":0.00031448173,"about_ca_system_score_gemma":0.0008314715,"threshold_uncertainty_score":0.009426415},"labels":[],"label_agreement":null},{"id":"W2143564454","doi":"10.18632/oncotarget.4405","title":"Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration","year":2015,"lang":"en","type":"article","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; Fondazione Pezcoller; Associazione Italiana per la Ricerca sul Cancro; Cancer Research UK","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Metastatic breast cancer; Cancer","score_opus":0.025957806823524852,"score_gpt":0.31786258972631415,"score_spread":0.2919047829027893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143564454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845866,0.0045931935,0.0031439532,0.00022256873,0.00005110252,0.000020056896,0.0058705327,0.0001314119,0.0013805979],"genre_scores_gemma":[0.9843664,0.0020432035,0.0018833852,0.0002644429,0.000043475433,0.00004935935,0.009621867,0.00009484812,0.0016330839],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997228,0.00003124401,0.000014477282,0.00010688881,0.000061057755,0.00006365408],"domain_scores_gemma":[0.99980396,0.00006234943,0.000052573123,0.000024051074,0.000032231874,0.000024962172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002127796,0.00023643454,0.0005776445,0.00040553938,0.0002395692,0.00093905185,0.00012903493,0.00032690042,0.0015104925],"category_scores_gemma":[0.00040591008,0.0001729727,0.00048080727,0.00047584888,0.00016824206,0.0002681922,0.00048017706,0.0005346523,0.0006297424],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071605336,0.00007702132,0.0462718,0.00026783766,0.0002141147,0.00016662932,0.00016981762,0.00067711994,0.9296583,0.00015183062,0.0014090068,0.020220477],"study_design_scores_gemma":[0.000042822074,0.00048512965,0.89838797,0.00008228878,0.0004045908,0.0011150349,0.0005613628,0.009925905,0.07670517,0.00080310035,0.01144029,0.000046209152],"about_ca_topic_score_codex":0.00061308144,"about_ca_topic_score_gemma":0.00081361196,"teacher_disagreement_score":0.0015104925,"about_ca_system_score_codex":0.0002321862,"about_ca_system_score_gemma":0.00018760163,"threshold_uncertainty_score":0.005053103},"labels":[],"label_agreement":null},{"id":"W2143666642","doi":"10.1517/14740338.2011.533168","title":"Lapatinib for breast cancer: a review of the current literature","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Drug Safety","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lapatinib; Medicine; Breast cancer; Trastuzumab; Cancer; Oncology; Metastatic breast cancer; Internal medicine; Tyrosine-kinase inhibitor; Disease","score_opus":0.0746250945156274,"score_gpt":0.4797467624904513,"score_spread":0.40512166797482385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143666642","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004688298,0.9993419,0.000026310332,0.00018655727,0.000109169945,0.0000037298873,0.000012599096,0.0000025932147,0.00027022787],"genre_scores_gemma":[0.00026749127,0.9992638,0.000069782334,0.00016967372,0.00009482101,0.0000053687486,0.000013818924,5.9968824e-7,0.000114723465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99960965,0.000076970726,0.0000894364,0.00005480281,0.00014698156,0.000022141621],"domain_scores_gemma":[0.9992163,0.00041333513,0.00014577436,0.000013308873,0.00016855929,0.00004261948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008841311,0.0009741227,0.0020137106,0.003532989,0.00029678075,0.0010477608,0.0010776228,0.0011532838,0.004637272],"category_scores_gemma":[0.0015643887,0.00031850688,0.00088405574,0.005348185,0.00035061556,0.00147843,0.00048733634,0.00115715,0.0015744736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010432686,0.00005856059,0.00026594268,0.10436321,0.00026206239,0.00033321136,0.00012517981,0.0002494693,0.0007621682,0.0010368704,0.053662807,0.83877623],"study_design_scores_gemma":[0.00005819167,0.00026737497,0.0024809933,0.06302494,0.0009868413,0.0030065218,0.00022354892,0.00013437076,0.00029900146,0.0014111343,0.92806643,0.00004068869],"about_ca_topic_score_codex":0.0017662336,"about_ca_topic_score_gemma":0.0031562857,"teacher_disagreement_score":0.004637272,"about_ca_system_score_codex":0.00082525046,"about_ca_system_score_gemma":0.0017800608,"threshold_uncertainty_score":0.015513241},"labels":[],"label_agreement":null},{"id":"W2143681410","doi":"10.1038/bjc.2011.516","title":"Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer","year":2012,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Terry Fox Foundation; Boehringer Ingelheim","keywords":"Trastuzumab; Lapatinib; Medicine; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Bevacizumab; Adjuvant; Cancer; Cancer research; Chemotherapy","score_opus":0.0989027358661728,"score_gpt":0.4448493664120509,"score_spread":0.3459466305458781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143681410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013477058,0.9990404,0.00006058035,0.0001503922,0.000077252946,0.0000031814052,0.0000069296425,0.0000034129378,0.0005230767],"genre_scores_gemma":[0.0008155997,0.9983589,0.00010286619,0.00015321099,0.000100488665,0.0000047246253,0.000016869039,9.831421e-7,0.00044630058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999856,0.000031783973,0.000019083456,0.000020736756,0.00005547274,0.0000169526],"domain_scores_gemma":[0.99987566,0.000057982757,0.000020255009,0.0000040096106,0.000026889016,0.000015079429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004799423,0.0006413669,0.00140547,0.0018140579,0.00019943036,0.0008162265,0.0007417416,0.0009071494,0.0026690555],"category_scores_gemma":[0.00040112255,0.00020225515,0.0004057416,0.0015965521,0.0003827886,0.0010885451,0.0005405739,0.0017335014,0.0015122634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111193964,0.00009994348,0.00011098727,0.010142877,0.0000806793,0.00029642816,0.000060722523,0.00039623296,0.0020127466,0.0028940835,0.018328993,0.965465],"study_design_scores_gemma":[0.00006316381,0.00017365915,0.0008049516,0.0029031713,0.000093906514,0.0020232052,0.000054224565,0.0001285158,0.00059707207,0.0021018041,0.99103945,0.000016923215],"about_ca_topic_score_codex":0.0006565643,"about_ca_topic_score_gemma":0.0016781728,"teacher_disagreement_score":0.0026690555,"about_ca_system_score_codex":0.00053698657,"about_ca_system_score_gemma":0.0005117233,"threshold_uncertainty_score":0.008928895},"labels":[],"label_agreement":null},{"id":"W2144648936","doi":"10.1634/theoncologist.12-5-610","title":"Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency; Vrije Universiteit Amsterdam; Institut Claudius Regaud; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Epidermal growth factor receptor; EGFR inhibitors; Cetuximab; Colorectal cancer; Toxicity; Grading (engineering); Quality of life (healthcare); Gefitinib; Cancer; Oncology; Internal medicine","score_opus":0.2509656558099983,"score_gpt":0.5050140510855577,"score_spread":0.25404839527555945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144648936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016369409,0.995544,0.00032578126,0.0028249354,0.000323734,0.0000052247697,0.0000038423805,0.000009082852,0.00079964945],"genre_scores_gemma":[0.0015414051,0.9953295,0.0009462024,0.0011680613,0.00064081006,0.0000111336185,0.00001150336,0.0000024227468,0.00034892245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890804,0.00039556244,0.00016315798,0.00011210455,0.00036942906,0.000051778836],"domain_scores_gemma":[0.99853873,0.0007312145,0.00018470903,0.000040776282,0.00041354637,0.00009106861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029501994,0.0009483678,0.002447513,0.0026640606,0.00046203862,0.002170652,0.0016844406,0.0021843226,0.0013718826],"category_scores_gemma":[0.0027278052,0.00032691448,0.0006213221,0.0030680087,0.0016181845,0.0032721502,0.0008790428,0.0037740043,0.0009932261],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060007096,0.00007309213,0.00030604596,0.008363609,0.00006379673,0.0004498687,0.0001739414,0.00046052955,0.00062793144,0.008172874,0.03238411,0.9488642],"study_design_scores_gemma":[0.000074956304,0.00020519109,0.0018607866,0.010870665,0.000108499036,0.0055517317,0.00063200673,0.00045768014,0.00030100936,0.010792134,0.9690934,0.000051879437],"about_ca_topic_score_codex":0.0014206682,"about_ca_topic_score_gemma":0.0029705158,"teacher_disagreement_score":0.0029501994,"about_ca_system_score_codex":0.0019565346,"about_ca_system_score_gemma":0.0022535631,"threshold_uncertainty_score":0.01560235},"labels":[],"label_agreement":null},{"id":"W2144847294","doi":"10.1517/14712590903439702","title":"Trastuzumab for gastric cancer","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Trastuzumab; Cancer; Oncology; Chemotherapy; Internal medicine; Targeted therapy; Breast cancer","score_opus":0.4923854008211455,"score_gpt":0.5606512124964915,"score_spread":0.06826581167534601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144847294","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014978112,0.9982572,0.000064439344,0.00026825262,0.00017470402,0.000004890494,0.000009175626,0.0000050977396,0.0010664096],"genre_scores_gemma":[0.0020146505,0.99573886,0.0001728605,0.00040631482,0.00029336245,0.000011030965,0.000037669153,0.0000016667612,0.0013235802],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981076,0.00004770846,0.000025035413,0.000028111373,0.000071021765,0.000017409264],"domain_scores_gemma":[0.999838,0.00006417467,0.000043694094,0.000004904806,0.000035258035,0.0000138191535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052534515,0.00071139133,0.0011629188,0.001644592,0.00016900287,0.00061530294,0.00067921635,0.0009588954,0.0035750854],"category_scores_gemma":[0.00065465976,0.00016006647,0.0004679117,0.0015576791,0.00024493053,0.0006086955,0.00042780512,0.0009897287,0.0020241211],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012371887,0.000058621852,0.00020688468,0.014239223,0.00014920314,0.00047563895,0.0000480629,0.00029650412,0.0016781144,0.0016148252,0.04752474,0.9335845],"study_design_scores_gemma":[0.000119480625,0.00012314948,0.0010859073,0.0045747478,0.00022087544,0.0035645026,0.00003233284,0.00012865831,0.001029729,0.0013447468,0.9877626,0.000013315514],"about_ca_topic_score_codex":0.0008081094,"about_ca_topic_score_gemma":0.0012831099,"teacher_disagreement_score":0.0035750854,"about_ca_system_score_codex":0.0006235987,"about_ca_system_score_gemma":0.00064866623,"threshold_uncertainty_score":0.011959851},"labels":[],"label_agreement":null},{"id":"W2145136050","doi":"10.1200/jco.2005.04.1558","title":"Trastuzumab Cardiac Side Effects: Only Time Will Tell","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Cardiotoxicity; Internal medicine; Oncology; Cancer; Breast cancer; Chemotherapy","score_opus":0.10497524475678915,"score_gpt":0.5073804816476659,"score_spread":0.40240523689087676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145136050","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066884514,0.002511064,0.00008343224,0.98639107,0.007360595,0.000004581816,0.0000226378,0.00002027469,0.0029374857],"genre_scores_gemma":[0.009297381,0.0032350004,0.00027980196,0.9145627,0.0635489,0.000020833557,0.00003028066,0.000019208594,0.009005957],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824524,0.0005338043,0.0002660162,0.00022233842,0.00047583203,0.00025682777],"domain_scores_gemma":[0.99189234,0.0044726273,0.0007166034,0.00022127938,0.001007577,0.0016896211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019896433,0.00071973604,0.0016885237,0.0005472182,0.0025504294,0.0031087748,0.0012021031,0.05264506,0.0073133805],"category_scores_gemma":[0.018893868,0.0005378779,0.0011752319,0.0005199817,0.00217664,0.0037449365,0.0010910685,0.03533694,0.004488766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024619955,0.00007428208,0.0018566899,0.00010541455,0.000068544265,0.008567311,0.00013438232,0.00011097454,0.00048659777,0.0038873453,0.9562948,0.028167497],"study_design_scores_gemma":[0.0005221837,0.0004237937,0.004032759,0.0007812971,0.00018223611,0.016943205,0.0006498972,0.0007251151,0.000433095,0.01882548,0.9563497,0.00013115727],"about_ca_topic_score_codex":0.0026095419,"about_ca_topic_score_gemma":0.006325777,"teacher_disagreement_score":0.05264506,"about_ca_system_score_codex":0.0038033524,"about_ca_system_score_gemma":0.0019090298,"threshold_uncertainty_score":0.0275954},"labels":[],"label_agreement":null},{"id":"W2145330014","doi":"10.1093/annonc/mdu327.46","title":"Data-Driven Timing of Optimal Lvef Assessment in Breast Cancer Patients Exposed to Trastuzumab","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.2328503529427616,"score_gpt":0.5129398822640531,"score_spread":0.2800895293212915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145330014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94203883,0.0047248937,0.037862543,0.0032001452,0.00034900804,0.0001405758,0.005014795,0.0008320664,0.005837075],"genre_scores_gemma":[0.9931813,0.00026820952,0.0048163556,0.00022109199,0.00007900867,0.00003558555,0.00119288,0.00003935875,0.00016621697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988588,0.00045890454,0.00012026562,0.00028690152,0.00018796665,0.000087164546],"domain_scores_gemma":[0.992411,0.0052341204,0.0009578585,0.0003389728,0.00061069534,0.00044729904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00261704,0.00039531922,0.0009897853,0.000666045,0.00015035765,0.0013530576,0.0005062905,0.00050622516,0.0010644526],"category_scores_gemma":[0.015928352,0.0002677691,0.00033266898,0.00056403514,0.00014436225,0.0005683562,0.00041065572,0.0010897845,0.00045120373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013773803,0.00047877885,0.6962772,0.00023995398,0.00043682556,0.0007338399,0.00028719965,0.053124722,0.008629135,0.0014831566,0.0096587185,0.21487662],"study_design_scores_gemma":[0.0008504823,0.004050751,0.50069314,0.00035583656,0.0008205967,0.0019407971,0.0005589325,0.43826935,0.028372714,0.009650043,0.014283783,0.00015359068],"about_ca_topic_score_codex":0.0012947959,"about_ca_topic_score_gemma":0.001639635,"teacher_disagreement_score":0.00261704,"about_ca_system_score_codex":0.00045475786,"about_ca_system_score_gemma":0.0007334631,"threshold_uncertainty_score":0.013840437},"labels":[],"label_agreement":null},{"id":"W2145344722","doi":"10.1007/s10585-013-9629-y","title":"Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread","year":2013,"lang":"en","type":"article","venue":"Clinical & Experimental Metastasis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Immunohistochemistry; Pathology; Gastroenterology; Oncology","score_opus":0.12165425616383725,"score_gpt":0.4458009730392224,"score_spread":0.32414671687538515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145344722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989711,0.00013006528,0.000056986722,0.000017707214,0.0000059050376,0.000004144447,0.00007426745,0.0000030688032,0.0007367541],"genre_scores_gemma":[0.9993616,0.00009555509,0.00004428967,0.000007900869,0.000010469137,0.0000047731137,0.0001564734,0.000001909075,0.00031714965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997907,0.00004181514,0.00002907024,0.000034629225,0.00004719083,0.0000566196],"domain_scores_gemma":[0.999156,0.00023145288,0.0002469442,0.000059504346,0.00008997278,0.00021622513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004324822,0.0003706584,0.0003000972,0.00092437846,0.0005370859,0.00088015705,0.0003962685,0.0005368067,0.00330781],"category_scores_gemma":[0.0016135713,0.0002614776,0.0003130104,0.00079262373,0.00056027883,0.00047206855,0.0006980584,0.0004287997,0.0005460266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028325347,0.00002451662,0.99578434,0.00000984249,0.000016639779,0.00073612493,0.00004659719,0.000052308904,0.0015089825,0.000012733691,0.000052399726,0.0014722554],"study_design_scores_gemma":[0.0000061424835,0.00010089526,0.99526477,0.000004493375,0.000058269256,0.003087978,0.00041134536,0.0002852132,0.00047871209,0.00007117673,0.00022658413,0.0000044189433],"about_ca_topic_score_codex":0.0017668003,"about_ca_topic_score_gemma":0.0034707761,"teacher_disagreement_score":0.00330781,"about_ca_system_score_codex":0.00026169833,"about_ca_system_score_gemma":0.00036741752,"threshold_uncertainty_score":0.011065781},"labels":[],"label_agreement":null},{"id":"W2145378676","doi":"10.1093/annonc/mdn292","title":"Anthracycline–trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies","year":2008,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Dalhousie University","funders":"","keywords":"Trastuzumab; Cardiotoxicity; Medicine; Anthracycline; Doxorubicin; Breast cancer; Oncology; Internal medicine; Adjuvant; Pharmacology; Cancer; Chemotherapy","score_opus":0.2965734513227626,"score_gpt":0.5799490487503968,"score_spread":0.2833755974276342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145378676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005352539,0.99812955,0.00012660846,0.00019892034,0.000099593955,0.000007898244,0.00001686835,0.0000062376416,0.000879121],"genre_scores_gemma":[0.0024238199,0.9962509,0.00030552648,0.0002886381,0.00014004292,0.000011203556,0.00004463853,0.00000214015,0.0005331389],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998617,0.00003216308,0.000024878364,0.000027380767,0.00003936871,0.000014484487],"domain_scores_gemma":[0.99969125,0.00018692296,0.000054023436,0.000008032371,0.000041298335,0.000018448143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006995842,0.00059427513,0.0017558952,0.0008845456,0.00015493066,0.00065573695,0.00079483836,0.0005405299,0.0034650909],"category_scores_gemma":[0.00068565825,0.00019058824,0.00051936845,0.0012392205,0.00024746612,0.0008078546,0.0002914662,0.0011630041,0.00088043296],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028154024,0.00013544089,0.00021542078,0.0077501982,0.00014961802,0.00016138349,0.00003463299,0.00035690356,0.0011924653,0.0006631233,0.012395127,0.9766642],"study_design_scores_gemma":[0.00056294334,0.001304088,0.0049371556,0.0076479064,0.0013037211,0.003222534,0.00011300421,0.0004161959,0.0013707647,0.0013250728,0.97775936,0.000037281538],"about_ca_topic_score_codex":0.00052611216,"about_ca_topic_score_gemma":0.002360461,"teacher_disagreement_score":0.0034650909,"about_ca_system_score_codex":0.0003941027,"about_ca_system_score_gemma":0.0005606378,"threshold_uncertainty_score":0.011591852},"labels":[],"label_agreement":null},{"id":"W2145824104","doi":"10.1186/1476-4598-9-75","title":"Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Tyrosine kinase; Biology; Angiogenesis; Receptor tyrosine kinase; Cancer research; Tyrosine-kinase inhibitor; Monoclonal antibody; Cancer; Kinase; Acquired resistance; Cancer cell; Signal transduction; Immunology; Antibody; Cell biology; Genetics","score_opus":0.019740080904640748,"score_gpt":0.33466908602350537,"score_spread":0.3149290051188646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145824104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6273562,0.32923046,0.013865972,0.004281013,0.00028366366,0.00027185446,0.0006779323,0.00041385563,0.02361902],"genre_scores_gemma":[0.9311051,0.061955802,0.001191742,0.00058722397,0.00017504497,0.000108624066,0.00036618445,0.000022310125,0.004487953],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997043,0.000077130564,0.00002137543,0.0000403475,0.00009403772,0.000062867475],"domain_scores_gemma":[0.99979645,0.000053954514,0.00006809597,0.00002296314,0.000039544422,0.000019023792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005704013,0.00034707258,0.0006058025,0.0006063036,0.00013547686,0.0007452083,0.0005742775,0.00061856426,0.00221738],"category_scores_gemma":[0.00049925066,0.00014624179,0.00030134033,0.00030825313,0.0004349992,0.00049667136,0.00031233876,0.0008444404,0.00048802575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011354414,0.0006559199,0.012427514,0.0023706474,0.00036276336,0.0073012244,0.00041481177,0.004289664,0.7118787,0.028109297,0.0076364977,0.22341746],"study_design_scores_gemma":[0.00065054686,0.0050413962,0.09253763,0.0005316677,0.0007364579,0.06660104,0.00053077476,0.0131413145,0.5327647,0.029160952,0.25816393,0.00013967893],"about_ca_topic_score_codex":0.00019344524,"about_ca_topic_score_gemma":0.00014041677,"teacher_disagreement_score":0.00221738,"about_ca_system_score_codex":0.0007288189,"about_ca_system_score_gemma":0.00020273821,"threshold_uncertainty_score":0.0074178576},"labels":[],"label_agreement":null},{"id":"W2145944809","doi":"10.2967/jnumed.108.060772","title":"Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer Therapy","year":2009,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Oncogene; Cancer; Targeted therapy; Cancer research; Gene; Cancer therapy; Biology; Computational biology; Term (time); Addiction; Genetics; Neuroscience; Physics","score_opus":0.03568112765676891,"score_gpt":0.3784747913586057,"score_spread":0.3427936637018368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145944809","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08021913,0.08542352,0.7749621,0.013030832,0.0013262855,0.0004565707,0.00031754837,0.0027617447,0.041502204],"genre_scores_gemma":[0.59058356,0.050216086,0.32352883,0.009828504,0.0012647605,0.00049571757,0.00028143765,0.0005003613,0.023300627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999713,0.000059268426,0.000008558824,0.00007151441,0.000102363505,0.00004524355],"domain_scores_gemma":[0.999826,0.00009715184,0.000022121907,0.000018690065,0.0000130579765,0.00002291038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006176838,0.00093536044,0.0012617691,0.00065229693,0.00040991703,0.0019496054,0.001347078,0.001843992,0.0043109613],"category_scores_gemma":[0.0006378201,0.00047534567,0.00050599116,0.0004623968,0.0013496656,0.0029609306,0.0015997156,0.002321165,0.0016708369],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049611356,0.00029796336,0.00054400077,0.000927221,0.00012814303,0.00077646226,0.00019460703,0.001737815,0.78655964,0.051231474,0.009738113,0.14736836],"study_design_scores_gemma":[0.00015695512,0.0015501333,0.00084519706,0.00017577753,0.00022886631,0.0046938737,0.00016577051,0.015041926,0.8749201,0.030441651,0.07166,0.00011976085],"about_ca_topic_score_codex":0.00024777208,"about_ca_topic_score_gemma":0.00037837232,"teacher_disagreement_score":0.0043109613,"about_ca_system_score_codex":0.00058860314,"about_ca_system_score_gemma":0.00035557145,"threshold_uncertainty_score":0.014421642},"labels":[],"label_agreement":null},{"id":"W2146284460","doi":"10.1158/0008-5472.can-11-3594","title":"HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Epithelium; Cancer research; Breast cancer; Medicine; Internal medicine; Oncology; Pathology; Cancer","score_opus":0.19696368002746906,"score_gpt":0.46742808663521285,"score_spread":0.2704644066077438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146284460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252725,0.0017864439,0.0029208222,0.00014544872,0.000027238042,0.000030380086,0.0008567341,0.00022334691,0.0014823719],"genre_scores_gemma":[0.9939231,0.00058544363,0.0012217768,0.00006276298,0.0000048826955,0.000028653247,0.0009853272,0.00005498698,0.0031330027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998062,0.000025137937,0.000019885061,0.000031913874,0.00006701724,0.000049898492],"domain_scores_gemma":[0.99967813,0.000032701788,0.00013200796,0.000037080197,0.000034447927,0.00008559428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001663819,0.00033880255,0.00026769278,0.00020980586,0.00022924799,0.0003212304,0.00022152958,0.00039048435,0.0019998632],"category_scores_gemma":[0.0001875587,0.0002516048,0.00036145668,0.00013042921,0.00020108851,0.00026301906,0.000412914,0.00053291407,0.0008499155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008064497,0.000012825302,0.00016166591,0.000013410023,0.000002019483,0.00007963925,0.0000066911207,0.000020946729,0.99921453,0.000050728733,0.000016584723,0.00034025067],"study_design_scores_gemma":[0.000013617292,0.00011305191,0.015097104,0.0000064568885,0.000009219319,0.00082755636,0.000044338565,0.00051745045,0.98041165,0.00009821876,0.0028544934,0.0000067769133],"about_ca_topic_score_codex":0.0016736287,"about_ca_topic_score_gemma":0.0020795432,"teacher_disagreement_score":0.0019998632,"about_ca_system_score_codex":0.00047021892,"about_ca_system_score_gemma":0.0004086422,"threshold_uncertainty_score":0.006690204},"labels":[],"label_agreement":null},{"id":"W2146684793","doi":"10.1158/1078-0432.ccr-05-1855","title":"Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers <i>In vitro</i> and in an Animal Model","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Cetuximab; Epidermal growth factor receptor; Cancer research; Pancreatic cancer; EGFR inhibitors; Monoclonal antibody; Cytotoxic T cell; Medicine; In vivo; CD3; Antibody; Cancer; Epidermal growth factor; Immunology; Receptor; Biology; Antigen; In vitro; Internal medicine; CD8","score_opus":0.1702311512438923,"score_gpt":0.505965953970119,"score_spread":0.3357348027262267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146684793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958823,0.00066025,0.0016999337,0.00004129842,0.000018400648,0.000037828053,0.000096555035,0.00009449977,0.001469022],"genre_scores_gemma":[0.99647105,0.00041592782,0.0014973672,0.000040874493,0.000013543739,0.00003353665,0.00024483705,0.000015946498,0.0012669716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998543,0.000023156572,0.000011337392,0.000033117598,0.000034987228,0.00004305851],"domain_scores_gemma":[0.9999217,0.000017611732,0.000019650302,0.000011110015,0.000009651132,0.000020212525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014222489,0.00046290134,0.00025255317,0.00019295322,0.00010538966,0.00022718782,0.00015601062,0.00022189213,0.0009115044],"category_scores_gemma":[0.00008079317,0.00009503734,0.00023540275,0.000116747775,0.00017394737,0.00012645722,0.00009539689,0.00064857287,0.0003239577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018409046,0.000146919,0.0001371655,0.000026787826,0.0000061235223,0.000022230945,0.0000068837717,0.00012102089,0.9979662,0.000033995813,0.000045754918,0.0013030953],"study_design_scores_gemma":[0.000041870167,0.0013310366,0.0016223689,0.0000038811395,0.000017660463,0.00019641798,0.0000048591482,0.0008581955,0.9952728,0.000009190087,0.0006399205,0.0000016940783],"about_ca_topic_score_codex":0.0006135087,"about_ca_topic_score_gemma":0.0009964478,"teacher_disagreement_score":0.0009115044,"about_ca_system_score_codex":0.00030041495,"about_ca_system_score_gemma":0.00022753356,"threshold_uncertainty_score":0.003049314},"labels":[],"label_agreement":null},{"id":"W2146706444","doi":"10.1016/j.clon.2012.05.009","title":"Dual Blockade of HER2 — Twice as Good or Twice as Toxic?","year":2012,"lang":"en","type":"review","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital; University of Toronto","funders":"","keywords":"Medicine; Blockade; Dual (grammatical number); Oncology; Pharmacology; Internal medicine; Receptor","score_opus":0.557896555394812,"score_gpt":0.6558580151693912,"score_spread":0.09796145977457926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146706444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008499868,0.99639064,0.00016318509,0.0008814911,0.0003395482,0.000009789526,0.00003581707,0.000012322891,0.0013172777],"genre_scores_gemma":[0.0068063564,0.98887664,0.00036178238,0.0014728013,0.00034394194,0.000020866912,0.000084298816,0.0000042364804,0.0020290632],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998951,0.00002560799,0.000015544982,0.00002057687,0.000027969896,0.000015211305],"domain_scores_gemma":[0.9998758,0.000057650665,0.000028413275,0.0000048840097,0.000018722536,0.0000145427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049866585,0.0005719382,0.0016814363,0.0006851197,0.00012642996,0.0005732857,0.00066622725,0.00070057355,0.0047158953],"category_scores_gemma":[0.00044742442,0.00018073214,0.00050534453,0.0007339372,0.00028,0.0008368284,0.00029735512,0.0018224785,0.00122553],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059664244,0.00014488563,0.00017066344,0.007998015,0.00021821549,0.00015448433,0.000025215364,0.00019136746,0.0034462013,0.001597564,0.036199,0.9492578],"study_design_scores_gemma":[0.0008464749,0.0013046563,0.0019296672,0.004111844,0.00096243597,0.0031309512,0.000079957616,0.00019821641,0.0028040183,0.002547789,0.9820467,0.000037330345],"about_ca_topic_score_codex":0.0003428954,"about_ca_topic_score_gemma":0.0015055011,"teacher_disagreement_score":0.0047158953,"about_ca_system_score_codex":0.00036409995,"about_ca_system_score_gemma":0.0004197525,"threshold_uncertainty_score":0.015776217},"labels":[],"label_agreement":null},{"id":"W2147073360","doi":"10.1164/rccm.200909-1396oc","title":"The Metalloprotease-Disintegrin ADAM8 Is Essential for the Development of Experimental Asthma","year":2010,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Immunology; Proinflammatory cytokine; Asthma; Inflammation; Context (archaeology); Ovalbumin; Metalloproteinase; Biology; Internal medicine; Matrix metalloproteinase; Immune system","score_opus":0.037281504803695624,"score_gpt":0.4054293672336085,"score_spread":0.3681478624299129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147073360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830115,0.007507185,0.0058405106,0.00051281677,0.00010271213,0.00016299529,0.00078132603,0.00029722755,0.0017836868],"genre_scores_gemma":[0.98898727,0.0038542189,0.0043957625,0.00010283799,0.000065720655,0.00018371007,0.0006612472,0.000037146343,0.001712052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99963784,0.000094087714,0.00005138289,0.0000616464,0.0000969923,0.000058103906],"domain_scores_gemma":[0.9995055,0.000092177674,0.00018814845,0.000075419,0.00003339352,0.00010537668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038629756,0.0006320553,0.00042639725,0.00038283842,0.00023140252,0.0003325266,0.0003894691,0.000628722,0.0019416615],"category_scores_gemma":[0.0004408016,0.00022272747,0.00030612428,0.00015980782,0.00061244046,0.00034957688,0.0003725995,0.0011492847,0.0005745148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006873494,0.00014169783,0.0013732588,0.00016332185,0.000010738016,0.00043349632,0.000013696932,0.00009037527,0.99380976,0.00023315503,0.00012862802,0.002914477],"study_design_scores_gemma":[0.00027813038,0.00363484,0.029239934,0.00010556416,0.000114613176,0.00528331,0.00008091014,0.0012679066,0.9492612,0.00047052698,0.0102458075,0.000017176499],"about_ca_topic_score_codex":0.00016353735,"about_ca_topic_score_gemma":0.00019131544,"teacher_disagreement_score":0.0019416615,"about_ca_system_score_codex":0.000287203,"about_ca_system_score_gemma":0.00029903275,"threshold_uncertainty_score":0.006495476},"labels":[],"label_agreement":null},{"id":"W2147874203","doi":"10.2217/cpr.12.25","title":"Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach","year":2012,"lang":"en","type":"article","venue":"Clinical Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Metastatic breast cancer; Breast cancer; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.2620384103364028,"score_gpt":0.593386484545966,"score_spread":0.3313480742095632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147874203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013408264,0.9784242,0.0010193919,0.0119615905,0.0015056543,0.000030898722,0.000031736916,0.0000252484,0.0056604245],"genre_scores_gemma":[0.010393726,0.97741437,0.0018247801,0.004099793,0.00393977,0.00005036429,0.00009071678,0.000008675474,0.002177781],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962294,0.00012137601,0.00006012073,0.000054581036,0.00010742412,0.000033553908],"domain_scores_gemma":[0.9993357,0.00020945103,0.00009036979,0.000031487976,0.00024973325,0.00008319492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013713816,0.0006363049,0.00077841524,0.0012430447,0.00032364222,0.0013470806,0.00067976385,0.0012134336,0.003748069],"category_scores_gemma":[0.0014262003,0.00014795848,0.0005046983,0.0013292594,0.0005547463,0.0017168411,0.0007005308,0.0018177337,0.0011700479],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021593203,0.00021267372,0.0006426724,0.005049436,0.00007597006,0.0005318025,0.00010120299,0.00049272826,0.0020826443,0.005728501,0.032496907,0.9523695],"study_design_scores_gemma":[0.0002325417,0.0010920995,0.0036107162,0.0041820337,0.00034840513,0.005346042,0.00028235096,0.0007202497,0.0016624214,0.006952023,0.9755297,0.000041348216],"about_ca_topic_score_codex":0.000522739,"about_ca_topic_score_gemma":0.0015785865,"teacher_disagreement_score":0.003748069,"about_ca_system_score_codex":0.0009429483,"about_ca_system_score_gemma":0.0011998878,"threshold_uncertainty_score":0.012538493},"labels":[],"label_agreement":null},{"id":"W2148454974","doi":"10.1155/2014/289836","title":"Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series","year":2014,"lang":"en","type":"article","venue":"ISRN Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital","funders":"","keywords":"Vinorelbine; Medicine; Trastuzumab; Metastatic breast cancer; Concomitant; Breast cancer; Internal medicine; Oncology; Cancer; Chemotherapy; Surgery","score_opus":0.042178716202751834,"score_gpt":0.381553796655331,"score_spread":0.3393750804525792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148454974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648285,0.0023991745,0.00018165054,0.00005698547,0.000014644083,0.00001981919,0.00012321206,0.000010004051,0.0007117077],"genre_scores_gemma":[0.9982377,0.0010142674,0.00015133026,0.00009020879,0.000052807387,0.000013859386,0.00024296543,0.000007882462,0.00018896307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992712,0.00015192691,0.00010517289,0.0001872465,0.00014039718,0.00014397038],"domain_scores_gemma":[0.99831057,0.0003930723,0.0006814488,0.00014329323,0.00014739191,0.00032423268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004639381,0.00030415104,0.00045756795,0.00069834554,0.00057773833,0.0008341984,0.00037727554,0.0004933519,0.0015516867],"category_scores_gemma":[0.0026040063,0.0003139569,0.00033882936,0.00087810814,0.00032708593,0.00031905514,0.0004248844,0.00043445153,0.0005028625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002991944,0.00013498437,0.97972083,0.000070366434,0.0000766712,0.007203249,0.00015244413,0.00007737998,0.00065216207,0.000032356227,0.00046892997,0.011111488],"study_design_scores_gemma":[0.00012780783,0.001988658,0.8689023,0.00008006564,0.000307741,0.12035103,0.0008500446,0.00039698032,0.0014958625,0.00006031805,0.0054111592,0.000027972277],"about_ca_topic_score_codex":0.0016445857,"about_ca_topic_score_gemma":0.0020701892,"teacher_disagreement_score":0.0016445857,"about_ca_system_score_codex":0.0004635716,"about_ca_system_score_gemma":0.00051326695,"threshold_uncertainty_score":0.005190909},"labels":[],"label_agreement":null},{"id":"W2148572592","doi":"10.1200/jco.2011.37.5824","title":"Quantitative Reverse Transcriptase Polymerase Chain Reaction and the Onco<i>type</i> DX Test for Assessment of Human Epidermal Growth Factor Receptor 2 Status: Time to Reflect Again?","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Reverse transcriptase; Epidermal growth factor receptor; Polymerase chain reaction; Real-time polymerase chain reaction; Receptor; Cancer research; Molecular biology; Virology; Internal medicine; Biology; Genetics; Gene","score_opus":0.3018020567412538,"score_gpt":0.5489705288848127,"score_spread":0.24716847214355886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148572592","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022200877,0.23180808,0.3175493,0.3583064,0.05293568,0.0007089738,0.0003280695,0.0027589244,0.013403635],"genre_scores_gemma":[0.13162465,0.076169066,0.48098063,0.25921476,0.030926615,0.0022851261,0.0008452601,0.0019193772,0.016034598],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8877949,0.065125674,0.010445212,0.007894343,0.026911546,0.0018283379],"domain_scores_gemma":[0.8684365,0.076308906,0.015057946,0.013795984,0.022906616,0.0034940543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11706743,0.0018605669,0.00417804,0.0031027866,0.0010402085,0.0076350924,0.004251614,0.00942795,0.00228435],"category_scores_gemma":[0.09248993,0.0021418862,0.001846612,0.0029780678,0.012280214,0.008534376,0.0024387876,0.01582041,0.0030394327],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015091044,0.0013772681,0.050043587,0.0035317207,0.0012358143,0.002684078,0.0029000358,0.0019184672,0.03527445,0.06449317,0.144572,0.6904603],"study_design_scores_gemma":[0.0006980336,0.0051996885,0.044704318,0.004645173,0.0008235235,0.018814549,0.003538613,0.023473248,0.039513472,0.09402696,0.7628542,0.0017082265],"about_ca_topic_score_codex":0.001797763,"about_ca_topic_score_gemma":0.00410145,"teacher_disagreement_score":0.11706743,"about_ca_system_score_codex":0.003076952,"about_ca_system_score_gemma":0.0034521208,"threshold_uncertainty_score":0.61911917},"labels":[],"label_agreement":null},{"id":"W2148689234","doi":"","title":"Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Metastatic breast cancer; Cancer; Chemotherapy; Oncology; Univariate analysis; Anthracycline; Gastroenterology; Multivariate analysis","score_opus":0.033990501467147397,"score_gpt":0.2991339824245392,"score_spread":0.2651434809573918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148689234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99870706,0.0004078631,0.000081653205,0.00005312207,0.000008298673,0.000033051027,0.0004839918,0.00000460158,0.00022041617],"genre_scores_gemma":[0.9980013,0.00016185582,0.00011678981,0.000069075475,0.000037707996,0.000048200473,0.0012109015,0.0000024618287,0.00035168623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996952,0.000102571095,0.00002258801,0.0000793866,0.00004936485,0.00005086138],"domain_scores_gemma":[0.9993606,0.000089699635,0.00014983646,0.00004670362,0.00004985785,0.00030323848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062893296,0.00051141094,0.00067154143,0.0003428029,0.00045580853,0.00062309724,0.00035029527,0.00065242936,0.0013538722],"category_scores_gemma":[0.0009875594,0.00038477342,0.00036730457,0.00056589156,0.00029427206,0.00040006763,0.00031371452,0.0006758097,0.00037039665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064601703,0.00033096262,0.9884759,0.000032994645,0.00017985926,0.0001677784,0.00005300035,0.00014860247,0.0015282787,0.000021125292,0.00039641347,0.0022047914],"study_design_scores_gemma":[0.0013511232,0.0024686167,0.99336046,0.000015012952,0.00017567552,0.0007256584,0.00008812257,0.0005616263,0.00040868478,0.000041436633,0.00079315656,0.000010410619],"about_ca_topic_score_codex":0.0016276496,"about_ca_topic_score_gemma":0.0018664934,"teacher_disagreement_score":0.0016276496,"about_ca_system_score_codex":0.00034229507,"about_ca_system_score_gemma":0.00041978792,"threshold_uncertainty_score":0.0045291185},"labels":[],"label_agreement":null},{"id":"W2149775431","doi":"10.1158/0008-5472.can-05-3561","title":"Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; Child and Family Research Institute; University of British Columbia","funders":"","keywords":"Chromatin immunoprecipitation; Epidermal growth factor receptor; Biology; Receptor; Estrogen receptor; Molecular biology; Cancer research; Epidermal growth factor; Promoter; Breast cancer; Cancer; Gene expression; Gene; Genetics","score_opus":0.09333588458577985,"score_gpt":0.4254608625046686,"score_spread":0.33212497791888873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149775431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764085,0.0004924087,0.001076004,0.00006842371,0.000028815195,0.0000146137245,0.00019352738,0.000066969544,0.00041842798],"genre_scores_gemma":[0.9966492,0.00027925946,0.0008168201,0.000034117296,0.0000065300865,0.0000182557,0.0002637219,0.00001739866,0.001914665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998784,0.00001522799,0.000012681474,0.000033176908,0.000030377762,0.000030183528],"domain_scores_gemma":[0.99981576,0.000032602715,0.0000903551,0.000012838271,0.000005472112,0.000043019743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009093384,0.0003051333,0.00023040696,0.00018940346,0.0001299779,0.0001966833,0.00020375251,0.00027106827,0.0012803643],"category_scores_gemma":[0.000144836,0.0001971822,0.00022932996,0.00012784997,0.00022494294,0.00007091099,0.00019184883,0.00041672622,0.00041327396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013780755,0.000036735313,0.00025061663,0.000012752209,0.000007008904,0.00012588955,0.000009345362,0.00008589475,0.99851424,0.00007376222,0.000050748273,0.0006952378],"study_design_scores_gemma":[0.000058047644,0.00060671824,0.02150304,0.000010605494,0.000029994913,0.0019177173,0.00006194108,0.0032675448,0.9677346,0.000133193,0.0046640304,0.000012594335],"about_ca_topic_score_codex":0.00071614026,"about_ca_topic_score_gemma":0.0008783278,"teacher_disagreement_score":0.0012803643,"about_ca_system_score_codex":0.00028822367,"about_ca_system_score_gemma":0.00016179399,"threshold_uncertainty_score":0.0042832494},"labels":[],"label_agreement":null},{"id":"W2149908785","doi":"10.1056/nejmoa052306","title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5098,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Chemotherapy; Adjuvant; Monoclonal antibody; Internal medicine; Adjuvant chemotherapy; Cancer; Stage (stratigraphy); Antibody; Immunology","score_opus":0.016119267416777456,"score_gpt":0.34601867080272986,"score_spread":0.3298994033859524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149908785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837577,0.014024414,0.0002840728,0.00031073065,0.00013880522,0.00017273486,0.00006956055,0.000010284761,0.0012317126],"genre_scores_gemma":[0.9949072,0.003584093,0.00029566893,0.00021705912,0.00013597937,0.00018688837,0.00018961939,0.0000027873093,0.00048063233],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999585,0.00024235129,0.000025752082,0.00003484609,0.000050464965,0.00006155474],"domain_scores_gemma":[0.99934906,0.0002713102,0.00018221194,0.00004067579,0.00003107558,0.00012553066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013078742,0.00018842572,0.00058635336,0.00017756473,0.00012283413,0.00030113469,0.0002575014,0.00034186247,0.00082422415],"category_scores_gemma":[0.0014875571,0.00007307741,0.00034837454,0.00030007947,0.00022085554,0.00020270534,0.00018977765,0.00067717035,0.00009323444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46961865,0.009856511,0.043311685,0.0018129988,0.0011749044,0.0008342626,0.00020962511,0.0051798937,0.023814607,0.0007855524,0.0029690997,0.44043222],"study_design_scores_gemma":[0.3173281,0.47501892,0.1349772,0.00064394006,0.0027764658,0.0021265664,0.0001115352,0.005072367,0.023274817,0.0017331899,0.036897346,0.000039588376],"about_ca_topic_score_codex":0.000313991,"about_ca_topic_score_gemma":0.0006878774,"teacher_disagreement_score":0.0013078742,"about_ca_system_score_codex":0.0003988289,"about_ca_system_score_gemma":0.00044136652,"threshold_uncertainty_score":0.0069167614},"labels":[],"label_agreement":null},{"id":"W2149953725","doi":"10.1093/annonc/mdt069","title":"Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Capital District Health Authority","funders":"Breast Cancer Society of Canada; Beatrice Hunter Cancer Research Institute","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Chemotherapy; Cancer","score_opus":0.14112045725974376,"score_gpt":0.4968204685723518,"score_spread":0.35570001131260803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149953725","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3128979,0.31652728,0.003042595,0.33218548,0.0064367303,0.00015395456,0.001273904,0.0001151953,0.027367013],"genre_scores_gemma":[0.8674222,0.08885041,0.0027745555,0.025287144,0.010579792,0.000079908605,0.0006665185,0.000034309967,0.0043051406],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.999265,0.00029076228,0.00008399379,0.00006316099,0.00018549376,0.000111561225],"domain_scores_gemma":[0.9963619,0.0019685219,0.0006730713,0.00011863567,0.00039103857,0.00048687382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016280947,0.0003455227,0.00094118016,0.0005390404,0.00019422556,0.0015523762,0.00056921924,0.0014895252,0.007221433],"category_scores_gemma":[0.00923934,0.00016754169,0.00089330133,0.00075400574,0.00069179694,0.0018700832,0.00032431865,0.001363889,0.0007212768],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010778839,0.00097316486,0.02756458,0.0014363385,0.0010945286,0.0009696653,0.0000648079,0.0029702676,0.003852243,0.0060963924,0.033822455,0.9103767],"study_design_scores_gemma":[0.010856033,0.019904451,0.39725587,0.0068272077,0.011432522,0.01213768,0.0016941932,0.016110374,0.0062000453,0.060522173,0.45668295,0.00037649542],"about_ca_topic_score_codex":0.0013501381,"about_ca_topic_score_gemma":0.003537893,"teacher_disagreement_score":0.007221433,"about_ca_system_score_codex":0.001619366,"about_ca_system_score_gemma":0.0015206214,"threshold_uncertainty_score":0.02415812},"labels":[],"label_agreement":null},{"id":"W2150308444","doi":"10.1007/s10637-010-9444-0","title":"A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Académie française","keywords":"Nimotuzumab; Medicine; Toxicity; Epidermal growth factor receptor; Pharmacodynamics; Rash; Pharmacology; Internal medicine; Cetuximab; Pharmacokinetics; Phases of clinical research; Oncology; Monoclonal antibody; Antibody; Cancer; Immunology","score_opus":0.027555083651461375,"score_gpt":0.35338870311606624,"score_spread":0.3258336194646049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150308444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99097276,0.0014926362,0.0006268179,0.0012241155,0.00022129317,0.0014236288,0.0009527787,0.000114090486,0.002971947],"genre_scores_gemma":[0.9863121,0.001360706,0.0025107877,0.0015367821,0.00016667768,0.0015148551,0.002764375,0.000051971463,0.003781755],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999632,0.00016883103,0.000014564176,0.000064079504,0.000031470197,0.00008902134],"domain_scores_gemma":[0.9993998,0.00011094579,0.0000682813,0.000056933535,0.000025351377,0.00033871699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013175557,0.0014062125,0.0018798306,0.00048401213,0.00042943933,0.0009396631,0.0008354723,0.0010957317,0.0030765408],"category_scores_gemma":[0.0011089029,0.0003973426,0.001071376,0.0004602381,0.00093725475,0.0010992509,0.00048696206,0.0036106962,0.00074527756],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67665875,0.06611189,0.008279435,0.00065661257,0.0015167171,0.00046496553,0.00069317396,0.0073652198,0.033413697,0.0011600577,0.012271351,0.19140805],"study_design_scores_gemma":[0.76467335,0.20656553,0.014955079,0.00003254411,0.0003624628,0.00043980367,0.00009342579,0.003267334,0.0029820027,0.0008807951,0.0057088397,0.00003890587],"about_ca_topic_score_codex":0.0010244513,"about_ca_topic_score_gemma":0.003189988,"teacher_disagreement_score":0.0030765408,"about_ca_system_score_codex":0.0010681571,"about_ca_system_score_gemma":0.0011465023,"threshold_uncertainty_score":0.010292113},"labels":[],"label_agreement":null},{"id":"W2150713593","doi":"10.1309/ajcpv2i0hgpmgbsq","title":"Emerging Technologies for Assessing HER2 Amplification","year":2009,"lang":"en","type":"review","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Immunohistochemistry; In situ hybridization; Trastuzumab; Human Epidermal Growth Factor Receptor 2; Fluorescence in situ hybridization; Chromogenic; Concordance; Breast cancer; Pathology; In situ; Fish <Actinopterygii>; Biology; Medicine; Cancer; Internal medicine; Chemistry; Bioinformatics; Genetics; Messenger RNA","score_opus":0.3066237885235228,"score_gpt":0.620314042129059,"score_spread":0.31369025360553626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150713593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028733313,0.9960871,0.00120319,0.00017938338,0.00015753928,0.000016093345,0.0000335267,0.000023473722,0.0020123906],"genre_scores_gemma":[0.0012243468,0.9953296,0.0021285934,0.00014934,0.00013936423,0.000027729091,0.00007106931,0.0000040583514,0.0009258205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913436,0.0001361701,0.0000948838,0.00015849953,0.0004339052,0.000042200587],"domain_scores_gemma":[0.999015,0.00044185205,0.00012685824,0.000034909284,0.00034482434,0.000036699897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015288106,0.0014569646,0.002237984,0.008371918,0.00030586054,0.0010168867,0.0017801395,0.0012466629,0.0034587989],"category_scores_gemma":[0.001573229,0.0005735751,0.0007795551,0.004724847,0.0006547044,0.0017750798,0.0006559298,0.0016123503,0.0043940446],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003552339,0.00006172001,0.0005564387,0.009858603,0.00008427657,0.00034534748,0.000051824576,0.00021006036,0.00510417,0.0012892759,0.0084576495,0.97394514],"study_design_scores_gemma":[0.000027500846,0.0002003153,0.0048591793,0.0041179615,0.000308621,0.009498671,0.00018221147,0.0003538806,0.008238032,0.0028540778,0.96927714,0.00008241577],"about_ca_topic_score_codex":0.0011727152,"about_ca_topic_score_gemma":0.0016712245,"teacher_disagreement_score":0.008371918,"about_ca_system_score_codex":0.000803441,"about_ca_system_score_gemma":0.00084411656,"threshold_uncertainty_score":0.011570811},"labels":[],"label_agreement":null},{"id":"W2151247845","doi":"10.1128/mcb.00895-14","title":"ERBB2 Deficiency Alters an E2F-1-Dependent Adaptive Stress Response and Leads to Cardiac Dysfunction","year":2014,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Biology; Cardiac function curve; Tyrosine kinase; Breast cancer; Gene silencing; E2F; Tamoxifen; Cancer research; Heart failure; Cancer; Internal medicine; Signal transduction; Medicine; Cell biology; Gene; Cell cycle; Genetics","score_opus":0.017575858495515035,"score_gpt":0.2986838417813371,"score_spread":0.2811079832858221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151247845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972409,0.000334668,0.0010361902,0.000072160175,0.000023313823,0.000013002272,0.00034472084,0.000043909087,0.000891072],"genre_scores_gemma":[0.9966773,0.0003230398,0.0005936822,0.00005386318,0.000005586116,0.000015642792,0.00026041627,0.000022181895,0.0020481695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988365,0.00002184543,0.000014508668,0.000026221991,0.00002282068,0.000030903717],"domain_scores_gemma":[0.9998969,0.00001853161,0.00003051776,0.000010049648,0.0000040100285,0.000039984294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010316369,0.0004394672,0.00019571705,0.00035562165,0.00013630811,0.00022960105,0.00018479585,0.00039779345,0.002090185],"category_scores_gemma":[0.00009141516,0.00018553773,0.00022365402,0.0001645795,0.00034842137,0.00015273527,0.00017742273,0.000508064,0.00029432256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021615204,0.00006062148,0.00021134554,0.000012947409,0.000006291688,0.000119314616,0.000009710598,0.0000891651,0.99836963,0.00013850164,0.000033548004,0.0007327792],"study_design_scores_gemma":[0.000089253874,0.00063364155,0.012689915,0.000010715097,0.000032461045,0.0012845452,0.00006645067,0.0015184985,0.98106843,0.00020696927,0.0023879542,0.000011185824],"about_ca_topic_score_codex":0.0003920076,"about_ca_topic_score_gemma":0.00066603074,"teacher_disagreement_score":0.002090185,"about_ca_system_score_codex":0.0002550373,"about_ca_system_score_gemma":0.00014558008,"threshold_uncertainty_score":0.00699234},"labels":[],"label_agreement":null},{"id":"W2151287258","doi":"10.1634/theoncologist.2013-0217","title":"HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Jewish General Hospital; St. Michael's Hospital; University of Toronto; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Disease; Breast cancer; Clinical trial; Cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2","score_opus":0.25965523279335295,"score_gpt":0.48847452959125165,"score_spread":0.2288192967978987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151287258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009084487,0.98112434,0.00014914898,0.007570753,0.006639483,0.000009784158,0.000032961783,0.000013542179,0.0043690517],"genre_scores_gemma":[0.0006029675,0.98135996,0.00021782574,0.0062068813,0.0032245375,0.000009616211,0.000040986015,0.00000638092,0.008330805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997377,0.000060065795,0.000022424256,0.00003322771,0.00012620691,0.000020366528],"domain_scores_gemma":[0.9996977,0.00015205235,0.000026657797,0.000007967527,0.0000760825,0.000039589264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006356939,0.00076079054,0.0008404856,0.0010297303,0.00045319757,0.0012804632,0.0008205762,0.0018407353,0.009525711],"category_scores_gemma":[0.0013740531,0.00018832856,0.00051403465,0.0013858012,0.0005207902,0.0025526674,0.0007612018,0.0037138208,0.007895495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004922211,0.00004881648,0.000120535035,0.0058110496,0.000034184173,0.0002733012,0.00011649024,0.00011983335,0.00060933986,0.003942664,0.46189287,0.5269816],"study_design_scores_gemma":[0.0000059971585,0.00002228848,0.00015417863,0.0015460209,0.000012258378,0.00087429275,0.000046624944,0.00001615098,0.00008265276,0.0011311972,0.99610186,0.000006520105],"about_ca_topic_score_codex":0.001006366,"about_ca_topic_score_gemma":0.0023309006,"teacher_disagreement_score":0.009525711,"about_ca_system_score_codex":0.0005373908,"about_ca_system_score_gemma":0.00079537055,"threshold_uncertainty_score":0.03186667},"labels":[],"label_agreement":null},{"id":"W2151480309","doi":"10.1016/j.biopha.2006.08.003","title":"Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors","year":2006,"lang":"en","type":"review","venue":"Biomedicine & Pharmacotherapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"National Cancer Institute","keywords":"Receptor tyrosine kinase; Tyrosine kinase; Cancer research; Biology; Kinase; Signal transduction; JAK-STAT signaling pathway; Cell biology","score_opus":0.08842263659665611,"score_gpt":0.4154246812867952,"score_spread":0.3270020446901391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151480309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00136957,0.9964863,0.00027292824,0.0002172629,0.00010764386,0.0000048028246,0.000022491515,0.000009967451,0.0015090185],"genre_scores_gemma":[0.0067696366,0.9915645,0.00023137974,0.00018697129,0.00013819782,0.000009275911,0.000041926814,0.0000013830025,0.0010567777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998884,0.00001814639,0.000017303155,0.00002292676,0.000038735594,0.000014452641],"domain_scores_gemma":[0.99986255,0.00006904503,0.000029442977,0.0000056238528,0.00002477884,0.000008482464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037106677,0.0005155494,0.001562173,0.0010462053,0.00011042476,0.00048511397,0.000457537,0.00044425332,0.0017011694],"category_scores_gemma":[0.0004609623,0.00015966069,0.00026419226,0.0010968423,0.00026920412,0.00060171005,0.0002826869,0.00061515695,0.0006339493],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027658948,0.00007572677,0.0005960003,0.0045415726,0.0001247225,0.0005366016,0.00003490673,0.0005210189,0.007535767,0.0020608143,0.009481284,0.97421503],"study_design_scores_gemma":[0.00013590566,0.0005958246,0.0062446143,0.0016285055,0.00063318474,0.008830135,0.00010627553,0.00036913512,0.008289766,0.00316612,0.9699718,0.000028729786],"about_ca_topic_score_codex":0.00038373747,"about_ca_topic_score_gemma":0.0007915364,"teacher_disagreement_score":0.0017011694,"about_ca_system_score_codex":0.0003290978,"about_ca_system_score_gemma":0.00035643217,"threshold_uncertainty_score":0.005690992},"labels":[],"label_agreement":null},{"id":"W2151570682","doi":"10.1093/annonc/mdt393","title":"Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"Roche","keywords":"Medicine; CISH; Trastuzumab; Immunohistochemistry; Adenocarcinoma; Internal medicine; Biopsy; Pathology; Oncology; Cancer; Gastroenterology; In situ hybridization; Breast cancer; Gene expression","score_opus":0.07667223111877967,"score_gpt":0.4079110863048577,"score_spread":0.331238855186078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151570682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966414,0.0020319053,0.00024313205,0.00013099227,0.000030860636,0.000066849774,0.00014214696,0.00000888655,0.00070377754],"genre_scores_gemma":[0.99794,0.0004859877,0.00076005684,0.00031754078,0.00006791147,0.000032670403,0.00020401817,0.000012043934,0.0001797222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977791,0.0011719973,0.00012473854,0.00043308112,0.00026209393,0.00022910001],"domain_scores_gemma":[0.9973888,0.0009177668,0.0004464098,0.00043073195,0.0004328048,0.00038348767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051872446,0.001246803,0.0012389424,0.0010772865,0.00036414404,0.0013551861,0.0006685217,0.0010298506,0.0008114382],"category_scores_gemma":[0.004006528,0.00069433555,0.0011489678,0.00061490695,0.0007331843,0.0009874918,0.0010463354,0.0009401852,0.00027610236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01782779,0.0010938742,0.9421953,0.0001819615,0.0013295219,0.00044614618,0.00025872476,0.00025949176,0.008482159,0.00006703272,0.00032674187,0.02753134],"study_design_scores_gemma":[0.0023602087,0.00898089,0.9739536,0.00008809272,0.002372535,0.0019561509,0.00064232387,0.0018931308,0.0052191047,0.00020019687,0.0022952205,0.000038467977],"about_ca_topic_score_codex":0.0007758389,"about_ca_topic_score_gemma":0.00240624,"teacher_disagreement_score":0.0051872446,"about_ca_system_score_codex":0.00055698457,"about_ca_system_score_gemma":0.0006554046,"threshold_uncertainty_score":0.027433097},"labels":[],"label_agreement":null},{"id":"W2151726776","doi":"10.1200/jco.2012.30.15_suppl.lba506","title":"Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lapatinib; Breast cancer; Oncology; Protocol (science); Internal medicine; Clinical Oncology; Trastuzumab; Cancer; Family medicine; Gynecology; Medical physics; Alternative medicine; Pathology","score_opus":0.45636250260094796,"score_gpt":0.651772909540381,"score_spread":0.19541040693943307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151726776","genre_codex":"protocol","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22195897,0.020898892,0.013340544,0.009472269,0.0017098102,0.5387487,0.08516811,0.0009958517,0.10770685],"genre_scores_gemma":[0.2953069,0.014241779,0.025808165,0.008656655,0.00037985537,0.54757273,0.06863826,0.00027247844,0.039123144],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99693006,0.0020789963,0.0003078187,0.00013218363,0.00031680585,0.00023412007],"domain_scores_gemma":[0.99746776,0.0003868214,0.000564457,0.0002282453,0.00050037174,0.0008523355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071950345,0.0010096274,0.0013132723,0.00074610714,0.00093083916,0.0015295015,0.0026859064,0.0023471296,0.020509714],"category_scores_gemma":[0.0064236,0.0006594757,0.0016721477,0.0013832821,0.00058532093,0.0010518178,0.0009963774,0.0026999651,0.006164865],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6351563,0.012310531,0.0043142433,0.007264286,0.0014776607,0.0002464516,0.0003398488,0.003543409,0.019720964,0.0022604954,0.095373034,0.21799275],"study_design_scores_gemma":[0.50366163,0.14987323,0.03608572,0.0040627844,0.0022374883,0.0006242979,0.0005528114,0.002609143,0.0113716265,0.0033457985,0.28540155,0.00017392231],"about_ca_topic_score_codex":0.002912011,"about_ca_topic_score_gemma":0.0098037,"teacher_disagreement_score":0.020509714,"about_ca_system_score_codex":0.00246653,"about_ca_system_score_gemma":0.008496921,"threshold_uncertainty_score":0.06861186},"labels":[],"label_agreement":null},{"id":"W2152175171","doi":"10.1200/jco.2014.55.6092","title":"Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Saskatchewan; Saskatoon City Hospital; University of British Columbia; Health Sciences Centre; Ottawa Hospital; Kingston General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Breast cancer; Cancer; Epidermal growth factor receptor; Internal medicine; Gynecology","score_opus":0.19290715174566359,"score_gpt":0.5111243683464978,"score_spread":0.3182172166008342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152175171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588144,0.00066339615,0.00013590459,0.00020321325,0.000016071774,0.00006372102,0.001111256,0.000008369681,0.0019167156],"genre_scores_gemma":[0.9981852,0.0005566494,0.0001492419,0.000100446276,0.000009195136,0.000013577936,0.00067426823,0.0000051001534,0.00030628234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712914,0.0002542201,0.00014059545,0.00049882755,0.0012865758,0.00069062755],"domain_scores_gemma":[0.99079263,0.0005287818,0.0015485348,0.00045145157,0.0054034744,0.0012750699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019066647,0.0005853745,0.0004922164,0.0014375452,0.0029400773,0.0014286197,0.0013706987,0.0007434024,0.0021531782],"category_scores_gemma":[0.006723276,0.00068484095,0.0005178928,0.0042045433,0.0013849905,0.0005829014,0.0011259983,0.0011498694,0.00034548188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044438202,0.000018374323,0.9980983,0.000013735522,0.00001673175,0.00010324893,0.00020090272,0.000027545273,0.00009045574,0.000021384343,0.00021085814,0.0011540632],"study_design_scores_gemma":[0.000010503931,0.000052853233,0.99817955,0.000018559407,0.000026754871,0.00030981237,0.00063898496,0.00014321896,0.000055225464,0.000013074721,0.0005406092,0.000010975025],"about_ca_topic_score_codex":0.9626652,"about_ca_topic_score_gemma":0.9668723,"teacher_disagreement_score":0.0373348,"about_ca_system_score_codex":0.015313126,"about_ca_system_score_gemma":0.026045399,"threshold_uncertainty_score":0.111105025},"labels":[],"label_agreement":null},{"id":"W2152419134","doi":"10.1200/jco.2005.08.091","title":"Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Ovarian cancer; Gastroenterology; Adverse effect; Toxicity; Population; Nausea; Cancer; Phases of clinical research; Oncology","score_opus":0.23491025272936084,"score_gpt":0.6057291711774904,"score_spread":0.37081891844812953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152419134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257386,0.0019929616,0.00037403294,0.00041766322,0.00018880627,0.0028028698,0.00059962034,0.0000796315,0.0009704526],"genre_scores_gemma":[0.990625,0.0010012946,0.0012737392,0.0008305894,0.00023512993,0.0033493652,0.0011216331,0.00001876321,0.0015444298],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99951136,0.00026403545,0.000025751096,0.000076451004,0.00004299869,0.00007935626],"domain_scores_gemma":[0.99901414,0.00020747523,0.0002759242,0.000076052595,0.000044573884,0.00038186382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001516381,0.0013016317,0.0018805832,0.00032643016,0.00037609937,0.00092116016,0.00079318666,0.0011031196,0.0053237295],"category_scores_gemma":[0.0013668186,0.0005337892,0.00075747987,0.0004925895,0.0010328084,0.0005646607,0.00030755185,0.002518731,0.0007129884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94674313,0.0126059465,0.0035799132,0.00033450744,0.00055156293,0.00009803486,0.000074714044,0.0006271721,0.008893314,0.00013929245,0.0013865278,0.024965892],"study_design_scores_gemma":[0.90433353,0.09032737,0.0032737888,0.000013869074,0.00014533052,0.00007043036,0.00001688376,0.00042148095,0.00064045214,0.00006699586,0.00068074744,0.000009110294],"about_ca_topic_score_codex":0.0009776284,"about_ca_topic_score_gemma":0.0024065718,"teacher_disagreement_score":0.0053237295,"about_ca_system_score_codex":0.0008957889,"about_ca_system_score_gemma":0.0017167316,"threshold_uncertainty_score":0.017809689},"labels":[],"label_agreement":null},{"id":"W2152647863","doi":"10.1200/jco.2007.13.5467","title":"Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":545,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Trastuzumab; Medicine; Ejection fraction; Heart failure; Internal medicine; Breast cancer; Cyclophosphamide; Cardiac function curve; Cardiology; Cardiotoxicity; Oncology; Paclitaxel; Cancer; Surgery; Chemotherapy","score_opus":0.11133423106210778,"score_gpt":0.47525447235477447,"score_spread":0.3639202412926667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152647863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508107,0.002439423,0.000100622696,0.00049137225,0.00006968514,0.00032528554,0.00024147522,0.000012162076,0.0012388772],"genre_scores_gemma":[0.9956285,0.0010553766,0.00031751362,0.00052569574,0.00016334461,0.00046527802,0.0007337534,0.0000071516506,0.0011034783],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986449,0.001045424,0.0000345714,0.00011459655,0.0000852082,0.0000752828],"domain_scores_gemma":[0.9987362,0.0003256209,0.00045711448,0.00009815881,0.000066376095,0.00031654155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024816568,0.00064881676,0.00093118916,0.00024292254,0.00028636795,0.00054533145,0.000566269,0.0007276644,0.0023557262],"category_scores_gemma":[0.0018512143,0.00027977105,0.00085066375,0.00031844917,0.00058352394,0.00038669308,0.00029331382,0.0014662637,0.00029951837],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.952344,0.004922639,0.008308463,0.00034379703,0.0010230984,0.000062023755,0.00006741939,0.000956213,0.0031611838,0.00015282142,0.0019165423,0.026741652],"study_design_scores_gemma":[0.78746665,0.13457325,0.06927223,0.00016437336,0.0016066446,0.00024679198,0.000055188077,0.0019078475,0.0011538193,0.0003559184,0.0031652744,0.00003204772],"about_ca_topic_score_codex":0.0013813351,"about_ca_topic_score_gemma":0.004711665,"teacher_disagreement_score":0.0024816568,"about_ca_system_score_codex":0.0009933216,"about_ca_system_score_gemma":0.0011760354,"threshold_uncertainty_score":0.013124406},"labels":[],"label_agreement":null},{"id":"W2152734037","doi":"10.1038/sj.bjc.6605560","title":"Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer","year":2010,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of New Brunswick","funders":"","keywords":"NONMEM; Dosing; Medicine; Pharmacokinetics; Population; Breast cancer; Covariate; Monoclonal antibody; Oncology; Cancer; Pharmacology; Antibody; Internal medicine; Immunology; Statistics; Mathematics","score_opus":0.03689079871606183,"score_gpt":0.4347484097484792,"score_spread":0.3978576110324174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152734037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772271,0.00048540503,0.019709611,0.000101640915,0.000010019818,0.00030504505,0.0012306236,0.00017263586,0.00075791037],"genre_scores_gemma":[0.98354834,0.0003823295,0.010610676,0.00011594733,0.000016582882,0.000375227,0.004200881,0.000036879537,0.00071306416],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99928623,0.0004204528,0.00002687624,0.000106061045,0.00012784512,0.000032534892],"domain_scores_gemma":[0.99875176,0.0007062535,0.00022790163,0.00014059505,0.000115255716,0.000058291782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031380532,0.00046998143,0.00094689976,0.00023694523,0.00011693194,0.0005644807,0.00045289245,0.00047852984,0.0014390231],"category_scores_gemma":[0.0036560455,0.00027225298,0.0006170633,0.00034510545,0.00027677204,0.0003239222,0.00024230538,0.0009974213,0.00030403535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051499583,0.0053946422,0.09493023,0.0016456174,0.003460007,0.00095350493,0.0012582119,0.34699506,0.29726622,0.0015413383,0.0067721833,0.18828346],"study_design_scores_gemma":[0.0066349925,0.10895961,0.21775691,0.00007779517,0.0036030973,0.005229739,0.00016476873,0.46404877,0.17022914,0.0027711648,0.020236684,0.00028733353],"about_ca_topic_score_codex":0.0010672448,"about_ca_topic_score_gemma":0.00083072163,"teacher_disagreement_score":0.0031380532,"about_ca_system_score_codex":0.0006982819,"about_ca_system_score_gemma":0.00088568125,"threshold_uncertainty_score":0.01659578},"labels":[],"label_agreement":null},{"id":"W2152743371","doi":"10.1186/s12964-014-0047-9","title":"TrkB interacts with ErbB4 and regulates NRG1-induced NR2B phosphorylation in cortical neurons before synaptogenesis","year":2014,"lang":"en","type":"article","venue":"Cell Communication and Signaling","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, New York University; National Institutes of Health; York University; Multiple Sclerosis Society; Okinawa Institute of Science and Technology Graduate University; National Institute of Neurological Disorders and Stroke; University of South Carolina","keywords":"Tropomyosin receptor kinase B; ErbB; Neuregulin 1; Cell biology; Neuroscience; Chemistry; Synaptogenesis; Neurotrophic factors; Receptor; Signal transduction; Biology; Biochemistry","score_opus":0.027448658851044132,"score_gpt":0.297390197927738,"score_spread":0.2699415390766939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152743371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107504,0.005412249,0.0009512173,0.00019316674,0.00005231595,0.0000177281,0.0005429169,0.00008198265,0.0016732351],"genre_scores_gemma":[0.9915843,0.0022642338,0.00095416204,0.00011377537,0.000011500509,0.000042127012,0.0008557455,0.00002945554,0.0041448255],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987316,0.000011025545,0.0000076011174,0.00003071804,0.000025348078,0.000052077587],"domain_scores_gemma":[0.999938,0.0000031308564,0.000023460472,0.0000042358993,0.000008417281,0.000022623339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008282113,0.00040921097,0.00023955139,0.00018400374,0.00024795238,0.00018948746,0.00027566572,0.00019993375,0.0023438046],"category_scores_gemma":[0.00010374028,0.00015771844,0.00043357385,0.00012672458,0.0001685751,0.00015024056,0.00022438448,0.00047337622,0.00074270956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032204736,0.000025788848,0.00054609386,0.00011203383,0.000014633211,0.000095918396,0.000016047745,0.000037641512,0.99751556,0.000053898664,0.00012388686,0.001136536],"study_design_scores_gemma":[0.00014326014,0.0004890252,0.093453206,0.00006224347,0.00009295678,0.00097003934,0.00017282252,0.0012058729,0.8988227,0.00014020683,0.004431547,0.000016111127],"about_ca_topic_score_codex":0.0024121327,"about_ca_topic_score_gemma":0.004422032,"teacher_disagreement_score":0.0024121327,"about_ca_system_score_codex":0.0005045843,"about_ca_system_score_gemma":0.00027858926,"threshold_uncertainty_score":0.007840812},"labels":[],"label_agreement":null},{"id":"W2152770850","doi":"10.1158/1078-0432.ccr-07-1216","title":"TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Amphiregulin; Epidermal growth factor receptor; Ectodomain; Cancer research; Epidermal growth factor; TGF alpha; Tyrosine kinase; Receptor tyrosine kinase; Growth factor receptor; EGFR inhibitors; Transforming growth factor; Biology; Chemistry; Kinase; Signal transduction; Cell biology; Receptor; Biochemistry","score_opus":0.30923134052828233,"score_gpt":0.5201451766951082,"score_spread":0.21091383616682585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152770850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392438,0.050958548,0.005060231,0.0008905658,0.00009886436,0.00009452561,0.0002796207,0.0001967749,0.0031771187],"genre_scores_gemma":[0.9806157,0.012345282,0.0037893432,0.00016937473,0.00006675187,0.00004390639,0.0004246298,0.000015036417,0.0025300067],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991715,0.000015661795,0.0000053934136,0.000011560582,0.000026380341,0.000023940445],"domain_scores_gemma":[0.999933,0.000007792607,0.0000207449,0.0000046279342,0.000013167574,0.000020662861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016463554,0.00032951534,0.00036887085,0.00024068073,0.00013741398,0.00039386854,0.00017912529,0.0002553962,0.0009379355],"category_scores_gemma":[0.00008954637,0.0000973979,0.00015494469,0.00020056078,0.00024487634,0.0002619824,0.0001690522,0.00056967355,0.00029121232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041415307,0.00009630376,0.0015124629,0.00024890713,0.000021218735,0.00035473326,0.000022260638,0.00019936533,0.97544503,0.00021944537,0.00026726536,0.021198813],"study_design_scores_gemma":[0.00014390932,0.0021150615,0.014611988,0.000029716406,0.000110992165,0.004743411,0.00007846302,0.0017433276,0.95681983,0.00018062412,0.019413238,0.000009383698],"about_ca_topic_score_codex":0.00025371043,"about_ca_topic_score_gemma":0.00059672934,"teacher_disagreement_score":0.0009379355,"about_ca_system_score_codex":0.00032983968,"about_ca_system_score_gemma":0.00025985276,"threshold_uncertainty_score":0.0031377077},"labels":[],"label_agreement":null},{"id":"W2153242757","doi":"10.3816/cbc.2004.n.010","title":"Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories","year":2004,"lang":"en","type":"review","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Roche (Canada); St. Boniface Hospital; Lions Gate Hospital; Ottawa Regional Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Regimen; Oncology; Internal medicine; Vinorelbine; Taxane; Metastatic breast cancer; Breast cancer; Chemotherapy; Cardiotoxicity; Cancer; Surgery; Cisplatin","score_opus":0.3380781820358026,"score_gpt":0.5386034532522701,"score_spread":0.20052527121646752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153242757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20248513,0.7913946,0.0006891155,0.00064197934,0.00006712859,0.000027667185,0.00045780977,0.000018591101,0.004217974],"genre_scores_gemma":[0.4848013,0.5124043,0.0007850423,0.0004842817,0.000096841424,0.000021810121,0.000700436,0.000015209461,0.00069069926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991704,0.00016765729,0.00023939194,0.00017921544,0.00017905398,0.00006429735],"domain_scores_gemma":[0.9961994,0.0021850334,0.00090539426,0.00022714435,0.00038512333,0.00009782567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007582078,0.00027087762,0.0006215521,0.0021295433,0.00025949674,0.0008844972,0.0006194291,0.00047516872,0.000958059],"category_scores_gemma":[0.005195558,0.00022045727,0.00037449438,0.003325878,0.00037957012,0.00074685627,0.0003307775,0.0003622408,0.00040813882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045105774,0.000106655556,0.47234562,0.006387965,0.00062312075,0.06496121,0.0024916155,0.0002361349,0.0041247085,0.0006417093,0.0063878642,0.44124237],"study_design_scores_gemma":[0.000027460987,0.00017582484,0.44315967,0.0048681824,0.0026153126,0.4532767,0.0031790766,0.00016790848,0.0027626858,0.0004753219,0.089236036,0.00005578525],"about_ca_topic_score_codex":0.0016917904,"about_ca_topic_score_gemma":0.0030600068,"teacher_disagreement_score":0.0021295433,"about_ca_system_score_codex":0.00037942198,"about_ca_system_score_gemma":0.00077781687,"threshold_uncertainty_score":0.0040097833},"labels":[],"label_agreement":null},{"id":"W2153491150","doi":"10.1093/annonc/mdf651","title":"Novel endpoints and design of early clinical trials","year":2002,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical trial; Clinical study design; Endpoint Determination; Surrogate endpoint; Medical physics; Intensive care medicine; Oncology; Internal medicine","score_opus":0.9128397694569303,"score_gpt":0.7023489934726278,"score_spread":0.21049077598430255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153491150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00082549464,0.98377764,0.00905713,0.0027361955,0.0015672526,0.0007442365,0.0001913652,0.000045029403,0.0010556726],"genre_scores_gemma":[0.02080967,0.9264272,0.038858987,0.006364074,0.003041784,0.0030304252,0.00044584507,0.000036886337,0.0009852307],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97244316,0.020531416,0.0028965536,0.001365676,0.0023798582,0.00038328278],"domain_scores_gemma":[0.9023519,0.085943155,0.0060814605,0.0017366011,0.0030675512,0.00081925455],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.06287299,0.0029404673,0.013226076,0.0023855271,0.00042777392,0.0053155096,0.004396926,0.004469396,0.004131166],"category_scores_gemma":[0.0788192,0.0009768384,0.004364889,0.0020573265,0.0016380909,0.0040039616,0.0017212664,0.0077747586,0.00086348323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009376723,0.00039101962,0.0012527242,0.06964909,0.0027807988,0.0002226223,0.00012273052,0.005262434,0.000935348,0.022901025,0.014806441,0.872299],"study_design_scores_gemma":[0.037309095,0.010387395,0.007513812,0.19160093,0.029579988,0.0018549613,0.00033958378,0.010300266,0.0047017448,0.19202255,0.51402783,0.00036183995],"about_ca_topic_score_codex":0.0004990146,"about_ca_topic_score_gemma":0.00096380437,"teacher_disagreement_score":0.937127,"about_ca_system_score_codex":0.002962505,"about_ca_system_score_gemma":0.0045908056,"threshold_uncertainty_score":0.33250815},"labels":[],"label_agreement":null},{"id":"W2154671238","doi":"10.1016/j.breast.2012.12.004","title":"Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status","year":2013,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Hormone receptor; Oncology; Breast cancer; Human Epidermal Growth Factor Receptor 2; Hormone; Metastatic breast cancer; Internal medicine; Cancer; Regimen; Hormone therapy; Receptor","score_opus":0.08686729125714283,"score_gpt":0.3959840605294179,"score_spread":0.3091167692722751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154671238","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010954322,0.004762935,0.0037328412,0.8901518,0.09090583,0.0004492824,0.00045851173,0.00030485005,0.008138492],"genre_scores_gemma":[0.0076470673,0.0073804995,0.028854894,0.8694033,0.06692289,0.0009871797,0.00060964574,0.00017224002,0.018022297],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9761969,0.006915653,0.0055119838,0.0012330489,0.008962818,0.0011796699],"domain_scores_gemma":[0.7778236,0.042339332,0.008244549,0.0049150134,0.15940155,0.007275858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020912586,0.0010378818,0.0018682656,0.0022308198,0.002333308,0.0028328637,0.0059686005,0.032077365,0.009197447],"category_scores_gemma":[0.11401742,0.0010067957,0.002652117,0.0020650004,0.0036353131,0.0038633177,0.0016186868,0.018696534,0.016901573],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004033835,0.00004555333,0.00052347203,0.00026011866,0.000016496717,0.0003879244,0.00013473048,0.0001043716,0.0003301328,0.00030191304,0.97909683,0.018758187],"study_design_scores_gemma":[0.00011746223,0.000068747206,0.0020006986,0.0019544198,0.000101947895,0.0016742205,0.00073376065,0.0006801859,0.00076218706,0.0035340223,0.98821485,0.00015749813],"about_ca_topic_score_codex":0.007409646,"about_ca_topic_score_gemma":0.014131234,"teacher_disagreement_score":0.032077365,"about_ca_system_score_codex":0.0024626378,"about_ca_system_score_gemma":0.009708137,"threshold_uncertainty_score":0.11059767},"labels":[],"label_agreement":null},{"id":"W2155724119","doi":"10.1158/1078-0432.ccr-05-1652","title":"Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Imatinib mesylate; Prostate cancer; Tissue microarray; Cancer research; Medicine; Cancer; Immunohistochemistry; Pathology; Laser capture microdissection; Gene expression; Oncology; Biology; Internal medicine; Imatinib; Gene","score_opus":0.27743457004309985,"score_gpt":0.5688233716791935,"score_spread":0.29138880163609365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155724119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840285,0.002168245,0.01086132,0.00015984272,0.00003646722,0.00010010928,0.0012979949,0.0001255229,0.0012219686],"genre_scores_gemma":[0.97627705,0.0010989663,0.01882103,0.00017343607,0.000024607147,0.00028807585,0.0022548456,0.00001243156,0.0010497007],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997557,0.0000668785,0.000015653266,0.00006187923,0.0000731261,0.000026808004],"domain_scores_gemma":[0.99986625,0.000052494233,0.000031857893,0.000013823472,0.000024445912,0.0000111271065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023548875,0.00019949654,0.0002116241,0.00028004326,0.00013971106,0.00019324874,0.00009116175,0.00021917504,0.00069894636],"category_scores_gemma":[0.00034235578,0.0001327616,0.00014959229,0.00023286395,0.00012993341,0.00011732364,0.00008685299,0.0002829336,0.00024063209],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015486793,0.000032347463,0.0034348844,0.000041125517,0.000018549596,0.000018737957,0.00001677364,0.00032573708,0.9911691,0.000023469469,0.000079932106,0.004684483],"study_design_scores_gemma":[0.00004239194,0.001649949,0.13679546,0.000016247322,0.00014622464,0.00053123076,0.00009039078,0.0086783925,0.84818226,0.00019626881,0.0036491842,0.00002205915],"about_ca_topic_score_codex":0.00027531272,"about_ca_topic_score_gemma":0.0007298973,"teacher_disagreement_score":0.00069894636,"about_ca_system_score_codex":0.0002583816,"about_ca_system_score_gemma":0.00017197529,"threshold_uncertainty_score":0.0023382306},"labels":[],"label_agreement":null},{"id":"W2155980759","doi":"10.3747/co.2008.199","title":"Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group","year":2008,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Oncology; Anthracycline; Breast cancer; Internal medicine; Adjuvant therapy; Population; Clinical trial; Adjuvant; Targeted therapy; Intensive care medicine; Cancer; Chemotherapy","score_opus":0.22211101870424318,"score_gpt":0.42467998267004725,"score_spread":0.20256896396580407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155980759","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027011747,0.020990942,0.005912869,0.91549057,0.014588118,0.0019449356,0.0014912225,0.00027206328,0.03660809],"genre_scores_gemma":[0.04783632,0.09494016,0.1620773,0.58863187,0.026401902,0.0046551307,0.0076435274,0.00032171165,0.067492105],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98680633,0.0029706338,0.0021336458,0.00035004137,0.006332428,0.0014069102],"domain_scores_gemma":[0.92657715,0.007395489,0.0032976484,0.0010164256,0.0522984,0.009414755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018038081,0.0012343586,0.0018520799,0.0039669345,0.004136969,0.0028043268,0.0074462327,0.013178069,0.0031335677],"category_scores_gemma":[0.043449078,0.0006935397,0.0023588224,0.0028071871,0.0026995877,0.0020189965,0.0020017438,0.014748369,0.0023774598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007855558,0.0001519719,0.0032533268,0.0005011308,0.000041708656,0.00048098827,0.00038800648,0.00077417237,0.00048171106,0.0019402137,0.89344627,0.09846195],"study_design_scores_gemma":[0.00016784394,0.00009129243,0.010146342,0.0036095737,0.00014617539,0.0003938291,0.00078928954,0.0010154777,0.00041912377,0.003162875,0.97991735,0.00014086081],"about_ca_topic_score_codex":0.40290985,"about_ca_topic_score_gemma":0.5641802,"teacher_disagreement_score":0.9855036,"about_ca_system_score_codex":0.014496384,"about_ca_system_score_gemma":0.10169942,"threshold_uncertainty_score":0.8011293},"labels":[],"label_agreement":null},{"id":"W2156373035","doi":"10.1021/cb500129t","title":"Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?","year":2014,"lang":"en","type":"review","venue":"ACS Chemical Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Small molecule; Drug discovery; Kinase; Binding site; Chemistry; Stereochemistry; Active site; Plasma protein binding; Biophysics; Enzyme; Combinatorial chemistry; Biochemistry; Biology","score_opus":0.13086901584217306,"score_gpt":0.41855666171176176,"score_spread":0.2876876458695887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156373035","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015373973,0.98537165,0.0032723856,0.0008731115,0.00035547587,0.000032033495,0.000059887665,0.00006653389,0.008431493],"genre_scores_gemma":[0.007010276,0.9858372,0.002306978,0.0006715449,0.00021365315,0.000030038615,0.00007088938,0.000008280977,0.0038510622],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998919,0.000018119508,0.000007972922,0.000022313367,0.000039408595,0.000020225574],"domain_scores_gemma":[0.99993217,0.00001843686,0.000012970283,0.000005344831,0.000019245566,0.0000118570315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003536801,0.0006745996,0.0010803399,0.0009492632,0.00024544785,0.0009156979,0.00094586506,0.00075041805,0.003085321],"category_scores_gemma":[0.0002298687,0.00031413592,0.00045679705,0.0009840741,0.00051388936,0.0014589619,0.00057016267,0.0013204771,0.0027567819],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009783224,0.00011481922,0.00024191807,0.009417305,0.00009897338,0.00043855282,0.00013631715,0.00092129974,0.027451886,0.026018929,0.0264326,0.9086295],"study_design_scores_gemma":[0.000031953823,0.00029124308,0.00038052627,0.0012090806,0.0000742535,0.0020274895,0.0000736368,0.00039928663,0.005495705,0.006011841,0.98397315,0.00003178629],"about_ca_topic_score_codex":0.0004602287,"about_ca_topic_score_gemma":0.0010892992,"teacher_disagreement_score":0.003085321,"about_ca_system_score_codex":0.00045063873,"about_ca_system_score_gemma":0.00053748995,"threshold_uncertainty_score":0.010321379},"labels":[],"label_agreement":null},{"id":"W2158179945","doi":"10.1016/s1470-2045(03)01137-9","title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto","funders":"Cancer Research Society; American Association for Cancer Research","keywords":"Erlotinib; Gefitinib; Cetuximab; Epidermal growth factor receptor; Medicine; Lung cancer; Amphiregulin; Cancer research; Epidermal growth factor; Tyrosine kinase; Cancer; Carcinogenesis; Trastuzumab; Oncology; Receptor; Internal medicine; Colorectal cancer; Breast cancer","score_opus":0.39172005433816587,"score_gpt":0.5739504872546254,"score_spread":0.18223043291645952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158179945","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004716542,0.99932003,0.00005771426,0.00013754886,0.00015167113,0.0000053647364,0.000017415792,0.0000053588356,0.00025768828],"genre_scores_gemma":[0.00023900547,0.99904066,0.00016061883,0.00021115121,0.000100892816,0.000005061541,0.000025945295,9.353182e-7,0.0002156656],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996449,0.00006148045,0.00006578351,0.000057333968,0.00014339185,0.000027158792],"domain_scores_gemma":[0.9992262,0.0004164919,0.00011855074,0.000014608303,0.00016776293,0.0000564644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010755084,0.0013391139,0.0038057612,0.003485259,0.00026332392,0.001321201,0.0013837051,0.001503761,0.003245525],"category_scores_gemma":[0.00126512,0.00035735863,0.0009522502,0.004961019,0.00047969006,0.0016331279,0.0005940362,0.001866665,0.0015335513],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026745233,0.000092680966,0.00014551869,0.040974498,0.0002793859,0.00026088135,0.000050737926,0.0003677433,0.0015989777,0.0014728556,0.06305405,0.89143527],"study_design_scores_gemma":[0.00019223952,0.0002791893,0.0011981896,0.013436478,0.000812893,0.001614105,0.000108762724,0.00014231133,0.00041565357,0.0012787783,0.9804834,0.00003798066],"about_ca_topic_score_codex":0.0020737515,"about_ca_topic_score_gemma":0.0059457175,"teacher_disagreement_score":0.0038057612,"about_ca_system_score_codex":0.0009511952,"about_ca_system_score_gemma":0.0016443095,"threshold_uncertainty_score":0.010857403},"labels":[],"label_agreement":null},{"id":"W2158757667","doi":"10.1124/mol.107.036111","title":"The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor","year":2007,"lang":"en","type":"article","venue":"Molecular Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"National Cancer Institute; Canadian Breast Cancer Research Alliance; Breast Cancer Alliance","keywords":"Chromatin immunoprecipitation; Molecular biology; Protein kinase B; Biology; Cell culture; Epidermal growth factor receptor; Growth inhibition; Cancer research; Cell growth; Phosphorylation; Receptor; Promoter; Biochemistry; Gene expression; Gene","score_opus":0.025892257351910173,"score_gpt":0.3415121767235288,"score_spread":0.3156199193716186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158757667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97701013,0.005440099,0.0043827323,0.00054489885,0.0003003118,0.00016260757,0.0014723408,0.00091796863,0.009768874],"genre_scores_gemma":[0.9856301,0.0031281027,0.0037582922,0.00012287061,0.00005419225,0.00015716905,0.0018464469,0.000046103207,0.005256798],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997634,0.00003359939,0.000021947855,0.000030474166,0.000055911383,0.00009472295],"domain_scores_gemma":[0.99990964,0.000017179316,0.000024392572,0.000015727595,0.0000052475157,0.000027723274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020808498,0.0006259645,0.0006293293,0.00044750585,0.00028293763,0.00038125066,0.0006810822,0.00039100993,0.0026084746],"category_scores_gemma":[0.00016466239,0.00029375992,0.00043405022,0.00030804484,0.0003289237,0.00032306943,0.00019556987,0.0012493083,0.0010330963],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014200808,0.0002768895,0.0002224384,0.00010702177,0.000033724966,0.0001495577,0.000031627063,0.0001591499,0.98742515,0.00068120006,0.00079880154,0.008694288],"study_design_scores_gemma":[0.00039043478,0.0012531264,0.0033491214,0.000009003303,0.000030434552,0.00040143987,0.000028414152,0.00079644786,0.9877588,0.000095851865,0.0058749374,0.0000120616605],"about_ca_topic_score_codex":0.0015807134,"about_ca_topic_score_gemma":0.0041147997,"teacher_disagreement_score":0.0026084746,"about_ca_system_score_codex":0.00058157207,"about_ca_system_score_gemma":0.00067293685,"threshold_uncertainty_score":0.008726239},"labels":[],"label_agreement":null},{"id":"W2158888632","doi":"10.1177/1078155206069163","title":"Acute reactions to chemotherapy agents","year":2006,"lang":"en","type":"review","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Chemotherapy; Drug reaction; Cancer chemotherapy; Intensive care medicine; Hypersensitivity reaction; Pharmacology; Drug; Internal medicine","score_opus":0.29334632879909167,"score_gpt":0.6308276500863238,"score_spread":0.3374813212872321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158888632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013052397,0.99157786,0.0005216019,0.00042422276,0.00031968005,0.000081057806,0.000060113325,0.00003883393,0.0056713386],"genre_scores_gemma":[0.011497416,0.98250383,0.00059886405,0.0011660072,0.00046576056,0.00007753284,0.00011371771,0.0000072308985,0.0035696207],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984982,0.00041226673,0.00023849057,0.00012542377,0.0005915682,0.00013398204],"domain_scores_gemma":[0.9978033,0.0008711438,0.00083677314,0.000056633722,0.0003412374,0.00009092208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009961881,0.001098483,0.0019359398,0.0011247713,0.00038428273,0.0009693663,0.0008034548,0.0012786442,0.0059603173],"category_scores_gemma":[0.0027586638,0.0003170188,0.0011804457,0.0013945723,0.0004719709,0.0008306203,0.00074939214,0.0014588847,0.0022370333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029028443,0.00021513349,0.0022340526,0.024171807,0.0003230024,0.002275831,0.00015753032,0.0003194399,0.0044763456,0.0012857195,0.047400344,0.9168505],"study_design_scores_gemma":[0.0003004156,0.00088185375,0.01190287,0.014021945,0.0006221183,0.027145892,0.0002398779,0.00019505677,0.0053782603,0.0018581417,0.93740684,0.00004668304],"about_ca_topic_score_codex":0.00089576066,"about_ca_topic_score_gemma":0.0015652701,"teacher_disagreement_score":0.0059603173,"about_ca_system_score_codex":0.00049080426,"about_ca_system_score_gemma":0.00068770204,"threshold_uncertainty_score":0.019939244},"labels":[],"label_agreement":null},{"id":"W2159471993","doi":"10.2217/14796694.2.6.765","title":"Erbb Receptors and Epithelial-Cadherin–Catenin Complex In Human Carcinomas","year":2006,"lang":"en","type":"review","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Cadherin; Medicine; Receptor; Catenin; ErbB; Cancer research; Signal transduction; Internal medicine; Biology; Cell biology; Cell; Wnt signaling pathway; Genetics","score_opus":0.1385490509996071,"score_gpt":0.46228533226736784,"score_spread":0.3237362812677608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159471993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011091844,0.99881893,0.000064791624,0.00010666698,0.000100955505,0.0000026745965,0.0000056165422,0.000005520377,0.0007839612],"genre_scores_gemma":[0.00060004677,0.9982187,0.00010607634,0.00009011283,0.00009679772,0.0000029243959,0.000014994291,6.715752e-7,0.0008695211],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983895,0.000024107374,0.000020155667,0.00002748909,0.00007376329,0.000015511425],"domain_scores_gemma":[0.99987125,0.000044335593,0.000019370671,0.0000044725084,0.000046266272,0.00001420356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003924675,0.0007840191,0.0012337974,0.0021506238,0.00023982425,0.00063935196,0.0006916624,0.0009325564,0.0032260166],"category_scores_gemma":[0.0003521936,0.00026389997,0.0003266017,0.0022610936,0.00035162678,0.0010494275,0.00043725167,0.0011282606,0.0027032478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007897299,0.000084255174,0.0002656855,0.008208491,0.00006056005,0.0005267335,0.00006483633,0.00030955262,0.0028376323,0.0022841855,0.031051543,0.95422757],"study_design_scores_gemma":[0.000018841674,0.00008382271,0.0012951164,0.0016707061,0.00007639914,0.003554938,0.00005471959,0.00006423852,0.0006820993,0.0012236986,0.9912617,0.000013694111],"about_ca_topic_score_codex":0.0012552291,"about_ca_topic_score_gemma":0.0021383627,"teacher_disagreement_score":0.0032260166,"about_ca_system_score_codex":0.00070039165,"about_ca_system_score_gemma":0.00072476297,"threshold_uncertainty_score":0.010792077},"labels":[],"label_agreement":null},{"id":"W2159702901","doi":"","title":"A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Colorectal cancer; Epidermal growth factor receptor; Cancer; Medicine; Epidermal growth factor; Immunohistochemistry; Cancer research; Apoptosis; Pathology; Internal medicine; Biology; Receptor","score_opus":0.041943268200244736,"score_gpt":0.32484394502425135,"score_spread":0.2829006768240066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159702901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968003,0.0017266579,0.0002449063,0.00015916262,0.000027428843,0.00019398678,0.0003702901,0.000024696637,0.00045247926],"genre_scores_gemma":[0.9980013,0.00049319596,0.0003974653,0.0001250416,0.000049944494,0.0001181604,0.00042923205,0.0000041270046,0.0003815534],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999691,0.00011750434,0.00002039794,0.00005889694,0.00006755582,0.000044613105],"domain_scores_gemma":[0.9995198,0.00008292253,0.00016656413,0.000024255296,0.000038519847,0.00016792654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004488786,0.00064880593,0.0012042389,0.0002819905,0.0002600664,0.00037871877,0.00030034105,0.00048767042,0.0015750095],"category_scores_gemma":[0.0010472593,0.0002837221,0.0006437798,0.00035182963,0.0003285044,0.0003140341,0.00016932774,0.00091519987,0.0003062603],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5259943,0.016712349,0.18839312,0.0008767205,0.002271595,0.000970954,0.00019969458,0.0032138175,0.09629372,0.0002228909,0.002158612,0.16269213],"study_design_scores_gemma":[0.079023615,0.4158558,0.4719714,0.000040803392,0.001897792,0.0017600205,0.00011030109,0.0037278333,0.01698161,0.00015187809,0.008415684,0.00006321043],"about_ca_topic_score_codex":0.000652107,"about_ca_topic_score_gemma":0.0013647382,"teacher_disagreement_score":0.0015750095,"about_ca_system_score_codex":0.0007708413,"about_ca_system_score_gemma":0.0005933424,"threshold_uncertainty_score":0.005592823},"labels":[],"label_agreement":null},{"id":"W2159967578","doi":"10.1056/nejmoa1209124","title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3784,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Trastuzumab emtansine; Trastuzumab; Antibody-drug conjugate; Medicine; Cytotoxic T cell; Metastatic breast cancer; Conjugate; Breast cancer; Oncology; Antibody; Linker; Cancer research; Cancer; Monoclonal antibody; Pharmacology; Internal medicine; Immunology; In vitro; Biology","score_opus":0.0357706020618461,"score_gpt":0.39034594249539695,"score_spread":0.3545753404335508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159967578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95177466,0.03665848,0.0018413197,0.0016850499,0.00027386137,0.0014278047,0.00037884383,0.00004560623,0.0059142495],"genre_scores_gemma":[0.9864075,0.008929901,0.0015379615,0.0006324224,0.0002217745,0.000512834,0.00033848177,0.00000675912,0.001412186],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99952006,0.00028304892,0.00004914189,0.000048744118,0.00006438853,0.000034663193],"domain_scores_gemma":[0.99961436,0.00014382506,0.00011113599,0.000022235508,0.000029602581,0.00007883421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012525121,0.00020496194,0.0006377842,0.00022862785,0.00012620736,0.00024867355,0.00018205908,0.00023799375,0.0022084403],"category_scores_gemma":[0.0012695919,0.000062077896,0.00030394955,0.0001897603,0.00016769735,0.00014288852,0.00017512948,0.0004034406,0.00026079267],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17942913,0.0032851717,0.0196005,0.003576882,0.0010460559,0.000815886,0.00020496461,0.0041920445,0.029896537,0.0012851312,0.0070850938,0.74958265],"study_design_scores_gemma":[0.3092201,0.28321773,0.14114402,0.0018335914,0.004356595,0.00910824,0.00020054694,0.009094613,0.041342277,0.005316231,0.19506858,0.00009758649],"about_ca_topic_score_codex":0.0001707179,"about_ca_topic_score_gemma":0.00046637724,"teacher_disagreement_score":0.0022084403,"about_ca_system_score_codex":0.00045418172,"about_ca_system_score_gemma":0.00044506244,"threshold_uncertainty_score":0.0073879957},"labels":[],"label_agreement":null},{"id":"W2160094174","doi":"10.1074/jbc.m107430200","title":"Phosphorylation-dependent Interactions between ADAM15 Cytoplasmic Domain and Src Family Protein-tyrosine Kinases","year":2002,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Proto-oncogene tyrosine-protein kinase Src; Cell biology; Phosphorylation; Tyrosine phosphorylation; SH2 domain; Biology; Src family kinase; Tyrosine-protein kinase CSK; Jurkat cells; SH3 domain; Biochemistry; Chemistry; T cell","score_opus":0.07511904364356263,"score_gpt":0.32698705736043826,"score_spread":0.2518680137168756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160094174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995773,0.0017923791,0.0012624077,0.000034980192,0.000016209211,0.000009351506,0.00013097428,0.000014582413,0.0009660722],"genre_scores_gemma":[0.9960486,0.00085931964,0.00096676906,0.000028559427,0.0000080494665,0.0000157568,0.0005770883,0.000005324474,0.0014905311],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997805,0.00004924107,0.000019977953,0.000035749646,0.000052426345,0.000062071194],"domain_scores_gemma":[0.99990463,0.000023578432,0.000023186067,0.000012872479,0.000012979193,0.000022727418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001547886,0.00027926124,0.00018847855,0.00011626052,0.00015463606,0.00023596207,0.00020979567,0.00016042386,0.0013612716],"category_scores_gemma":[0.00016144586,0.00014223425,0.00033499417,0.00012948246,0.00014247533,0.00021029335,0.00029828842,0.00032734455,0.00035041335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017229775,0.00002240825,0.0009893482,0.000056872195,0.000017303471,0.00018083445,0.000029273147,0.00004995145,0.9972953,0.00015345831,0.000051169918,0.0009817535],"study_design_scores_gemma":[0.000013596848,0.00010110302,0.018434823,0.000008196223,0.00002145553,0.00092683727,0.000033999335,0.0013894335,0.97629935,0.000060633665,0.0027050725,0.000005619901],"about_ca_topic_score_codex":0.00044517533,"about_ca_topic_score_gemma":0.0007169552,"teacher_disagreement_score":0.0013612716,"about_ca_system_score_codex":0.0002969684,"about_ca_system_score_gemma":0.00014760732,"threshold_uncertainty_score":0.004553914},"labels":[],"label_agreement":null},{"id":"W2160227358","doi":"10.1016/j.bmcl.2007.01.002","title":"New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases","year":2007,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Industrielle du Québec","funders":"","keywords":"Chemistry; Morpholine; Kinase; Tyrosine kinase; Biochemistry; Receptor tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Signal transduction; Cancer","score_opus":0.017555498955955266,"score_gpt":0.2870311224545731,"score_spread":0.2694756234986178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160227358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94337475,0.016551025,0.014600874,0.00056956394,0.00030682154,0.00026648527,0.00071120204,0.0007296163,0.022889663],"genre_scores_gemma":[0.9806645,0.0051175635,0.0040332237,0.00024886773,0.00006484911,0.00010652322,0.00056306116,0.00003078132,0.0091705015],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989486,0.000013024299,0.000006665726,0.000012971196,0.00001843489,0.000053976393],"domain_scores_gemma":[0.9999603,0.0000050406725,0.000011444711,0.000003016377,0.000004339914,0.000015959024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001791265,0.00051802985,0.0004997177,0.00027473507,0.00023596139,0.00026845007,0.0005607642,0.0003147577,0.002978895],"category_scores_gemma":[0.00009927922,0.00020538198,0.0002520413,0.00022088797,0.00017716477,0.00034548732,0.00028990066,0.0007388083,0.00050348986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019509133,0.00032067703,0.0003442808,0.0004701239,0.000065954366,0.0010311059,0.00016107594,0.0016231652,0.9292618,0.0035939293,0.002107365,0.05906976],"study_design_scores_gemma":[0.0014275135,0.007334754,0.005467756,0.000075744465,0.00019638488,0.0045365854,0.00008347941,0.008103825,0.9168492,0.0006311819,0.055213034,0.00008049956],"about_ca_topic_score_codex":0.0006324035,"about_ca_topic_score_gemma":0.00211437,"teacher_disagreement_score":0.002978895,"about_ca_system_score_codex":0.0004641221,"about_ca_system_score_gemma":0.00022862261,"threshold_uncertainty_score":0.00996536},"labels":[],"label_agreement":null},{"id":"W2161167126","doi":"10.1186/2191-219x-1-15","title":"A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT","year":2011,"lang":"en","type":"article","venue":"EJNMMI Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; DOTA; Biodistribution; Trastuzumab; Nuclear medicine; Radioligand; Cancer research; Molecular biology; Receptor; Cancer; Chemistry; Internal medicine; In vitro; Chelation; Breast cancer; Biology; Biochemistry","score_opus":0.27577670028732565,"score_gpt":0.5097644154305634,"score_spread":0.23398771514323774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161167126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725963,0.00439141,0.019983288,0.000117451484,0.00003138589,0.00017439558,0.0006207003,0.0002160187,0.0018689657],"genre_scores_gemma":[0.96635365,0.0023990797,0.027505258,0.00009722029,0.000020192701,0.00019242038,0.0012680183,0.00013387119,0.0020302061],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997805,0.000050103437,0.0000106954885,0.000053863216,0.00005964759,0.00004527444],"domain_scores_gemma":[0.99968255,0.000092317176,0.00007517002,0.000019757,0.00005434261,0.00007588975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006326893,0.0006309373,0.0003552396,0.0005169969,0.00014784734,0.00046774404,0.00049021747,0.00059118494,0.0012370775],"category_scores_gemma":[0.0003314802,0.00025989115,0.00021286076,0.00023028135,0.00026093345,0.0004539263,0.00015282282,0.00057244644,0.000254525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005354733,0.000049715203,0.0002140874,0.000048418762,0.000009602842,0.000022408676,0.000012183468,0.00020299623,0.9975217,0.000037793103,0.000041602638,0.0013039231],"study_design_scores_gemma":[0.00008052535,0.0021245328,0.0036290295,0.000008272805,0.000053183976,0.00043811952,0.000017670205,0.0037715982,0.98906124,0.000024798552,0.00078132603,0.000009752618],"about_ca_topic_score_codex":0.0015796894,"about_ca_topic_score_gemma":0.0017124133,"teacher_disagreement_score":0.0015796894,"about_ca_system_score_codex":0.0006289893,"about_ca_system_score_gemma":0.00027595865,"threshold_uncertainty_score":0.004563689},"labels":[],"label_agreement":null},{"id":"W2161820433","doi":"10.1016/j.schres.2007.12.474","title":"Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients","year":2008,"lang":"en","type":"article","venue":"Schizophrenia Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; National Institutes of Health","keywords":"Neuregulin 1; ERBB4; Prefrontal cortex; Cytoplasm; Schizophrenia (object-oriented programming); Neuregulin; Internal medicine; Receptor; Endocrinology; Psychosis; Chemistry; Psychology; Biology; Medicine; Neuroscience; Cognition; Biochemistry; Psychiatry; Receptor tyrosine kinase","score_opus":0.07418656636318365,"score_gpt":0.36201245867689796,"score_spread":0.2878258923137143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161820433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99956626,0.00016372392,0.000019211424,0.000023095126,0.0000018404742,0.0000010219076,0.000053295244,0.0000014892211,0.00017013313],"genre_scores_gemma":[0.9996873,0.00009525127,0.000028150878,0.000017254875,0.0000018980553,0.0000015500372,0.000038522558,8.8069663e-7,0.00012928118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99994934,0.000008503937,0.0000043945843,0.000009918812,0.000011405057,0.00001642754],"domain_scores_gemma":[0.99985075,0.000027814458,0.000062405285,0.0000066317502,0.00001916998,0.000033132954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013737245,0.00026852687,0.0002338333,0.00063393847,0.00036190628,0.0003458958,0.00012985984,0.00021751289,0.0014228582],"category_scores_gemma":[0.00045637594,0.00021574978,0.000110692636,0.00019952927,0.00025340947,0.00015226618,0.00019787134,0.00024143091,0.000121811645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048443144,0.00021530293,0.7644718,0.0001479363,0.000301317,0.007933019,0.0014642379,0.00025381302,0.20932384,0.00027433576,0.00034829997,0.010421811],"study_design_scores_gemma":[0.000031034982,0.000098323086,0.9939183,0.0000067441943,0.000049083144,0.0030136933,0.000551501,0.00014161899,0.0019184565,0.00012374762,0.0001413846,0.0000060617363],"about_ca_topic_score_codex":0.008778428,"about_ca_topic_score_gemma":0.008739723,"teacher_disagreement_score":0.008778428,"about_ca_system_score_codex":0.00046029693,"about_ca_system_score_gemma":0.0002782033,"threshold_uncertainty_score":0.017454624},"labels":[],"label_agreement":null},{"id":"W2162419009","doi":"10.1080/02841860410028574","title":"ErbB4 is downregulated in renal cell carcinoma A quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family","year":2004,"lang":"en","type":"article","venue":"Acta Oncologica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Cancerfonden","keywords":"Immunohistochemistry; ERBB4; Renal cell carcinoma; Medicine; Pathology; Epidermal growth factor receptor; ERBB3; Messenger RNA; Renal cortex; Kidney; Real-time polymerase chain reaction; Cancer research; Kidney cancer; Receptor; Biology; Internal medicine; Gene","score_opus":0.051236160636602135,"score_gpt":0.34623992357320915,"score_spread":0.295003762936607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162419009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769294,0.000838613,0.0010006358,0.0000152112625,0.0000037825896,0.0000059808035,0.000059292288,0.000014819213,0.00036864151],"genre_scores_gemma":[0.9968195,0.00043807336,0.0016856005,0.000017366652,0.0000055158444,0.00001674185,0.00018927819,0.000006644729,0.0008211902],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99977595,0.00003814852,0.00001217781,0.00003880426,0.00009508971,0.00003982146],"domain_scores_gemma":[0.9997731,0.00006379633,0.00007309858,0.000020996707,0.000051414547,0.00001771996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021594964,0.00017459161,0.00018271385,0.00036002704,0.00015587262,0.00028207977,0.000115601324,0.00018975792,0.0009395718],"category_scores_gemma":[0.00040424828,0.0001503069,0.00014305551,0.00019712091,0.00020328736,0.00015011584,0.00011758762,0.00019100084,0.00026321525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031622438,0.000027746588,0.02717225,0.00007134668,0.000030611962,0.00034855996,0.000094247254,0.0001300581,0.96558684,0.00004788003,0.000039530514,0.006134734],"study_design_scores_gemma":[0.000049532846,0.0006188778,0.48706007,0.000014829968,0.00015660872,0.0042205574,0.0004377898,0.0018667126,0.50140923,0.0001838324,0.003958518,0.000023493716],"about_ca_topic_score_codex":0.0007836474,"about_ca_topic_score_gemma":0.0011795581,"teacher_disagreement_score":0.0009395718,"about_ca_system_score_codex":0.00019074677,"about_ca_system_score_gemma":0.00017487985,"threshold_uncertainty_score":0.0031431913},"labels":[],"label_agreement":null},{"id":"W2162804910","doi":"10.1158/1078-0432.ccr-04-1347","title":"Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Gefitinib; Paclitaxel; Pharmacology; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Medicine; Dosing; Chemotherapy; Internal medicine; Cancer","score_opus":0.17029377243080993,"score_gpt":0.516426543690462,"score_spread":0.34613277125965214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162804910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936213,0.0028653208,0.0021365609,0.0000936086,0.00009921033,0.00006000568,0.00007800709,0.00009806768,0.00094794313],"genre_scores_gemma":[0.9962924,0.0010185816,0.0017059292,0.000054767625,0.00007096797,0.000062016545,0.00011369553,0.000023218709,0.0006582916],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976665,0.000047771275,0.00001834206,0.000045630164,0.000073127594,0.00004840515],"domain_scores_gemma":[0.9995024,0.00016642768,0.00015382243,0.00006751918,0.000018165349,0.00009171852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036365716,0.00024684166,0.00051323685,0.00036686927,0.0001300668,0.00042753667,0.00023040059,0.00025296022,0.0016384888],"category_scores_gemma":[0.0005602065,0.00011408735,0.00028879553,0.00025357574,0.00031465627,0.00040166767,0.00013991904,0.00073680305,0.00016558154],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005721559,0.0020739145,0.0019215378,0.00015473037,0.00007000593,0.000056396802,0.00004892821,0.0010716763,0.9126971,0.00028114545,0.00047374642,0.07542923],"study_design_scores_gemma":[0.0009933533,0.07308034,0.03953933,0.000049827024,0.00030807094,0.00074069673,0.000056016048,0.0051287194,0.8729885,0.00019707196,0.006886124,0.00003188288],"about_ca_topic_score_codex":0.000211612,"about_ca_topic_score_gemma":0.00037018344,"teacher_disagreement_score":0.0016384888,"about_ca_system_score_codex":0.0003062244,"about_ca_system_score_gemma":0.00028278204,"threshold_uncertainty_score":0.0054813623},"labels":[],"label_agreement":null},{"id":"W2162816109","doi":"10.1016/j.nucmedbio.2010.06.010","title":"A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer","year":2010,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Internal medicine; Nuclear medicine; Cancer research; Cancer","score_opus":0.06651125855918073,"score_gpt":0.4213531490704426,"score_spread":0.35484189051126186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162816109","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16868652,0.0029990408,0.7827717,0.00077635306,0.00062877487,0.0075040725,0.0050344225,0.013065872,0.018533243],"genre_scores_gemma":[0.13137798,0.0025794283,0.7822244,0.001048368,0.00030514723,0.014278352,0.02072585,0.0024464682,0.045014016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993042,0.00012320941,0.00007310952,0.0001920779,0.00017544017,0.0001318753],"domain_scores_gemma":[0.99873966,0.00045306896,0.00012402894,0.00022513897,0.00023312985,0.00022502412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011297098,0.0018281048,0.0009009818,0.0020450018,0.00079123967,0.00047335817,0.0014779556,0.0014275591,0.021361217],"category_scores_gemma":[0.0016247273,0.0017714393,0.0009158838,0.0008113493,0.0004964108,0.00070614414,0.0007369877,0.0019276281,0.012043545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004503371,0.00028371706,0.00033541443,0.0003898012,0.000046072575,0.00024796964,0.00008306655,0.00030975224,0.9755604,0.0010738651,0.002484639,0.018735072],"study_design_scores_gemma":[0.00075775717,0.0019429453,0.0044534225,0.00014975671,0.00025379978,0.0021286388,0.00003200624,0.0045430665,0.9175529,0.0008249411,0.067272656,0.00008813656],"about_ca_topic_score_codex":0.00048543775,"about_ca_topic_score_gemma":0.0012737674,"teacher_disagreement_score":0.021361217,"about_ca_system_score_codex":0.00049310416,"about_ca_system_score_gemma":0.0009401991,"threshold_uncertainty_score":0.071460366},"labels":[],"label_agreement":null},{"id":"W2162854541","doi":"10.1016/s1470-2045(12)70508-9","title":"Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"GlaxoSmithKline","keywords":"Lapatinib; Adjuvant; Medicine; Oncology; Breast cancer; Stage (stratigraphy); Internal medicine; Cancer; Trastuzumab; Gynecology","score_opus":0.07012591633160038,"score_gpt":0.43312643149354113,"score_spread":0.36300051516194076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162854541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95913774,0.020096423,0.0019428473,0.0026215762,0.0019432893,0.0074808206,0.0026425682,0.00027387176,0.0038608573],"genre_scores_gemma":[0.9673303,0.00968612,0.0023906399,0.002575814,0.0007502039,0.008140087,0.0020969398,0.000050215353,0.006979674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999361,0.0003558768,0.000034994184,0.00009983806,0.000042789783,0.0001055787],"domain_scores_gemma":[0.99921477,0.00027563295,0.0001655318,0.000067321926,0.000039195835,0.00023748925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018723283,0.0021679755,0.0034869122,0.00038949357,0.0004191054,0.0010726741,0.0008170012,0.001900314,0.007975633],"category_scores_gemma":[0.0024712097,0.000786708,0.0024967184,0.0005387787,0.0011856203,0.0013050615,0.0005826303,0.0035621317,0.0010075258],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9880747,0.0012454968,0.00026228864,0.00077348226,0.0008150333,0.000030126752,0.00003136061,0.00021294369,0.0010067513,0.00006274172,0.0005896451,0.006895386],"study_design_scores_gemma":[0.98677737,0.0118145645,0.0004396388,0.000027001592,0.00033453037,0.000016379154,0.000010934065,0.00011021972,0.00006606536,0.00009110779,0.0003056446,0.000006497784],"about_ca_topic_score_codex":0.0016016108,"about_ca_topic_score_gemma":0.00402389,"teacher_disagreement_score":0.007975633,"about_ca_system_score_codex":0.0009549427,"about_ca_system_score_gemma":0.0011867152,"threshold_uncertainty_score":0.026681185},"labels":[],"label_agreement":null},{"id":"W2162901058","doi":"10.1016/s1470-2045(15)00051-0","title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Placebo; Cancer; Clinical trial; Phases of clinical research; Pathology","score_opus":0.10727531899554954,"score_gpt":0.43749981331845356,"score_spread":0.330224494322904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162901058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781843,0.011226097,0.0007166324,0.0015883205,0.0012177222,0.0022852768,0.0013957007,0.0002465476,0.003139379],"genre_scores_gemma":[0.9726847,0.0082117,0.002129836,0.0024638402,0.00087045354,0.0030329402,0.002453577,0.00007356295,0.008079429],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994649,0.0002756144,0.000027391314,0.00010529244,0.000034586257,0.000092205235],"domain_scores_gemma":[0.9993445,0.0001718508,0.00013589591,0.00005718069,0.000028686301,0.00026172973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019550147,0.0021100321,0.0037827003,0.0005106498,0.00040134403,0.0015340217,0.001366138,0.0019992858,0.006876017],"category_scores_gemma":[0.0015189389,0.0008662059,0.0023180775,0.0004941671,0.0013851395,0.0017728758,0.0005771789,0.004396446,0.0014680171],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97877675,0.004434233,0.00035243787,0.0006142916,0.0011357868,0.00003248284,0.000052898005,0.0004422448,0.0015282435,0.00010366671,0.0010137712,0.011513311],"study_design_scores_gemma":[0.9610267,0.03674922,0.0008138993,0.000028126427,0.00035929267,0.00002726593,0.000015471225,0.00024205058,0.00016025399,0.00009573939,0.0004689654,0.000012984082],"about_ca_topic_score_codex":0.0011607822,"about_ca_topic_score_gemma":0.0031211518,"teacher_disagreement_score":0.006876017,"about_ca_system_score_codex":0.00092975167,"about_ca_system_score_gemma":0.0010454779,"threshold_uncertainty_score":0.023002565},"labels":[],"label_agreement":null},{"id":"W2163167967","doi":"10.1136/jclinpath-2014-202571","title":"Updated UK Recommendations for HER2 assessment in breast cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Bioinformatics; Oncology; Medical physics; Cancer; Internal medicine; Biology","score_opus":0.18503428653284512,"score_gpt":0.5861699026089259,"score_spread":0.4011356160760807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163167967","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032519584,0.2654861,0.0185023,0.43933675,0.05230609,0.0041218423,0.020461883,0.002659194,0.19387388],"genre_scores_gemma":[0.024628622,0.31204164,0.17960532,0.21597008,0.011556702,0.010706747,0.056331668,0.0011708542,0.18798834],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.986796,0.0049742186,0.0029868959,0.00038875855,0.00413608,0.00071810506],"domain_scores_gemma":[0.9530657,0.00840288,0.003901566,0.0012333025,0.031436123,0.0019604026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0103104655,0.0010299605,0.0018505985,0.0057135415,0.00090713083,0.0025511296,0.0044386555,0.0065667783,0.02108801],"category_scores_gemma":[0.04670572,0.00084958796,0.0028254276,0.0053314436,0.0012726142,0.0022179827,0.002663564,0.0061763837,0.016281577],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006388542,0.00007094309,0.00080886803,0.0014956442,0.000023906752,0.00026910595,0.0001539748,0.0002510375,0.00020842406,0.0011328583,0.8440601,0.15146124],"study_design_scores_gemma":[0.0000722394,0.00006299277,0.0028455767,0.005462837,0.000050061204,0.0006757477,0.00017232758,0.0001393228,0.00013777951,0.0013941963,0.988946,0.00004093611],"about_ca_topic_score_codex":0.030935315,"about_ca_topic_score_gemma":0.037939608,"teacher_disagreement_score":0.030935315,"about_ca_system_score_codex":0.005016552,"about_ca_system_score_gemma":0.009806765,"threshold_uncertainty_score":0.07054639},"labels":[],"label_agreement":null},{"id":"W2164130095","doi":"10.1200/jco.2009.22.6449","title":"Topoisomerase IIα Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out","year":2009,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anthracycline; Topoisomerase; Chemotherapy; Cancer research; Jury; Oncology; Internal medicine; Pharmacology; Cancer; DNA; Genetics; Breast cancer; Biology; Law","score_opus":0.16040805004886502,"score_gpt":0.5645761933137886,"score_spread":0.40416814326492356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164130095","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018321637,0.7844395,0.00038397525,0.18818432,0.005371265,0.0000421376,0.000084153406,0.00002311155,0.0031498282],"genre_scores_gemma":[0.22364824,0.6055407,0.0009823332,0.10554112,0.058528412,0.00010452081,0.0001855044,0.00003802147,0.0054311585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960806,0.0022126646,0.00054433517,0.00029998782,0.00062000134,0.00024254677],"domain_scores_gemma":[0.9768693,0.014112419,0.0034188065,0.0010596853,0.0024111967,0.0021286225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0118574,0.00049629726,0.0027257355,0.0010725479,0.0009726347,0.0043556793,0.0010409554,0.005930746,0.005757208],"category_scores_gemma":[0.014857073,0.0005506171,0.0011560952,0.0015793653,0.0023102665,0.0056941947,0.0017807565,0.008734973,0.0011726761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019618113,0.0014417664,0.039018672,0.006821206,0.0028550474,0.00098624,0.0010438296,0.00037857605,0.002474778,0.017066117,0.11808511,0.79021055],"study_design_scores_gemma":[0.009128691,0.010837332,0.14070615,0.019703684,0.0061386684,0.003602417,0.006001919,0.0019738995,0.001274209,0.0773703,0.72275215,0.0005105821],"about_ca_topic_score_codex":0.002268686,"about_ca_topic_score_gemma":0.0051972806,"teacher_disagreement_score":0.0118574,"about_ca_system_score_codex":0.0016858171,"about_ca_system_score_gemma":0.0034877406,"threshold_uncertainty_score":0.062708676},"labels":[],"label_agreement":null},{"id":"W2165824128","doi":"10.1200/jco.2005.04.1764","title":"Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":484,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Metastatic breast cancer; Carboplatin; Oncology; Breast cancer; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Cisplatin","score_opus":0.1106490242730566,"score_gpt":0.49162201900925406,"score_spread":0.38097299473619745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165824128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818917,0.0044671884,0.00123552,0.0014690825,0.0010043791,0.0067730583,0.0012318797,0.00015119158,0.0017760566],"genre_scores_gemma":[0.9765537,0.0026540034,0.0028902732,0.0022073868,0.00089498586,0.009694465,0.0015458204,0.00005073023,0.0035086425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985814,0.0009997748,0.000056421723,0.00015745647,0.00008090984,0.00012399025],"domain_scores_gemma":[0.9975414,0.0008238904,0.0005811871,0.0001882004,0.00012881742,0.0007365576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034371468,0.0020180466,0.0036823782,0.0005254386,0.00058758946,0.0011395741,0.0012449228,0.0018890863,0.005370446],"category_scores_gemma":[0.0038722851,0.0010555595,0.0017543631,0.0005663902,0.001654539,0.0011176239,0.0005128246,0.0041506565,0.0010930217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9857982,0.0058635925,0.00044082166,0.00014569107,0.0004995629,0.000019753486,0.00002899009,0.0002655509,0.0010837038,0.000046711153,0.00046344794,0.005343945],"study_design_scores_gemma":[0.96279573,0.035755195,0.0005832045,0.00000829281,0.00016828532,0.00001545585,0.000007226278,0.00021873819,0.00014345173,0.00005593946,0.00024347194,0.0000049854825],"about_ca_topic_score_codex":0.0013456291,"about_ca_topic_score_gemma":0.003101069,"teacher_disagreement_score":0.005370446,"about_ca_system_score_codex":0.0012295347,"about_ca_system_score_gemma":0.0020571435,"threshold_uncertainty_score":0.018177569},"labels":[],"label_agreement":null},{"id":"W2165862193","doi":"10.1200/jco.2008.16.5282","title":"Mathematics in the Realm of Lapatinib: 500 + 500 = 1,500?","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lapatinib; Medicine; Realm; Internal medicine; Cancer; Trastuzumab; Breast cancer","score_opus":0.4819093635843679,"score_gpt":0.6027211488448957,"score_spread":0.12081178526052777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165862193","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062381425,0.16389209,0.004525168,0.43459228,0.06466997,0.00008544788,0.00060150516,0.00058960216,0.3248057],"genre_scores_gemma":[0.11701754,0.2300602,0.0070618712,0.18356659,0.07282921,0.00020041941,0.0010157285,0.00037382226,0.3878746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935204,0.00018588411,0.000039517046,0.00007756744,0.00026164085,0.00008330926],"domain_scores_gemma":[0.9990368,0.00017843005,0.00009333427,0.000051347488,0.00017883824,0.0004611615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012134769,0.00047829474,0.0005088215,0.00055624946,0.00075676164,0.0032288267,0.00058312365,0.0017745501,0.079788946],"category_scores_gemma":[0.0039184736,0.00017193051,0.00032136514,0.0006209423,0.0012740472,0.003889792,0.0013816778,0.0028615885,0.02514602],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029805666,0.000081144586,0.0008810501,0.0003606988,0.000020720372,0.00022478017,0.00009173243,0.00016740715,0.0008463067,0.022717483,0.6318276,0.34248304],"study_design_scores_gemma":[0.000044005723,0.00009258663,0.0009997425,0.0002344964,0.000012033273,0.0004913892,0.00012206561,0.00014501388,0.00024255672,0.013024392,0.98457736,0.00001437735],"about_ca_topic_score_codex":0.0007928669,"about_ca_topic_score_gemma":0.0017921635,"teacher_disagreement_score":0.079788946,"about_ca_system_score_codex":0.0009869274,"about_ca_system_score_gemma":0.00095041166,"threshold_uncertainty_score":0.26692063},"labels":[],"label_agreement":null},{"id":"W2166317024","doi":"10.1200/jco.2010.29.5071","title":"Human Epidermal Growth Factor Receptor 2 Testing: Where Are We?","year":2010,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Human Epidermal Growth Factor Receptor 2; Cancer research; Epidermal growth factor; Receptor; Oncology; Internal medicine; Cancer; Breast cancer","score_opus":0.41265828075769156,"score_gpt":0.5553228378694964,"score_spread":0.14266455711180487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166317024","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010479861,0.08804448,0.0012754858,0.7059441,0.19848084,0.00003872421,0.0001526502,0.00017036783,0.0048453645],"genre_scores_gemma":[0.01172475,0.18194245,0.002360802,0.25810853,0.5402822,0.00005928221,0.0003513526,0.0001432526,0.0050274627],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99579334,0.0010496583,0.00092204474,0.0004064911,0.0015714454,0.00025704273],"domain_scores_gemma":[0.975568,0.009748898,0.0020520277,0.0005995852,0.009296818,0.0027347028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074767014,0.0009693788,0.0018226479,0.0030834428,0.0021098002,0.006933846,0.0026943383,0.0105959475,0.004467413],"category_scores_gemma":[0.026414666,0.0009750006,0.0007442899,0.0023777357,0.0027545623,0.00989796,0.0012459963,0.015307684,0.0030114441],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009177395,0.00006213889,0.0034053281,0.00039231376,0.000041693573,0.0007732786,0.00007549385,0.00007889686,0.00023423253,0.0012319756,0.8450511,0.14856178],"study_design_scores_gemma":[0.0000835311,0.00010314644,0.006962681,0.0022842132,0.000147367,0.003867714,0.00081583654,0.00059278274,0.00032057377,0.0055174944,0.9792132,0.00009153123],"about_ca_topic_score_codex":0.0035946032,"about_ca_topic_score_gemma":0.010639277,"teacher_disagreement_score":0.0105959475,"about_ca_system_score_codex":0.0025850947,"about_ca_system_score_gemma":0.0032596036,"threshold_uncertainty_score":0.039541066},"labels":[],"label_agreement":null},{"id":"W2166653378","doi":"10.1016/j.jval.2014.03.522","title":"Cost-Utility Analysis of Newer HER2- Testing Technologies to Target Trastuzumab in the Adjuvant Breast Cancer Setting","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Calgary; Ontario Institute for Cancer Research; McMaster University","funders":"","keywords":"CISH; Trastuzumab; Medicine; Chromogenic in situ hybridization; Oncology; Breast cancer; Internal medicine; Cost effectiveness; Cancer; Biology; In situ hybridization","score_opus":0.1293870136368234,"score_gpt":0.426012675525422,"score_spread":0.2966256618885986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166653378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9450695,0.009941342,0.025042025,0.0023427862,0.00010890832,0.0005600424,0.0033332354,0.0001124629,0.013489674],"genre_scores_gemma":[0.9936581,0.0007979702,0.0039704926,0.0001294208,0.000030586492,0.00005874587,0.0006587105,0.0000117472455,0.0006843054],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99815136,0.0011621995,0.000049995186,0.00013233737,0.00029244274,0.00021165873],"domain_scores_gemma":[0.98811126,0.010008205,0.0005396975,0.0002703759,0.0007691422,0.0003012751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003683435,0.0008335007,0.0008313828,0.0016353326,0.00020942352,0.0015488244,0.0011216005,0.000712684,0.0043620714],"category_scores_gemma":[0.014204061,0.00031487233,0.0014935047,0.001570265,0.00043570634,0.0010866771,0.00062963885,0.00097459333,0.00019908609],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010135724,0.0010480569,0.05665112,0.00045650054,0.00093688554,0.00043370508,0.00009142933,0.786991,0.0024424684,0.01805426,0.0045746155,0.11818425],"study_design_scores_gemma":[0.00056785526,0.0026667432,0.046230167,0.00013952907,0.0010897923,0.00045256637,0.00025295562,0.9373957,0.0015043279,0.0065344158,0.0030982739,0.000067633686],"about_ca_topic_score_codex":0.011823651,"about_ca_topic_score_gemma":0.006658856,"teacher_disagreement_score":0.011823651,"about_ca_system_score_codex":0.004014053,"about_ca_system_score_gemma":0.0019118049,"threshold_uncertainty_score":0.0291242},"labels":[],"label_agreement":null},{"id":"W2166656480","doi":"10.1016/s1470-2045(09)70230-x","title":"Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009","year":2009,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Summit; Statement (logic); Breast cancer; Oncology; Internal medicine; Medicine; Political science; Cancer; Geography; Cartography; Law","score_opus":0.12434831521486477,"score_gpt":0.48312958374674864,"score_spread":0.35878126853188386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166656480","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009136263,0.99164516,0.00009120237,0.0070401365,0.00067829224,0.000008146875,0.000036459223,0.000003901049,0.00040527814],"genre_scores_gemma":[0.0008508025,0.9950311,0.00031087795,0.0030423084,0.00042625467,0.000013921132,0.000055640896,0.0000017058424,0.00026728702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937266,0.00014655192,0.00014619401,0.000053863485,0.00020043406,0.00008037048],"domain_scores_gemma":[0.9986979,0.00048520925,0.00025722716,0.000018154085,0.00042902053,0.00011237873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036118424,0.0008215765,0.0022699859,0.001439211,0.00031347026,0.0013611161,0.00152047,0.0021411749,0.0018654853],"category_scores_gemma":[0.002942351,0.00032904226,0.0014215796,0.0017859167,0.0005116257,0.001693268,0.001199625,0.0032462534,0.000683689],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020615848,0.00007083982,0.00062949397,0.028118491,0.00029766458,0.0002485959,0.00008652336,0.0005908599,0.00049784157,0.0017233436,0.16144665,0.8060837],"study_design_scores_gemma":[0.00021903364,0.00019714373,0.0040796725,0.052989315,0.0010507115,0.0013095328,0.0003505957,0.00021945704,0.00049219537,0.0022557506,0.93678874,0.00004781897],"about_ca_topic_score_codex":0.0067386418,"about_ca_topic_score_gemma":0.019245915,"teacher_disagreement_score":0.0067386418,"about_ca_system_score_codex":0.0024275144,"about_ca_system_score_gemma":0.00666523,"threshold_uncertainty_score":0.0191015},"labels":[],"label_agreement":null},{"id":"W2167505689","doi":"10.1158/0008-5472.can-05-0108","title":"Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Environmental Health Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Breast cancer; Metastasis; Cancer research; Biology; Tissue microarray; Cancer; Microarray analysis techniques; Microarray; Pathology; Gene expression; Gene; Medicine; Genetics","score_opus":0.3637211878877031,"score_gpt":0.5562513565462694,"score_spread":0.19253016865856637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167505689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95054597,0.0052707773,0.026274122,0.00091480813,0.0007218765,0.0009360552,0.008532143,0.0008522682,0.005951916],"genre_scores_gemma":[0.93084764,0.004135179,0.03638587,0.00046518675,0.00010151958,0.0017386266,0.012015365,0.00017819485,0.014132348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996419,0.00008352734,0.00002643553,0.00007457568,0.00008564973,0.000087868444],"domain_scores_gemma":[0.99951255,0.00014204472,0.00008204079,0.00007318965,0.00005551136,0.00013464616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062236306,0.0010174322,0.00074589817,0.0008233536,0.00029091485,0.00045644748,0.000436093,0.00063233724,0.0025996692],"category_scores_gemma":[0.00024913868,0.00029359333,0.00063083833,0.0006431763,0.00035345243,0.00033649342,0.0003312963,0.001904266,0.00080148195],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009323015,0.0008205489,0.0007950197,0.00009731207,0.000030496454,0.0001751726,0.00004283706,0.00035799848,0.9941175,0.0003380729,0.0006769139,0.0016159231],"study_design_scores_gemma":[0.000525283,0.014205667,0.0134758465,0.00003735185,0.0001459681,0.0022591127,0.00016896205,0.0069658575,0.94878256,0.00044958683,0.012939509,0.00004418328],"about_ca_topic_score_codex":0.001341556,"about_ca_topic_score_gemma":0.0020456237,"teacher_disagreement_score":0.0025996692,"about_ca_system_score_codex":0.00047747296,"about_ca_system_score_gemma":0.00038505942,"threshold_uncertainty_score":0.008696735},"labels":[],"label_agreement":null},{"id":"W2167525778","doi":"10.1128/mcb.01731-08","title":"c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential","year":2009,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; McGill University","funders":"National Institutes of Health; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Proto-oncogene tyrosine-protein kinase Src; Gefitinib; Biology; Erlotinib; Tyrosine kinase; Protein kinase domain; SH3 domain; SH2 domain; Epidermal growth factor receptor; Cancer research; Cell biology; Signal transduction; Mutant; Biochemistry; Receptor; Gene","score_opus":0.016692664800076164,"score_gpt":0.3224125090321391,"score_spread":0.30571984423206294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167525778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99469614,0.0011990431,0.0017040432,0.000064599684,0.000012171907,0.000011724267,0.00007590912,0.00004154893,0.0021947077],"genre_scores_gemma":[0.9957403,0.00040061184,0.0010621551,0.000030457924,0.000011668741,0.00000991553,0.00037572155,0.000012934016,0.002356366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982125,0.000026149386,0.000009176627,0.000022531452,0.00006589779,0.00005497461],"domain_scores_gemma":[0.999905,0.000016276736,0.000023803039,0.00001708138,0.000009864104,0.000027964197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015614783,0.0002844477,0.00016635827,0.00018275462,0.00014225852,0.0002993528,0.0001589842,0.00018662536,0.0016936912],"category_scores_gemma":[0.00013570608,0.00017054772,0.0002593941,0.00022809376,0.00017600786,0.00016131092,0.00038886303,0.000336724,0.00079157],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050232517,0.000025015177,0.00039876625,0.000017648006,0.0000058348946,0.00009654401,0.000010516752,0.00003137609,0.99782854,0.00017969648,0.000044289132,0.001311548],"study_design_scores_gemma":[0.00002726741,0.00023785883,0.0130881695,0.0000058325422,0.000015917913,0.0020045831,0.000022424596,0.0012129688,0.97692424,0.00010206665,0.006352197,0.0000064794626],"about_ca_topic_score_codex":0.00037241503,"about_ca_topic_score_gemma":0.00052652374,"teacher_disagreement_score":0.0016936912,"about_ca_system_score_codex":0.00032845838,"about_ca_system_score_gemma":0.00016870938,"threshold_uncertainty_score":0.005665958},"labels":[],"label_agreement":null},{"id":"W2167610854","doi":"10.1158/1541-7786.mcr-11-0531","title":"<i>In Situ</i> Analysis of Mutant EGFRs Prevalent in Glioblastoma Multiforme Reveals Aberrant Dimerization, Activation, and Differential Response to Anti-EGFR Targeted Therapy","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; Toronto Western Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Proximity ligation assay; Cetuximab; Epidermal growth factor receptor; Mutant; Cancer research; Cell culture; EGFR inhibitors; Biology; Chemistry; Monoclonal antibody; Receptor; Molecular biology; Antibody; Biochemistry; Immunology; Gene","score_opus":0.04354928422118057,"score_gpt":0.40579152181399997,"score_spread":0.36224223759281937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167610854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885527,0.0012624549,0.0076865074,0.0001283706,0.000023795412,0.00001915766,0.0004330769,0.0001701713,0.0017237011],"genre_scores_gemma":[0.9938573,0.0007262721,0.003446747,0.00007983612,0.000016886637,0.000038429247,0.0006756936,0.000021456373,0.0011373332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998715,0.000024386036,0.0000095737005,0.00003433218,0.000027181015,0.00003304097],"domain_scores_gemma":[0.99991953,0.000010761572,0.000032512384,0.0000070213787,0.000013561402,0.000016490763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018062223,0.0002606383,0.00020650083,0.00034067154,0.000097782045,0.00026679615,0.0001526348,0.00024816243,0.0011344461],"category_scores_gemma":[0.00012960451,0.00012380944,0.00020900002,0.00022107866,0.00015172528,0.00013702236,0.00013202071,0.00031796316,0.00022072798],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007419373,0.00001028601,0.00060844887,0.000021251872,0.0000071563177,0.000048002858,0.00001513661,0.000022275595,0.99832124,0.000027936125,0.00003553186,0.0008086697],"study_design_scores_gemma":[0.000006633333,0.0002629161,0.02556215,0.0000040863856,0.000040012284,0.001191859,0.000059414146,0.0013575729,0.9701892,0.00007479686,0.0012460065,0.0000053230333],"about_ca_topic_score_codex":0.000553078,"about_ca_topic_score_gemma":0.00046788563,"teacher_disagreement_score":0.0011344461,"about_ca_system_score_codex":0.00017083091,"about_ca_system_score_gemma":0.00006785613,"threshold_uncertainty_score":0.003795147},"labels":[],"label_agreement":null},{"id":"W2167655328","doi":"10.1038/cr.2014.37","title":"Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors","year":2014,"lang":"en","type":"article","venue":"Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Cancer Prevention and Research Institute of Texas; University of Texas MD Anderson Cancer Center; Susan G. Komen; University of Pennsylvania; National Cancer Institute; National Institutes of Health","keywords":"Lapatinib; Trastuzumab; PTEN; PI3K/AKT/mTOR pathway; Cancer research; Biomarker; Biology; Targeted therapy; Breast cancer; Cancer; Medicine; Bioinformatics; Pharmacology; Signal transduction; Cell biology; Genetics","score_opus":0.1014900660765387,"score_gpt":0.40599398359236116,"score_spread":0.30450391751582245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167655328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561147,0.02142844,0.016100988,0.0016764385,0.00019955207,0.00021002899,0.0002484214,0.00038051687,0.0036408745],"genre_scores_gemma":[0.9823784,0.0049863574,0.010355302,0.00028496273,0.0000637786,0.000076605815,0.00024945912,0.000042134627,0.0015629367],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987864,0.000019583007,0.000009696021,0.000030253766,0.000033235785,0.000028536728],"domain_scores_gemma":[0.9998933,0.000024302291,0.000032521082,0.000013380782,0.000018840328,0.000017659837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047779374,0.00031364034,0.0005982091,0.0005067308,0.00017935483,0.0007152488,0.00040499328,0.00035519473,0.0011062267],"category_scores_gemma":[0.00044874466,0.00020250192,0.000242623,0.00035244098,0.00019350521,0.0006567639,0.0003413852,0.0006942873,0.00024217373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002492131,0.000998258,0.010675769,0.0003841046,0.00016593208,0.00050261023,0.0001487668,0.009670464,0.49315998,0.0024945885,0.0047846176,0.4745228],"study_design_scores_gemma":[0.0012711715,0.011615194,0.0453989,0.00015496985,0.00096249,0.006940636,0.0004557511,0.099255756,0.75864714,0.0061955443,0.06900591,0.00009640373],"about_ca_topic_score_codex":0.00049850263,"about_ca_topic_score_gemma":0.0016735023,"teacher_disagreement_score":0.0011062267,"about_ca_system_score_codex":0.00052877766,"about_ca_system_score_gemma":0.0004195405,"threshold_uncertainty_score":0.0038366318},"labels":[],"label_agreement":null},{"id":"W2167955103","doi":"10.1093/annonc/mdq786","title":"Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Breast Cancer Research Foundation","keywords":"Medicine; Coping (psychology); Breast cancer; Oncology; Internal medicine; Gynecology; Clinical psychology; Cancer","score_opus":0.2047006578842925,"score_gpt":0.45608003687345433,"score_spread":0.25137937898916185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167955103","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38085225,0.02001448,0.0015626642,0.5767713,0.001155671,0.00004575874,0.0001684495,0.000014812737,0.01941464],"genre_scores_gemma":[0.9719145,0.00827788,0.0008019368,0.017205643,0.0010519814,0.000029767036,0.000056641107,0.0000053327685,0.0006561895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992662,0.0003833414,0.00003813125,0.0000519207,0.00010304425,0.00015740494],"domain_scores_gemma":[0.99786997,0.0010160398,0.00038012065,0.000030387426,0.00014344364,0.0005601021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019141028,0.00019290153,0.00055293436,0.0003362712,0.0012730446,0.0023742195,0.00046174251,0.0020126645,0.0041729007],"category_scores_gemma":[0.011043846,0.00016926834,0.00032775017,0.00040040683,0.0011864665,0.0030279243,0.0010057588,0.0033370086,0.00026167737],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022872183,0.0023289246,0.21493189,0.0013387059,0.0003599293,0.014130015,0.023459967,0.0017336841,0.002310977,0.03910677,0.097964294,0.60004765],"study_design_scores_gemma":[0.00074907596,0.0017765174,0.26807943,0.004354008,0.00066171703,0.030918764,0.17525081,0.010321767,0.0013626091,0.42467728,0.0814746,0.00037346638],"about_ca_topic_score_codex":0.0029674638,"about_ca_topic_score_gemma":0.005532897,"teacher_disagreement_score":0.0041729007,"about_ca_system_score_codex":0.0014341733,"about_ca_system_score_gemma":0.0024616776,"threshold_uncertainty_score":0.013959706},"labels":[],"label_agreement":null},{"id":"W2168110569","doi":"10.1186/1559-0275-9-5","title":"Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue","year":2012,"lang":"en","type":"article","venue":"Clinical Proteomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; Canada Research Chairs; Medical Council of Canada; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Epidermal growth factor receptor; Immunohistochemistry; Immunoassay; Epidermal growth factor; Receptor tyrosine kinase; EGFR inhibitors; Cancer research; Lung cancer; Molecular biology; Receptor; Pathology; Chemistry; Biology; Antibody; Medicine; Internal medicine; Immunology","score_opus":0.12304287529507994,"score_gpt":0.4495219361459454,"score_spread":0.3264790608508654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168110569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.620293,0.004896067,0.36606818,0.0002611934,0.00014795772,0.0004194051,0.001260002,0.0022108643,0.004443228],"genre_scores_gemma":[0.6669513,0.003939723,0.31956524,0.00031247482,0.00007152278,0.0009437447,0.0018535038,0.00020942536,0.0061529996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985876,0.0003746246,0.00006834015,0.00036230925,0.0005453379,0.000061832274],"domain_scores_gemma":[0.99893445,0.0003247675,0.00036386767,0.00008924771,0.00024032235,0.000047353828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017910304,0.0008013456,0.00031201437,0.0011903964,0.00025413992,0.00033645157,0.00063574023,0.00052873004,0.0009915677],"category_scores_gemma":[0.0013493154,0.00023286993,0.00047629408,0.00053366,0.00039975255,0.00027721148,0.00031220212,0.00054425735,0.0006586343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119569806,0.00003979991,0.0021344547,0.000118603784,0.00003176347,0.00009017515,0.000055861896,0.00022680756,0.9895119,0.000116019524,0.00017032246,0.0073847915],"study_design_scores_gemma":[0.00000993218,0.0004382847,0.005589753,0.000017407694,0.00004376878,0.0004568674,0.000031285865,0.0034316874,0.98830533,0.00006976032,0.0015946459,0.000011200988],"about_ca_topic_score_codex":0.00034436613,"about_ca_topic_score_gemma":0.0007324203,"teacher_disagreement_score":0.0017910304,"about_ca_system_score_codex":0.000389074,"about_ca_system_score_gemma":0.0004018381,"threshold_uncertainty_score":0.0094720125},"labels":[],"label_agreement":null},{"id":"W2168114460","doi":"10.1093/protein/13.3.143","title":"NMR study of the differential contributions of residues of transforming growth factor alpha to association with its receptor","year":2000,"lang":"en","type":"article","venue":"Protein Engineering Design and Selection","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute; University of Alberta","funders":"","keywords":"Heteronuclear molecule; Receptor; Epitope; TGF alpha; Transforming growth factor; Chemistry; Ligand (biochemistry); Epidermal growth factor receptor; Biophysics; Biochemistry; Stereochemistry; Nuclear magnetic resonance spectroscopy; Biology; Cell biology; Genetics; Antibody","score_opus":0.014903116135764451,"score_gpt":0.26236625666395147,"score_spread":0.24746314052818702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168114460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720216,0.0003146512,0.0015564923,0.000046150602,0.0000060820194,0.0000025824656,0.00002161398,0.000009510173,0.0008408169],"genre_scores_gemma":[0.99880254,0.00020542485,0.00058103236,0.000020338126,0.000004635916,0.0000030146407,0.000059190854,0.000006580042,0.00031718996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999962,0.000008948392,9.3587994e-7,0.0000064544993,0.0000100524885,0.000011614043],"domain_scores_gemma":[0.9999187,0.000028350862,0.00001807057,0.0000044046114,0.000011288125,0.000019128856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010057704,0.000120111734,0.00009251707,0.00009118401,0.00016662895,0.00011692012,0.00013073302,0.00013275199,0.00082430145],"category_scores_gemma":[0.00022594028,0.00007685592,0.00007367504,0.000097423166,0.000160039,0.00014286822,0.00008864427,0.00027611447,0.00009480318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024976398,0.00002597723,0.0006043087,0.000026441752,0.00001118833,0.000069981776,0.000044232474,0.0004012739,0.9963325,0.00017043068,0.00004810859,0.0020157404],"study_design_scores_gemma":[0.00008094883,0.00044339066,0.023472592,0.000015770916,0.00006522267,0.00059724937,0.00018102402,0.021903876,0.95008564,0.00034152993,0.0027903626,0.00002239747],"about_ca_topic_score_codex":0.00062063406,"about_ca_topic_score_gemma":0.00089983165,"teacher_disagreement_score":0.00082430145,"about_ca_system_score_codex":0.00013971746,"about_ca_system_score_gemma":0.000101990496,"threshold_uncertainty_score":0.0027575493},"labels":[],"label_agreement":null},{"id":"W2168198903","doi":"10.1007/s00259-008-0923-x","title":"Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts","year":2008,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital; University Health Network; University of Toronto","funders":"","keywords":"Trastuzumab; Medicine; Biodistribution; Nuclear medicine; Immunohistochemistry; Breast cancer; Cancer research; Cancer; Internal medicine; Chemistry; In vitro","score_opus":0.03705302276047759,"score_gpt":0.3158584600833648,"score_spread":0.2788054373228872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168198903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790907,0.0005723772,0.00042939812,0.000035566507,0.000011905031,0.000008656849,0.00028563492,0.000033071294,0.0007143752],"genre_scores_gemma":[0.9969681,0.00021951133,0.0002666895,0.00002731205,0.000009965994,0.000015853862,0.00040069406,0.0000133629765,0.0020785136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998276,0.000038402286,0.000013244417,0.00003848867,0.000028208608,0.000053930573],"domain_scores_gemma":[0.99942774,0.00027462575,0.00011365701,0.000041774852,0.00003933219,0.000102897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031590878,0.0002238202,0.0003576603,0.00028800502,0.0000948693,0.0003758309,0.00017547666,0.00041000027,0.0015627303],"category_scores_gemma":[0.00047065568,0.00022475683,0.0001682958,0.00023061663,0.0002701485,0.0003281019,0.00012408732,0.00063151005,0.00032316064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007900372,0.000334166,0.00438757,0.000034878725,0.000035292185,0.00012788012,0.00007342032,0.00056078477,0.9845643,0.00011496403,0.00017773421,0.0016885014],"study_design_scores_gemma":[0.00021636466,0.008465332,0.106573015,0.0000052931664,0.00013068564,0.00077410846,0.00015057296,0.006111337,0.8760033,0.0001650681,0.0013754737,0.000029420775],"about_ca_topic_score_codex":0.001782865,"about_ca_topic_score_gemma":0.0012312932,"teacher_disagreement_score":0.001782865,"about_ca_system_score_codex":0.00036283556,"about_ca_system_score_gemma":0.00013441092,"threshold_uncertainty_score":0.0052279234},"labels":[],"label_agreement":null},{"id":"W2168372454","doi":"10.1200/jco.2014.56.9590","title":"Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Cancer Society Research Institute; GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Taxane; Internal medicine; Metastatic breast cancer; Oncology; Hazard ratio; Breast cancer; Docetaxel; Clinical endpoint; Pertuzumab; Cancer; Clinical trial; Confidence interval","score_opus":0.3663924786049742,"score_gpt":0.5653644802031109,"score_spread":0.19897200159813672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168372454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85458577,0.10935316,0.0010768685,0.003666921,0.00047712846,0.0034578533,0.0075554736,0.00014477913,0.019682057],"genre_scores_gemma":[0.95065564,0.018245641,0.002167054,0.0033520036,0.00067339983,0.002323132,0.013141448,0.00007741765,0.009364241],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99906164,0.0006679098,0.000041223393,0.00006286644,0.000086069456,0.000080299964],"domain_scores_gemma":[0.9990245,0.0003349871,0.00022352926,0.00008214161,0.00010696187,0.00022793365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002123461,0.0006937423,0.001390591,0.00043601028,0.00025440927,0.0007501699,0.00066888274,0.00068529806,0.003538113],"category_scores_gemma":[0.0021259382,0.00022188049,0.0016531062,0.00059293286,0.0003390659,0.00039926104,0.00029301897,0.0014246432,0.0004292952],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5007622,0.006488906,0.028768195,0.004942805,0.009550965,0.0004625252,0.00025761407,0.0077939453,0.013332502,0.00093182345,0.032300603,0.3944079],"study_design_scores_gemma":[0.58149564,0.18169662,0.15154245,0.0015359492,0.016845984,0.0010148782,0.00013080405,0.0030439566,0.0064767343,0.0006910427,0.05542626,0.00009964837],"about_ca_topic_score_codex":0.0035632323,"about_ca_topic_score_gemma":0.012220685,"teacher_disagreement_score":0.0035632323,"about_ca_system_score_codex":0.0010521255,"about_ca_system_score_gemma":0.0011227385,"threshold_uncertainty_score":0.011836112},"labels":[],"label_agreement":null},{"id":"W2168391786","doi":"10.2174/092986706779026174","title":"Targeting the EGFR Pathway for Cancer Therapy","year":2006,"lang":"en","type":"review","venue":"Current Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Strong; CancerCare Manitoba Foundation; Manitoba Medical Service Foundation; Manitoba Health Research Council","keywords":"Cetuximab; Medicine; Gefitinib; Panitumumab; Pertuzumab; Lapatinib; Erlotinib; Amphiregulin; Epidermal growth factor receptor; Lung cancer; Targeted therapy; Trastuzumab; Cancer; Cancer research; Breast cancer; Epidermal growth factor; Oncology; Internal medicine; Colorectal cancer; Receptor","score_opus":0.19499287347279368,"score_gpt":0.49035764617935623,"score_spread":0.2953647727065626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168391786","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00077897887,0.98263955,0.0016000124,0.002013846,0.0009660454,0.00001987307,0.00007343874,0.000060946644,0.011847344],"genre_scores_gemma":[0.011009498,0.96489966,0.0016186178,0.0019931558,0.0011455924,0.000038002763,0.0001902463,0.000017183722,0.019088184],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998173,0.000031849344,0.0000125452825,0.000038364113,0.000072511066,0.000027493214],"domain_scores_gemma":[0.99993956,0.000017457163,0.000011487009,0.000004394106,0.000017657823,0.000009508291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025445074,0.00059001433,0.0005492595,0.0008331708,0.00018694272,0.00077202125,0.000512422,0.0010683943,0.008880743],"category_scores_gemma":[0.00021470505,0.00012866326,0.0004191024,0.00054453214,0.00032081627,0.0008786254,0.00063495757,0.0021657138,0.0047295494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012227263,0.00011970109,0.00015962239,0.0052170553,0.00007414874,0.00038775077,0.000074169744,0.00082490756,0.02103741,0.017643707,0.0730963,0.88124305],"study_design_scores_gemma":[0.000016050175,0.00010490421,0.00025059216,0.00062776654,0.00003341477,0.0009995106,0.000016308899,0.00020029867,0.0022660976,0.0031157131,0.9923584,0.000011012151],"about_ca_topic_score_codex":0.00043035764,"about_ca_topic_score_gemma":0.0008571763,"teacher_disagreement_score":0.008880743,"about_ca_system_score_codex":0.0007762468,"about_ca_system_score_gemma":0.0004734692,"threshold_uncertainty_score":0.029709041},"labels":[],"label_agreement":null},{"id":"W2168482167","doi":"10.1158/1078-0432.ccr-03-0244","title":"Treatment of HER-2/<b> <i>neu</i> </b> Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/<b> <i>neu</i> </b> and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Gefitinib; Trastuzumab; Medicine; Cancer research; Epidermal growth factor receptor; In vivo; Estrogen receptor; Breast cancer; Growth inhibition; Cell growth; Cancer; Internal medicine; Pharmacology; Biology","score_opus":0.08032479363375436,"score_gpt":0.4131441111757406,"score_spread":0.33281931754198624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168482167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969627,0.001306019,0.0005249599,0.00007190014,0.000045071174,0.000060221257,0.0003399157,0.00005756236,0.000631633],"genre_scores_gemma":[0.9922388,0.0014893028,0.0033005804,0.00005381194,0.00003017497,0.00011318047,0.0009224778,0.000026372994,0.0018252585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998276,0.000026657728,0.000017501381,0.00003703778,0.000048674654,0.00004248079],"domain_scores_gemma":[0.99988735,0.000015617361,0.000028962715,0.000013359447,0.000012584579,0.00004207031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020037747,0.000547687,0.0008262143,0.00027423888,0.00019139079,0.0002564337,0.00035533274,0.00035486204,0.0010825122],"category_scores_gemma":[0.000093665396,0.00018721743,0.00036559,0.0001787767,0.00014178846,0.00027026187,0.00013461152,0.0006880974,0.00024615045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010472552,0.00064006593,0.00045047599,0.000059647504,0.000025614761,0.00003383368,0.000011121565,0.00020062765,0.99493575,0.000021134365,0.000121632285,0.002452868],"study_design_scores_gemma":[0.00019503114,0.0063216737,0.0051417714,0.0000048709476,0.000058005877,0.0003081049,0.00001920365,0.000936792,0.9855876,0.000012558979,0.0014051291,0.000009204438],"about_ca_topic_score_codex":0.0008523039,"about_ca_topic_score_gemma":0.0021827123,"teacher_disagreement_score":0.0010825122,"about_ca_system_score_codex":0.00041084856,"about_ca_system_score_gemma":0.00029793943,"threshold_uncertainty_score":0.0036213398},"labels":[],"label_agreement":null},{"id":"W2168960014","doi":"10.1158/1078-0432.ccr-04-2208","title":"A Haplotype Analysis of <i>HER-2</i> Gene Polymorphisms: Association with Breast Cancer Risk, HER-2 Protein Expression in the Tumor, and Disease Recurrence in Korea","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"College of Medicine, Seoul National University; Seoul National University","keywords":"Haplotype; Single-nucleotide polymorphism; Linkage disequilibrium; Breast cancer; Genetics; Biology; Tag SNP; Allele; SNP; Minor allele frequency; Case-control study; Cancer; Genotype; Oncology; Internal medicine; Medicine; Gene","score_opus":0.10833714557625322,"score_gpt":0.4753167939647972,"score_spread":0.36697964838854397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168960014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99969137,0.000039334274,0.00017501226,0.000006729192,8.5506315e-7,0.0000037405869,0.000039470753,0.0000013686158,0.000042156036],"genre_scores_gemma":[0.9996865,0.000017456641,0.00017586317,0.0000061187066,0.0000012846291,0.0000038360536,0.00007051886,9.825753e-7,0.000037568618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999826,0.00005607247,0.000017027709,0.00006433874,0.00001663664,0.000019877909],"domain_scores_gemma":[0.9995896,0.000086422,0.00019512157,0.000042151423,0.00003123276,0.000055497694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003057221,0.00017606175,0.00012046536,0.000267579,0.00016845507,0.00014296238,0.00013468188,0.00013507776,0.0008517401],"category_scores_gemma":[0.0005864545,0.00011635389,0.00023113747,0.00023152346,0.00013693799,0.00008597589,0.00014836252,0.00016534411,0.00010633574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045232085,0.000052281954,0.9825088,0.000018800332,0.00016612413,0.00019780856,0.000076403,0.00015948054,0.011619469,0.000023252273,0.000070097354,0.004655263],"study_design_scores_gemma":[0.00006145651,0.0004877027,0.9949269,0.0000071691647,0.0001629696,0.0010378245,0.00008508793,0.0009089966,0.0019861565,0.0000584415,0.00027106472,0.0000062929116],"about_ca_topic_score_codex":0.0009992465,"about_ca_topic_score_gemma":0.0015079611,"teacher_disagreement_score":0.0009992465,"about_ca_system_score_codex":0.00009150962,"about_ca_system_score_gemma":0.00012208236,"threshold_uncertainty_score":0.0028494},"labels":[],"label_agreement":null},{"id":"W2169031646","doi":"10.1309/ajcpw37qgecdycdo","title":"Tissue Microarray for Routine Analysis of Breast Biomarkers in the Clinical Laboratory","year":2009,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tissue microarray; Concordance; Medicine; Pathology; Stain; Histopathology; Breast cancer; Immunohistochemistry; Staining; Internal medicine; Cancer","score_opus":0.07992140352272116,"score_gpt":0.5231641085861471,"score_spread":0.443242705063426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169031646","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.062362496,0.008738444,0.8865084,0.0011678312,0.0017809188,0.0047266306,0.010111543,0.0076097827,0.016993932],"genre_scores_gemma":[0.10957702,0.00412862,0.8548001,0.00071618496,0.0003797653,0.009603051,0.01143232,0.000656563,0.0087063415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952781,0.00206412,0.0004987441,0.0005379637,0.0013970267,0.00022390805],"domain_scores_gemma":[0.99760544,0.0006316546,0.00020414048,0.00081545534,0.0005893086,0.0001539579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039821374,0.00074453076,0.0015685435,0.0019886163,0.0007267382,0.0010890104,0.0011929901,0.00066595775,0.014633873],"category_scores_gemma":[0.004309099,0.0006124997,0.0008323086,0.0018645711,0.00031371514,0.0009943183,0.0008097956,0.0013271531,0.012513199],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001015109,0.0003369867,0.005227719,0.00085219915,0.00012662902,0.0005172254,0.00010717431,0.0005307456,0.8927396,0.0021739411,0.015679404,0.080693394],"study_design_scores_gemma":[0.0004680983,0.0057515693,0.08035127,0.00057806174,0.0006429361,0.011480632,0.00028148765,0.03119582,0.64201534,0.0043197144,0.2227029,0.00021214374],"about_ca_topic_score_codex":0.00040427755,"about_ca_topic_score_gemma":0.0008458251,"teacher_disagreement_score":0.014633873,"about_ca_system_score_codex":0.00043730004,"about_ca_system_score_gemma":0.000921719,"threshold_uncertainty_score":0.048955142},"labels":[],"label_agreement":null},{"id":"W2169052759","doi":"","title":"Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"ErbB; Biology; Cancer research; Tumor microenvironment; Angiogenesis; Receptor; Tumor progression; Cancer; Genetics","score_opus":0.04022559267485461,"score_gpt":0.2614301391182426,"score_spread":0.221204546443388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169052759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351656,0.0015517286,0.0040150094,0.00003150024,0.000010427199,0.000021710772,0.00022739972,0.00004592801,0.0005797908],"genre_scores_gemma":[0.99403304,0.0010183984,0.0037170907,0.000024563711,0.0000063573,0.000028306384,0.00045249762,0.0000103187895,0.00070939655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985945,0.000020844609,0.0000105008785,0.000037183567,0.000044126944,0.00002794421],"domain_scores_gemma":[0.99985623,0.00004362003,0.000047808007,0.000019735142,0.000012192081,0.000020433148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012876968,0.0003128287,0.00022778362,0.00027424202,0.00007050387,0.0002273425,0.00011835448,0.00014723915,0.00063944183],"category_scores_gemma":[0.00013023271,0.0001316555,0.00021157184,0.00014140892,0.00015436264,0.0001803405,0.00021091884,0.00031490295,0.00017687648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025546993,0.0000061522464,0.00051496323,0.000013539159,0.00000408203,0.000023556773,0.0000045029046,0.00003250255,0.998588,0.00001932925,0.000003514419,0.00076427415],"study_design_scores_gemma":[0.000005565975,0.00038344512,0.02337748,0.0000046643463,0.00006100032,0.00074490206,0.000036026624,0.0006749204,0.97338164,0.00004766357,0.0012764048,0.000006199861],"about_ca_topic_score_codex":0.00022216987,"about_ca_topic_score_gemma":0.00047841307,"teacher_disagreement_score":0.00063944183,"about_ca_system_score_codex":0.00014484332,"about_ca_system_score_gemma":0.000120191704,"threshold_uncertainty_score":0.002139151},"labels":[],"label_agreement":null},{"id":"W2169149961","doi":"10.2967/jnumed.109.067231","title":"<sup>18</sup>F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice","year":2009,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Biodistribution; Medicine; Breast cancer; Cancer; Nuclear medicine; Internal medicine; In vivo; Biology","score_opus":0.0455967457794242,"score_gpt":0.36205929155645106,"score_spread":0.31646254577702687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169149961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863712,0.0035770459,0.0053453487,0.00020826982,0.000030267567,0.00012103344,0.0012985476,0.00021440753,0.0028339175],"genre_scores_gemma":[0.9772923,0.0023589719,0.011884772,0.000193018,0.00002949266,0.00026035585,0.0027326907,0.00012265357,0.005125782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984574,0.00002566327,0.00001711154,0.000047785536,0.000026487105,0.00003717969],"domain_scores_gemma":[0.99984086,0.00002710165,0.000053777312,0.000019332618,0.000020458941,0.00003848514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034586992,0.00045985045,0.00033942165,0.0005140097,0.0001642213,0.00048223705,0.00028909885,0.0005688345,0.0015974499],"category_scores_gemma":[0.00014051991,0.0002870828,0.00021628015,0.00031691967,0.0003336781,0.00035191502,0.00014285826,0.0006263977,0.00070782343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006554443,0.00006557196,0.0007140546,0.000028472341,0.0000059639106,0.00006045902,0.000013374952,0.000060135964,0.9970529,0.00004261851,0.00008910383,0.001211883],"study_design_scores_gemma":[0.000108101114,0.0016015767,0.0219054,0.00001359772,0.0000610878,0.0022263806,0.00005360286,0.0018160621,0.9684747,0.00007095167,0.0036570888,0.000011587479],"about_ca_topic_score_codex":0.00057645736,"about_ca_topic_score_gemma":0.0008619591,"teacher_disagreement_score":0.0015974499,"about_ca_system_score_codex":0.00028536282,"about_ca_system_score_gemma":0.00014284819,"threshold_uncertainty_score":0.0053440332},"labels":[],"label_agreement":null},{"id":"W2169519275","doi":"10.1158/0008-5472.can-13-1055","title":"Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 Activation","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Neuregulin; Breast cancer; Autocrine signalling; Neuregulin 1; Medicine; Cancer research; Trastuzumab; Lapatinib; Cancer; In vivo; Oncology; Internal medicine; Receptor; Biology","score_opus":0.06370755747525297,"score_gpt":0.39784602243945827,"score_spread":0.3341384649642053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169519275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135464,0.0028460224,0.0020755243,0.0001407567,0.000021034211,0.000019998568,0.00021065076,0.00007803539,0.0032533032],"genre_scores_gemma":[0.99560803,0.0012805767,0.0011640873,0.00003861313,0.000007565085,0.000012169247,0.00017503665,0.000007661973,0.0017062407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999312,0.0000125286915,0.0000027793296,0.000011373493,0.000022273252,0.000019806726],"domain_scores_gemma":[0.9999583,0.000007701904,0.000010501235,0.000004851669,0.000004289593,0.000014405047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009163353,0.00018404938,0.00013516034,0.00015293347,0.00009149819,0.00022594028,0.00009864977,0.000096091324,0.0013531252],"category_scores_gemma":[0.00006551291,0.000057899473,0.00012778025,0.000086509215,0.00013559007,0.000118944154,0.00016664992,0.00029038114,0.0003027349],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008801422,0.000023300237,0.00086729135,0.000030167099,0.000005045473,0.00006954733,0.000009247534,0.00006605641,0.9953194,0.00012309143,0.000079502,0.003319125],"study_design_scores_gemma":[0.000015614269,0.00020895548,0.0241748,0.000005787217,0.000019354115,0.0005383508,0.000060494156,0.0014960922,0.9668628,0.0001263692,0.0064882166,0.0000031141815],"about_ca_topic_score_codex":0.00036711065,"about_ca_topic_score_gemma":0.00095965323,"teacher_disagreement_score":0.0013531252,"about_ca_system_score_codex":0.0001982908,"about_ca_system_score_gemma":0.00016602976,"threshold_uncertainty_score":0.004526615},"labels":[],"label_agreement":null},{"id":"W2169680251","doi":"10.5858/2000-124-0234-peatei","title":"p53, ErbB2, and TAG-72 Expression in the Spectrum of Ductal Carcinoma In Situ of the Breast Classified by the Van Nuys System","year":2000,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ductal carcinoma; Pathology; Breast cancer; Differential diagnosis; Immunohistochemistry; Context (archaeology); Carcinoma in situ; Carcinoma; P53 expression; Biology; Breast carcinoma; Cancer; Medicine; Internal medicine","score_opus":0.012849247681886283,"score_gpt":0.2772095502662124,"score_spread":0.26436030258432613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169680251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99931514,0.00020107115,0.00019077217,0.000004948749,0.0000019581073,0.0000045533175,0.00002912238,0.0000016830944,0.00025077868],"genre_scores_gemma":[0.99969363,0.000054429627,0.00015907797,0.0000020005282,0.0000019110084,0.0000033018352,0.000055703757,5.380986e-7,0.000029482788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996406,0.00009697416,0.00004123021,0.00006384094,0.000081677645,0.000075771655],"domain_scores_gemma":[0.9993944,0.0001512384,0.00023494313,0.00004392726,0.00008407978,0.00009139446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057800167,0.00020787439,0.00016718102,0.001298862,0.0002533097,0.0003321689,0.00016751357,0.00019685739,0.0007030158],"category_scores_gemma":[0.0014350681,0.000117716074,0.00015187901,0.0005703633,0.00048017115,0.00019353731,0.00030567602,0.00013461409,0.00013523627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033748517,0.0000202795,0.9789068,0.000028460001,0.00002953665,0.00070784194,0.00010449724,0.00031019052,0.013608549,0.00007906091,0.0000588881,0.0058083017],"study_design_scores_gemma":[0.000011906332,0.00018778858,0.98900944,0.000012706925,0.000027153568,0.006971678,0.0002223086,0.000856571,0.0022319467,0.0001726296,0.0002899036,0.0000059571043],"about_ca_topic_score_codex":0.001025087,"about_ca_topic_score_gemma":0.0015243602,"teacher_disagreement_score":0.001298862,"about_ca_system_score_codex":0.00028033232,"about_ca_system_score_gemma":0.00021276335,"threshold_uncertainty_score":0.0030568242},"labels":[],"label_agreement":null},{"id":"W2170181527","doi":"10.1186/s13058-015-0568-1","title":"Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy","year":2015,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"GlaxoSmithKline; Avon Foundation for Women","keywords":"Medicine; Hazard ratio; Breast cancer; Internal medicine; Oncology; Hormone receptor; Adjuvant therapy; Hormone therapy; Proportional hazards model; Trastuzumab; Estrogen receptor; Cancer; Adjuvant; Surgical oncology; Gynecology; Confidence interval","score_opus":0.10834116408560235,"score_gpt":0.43908163209744927,"score_spread":0.3307404680118469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170181527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997168,0.0021974505,0.0001176008,0.000050146104,0.000010805563,0.000011702456,0.00016783077,0.0000050300737,0.00027137462],"genre_scores_gemma":[0.99873215,0.00052485074,0.00006642542,0.000057371824,0.000035684658,0.000017892486,0.00038688016,0.0000013314018,0.00017737785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958223,0.00018780917,0.00002999195,0.000060190105,0.00006715691,0.00007256555],"domain_scores_gemma":[0.99800605,0.000790801,0.0007099997,0.0001242728,0.00005869212,0.00031016878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016097067,0.00019385054,0.0006417374,0.00016221942,0.00015373895,0.00031612875,0.00017877926,0.00046334788,0.0009035828],"category_scores_gemma":[0.0017009516,0.00012919793,0.0006664869,0.00018672807,0.00016525804,0.0002627391,0.00018371642,0.00049539335,0.00011482076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16029559,0.0016464983,0.7640427,0.0003334986,0.0019352422,0.0004954281,0.00015674728,0.0022915495,0.00859682,0.00019193268,0.00088843703,0.05912558],"study_design_scores_gemma":[0.0063398043,0.054775618,0.93024296,0.00005042582,0.001304033,0.0011525211,0.00006502185,0.0015150522,0.0024270688,0.00033945157,0.0017568588,0.00003120312],"about_ca_topic_score_codex":0.00035391553,"about_ca_topic_score_gemma":0.0004597264,"teacher_disagreement_score":0.0016097067,"about_ca_system_score_codex":0.0001918492,"about_ca_system_score_gemma":0.00025294116,"threshold_uncertainty_score":0.008513093},"labels":[],"label_agreement":null},{"id":"W2171670688","doi":"10.1186/bcr2427","title":"Tailored targeted therapy for all: a realistic and worthwhile objective against","year":2009,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Tamoxifen; Endocrine system; Breast cancer; Oncology; Metastatic breast cancer; Diethylstilbestrol; Cancer; Internal medicine; Adjuvant; Surgical oncology; Adjuvant therapy; Ovarian cancer; Targeted therapy; Hormone","score_opus":0.0992520777201737,"score_gpt":0.45478780698907706,"score_spread":0.35553572926890337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171670688","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09445899,0.12492468,0.04910138,0.6521732,0.012342538,0.00023788617,0.00042228325,0.0003620008,0.065977044],"genre_scores_gemma":[0.64351434,0.058831442,0.03765203,0.20419773,0.021456009,0.00020267631,0.00038246423,0.00009176174,0.03367166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996099,0.0001341486,0.000024768256,0.00006253596,0.000108403176,0.000060260812],"domain_scores_gemma":[0.99934906,0.00023220072,0.00008172822,0.00006551303,0.000109189576,0.00016229558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018485817,0.00041693661,0.00049225905,0.00022332097,0.0004623014,0.001090314,0.00043049574,0.0020063394,0.0028550378],"category_scores_gemma":[0.0013788812,0.000106716565,0.00026951384,0.00013360895,0.0010408375,0.0013645835,0.0009881764,0.002568795,0.00078208453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010793282,0.0008163176,0.007178531,0.0011646206,0.00027250437,0.0015309316,0.00038663772,0.0053332015,0.030108681,0.16577826,0.108852975,0.67749804],"study_design_scores_gemma":[0.00062718097,0.002342499,0.007850461,0.0008165652,0.00035307725,0.0052898596,0.00093255745,0.0035406558,0.009502855,0.2225511,0.7461204,0.000072799725],"about_ca_topic_score_codex":0.00019098881,"about_ca_topic_score_gemma":0.00071394845,"teacher_disagreement_score":0.0028550378,"about_ca_system_score_codex":0.00073842326,"about_ca_system_score_gemma":0.0010122774,"threshold_uncertainty_score":0.009776354},"labels":[],"label_agreement":null},{"id":"W2172081236","doi":"10.1124/mol.106.023911","title":"Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor","year":2006,"lang":"en","type":"article","venue":"Molecular Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia","funders":"National Cancer Institute","keywords":"Trastuzumab; SKBR3; Protein kinase B; PI3K/AKT/mTOR pathway; Cancer research; Medicine; Apoptosis; Growth inhibition; Breast cancer; Pharmacology; Chemistry; Cancer; Internal medicine; Biochemistry","score_opus":0.01630541155249776,"score_gpt":0.32560526798965805,"score_spread":0.3092998564371603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172081236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98499763,0.006670492,0.0028851475,0.00044802614,0.00016479281,0.0001043226,0.0003037671,0.00020362591,0.004222252],"genre_scores_gemma":[0.98774594,0.0045629255,0.002856054,0.0000984428,0.000038983122,0.000049768725,0.00060771103,0.000018605338,0.0040215235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999347,0.0000073089154,0.000007635283,0.000008231354,0.000018399143,0.000023759903],"domain_scores_gemma":[0.9999814,0.000003149719,0.0000036165957,0.0000030499841,0.000003201313,0.000005659452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012915814,0.00035092636,0.0005480022,0.00020019531,0.00022889984,0.0005226227,0.00023705325,0.00022659634,0.0007160403],"category_scores_gemma":[0.00007988245,0.00012984127,0.00021412015,0.00026586856,0.00012304854,0.00021461357,0.00016319948,0.0005188759,0.00021971714],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074138126,0.00023279182,0.000337655,0.00011734982,0.000023645673,0.0002309148,0.00004005269,0.0005073754,0.9798749,0.00036182225,0.00040669445,0.01712554],"study_design_scores_gemma":[0.00029320238,0.0006718962,0.0021172531,0.000006951344,0.000054641525,0.00051496195,0.000022084352,0.0026237175,0.9825717,0.00004920188,0.0110658975,0.000008572001],"about_ca_topic_score_codex":0.001140714,"about_ca_topic_score_gemma":0.0030492204,"teacher_disagreement_score":0.001140714,"about_ca_system_score_codex":0.0004938493,"about_ca_system_score_gemma":0.00033073555,"threshold_uncertainty_score":0.0035831928},"labels":[],"label_agreement":null},{"id":"W2178732328","doi":"10.1093/annonc/mdv395","title":"Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Immune system; Immunology; Trastuzumab; Cancer research; Breast cancer; Cancer; Internal medicine","score_opus":0.2799415670746014,"score_gpt":0.4692287805792134,"score_spread":0.18928721350461203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178732328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937868,0.0027564,0.00019303143,0.00087450974,0.000164513,0.00013976624,0.00026426726,0.000021191248,0.0017995341],"genre_scores_gemma":[0.99403197,0.0013656601,0.00033532837,0.0011587118,0.00014196448,0.00027409737,0.0006783671,0.000011907438,0.0020019554],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970454,0.00014965607,0.000013090714,0.000035864123,0.0000340227,0.000062852145],"domain_scores_gemma":[0.9996815,0.00009295918,0.000070002905,0.000032460626,0.00002043667,0.00010278276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009966946,0.0004063774,0.0009712623,0.000091365306,0.000140592,0.0004465222,0.00034013932,0.00040392258,0.0018782574],"category_scores_gemma":[0.0006691713,0.00013864473,0.00060103653,0.00013635165,0.0003993564,0.00062893354,0.00027991645,0.0017919273,0.00026481893],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.599061,0.0121306395,0.01741997,0.0009883444,0.0026105063,0.000184516,0.0002423417,0.0055478495,0.030790782,0.0014612469,0.008532861,0.3210299],"study_design_scores_gemma":[0.31525505,0.52844316,0.109252416,0.00024840163,0.002945796,0.00061263144,0.00030988516,0.005982662,0.012754702,0.0038338655,0.02027577,0.000085594176],"about_ca_topic_score_codex":0.0002559288,"about_ca_topic_score_gemma":0.0014315691,"teacher_disagreement_score":0.0018782574,"about_ca_system_score_codex":0.0005952221,"about_ca_system_score_gemma":0.0005607586,"threshold_uncertainty_score":0.0062834024},"labels":[],"label_agreement":null},{"id":"W2185702273","doi":"","title":"Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Laser capture microdissection; Microdissection; Breast cancer; Biology; Gene duplication; Ductal carcinoma; Immunohistochemistry; Pathology; Polymerase chain reaction; Concordance; Mammary gland; genomic DNA; Cancer; Carcinoma; DNA; Molecular biology; Gene; Medicine; Gene expression; Genetics","score_opus":0.03769942574498235,"score_gpt":0.30197102997128955,"score_spread":0.2642716042263072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185702273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95171344,0.0034985307,0.036730573,0.00011832453,0.00007023171,0.00040994264,0.0029439067,0.00036583937,0.0041492246],"genre_scores_gemma":[0.9326339,0.002455538,0.052496836,0.00021856478,0.00004761483,0.0005896872,0.0053886487,0.00008800423,0.0060812137],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998486,0.000018215678,0.000011952104,0.0000406754,0.00006028371,0.00002020091],"domain_scores_gemma":[0.9996885,0.00013449184,0.000029139846,0.000039470568,0.000082760496,0.000025669051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023784337,0.00018437502,0.0001997396,0.0009260014,0.00022929652,0.00018062464,0.00015452935,0.00023622498,0.001070596],"category_scores_gemma":[0.00037088234,0.00010580585,0.0001195719,0.00045601372,0.00015492017,0.000079424804,0.00012506674,0.00016174308,0.0005247121],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005767478,0.000018673438,0.0019157147,0.000039472332,0.000008385635,0.00017800306,0.000056771845,0.000026992779,0.99355894,0.00002629547,0.00007001554,0.0040430133],"study_design_scores_gemma":[0.00003799777,0.00046062667,0.13408221,0.000020787906,0.000102686776,0.0044593536,0.00023107213,0.002142965,0.84838253,0.00015876116,0.009909495,0.000011558444],"about_ca_topic_score_codex":0.0009541116,"about_ca_topic_score_gemma":0.003010548,"teacher_disagreement_score":0.001070596,"about_ca_system_score_codex":0.00011877618,"about_ca_system_score_gemma":0.00015243425,"threshold_uncertainty_score":0.0035814643},"labels":[],"label_agreement":null},{"id":"W2188941506","doi":"10.1152/ajpheart.2000.278.6.h1815","title":"Somatostatin receptor subtype expression and function in human vascular tissue","year":2000,"lang":"en","type":"article","venue":"American Journal of Physiology-Heart and Circulatory Physiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Somatostatin receptor; Endocrinology; Somatostatin; Internal medicine; Umbilical vein; Receptor; Vascular smooth muscle; Chemistry; Biology; Pathology; Medicine; In vitro; Smooth muscle","score_opus":0.01630701663107245,"score_gpt":0.30391253841830324,"score_spread":0.2876055217872308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2188941506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829759,0.008776906,0.0015391585,0.000058278052,0.000020421907,0.00001648513,0.0005536655,0.000032109576,0.0060271644],"genre_scores_gemma":[0.9938589,0.002499286,0.00078833057,0.00003882509,0.000013102461,0.000015114272,0.0007203297,0.0000063514294,0.0020596774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998654,0.000040210096,0.000009248374,0.0000357517,0.000027580623,0.000021732429],"domain_scores_gemma":[0.9999087,0.000025190408,0.000019094401,0.000013262808,0.00001850308,0.000015354886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027515186,0.000081575934,0.00012330871,0.00040088347,0.00007030882,0.0002936034,0.000088919674,0.00020724168,0.0022294195],"category_scores_gemma":[0.0003442821,0.00008377462,0.00009337021,0.0003852195,0.000097297736,0.00011039433,0.00007539474,0.00013272642,0.00054338423],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002042249,0.00010094552,0.06404387,0.00026393795,0.000091241214,0.0026122632,0.00044818982,0.0003088064,0.8670075,0.0006995921,0.00089610793,0.061485354],"study_design_scores_gemma":[0.00007992445,0.002084303,0.7788903,0.000076578704,0.00018191925,0.023221832,0.00071621034,0.001883818,0.159269,0.00056582224,0.03299439,0.000035837267],"about_ca_topic_score_codex":0.00067514763,"about_ca_topic_score_gemma":0.000566533,"teacher_disagreement_score":0.0022294195,"about_ca_system_score_codex":0.000115277915,"about_ca_system_score_gemma":0.00007951006,"threshold_uncertainty_score":0.0074581504},"labels":[],"label_agreement":null},{"id":"W2222365833","doi":"10.1080/15384047.2015.1071737","title":"The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors","year":2015,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Gefitinib; Cancer research; Epidermal growth factor receptor; Small GTPase; Tyrosine kinase; Protein kinase B; Receptor tyrosine kinase; Signal transduction; Proto-oncogene tyrosine-protein kinase Src; Biology; Cell biology; Chemistry; Receptor; Biochemistry","score_opus":0.07590822992918955,"score_gpt":0.3694510427871348,"score_spread":0.29354281285794526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222365833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99103045,0.0056630126,0.0010735281,0.00015437722,0.00003674692,0.000021513502,0.00029007302,0.00007522275,0.0016551822],"genre_scores_gemma":[0.9955713,0.0018875846,0.00044853348,0.00005455935,0.000010497156,0.00003547388,0.00039155228,0.000009068301,0.001591409],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998727,0.000018594079,0.000012886979,0.00001909262,0.00004286452,0.000033853536],"domain_scores_gemma":[0.99993336,0.000015387119,0.000017156293,0.000009068814,0.000009285832,0.000015736683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011725139,0.00037029042,0.00049264793,0.00024908382,0.0001840334,0.00031681333,0.00013898239,0.00026798004,0.0008988244],"category_scores_gemma":[0.00012877237,0.00013381064,0.00024925772,0.00013763572,0.0001450895,0.00018442847,0.00016727559,0.0005047255,0.00032523824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010772978,0.000028242059,0.00017414923,0.000040391078,0.0000044939447,0.00005695854,0.000015471622,0.00005815633,0.99808574,0.00006590314,0.00005579771,0.0013070202],"study_design_scores_gemma":[0.000014763207,0.00033726948,0.009886014,0.0000061635355,0.000014670253,0.0004635744,0.000022857896,0.00069428876,0.98566574,0.000060185906,0.002828425,0.0000060271004],"about_ca_topic_score_codex":0.00055455073,"about_ca_topic_score_gemma":0.000737965,"teacher_disagreement_score":0.0008988244,"about_ca_system_score_codex":0.00024794933,"about_ca_system_score_gemma":0.00016662052,"threshold_uncertainty_score":0.0030069351},"labels":[],"label_agreement":null},{"id":"W2227532783","doi":"10.1002/bimj.201500051","title":"Relaxed Poisson cure rate models","year":2015,"lang":"en","type":"article","venue":"Biometrical Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Poisson distribution; Cure rate; Negative binomial distribution; Mathematics; Applied mathematics; Computer science; Statistics; Mathematical optimization; Medicine; Surgery","score_opus":0.34782676182974553,"score_gpt":0.4396721505269094,"score_spread":0.09184538869716385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227532783","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022451991,0.0016587346,0.963453,0.0016730689,0.00030307152,0.00024995688,0.0008730208,0.00031673268,0.009020518],"genre_scores_gemma":[0.73667455,0.0051492504,0.19897966,0.0014672185,0.001180031,0.0015294302,0.0021640402,0.0003589708,0.052496903],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99442,0.0026934699,0.00026155933,0.00096996495,0.0010433198,0.0006117245],"domain_scores_gemma":[0.9915803,0.00476668,0.0012472128,0.0010525159,0.001034457,0.00031882833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010276552,0.0017822719,0.002400615,0.0019097051,0.0006039963,0.002078835,0.006807848,0.0033536842,0.009490392],"category_scores_gemma":[0.024446521,0.0010802489,0.0028732042,0.001516075,0.0020333864,0.0035944257,0.0022906947,0.005175096,0.0025585468],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046361767,0.00012607622,0.002384975,0.00044965162,0.00015707448,0.00064913183,0.00062453997,0.27010044,0.002670089,0.67431647,0.007683688,0.04037437],"study_design_scores_gemma":[0.00013495047,0.0003155623,0.0011479497,0.000120380064,0.0001848515,0.0014071258,0.00014237472,0.719931,0.0012223189,0.25884202,0.016433775,0.00011765383],"about_ca_topic_score_codex":0.002894226,"about_ca_topic_score_gemma":0.0012486231,"teacher_disagreement_score":0.010276552,"about_ca_system_score_codex":0.001706101,"about_ca_system_score_gemma":0.001166918,"threshold_uncertainty_score":0.05434829},"labels":[],"label_agreement":null},{"id":"W2231730507","doi":"10.1242/dmm.023143","title":"Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer","year":2015,"lang":"en","type":"article","venue":"Disease Models & Mechanisms","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Medical Research Council; Indian Council of Medical Research; World Cancer Research Fund; Cancer Research UK; AstraZeneca","keywords":"Genetically engineered; Breast cancer; Genetically modified organism; Cancer; Computational biology; Biology; Medicine; Cancer research; Genetics; Gene","score_opus":0.18130911999274252,"score_gpt":0.40367889509363825,"score_spread":0.22236977510089573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231730507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84783393,0.007851496,0.112639174,0.0021730568,0.0014789691,0.0023150297,0.006575733,0.0029298929,0.016202703],"genre_scores_gemma":[0.8739005,0.008142229,0.07613459,0.0007012881,0.00018316033,0.0038494233,0.006774852,0.00050226704,0.029811867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989967,0.00019463665,0.00012666565,0.0002145893,0.00029833458,0.00016903377],"domain_scores_gemma":[0.9992912,0.00015035106,0.00015835489,0.00016390705,0.000092894355,0.00014326868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011716288,0.0013506737,0.0007429393,0.0019296352,0.0005579532,0.000929783,0.0011623224,0.0015727946,0.0042236866],"category_scores_gemma":[0.00042467503,0.000558386,0.0007744488,0.0005146889,0.00065062277,0.0009977359,0.0005896268,0.0033184167,0.001374402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039887906,0.0005437559,0.000319782,0.00013801098,0.000026592204,0.00015588883,0.000053096304,0.00029318326,0.99148643,0.0017523026,0.0004351501,0.004396934],"study_design_scores_gemma":[0.00012881089,0.0031164868,0.00134073,0.000053452248,0.00007373857,0.00086861535,0.000044747405,0.0024054924,0.9747576,0.00042436368,0.016763426,0.000022427139],"about_ca_topic_score_codex":0.0007300044,"about_ca_topic_score_gemma":0.0013139128,"teacher_disagreement_score":0.0042236866,"about_ca_system_score_codex":0.00075427373,"about_ca_system_score_gemma":0.0006164537,"threshold_uncertainty_score":0.014129579},"labels":[],"label_agreement":null},{"id":"W2238367440","doi":"","title":"Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.","year":2014,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Immunohistochemistry; Real-time polymerase chain reaction; Biology; Human Epidermal Growth Factor Receptor 2; Fluorescence in situ hybridization; Cancer; Pathology; Fish <Actinopterygii>; Molecular biology; Oncology; Medicine; Internal medicine; Gene; Genetics","score_opus":0.04828264927471493,"score_gpt":0.34999250503658097,"score_spread":0.30170985576186604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2238367440","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16156654,0.005886497,0.810255,0.00032375532,0.00073729,0.002567218,0.009090149,0.0035673152,0.0060062567],"genre_scores_gemma":[0.15082516,0.0042251293,0.8100981,0.00052558037,0.00020995697,0.008267669,0.010834893,0.00063843286,0.0143750515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959714,0.0008820766,0.0004872544,0.001262941,0.0011185347,0.00027781856],"domain_scores_gemma":[0.9983297,0.0005846528,0.00025213827,0.00022504998,0.00055108895,0.000057244015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028763958,0.0020182233,0.0012521024,0.0021668258,0.00059993396,0.00075046485,0.0013217146,0.000865061,0.0033324696],"category_scores_gemma":[0.0016942985,0.0010501482,0.0011852251,0.0015558323,0.0009015176,0.00081349874,0.00060974795,0.0019250262,0.0021645175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106228916,0.00016196183,0.00063822506,0.00038697093,0.000046624635,0.00007866171,0.00011652653,0.00033620806,0.9907907,0.00030565975,0.0002795886,0.006752643],"study_design_scores_gemma":[0.0000622651,0.0008809804,0.0042625247,0.00007905274,0.00016898844,0.00047249117,0.000108516986,0.008837818,0.9710941,0.00048493614,0.013470159,0.00007805326],"about_ca_topic_score_codex":0.00044341348,"about_ca_topic_score_gemma":0.0012209783,"teacher_disagreement_score":0.0033324696,"about_ca_system_score_codex":0.000653472,"about_ca_system_score_gemma":0.00077636295,"threshold_uncertainty_score":0.015212059},"labels":[],"label_agreement":null},{"id":"W2240030606","doi":"","title":"Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Trastuzumab; Receptor tyrosine kinase; Cancer research; Tyrosine kinase; Receptor; Growth inhibition; Insulin-like growth factor; Cancer cell; Breast cancer; Biology; Insulin-like growth factor 1 receptor; Growth factor; Cancer; Signal transduction; Cell growth; Cell biology; Biochemistry","score_opus":0.03867077100561481,"score_gpt":0.28176609990914636,"score_spread":0.24309532890353155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240030606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832524,0.0056358734,0.005010714,0.00013063394,0.00008745026,0.00009719267,0.0006772171,0.00020011322,0.004908421],"genre_scores_gemma":[0.987928,0.00220926,0.0057320525,0.000050921084,0.000020093647,0.00007144628,0.00080713985,0.0000392163,0.00314187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976045,0.000038055015,0.00001663693,0.000040469542,0.00009291121,0.000051340892],"domain_scores_gemma":[0.9999119,0.000022280894,0.00002192676,0.000014684055,0.000007176017,0.000022094415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001816651,0.0005298298,0.00033560902,0.00029354435,0.00012414105,0.00023171358,0.00021724863,0.00021328739,0.0016614649],"category_scores_gemma":[0.00010590729,0.00018324528,0.00030800723,0.00033277902,0.00018572854,0.00014434628,0.00019076296,0.0004429131,0.0005777067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002373802,0.00007843556,0.00013558395,0.000046262376,0.000010692775,0.000035807927,0.0000050356334,0.00006609044,0.99774396,0.000053729258,0.000080929705,0.0015060605],"study_design_scores_gemma":[0.000025285955,0.00044257738,0.0011824882,0.0000025688694,0.000017985589,0.00020108579,0.0000054595034,0.00033587267,0.99616784,0.000011764681,0.0016048937,0.000002281414],"about_ca_topic_score_codex":0.0003139126,"about_ca_topic_score_gemma":0.0009452556,"teacher_disagreement_score":0.0016614649,"about_ca_system_score_codex":0.0003215055,"about_ca_system_score_gemma":0.00019500902,"threshold_uncertainty_score":0.0055581927},"labels":[],"label_agreement":null},{"id":"W2240108656","doi":"10.1074/jbc.m115.686782","title":"Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells","year":2015,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Genentech; Bundesministerium für Bildung und Forschung","keywords":"Importin; Cell biology; Receptor tyrosine kinase; Nuclear transport; ERBB3; Nucleus; Endocytosis; Cell nucleus; Biology; Nuclear localization sequence; Clathrin; Phosphorylation; Receptor; Biochemistry","score_opus":0.06859584557137426,"score_gpt":0.3241824761786407,"score_spread":0.25558663060726644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240108656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97055715,0.0110240085,0.009257892,0.00023294022,0.0000895352,0.00004709277,0.00052244397,0.00016045697,0.008108457],"genre_scores_gemma":[0.98150027,0.0049203155,0.0037451172,0.00010880702,0.000020116911,0.000043095264,0.00074602896,0.00002209381,0.0088940505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998847,0.000011524278,0.000007173762,0.000022698114,0.00004334067,0.000030526706],"domain_scores_gemma":[0.9999509,0.000004832806,0.000015996357,0.000005979614,0.0000099733115,0.00001231805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072540926,0.00030161167,0.00018356198,0.00018348289,0.00023218353,0.00023836961,0.00014056762,0.00020220075,0.0016185999],"category_scores_gemma":[0.000061986386,0.00010913247,0.00043495005,0.00018615458,0.0001835688,0.00020679065,0.00028898558,0.00041331316,0.0005262453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009277003,0.000015203085,0.0007054355,0.00010442757,0.0000125752385,0.00014468939,0.000027638638,0.000042369287,0.9946568,0.00046230052,0.000097670454,0.0036382454],"study_design_scores_gemma":[0.000021274185,0.0002547009,0.027222505,0.00002975082,0.00004070956,0.0022495983,0.000095255295,0.0012494348,0.9542189,0.00033029937,0.014272308,0.000015258619],"about_ca_topic_score_codex":0.0016079625,"about_ca_topic_score_gemma":0.0018745075,"teacher_disagreement_score":0.0016185999,"about_ca_system_score_codex":0.0005412486,"about_ca_system_score_gemma":0.00032287577,"threshold_uncertainty_score":0.0054147243},"labels":[],"label_agreement":null},{"id":"W2240613603","doi":"10.1200/jco.2007.25.18_suppl.10587","title":"Gamma-Secretase, ErbB4 nuclear localization and neuregulin expression correlates with prostate cancer patient clinical outcome","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"ERBB4; Neuregulin 1; Tissue microarray; Prostate cancer; Neuregulin; ErbB; Cancer research; ERBB3; Cancer; Medicine; Nuclear receptor; Prostate; Pathology; Biology; Receptor; Internal medicine; Epidermal growth factor receptor","score_opus":0.15648146223078616,"score_gpt":0.5332042680161554,"score_spread":0.3767228057853692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240613603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989297,0.0003544479,0.000079209174,0.000020295101,0.0000046312252,0.0000028269426,0.00015178537,0.00000878016,0.00044837236],"genre_scores_gemma":[0.99959034,0.000055136315,0.000032585478,0.000007474039,0.000004931791,0.0000033412714,0.00016763773,0.0000012277497,0.00013734197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998599,0.000027929864,0.000011020091,0.00003613841,0.000032422697,0.000032604337],"domain_scores_gemma":[0.99950564,0.0001344766,0.00015806037,0.000023420695,0.0000449455,0.00013347426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021943159,0.00018237757,0.00025016314,0.00044163797,0.00016936634,0.00032199535,0.0001705801,0.00023187096,0.0026743968],"category_scores_gemma":[0.00065012806,0.00010042122,0.00018684223,0.00038898856,0.00019681986,0.0002069076,0.0001931953,0.00029755707,0.00030718086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030452953,0.000030409925,0.9943334,0.000011692873,0.00005654776,0.00014382982,0.000023247823,0.0000689041,0.0026986217,0.0000104506125,0.00013533072,0.002183019],"study_design_scores_gemma":[0.0000045321626,0.00008378742,0.9982529,0.0000023357354,0.000034580018,0.0008507138,0.000036595182,0.0001630213,0.00039264027,0.000014574602,0.00016231374,0.000001965795],"about_ca_topic_score_codex":0.0005296309,"about_ca_topic_score_gemma":0.0006804266,"teacher_disagreement_score":0.0026743968,"about_ca_system_score_codex":0.00016441496,"about_ca_system_score_gemma":0.00013363175,"threshold_uncertainty_score":0.008946776},"labels":[],"label_agreement":null},{"id":"W2242287470","doi":"10.1309/ajcp95qbhqwggnjp","title":"Is “Polysomy” in Breast Carcinoma the “New Equivocal” in<i>HER2</i>Testing?","year":2015,"lang":"en","type":"editorial","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Concordance; Guideline; Medicine; Polysomy; Medical physics; Breast cancer; MEDLINE; Test (biology); Oncology; Pathology; Internal medicine; Cancer; Fluorescence in situ hybridization","score_opus":0.12071685347181535,"score_gpt":0.492529699416863,"score_spread":0.3718128459450476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242287470","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4770187,0.13141784,0.036846172,0.28660703,0.018381169,0.00025692335,0.0011415173,0.000433473,0.047897164],"genre_scores_gemma":[0.9149636,0.026842909,0.010105108,0.031095298,0.015280707,0.000053010106,0.0004772753,0.00013994862,0.0010420633],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932881,0.0020807486,0.0013432746,0.0009745354,0.0018279653,0.0004853734],"domain_scores_gemma":[0.97104394,0.013649536,0.005051039,0.0022817997,0.0067655025,0.0012080681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011716044,0.0006230331,0.0009290543,0.0033436853,0.0012057855,0.002833575,0.001845756,0.0026908016,0.0017987655],"category_scores_gemma":[0.05456677,0.00046090412,0.0006551563,0.002748584,0.010322739,0.0051690303,0.0019964857,0.0024681438,0.0010531332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001714418,0.000111750705,0.52422684,0.0024984821,0.00034550345,0.033514064,0.0035422244,0.0007827066,0.00845054,0.024445806,0.051501956,0.34886575],"study_design_scores_gemma":[0.0001754757,0.0010669883,0.3142387,0.00983709,0.0010511698,0.31020233,0.018625354,0.005485706,0.013270548,0.13001038,0.19542913,0.00060710195],"about_ca_topic_score_codex":0.002757339,"about_ca_topic_score_gemma":0.0040173386,"teacher_disagreement_score":0.011716044,"about_ca_system_score_codex":0.0013554784,"about_ca_system_score_gemma":0.0016109569,"threshold_uncertainty_score":0.061961055},"labels":[],"label_agreement":null},{"id":"W2244529370","doi":"10.1200/jco.2009.27.15_suppl.1022","title":"Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Tolerability; Internal medicine; Oncology; Metastatic breast cancer; Adverse effect; Breast cancer; Cancer; Pharmacology","score_opus":0.06210822724411943,"score_gpt":0.48343892075951683,"score_spread":0.4213306935153974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244529370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983103,0.000995563,0.00006574501,0.00005650973,0.000008579866,0.00006482618,0.00006447295,0.00000829457,0.00042570644],"genre_scores_gemma":[0.99876153,0.0004039138,0.00011920515,0.00013296025,0.00003567662,0.00006775297,0.00024212348,0.0000028728014,0.00023391844],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99979025,0.00008827922,0.000021248788,0.000033315802,0.000037416045,0.000029516612],"domain_scores_gemma":[0.9996474,0.00007416338,0.000082995226,0.000017826782,0.000029968056,0.00014773391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005552282,0.00029039304,0.00091669307,0.0001906864,0.00024778084,0.00044318,0.00015599203,0.0003613299,0.0008427703],"category_scores_gemma":[0.00094112044,0.00015718487,0.00028241024,0.0003292597,0.0001349346,0.00027426085,0.00017417292,0.00055194757,0.0002475992],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27939516,0.016012369,0.23866321,0.0011114405,0.0012577113,0.0042521623,0.0012075214,0.0040065716,0.103620455,0.0001388106,0.0038197574,0.34651482],"study_design_scores_gemma":[0.030990126,0.446297,0.49572483,0.00010819861,0.0008418753,0.004372695,0.00023332261,0.0031771117,0.010052729,0.0001808145,0.007967223,0.000054061733],"about_ca_topic_score_codex":0.0003618756,"about_ca_topic_score_gemma":0.000769785,"teacher_disagreement_score":0.00091669307,"about_ca_system_score_codex":0.00040943237,"about_ca_system_score_gemma":0.00036187022,"threshold_uncertainty_score":0.0029706955},"labels":[],"label_agreement":null},{"id":"W2248932904","doi":"10.1200/jco.2009.27.15_suppl.e12006","title":"HER-2 gene amplification in circulating tumor cells (CTCs): Concordance with amplification status in primary breast cancers and metastatic lesions","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Circulating tumor cell; Medicine; Concordance; Metastatic breast cancer; Breast cancer; DAPI; Cancer; Primary tumor; Pathology; Oncology; Fish <Actinopterygii>; Immunohistochemistry; Gene duplication; Liquid biopsy; Internal medicine; Metastasis; Staining; Gene; Biology","score_opus":0.15562619119841944,"score_gpt":0.4837212781029476,"score_spread":0.32809508690452815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248932904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959637,0.0011053493,0.0010157999,0.00003337244,0.00001181369,0.000023566856,0.00023297548,0.000027185419,0.0015861691],"genre_scores_gemma":[0.99864894,0.0001457194,0.00075950444,0.000012331095,0.000006029225,0.000008418834,0.00016832963,0.0000037005739,0.00024707813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99962854,0.00007093389,0.000045066576,0.000078380064,0.00012512562,0.00005200604],"domain_scores_gemma":[0.99890256,0.00046989985,0.00024020881,0.000056837198,0.00021524192,0.000115195755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069089135,0.000110876135,0.000244931,0.00068613613,0.00009551305,0.00035567503,0.00017295193,0.00033669078,0.0032362123],"category_scores_gemma":[0.001986267,0.000097552576,0.00010347245,0.00051836943,0.00017941196,0.00016791752,0.000209509,0.00021055898,0.00040999483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082976726,0.000057259476,0.94265676,0.000111998655,0.000026614725,0.0018144103,0.00011456686,0.00011557504,0.03891906,0.00008505057,0.00030152182,0.014967394],"study_design_scores_gemma":[0.000038671624,0.00045679044,0.9623125,0.000022396986,0.000064418324,0.019311424,0.00014334652,0.0018411983,0.01407968,0.00019415565,0.0015268328,0.000008455586],"about_ca_topic_score_codex":0.00062141265,"about_ca_topic_score_gemma":0.0007999807,"teacher_disagreement_score":0.0032362123,"about_ca_system_score_codex":0.00016333975,"about_ca_system_score_gemma":0.00009826475,"threshold_uncertainty_score":0.01082617},"labels":[],"label_agreement":null},{"id":"W2252494760","doi":"10.1200/jco.2006.24.18_suppl.10565","title":"Adjuvant trastuzumab (T) therapy in HER2+ breast cancer after ASCO 2005: Patients’ attitudes and immediate economic burden","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adjuvant; Trastuzumab; Breast cancer; Adjuvant therapy; Internal medicine; Cancer; Disease; Clinical trial; Oncology; Chemotherapy; Medical record; Adjuvant chemotherapy; Gynecology; Family medicine","score_opus":0.0655376748397551,"score_gpt":0.47146357321154275,"score_spread":0.40592589837178766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252494760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960466,0.0007875413,0.000027101374,0.0013084159,0.000009887207,0.0000127003905,0.00008759994,0.0000014015848,0.0017187856],"genre_scores_gemma":[0.9988525,0.0004842996,0.000042800533,0.0003740358,0.000031127212,0.0000068025925,0.00005978919,7.536734e-7,0.00014794184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856275,0.0008559187,0.00010621678,0.000059708607,0.00023117299,0.00018433407],"domain_scores_gemma":[0.9928766,0.0030428295,0.0029893948,0.0001253862,0.00019704395,0.0007686411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023268347,0.000098640645,0.0002194864,0.0005091953,0.0006170824,0.0010515057,0.00020526178,0.00033551676,0.0023319498],"category_scores_gemma":[0.009231717,0.00009145535,0.00022980406,0.0009861571,0.0003994234,0.00064479327,0.0005276552,0.00045242562,0.00018655472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079711765,0.00017225198,0.9715621,0.000044547483,0.000040649393,0.00042422442,0.00056793226,0.00018730739,0.0001266694,0.00015827456,0.002232622,0.023686243],"study_design_scores_gemma":[0.000110046865,0.0008314375,0.99304235,0.00008830009,0.000052952648,0.00092140853,0.0014757497,0.0008583281,0.00013373017,0.00023566572,0.00223688,0.000013127241],"about_ca_topic_score_codex":0.0027590862,"about_ca_topic_score_gemma":0.004855318,"teacher_disagreement_score":0.0027590862,"about_ca_system_score_codex":0.0008678024,"about_ca_system_score_gemma":0.0006164479,"threshold_uncertainty_score":0.012305617},"labels":[],"label_agreement":null},{"id":"W2252768637","doi":"","title":"Recomendaciones para la determinación de HER2 en cáncer de mama. Consenso Nacional de la Sociedad Española de Anatomía Patológica ( SEAP ) y de la Sociedad Española de Oncología Médica ( SEOM )","year":2009,"lang":"es","type":"article","venue":"Repository of Digital Objects for Teaching Research and Culture (University of Valencia)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Breast tumours; Cancer; Pathology; Oncology; Internal medicine","score_opus":0.026112584638773452,"score_gpt":0.3695545830909914,"score_spread":0.3434419984522179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252768637","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028862609,0.6378261,0.040748857,0.20113353,0.04563888,0.0008261914,0.0010870327,0.0009876454,0.04288924],"genre_scores_gemma":[0.21391499,0.34745693,0.21893398,0.12693027,0.032136273,0.0017987051,0.0033774727,0.00070411403,0.054747388],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9851324,0.0054079825,0.0018699312,0.0011147049,0.005951755,0.00052323745],"domain_scores_gemma":[0.94504917,0.020550571,0.003019481,0.0026950622,0.026694557,0.0019911544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04488346,0.0009833538,0.001196587,0.003789826,0.0009874683,0.0023553967,0.0044800616,0.005735571,0.0025459998],"category_scores_gemma":[0.06537807,0.0006819236,0.0013988607,0.0022528407,0.002178275,0.0024833702,0.0011668463,0.00469348,0.0027288196],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081072276,0.0003183779,0.019317642,0.0029942624,0.00014458009,0.0030724895,0.0009646393,0.0010171535,0.015532592,0.0056447745,0.13241017,0.81777257],"study_design_scores_gemma":[0.00017929803,0.0005252572,0.023334734,0.003299045,0.0003137603,0.005317644,0.0005520984,0.0019229169,0.017082784,0.004924921,0.9424479,0.000099757664],"about_ca_topic_score_codex":0.011910284,"about_ca_topic_score_gemma":0.014858552,"teacher_disagreement_score":0.04488346,"about_ca_system_score_codex":0.0021750624,"about_ca_system_score_gemma":0.0041872296,"threshold_uncertainty_score":0.23736924},"labels":[],"label_agreement":null},{"id":"W2257109151","doi":"10.1200/jco.2008.26.15_suppl.1026","title":"Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Rash; Internal medicine; Clinical endpoint; Mucositis; Gastroenterology; Metastatic breast cancer; Phases of clinical research; Nausea; Oncology; Cancer; Clinical trial; Breast cancer; Chemotherapy","score_opus":0.13427893998033577,"score_gpt":0.4944826051640951,"score_spread":0.36020366518375935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257109151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957461,0.0011062219,0.00021907549,0.00028466727,0.00007357415,0.0009820103,0.00043117773,0.000036479305,0.0011207212],"genre_scores_gemma":[0.99306124,0.0011198738,0.0009041238,0.00036717707,0.0001842179,0.0011126064,0.0018704542,0.00001148296,0.001368807],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995628,0.00024887145,0.000029313134,0.000053795386,0.000032641867,0.00007257749],"domain_scores_gemma":[0.9990938,0.00020060623,0.00014006549,0.00004719069,0.000040376075,0.00047794814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021039045,0.0015081564,0.0016486783,0.00033247113,0.00032610886,0.0006757688,0.00054155383,0.0009228205,0.0032294914],"category_scores_gemma":[0.0013177508,0.00044734613,0.0013214187,0.00036058712,0.0007459454,0.00066062214,0.00032283238,0.002134752,0.0004727296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9053059,0.026479429,0.0053266212,0.00040442913,0.0010248856,0.00020811183,0.00017867112,0.0016046974,0.013084787,0.0001238588,0.0014694878,0.044789053],"study_design_scores_gemma":[0.6347618,0.34887117,0.012411009,0.000021966254,0.00049155124,0.00019977844,0.000032654858,0.0006464829,0.0011676496,0.000099033976,0.0012809075,0.00001603457],"about_ca_topic_score_codex":0.0006845252,"about_ca_topic_score_gemma":0.0015433193,"teacher_disagreement_score":0.0032294914,"about_ca_system_score_codex":0.00081415405,"about_ca_system_score_gemma":0.0013338622,"threshold_uncertainty_score":0.011126697},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2259869327","doi":"10.1111/his.12795","title":"Biomarker assessment and molecular testing for prognostication in breast cancer","year":2015,"lang":"en","type":"review","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Breast cancer; Biomarker; Molecular pathology; Progesterone receptor; Biomarker discovery; Cancer; Medicine; Oncology; Molecular biomarkers; Pathological; Internal medicine; Oestrogen receptor; Targeted therapy; Bioinformatics; Pathology; Estrogen receptor; Biology; Gene; Proteomics; Genetics","score_opus":0.23248445004154325,"score_gpt":0.5190583341670709,"score_spread":0.28657388412552764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259869327","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000113990915,0.997687,0.00045957338,0.0006398157,0.00020383987,0.000008341324,0.000031157113,0.000009374863,0.00084696646],"genre_scores_gemma":[0.0013412703,0.996915,0.00061863,0.00037655263,0.00023105844,0.000011970754,0.000051753104,0.0000024808344,0.0004512994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917066,0.00022203808,0.000120052406,0.00012860031,0.00031581428,0.000042859676],"domain_scores_gemma":[0.9984059,0.00097292685,0.00014931377,0.000051997646,0.0003739584,0.000045847602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002011996,0.0008333752,0.0015886305,0.0035710451,0.0002447146,0.001195096,0.0010453734,0.0012449601,0.0021878716],"category_scores_gemma":[0.00306622,0.00028933986,0.0007752828,0.0024255014,0.0010061667,0.0014462445,0.00085703627,0.0018932393,0.001742978],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004568343,0.00003597427,0.0006588438,0.010886993,0.00013281679,0.00016075707,0.000066891625,0.00030106874,0.001076535,0.0053575267,0.018957367,0.96231955],"study_design_scores_gemma":[0.000010512426,0.00011807041,0.0023202708,0.007427554,0.00020399707,0.002106194,0.00011283357,0.00022582398,0.0010270234,0.00786232,0.9785443,0.0000411586],"about_ca_topic_score_codex":0.0012047855,"about_ca_topic_score_gemma":0.0014751976,"teacher_disagreement_score":0.0035710451,"about_ca_system_score_codex":0.00090858276,"about_ca_system_score_gemma":0.0014841789,"threshold_uncertainty_score":0.010640621},"labels":[],"label_agreement":null},{"id":"W2261765766","doi":"10.1093/annonc/mdw047","title":"Statistical controversies in clinical research: statistical significance—too much of a good thing …","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Breast cancer; Hazard ratio; Oncology; Trastuzumab; Internal medicine; Clinical trial; Statistical significance; Medical physics; Cancer; Confidence interval","score_opus":0.7268183586394775,"score_gpt":0.6943052263126884,"score_spread":0.032513132326789096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261765766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012503128,0.87866044,0.0019211418,0.10907035,0.009610364,0.000025398764,0.0000573982,0.000030346144,0.0004995474],"genre_scores_gemma":[0.011772621,0.7595785,0.011261231,0.16470437,0.051542006,0.00025486803,0.00017173316,0.00013669569,0.0005779537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8526788,0.100205876,0.017906196,0.0060787397,0.021908417,0.0012219684],"domain_scores_gemma":[0.35713458,0.5966851,0.011219979,0.008925126,0.023611277,0.0024238946],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.18692225,0.0017098311,0.011455014,0.0074570635,0.002460671,0.01076949,0.0067562955,0.0117987795,0.0047017382],"category_scores_gemma":[0.36428115,0.0018691621,0.004600084,0.008780815,0.019277258,0.018192535,0.0047339783,0.023959866,0.0017032478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005420135,0.00009070826,0.0022667293,0.08032433,0.006096289,0.00035814694,0.0015240584,0.000551759,0.0003440759,0.05444005,0.29109582,0.56236607],"study_design_scores_gemma":[0.00070133683,0.00032051365,0.003180505,0.1628848,0.005187822,0.0011384574,0.0016632605,0.0013421909,0.00036962843,0.24055421,0.58225554,0.00040176426],"about_ca_topic_score_codex":0.0047889953,"about_ca_topic_score_gemma":0.0071221907,"teacher_disagreement_score":0.81307775,"about_ca_system_score_codex":0.005843167,"about_ca_system_score_gemma":0.017475056,"threshold_uncertainty_score":0.98855114},"labels":[],"label_agreement":null},{"id":"W2264000214","doi":"10.1016/s1470-2045(15)00551-3","title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Placebo; Regimen; Cancer; Metastatic breast cancer; Adjuvant therapy; Gynecology; Pathology","score_opus":0.04734896813518842,"score_gpt":0.3900358492526455,"score_spread":0.3426868811174571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264000214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791494,0.010992751,0.00096666114,0.0012506078,0.0011406696,0.0025635539,0.0013146811,0.00021694183,0.0024047075],"genre_scores_gemma":[0.98270345,0.005118908,0.0013781518,0.0015176336,0.00049584755,0.002419985,0.001422882,0.000038989267,0.0049041323],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99937063,0.00031253492,0.000044272252,0.00012025807,0.000039786042,0.000112471374],"domain_scores_gemma":[0.9993926,0.00016833359,0.00013912622,0.00006395531,0.000037288766,0.00019861764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018887212,0.0020481923,0.00392972,0.0003642701,0.0003985617,0.0011900319,0.0010400326,0.001955599,0.006115931],"category_scores_gemma":[0.0018132239,0.0006418989,0.0023980525,0.00044734016,0.0012236095,0.0017342477,0.0004992737,0.003699146,0.0011609243],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9839544,0.0018076351,0.00029833263,0.00080582465,0.001067818,0.000038660364,0.0000430554,0.00028335248,0.0014581569,0.00010842072,0.0007803575,0.0093540205],"study_design_scores_gemma":[0.9789948,0.019079393,0.0006909075,0.000024659625,0.0003318458,0.000030575793,0.00001609167,0.00015665682,0.00014823796,0.00012111759,0.00039453217,0.000011227585],"about_ca_topic_score_codex":0.0006303002,"about_ca_topic_score_gemma":0.0017768398,"teacher_disagreement_score":0.006115931,"about_ca_system_score_codex":0.00066215766,"about_ca_system_score_gemma":0.00074724463,"threshold_uncertainty_score":0.02045989},"labels":[],"label_agreement":null},{"id":"W2268024701","doi":"10.1200/jco.2009.27.15_suppl.e11550","title":"Trastuzumab-mediated cardiotoxicity in the nontrial setting: Evaluation of patients receiving adjuvant trastuzumab at an academic centre","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cardiotoxicity; Trastuzumab; Ejection fraction; Internal medicine; Discontinuation; Breast cancer; Incidence (geometry); Hazard ratio; Oncology; Cancer; Heart failure; Chemotherapy; Confidence interval","score_opus":0.25340602469883244,"score_gpt":0.5571225239931855,"score_spread":0.30371649929435307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268024701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993864,0.00015680386,0.000016274284,0.000035815603,0.0000021024196,0.000016575083,0.00005147491,0.0000012812673,0.0003331132],"genre_scores_gemma":[0.999673,0.00009562325,0.00004269401,0.000038179016,0.000009625515,0.000006325994,0.00007577281,7.28372e-7,0.00005799639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999193,0.00024883467,0.00010187321,0.00010831012,0.00018046876,0.0001675909],"domain_scores_gemma":[0.9952609,0.0007562174,0.0021637299,0.000091026865,0.0005921588,0.0011360052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011765513,0.00017966257,0.0002624244,0.00058894715,0.00072398316,0.0008537344,0.0004244399,0.00034510248,0.0017375487],"category_scores_gemma":[0.006661042,0.00015545258,0.00020739686,0.0008928137,0.0003747349,0.00042878604,0.00040149636,0.00046421835,0.00018603355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041785056,0.00015086899,0.9965996,0.000015224518,0.000011820095,0.00020561137,0.00013785873,0.000030346428,0.00013739648,0.000012725851,0.00009726993,0.002183442],"study_design_scores_gemma":[0.000046582496,0.0012732912,0.99674326,0.000012007472,0.000021655065,0.0006792567,0.0005821389,0.00025145325,0.00011769383,0.000014507055,0.0002520602,0.0000061911464],"about_ca_topic_score_codex":0.017024765,"about_ca_topic_score_gemma":0.017637182,"teacher_disagreement_score":0.017024765,"about_ca_system_score_codex":0.0014455995,"about_ca_system_score_gemma":0.0017105736,"threshold_uncertainty_score":0.033851326},"labels":[],"label_agreement":null},{"id":"W2268068174","doi":"","title":"Bivalent binding properties of epidermal growth factor receptor targeted monoclonal antibodies: Factors contributing to differences in observed clinical profiles.","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nimotuzumab; Cetuximab; Monoclonal antibody; Epidermal growth factor receptor; Antibody; Chemistry; Panitumumab; Cancer research; Cell culture; Molecular biology; Antibody-dependent cell-mediated cytotoxicity; A431 cells; Cell growth; Monoclonal; Cell; Receptor; Immunology; Cell cycle; Medicine; Biology; Biochemistry; Molecular medicine","score_opus":0.6654379160890438,"score_gpt":0.5353623484376453,"score_spread":0.1300755676513985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268068174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563971,0.02620897,0.0093601765,0.00050462084,0.00006676517,0.0002082665,0.00049164775,0.00014908344,0.006613242],"genre_scores_gemma":[0.99448544,0.0017232847,0.0018965364,0.0002505826,0.00003245792,0.000084080646,0.0005282117,0.000028638988,0.0009706678],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986338,0.0003810841,0.00011175626,0.00023649549,0.000501471,0.00013535564],"domain_scores_gemma":[0.9980647,0.0008914909,0.000478917,0.00014037189,0.00024335738,0.0001812391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017140189,0.00029785818,0.000493942,0.0005927975,0.00021883092,0.0007739603,0.00041342722,0.0005190137,0.0022579343],"category_scores_gemma":[0.0026023807,0.00020381312,0.00020289775,0.0004738024,0.0002954505,0.00041535244,0.00031299575,0.00062935625,0.00069500785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014470046,0.0003647936,0.024863677,0.00040862933,0.00015627172,0.00037580958,0.00013980707,0.000851305,0.8721248,0.00066290726,0.0008793325,0.09772572],"study_design_scores_gemma":[0.00028706467,0.008117986,0.25714812,0.000096795535,0.0004777864,0.011537785,0.00021970627,0.008269947,0.684993,0.0014752717,0.02730174,0.00007478894],"about_ca_topic_score_codex":0.00032982524,"about_ca_topic_score_gemma":0.0003800472,"teacher_disagreement_score":0.0022579343,"about_ca_system_score_codex":0.00042057823,"about_ca_system_score_gemma":0.00016944841,"threshold_uncertainty_score":0.009064734},"labels":[],"label_agreement":null},{"id":"W2273027008","doi":"10.1200/jco.2004.22.14_suppl.581","title":"Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Gefitinib; Medicine; Breast cancer; Lung cancer; Pharmacokinetics; Internal medicine; Cancer; Adenocarcinoma; Oncology; Colorectal cancer; Epidermal growth factor receptor","score_opus":0.14831609006630797,"score_gpt":0.48750950387369624,"score_spread":0.33919341380738827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273027008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99698764,0.00040509013,0.00022173455,0.00012290833,0.000011266752,0.0005443426,0.00065701536,0.000033565906,0.0010163516],"genre_scores_gemma":[0.99308103,0.00039453706,0.0010417899,0.00044792,0.00009765048,0.00089426857,0.002942452,0.000022051454,0.00107836],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9988599,0.0005101299,0.000056992714,0.00021395119,0.00022783132,0.00013126509],"domain_scores_gemma":[0.99857795,0.0003256075,0.00024640758,0.00012987766,0.00022353294,0.00049663044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016956062,0.00091058644,0.0010757452,0.00041137566,0.00061393686,0.00047990368,0.00036893328,0.00087855,0.0021265633],"category_scores_gemma":[0.0015827992,0.0003689746,0.0005760635,0.00055510254,0.00058826664,0.00044592816,0.00032594876,0.0013684,0.0009544497],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36046913,0.051692434,0.2933843,0.00069972407,0.0010816372,0.0027068963,0.0021063818,0.0010982117,0.15048008,0.00009415876,0.005654298,0.13053271],"study_design_scores_gemma":[0.05505019,0.30802226,0.611243,0.000027472792,0.0007362868,0.0027203308,0.00033104856,0.00085001707,0.013788987,0.00008382433,0.007063757,0.000082861254],"about_ca_topic_score_codex":0.0018822075,"about_ca_topic_score_gemma":0.002818178,"teacher_disagreement_score":0.0021265633,"about_ca_system_score_codex":0.0007614314,"about_ca_system_score_gemma":0.001141905,"threshold_uncertainty_score":0.00896734},"labels":[],"label_agreement":null},{"id":"W2273061735","doi":"10.1186/s40064-016-1736-1","title":"Patterns in target-directed breast cancer research","year":2016,"lang":"en","type":"article","venue":"SpringerPlus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Jewish General Hospital; BC Cancer Agency; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Canada","keywords":"Medicine; Breast cancer; Clinical trial; Oncology; Internal medicine; Adjuvant; Targeted therapy; Cancer","score_opus":0.07568231208982774,"score_gpt":0.4258451894115393,"score_spread":0.3501628773217116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273061735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33746636,0.24787393,0.053392757,0.07271186,0.002485606,0.01750677,0.08352311,0.0022166602,0.18282285],"genre_scores_gemma":[0.68890476,0.09220816,0.08540057,0.053495135,0.002023231,0.017307527,0.036949717,0.0026465317,0.021064375],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.8219178,0.08285533,0.036917787,0.017045526,0.035763886,0.00549973],"domain_scores_gemma":[0.6721734,0.14279632,0.08288869,0.037098233,0.05495272,0.010090703],"candidate_categories":["metaresearch","bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.09753773,0.00060073845,0.0016281853,0.019973667,0.0015404299,0.007057955,0.0027230745,0.0016852748,0.011441443],"category_scores_gemma":[0.19001165,0.000883141,0.0023274533,0.045746706,0.0024726337,0.0039710626,0.005891641,0.0025815573,0.0046179],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048023034,0.00048692536,0.20845431,0.014849501,0.0015967945,0.00076837477,0.0044975295,0.0014317668,0.0043119905,0.05101791,0.059640244,0.64814234],"study_design_scores_gemma":[0.00141732,0.0021978098,0.23215137,0.016533047,0.0014034077,0.005487285,0.0052666906,0.0023162237,0.0051310933,0.019283269,0.70855165,0.000260833],"about_ca_topic_score_codex":0.005629312,"about_ca_topic_score_gemma":0.0071814293,"teacher_disagreement_score":0.9800263,"about_ca_system_score_codex":0.006581287,"about_ca_system_score_gemma":0.017226817,"threshold_uncertainty_score":0.51583505},"labels":[],"label_agreement":null},{"id":"W2273565724","doi":"10.1016/j.ejca.2015.12.024","title":"Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Internal medicine; Oncology; Breast cancer; Hazard ratio; Adjuvant therapy; Cancer; Confidence interval","score_opus":0.03275624306295245,"score_gpt":0.33879298892192,"score_spread":0.30603674585896756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273565724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975827,0.00035481897,0.0002456962,0.00025660126,0.000021060963,0.000029723276,0.00041240404,0.0000074664076,0.0010896135],"genre_scores_gemma":[0.99760604,0.00018773432,0.00040407295,0.00017590636,0.00005346622,0.000025694999,0.0008964575,0.000010216545,0.0006402799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997147,0.00005210649,0.000022498714,0.0000612496,0.00003615288,0.000113269634],"domain_scores_gemma":[0.9994511,0.00013824752,0.00016571232,0.000029419776,0.000059383237,0.00015621424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003666495,0.00036283696,0.0007503987,0.00093534176,0.0005538553,0.0012209424,0.0004940378,0.00059046806,0.004006267],"category_scores_gemma":[0.0016055601,0.00017968878,0.0005680402,0.0007730541,0.0002263301,0.00063821167,0.0006076258,0.00067288685,0.0006443402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020592618,0.00018406849,0.97705305,0.000024891202,0.00007569877,0.000718238,0.00011408991,0.00018722606,0.005389804,0.00015533713,0.0009309936,0.013107284],"study_design_scores_gemma":[0.000115003066,0.0004294698,0.9905409,0.000023742956,0.00018537902,0.0024277116,0.0006650858,0.0014869764,0.0011584322,0.0006778071,0.0022682915,0.000021192007],"about_ca_topic_score_codex":0.0012778802,"about_ca_topic_score_gemma":0.0023031926,"teacher_disagreement_score":0.004006267,"about_ca_system_score_codex":0.00027916196,"about_ca_system_score_gemma":0.00039758513,"threshold_uncertainty_score":0.013402283},"labels":[],"label_agreement":null},{"id":"W2277879584","doi":"10.1007/s40259-016-0162-9","title":"Trastuzumab in the Treatment of Breast Cancer","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Norwegian Institute of Public Health; Direktorat Jenderal Pendidikan Tinggi; Sanofi Pasteur; Johns Hopkins Bloomberg School of Public Health; University of Illinois at Urbana-Champaign; National Institutes of Health; Seqirus; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja; Ministero della Salute; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Bundesministerium für Bildung und Forschung; Novavax; Sanofi; Comunidad de Madrid; Boston Scientific Corporation; Public Health England; University of Calgary; Arizona State University; GlaxoSmithKline; Bristol-Myers Squibb; Australian Government; Pfizer; Lembaga Pengelola Dana Pendidikan; Johns Hopkins University; Edwards Lifesciences; Bill and Melinda Gates Foundation; Instituto de Salud Carlos III; Amgen; Damon Runyon Cancer Research Foundation; Medical Research Council; Teva Pharmaceutical Industries; South African Medical Research Council; Seoul National University; U.S. Department of Veterans Affairs; Genentech; U.S. Environmental Protection Agency","keywords":"Trastuzumab; Pertuzumab; Medicine; Lapatinib; Breast cancer; Cardiotoxicity; Cancer; Disease; Oncology; Targeted therapy; Internal medicine; Pharmacology; Chemotherapy","score_opus":0.13866766770733222,"score_gpt":0.47618576035695515,"score_spread":0.33751809264962296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277879584","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005737072,0.9993703,0.000038928036,0.00010909416,0.000086028915,0.0000026668502,0.000009374323,0.0000025104064,0.0003237922],"genre_scores_gemma":[0.0004396165,0.99898905,0.000062557105,0.00013428589,0.00008559346,0.0000027385622,0.00001608973,6.65057e-7,0.00026936532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997869,0.000043553242,0.000035773002,0.00003232361,0.00007680229,0.000024766761],"domain_scores_gemma":[0.9996655,0.00018193378,0.000058887854,0.000007706467,0.00005941229,0.000026566842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006767204,0.00090885157,0.0019319574,0.0023996239,0.00020840128,0.0009851636,0.0008751166,0.0010139777,0.0035418118],"category_scores_gemma":[0.0009819958,0.00029097724,0.00060175476,0.002257132,0.00041040775,0.001080005,0.0007754232,0.0018588719,0.0011558089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013500244,0.00006698688,0.000104221566,0.022596242,0.00016545343,0.0001403438,0.00003863789,0.000385366,0.0010927927,0.0022719905,0.022024453,0.95097864],"study_design_scores_gemma":[0.00009430505,0.00015813636,0.0006934064,0.008471993,0.00044272092,0.0009588999,0.000054407556,0.0001519404,0.00048774434,0.001736134,0.98672837,0.000021924083],"about_ca_topic_score_codex":0.0015415254,"about_ca_topic_score_gemma":0.0035368188,"teacher_disagreement_score":0.0035418118,"about_ca_system_score_codex":0.0006616839,"about_ca_system_score_gemma":0.0009574449,"threshold_uncertainty_score":0.011848509},"labels":[],"label_agreement":null},{"id":"W2280120506","doi":"10.1136/jclinpath-2015-203066","title":"Evaluation of cell-line-derived xenograft tumours as controls for immunohistochemical testing for ER and PR","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. John’s Health Sciences Centre; Memorial University of Newfoundland","funders":"","keywords":"Immunohistochemistry; Biomarker; Estrogen receptor; Medicine; Pathology; Breast tumours; Progesterone receptor; Oncology; Anatomical pathology; Breast cancer; Cancer research; Biology; Internal medicine; Cancer","score_opus":0.4007843313420886,"score_gpt":0.5600717471712227,"score_spread":0.15928741582913408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280120506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78031355,0.002165142,0.19896072,0.00031977016,0.0005224512,0.0043926006,0.0025802976,0.001864119,0.008881319],"genre_scores_gemma":[0.79955065,0.001660996,0.17408349,0.00042863167,0.00005954847,0.0053097834,0.008102903,0.0009117174,0.009892302],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960847,0.0013205123,0.00046097548,0.0005554203,0.0012912013,0.000287167],"domain_scores_gemma":[0.99303186,0.0016353958,0.00051323784,0.0023525276,0.0022425028,0.00022446027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055145044,0.0007059325,0.0005272972,0.0008898909,0.0005239297,0.00073171215,0.00053858693,0.0009404181,0.0028872176],"category_scores_gemma":[0.0032878392,0.0004436217,0.00048278482,0.00070722104,0.00079877145,0.0003487954,0.0005719142,0.0009424494,0.000988798],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036322093,0.00029246084,0.0036233994,0.00011725548,0.000030456087,0.00017044845,0.00021931667,0.00020476902,0.99143827,0.00036648678,0.00037743783,0.002796413],"study_design_scores_gemma":[0.000080624464,0.0016575608,0.025926858,0.000023030845,0.00010448608,0.0012269045,0.00014166806,0.0029068135,0.9586364,0.0001338396,0.009140373,0.00002145706],"about_ca_topic_score_codex":0.0018120739,"about_ca_topic_score_gemma":0.0039793416,"teacher_disagreement_score":0.0055145044,"about_ca_system_score_codex":0.0005008603,"about_ca_system_score_gemma":0.0004976151,"threshold_uncertainty_score":0.029163837},"labels":[],"label_agreement":null},{"id":"W2281951751","doi":"10.1159/000419801","title":"Tumor Cell Subpopulation Interactions Mediated by Transforming Growth Factor � May Contribute to Clonal Dominance of Metastatically Competent Cells in Primary Tumors","year":2015,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Dominance (genetics); Primary (astronomy); Biology; Cancer research; Transforming growth factor; Tumor cells; Cell biology; Genetics; Gene; Physics","score_opus":0.04378340730407314,"score_gpt":0.32215297821723077,"score_spread":0.2783695709131576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281951751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5270857,0.06877257,0.08837618,0.0027182624,0.00118669,0.0001186196,0.0005948393,0.0012440283,0.30990312],"genre_scores_gemma":[0.686368,0.024853613,0.020146672,0.00053254084,0.00030778538,0.0000666253,0.0004902012,0.00031176498,0.2669228],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999335,0.00000716109,0.0000022737343,0.000012705889,0.000029815947,0.000014537618],"domain_scores_gemma":[0.99994063,0.00002753048,0.0000060074117,0.000004681728,0.000011343627,0.000009881282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014495192,0.00023449239,0.00023465721,0.00025881996,0.0002808928,0.00077344466,0.00034698952,0.0002806112,0.0034915926],"category_scores_gemma":[0.00012203313,0.00018322309,0.00022544578,0.0002315782,0.00020536395,0.00041375903,0.00038493448,0.0008864479,0.0012144106],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009793713,0.00005973055,0.00088136236,0.00010427979,0.000009481992,0.0006887019,0.00027502584,0.00050553645,0.89155614,0.023857713,0.005005234,0.07695897],"study_design_scores_gemma":[0.000018757297,0.00034395992,0.010485575,0.000060203824,0.00006369692,0.005101737,0.00030072947,0.0050044684,0.73736274,0.013695017,0.22753029,0.000032808035],"about_ca_topic_score_codex":0.00053235004,"about_ca_topic_score_gemma":0.0014261112,"teacher_disagreement_score":0.0034915926,"about_ca_system_score_codex":0.0004437687,"about_ca_system_score_gemma":0.00021561756,"threshold_uncertainty_score":0.011680484},"labels":[],"label_agreement":null},{"id":"W2286693725","doi":"10.1158/1078-0432.ccr-15-2499","title":"Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Lapatinib; Trastuzumab emtansine; Trastuzumab; Capecitabine; Medicine; Cancer; Breast cancer; Metastatic breast cancer; Biomarker; Cancer research; Oncology; PTEN; Antibody-drug conjugate; Internal medicine; Antibody; Immunology; Biology; Monoclonal antibody; Apoptosis; Colorectal cancer","score_opus":0.3463970865185873,"score_gpt":0.593692150892299,"score_spread":0.24729506437371168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286693725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969909,0.0010705293,0.00015809287,0.00013587512,0.000013540148,0.0003667425,0.00033923492,0.00002677832,0.0008982356],"genre_scores_gemma":[0.9948656,0.00065624184,0.00097076845,0.00045440745,0.00005138647,0.0003523191,0.0017041743,0.000011530161,0.0009335656],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99944156,0.00031402378,0.000029736266,0.00006369069,0.000076690514,0.000074159565],"domain_scores_gemma":[0.9990395,0.0001571501,0.00035120166,0.0000874863,0.000074516516,0.0002900506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024445332,0.00069760915,0.0008823028,0.00047490478,0.00022590475,0.0005501644,0.000582456,0.000502095,0.00090193824],"category_scores_gemma":[0.0010759865,0.0002644019,0.0006423867,0.00036889352,0.00037056158,0.00035515017,0.00025913873,0.0014084284,0.0002973798],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41345698,0.059012767,0.17253545,0.0010284029,0.0029906936,0.00040054493,0.00046781087,0.0053069126,0.14748344,0.0002642678,0.0045600347,0.19249266],"study_design_scores_gemma":[0.08557031,0.44578835,0.42443955,0.00008354282,0.0017396209,0.00089358503,0.000114046285,0.003500733,0.031831414,0.00011098817,0.0058656163,0.00006222857],"about_ca_topic_score_codex":0.00040360025,"about_ca_topic_score_gemma":0.001543944,"teacher_disagreement_score":0.0024445332,"about_ca_system_score_codex":0.00084157835,"about_ca_system_score_gemma":0.0007602626,"threshold_uncertainty_score":0.012928069},"labels":[],"label_agreement":null},{"id":"W2290707026","doi":"10.1158/0008-5472.can-15-2782","title":"Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"National Cancer Institute; National Institutes of Health; Chesapeake Research Consortium; Cancer Research UK; Susan G. Komen for the Cure","keywords":"Cancer; Cancer research; Breast cancer; Oncogene; Carcinogenesis; Mammary tumor; Biology; Tumor progression; CDH1; Mouse mammary tumor virus; Cre recombinase; Suppressor; Immunology; Cell cycle; Cell; Genetically modified mouse; Transgene; Gene; Genetics","score_opus":0.12419411833151517,"score_gpt":0.5201761263797922,"score_spread":0.395982008048277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290707026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688626,0.0070471615,0.002646138,0.00019013512,0.000028712244,0.000046997073,0.0011138411,0.00019538426,0.0018453853],"genre_scores_gemma":[0.9928229,0.0015893223,0.0010748619,0.000038856884,0.000007118465,0.000056917503,0.0011418908,0.000017367702,0.0032506806],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985385,0.000016121452,0.000012724023,0.000039650542,0.000043646432,0.000033961835],"domain_scores_gemma":[0.9998772,0.000012495155,0.000042891294,0.0000109362,0.00001832213,0.000038017704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013549313,0.0005783623,0.0002230473,0.00044686775,0.0003003485,0.00037315118,0.00020299316,0.00034682814,0.0011735344],"category_scores_gemma":[0.0001442545,0.00017068682,0.00018947643,0.00019926841,0.00021310424,0.00014395811,0.00024997574,0.00039668466,0.00044885438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109502784,0.0000149969665,0.0006183731,0.000039203704,0.000006161479,0.00012533991,0.0000056305657,0.00006753236,0.9973416,0.00013970867,0.00010007026,0.0014319546],"study_design_scores_gemma":[0.000025805472,0.00014617774,0.035909604,0.000015542719,0.00002873553,0.0015390998,0.000024602816,0.0021331636,0.9513139,0.00009256695,0.00876014,0.000010636498],"about_ca_topic_score_codex":0.0010419129,"about_ca_topic_score_gemma":0.0009867097,"teacher_disagreement_score":0.0011735344,"about_ca_system_score_codex":0.00078253483,"about_ca_system_score_gemma":0.0003527095,"threshold_uncertainty_score":0.0056777},"labels":[],"label_agreement":null},{"id":"W2306887678","doi":"10.1038/srep23383","title":"Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; Cancer Research UK; Public Health Agency; Friends of the Cancer Centre","keywords":"Genetic heterogeneity; Breast cancer; Computational biology; Tumour heterogeneity; Identification (biology); Disease; Spatial heterogeneity; Phenotype; Tumor heterogeneity; Biology; Bioinformatics; Medicine; Cancer; Internal medicine; Genetics; Gene","score_opus":0.09417006070467217,"score_gpt":0.4169705485494891,"score_spread":0.32280048784481696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306887678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9339449,0.014863324,0.045191936,0.0008859086,0.000054318905,0.00016071813,0.0005721517,0.00032157594,0.0040051816],"genre_scores_gemma":[0.9766619,0.0018049317,0.020394456,0.00011728717,0.00002543875,0.000052141506,0.00022548804,0.000034573706,0.0006837592],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992113,0.00034173194,0.000055561035,0.000118818694,0.00020699634,0.000065607026],"domain_scores_gemma":[0.99851197,0.00072761456,0.00033963795,0.00016247017,0.00016729455,0.00009110153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023896305,0.0003287074,0.0006143838,0.0016370565,0.00020885961,0.0011988528,0.00036475572,0.00044070475,0.001250435],"category_scores_gemma":[0.0032383818,0.00019545373,0.00023350402,0.0009049101,0.00037400133,0.0010346924,0.0005839011,0.0005721685,0.00029882014],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015172712,0.00023913501,0.17271128,0.0005271313,0.00015506835,0.0004527697,0.0006583649,0.008630578,0.6078574,0.00208367,0.0009322714,0.204235],"study_design_scores_gemma":[0.0000715662,0.0015026148,0.54842216,0.00021586198,0.00038140677,0.0037668312,0.0018720847,0.06285342,0.35446608,0.01247146,0.013802508,0.00017400533],"about_ca_topic_score_codex":0.00047545487,"about_ca_topic_score_gemma":0.00076206436,"teacher_disagreement_score":0.0023896305,"about_ca_system_score_codex":0.00041296068,"about_ca_system_score_gemma":0.0002176187,"threshold_uncertainty_score":0.012637675},"labels":[],"label_agreement":null},{"id":"W2312520979","doi":"10.1158/1538-7445.am10-535a","title":"Abstract 535A: The tyrosine kinase Src co-operates with the ERM family member ezrin to promote Met activation and ECM degradation in a breast epithelial cell model","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Ezrin; Proto-oncogene tyrosine-protein kinase Src; Invadopodia; Filopodia; Phosphorylation; Src family kinase; Cortactin; Cell biology; Moesin; Cancer research; Chemistry; Tyrosine phosphorylation; Cell migration; Biology; Cell; Cancer cell; Cytoskeleton; Cancer; Actin; Biochemistry","score_opus":0.0869883775831335,"score_gpt":0.4163157521679209,"score_spread":0.3293273745847874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312520979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911249,0.0013036334,0.0023844445,0.00038636476,0.00010703845,0.000047284524,0.0009201694,0.00010000964,0.0036262153],"genre_scores_gemma":[0.991356,0.0005214185,0.0018106608,0.00007159943,0.000015577092,0.00005216421,0.0008453746,0.000020892854,0.005306214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996648,0.000046960427,0.000033089,0.00005332388,0.00011712569,0.00008471819],"domain_scores_gemma":[0.9999242,0.000010073509,0.000015807083,0.000015422649,0.000009400805,0.000025014626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021610534,0.0003903176,0.0004142079,0.00024129926,0.00023960142,0.00035159662,0.00032299338,0.00045557768,0.0024639396],"category_scores_gemma":[0.000084838626,0.00018305249,0.00035445392,0.00022932231,0.0002023676,0.00021368942,0.0002389084,0.0007068066,0.0011415831],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017230293,0.000073337906,0.00008888853,0.000025648478,0.000006012942,0.00010219744,0.0000075289404,0.000069526504,0.9985044,0.00019143354,0.0001823636,0.0005763389],"study_design_scores_gemma":[0.000053637857,0.0004352503,0.0023754423,0.000005084628,0.00002175411,0.0004513415,0.000026918953,0.002983689,0.9891856,0.000061258346,0.004395239,0.0000049145606],"about_ca_topic_score_codex":0.001186267,"about_ca_topic_score_gemma":0.0012468202,"teacher_disagreement_score":0.0024639396,"about_ca_system_score_codex":0.00049948005,"about_ca_system_score_gemma":0.00025855974,"threshold_uncertainty_score":0.008242667},"labels":[],"label_agreement":null},{"id":"W2313186082","doi":"10.1158/0008-5472.sabcs-09-606","title":"Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 &amp; ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148).","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Tissue microarray; Immunohistochemistry; Breast cancer; Paclitaxel; Medicine; Concordance; Internal medicine; Doxorubicin; Cyclophosphamide; Oncology; Adjuvant; Cancer; Proportional hazards model; Chemotherapy","score_opus":0.05532989185998875,"score_gpt":0.42910622241684604,"score_spread":0.3737763305568573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313186082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994272,0.00022668643,0.000041775904,0.000031990585,0.0000027485355,0.000012555429,0.000115227675,0.0000025892623,0.00013925474],"genre_scores_gemma":[0.9988682,0.00015319606,0.00016107381,0.000057392557,0.000006650536,0.000033778237,0.00055652886,0.0000020274538,0.0001611179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997148,0.00011626481,0.000013648582,0.000043123095,0.000057796064,0.000054322965],"domain_scores_gemma":[0.99969816,0.00013193785,0.00006855834,0.000021059986,0.000021767411,0.000058537637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071588025,0.0002496587,0.00030845654,0.000273337,0.00017135493,0.00024469313,0.00027979666,0.00027749946,0.0006329918],"category_scores_gemma":[0.00074717304,0.00017065198,0.00025676127,0.00030812502,0.00019056679,0.00016224138,0.00018282606,0.0003906709,0.00011429347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1423989,0.007050204,0.5330961,0.00039546777,0.0015865683,0.0007292972,0.0004423689,0.0043546637,0.21607387,0.00015254131,0.0034257148,0.090294346],"study_design_scores_gemma":[0.0029598847,0.028115828,0.94088197,0.000014770455,0.0007716573,0.0007028948,0.00019824509,0.004334192,0.020308506,0.00011405535,0.0015803954,0.000017635537],"about_ca_topic_score_codex":0.0045786602,"about_ca_topic_score_gemma":0.008804274,"teacher_disagreement_score":0.0045786602,"about_ca_system_score_codex":0.00076149014,"about_ca_system_score_gemma":0.00038270303,"threshold_uncertainty_score":0.009104013},"labels":[],"label_agreement":null},{"id":"W2313487475","doi":"10.1158/0008-5472.sabcs-3045","title":"Deletion of STAT5 prevents HER2/Neu/ErbB2-induced mammary tumor development.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"STAT5; Cancer research; Biology; Oncogene; HER2/neu; Genetically modified mouse; Mammary tumor; Cytokine; Mouse mammary tumor virus; Cancer; Breast cancer; Transgene; Signal transduction; Immunology; Cell cycle; Cell biology; Gene; Virus","score_opus":0.16704424792469927,"score_gpt":0.488980963841901,"score_spread":0.32193671591720174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313487475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848359,0.0017480471,0.0036703537,0.00018916736,0.00010694308,0.00011456086,0.004034133,0.0002847687,0.005016111],"genre_scores_gemma":[0.97918624,0.0006990267,0.0026850405,0.00010960257,0.000019191515,0.00011119636,0.0044276817,0.00007934963,0.012682739],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996395,0.000058459333,0.000043352735,0.000058594633,0.000111081885,0.00008900682],"domain_scores_gemma":[0.99973756,0.000032656735,0.0000884717,0.000026650421,0.000015666226,0.00009906168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024721518,0.00048681864,0.00022838688,0.00056938967,0.00021084848,0.00028131384,0.00044833717,0.0004981927,0.0041060178],"category_scores_gemma":[0.00010100668,0.00026221157,0.00041810502,0.00026940106,0.0003601146,0.0002381379,0.0002877624,0.0006304402,0.0012008363],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021551842,0.000062526364,0.0002358937,0.000042316045,0.0000065261042,0.000069702255,0.000015121037,0.000093415336,0.9977964,0.00029785736,0.00009588494,0.0010688754],"study_design_scores_gemma":[0.00005479717,0.000582634,0.005563399,0.000019406867,0.00002104985,0.00046504932,0.000058807622,0.0017586425,0.9859195,0.0000615942,0.0054883864,0.0000069156413],"about_ca_topic_score_codex":0.0012161117,"about_ca_topic_score_gemma":0.002660361,"teacher_disagreement_score":0.0041060178,"about_ca_system_score_codex":0.00049678166,"about_ca_system_score_gemma":0.0003535033,"threshold_uncertainty_score":0.01373601},"labels":[],"label_agreement":null},{"id":"W2315066014","doi":"10.1002/cam4.573","title":"A time and motion study of subcutaneous versus intravenous trastuzumab in patients with <scp>HER</scp>2‐positive early breast cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; Medicine; Cohort; Breast cancer; Adjuvant; Internal medicine; Cohort study; Cancer; Surgery","score_opus":0.01498154332615628,"score_gpt":0.29637300469971,"score_spread":0.28139146137355375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315066014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990343,0.00027342318,0.00010438113,0.000036057918,0.0000068532518,0.000058004898,0.0001970883,0.0000018861942,0.0002879182],"genre_scores_gemma":[0.9988588,0.00013936828,0.00018123719,0.00007982498,0.000022874297,0.00012665952,0.0004273579,0.0000024896808,0.00016141938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984653,0.00089958153,0.00010476625,0.00022921625,0.00013387762,0.00016730189],"domain_scores_gemma":[0.9964386,0.001068903,0.001600105,0.0002241405,0.00019506228,0.00047311507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017741836,0.00031460918,0.0005614512,0.00032904948,0.00028630625,0.0005822307,0.00032855952,0.00045775337,0.0017012618],"category_scores_gemma":[0.0046857637,0.00028084993,0.0010237616,0.000674328,0.00032553327,0.00057808537,0.00047045722,0.0007032409,0.0002675662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11896612,0.005448054,0.8318101,0.0003409513,0.0019634974,0.00015076187,0.0007359848,0.0012491086,0.002075903,0.00019777851,0.001142915,0.035918765],"study_design_scores_gemma":[0.006181646,0.0585818,0.9284842,0.000060476406,0.00096907845,0.00025067112,0.00074668636,0.0020430898,0.0005701056,0.00013410536,0.0019213014,0.00005689137],"about_ca_topic_score_codex":0.0025861042,"about_ca_topic_score_gemma":0.0036879247,"teacher_disagreement_score":0.0025861042,"about_ca_system_score_codex":0.00091159955,"about_ca_system_score_gemma":0.0008358816,"threshold_uncertainty_score":0.009382844},"labels":[],"label_agreement":null},{"id":"W2318415095","doi":"10.1186/s40064-016-2008-9","title":"Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice","year":2016,"lang":"en","type":"article","venue":"SpringerPlus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"U.S. Navy; Genentech; U.S. Department of Defense","keywords":"Trastuzumab; Medicine; Adjuvant; Breast cancer; Clinical Practice; Oncology; Metastatic breast cancer; Internal medicine; Cancer; Family medicine","score_opus":0.02936261070029393,"score_gpt":0.37791381142766783,"score_spread":0.3485512007273739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318415095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710065,0.0015124305,0.000058289846,0.000304459,0.000008439389,0.000011929764,0.00038371963,0.000004125404,0.00061587786],"genre_scores_gemma":[0.99899524,0.00043806178,0.00005166236,0.000073122756,0.000015065835,0.000008180505,0.00034772666,6.613724e-7,0.00007018646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995467,0.00013731045,0.000058013728,0.00012103513,0.00008202934,0.00005487509],"domain_scores_gemma":[0.9984023,0.0002675315,0.0009903185,0.000042075426,0.00010431342,0.00019350764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053066324,0.00012818041,0.00029329647,0.0004355309,0.0002155674,0.00046147036,0.00023435806,0.00037129747,0.0011214195],"category_scores_gemma":[0.0035280338,0.00011716254,0.0002529684,0.001015184,0.0001950955,0.00035206182,0.00033627666,0.00036959685,0.00015677801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019094408,0.00004239074,0.995618,0.000026331525,0.000049324648,0.00007489331,0.00004492654,0.000077275174,0.000071006834,0.000023645873,0.00022855912,0.0035526636],"study_design_scores_gemma":[0.00006069458,0.0002263858,0.9979809,0.000030048088,0.00005317642,0.0005312978,0.00010381118,0.00034722817,0.00006828613,0.00012023764,0.00047378274,0.000004211472],"about_ca_topic_score_codex":0.002544955,"about_ca_topic_score_gemma":0.0034217348,"teacher_disagreement_score":0.002544955,"about_ca_system_score_codex":0.00051829685,"about_ca_system_score_gemma":0.00044407102,"threshold_uncertainty_score":0.0050602555},"labels":[],"label_agreement":null},{"id":"W2318605753","doi":"10.1056/nejm200103153441101","title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2","year":2001,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11512,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Trastuzumab; Epirubicin; Anthracycline; Internal medicine; Breast cancer; Oncology; Cyclophosphamide; Chemotherapy; Doxorubicin; Metastatic breast cancer; Paclitaxel; Cancer; Gastroenterology","score_opus":0.10357860673608633,"score_gpt":0.40995768050192266,"score_spread":0.30637907376583634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318605753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948978,0.0027637428,0.0005166555,0.00022258407,0.00010176724,0.00027405762,0.00007373931,0.000024319359,0.0011253536],"genre_scores_gemma":[0.99698895,0.0010791672,0.0009193358,0.0001575154,0.00011535003,0.00021201209,0.0001737044,0.0000039122165,0.00035000267],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996462,0.00011973807,0.0000472175,0.00007252943,0.00006628254,0.000048142858],"domain_scores_gemma":[0.9989654,0.00041448427,0.00023872915,0.00008413076,0.000038342794,0.00025887572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005369638,0.00033561463,0.00083906815,0.0003533569,0.00022260644,0.00018214245,0.0002903158,0.00034913688,0.0014168094],"category_scores_gemma":[0.001643994,0.00014126863,0.00041935878,0.00029559026,0.00033356232,0.00017037512,0.0002415541,0.00055031123,0.00020518721],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1876869,0.018254561,0.13362025,0.0013377896,0.00232194,0.0012691999,0.0002920346,0.007941682,0.09358046,0.0006239227,0.0023629,0.5507085],"study_design_scores_gemma":[0.07531156,0.56448454,0.28118742,0.00041017582,0.0022736804,0.0066212565,0.00011889715,0.005788987,0.034502532,0.0005701912,0.028647365,0.00008345491],"about_ca_topic_score_codex":0.00040331003,"about_ca_topic_score_gemma":0.0011684124,"teacher_disagreement_score":0.0014168094,"about_ca_system_score_codex":0.00049879303,"about_ca_system_score_gemma":0.00049346127,"threshold_uncertainty_score":0.0047397017},"labels":[],"label_agreement":null},{"id":"W2318822787","doi":"10.1158/0008-5472.sabcs11-p1-12-12","title":"P1-12-12: Evaluation of Ile655Val HER2 Polymorphism Associated with Cardiac Toxicity Following the Administration of Trastuzumab in Women with Non-Metastatic Breast Cancer.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Trastuzumab; Breast cancer; Medicine; Metastatic breast cancer; Ejection fraction; Population; Toxicity; Oncology; Internal medicine; Genotype; Cardiac toxicity; Genotyping; Cancer; Biology; Heart failure; Genetics","score_opus":0.15211811148307627,"score_gpt":0.4311966634983403,"score_spread":0.279078552015264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318822787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994917,0.00017490354,0.000052312476,0.00003008118,0.0000041570243,0.000011178523,0.000058331636,0.000001668868,0.00017566768],"genre_scores_gemma":[0.9996294,0.000044207594,0.00006471953,0.000027122083,0.0000066551083,0.0000072962043,0.00006701669,0.0000011302409,0.00015258494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974316,0.000091004455,0.00002092791,0.000065324704,0.000049653638,0.000029803534],"domain_scores_gemma":[0.99945515,0.00014989037,0.00022506768,0.000016901742,0.000038264112,0.000114734605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037392374,0.0002776622,0.00030079926,0.00030455057,0.0002593963,0.0002527312,0.00016984939,0.00045324594,0.00090003066],"category_scores_gemma":[0.0011509204,0.00017298441,0.000289224,0.0004602425,0.00017464155,0.000109130175,0.00012835312,0.00034567245,0.00021160109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016372575,0.0002738434,0.9866651,0.00003789521,0.00007266321,0.0021982521,0.00017542097,0.00008739816,0.004400158,0.000014753842,0.000096068055,0.0043412205],"study_design_scores_gemma":[0.000050514274,0.0025294595,0.9925574,0.000006111402,0.0000627749,0.0034073666,0.00010730024,0.0002860322,0.00069885293,0.000024993218,0.00026361732,0.0000055632745],"about_ca_topic_score_codex":0.0010036473,"about_ca_topic_score_gemma":0.0008593881,"teacher_disagreement_score":0.0010036473,"about_ca_system_score_codex":0.00021087803,"about_ca_system_score_gemma":0.00015453849,"threshold_uncertainty_score":0.0030109286},"labels":[],"label_agreement":null},{"id":"W2319127466","doi":"10.1158/0008-5472.sabcs-09-5086","title":"Outcomes of Women with Early Stage HER2 Overexpressing Breast Cancer Receiving Adjuvant Trastuzumab: A Population Based Analysis.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Stage (stratigraphy); Population; Cancer; Adjuvant; Gynecology","score_opus":0.07056468673399381,"score_gpt":0.4438137434065366,"score_spread":0.3732490566725428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319127466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987758,0.0001623893,0.000025950962,0.000023662624,0.0000018523644,0.000009389632,0.0007258677,0.000002136296,0.00027302286],"genre_scores_gemma":[0.99915063,0.00009001067,0.000021864,0.000019113455,0.0000039230845,0.000010308546,0.00059981307,9.342452e-7,0.00010336676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99969923,0.00006454665,0.0000278887,0.0000733789,0.00007322825,0.00006183815],"domain_scores_gemma":[0.9994555,0.00008813385,0.00023844503,0.00004032923,0.00007653536,0.000101160505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040919182,0.00020564161,0.00034211125,0.0008233477,0.0003330069,0.00047065836,0.00029589984,0.00044471346,0.0009434763],"category_scores_gemma":[0.0010610285,0.0002494503,0.0003766598,0.0015071988,0.00024429266,0.00029820713,0.00033835956,0.00042686146,0.00021547411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011131345,0.000022803393,0.9990996,0.000004730011,0.000043098,0.00005193056,0.000026389585,0.000028273764,0.00007415718,0.0000039778492,0.00006588157,0.00046788974],"study_design_scores_gemma":[0.000011475093,0.000083637555,0.9992834,0.0000030005222,0.000028793931,0.00017381017,0.00012494673,0.0001431859,0.000021735092,0.0000092560995,0.000114011855,0.0000027428773],"about_ca_topic_score_codex":0.027472705,"about_ca_topic_score_gemma":0.023816634,"teacher_disagreement_score":0.027472705,"about_ca_system_score_codex":0.00069907395,"about_ca_system_score_gemma":0.0004798618,"threshold_uncertainty_score":0.05462557},"labels":[],"label_agreement":null},{"id":"W2320592393","doi":"10.1158/0008-5472.sabcs-2014","title":"Role of radiation induced ß1 – integrin expression in trastuzumab resistance in Her-2 positive breast cancer.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trastuzumab; Breast cancer; Integrin; Protein kinase B; Cancer research; Transactivation; Cancer; Phosphorylation; Radiation therapy; Medicine; Cell; Chemistry; Biology; Internal medicine; Cell biology; Gene expression; Biochemistry","score_opus":0.057727053875883415,"score_gpt":0.4423883504464646,"score_spread":0.3846612965705812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320592393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890961,0.0065809246,0.00034907673,0.0004404994,0.00003536177,0.000039936796,0.0004055227,0.00004311671,0.0030093573],"genre_scores_gemma":[0.9958787,0.0016064917,0.00028381954,0.00012341021,0.000024190342,0.000025133806,0.00044101154,0.0000053546246,0.0016119191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987185,0.00003312848,0.0000113730885,0.000019903595,0.000037768656,0.000026016582],"domain_scores_gemma":[0.99989796,0.000028627832,0.000036799727,0.000011542711,0.0000148118515,0.000010290119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022606376,0.00013863745,0.00015905865,0.0002250459,0.00012058949,0.000286454,0.00022522899,0.00043501597,0.002919845],"category_scores_gemma":[0.00026127475,0.00014021246,0.00021997519,0.00024280051,0.0001464842,0.00015899996,0.00009741843,0.0003391029,0.0004889885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017118432,0.0003333477,0.027322913,0.00038258013,0.00003802946,0.0012890494,0.000084987645,0.0001770354,0.9438469,0.00028939606,0.0019941754,0.022529874],"study_design_scores_gemma":[0.00020855115,0.0033386026,0.47041744,0.000055915094,0.00014640865,0.014024713,0.00021046966,0.0019272063,0.494016,0.000329883,0.0153073445,0.00001740375],"about_ca_topic_score_codex":0.00028670343,"about_ca_topic_score_gemma":0.00018188696,"teacher_disagreement_score":0.002919845,"about_ca_system_score_codex":0.00025497164,"about_ca_system_score_gemma":0.000075120806,"threshold_uncertainty_score":0.00976789},"labels":[],"label_agreement":null},{"id":"W2322736930","doi":"10.1021/acs.jproteome.5b00691","title":"Skin Barrier Defects Caused by Keratinocyte-Specific Deletion of ADAM17 or EGFR Are Based on Highly Similar Proteome and Degradome Alterations","year":2016,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Research Council; Fritz Thyssen Stiftung; Deutsche Forschungsgemeinschaft; Michael Smith Health Research BC","keywords":"Filaggrin; Keratinocyte; Epidermal growth factor receptor; Biology; Cell biology; Proteases; Involucrin; Proteome; Receptor; Immunology; Biochemistry; Cell culture; Genetics","score_opus":0.1024478522872253,"score_gpt":0.39434117547165937,"score_spread":0.29189332318443406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322736930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327236,0.0011757731,0.0034541318,0.00004633881,0.000025106765,0.00002026475,0.00077897456,0.00015977355,0.0010673387],"genre_scores_gemma":[0.99153614,0.0012464094,0.0034361812,0.000048352736,0.000007557108,0.000027487678,0.001076179,0.000045979537,0.0025755928],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998636,0.000015520185,0.000012744563,0.000037258553,0.00004603169,0.000024827807],"domain_scores_gemma":[0.9998412,0.000011019822,0.00007947099,0.000015874099,0.000011256689,0.000041175295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101142956,0.0004501231,0.00021690775,0.00048784015,0.00013986662,0.0002822864,0.00013741791,0.0002648073,0.0015326075],"category_scores_gemma":[0.00007696967,0.00015168347,0.0003891141,0.00017975921,0.00026475632,0.0002348506,0.000234289,0.0005585023,0.00039469282],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003590627,0.0000070947744,0.00020650084,0.00001607547,0.0000063670946,0.00012791323,0.000005817021,0.000013840144,0.999035,0.00003885138,0.000012878037,0.00049390935],"study_design_scores_gemma":[0.0000047953467,0.00008957602,0.023042172,0.0000048805346,0.00002675691,0.0018066231,0.000028821185,0.00023847356,0.9732293,0.000072096984,0.0014518832,0.0000046743426],"about_ca_topic_score_codex":0.00029095312,"about_ca_topic_score_gemma":0.0003878514,"teacher_disagreement_score":0.0015326075,"about_ca_system_score_codex":0.0001891995,"about_ca_system_score_gemma":0.0001772381,"threshold_uncertainty_score":0.005127132},"labels":[],"label_agreement":null},{"id":"W2324246178","doi":"10.1038/sj.bmt.1703005","title":"HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support","year":2001,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Northeast Cancer Centre","funders":"","keywords":"Medicine; Mitoxantrone; Paclitaxel; Metastatic breast cancer; Cyclophosphamide; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer","score_opus":0.01132225414054212,"score_gpt":0.25430958259055975,"score_spread":0.24298732845001764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324246178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998218,0.0008994573,0.000071244904,0.0001395622,0.000017135293,0.0000057620023,0.000058468973,0.000006269165,0.00058402517],"genre_scores_gemma":[0.999292,0.00022223391,0.000059349783,0.00005305792,0.00004322597,0.0000056323415,0.00014041322,0.0000017316921,0.00018230654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998857,0.000037463324,0.000009936946,0.0000162945,0.000024419267,0.000026235475],"domain_scores_gemma":[0.99948955,0.00020380697,0.000105131985,0.00001912404,0.000022381586,0.00016004531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028030825,0.00023407376,0.0005063103,0.00035297882,0.00029030943,0.00041963332,0.00020595576,0.0004478748,0.0010103605],"category_scores_gemma":[0.0013361789,0.00016466269,0.00031447754,0.0004673434,0.00021394262,0.0002908685,0.00013834111,0.0005053455,0.00014179334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012612928,0.00044915473,0.95669895,0.000036034413,0.0002373898,0.0017791583,0.00007824232,0.00052839844,0.011345552,0.000060106664,0.00054480106,0.015629308],"study_design_scores_gemma":[0.00030795834,0.0031167495,0.9888791,0.000009671445,0.0002782198,0.0042543546,0.00007643155,0.0010204937,0.0012908499,0.00009543644,0.00066150754,0.000009174475],"about_ca_topic_score_codex":0.0005814917,"about_ca_topic_score_gemma":0.0012656727,"teacher_disagreement_score":0.0010103605,"about_ca_system_score_codex":0.00024153726,"about_ca_system_score_gemma":0.0002539861,"threshold_uncertainty_score":0.0033800006},"labels":[],"label_agreement":null},{"id":"W2324268404","doi":"10.1021/cn500193f","title":"Syntheses and Evaluation of Carbon-11- and Fluorine-18-Radiolabeled pan-Tropomyosin Receptor Kinase (Trk) Inhibitors: Exploration of the 4-Aza-2-oxindole Scaffold as Trk PET Imaging Agents","year":2014,"lang":"en","type":"article","venue":"ACS Chemical Neuroscience","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Montreal Neurological Institute and Hospital; Douglas Mental Health University Institute; McGill University; University of Alberta","funders":"Canada Foundation for Innovation","keywords":"Trk receptor; Tropomyosin; Oxindole; Chemistry; Kinase; Pharmacology; Tropomyosin receptor kinase A; Receptor; Cancer research; Biochemistry; Medicine; Neurotrophin","score_opus":0.07076252528135317,"score_gpt":0.3507855952758984,"score_spread":0.28002306999454524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324268404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91341454,0.024741301,0.044478558,0.00035665926,0.00015546002,0.0012961662,0.0022895522,0.0005278417,0.012739875],"genre_scores_gemma":[0.94353676,0.016901223,0.031388864,0.00013270021,0.000047141188,0.0005006079,0.0017372194,0.000089841276,0.0056656483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985087,0.00002797306,0.000015396214,0.000029762463,0.000037461054,0.0000385515],"domain_scores_gemma":[0.9998952,0.000012540314,0.00002760892,0.000010724499,0.000022104141,0.000031805295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029595656,0.00064588164,0.0005299483,0.00033338013,0.00019143605,0.00023860588,0.0006249302,0.00048220117,0.0012394553],"category_scores_gemma":[0.00021260763,0.00027488492,0.00035098023,0.0003551768,0.0001794987,0.00039012288,0.00025099958,0.0005565428,0.00084656454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002803505,0.00021377263,0.00012039559,0.00053449196,0.000037062055,0.00042394386,0.00009794871,0.0030468334,0.98018163,0.0009010461,0.00043698642,0.013725607],"study_design_scores_gemma":[0.00012020928,0.0019443146,0.0005918369,0.000030593157,0.000057665053,0.00061083736,0.000026970576,0.0023066052,0.98009104,0.00011571333,0.014066433,0.000037693517],"about_ca_topic_score_codex":0.0005391686,"about_ca_topic_score_gemma":0.0013347047,"teacher_disagreement_score":0.0012394553,"about_ca_system_score_codex":0.00042141275,"about_ca_system_score_gemma":0.00032731643,"threshold_uncertainty_score":0.004146397},"labels":[],"label_agreement":null},{"id":"W2324445651","doi":"10.1097/pai.0000000000000136","title":"HER2 Genetic Heterogeneity in Gastric Cancer","year":2015,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Cancer; Immunohistochemistry; Internal medicine; Medicine; Pathology; Breast cancer; Stomach; Epithelium; Gastroenterology; Biology; Oncology","score_opus":0.029831324548665352,"score_gpt":0.34917058982172816,"score_spread":0.31933926527306283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324445651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983614,0.0009375253,0.00012001536,0.000019518488,0.0000015947087,0.0000037751129,0.00002468018,0.0000033236206,0.00052819774],"genre_scores_gemma":[0.9995902,0.00024085582,0.000073129195,0.000008055246,0.0000048068528,0.0000016718985,0.000033875906,0.0000011939442,0.000046244975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997744,0.000048220398,0.000022794131,0.000043705815,0.00006747909,0.00004341262],"domain_scores_gemma":[0.99975246,0.000058937254,0.00008709971,0.000022464359,0.000042099153,0.00003692595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028792294,0.000102050915,0.00016406496,0.0011496667,0.00019135521,0.000320156,0.00012313528,0.00018017259,0.00053879205],"category_scores_gemma":[0.000745734,0.000111125824,0.00010895934,0.0006656633,0.00026552,0.00026120277,0.0002941032,0.00010550209,0.000100102465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041567307,0.000016673637,0.90799284,0.00007257079,0.000040313687,0.004671642,0.0002755466,0.00037545303,0.063558735,0.0002122447,0.00019658408,0.022171767],"study_design_scores_gemma":[0.0000051389407,0.00006794839,0.9804186,0.000008281007,0.000021959535,0.014359922,0.00034253253,0.0005404637,0.0030013067,0.00025093567,0.0009757728,0.0000071391505],"about_ca_topic_score_codex":0.0010338983,"about_ca_topic_score_gemma":0.0014356086,"teacher_disagreement_score":0.0011496667,"about_ca_system_score_codex":0.00026505208,"about_ca_system_score_gemma":0.000091120906,"threshold_uncertainty_score":0.0020557642},"labels":[],"label_agreement":null},{"id":"W2325353319","doi":"10.1093/annonc/mdt084.3","title":"Prognostic and Predictive Value of IHC4 and ERB1 in the Intergroup Exemestane Study (IES) - On Behalf of the Pathies Investigators","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Exemestane; Internal medicine; Oncology; Breast cancer; Proportional hazards model; Gynecology; Biomarker; Immunohistochemistry; Cancer; Tamoxifen","score_opus":0.09515554137456515,"score_gpt":0.41380081089359,"score_spread":0.31864526951902483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325353319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990004,0.0019250319,0.00013157526,0.001112194,0.00013640414,0.000013651547,0.00162618,0.0000116404635,0.005039242],"genre_scores_gemma":[0.99660194,0.0004367336,0.00012272448,0.00016926353,0.00021576561,0.000010355821,0.0013868011,0.000006055759,0.0010503269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997174,0.00010608526,0.00002796818,0.000044019806,0.000053242133,0.00005113882],"domain_scores_gemma":[0.998425,0.00054563745,0.00040784085,0.00020566744,0.00016253491,0.0002532024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013069249,0.00025503244,0.0003006459,0.00038153116,0.00016417356,0.0006287864,0.00027762912,0.00037830396,0.0018933439],"category_scores_gemma":[0.002689154,0.0001203222,0.00043874435,0.0004393135,0.00022715768,0.0003498316,0.00027617475,0.000676871,0.00030060345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044281427,0.00003894514,0.97841454,0.00003455156,0.00032400308,0.00009420587,0.000032140302,0.00050963333,0.0011622859,0.00011509863,0.0022434134,0.012603116],"study_design_scores_gemma":[0.00045737412,0.0003409171,0.9916781,0.00003696474,0.00067451264,0.00034491305,0.00015656311,0.0018082598,0.0006155238,0.0004510923,0.0034226056,0.000013282403],"about_ca_topic_score_codex":0.00095493504,"about_ca_topic_score_gemma":0.0026402136,"teacher_disagreement_score":0.0018933439,"about_ca_system_score_codex":0.00015799313,"about_ca_system_score_gemma":0.0002840661,"threshold_uncertainty_score":0.0069117546},"labels":[],"label_agreement":null},{"id":"W2326303359","doi":"10.1097/pai.0b013e3182910967","title":"Expression of Topoisomerase II-α in Triple Negative Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Triple-negative breast cancer; Anthracycline; Epidermal growth factor receptor; Medicine; Estrogen receptor; Progesterone receptor; Breast cancer; Immunophenotyping; Cancer research; Internal medicine; Oncology; Ki-67; Immunohistochemistry; Receptor; Cancer; Pathology; Immunology; Flow cytometry","score_opus":0.009304854452362104,"score_gpt":0.302455079980057,"score_spread":0.2931502255276949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326303359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989562,0.0006753579,0.00005890688,0.000013354148,0.000003559196,0.000004141742,0.00003864711,0.0000015171325,0.00024829645],"genre_scores_gemma":[0.99960107,0.00022781412,0.000041891297,0.0000039648135,0.000004147167,0.0000021279147,0.000051476443,3.425504e-7,0.00006703148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99988186,0.000023418028,0.000016465316,0.000024358931,0.000036270652,0.000017688422],"domain_scores_gemma":[0.9997687,0.000036964037,0.0001038681,0.000011064734,0.000036354264,0.000042987533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022124418,0.00011117734,0.00014228755,0.00044868435,0.00017112715,0.00032150518,0.00009788551,0.00013728328,0.0006155922],"category_scores_gemma":[0.00074448285,0.000116042764,0.00009976131,0.0004216336,0.00017275003,0.00014075606,0.00015412526,0.00015566737,0.00012695657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002656695,0.000017416227,0.9884871,0.000034099383,0.000016234344,0.00039375297,0.00008530201,0.000033647164,0.0069174743,0.00001110203,0.0000467515,0.003691378],"study_design_scores_gemma":[0.000005249313,0.000111671965,0.9961928,0.000009343252,0.000029559607,0.0020927733,0.00015571197,0.0001237614,0.0009861479,0.000018149907,0.00027286998,0.0000019207591],"about_ca_topic_score_codex":0.0014371825,"about_ca_topic_score_gemma":0.001550063,"teacher_disagreement_score":0.0014371825,"about_ca_system_score_codex":0.00017724148,"about_ca_system_score_gemma":0.0001413597,"threshold_uncertainty_score":0.0028576255},"labels":[],"label_agreement":null},{"id":"W2326917709","doi":"10.1158/1538-7445.am2012-1249","title":"Abstract 1249: Modulation of epidermal growth factor induction of migration by integrin-linked kinase","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"RAC1; Cell biology; Cell migration; Motility; Integrin; Integrin-linked kinase; Epidermal growth factor; Cancer research; Tyrosine kinase; Signal transduction; Epidermal growth factor receptor; Biology; Kinase; Chemistry; Cell; Protein kinase A; Receptor; Cyclin-dependent kinase 2; Biochemistry","score_opus":0.19814498477933895,"score_gpt":0.46903170139245454,"score_spread":0.2708867166131156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326917709","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91156274,0.011554296,0.0049238466,0.0014793673,0.00075576344,0.00023614183,0.004656761,0.0005052507,0.06432583],"genre_scores_gemma":[0.95616317,0.0044336137,0.0026082047,0.00024052245,0.00011378511,0.00012020051,0.0030451242,0.000059458922,0.03321598],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99993634,0.000012015029,0.0000045608044,0.000009702195,0.000017797343,0.000019673673],"domain_scores_gemma":[0.99997914,0.0000028405875,0.0000046129235,0.0000024278027,0.0000043054906,0.000006634981],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005892471,0.00035710543,0.000119290606,0.00023585837,0.00013400268,0.00025296118,0.00017161702,0.00017112485,0.008280901],"category_scores_gemma":[0.00006216125,0.000096702795,0.00016155058,0.00014374852,0.000089026405,0.00012027139,0.00013170787,0.00043879953,0.00273231],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034075126,0.00013549624,0.00008854735,0.0000783443,0.000006568709,0.00008199787,0.00000409967,0.0000672528,0.9902895,0.00029214346,0.0015672001,0.0070481175],"study_design_scores_gemma":[0.00013097795,0.00050450634,0.006357357,0.000024386816,0.000022675995,0.00033429937,0.000015583468,0.0010271473,0.9703058,0.0001473746,0.021123158,0.000006781882],"about_ca_topic_score_codex":0.0005068632,"about_ca_topic_score_gemma":0.0006856024,"teacher_disagreement_score":0.9917191,"about_ca_system_score_codex":0.00032428218,"about_ca_system_score_gemma":0.00017627272,"threshold_uncertainty_score":0.027702391},"labels":[],"label_agreement":null},{"id":"W2327283214","doi":"10.1158/0008-5472.sabcs-09-706","title":"Biomarker Profiles in Trastuzumab (T) Refractory HER2+ Inflammatory Breast Cancer (IBC) That Predict for Survival Benefit from Lapatinib (L) Monotherapy.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Oncology; Trastuzumab; Cohort; Biomarker; Breast cancer; Cancer; Immunohistochemistry; Progression-free survival; Overall survival; Proportional hazards model; Gastroenterology","score_opus":0.13191626037152934,"score_gpt":0.4425371703677506,"score_spread":0.3106209099962213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327283214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99948955,0.00018743608,0.00006669435,0.00001612677,0.0000013163735,0.0000058130563,0.00009852219,0.0000024975427,0.00013202433],"genre_scores_gemma":[0.9996049,0.00003693293,0.000094881776,0.000018204413,0.0000027398585,0.000004972061,0.00017256128,7.375227e-7,0.0000641189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999151,0.000020422389,0.000010321314,0.000018399976,0.000017187538,0.000018537377],"domain_scores_gemma":[0.99964654,0.00007083817,0.00018300468,0.0000114906325,0.00002058524,0.00006745567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002667911,0.00015842504,0.00025279264,0.0003238555,0.00011145832,0.00026610948,0.00009085531,0.00025080988,0.0008329652],"category_scores_gemma":[0.00072926213,0.00007671738,0.0001397505,0.0003492789,0.00013074736,0.00016087804,0.00013548991,0.0002605136,0.000156024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036065835,0.00018648758,0.96896243,0.00002936074,0.000056386732,0.00037343605,0.000060568833,0.00039046182,0.01611043,0.000020892103,0.00021238568,0.009990623],"study_design_scores_gemma":[0.0000486617,0.0009444528,0.99507034,0.0000041024323,0.000033932807,0.00088007085,0.000040923092,0.00095599866,0.0017360399,0.0000329076,0.0002492281,0.0000034079185],"about_ca_topic_score_codex":0.0006184693,"about_ca_topic_score_gemma":0.0007467417,"teacher_disagreement_score":0.0008329652,"about_ca_system_score_codex":0.00025548486,"about_ca_system_score_gemma":0.0001320168,"threshold_uncertainty_score":0.0027865767},"labels":[],"label_agreement":null},{"id":"W2327569758","doi":"10.1136/jclinpath-2012-200974","title":"Validation of tissue microarrays in oral epithelial dysplasia using a novel virtual-array technique","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Cancer Research UK","keywords":"Tissue microarray; Immunohistochemistry; Virtual microscopy; Pathology; Reliability (semiconductor); Computer science; Intraclass correlation; Dysplasia; Oral mucosa; Medicine; Reproducibility; Computational biology; Pattern recognition (psychology); Artificial intelligence; Biology; Mathematics; Statistics; Physics","score_opus":0.16888939577211667,"score_gpt":0.49976395239135873,"score_spread":0.33087455661924203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327569758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55637676,0.0016744934,0.43658775,0.0001971509,0.00022124582,0.00050773757,0.00052396936,0.00094240485,0.0029684685],"genre_scores_gemma":[0.6818498,0.00076340785,0.3145524,0.0001314683,0.000058704776,0.00088958076,0.0007420883,0.000079649806,0.0009329722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99593323,0.0015730743,0.0003239749,0.0007930345,0.001215843,0.00016087737],"domain_scores_gemma":[0.9956559,0.0016710088,0.00048842345,0.0007566647,0.0013411735,0.00008676092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005050484,0.00056732004,0.00046424178,0.0010550406,0.00042853144,0.00090917124,0.00059576525,0.0006141687,0.0010471187],"category_scores_gemma":[0.0061177257,0.00037729947,0.0004835406,0.00054879824,0.0005257775,0.0004963973,0.0010147643,0.00045021964,0.0007357159],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004475577,0.00013981256,0.025437409,0.0003083573,0.00013060556,0.00016808225,0.00038846012,0.006315314,0.9132037,0.00071382214,0.00038020985,0.05236666],"study_design_scores_gemma":[0.00006854339,0.0018891995,0.0881657,0.00010633119,0.00030199226,0.0030534524,0.00044363012,0.103984796,0.7890208,0.0013217535,0.011526659,0.0001170806],"about_ca_topic_score_codex":0.0003593522,"about_ca_topic_score_gemma":0.0006976068,"teacher_disagreement_score":0.005050484,"about_ca_system_score_codex":0.00029791726,"about_ca_system_score_gemma":0.00033404824,"threshold_uncertainty_score":0.026709795},"labels":[],"label_agreement":null},{"id":"W2328501245","doi":"10.1097/igc.0b013e31826d1438","title":"Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile","year":2012,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Topotecan; Medicine; Lapatinib; Internal medicine; Oncology; Gefitinib; Epidermal growth factor receptor; Cancer; Chemotherapy; Pharmacology; Trastuzumab; Breast cancer","score_opus":0.09748817472018313,"score_gpt":0.41249245806051915,"score_spread":0.31500428334033603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328501245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96333194,0.019845081,0.0027754658,0.0020243803,0.00022658957,0.00023230967,0.002401836,0.000058303394,0.009104126],"genre_scores_gemma":[0.99489117,0.0016620384,0.0008315476,0.0005032411,0.00018939603,0.00006473829,0.0010216492,0.000010799474,0.0008253141],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986117,0.0005760181,0.00015716838,0.0001399704,0.0002156388,0.00029953217],"domain_scores_gemma":[0.9934263,0.0045469725,0.0007071178,0.00017245329,0.00026451855,0.000882611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037260533,0.00054968323,0.0013662188,0.0006660526,0.00019682474,0.00068888505,0.00038163594,0.00060550985,0.0033208905],"category_scores_gemma":[0.0082880305,0.00021991646,0.0030797045,0.0004723591,0.00036085467,0.00077029056,0.000447935,0.0010039605,0.00048145826],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3096515,0.0018507094,0.32289082,0.0015680973,0.012348793,0.0021192967,0.00011598194,0.02692101,0.016705886,0.001621463,0.0021904963,0.302016],"study_design_scores_gemma":[0.008035885,0.052876752,0.89303386,0.00019282373,0.017537361,0.0027105394,0.00024449447,0.012246171,0.005197552,0.0038608995,0.0039583636,0.00010525308],"about_ca_topic_score_codex":0.0011519475,"about_ca_topic_score_gemma":0.0043340013,"teacher_disagreement_score":0.0037260533,"about_ca_system_score_codex":0.0010387048,"about_ca_system_score_gemma":0.00054666406,"threshold_uncertainty_score":0.019705474},"labels":[],"label_agreement":null},{"id":"W2329129089","doi":"10.1158/0008-5472.sabcs10-p5-12-03","title":"Abstract P5-12-03: Concurrent vs. Sequential Administration of Adjuvant Trastuzumab in Early Stage Breast Cancer: A Systematic Review and Meta-Analysis","year":2010,"lang":"en","type":"review","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Breast cancer; Meta-analysis; Internal medicine; Randomized controlled trial; Stage (stratigraphy); Adjuvant; Clinical trial; Inclusion and exclusion criteria; Cancer; Pathology; Alternative medicine","score_opus":0.3509230911295733,"score_gpt":0.5485707472303206,"score_spread":0.1976476561007473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329129089","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005221408,0.9906466,0.0010503792,0.00032879008,0.00032116906,0.0014709192,0.0006059718,0.000045755918,0.0003089905],"genre_scores_gemma":[0.20297794,0.7788457,0.0055906624,0.0015047279,0.00057571486,0.008438163,0.0010437752,0.00006353916,0.00095966755],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9791019,0.012709942,0.0046617207,0.0011801501,0.0019267452,0.00041955008],"domain_scores_gemma":[0.9701294,0.022123717,0.0043694237,0.00063477387,0.00235441,0.00038830005],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.023282098,0.0037229075,0.02682426,0.008492006,0.0007581591,0.0047737043,0.0028413623,0.0035330446,0.006786502],"category_scores_gemma":[0.054697517,0.0017678973,0.044306595,0.009394103,0.0010213617,0.0028230532,0.0020677329,0.0023437166,0.0005474889],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022718615,0.000030928637,0.0013966146,0.51049936,0.47741064,0.00014768011,0.00007252558,0.00044252028,0.00018724681,0.00013432508,0.0006487494,0.0067575304],"study_design_scores_gemma":[0.0015401145,0.00028951408,0.0016547578,0.04269325,0.95166737,0.00009763224,0.000055353197,0.0003422307,0.00013315544,0.00020992951,0.0012889657,0.000027738179],"about_ca_topic_score_codex":0.0062892935,"about_ca_topic_score_gemma":0.012925425,"teacher_disagreement_score":0.97317576,"about_ca_system_score_codex":0.004653559,"about_ca_system_score_gemma":0.004877801,"threshold_uncertainty_score":0.12312895},"labels":[],"label_agreement":null},{"id":"W2329465541","doi":"10.1158/0008-5472.sabcs-5118","title":"Phase II trial of neoadjuvant chemotherapy of sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): a multi-centre study from British Columbia.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kelowna General Hospital; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Docetaxel; Carboplatin; Breast cancer; Internal medicine; Epirubicin; Oncology; Chemotherapy; Cancer; Surgery; Cisplatin","score_opus":0.05717163578144839,"score_gpt":0.44103397805998534,"score_spread":0.38386234227853694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329465541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98988616,0.00073119375,0.00031902755,0.00039128782,0.00007200413,0.005767174,0.0009972822,0.000077724755,0.0017581182],"genre_scores_gemma":[0.9797537,0.0011757585,0.0017897394,0.0011169418,0.00011988459,0.006404455,0.003226221,0.0000438432,0.006369531],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99925166,0.00033614086,0.000029792489,0.00012641483,0.000084088286,0.00017188383],"domain_scores_gemma":[0.99821824,0.00019037222,0.00018381307,0.00015277724,0.0001363649,0.0011184253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020621587,0.0018945344,0.0023987805,0.00067396346,0.0009466846,0.0010438096,0.0018050805,0.0018329204,0.004525408],"category_scores_gemma":[0.0011384767,0.0010050951,0.00079285033,0.0007724951,0.0016177277,0.00063786353,0.00060571707,0.0031795728,0.0012521913],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83653325,0.09087915,0.0066855475,0.00041630463,0.0007154165,0.0003360419,0.00029417194,0.0011516369,0.025161056,0.000068423804,0.0020956183,0.035663404],"study_design_scores_gemma":[0.6126899,0.35961616,0.022403201,0.000031258744,0.00034387354,0.0001999641,0.000081625185,0.00054755114,0.001865076,0.00008409642,0.0020931868,0.000044094213],"about_ca_topic_score_codex":0.025929997,"about_ca_topic_score_gemma":0.068538964,"teacher_disagreement_score":0.025929997,"about_ca_system_score_codex":0.0029633613,"about_ca_system_score_gemma":0.0060979957,"threshold_uncertainty_score":0.051558137},"labels":[],"label_agreement":null},{"id":"W2329752051","doi":"10.1158/1538-7445.am10-5064","title":"Abstract 5064: The non-receptor tyrosine kinase Fer is required for activated ErbB2-mediated tumorigenesis","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Carcinogenesis; Cell biology; Focal adhesion; Endocytosis; Biology; Internalization; Receptor tyrosine kinase; Tyrosine kinase; Cancer research; Signal transduction; Proto-oncogene tyrosine-protein kinase Src; Signal transducing adaptor protein; Cell; Cancer; Biochemistry","score_opus":0.12733841121686232,"score_gpt":0.4613987581692534,"score_spread":0.33406034695239106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329752051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97776276,0.002280533,0.0055980645,0.00056062755,0.00023228537,0.00007402659,0.005732152,0.0007481849,0.0070114015],"genre_scores_gemma":[0.97248435,0.0006503341,0.0028058232,0.00016143378,0.00004534555,0.000076316086,0.00662342,0.00023811724,0.016914858],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997515,0.0000298302,0.000027219101,0.000051235955,0.00008960097,0.00005060809],"domain_scores_gemma":[0.99968433,0.000045474586,0.00009605583,0.000031653206,0.000022063006,0.00012048227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015553473,0.0009131573,0.00038419684,0.00061383715,0.00036533742,0.00042096592,0.00042888045,0.00064505724,0.008065829],"category_scores_gemma":[0.00018091575,0.00031659383,0.00042595892,0.00024549724,0.00041183003,0.00024374475,0.0004312441,0.0009879359,0.0037720466],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014147391,0.000027632323,0.00009362561,0.00002202734,0.0000045527004,0.0002561239,0.0000060729453,0.000043966018,0.99866056,0.00009304358,0.00011378301,0.00053718366],"study_design_scores_gemma":[0.00007964209,0.00020849629,0.010862719,0.0000194536,0.000022427948,0.0022324699,0.000042437554,0.0016043338,0.97592205,0.00015789134,0.008831332,0.000016805496],"about_ca_topic_score_codex":0.00065006333,"about_ca_topic_score_gemma":0.0006516591,"teacher_disagreement_score":0.008065829,"about_ca_system_score_codex":0.00055849936,"about_ca_system_score_gemma":0.00026061322,"threshold_uncertainty_score":0.026982844},"labels":[],"label_agreement":null},{"id":"W2330598133","doi":"10.1158/1538-7445.am2012-1243","title":"Abstract 1243: RET and integrin crosstalk provides functional plasticity","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cell biology; Integrin; Glial cell line-derived neurotrophic factor; Proto-oncogene tyrosine-protein kinase Src; Cancer research; Receptor tyrosine kinase; Biology; Cell adhesion; Chemistry; Neurotrophic factors; Signal transduction; Cell; Receptor; Genetics","score_opus":0.25617715126673013,"score_gpt":0.49153109932044164,"score_spread":0.23535394805371151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330598133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734803,0.008236224,0.0024316206,0.00082281063,0.00020598475,0.000020192734,0.00082987477,0.00018331656,0.013789587],"genre_scores_gemma":[0.9841059,0.0016860374,0.0007300086,0.00024083372,0.00005568459,0.000020102105,0.0005648792,0.000032935128,0.012563567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988174,0.000009635508,0.000005803669,0.000018473524,0.000041395648,0.00004291624],"domain_scores_gemma":[0.9999504,0.0000050542258,0.000011157736,0.000004662836,0.000010566712,0.000018069783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005134767,0.0002712777,0.0001881835,0.00013800764,0.00020717648,0.0003978437,0.00016059283,0.0003549615,0.0060092183],"category_scores_gemma":[0.00007743266,0.00010212548,0.00023021262,0.00017978734,0.00015900134,0.00027368878,0.00020595909,0.0005714338,0.0013873304],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070025744,0.00000710137,0.00006580913,0.000023392711,0.0000027051824,0.00008738488,0.000008188872,0.000019358906,0.99762243,0.000118504475,0.00019528024,0.0017797424],"study_design_scores_gemma":[0.000039370894,0.00032275525,0.029785223,0.000028578132,0.000037033635,0.0016527977,0.00015608898,0.0010993062,0.9409059,0.0006895545,0.025262577,0.000020826656],"about_ca_topic_score_codex":0.0007328591,"about_ca_topic_score_gemma":0.0010362403,"teacher_disagreement_score":0.0060092183,"about_ca_system_score_codex":0.0003803036,"about_ca_system_score_gemma":0.0001496592,"threshold_uncertainty_score":0.020102859},"labels":[],"label_agreement":null},{"id":"W2331118477","doi":"10.1177/171516350613900109","title":"Use of Trastuzumab for Early-Stage Invasive Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Breast cancer; Oncology; Medicine; Stage (stratigraphy); Internal medicine; Cancer; Biology","score_opus":0.09665679366048885,"score_gpt":0.3418393889493365,"score_spread":0.24518259528884767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331118477","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9186185,0.052512124,0.00030886682,0.008285558,0.00032028256,0.000068013265,0.00049302017,0.000026713438,0.019366914],"genre_scores_gemma":[0.9875535,0.00893189,0.00017024737,0.00092723704,0.00023859952,0.000010351399,0.00018762141,0.0000042119673,0.0019764276],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99960047,0.000098739125,0.000029564308,0.00003066079,0.00015217217,0.00008842448],"domain_scores_gemma":[0.9988951,0.00043426282,0.00021481745,0.00003434232,0.00016680852,0.0002546485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005092934,0.00011873158,0.00037449205,0.00044754808,0.0003885733,0.000488642,0.00027116135,0.00045790372,0.0015481507],"category_scores_gemma":[0.0026981453,0.000100365214,0.00033544112,0.0005394151,0.00020270787,0.00022724197,0.00014877874,0.0006037718,0.00013922101],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045227176,0.0008310787,0.65246063,0.00038871457,0.0002586874,0.0029956875,0.00037667318,0.00046577206,0.006429294,0.0004976966,0.006179971,0.3245931],"study_design_scores_gemma":[0.00034631652,0.0019742206,0.96515036,0.00034500653,0.00048607247,0.0043576807,0.00034881828,0.00076900324,0.0021142326,0.0003208753,0.023762014,0.000025297883],"about_ca_topic_score_codex":0.03747977,"about_ca_topic_score_gemma":0.11191539,"teacher_disagreement_score":0.03747977,"about_ca_system_score_codex":0.0024790224,"about_ca_system_score_gemma":0.002546862,"threshold_uncertainty_score":0.07452321},"labels":[],"label_agreement":null},{"id":"W2334856590","doi":"10.1097/pai.0000000000000039","title":"Predicting OncoDX Recurrence Scores With Immunohistochemical Markers","year":2014,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; Ottawa Hospital","funders":"","keywords":"Immunohistochemistry; Medicine; Breast cancer; Internal medicine; Estrogen receptor; Oncology; Estrogen; Population; Cohort; Cancer; Gynecology","score_opus":0.008528528665359796,"score_gpt":0.2845737855243071,"score_spread":0.2760452568589473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334856590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975025,0.0002446116,0.0014228248,0.00004982104,0.000013535125,0.000018043056,0.00014846733,0.000022879953,0.0005773745],"genre_scores_gemma":[0.9986935,0.00008704687,0.00068520807,0.0000086971895,0.000012898606,0.000011335121,0.00027253915,0.0000046019604,0.0002241662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993468,0.00025665015,0.00008077672,0.00006917097,0.00017628155,0.00007034782],"domain_scores_gemma":[0.9979334,0.0009582511,0.0005331569,0.000158586,0.00025992366,0.00015664667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017652704,0.0004480076,0.000334734,0.0014275522,0.00010744685,0.0004698244,0.00026152373,0.00026118036,0.0009182579],"category_scores_gemma":[0.004953144,0.00012557606,0.0005147772,0.0005828925,0.00016477234,0.00030331704,0.00045054013,0.000294122,0.00034969536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026937647,0.000019679504,0.9921555,0.000006694599,0.000038587892,0.000047326917,0.000014165115,0.0008216746,0.0004047957,0.000017254233,0.00011329321,0.0060916813],"study_design_scores_gemma":[0.00003071989,0.00042289455,0.96848494,0.000009512659,0.00013560885,0.0006440609,0.00011930222,0.027557392,0.0017788131,0.00019118824,0.0006140095,0.000011562775],"about_ca_topic_score_codex":0.0011027666,"about_ca_topic_score_gemma":0.0019713102,"teacher_disagreement_score":0.0017652704,"about_ca_system_score_codex":0.00022786508,"about_ca_system_score_gemma":0.0001809846,"threshold_uncertainty_score":0.009335756},"labels":[],"label_agreement":null},{"id":"W2336389733","doi":"10.1200/jco.2006.24.18_suppl.13100","title":"Synergistic inhibition of breast cancer cell lines with the combination of a dual inhibitor of EGFR/HER-2/neu and a Bcl-2 inhibitor","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lapatinib; Erlotinib; Tyrosine-kinase inhibitor; Cancer research; Hsp90 inhibitor; Trastuzumab; SKBR3; EGFR inhibitors; Medicine; Apoptosis; Breast cancer; ErbB; Epidermal growth factor receptor; Transfection; Growth inhibition; MTT assay; Cell culture; Pharmacology; Cancer; Internal medicine; Biology; Hsp90; Heat shock protein; Human breast; Biochemistry","score_opus":0.06359530791566989,"score_gpt":0.43699860877867275,"score_spread":0.3734033008630029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336389733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98740584,0.0045747245,0.0014424279,0.00019108818,0.00018288428,0.00019065588,0.00057221914,0.0001636699,0.005276411],"genre_scores_gemma":[0.990669,0.0022563576,0.0029298558,0.0001004287,0.000028948629,0.00015523698,0.00076273776,0.000014354712,0.0030830987],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998368,0.00003258251,0.000014710338,0.000024726742,0.00005233014,0.000038827315],"domain_scores_gemma":[0.9999348,0.000015791626,0.000009840598,0.000008983341,0.000009156303,0.000021401676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019280553,0.00045591092,0.0004725041,0.00032438638,0.00013089056,0.00027954736,0.00035276214,0.00028112775,0.0017055138],"category_scores_gemma":[0.000080287355,0.00015733331,0.00038701668,0.0003107835,0.00014596038,0.00019259901,0.00020899983,0.0005484965,0.00042758413],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017043113,0.001236314,0.0006510243,0.00025299288,0.00009344486,0.0001285172,0.000056787925,0.0005877054,0.9789251,0.0002745374,0.0011524851,0.014936677],"study_design_scores_gemma":[0.00050961814,0.007767607,0.0056232605,0.000020626801,0.00013238477,0.00050849473,0.000060751485,0.0027633132,0.9725427,0.00005644997,0.009996101,0.000018619736],"about_ca_topic_score_codex":0.0007284536,"about_ca_topic_score_gemma":0.002472575,"teacher_disagreement_score":0.0017055138,"about_ca_system_score_codex":0.00031042518,"about_ca_system_score_gemma":0.00039032244,"threshold_uncertainty_score":0.0057055354},"labels":[],"label_agreement":null},{"id":"W2338010368","doi":"10.1093/jnci/djw037","title":"Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial","year":2016,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Lapatinib; Rash; Medicine; Hazard ratio; Internal medicine; Trastuzumab; Breast cancer; Confidence interval; Oncology; Proportional hazards model; Cancer; Surgery","score_opus":0.10597184761811394,"score_gpt":0.4644820131216851,"score_spread":0.3585101655035711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338010368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245197,0.00403874,0.00037203296,0.0006036918,0.00013134477,0.00047258555,0.0006253092,0.000041198113,0.0012631611],"genre_scores_gemma":[0.9954585,0.00086364395,0.00055248255,0.00045546875,0.00016761193,0.00069491967,0.00091377186,0.000009838837,0.0008837841],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990233,0.00073681655,0.00003511921,0.00008268476,0.00005510283,0.00006691841],"domain_scores_gemma":[0.9982973,0.0004764017,0.0007407752,0.00012006202,0.00006794984,0.00029748413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002277907,0.0005950908,0.0011884437,0.00018647168,0.00016078957,0.0007735216,0.00039344802,0.0005579319,0.0022581858],"category_scores_gemma":[0.0030212037,0.00018794753,0.0014332428,0.00021708217,0.0004162004,0.0005840228,0.00046769305,0.001214874,0.00017467787],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96390545,0.0012085891,0.014956455,0.00071262225,0.0023883553,0.00006523428,0.000043542845,0.001292949,0.0015521218,0.00031512778,0.0016364143,0.011923187],"study_design_scores_gemma":[0.8144713,0.0982311,0.068352655,0.00024373451,0.0059257033,0.0003774875,0.000091847294,0.005767644,0.001061297,0.0016388408,0.0037786788,0.000059777634],"about_ca_topic_score_codex":0.0003427413,"about_ca_topic_score_gemma":0.0011919888,"teacher_disagreement_score":0.002277907,"about_ca_system_score_codex":0.00045444,"about_ca_system_score_gemma":0.0006343745,"threshold_uncertainty_score":0.012046874},"labels":[],"label_agreement":null},{"id":"W2338311228","doi":"10.1136/annrheumdis-2015-eular.2291","title":"OP0251 Effects of 2 Years of Treatment with Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bone mineral; Femoral neck; Denosumab; Sclerostin; Placebo; Postmenopausal women; Urology; Osteoporosis; Lumbar spine; Internal medicine; Surgery; Chemistry","score_opus":0.027252637847661573,"score_gpt":0.3156595177510587,"score_spread":0.28840687990339714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338311228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99261826,0.0034175685,0.000110703295,0.0004581187,0.00042606334,0.0001686889,0.0007749052,0.000066646186,0.0019590317],"genre_scores_gemma":[0.9926622,0.0018510849,0.0002607073,0.00042420576,0.00026427626,0.00024832494,0.0011234221,0.000011892879,0.0031538475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996383,0.00012503416,0.000024642506,0.000051432136,0.000018867398,0.00014173212],"domain_scores_gemma":[0.99929416,0.0002655425,0.00009560151,0.00005849289,0.000030452455,0.0002555732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079562754,0.0009872514,0.0033041947,0.0003375481,0.0003209353,0.00069116004,0.00073276483,0.0018257926,0.006782232],"category_scores_gemma":[0.0016038691,0.0004830942,0.0018009448,0.00028661735,0.0006718981,0.0007974872,0.00035532782,0.002404423,0.0010824503],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95347476,0.0110111805,0.0009023675,0.00029144227,0.0005891958,0.00014123756,0.000052827483,0.0006030594,0.0068877665,0.00009579524,0.00092474313,0.025025532],"study_design_scores_gemma":[0.39891866,0.5556647,0.035717245,0.0001306119,0.0019796968,0.00023111307,0.00018133318,0.0017462317,0.0030930727,0.00029404328,0.001955819,0.00008742106],"about_ca_topic_score_codex":0.003282852,"about_ca_topic_score_gemma":0.005759583,"teacher_disagreement_score":0.006782232,"about_ca_system_score_codex":0.0003254566,"about_ca_system_score_gemma":0.0012376369,"threshold_uncertainty_score":0.022688806},"labels":[],"label_agreement":null},{"id":"W2341528474","doi":"10.3747/co.23.2743","title":"Duration of Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer in Prolonged Remission","year":2016,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Metastatic breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.13617154897183445,"score_gpt":0.5050269679512784,"score_spread":0.36885541897944396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341528474","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86616313,0.12661839,0.000106702144,0.0021737884,0.000048038775,0.000016664892,0.0010553707,0.000004231121,0.0038137694],"genre_scores_gemma":[0.9738361,0.024859348,0.00012998944,0.00052554253,0.00006148359,0.000012386486,0.00039148846,0.0000015694665,0.00018208509],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9994837,0.00014207639,0.00013192113,0.00005558127,0.00013667939,0.00004999455],"domain_scores_gemma":[0.9954631,0.0015466881,0.0025235629,0.00003694347,0.00023598642,0.00019361074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007381404,0.000056948735,0.0002347333,0.0009245957,0.00020130894,0.0004321408,0.00022023015,0.00031147344,0.0011364293],"category_scores_gemma":[0.00564661,0.00006586772,0.00024916884,0.0025562516,0.00012889621,0.00044282843,0.00016206992,0.0002616674,0.000083440646],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003324962,0.000056701734,0.94798756,0.0019859388,0.00015258,0.0015524916,0.0013580238,0.0000591453,0.00043775962,0.00011797319,0.0012199075,0.044739433],"study_design_scores_gemma":[0.000028187067,0.00019048066,0.9838396,0.0012108514,0.00023909018,0.0043922877,0.0026262666,0.00008617135,0.00016303538,0.00008565877,0.0071283225,0.00000993579],"about_ca_topic_score_codex":0.0073800636,"about_ca_topic_score_gemma":0.014164021,"teacher_disagreement_score":0.0073800636,"about_ca_system_score_codex":0.000636264,"about_ca_system_score_gemma":0.0006708152,"threshold_uncertainty_score":0.014674246},"labels":[],"label_agreement":null},{"id":"W2343337356","doi":"10.1038/modpathol.2016.74","title":"A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort","year":2016,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services; Alberta Health Services","funders":"Breast Cancer Society of Canada; Calgary Laboratory Services","keywords":"Medicine; Breast cancer; Oncology; Cohort; Pathology; Estrogen receptor; Internal medicine; Univariate analysis; Concordance; Tamoxifen; Predictive value; Estrogen; Multivariate analysis; Gynecology; Cancer","score_opus":0.18187959293200343,"score_gpt":0.46552209598601646,"score_spread":0.28364250305401306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343337356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96670616,0.028597526,0.002171449,0.00010606754,0.00014102506,0.0001464296,0.0013858184,0.000031253167,0.00071421184],"genre_scores_gemma":[0.9962064,0.0015154547,0.0006378523,0.00014695592,0.000069649745,0.000086021944,0.0011077169,0.000030370986,0.00019952998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9837593,0.0055111623,0.0025086468,0.0051219473,0.0025137214,0.0005852447],"domain_scores_gemma":[0.9720703,0.013495715,0.005633392,0.005115859,0.003171714,0.0005130431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011397839,0.0009895675,0.0022027253,0.0021197584,0.00061654334,0.0019137238,0.0009562602,0.0011352521,0.0009256401],"category_scores_gemma":[0.029770566,0.0007852632,0.003440392,0.0018877814,0.00093489257,0.0008956865,0.0012544672,0.00064701826,0.00032362988],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010392562,0.00010786681,0.9437824,0.0012921588,0.026894886,0.00021974041,0.00041080857,0.00017235505,0.0028464294,0.00017289074,0.00056613435,0.013141876],"study_design_scores_gemma":[0.0010059795,0.0018964431,0.9559787,0.000387678,0.034856368,0.00093018863,0.00034776714,0.00046217322,0.0012504891,0.00023443208,0.0025943266,0.00005538956],"about_ca_topic_score_codex":0.0030182034,"about_ca_topic_score_gemma":0.0058956305,"teacher_disagreement_score":0.011397839,"about_ca_system_score_codex":0.0009383686,"about_ca_system_score_gemma":0.0012074836,"threshold_uncertainty_score":0.060278237},"labels":[],"label_agreement":null},{"id":"W2343845543","doi":"10.1007/s10549-016-3812-1","title":"Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer","year":2016,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Hôpital Charles-Le Moyne; Juravinski Cancer Centre; University Health Network; Hamilton Health Sciences; Princess Margaret Cancer Centre; Kingston General Hospital; Interior Health; Ottawa Hospital; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Ipsen; AstraZeneca; Celgene; Genomic Health; Cancer Care Ontario; Pfizer; Cancer Research Institute","keywords":"Medicine; Internal medicine; PTEN; Cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Progressive disease; Metastatic breast cancer; Triple-negative breast cancer; Estrogen receptor; Clinical endpoint; Adverse effect; Clinical trial; Disease; Biology; PI3K/AKT/mTOR pathway","score_opus":0.12762285403095874,"score_gpt":0.4400756633405633,"score_spread":0.31245280930960456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343845543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9501621,0.011759578,0.0006150793,0.004174784,0.0005856257,0.0037586372,0.010569141,0.00036464268,0.018010408],"genre_scores_gemma":[0.94446343,0.010604436,0.0027790666,0.0049805846,0.00029643293,0.0020708696,0.017856125,0.00013816947,0.01681083],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99962485,0.00012845572,0.000009616922,0.00004559938,0.00006536489,0.00012601576],"domain_scores_gemma":[0.9995499,0.00006294013,0.000050495983,0.000024947572,0.000038111713,0.00027356797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013999669,0.0017585518,0.0021332502,0.0005039568,0.00077608146,0.0010644027,0.0012822596,0.0013512959,0.006843483],"category_scores_gemma":[0.0011205091,0.0005381905,0.0016116496,0.0007120605,0.0011180919,0.000618916,0.0003940653,0.0038849744,0.001059314],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7571575,0.018326163,0.0077345143,0.0017613008,0.003033408,0.0003808957,0.0003761737,0.0036388726,0.014896067,0.0013083373,0.046182122,0.1452047],"study_design_scores_gemma":[0.8645236,0.08591732,0.025606876,0.000116393945,0.0014981251,0.00042248605,0.00019009407,0.0016864868,0.0015736974,0.0005601927,0.01781142,0.00009324249],"about_ca_topic_score_codex":0.07882568,"about_ca_topic_score_gemma":0.3303452,"teacher_disagreement_score":0.07882568,"about_ca_system_score_codex":0.0048322226,"about_ca_system_score_gemma":0.0088252,"threshold_uncertainty_score":0.15673375},"labels":[],"label_agreement":null},{"id":"W2344122381","doi":"10.1038/onc.2016.109","title":"ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells","year":2016,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Anoikis; Downregulation and upregulation; Biology; Cancer research; Lapatinib; Cell biology; Epidermal growth factor receptor; Carcinogenesis; Apoptosis; Cancer; Breast cancer; Programmed cell death","score_opus":0.039807096853957544,"score_gpt":0.3321288980800575,"score_spread":0.29232180122609996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344122381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899995,0.0015569536,0.004034637,0.00027756745,0.00004818654,0.000025062775,0.0010104311,0.00019018057,0.0028575882],"genre_scores_gemma":[0.9938501,0.0003590676,0.0012215677,0.000056778517,0.00000718683,0.000024598055,0.0013178175,0.000043293137,0.003119467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997824,0.000033637793,0.000019457853,0.000033051478,0.00006409269,0.000067357156],"domain_scores_gemma":[0.9998393,0.000022952674,0.000037666603,0.00003364324,0.00002237866,0.000043973603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014954637,0.00032122975,0.00026019313,0.00028640754,0.00025851637,0.0005110026,0.00025793386,0.00023667362,0.0023265213],"category_scores_gemma":[0.00020056329,0.00023285794,0.00030831163,0.00021865487,0.00022864921,0.00032758433,0.00036964,0.00072057155,0.0011771736],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001115129,0.00002323223,0.00016821735,0.00001580496,0.0000045361717,0.00013863495,0.000005551932,0.000036005684,0.9986731,0.000102690334,0.00007159526,0.0006491198],"study_design_scores_gemma":[0.000013046382,0.00006938592,0.009850844,0.0000027181804,0.00000999475,0.0012307679,0.000037990012,0.0011871874,0.9849812,0.00008598435,0.002527411,0.000003508119],"about_ca_topic_score_codex":0.0004815361,"about_ca_topic_score_gemma":0.00065174606,"teacher_disagreement_score":0.0023265213,"about_ca_system_score_codex":0.00046271537,"about_ca_system_score_gemma":0.00023401127,"threshold_uncertainty_score":0.0077829957},"labels":[],"label_agreement":null},{"id":"W2346540202","doi":"10.1038/onc.2016.129","title":"The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment","year":2016,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Terry Fox Foundation; Susan G. Komen; U.S. Department of Defense; McGill University; Genentech; Susan G. Komen for the Cure","keywords":"Biology; Cancer research; Breast cancer; Oncogene; Metastasis; Cancer; Mammary gland; Carcinogenesis; Alternative splicing; Exon; Gene; Genetics; Cell cycle","score_opus":0.03296888147554756,"score_gpt":0.32506167720448775,"score_spread":0.2920927957289402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346540202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996914,0.00061480986,0.00082266185,0.0001811234,0.000040254075,0.000007458821,0.00023027926,0.000038697497,0.0011505736],"genre_scores_gemma":[0.9962436,0.0003666976,0.00071845297,0.000050266928,0.000009108047,0.000006674975,0.00038135357,0.000030609513,0.0021931394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998492,0.000025531783,0.000016983504,0.00002843014,0.00005205524,0.000027751725],"domain_scores_gemma":[0.99985504,0.000017444256,0.000050345046,0.000019824985,0.000014968323,0.000042406264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002366109,0.00030726462,0.00019255218,0.00022536905,0.00019271363,0.0004254512,0.00021790294,0.0003213759,0.0027627125],"category_scores_gemma":[0.00019123299,0.0001548546,0.00022000539,0.00020677647,0.0003381188,0.00022587589,0.00028357064,0.00057268306,0.00088434375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002748078,0.00004782799,0.0064704795,0.000026742859,0.000022742,0.0010204527,0.000022541297,0.00019014259,0.98681587,0.00087897026,0.0002670727,0.0039623966],"study_design_scores_gemma":[0.00007754541,0.00046350365,0.04973192,0.000022527951,0.000060901217,0.023242667,0.00024003223,0.0021603147,0.9074767,0.0012007869,0.0153022725,0.000020728126],"about_ca_topic_score_codex":0.00041979275,"about_ca_topic_score_gemma":0.00077314983,"teacher_disagreement_score":0.0027627125,"about_ca_system_score_codex":0.00025855433,"about_ca_system_score_gemma":0.00029693812,"threshold_uncertainty_score":0.009242177},"labels":[],"label_agreement":null},{"id":"W2348629818","doi":"10.1016/j.gheart.2014.03.2169","title":"PW005 Safety and efficacy of dabigatran compared to warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation","year":2014,"lang":"en","type":"article","venue":"Global Heart","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Rheumatoid arthritis; Transforming growth factor; Angiogenesis; Apoptosis; Arthritis; Dabigatran; Cancer research; Atrial fibrillation; Immunology; Internal medicine; Warfarin; Biology","score_opus":0.03463131366891612,"score_gpt":0.3618158134097806,"score_spread":0.32718449974086444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2348629818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9029114,0.06944613,0.0017063393,0.0018752886,0.0010510412,0.0004227048,0.0043663853,0.00010174636,0.018118896],"genre_scores_gemma":[0.9835755,0.0077680065,0.00056747405,0.0008433828,0.00054485846,0.00023045667,0.0023737543,0.00001880738,0.004077625],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99915755,0.0002588376,0.00014238032,0.00012401506,0.00024430113,0.00007296298],"domain_scores_gemma":[0.9987099,0.0005686015,0.00034508217,0.000052845826,0.00017773084,0.00014582311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009471154,0.00023973806,0.0010839666,0.0004882402,0.00022884137,0.0008500767,0.00019637785,0.00055894564,0.0073731435],"category_scores_gemma":[0.0034607782,0.0001188716,0.0012810798,0.0006835633,0.00019899065,0.00037968124,0.0002480872,0.0009820313,0.00091867405],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1938798,0.0017059612,0.18818058,0.0051380023,0.0052185208,0.0012976299,0.00031457172,0.0005730576,0.009574824,0.0010173041,0.007943605,0.58515614],"study_design_scores_gemma":[0.031543314,0.09372507,0.80426717,0.0016770256,0.008708479,0.0035878636,0.00048261293,0.0023314867,0.0047172015,0.0026962988,0.046118163,0.00014528962],"about_ca_topic_score_codex":0.00068834494,"about_ca_topic_score_gemma":0.0010147933,"teacher_disagreement_score":0.0073731435,"about_ca_system_score_codex":0.0004071021,"about_ca_system_score_gemma":0.0008443153,"threshold_uncertainty_score":0.024665654},"labels":[],"label_agreement":null},{"id":"W2356610050","doi":"10.1097/pai.0000000000000393","title":"The International Society for Immunohistochemistry and Molecular Morphology (ISIMM)","year":2016,"lang":"en","type":"editorial","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Excellence; Medicine; Pathology; Political science; Law","score_opus":0.008141490304131496,"score_gpt":0.3298680063074395,"score_spread":0.32172651600330804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356610050","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0109082535,0.2522449,0.15844905,0.11744642,0.11616953,0.0018794828,0.0035790156,0.0070191342,0.3323042],"genre_scores_gemma":[0.07475654,0.29209056,0.21401812,0.04683989,0.052291937,0.0042121955,0.014137953,0.0041280165,0.2975248],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9859502,0.0029395237,0.0014787606,0.0018837915,0.0063859285,0.0013617949],"domain_scores_gemma":[0.9650028,0.0038543255,0.0027072208,0.0064062467,0.016066767,0.0059626517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022939622,0.0018353532,0.0015080136,0.010934522,0.002474235,0.010665127,0.003936041,0.0043675797,0.024197664],"category_scores_gemma":[0.021518756,0.0011612927,0.0014136779,0.0047394405,0.0055893715,0.0058453563,0.008498111,0.009682257,0.026110165],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021290248,0.000078523175,0.00316836,0.0011993474,0.000075412805,0.00092018436,0.000726389,0.00027639026,0.012033475,0.04749584,0.5217908,0.4120224],"study_design_scores_gemma":[0.000008370517,0.00004075978,0.001287186,0.0005297291,0.000014360371,0.0018091692,0.00011722846,0.00014702411,0.0013065576,0.0043794466,0.99033207,0.000028060524],"about_ca_topic_score_codex":0.002205919,"about_ca_topic_score_gemma":0.0026476483,"teacher_disagreement_score":0.024197664,"about_ca_system_score_codex":0.0040360605,"about_ca_system_score_gemma":0.014103877,"threshold_uncertainty_score":0.121317744},"labels":[],"label_agreement":null},{"id":"W2379981061","doi":"10.1016/s1470-2045(16)00163-7","title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":874,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"European Society for Medical Oncology","keywords":"Pertuzumab; Docetaxel; Medicine; Trastuzumab; Clinical endpoint; Epirubicin; Internal medicine; Breast cancer; Oncology; Neoadjuvant therapy; Surgery; Cancer; Clinical trial","score_opus":0.0391025579184239,"score_gpt":0.3926124320995352,"score_spread":0.35350987418111135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2379981061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222213,0.0035468948,0.00046633522,0.0007316092,0.00051818654,0.0006323385,0.0006910554,0.000049381288,0.0011420498],"genre_scores_gemma":[0.9907951,0.001767138,0.000780492,0.000913752,0.00049577036,0.00094259536,0.0015741265,0.000031088384,0.002699999],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983248,0.0009992654,0.000073903466,0.00024582463,0.000091569396,0.0002647072],"domain_scores_gemma":[0.99780744,0.00069550634,0.00047322855,0.00022217268,0.0001142158,0.0006875664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038641982,0.0024674477,0.0034245197,0.0004077828,0.00042402415,0.0017303795,0.0011310611,0.0022413384,0.005341908],"category_scores_gemma":[0.0032710726,0.000933811,0.003972881,0.00047073534,0.0015729235,0.002107309,0.0007905553,0.0044127037,0.0011001937],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9913191,0.0016959856,0.0006614439,0.00017325534,0.0010796571,0.00002540676,0.00003991152,0.00032268406,0.00089299824,0.00005777186,0.00028495514,0.0034467527],"study_design_scores_gemma":[0.91559786,0.07646539,0.0044145132,0.000040791492,0.0016781597,0.00004913462,0.000056607136,0.0006028629,0.00025456032,0.00023622661,0.0005730079,0.000030928146],"about_ca_topic_score_codex":0.0013393245,"about_ca_topic_score_gemma":0.0026891618,"teacher_disagreement_score":0.005341908,"about_ca_system_score_codex":0.0015213889,"about_ca_system_score_gemma":0.0011934959,"threshold_uncertainty_score":0.020436108},"labels":[],"label_agreement":null},{"id":"W2384003525","doi":"10.1097/pai.0000000000000372","title":"Paraffin-embedded Tissue Fragment Suspension (PETFS): A Novel Method for Quality Control Preparation in Immunohistochemistry","year":2016,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"University of Texas Medical Branch","keywords":"Immunohistochemistry; Staining; Pathology; Medicine","score_opus":0.02159386153486607,"score_gpt":0.4028005810116338,"score_spread":0.3812067194767677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2384003525","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09012347,0.0040531857,0.8987316,0.00027947983,0.00033702445,0.0010373612,0.00043601394,0.0018855501,0.0031162668],"genre_scores_gemma":[0.16306129,0.0046850755,0.82008487,0.00028474635,0.00019891308,0.0014261254,0.002318659,0.00066164543,0.007278708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816006,0.00035844508,0.00018780901,0.00044551818,0.0007563955,0.0000917976],"domain_scores_gemma":[0.99851435,0.0003156484,0.00033595916,0.00033058473,0.00040494316,0.00009852843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002283697,0.0009644856,0.0004024793,0.0016495168,0.00055315363,0.00050125667,0.0008423866,0.000583509,0.0024359643],"category_scores_gemma":[0.001304657,0.0005523955,0.00046496058,0.00076688704,0.0007499104,0.000989683,0.000831739,0.001172283,0.0014663341],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006655286,0.00004537758,0.00060309586,0.0001514968,0.000015773612,0.00019989265,0.000075890806,0.00010202276,0.9773687,0.00031901654,0.00036500336,0.020687288],"study_design_scores_gemma":[0.00004047543,0.00056966336,0.00595009,0.000057584486,0.00009697927,0.0035834478,0.00007218678,0.003624065,0.9569217,0.00036801895,0.028655656,0.00006018612],"about_ca_topic_score_codex":0.000458623,"about_ca_topic_score_gemma":0.0011466012,"teacher_disagreement_score":0.0024359643,"about_ca_system_score_codex":0.00027004446,"about_ca_system_score_gemma":0.0005562951,"threshold_uncertainty_score":0.012077451},"labels":[],"label_agreement":null},{"id":"W2394193965","doi":"","title":"Expression of ERα and ERβ in normal human mammary gland and significance","year":2009,"lang":"en","type":"article","venue":"Journal of Jilin University","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Mammary gland; Stromal cell; Epithelium; Biology; Pathology; Myoepithelial cell; Staining; Endocrinology; Internal medicine; Medicine; Cancer research; Immunology; Breast cancer; Cancer","score_opus":0.02180350288837481,"score_gpt":0.30066919022028343,"score_spread":0.27886568733190864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394193965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829912,0.011625109,0.0017609148,0.00011187356,0.00002074739,0.00002240264,0.00026688477,0.00003749919,0.0031633761],"genre_scores_gemma":[0.99514246,0.0019620326,0.00085739966,0.000035887253,0.000021479509,0.000015564608,0.00023237348,0.0000068399195,0.001726034],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997229,0.00004535113,0.000028076165,0.0000689855,0.000078983576,0.000055609686],"domain_scores_gemma":[0.99980015,0.000031521307,0.00006139157,0.000023870487,0.000054027158,0.000029096667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037760875,0.00018374129,0.00018363971,0.000706377,0.00019309309,0.00034330884,0.0001422474,0.00018546627,0.0015837181],"category_scores_gemma":[0.00045535254,0.000116232586,0.00013910874,0.0003751111,0.00025476026,0.00022537788,0.00019817606,0.00013135017,0.0004084572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013143861,0.00006125309,0.19966897,0.00033959164,0.000049225757,0.0019847385,0.00036317104,0.00017780412,0.7599815,0.0004709813,0.0002756903,0.03531274],"study_design_scores_gemma":[0.000047698388,0.0010116462,0.8280431,0.000083222854,0.00012026051,0.02972191,0.0015584871,0.00091079297,0.11562107,0.00089351996,0.021966996,0.000021312599],"about_ca_topic_score_codex":0.00065193675,"about_ca_topic_score_gemma":0.00047695645,"teacher_disagreement_score":0.0015837181,"about_ca_system_score_codex":0.00019816606,"about_ca_system_score_gemma":0.00012918659,"threshold_uncertainty_score":0.005298078},"labels":[],"label_agreement":null},{"id":"W2397992828","doi":"10.1093/annonc/mdv336.12","title":"First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (NEO)adjuvant trastuzumab","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Lapatinib; Trastuzumab; Medicine; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Adjuvant therapy; Adjuvant; Cohort; Cancer","score_opus":0.1588409169490382,"score_gpt":0.45825894837672276,"score_spread":0.29941803142768453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397992828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776455,0.01602221,0.00022510205,0.00091026636,0.00015813262,0.00004417941,0.00025968824,0.000019731533,0.0047151274],"genre_scores_gemma":[0.99375373,0.0039247777,0.00016306706,0.00046389064,0.00018552257,0.00002273704,0.0004838667,0.000004675901,0.0009977415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99987674,0.000029134218,0.000011418746,0.000017279472,0.000021091408,0.000044283355],"domain_scores_gemma":[0.9996654,0.00010337455,0.00006823036,0.000014210593,0.000019110737,0.00012970118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030113297,0.00020148155,0.0005853547,0.00026385242,0.00026381697,0.0005209632,0.00020283606,0.00033795802,0.0014990781],"category_scores_gemma":[0.0010723098,0.000099889156,0.00045990784,0.00030229366,0.00014620666,0.00037393247,0.00017694697,0.0007739802,0.00019315016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050980847,0.0027448083,0.48655283,0.0007105189,0.000794737,0.009035577,0.00037817366,0.0022701202,0.018680891,0.0006092298,0.008673104,0.41856915],"study_design_scores_gemma":[0.0026360876,0.024980212,0.9236906,0.00034058,0.0012401014,0.015418343,0.0003716694,0.0031175967,0.0068166824,0.0009100493,0.020430759,0.000047341186],"about_ca_topic_score_codex":0.0007647029,"about_ca_topic_score_gemma":0.0036520874,"teacher_disagreement_score":0.0014990781,"about_ca_system_score_codex":0.0005483506,"about_ca_system_score_gemma":0.00055025145,"threshold_uncertainty_score":0.005014956},"labels":[],"label_agreement":null},{"id":"W2398096674","doi":"10.1097/pas.0000000000000375","title":"Quantification of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Using the Ventana Image Analysis System","year":2015,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Pharmacists Association","funders":"","keywords":"Immunohistochemistry; Pathology; Medicine; Anatomy","score_opus":0.0825704966981115,"score_gpt":0.40592924277059794,"score_spread":0.32335874607248644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398096674","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30894166,0.0027633163,0.65914196,0.00035171714,0.00029130737,0.0016136107,0.001338639,0.0077543627,0.017803362],"genre_scores_gemma":[0.21341236,0.0011219265,0.7742882,0.00020055061,0.000051680232,0.0021245317,0.0015737106,0.0009013708,0.006325654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978842,0.0005576429,0.00024096217,0.0005564025,0.0006457836,0.00011485837],"domain_scores_gemma":[0.99868876,0.0003177499,0.0001705082,0.00014191167,0.00061376544,0.00006734459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004220096,0.00083342846,0.00044117408,0.0028185812,0.0004504332,0.00091200956,0.00074773363,0.00051561155,0.0073881443],"category_scores_gemma":[0.002450348,0.00050848065,0.0004752437,0.0008240918,0.00047320838,0.00058150943,0.00060305063,0.00076810445,0.001230663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003443446,0.000105540355,0.0059713875,0.00043113573,0.00008424295,0.00017021991,0.00019698626,0.0005845634,0.93822837,0.0017092794,0.0019322262,0.050241657],"study_design_scores_gemma":[0.00019565917,0.0013006338,0.0883098,0.00017336542,0.0002997272,0.0037574552,0.00023059781,0.083722286,0.7832891,0.0018849254,0.036612336,0.00022410753],"about_ca_topic_score_codex":0.0009629563,"about_ca_topic_score_gemma":0.0018905228,"teacher_disagreement_score":0.0073881443,"about_ca_system_score_codex":0.000524971,"about_ca_system_score_gemma":0.00076377834,"threshold_uncertainty_score":0.024715781},"labels":[],"label_agreement":null},{"id":"W2400932267","doi":"10.1200/jco.2001.19.18.3795","title":"Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?","year":2001,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Citation; Medicine; Clinical Oncology; Breast cancer; Oncology; Cancer; Internal medicine; Library science","score_opus":0.3115095867459364,"score_gpt":0.5702496648245066,"score_spread":0.2587400780785702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400932267","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004103843,0.0056784237,0.00011811522,0.9616292,0.0044796737,0.0000149095695,0.000031517837,0.000014307249,0.023929926],"genre_scores_gemma":[0.101647794,0.02428431,0.00062475627,0.76916367,0.055137545,0.0000556952,0.000077328375,0.00004033672,0.04896849],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990307,0.00026392486,0.00012023379,0.00008336854,0.00030032874,0.00020137003],"domain_scores_gemma":[0.9975769,0.0010745958,0.00024890006,0.000082913175,0.00045471187,0.0005619865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013417087,0.00032384685,0.00064592774,0.000652782,0.0017503452,0.0015839889,0.0005615772,0.010654737,0.008736175],"category_scores_gemma":[0.009028484,0.0002592277,0.00033960244,0.00064318365,0.0025076522,0.0027758083,0.00063521427,0.008261079,0.0038887707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022563904,0.00015064121,0.022731313,0.00013719649,0.000019435602,0.030703994,0.00066861935,0.00014402084,0.00070746295,0.007961476,0.8414904,0.09505982],"study_design_scores_gemma":[0.00022025914,0.00023629253,0.016228253,0.0014548345,0.00005161066,0.07751071,0.00267275,0.00086015306,0.0005482268,0.017787565,0.8823539,0.00007550958],"about_ca_topic_score_codex":0.004141179,"about_ca_topic_score_gemma":0.0109686,"teacher_disagreement_score":0.010654737,"about_ca_system_score_codex":0.0030097151,"about_ca_system_score_gemma":0.0018283929,"threshold_uncertainty_score":0.02922535},"labels":[],"label_agreement":null},{"id":"W2402233591","doi":"10.1200/jco.2016.67.0182","title":"Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Cancer Care Ontario; American Society of Clinical Oncology","keywords":"Medicine; Trastuzumab; Oncology; Docetaxel; Internal medicine; Guideline; Breast cancer; Taxane; Regimen; Carboplatin; Context (archaeology); Population; Anthracycline; Cancer; Gynecology; Chemotherapy; Pathology; Cisplatin","score_opus":0.1880175702403382,"score_gpt":0.5514264082407141,"score_spread":0.36340883800037593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402233591","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02435466,0.1878269,0.05616241,0.50182134,0.01283925,0.028218755,0.014046698,0.0009500267,0.17378004],"genre_scores_gemma":[0.1208191,0.22555499,0.4548703,0.11659379,0.0041535785,0.016486207,0.027742488,0.00035034973,0.033429172],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98610455,0.004855051,0.0028589675,0.00045998997,0.0049488726,0.00077253464],"domain_scores_gemma":[0.96639764,0.005138591,0.0032806867,0.0004863044,0.022825722,0.0018710223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017709851,0.00092282007,0.0016323063,0.0031485255,0.0015030734,0.0025211305,0.004427014,0.0039545284,0.0022850132],"category_scores_gemma":[0.03604361,0.00065913703,0.0029244549,0.003195436,0.001222235,0.0016493921,0.0017885836,0.005460862,0.0013061434],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012306566,0.00031501835,0.005479197,0.007851401,0.00022168411,0.0005836278,0.001249075,0.0028509577,0.0016496371,0.0061362046,0.6763642,0.297176],"study_design_scores_gemma":[0.0006243247,0.00021041975,0.018716276,0.040750694,0.000813427,0.00080645207,0.00087193935,0.0033792064,0.0010954712,0.0059814155,0.92656124,0.00018915189],"about_ca_topic_score_codex":0.12700367,"about_ca_topic_score_gemma":0.28679878,"teacher_disagreement_score":0.985943,"about_ca_system_score_codex":0.014056984,"about_ca_system_score_gemma":0.06578337,"threshold_uncertainty_score":0.25252885},"labels":[],"label_agreement":null},{"id":"W2406500056","doi":"10.1158/1538-7445.sabcs15-pd5-04","title":"Abstract PD5-04: NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neratinib; Trastuzumab; Medicine; Pertuzumab; Internal medicine; Breast cancer; Regimen; Docetaxel; Oncology; Neoadjuvant therapy; Lapatinib; Metastatic breast cancer; Chemotherapy; Cancer","score_opus":0.050687440653441856,"score_gpt":0.424429407720223,"score_spread":0.3737419670667811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406500056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849294,0.0030857953,0.0005911035,0.0011651829,0.0004384986,0.0037509082,0.0022361635,0.00013380239,0.0036691655],"genre_scores_gemma":[0.9836927,0.0017308614,0.0017287934,0.0014310451,0.0002224689,0.0032601964,0.0029409295,0.00002063576,0.004972275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99954,0.0002715062,0.00002419537,0.00006659393,0.000041310443,0.000056381115],"domain_scores_gemma":[0.99944955,0.000107733664,0.00008107933,0.000026963975,0.00004021327,0.00029430466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016340892,0.0012837658,0.0014480134,0.00032108495,0.00032849688,0.0010015235,0.0008850313,0.0011126106,0.007778327],"category_scores_gemma":[0.0009424198,0.0004391117,0.0011923874,0.00028095866,0.0010454287,0.00077760493,0.00032669885,0.0035538292,0.0010405539],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9621599,0.008747699,0.0009838834,0.00045358078,0.0009469496,0.000038843154,0.00003853933,0.00062353455,0.0045083375,0.00017493153,0.0021050393,0.019218775],"study_design_scores_gemma":[0.9171866,0.07792758,0.0015900697,0.000029576137,0.00044475705,0.00004059427,0.000020967582,0.00074502715,0.0008162618,0.00013597423,0.0010495251,0.000012954715],"about_ca_topic_score_codex":0.0013398724,"about_ca_topic_score_gemma":0.0033393295,"teacher_disagreement_score":0.007778327,"about_ca_system_score_codex":0.0010857458,"about_ca_system_score_gemma":0.0014638402,"threshold_uncertainty_score":0.026021063},"labels":[],"label_agreement":null},{"id":"W2407897745","doi":"","title":"[Expression of human epidermal growth factor receptor 2 in mucinous carcinoma of breast].","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Mucinous carcinoma; Epidermal growth factor receptor; Breast carcinoma; Human Epidermal Growth Factor Receptor 2; Cancer research; Oncology; Epidermal growth factor; Carcinoma; Internal medicine; Receptor; Biology; Medicine; Breast cancer; Adenocarcinoma; Cancer","score_opus":0.09909011265428457,"score_gpt":0.3295671305210075,"score_spread":0.23047701786672292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407897745","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1405856,0.4556212,0.0050807907,0.075406805,0.09604704,0.0009557317,0.017240725,0.001294995,0.20776707],"genre_scores_gemma":[0.44415453,0.25745517,0.009901522,0.032045398,0.038024817,0.00064279477,0.027845588,0.00020087445,0.18972932],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99982613,0.000031478747,0.000033515917,0.00001903149,0.00005463348,0.00003531907],"domain_scores_gemma":[0.9997991,0.000073094336,0.000032510885,0.000014306707,0.000051701118,0.000029226654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034264883,0.0003607704,0.00036627325,0.0026094648,0.00046407318,0.0005716065,0.0009211431,0.0012334184,0.007933182],"category_scores_gemma":[0.0011654883,0.00020794338,0.00041397818,0.0011396854,0.00051285565,0.0007848701,0.00029870364,0.00056689756,0.0024809465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017371312,0.00017541791,0.010489537,0.0034873493,0.00019430496,0.058963798,0.00035849863,0.000530703,0.038014542,0.010931922,0.6991132,0.17600363],"study_design_scores_gemma":[0.00040295516,0.000648539,0.08459762,0.0009811694,0.00040137343,0.12512302,0.000563415,0.00088237884,0.018359695,0.005053732,0.7629021,0.00008405738],"about_ca_topic_score_codex":0.008611329,"about_ca_topic_score_gemma":0.012533827,"teacher_disagreement_score":0.008611329,"about_ca_system_score_codex":0.0005637895,"about_ca_system_score_gemma":0.0009255872,"threshold_uncertainty_score":0.026539087},"labels":[],"label_agreement":null},{"id":"W2408503479","doi":"10.1158/1538-7445.sabcs15-p4-14-01","title":"Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Capecitabine; Lapatinib; Trastuzumab emtansine; Medicine; Taxane; Trastuzumab; Interim analysis; Internal medicine; Metastatic breast cancer; Gastroenterology; Confidence interval; Hazard ratio; Breast cancer; Cancer; Oncology; Randomized controlled trial","score_opus":0.07246694683704773,"score_gpt":0.4110668480894483,"score_spread":0.3385999012524006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2408503479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853204,0.005658623,0.0005487724,0.0007861679,0.00021528351,0.0019505278,0.0023774747,0.0001040903,0.0030386373],"genre_scores_gemma":[0.98389316,0.0023688246,0.001576023,0.0017395187,0.0004129531,0.001796421,0.0051892237,0.000034825243,0.002989051],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993241,0.00041055883,0.000038973452,0.000084700936,0.000052573356,0.00008913772],"domain_scores_gemma":[0.9992424,0.00013450671,0.00021226345,0.00007641958,0.000051521514,0.00028278143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024169567,0.0011401995,0.0018003861,0.0003871268,0.0003326661,0.0009598571,0.0010826982,0.00093617797,0.0039244783],"category_scores_gemma":[0.0011129864,0.0004501656,0.0030553988,0.00037508822,0.00059076195,0.00069630134,0.00045738462,0.0030859883,0.0006856158],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8816577,0.021414494,0.007815301,0.0008997943,0.0046300394,0.00013235865,0.00010948417,0.002037568,0.015217021,0.0001603094,0.0055332095,0.06039267],"study_design_scores_gemma":[0.6764061,0.27542162,0.035985,0.00010586851,0.0031878806,0.00020665792,0.000051361272,0.0013773589,0.002936952,0.00016637324,0.004108342,0.000046613135],"about_ca_topic_score_codex":0.0005854389,"about_ca_topic_score_gemma":0.0027159397,"teacher_disagreement_score":0.0039244783,"about_ca_system_score_codex":0.00095920655,"about_ca_system_score_gemma":0.0012058027,"threshold_uncertainty_score":0.013128698},"labels":[],"label_agreement":null},{"id":"W2409578170","doi":"10.1038/modpathol.2008.131","title":"Letter to the Editor","year":2008,"lang":"en","type":"letter","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Pathology; Medicine; Medical physics","score_opus":0.054108918829823174,"score_gpt":0.3420044143705634,"score_spread":0.28789549554074023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409578170","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066200295,0.0025429847,0.00007448961,0.92575115,0.060126804,0.000013857246,0.000032730404,0.000029682386,0.010766254],"genre_scores_gemma":[0.007466057,0.0017525969,0.00015435985,0.91662675,0.046967123,0.000033091936,0.000023615616,0.000024209652,0.026952153],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983199,0.00053352775,0.000117875396,0.0002635882,0.00046949813,0.00029557722],"domain_scores_gemma":[0.9970673,0.0012676866,0.0001948961,0.00012598629,0.000769069,0.000575141],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019388158,0.00075056707,0.0013858969,0.00075526634,0.0030492623,0.0027539178,0.0015609842,0.031206816,0.009606966],"category_scores_gemma":[0.016833814,0.00057382113,0.0008369205,0.0004466884,0.0015824008,0.0020330807,0.001091215,0.021362847,0.006665571],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037028934,0.000017144512,0.00029400006,0.000027556907,0.000008824431,0.0032340547,0.000062618914,0.00003468698,0.000059459147,0.0012055662,0.99124265,0.0037764632],"study_design_scores_gemma":[0.000079318466,0.000048725684,0.0009462595,0.0002114066,0.000025885296,0.005539503,0.00031519623,0.00026468022,0.00019267743,0.004470246,0.9878671,0.00003903884],"about_ca_topic_score_codex":0.0023158311,"about_ca_topic_score_gemma":0.004032955,"teacher_disagreement_score":0.99039304,"about_ca_system_score_codex":0.0027760922,"about_ca_system_score_gemma":0.0028178096,"threshold_uncertainty_score":0.032138467},"labels":[],"label_agreement":null},{"id":"W2410015475","doi":"","title":"AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate cancer models","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Pancreatic cancer; In vivo; Cancer research; Monoclonal antibody; Cancer; Cytotoxicity; Antibody; Signal transduction; Prostate cancer; Colorectal cancer; Biology; In vitro; Immunology; Medicine; Internal medicine; Cell biology; Biochemistry","score_opus":0.041043055824262084,"score_gpt":0.36784482769629,"score_spread":0.3268017718720279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410015475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784494,0.0058476655,0.009142565,0.0002257814,0.00011643631,0.00010284929,0.000746619,0.000488427,0.004880268],"genre_scores_gemma":[0.98041874,0.00317645,0.0072739595,0.00008005568,0.000031189582,0.000111075096,0.0018639965,0.000056121437,0.006988254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998103,0.000031781274,0.000012889186,0.000039771217,0.00006199484,0.000043341865],"domain_scores_gemma":[0.9998869,0.000018086166,0.00003642742,0.000016292033,0.000020608144,0.000021686103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029775483,0.0005215739,0.00036365076,0.00046699628,0.000120254525,0.00019867404,0.00027658715,0.00035178184,0.001644307],"category_scores_gemma":[0.00010382758,0.00018145409,0.0003442611,0.00020251506,0.00016127738,0.0001833138,0.00010969587,0.0006925542,0.0004791513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020447858,0.00014110064,0.00011331594,0.000059779344,0.000010553332,0.000032977605,0.000008882796,0.00006970136,0.99691427,0.000038685295,0.00013759184,0.0022685993],"study_design_scores_gemma":[0.000042980333,0.001908856,0.0017891941,0.000004866449,0.000035392677,0.0004011229,0.0000069206503,0.00061064336,0.99287087,0.0000121023895,0.0023131566,0.0000038532376],"about_ca_topic_score_codex":0.00077096844,"about_ca_topic_score_gemma":0.0008822532,"teacher_disagreement_score":0.001644307,"about_ca_system_score_codex":0.00023072617,"about_ca_system_score_gemma":0.00022866054,"threshold_uncertainty_score":0.0055007935},"labels":[],"label_agreement":null},{"id":"W2414802120","doi":"10.1038/sj.gt.3301712","title":"Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth","year":2002,"lang":"en","type":"article","venue":"Gene Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Breast Cancer Society of Canada","keywords":"Immune system; Cancer research; Biology; ErbB; Receptor; Immunology","score_opus":0.07684677624089369,"score_gpt":0.3485078335019935,"score_spread":0.2716610572610998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414802120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985261,0.0035996768,0.004573546,0.00038449754,0.00033954027,0.00008769093,0.000427746,0.0003260019,0.0050002905],"genre_scores_gemma":[0.9899018,0.0014742938,0.0021723965,0.000055008848,0.0000461577,0.000051632236,0.00056415267,0.000038383987,0.005696243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997522,0.000032876076,0.000012318704,0.000037830898,0.000045511777,0.00011920964],"domain_scores_gemma":[0.99978834,0.00008449376,0.000025790825,0.000039019636,0.000013514734,0.000048969698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035112564,0.0008048606,0.00064715336,0.0007573843,0.00035146842,0.00054756383,0.00044837242,0.0006215077,0.0015937763],"category_scores_gemma":[0.00019969333,0.00030113984,0.00045814714,0.00050387776,0.0005966884,0.00049239094,0.00018524783,0.0013540128,0.00049640465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012949674,0.0006829545,0.0001935872,0.000059848935,0.000022824388,0.00008158923,0.000032798078,0.00039616853,0.99145496,0.0005837148,0.00034486962,0.0048517883],"study_design_scores_gemma":[0.00017384271,0.0018654185,0.0008694793,0.000005222555,0.000039477352,0.00019018305,0.000028413002,0.0022911357,0.9927523,0.00008527303,0.001692522,0.0000066570274],"about_ca_topic_score_codex":0.003711034,"about_ca_topic_score_gemma":0.0037694585,"teacher_disagreement_score":0.003711034,"about_ca_system_score_codex":0.00080320827,"about_ca_system_score_gemma":0.0008348882,"threshold_uncertainty_score":0.007378876},"labels":[],"label_agreement":null},{"id":"W2418561090","doi":"10.1186/s12885-016-2385-z","title":"HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer","year":2016,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Pertuzumab; Anthracycline; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Vinorelbine; Cardiotoxicity; Chemotherapy; Cancer","score_opus":0.02509831432039076,"score_gpt":0.3684742946253877,"score_spread":0.34337598030499694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418561090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97372776,0.0026114264,0.00081271713,0.0013938423,0.0011454166,0.013505513,0.0016834518,0.00018148289,0.0049383845],"genre_scores_gemma":[0.95616615,0.001954147,0.0031443594,0.0036633285,0.001167206,0.019476157,0.0030188009,0.000044529417,0.011365418],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99930286,0.0003503845,0.000030673833,0.00015099657,0.000041831663,0.00012326367],"domain_scores_gemma":[0.99913055,0.00018176186,0.00020989188,0.00006856524,0.000044379078,0.00036479707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027700013,0.0027613805,0.0021784303,0.000578584,0.00040943004,0.0012873864,0.0014382203,0.0022230663,0.00832349],"category_scores_gemma":[0.0019753962,0.00095447566,0.0018546105,0.00036783158,0.0017622624,0.0016299154,0.0005875197,0.003408594,0.001271551],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9689288,0.013980043,0.0007386286,0.00046134298,0.00043471687,0.00008206229,0.000080973,0.00060365367,0.0041459124,0.0003368633,0.0014153728,0.0087914225],"study_design_scores_gemma":[0.9216459,0.075261354,0.0009737008,0.00002725307,0.0001724158,0.000036101217,0.000022267823,0.00030944098,0.00036600378,0.00018161151,0.0009893334,0.000014641149],"about_ca_topic_score_codex":0.00067933544,"about_ca_topic_score_gemma":0.0016587757,"teacher_disagreement_score":0.00832349,"about_ca_system_score_codex":0.0011245463,"about_ca_system_score_gemma":0.001662625,"threshold_uncertainty_score":0.027844846},"labels":[],"label_agreement":null},{"id":"W2435490795","doi":"10.1200/jco.2014.32.15_suppl.2530","title":"A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Nausea; Gastroenterology; Cancer; Vomiting; Paclitaxel; Oncology; Discontinuation; Pharmacology","score_opus":0.11987352055479122,"score_gpt":0.4955037543018407,"score_spread":0.37563023374704946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2435490795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797078,0.0042705727,0.0011052062,0.00089410564,0.00024931965,0.0072629233,0.0022499133,0.00023000097,0.0040301136],"genre_scores_gemma":[0.97465724,0.004331646,0.003365406,0.0015756532,0.0002693217,0.005664432,0.00528836,0.0000676953,0.0047802427],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958485,0.00015426484,0.000025863254,0.00008646032,0.000059045335,0.00008952618],"domain_scores_gemma":[0.99948585,0.00005516137,0.00011363013,0.000037582435,0.000044372722,0.00026344042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012156159,0.0016876446,0.00252885,0.0007510297,0.00046313193,0.0009871883,0.0009229625,0.0014370586,0.0049030087],"category_scores_gemma":[0.0006236656,0.00082651083,0.0010955203,0.0007371619,0.00080097374,0.0007034185,0.0003973114,0.0034628755,0.0014927399],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54534924,0.14897867,0.0081153475,0.0016737244,0.0015177646,0.00056767854,0.00037889407,0.0031099992,0.11677743,0.0004385122,0.009118268,0.16397452],"study_design_scores_gemma":[0.49655914,0.47904673,0.010561908,0.000052106083,0.00043851638,0.00039766173,0.000047224283,0.0011195613,0.006655355,0.00017658084,0.004917616,0.000027605745],"about_ca_topic_score_codex":0.0014717333,"about_ca_topic_score_gemma":0.0027643982,"teacher_disagreement_score":0.0049030087,"about_ca_system_score_codex":0.0010309853,"about_ca_system_score_gemma":0.0021127246,"threshold_uncertainty_score":0.016402245},"labels":[],"label_agreement":null},{"id":"W2442066587","doi":"10.1016/j.clbc.2016.06.004","title":"Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer","year":2016,"lang":"en","type":"review","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Breast cancer; Hormone; Blockade; Internal medicine; Oncology; Cancer; Hormone receptor; Gynecology; Endocrinology; Receptor","score_opus":0.07345930812789521,"score_gpt":0.42714991484241327,"score_spread":0.3536906067145181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2442066587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048598365,0.99872714,0.00004447146,0.00015665499,0.000082034196,0.0000051226207,0.000032458567,0.0000026514467,0.00046343796],"genre_scores_gemma":[0.0050470745,0.99390715,0.00015169442,0.0003963054,0.00011164868,0.000008776172,0.000068499336,0.0000016763345,0.00030725313],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9998653,0.000035889057,0.000026616106,0.000026126432,0.00003312744,0.000013005098],"domain_scores_gemma":[0.99972945,0.0001918769,0.000038324033,0.0000044262706,0.000025178184,0.0000106518655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052149734,0.00047514247,0.0018787588,0.000668994,0.00007135822,0.00055896456,0.00051042694,0.00043515305,0.0036150855],"category_scores_gemma":[0.0007946902,0.00013720436,0.0008533522,0.00069687323,0.0001632608,0.00047516034,0.00026507408,0.0011011484,0.0005217213],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011855352,0.000082508945,0.00044606425,0.04995608,0.0013079011,0.00013706536,0.00003412331,0.00026029095,0.0022720082,0.0012365518,0.01435353,0.92872834],"study_design_scores_gemma":[0.0023334909,0.0018412374,0.010993179,0.033883244,0.0084363585,0.0029172169,0.00020630007,0.00028312937,0.002363897,0.003136386,0.9335336,0.00007197624],"about_ca_topic_score_codex":0.0004050892,"about_ca_topic_score_gemma":0.0016203091,"teacher_disagreement_score":0.0036150855,"about_ca_system_score_codex":0.00028317972,"about_ca_system_score_gemma":0.0003673909,"threshold_uncertainty_score":0.012093663},"labels":[],"label_agreement":null},{"id":"W2463246825","doi":"10.1159/000394715","title":"The Differentiation and Organization of Tumors in vitro","year":2015,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"In vitro; Biology; Cell biology; Genetics","score_opus":0.04487894248190542,"score_gpt":0.3180234379174945,"score_spread":0.27314449543558905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463246825","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016494079,0.094385736,0.13693444,0.003061166,0.0024694656,0.00019357831,0.0014818812,0.00072690804,0.7442527],"genre_scores_gemma":[0.0647583,0.09052769,0.06744805,0.0015598027,0.0003899153,0.00022683128,0.0017290463,0.0007580833,0.77260226],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999887,0.000016890284,0.000006938174,0.000020318545,0.000051314004,0.000017481985],"domain_scores_gemma":[0.99992204,0.000035972953,0.000005362207,0.000015342166,0.000012234141,0.000008941909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028311464,0.00045105434,0.00027830226,0.0005704875,0.0003784611,0.0014581416,0.00053709815,0.0004660782,0.0054386198],"category_scores_gemma":[0.0002026381,0.00041788802,0.0004604683,0.00047340896,0.00070463127,0.0010620245,0.00081348093,0.0018224492,0.0060697473],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006979767,0.00008716543,0.0001986014,0.0008506979,0.000014618115,0.00042745253,0.0013414453,0.0033916319,0.32739142,0.28657386,0.04873997,0.3309134],"study_design_scores_gemma":[0.000004299527,0.000038398935,0.0004563382,0.00014874578,0.000008157605,0.0005319877,0.00013471436,0.0006721639,0.08512442,0.024382329,0.88848305,0.000015379324],"about_ca_topic_score_codex":0.001357267,"about_ca_topic_score_gemma":0.0025840756,"teacher_disagreement_score":0.0054386198,"about_ca_system_score_codex":0.0009677099,"about_ca_system_score_gemma":0.0005083968,"threshold_uncertainty_score":0.01819402},"labels":[],"label_agreement":null},{"id":"W2465741927","doi":"","title":"[Her-2/neu analysis--new data?].","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CISH; Lapatinib; Pertuzumab; Trastuzumab; Breast cancer; Medicine; Internal medicine; Oncology; Cancer; Fish <Actinopterygii>; Immunohistochemistry; Antibody; Biology; Immunology; Gene; Messenger RNA","score_opus":0.137500939092921,"score_gpt":0.366092862524219,"score_spread":0.22859192343129803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465741927","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005904582,0.2876266,0.012986168,0.059635065,0.04591751,0.0017085205,0.321776,0.005590311,0.2588553],"genre_scores_gemma":[0.0353852,0.25862178,0.03433106,0.06994842,0.016106116,0.0026451966,0.38073003,0.0023866952,0.1998455],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980787,0.0004059831,0.00040017447,0.00025118672,0.0007266409,0.00013741902],"domain_scores_gemma":[0.9944312,0.0010751799,0.00094326626,0.00070095056,0.0023307668,0.0005186429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031986192,0.00065880193,0.0010341204,0.004402175,0.00034098024,0.0029458406,0.0015124759,0.0014708107,0.09083843],"category_scores_gemma":[0.008253772,0.0003677576,0.0010148735,0.00470814,0.00042961165,0.0022319474,0.0015879014,0.0022296084,0.067157514],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036093092,0.000049841274,0.0024202194,0.0035187046,0.00013206038,0.0002474349,0.00004005489,0.00009208913,0.00086531404,0.002307581,0.64893425,0.34103155],"study_design_scores_gemma":[0.000039579125,0.000039093513,0.0021449146,0.001326305,0.00004397733,0.00044360117,0.000025736925,0.000062606996,0.00026182554,0.00088766863,0.9947109,0.00001363373],"about_ca_topic_score_codex":0.0019794558,"about_ca_topic_score_gemma":0.0027662972,"teacher_disagreement_score":0.09083843,"about_ca_system_score_codex":0.0007446532,"about_ca_system_score_gemma":0.0018991793,"threshold_uncertainty_score":0.3038848},"labels":[],"label_agreement":null},{"id":"W2468868288","doi":"10.1007/s10555-016-9631-3","title":"Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review","year":2016,"lang":"en","type":"review","venue":"Cancer and Metastasis Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Metastasis; Oncology; Metastatic breast cancer; Progesterone receptor; Estrogen receptor; Estrogen; Internal medicine; Breast cancer; Cancer","score_opus":0.14047034859132446,"score_gpt":0.44881871120596106,"score_spread":0.3083483626146366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468868288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049085127,0.99972516,0.000011455864,0.00006313129,0.00005012834,0.0000018915188,0.000015240053,7.6391547e-7,0.000083171886],"genre_scores_gemma":[0.0003781133,0.9993438,0.000040138057,0.00010333372,0.000062200845,0.0000023823154,0.000018545788,3.8679917e-7,0.000050990588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995914,0.000075817225,0.00012221042,0.00007638388,0.00011000738,0.000024102466],"domain_scores_gemma":[0.9987047,0.0008798491,0.00022150045,0.000017106167,0.00014601214,0.000030932933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009697691,0.0007621,0.0025853748,0.0036770864,0.00021210972,0.0011417983,0.00090233353,0.00093462324,0.0031406689],"category_scores_gemma":[0.0027089177,0.00042702345,0.0009869613,0.003827664,0.0004889379,0.0012107989,0.00071675336,0.0009628706,0.0005130669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027121822,0.000043034754,0.000710951,0.16634595,0.0008942907,0.00034842116,0.00013214326,0.00024079115,0.0009927645,0.0014500454,0.029247178,0.79932326],"study_design_scores_gemma":[0.0001387482,0.00024781053,0.0053014206,0.09763004,0.0056633507,0.0041932687,0.00042921628,0.00012085318,0.0004985061,0.0017744972,0.88392544,0.000076915574],"about_ca_topic_score_codex":0.0025574847,"about_ca_topic_score_gemma":0.0057890494,"teacher_disagreement_score":0.0036770864,"about_ca_system_score_codex":0.0007036505,"about_ca_system_score_gemma":0.0018282831,"threshold_uncertainty_score":0.01050657},"labels":[],"label_agreement":null},{"id":"W2469000447","doi":"10.1093/jnci/djw111","title":"RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer","year":2016,"lang":"en","type":"letter","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Science Foundation Ireland; Irish Cancer Society; Health Research Board; GlaxoSmithKline","keywords":"Trastuzumab; Human Epidermal Growth Factor Receptor 2; Breast cancer; Oncology; Biomarker; Epidermal growth factor receptor; Medicine; Pathological; Cancer research; Internal medicine; Cancer; Neoadjuvant therapy; Biology","score_opus":0.12292834570016804,"score_gpt":0.41298595279302047,"score_spread":0.29005760709285244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469000447","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044523653,0.005644203,0.0019271636,0.8699005,0.04613115,0.0001182109,0.00051699806,0.00039070178,0.030847352],"genre_scores_gemma":[0.3182273,0.004578943,0.003964692,0.55382085,0.0663276,0.00020418325,0.0005503114,0.00018083544,0.05214529],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99903417,0.00028642802,0.00016876966,0.00011336722,0.00027313438,0.00012423459],"domain_scores_gemma":[0.9974299,0.0013528443,0.0001936685,0.00011688937,0.00059179484,0.0003149344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010061522,0.00048098722,0.00060235785,0.00056582066,0.0007001568,0.0011401984,0.0007418267,0.008021675,0.0022429724],"category_scores_gemma":[0.010257515,0.00028693175,0.00036991324,0.00033562278,0.00073701545,0.0006838093,0.00027027758,0.0058662617,0.003084003],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012925402,0.00029686635,0.03676892,0.00021483228,0.00008361586,0.064882495,0.0004609283,0.0004285057,0.015389082,0.0026760227,0.7831946,0.09431164],"study_design_scores_gemma":[0.00051522447,0.0016995381,0.049238104,0.00069802994,0.00034098973,0.1564332,0.0014239688,0.008561513,0.0314949,0.009474653,0.7399325,0.00018740393],"about_ca_topic_score_codex":0.0011376721,"about_ca_topic_score_gemma":0.0020471078,"teacher_disagreement_score":0.008021675,"about_ca_system_score_codex":0.0014504084,"about_ca_system_score_gemma":0.0007682132,"threshold_uncertainty_score":0.010523498},"labels":[],"label_agreement":null},{"id":"W2482099568","doi":"10.3390/ijms17081200","title":"Non-Ligand-Induced Dimerization is Sufficient to Initiate the Signalling and Endocytosis of EGF Receptor","year":2016,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Endocytosis; Cell biology; ERBB3; Autophosphorylation; Epidermal growth factor; Proto-oncogene tyrosine-protein kinase Src; Internalization; Epidermal growth factor receptor; Endosome; Receptor tyrosine kinase; Tyrosine kinase; Protein kinase B; Chemistry; Phosphorylation; Biology; Endocytic cycle; Signal transduction; Receptor; Biochemistry; Intracellular; Protein kinase A","score_opus":0.051410785751539546,"score_gpt":0.37464456138699725,"score_spread":0.3232337756354577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2482099568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99359834,0.0013282228,0.0028632798,0.000087257795,0.00002614418,0.000028439928,0.00013944393,0.000038605664,0.0018903062],"genre_scores_gemma":[0.9961469,0.0003198379,0.00095598714,0.000045192486,0.000007396026,0.000014906568,0.00039190627,0.000007753467,0.0021100186],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997521,0.00008069697,0.000015827969,0.000040347888,0.00006445588,0.000046502533],"domain_scores_gemma":[0.99989915,0.000017352124,0.000021677686,0.000013660293,0.000011739018,0.000036465543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018180998,0.00017268713,0.00017020234,0.000077674355,0.00013173299,0.00018334892,0.00013069488,0.00020337306,0.0017397443],"category_scores_gemma":[0.00014534485,0.000087751,0.00015503632,0.00007295709,0.00012208993,0.00017420083,0.00017387855,0.0004160086,0.00045320322],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004668913,0.000034468452,0.0001386379,0.00001983972,0.000002768703,0.00003822357,0.0000060005364,0.000030116635,0.998882,0.000111485606,0.00003949319,0.00065037725],"study_design_scores_gemma":[0.000023328254,0.00022114727,0.005868964,0.0000054105362,0.000008677941,0.00072022417,0.000028476401,0.0017517154,0.98694974,0.00009218895,0.004325502,0.000004596406],"about_ca_topic_score_codex":0.00017925994,"about_ca_topic_score_gemma":0.00029619734,"teacher_disagreement_score":0.0017397443,"about_ca_system_score_codex":0.00019702659,"about_ca_system_score_gemma":0.00017916305,"threshold_uncertainty_score":0.005820036},"labels":[],"label_agreement":null},{"id":"W2491668168","doi":"10.1158/1538-7445.am2016-3940","title":"Abstract 3940: Baseline molecular markers and risk of distant relapse in the NeoSphere study","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Internal medicine; Oncology; Breast cancer; Trastuzumab; Cancer; CD8; Immune system; Immunology","score_opus":0.06699181598170728,"score_gpt":0.44153113491877855,"score_spread":0.37453931893707126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2491668168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998063,0.00027800698,0.00010431895,0.0000654145,0.000007303018,0.000019452587,0.0010937215,0.000003456386,0.00036542228],"genre_scores_gemma":[0.9968194,0.000103523875,0.00011010594,0.000104296916,0.000022200209,0.000033445285,0.0022336699,0.0000039346496,0.00056948746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997352,0.000108921464,0.000015534717,0.00007180194,0.000040428822,0.000028145569],"domain_scores_gemma":[0.9994,0.00012670616,0.000198373,0.0000847014,0.00003755259,0.00015265093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006669807,0.00023177368,0.00041240596,0.00011526747,0.00012441361,0.0003185102,0.0002449289,0.00029913883,0.0019906692],"category_scores_gemma":[0.00078960444,0.0001494252,0.000440091,0.00025159665,0.00015864757,0.00026286012,0.00031298772,0.00044737326,0.00019739363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054355808,0.00047733984,0.9265088,0.00012338394,0.0012455349,0.00016996873,0.00005677759,0.00062970264,0.0055959346,0.00011295158,0.0011288859,0.009594936],"study_design_scores_gemma":[0.0028243642,0.005182383,0.9870936,0.000019060566,0.0006645062,0.00022653652,0.00004516124,0.00077387947,0.0011202149,0.00022642378,0.0018106787,0.000013097588],"about_ca_topic_score_codex":0.00056151673,"about_ca_topic_score_gemma":0.0011685648,"teacher_disagreement_score":0.0019906692,"about_ca_system_score_codex":0.00020208878,"about_ca_system_score_gemma":0.00021321338,"threshold_uncertainty_score":0.006659448},"labels":[],"label_agreement":null},{"id":"W2501964380","doi":"10.1007/978-1-907673-94-8","title":"Handbook of HER2-targeted agents in breast cancer","year":2013,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Cancer; Medicine; Oncology; Quarter (Canadian coin); Internal medicine; History","score_opus":0.057967900286424255,"score_gpt":0.3935470452836446,"score_spread":0.33557914499722036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501964380","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008979722,0.98317486,0.0019334866,0.0020318425,0.0040455675,0.000020400636,0.00009268587,0.00008177065,0.008529597],"genre_scores_gemma":[0.0010675984,0.96741796,0.0026857716,0.0025629755,0.0052584657,0.00005011006,0.00013648267,0.000030433139,0.020790087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935836,0.00010424615,0.000083351755,0.000059816273,0.00035579986,0.000038333965],"domain_scores_gemma":[0.998686,0.00067040056,0.00014362475,0.00007572255,0.0003082856,0.000116021285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013990619,0.0013665525,0.0014758453,0.0042544194,0.00033244354,0.001308359,0.0018003182,0.002200312,0.011059475],"category_scores_gemma":[0.0018117228,0.00069242064,0.000798993,0.0042501874,0.0007935339,0.0022710608,0.0008523181,0.0038268133,0.008801636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009129872,0.00010401008,0.00011207284,0.0038548403,0.00004208347,0.00013361682,0.000057730722,0.0007293788,0.0022026454,0.0038719212,0.37304968,0.61575073],"study_design_scores_gemma":[0.0000106424,0.00005211431,0.00018614272,0.0004401628,0.000014619814,0.0005155702,0.0000097777765,0.000106695705,0.00023173768,0.00090966927,0.9975141,0.000008851059],"about_ca_topic_score_codex":0.0019375889,"about_ca_topic_score_gemma":0.0058229263,"teacher_disagreement_score":0.011059475,"about_ca_system_score_codex":0.000982921,"about_ca_system_score_gemma":0.0014998463,"threshold_uncertainty_score":0.036997616},"labels":[],"label_agreement":null},{"id":"W2511312089","doi":"10.1093/ajcp/aqw117","title":"Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer","year":2016,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Fluorescence in situ hybridization; Human Epidermal Growth Factor Receptor 2; Fish <Actinopterygii>; Breast cancer; Biology; Cohort; In situ hybridization; Copy-number variation; Pathology; Cancer; Oncology; Medicine; Internal medicine; Chromosome; Genetics; Gene; Fishery; Gene expression","score_opus":0.08438104769738537,"score_gpt":0.507046366395642,"score_spread":0.4226653186982567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511312089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783796,0.004015545,0.015236283,0.00010690771,0.00005572575,0.00007725754,0.00018030436,0.00009872724,0.0018495759],"genre_scores_gemma":[0.9869431,0.0007358996,0.011097398,0.00006324656,0.00002226486,0.00006678709,0.00034101607,0.000027700715,0.00070254557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944706,0.0025461658,0.00037530705,0.001156749,0.0011695223,0.00028169525],"domain_scores_gemma":[0.9949649,0.0024302593,0.000780991,0.00044073653,0.0012153538,0.00016759241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008075093,0.00050302263,0.00035669253,0.0021491293,0.0001789348,0.0005716948,0.00058489176,0.0006576944,0.00097147987],"category_scores_gemma":[0.0100962985,0.0003697792,0.00037784228,0.0006560048,0.0005477763,0.0005304243,0.00092532975,0.00030611875,0.00035311445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004398752,0.00012768531,0.65199625,0.0007334778,0.00079793396,0.0004743674,0.0009002314,0.0021659988,0.26934606,0.00039534835,0.0004492717,0.06821469],"study_design_scores_gemma":[0.00013601691,0.0014719908,0.8601813,0.0001218942,0.00052262784,0.005792316,0.00068262045,0.014868708,0.11282785,0.0005263703,0.0027950557,0.00007327451],"about_ca_topic_score_codex":0.0010884011,"about_ca_topic_score_gemma":0.0019597393,"teacher_disagreement_score":0.008075093,"about_ca_system_score_codex":0.00058683445,"about_ca_system_score_gemma":0.00025194086,"threshold_uncertainty_score":0.042705655},"labels":[],"label_agreement":null},{"id":"W2511927825","doi":"10.1038/srep32259","title":"A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"First Quantum Minerals (Canada)","funders":"National Institute of Dental and Craniofacial Research; Japan Science and Technology Agency; National Institutes of Health; Astellas Foundation for Research on Metabolic Disorders; Ministry of Education, Culture, Sports, Science and Technology; Japan Society for the Promotion of Science; Astellas Pharma","keywords":"Disintegrin; Metalloproteinase; Cancer research; Interferon gamma; Osteolysis; Cytokine; Cancer cell; Immune system; Cell culture; Interferon; Cancer; Chemistry; Biology; Immunology; Matrix metalloproteinase; Medicine; Biochemistry","score_opus":0.037022784823903636,"score_gpt":0.32472471828609584,"score_spread":0.2877019334621922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511927825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94745284,0.030207923,0.016318765,0.00041692154,0.00022745726,0.00015082187,0.0010067514,0.00023093149,0.0039874967],"genre_scores_gemma":[0.9753645,0.01297123,0.005770582,0.00014024954,0.000056380995,0.00009638833,0.00079412345,0.000018955025,0.004787531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998042,0.00003884138,0.00003403719,0.000031948523,0.00004442971,0.000046530156],"domain_scores_gemma":[0.99986184,0.00001847041,0.000058238544,0.000016199532,0.000020404326,0.000024796078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029100056,0.00056924013,0.00036799524,0.00031160738,0.00019337922,0.00040835558,0.00016052577,0.00025211988,0.0010579126],"category_scores_gemma":[0.00021125113,0.00016262503,0.0005710726,0.00019961491,0.0002970109,0.00023188574,0.00027966945,0.00054832926,0.00044411444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031082085,0.00004837446,0.0019895977,0.0002459154,0.000038788727,0.00043236784,0.000040934065,0.00014539692,0.98487604,0.00031478176,0.00020758179,0.011349406],"study_design_scores_gemma":[0.000063848194,0.0006674921,0.011120616,0.000046262358,0.000090011374,0.0027680977,0.00009899033,0.0011569816,0.9649476,0.0003569776,0.018672122,0.000011035436],"about_ca_topic_score_codex":0.00027459968,"about_ca_topic_score_gemma":0.0002823825,"teacher_disagreement_score":0.0010579126,"about_ca_system_score_codex":0.00021352016,"about_ca_system_score_gemma":0.00026323355,"threshold_uncertainty_score":0.0035390854},"labels":[],"label_agreement":null},{"id":"W2512472999","doi":"10.1371/journal.pone.0161219","title":"HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis","year":2016,"lang":"en","type":"review","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Meta-analysis; Medicine; Pathology; Internal medicine","score_opus":0.41513450105349264,"score_gpt":0.46032270942430625,"score_spread":0.04518820837081361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512472999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012117181,0.9853756,0.00077363546,0.00034778123,0.00016565634,0.00014061136,0.000724376,0.000028075858,0.00032704163],"genre_scores_gemma":[0.46245518,0.53026164,0.0025172548,0.001241443,0.00041956562,0.0008792909,0.0015528483,0.00006592242,0.0006067827],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99148434,0.004020272,0.0022274072,0.0010199117,0.0009009483,0.00034706786],"domain_scores_gemma":[0.9813169,0.014105474,0.002145674,0.00085228804,0.0012973639,0.0002823031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013892903,0.0024181816,0.01336335,0.005664193,0.000845813,0.0029785,0.0019468359,0.0019956802,0.0032073443],"category_scores_gemma":[0.023345279,0.0012313542,0.046182144,0.008319094,0.00064001925,0.00160475,0.0014455878,0.001701035,0.0002967406],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021068477,0.000023824015,0.025262091,0.1425754,0.81998277,0.0002448011,0.00008960753,0.0008493298,0.00034345983,0.0001097463,0.00067587855,0.007736312],"study_design_scores_gemma":[0.0002192313,0.00011128457,0.008034745,0.007028232,0.98312324,0.00011143261,0.000037102975,0.00024998066,0.000084071566,0.0001340308,0.00084901176,0.000017651202],"about_ca_topic_score_codex":0.007125712,"about_ca_topic_score_gemma":0.014985454,"teacher_disagreement_score":0.013892903,"about_ca_system_score_codex":0.0017924852,"about_ca_system_score_gemma":0.00260672,"threshold_uncertainty_score":0.07347357},"labels":[],"label_agreement":null},{"id":"W2513036042","doi":"10.21873/anticanres.11017","title":"Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer","year":2016,"lang":"en","type":"article","venue":"Anticancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Fondation du cancer du sein du Québec; Université Laval","keywords":"Concordance; Tissue microarray; Breast cancer; Fluorescence in situ hybridization; Gene duplication; Oncology; Pathology; Cancer; Microarray; Medicine; Biopsy; Internal medicine; Biology; Gene; Gene expression; Genetics","score_opus":0.23726570701125313,"score_gpt":0.5396638585272922,"score_spread":0.302398151516039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513036042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81106836,0.009698736,0.16765384,0.00069224945,0.00015235183,0.0003417823,0.0020653766,0.0011640657,0.0071632178],"genre_scores_gemma":[0.8767036,0.0032038095,0.11353264,0.00022520577,0.00007485445,0.00043935576,0.0017139642,0.000105396015,0.004001166],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985495,0.00046287567,0.00012786618,0.00024454092,0.00055247545,0.000062716215],"domain_scores_gemma":[0.9986743,0.0004935591,0.00024612885,0.00019757912,0.0003408175,0.000047707523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017660462,0.00043685257,0.00038352972,0.0014794258,0.00031851596,0.00045024735,0.00031489844,0.00043071472,0.0019174232],"category_scores_gemma":[0.0019799268,0.00030506725,0.00018855729,0.00063827983,0.00032603674,0.00051667274,0.0003416113,0.0003437241,0.0011438418],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017901129,0.00003184185,0.03249827,0.00011318118,0.000033548247,0.0001317602,0.000053959713,0.0002202101,0.9495132,0.000107374355,0.00026766042,0.016849993],"study_design_scores_gemma":[0.000027098755,0.0009845943,0.29666784,0.00004964309,0.00015146764,0.005630766,0.00027148108,0.005719126,0.67665124,0.0003664984,0.013437866,0.000042360265],"about_ca_topic_score_codex":0.0004306392,"about_ca_topic_score_gemma":0.0007833141,"teacher_disagreement_score":0.0019174232,"about_ca_system_score_codex":0.00023850259,"about_ca_system_score_gemma":0.00021811391,"threshold_uncertainty_score":0.009339809},"labels":[],"label_agreement":null},{"id":"W2513447495","doi":"10.1038/modpathol.2016.151","title":"Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort","year":2016,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services; Alberta Health Services","funders":"Breast Cancer Society of Canada; Calgary Laboratory Services","keywords":"Concordance; Progesterone receptor; Breast cancer; Immunohistochemistry; Medicine; Oncology; Tamoxifen; Pathology; Internal medicine; Cohort; Estrogen receptor; Cancer; Companion diagnostic; Lymph node; Gynecology","score_opus":0.11420820221566332,"score_gpt":0.381436496236264,"score_spread":0.2672282940206007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513447495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979499,0.00041896736,0.0005641646,0.000066844856,0.000016722932,0.000026544403,0.0003393011,0.000020850224,0.00059675606],"genre_scores_gemma":[0.9983228,0.00012585474,0.00057453715,0.0000403,0.000017147227,0.000021859327,0.00053710415,0.00001554188,0.00034492783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705076,0.0006452233,0.00020171268,0.0008438319,0.00095323916,0.00030524618],"domain_scores_gemma":[0.9961605,0.0010977988,0.00065631815,0.0006965162,0.0010274069,0.00036136954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031830554,0.0006177889,0.0006594889,0.0016377011,0.000621407,0.0014339774,0.0007805389,0.0007478352,0.0008844757],"category_scores_gemma":[0.0069347424,0.000498486,0.0007396854,0.00090429076,0.000542821,0.00052452483,0.00082215597,0.00061304757,0.00046714497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00126121,0.00011017798,0.97992194,0.000020778632,0.00019761294,0.0001834342,0.00032731603,0.000105766616,0.0098004425,0.00006477307,0.00019491045,0.007811593],"study_design_scores_gemma":[0.000051708776,0.0007716943,0.9904062,0.000009353909,0.00028775755,0.00090056146,0.00037363687,0.00081522437,0.00529252,0.000058567406,0.0010165175,0.00001620829],"about_ca_topic_score_codex":0.005258131,"about_ca_topic_score_gemma":0.006356435,"teacher_disagreement_score":0.005258131,"about_ca_system_score_codex":0.0008157304,"about_ca_system_score_gemma":0.0007333757,"threshold_uncertainty_score":0.016833782},"labels":[],"label_agreement":null},{"id":"W2517870508","doi":"10.1200/jco.2010.28.15_suppl.1095","title":"Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Antibody-drug conjugate; Breast cancer; Oncology; Correlation; Conjugate; Drug; Internal medicine; Cancer; Antibody; Monoclonal antibody; Immunology; Pharmacology","score_opus":0.08273252036991065,"score_gpt":0.494299588317368,"score_spread":0.41156706794745734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517870508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813384,0.00056791614,0.000044652796,0.000082881656,0.00001212852,0.0000051057796,0.00013858639,0.0000035108376,0.0010114448],"genre_scores_gemma":[0.9992507,0.00011043567,0.000021728723,0.00002954686,0.000010607947,0.0000045499505,0.00023294614,8.7170304e-7,0.0003385231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999058,0.000027616506,0.0000073580445,0.000017415437,0.000014996317,0.000026737524],"domain_scores_gemma":[0.99959916,0.00012537911,0.000108520544,0.000016168766,0.00003076708,0.00012004342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024023229,0.000085693915,0.00018273511,0.0001648047,0.00014726233,0.0002685796,0.00012038796,0.00028586385,0.0014445626],"category_scores_gemma":[0.000785432,0.00007009025,0.00016102307,0.00020387804,0.00015507046,0.00019873372,0.00013162651,0.00045338727,0.00021343897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0101195015,0.000327026,0.9652465,0.000030212545,0.00013418333,0.00034476593,0.00008088304,0.00047235927,0.0034097747,0.000076712284,0.000844656,0.018913409],"study_design_scores_gemma":[0.00010966711,0.0019001138,0.99526584,0.000008317251,0.00010300209,0.0005411731,0.00005741388,0.0007255162,0.00052890857,0.000088524306,0.0006650343,0.000006623904],"about_ca_topic_score_codex":0.0013456425,"about_ca_topic_score_gemma":0.0019083114,"teacher_disagreement_score":0.0014445626,"about_ca_system_score_codex":0.0003078537,"about_ca_system_score_gemma":0.00012906211,"threshold_uncertainty_score":0.004832506},"labels":[],"label_agreement":null},{"id":"W2518302135","doi":"10.5858/arpa.2016-0119-ra","title":"Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It","year":2016,"lang":"en","type":"review","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Context (archaeology); Immunohistochemistry; Computer science; Epitope; Vendor; Antibody; Task (project management); Primary and secondary antibodies; Process (computing); Medicine; Pathology; Immunology; Biology","score_opus":0.0343991355478382,"score_gpt":0.3853445796393571,"score_spread":0.3509454440915189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518302135","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024114056,0.17681949,0.024086477,0.7595026,0.025179425,0.00015133289,0.0002240838,0.0013032437,0.010322],"genre_scores_gemma":[0.08629461,0.4344601,0.14464018,0.27237356,0.048562076,0.00049421453,0.00062266504,0.0014455473,0.011107007],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9643049,0.016835874,0.004065239,0.0020244948,0.011505353,0.0012641997],"domain_scores_gemma":[0.83160496,0.08617728,0.013632226,0.013920108,0.046796884,0.007868534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07329248,0.0017165053,0.0026726336,0.0038461688,0.004139881,0.011106542,0.0037750495,0.009439985,0.0069503775],"category_scores_gemma":[0.15738615,0.0009279785,0.0015176776,0.002244545,0.01488108,0.021341514,0.0037349127,0.010639815,0.0092096655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016871498,0.00018708022,0.010929723,0.009100566,0.00025104175,0.0029881753,0.0012680538,0.00035224945,0.002176319,0.024504678,0.44469061,0.50338286],"study_design_scores_gemma":[0.00006307666,0.00017315726,0.0070101083,0.036048006,0.00038003433,0.010898819,0.006517585,0.0011411641,0.0037461354,0.12583335,0.80790544,0.0002831184],"about_ca_topic_score_codex":0.003127446,"about_ca_topic_score_gemma":0.004552642,"teacher_disagreement_score":0.07329248,"about_ca_system_score_codex":0.003197043,"about_ca_system_score_gemma":0.009361028,"threshold_uncertainty_score":0.38761228},"labels":[],"label_agreement":null},{"id":"W2520503678","doi":"10.1111/bcpt.12675","title":"Use of a Target‐Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of <scp>GC</scp>1118, an Anti‐epidermal Growth Factor Receptor Antibody","year":2016,"lang":"en","type":"article","venue":"Basic & Clinical Pharmacology & Toxicology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Pharmacokinetics; Cetuximab; Chemistry; Epidermal growth factor receptor; Volume of distribution; Pharmacology; Receptor; Monoclonal antibody; Antibody; Biochemistry; Biology; Immunology","score_opus":0.1078287518249041,"score_gpt":0.45242553987766054,"score_spread":0.34459678805275645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520503678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89963627,0.0004712295,0.095697075,0.00019251648,0.000019011497,0.00010493645,0.00044181835,0.000247519,0.0031895326],"genre_scores_gemma":[0.99584633,0.00010094845,0.0032552655,0.000030313313,0.0000024076996,0.00004729148,0.000094685805,0.000011106707,0.00061158993],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99989283,0.000050766605,0.000004326051,0.000021116502,0.00001653973,0.000014465335],"domain_scores_gemma":[0.9996045,0.0002846755,0.000048222046,0.000012891142,0.000037786118,0.000011952629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038345993,0.0004720521,0.00043057906,0.00027573065,0.00014823893,0.00052401115,0.00025549316,0.0006469964,0.0008863908],"category_scores_gemma":[0.0011275843,0.00029744586,0.0007858014,0.00016525757,0.00019402399,0.00020210283,0.00017962676,0.00047496497,0.00014825462],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078604906,0.00001999485,0.0010509075,0.000017378936,0.00003475308,0.000063810214,0.000013083151,0.99369824,0.0030020121,0.00019479761,0.000065131964,0.0017612502],"study_design_scores_gemma":[0.000010233935,0.000077021796,0.000640123,0.000002567114,0.00001731379,0.000028425351,0.0000033092826,0.99795663,0.0009936643,0.00012335346,0.00014351399,0.0000038863313],"about_ca_topic_score_codex":0.015203179,"about_ca_topic_score_gemma":0.0043492215,"teacher_disagreement_score":0.015203179,"about_ca_system_score_codex":0.0008952756,"about_ca_system_score_gemma":0.00079554564,"threshold_uncertainty_score":0.03022939},"labels":[],"label_agreement":null},{"id":"W2522392425","doi":"10.1007/s10549-016-3979-5","title":"Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer","year":2016,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Jewish General Hospital","funders":"National Institute for Health and Care Research; AstraZeneca; Pfizer","keywords":"Anastrozole; Medicine; Internal medicine; Tolerability; Placebo; Breast cancer; Rash; Combination therapy; Adverse effect; Oncology; Gastroenterology; Cancer; Aromatase; Pathology","score_opus":0.041784829547201,"score_gpt":0.392317485535919,"score_spread":0.35053265598871797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522392425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938319,0.0027053456,0.00034536162,0.00042863877,0.00016300834,0.00088836555,0.00047556133,0.000083293926,0.0010785694],"genre_scores_gemma":[0.99190897,0.0026221054,0.0009449478,0.0005135863,0.00021265086,0.0011239954,0.00086749677,0.000026149506,0.0017801406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99945456,0.0002734211,0.000027174086,0.00008812182,0.000046018566,0.00011072493],"domain_scores_gemma":[0.999471,0.0001375084,0.00008216986,0.000053216525,0.000023730729,0.00023241517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013836253,0.0014720529,0.002600249,0.00065999065,0.0004171553,0.00096540444,0.0009754322,0.0013158456,0.0032119239],"category_scores_gemma":[0.0010663967,0.0007842694,0.0013106433,0.0006167108,0.0013403478,0.0012417678,0.00039434302,0.0032095632,0.0006878174],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93277675,0.019666286,0.002017237,0.00024991433,0.00093870336,0.00005163656,0.00007520402,0.00086800224,0.008342844,0.00014083352,0.00073747046,0.034134984],"study_design_scores_gemma":[0.7753814,0.21594538,0.004706544,0.000014974348,0.00075854146,0.000056597924,0.00004062101,0.00070373167,0.0013422593,0.00015601382,0.0008716103,0.000022318289],"about_ca_topic_score_codex":0.0013191754,"about_ca_topic_score_gemma":0.003601419,"teacher_disagreement_score":0.0032119239,"about_ca_system_score_codex":0.0008935389,"about_ca_system_score_gemma":0.0011905942,"threshold_uncertainty_score":0.010744929},"labels":[],"label_agreement":null},{"id":"W2525265150","doi":"10.1093/annonc/mdw434","title":"Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Breast Cancer Research Foundation; Yale University; U.S. Department of Health and Human Services","keywords":"Lapatinib; Trastuzumab; Medicine; RHOA; Gene; Mutation; Internal medicine; Oncology; Proportional hazards model; Cancer; Cancer research; Genetics; Breast cancer; Biology; Signal transduction","score_opus":0.2949287766874463,"score_gpt":0.4705472389473932,"score_spread":0.17561846225994687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525265150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931409,0.0014511925,0.00027768713,0.0009667663,0.00007074436,0.00006255994,0.00062022684,0.000021076552,0.0033888905],"genre_scores_gemma":[0.9964915,0.00036016342,0.00030825922,0.0005370479,0.000057803984,0.00004248218,0.00096594717,0.000011332952,0.0012254769],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996481,0.00015799518,0.000026150141,0.00006043647,0.000042713105,0.000064667314],"domain_scores_gemma":[0.9991689,0.0003258521,0.00018007672,0.00008472317,0.000057767036,0.0001826913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012103089,0.00037650397,0.00085518043,0.00014228471,0.00016672495,0.0008645901,0.00024797698,0.00046158032,0.0024787383],"category_scores_gemma":[0.0015148137,0.00013352756,0.0008652247,0.00019552307,0.00033573352,0.0010043035,0.000298776,0.0014770412,0.0004335261],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40489978,0.0027079883,0.32571578,0.0007557142,0.00462751,0.00039638134,0.0002447075,0.0071921377,0.040147923,0.0019293294,0.007738674,0.20364416],"study_design_scores_gemma":[0.05241879,0.07423862,0.78423995,0.00030925838,0.0092213815,0.0023662543,0.00044669962,0.015104383,0.017149577,0.01278299,0.031574026,0.0001480916],"about_ca_topic_score_codex":0.00014872484,"about_ca_topic_score_gemma":0.0008196653,"teacher_disagreement_score":0.0024787383,"about_ca_system_score_codex":0.00034377965,"about_ca_system_score_gemma":0.000416375,"threshold_uncertainty_score":0.008292258},"labels":[],"label_agreement":null},{"id":"W2527179162","doi":"10.1016/j.jasc.2016.07.018","title":"Toward Standard Controls for Her2 Immunohistochemistry","year":2016,"lang":"en","type":"article","venue":"Journal of the American Society of Cytopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Immunohistochemistry; Pathology","score_opus":0.034992448729536406,"score_gpt":0.37849243487914186,"score_spread":0.3434999861496055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527179162","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02934461,0.0036726773,0.94590074,0.0009181326,0.0012697633,0.002242946,0.0007102923,0.0048913565,0.011049463],"genre_scores_gemma":[0.06367047,0.0021801325,0.91074115,0.0011694196,0.00038686674,0.0055035925,0.0032358717,0.0017273945,0.011385029],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.94965196,0.01938573,0.005006858,0.0063962024,0.017358815,0.0022005502],"domain_scores_gemma":[0.9672445,0.007635703,0.0019425026,0.008940209,0.013544105,0.00069293915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.041933384,0.002381077,0.0018239616,0.0069803847,0.0031506184,0.0039812657,0.005864296,0.0034532694,0.006982732],"category_scores_gemma":[0.027349891,0.0035711776,0.0014871329,0.0027890652,0.004658777,0.0030925102,0.003932539,0.005654088,0.0053025843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009122433,0.0008918218,0.014662936,0.0016396615,0.0003257559,0.00054509897,0.0017681582,0.0009215821,0.8210786,0.032384224,0.017642358,0.1072275],"study_design_scores_gemma":[0.00016097035,0.0012661237,0.028445525,0.0008703103,0.00055660616,0.002665074,0.0008791537,0.009967491,0.81006783,0.015996462,0.12897314,0.00015134922],"about_ca_topic_score_codex":0.0022372324,"about_ca_topic_score_gemma":0.0073047555,"teacher_disagreement_score":0.041933384,"about_ca_system_score_codex":0.0020223968,"about_ca_system_score_gemma":0.00226765,"threshold_uncertainty_score":0.2217676},"labels":[],"label_agreement":null},{"id":"W2528319239","doi":"10.1038/ncomms12991","title":"Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers","year":2016,"lang":"en","type":"article","venue":"Nature Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; Stand Up To Cancer; National Cancer Institute; Cancer Research UK; National Institutes of Health; Nancy Owens Memorial Foundation; Congressionally Directed Medical Research Programs; National Institute of Allergy and Infectious Diseases; Breast Cancer Research Foundation; BC Cancer Agency; Susan G. Komen for the Cure","keywords":"Cancer research; Breast cancer; Kinase; Ectopic expression; Biology; Cancer; Cell cycle; Apoptosis; Medicine; Internal medicine; Oncology; Gene; Cell biology; Genetics","score_opus":0.05021994215550371,"score_gpt":0.36579579989605654,"score_spread":0.31557585774055286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528319239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385613,0.0009641279,0.0020744763,0.0000687954,0.000010516725,0.000021523814,0.001990864,0.00007582397,0.0009377125],"genre_scores_gemma":[0.992829,0.00070291816,0.0019055733,0.00005338169,0.000004392371,0.000020033318,0.0033733796,0.000019692321,0.0010915376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994814,0.000004821339,0.000004433213,0.000010579635,0.00002106208,0.000010924987],"domain_scores_gemma":[0.99994624,0.0000076238084,0.00001658133,0.0000051252555,0.0000074799095,0.000016968816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008733777,0.00026518453,0.00021002283,0.00046834434,0.00014583045,0.00020640792,0.00013970493,0.00015416127,0.00088783837],"category_scores_gemma":[0.00009767544,0.00008991602,0.00022034234,0.0002847603,0.00013149466,0.0000933792,0.00013278148,0.00020035857,0.00033225596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010357994,0.000009900918,0.0011875024,0.000036525966,0.000009827344,0.00009653838,0.000010098622,0.00017611966,0.9963953,0.00006309154,0.00005140515,0.0018601828],"study_design_scores_gemma":[0.00003342159,0.0004387625,0.10116471,0.000012076467,0.00011488962,0.0031800251,0.00010093986,0.0025371683,0.88268745,0.00021159144,0.00950131,0.000017645296],"about_ca_topic_score_codex":0.00080777524,"about_ca_topic_score_gemma":0.0015382518,"teacher_disagreement_score":0.00088783837,"about_ca_system_score_codex":0.000309729,"about_ca_system_score_gemma":0.00021947554,"threshold_uncertainty_score":0.0029700994},"labels":[],"label_agreement":null},{"id":"W2528759573","doi":"10.20381/ruor-4859","title":"The combination of pan-ErbB tyrosine kinase inhibitor CI-1033 and lovastatin: A potential novel therapeutic approach in squamous cell carcinoma of the head and neck","year":2011,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"ErbB; Head and neck; Tyrosine-kinase inhibitor; Cancer research; Tyrosine kinase; Head and neck squamous-cell carcinoma; Medicine; Basal cell; Lovastatin; Oncology; Internal medicine; Head and neck cancer; Cancer; Receptor; Surgery","score_opus":0.008760140810670305,"score_gpt":0.19491737962453248,"score_spread":0.18615723881386217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528759573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8306146,0.13856225,0.003797952,0.0017466054,0.00041927624,0.00045086694,0.000782541,0.00027004257,0.023355793],"genre_scores_gemma":[0.90985143,0.06844469,0.004509771,0.00032758128,0.00010324094,0.00011788755,0.00077034376,0.000018810326,0.015856288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996674,0.0000038094076,0.0000023818961,0.000005259394,0.000008358934,0.000013449778],"domain_scores_gemma":[0.99998987,0.00000107691,0.0000018952504,8.1733685e-7,0.0000023127475,0.0000040422947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009820263,0.00023231572,0.00025455386,0.00030869574,0.00019206482,0.00028273542,0.00018216675,0.00023221166,0.002212783],"category_scores_gemma":[0.000038160782,0.00007939375,0.00025916737,0.0003026264,0.000102507656,0.00017955297,0.00010673845,0.00042302374,0.00050732895],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014497687,0.0007616668,0.00055373134,0.0007189061,0.000044370234,0.000288885,0.00007049841,0.0003457298,0.81602055,0.0008512694,0.0021799125,0.17671482],"study_design_scores_gemma":[0.0008741047,0.007761758,0.021292686,0.00014922854,0.00028161536,0.002025692,0.0001518035,0.0008207226,0.84877837,0.00044866098,0.117379166,0.000036243935],"about_ca_topic_score_codex":0.0016351248,"about_ca_topic_score_gemma":0.006692693,"teacher_disagreement_score":0.002212783,"about_ca_system_score_codex":0.0004797694,"about_ca_system_score_gemma":0.0006599193,"threshold_uncertainty_score":0.0074025393},"labels":[],"label_agreement":null},{"id":"W2528766886","doi":"10.1093/annonc/mdv336.24","title":"First line trastuzumab-based therapy in her2-positive metastatic breast cancer patients presenting with de novo or recurrent disease","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Proportional hazards model; Retrospective cohort study; Adjuvant therapy; Cohort; Cancer; Stage (stratigraphy)","score_opus":0.19802956454535903,"score_gpt":0.4781728379178396,"score_spread":0.2801432733724806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528766886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786066,0.012712837,0.00020598853,0.0012371317,0.00012705225,0.000030419751,0.0001966578,0.000020164276,0.006863207],"genre_scores_gemma":[0.9943719,0.003933711,0.00018330924,0.00041636245,0.00018604027,0.000010625431,0.0002830881,0.0000047859835,0.0006101218],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999064,0.000021479791,0.00001041342,0.000013837375,0.000015097004,0.000032714433],"domain_scores_gemma":[0.9997533,0.00007566985,0.00006049023,0.000007075056,0.0000142871,0.00008910324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016563681,0.00018623286,0.00047916357,0.00032452063,0.00024093903,0.00052904006,0.00021057804,0.0004264125,0.0015243494],"category_scores_gemma":[0.0009774105,0.00010596476,0.00027131365,0.00036748932,0.00013237998,0.00034769598,0.00017343431,0.0005084441,0.00020170705],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063690017,0.000624954,0.78105116,0.00035451702,0.00023647657,0.033091627,0.00034467192,0.00089925894,0.010775858,0.00042776988,0.0066846283,0.15914005],"study_design_scores_gemma":[0.0007809525,0.004979004,0.8633215,0.00029935525,0.0005724697,0.10487707,0.0009101817,0.0028146415,0.0035298124,0.00094197073,0.016931806,0.0000412302],"about_ca_topic_score_codex":0.0007659598,"about_ca_topic_score_gemma":0.0025377895,"teacher_disagreement_score":0.0015243494,"about_ca_system_score_codex":0.0004122069,"about_ca_system_score_gemma":0.00046479152,"threshold_uncertainty_score":0.0050994754},"labels":[],"label_agreement":null},{"id":"W2529742963","doi":"","title":"First-in-class GnRH analog for cancer therapy","year":2016,"lang":"en","type":"article","venue":"Journal of Cancer Science & Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Monoclonal antibody; Ovarian cancer; Gonadotropin-releasing hormone; Receptor; Peptide; Gonadotropin-releasing hormone receptor; Pharmacology; Cancer cell; Cancer; Antibody; Cancer research; Biology; Chemistry; Biochemistry; Hormone; Medicine; Immunology; Internal medicine; Luteinizing hormone","score_opus":0.08549783948216659,"score_gpt":0.44408235902671456,"score_spread":0.35858451954454795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529742963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78846145,0.110642046,0.036267247,0.002989899,0.0024031007,0.0013020517,0.0016467074,0.00064587075,0.055641502],"genre_scores_gemma":[0.94020504,0.02010642,0.015943762,0.0012240249,0.00027723217,0.0003845898,0.0014016576,0.00006061371,0.020396687],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990666,0.000025087244,0.000005671618,0.000013790901,0.000031824828,0.000016928352],"domain_scores_gemma":[0.9999577,0.000006844445,0.000009770035,0.0000062158474,0.000007986894,0.000011503575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014849189,0.00020150328,0.00028059137,0.00020003559,0.00011463816,0.0002724802,0.0002462784,0.00028887126,0.0029267054],"category_scores_gemma":[0.00012402746,0.000069427566,0.00018574182,0.00014201632,0.00011989981,0.000104227045,0.00016708556,0.00060301495,0.00075905834],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096551,0.0004911653,0.00062592234,0.0005110449,0.00004646893,0.0005038856,0.00004339393,0.0006770778,0.8690454,0.0019791406,0.0038751892,0.1212357],"study_design_scores_gemma":[0.00084361393,0.008196062,0.0039705923,0.00009149115,0.00012657052,0.008994603,0.00003873355,0.0031154675,0.7107857,0.00074474665,0.2630675,0.000024944375],"about_ca_topic_score_codex":0.00016361238,"about_ca_topic_score_gemma":0.00031434954,"teacher_disagreement_score":0.0029267054,"about_ca_system_score_codex":0.0003691479,"about_ca_system_score_gemma":0.00017321201,"threshold_uncertainty_score":0.009790838},"labels":[],"label_agreement":null},{"id":"W2533474121","doi":"10.1016/j.breast.2016.09.014","title":"Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors","year":2016,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Fondation Cancer; Fondation du cancer du sein du Québec; Université Laval","keywords":"Breast cancer; Medicine; Oncology; Internal medicine; Single-nucleotide polymorphism; Lymphovascular invasion; Carcinogenesis; Genotype; Cancer; CA15-3; Pathology; Metastasis; Gene; Biology; Genetics","score_opus":0.044005681133845204,"score_gpt":0.31511709530617416,"score_spread":0.271111414172329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533474121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99938536,0.00026363635,0.00012633255,0.00000856982,0.0000026263756,0.000002586427,0.000112413196,0.0000021592155,0.00009627018],"genre_scores_gemma":[0.99939144,0.00009297077,0.0001290017,0.000011281291,0.00000457393,0.000006198213,0.00017652428,0.0000020626483,0.00018611993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996062,0.00009899937,0.000046922403,0.00010950166,0.00009672127,0.00004163212],"domain_scores_gemma":[0.9994241,0.0002147026,0.00020287717,0.00003988984,0.000052136027,0.00006621569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003944047,0.00021689327,0.00023392138,0.00054231804,0.00019438527,0.0003093365,0.00014671627,0.00026766115,0.00079568935],"category_scores_gemma":[0.0009829019,0.00015637641,0.00022785377,0.00065958383,0.00015501799,0.00011245371,0.00013233454,0.0002235892,0.00014983812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010089542,0.00010058793,0.970333,0.00003133203,0.00018821911,0.00045126126,0.0001156202,0.00012026899,0.022799047,0.000041183805,0.00006485644,0.0047456753],"study_design_scores_gemma":[0.000019470477,0.00027715162,0.993751,0.000004886046,0.00010138157,0.0012599952,0.0000681789,0.00029899096,0.0038358993,0.00004590202,0.00033332495,0.000003734369],"about_ca_topic_score_codex":0.0006358406,"about_ca_topic_score_gemma":0.0006858445,"teacher_disagreement_score":0.00079568935,"about_ca_system_score_codex":0.00011530583,"about_ca_system_score_gemma":0.00010920679,"threshold_uncertainty_score":0.0026618838},"labels":[],"label_agreement":null},{"id":"W2546973056","doi":"10.1001/jamaoncol.2016.4884","title":"Association of Polymorphisms in <i>FCGR2A</i> and <i>FCGR3A</i> With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer","year":2016,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Breast cancer; Regimen; Cyclophosphamide; Cohort; Cancer; Chemotherapy","score_opus":0.02793474528304624,"score_gpt":0.3318939157411339,"score_spread":0.3039591704580877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546973056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989427,0.00030114775,0.00017784772,0.000045766552,0.000005035855,0.000013875127,0.0002428705,0.0000026210796,0.00026815612],"genre_scores_gemma":[0.9995523,0.00005320892,0.000097852375,0.00003763379,0.00000896117,0.000008133646,0.00016774217,0.0000023934804,0.000071697184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942374,0.00022844503,0.000067758,0.00014835462,0.00008072865,0.000050880604],"domain_scores_gemma":[0.99889565,0.0003827219,0.00048873347,0.00011823077,0.000036694746,0.00007797544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011148704,0.00020846487,0.00024776784,0.00026744636,0.00020766103,0.0003102657,0.00022848076,0.00039152562,0.0008617489],"category_scores_gemma":[0.0017255684,0.00012625298,0.00035945073,0.00048606796,0.00037251605,0.00013402964,0.00011711126,0.00036256414,0.00009974514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069908286,0.00013660482,0.9769693,0.000032201173,0.0007309063,0.00017133314,0.000060314353,0.0005577818,0.008721365,0.00011253406,0.0002538225,0.0052631083],"study_design_scores_gemma":[0.00033021253,0.0007436492,0.99531305,0.000010947914,0.0003681506,0.0005546221,0.000031100295,0.00063257763,0.001350192,0.00011597798,0.0005409913,0.000008528724],"about_ca_topic_score_codex":0.0030238733,"about_ca_topic_score_gemma":0.0033033343,"teacher_disagreement_score":0.0030238733,"about_ca_system_score_codex":0.00025297928,"about_ca_system_score_gemma":0.00024240218,"threshold_uncertainty_score":0.0060124993},"labels":[],"label_agreement":null},{"id":"W2547090396","doi":"10.1080/19420862.2016.1255389","title":"Development and preclinical studies of <sup>64</sup>Cu-NOTA-pertuzumab F(ab′)<sub>2</sub> for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT","year":2016,"lang":"en","type":"article","venue":"mAbs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Pertuzumab; Trastuzumab; Biodistribution; Medicine; Nuclear medicine; Breast cancer; Cancer; Cancer research; Chemistry; Internal medicine; Biochemistry; In vitro","score_opus":0.06149780428111189,"score_gpt":0.37061000100646496,"score_spread":0.30911219672535306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547090396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558225,0.0074709635,0.02482609,0.00090283854,0.00021733087,0.0024333382,0.0016347094,0.00038140992,0.006310898],"genre_scores_gemma":[0.9688112,0.0038726153,0.017137045,0.0002759928,0.000065904685,0.0009064229,0.002933408,0.00012976356,0.0058676163],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996418,0.000119743585,0.000016944312,0.000049818063,0.00007269641,0.00009905153],"domain_scores_gemma":[0.9996153,0.000045955574,0.000075914104,0.000050760646,0.00008482539,0.00012715328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011188559,0.00080825534,0.0005260143,0.00041950433,0.00032965484,0.0005370703,0.0010716808,0.00076414994,0.0014086001],"category_scores_gemma":[0.0007938921,0.0005157765,0.00039518226,0.00031369,0.0003752602,0.00056023395,0.00021884927,0.00095424236,0.00073244615],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002873533,0.0032972924,0.00074498804,0.00020182267,0.00008808793,0.0002542594,0.00016166936,0.0021046465,0.9688575,0.00054647727,0.0017443191,0.019125242],"study_design_scores_gemma":[0.0015186764,0.022796229,0.0044395053,0.000034696375,0.00019234694,0.0016151246,0.000046815254,0.0033639,0.9482374,0.00022488621,0.017497007,0.000033357883],"about_ca_topic_score_codex":0.0034849045,"about_ca_topic_score_gemma":0.003928201,"teacher_disagreement_score":0.0034849045,"about_ca_system_score_codex":0.0007413465,"about_ca_system_score_gemma":0.0008943493,"threshold_uncertainty_score":0.006929219},"labels":[],"label_agreement":null},{"id":"W2554303407","doi":"10.1038/bjc.2016.360","title":"Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly","year":2016,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Trastuzumab; Breast cancer; Clinical trial; Systemic therapy; Oncology; Internal medicine; Population; Intensive care medicine; Adjuvant therapy; Randomized controlled trial; Cancer; Stage (stratigraphy); Adjuvant; Chemotherapy","score_opus":0.053753720127942994,"score_gpt":0.4222511520062968,"score_spread":0.3684974318783538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554303407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013718983,0.9995939,0.000018226276,0.000058529913,0.00002970712,0.000004052677,0.000009218331,9.434747e-7,0.00014827591],"genre_scores_gemma":[0.0010864426,0.9986266,0.00008000348,0.0000718711,0.000030394029,0.0000060004786,0.000014152786,3.9427658e-7,0.00008424127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972695,0.0000912672,0.00006940078,0.000030309848,0.000067335815,0.000014726885],"domain_scores_gemma":[0.9994265,0.00040383422,0.00009921245,0.00000794255,0.000047506368,0.0000150319165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007526073,0.00046510133,0.0017471395,0.0016299566,0.00014066925,0.00053324667,0.00048671052,0.00073943875,0.0023343929],"category_scores_gemma":[0.0016392767,0.000183443,0.00096266094,0.0015455738,0.0002079949,0.00053182105,0.0003507327,0.0006954551,0.00040230263],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019252149,0.00004477798,0.0003194893,0.08080661,0.0005080413,0.00012072104,0.000045039145,0.00025717964,0.00040062715,0.0006116564,0.007902324,0.9087909],"study_design_scores_gemma":[0.00041997398,0.00080705737,0.012030145,0.16598591,0.0063878493,0.0043521416,0.00028400132,0.0004632084,0.0010920789,0.0025645383,0.80555004,0.0000631471],"about_ca_topic_score_codex":0.001370467,"about_ca_topic_score_gemma":0.003938953,"teacher_disagreement_score":0.0023343929,"about_ca_system_score_codex":0.00040483213,"about_ca_system_score_gemma":0.0008391528,"threshold_uncertainty_score":0.0078092813},"labels":[],"label_agreement":null},{"id":"W2556607246","doi":"10.5858/arpa.2016-0331-cp","title":"HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","year":2016,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Guideline; Clinical Oncology; Internal medicine; Adenocarcinoma; Biomarker; Clinical pathology; Oncology; Pathology; Cancer","score_opus":0.1289693971999853,"score_gpt":0.4916737082039777,"score_spread":0.3627043110039924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556607246","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024135318,0.29292017,0.015290117,0.63778377,0.014929115,0.005401826,0.004897001,0.0004260959,0.025938386],"genre_scores_gemma":[0.035600025,0.42075858,0.2081963,0.28339508,0.010660923,0.013414307,0.015284958,0.00027895652,0.0124109145],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9624736,0.019804904,0.008775497,0.001228581,0.006839802,0.00087765214],"domain_scores_gemma":[0.93287003,0.02220467,0.008652298,0.0010617002,0.031857934,0.0033533615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.032603983,0.0017336212,0.0026525739,0.005328234,0.0018317455,0.003548526,0.0070389393,0.010418108,0.0030819322],"category_scores_gemma":[0.082166485,0.0011634396,0.0057598804,0.0050478876,0.0020392267,0.003546731,0.0035024185,0.0111317355,0.0027521623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120648336,0.00015180855,0.0017076345,0.01283777,0.00043381492,0.00038760106,0.00064397074,0.0011877815,0.0003076283,0.004910772,0.7835465,0.193764],"study_design_scores_gemma":[0.0010199007,0.00025561205,0.0072077247,0.17232628,0.0020921424,0.001251106,0.00089241756,0.0024763069,0.00055544503,0.020747334,0.7909256,0.00025002394],"about_ca_topic_score_codex":0.026763638,"about_ca_topic_score_gemma":0.049518634,"teacher_disagreement_score":0.032603983,"about_ca_system_score_codex":0.008074791,"about_ca_system_score_gemma":0.032520983,"threshold_uncertainty_score":0.17242837},"labels":[],"label_agreement":null},{"id":"W2559761169","doi":"10.1093/ajcp/aqw206","title":"<i>HER2</i>Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma","year":2016,"lang":"en","type":"review","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Guideline; Medicine; Targeted therapy; Clinical trial; Medical physics; Oncology; Internal medicine; Biomarker; Intensive care medicine; Pathology; Cancer","score_opus":0.21422844248419573,"score_gpt":0.5662473226282525,"score_spread":0.3520188801440568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559761169","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004010583,0.4121232,0.0068270313,0.54412043,0.009038061,0.0014407727,0.0015290773,0.00015962735,0.020751279],"genre_scores_gemma":[0.1152287,0.48798877,0.07314163,0.2984579,0.013449299,0.004389003,0.0034905174,0.00015248536,0.003701657],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9296619,0.05044028,0.010810338,0.0015973741,0.006580396,0.00090966077],"domain_scores_gemma":[0.8397919,0.10364898,0.0190399,0.0024535079,0.031949997,0.0031157073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05122598,0.0010119785,0.0017570893,0.0040824357,0.0015574329,0.004813349,0.0042502983,0.007491915,0.0031323764],"category_scores_gemma":[0.19792455,0.00082954374,0.00399899,0.0043497793,0.003689286,0.003809813,0.0029844544,0.007173944,0.0014110988],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021198801,0.00015970579,0.008196498,0.046676725,0.0012620264,0.00069107313,0.001854642,0.0018702606,0.00037746126,0.009347723,0.58426625,0.34508562],"study_design_scores_gemma":[0.0006993169,0.00031713521,0.014729674,0.39207333,0.0027296701,0.0014738735,0.0021858017,0.0027275286,0.00072492415,0.036134325,0.5458477,0.00035682984],"about_ca_topic_score_codex":0.0233496,"about_ca_topic_score_gemma":0.037684664,"teacher_disagreement_score":0.05122598,"about_ca_system_score_codex":0.006822996,"about_ca_system_score_gemma":0.022175316,"threshold_uncertainty_score":0.2709121},"labels":[],"label_agreement":null},{"id":"W2559964267","doi":"10.1200/jco.2011.29.27_suppl.286","title":"The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Trastuzumab; Cohort; Internal medicine; Oncology; Cancer; Gynecology","score_opus":0.12100030117918352,"score_gpt":0.5276321636059318,"score_spread":0.40663186242674826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559964267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963993,0.0028292907,0.000045587723,0.00009750446,0.000016730612,0.000025797724,0.000053914235,0.0000052376386,0.0005265462],"genre_scores_gemma":[0.9989311,0.00068118115,0.000064487955,0.000046102276,0.000018318098,0.000011848697,0.00007829147,0.0000011869748,0.00016738057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99978346,0.00011957545,0.000016897784,0.000019425761,0.000030392028,0.00003027718],"domain_scores_gemma":[0.9991572,0.00040841932,0.00021328809,0.000028482953,0.000051871433,0.00014079867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071001647,0.000118342294,0.00023999922,0.000136988,0.000089622146,0.00022998052,0.00015346272,0.00014022063,0.0007654389],"category_scores_gemma":[0.0022005434,0.00005697182,0.000253041,0.00019162652,0.00014495468,0.00020099516,0.00013299183,0.00027507317,0.00008319252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16758552,0.0042909603,0.46105212,0.0010601087,0.00058439915,0.00096648856,0.0003074066,0.0024810534,0.013416746,0.00009947533,0.0018508409,0.34630486],"study_design_scores_gemma":[0.004082668,0.096428275,0.88891065,0.00008854804,0.00058633025,0.0013235788,0.00023504405,0.0018599571,0.00395476,0.00007747346,0.002439697,0.000013023534],"about_ca_topic_score_codex":0.0012069448,"about_ca_topic_score_gemma":0.0024309545,"teacher_disagreement_score":0.0012069448,"about_ca_system_score_codex":0.00036587904,"about_ca_system_score_gemma":0.00028389553,"threshold_uncertainty_score":0.0037549138},"labels":[],"label_agreement":null},{"id":"W2560641415","doi":"10.1016/j.jmb.2016.12.006","title":"Systematic Identification of Oncogenic EGFR Interaction Partners","year":2016,"lang":"en","type":"article","venue":"Journal of Molecular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council","keywords":"Epidermal growth factor receptor; Cyclin-dependent kinase 8; ERBB3; Signal transduction; Biology; Small hairpin RNA; Cell biology; Receptor tyrosine kinase; Protein kinase B; Tyrosine kinase; Gene knockdown; Cancer research; Epidermal growth factor; Receptor; Cell culture; Biochemistry; Genetics; Notch signaling pathway","score_opus":0.040649225039150895,"score_gpt":0.4500055448296283,"score_spread":0.4093563197904774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560641415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659989,0.0024824517,0.028029665,0.00015820433,0.000032506785,0.00018853278,0.0008817586,0.0002499369,0.0019780549],"genre_scores_gemma":[0.95583665,0.0016660914,0.03792131,0.00015263943,0.000009822925,0.00012847548,0.002149077,0.00008536653,0.0020506615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99966156,0.00005205361,0.000027749958,0.00007880929,0.00012649431,0.00005341782],"domain_scores_gemma":[0.999808,0.000041195966,0.000047506335,0.000037434413,0.000039121984,0.000026779793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002996192,0.00037448027,0.0003461508,0.00050152146,0.0002781585,0.00028541152,0.0003133788,0.000286309,0.000518642],"category_scores_gemma":[0.00026821677,0.00024517163,0.00028602008,0.00036530348,0.00023042102,0.00024559605,0.00048971263,0.0005809266,0.0003335181],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028649507,0.000009416571,0.00022777979,0.000020649366,0.0000047417957,0.00004352584,0.000006456792,0.000054154014,0.9982607,0.000062140956,0.000034065637,0.0012475983],"study_design_scores_gemma":[0.0000060367097,0.000061082676,0.0029285902,0.0000036278147,0.000021159636,0.0003895545,0.000015150546,0.001768932,0.99233454,0.000039498693,0.0024265333,0.000005290388],"about_ca_topic_score_codex":0.00043014932,"about_ca_topic_score_gemma":0.0013344925,"teacher_disagreement_score":0.000518642,"about_ca_system_score_codex":0.00035528568,"about_ca_system_score_gemma":0.0003026013,"threshold_uncertainty_score":0.0025777817},"labels":[],"label_agreement":null},{"id":"W2563445076","doi":"10.1021/acs.molpharmaceut.6b00963","title":"<sup>64</sup>Cu-Labeled Trastuzumab Fab-PEG<sub>24</sub>-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents","year":2017,"lang":"en","type":"article","venue":"Molecular Pharmaceutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; Institute of Cancer Research; Ontario Institute for Cancer Research; University of Toronto","keywords":"Biodistribution; Trastuzumab; Chemistry; Pharmacokinetics; Cancer research; In vitro; Pharmacology; Cancer; Medicine; Breast cancer; Biochemistry; Internal medicine","score_opus":0.0501293980763969,"score_gpt":0.38584092137977055,"score_spread":0.33571152330337367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563445076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935243,0.0012671703,0.004086739,0.00004091383,0.00001020189,0.000019539373,0.000074431184,0.00006479427,0.0009117955],"genre_scores_gemma":[0.9924144,0.0006535739,0.004190457,0.00005135131,0.000008711704,0.00003219348,0.00024020583,0.00002623699,0.0023829313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999913,0.00002157441,0.000005116597,0.000016610851,0.000025771837,0.000017944449],"domain_scores_gemma":[0.9999441,0.00000979897,0.000018450555,0.0000048387315,0.000010939122,0.000011791114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113354836,0.00027633912,0.00016416886,0.00010068452,0.00005244031,0.00015404167,0.00017291878,0.00015677429,0.00044582575],"category_scores_gemma":[0.00013754376,0.0001136113,0.00007489564,0.000113685855,0.00013412848,0.00013153705,0.00009979204,0.00019000599,0.00019675249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033727774,0.000019785226,0.00024624792,0.000022084858,0.0000051259126,0.00003044956,0.0000074083096,0.00028664042,0.99613935,0.000073591764,0.000062804735,0.0027692565],"study_design_scores_gemma":[0.000015598527,0.0003708176,0.0017257232,0.0000018990123,0.000018465293,0.00022959893,0.000006393179,0.0015918246,0.99462116,0.000016851398,0.0013986498,0.0000029260839],"about_ca_topic_score_codex":0.00073996314,"about_ca_topic_score_gemma":0.00053878076,"teacher_disagreement_score":0.00073996314,"about_ca_system_score_codex":0.00030833835,"about_ca_system_score_gemma":0.00011868596,"threshold_uncertainty_score":0.0022371411},"labels":[],"label_agreement":null},{"id":"W2566727384","doi":"","title":"進行・再発の薬物療法Pertuzumab（パージェタ(R)）を用いた進行乳癌症例１ Trastuzumab＋Pertuzumab＋DTX（1st line）（臨床報告）","year":2014,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Internal medicine","score_opus":0.06880277521345375,"score_gpt":0.39063594190029527,"score_spread":0.32183316668684153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566727384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47573525,0.08648252,0.036378857,0.027412867,0.0034120907,0.0008066772,0.0008844096,0.0010400385,0.3678473],"genre_scores_gemma":[0.817944,0.0208143,0.019787336,0.007990614,0.002080878,0.0002516198,0.0004298822,0.000100736404,0.13060068],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9995938,0.00008218254,0.000028569573,0.000085629516,0.00015664371,0.000053144748],"domain_scores_gemma":[0.9996209,0.00009191048,0.00007130021,0.000038338294,0.000113595095,0.00006396346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000909182,0.000260053,0.0003069648,0.00036850234,0.00052788534,0.0009922902,0.00027868542,0.0007106199,0.008292861],"category_scores_gemma":[0.00119189,0.00014199222,0.00031549254,0.00022808962,0.00069210626,0.00059925794,0.00029849928,0.00094705314,0.003337659],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016477131,0.0007747263,0.009018139,0.0007605108,0.00020288267,0.0020717985,0.00069676,0.00080917816,0.16191109,0.02788428,0.028969498,0.7652534],"study_design_scores_gemma":[0.000665121,0.0043163453,0.026044495,0.0003140816,0.0005097054,0.013731873,0.0005435859,0.002192434,0.31593513,0.018339567,0.6172835,0.0001241311],"about_ca_topic_score_codex":0.0013896484,"about_ca_topic_score_gemma":0.001237836,"teacher_disagreement_score":0.008292861,"about_ca_system_score_codex":0.0008139535,"about_ca_system_score_gemma":0.0008126132,"threshold_uncertainty_score":0.027742386},"labels":[],"label_agreement":null},{"id":"W2566808867","doi":"10.1007/s40262-016-0496-y","title":"A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacokinetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab emtansine; Medicine; Internal medicine; Pharmacokinetics; Metastatic breast cancer; Breast cancer; Gastroenterology; Endocrinology; Cancer","score_opus":0.08172419646481328,"score_gpt":0.4483246871888897,"score_spread":0.3666004907240764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566808867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774617,0.0005301784,0.00029603794,0.00016405933,0.000028449238,0.00026421316,0.0002559748,0.00004132658,0.000673563],"genre_scores_gemma":[0.9971053,0.00047771895,0.00050720305,0.00022549559,0.000049354916,0.00025291427,0.0005671759,0.000022123695,0.000792673],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996793,0.00012609885,0.0000122468,0.00007725201,0.000028792296,0.00007621865],"domain_scores_gemma":[0.99949706,0.000107379565,0.00007924403,0.00004924688,0.0000222912,0.0002448206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000753314,0.0012117629,0.0015475191,0.00034069494,0.00044728667,0.00083529565,0.00047144663,0.000770157,0.0019694918],"category_scores_gemma":[0.0012620679,0.00058415916,0.0009111584,0.00042784528,0.0008429013,0.00094744755,0.00026003862,0.0023609395,0.00052217353],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68942314,0.060714766,0.019558584,0.00036553468,0.00096439477,0.0008860302,0.0007470749,0.0069914544,0.099089555,0.0005122179,0.003192723,0.11755452],"study_design_scores_gemma":[0.34439203,0.57761467,0.05284909,0.000028649512,0.0007876641,0.0012346493,0.00019782572,0.0052852477,0.012253512,0.0003816152,0.0048739463,0.00010098834],"about_ca_topic_score_codex":0.0014157871,"about_ca_topic_score_gemma":0.002360951,"teacher_disagreement_score":0.0019694918,"about_ca_system_score_codex":0.0012131181,"about_ca_system_score_gemma":0.0013352133,"threshold_uncertainty_score":0.008801818},"labels":[],"label_agreement":null},{"id":"W2569849644","doi":"10.1016/j.jtho.2016.11.1504","title":"P2.06-011 Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cancer; Oncology; Chemotherapy; Monoclonal antibody; Neuregulin; Lung cancer; In situ hybridization; Phases of clinical research; Cancer research; Pathology; Antibody; Receptor; Messenger RNA; Immunology","score_opus":0.06833756263630814,"score_gpt":0.51890546857189,"score_spread":0.4505679059355819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569849644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921274,0.0012413205,0.0003549202,0.00059836527,0.00041925322,0.0015699096,0.0010263309,0.0001083348,0.0025540856],"genre_scores_gemma":[0.98397726,0.0019486751,0.001460185,0.0009883734,0.00039433135,0.0022979327,0.0023849132,0.00007811563,0.006470245],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954647,0.0002200165,0.000016208809,0.0000779098,0.000026435577,0.000112956],"domain_scores_gemma":[0.9994741,0.00010244392,0.00007102155,0.00003805758,0.000029662853,0.00028475566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013985377,0.0018103592,0.0032365324,0.00070448924,0.0004628164,0.0013425874,0.0012705366,0.0016586367,0.0065138442],"category_scores_gemma":[0.001009624,0.0007050376,0.0017660571,0.00050028175,0.0011520145,0.0013583901,0.00045374437,0.0045296336,0.0012508954],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85999525,0.0621008,0.001386472,0.000511129,0.00088313356,0.00009844098,0.0001387617,0.0018897541,0.024514517,0.00036167042,0.0025656156,0.045554478],"study_design_scores_gemma":[0.4772506,0.5143131,0.003238358,0.00002546126,0.0004432237,0.00008317718,0.000060182458,0.00093938527,0.0020867612,0.00018332161,0.001345778,0.00003066988],"about_ca_topic_score_codex":0.0018582845,"about_ca_topic_score_gemma":0.003771613,"teacher_disagreement_score":0.0065138442,"about_ca_system_score_codex":0.0011494291,"about_ca_system_score_gemma":0.001779538,"threshold_uncertainty_score":0.021790922},"labels":[],"label_agreement":null},{"id":"W2571057012","doi":"10.1158/1078-0432.ccr-16-1496","title":"Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Rash; Gastroenterology; Nausea; Cohort; Anemia; Metastatic breast cancer; Pharmacokinetics; Diarrhea; Vomiting; Neutropenia; Breast cancer; Cancer; Toxicity","score_opus":0.18753899173105087,"score_gpt":0.5709110171428204,"score_spread":0.38337202541176957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571057012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986771,0.00021284574,0.00014084623,0.000040759303,0.000008708501,0.00036085473,0.0001679537,0.00001894813,0.00037200018],"genre_scores_gemma":[0.99606824,0.00029902553,0.00089255976,0.00012306767,0.000033808064,0.00060673745,0.0010602584,0.000010314162,0.00090597896],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997979,0.00007510295,0.000010481662,0.000036605183,0.000031082924,0.00004886944],"domain_scores_gemma":[0.9996158,0.00005174219,0.000057065663,0.000039707396,0.00002468297,0.00021092893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080092764,0.0009221596,0.0010140897,0.00021379092,0.00024756027,0.0003624487,0.0005067965,0.0003692811,0.0018218281],"category_scores_gemma":[0.00041430743,0.00030467284,0.0004817179,0.00024135842,0.0005249552,0.0005028925,0.00027436833,0.0014355049,0.00032215935],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44628525,0.14139627,0.033147328,0.0006607147,0.0008914559,0.0008682413,0.0008376227,0.0067544812,0.17859432,0.00047600004,0.0047474857,0.18534087],"study_design_scores_gemma":[0.14810745,0.79665506,0.037469845,0.000023592907,0.00031083415,0.0007454402,0.00009567702,0.002458066,0.0110803535,0.00014996901,0.0028787407,0.000025021998],"about_ca_topic_score_codex":0.0010769546,"about_ca_topic_score_gemma":0.0028288323,"teacher_disagreement_score":0.0018218281,"about_ca_system_score_codex":0.0007356457,"about_ca_system_score_gemma":0.0009837662,"threshold_uncertainty_score":0.006094575},"labels":[],"label_agreement":null},{"id":"W2577984904","doi":"10.12788/j.cmonc.0037","title":"When is an answer not an answer?","year":2013,"lang":"en","type":"article","venue":"Community Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Computer science","score_opus":0.22753971955614408,"score_gpt":0.4586631591440516,"score_spread":0.23112343958790751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577984904","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001468336,0.005447955,0.0010906415,0.94621545,0.044575077,0.000019607185,0.000111077716,0.00007503561,0.0023183317],"genre_scores_gemma":[0.011311627,0.01803692,0.0056081265,0.89595747,0.057509836,0.00017693912,0.00036553747,0.00036470455,0.010668888],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9653847,0.017074594,0.0036900593,0.0031091617,0.008656688,0.0020848557],"domain_scores_gemma":[0.7784903,0.12249572,0.011549059,0.005505215,0.062389996,0.019569758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035048675,0.0014028336,0.002581264,0.002424522,0.0063155196,0.010862969,0.0034409754,0.026581386,0.04103977],"category_scores_gemma":[0.31590804,0.0008604493,0.0019296409,0.0018940892,0.01185941,0.020998953,0.004831081,0.03432303,0.026880361],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092371716,0.000054546683,0.00062211184,0.00051867997,0.00007208552,0.0004213855,0.00058498816,0.000071411734,0.00010968962,0.018033793,0.9478021,0.03161695],"study_design_scores_gemma":[0.00009793513,0.000089651876,0.000743956,0.0033259892,0.000074497024,0.0014955152,0.0049107797,0.00026211375,0.00023470196,0.07311221,0.91547847,0.00017414012],"about_ca_topic_score_codex":0.004700404,"about_ca_topic_score_gemma":0.0049197203,"teacher_disagreement_score":0.04103977,"about_ca_system_score_codex":0.005357027,"about_ca_system_score_gemma":0.01074602,"threshold_uncertainty_score":0.18535733},"labels":[],"label_agreement":null},{"id":"W2582500594","doi":"10.1200/jco.2005.23.16_suppl.6070","title":"Patterns of trastuzumab use and cost in a single Canadian cancer institute","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Pharmacy; Metastatic breast cancer; Cancer; Breast cancer; Chemotherapy; Internal medicine; Family medicine","score_opus":0.4083267166461031,"score_gpt":0.5638005249704544,"score_spread":0.15547380832435131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582500594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722739,0.0033372892,0.00018210393,0.0019882657,0.000015978669,0.00019635337,0.006889313,0.00004756866,0.015069221],"genre_scores_gemma":[0.99438226,0.0018586852,0.0003551621,0.00032567332,0.0000107470305,0.000041703162,0.0019030991,0.000017999673,0.0011045019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961278,0.00023951412,0.00020500823,0.00034830396,0.0019059209,0.0011735142],"domain_scores_gemma":[0.99057806,0.0008192025,0.0032215654,0.00017672607,0.003307085,0.0018974076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097629457,0.00034453,0.0004518444,0.004411784,0.0022807969,0.002248198,0.002391326,0.00063846173,0.0030406683],"category_scores_gemma":[0.007740931,0.00043326893,0.000605166,0.012165957,0.00079841074,0.00043247457,0.0013594332,0.000860621,0.00025045048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019953957,0.00006624475,0.9697278,0.0001464199,0.00013636152,0.0004988111,0.0008504417,0.00092919247,0.000285582,0.000593952,0.004977657,0.02158802],"study_design_scores_gemma":[0.000018736091,0.000070340895,0.9911006,0.00010690015,0.000069062466,0.00040890518,0.0017987273,0.0008678949,0.00016123733,0.000052793697,0.0053088604,0.00003592295],"about_ca_topic_score_codex":0.97786796,"about_ca_topic_score_gemma":0.9857022,"teacher_disagreement_score":0.08047466,"about_ca_system_score_codex":0.08047466,"about_ca_system_score_gemma":0.06714246,"threshold_uncertainty_score":0.5838872},"labels":[],"label_agreement":null},{"id":"W2586584461","doi":"10.1007/978-1-4939-6759-9_5","title":"Using Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Signal Transduction","year":2017,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tissue microarray; DNA microarray; Protein microarray; Computational biology; Transduction (biophysics); Signal transduction; Throughput; Immunohistochemistry; Biology; Cell biology; Computer science; Biophysics; Biochemistry; Gene expression; Gene; Immunology","score_opus":0.20833832949128106,"score_gpt":0.5520613957039319,"score_spread":0.3437230662126508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586584461","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03745459,0.0018411408,0.9491452,0.00046493072,0.00047037486,0.00035426917,0.001605387,0.003990796,0.004673304],"genre_scores_gemma":[0.09277662,0.0027067997,0.88982236,0.0006238655,0.00015961188,0.0018936811,0.0016993765,0.0005362035,0.009781457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957054,0.0007860539,0.00023445503,0.0011669669,0.0018273486,0.0002797813],"domain_scores_gemma":[0.9971222,0.0011507227,0.0003771091,0.00046681231,0.0007520799,0.0001309524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035187039,0.002084102,0.0015343459,0.003337973,0.0011285438,0.0028147628,0.0029220171,0.002126283,0.004421784],"category_scores_gemma":[0.0028486904,0.0014729335,0.0010356535,0.002981791,0.0015199148,0.0018898337,0.0013652191,0.003855814,0.002321068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009006384,0.00008593911,0.00034934102,0.00030824385,0.0000432103,0.00002829604,0.00012107505,0.0006160096,0.9784557,0.0019925602,0.0009405754,0.01696904],"study_design_scores_gemma":[0.000022861681,0.00011634083,0.002015327,0.00003797629,0.000061306724,0.00017044465,0.00005016811,0.021723699,0.9681434,0.0013785881,0.006203288,0.00007660433],"about_ca_topic_score_codex":0.0018630417,"about_ca_topic_score_gemma":0.0052302554,"teacher_disagreement_score":0.004421784,"about_ca_system_score_codex":0.002387023,"about_ca_system_score_gemma":0.0012883088,"threshold_uncertainty_score":0.018608868},"labels":[],"label_agreement":null},{"id":"W2586974551","doi":"10.1074/mcp.m116.061267","title":"Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells","year":2017,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council Canada; Association for International Cancer Research; Cancer Research UK; National Institute for Health and Care Research; National Institute for Social Care and Health Research","keywords":"Stable isotope labeling by amino acids in cell culture; ErbB; Biology; Cancer research; Signal transduction; Epidermal growth factor receptor; Cell biology; Epidermal growth factor; Phosphorylation; Receptor; Proteomics; Genetics","score_opus":0.015341490539569777,"score_gpt":0.2663836283510436,"score_spread":0.25104213781147383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586974551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749583,0.0007593183,0.0004819962,0.00004352237,0.000017989927,0.0000114538225,0.00033255943,0.000024423081,0.00083291595],"genre_scores_gemma":[0.99614775,0.00065804203,0.0009767633,0.000043103395,0.0000071352233,0.000024492563,0.00042537614,0.000011723385,0.0017057197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999,0.000019186233,0.000008598742,0.000019262263,0.000024061988,0.000028872128],"domain_scores_gemma":[0.9999578,0.00000792998,0.000009204827,0.0000066616585,0.0000051691004,0.000013294588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012007406,0.00020069088,0.0001884268,0.00011974852,0.0001199045,0.00022645078,0.00009158224,0.00014935099,0.0008196938],"category_scores_gemma":[0.00006333952,0.000095524614,0.00015865195,0.00019310873,0.00012888847,0.00014164684,0.00014966849,0.00024640898,0.00016639999],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013593554,0.000019092306,0.00011316343,0.0000140650345,0.000002687817,0.000024920255,0.000009182253,0.000026601501,0.9992842,0.000023864766,0.000012552053,0.0003337344],"study_design_scores_gemma":[0.000010269522,0.00027808017,0.009542812,0.000002344624,0.000012381597,0.00012372845,0.000041548556,0.0006844974,0.9881556,0.000027260943,0.0011180205,0.0000035009302],"about_ca_topic_score_codex":0.00068229967,"about_ca_topic_score_gemma":0.0009093241,"teacher_disagreement_score":0.0008196938,"about_ca_system_score_codex":0.00018413749,"about_ca_system_score_gemma":0.00014994731,"threshold_uncertainty_score":0.0027421117},"labels":[],"label_agreement":null},{"id":"W2588395233","doi":"10.1093/annonc/mdw365.94","title":"HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Anthracycline; Internal medicine; Metastatic breast cancer; Trastuzumab emtansine; Taxane; Oncology; Clinical endpoint; Capecitabine; Vinorelbine; Breast cancer; Epirubicin; Chemotherapy; Cancer; Clinical trial","score_opus":0.0772610085246743,"score_gpt":0.4431137932374388,"score_spread":0.3658527847127645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588395233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826788,0.0036463425,0.00073284504,0.0013832249,0.00096472976,0.0038655638,0.0019533257,0.00026804913,0.004507203],"genre_scores_gemma":[0.9727716,0.0031077976,0.0026883658,0.0023146127,0.0008596856,0.005553931,0.0030763703,0.000055537905,0.009572198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996648,0.00016303465,0.000015773367,0.00007281077,0.000018650126,0.000064969936],"domain_scores_gemma":[0.9995229,0.000118702825,0.0000870543,0.000033532157,0.000017630698,0.00022015761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012124636,0.0017444305,0.0023244096,0.0004949371,0.00034125664,0.0011451347,0.0009748255,0.0014431642,0.009190636],"category_scores_gemma":[0.0012806376,0.00054570014,0.0015706583,0.00038683187,0.0010627203,0.0011527905,0.00043781952,0.0030541196,0.0014326429],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9677864,0.010508336,0.0005765893,0.00044683047,0.00062720437,0.00003883571,0.000052120988,0.00051825977,0.003245619,0.00023570699,0.0013307232,0.014633434],"study_design_scores_gemma":[0.9487022,0.048882574,0.0009252621,0.000018883997,0.00021218802,0.000022230042,0.000017970737,0.00023863358,0.00022269094,0.00012139501,0.00062555843,0.000010437549],"about_ca_topic_score_codex":0.001007932,"about_ca_topic_score_gemma":0.0027381543,"teacher_disagreement_score":0.009190636,"about_ca_system_score_codex":0.0007339529,"about_ca_system_score_gemma":0.0012695349,"threshold_uncertainty_score":0.030745804},"labels":[],"label_agreement":null},{"id":"W2588570873","doi":"10.1016/j.ejca.2017.08.019","title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Universitätsklinikum Hamburg-Eppendorf; Centre Léon Bérard; Assistance publique-Hôpitaux de Paris; Baskent Üniversitesi; Gaziantep Üniversitesi; Ege Üniversitesi; Institut Bergonié; University of Sussex; F. Hoffmann-La Roche; Roche","keywords":"Trastuzumab; Medicine; Breast cancer; Adjuvant; Oncology; Internal medicine; Adjuvant therapy; Cancer","score_opus":0.028440997345682596,"score_gpt":0.3521403557355309,"score_spread":0.32369935838984826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588570873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970203,0.0013380817,0.00032986133,0.000114636205,0.000109760105,0.000275748,0.0003541022,0.000024534413,0.00043297943],"genre_scores_gemma":[0.99704856,0.00058186025,0.0003459449,0.00014922999,0.00017415584,0.000257247,0.0006667092,0.000019142322,0.0007572218],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99511343,0.0032042244,0.00024263361,0.00057565223,0.000338812,0.0005253677],"domain_scores_gemma":[0.99497896,0.0022620305,0.0008605705,0.0009486393,0.00023352598,0.0007163444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062378678,0.0019482883,0.0042781984,0.00047624772,0.00037271442,0.0014654917,0.0014231136,0.0023111757,0.0031670884],"category_scores_gemma":[0.006369546,0.0011283777,0.004008585,0.00058716314,0.0023036245,0.001966056,0.000800423,0.0032757856,0.0007002415],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98829854,0.0022512,0.0013440939,0.00009443674,0.0008864741,0.000018903314,0.000037896785,0.00028242392,0.0012759562,0.000038234062,0.00009472683,0.005377145],"study_design_scores_gemma":[0.7838093,0.191481,0.018808428,0.00003383883,0.0030160162,0.00006263779,0.000054736232,0.0008397765,0.0011309894,0.00026888034,0.00043868675,0.00005582134],"about_ca_topic_score_codex":0.0010933591,"about_ca_topic_score_gemma":0.0011748419,"teacher_disagreement_score":0.0062378678,"about_ca_system_score_codex":0.001319876,"about_ca_system_score_gemma":0.0013733539,"threshold_uncertainty_score":0.032989383},"labels":[],"label_agreement":null},{"id":"W2588914509","doi":"10.1016/j.jtho.2017.01.007","title":"HER2 Transmembrane Domain Mutations: Rare New Target for Non–Small Cell Lung Cancer Therapy","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Medicine; Lung cancer; Breast cancer; ErbB; Targeted therapy; Cancer; Cancer research; Oncology; Internal medicine; Epidermal growth factor receptor; Receptor tyrosine kinase; Receptor","score_opus":0.06442857875986661,"score_gpt":0.4781557608819319,"score_spread":0.4137271821220653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588914509","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0557001,0.014864103,0.0024233137,0.8702043,0.01767354,0.000100882986,0.00042702924,0.00022781733,0.03837888],"genre_scores_gemma":[0.4370336,0.014608555,0.0040942035,0.42695296,0.086768426,0.00012831393,0.0004931217,0.00015148026,0.02976939],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995307,0.00010257896,0.00005537753,0.000080034304,0.00010874642,0.00012252368],"domain_scores_gemma":[0.99912125,0.0004380748,0.000073033996,0.00004387059,0.000109173634,0.00021462239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003837885,0.00044494096,0.0008556817,0.0004029484,0.0010155133,0.0012567707,0.0005851784,0.010160154,0.0034401272],"category_scores_gemma":[0.0034058592,0.00023857855,0.00081477454,0.00029161433,0.00088892225,0.0013860428,0.00055684603,0.00836268,0.0017008173],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034084532,0.00014516445,0.01123291,0.00017732775,0.00006313512,0.61945647,0.00024388335,0.00070594694,0.004388808,0.010298154,0.30728593,0.04566151],"study_design_scores_gemma":[0.0003005468,0.00035580908,0.005285469,0.00026484174,0.00013347862,0.7016806,0.0005220614,0.004339709,0.0027360702,0.02253701,0.26178038,0.000064034335],"about_ca_topic_score_codex":0.0006230251,"about_ca_topic_score_gemma":0.0015590102,"teacher_disagreement_score":0.010160154,"about_ca_system_score_codex":0.0013583028,"about_ca_system_score_gemma":0.000715543,"threshold_uncertainty_score":0.011508405},"labels":[],"label_agreement":null},{"id":"W2589233229","doi":"10.1200/jco.2012.30.15_suppl.tps658","title":"HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Metastatic breast cancer; Internal medicine; Discontinuation; Oncology; Clinical endpoint; Breast cancer; Chemotherapy; Blockade; Cancer; Adverse effect; Clinical trial; Receptor","score_opus":0.1545185930237691,"score_gpt":0.5411181389432805,"score_spread":0.3865995459195114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589233229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639255,0.0011161859,0.00017177968,0.00027263776,0.000063054424,0.00041373464,0.00036504262,0.000082043574,0.0011230435],"genre_scores_gemma":[0.99453175,0.0010248565,0.00063764665,0.00027926237,0.00007647302,0.00061201496,0.0011769303,0.000013926479,0.0016470973],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99980634,0.000050315954,0.000011958965,0.00003438145,0.000031397623,0.00006575826],"domain_scores_gemma":[0.99982494,0.000024004992,0.000040989933,0.00001465874,0.0000067844285,0.0000886311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005587118,0.0008350987,0.0011217822,0.0004044838,0.00024583313,0.0005194772,0.0008007731,0.00074658124,0.003177192],"category_scores_gemma":[0.0003534846,0.00030587454,0.00063068664,0.00034284816,0.0005607036,0.00058903865,0.00039077632,0.0021699765,0.0006581095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36302847,0.07883252,0.012832084,0.0013690284,0.0009937733,0.0011983698,0.00030376608,0.00402893,0.2589943,0.0007682266,0.006659656,0.2709908],"study_design_scores_gemma":[0.20675054,0.709809,0.026672306,0.00006966165,0.00054722634,0.0018959029,0.000077494864,0.0021561629,0.043673337,0.00022832029,0.008068503,0.000051548122],"about_ca_topic_score_codex":0.00087162596,"about_ca_topic_score_gemma":0.0022440304,"teacher_disagreement_score":0.003177192,"about_ca_system_score_codex":0.0005773178,"about_ca_system_score_gemma":0.00090798305,"threshold_uncertainty_score":0.01062876},"labels":[],"label_agreement":null},{"id":"W2590097386","doi":"10.1200/jco.2012.30.34_suppl.166","title":"Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Bone and Joint Health Institute; Princess Margaret Cancer Centre; University of Toronto; Cancer Care Ontario; McMaster University; Sunnybrook Health Science Centre; University of Calgary; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Cohort; Breast cancer; Odds ratio; Population; Cancer; Cancer registry; Medical record; Exact test","score_opus":0.5359880732810848,"score_gpt":0.5793496880569081,"score_spread":0.04336161477582334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590097386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894838,0.00063618255,0.00012571446,0.00051762874,0.000011768233,0.000078515775,0.007130967,0.000016498707,0.0019990357],"genre_scores_gemma":[0.9975896,0.0002289532,0.00016217031,0.00009180553,0.000004702996,0.00003164199,0.0013566724,0.000003952747,0.0005304439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984439,0.00014812638,0.00019257881,0.00027407822,0.0006282892,0.00031297017],"domain_scores_gemma":[0.9907788,0.0005995735,0.0049219555,0.00031247328,0.0023644613,0.0010227204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011920398,0.00020022679,0.00024031867,0.0010242468,0.0014421296,0.0008361218,0.0010692374,0.00032111033,0.0022156127],"category_scores_gemma":[0.0053677903,0.00048125366,0.00036209315,0.0031719515,0.0007618429,0.000310143,0.0010149934,0.00031926448,0.00018847064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026821192,0.000008561375,0.99739456,0.000031732678,0.000015566515,0.00004066366,0.00039029052,0.000036700207,0.00008671341,0.00002410113,0.00064388267,0.0013003191],"study_design_scores_gemma":[0.0000048503716,0.00001063423,0.9989504,0.000016170128,0.000007975236,0.00003838624,0.00028377736,0.00011572056,0.000028504253,0.000006901076,0.00053375214,0.0000029282062],"about_ca_topic_score_codex":0.97611463,"about_ca_topic_score_gemma":0.97938365,"teacher_disagreement_score":0.97911054,"about_ca_system_score_codex":0.020889461,"about_ca_system_score_gemma":0.029345365,"threshold_uncertainty_score":0.15156436},"labels":[],"label_agreement":null},{"id":"W2591046956","doi":"10.1634/theoncologist.2016-0265","title":"Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"U.S. Food and Drug Administration; Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Capecitabine; Internal medicine; Hazard ratio; Gastroenterology; Adverse effect; Clinical endpoint; Phases of clinical research; Cancer; Randomized controlled trial; Confidence interval; Oncology; Chemotherapy; Colorectal cancer","score_opus":0.051736645608612145,"score_gpt":0.408330866346466,"score_spread":0.35659422073785385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591046956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822442,0.0036948936,0.0009343976,0.0008627067,0.0006312564,0.007321375,0.0014628172,0.00017906264,0.0026692383],"genre_scores_gemma":[0.9803689,0.0025298996,0.0025182755,0.0017672194,0.0005418607,0.006334945,0.002237085,0.00005168023,0.0036501586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991935,0.00048567462,0.000039623224,0.00012691286,0.00005642939,0.00009781258],"domain_scores_gemma":[0.998871,0.00023502686,0.0002538335,0.00009745602,0.0000750495,0.00046757885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022649027,0.0016968045,0.0033217224,0.00041758595,0.00037965464,0.0011796756,0.0011025288,0.0014881747,0.0066407453],"category_scores_gemma":[0.0018403935,0.0010085616,0.0012872258,0.0004410555,0.0011495218,0.0010822822,0.00039161314,0.0033217066,0.0013787872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9460851,0.024013475,0.0012868177,0.00052006816,0.0010735361,0.00008634418,0.000080423,0.00058443955,0.006224033,0.00011746269,0.0017385606,0.01818976],"study_design_scores_gemma":[0.91709745,0.07968563,0.0013831751,0.000013161861,0.00022253596,0.000047315392,0.000013497881,0.0004101587,0.00033508087,0.00006310587,0.0007191555,0.000009633427],"about_ca_topic_score_codex":0.0010749559,"about_ca_topic_score_gemma":0.0027439543,"teacher_disagreement_score":0.0066407453,"about_ca_system_score_codex":0.001105277,"about_ca_system_score_gemma":0.0020105776,"threshold_uncertainty_score":0.022215486},"labels":[],"label_agreement":null},{"id":"W2591342011","doi":"10.1200/jco.2015.33.28_suppl.117","title":"Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Placebo; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Population; Breast cancer; Trastuzumab; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.14825902496273938,"score_gpt":0.4963269494320232,"score_spread":0.3480679244692838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591342011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98440486,0.007889325,0.0006537645,0.0005009275,0.0005401544,0.0023117699,0.0011257968,0.000097852935,0.0024755273],"genre_scores_gemma":[0.9905558,0.0022173051,0.0008739035,0.00061965076,0.00036650838,0.0019041945,0.0013156947,0.000014236053,0.0021326474],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994905,0.00027130696,0.00003946783,0.00009197959,0.000036051995,0.0000706968],"domain_scores_gemma":[0.9994624,0.00013068879,0.00017185895,0.000052474934,0.00003598335,0.00014658213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015414086,0.0012152363,0.002883711,0.00031017253,0.00025943687,0.0008631837,0.00072338735,0.0012315324,0.004553891],"category_scores_gemma":[0.0015647718,0.00035498655,0.0016719493,0.0003670585,0.00062007474,0.00095041614,0.0003588281,0.0019052867,0.0005527049],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9800664,0.002579924,0.0006141687,0.00054129737,0.000779233,0.00004460864,0.000021799644,0.00028383912,0.0015528158,0.000097075375,0.00047446202,0.012944367],"study_design_scores_gemma":[0.9375028,0.057927076,0.0023696455,0.000044331937,0.0006069883,0.00006980269,0.00001922683,0.00033291345,0.00036274717,0.00017364058,0.00057866034,0.000012200286],"about_ca_topic_score_codex":0.00035291773,"about_ca_topic_score_gemma":0.0010278353,"teacher_disagreement_score":0.004553891,"about_ca_system_score_codex":0.00045816938,"about_ca_system_score_gemma":0.0006187624,"threshold_uncertainty_score":0.015234232},"labels":[],"label_agreement":null},{"id":"W2591351447","doi":"10.1200/jco.2008.26.15_suppl.6615","title":"Review of utilization of trastuzumab in the adjuvant treatment of breast cancer in four university-teaching hospitals in Quebec, Canada","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Adjuvant; Taxane; Regimen; Anthracycline; Metastatic breast cancer; Cancer","score_opus":0.20308625434264685,"score_gpt":0.4986246580019878,"score_spread":0.2955384036593409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591351447","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01270035,0.9798696,0.00008546973,0.0026921546,0.00027950588,0.000051165887,0.0012798825,0.000015737605,0.0030261015],"genre_scores_gemma":[0.06197949,0.9326821,0.0005474474,0.0019839744,0.00021997883,0.000036867936,0.0012779613,0.000011909648,0.0012602884],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975853,0.0003123231,0.00058127585,0.00021864865,0.0009598729,0.0003426092],"domain_scores_gemma":[0.985114,0.0024856015,0.0021438894,0.00013296441,0.008960766,0.0011628406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027721834,0.00042137742,0.0013416532,0.0072367913,0.0011194582,0.0024604974,0.00172706,0.00081935606,0.0029280998],"category_scores_gemma":[0.008400806,0.0003835319,0.0008361696,0.021546429,0.00065553794,0.0005610457,0.0005211517,0.0005243299,0.00023590133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061752734,0.000083220184,0.11992974,0.053035572,0.0013169155,0.0012468245,0.0017844002,0.0010234023,0.0011153837,0.0016544621,0.08614243,0.7320501],"study_design_scores_gemma":[0.00016473197,0.0002979218,0.632052,0.059575237,0.0030423864,0.0016311329,0.0031536,0.00048300767,0.0005140097,0.00012840479,0.29880694,0.0001505946],"about_ca_topic_score_codex":0.95291704,"about_ca_topic_score_gemma":0.98691535,"teacher_disagreement_score":0.050633058,"about_ca_system_score_codex":0.050633058,"about_ca_system_score_gemma":0.103192516,"threshold_uncertainty_score":0.36737025},"labels":[],"label_agreement":null},{"id":"W2592670291","doi":"10.3747/co.24.3413","title":"Trastuzumab in Metastatic Breast Cancer after Complete Remission: An Expensive Commitment for an Entire Life?","year":2017,"lang":"en","type":"letter","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Complete remission; Cancer; Bioinformatics; Chemotherapy","score_opus":0.40544019414483634,"score_gpt":0.5395140546614471,"score_spread":0.13407386051661074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592670291","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060938403,0.004855262,0.00006803614,0.9859255,0.006547891,0.0000053796975,0.000027018628,0.000014801416,0.0019467574],"genre_scores_gemma":[0.009723006,0.012858927,0.00022510941,0.9019388,0.06981821,0.000022871227,0.00005925266,0.000024414116,0.0053294525],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982722,0.00070608204,0.00019356143,0.00013790544,0.00047508263,0.00021510443],"domain_scores_gemma":[0.99496055,0.0030961814,0.0003757816,0.00015743301,0.0006881692,0.0007219322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024684314,0.0004244721,0.0011262526,0.00039929114,0.0016968214,0.0017245814,0.0012596342,0.020330135,0.004351409],"category_scores_gemma":[0.017077368,0.00029844264,0.0008016129,0.00053054694,0.0019109371,0.0034239665,0.00093840965,0.020975994,0.0045253504],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012367153,0.000049632134,0.0008155046,0.00009009427,0.000018107865,0.003159292,0.00009178689,0.00011914025,0.00029606093,0.0046109576,0.9515445,0.039081275],"study_design_scores_gemma":[0.00025785013,0.00024708043,0.0016310543,0.000629664,0.00004712924,0.009015229,0.00036902612,0.0005889074,0.00034241047,0.020604435,0.96621263,0.00005452529],"about_ca_topic_score_codex":0.0028080696,"about_ca_topic_score_gemma":0.0055499566,"teacher_disagreement_score":0.020330135,"about_ca_system_score_codex":0.0032211472,"about_ca_system_score_gemma":0.0022555238,"threshold_uncertainty_score":0.02337122},"labels":[],"label_agreement":null},{"id":"W2592770830","doi":"10.1158/1538-7445.sabcs16-p3-07-03","title":"Abstract P3-07-03: GPNMB activates EGFR to overcome Mek-inhibition: Implications for the development of rational targeted therapy combinations in triple negative breast cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Occupational Cancer Research Centre","funders":"","keywords":"Triple-negative breast cancer; MAPK/ERK pathway; Medicine; Cancer research; Targeted therapy; Breast cancer; Melanoma; Oncology; Cancer; Internal medicine; Signal transduction; Biology; Cell biology","score_opus":0.2165357930011002,"score_gpt":0.5071941370836902,"score_spread":0.29065834408259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592770830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649214,0.013590639,0.0039517856,0.0030225075,0.00008582032,0.0003850736,0.006178347,0.00045340057,0.0074110227],"genre_scores_gemma":[0.9782137,0.0062604654,0.0061216615,0.0005142126,0.00003605503,0.0001695112,0.006085387,0.000058712543,0.0025403253],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987674,0.000027656319,0.000007861915,0.000019649062,0.000041690833,0.000026300451],"domain_scores_gemma":[0.9998913,0.00002237711,0.000026721405,0.00001275255,0.00002127809,0.000025488285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005267225,0.00029877972,0.0004942533,0.0003034521,0.00012248324,0.0007443513,0.0003847226,0.0003158314,0.0030915255],"category_scores_gemma":[0.000337744,0.00013007176,0.0003641128,0.00036636367,0.00014235705,0.0003240303,0.00027380596,0.00076310686,0.0006776555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007436555,0.001852651,0.01901664,0.0014909593,0.0005053072,0.00051414035,0.00010785342,0.017248683,0.68813574,0.0025448808,0.017760646,0.24338596],"study_design_scores_gemma":[0.005297596,0.01737566,0.10137082,0.00047955304,0.0009803681,0.0051027494,0.00030349684,0.075810224,0.6603752,0.0060518854,0.12672326,0.00012925385],"about_ca_topic_score_codex":0.0014421187,"about_ca_topic_score_gemma":0.0035323934,"teacher_disagreement_score":0.0030915255,"about_ca_system_score_codex":0.00078419916,"about_ca_system_score_gemma":0.0005668768,"threshold_uncertainty_score":0.010342121},"labels":[],"label_agreement":null},{"id":"W2593203574","doi":"10.1158/1538-7445.sabcs16-p6-07-06","title":"Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Metastatic breast cancer; Taxane; Breast cancer; Univariate analysis; Proportional hazards model; Multivariate analysis; Cancer; Oncology; Gastroenterology","score_opus":0.07355459369102431,"score_gpt":0.430158884603077,"score_spread":0.3566042909120527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593203574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718034,0.0003699002,0.000050294857,0.00018245555,0.00001642244,0.000046716705,0.0013155725,0.00001181029,0.0008265337],"genre_scores_gemma":[0.99649304,0.0000888263,0.00009656387,0.00006314967,0.000036090987,0.00004940888,0.0022616053,0.0000054292655,0.0009059108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998435,0.000047363395,0.000011404981,0.000033075008,0.00003032992,0.000034390498],"domain_scores_gemma":[0.99917716,0.00014837545,0.0001424695,0.00004934849,0.00013070581,0.00035199348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036347276,0.0002464997,0.000409202,0.0002458976,0.00017721005,0.00028806765,0.00026954367,0.0002525207,0.003851048],"category_scores_gemma":[0.0010280801,0.000102694816,0.0003568531,0.0003080704,0.00013362832,0.0001348042,0.0001963786,0.00050014275,0.00052478013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08373747,0.0019483581,0.81890684,0.00020384598,0.0007558669,0.00049786223,0.00011296397,0.0012131789,0.019483604,0.00008636363,0.014184863,0.0588688],"study_design_scores_gemma":[0.0021130166,0.011428146,0.9800326,0.000025805213,0.00028982456,0.00031308443,0.00003588009,0.0014013404,0.0026663428,0.000031012893,0.0016518842,0.000011017682],"about_ca_topic_score_codex":0.0062682834,"about_ca_topic_score_gemma":0.013231218,"teacher_disagreement_score":0.0062682834,"about_ca_system_score_codex":0.0009572132,"about_ca_system_score_gemma":0.0007908843,"threshold_uncertainty_score":0.012883067},"labels":[],"label_agreement":null},{"id":"W2594604923","doi":"10.1158/1538-7445.sabcs16-p4-21-23","title":"Abstract P4-21-23: A retrospective evaluation of cardiovascular recovery and oncologic outcomes associated with interrupted and continuous adjuvant trastuzumab in the setting of mild left ventricular dysfunction","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Ejection fraction; Breast cancer; Internal medicine; Asymptomatic; Oncology; Cancer; Adjuvant therapy; Cardiac function curve; Cardiology; Metastatic breast cancer; Surgery; Heart failure","score_opus":0.13438231319708782,"score_gpt":0.43730653060470037,"score_spread":0.30292421740761255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594604923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99914753,0.000116228104,0.000027182972,0.000014551857,0.0000025161692,0.000032265685,0.00033360763,0.0000016354064,0.00032443707],"genre_scores_gemma":[0.9992366,0.00006823388,0.00003692844,0.000029761313,0.000006932775,0.000030258368,0.00047265718,0.0000014313304,0.00011719437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925405,0.00011810333,0.00012636042,0.00016524273,0.00017554301,0.00016056921],"domain_scores_gemma":[0.99756455,0.0003402413,0.0009842124,0.0001555386,0.00042060233,0.00053486665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007231137,0.00021304697,0.00035134496,0.00094686274,0.0007550195,0.00060849683,0.00059678167,0.00038339084,0.0014582125],"category_scores_gemma":[0.0017363125,0.00028652363,0.00029465722,0.0013170964,0.00047288666,0.00039406682,0.0007186853,0.0005744329,0.0003668154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011848885,0.000033115655,0.99867505,0.000009401561,0.000012778138,0.0004692861,0.00006676526,0.000009583973,0.000067179964,0.00000475535,0.00007310665,0.00046046218],"study_design_scores_gemma":[0.000013147032,0.00031867385,0.9972217,0.000011348441,0.000020123067,0.0015928261,0.00042173703,0.000060567658,0.0000665839,0.000008544534,0.00025925058,0.0000054127454],"about_ca_topic_score_codex":0.021380149,"about_ca_topic_score_gemma":0.021492463,"teacher_disagreement_score":0.021380149,"about_ca_system_score_codex":0.0016002159,"about_ca_system_score_gemma":0.0012108543,"threshold_uncertainty_score":0.042511404},"labels":[],"label_agreement":null},{"id":"W2596210945","doi":"10.1200/jco.2012.30.15_suppl.e11061","title":"Development of preclinical models of human BT474 and MDA-MB-361 breast cancer that endogenously overexpress HER2 and that respond to trastuzumab.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Trastuzumab; Medicine; Bioluminescence imaging; In vivo; Breast cancer; Cancer research; Cancer; Lymph node; Chemotherapy; Metastatic breast cancer; Metastasis; Oncology; Internal medicine; Pathology; Cell culture; Luciferase; Biology; Transfection","score_opus":0.47719018676011143,"score_gpt":0.5664286975740835,"score_spread":0.0892385108139721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596210945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9423399,0.008550449,0.018116403,0.0011857755,0.0005573562,0.0020534664,0.014133681,0.0007004982,0.012362388],"genre_scores_gemma":[0.90993726,0.0064881477,0.027447537,0.00046139344,0.000080191996,0.0037527212,0.026670694,0.00016550772,0.024996463],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99939907,0.0001031551,0.000054019136,0.00009289366,0.00018674968,0.00016415301],"domain_scores_gemma":[0.9996841,0.00003422311,0.000093575465,0.00005672549,0.00003897689,0.000092489856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078332226,0.0011966126,0.00056128285,0.000813843,0.0003529438,0.000512005,0.00096574903,0.0008663024,0.004192926],"category_scores_gemma":[0.0002573291,0.00045492197,0.0007010905,0.0006056236,0.00037043603,0.00046822874,0.00039715442,0.0015676931,0.0016824172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013367499,0.0012957577,0.00045807686,0.00016495517,0.00004016335,0.00020902182,0.00008039978,0.00057333376,0.99041337,0.000905779,0.0013645606,0.0031578515],"study_design_scores_gemma":[0.0005696152,0.0070556705,0.0058283275,0.000037540754,0.00010815207,0.0015257299,0.000093223935,0.0026309679,0.95511633,0.0002338189,0.026776347,0.000024207617],"about_ca_topic_score_codex":0.0028105315,"about_ca_topic_score_gemma":0.0043508615,"teacher_disagreement_score":0.004192926,"about_ca_system_score_codex":0.0012259247,"about_ca_system_score_gemma":0.00085671945,"threshold_uncertainty_score":0.014026701},"labels":[],"label_agreement":null},{"id":"W2597431707","doi":"10.1200/jco.2012.30.15_suppl.3027","title":"Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Neutropenia; Febrile neutropenia; Adverse effect; Internal medicine; Leukopenia; Pharmacology; Oncology; Toxicity; Gastroenterology","score_opus":0.06951995384007696,"score_gpt":0.45923291073914174,"score_spread":0.38971295689906477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597431707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926831,0.0009937641,0.0006443702,0.00032127977,0.00011090676,0.0030097426,0.0007312701,0.00008602679,0.0014195571],"genre_scores_gemma":[0.98794425,0.0015958961,0.0023815152,0.0004904234,0.0001533193,0.003830604,0.0012069421,0.00002720873,0.0023699421],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99960643,0.00016055984,0.000021584072,0.000078424084,0.000043570555,0.0000894484],"domain_scores_gemma":[0.99952805,0.000069694426,0.00010479138,0.000050284638,0.000026346146,0.00022089882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014549812,0.0023691538,0.0018257875,0.00076328067,0.00035447368,0.0011326494,0.0012535995,0.0011964069,0.0033270197],"category_scores_gemma":[0.0008917226,0.0008483031,0.001178347,0.0005607685,0.0011105696,0.0010281947,0.00063440803,0.0030435014,0.0008966471],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7642344,0.10422217,0.0027265626,0.00071811344,0.00069498474,0.00022021841,0.0003186199,0.006456914,0.03438417,0.0005949039,0.0029937667,0.08243522],"study_design_scores_gemma":[0.6246396,0.36699152,0.0022054408,0.000016972344,0.00019298134,0.00012503486,0.000031811225,0.0012950904,0.0029151835,0.00024904564,0.0013104611,0.00002676802],"about_ca_topic_score_codex":0.000893358,"about_ca_topic_score_gemma":0.0016108027,"teacher_disagreement_score":0.0033270197,"about_ca_system_score_codex":0.00096696755,"about_ca_system_score_gemma":0.001571083,"threshold_uncertainty_score":0.011129975},"labels":[],"label_agreement":null},{"id":"W2597614090","doi":"10.1007/s10549-017-4203-y","title":"Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Trastuzumab; Medicine; Internal medicine; Breast cancer; Metastatic breast cancer; Chemotherapy; Cardiotoxicity; Oncology; Cancer; Gastroenterology; Surgery","score_opus":0.061904357849037736,"score_gpt":0.37300700441964424,"score_spread":0.3111026465706065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597614090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628395,0.0021352852,0.00021510065,0.00016171312,0.00003516418,0.000038296042,0.00022924438,0.000011864059,0.00088945485],"genre_scores_gemma":[0.9986708,0.000350032,0.000099151424,0.00013766285,0.00010140956,0.000026101616,0.00035996622,0.0000045469724,0.00025031602],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99918705,0.00043402036,0.00004307765,0.00013403907,0.00012011884,0.000081729086],"domain_scores_gemma":[0.99854773,0.0005722401,0.00040361803,0.00018013787,0.00007504403,0.00022125705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002606234,0.00069629867,0.00098923,0.00021756144,0.00015512445,0.00065500056,0.0003823624,0.00067720166,0.0007175458],"category_scores_gemma":[0.0030771876,0.00025789082,0.0006756178,0.00028903875,0.00054309296,0.00054539304,0.00019701757,0.0011815048,0.00018264224],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.664348,0.005616879,0.20236374,0.0002739723,0.0037205284,0.00027683892,0.00012616657,0.0030978778,0.023692505,0.00025878107,0.0014356149,0.094789095],"study_design_scores_gemma":[0.06686264,0.21557136,0.69544953,0.000064883,0.004142805,0.0006511549,0.000105265106,0.0058522187,0.00806487,0.000685178,0.0024763406,0.000073701085],"about_ca_topic_score_codex":0.00034520417,"about_ca_topic_score_gemma":0.00050182606,"teacher_disagreement_score":0.002606234,"about_ca_system_score_codex":0.00046469006,"about_ca_system_score_gemma":0.00037351385,"threshold_uncertainty_score":0.0137832165},"labels":[],"label_agreement":null},{"id":"W2598244667","doi":"10.1200/jco.2014.32.15_suppl.647","title":"Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Lapatinib; Breast cancer; Adjuvant; Oncology; Internal medicine; Quality of life (healthcare); Cancer","score_opus":0.20429124569115753,"score_gpt":0.5118660664074929,"score_spread":0.30757482071633535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598244667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998569,0.0006230461,0.00003764843,0.000091374815,0.000012413406,0.00004330193,0.00033911824,0.0000022732834,0.00028183998],"genre_scores_gemma":[0.9987675,0.00025722155,0.000059510035,0.00010663026,0.000020065732,0.000065226726,0.0005257954,5.280035e-7,0.00019756214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997738,0.000104938874,0.000015888414,0.000037006128,0.00003034916,0.000038036833],"domain_scores_gemma":[0.99964833,0.00005190896,0.00013840567,0.000012383642,0.00001612601,0.000132919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065108296,0.0002531764,0.0004272696,0.00014328527,0.00020193949,0.00039997438,0.00015764551,0.00034337575,0.0013760306],"category_scores_gemma":[0.00069079886,0.0001566637,0.0005892464,0.0003492664,0.00018626022,0.00030123375,0.00031502158,0.0006390431,0.00014748337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13538621,0.007733809,0.79601043,0.00046912167,0.0024088821,0.00022526785,0.0002413022,0.0012830371,0.0035210492,0.00009911082,0.0034449417,0.0491768],"study_design_scores_gemma":[0.01517654,0.043569002,0.9372002,0.000042421838,0.00077568495,0.00025303315,0.000112946174,0.0009838234,0.00036512638,0.00009340591,0.0014111723,0.000016621061],"about_ca_topic_score_codex":0.000851113,"about_ca_topic_score_gemma":0.0013698407,"teacher_disagreement_score":0.0013760306,"about_ca_system_score_codex":0.0003551519,"about_ca_system_score_gemma":0.00024375798,"threshold_uncertainty_score":0.0046032667},"labels":[],"label_agreement":null},{"id":"W2598547790","doi":"10.2196/resprot.7289","title":"Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility","year":2017,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Louisville; Takeda Oncology; Virginia Commonwealth University; Moffitt Cancer Center; Quest Diagnostics","keywords":"Brentuximab vedotin; Medicine; Clinical trial; Oncology; Cancer; Medical physics; Internal medicine; CD30; Lymphoma","score_opus":0.6744726766871684,"score_gpt":0.6790201270023464,"score_spread":0.004547450315178003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598547790","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866111,0.00024878661,0.0025397718,0.0003340126,0.000035869693,0.0068389345,0.001368406,0.00008113736,0.0019419659],"genre_scores_gemma":[0.9865242,0.00010963359,0.0046882443,0.00046894985,0.000065148,0.006435142,0.001289719,0.000017045046,0.00040188865],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9934769,0.0048916736,0.00035070057,0.000553685,0.00038915797,0.00033794815],"domain_scores_gemma":[0.9849032,0.004681335,0.0036849498,0.0017649685,0.0017356311,0.00322989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013792829,0.00039229338,0.00048577748,0.0005980446,0.00074610504,0.0010649342,0.0005377736,0.0005593,0.0047807978],"category_scores_gemma":[0.012436077,0.00023706612,0.0006997428,0.00082757,0.0006542242,0.0006677057,0.0009083222,0.0007363861,0.000702856],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17954506,0.01785668,0.7002384,0.00030699527,0.00042854316,0.00028680265,0.0007450547,0.0014956613,0.0050061103,0.00059728767,0.004769016,0.0887244],"study_design_scores_gemma":[0.0636174,0.19683915,0.71054834,0.00010626172,0.0009855803,0.000599648,0.000569812,0.012952416,0.004848287,0.0005518779,0.008297499,0.0000837212],"about_ca_topic_score_codex":0.0031079445,"about_ca_topic_score_gemma":0.0037988364,"teacher_disagreement_score":0.013792829,"about_ca_system_score_codex":0.0013619855,"about_ca_system_score_gemma":0.004395188,"threshold_uncertainty_score":0.07294434},"labels":[],"label_agreement":null},{"id":"W2598916155","doi":"10.1200/jco.2004.22.90140.2622","title":"ARH460–16-2: a therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Immunohistochemistry; CD44; Medicine; Breast cancer; Monoclonal antibody; Epitope; Cancer; Antigen; Cancer research; HER2/neu; Antibody; Pathology; Internal medicine; Immunology; Biology; Cell","score_opus":0.18380388789095847,"score_gpt":0.5762637421299914,"score_spread":0.39245985423903296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598916155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781095,0.011381375,0.0027773713,0.00035276622,0.0001128891,0.00013516392,0.00029004668,0.00016588828,0.0066750734],"genre_scores_gemma":[0.98491687,0.0044009,0.0046675517,0.00020663186,0.00009985052,0.00007494552,0.00075145235,0.00001667925,0.0048651826],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998404,0.00003256132,0.000012275668,0.000027583721,0.00004811297,0.00003901408],"domain_scores_gemma":[0.9999298,0.000009226461,0.000014810557,0.000007002754,0.0000116737665,0.000027532098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003762146,0.00031553317,0.00021159889,0.0004840661,0.00015471631,0.00023272833,0.00027612815,0.0004643155,0.0027901146],"category_scores_gemma":[0.00013277263,0.00013140166,0.00015290198,0.00024421138,0.00014565868,0.00018092888,0.00017411415,0.00038039952,0.001051726],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088543375,0.0005268649,0.004311257,0.00017100066,0.000032249704,0.00035273583,0.000025245943,0.00034343763,0.9570103,0.00018693566,0.0013831967,0.034771256],"study_design_scores_gemma":[0.0006248417,0.0072559505,0.053743478,0.000058083482,0.0001385412,0.013273499,0.00003704662,0.0046758223,0.8821608,0.00019721365,0.037809372,0.000025386169],"about_ca_topic_score_codex":0.00021463465,"about_ca_topic_score_gemma":0.0003606509,"teacher_disagreement_score":0.0027901146,"about_ca_system_score_codex":0.00026280398,"about_ca_system_score_gemma":0.00019371622,"threshold_uncertainty_score":0.009333909},"labels":[],"label_agreement":null},{"id":"W2599026586","doi":"10.1016/j.ejcb.2017.03.006","title":"PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression","year":2017,"lang":"en","type":"article","venue":"European Journal of Cell Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Canadian Cancer Society; Heart and Stroke Foundation of Canada","keywords":"Cancer research; Breast cancer; Estrogen receptor; Tumor progression; Cancer; Medicine; Cell growth; Estrogen; Internal medicine; Biology","score_opus":0.029916881052933348,"score_gpt":0.35842537930141255,"score_spread":0.3285084982484792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599026586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969085,0.0035847833,0.0031567959,0.0006990308,0.0002655654,0.00004820498,0.0038662786,0.00041938626,0.0082690185],"genre_scores_gemma":[0.98841405,0.0011923668,0.000909323,0.00012837905,0.00006141575,0.000024783603,0.0029794376,0.000063604384,0.0062266267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996228,0.000042923093,0.000021932465,0.00008958098,0.00013924271,0.000083581675],"domain_scores_gemma":[0.9997174,0.00005041465,0.00009619827,0.00004158358,0.00004547045,0.0000488677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036242369,0.0003734163,0.00035618537,0.00084339344,0.00040561784,0.0010250327,0.0005252793,0.0005451415,0.006601282],"category_scores_gemma":[0.0006533938,0.00033060313,0.00047167361,0.00068748905,0.0003238697,0.0004186063,0.00047117705,0.000707698,0.0017281832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021923862,0.0002477479,0.1062545,0.00035034845,0.00036358734,0.00290313,0.00015633523,0.0013803595,0.82256335,0.005860123,0.008338821,0.049389366],"study_design_scores_gemma":[0.00023970776,0.0006819472,0.47745752,0.00007193987,0.000570237,0.012604077,0.00055185385,0.009270854,0.39302638,0.0034035149,0.10202274,0.00009922448],"about_ca_topic_score_codex":0.00092088245,"about_ca_topic_score_gemma":0.0009942974,"teacher_disagreement_score":0.006601282,"about_ca_system_score_codex":0.00052067655,"about_ca_system_score_gemma":0.0005105919,"threshold_uncertainty_score":0.022083461},"labels":[],"label_agreement":null},{"id":"W2600462870","doi":"10.1200/jco.2012.30.15_suppl.531","title":"A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Clinical endpoint; Cohort; Placebo; Population; Randomized controlled trial; Pazopanib; Surgery; Cancer; Toxicity; Pathology","score_opus":0.1521543493657456,"score_gpt":0.5263324141883701,"score_spread":0.3741780648226245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600462870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435533,0.0020643098,0.0008474896,0.000935557,0.00045133065,0.007280885,0.0017100049,0.00015394021,0.0022011176],"genre_scores_gemma":[0.97991264,0.0018048194,0.002020101,0.0014770909,0.0004667539,0.009025539,0.0017356555,0.000036418907,0.0035209008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99932826,0.00038420444,0.000027578926,0.000112312264,0.000040893687,0.0001067966],"domain_scores_gemma":[0.9990644,0.00019235311,0.00024568808,0.00007501422,0.000040137595,0.00038237608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016812194,0.0021157064,0.0024227987,0.00045577314,0.00037890422,0.0009249948,0.0010856858,0.0016006922,0.006787508],"category_scores_gemma":[0.0015026211,0.00087599515,0.0014633824,0.00043049947,0.0012549661,0.0011259355,0.0005006362,0.0030952503,0.0013491015],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95962304,0.015663868,0.00084980176,0.00033928495,0.0004851919,0.000054498785,0.000051549818,0.00046071273,0.005686651,0.00009618236,0.0009236047,0.015765732],"study_design_scores_gemma":[0.8917937,0.10572323,0.0011281753,0.000013655102,0.00017306593,0.000033985292,0.0000127602225,0.0002852648,0.00032722854,0.00008445281,0.00041526154,0.000009224968],"about_ca_topic_score_codex":0.00103356,"about_ca_topic_score_gemma":0.0028942875,"teacher_disagreement_score":0.006787508,"about_ca_system_score_codex":0.0011018431,"about_ca_system_score_gemma":0.0017835975,"threshold_uncertainty_score":0.022706449},"labels":[],"label_agreement":null},{"id":"W2600507632","doi":"10.2217/ebo.13.381","title":"EGF receptor inhibitors: patient selection and clinical outcomes","year":2013,"lang":"en","type":"other","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HEC Montréal","funders":"","keywords":"Miami; Medicine; Clinical Oncology; Internal medicine; Breast cancer; Oncology; Pharmacy; Family medicine; Cancer; Library science","score_opus":0.04510780986228854,"score_gpt":0.4086447254697415,"score_spread":0.363536915607453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600507632","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97020006,0.009299886,0.0007995178,0.0019233964,0.00011551003,0.00011864577,0.002595064,0.000032272474,0.014915664],"genre_scores_gemma":[0.9950771,0.0014059524,0.0003363027,0.00041424565,0.000117598545,0.000040316972,0.0020320874,0.000008815434,0.00056756334],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959713,0.00011416975,0.00006767624,0.00005757988,0.000098883545,0.00006450413],"domain_scores_gemma":[0.9994117,0.00009897435,0.00024200075,0.000021066204,0.00006863865,0.00015768719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006661167,0.000112131944,0.0002935186,0.00033784396,0.00027290528,0.0004882423,0.00015951111,0.0002740162,0.002647909],"category_scores_gemma":[0.002465715,0.000050685827,0.0002861979,0.0006243682,0.00011841611,0.000380074,0.00024094203,0.0003490324,0.00052306824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001162397,0.00020120075,0.9329049,0.000058823032,0.00010260357,0.00046289878,0.000035972167,0.0003035046,0.00030853148,0.00016879775,0.004762669,0.059527762],"study_design_scores_gemma":[0.00013479976,0.00076986995,0.9881576,0.000097848715,0.00012268075,0.0036278737,0.00016438072,0.0010431007,0.00025172287,0.00055551715,0.00505342,0.000021252967],"about_ca_topic_score_codex":0.00075820606,"about_ca_topic_score_gemma":0.0014974596,"teacher_disagreement_score":0.002647909,"about_ca_system_score_codex":0.00037964704,"about_ca_system_score_gemma":0.0003691083,"threshold_uncertainty_score":0.008858144},"labels":[],"label_agreement":null},{"id":"W2601086841","doi":"10.1200/jco.2014.32.15_suppl.8051","title":"A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; ERBB3; Progression-free survival; Log-rank test; Epidermal growth factor receptor; Cancer; Chemotherapy; Survival analysis","score_opus":0.12330918582681002,"score_gpt":0.5359127661219609,"score_spread":0.4126035802951509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601086841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884857,0.0010733608,0.0005880007,0.0005212095,0.00022595994,0.0056910543,0.0013319444,0.0001028377,0.0019798956],"genre_scores_gemma":[0.98503137,0.00071685406,0.0014349516,0.0011381487,0.0002871076,0.0066239424,0.0019725864,0.00002581988,0.0027691864],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993118,0.00039055588,0.000028235225,0.00011706804,0.000041963252,0.0001103724],"domain_scores_gemma":[0.9993457,0.000121426274,0.0001631358,0.00006133359,0.00003807494,0.00027027656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001983488,0.0020402342,0.0018946293,0.00052643794,0.00035287836,0.0009451448,0.0008117793,0.0015496771,0.0051783416],"category_scores_gemma":[0.001270026,0.0006581603,0.0012489704,0.0003543139,0.0010127872,0.001183857,0.00061624986,0.002345733,0.0009765998],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9675994,0.0116535295,0.0014710038,0.00016509472,0.0003483146,0.00005783422,0.000049284532,0.000494805,0.004196541,0.0001207823,0.00093444216,0.012908984],"study_design_scores_gemma":[0.8829347,0.113000214,0.0021690165,0.0000086455775,0.00014306043,0.000057142883,0.000015681702,0.00041118712,0.0005088997,0.00013245357,0.0006067753,0.000012252282],"about_ca_topic_score_codex":0.00048756727,"about_ca_topic_score_gemma":0.0012714778,"teacher_disagreement_score":0.0051783416,"about_ca_system_score_codex":0.0009413877,"about_ca_system_score_gemma":0.0012763226,"threshold_uncertainty_score":0.017323256},"labels":[],"label_agreement":null},{"id":"W2602586354","doi":"10.1021/acsami.6b15987","title":"A New Spin on Antibody–Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells","year":2017,"lang":"en","type":"article","venue":"ACS Applied Materials & Interfaces","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences; Natural Sciences and Engineering Research Council of Canada; Canadian Cancer Society Research Institute","keywords":"Trastuzumab; Fulvestrant; Materials science; Drug; Conjugate; Antibody-drug conjugate; Colloid; Nanotechnology; Combinatorial chemistry; Pharmacology; Antibody; Cancer; Monoclonal antibody; Chemical engineering; Medicine; Breast cancer; Tamoxifen; Immunology; Internal medicine; Chemistry","score_opus":0.017780271233533304,"score_gpt":0.33513220597890825,"score_spread":0.31735193474537493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602586354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792189,0.002516413,0.012369138,0.00030571167,0.000107330554,0.0001306596,0.000092172435,0.00020761754,0.0050521893],"genre_scores_gemma":[0.9813213,0.0009202645,0.010847804,0.0002520819,0.000041745105,0.000052900345,0.00014184111,0.000053470965,0.006368495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986815,0.000014864035,0.000008422257,0.00004572768,0.00004341189,0.000019436264],"domain_scores_gemma":[0.999897,0.000020518732,0.000020537525,0.000009755366,0.00002934249,0.00002293225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017142731,0.0002829773,0.00020148118,0.00025478163,0.0002517591,0.00042229812,0.00022042576,0.00044387995,0.0010779959],"category_scores_gemma":[0.00018638653,0.00017480066,0.00016699191,0.00012434268,0.00023228052,0.00028683056,0.00026121075,0.00041162185,0.00024134251],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000557655,0.000028588716,0.00016636489,0.000044576165,0.00000878802,0.000063875064,0.00003572288,0.000070394366,0.9949557,0.000243894,0.0001231331,0.004203171],"study_design_scores_gemma":[0.00004772131,0.0004033075,0.0011693729,0.0000050313724,0.000028923108,0.00026941297,0.000012539464,0.0011282683,0.99177516,0.00004980617,0.005102738,0.000007568934],"about_ca_topic_score_codex":0.0009044804,"about_ca_topic_score_gemma":0.0019763582,"teacher_disagreement_score":0.0010779959,"about_ca_system_score_codex":0.00034105292,"about_ca_system_score_gemma":0.00026050938,"threshold_uncertainty_score":0.0036063194},"labels":[],"label_agreement":null},{"id":"W2603167024","doi":"10.1200/jco.2014.32.15_suppl.617","title":"Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Taxane; Metastatic breast cancer; Oncology; Breast cancer; Multivariate analysis; Univariate analysis; Cancer","score_opus":0.08082417327815228,"score_gpt":0.4823661614697947,"score_spread":0.40154198819164244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603167024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994337,0.00021317728,0.00001726582,0.000039327773,0.0000027332935,0.0000063200423,0.00010632757,0.0000022302788,0.00017892584],"genre_scores_gemma":[0.99947566,0.000046433757,0.000027813623,0.000022108567,0.000007632781,0.000008586433,0.00027171773,6.365624e-7,0.00013945674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99990165,0.000028587721,0.000006846216,0.000021936785,0.00001893339,0.000022015209],"domain_scores_gemma":[0.99957687,0.00009742831,0.00011410071,0.000018020342,0.000024502175,0.00016902534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003597392,0.00018022241,0.00029409508,0.00017640858,0.00010904716,0.00027537835,0.00015441814,0.000192434,0.0011242261],"category_scores_gemma":[0.00080669683,0.000072148105,0.00026454363,0.00017906229,0.00012495922,0.00014939642,0.00015486834,0.00036754014,0.00015130687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03266478,0.0006852537,0.9345551,0.00005220665,0.00033970465,0.0003071845,0.00008802285,0.00062896265,0.0060728067,0.000038745813,0.0010189657,0.0235483],"study_design_scores_gemma":[0.00061041047,0.006559435,0.9897814,0.000011808101,0.00016715887,0.00041225133,0.000035730493,0.0010356647,0.00090457534,0.000039620238,0.00043636642,0.0000055856144],"about_ca_topic_score_codex":0.00159482,"about_ca_topic_score_gemma":0.003730072,"teacher_disagreement_score":0.00159482,"about_ca_system_score_codex":0.0004963344,"about_ca_system_score_gemma":0.00036572092,"threshold_uncertainty_score":0.0037609339},"labels":[],"label_agreement":null},{"id":"W2604129376","doi":"10.5772/66437","title":"Cardiac Toxicity of HER2-Directed Therapy in Women with Breast Cancer: Epidemiology, Etiology, Risk Factors, and Management","year":2017,"lang":"en","type":"book-chapter","venue":"InTech eBooks","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Lapatinib; Pertuzumab; Trastuzumab; Trastuzumab emtansine; Medicine; Neratinib; Oncology; Breast cancer; Human Epidermal Growth Factor Receptor 2; Internal medicine; Metastatic breast cancer; Targeted therapy; Cancer","score_opus":0.054806164819263814,"score_gpt":0.35238366588232156,"score_spread":0.29757750106305775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604129376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014730002,0.88969374,0.002853754,0.017112363,0.0016139187,0.000038430142,0.00068336114,0.00017348166,0.07310098],"genre_scores_gemma":[0.06165276,0.8804887,0.0039962693,0.0073463386,0.0049312804,0.00006114224,0.00077958655,0.00007178597,0.04067205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999336,0.000019012925,0.0000057191446,0.0000079200545,0.000028135266,0.0000055771484],"domain_scores_gemma":[0.99982363,0.00011444004,0.000023223312,0.000003683208,0.000016973629,0.00001816102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002074465,0.00029474404,0.000370675,0.00034148188,0.00010549725,0.00046822944,0.0002587627,0.00039139183,0.0028847903],"category_scores_gemma":[0.0005563142,0.000100280835,0.00022330819,0.00045621977,0.000157971,0.0003629764,0.00021411505,0.0010340426,0.0011078259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008903127,0.0000958272,0.0063613798,0.00080383976,0.00006401195,0.001311508,0.00021868809,0.00051473913,0.0010826067,0.0029197938,0.20748669,0.7790519],"study_design_scores_gemma":[0.00011246474,0.000727344,0.120027535,0.0068228194,0.00020414729,0.05113071,0.0006927467,0.0019024131,0.0012173734,0.021107519,0.79594994,0.00010498313],"about_ca_topic_score_codex":0.00068260403,"about_ca_topic_score_gemma":0.002048672,"teacher_disagreement_score":0.0028847903,"about_ca_system_score_codex":0.00026812038,"about_ca_system_score_gemma":0.00023512596,"threshold_uncertainty_score":0.009650528},"labels":[],"label_agreement":null},{"id":"W2604499807","doi":"10.1021/acschembio.6b00990","title":"Structure-Directed and Tailored Diversity Synthetic Antibody Libraries Yield Novel Anti-EGFR Antagonists","year":2017,"lang":"en","type":"article","venue":"ACS Chemical Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Toronto","funders":"Canadian Institutes of Health Research; Western Economic Diversification Canada; Government of Canada","keywords":"Antibody; Computational biology; Yield (engineering); Diversity (politics); Biology; Immunology; Political science","score_opus":0.04756236875923106,"score_gpt":0.3427056118638686,"score_spread":0.2951432431046376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604499807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836908,0.00047283006,0.013241405,0.0000697933,0.000017905728,0.000057550737,0.00018740854,0.00011101069,0.0021511859],"genre_scores_gemma":[0.98960215,0.0003797289,0.008250974,0.00009687682,0.00000855233,0.000028861527,0.0002538859,0.000026402713,0.0013525004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981266,0.000033687484,0.000010958106,0.000031414023,0.000063557825,0.000047722475],"domain_scores_gemma":[0.9999206,0.000014897341,0.000022524348,0.000009035849,0.000014122367,0.00001890434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022555566,0.00028236877,0.00023356992,0.00023833891,0.0000863868,0.00036449553,0.00028984094,0.00019668817,0.00062685314],"category_scores_gemma":[0.00024081685,0.00013233062,0.00014892139,0.00020376785,0.00014092622,0.00019000273,0.00024307174,0.00035152523,0.00022174577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071449234,0.000053444404,0.00020798376,0.00002492942,0.00001022172,0.000056744266,0.000018737255,0.001506605,0.9920304,0.00043139813,0.000058369747,0.005529748],"study_design_scores_gemma":[0.00003096941,0.00053946493,0.00070508145,0.0000031997965,0.000018783789,0.00020541094,0.000016708467,0.003959046,0.9919688,0.00014041447,0.0024055855,0.000006446899],"about_ca_topic_score_codex":0.00013638637,"about_ca_topic_score_gemma":0.00035768072,"teacher_disagreement_score":0.00062685314,"about_ca_system_score_codex":0.00027055677,"about_ca_system_score_gemma":0.00013784431,"threshold_uncertainty_score":0.0020970702},"labels":[],"label_agreement":null},{"id":"W2604691720","doi":"10.1200/jco.2012.30.15_suppl.517","title":"Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Immunohistochemistry; Oncology; Breast cancer; Internal medicine; Hazard ratio; Proportional hazards model; Univariate; Algorithm; Univariate analysis; Cancer; Gynecology; Multivariate analysis; Multivariate statistics; Confidence interval; Machine learning; Computer science","score_opus":0.5361192643362197,"score_gpt":0.5720454570989529,"score_spread":0.03592619276273323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604691720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69029725,0.0009492002,0.29984242,0.00034470778,0.00016231339,0.000802878,0.001426948,0.0020246583,0.0041497536],"genre_scores_gemma":[0.8190509,0.000119228476,0.1763531,0.000110208595,0.000028419128,0.00050444785,0.0024544764,0.00023080861,0.0011484158],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940089,0.0029432694,0.00044496535,0.00079396,0.001564148,0.00024480108],"domain_scores_gemma":[0.9849791,0.008337966,0.0015958325,0.0013986875,0.0034295327,0.0002588948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019418312,0.00093493046,0.0006543769,0.002093148,0.0004090339,0.0014758988,0.0013569406,0.00086357695,0.0020522254],"category_scores_gemma":[0.029931312,0.00041849978,0.0012127709,0.0007992153,0.0005480071,0.0010702228,0.0016483637,0.0009392389,0.0008022357],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053433045,0.0006217283,0.6005514,0.00040373034,0.002009441,0.00014498063,0.0003532842,0.10092403,0.017974636,0.002075054,0.0050671254,0.2645313],"study_design_scores_gemma":[0.0004317108,0.0013689321,0.14763063,0.000075685595,0.0005054556,0.000607925,0.00020912834,0.8247192,0.01713662,0.0029564083,0.004257656,0.00010059324],"about_ca_topic_score_codex":0.0023908152,"about_ca_topic_score_gemma":0.002718307,"teacher_disagreement_score":0.019418312,"about_ca_system_score_codex":0.0012473251,"about_ca_system_score_gemma":0.001303222,"threshold_uncertainty_score":0.10269511},"labels":[],"label_agreement":null},{"id":"W2606271249","doi":"","title":"A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer","year":2016,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Oncology; Cancer therapy; Internal medicine; Cancer research; Cancer","score_opus":0.03887320266124419,"score_gpt":0.37596619975551926,"score_spread":0.3370929970942751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606271249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8161507,0.13486788,0.017007068,0.0017029077,0.00077596103,0.00040323453,0.00077633926,0.0004280905,0.027887829],"genre_scores_gemma":[0.9554893,0.027667588,0.008904766,0.00042872064,0.00015419231,0.00011201053,0.00044059427,0.000036863286,0.0067659984],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99988484,0.00003032062,0.000008989844,0.000026467966,0.000023343711,0.000025999407],"domain_scores_gemma":[0.9999589,0.000013307947,0.0000061745386,0.0000066597727,0.0000062821537,0.000008603555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027947593,0.00033316665,0.000602815,0.0004894361,0.0002746955,0.00061644666,0.00043995364,0.00043710208,0.002843398],"category_scores_gemma":[0.00017500362,0.00019315092,0.0005356169,0.0004089844,0.00020530188,0.00043032732,0.00030943914,0.0006620983,0.0006386519],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005967281,0.001956595,0.0028765118,0.00087568205,0.0002783591,0.0014331461,0.00008997418,0.0017650707,0.5685262,0.0025196995,0.0035234666,0.41018808],"study_design_scores_gemma":[0.0026323297,0.015385886,0.01563731,0.00016962687,0.0012289599,0.014337087,0.0001758766,0.009888899,0.77253246,0.0018102214,0.16610338,0.00009797702],"about_ca_topic_score_codex":0.00035906062,"about_ca_topic_score_gemma":0.0008907226,"teacher_disagreement_score":0.002843398,"about_ca_system_score_codex":0.0002470717,"about_ca_system_score_gemma":0.00031599464,"threshold_uncertainty_score":0.009512126},"labels":[],"label_agreement":null},{"id":"W2607754295","doi":"10.1200/jco.2016.70.5319","title":"Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical Oncology; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Guideline; Cancer; Immunohistochemistry; Metastatic breast cancer; Biomarker; Gynecology; Pathology","score_opus":0.47689772601224484,"score_gpt":0.6404764171538218,"score_spread":0.16357869114157692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607754295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624485,0.0010572629,0.0005549267,0.00015150651,0.000029927469,0.000037759055,0.00074687926,0.000022134158,0.0011548134],"genre_scores_gemma":[0.99793303,0.00020104482,0.0004663314,0.00009487769,0.000026584945,0.000032020136,0.0011229947,0.000011407227,0.00011175592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98931646,0.003790038,0.0013239783,0.0020567605,0.002851389,0.0006615392],"domain_scores_gemma":[0.97947913,0.0071080006,0.007917424,0.0011819042,0.003569646,0.0007438266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005802383,0.00028697797,0.00046031337,0.00206213,0.00021910378,0.0009018871,0.0008672105,0.0006138775,0.00057235535],"category_scores_gemma":[0.02496568,0.00027021288,0.0004945021,0.0019611751,0.0005150165,0.00076412957,0.0006481385,0.0005235468,0.00019181518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003307753,0.000038709724,0.99478406,0.000018667848,0.0001048507,0.00004485091,0.000049469618,0.0001865179,0.00037249117,0.000030385496,0.00030185326,0.003737398],"study_design_scores_gemma":[0.000008510704,0.0001634897,0.9984363,0.0000062701597,0.00003197115,0.00018874723,0.00011381768,0.00047552996,0.00029090594,0.00001789795,0.00026174437,0.0000049237156],"about_ca_topic_score_codex":0.006079994,"about_ca_topic_score_gemma":0.009990562,"teacher_disagreement_score":0.006079994,"about_ca_system_score_codex":0.001477943,"about_ca_system_score_gemma":0.00082047016,"threshold_uncertainty_score":0.03068626},"labels":[],"label_agreement":null},{"id":"W2608357984","doi":"10.3390/cancers9050040","title":"HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance","year":2017,"lang":"en","type":"review","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Alberta; Women and Children's Health Research Institute; Children's Health Research Institute","keywords":"Lapatinib; Trastuzumab; Cancer research; Cancer stem cell; Medicine; Epithelial–mesenchymal transition; Wnt signaling pathway; Breast cancer; Tumor microenvironment; Cancer; Biology; Internal medicine; Metastasis; Signal transduction; Cell biology","score_opus":0.17106005455353648,"score_gpt":0.466605342863232,"score_spread":0.2955452883096955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608357984","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8411859,0.09750375,0.010472456,0.016012007,0.0009435665,0.00015622072,0.00096393464,0.0012250992,0.03153693],"genre_scores_gemma":[0.9773882,0.011665652,0.001131228,0.0016987616,0.00024324948,0.000056377037,0.00032956235,0.000045611905,0.0074413577],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974614,0.00004964417,0.00001308543,0.00004109489,0.00008953122,0.000060450293],"domain_scores_gemma":[0.9997812,0.000037048492,0.000057668472,0.000013552285,0.000056266275,0.000054310825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036412323,0.00032943147,0.0003529719,0.00028889716,0.00024140903,0.0009012617,0.0003460647,0.00046528535,0.003035762],"category_scores_gemma":[0.0005455875,0.00015036926,0.00021885554,0.0001978021,0.00032122273,0.0004227071,0.00045899604,0.000809307,0.00084824325],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015508042,0.0004429478,0.01995716,0.0009957714,0.00011684669,0.0028606402,0.00068243005,0.0019477237,0.6857538,0.011600889,0.025186148,0.24890481],"study_design_scores_gemma":[0.0006699812,0.0034015009,0.090134196,0.0004315439,0.00043275306,0.0127384085,0.0010708096,0.016020376,0.5052316,0.025034375,0.3447042,0.0001302401],"about_ca_topic_score_codex":0.00033308406,"about_ca_topic_score_gemma":0.00044074532,"teacher_disagreement_score":0.003035762,"about_ca_system_score_codex":0.000709939,"about_ca_system_score_gemma":0.00025954994,"threshold_uncertainty_score":0.010155618},"labels":[],"label_agreement":null},{"id":"W2609600658","doi":"10.1200/jco.2009.27.15_suppl.1067","title":"A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Rash; Taxane; Gastroenterology; Mucositis; Metastatic breast cancer; Cancer; Chemotherapy; Oncology; Surgery","score_opus":0.14103104228452873,"score_gpt":0.5760817173539257,"score_spread":0.43505067506939693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609600658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266785,0.0012720355,0.00063869735,0.00024338052,0.0000785975,0.0027214584,0.00068635965,0.00010094073,0.0015907558],"genre_scores_gemma":[0.9899419,0.0013362175,0.0018424814,0.00056950125,0.00009778059,0.0017396028,0.0019017042,0.000038379756,0.0025324146],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996865,0.00012436742,0.000015731104,0.00007152289,0.000033390806,0.000068522706],"domain_scores_gemma":[0.9995454,0.000059484068,0.00006555577,0.00004429089,0.000039756203,0.0002454136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095547654,0.0011644696,0.0017306563,0.00042930996,0.0003629361,0.000994966,0.0009280196,0.0011190216,0.0034603998],"category_scores_gemma":[0.0007496172,0.00066856726,0.00083455135,0.00047551873,0.00076101976,0.0005807517,0.00032000343,0.0025126082,0.0011075337],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57297087,0.11825601,0.011142491,0.0011623248,0.0011874693,0.0005134236,0.0005359438,0.0041854004,0.13723135,0.0004193865,0.0050965426,0.1472988],"study_design_scores_gemma":[0.42916483,0.5468036,0.01309536,0.000025038522,0.00031062038,0.00043742923,0.00007060443,0.0016374876,0.005082511,0.00011702378,0.0032286246,0.000026833737],"about_ca_topic_score_codex":0.0017663983,"about_ca_topic_score_gemma":0.0031946613,"teacher_disagreement_score":0.0034603998,"about_ca_system_score_codex":0.0010431097,"about_ca_system_score_gemma":0.0015287764,"threshold_uncertainty_score":0.011576235},"labels":[],"label_agreement":null},{"id":"W2610975296","doi":"10.5430/jst.v7n2p28","title":"A phase II trial of neoadjuvant doxorubicin plus cyclophosphamide followed by lapatinib plus docetaxel sequential with adjuvant trastuzumab for treatment of early HER2 positive breast cancers","year":2017,"lang":"en","type":"article","venue":"Journal of Solid Tumors","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Lapatinib; Docetaxel; Breast cancer; Internal medicine; Oncology; Pertuzumab; Population; Anemia; Cyclophosphamide; Lumpectomy; Phases of clinical research; Gastroenterology; Surgery; Chemotherapy; Cancer; Mastectomy","score_opus":0.035304341008534315,"score_gpt":0.38008501407414963,"score_spread":0.34478067306561533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610975296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941754,0.0010815784,0.00035981528,0.00035381145,0.00014925704,0.0025220152,0.0003406692,0.000060215985,0.0009572786],"genre_scores_gemma":[0.98899674,0.0013747931,0.002223384,0.0006702037,0.00022207774,0.0036920893,0.0009964411,0.000018956924,0.0018053624],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994956,0.00025929906,0.000031191666,0.00009196795,0.00004590461,0.00007605776],"domain_scores_gemma":[0.9991115,0.00014680452,0.00020843474,0.000073097246,0.00004624046,0.00041397993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017444721,0.001429614,0.0017843329,0.00047898645,0.0004211172,0.00085203274,0.0009602074,0.0010193392,0.003292618],"category_scores_gemma":[0.0010618111,0.00064227526,0.000806756,0.00040310767,0.0011396393,0.0008345859,0.00037334175,0.0030843562,0.0007036914],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.833791,0.08539118,0.0034947412,0.0006177321,0.0007587123,0.00014230749,0.00015294047,0.0015250383,0.018922113,0.00016599252,0.0015653668,0.05347285],"study_design_scores_gemma":[0.7038011,0.29076654,0.002629862,0.00001897122,0.00014574891,0.000125022,0.000022209468,0.00050488627,0.001301266,0.000060858674,0.0006116563,0.000011949602],"about_ca_topic_score_codex":0.00076979125,"about_ca_topic_score_gemma":0.0024585577,"teacher_disagreement_score":0.003292618,"about_ca_system_score_codex":0.0010245871,"about_ca_system_score_gemma":0.0023176332,"threshold_uncertainty_score":0.011014938},"labels":[],"label_agreement":null},{"id":"W2611085088","doi":"10.71781/29231","title":"Effet de la signalisation de ErbB2 et ErbB3 sur l'activité transcriptionnelle des récepteurs des estrogènes et sur la prolifération cellulaire","year":2003,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Chemistry","score_opus":0.06920749747848025,"score_gpt":0.3975885247861963,"score_spread":0.328381027307716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611085088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.938222,0.016336933,0.00096632686,0.0024634355,0.00028142802,0.000046673846,0.0019880736,0.000076878445,0.03961837],"genre_scores_gemma":[0.87127763,0.008545326,0.0008064761,0.0004614577,0.00006916168,0.00005680237,0.00086657354,0.00004065255,0.117875926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998652,0.000017550577,0.0000037757582,0.000020393558,0.000029538425,0.000063529595],"domain_scores_gemma":[0.9997845,0.0000792672,0.000015310972,0.000012544046,0.000049989194,0.000058535992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002762435,0.00017282549,0.00021419408,0.00019011326,0.0003549106,0.0006596542,0.00019762415,0.0004193134,0.018352844],"category_scores_gemma":[0.0005047611,0.00013881273,0.00028736104,0.00025310979,0.00031531003,0.00019375667,0.00019678628,0.0005713647,0.0012372996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005786519,0.00021161261,0.002506813,0.00030992107,0.0000681383,0.00018099375,0.00039733917,0.00039006778,0.93653566,0.002246109,0.00466242,0.04670451],"study_design_scores_gemma":[0.00080115465,0.0018130615,0.18926105,0.00014495137,0.00022549793,0.00027321366,0.00077828363,0.00069060194,0.72147065,0.0009049437,0.083574906,0.00006162354],"about_ca_topic_score_codex":0.056833554,"about_ca_topic_score_gemma":0.083632395,"teacher_disagreement_score":0.056833554,"about_ca_system_score_codex":0.0011916624,"about_ca_system_score_gemma":0.0017168467,"threshold_uncertainty_score":0.11300552},"labels":[],"label_agreement":null},{"id":"W2612557208","doi":"10.1007/s10549-017-4273-x","title":"Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"Canadian Cancer Society Research Institute; GlaxoSmithKline; Pfizer","keywords":"Lapatinib; Trastuzumab; Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Metastatic breast cancer","score_opus":0.13082130753244084,"score_gpt":0.49038875891903344,"score_spread":0.35956745138659263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612557208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193054,0.0052207536,0.00004705443,0.0009216479,0.0001055257,0.000016491984,0.00026614737,0.00001494234,0.0014769172],"genre_scores_gemma":[0.9981554,0.00055720593,0.000037674417,0.00022560825,0.00011607051,0.0000127440035,0.00037381198,0.0000032891078,0.00051816186],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996542,0.00010162826,0.000023043121,0.00004950543,0.000037745533,0.00013396035],"domain_scores_gemma":[0.99919575,0.00021950701,0.00012764132,0.00003575724,0.00002790234,0.00039347186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006663393,0.00032843737,0.0010839998,0.0001972168,0.00018091731,0.0006046535,0.00045505058,0.0006527524,0.002963832],"category_scores_gemma":[0.0016523941,0.00011377999,0.0012237367,0.00021978357,0.00027596866,0.00056747656,0.0003289582,0.001243946,0.0003117747],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65028703,0.0027198743,0.15533073,0.00033408013,0.0027675543,0.0003292137,0.00015590292,0.0038375128,0.0073063537,0.0005255154,0.0077264807,0.16867971],"study_design_scores_gemma":[0.029934455,0.13610195,0.80967385,0.00032695982,0.0064170025,0.0007691232,0.0004053037,0.007092272,0.002793846,0.0013478909,0.005021137,0.000116233525],"about_ca_topic_score_codex":0.0035523316,"about_ca_topic_score_gemma":0.008396465,"teacher_disagreement_score":0.0035523316,"about_ca_system_score_codex":0.00093554537,"about_ca_system_score_gemma":0.0010542901,"threshold_uncertainty_score":0.009915054},"labels":[],"label_agreement":null},{"id":"W2613907595","doi":"10.1016/j.ejca.2017.03.033","title":"HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Tamoxifen; Medicine; Exemestane; Hazard ratio; Oncology; Internal medicine; Clinical trial; Breast cancer; Adjuvant therapy; Confidence interval; Cancer","score_opus":0.19449919099568974,"score_gpt":0.41727949380375684,"score_spread":0.2227803028080671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613907595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05464205,0.94204485,0.00061216153,0.00036699424,0.00029265916,0.0001111007,0.0013961043,0.000036529804,0.00049762166],"genre_scores_gemma":[0.71534574,0.2763307,0.001916516,0.0018135306,0.0003551751,0.00022958023,0.0029715088,0.000062166124,0.00097508106],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.998198,0.0008179817,0.00036662872,0.00032584261,0.00016355765,0.00012809513],"domain_scores_gemma":[0.997696,0.0015466673,0.00034773673,0.0001585711,0.00015999077,0.00009098516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039248383,0.0017600391,0.007811467,0.0010329167,0.000358953,0.0015021969,0.0010141182,0.0010788265,0.0025863305],"category_scores_gemma":[0.0066353776,0.00091101945,0.019575607,0.0021026914,0.00031125793,0.0008599636,0.00087995455,0.0019855374,0.00030889947],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017860377,0.000078123674,0.024751669,0.046889152,0.8837154,0.00018960611,0.00009665034,0.00064645207,0.0006003924,0.00013933361,0.0015720909,0.023460733],"study_design_scores_gemma":[0.0024082763,0.00041750548,0.014774333,0.0015069732,0.97800577,0.00009648588,0.00005071876,0.00014135489,0.000103973805,0.0002445267,0.0022217587,0.000028337621],"about_ca_topic_score_codex":0.0047988957,"about_ca_topic_score_gemma":0.018330282,"teacher_disagreement_score":0.007811467,"about_ca_system_score_codex":0.00091515284,"about_ca_system_score_gemma":0.0011663273,"threshold_uncertainty_score":0.020756721},"labels":[],"label_agreement":null},{"id":"W2614328947","doi":"10.3969/j.issn.1008-7125.2013.12.003","title":"Role of epidermal growth factor and its receptor in regulating proliferation of colon cancer stem cells","year":2013,"lang":"en","type":"article","venue":"Weichangbingxue","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Biological Sciences","funders":"","keywords":"Epidermal growth factor receptor; Colorectal cancer; Cancer research; Epidermal growth factor; Stem cell; Growth factor receptor inhibitor; Cancer; Cancer stem cell; Cell biology; Biology; Receptor; Oncology; Internal medicine; Chemistry; Medicine","score_opus":0.0405483809262111,"score_gpt":0.322165437905933,"score_spread":0.2816170569797219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614328947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713249,0.019316142,0.0015809142,0.0004988432,0.000064249645,0.000028728957,0.00018817234,0.00007310174,0.0069248383],"genre_scores_gemma":[0.9924655,0.002862408,0.00046346386,0.00005616361,0.000011450871,0.000017541457,0.000104130944,0.0000062209297,0.0040132124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990976,0.000016046853,0.0000054431916,0.00001400709,0.000019553758,0.000035160363],"domain_scores_gemma":[0.99997497,0.0000042430015,0.000005571754,0.000002833444,0.0000032340743,0.000009082823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013620702,0.00022189932,0.00019349027,0.00036823036,0.00027784705,0.0003539722,0.00016657033,0.00028707105,0.0014219338],"category_scores_gemma":[0.0000904831,0.0001570993,0.00021168301,0.00019513867,0.00020392257,0.0003363831,0.00021238213,0.00043903256,0.00014337397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008237157,0.00014129303,0.003427879,0.0002221868,0.00003393718,0.000778451,0.000090616944,0.0005190844,0.95512176,0.0021498774,0.00069225667,0.035998978],"study_design_scores_gemma":[0.0002123453,0.00084739004,0.06387381,0.00003959284,0.0001854157,0.0021187854,0.00044146494,0.005362207,0.8974648,0.0013369225,0.028071048,0.000046195008],"about_ca_topic_score_codex":0.0010880672,"about_ca_topic_score_gemma":0.0013938686,"teacher_disagreement_score":0.0014219338,"about_ca_system_score_codex":0.0002969452,"about_ca_system_score_gemma":0.00031886355,"threshold_uncertainty_score":0.0047568083},"labels":[],"label_agreement":null},{"id":"W2616596696","doi":"10.1016/s1470-2045(17)30312-1","title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":656,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Capecitabine; Trastuzumab emtansine; Taxane; Trastuzumab; Internal medicine; Oncology; Breast cancer; Interim analysis; Metastatic breast cancer; Pertuzumab; Population; Cancer; Clinical trial; Colorectal cancer","score_opus":0.1471450445887598,"score_gpt":0.43954737622099455,"score_spread":0.2924023316322347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616596696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990703,0.0060637635,0.00035097948,0.00024350714,0.0001497291,0.0007176925,0.0007722963,0.000031173546,0.0009678557],"genre_scores_gemma":[0.99451315,0.0017415995,0.00055072014,0.0004577847,0.00017700998,0.0005268799,0.0011319157,0.000013474192,0.0008875315],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977018,0.0015729631,0.0001561477,0.0002551998,0.000118115146,0.0001957784],"domain_scores_gemma":[0.99703646,0.0016806226,0.00072133105,0.00019548667,0.0000796403,0.00028649936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004610684,0.0012671184,0.002465228,0.0005863075,0.0002453,0.00096660596,0.0006505223,0.0010355938,0.0032818816],"category_scores_gemma":[0.0045578745,0.00047188456,0.0035997014,0.0005857389,0.0008437314,0.0013039613,0.00046042592,0.0020685084,0.00040459388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9762517,0.0015410244,0.0022000263,0.00044985517,0.0030451878,0.00003522774,0.00006083401,0.0005912848,0.001098493,0.00005551014,0.00029394196,0.014376831],"study_design_scores_gemma":[0.80685806,0.15891135,0.02463636,0.0001409268,0.0056475573,0.0001451757,0.00009211671,0.0013227618,0.00070148543,0.00034906776,0.0011421633,0.000052913718],"about_ca_topic_score_codex":0.0005156995,"about_ca_topic_score_gemma":0.0017198699,"teacher_disagreement_score":0.004610684,"about_ca_system_score_codex":0.0010620094,"about_ca_system_score_gemma":0.0005846418,"threshold_uncertainty_score":0.024383962},"labels":[],"label_agreement":null},{"id":"W2617889858","doi":"10.1016/j.breast.2017.05.004","title":"Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial","year":2017,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; Trastuzumab; Tolerability; Discontinuation; Adverse effect; Cohort; Internal medicine; Adjuvant; Syringe; Oncology; Breast cancer; Cancer","score_opus":0.05830078814096429,"score_gpt":0.3442258103662161,"score_spread":0.2859250222252518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617889858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958389,0.0015402795,0.00033357707,0.00015608923,0.000052723415,0.0002933785,0.0005419605,0.000033031436,0.0012101848],"genre_scores_gemma":[0.99520195,0.00084528513,0.0006104026,0.0004765747,0.00015060784,0.00037350063,0.0016487914,0.000016659904,0.0006762159],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983279,0.0010913736,0.000098235716,0.00020480194,0.00015923835,0.000118491276],"domain_scores_gemma":[0.997521,0.0009701313,0.00071778666,0.00039504218,0.00012950729,0.00026652205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036313792,0.00053514895,0.0012711429,0.000119050594,0.00016168156,0.00049585465,0.00045324967,0.0008166397,0.0031648865],"category_scores_gemma":[0.003938996,0.00019492034,0.001014542,0.00019674351,0.00054165424,0.00075078564,0.00025111184,0.0018002635,0.0004264338],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8608679,0.009727398,0.00835724,0.00072515185,0.0019137975,0.000109916655,0.00017146526,0.0011665466,0.0106791025,0.00012894729,0.0021014144,0.10405105],"study_design_scores_gemma":[0.40053174,0.5405377,0.04442436,0.0001307149,0.002447876,0.00052881683,0.000081762475,0.0019374694,0.0042204224,0.00041997046,0.004679795,0.000059293336],"about_ca_topic_score_codex":0.00017243867,"about_ca_topic_score_gemma":0.00042533828,"teacher_disagreement_score":0.0036313792,"about_ca_system_score_codex":0.00034070795,"about_ca_system_score_gemma":0.00037759202,"threshold_uncertainty_score":0.019204795},"labels":[],"label_agreement":null},{"id":"W2619487615","doi":"10.1097/pai.0000000000000525","title":"Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens","year":2017,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Occupational Therapists","funders":"","keywords":"Progesterone receptor; Estrogen receptor; Biopsy; Breast cancer; Immunohistochemistry; Medicine; Human Epidermal Growth Factor Receptor 2; Receptor; Hormone receptor; Fluorescence in situ hybridization; Estrogen; Epidermal growth factor receptor; Cancer; Pathology; Internal medicine; Gynecology; Oncology; Biology; Gene","score_opus":0.03757101817127356,"score_gpt":0.36035404963979445,"score_spread":0.3227830314685209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619487615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982564,0.00085007446,0.0003489086,0.000048317095,0.000007393136,0.000012281436,0.000058167494,0.000011224203,0.00040717973],"genre_scores_gemma":[0.999286,0.00013103547,0.0004171224,0.000024054369,0.000016317685,0.0000064940946,0.00006921705,0.000002325943,0.00004742872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950728,0.0024090612,0.0004500884,0.0007286879,0.0011173374,0.00022210833],"domain_scores_gemma":[0.9846939,0.0075439713,0.003391517,0.002042676,0.0016930599,0.0006349344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008046939,0.00026605546,0.00038081076,0.0012813733,0.00032330363,0.0006826177,0.0007647142,0.00061525573,0.00039227205],"category_scores_gemma":[0.02225982,0.00022717784,0.0003230328,0.0008205637,0.00079267245,0.00070290687,0.0004702922,0.000520855,0.00014403884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012201531,0.00002510512,0.9938251,0.000010748653,0.000028455235,0.00016287359,0.00006722029,0.00012657105,0.0005643451,0.000007664534,0.000048719925,0.0050112056],"study_design_scores_gemma":[0.000009791476,0.000371795,0.9958091,0.000015085337,0.000043403295,0.0013832578,0.00016015687,0.0009197149,0.0010937838,0.0000161062,0.00016935272,0.000008416231],"about_ca_topic_score_codex":0.0050202375,"about_ca_topic_score_gemma":0.007843663,"teacher_disagreement_score":0.008046939,"about_ca_system_score_codex":0.0007462679,"about_ca_system_score_gemma":0.00049985276,"threshold_uncertainty_score":0.042556822},"labels":[],"label_agreement":null},{"id":"W2620843145","doi":"10.1016/j.ejca.2017.04.028","title":"Getting under the skin","year":2017,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pertuzumab; Lapatinib; Medicine; Trastuzumab; Trastuzumab emtansine; Breast cancer; Oncology; Internal medicine; Metastatic breast cancer; Capecitabine; Cancer; Colorectal cancer","score_opus":0.08659865713768121,"score_gpt":0.4007143997159772,"score_spread":0.314115742578296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620843145","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037367851,0.0021626751,0.000038457987,0.97153014,0.020073073,0.000005201477,0.000013983395,0.000012152981,0.005790649],"genre_scores_gemma":[0.004611043,0.001761782,0.00007987034,0.9571216,0.01996561,0.000016274531,0.000012953773,0.000019273457,0.016411534],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973441,0.00071377633,0.00017450993,0.00035477892,0.00080121827,0.0006115887],"domain_scores_gemma":[0.9963595,0.0011211684,0.00019442356,0.00015404742,0.0006061745,0.0015645765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002117617,0.00070625346,0.0010621849,0.00060322054,0.007271433,0.0049549513,0.001232837,0.039019015,0.0140250465],"category_scores_gemma":[0.016540878,0.0006143405,0.001099432,0.00037169535,0.003524018,0.0054717157,0.0027297942,0.048019078,0.006800832],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028241926,0.000037542573,0.00061555905,0.00003009286,0.000013732588,0.0025917722,0.00019936002,0.00002936791,0.00010733333,0.0040463996,0.98531175,0.006988878],"study_design_scores_gemma":[0.00005498747,0.00006452131,0.000859867,0.00032188036,0.000019992707,0.0042174514,0.0012215511,0.00015870189,0.000119290795,0.010028007,0.98289204,0.00004169724],"about_ca_topic_score_codex":0.0058337767,"about_ca_topic_score_gemma":0.013157968,"teacher_disagreement_score":0.039019015,"about_ca_system_score_codex":0.003678397,"about_ca_system_score_gemma":0.004720634,"threshold_uncertainty_score":0.046918392},"labels":[],"label_agreement":null},{"id":"W2726739357","doi":"10.1158/1078-0432.ccr-17-0900","title":"Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Puma Biotechnology","keywords":"Neratinib; Metastatic breast cancer; Breast cancer; Circulating tumor DNA; Cancer; Medicine; Oncology; Trastuzumab; Cancer research; Internal medicine; Biology","score_opus":0.3070330761576317,"score_gpt":0.5647289912994085,"score_spread":0.25769591514177675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726739357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898857,0.00043012918,0.00011619442,0.000039419727,0.000007790734,0.00006572791,0.000048443602,0.000008800773,0.00029496787],"genre_scores_gemma":[0.99935013,0.00011784769,0.00017301868,0.00004350508,0.000016229398,0.000047147638,0.0000827751,0.0000027280337,0.0001666504],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9996749,0.0001366491,0.000038694354,0.00006273836,0.000049017308,0.00003805314],"domain_scores_gemma":[0.9995128,0.0001515652,0.0001594015,0.00003382228,0.000036794005,0.00010553272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092140905,0.00034437762,0.00095835386,0.00013137083,0.000120545796,0.00033386616,0.00025987258,0.00027880925,0.0010931382],"category_scores_gemma":[0.0009864151,0.00013327404,0.00028012603,0.000109988105,0.0003125616,0.0002810093,0.00012118637,0.0007843041,0.0001827459],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3456404,0.018419039,0.058163624,0.0010116566,0.0010628853,0.0004367557,0.00027961066,0.0044632745,0.37135267,0.00033848255,0.0017099407,0.19712165],"study_design_scores_gemma":[0.09888995,0.6104384,0.13115832,0.00006839356,0.0011688335,0.0028360107,0.00012584649,0.006212597,0.14553323,0.00036566093,0.0031407885,0.00006199177],"about_ca_topic_score_codex":0.00021471859,"about_ca_topic_score_gemma":0.00039985887,"teacher_disagreement_score":0.0010931382,"about_ca_system_score_codex":0.00045094657,"about_ca_system_score_gemma":0.0003373332,"threshold_uncertainty_score":0.0048729777},"labels":[],"label_agreement":null},{"id":"W2735826756","doi":"10.3821/1913-701x-143.sp1.s7","title":"Le traitement du cancer du sein au trastuzumab","year":2010,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Gynecology; Breast cancer; Cancer; Internal medicine","score_opus":0.051851486151688025,"score_gpt":0.3415804289907829,"score_spread":0.2897289428390949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735826756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5439043,0.21856335,0.01220087,0.08389705,0.0045809494,0.00020492794,0.00049085263,0.00052197103,0.13563572],"genre_scores_gemma":[0.8335856,0.05343743,0.0040013036,0.0055750404,0.0023196097,0.000058492544,0.0002720012,0.00007583869,0.10067468],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999408,0.00013336746,0.00002565096,0.00005835295,0.0002575137,0.00011718855],"domain_scores_gemma":[0.99932706,0.00030992634,0.00007889901,0.000026783406,0.00015520639,0.00010217548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058366696,0.00046075784,0.0006757784,0.00063050084,0.0010124997,0.0018319486,0.00036641382,0.0015853693,0.0036334412],"category_scores_gemma":[0.0027461213,0.00023272233,0.00062286004,0.00050553755,0.0008985311,0.0005712672,0.0002899471,0.0022619104,0.0009842104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003406799,0.00052818796,0.03147823,0.0009905007,0.00036580826,0.048045356,0.0029124294,0.005574889,0.06192523,0.029505396,0.05117175,0.7640954],"study_design_scores_gemma":[0.001164579,0.0016576903,0.0856611,0.0007403884,0.00043048803,0.08767236,0.0024102393,0.0081498865,0.05562657,0.005753542,0.7505473,0.00018583024],"about_ca_topic_score_codex":0.108539216,"about_ca_topic_score_gemma":0.08880005,"teacher_disagreement_score":0.108539216,"about_ca_system_score_codex":0.004984847,"about_ca_system_score_gemma":0.0029523408,"threshold_uncertainty_score":0.21581489},"labels":[],"label_agreement":null},{"id":"W2735832888","doi":"10.1021/acs.jmedchem.7b00396","title":"A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human","year":2017,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Jewish General Hospital; University of Toronto; Montreal Neurological Institute and Hospital; McGill University; Douglas Mental Health University Institute; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Cancer Research Society; Canada Foundation for Innovation; National Institute of Biomedical Imaging and Bioengineering; Weston Brain Institute; U.S. Department of Energy","keywords":"Kinome; Chemistry; In vivo; In vitro; Pharmacology; Neuroimaging; Neuroscience; Biochemistry; Kinase","score_opus":0.062075990788290965,"score_gpt":0.4165301395666692,"score_spread":0.3544541487783782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735832888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8571723,0.0476941,0.06906546,0.0013309094,0.00015845925,0.0015213161,0.0027926383,0.0007386045,0.01952624],"genre_scores_gemma":[0.9572402,0.016891038,0.017638547,0.000327607,0.000033019394,0.00036641938,0.0014992072,0.00008619783,0.005917822],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982905,0.000056433848,0.000008148618,0.000027335442,0.000032784857,0.000046289915],"domain_scores_gemma":[0.9999243,0.00001148747,0.000021944355,0.000010650832,0.000012640786,0.000018945128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045841752,0.00076180807,0.00041466422,0.00033745365,0.00026909017,0.000364642,0.0004940331,0.00061713386,0.0012779386],"category_scores_gemma":[0.00024038053,0.00025736346,0.00028316246,0.00029491071,0.00027359175,0.0005219703,0.00024776784,0.000990087,0.0007790501],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008748918,0.00060885784,0.00030566662,0.0004777139,0.000038169044,0.00044211955,0.00020026138,0.002182865,0.9545327,0.0013688658,0.0017078869,0.037260085],"study_design_scores_gemma":[0.00027863967,0.0051797647,0.0012756623,0.000042967586,0.00007899467,0.0030360175,0.00005487164,0.0019181687,0.964111,0.00024880626,0.023723979,0.000051319887],"about_ca_topic_score_codex":0.0016781194,"about_ca_topic_score_gemma":0.0034624708,"teacher_disagreement_score":0.0016781194,"about_ca_system_score_codex":0.0006233737,"about_ca_system_score_gemma":0.00057669415,"threshold_uncertainty_score":0.0045229197},"labels":[],"label_agreement":null},{"id":"W2738212876","doi":"10.1161/hyp.60.suppl_1.a244","title":"Abstract 244: Vascular Induction of Adam17 in vitro and in Vivo By Angiotensin Ii: Potential Involvement of a Hypoxia Responsible Element","year":2012,"lang":"en","type":"article","venue":"Hypertension","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Angiotensin II; In vivo; Internal medicine; Endocrinology; Renin–angiotensin system; Biology; In vitro; Hypoxia (environmental); Chemistry; Medicine; Receptor; Biochemistry","score_opus":0.04903374367959088,"score_gpt":0.2951052024496921,"score_spread":0.2460714587701012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738212876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876488,0.0020547817,0.006701215,0.0002575309,0.000119170545,0.000034555713,0.0011692774,0.00012498675,0.0018897203],"genre_scores_gemma":[0.9811389,0.001331446,0.0048977095,0.00015118232,0.00008518226,0.000058155052,0.0027494314,0.000047729587,0.009540216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984086,0.0000294704,0.000018049548,0.00003051052,0.000048152462,0.000032934287],"domain_scores_gemma":[0.99983084,0.000033326367,0.000050840055,0.000019359379,0.000020584343,0.000044966295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016402226,0.00035670513,0.00024667743,0.0001630895,0.00012746871,0.00022861172,0.00018527379,0.00022634414,0.0052572177],"category_scores_gemma":[0.000116061135,0.00012282452,0.0003123647,0.00011474163,0.00022933063,0.00020401475,0.00015592095,0.00054680574,0.0011998602],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014808215,0.000015951624,0.00013315979,0.000039749033,0.000003391901,0.00008915371,0.0000062597283,0.000013023819,0.99886394,0.00004721458,0.000035191653,0.00060499244],"study_design_scores_gemma":[0.000011888472,0.00022262834,0.006597348,0.0000068369304,0.0000103936945,0.0004741982,0.00001476956,0.00019125747,0.99074453,0.000055757333,0.0016677463,0.000002719105],"about_ca_topic_score_codex":0.00019958979,"about_ca_topic_score_gemma":0.00015302129,"teacher_disagreement_score":0.0052572177,"about_ca_system_score_codex":0.00019267596,"about_ca_system_score_gemma":0.000110533794,"threshold_uncertainty_score":0.017587125},"labels":[],"label_agreement":null},{"id":"W2738553575","doi":"10.1200/jco.2017.35.15_suppl.e13078","title":"Relationship between survival to breast cancer and level of HER2 expression by immunohistochemistry.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Immunohistochemistry; Breast cancer; Trastuzumab; Internal medicine; Oncology; Cancer; Retrospective cohort study; Gynecology","score_opus":0.5335075287104397,"score_gpt":0.6202554639857291,"score_spread":0.08674793527528935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738553575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979202,0.00057457475,0.000076049204,0.000043430366,0.0000035137937,0.00000586876,0.0005005616,0.000004129267,0.0008716802],"genre_scores_gemma":[0.99940085,0.00006744925,0.000024481977,0.000012092835,0.0000032227038,0.0000029543,0.00031579065,0.000001154051,0.00017198935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982786,0.00002591228,0.000015791415,0.000031663367,0.00004503178,0.000053748925],"domain_scores_gemma":[0.9989672,0.000255284,0.00044650477,0.000033635697,0.00013582232,0.00016158735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004363315,0.0001032884,0.00012904328,0.00049998594,0.00013850031,0.00023954682,0.00023109165,0.00021087138,0.0025880567],"category_scores_gemma":[0.001063013,0.0000716362,0.00018949107,0.00047677918,0.00026132283,0.00021346624,0.00018306,0.0002533568,0.00023287549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019160485,0.00000721895,0.9980216,0.0000068850995,0.000029995514,0.000052064148,0.000011258492,0.000044411445,0.00033554365,0.0000063426032,0.00009945941,0.0011935877],"study_design_scores_gemma":[0.00000406435,0.000046327204,0.9993394,0.0000019908548,0.000014918331,0.00022224402,0.000024455061,0.00011481325,0.0000789913,0.000008311168,0.00014317084,0.0000013129239],"about_ca_topic_score_codex":0.009059047,"about_ca_topic_score_gemma":0.013238815,"teacher_disagreement_score":0.009059047,"about_ca_system_score_codex":0.000527206,"about_ca_system_score_gemma":0.00026571145,"threshold_uncertainty_score":0.018012643},"labels":[],"label_agreement":null},{"id":"W2739675795","doi":"","title":"EGFR遺伝子変異陽性の肺癌患者におけるirreversible ErbB family blockerアファチニブの有用性","year":2012,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Neuregulin; Medicine; Internal medicine; Receptor","score_opus":0.091182672881219,"score_gpt":0.4042391389252187,"score_spread":0.31305646604399967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739675795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7875875,0.0215735,0.027207408,0.0018440069,0.0004795955,0.00024381586,0.00081875233,0.0005904109,0.15965502],"genre_scores_gemma":[0.9388757,0.006907982,0.008780844,0.00065470417,0.00013755113,0.00008967378,0.00072623324,0.000060924183,0.043766513],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9996375,0.00005202327,0.000024663812,0.00008048613,0.00013550783,0.00006989229],"domain_scores_gemma":[0.99972385,0.00009073034,0.000044684617,0.000046400484,0.00006224634,0.000032091484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009603052,0.00040235918,0.00026858217,0.00033352,0.00047862175,0.0006415521,0.00035713537,0.00039903712,0.008822735],"category_scores_gemma":[0.0006323116,0.00024725057,0.00042821883,0.00016044389,0.00057888794,0.00057396805,0.0001975211,0.00090312795,0.0028698046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009343953,0.00030982695,0.006594996,0.0004989329,0.00016537284,0.0014166195,0.0004071288,0.000668123,0.84358096,0.015026491,0.003850259,0.12654686],"study_design_scores_gemma":[0.000109164765,0.0010218389,0.013032957,0.000079042096,0.00024642644,0.005380806,0.00021110018,0.0011879698,0.8969637,0.002606804,0.07911287,0.00004727996],"about_ca_topic_score_codex":0.0012479121,"about_ca_topic_score_gemma":0.0012867202,"teacher_disagreement_score":0.008822735,"about_ca_system_score_codex":0.00050929846,"about_ca_system_score_gemma":0.0004719086,"threshold_uncertainty_score":0.029515028},"labels":[],"label_agreement":null},{"id":"W2739843036","doi":"10.1158/1538-7445.am2017-5868","title":"Abstract 5868: Role of STAT3 vs AKT in cellular survival","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Focal adhesion; Protein kinase B; Cell biology; PI3K/AKT/mTOR pathway; Proto-oncogene tyrosine-protein kinase Src; Integrin; Cell adhesion; Phosphorylation; Chemistry; Cell migration; Kinase; Biology; Signal transduction; Cell; Biochemistry","score_opus":0.20821498026634186,"score_gpt":0.5194455924197172,"score_spread":0.31123061215337533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739843036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9423452,0.030329237,0.0019688513,0.0017623625,0.0006201088,0.000080110745,0.003440449,0.00033142764,0.01912222],"genre_scores_gemma":[0.98638374,0.00448895,0.0004893631,0.00023902158,0.00012000022,0.000042554304,0.0014018823,0.000015884556,0.006818465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998847,0.000014319536,0.000007859684,0.00001822558,0.000026600661,0.00004824973],"domain_scores_gemma":[0.999907,0.000010038448,0.000022781267,0.0000058534315,0.000010308904,0.00004403899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013166969,0.00034900315,0.0002455024,0.00025957418,0.0002050673,0.00048945035,0.00019486589,0.0003559639,0.0102547025],"category_scores_gemma":[0.00009781292,0.00010594618,0.00027249163,0.00022518692,0.00017913435,0.0002644478,0.0001798043,0.0006749392,0.0019141374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008791706,0.0005251349,0.0035859586,0.0008190469,0.0000750749,0.00069976336,0.00005585662,0.0005266663,0.93975115,0.0041025034,0.003372113,0.037695143],"study_design_scores_gemma":[0.0013191447,0.006978175,0.1337162,0.00032662504,0.00036812137,0.00313687,0.0003677624,0.00724085,0.7875686,0.0049705915,0.05395771,0.000049229533],"about_ca_topic_score_codex":0.00026839608,"about_ca_topic_score_gemma":0.0002944087,"teacher_disagreement_score":0.0102547025,"about_ca_system_score_codex":0.0002942047,"about_ca_system_score_gemma":0.0003515182,"threshold_uncertainty_score":0.034305453},"labels":[],"label_agreement":null},{"id":"W2741665883","doi":"10.1038/nrclinonc.2017.96","title":"HER2-positive breast cancer is lost in translation: time for patient-centered research","year":2017,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Breast cancer; Biomarker; Translational research; Disease; Drug development; Biomarker discovery; Cancer; Translational science; Oncology; Clinical research; Trastuzumab; Internal medicine; Bioinformatics; Drug; Pathology; Proteomics","score_opus":0.5935254299144336,"score_gpt":0.6815331907619722,"score_spread":0.08800776084753859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741665883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003939806,0.98808134,0.000106190186,0.009280685,0.0019970527,0.000002443815,0.000017078984,0.0000114561,0.00046437114],"genre_scores_gemma":[0.0009117416,0.9879616,0.00030784958,0.0075837597,0.002705601,0.000008315047,0.000039387087,0.000008092359,0.00047358827],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997767,0.0009025336,0.00025244404,0.00020005116,0.0006720981,0.00020588521],"domain_scores_gemma":[0.9892771,0.0074625956,0.0005996387,0.00028514402,0.0017336416,0.00064183475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061505777,0.000987282,0.0034244235,0.0018716964,0.00076946564,0.004644603,0.0018702095,0.0046236375,0.0093482165],"category_scores_gemma":[0.009931719,0.00044756237,0.0012074043,0.0021237978,0.0025371343,0.008263157,0.0029243964,0.008084842,0.003183119],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001143379,0.000064296604,0.0002111905,0.020741072,0.00017733149,0.0002187733,0.00028568215,0.00027688168,0.00054307486,0.01654741,0.24658296,0.7142369],"study_design_scores_gemma":[0.000025404297,0.000042155105,0.00022083375,0.007760437,0.000087661254,0.00029872454,0.00026859823,0.00005612616,0.000079412785,0.0067792786,0.9843604,0.000021029233],"about_ca_topic_score_codex":0.0014807935,"about_ca_topic_score_gemma":0.0038817078,"teacher_disagreement_score":0.0093482165,"about_ca_system_score_codex":0.0021255326,"about_ca_system_score_gemma":0.0063644513,"threshold_uncertainty_score":0.032527745},"labels":[],"label_agreement":null},{"id":"W2742539909","doi":"10.1007/978-1-4939-7219-7_6","title":"Dimerization Assessment of Epithelial Growth Factor Family of Receptor Tyrosine Kinases by Using Cross-Linking Reagent","year":2017,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Receptor tyrosine kinase; Tyrosine kinase; Kinase; Reagent; Cell biology; Chemistry; Receptor; Cancer research; Biochemistry; Biology; Organic chemistry","score_opus":0.1107430438792326,"score_gpt":0.5423649582831309,"score_spread":0.4316219144038983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742539909","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93899024,0.0033217971,0.050255068,0.0002394178,0.00006847644,0.00009106942,0.00019962064,0.0001695618,0.0066647613],"genre_scores_gemma":[0.975641,0.0015881268,0.016357167,0.00017855925,0.000016088381,0.0000776399,0.0006074504,0.000027273463,0.0055066673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971765,0.00011207981,0.000018234668,0.00005889632,0.000049055183,0.000044051605],"domain_scores_gemma":[0.99985886,0.000040108876,0.000024810293,0.000020624513,0.000031211603,0.000024351775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004264011,0.00045633918,0.000118704644,0.0003595909,0.00032012275,0.00018302718,0.0003371959,0.00039058898,0.0016746161],"category_scores_gemma":[0.00022964811,0.00017595719,0.00024878714,0.00022477827,0.00013520572,0.00029311478,0.00022214508,0.0006870123,0.00031706959],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033397508,0.000024890527,0.000070371956,0.000021426302,0.000005532027,0.000017499518,0.000021273536,0.000054416847,0.9986072,0.00020191433,0.000057108427,0.0008849063],"study_design_scores_gemma":[0.0000033721597,0.00004357817,0.00030957343,0.0000023164164,0.00000725129,0.000053738982,0.0000086932705,0.0007272493,0.9979607,0.000034727876,0.0008462706,0.0000025264717],"about_ca_topic_score_codex":0.00023836232,"about_ca_topic_score_gemma":0.00035851952,"teacher_disagreement_score":0.0016746161,"about_ca_system_score_codex":0.00028086037,"about_ca_system_score_gemma":0.00012098869,"threshold_uncertainty_score":0.005602181},"labels":[],"label_agreement":null},{"id":"W2743114779","doi":"10.1007/978-1-4939-7219-7_7","title":"Application of Immunofluorescence Staining to Study ErbB Family of Receptor Tyrosine Kinases","year":2017,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunofluorescence; Staining; ErbB; Receptor tyrosine kinase; Intracellular; Cell biology; Phosphorylation; Receptor; Kinase; Biology; Tyrosine kinase; Signal transduction; Molecular biology; Chemistry; Antibody; Biochemistry; Immunology; Genetics","score_opus":0.07838037049551468,"score_gpt":0.5294343681556881,"score_spread":0.45105399766017346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743114779","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39097393,0.028944815,0.5444107,0.0012459347,0.000572538,0.00028143803,0.00064506946,0.00093295873,0.0319926],"genre_scores_gemma":[0.7334483,0.029001426,0.22013591,0.0003450588,0.00019735492,0.00041368572,0.001058365,0.00019031111,0.015209529],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974877,0.000054923777,0.000015996266,0.000059684677,0.000051818413,0.00006885097],"domain_scores_gemma":[0.9997738,0.00007762741,0.000019619873,0.000053244832,0.0000516136,0.000024025112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056722434,0.0006184953,0.00036819876,0.0009794146,0.0007553228,0.00050644594,0.0006424295,0.0005537489,0.0019190629],"category_scores_gemma":[0.00022546921,0.00037193354,0.00056740193,0.0005718842,0.0005340554,0.000683821,0.0005162433,0.0012471802,0.0006951841],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006251829,0.00004532069,0.00029997443,0.00015818476,0.000013839441,0.00014101778,0.000053618623,0.00005801228,0.98902696,0.0014126269,0.00013311362,0.00859492],"study_design_scores_gemma":[0.000025918052,0.00019110418,0.0049826936,0.000033367596,0.00007054704,0.0015915708,0.000110298206,0.0029629353,0.9687942,0.0013014065,0.019917317,0.000018594654],"about_ca_topic_score_codex":0.0014589451,"about_ca_topic_score_gemma":0.0017544816,"teacher_disagreement_score":0.0019190629,"about_ca_system_score_codex":0.00049218116,"about_ca_system_score_gemma":0.0003971491,"threshold_uncertainty_score":0.006419897},"labels":[],"label_agreement":null},{"id":"W2744282918","doi":"10.1007/978-1-4939-7219-7_4","title":"Targeting HER2 in Advanced Breast Cancer","year":2017,"lang":"en","type":"review","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Clinical trial; Cancer; Targeted therapy; Disease","score_opus":0.18600482413268593,"score_gpt":0.6291759151960609,"score_spread":0.44317109106337493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744282918","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000835073,0.99828005,0.00020107045,0.00026765643,0.00030209415,0.0000095978685,0.000021716083,0.000010212582,0.0008240535],"genre_scores_gemma":[0.0005709131,0.99783903,0.00024059443,0.00033767623,0.00021186429,0.000011395182,0.000037139802,0.000002254507,0.00074915675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998097,0.00003229442,0.000026540007,0.00002880632,0.000075658674,0.000027021062],"domain_scores_gemma":[0.99971896,0.00012394413,0.000045372843,0.000009077208,0.00006940334,0.000033183896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079308497,0.0012886893,0.0018266897,0.0022021553,0.0002101873,0.0010465009,0.0008836376,0.0010784931,0.0042703687],"category_scores_gemma":[0.0009438472,0.00040654227,0.0005185429,0.0015022097,0.0004842041,0.0016411821,0.00095849996,0.0026018498,0.0021696307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011647689,0.000099667406,0.000080100435,0.018635841,0.000112113376,0.0001264879,0.00003376266,0.000349205,0.0020258862,0.0028121776,0.045999616,0.92960876],"study_design_scores_gemma":[0.000087316104,0.00013641737,0.0004056781,0.0041136164,0.00026358606,0.0006985705,0.000032009695,0.00016960423,0.00090703904,0.0022674052,0.99089444,0.000024359542],"about_ca_topic_score_codex":0.0006464777,"about_ca_topic_score_gemma":0.0018490165,"teacher_disagreement_score":0.0042703687,"about_ca_system_score_codex":0.00060892355,"about_ca_system_score_gemma":0.0010551885,"threshold_uncertainty_score":0.014285803},"labels":[],"label_agreement":null},{"id":"W2744674968","doi":"10.1007/978-1-4939-7219-7_19","title":"Isolation of Human Mesenchymal Stem Cells for Studying ErbB Receptor Signaling","year":2017,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"ErbB; Mesenchymal stem cell; Carcinogenesis; Cancer research; Signal transduction; Biology; Receptor; Cell biology; Cancer; Biochemistry; Genetics","score_opus":0.1837056690886039,"score_gpt":0.544444254645198,"score_spread":0.3607385855565941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744674968","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79678875,0.0058814357,0.16621043,0.0006860469,0.0005451183,0.0018810999,0.009757684,0.0006170187,0.017632393],"genre_scores_gemma":[0.88563526,0.0034493986,0.089214094,0.00040356044,0.00009581424,0.00091868447,0.00820624,0.00013362274,0.011943259],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999874,0.000011574688,0.00001567213,0.000018963263,0.000053831634,0.000025922745],"domain_scores_gemma":[0.9998971,0.000028893255,0.000011984072,0.000016180806,0.000023591705,0.000022205048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003084798,0.00028254758,0.00028112694,0.0004904921,0.00029536543,0.00038734297,0.00022358322,0.00025142805,0.0024469586],"category_scores_gemma":[0.00017387424,0.00019474053,0.00036030673,0.00032881333,0.00015140603,0.00016053418,0.00024783114,0.00064251525,0.001041775],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011877895,0.000041292496,0.00044431735,0.000055527886,0.000010466238,0.00009807347,0.000051291026,0.00015445995,0.99300355,0.00061256386,0.00019123033,0.0052185445],"study_design_scores_gemma":[0.000050463612,0.00022319931,0.0034383393,0.000015489099,0.000049734153,0.00032292568,0.00005983645,0.0011389429,0.98019505,0.00026448054,0.014234725,0.0000067311707],"about_ca_topic_score_codex":0.00064168294,"about_ca_topic_score_gemma":0.0013847208,"teacher_disagreement_score":0.0024469586,"about_ca_system_score_codex":0.00015280025,"about_ca_system_score_gemma":0.00031201285,"threshold_uncertainty_score":0.0081858635},"labels":[],"label_agreement":null},{"id":"W2744689594","doi":"10.1007/s12032-017-1018-y","title":"Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single “real-world” setting","year":2017,"lang":"en","type":"article","venue":"Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Genentech","keywords":"Trastuzumab; Medicine; Internal medicine; Breast cancer; Anthracycline; Oncology; Cardiotoxicity; Incidence (geometry); Population; Ejection fraction; Cancer; Surgery; Chemotherapy; Heart failure","score_opus":0.054160820954944164,"score_gpt":0.42862162170200696,"score_spread":0.3744608007470628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744689594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972101,0.0005587158,0.00027891024,0.00006399366,0.0000063862553,0.00005645364,0.0009944141,0.000016512133,0.0008144992],"genre_scores_gemma":[0.998648,0.00025973129,0.00022649436,0.000050449165,0.0000092508135,0.000021755868,0.0007088004,0.000006797504,0.000068834546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971027,0.0009557425,0.0005623669,0.00053998036,0.0005292459,0.0003099711],"domain_scores_gemma":[0.99257845,0.0013237584,0.0034282606,0.00069540157,0.0012914187,0.0006828201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017454437,0.00026977685,0.0005416008,0.0015895994,0.00044093272,0.0009008805,0.0004865862,0.00053057173,0.00070960075],"category_scores_gemma":[0.005183734,0.00033352192,0.00063724717,0.0015117134,0.00055185315,0.00067642285,0.0009297392,0.0004740802,0.00019511374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023797479,0.000053228036,0.995899,0.000041513533,0.00005953332,0.00026633238,0.00010936692,0.00009920474,0.00030566333,0.000018082384,0.00017635993,0.0027335647],"study_design_scores_gemma":[0.000019336037,0.0004963171,0.9962025,0.000021737831,0.000066696186,0.0016516512,0.00034337136,0.00023387025,0.00044983128,0.000017218208,0.0004862055,0.000011318165],"about_ca_topic_score_codex":0.0035625244,"about_ca_topic_score_gemma":0.004354645,"teacher_disagreement_score":0.0035625244,"about_ca_system_score_codex":0.0008659204,"about_ca_system_score_gemma":0.0010552533,"threshold_uncertainty_score":0.009230912},"labels":[],"label_agreement":null},{"id":"W2745112655","doi":"10.1007/978-1-4939-7219-7_1","title":"ErbB Receptors and Cancer","year":2017,"lang":"en","type":"review","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":431,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"ErbB; Receptor tyrosine kinase; ERBB3; ERBB4; Cancer research; Receptor; Epidermal growth factor receptor; Biology; Epidermal growth factor; Signal transduction; Neuregulin; Tyrosine kinase; Growth factor receptor; Cell biology; Biochemistry","score_opus":0.3336806821133151,"score_gpt":0.6622974962907782,"score_spread":0.3286168141774631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745112655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043328,0.99670815,0.00019881711,0.00045500556,0.0008827741,0.000007191787,0.000022541277,0.000012388431,0.0016696574],"genre_scores_gemma":[0.00048476597,0.9958556,0.0002619569,0.0004702287,0.00082142686,0.0000112523185,0.000043134092,0.0000030282952,0.0020485919],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964905,0.00006905524,0.00004204344,0.000046197973,0.0001505075,0.00004309958],"domain_scores_gemma":[0.99964297,0.00016043743,0.00004675077,0.000020217376,0.000084276035,0.000045440014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009013785,0.001466212,0.0016663498,0.0028717045,0.000321227,0.0016970162,0.0010379772,0.0013301945,0.009041411],"category_scores_gemma":[0.0013237876,0.00046017033,0.00047903552,0.002481167,0.0008542606,0.0023629575,0.001679758,0.002886202,0.0048267683],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073983705,0.000059745398,0.000084933396,0.01105909,0.000070585236,0.000108746295,0.000061593324,0.00026807815,0.0011254202,0.007075954,0.094100066,0.8859118],"study_design_scores_gemma":[0.000017819008,0.000030307918,0.00016923659,0.0020624297,0.000058507685,0.00032884398,0.000027028187,0.00005168527,0.00021026772,0.003218307,0.9938154,0.000010226781],"about_ca_topic_score_codex":0.0008477321,"about_ca_topic_score_gemma":0.0018727419,"teacher_disagreement_score":0.009041411,"about_ca_system_score_codex":0.0008958879,"about_ca_system_score_gemma":0.0018448392,"threshold_uncertainty_score":0.030246496},"labels":[],"label_agreement":null},{"id":"W2746712977","doi":"10.1016/j.ctrv.2017.08.001","title":"Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials","year":2017,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Trastuzumab; Hazard ratio; Internal medicine; Breast cancer; Oncology; Meta-analysis; Confidence interval; Randomized controlled trial; Odds ratio; Cancer","score_opus":0.47897338594908834,"score_gpt":0.54750043717925,"score_spread":0.06852705123016167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746712977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031453737,0.9960508,0.00026685756,0.00008057368,0.00010397784,0.00005089939,0.00017173991,0.000012281292,0.00011754266],"genre_scores_gemma":[0.11678083,0.87931484,0.0015047656,0.0008768502,0.00026688268,0.00023979558,0.0005918522,0.000033129476,0.0003910934],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99529856,0.0022334144,0.0012282848,0.00059854425,0.00044927312,0.00019187586],"domain_scores_gemma":[0.98887014,0.008931776,0.0013896294,0.0003046387,0.00035206473,0.00015177522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008751426,0.0023865884,0.01455406,0.001911459,0.00029353314,0.0021024253,0.0018021909,0.0017413526,0.0036225803],"category_scores_gemma":[0.018641777,0.0011679049,0.025056668,0.0030455366,0.00052106334,0.0015213217,0.0010926776,0.0026542218,0.0002440822],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011887535,0.00004398453,0.0027342036,0.25904503,0.6920743,0.00008904095,0.000072350784,0.00077955896,0.00041534353,0.00019254263,0.0010931313,0.031572886],"study_design_scores_gemma":[0.0026111202,0.00040318552,0.003873515,0.010024048,0.9796719,0.000076168515,0.000036374946,0.00014614561,0.00012256143,0.00036014753,0.0026492528,0.000025528785],"about_ca_topic_score_codex":0.0036322123,"about_ca_topic_score_gemma":0.008688467,"teacher_disagreement_score":0.01455406,"about_ca_system_score_codex":0.0017523441,"about_ca_system_score_gemma":0.0015868971,"threshold_uncertainty_score":0.04628247},"labels":[],"label_agreement":null},{"id":"W2754755063","doi":"10.1007/s11095-017-2259-3","title":"Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer","year":2017,"lang":"en","type":"review","venue":"Pharmaceutical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Pharmacokinetics; Antibody-drug conjugate; Drug; Cancer; Distribution (mathematics); Payload (computing); Medicine; Pharmacology; Monoclonal antibody; Cancer research; Antibody; Chemistry; Internal medicine; Immunology; Computer science","score_opus":0.8113589362850359,"score_gpt":0.7279344229882478,"score_spread":0.08342451329678802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754755063","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021756414,0.9981173,0.0003617988,0.0002441336,0.00017760608,0.000007455399,0.000017763225,0.000008198757,0.0008480768],"genre_scores_gemma":[0.0020247581,0.99567527,0.0004844046,0.00035637236,0.0002155537,0.000014291218,0.000039354687,0.0000033809376,0.0011866584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969137,0.00007341851,0.000037203918,0.00004535489,0.000120074874,0.000032627395],"domain_scores_gemma":[0.9996118,0.00022677566,0.000062738574,0.000010072637,0.00006929623,0.000019371924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009984324,0.0010176746,0.0016819896,0.0014229998,0.00020717017,0.0011880758,0.0008881011,0.0014780205,0.0037209839],"category_scores_gemma":[0.0012427694,0.0003806527,0.0007767107,0.0012557906,0.0004522223,0.0013863788,0.0006412477,0.0024342777,0.0018472553],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024777677,0.00013459448,0.00012593607,0.016367981,0.00017462828,0.00039579667,0.000049216065,0.0010504881,0.0062881047,0.005816206,0.028982338,0.9403669],"study_design_scores_gemma":[0.00009941661,0.0002829532,0.0004687256,0.002439172,0.00026201882,0.0017951406,0.000034511017,0.00047058682,0.0029853,0.0028856907,0.988247,0.00002949551],"about_ca_topic_score_codex":0.00068102113,"about_ca_topic_score_gemma":0.0011865998,"teacher_disagreement_score":0.0037209839,"about_ca_system_score_codex":0.00064373034,"about_ca_system_score_gemma":0.00076802354,"threshold_uncertainty_score":0.012447894},"labels":[],"label_agreement":null},{"id":"W2754815061","doi":"10.1186/s12885-017-3641-6","title":"A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer","year":2017,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Pharmacodynamics; Oncology; Tolerability; Pharmacokinetics; Cancer; Surgical oncology; Esophagus; Adverse effect","score_opus":0.06740690104374676,"score_gpt":0.41182605596332345,"score_spread":0.3444191549195767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754815061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432606,0.0009511773,0.0006623847,0.00023776962,0.00006593047,0.0023625554,0.0004132039,0.00008654339,0.00089440524],"genre_scores_gemma":[0.99008334,0.0009817231,0.00262433,0.00073046744,0.000105713814,0.002839517,0.0011759772,0.000028315382,0.0014304988],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99945956,0.00026014546,0.000026261061,0.000083195395,0.000065998705,0.00010491259],"domain_scores_gemma":[0.9993136,0.0001206444,0.00012983198,0.00007089971,0.00004754669,0.00031750635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017178914,0.0015084593,0.0020076747,0.00060652033,0.00052016386,0.0007897764,0.001016582,0.0011054529,0.0023409417],"category_scores_gemma":[0.0009487745,0.0006913043,0.0010369963,0.0005299518,0.0010737015,0.00091265584,0.00040493964,0.0034119668,0.0007287616],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50990146,0.1943209,0.013887734,0.0011001363,0.0015470384,0.00064390025,0.0009011606,0.0064581092,0.10540213,0.00042631757,0.004803951,0.1606072],"study_design_scores_gemma":[0.37509778,0.601812,0.012976722,0.000024662368,0.00027011387,0.00038883233,0.0000774248,0.0017956865,0.004970648,0.00016405,0.002386861,0.000035161138],"about_ca_topic_score_codex":0.00067841733,"about_ca_topic_score_gemma":0.0017031659,"teacher_disagreement_score":0.0023409417,"about_ca_system_score_codex":0.0010289904,"about_ca_system_score_gemma":0.0018442351,"threshold_uncertainty_score":0.009085178},"labels":[],"label_agreement":null},{"id":"W2755901387","doi":"10.1136/annrheumdis-2017-eular.4594","title":"THU0064 ADAM-10 as a tocilizumab treatment predictive factor in rheumatoid arthritis","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; St. Olavs Hospital Universitetssykehuset i Trondheim","keywords":"Tocilizumab; Medicine; Rheumatoid arthritis; Adalimumab; Internal medicine; CX3CL1; Rheumatology; Cytokine; Tumor necrosis factor alpha; Gastroenterology; Receptor; Immunology; Chemokine; Chemokine receptor","score_opus":0.09281284942180426,"score_gpt":0.40234021715342017,"score_spread":0.30952736773161593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755901387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888286,0.0062366147,0.00030886702,0.0004682118,0.00016979192,0.000015312491,0.0005867569,0.000043812757,0.0033421102],"genre_scores_gemma":[0.997664,0.00060307566,0.0003689315,0.00007183265,0.00011136709,0.000005508747,0.00044853764,0.0000060721413,0.00072086666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996699,0.000092081675,0.00004089269,0.00003491585,0.000105058636,0.000057176723],"domain_scores_gemma":[0.9992811,0.00022943263,0.00024340222,0.000031298965,0.00007841658,0.00013642252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044926745,0.00040454225,0.00046556196,0.0007125397,0.0002609546,0.0006478476,0.00031455702,0.0004524588,0.0027537488],"category_scores_gemma":[0.0015183548,0.00012354975,0.00052324875,0.00072778924,0.0001529937,0.00024098935,0.00017825991,0.00069968245,0.00043244864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005597453,0.0002737596,0.93319505,0.00013824317,0.0005623673,0.0018695439,0.00007334209,0.0002969468,0.008385305,0.00015781153,0.0021216013,0.047328644],"study_design_scores_gemma":[0.00016967775,0.0007880578,0.9868312,0.0000657733,0.00063843577,0.0033243513,0.00013467917,0.0026518232,0.0022373202,0.00025793267,0.0028803365,0.000020482283],"about_ca_topic_score_codex":0.0015768898,"about_ca_topic_score_gemma":0.0022920235,"teacher_disagreement_score":0.0027537488,"about_ca_system_score_codex":0.0002773236,"about_ca_system_score_gemma":0.00034611713,"threshold_uncertainty_score":0.009212136},"labels":[],"label_agreement":null},{"id":"W2761835480","doi":"10.1186/s13058-017-0900-z","title":"Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Genentech; Queen's University; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Trastuzumab; Surgical oncology; Medicine; Breast cancer; Internalization; Oncology; Internal medicine; Cancer; Receptor","score_opus":0.08054531900090665,"score_gpt":0.4435854263303194,"score_spread":0.3630401073294127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761835480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817693,0.00066189317,0.000343166,0.000033763547,0.000008534467,0.000010731922,0.000108785294,0.000019080044,0.0006370241],"genre_scores_gemma":[0.9983558,0.00024662452,0.00021319813,0.000021989477,0.000003493234,0.000013917054,0.00021071912,0.000005006987,0.0009292807],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993217,0.000010608259,0.000005747043,0.000010542442,0.000019928118,0.000021105154],"domain_scores_gemma":[0.99994254,0.000010901072,0.000012037468,0.000007373066,0.000009083586,0.00001813308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010103874,0.00016077407,0.00016921492,0.000113389215,0.00011367589,0.00024908452,0.000092220325,0.00015050855,0.001102713],"category_scores_gemma":[0.000093229195,0.00008321807,0.00015143404,0.000113793125,0.00010031585,0.00009464727,0.00011735194,0.00032425,0.00023849781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017163872,0.00003768896,0.0005243119,0.000014747025,0.000006439844,0.000029851237,0.00000844928,0.000059792244,0.9983902,0.000027365984,0.0000674784,0.0006621804],"study_design_scores_gemma":[0.00003180872,0.0005480151,0.02229154,0.0000045329434,0.000022055247,0.00029936022,0.000034640074,0.0018221828,0.973089,0.000023857121,0.0018288261,0.000004154485],"about_ca_topic_score_codex":0.0006783068,"about_ca_topic_score_gemma":0.0008573834,"teacher_disagreement_score":0.001102713,"about_ca_system_score_codex":0.0002620119,"about_ca_system_score_gemma":0.00015869082,"threshold_uncertainty_score":0.0036889315},"labels":[],"label_agreement":null},{"id":"W2762364343","doi":"10.1186/s13643-017-0588-2","title":"Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis","year":2017,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; St. Michael's Hospital; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Observational study; Internal medicine; Randomized controlled trial; Meta-analysis; Cochrane Library; Clinical trial; Systematic review; MEDLINE; Cancer","score_opus":0.47108867253015685,"score_gpt":0.5680127958106302,"score_spread":0.0969241232804734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762364343","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010754195,0.01080482,0.003154684,0.000733288,0.00040948953,0.96803045,0.014557782,0.00020420822,0.0010298778],"genre_scores_gemma":[0.0011875792,0.0024453083,0.0033572142,0.0002404231,0.000024884905,0.991165,0.001209621,0.0000133749445,0.00035656948],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97843766,0.010658224,0.0057863267,0.0021061662,0.0021279166,0.0008836252],"domain_scores_gemma":[0.9764173,0.010039799,0.0054932423,0.0023382085,0.0049226787,0.0007886831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04494202,0.004471773,0.015050057,0.009847419,0.0020570534,0.005348943,0.0047620153,0.0037683127,0.054484725],"category_scores_gemma":[0.071187146,0.0031768673,0.022473803,0.010336145,0.0021806476,0.0040322286,0.0038745587,0.0038748498,0.004487057],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069128075,0.0001425114,0.0007822628,0.9290152,0.015858388,0.00023565702,0.0006469885,0.0018475547,0.0007411328,0.002692108,0.020461649,0.02066363],"study_design_scores_gemma":[0.060142506,0.0027943186,0.00936797,0.56507605,0.11543893,0.0005825413,0.0011506088,0.003804175,0.0020903964,0.014103772,0.22481513,0.00063367555],"about_ca_topic_score_codex":0.008705193,"about_ca_topic_score_gemma":0.01598878,"teacher_disagreement_score":0.054484725,"about_ca_system_score_codex":0.012047857,"about_ca_system_score_gemma":0.030136146,"threshold_uncertainty_score":0.23767895},"labels":[],"label_agreement":null},{"id":"W2762812042","doi":"10.1093/annonc/mdx362.001","title":"Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Trastuzumab; Oncology; Adjuvant; Internal medicine; Breast cancer; Stage (stratigraphy); Adjuvant therapy; Cancer","score_opus":0.1519478025427769,"score_gpt":0.5029018058917327,"score_spread":0.3509540033489558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762812042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98874027,0.007393533,0.00040518318,0.0005137305,0.00016602459,0.00023383745,0.0012481866,0.000043865704,0.0012554384],"genre_scores_gemma":[0.9923522,0.002905592,0.00036925348,0.0005078306,0.00012975969,0.00019241613,0.002166198,0.000022114593,0.0013546514],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99892116,0.0005765135,0.00007327999,0.00017688872,0.00008463449,0.00016756912],"domain_scores_gemma":[0.99867165,0.00040178964,0.000363585,0.00015660506,0.0000706042,0.00033574624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004400888,0.0010514485,0.0026186658,0.0002980386,0.00025187052,0.0013420294,0.00076932926,0.00094993267,0.0018001058],"category_scores_gemma":[0.0026596335,0.000289739,0.0026657118,0.000555901,0.00067803275,0.0018893194,0.00057429716,0.0027639146,0.0003985205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8802243,0.0049303165,0.016028002,0.0010703406,0.006457545,0.00018092642,0.0001330122,0.00597256,0.00402107,0.0003637326,0.0031256261,0.077492595],"study_design_scores_gemma":[0.63268924,0.22482932,0.1088037,0.0003031612,0.011643857,0.0009115968,0.00030871996,0.007269686,0.0031137315,0.0020671375,0.007904117,0.00015564453],"about_ca_topic_score_codex":0.00073906954,"about_ca_topic_score_gemma":0.002011953,"teacher_disagreement_score":0.004400888,"about_ca_system_score_codex":0.00082831195,"about_ca_system_score_gemma":0.0007783381,"threshold_uncertainty_score":0.023274422},"labels":[],"label_agreement":null},{"id":"W2762949878","doi":"10.1590/1678-4324-2017160733","title":"Gene Expression Analyses of HER-2/neu and ESR1 in Patients with Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Brazilian Archives of Biology and Technology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Tabriz; Tabriz University of Medical Sciences","keywords":"Breast cancer; Pathological; Gene; Estrogen receptor alpha; Lymph node; Cancer; Biology; Gene expression; Oncology; Internal medicine; Cancer research; Medicine; Pathology; Genetics; Estrogen receptor","score_opus":0.019419365488782862,"score_gpt":0.36091302432139455,"score_spread":0.3414936588326117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762949878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999495,0.00023048717,0.000037154918,0.000009520812,0.000001779094,0.0000015577539,0.00009356356,0.000001666825,0.00012922083],"genre_scores_gemma":[0.999637,0.00008808414,0.00006839859,0.000008370774,0.000004516727,0.0000034706563,0.00012606586,6.090521e-7,0.00006341674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998691,0.000029550036,0.000016818905,0.000033779976,0.00002722111,0.000023515258],"domain_scores_gemma":[0.9997675,0.000065610126,0.00009667056,0.000011795691,0.00002835509,0.000030074449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019391062,0.00011047773,0.0001745425,0.00050317106,0.00012630525,0.00020044301,0.000082396604,0.00016559214,0.00057878694],"category_scores_gemma":[0.0005230727,0.00007691743,0.00011827697,0.0005464955,0.00011942922,0.00012852495,0.00011103113,0.0001357123,0.00009495518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002542374,0.000019082157,0.9930005,0.000019497493,0.000018507095,0.0002929625,0.000085491025,0.00004713003,0.0038210696,0.00000891283,0.000056618963,0.002376128],"study_design_scores_gemma":[0.000005946624,0.00015641062,0.9965018,0.0000031285683,0.000030609706,0.001474492,0.0001527684,0.0001508326,0.0012392624,0.000022411376,0.00025954214,0.0000027251763],"about_ca_topic_score_codex":0.0002272554,"about_ca_topic_score_gemma":0.0003084154,"teacher_disagreement_score":0.00057878694,"about_ca_system_score_codex":0.000104593535,"about_ca_system_score_gemma":0.00007253926,"threshold_uncertainty_score":0.0019362569},"labels":[],"label_agreement":null},{"id":"W2762963596","doi":"10.1093/annonc/mdx362.009","title":"Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Lapatinib; Breast cancer; Trastuzumab; Confidence interval; Adjuvant; Gynecology; Cancer; Oncology; Gastroenterology","score_opus":0.1485413740334905,"score_gpt":0.43702328293874504,"score_spread":0.28848190890525455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762963596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930748,0.005298757,0.00006677145,0.00021397391,0.00005129143,0.00002871002,0.0007945532,0.000009063367,0.0004620045],"genre_scores_gemma":[0.99555826,0.0019700013,0.00013664065,0.0002683266,0.00013851197,0.000039428498,0.0014325321,0.0000030438923,0.00045318413],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99975246,0.00012818772,0.000018836668,0.00003997501,0.000022477194,0.000038006616],"domain_scores_gemma":[0.99934894,0.00025302108,0.00016561404,0.00005666695,0.000015990143,0.00015979662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000945434,0.0004294278,0.00092967105,0.00022091661,0.00020393987,0.00056970556,0.00036841683,0.0007333894,0.001327605],"category_scores_gemma":[0.0013343672,0.00023723119,0.0015280523,0.00047401944,0.0002783933,0.0004172118,0.00035128536,0.00097511633,0.000113826776],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5516048,0.0025490501,0.3742361,0.0009342142,0.010436482,0.0002752731,0.000113063266,0.0018970928,0.003884975,0.00028446448,0.002706978,0.051077522],"study_design_scores_gemma":[0.07957965,0.04358287,0.85042727,0.00022063701,0.016625939,0.00059025484,0.00020915687,0.0023505413,0.00082500814,0.0010741751,0.004441232,0.00007332677],"about_ca_topic_score_codex":0.0015772547,"about_ca_topic_score_gemma":0.0045568617,"teacher_disagreement_score":0.0015772547,"about_ca_system_score_codex":0.00030601572,"about_ca_system_score_gemma":0.0004761,"threshold_uncertainty_score":0.004999995},"labels":[],"label_agreement":null},{"id":"W2766013741","doi":"10.3389/fpsyt.2017.00225","title":"Peripheral Transcription of NRG-ErbB Pathway Genes Are Upregulated in Treatment-Resistant Schizophrenia","year":2017,"lang":"en","type":"article","venue":"Frontiers in Psychiatry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Health and Medical Research Council; Medical Research Council; Macquarie Group Foundation; Neuroscience Research Australia; NSW Ministry of Health; University of New South Wales; National Alliance for Research on Schizophrenia and Depression","keywords":"ERBB4; ErbB; Downregulation and upregulation; Neuregulin 1; Clozapine; PI3K/AKT/mTOR pathway; Peripheral blood mononuclear cell; Signal transduction; ERBB3; Biology; Internal medicine; Endocrinology; Medicine; Gene; Schizophrenia (object-oriented programming); Cancer research; Receptor; Genetics; In vitro; Epidermal growth factor receptor; Psychiatry","score_opus":0.024365082173259563,"score_gpt":0.3092000873199102,"score_spread":0.28483500514665067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766013741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994073,0.00016786922,0.00006567035,0.0000075702724,0.0000012399603,0.0000021101146,0.00018285851,0.0000045474617,0.00016098315],"genre_scores_gemma":[0.9992055,0.0001548952,0.00012662931,0.000010740604,0.000001751938,0.0000057644856,0.00024843824,0.0000037502068,0.0002424627],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999915,0.000013851066,0.000008904599,0.000026138174,0.000019710908,0.000016447057],"domain_scores_gemma":[0.99982005,0.000020887845,0.00010237408,0.00001266576,0.000017182856,0.000026878546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008470193,0.00019639301,0.00023941531,0.00041520552,0.00015734097,0.00021251824,0.00007124345,0.0001285676,0.0014608414],"category_scores_gemma":[0.00027538493,0.00012689013,0.00016830159,0.0002492563,0.00016634096,0.00006743387,0.00013297358,0.00019641548,0.0001403904],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037942128,0.00007259394,0.22148356,0.00013746551,0.00010489658,0.0009977065,0.0006646951,0.00013696158,0.76092756,0.00006738255,0.00012407456,0.0114889005],"study_design_scores_gemma":[0.000017638646,0.0003103031,0.98658025,0.000009126179,0.00004003566,0.0010065382,0.0002968428,0.00015467976,0.011266437,0.00005075012,0.00026106377,0.000006176224],"about_ca_topic_score_codex":0.0015772338,"about_ca_topic_score_gemma":0.002763991,"teacher_disagreement_score":0.0015772338,"about_ca_system_score_codex":0.00017923584,"about_ca_system_score_gemma":0.00012887323,"threshold_uncertainty_score":0.0048870444},"labels":[],"label_agreement":null},{"id":"W2766249538","doi":"10.1016/j.ctrv.2017.10.008","title":"Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis","year":2017,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Meta-analysis; Oncology; Internal medicine; Hazard ratio; Epidermal growth factor receptor; Triple-negative breast cancer; Cancer; Confidence interval","score_opus":0.32236565591717875,"score_gpt":0.5041202922561302,"score_spread":0.18175463633895145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766249538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047156042,0.99390525,0.00030412708,0.00014409731,0.00012876299,0.00012823578,0.0004933933,0.000018660094,0.00016184372],"genre_scores_gemma":[0.16933765,0.82579976,0.0016165966,0.0013238669,0.00021986906,0.000562391,0.0006400685,0.000029986475,0.00046978323],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9944207,0.0021402845,0.0018548559,0.0007212223,0.0005689041,0.0002940229],"domain_scores_gemma":[0.99124336,0.0058133663,0.0018640918,0.00031649496,0.0005978526,0.00016496041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074161408,0.0028111916,0.01566959,0.004153367,0.0005321963,0.0026352797,0.0017874433,0.0021473332,0.004625053],"category_scores_gemma":[0.018507507,0.0018173403,0.030059632,0.006101785,0.00070101506,0.0017703393,0.0019431823,0.002205348,0.0003828105],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015721442,0.000031778014,0.0051610586,0.34803194,0.6348895,0.00015736878,0.000101282465,0.00031529108,0.0002511484,0.00011509921,0.0008648798,0.008508562],"study_design_scores_gemma":[0.00050393055,0.000097048796,0.0028785625,0.013910431,0.98099947,0.000074805066,0.000049099734,0.00006328264,0.00005065437,0.00010810172,0.0012434572,0.000021163016],"about_ca_topic_score_codex":0.00921774,"about_ca_topic_score_gemma":0.029285563,"teacher_disagreement_score":0.01566959,"about_ca_system_score_codex":0.0023188,"about_ca_system_score_gemma":0.0033789128,"threshold_uncertainty_score":0.03922081},"labels":[],"label_agreement":null},{"id":"W2766565770","doi":"10.1097/md.0000000000008437","title":"Clinicopathological factors associated with HER2-positive gastric cancer","year":2017,"lang":"en","type":"review","venue":"Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Cancer; Cochrane Library; Oncology; Odds ratio; Chemotherapy; Meta-analysis; Clinical trial; Breast cancer","score_opus":0.5193196599766069,"score_gpt":0.5682100767777455,"score_spread":0.04889041680113859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766565770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04024988,0.9571039,0.00014717672,0.00034911308,0.00007194551,0.00006533718,0.0010339175,0.000005788197,0.00097284047],"genre_scores_gemma":[0.48811725,0.5079505,0.00090825115,0.00049809366,0.00033018918,0.00020945254,0.0016900037,0.000009758742,0.0002864951],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99621826,0.00085724995,0.0015050896,0.0004565623,0.00086035,0.000102407146],"domain_scores_gemma":[0.9815207,0.009492239,0.0074261166,0.00032638005,0.0009870108,0.00024738876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003622751,0.00062813296,0.0020035268,0.008074997,0.00032380983,0.0013650163,0.00071623106,0.00065962435,0.002325874],"category_scores_gemma":[0.013179675,0.00033241534,0.0030486654,0.011819858,0.000568989,0.00096330594,0.0006160637,0.0004761068,0.0001539863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031169448,0.00011030907,0.57868344,0.24573043,0.031827282,0.0018684109,0.00049370213,0.000545233,0.0014257455,0.00039840883,0.003453964,0.13234615],"study_design_scores_gemma":[0.0005284577,0.00053395727,0.78868526,0.0727568,0.09295276,0.010925806,0.0011072147,0.00035390025,0.0011306321,0.0010662756,0.029829513,0.00012940916],"about_ca_topic_score_codex":0.001560326,"about_ca_topic_score_gemma":0.003489987,"teacher_disagreement_score":0.008074997,"about_ca_system_score_codex":0.0007481096,"about_ca_system_score_gemma":0.0014905921,"threshold_uncertainty_score":0.019159198},"labels":[],"label_agreement":null},{"id":"W2768649895","doi":"10.1016/s1470-2045(17)30716-7","title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":529,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Johnson and Johnson; F. Hoffmann-La Roche; Eli Lilly and Company","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Docetaxel; Oncology; Internal medicine; Breast cancer; Carboplatin; Regimen; Neoadjuvant therapy; Metastatic breast cancer; Cancer; Chemotherapy","score_opus":0.09179359523436297,"score_gpt":0.4422125994061898,"score_spread":0.3504190041718268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768649895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868058,0.0028077904,0.0005574957,0.00070151663,0.00046057484,0.0063402047,0.00057315204,0.00007408715,0.0016795353],"genre_scores_gemma":[0.98126596,0.0017666381,0.0025453821,0.0012684839,0.0004835172,0.009640353,0.000724344,0.00002018453,0.0022852556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984067,0.001050591,0.000091020454,0.00019017061,0.000076545,0.00018502114],"domain_scores_gemma":[0.9982352,0.00053670886,0.00038062292,0.00014757122,0.00009002868,0.0006096984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035026232,0.0012701488,0.0025950589,0.0003341782,0.00052848516,0.0009900918,0.0008576257,0.0017002448,0.004709816],"category_scores_gemma":[0.002653496,0.00064938684,0.0018163812,0.00037603677,0.001364842,0.0013132753,0.0005947174,0.0023016646,0.0006645056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98607475,0.0048883785,0.00031489722,0.00025641816,0.00025322137,0.00002070734,0.000053018786,0.0002452843,0.0013727287,0.00006182354,0.0003446593,0.0061140847],"study_design_scores_gemma":[0.92932355,0.06873528,0.0008405058,0.000022160179,0.00015935501,0.000024671817,0.000013645605,0.00020331902,0.00016714234,0.00009870732,0.00039988765,0.000011723668],"about_ca_topic_score_codex":0.00075084006,"about_ca_topic_score_gemma":0.0022693705,"teacher_disagreement_score":0.004709816,"about_ca_system_score_codex":0.00094509125,"about_ca_system_score_gemma":0.0019190265,"threshold_uncertainty_score":0.018523872},"labels":[],"label_agreement":null},{"id":"W2768980003","doi":"10.1016/s1470-2045(17)30717-9","title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"National Institute for Health and Care Research; Puma Biotechnology","keywords":"Medicine; Neratinib; Trastuzumab; Internal medicine; Breast cancer; Oncology; Clinical endpoint; Placebo; Regimen; Metastatic breast cancer; Adverse effect; Cancer; Clinical trial; Pathology","score_opus":0.09916280515671266,"score_gpt":0.4624950642930083,"score_spread":0.36333225913629563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768980003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97624683,0.015154864,0.0012905045,0.0010499799,0.001055766,0.0017069249,0.0014288902,0.00019241255,0.001873843],"genre_scores_gemma":[0.9867225,0.0046344716,0.0011193507,0.0010664297,0.0004391076,0.0013979733,0.0014365155,0.00004223547,0.0031412926],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99864286,0.0007343357,0.000086980384,0.00022966668,0.000083605635,0.00022251568],"domain_scores_gemma":[0.99850625,0.0004913181,0.0003563138,0.00017337284,0.000091421025,0.00038134604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036568134,0.0022078059,0.0050506205,0.00046603687,0.00045831114,0.0015948701,0.0012633096,0.0022854123,0.0051443605],"category_scores_gemma":[0.0030249518,0.00069535634,0.004394197,0.0005563044,0.0014974716,0.002510563,0.0005829897,0.004596834,0.0010390492],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98885286,0.0011325472,0.00031085775,0.00051276863,0.0015207169,0.000029232688,0.000031368585,0.00030426262,0.0007890726,0.00007557468,0.0004000105,0.006040598],"study_design_scores_gemma":[0.97229385,0.024257781,0.0013884794,0.000041238152,0.0009188283,0.000037094644,0.000025082454,0.00028438968,0.00018833025,0.00017509617,0.0003718367,0.000018033785],"about_ca_topic_score_codex":0.0009790853,"about_ca_topic_score_gemma":0.0022011623,"teacher_disagreement_score":0.0051443605,"about_ca_system_score_codex":0.0009729541,"about_ca_system_score_gemma":0.0008754494,"threshold_uncertainty_score":0.019339323},"labels":[],"label_agreement":null},{"id":"W2770903255","doi":"10.1016/j.clbc.2017.11.012","title":"Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients","year":2017,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval; Hôtel-Dieu de Québec; Centre hospitalier de l'Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Cancer Society","keywords":"Medicine; Trastuzumab; Breast cancer; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Genotype; Cancer; Gynecology; Confidence interval","score_opus":0.06898295181947652,"score_gpt":0.4281602336921043,"score_spread":0.3591772818726278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770903255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99938095,0.00020458671,0.000018619277,0.00003844217,0.0000067646347,0.0000018286464,0.00008633937,0.0000013502342,0.00026108188],"genre_scores_gemma":[0.9995067,0.00006766451,0.000016234588,0.000026387173,0.000011616297,0.0000024687279,0.00012054614,0.0000015157177,0.00024690034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997451,0.00007389633,0.000030157811,0.00005750153,0.000032246608,0.00006103775],"domain_scores_gemma":[0.999356,0.00020884213,0.00019851867,0.00004565716,0.000046991252,0.00014408011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032406987,0.00024097165,0.00036241158,0.00034775335,0.00029358576,0.0005163709,0.00023570235,0.00047309723,0.001881389],"category_scores_gemma":[0.0011192727,0.0002559835,0.00056179485,0.0005976389,0.00022885771,0.0003420995,0.00020712198,0.0006308645,0.00020124523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009862547,0.00007423464,0.9969379,0.0000063165608,0.00015138205,0.00010899003,0.000030410682,0.000042850163,0.00071138644,0.000013021262,0.00006362245,0.00087372866],"study_design_scores_gemma":[0.000027069642,0.00011687068,0.9989924,0.000002421187,0.00009960156,0.00017600037,0.00007997602,0.00025746625,0.00009698718,0.000026497732,0.000120702854,0.000003936306],"about_ca_topic_score_codex":0.0024843225,"about_ca_topic_score_gemma":0.0026832523,"teacher_disagreement_score":0.0024843225,"about_ca_system_score_codex":0.00024820573,"about_ca_system_score_gemma":0.0002199083,"threshold_uncertainty_score":0.006293893},"labels":[],"label_agreement":null},{"id":"W2773416496","doi":"10.1016/j.ejca.2017.10.037","title":"A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Human Epidermal Growth Factor Receptor 2; Medicine; Breast cancer; Cancer; Intensive care medicine; Metastatic breast cancer; Epidermal growth factor receptor; Targeted therapy; Value (mathematics); Oncology; Internal medicine; Computer science","score_opus":0.14677084885074435,"score_gpt":0.4564360463690129,"score_spread":0.3096651975182686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773416496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044334814,0.99932563,0.000035366018,0.00016788015,0.00014393566,0.0000035242504,0.000023350243,0.0000025343343,0.00025330033],"genre_scores_gemma":[0.00025538265,0.9991978,0.00007731855,0.00021374658,0.00011218873,0.000003140499,0.000021810467,5.6150105e-7,0.00011816168],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996804,0.00006116963,0.00007835886,0.000047675498,0.00010852543,0.000023804003],"domain_scores_gemma":[0.999183,0.00045056266,0.00013761868,0.0000136577755,0.00016701994,0.000048159345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009704104,0.0008339043,0.002047629,0.0032129774,0.00027500893,0.0011402061,0.0010681587,0.0011812695,0.004548462],"category_scores_gemma":[0.0018417554,0.00030927398,0.0009578719,0.003223696,0.00036429302,0.0013838896,0.000746286,0.0017040953,0.0009637874],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019322582,0.000074492775,0.00019198633,0.09746951,0.00037132594,0.0002803205,0.00008287887,0.00034259452,0.0013462637,0.0025303736,0.05072365,0.8463935],"study_design_scores_gemma":[0.000074466465,0.0001709218,0.0011356659,0.022505423,0.00094328186,0.00118047,0.000091633585,0.00011404495,0.0003116173,0.00146322,0.9719747,0.000034562385],"about_ca_topic_score_codex":0.0015043154,"about_ca_topic_score_gemma":0.0034272203,"teacher_disagreement_score":0.004548462,"about_ca_system_score_codex":0.0007058329,"about_ca_system_score_gemma":0.0017144457,"threshold_uncertainty_score":0.015216112},"labels":[],"label_agreement":null},{"id":"W2773743704","doi":"10.1038/s41398-017-0041-2","title":"Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients","year":2017,"lang":"en","type":"article","venue":"Translational Psychiatry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Health and Medical Research Council; Macquarie Group Foundation; Ramsay Health Care; University of New South Wales; Australian Schizophrenia Research Bank; Sylvia and Charles Viertel Charitable Foundation; Australian Government; Neuroscience Research Australia; Murdoch Children's Research Institute; Pratt Foundation; National Alliance for Research on Schizophrenia and Depression; Medical Research Council; NSW Ministry of Health; Children’s Hospital of Wisconsin Research Institute","keywords":"Neuregulin 1; Clozapine; Schizophrenia (object-oriented programming); Neuregulin; Peripheral; Gene isoform; Psychosis; Medicine; Internal medicine; Pharmacology; Psychology; Psychiatry; Biology; Receptor; Genetics; Gene","score_opus":0.02501492277253212,"score_gpt":0.3361033545480111,"score_spread":0.31108843177547896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773743704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994466,0.00019377083,0.000042269367,0.00000963554,0.0000017585751,0.0000025991867,0.00011068994,0.0000038012402,0.00018887967],"genre_scores_gemma":[0.99930024,0.00013689966,0.00009588652,0.000017968396,0.0000019735407,0.0000042477554,0.00013612623,0.0000020848522,0.0003045088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99993074,0.000012571774,0.000007588025,0.000021520831,0.000015730642,0.0000118225635],"domain_scores_gemma":[0.99986196,0.000020865862,0.0000678152,0.000006946541,0.000015169225,0.000027288754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069914895,0.00029671655,0.0002200782,0.0003941262,0.00022281773,0.00022296012,0.0000735395,0.00016811152,0.0015797608],"category_scores_gemma":[0.0002983763,0.00014116266,0.000119746925,0.00020186578,0.00013327404,0.00006598604,0.000101039135,0.00019321687,0.00017921225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004002837,0.00010967632,0.7118206,0.000110620465,0.00015566654,0.0016074245,0.00052293617,0.00009067548,0.2712158,0.000041153893,0.00020918775,0.010113358],"study_design_scores_gemma":[0.000017862389,0.00021222785,0.99501944,0.000006142398,0.00003899518,0.0009889321,0.00013287048,0.00008941003,0.0033094576,0.000015023717,0.0001664444,0.0000031960294],"about_ca_topic_score_codex":0.0040284353,"about_ca_topic_score_gemma":0.0062658726,"teacher_disagreement_score":0.0040284353,"about_ca_system_score_codex":0.00022688843,"about_ca_system_score_gemma":0.00009609114,"threshold_uncertainty_score":0.00800997},"labels":[],"label_agreement":null},{"id":"W2774227900","doi":"10.1016/j.ejca.2017.10.021","title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"F. Hoffmann-La Roche; Roche","keywords":"Pertuzumab; Anthracycline; Trastuzumab; Medicine; Oncology; Internal medicine; Chemotherapy; Cancer; Breast cancer","score_opus":0.02363119783183756,"score_gpt":0.37978011214785656,"score_spread":0.356148914316019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774227900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932051,0.0018097683,0.0005683387,0.00048796242,0.00020514021,0.0009098698,0.0013620054,0.00006669525,0.0013850874],"genre_scores_gemma":[0.99123,0.00084106217,0.0007499043,0.0009197471,0.0005023105,0.0012960504,0.0025932926,0.000039002727,0.0018286436],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968798,0.0019527954,0.00013186825,0.0004523935,0.00021496713,0.00036813226],"domain_scores_gemma":[0.99439514,0.0016061185,0.0013857548,0.00070973986,0.0003364938,0.0015667103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058729867,0.002131372,0.0036440094,0.00050680235,0.0006460848,0.0018805849,0.0014337186,0.0025613788,0.0052529727],"category_scores_gemma":[0.0053827674,0.0009817722,0.0036775917,0.0005866233,0.002436698,0.0021166317,0.001000219,0.0053137927,0.00131742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98303854,0.0046329084,0.0019024484,0.00013617246,0.0017001075,0.000035087196,0.00005498303,0.00045155702,0.0019605889,0.00006675999,0.00048015555,0.0055406527],"study_design_scores_gemma":[0.8896674,0.09666484,0.010461664,0.000017727354,0.0015476908,0.000058586338,0.000039824594,0.00040362592,0.0003933706,0.00017585719,0.00053840707,0.000031027972],"about_ca_topic_score_codex":0.0010450856,"about_ca_topic_score_gemma":0.002024158,"teacher_disagreement_score":0.0058729867,"about_ca_system_score_codex":0.0014649468,"about_ca_system_score_gemma":0.001575722,"threshold_uncertainty_score":0.031059682},"labels":[],"label_agreement":null},{"id":"W2774414712","doi":"10.18632/oncotarget.22958","title":"FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Royal University Hospital; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Epithelial–mesenchymal transition; Cancer research; Biology; Kinome; Cell growth; Cell migration; Signal transduction; Vimentin; Mesenchymal stem cell; Cell biology; Cell culture; Downregulation and upregulation; Immunology; Gene","score_opus":0.023451253549584283,"score_gpt":0.33013123874951367,"score_spread":0.3066799851999294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774414712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726352,0.0146503365,0.0011145766,0.00095888576,0.00017711353,0.000051230265,0.0008408244,0.00020478276,0.009366871],"genre_scores_gemma":[0.98799706,0.004337796,0.0005649734,0.00020302988,0.000024814455,0.000031097567,0.0007313113,0.00001733508,0.006092532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992883,0.0000075544644,0.0000044783224,0.000005401126,0.000017802897,0.000035943336],"domain_scores_gemma":[0.99997985,0.0000024786746,0.000005235642,0.0000021107014,0.0000029772757,0.0000073333763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098610646,0.00023870688,0.00019866759,0.00020137036,0.00017730572,0.0003027121,0.00013939408,0.00020259502,0.0027367442],"category_scores_gemma":[0.00009231605,0.00007877303,0.00027894566,0.00014007896,0.00012427062,0.00012901326,0.00013533831,0.00046726366,0.00072567695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028648463,0.0006288099,0.0040723654,0.0004833868,0.00007973882,0.00032277795,0.00006788191,0.0006935246,0.9169739,0.0006056302,0.0066606747,0.06654659],"study_design_scores_gemma":[0.0012113383,0.004664575,0.092969045,0.0001394256,0.00021212068,0.002395642,0.00048810727,0.008927362,0.8190924,0.0004843979,0.06937069,0.000044917662],"about_ca_topic_score_codex":0.0021752012,"about_ca_topic_score_gemma":0.004930814,"teacher_disagreement_score":0.0027367442,"about_ca_system_score_codex":0.00029249422,"about_ca_system_score_gemma":0.00044625858,"threshold_uncertainty_score":0.009155333},"labels":[],"label_agreement":null},{"id":"W2779273646","doi":"10.1038/labinvest.2017.131","title":"Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer","year":2017,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health and Social Care Research and Development Division; Public Health Agency; Queen's University Belfast; Queen's University; European Commission; Cancer Research UK; Friends of the Cancer Centre; Invest Northern Ireland","keywords":"Tissue microarray; Concordance; Breast cancer; Medicine; Digital pathology; Cutoff; Receiver operating characteristic; Biomarker; Pathology; Immunohistochemistry; Cancer; Oncology; Bioinformatics; Internal medicine; Biology","score_opus":0.0499341235382879,"score_gpt":0.34217540971966565,"score_spread":0.29224128618137774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779273646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49363145,0.006218366,0.4797545,0.0015499765,0.00030052522,0.00048412915,0.0017622517,0.005452024,0.010846745],"genre_scores_gemma":[0.77301395,0.00090271275,0.2187098,0.0003826132,0.0003125533,0.00018472664,0.001346968,0.00045171595,0.004694962],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99499965,0.0022930712,0.0003446734,0.0007482314,0.0013348912,0.00027955766],"domain_scores_gemma":[0.99315214,0.0022800425,0.00095580105,0.001346334,0.0020178687,0.00024785116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053244974,0.0008704272,0.0012349096,0.0034397754,0.00046533698,0.002392375,0.0010778691,0.0008301356,0.0032353066],"category_scores_gemma":[0.0074854894,0.00068378804,0.0005738203,0.001787153,0.00040731326,0.0016398481,0.0017392393,0.0007692391,0.0013175242],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014334611,0.00063614117,0.19488765,0.00044574996,0.0005005244,0.0003622505,0.00029036918,0.0068602064,0.09540924,0.0015500155,0.0061106402,0.6915137],"study_design_scores_gemma":[0.0002906504,0.0011618966,0.43855342,0.00026109573,0.0012683718,0.0056358483,0.00066452165,0.31631127,0.1906945,0.011842336,0.033106256,0.00020979413],"about_ca_topic_score_codex":0.001116211,"about_ca_topic_score_gemma":0.004051399,"teacher_disagreement_score":0.0053244974,"about_ca_system_score_codex":0.00056736515,"about_ca_system_score_gemma":0.001112121,"threshold_uncertainty_score":0.028158963},"labels":[],"label_agreement":null},{"id":"W2779627475","doi":"10.1021/acs.jmedchem.7b01607","title":"Identification of [<sup>18</sup>F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging","year":2017,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Montreal Neurological Institute and Hospital; McGill University; Douglas Mental Health University Institute; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Cancer Research Society; Canada Foundation for Innovation; National Institute of Biomedical Imaging and Bioengineering; Weston Brain Institute; U.S. Department of Energy","keywords":"Trk receptor; Chemistry; Tropomyosin receptor kinase A; Pharmacophore; In vivo; Radioligand; Receptor; Tropomyosin; HEK 293 cells; Biochemistry; Neurotrophin","score_opus":0.03909447434663377,"score_gpt":0.3800916285491597,"score_spread":0.3409971542025259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779627475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9136921,0.0052120457,0.06397769,0.0006415394,0.000120425975,0.0005800841,0.0010740367,0.00037604562,0.014326049],"genre_scores_gemma":[0.94931597,0.0033800157,0.03567782,0.00024120098,0.00003627012,0.00011527567,0.0010516796,0.00009030126,0.010091445],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999138,0.000011933363,0.0000035499304,0.000025711519,0.00002304704,0.000021979225],"domain_scores_gemma":[0.99989605,0.000012688208,0.000035022505,0.0000059294625,0.000024567662,0.000025771056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018862543,0.00039008958,0.00022747,0.00014085541,0.00016209186,0.00041704156,0.00032573848,0.00052381214,0.0010731601],"category_scores_gemma":[0.00016523064,0.00014820798,0.00018936771,0.00011542256,0.0002620164,0.00032869485,0.0001953587,0.00045767787,0.00038732027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002681182,0.000074972944,0.0002829757,0.00008093137,0.000014466795,0.0002541428,0.000051915405,0.00053558603,0.98757744,0.00094272586,0.00040228147,0.0095144175],"study_design_scores_gemma":[0.000036372094,0.00082685414,0.0005613352,0.000004820365,0.000016841517,0.0005031755,0.000013570431,0.0007131774,0.99003416,0.00006797003,0.0072128545,0.000008847274],"about_ca_topic_score_codex":0.0012701045,"about_ca_topic_score_gemma":0.0020670414,"teacher_disagreement_score":0.0012701045,"about_ca_system_score_codex":0.0005007844,"about_ca_system_score_gemma":0.0004784053,"threshold_uncertainty_score":0.0036334395},"labels":[],"label_agreement":null},{"id":"W2789664849","doi":"10.1158/1078-0432.ccr-17-3473","title":"Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research","keywords":"Trastuzumab; Medicine; Tissue microarray; Hazard ratio; Internal medicine; Breast cancer; Cyclin D1; Oncology; Clinical endpoint; Proportional hazards model; Cancer; Clinical trial; Cell cycle; Confidence interval","score_opus":0.14554333420835522,"score_gpt":0.5289420088485274,"score_spread":0.3833986746401722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789664849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991953,0.00048816073,0.0000626795,0.000034436347,0.000004914202,0.000011856532,0.00007327409,0.0000019050076,0.00012756349],"genre_scores_gemma":[0.9991375,0.00018703673,0.00007194128,0.000045657238,0.000035754914,0.00001875067,0.0002226121,0.000002359498,0.0002783065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943846,0.00031984187,0.000028430359,0.00009952883,0.000065682485,0.00004804214],"domain_scores_gemma":[0.9985039,0.00052263547,0.00033217913,0.00025294317,0.00008707003,0.0003013162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019923286,0.0005723332,0.0009197622,0.00023369602,0.00016300804,0.00049456436,0.0003095696,0.000460447,0.0012477195],"category_scores_gemma":[0.0013729321,0.00027999628,0.0009188504,0.00023935025,0.0003246252,0.00024306848,0.00029685916,0.0007076754,0.00023022735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45697477,0.0046385727,0.45738572,0.00040825258,0.006387616,0.0006541872,0.00030658743,0.0008589167,0.040537566,0.0001512265,0.00068656966,0.031010112],"study_design_scores_gemma":[0.029752694,0.04808794,0.9050562,0.000040907045,0.0056432537,0.0014545568,0.00014084595,0.0023495313,0.00531758,0.00019918743,0.0019080997,0.00004930536],"about_ca_topic_score_codex":0.0004893554,"about_ca_topic_score_gemma":0.00074146915,"teacher_disagreement_score":0.0019923286,"about_ca_system_score_codex":0.00032539273,"about_ca_system_score_gemma":0.0002990416,"threshold_uncertainty_score":0.0105365515},"labels":[],"label_agreement":null},{"id":"W2790006193","doi":"10.1093/annonc/mdy023","title":"Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Gastroenterology; Adverse effect; Population; Ovarian cancer; Confidence interval; Cancer; Pharmacology","score_opus":0.0897298999838671,"score_gpt":0.46234936169323504,"score_spread":0.37261946170936794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790006193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472576,0.0020283046,0.0004233165,0.0003163276,0.0002244727,0.000894886,0.00035669626,0.000068440524,0.00096184405],"genre_scores_gemma":[0.9927483,0.0017715,0.00093492615,0.00044724543,0.00023101507,0.0010472194,0.00061304244,0.000022706326,0.002184052],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99959534,0.00020356066,0.000020180354,0.000076002485,0.000029919267,0.00007508265],"domain_scores_gemma":[0.9993561,0.00017673467,0.000110328045,0.000057389716,0.000034926063,0.0002646236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00132085,0.0014047534,0.0024240594,0.0004178982,0.00028807588,0.0010102435,0.0008386269,0.0012340172,0.0040484276],"category_scores_gemma":[0.0011301005,0.00068798126,0.0013756972,0.00038466812,0.0011513003,0.0013481207,0.0003388678,0.00296534,0.00078242074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95408386,0.013378849,0.00066326803,0.00034683064,0.00077853963,0.000035286794,0.000066712324,0.0005696189,0.0074008675,0.00010280492,0.00050681486,0.022066582],"study_design_scores_gemma":[0.8052585,0.18902552,0.002483991,0.000019970223,0.00052697264,0.000045955196,0.000032758144,0.00073927967,0.0010024479,0.000115416595,0.00073071104,0.000018382681],"about_ca_topic_score_codex":0.000771047,"about_ca_topic_score_gemma":0.0017814458,"teacher_disagreement_score":0.0040484276,"about_ca_system_score_codex":0.0007742908,"about_ca_system_score_gemma":0.00084823114,"threshold_uncertainty_score":0.013543367},"labels":[],"label_agreement":null},{"id":"W2794142549","doi":"10.1007/s10549-018-4734-x","title":"Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Institute of Cancer Research; Ontario Institute for Cancer Research; McMaster University; Health Sciences Centre; CancerCare Manitoba; University of Toronto; Institute of Health Services and Policy Research; Western University","funders":"Canadian Cancer Society; Canadian Institutes of Health Research; Sunnybrook Research Institute","keywords":"Medicine; Hazard ratio; Internal medicine; Trastuzumab; Proportional hazards model; Breast cancer; Metastatic breast cancer; Oncology; Confidence interval; Cancer; Metastasis","score_opus":0.06202613288929283,"score_gpt":0.3763758606711169,"score_spread":0.3143497277818241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794142549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987675,0.00036658542,0.000025054169,0.00015927746,0.000010618422,0.0000024566896,0.000110057044,0.0000018741822,0.0005565791],"genre_scores_gemma":[0.99952185,0.000112857386,0.000013917134,0.00005952097,0.000022270162,0.0000024054116,0.000113952956,0.0000010994371,0.00015221159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99978715,0.000052263655,0.000019610296,0.000032281878,0.00003124072,0.00007747691],"domain_scores_gemma":[0.9990758,0.00030421637,0.00026979542,0.000031327887,0.00005837301,0.00026058828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002151838,0.00012741379,0.0002872068,0.00026584475,0.0003231169,0.0005410363,0.0001738106,0.00043706788,0.001564619],"category_scores_gemma":[0.0019720495,0.000107891836,0.00037356088,0.0006768719,0.00018824794,0.0003405014,0.00020151366,0.00059283513,0.00014732764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004123144,0.000058631846,0.99708,0.0000054327434,0.000045818124,0.00012065576,0.000045746085,0.000073997115,0.00023544552,0.000018006764,0.00015831868,0.0017455876],"study_design_scores_gemma":[0.000017554894,0.00016100374,0.99880326,0.0000041346325,0.00005867949,0.00022336365,0.00017889313,0.00020312333,0.000060583414,0.000035860165,0.00025031317,0.000003324305],"about_ca_topic_score_codex":0.0032653084,"about_ca_topic_score_gemma":0.0039635426,"teacher_disagreement_score":0.0032653084,"about_ca_system_score_codex":0.00032283823,"about_ca_system_score_gemma":0.00042423847,"threshold_uncertainty_score":0.0064926147},"labels":[],"label_agreement":null},{"id":"W2802296799","doi":"10.1200/jco.2012.30.15_suppl.596","title":"Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Hazard ratio; Internal medicine; Clinical endpoint; Breast cancer; Population; Hormone receptor; Subgroup analysis; Randomization; Oncology; Intention-to-treat analysis; Placebo; Trastuzumab; Gastroenterology; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.08460041507953373,"score_gpt":0.4613426568447472,"score_spread":0.3767422417652134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802296799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550533,0.0025724045,0.00033283085,0.00015991819,0.00004476288,0.0005476903,0.00036121695,0.00001335116,0.00046259386],"genre_scores_gemma":[0.9965874,0.0009432282,0.00038206752,0.00021167785,0.00011219794,0.0007165581,0.00059270125,0.000004141898,0.0004500471],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9993142,0.00045410672,0.00003720201,0.00008223348,0.00004524819,0.00006704919],"domain_scores_gemma":[0.9992681,0.00027784004,0.00021923566,0.00006894899,0.000029411192,0.00013649558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019066174,0.00067259255,0.0015029452,0.00027768448,0.00014039414,0.00041377044,0.00034860062,0.0006412581,0.002115631],"category_scores_gemma":[0.0021700624,0.00024187118,0.0012979624,0.0003345952,0.00034251134,0.0003648397,0.00032430724,0.00080231635,0.00019454584],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9489072,0.0023582361,0.016237035,0.00059916056,0.002657043,0.000089551926,0.00006595328,0.0007491858,0.0025446517,0.00010114114,0.00045801458,0.025232853],"study_design_scores_gemma":[0.74651283,0.18097326,0.058662936,0.00009380867,0.006988616,0.000251176,0.000106592015,0.0026001653,0.001463158,0.00060935185,0.0017020991,0.00003607356],"about_ca_topic_score_codex":0.00056639314,"about_ca_topic_score_gemma":0.0011930258,"teacher_disagreement_score":0.002115631,"about_ca_system_score_codex":0.00040623624,"about_ca_system_score_gemma":0.000520204,"threshold_uncertainty_score":0.010083258},"labels":[],"label_agreement":null},{"id":"W2802334461","doi":"10.15761/cpb.1000119","title":"Antibody microarray and immunoblotting analyses of the EGF signaling phosphorylation network in human A431 epidermoid carcinoma cells","year":2017,"lang":"en","type":"article","venue":"Clinical Proteomics and Bioinformatics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kinexus Bioinformatics Corporation (Canada); University of British Columbia","funders":"","keywords":"A431 cells; Phosphorylation; Epidermoid carcinoma; Antibody; Cancer research; Biology; Carcinoma; Epidermal growth factor; Pathology; Medicine; Immunology; Cancer; Receptor; Cell biology; Molecular medicine; Genetics","score_opus":0.11968787697014388,"score_gpt":0.4536997581995993,"score_spread":0.3340118812294554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802334461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638061,0.0015686447,0.025083238,0.00025721206,0.000107114414,0.00012181836,0.004244511,0.00037404257,0.004437299],"genre_scores_gemma":[0.9085432,0.0030513955,0.06992769,0.00037812378,0.000054944136,0.0006069244,0.009808336,0.00008175051,0.0075477227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978954,0.000025022566,0.000025828343,0.00006290048,0.00006232623,0.000034365858],"domain_scores_gemma":[0.9999181,0.000018346274,0.000011497833,0.000010108207,0.00003206211,0.000009921681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020394784,0.00026060178,0.00028005286,0.0007026185,0.0003288337,0.00021952367,0.00020528995,0.00027933368,0.001430807],"category_scores_gemma":[0.0001137122,0.00018381332,0.00032825646,0.0007878401,0.000100734746,0.00016860002,0.000099421144,0.00036682465,0.00047342223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044124317,0.000016340764,0.00017899823,0.000027610658,0.000005798353,0.000024995803,0.000013708201,0.00005740299,0.99885356,0.000042800417,0.00006484444,0.0006697247],"study_design_scores_gemma":[0.000017075276,0.00026649414,0.053786125,0.000008420144,0.0000655038,0.00042884742,0.00010995976,0.00520999,0.9353202,0.0001410587,0.0046322304,0.000014156061],"about_ca_topic_score_codex":0.00079986145,"about_ca_topic_score_gemma":0.001453871,"teacher_disagreement_score":0.001430807,"about_ca_system_score_codex":0.00021455095,"about_ca_system_score_gemma":0.00015237293,"threshold_uncertainty_score":0.004786551},"labels":[],"label_agreement":null},{"id":"W2803726086","doi":"10.1186/s12885-018-4143-x","title":"The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2","year":2018,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Cure Brain Cancer Foundation; Canadian Cancer Society; Canadian Institutes of Health Research; Women and Children's Health Research Institute","keywords":"Trastuzumab; Antibody-dependent cell-mediated cytotoxicity; Chinese hamster ovary cell; Cancer research; Cytotoxicity; Phosphorylation; Cell culture; Receptor; Cancer cell; Signal transduction; Cell; Breast cancer; Cell biology; Cancer; In vitro; Chemistry; Medicine; Biology; Biochemistry; Internal medicine","score_opus":0.036347423481242064,"score_gpt":0.3707843810947666,"score_spread":0.33443695761352454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803726086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908993,0.004145276,0.0017570882,0.00017060796,0.00008393034,0.000040364113,0.00057108596,0.0000443245,0.0022877809],"genre_scores_gemma":[0.9931519,0.0023373,0.0020411878,0.00009244673,0.000017456912,0.000070443064,0.0007213907,0.000013692382,0.0015542397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997142,0.00006120443,0.000042489908,0.000038620117,0.00008324096,0.000060169245],"domain_scores_gemma":[0.9999198,0.000021909502,0.000014472003,0.000014025048,0.0000192909,0.000010528144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002648025,0.00045612344,0.0003717246,0.00016651314,0.00025206077,0.00033440164,0.00028413598,0.00038153006,0.0009580175],"category_scores_gemma":[0.00011431189,0.0001158895,0.0005485914,0.0003584944,0.00019683356,0.0002666718,0.00016879626,0.00061383215,0.00032970766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021060045,0.000062866035,0.00017828026,0.000059357622,0.000012233412,0.000069940965,0.000033123713,0.00005936136,0.9983999,0.00007786869,0.000049622828,0.00078692],"study_design_scores_gemma":[0.000029742174,0.00033950794,0.0021306614,0.000004973484,0.000021011261,0.00014934475,0.00003112575,0.00065536675,0.99527776,0.000029472469,0.0013255827,0.0000053749263],"about_ca_topic_score_codex":0.0012399022,"about_ca_topic_score_gemma":0.000998061,"teacher_disagreement_score":0.0012399022,"about_ca_system_score_codex":0.00046149257,"about_ca_system_score_gemma":0.0002298869,"threshold_uncertainty_score":0.0033483505},"labels":[],"label_agreement":null},{"id":"W2807161544","doi":"10.1093/jnci/djy094","title":"Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients","year":2018,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"National Cancer Institute; Genentech; Novartis Pharma; Astellas Pharma; European Society for Medical Oncology; Alliance for Clinical Trials in Oncology Foundation; Teva Pharmaceutical Industries; Novartis; GlaxoSmithKline; Eli Lilly and Company","keywords":"Lapatinib; Trastuzumab; Medicine; Oncology; Internal medicine; Hazard ratio; Breast cancer; Interquartile range; Cohort; Gynecology; Cancer; Confidence interval","score_opus":0.05072946608820937,"score_gpt":0.37832727657369003,"score_spread":0.32759781048548064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807161544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981452,0.001383884,0.000023582712,0.000034196575,0.0000049482755,0.000008198658,0.00020669623,0.0000013773888,0.00019190783],"genre_scores_gemma":[0.9993529,0.00027756355,0.0000367588,0.000037175858,0.000008622368,0.000010281195,0.00019273153,4.7131178e-7,0.000083621526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99986565,0.000045387682,0.000014062418,0.000025247382,0.0000234281,0.000026150894],"domain_scores_gemma":[0.99932396,0.00020215639,0.00028417038,0.000026171996,0.000024182644,0.00013937919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053509534,0.00009993812,0.00030588242,0.00019501924,0.00017571592,0.00025941286,0.00011606169,0.00023312695,0.0011027965],"category_scores_gemma":[0.00139157,0.000092297654,0.000345671,0.00036692715,0.00011853734,0.00014918318,0.000141398,0.00028133098,0.00007813264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009387335,0.0001848258,0.9787637,0.000057590365,0.00019211622,0.00011321666,0.00004320684,0.00018674035,0.00052449026,0.0000235393,0.00018308044,0.0103401495],"study_design_scores_gemma":[0.00031658966,0.0017138832,0.99661,0.00001652552,0.00014018669,0.00025317757,0.00004878052,0.0002636348,0.00011052736,0.000055373916,0.00046671333,0.0000045642023],"about_ca_topic_score_codex":0.0012242618,"about_ca_topic_score_gemma":0.0024550345,"teacher_disagreement_score":0.0012242618,"about_ca_system_score_codex":0.00023621079,"about_ca_system_score_gemma":0.00027684172,"threshold_uncertainty_score":0.0036892295},"labels":[],"label_agreement":null},{"id":"W2807192583","doi":"10.1186/s13000-018-0696-x","title":"Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer","year":2018,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Magnification; Immunohistochemistry; Pathology; Breast cancer; Biopsy; Cancer; Medicine; Intensity (physics); Nuclear medicine; Internal medicine; Physics; Optics","score_opus":0.02379823563574092,"score_gpt":0.3652826096877164,"score_spread":0.3414843740519755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807192583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67300004,0.006350908,0.31035537,0.00093734567,0.0006237926,0.0003687192,0.0004018561,0.0010083573,0.0069536488],"genre_scores_gemma":[0.831275,0.0005282854,0.16625609,0.00027427243,0.00015889392,0.00028557188,0.0005529347,0.00012051041,0.0005484246],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.990973,0.0030169026,0.0012633891,0.0011571485,0.0033566887,0.0002328592],"domain_scores_gemma":[0.9845548,0.0074322196,0.0025157686,0.0026066415,0.00257235,0.00031814593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009794688,0.0005362815,0.00050717394,0.0012882984,0.00047449386,0.0010457444,0.0013101452,0.00082615647,0.00092252635],"category_scores_gemma":[0.020143,0.00039911337,0.00041768214,0.0006726605,0.0017074316,0.0008836296,0.0011925356,0.00087798596,0.0006258192],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018183633,0.00027825838,0.22433263,0.0008557427,0.00023810734,0.00066362385,0.0006132561,0.003900044,0.5399417,0.006680781,0.0038552687,0.21682224],"study_design_scores_gemma":[0.00016289073,0.0028398426,0.515853,0.0003153849,0.00035770528,0.008745604,0.00047006246,0.038186517,0.40371984,0.010611028,0.018548999,0.00018913164],"about_ca_topic_score_codex":0.00026338844,"about_ca_topic_score_gemma":0.00043396748,"teacher_disagreement_score":0.009794688,"about_ca_system_score_codex":0.00048319664,"about_ca_system_score_gemma":0.00055811467,"threshold_uncertainty_score":0.051799834},"labels":[],"label_agreement":null},{"id":"W2807205027","doi":"10.1139/cjpp-2018-0005","title":"Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker","year":2018,"lang":"en","type":"review","venue":"Canadian Journal of Physiology and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab emtansine; Trastuzumab; Breast cancer; Medicine; Cancer; Metastatic breast cancer; Epidermal growth factor receptor; Oncology; Toxicity; Doxorubicin; Cancer research; Internal medicine; Pharmacology; Human Epidermal Growth Factor Receptor 2; Chemotherapy","score_opus":0.06798067259086966,"score_gpt":0.4170400817295677,"score_spread":0.34905940913869804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807205027","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005913518,0.997349,0.00014039142,0.00018889947,0.00012833843,0.000007834184,0.000024496901,0.000006407883,0.0015631645],"genre_scores_gemma":[0.0035582474,0.994709,0.00019511816,0.00017926817,0.00010277034,0.000009576157,0.000044948876,0.0000017301155,0.0011993634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998759,0.000020529924,0.000017037592,0.00001993791,0.000054426102,0.000012063558],"domain_scores_gemma":[0.9998301,0.000076602904,0.000024014756,0.000004780966,0.00005249339,0.000012081011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033096957,0.00040858574,0.00088702707,0.0015738124,0.00019621258,0.0005722342,0.00047073577,0.00063428533,0.002495372],"category_scores_gemma":[0.0004187532,0.00018089991,0.00048515142,0.0010776576,0.00023725425,0.00057928916,0.00031083237,0.0010357236,0.0009054405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014847305,0.00016229745,0.00050229987,0.01842253,0.00014727448,0.0005245322,0.00008983892,0.00044321213,0.007827544,0.004355189,0.022091417,0.9452854],"study_design_scores_gemma":[0.000042223226,0.00035459,0.0017897802,0.0021971215,0.0002463189,0.0032449807,0.000063549385,0.00024800262,0.0048919027,0.0012110842,0.98568326,0.00002710352],"about_ca_topic_score_codex":0.00076663535,"about_ca_topic_score_gemma":0.0017063543,"teacher_disagreement_score":0.002495372,"about_ca_system_score_codex":0.00042635357,"about_ca_system_score_gemma":0.000528458,"threshold_uncertainty_score":0.008347869},"labels":[],"label_agreement":null},{"id":"W2809727906","doi":"10.1136/esmoopen-2018-eacr25.104","title":"PO-060 ErbB2/Her2-dependent downregulation of a transcription factor IRF6 in breast cancer cells is required for their three-dimensional growth","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Downregulation and upregulation; Transcription factor; Cancer research; Breast cancer; Cancer; Oncology; Medicine; Internal medicine; Biology; Gene; Genetics","score_opus":0.07786127573367449,"score_gpt":0.37090880091018413,"score_spread":0.29304752517650967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809727906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98369575,0.0026597308,0.0049963375,0.0003252168,0.00009352355,0.00006175684,0.0025065439,0.00017146517,0.0054897303],"genre_scores_gemma":[0.97979903,0.001069749,0.004009147,0.00011744474,0.000016044014,0.00011719591,0.003846805,0.000034028304,0.010990596],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984133,0.000017789374,0.000014158358,0.000030163303,0.000058454076,0.000038046404],"domain_scores_gemma":[0.99993503,0.000008937166,0.000018472518,0.000010670569,0.000010122154,0.000016709471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090541274,0.00021270534,0.00016525364,0.00010990727,0.00017351007,0.0002552195,0.00018171623,0.00024451542,0.0045470158],"category_scores_gemma":[0.00006648224,0.000120836965,0.0002952424,0.00013574945,0.00015433188,0.00014839918,0.0001375523,0.00061138807,0.0013822042],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007732766,0.000030076882,0.00013635683,0.000034817862,0.0000020955667,0.00003827026,0.000008305709,0.000024313578,0.99867815,0.00006772883,0.00007523915,0.0008272267],"study_design_scores_gemma":[0.000016081236,0.00013428184,0.007418365,0.0000052886853,0.000005825799,0.00037096444,0.000031688265,0.00065705995,0.98461825,0.000049048347,0.006689106,0.0000039929355],"about_ca_topic_score_codex":0.00032486112,"about_ca_topic_score_gemma":0.0003389717,"teacher_disagreement_score":0.0045470158,"about_ca_system_score_codex":0.00019319364,"about_ca_system_score_gemma":0.00016541097,"threshold_uncertainty_score":0.015211344},"labels":[],"label_agreement":null},{"id":"W2810215276","doi":"10.1016/j.jval.2018.04.115","title":"Long-Term Epidemiological Impact of Pertuzumab+Trastuzmab on Metastatic Breast Cancer Incidence in Canada","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Pertuzumab; Breast cancer; Incidence (geometry); Population; Internal medicine; Trastuzumab; Epidemiology; Cancer registry; Oncology; Cancer; Demography; Environmental health","score_opus":0.15389497500984478,"score_gpt":0.4715576909005265,"score_spread":0.31766271589068173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810215276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534607,0.010136588,0.00023735128,0.0058808993,0.00013278365,0.000051864856,0.025420971,0.00005548184,0.0046234494],"genre_scores_gemma":[0.9903447,0.00312947,0.0001409452,0.00036725472,0.00004915599,0.000013747545,0.004102768,0.000012742563,0.0018392566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982279,0.00015775897,0.00017564108,0.0002299707,0.0005218481,0.0006869538],"domain_scores_gemma":[0.9928964,0.0003737882,0.0015667484,0.00021776189,0.0029970433,0.0019483246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081944425,0.0003450051,0.0007358659,0.001872684,0.0017628873,0.0018077975,0.0016841375,0.0010957286,0.0036993886],"category_scores_gemma":[0.00464479,0.00048423893,0.0015396065,0.006615346,0.00078864757,0.0005974532,0.0011273093,0.0019082525,0.00029339662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029814016,0.000046994992,0.9930073,0.00005816127,0.00028711397,0.000103165454,0.0001506037,0.00027061682,0.000111983856,0.00024842122,0.0017616468,0.0036558],"study_design_scores_gemma":[0.000019217345,0.000037604856,0.9972154,0.000051027913,0.00017259772,0.00006031228,0.00043287216,0.0003540388,0.000067525296,0.000041164014,0.0015287899,0.000019432044],"about_ca_topic_score_codex":0.99610364,"about_ca_topic_score_gemma":0.9955872,"teacher_disagreement_score":0.04486014,"about_ca_system_score_codex":0.04486014,"about_ca_system_score_gemma":0.06271233,"threshold_uncertainty_score":0.32548463},"labels":[],"label_agreement":null},{"id":"W2810295565","doi":"10.1021/acs.molpharmaceut.8b00392","title":"Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with <sup>89</sup>Zr-Labeled Trastuzumab-DM1: A Comparison with <sup>89</sup>Zr-Labeled Trastuzumab","year":2018,"lang":"en","type":"article","venue":"Molecular Pharmaceutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Ontario Institute for Cancer Research; University of Toronto; Terry Fox Foundation","keywords":"Trastuzumab; Chemistry; Immunoconjugate; Positron emission tomography; Trastuzumab emtansine; Breast cancer; Nuclear medicine; Cancer; Medicine; Monoclonal antibody; Antibody; Immunology","score_opus":0.023633541708159896,"score_gpt":0.36119830935695424,"score_spread":0.33756476764879434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810295565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98592675,0.003406568,0.0064902953,0.00014615836,0.00003093404,0.000049722043,0.00069559185,0.00012050967,0.0031334609],"genre_scores_gemma":[0.97971994,0.003311779,0.009267953,0.000078221135,0.000015648255,0.00009728235,0.0012649845,0.000084995416,0.0061591296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991715,0.000016661626,0.000004129568,0.000023480083,0.00001595885,0.000022565098],"domain_scores_gemma":[0.9999583,0.000009179347,0.000011583008,0.0000047047893,0.00000608184,0.000010173933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024182646,0.0004367522,0.00028584042,0.00022831699,0.00007618191,0.00021850421,0.00025810162,0.00034406557,0.0008395287],"category_scores_gemma":[0.000090084235,0.0002212672,0.0001996604,0.00022254829,0.00013739485,0.00023868619,0.00012341423,0.0004918116,0.00023041574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025450418,0.000029234992,0.00020234435,0.000032078606,0.000008019759,0.000041922027,0.00001533888,0.00014531834,0.9982253,0.0000633122,0.000033275388,0.0009493756],"study_design_scores_gemma":[0.00005223544,0.0009871061,0.004488365,0.000007136623,0.000051768227,0.0005943575,0.000031903703,0.0025136122,0.98871404,0.000035594137,0.0025173111,0.000006594861],"about_ca_topic_score_codex":0.00097431015,"about_ca_topic_score_gemma":0.00091351545,"teacher_disagreement_score":0.00097431015,"about_ca_system_score_codex":0.00024983636,"about_ca_system_score_gemma":0.0001512414,"threshold_uncertainty_score":0.0028085113},"labels":[],"label_agreement":null},{"id":"W2810342468","doi":"10.1001/jamaoncol.2018.1812","title":"Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i>-Positive Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Bausch Health (Canada); London Health Sciences Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Trastuzumab emtansine; Trastuzumab; Metastatic breast cancer; Taxane; Internal medicine; Adverse effect; Breast cancer; Pharmacokinetics; Oncology; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Capecitabine; Gastroenterology; Pharmacology; Progressive disease; Chemotherapy; Colorectal cancer","score_opus":0.025182949452053863,"score_gpt":0.39367988303731133,"score_spread":0.3684969335852575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810342468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967315,0.0022011257,0.000089685076,0.00008574508,0.000024602881,0.0002163259,0.000095442956,0.000011433875,0.00054415996],"genre_scores_gemma":[0.99786526,0.0010954518,0.0002340297,0.00009883505,0.000046682366,0.00014336295,0.00018677897,0.0000023780922,0.00032719548],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997682,0.00010818609,0.000023629957,0.000033729444,0.000034534816,0.000031760395],"domain_scores_gemma":[0.99975854,0.000045306275,0.000082574865,0.000015643996,0.000017520628,0.00008043334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007274245,0.00033898282,0.0010421656,0.00022010191,0.00019896863,0.00046387815,0.0002761882,0.00035364486,0.0012968533],"category_scores_gemma":[0.00063982804,0.00017077554,0.00042401833,0.00023801917,0.00024354288,0.0003813752,0.00017674902,0.0006624199,0.00020764854],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5652175,0.03021937,0.037398804,0.0019476322,0.0022607425,0.00041107167,0.00027829784,0.0037242197,0.07317595,0.0002957855,0.003549868,0.2815208],"study_design_scores_gemma":[0.27522534,0.6127869,0.0803413,0.0001876172,0.0014465348,0.0012001274,0.00014096938,0.004739548,0.016733842,0.00021695074,0.0069372677,0.0000435667],"about_ca_topic_score_codex":0.0005640147,"about_ca_topic_score_gemma":0.0021912062,"teacher_disagreement_score":0.0012968533,"about_ca_system_score_codex":0.00042473074,"about_ca_system_score_gemma":0.0006637416,"threshold_uncertainty_score":0.0043383837},"labels":[],"label_agreement":null},{"id":"W2883651613","doi":"10.1188/18.cjon.e103-e114","title":"Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events","year":2018,"lang":"en","type":"review","venue":"Clinical journal of oncology nursing","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Brentuximab vedotin; Adverse effect; Clinical trial; Neutropenia; Oncology; Internal medicine; Intensive care medicine; Lymphoma; Hodgkin lymphoma; Chemotherapy","score_opus":0.45245779199719316,"score_gpt":0.6617095147735645,"score_spread":0.20925172277637138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883651613","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000678241,0.9557439,0.0007983272,0.03810195,0.0017236494,0.000038760092,0.000015039378,0.00001723098,0.0028829342],"genre_scores_gemma":[0.0057630027,0.9834283,0.002606081,0.0065355375,0.0010401778,0.00006842067,0.000017243978,0.0000036466377,0.0005375734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99698395,0.0015196062,0.0004105812,0.00013303256,0.0007912718,0.00016149372],"domain_scores_gemma":[0.9912055,0.00451098,0.0010733252,0.00011484681,0.0024224727,0.00067292067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059077665,0.00069684733,0.0011236683,0.0019889523,0.00090909837,0.002096578,0.0015392811,0.0029212434,0.0017721216],"category_scores_gemma":[0.01343702,0.0002586796,0.00079846854,0.0015651375,0.0010244244,0.0028579538,0.0015369386,0.004122077,0.0006378855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000466677,0.000189061,0.0011647859,0.026387574,0.00010984103,0.0007418167,0.0024608998,0.0004339233,0.00034785678,0.006090733,0.07803249,0.88399434],"study_design_scores_gemma":[0.0000847523,0.00044491596,0.006476463,0.14060426,0.0002315794,0.0062279464,0.009385261,0.00041808025,0.00031462192,0.013089964,0.8226008,0.000121335965],"about_ca_topic_score_codex":0.004089221,"about_ca_topic_score_gemma":0.00850135,"teacher_disagreement_score":0.0059077665,"about_ca_system_score_codex":0.001989828,"about_ca_system_score_gemma":0.00876625,"threshold_uncertainty_score":0.031243563},"labels":[],"label_agreement":null},{"id":"W2885940108","doi":"10.1158/1538-7445.am2018-3161","title":"Abstract 3161: The macrolide toxin mycalolide B disrupts actin-driven invasion and metastasis of HER2-positive cancers","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cancer research; Metastasis; Trastuzumab; Cancer; Medicine; Cancer cell; Actin cytoskeleton; Breast cancer; Biology; Cell; Internal medicine; Cytoskeleton","score_opus":0.13896822554050128,"score_gpt":0.47725381539821765,"score_spread":0.3382855898577164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885940108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948112,0.0008757401,0.0011368972,0.00008659056,0.000024577337,0.00003843595,0.00070943375,0.000044244527,0.002272951],"genre_scores_gemma":[0.9931318,0.0006812716,0.001339262,0.00007378906,0.000006659001,0.00003877856,0.0010614175,0.000014364416,0.0036525638],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999398,0.000010860574,0.000005883431,0.00000921797,0.000019514515,0.000014773069],"domain_scores_gemma":[0.9999641,0.000006783005,0.000008580263,0.0000036447727,0.0000061024543,0.000010780018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006616183,0.0002615267,0.00015382898,0.00012743821,0.00009243991,0.000119972545,0.000119640215,0.00023256062,0.0017746177],"category_scores_gemma":[0.00004961011,0.00008842047,0.00015079298,0.00009488132,0.000078307254,0.00008538435,0.0001161425,0.00030741876,0.0004401189],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011406922,0.000026053705,0.00014004124,0.0000123283135,0.0000021346325,0.000018357172,0.000002463451,0.000038767965,0.99908566,0.00001828123,0.00005315827,0.00048866565],"study_design_scores_gemma":[0.00002105918,0.0007477076,0.004951332,0.0000042621828,0.0000056699264,0.00015116869,0.000012277632,0.0005252593,0.99204975,0.000013344718,0.0015165639,0.0000016988281],"about_ca_topic_score_codex":0.00095314934,"about_ca_topic_score_gemma":0.0009641732,"teacher_disagreement_score":0.0017746177,"about_ca_system_score_codex":0.00016783684,"about_ca_system_score_gemma":0.00012665658,"threshold_uncertainty_score":0.005936682},"labels":[],"label_agreement":null},{"id":"W2887078648","doi":"10.1158/1538-7445.am2018-3465","title":"Abstract 3465: Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cancer research; Epidermal growth factor receptor; Signal transduction; Phosphorylation; MAPK/ERK pathway; Biology; Cell biology; ERBB3; EGFR inhibitors; Receptor tyrosine kinase; Cancer","score_opus":0.16573674846723718,"score_gpt":0.46068769895449674,"score_spread":0.29495095048725956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887078648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921788,0.0020007256,0.0017871883,0.0002047077,0.000049103568,0.000029306795,0.0006174205,0.000082451465,0.003050341],"genre_scores_gemma":[0.994418,0.00069724175,0.00087462424,0.00009622568,0.000014855457,0.000030178979,0.00059567427,0.00001681401,0.0032563568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998764,0.000015094778,0.00000946805,0.000022362314,0.000037339632,0.00003946801],"domain_scores_gemma":[0.9999466,0.000007851023,0.000013114941,0.0000036903452,0.0000057009006,0.000022972024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093984614,0.00032276375,0.00018724082,0.00022196215,0.00018323916,0.00035731334,0.00018040396,0.00029111488,0.0036058484],"category_scores_gemma":[0.00007368551,0.00013711701,0.0002045904,0.0001385612,0.00021573661,0.00016636556,0.00015213773,0.0005255162,0.00096304674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012879107,0.000024984318,0.00011843513,0.000024604527,0.0000026539406,0.000042664673,0.000005397974,0.00002179809,0.9987165,0.00015647145,0.000057048805,0.0007007627],"study_design_scores_gemma":[0.00004193421,0.00037592163,0.010980055,0.000013472513,0.000015632222,0.00060545193,0.00003026867,0.0008911109,0.984183,0.00013331685,0.0027231274,0.0000067948386],"about_ca_topic_score_codex":0.00033109265,"about_ca_topic_score_gemma":0.00036053074,"teacher_disagreement_score":0.0036058484,"about_ca_system_score_codex":0.00034434447,"about_ca_system_score_gemma":0.00019427353,"threshold_uncertainty_score":0.012062728},"labels":[],"label_agreement":null},{"id":"W2887131751","doi":"10.18632/oncotarget.25739","title":"Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results","year":2018,"lang":"en","type":"review","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Trastuzumab emtansine; Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Clinical trial","score_opus":0.25996172392567307,"score_gpt":0.4952517428112211,"score_spread":0.235290018885548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887131751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16592212,0.7512405,0.008350033,0.052287742,0.0023178428,0.0023964383,0.0020532846,0.00019712019,0.015234962],"genre_scores_gemma":[0.7418688,0.1939885,0.010514929,0.035904445,0.005151129,0.004534068,0.0033221447,0.00017817086,0.004537803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926772,0.0051563387,0.0006443547,0.0004182895,0.00067144603,0.0004324128],"domain_scores_gemma":[0.975871,0.016912831,0.0036538665,0.0010652454,0.0015947953,0.0009022172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030664206,0.0008846447,0.003364479,0.00054242584,0.00023540703,0.0038255013,0.0013023975,0.0020559758,0.0034184956],"category_scores_gemma":[0.028181063,0.00035589858,0.002313731,0.0009972511,0.0008600058,0.0033444546,0.0009977977,0.0041136374,0.0007679811],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11960407,0.0023055866,0.0153361205,0.017756697,0.008623984,0.00028199807,0.0008408284,0.005056362,0.005589439,0.011114306,0.025792317,0.7876982],"study_design_scores_gemma":[0.14026551,0.13660382,0.06905984,0.032007508,0.04111391,0.0018293553,0.0014656658,0.030817198,0.008013792,0.08757247,0.45078406,0.0004669184],"about_ca_topic_score_codex":0.00021344119,"about_ca_topic_score_gemma":0.0005306246,"teacher_disagreement_score":0.030664206,"about_ca_system_score_codex":0.001177053,"about_ca_system_score_gemma":0.0013902778,"threshold_uncertainty_score":0.16216975},"labels":[],"label_agreement":null},{"id":"W2887351902","doi":"10.1002/cjp2.112","title":"Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients","year":2018,"lang":"en","type":"article","venue":"The Journal of Pathology Clinical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cancer; Biomarker; Ductal carcinoma; Progesterone receptor; Gynecology; Estrogen receptor; Biology","score_opus":0.4502120533375113,"score_gpt":0.618210457192407,"score_spread":0.16799840385489567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887351902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.714034,0.0031106907,0.0051658703,0.00045345502,0.000061104554,0.0013530594,0.2727171,0.00025493448,0.0028497826],"genre_scores_gemma":[0.62952757,0.0008604747,0.007715504,0.00038952183,0.00004430081,0.0019345612,0.35862958,0.000082391365,0.0008160294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9764114,0.005686925,0.0066840784,0.0040823584,0.006002773,0.0011324991],"domain_scores_gemma":[0.9291624,0.02057791,0.025835637,0.009454821,0.012807517,0.0021617177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012627059,0.0005780229,0.001848923,0.0063947616,0.0005229244,0.0024907368,0.0013368827,0.00094134733,0.0019341636],"category_scores_gemma":[0.04387078,0.000581413,0.0008191133,0.011963065,0.00066867814,0.00070093054,0.0026650615,0.0006368033,0.0012993265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009611218,0.00009590713,0.96448684,0.00101951,0.00039650025,0.0006389222,0.00061391486,0.00084115076,0.0015484378,0.000246436,0.009676196,0.019475002],"study_design_scores_gemma":[0.0001562282,0.0001698348,0.9803065,0.00021670101,0.00017413762,0.0010383817,0.0002949231,0.001651451,0.0008951215,0.0000965922,0.014956614,0.000043463177],"about_ca_topic_score_codex":0.026848486,"about_ca_topic_score_gemma":0.019729929,"teacher_disagreement_score":0.026848486,"about_ca_system_score_codex":0.0027284473,"about_ca_system_score_gemma":0.0040248036,"threshold_uncertainty_score":0.06677908},"labels":[],"label_agreement":null},{"id":"W2887806952","doi":"10.1158/1538-7445.am2018-756","title":"Abstract 756: Development of next-generation antibody-drug conjugates for resistant HER2-positive tumors","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Antibody-drug conjugate; Cytotoxic T cell; Cancer research; Antibody; Cancer; Chemistry; Cancer cell; Drug delivery; In vivo; Pharmacology; In vitro; Medicine; Biology; Biochemistry; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.22731882205759396,"score_gpt":0.49274887540770745,"score_spread":0.2654300533501135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887806952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902339,0.0013618773,0.004639375,0.00007399743,0.00002816224,0.00011219822,0.00027002237,0.00008742741,0.0031930404],"genre_scores_gemma":[0.98666954,0.0007809221,0.007533311,0.000053523527,0.000008670266,0.000049897928,0.00041595058,0.000021549862,0.0044666366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994326,0.000008022253,0.00000491174,0.000013441461,0.000017848817,0.000012541394],"domain_scores_gemma":[0.99996185,0.000003900831,0.000011300374,0.0000040045984,0.0000080222035,0.000010985525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011805793,0.0002204224,0.0001913116,0.00016855389,0.00007815983,0.00021964134,0.0002070055,0.0002689732,0.0015025809],"category_scores_gemma":[0.000092154914,0.00009936986,0.00020616403,0.00010375147,0.00007399674,0.00017613714,0.00014984568,0.00026766982,0.00047324246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008368228,0.000078948666,0.00016531859,0.000038951523,0.000006699152,0.000051992865,0.000012621802,0.00034649635,0.9944155,0.00012833321,0.00009245125,0.00457888],"study_design_scores_gemma":[0.000032849683,0.000779359,0.0010678334,0.0000042909674,0.000013980195,0.00023111682,0.0000053267063,0.0011505131,0.9923476,0.000020572006,0.004341114,0.000005447432],"about_ca_topic_score_codex":0.000337914,"about_ca_topic_score_gemma":0.0004058987,"teacher_disagreement_score":0.0015025809,"about_ca_system_score_codex":0.00019833543,"about_ca_system_score_gemma":0.0001339802,"threshold_uncertainty_score":0.0050266385},"labels":[],"label_agreement":null},{"id":"W2888555396","doi":"10.1016/j.bbamcr.2018.08.013","title":"The LIM domain binding protein 1, Ldb1, has distinct roles in Neu-induced mammary tumorigenesis","year":2018,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Cancer research; Cell biology; Transgene; Genetically modified mouse; Biology; Carcinogenesis; Oncogene; Cell; Cancer; Cell cycle; Gene","score_opus":0.06951604189795799,"score_gpt":0.3693132207436446,"score_spread":0.2997971788456866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888555396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698294,0.00701289,0.0020852971,0.0002649949,0.000030194024,0.000013157548,0.0004506521,0.00007858024,0.003081255],"genre_scores_gemma":[0.99223363,0.0014849489,0.00082787476,0.000096571915,0.000009353686,0.00002742194,0.0008758355,0.000023915241,0.0044203727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998549,0.00002268651,0.000011081106,0.00002530658,0.00003845776,0.0000474693],"domain_scores_gemma":[0.99986434,0.00001713212,0.00003013283,0.000013797077,0.000012547726,0.00006209393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022541355,0.00027082986,0.0002722735,0.000663249,0.00028188055,0.00057632464,0.00030547092,0.00034368708,0.0013475104],"category_scores_gemma":[0.00019164753,0.00024073811,0.00026794657,0.00021347763,0.0003932656,0.00050317583,0.0004499045,0.0006916862,0.0005371448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052055455,0.000053357297,0.0010439303,0.000046034387,0.000008338251,0.000096830394,0.000026714255,0.000059687227,0.99529266,0.0005719658,0.0000983757,0.0021815998],"study_design_scores_gemma":[0.00007175611,0.0002762291,0.046269476,0.000014686047,0.00004016609,0.001333881,0.00019113367,0.0016272925,0.94412,0.0005790902,0.005458019,0.000018188903],"about_ca_topic_score_codex":0.0004545555,"about_ca_topic_score_gemma":0.0008247693,"teacher_disagreement_score":0.0013475104,"about_ca_system_score_codex":0.00054558465,"about_ca_system_score_gemma":0.00026895094,"threshold_uncertainty_score":0.0045078993},"labels":[],"label_agreement":null},{"id":"W2890098568","doi":"10.1007/s10585-018-9929-3","title":"Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment","year":2018,"lang":"en","type":"article","venue":"Clinical & Experimental Metastasis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Trastuzumab; Medicine; In vivo; Immunohistochemistry; Pathology; Cancer; Cancer research; Breast cancer; Internal medicine; Biology","score_opus":0.038091256455284744,"score_gpt":0.3937615804408038,"score_spread":0.355670323985519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890098568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551576,0.0013061076,0.0023081577,0.000023569693,0.0000041485387,0.000013714008,0.00009311608,0.000029084931,0.000706305],"genre_scores_gemma":[0.9980914,0.0003138832,0.0007657464,0.000017159986,0.0000030746628,0.000014300275,0.00012816563,0.000013073641,0.0006531842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989796,0.00001940297,0.000006180678,0.000021028469,0.000033775606,0.000021726213],"domain_scores_gemma":[0.99991024,0.000018483533,0.00002065524,0.000011238287,0.000013909032,0.00002549188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014692948,0.00016192456,0.00021907243,0.00019284949,0.00010560334,0.00031143276,0.00009283628,0.0001635442,0.00048573792],"category_scores_gemma":[0.00016772629,0.000116662966,0.000072856004,0.00012913377,0.00012664897,0.00026720882,0.00016615805,0.0002298926,0.000103067716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011118121,0.000023208611,0.001771447,0.000016933805,0.000004738511,0.00005933069,0.000015204663,0.00011039386,0.99655366,0.00004445851,0.000020330339,0.0012691754],"study_design_scores_gemma":[0.000029798724,0.0007698158,0.069344886,0.000007139884,0.000028857523,0.001180436,0.00008983628,0.004283224,0.92193264,0.00016095341,0.002162643,0.000009713631],"about_ca_topic_score_codex":0.0010725126,"about_ca_topic_score_gemma":0.00140494,"teacher_disagreement_score":0.0010725126,"about_ca_system_score_codex":0.00028234292,"about_ca_system_score_gemma":0.00014299933,"threshold_uncertainty_score":0.0021325946},"labels":[],"label_agreement":null},{"id":"W2890440333","doi":"10.1093/dote/doy089.ps02.153","title":"PS02.153: HER2 PATHWAY CONTROL SENSITIVITY TO CISPLATIN IN ESOPHAGEAL ADENOCARCINOMA CELL LINES","year":2018,"lang":"en","type":"article","venue":"Diseases of the Esophagus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Cisplatin; Medicine; Cancer research; Adenocarcinoma; Cell culture; Esophageal cancer; Chemotherapy; Downregulation and upregulation; Cell growth; Oncology; Cancer; Esophagus; Cell; Internal medicine; Biology; Gene; Genetics","score_opus":0.014250424507458932,"score_gpt":0.2992810073715946,"score_spread":0.28503058286413563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890440333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985953,0.0019055125,0.003348038,0.00029264428,0.00011587487,0.00013695178,0.0039333054,0.00018358992,0.0041311323],"genre_scores_gemma":[0.9763125,0.0013139591,0.0033692254,0.000176982,0.000014004334,0.00036482318,0.006526501,0.000044191685,0.011877784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996792,0.00004932867,0.00004498959,0.0000661277,0.000112587244,0.00004768094],"domain_scores_gemma":[0.99991024,0.000015200573,0.000014229643,0.000021634307,0.000023124145,0.000015563299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022044424,0.00027731934,0.00040859898,0.0002700092,0.00027248927,0.0003575861,0.0003030647,0.0004073428,0.003741851],"category_scores_gemma":[0.00017087343,0.00018858444,0.00032374283,0.0004818975,0.00020594691,0.00024373498,0.00019167842,0.00061602937,0.0011247145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021247778,0.000157331,0.000564701,0.00006510074,0.0000122250585,0.000099264325,0.00003891594,0.00019919251,0.99584454,0.00014875556,0.00062143774,0.0020361415],"study_design_scores_gemma":[0.0000874813,0.0010997494,0.013672267,0.0000104300625,0.000049061942,0.000797802,0.000113863636,0.0031206897,0.9700926,0.00008091068,0.010860998,0.0000142576455],"about_ca_topic_score_codex":0.0019370643,"about_ca_topic_score_gemma":0.001915364,"teacher_disagreement_score":0.003741851,"about_ca_system_score_codex":0.00039055862,"about_ca_system_score_gemma":0.00037340063,"threshold_uncertainty_score":0.01251775},"labels":[],"label_agreement":null},{"id":"W2891579961","doi":"10.3390/cancers10100342","title":"Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer","year":2018,"lang":"en","type":"review","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Women and Children's Health Research Institute; Children's Health Research Institute","keywords":"Pertuzumab; Trastuzumab; Medicine; Breast cancer; Oncology; Docetaxel; Cancer; Adjuvant; Monoclonal antibody; Internal medicine; Metastatic breast cancer; Regimen; Pharmacology; Antibody; Immunology","score_opus":0.12397561589420557,"score_gpt":0.4352357693218751,"score_spread":0.3112601534276695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891579961","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028415522,0.9985191,0.00009565883,0.00016926357,0.00006225534,0.000005845468,0.000015898817,0.000003851394,0.0008439801],"genre_scores_gemma":[0.0018371368,0.9975605,0.0001220516,0.00010639146,0.000045192657,0.00000723945,0.000017763323,5.1130536e-7,0.00030319614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998204,0.00004122945,0.000028889935,0.000030103558,0.00005930499,0.000020091387],"domain_scores_gemma":[0.9998305,0.00008723552,0.00003112401,0.0000047576204,0.000036658017,0.000009696756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044563945,0.00064429815,0.0008803181,0.0019096306,0.00023978949,0.00076364115,0.00078293687,0.00077875174,0.0025218066],"category_scores_gemma":[0.0005782871,0.00022678655,0.0007421393,0.0014444554,0.0003510751,0.0009938825,0.00044086823,0.0008508267,0.0007022407],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001403317,0.00012795371,0.0005277922,0.06120837,0.00037805788,0.0006004392,0.00020448661,0.0010340817,0.0047927215,0.012313735,0.017705932,0.9009661],"study_design_scores_gemma":[0.00004580489,0.0002772859,0.0020106514,0.010286718,0.0006268054,0.0031581619,0.00017828535,0.00029611946,0.0021978528,0.0062888553,0.9745969,0.000036538524],"about_ca_topic_score_codex":0.000835376,"about_ca_topic_score_gemma":0.0016691096,"teacher_disagreement_score":0.0025218066,"about_ca_system_score_codex":0.00057000865,"about_ca_system_score_gemma":0.0009892898,"threshold_uncertainty_score":0.008436322},"labels":[],"label_agreement":null},{"id":"W2892311857","doi":"10.1200/jco.2018.36.15_suppl.2500","title":"Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Pertuzumab; Lapatinib; Trastuzumab; Internal medicine; Oncology; Adverse effect; Cancer; Breast cancer","score_opus":0.2772677226377683,"score_gpt":0.5580802764934101,"score_spread":0.2808125538556418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892311857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786586,0.0008111747,0.00035286113,0.0000365279,0.000008423254,0.00011213507,0.00012389952,0.000028955477,0.00066017447],"genre_scores_gemma":[0.99792445,0.000492207,0.00040122741,0.000034435707,0.0000114568875,0.000071018505,0.00039478813,0.000008232043,0.0006623135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999018,0.000029309907,0.000006303519,0.00002224619,0.000018543195,0.000021699088],"domain_scores_gemma":[0.99988806,0.000015824295,0.000028968148,0.0000085362735,0.000008782335,0.000049788632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029538403,0.00045781163,0.00038950096,0.0003264753,0.00013175233,0.0002872457,0.00034394258,0.0002956759,0.0015159884],"category_scores_gemma":[0.0002009277,0.00017355241,0.0003046435,0.00022059647,0.00023797038,0.00034551232,0.00018382557,0.00060452643,0.00030558513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04902331,0.015266618,0.009840413,0.00047613887,0.00045085337,0.0005732775,0.0003233754,0.00456822,0.7633692,0.00030579406,0.0024844517,0.15331827],"study_design_scores_gemma":[0.016160563,0.5403407,0.050662193,0.000042945696,0.0006747591,0.0022175608,0.00015429704,0.005890494,0.37427956,0.00017258445,0.009370141,0.00003421178],"about_ca_topic_score_codex":0.0014015391,"about_ca_topic_score_gemma":0.00287896,"teacher_disagreement_score":0.0015159884,"about_ca_system_score_codex":0.0005744203,"about_ca_system_score_gemma":0.00043115325,"threshold_uncertainty_score":0.005071461},"labels":[],"label_agreement":null},{"id":"W2892343964","doi":"10.1007/s10549-018-4967-8","title":"Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials","year":2018,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Breast cancer; Hazard ratio; Oncology; Meta-analysis; Odds ratio; Randomized controlled trial; Population; Adjuvant; Confidence interval; Cancer","score_opus":0.3371883552928294,"score_gpt":0.5253974729976785,"score_spread":0.18820911770484905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892343964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010706252,0.9875492,0.00076020305,0.00016021173,0.0002028264,0.0001465461,0.0002100638,0.000022937793,0.00024178265],"genre_scores_gemma":[0.379832,0.61289376,0.0033778292,0.0014711932,0.00044884175,0.00051128445,0.000800758,0.000052284864,0.0006120645],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99376935,0.0035624965,0.00127213,0.0007439879,0.00039723061,0.00025483154],"domain_scores_gemma":[0.9894856,0.008458087,0.0012276138,0.00031207615,0.00031476773,0.00020184038],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010169067,0.0026304326,0.016020155,0.0016755244,0.00036240465,0.0023384297,0.0019680564,0.0020366197,0.0039011568],"category_scores_gemma":[0.019026391,0.0012801869,0.027333524,0.0022860342,0.0006340572,0.001951603,0.0010854691,0.00293861,0.00024371383],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032976437,0.0000844271,0.0036334333,0.15802665,0.77867484,0.00010666307,0.00007468614,0.0012153846,0.00042020774,0.00024122641,0.00061376876,0.023932273],"study_design_scores_gemma":[0.0072272634,0.00069917226,0.0026089856,0.005769156,0.98160535,0.000053917924,0.00003729343,0.000263757,0.000109457935,0.00042752913,0.0011743028,0.00002383013],"about_ca_topic_score_codex":0.0033146574,"about_ca_topic_score_gemma":0.007255404,"teacher_disagreement_score":0.9839798,"about_ca_system_score_codex":0.001868286,"about_ca_system_score_gemma":0.0017195375,"threshold_uncertainty_score":0.05377984},"labels":[],"label_agreement":null},{"id":"W2896257009","doi":"","title":"The combi-targeting concept: a new cell signaling-based model for the selective targeting of the epidermal growth factor receptor (EGFR)- and Her2-expressing solid tumor cells by the complex combi-molecule RB24 (NSC 741279)","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Canada","funders":"","keywords":"Transfection; Comet assay; DNA damage; Apoptosis; Biology; Epidermal growth factor receptor; Cancer cell; Cell biology; Cancer research; Annexin; Epidermal growth factor; Molecular biology; DNA; Cell culture; Receptor; Cancer; Biochemistry; Genetics","score_opus":0.08819268868269484,"score_gpt":0.4062163210851354,"score_spread":0.3180236324024406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896257009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88404346,0.0036177512,0.10021642,0.0006570275,0.0002032585,0.00041576277,0.00031504917,0.00057101564,0.009960218],"genre_scores_gemma":[0.9488228,0.0015338017,0.040540297,0.00018032211,0.00003293516,0.00026048254,0.0001765405,0.000032343447,0.008420501],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992764,0.000010521904,0.0000032524354,0.000019235387,0.00002524885,0.000014111884],"domain_scores_gemma":[0.9999597,0.000005274763,0.000016135406,0.0000041962257,0.000005371053,0.000009400968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011041054,0.0003683476,0.00023469479,0.00018649426,0.00011641438,0.00036898075,0.00047163587,0.00048524878,0.0007952414],"category_scores_gemma":[0.00008325958,0.00015274082,0.00021035149,0.000107351196,0.00023256194,0.0003718717,0.00018001324,0.00040721952,0.0004411324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000720271,0.00006447391,0.000054683926,0.00005042281,0.0000055797923,0.00012755091,0.000021901633,0.000488521,0.9920839,0.0027900173,0.00014120592,0.0040996526],"study_design_scores_gemma":[0.000055198012,0.0010014776,0.00043742932,0.000004971252,0.000018690715,0.0006135739,0.000010485441,0.00895528,0.9742886,0.00047763993,0.014120897,0.00001580266],"about_ca_topic_score_codex":0.00024247941,"about_ca_topic_score_gemma":0.00021253871,"teacher_disagreement_score":0.0007952414,"about_ca_system_score_codex":0.00028919257,"about_ca_system_score_gemma":0.0001670072,"threshold_uncertainty_score":0.002660334},"labels":[],"label_agreement":null},{"id":"W2897175439","doi":"10.1007/s00280-018-3689-2","title":"Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Rash; Trastuzumab; Diarrhea; Metastatic breast cancer; Cancer; Adverse effect; Oncology; Gastroenterology; Breast cancer; Surgery; Epidermal growth factor receptor; Erlotinib","score_opus":0.028446106103640956,"score_gpt":0.4090134797091505,"score_spread":0.3805673736055095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897175439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179006,0.0020126514,0.000503612,0.0007960611,0.00019134687,0.0025563077,0.00059783895,0.00008518453,0.001466985],"genre_scores_gemma":[0.98988426,0.0011222189,0.0019068354,0.0011235747,0.00018168836,0.0027546452,0.0014018363,0.00002789807,0.0015968966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994742,0.000226953,0.00003409365,0.00009238001,0.000048672722,0.00012371258],"domain_scores_gemma":[0.9989448,0.00013949303,0.00019922204,0.00008214446,0.000061734005,0.00057263306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018924744,0.0015800889,0.002260442,0.00040291,0.0005268518,0.001129167,0.0011854052,0.0017145037,0.0028335345],"category_scores_gemma":[0.0013924643,0.0007147317,0.001588889,0.000521111,0.001142874,0.00093970797,0.0004176871,0.0037395537,0.0007239611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81550545,0.06587776,0.0046526752,0.0007598073,0.0016830539,0.00033050904,0.0003785662,0.0035023023,0.025968328,0.00036899475,0.0048602605,0.07611228],"study_design_scores_gemma":[0.7824784,0.20970653,0.0044410727,0.000021071828,0.0001715805,0.0001977026,0.00002289595,0.00080962706,0.0009822791,0.0001447335,0.0010040031,0.000020087176],"about_ca_topic_score_codex":0.0012893836,"about_ca_topic_score_gemma":0.0031616734,"teacher_disagreement_score":0.0028335345,"about_ca_system_score_codex":0.0015361608,"about_ca_system_score_gemma":0.00250645,"threshold_uncertainty_score":0.011145651},"labels":[],"label_agreement":null},{"id":"W2898173867","doi":"10.1007/s40261-018-0719-0","title":"Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials","year":2018,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Neratinib; Medicine; Oncology; Internal medicine; Adverse effect; Diarrhea; Breast cancer; Clinical trial; Hazard ratio; Nausea; Cancer; Trastuzumab; Confidence interval","score_opus":0.5943309892068062,"score_gpt":0.6027997922926437,"score_spread":0.008468803085837528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898173867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009012305,0.98933125,0.0004689522,0.00014549174,0.000080841,0.00014796483,0.0005760429,0.000016321776,0.00022077287],"genre_scores_gemma":[0.27257362,0.72089094,0.002610993,0.0013719992,0.00019990305,0.00042988698,0.0014398413,0.00004214803,0.00044063324],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99250305,0.00271635,0.0027926778,0.00095517683,0.0007942374,0.00023846218],"domain_scores_gemma":[0.98630434,0.009554429,0.0026922044,0.0005562915,0.00071093685,0.0001817627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0101698255,0.0021157658,0.013810306,0.0033341676,0.00050443475,0.002433383,0.0019742881,0.0016286985,0.0033630193],"category_scores_gemma":[0.020355262,0.0011584796,0.024622018,0.0055019143,0.0008032768,0.001822496,0.0013941117,0.001711828,0.0003226219],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003675297,0.000039418297,0.0069916635,0.26007214,0.7112171,0.00016019269,0.00010086465,0.00047141954,0.0004077822,0.0001289835,0.00066239847,0.016072739],"study_design_scores_gemma":[0.0008437406,0.0002020606,0.004977574,0.007491328,0.98419225,0.00013145262,0.000051426705,0.0000869662,0.00011748597,0.00016123556,0.0017192947,0.000025209267],"about_ca_topic_score_codex":0.0028420622,"about_ca_topic_score_gemma":0.010375004,"teacher_disagreement_score":0.013810306,"about_ca_system_score_codex":0.0016252185,"about_ca_system_score_gemma":0.0025367301,"threshold_uncertainty_score":0.053783774},"labels":[],"label_agreement":null},{"id":"W2898265596","doi":"10.1093/annonc/mdy424.001","title":"PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Cost-effectiveness analysis; Adjuvant; Internal medicine; Cost effectiveness; Oncology; Surgery; Cancer","score_opus":0.06745822084552353,"score_gpt":0.43022346759668556,"score_spread":0.36276524675116206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898265596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979152,0.013076261,0.0010905361,0.0005924423,0.00025685344,0.00074383034,0.0020806391,0.000040147996,0.0029672896],"genre_scores_gemma":[0.9950197,0.0024387373,0.0006486616,0.00021330047,0.00007597966,0.0002145875,0.00065594394,0.000008137777,0.00072484574],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979809,0.0012729011,0.00012631332,0.00022103362,0.00010991606,0.0002889301],"domain_scores_gemma":[0.99848855,0.0008510116,0.00032109796,0.000047983624,0.000044034263,0.00024726542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024744314,0.0020818738,0.0032221596,0.0008109242,0.00020602194,0.0015719224,0.00091996166,0.0016890327,0.0059149596],"category_scores_gemma":[0.004620213,0.00069318025,0.009339649,0.0007758152,0.0006305297,0.0017479014,0.00086171477,0.002689489,0.0003150555],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91422063,0.0029289685,0.0056297686,0.002198532,0.013718859,0.00015448974,0.00007219227,0.017570933,0.0010854059,0.0004607301,0.0004648206,0.041494656],"study_design_scores_gemma":[0.4728405,0.30676636,0.053589705,0.0015927248,0.11593096,0.0006128876,0.0006321402,0.039124575,0.0027187457,0.0027898399,0.0031501087,0.00025149644],"about_ca_topic_score_codex":0.0052708383,"about_ca_topic_score_gemma":0.0064774742,"teacher_disagreement_score":0.0059149596,"about_ca_system_score_codex":0.002292136,"about_ca_system_score_gemma":0.0014638319,"threshold_uncertainty_score":0.01978749},"labels":[],"label_agreement":null},{"id":"W2898304683","doi":"10.1093/annonc/mdy270.187","title":"Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Internal medicine; Oncology; Docetaxel; Population; Pertuzumab; Trastuzumab; Chemotherapy; Breast cancer; Cancer","score_opus":0.1758411817290713,"score_gpt":0.5024193249183248,"score_spread":0.3265781431892535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898304683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990274,0.00037452392,0.000054231798,0.000035486628,0.0000044751987,0.000013095527,0.00015725149,0.0000034331918,0.00033000123],"genre_scores_gemma":[0.99915946,0.00008591526,0.00010926385,0.000033256732,0.000011996195,0.000013532574,0.00041166806,9.584995e-7,0.0001739017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997521,0.00013706583,0.000015930034,0.000033657536,0.000034102806,0.000027089893],"domain_scores_gemma":[0.99922633,0.00022348852,0.00032904363,0.00006605218,0.00003574933,0.00011942781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001011738,0.0001880888,0.00036359683,0.00013238414,0.00006810137,0.00027053332,0.00023063995,0.00023432767,0.0012953941],"category_scores_gemma":[0.0010077361,0.000085215244,0.00034902175,0.00015906077,0.00015190797,0.00016020832,0.00019785209,0.0003120798,0.00021330305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05374187,0.0007435474,0.8940001,0.00011398112,0.0005611046,0.000052104893,0.000036107464,0.0014851184,0.004774714,0.000068451416,0.00080210465,0.043620773],"study_design_scores_gemma":[0.0032115444,0.0187056,0.97183335,0.000029559746,0.00043556615,0.0002799404,0.00003867861,0.002715902,0.0015215866,0.0001448284,0.0010735573,0.000009772211],"about_ca_topic_score_codex":0.00028475514,"about_ca_topic_score_gemma":0.00064514426,"teacher_disagreement_score":0.0012953941,"about_ca_system_score_codex":0.00017965914,"about_ca_system_score_gemma":0.0001543254,"threshold_uncertainty_score":0.0053506494},"labels":[],"label_agreement":null},{"id":"W2898439681","doi":"10.4049/jimmunol.1701556","title":"Structural and Functional Analyses of the Shedding Protease ADAM17 in HoxB8-Immortalized Macrophages and Dendritic-like Cells","year":2018,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Exzellenzclusters Entzündungsforschung; Wellcome Trust","keywords":"Cell biology; Biology; Transfection; Embryonic stem cell; Metalloproteinase; Cell culture; Immune system; Immunology; Matrix metalloproteinase; Biochemistry; Genetics; Gene","score_opus":0.0530488482860415,"score_gpt":0.37016246966107225,"score_spread":0.31711362137503074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898439681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950206,0.00067033694,0.0027815541,0.00004153206,0.000015745853,0.000022019174,0.00078002986,0.000023061946,0.0006449802],"genre_scores_gemma":[0.9919899,0.00075329293,0.0030001297,0.000033052085,0.000009611994,0.000053317297,0.0019960087,0.000020614878,0.0021440173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989665,0.00001430041,0.000012934902,0.000019870897,0.000032673644,0.00002351725],"domain_scores_gemma":[0.99989426,0.000019491903,0.000023517598,0.000020978514,0.0000196292,0.000022148368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012300185,0.00015573461,0.00012161052,0.0001815974,0.00011717941,0.00017430683,0.00013786074,0.0001444012,0.00062606524],"category_scores_gemma":[0.00009440183,0.00008934942,0.00020085167,0.00015089309,0.00014455261,0.000098963246,0.000152945,0.0003235728,0.00045488856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004100674,0.000007745695,0.00024405826,0.0000117912705,0.0000020064122,0.00006528171,0.000013077937,0.000014367935,0.99930143,0.000041829524,0.000009024608,0.0002483851],"study_design_scores_gemma":[0.000011546047,0.000119879536,0.010842259,0.0000044141084,0.000016443659,0.0006392959,0.000075852055,0.0006605266,0.9839108,0.00005203872,0.0036634926,0.0000034722714],"about_ca_topic_score_codex":0.00030790505,"about_ca_topic_score_gemma":0.00022868149,"teacher_disagreement_score":0.00062606524,"about_ca_system_score_codex":0.00015287835,"about_ca_system_score_gemma":0.000094279836,"threshold_uncertainty_score":0.002094388},"labels":[],"label_agreement":null},{"id":"W2900133605","doi":"10.1093/neuonc/noy148.1115","title":"TMOD-02. DIFFUSE GLIOMATOSIS IN MOUSE MODEL OF GFAP TISSUE SPECIFIC KNOCK IN OF EGFRvIII AND KNOCK OUT OF p19 ARF","year":2018,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pathology; Immunohistochemistry; Biology; NeuN; Synaptophysin; Glioma; Nestin; Glial fibrillary acidic protein; Genetically modified mouse; Parenchyma; Leptomeninges; Cancer research; Transgene; Medicine; Neural stem cell; Stem cell; Central nervous system; Cell biology","score_opus":0.07303066409905097,"score_gpt":0.3795410821435967,"score_spread":0.30651041804454576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900133605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97815233,0.0013312876,0.0075635244,0.0005417008,0.00015411462,0.0004657431,0.0035390463,0.00077957025,0.007472705],"genre_scores_gemma":[0.9389736,0.0018116758,0.010928013,0.00030158594,0.000047064572,0.0010663392,0.006028277,0.00017103345,0.04067247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996629,0.000040431027,0.00003645741,0.000087987515,0.000086472515,0.0000856699],"domain_scores_gemma":[0.99981135,0.000014578101,0.000052819913,0.000027084525,0.000015352689,0.00007889096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033945288,0.0011119144,0.00044737768,0.0011956817,0.00044533898,0.0004421333,0.00048535332,0.0010809524,0.003891679],"category_scores_gemma":[0.000100657635,0.00042885653,0.0005334693,0.0004728835,0.0005273231,0.000447821,0.0003366261,0.0016095594,0.0015889866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045063082,0.0006928812,0.00044931637,0.000078521916,0.000015080535,0.00066914177,0.00006484546,0.00013662766,0.99368906,0.0007946543,0.00043820325,0.0025210434],"study_design_scores_gemma":[0.0003627706,0.0050875642,0.005491206,0.000042142106,0.000067743036,0.0052125975,0.00010399927,0.0019824698,0.9617216,0.00040960548,0.019495161,0.000023099677],"about_ca_topic_score_codex":0.00081077195,"about_ca_topic_score_gemma":0.0015233431,"teacher_disagreement_score":0.003891679,"about_ca_system_score_codex":0.00054982444,"about_ca_system_score_gemma":0.00040866635,"threshold_uncertainty_score":0.013018966},"labels":[],"label_agreement":null},{"id":"W2900581547","doi":"10.1038/s41598-018-35284-9","title":"Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis","year":2018,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Queen's University; Government of Canada","keywords":"Metastasis; Cancer research; Cancer; Motility; Cancer cell; Trastuzumab; Cortactin; Medicine; Biology; Cell; Breast cancer; Internal medicine; Cell biology; Cytoskeleton; Biochemistry","score_opus":0.025379370454895262,"score_gpt":0.3559277230747027,"score_spread":0.3305483526198075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900581547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996409,0.0014212962,0.00045499502,0.00007139971,0.000016399192,0.000015546771,0.00008300192,0.000021185067,0.0015072072],"genre_scores_gemma":[0.9972785,0.0011444292,0.0004783846,0.00004056222,0.0000074567324,0.000014472908,0.00006483333,0.0000067017563,0.0009646012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999522,0.000011709385,0.0000027359479,0.000007541712,0.000009822749,0.000016052738],"domain_scores_gemma":[0.9999635,0.000007713257,0.000009583425,0.0000030098522,0.0000041757626,0.000012084605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008513841,0.00018141187,0.00011617108,0.000060649207,0.00009307952,0.00015295345,0.00009863454,0.00014225555,0.0011722634],"category_scores_gemma":[0.00006138708,0.00006672092,0.000081432154,0.00005389666,0.00010153733,0.00010234317,0.00011394656,0.00024221597,0.00014927225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028746927,0.000060677503,0.00016997817,0.00003203694,0.0000042636316,0.00002492949,0.000005475629,0.00010687233,0.9969668,0.000048077323,0.000057321613,0.002236087],"study_design_scores_gemma":[0.00003217185,0.0009335497,0.003564411,0.0000057759175,0.000010380375,0.000083348496,0.000015014674,0.00083304953,0.9923637,0.000026414953,0.0021293187,0.0000028848965],"about_ca_topic_score_codex":0.0003948213,"about_ca_topic_score_gemma":0.0009330191,"teacher_disagreement_score":0.0011722634,"about_ca_system_score_codex":0.00013376446,"about_ca_system_score_gemma":0.00008810148,"threshold_uncertainty_score":0.003921628},"labels":[],"label_agreement":null},{"id":"W2901691660","doi":"10.1186/s13058-018-1064-1","title":"Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Breast Cancer Ireland; Trinity College Dublin; Science Foundation Ireland; Health Research Board","keywords":"Lapatinib; Gene silencing; Trastuzumab; Breast cancer; Cancer research; Medicine; Epidermal growth factor receptor; Cancer; Protein kinase B; Metastatic breast cancer; Internal medicine; Biology; Signal transduction; Cell biology","score_opus":0.03564888088784328,"score_gpt":0.3661277690871291,"score_spread":0.3304788881992858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901691660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987196,0.00076882495,0.00015020618,0.000031225343,0.0000032338608,0.000007251318,0.00008219191,0.000006710864,0.0002308942],"genre_scores_gemma":[0.9992199,0.00025280294,0.00014389848,0.00002700211,0.0000042486095,0.000007880073,0.00014480484,0.0000019515674,0.00019739263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998492,0.000025882728,0.000017692433,0.000034518813,0.000040672017,0.000032037195],"domain_scores_gemma":[0.9994646,0.00007046826,0.00030139703,0.000026628994,0.00005266154,0.00008420355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020474884,0.00015180184,0.00020114759,0.00032810814,0.00014650685,0.00031192423,0.00013031546,0.00029698512,0.0013018487],"category_scores_gemma":[0.0004158328,0.0000980431,0.00016677692,0.00022230527,0.00014529358,0.00014067328,0.00016737131,0.00045621023,0.00016972782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013781537,0.00020555267,0.08845891,0.00011642871,0.00011215508,0.00057619764,0.000065228596,0.00021659072,0.9005353,0.00010087612,0.00030904968,0.007925541],"study_design_scores_gemma":[0.000042400236,0.001460013,0.78895926,0.000020997466,0.00020433248,0.0072567216,0.00016337654,0.002228598,0.19686788,0.00013101133,0.0026490812,0.000016306421],"about_ca_topic_score_codex":0.00020338391,"about_ca_topic_score_gemma":0.00021485823,"teacher_disagreement_score":0.0013018487,"about_ca_system_score_codex":0.0001976852,"about_ca_system_score_gemma":0.0000818599,"threshold_uncertainty_score":0.0043551326},"labels":[],"label_agreement":null},{"id":"W2901824468","doi":"10.2967/jnumed.118.220921","title":"Measuring Estrogen Receptor Functionality Using Progesterone Receptor PET Imaging: Rising to the (Estradiol) Challenge!","year":2018,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Progesterone receptor; Estrogen receptor; Estrogen; Receptor; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Estrogen receptor beta; Endocrinology; Estrogen-related receptor gamma; Medicine; Cancer research; Chemistry; Cancer","score_opus":0.15688124416527063,"score_gpt":0.3730962132279249,"score_spread":0.21621496906265428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901824468","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018381022,0.3989096,0.036390986,0.47936723,0.028087499,0.00016535398,0.0009767229,0.002409212,0.035312355],"genre_scores_gemma":[0.18872687,0.37330797,0.06931119,0.2240923,0.055409938,0.0002807301,0.0011852736,0.0011121011,0.086573556],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99931276,0.00021503563,0.000053502306,0.00008939227,0.00026948343,0.00005985623],"domain_scores_gemma":[0.9977597,0.0010047611,0.00009424155,0.00013159678,0.00079058623,0.00021905321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024492037,0.0007538717,0.0010405708,0.00093993807,0.00037241433,0.00216335,0.00089307793,0.0034068646,0.0066324705],"category_scores_gemma":[0.0048050373,0.0003372136,0.0004580703,0.00044817335,0.0011423739,0.002361927,0.0007138974,0.0037941835,0.008010732],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006493392,0.00014586917,0.014794682,0.0010471047,0.00011625135,0.0037513087,0.00017164851,0.00025819967,0.025879469,0.007350287,0.3764765,0.5693594],"study_design_scores_gemma":[0.00011594993,0.00092987216,0.016762407,0.0018628205,0.00026239894,0.037011683,0.0008271357,0.0019305453,0.028526599,0.032744974,0.8787958,0.0002298433],"about_ca_topic_score_codex":0.0018608414,"about_ca_topic_score_gemma":0.0047906837,"teacher_disagreement_score":0.0066324705,"about_ca_system_score_codex":0.00061498344,"about_ca_system_score_gemma":0.000554524,"threshold_uncertainty_score":0.022187829},"labels":[],"label_agreement":null},{"id":"W2901939101","doi":"10.1186/s13643-018-0854-y","title":"Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis","year":2018,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Ottawa Public Health; St. Michael's Hospital; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Meta-analysis; Anthracycline; Randomized controlled trial; Chemotherapy; Cancer","score_opus":0.27067337043976175,"score_gpt":0.48490405594176067,"score_spread":0.21423068550199892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901939101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045142686,0.99217176,0.0011663538,0.000373327,0.00010953239,0.00029282045,0.00093557354,0.000027446367,0.0004088639],"genre_scores_gemma":[0.25532103,0.7342796,0.004945178,0.0012893282,0.00028995003,0.0017291612,0.0016579054,0.000045357607,0.00044262325],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9863201,0.008675246,0.0023979645,0.0011090788,0.0011586976,0.0003388246],"domain_scores_gemma":[0.9670665,0.027303778,0.0031666805,0.0007404018,0.0014619782,0.0002604742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021647697,0.0025066587,0.010413762,0.0078987,0.0004860844,0.0024437623,0.0020636793,0.0015810446,0.0036626852],"category_scores_gemma":[0.046591736,0.001062067,0.029194236,0.008224662,0.0004735308,0.0015032107,0.0015531664,0.0016502686,0.0002995398],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012393263,0.000033834527,0.0060940753,0.28749532,0.6823145,0.0001288502,0.00009226846,0.0019005949,0.00015585091,0.00034459552,0.00116895,0.019031812],"study_design_scores_gemma":[0.00036521227,0.00014863267,0.0038074958,0.025832253,0.965707,0.00009127202,0.000037900518,0.000702557,0.0000831885,0.0006016602,0.0025988647,0.00002401733],"about_ca_topic_score_codex":0.0089171855,"about_ca_topic_score_gemma":0.019452894,"teacher_disagreement_score":0.021647697,"about_ca_system_score_codex":0.002598643,"about_ca_system_score_gemma":0.0035703515,"threshold_uncertainty_score":0.11448532},"labels":[],"label_agreement":null},{"id":"W2904586743","doi":"10.1186/s13058-018-1080-1","title":"ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Faculty of Medicine, Dalhousie University; Canadian Institutes of Health Research; Dalhousie University; Breast Cancer Society of Canada; Beatrice Hunter Cancer Research Institute; Cancer Research Institute","keywords":"Anoikis; Lapatinib; Cancer research; Trastuzumab; Downregulation and upregulation; Breast cancer; HER2/neu; Biology; Cancer cell; Medicine; Cancer; Internal medicine","score_opus":0.09643598774559511,"score_gpt":0.3982481477689688,"score_spread":0.30181216002337363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904586743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98617387,0.0022154516,0.0051869275,0.00030025485,0.00008289871,0.000041678602,0.0020912376,0.00012305734,0.0037846935],"genre_scores_gemma":[0.9881747,0.0010414723,0.003792743,0.00010527061,0.000011600353,0.00005955134,0.0025305613,0.000031944983,0.0042523076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982774,0.000017773398,0.00001603697,0.000029314473,0.00006549692,0.000043501223],"domain_scores_gemma":[0.9998995,0.000012986234,0.000028870629,0.000022580412,0.00001713954,0.000018908304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014000005,0.00026205438,0.00018401604,0.0001467357,0.00024043395,0.00032064045,0.00019463897,0.00027561054,0.002418537],"category_scores_gemma":[0.00008305649,0.00013833914,0.0004400923,0.00014808819,0.00016975631,0.00018557877,0.00021875145,0.00078530033,0.0010402125],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005919943,0.00002508216,0.00016634096,0.000026000034,0.0000026800574,0.000032955795,0.00000971656,0.000034151675,0.99892825,0.00007363814,0.00006235693,0.0005795931],"study_design_scores_gemma":[0.0000118000435,0.00009648083,0.0085917795,0.0000057436196,0.000009282254,0.0002956173,0.00004170003,0.0009224818,0.9846599,0.000046531375,0.0053139743,0.0000047040357],"about_ca_topic_score_codex":0.00058955426,"about_ca_topic_score_gemma":0.0006749189,"teacher_disagreement_score":0.002418537,"about_ca_system_score_codex":0.00030217782,"about_ca_system_score_gemma":0.00016142415,"threshold_uncertainty_score":0.008090854},"labels":[],"label_agreement":null},{"id":"W2906141260","doi":"10.1016/j.cjca.2018.12.026","title":"Statins in Cardio-oncology: Holy Grail or Epiphenomenon","year":2018,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Epiphenomenon; Medicine; Holy Grail; Internal medicine; Oncology; Intensive care medicine; Cardiology; Epistemology","score_opus":0.08610786503211194,"score_gpt":0.36956553495169553,"score_spread":0.2834576699195836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906141260","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062739826,0.011138053,0.000055941317,0.97149223,0.012742231,0.0000047751655,0.000024924175,0.0000136100325,0.003900811],"genre_scores_gemma":[0.01890101,0.016144518,0.00027078207,0.74789053,0.21019305,0.000021234266,0.000039752675,0.000024085475,0.0065150284],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830014,0.0004952751,0.00025702984,0.0002110233,0.0004748683,0.0002616493],"domain_scores_gemma":[0.9938294,0.0034433452,0.00055702985,0.00016629783,0.0006553433,0.0013484802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015908162,0.0005470403,0.0016002716,0.0010726041,0.0027937521,0.002761634,0.0010023854,0.032716088,0.0074884086],"category_scores_gemma":[0.017614214,0.00043182864,0.0007782187,0.00076675223,0.002825285,0.0033649749,0.0011879654,0.023521338,0.0032226082],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012654824,0.00006337258,0.0019629095,0.00017241098,0.00004410992,0.018571332,0.00020357956,0.000091470254,0.00020466872,0.010180158,0.9401497,0.02822987],"study_design_scores_gemma":[0.00059326674,0.00014391963,0.0023711044,0.0017197457,0.00011722095,0.029834853,0.000610323,0.0007695331,0.00027666416,0.034340218,0.9291222,0.00010079572],"about_ca_topic_score_codex":0.004474697,"about_ca_topic_score_gemma":0.010878192,"teacher_disagreement_score":0.032716088,"about_ca_system_score_codex":0.0043121283,"about_ca_system_score_gemma":0.0036191312,"threshold_uncertainty_score":0.031286836},"labels":[],"label_agreement":null},{"id":"W2907374233","doi":"10.3390/ph12010007","title":"Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging","year":2019,"lang":"en","type":"review","venue":"Pharmaceuticals","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; Jewish General Hospital; Douglas Mental Health University Institute; McGill University; University of Toronto; SickKids Foundation; Montreal Neurological Institute and Hospital; Hospital for Sick Children; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Cancer Research Society; Weston Brain Institute; U.S. Department of Energy","keywords":"Positron emission tomography; Tropomyosin; Trk receptor; Medicine; Positron Emission Tomography-Computed Tomography; Radioligand; Nuclear medicine; Receptor; Internal medicine; Chemistry; Biochemistry; Neurotrophin; Actin","score_opus":0.21234201172078415,"score_gpt":0.5322720071699203,"score_spread":0.31992999544913614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907374233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055627787,0.99300003,0.0012214835,0.00022590387,0.0002899919,0.000017482065,0.000061590705,0.00003938592,0.0045878706],"genre_scores_gemma":[0.0036674882,0.99019367,0.0013633501,0.0003923025,0.0001939855,0.00003600849,0.00014400197,0.000007290454,0.0040018996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998963,0.000018072336,0.000008241193,0.000026863425,0.000035336372,0.000015214603],"domain_scores_gemma":[0.99993217,0.000027613652,0.000013639968,0.0000031488285,0.000016517115,0.000006857141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024086551,0.0009047644,0.000805727,0.0013181368,0.00013956046,0.0004552922,0.0007070077,0.001000657,0.0040379856],"category_scores_gemma":[0.00021781983,0.0002991408,0.00039404805,0.001256846,0.00027508158,0.00079958624,0.0003893419,0.0013312205,0.0038795809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012287423,0.0000990118,0.00019754648,0.014596661,0.00010968244,0.00059710763,0.00006648619,0.0009915908,0.04050416,0.009546218,0.045769446,0.88739914],"study_design_scores_gemma":[0.000021042355,0.00015563385,0.0004501264,0.00071774336,0.00008095521,0.0022364282,0.00002408915,0.0002646106,0.007502611,0.0012722847,0.9872476,0.000026812106],"about_ca_topic_score_codex":0.000781763,"about_ca_topic_score_gemma":0.001301747,"teacher_disagreement_score":0.0040379856,"about_ca_system_score_codex":0.00053348276,"about_ca_system_score_gemma":0.00040670298,"threshold_uncertainty_score":0.013508379},"labels":[],"label_agreement":null},{"id":"W2910682218","doi":"10.2967/jnumed.118.220095","title":"Preclinical Evaluation of<sup>111</sup>In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models","year":2019,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Nimotuzumab; Biodistribution; In vivo; Chemistry; PEG ratio; Ex vivo; Pharmacokinetics; Antibody-drug conjugate; DOTA; Monoclonal antibody; Epidermal growth factor receptor; In vitro; Pharmacology; Antibody; Medicine; Receptor; Biochemistry; Immunology","score_opus":0.09107480338629023,"score_gpt":0.4276933108519808,"score_spread":0.33661850746569055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910682218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344987,0.0013416688,0.002761149,0.00015693456,0.000059827806,0.00032586575,0.00033328973,0.00012809748,0.0014433746],"genre_scores_gemma":[0.99131036,0.0015157523,0.00432945,0.00007028932,0.000021103233,0.00022873933,0.0005724182,0.00004071655,0.0019112496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983144,0.000045473167,0.0000100152465,0.000023817658,0.000047468227,0.00004184301],"domain_scores_gemma":[0.99981207,0.000024024333,0.00005011138,0.000018526434,0.000034034765,0.00006125107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044432763,0.0006405877,0.00067347067,0.00024519456,0.00014325933,0.00036374698,0.0005406742,0.0005035098,0.00080820645],"category_scores_gemma":[0.0002607703,0.00020489082,0.00025617928,0.00023945386,0.00031958576,0.0003276886,0.000121783894,0.0008490741,0.00032934133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030836351,0.0035201896,0.00063674164,0.0001900625,0.00011037551,0.00011591671,0.000078016,0.003570103,0.9748906,0.00024999285,0.0005192406,0.013035048],"study_design_scores_gemma":[0.00036715745,0.016929567,0.0015599877,0.000007258606,0.00011318745,0.00012951894,0.000016073647,0.0032303634,0.97510827,0.000039562954,0.0024892848,0.000009714746],"about_ca_topic_score_codex":0.0012669294,"about_ca_topic_score_gemma":0.0016244443,"teacher_disagreement_score":0.0012669294,"about_ca_system_score_codex":0.00067361345,"about_ca_system_score_gemma":0.00055974134,"threshold_uncertainty_score":0.004887402},"labels":[],"label_agreement":null},{"id":"W2911042793","doi":"10.6026/97320630014482","title":"Molecular docking analysis of Cianidanol from Ginkgo biloba with HER2+ breast cancer target","year":2018,"lang":"en","type":"article","venue":"Bioinformation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ebro Foods (Canada)","funders":"","keywords":"Lapatinib; Ginkgo biloba; Trastuzumab emtansine; Trastuzumab; Medicine; Breast cancer; Pharmacology; Docking (animal); Cancer; Internal medicine","score_opus":0.014443804886816151,"score_gpt":0.31743929710637303,"score_spread":0.3029954922195569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911042793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818526,0.0031223998,0.005637675,0.0004364521,0.00008307561,0.00006949103,0.0010890095,0.0002629057,0.0074464628],"genre_scores_gemma":[0.9861232,0.0021067797,0.0075190077,0.00009436296,0.000006523182,0.00007695043,0.0015296746,0.00004642752,0.0024971133],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99991953,0.000015586287,0.000004095315,0.000013599129,0.00002444111,0.000022822238],"domain_scores_gemma":[0.9999651,0.000012618957,0.0000054311204,0.0000022232907,0.000007684122,0.00000699746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013013018,0.0007234015,0.0007255006,0.0003999233,0.0003598593,0.0003056058,0.0005351951,0.0003194688,0.004633112],"category_scores_gemma":[0.00023323145,0.00018024494,0.00084745506,0.00040511842,0.00010941527,0.0002988512,0.00036172246,0.00039388466,0.0004483511],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022437954,0.0012761713,0.010105205,0.002142644,0.0007885128,0.001362977,0.00014657428,0.63096046,0.29970682,0.0045532524,0.0064685396,0.040245075],"study_design_scores_gemma":[0.00025332766,0.0016105989,0.0053465595,0.00006145169,0.00028939755,0.00026534792,0.00021459408,0.8918951,0.09198837,0.0013143399,0.006675419,0.00008544572],"about_ca_topic_score_codex":0.0037875369,"about_ca_topic_score_gemma":0.004260779,"teacher_disagreement_score":0.004633112,"about_ca_system_score_codex":0.00032695904,"about_ca_system_score_gemma":0.00034550903,"threshold_uncertainty_score":0.015499234},"labels":[],"label_agreement":null},{"id":"W2911072167","doi":"10.1136/jclinpath-2018-205672","title":"Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Tropomyosin; Biology; Tropomyosin receptor kinase B; Tyrosine kinase; Gene; Fusion gene; Neurotrophin; Cancer research; Immunohistochemistry; Fusion protein; Receptor tyrosine kinase; Tropomyosin receptor kinase C; Trk receptor; Cell biology; Receptor; Kinase; Neurotrophic factors; Immunology; Actin; Signal transduction; Genetics; Platelet-derived growth factor receptor","score_opus":0.48134786745023955,"score_gpt":0.5904580397059904,"score_spread":0.10911017225575087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911072167","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012044297,0.9975681,0.00009975384,0.00024486575,0.00017510583,0.0000040691466,0.00003404742,0.000010073012,0.0017435323],"genre_scores_gemma":[0.0006281393,0.99793917,0.00015514182,0.000114038216,0.000119864766,0.0000045004253,0.000061587336,0.0000016735569,0.0009758332],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998846,0.000013433752,0.000016107197,0.000023586506,0.000050416635,0.000011884325],"domain_scores_gemma":[0.9997869,0.000084346146,0.000030900846,0.0000063734424,0.00006275741,0.000028691338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031496934,0.0007311107,0.0010323884,0.003143217,0.0002113936,0.00070870767,0.00063274323,0.00060930464,0.0058327424],"category_scores_gemma":[0.00045284972,0.00017423555,0.0003016597,0.002295079,0.00032576674,0.00087142753,0.0004973692,0.0011912766,0.004842008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034949044,0.0000290054,0.000128258,0.007744524,0.00003415374,0.00026518,0.000030409488,0.0001798416,0.0011674254,0.0019457852,0.03162936,0.95681113],"study_design_scores_gemma":[0.0000060874922,0.00003078318,0.0005398767,0.0018815876,0.000037296493,0.0017605238,0.00003058814,0.00003311889,0.000266701,0.0008450679,0.9945591,0.0000092438895],"about_ca_topic_score_codex":0.0008119618,"about_ca_topic_score_gemma":0.0017501177,"teacher_disagreement_score":0.0058327424,"about_ca_system_score_codex":0.00045382965,"about_ca_system_score_gemma":0.00066242745,"threshold_uncertainty_score":0.019512415},"labels":[],"label_agreement":null},{"id":"W2911209161","doi":"10.18433/jpps29891","title":"Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors","year":2019,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacology; Tyrosine kinase; Solid lipid nanoparticle; Cetuximab; Drug delivery; Monoclonal antibody; Medicine; Chemistry; Drug; Cancer research; Signal transduction; Biochemistry; Immunology; Antibody","score_opus":0.5152280653806227,"score_gpt":0.5376442910074799,"score_spread":0.02241622562685719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911209161","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15734427,0.40291837,0.39043537,0.0029677858,0.002113647,0.00090271235,0.0007253021,0.001253799,0.041338846],"genre_scores_gemma":[0.54184985,0.24242626,0.17117065,0.0016895398,0.000541366,0.0012959552,0.00074103096,0.00019121065,0.04009416],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973434,0.000029695715,0.000017397064,0.00005803646,0.00012201361,0.000038474434],"domain_scores_gemma":[0.9999485,0.000009576009,0.000020372396,0.0000042188935,0.000011172993,0.000006131124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003079852,0.00052861316,0.00048035517,0.00044231163,0.00022051636,0.00062059413,0.0004973697,0.0007245723,0.0015283215],"category_scores_gemma":[0.00016921155,0.00030763572,0.0005147458,0.00030555043,0.000284304,0.0009670938,0.0005571816,0.0011141712,0.00081071054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009816477,0.00011556229,0.000069944836,0.0015848418,0.000045073637,0.00035028142,0.0001004194,0.0009797781,0.9111468,0.0106460415,0.0024626758,0.072400466],"study_design_scores_gemma":[0.00007417233,0.00081106054,0.00047471738,0.00013621448,0.00007994268,0.001591169,0.00004894036,0.00711339,0.76028097,0.0021057692,0.22722813,0.000055577464],"about_ca_topic_score_codex":0.00036726746,"about_ca_topic_score_gemma":0.00042300115,"teacher_disagreement_score":0.0015283215,"about_ca_system_score_codex":0.0006040239,"about_ca_system_score_gemma":0.0002767636,"threshold_uncertainty_score":0.005112767},"labels":[],"label_agreement":null},{"id":"W2911757824","doi":"10.1002/jbm4.10177","title":"EGFR Signaling: Friend or Foe for Cartilage?","year":2019,"lang":"en","type":"review","venue":"JBMR Plus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Endochondral ossification; Osteoarthritis; Cartilage; Medicine; Signal transduction; Epidermal growth factor receptor; Neuroscience; Bioinformatics; Receptor; Cancer research; Cell biology; Biology; Pathology; Internal medicine; Anatomy","score_opus":0.3890660332608632,"score_gpt":0.5283927576351763,"score_spread":0.13932672437431315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911757824","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008425608,0.9969351,0.00009570666,0.0014675679,0.0005108787,0.0000012191483,0.0000144616215,0.000007587004,0.000883155],"genre_scores_gemma":[0.0013917858,0.9949293,0.00014978275,0.0010377384,0.00065900263,0.000003509111,0.000024825524,0.0000032778173,0.0018008007],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998288,0.000038364262,0.000018162515,0.00003253701,0.0000636669,0.000018547995],"domain_scores_gemma":[0.9997851,0.00009513739,0.000023202098,0.0000105121,0.000058734484,0.000027244167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006469943,0.000456,0.00096369284,0.0011400003,0.00022215143,0.0010423567,0.0006410354,0.0010818832,0.004307258],"category_scores_gemma":[0.0006993365,0.00015021779,0.00035463477,0.0007077078,0.00054248737,0.0014641462,0.0004617894,0.0022124713,0.003018301],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008121653,0.0000294524,0.0001496026,0.0062650163,0.00010103657,0.0003790091,0.000061573046,0.00013817215,0.0020658483,0.010802037,0.08126577,0.8986612],"study_design_scores_gemma":[0.000012562994,0.000044627614,0.0002399904,0.0016273638,0.000046651374,0.0012717424,0.00004145672,0.000040575043,0.00033792434,0.002820954,0.99350643,0.000009788363],"about_ca_topic_score_codex":0.0005841047,"about_ca_topic_score_gemma":0.0012813775,"teacher_disagreement_score":0.004307258,"about_ca_system_score_codex":0.00046262296,"about_ca_system_score_gemma":0.0005278911,"threshold_uncertainty_score":0.014409244},"labels":[],"label_agreement":null},{"id":"W2912108694","doi":"10.1093/annonc/mdz016","title":"Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Neratinib; Breast cancer; Oncology; Quality of life (healthcare); Stage (stratigraphy); Internal medicine; Randomized controlled trial; Gynecology; Cancer; Trastuzumab; Nursing","score_opus":0.15561644541174927,"score_gpt":0.5094365783830779,"score_spread":0.35382013297132864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912108694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830256,0.012853444,0.0005716429,0.00045651384,0.00011959306,0.0005588185,0.0016331022,0.00003809156,0.0007431076],"genre_scores_gemma":[0.9928606,0.0031003952,0.0005396459,0.0003358115,0.000116128955,0.00071937835,0.0018414214,0.000008832347,0.00047780582],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99826425,0.0012361173,0.0001431956,0.00013546449,0.00011189574,0.00010912358],"domain_scores_gemma":[0.99730635,0.0008707677,0.0010330381,0.00034114244,0.00017771478,0.00027095943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005952386,0.0006812552,0.0016013363,0.00017239197,0.00026401397,0.0006462131,0.00046267413,0.0005624021,0.0020298779],"category_scores_gemma":[0.0047684177,0.00025645422,0.002521802,0.00030817115,0.00042432197,0.00055750454,0.00041759413,0.0012930459,0.0002078502],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93273693,0.0031651305,0.020649098,0.0009812319,0.008379374,0.00007350251,0.00006343786,0.0009998677,0.0018082213,0.0001060994,0.0013074074,0.029729731],"study_design_scores_gemma":[0.69979864,0.15250741,0.12278755,0.000308154,0.015181023,0.00033733615,0.00010228744,0.0020715578,0.0021663888,0.000592456,0.0040660272,0.00008109479],"about_ca_topic_score_codex":0.00046051043,"about_ca_topic_score_gemma":0.0011125269,"teacher_disagreement_score":0.005952386,"about_ca_system_score_codex":0.00043169307,"about_ca_system_score_gemma":0.000760783,"threshold_uncertainty_score":0.031479597},"labels":[],"label_agreement":null},{"id":"W2912202910","doi":"10.7150/thno.30835","title":"Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments","year":2019,"lang":"en","type":"article","venue":"Theranostics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"Canadian Cancer Society Research Institute","keywords":"Epidermal growth factor receptor; Antibody; Cancer research; Monoclonal antibody; Nimotuzumab; Chemistry; Epitope; Antigen; Cetuximab; Epidermal growth factor; Molecular biology; EGFR inhibitors; Receptor; Medicine; Biology; Immunology","score_opus":0.014968737696984676,"score_gpt":0.30432931586403905,"score_spread":0.28936057816705435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912202910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727754,0.0020022844,0.018532356,0.0003454087,0.00011476487,0.0002289241,0.0011162541,0.0005368439,0.004347735],"genre_scores_gemma":[0.94833606,0.0022641208,0.033438664,0.00028242936,0.000045297984,0.00048536644,0.0024764512,0.00020951529,0.012462163],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998134,0.000023411802,0.000011354976,0.00006371553,0.000042082607,0.00004611792],"domain_scores_gemma":[0.99983084,0.000035242017,0.000050743227,0.000020778398,0.000022137314,0.000040215687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039057073,0.0007655468,0.00034222787,0.0005022848,0.00013920282,0.00020979327,0.0004609105,0.0006403786,0.0013474277],"category_scores_gemma":[0.00011709496,0.00033986542,0.0005497744,0.0001959613,0.00029393725,0.0004230806,0.00014402496,0.0012944586,0.0003618254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012381574,0.00007884361,0.000042570915,0.000018515108,0.0000047759236,0.000023549297,0.000007925903,0.000054912623,0.9991092,0.00005293592,0.000046463105,0.0004364528],"study_design_scores_gemma":[0.00004457662,0.001251788,0.0012530971,0.000007871047,0.00002499487,0.00032065704,0.000010999762,0.001831203,0.9940819,0.000032068594,0.0011351774,0.000005731942],"about_ca_topic_score_codex":0.0008301752,"about_ca_topic_score_gemma":0.0009077464,"teacher_disagreement_score":0.0013474277,"about_ca_system_score_codex":0.0003659293,"about_ca_system_score_gemma":0.00022855682,"threshold_uncertainty_score":0.0045076013},"labels":[],"label_agreement":null},{"id":"W2912998652","doi":"10.1038/s41586-019-0974-0","title":"Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers","year":2019,"lang":"en","type":"erratum","venue":"Nature","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Genentech; EMD Serono; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Eli Lilly and Company; Chinese University of Hong Kong; Juno Therapeutics; Eisai; Daiichi-Sankyo; Puma Biotechnology; Aminex Therapeutics; Symphogen; Pfizer; Incyte; Ipsen; Five Prime Therapeutics; Les Laboratories Pierre Fabre; BioMarin Pharmaceutical; Sanofi; Sierra Oncology; Genomic Health; Clovis Oncology; Varian Medical Systems; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Spectrum Pharmaceuticals; Jounce Therapeutics; Celgene; Servier; Foghorn Therapeutics; AstraZeneca; Bristol-Myers Squibb","keywords":"Mutant; Cancer research; Kinase; Internal medicine; Biology; Oncology; Medicine; Genetics; Gene","score_opus":0.010367093851211704,"score_gpt":0.31070624403118363,"score_spread":0.3003391501799719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912998652","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000117287665,0.0009941614,0.00025340592,0.07264526,0.92401975,0.000010126283,0.0004319326,0.000098627956,0.0014294629],"genre_scores_gemma":[0.015896361,0.010242106,0.0033748385,0.18889207,0.62963647,0.00015159388,0.0014350548,0.0008662393,0.14950523],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970696,0.0005201779,0.00050697644,0.0004177324,0.0011841086,0.00030148192],"domain_scores_gemma":[0.9832134,0.0055782036,0.0009215498,0.0008044587,0.008347109,0.0011351742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030903178,0.0016796069,0.0017479572,0.0025755407,0.002024997,0.002710593,0.002587257,0.007600832,0.020086171],"category_scores_gemma":[0.03913844,0.0008451652,0.0016885817,0.0012384031,0.0014954403,0.0012499344,0.0010272043,0.0122614885,0.011414949],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026114432,0.0000041806966,0.00005773255,0.00005455671,0.000011020205,0.0004744202,0.0000087214585,0.000026419566,0.000022445249,0.00023834278,0.9961451,0.0029309688],"study_design_scores_gemma":[0.00011732581,0.000037181155,0.0008923299,0.00037497582,0.00010834454,0.0025969397,0.00006057031,0.00031977496,0.00043753014,0.0011355531,0.9938758,0.000043558644],"about_ca_topic_score_codex":0.012431761,"about_ca_topic_score_gemma":0.017595477,"teacher_disagreement_score":0.020086171,"about_ca_system_score_codex":0.0034808214,"about_ca_system_score_gemma":0.004058129,"threshold_uncertainty_score":0.06719494},"labels":[],"label_agreement":null},{"id":"W2913513847","doi":"10.1097/md.0000000000014261","title":"The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer","year":2019,"lang":"en","type":"review","venue":"Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; PTEN; Tensin; Oncology; Breast cancer; Internal medicine; Lapatinib; Hazard ratio; Trastuzumab; Neoadjuvant therapy; Cochrane Library; Odds ratio; Meta-analysis; Confidence interval; Cancer; PI3K/AKT/mTOR pathway","score_opus":0.051905256061697144,"score_gpt":0.3797236229295417,"score_spread":0.32781836686784455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913513847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03298691,0.96467555,0.0007203787,0.00045192562,0.00020639924,0.00012496309,0.00025288586,0.000018712806,0.0005621712],"genre_scores_gemma":[0.7233031,0.27205366,0.0019153762,0.0009886294,0.0005440517,0.0003119183,0.00047303297,0.000023011886,0.00038725714],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99118304,0.0055970065,0.00162297,0.00077894755,0.0006386096,0.00017932229],"domain_scores_gemma":[0.9761164,0.019837812,0.00267968,0.0005400693,0.0006239168,0.00020206877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015240354,0.0015599449,0.0070564277,0.0027640369,0.00033743563,0.0022322596,0.0010546197,0.0014868587,0.0012530873],"category_scores_gemma":[0.027121518,0.0007590797,0.0244254,0.0029540143,0.0006427933,0.001392845,0.0007829626,0.0014979823,0.00013459176],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0146152405,0.00010189186,0.038532894,0.10622364,0.80809236,0.00016339237,0.00008174361,0.0017476544,0.0008170873,0.00021400969,0.0005269659,0.028883237],"study_design_scores_gemma":[0.0016840255,0.0009585365,0.019243244,0.005299085,0.9698892,0.00016250052,0.0000350664,0.0007525716,0.00041363642,0.00037361242,0.0011621782,0.000026211976],"about_ca_topic_score_codex":0.0018765613,"about_ca_topic_score_gemma":0.0034330364,"teacher_disagreement_score":0.015240354,"about_ca_system_score_codex":0.0009398453,"about_ca_system_score_gemma":0.0009862205,"threshold_uncertainty_score":0.080599666},"labels":[],"label_agreement":null},{"id":"W2917182113","doi":"10.3747/co.26.4220","title":"A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer","year":2019,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Hôpital du Saint-Sacrement; University Health Network; Roche (Canada); Memorial University of Newfoundland; Impact; Université Laval; Fluidigm (Canada); Dr. H. Bliss Murphy Cancer Centre; Princess Margaret Cancer Centre; Canadian Breast Cancer Network","funders":"","keywords":"Medicine; Trastuzumab; Dosing; Breast cancer; Pharmacokinetics; Quality of life (healthcare); Intensive care medicine; Health care; Drug administration; Metastatic breast cancer; Clinical trial; Multidisciplinary approach; Food and drug administration; Cancer; Oncology; Pharmacology; Internal medicine; Nursing","score_opus":0.2926029293163404,"score_gpt":0.569392238596131,"score_spread":0.27678930927979056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917182113","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003079185,0.99696094,0.00006372509,0.0013580982,0.0009205917,0.00000314699,0.0000053943577,0.0000038616568,0.00065344974],"genre_scores_gemma":[0.00028375062,0.99706984,0.00013734978,0.0011458632,0.0007478636,0.0000052070563,0.000012565897,0.0000014345128,0.00059601205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994467,0.0001679386,0.00008035559,0.00006632811,0.00018856254,0.000050150422],"domain_scores_gemma":[0.9989988,0.0004790458,0.0001111836,0.000022172579,0.00028357957,0.00010515555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001717594,0.0009975353,0.0012944599,0.0032112217,0.00034480536,0.0013284897,0.0011594031,0.002069305,0.004054956],"category_scores_gemma":[0.0015941262,0.00027243292,0.0009065476,0.0030516684,0.00063242647,0.0022444031,0.0010250327,0.003121452,0.0019769697],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007330534,0.00006837893,0.00011153472,0.02581971,0.00013387536,0.00025025744,0.00015260627,0.0002639998,0.0007494824,0.0068837004,0.12821914,0.837274],"study_design_scores_gemma":[0.000018477685,0.000069141184,0.0003654392,0.0100892065,0.0000738932,0.000920386,0.00007891074,0.000038154667,0.00006478578,0.0018316564,0.98643726,0.00001269265],"about_ca_topic_score_codex":0.0011347363,"about_ca_topic_score_gemma":0.0029619471,"teacher_disagreement_score":0.004054956,"about_ca_system_score_codex":0.0008412444,"about_ca_system_score_gemma":0.0018851749,"threshold_uncertainty_score":0.013565183},"labels":[],"label_agreement":null},{"id":"W2917891638","doi":"10.1158/1078-0432.ccr-18-2599","title":"Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fluidigm (Canada)","funders":"Hellenic Cooperative Oncology Group; National Cancer Institute; National Center for Advancing Translational Sciences; National Human Genome Research Institute; National Institute of General Medical Sciences; Breast Cancer Research Foundation","keywords":"Trastuzumab; Cytotoxic T cell; Medicine; Cancer research; Mass cytometry; CD8; PI3K/AKT/mTOR pathway; Antibody; Immune system; Internal medicine; Oncology; Cancer; Immunology; Breast cancer; Biology; Signal transduction; Cell biology; Phenotype","score_opus":0.3013185643104747,"score_gpt":0.5159816777818874,"score_spread":0.2146631134714127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917891638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971392,0.00028913445,0.001643255,0.000034180943,0.000009005725,0.000051717077,0.00030832874,0.000040005194,0.00048515567],"genre_scores_gemma":[0.9971258,0.00009307679,0.0017737391,0.000068954556,0.000020405972,0.000072116076,0.00042292345,0.0000037577583,0.00041922543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99959975,0.00008636981,0.000034471715,0.00013450248,0.00010226273,0.000042691656],"domain_scores_gemma":[0.9996586,0.00008907016,0.00012707782,0.00002938878,0.0000479898,0.00004785927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051478384,0.00030446667,0.00034035972,0.0006597007,0.00013678934,0.0005516599,0.00019264383,0.0003083889,0.0008785241],"category_scores_gemma":[0.0007340753,0.00011858539,0.00014291481,0.00042166753,0.00016598593,0.00017639226,0.00018107297,0.0004016328,0.00022865881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005229649,0.0011632646,0.73439103,0.00010313638,0.00015640566,0.00061764114,0.00030797618,0.0020134596,0.21612455,0.00015981784,0.00090974616,0.03882325],"study_design_scores_gemma":[0.00033644418,0.0061209863,0.7788195,0.000021873702,0.0002554627,0.0030151068,0.00016417156,0.016828347,0.19139092,0.00028006377,0.0027329565,0.000034204495],"about_ca_topic_score_codex":0.0002543542,"about_ca_topic_score_gemma":0.00024552838,"teacher_disagreement_score":0.0008785241,"about_ca_system_score_codex":0.00028605934,"about_ca_system_score_gemma":0.000118216194,"threshold_uncertainty_score":0.0029389262},"labels":[],"label_agreement":null},{"id":"W2920257759","doi":"10.1039/c9sc00285e","title":"Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates","year":2019,"lang":"en","type":"article","venue":"Chemical Science","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Centre National de la Recherche Scientifique; Bpifrance","keywords":"Conjugate; Pharmacokinetics; Linker; Drug; Potency; In vivo; Dispersity; Chemistry; Antibody-drug conjugate; Pharmacology; Combinatorial chemistry; Antibody; In vitro; Medicine; Monoclonal antibody; Computer science; Biochemistry; Organic chemistry; Mathematics; Biology; Immunology","score_opus":0.017916338028028944,"score_gpt":0.347806761276972,"score_spread":0.3298904232489431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920257759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.936089,0.006359803,0.045740988,0.00036909213,0.00014932716,0.00017949702,0.0009314719,0.00078699825,0.0093938345],"genre_scores_gemma":[0.96431446,0.001982423,0.022547416,0.00012113865,0.000043603093,0.000097471035,0.0004941509,0.00009297293,0.010306388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999907,0.000010162203,0.000007362623,0.000033582943,0.000027355516,0.0000145693775],"domain_scores_gemma":[0.9999168,0.000012391859,0.000033750322,0.000008092604,0.00001353604,0.00001540754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014677335,0.00046466925,0.00018559418,0.00015938294,0.00011851066,0.00021415426,0.00020355522,0.00026965828,0.0016816597],"category_scores_gemma":[0.00015451123,0.00017675188,0.00011204515,0.00016417073,0.0001668237,0.00037468487,0.00018527044,0.0003834151,0.00080887054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063523854,0.000012431858,0.000036275836,0.000041467953,0.000004369098,0.00003452283,0.000010416153,0.0002280283,0.9963008,0.00034273567,0.00017944924,0.0027458982],"study_design_scores_gemma":[0.000009297984,0.00011721499,0.00016544946,0.0000014426837,0.0000055984233,0.00005853597,0.0000020252799,0.000679517,0.9963462,0.000019252795,0.002592262,0.000003345433],"about_ca_topic_score_codex":0.000542354,"about_ca_topic_score_gemma":0.001264861,"teacher_disagreement_score":0.0016816597,"about_ca_system_score_codex":0.00042571063,"about_ca_system_score_gemma":0.00027226232,"threshold_uncertainty_score":0.005625725},"labels":[],"label_agreement":null},{"id":"W2921213784","doi":"10.3390/cancers11030375","title":"The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation","year":2019,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Cure Brain Cancer Foundation; Canadian Institutes of Health Research; Women and Children's Health Research Institute","keywords":"Pertuzumab; Trastuzumab; Phosphorylation; Chemistry; Chinese hamster ovary cell; Apoptosis; Molecular biology; Cancer research; Biochemistry; Biology; Receptor; Cancer; Breast cancer; Genetics","score_opus":0.00902042721348332,"score_gpt":0.2752201647484832,"score_spread":0.26619973753499987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921213784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161935,0.0065187984,0.00031700355,0.00012370464,0.00007702231,0.000026641386,0.0001169869,0.000020315243,0.0011800423],"genre_scores_gemma":[0.9940163,0.0034115175,0.00068648165,0.00007915862,0.00004410377,0.000041832376,0.00022317615,0.000006535241,0.0014909055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997669,0.000049644823,0.000025431531,0.000035794743,0.00006435482,0.000057941463],"domain_scores_gemma":[0.99990106,0.000026303798,0.000019332896,0.000009271196,0.000017384438,0.000026660704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018318082,0.0003506523,0.000494906,0.0003429964,0.00016402976,0.0002737068,0.00015929861,0.00024283105,0.00088214816],"category_scores_gemma":[0.00022766918,0.0001394131,0.00044922443,0.0003678884,0.000146583,0.00031020388,0.00016453762,0.0004260919,0.00017613865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024464368,0.000636303,0.0011118825,0.00025798348,0.00008078324,0.00017595061,0.00006901656,0.0005305939,0.97830564,0.00007163254,0.0002835684,0.016030176],"study_design_scores_gemma":[0.00016221113,0.0058075804,0.018477457,0.000013540231,0.00017553814,0.00057790446,0.0000965301,0.002394089,0.96765155,0.00006470744,0.004557755,0.000021102185],"about_ca_topic_score_codex":0.000552658,"about_ca_topic_score_gemma":0.00075211405,"teacher_disagreement_score":0.00088214816,"about_ca_system_score_codex":0.0001828177,"about_ca_system_score_gemma":0.0001883316,"threshold_uncertainty_score":0.0029510856},"labels":[],"label_agreement":null},{"id":"W2923651250","doi":"10.1093/jnci/djz032","title":"Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer","year":2019,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Yonsei University College of Medicine; University of Florida Health; Cancer Institute, University of Pittsburgh; Weill Cornell Medical College; Peter MacCallum Cancer Centre; Yonsei University; Department of Medicine, Georgetown University; KU Leuven; NRG Oncology; University of Ottawa; Allegheny Health Network; VCU Massey Cancer Center; Virginia Commonwealth University; National Cancer Institute; Kaiser Permanente; Breast Cancer Research Foundation; Pennsylvania Department of Health; AstraZeneca; Georgetown University; Genentech; University of Pittsburgh; Amgen","keywords":"Trastuzumab; Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; Confidence interval; Concordance; Stage (stratigraphy); Cancer","score_opus":0.0748041909655118,"score_gpt":0.42729085140462797,"score_spread":0.35248666043911614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923651250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983006,0.0011495305,0.00003493203,0.00009552413,0.000011511245,0.000047831647,0.000085349995,0.0000028994334,0.00027181997],"genre_scores_gemma":[0.99847084,0.00041405353,0.00011173066,0.00011885685,0.000025995343,0.00006347864,0.00037833827,0.0000010929481,0.0004156622],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996082,0.0002727955,0.00001685867,0.00002873969,0.000036714373,0.000036816407],"domain_scores_gemma":[0.99960345,0.00011611291,0.00010769662,0.000026418484,0.000023685214,0.00012262155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001509844,0.0002925787,0.00046747574,0.0001295709,0.000097174874,0.00027285065,0.00020528995,0.00023786536,0.0006434844],"category_scores_gemma":[0.0009737845,0.00013402288,0.00036618736,0.00014229855,0.00020302703,0.00020240116,0.0002223114,0.000460212,0.0001274427],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5101273,0.003697373,0.33732352,0.000608974,0.0018948311,0.00027036128,0.00015880227,0.0025938388,0.01293204,0.00023657801,0.0019044516,0.12825204],"study_design_scores_gemma":[0.084951624,0.1684635,0.72856426,0.00015498073,0.0018233064,0.0004646685,0.00013551659,0.0058613056,0.002652541,0.00065158884,0.0062491708,0.000027604903],"about_ca_topic_score_codex":0.0005960024,"about_ca_topic_score_gemma":0.0022928023,"teacher_disagreement_score":0.001509844,"about_ca_system_score_codex":0.00031926506,"about_ca_system_score_gemma":0.00039669487,"threshold_uncertainty_score":0.007984936},"labels":[],"label_agreement":null},{"id":"W2923800831","doi":"10.1186/s13058-019-1115-2","title":"PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; Eisai; MacroGenics; Puma Biotechnology; Daiichi-Sankyo; Teva Pharmaceutical Industries; Wyeth; Sanofi; GlaxoSmithKline; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Neratinib; Placebo; Surgical oncology; Double blind; Medicine; Randomized controlled trial; Oncology; Internal medicine; Breast cancer; Alternative medicine; Pathology; Cancer","score_opus":0.0792212121238377,"score_gpt":0.436616696189183,"score_spread":0.35739548406534527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923800831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98180974,0.0092379,0.0010597053,0.00070543104,0.0005000698,0.0025421565,0.0019955046,0.0001372807,0.0020121078],"genre_scores_gemma":[0.9908449,0.002280704,0.0009443541,0.00072238024,0.0003213161,0.0019597784,0.0016191155,0.000020910578,0.0012865729],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99837106,0.0009281568,0.0001799659,0.00025912124,0.000111982336,0.00014968467],"domain_scores_gemma":[0.9980464,0.0006335766,0.00062666833,0.00023428368,0.00012252819,0.00033659043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004389116,0.0017814907,0.0040332307,0.00037484814,0.0003216919,0.0011875468,0.0009725476,0.0014974753,0.0054640817],"category_scores_gemma":[0.0041537676,0.00050708913,0.0033285536,0.00046232739,0.0010375432,0.001491557,0.0005221972,0.0022155282,0.0005415577],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.987847,0.0013476124,0.0007788326,0.0005488726,0.0021087413,0.000030458521,0.000016777378,0.0002495143,0.00083479244,0.00006671126,0.0003498137,0.0058208806],"study_design_scores_gemma":[0.9706783,0.02397298,0.002539809,0.000032599586,0.0015622722,0.000050752016,0.000013826933,0.00033438051,0.00022440085,0.00017186682,0.00040249032,0.000016292885],"about_ca_topic_score_codex":0.00024353592,"about_ca_topic_score_gemma":0.00056072226,"teacher_disagreement_score":0.0054640817,"about_ca_system_score_codex":0.000598854,"about_ca_system_score_gemma":0.0007496179,"threshold_uncertainty_score":0.023212194},"labels":[],"label_agreement":null},{"id":"W2941033195","doi":"","title":"Effect of siRNA-mediated EGF receptor knockdown on cell growth and inhibitor response in A549 lung adenocarcinoma cells.","year":2005,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"A549 cell; Cell growth; Transfection; Epidermal growth factor receptor; Epidermal growth factor; Gene knockdown; Cancer research; Cell culture; Biology; Signal transduction; Growth inhibition; MTT assay; Cell biology; Growth factor receptor; Receptor; Chemistry; Biochemistry","score_opus":0.008810122317115547,"score_gpt":0.2967409756605052,"score_spread":0.2879308533433897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941033195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96305203,0.008488288,0.010942927,0.00053446554,0.00051995623,0.0006709555,0.005001017,0.0007702655,0.0100200875],"genre_scores_gemma":[0.96361744,0.004723898,0.013623881,0.0004186439,0.000040000043,0.0010146732,0.0054495833,0.00016857614,0.0109433215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994356,0.000087337314,0.00010883878,0.0001322859,0.00015727525,0.00007855109],"domain_scores_gemma":[0.99976426,0.00008842952,0.000035404155,0.00002902368,0.000048552425,0.000034382232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005121253,0.00056793465,0.00079507544,0.0003256795,0.00025651243,0.00042462826,0.0003926028,0.0006461036,0.0022691835],"category_scores_gemma":[0.00024235806,0.00022374232,0.00058398966,0.000365215,0.00024584273,0.00023935756,0.00027067726,0.00089492596,0.00083182857],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012300142,0.000105499355,0.0000822162,0.00013641333,0.000016989168,0.00004389826,0.000038148566,0.0000753461,0.99714345,0.00009258885,0.00028559708,0.0018568073],"study_design_scores_gemma":[0.00007415039,0.00092064927,0.0034652452,0.000012039303,0.000051958603,0.00015559621,0.000039023045,0.0014738305,0.9879892,0.000035112953,0.005773465,0.000009784851],"about_ca_topic_score_codex":0.0019636333,"about_ca_topic_score_gemma":0.0028160037,"teacher_disagreement_score":0.0022691835,"about_ca_system_score_codex":0.00039835888,"about_ca_system_score_gemma":0.00040192777,"threshold_uncertainty_score":0.007591188},"labels":[],"label_agreement":null},{"id":"W2944436740","doi":"10.1158/1538-7445.sabcs18-ot2-07-03","title":"Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Trastuzumab emtansine; Taxane; Internal medicine; Metastatic breast cancer; Oncology; Antibody-drug conjugate; Population; Breast cancer; Cancer; Antibody; Immunology; Monoclonal antibody","score_opus":0.061201817016351676,"score_gpt":0.4287969098125477,"score_spread":0.367595092796196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944436740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98669076,0.0027652055,0.0005466806,0.0011017952,0.0006826434,0.0032433819,0.0017788111,0.00013717693,0.0030535206],"genre_scores_gemma":[0.9838898,0.0017646984,0.0012317002,0.0018636193,0.0007723533,0.0032291112,0.0017573299,0.000040093335,0.0054513495],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992169,0.00041823558,0.00004225345,0.0001261183,0.000066858396,0.00012963817],"domain_scores_gemma":[0.9988888,0.00027992757,0.00021810619,0.00008670801,0.00006490997,0.0004615221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00198188,0.0019148134,0.0023674301,0.00043666892,0.00040997585,0.0015320494,0.0010303417,0.0019077483,0.00950832],"category_scores_gemma":[0.0014326022,0.00071730517,0.0022869033,0.00050636724,0.0013978973,0.0013154787,0.000427224,0.004238696,0.0020372053],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97883976,0.008919281,0.0003824619,0.00018581259,0.00049160834,0.000026430547,0.00002415406,0.00015613926,0.002195716,0.000077958364,0.0008437899,0.007856853],"study_design_scores_gemma":[0.90328157,0.09381187,0.0011781172,0.000017869363,0.00040868853,0.0000237441,0.000016726659,0.00030421405,0.0003440892,0.00014124288,0.0004614969,0.000010506019],"about_ca_topic_score_codex":0.0009801544,"about_ca_topic_score_gemma":0.0019528852,"teacher_disagreement_score":0.00950832,"about_ca_system_score_codex":0.0010869369,"about_ca_system_score_gemma":0.0013756342,"threshold_uncertainty_score":0.031808496},"labels":[],"label_agreement":null},{"id":"W2944662988","doi":"10.1093/jncics/pkz033","title":"Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"JNCI Cancer Spectrum","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Hazard ratio; Oncology; Breast cancer; Cardiotoxicity; Odds ratio; Confidence interval; Heart failure; Estrogen receptor; Subgroup analysis; Cancer; Chemotherapy","score_opus":0.13459750571490264,"score_gpt":0.4460231361980427,"score_spread":0.31142563048314004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944662988","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021090538,0.9970702,0.00022240925,0.00010400151,0.000078918594,0.00009334201,0.00017925331,0.000010162503,0.00013269244],"genre_scores_gemma":[0.08357146,0.9134347,0.00086320454,0.0007650599,0.00021213292,0.00042483813,0.0004524057,0.000019632069,0.00025652593],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9951332,0.0022430043,0.0013954951,0.0004787109,0.00057142496,0.00017806234],"domain_scores_gemma":[0.9887611,0.007904625,0.0019861537,0.00029381693,0.0008835219,0.00017073848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00992564,0.0024781935,0.017152488,0.0054658493,0.00040169485,0.0027007961,0.0017583133,0.0015769851,0.0035487912],"category_scores_gemma":[0.0168329,0.0009091777,0.026487505,0.007053281,0.000553897,0.001316702,0.0012046845,0.0012949809,0.00029376496],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027327284,0.000035590107,0.0022702783,0.49014968,0.48124105,0.00013204539,0.0000613202,0.00056204695,0.00033480217,0.00016771774,0.00083746976,0.021475252],"study_design_scores_gemma":[0.00062027277,0.00019015004,0.0029448923,0.02896299,0.9641926,0.00008900635,0.000030934047,0.00014457798,0.00013069407,0.00021806902,0.0024564383,0.000019289695],"about_ca_topic_score_codex":0.0035856583,"about_ca_topic_score_gemma":0.008296383,"teacher_disagreement_score":0.017152488,"about_ca_system_score_codex":0.0019664443,"about_ca_system_score_gemma":0.0021348943,"threshold_uncertainty_score":0.05249238},"labels":[],"label_agreement":null},{"id":"W2944776474","doi":"10.1158/1538-7445.sabcs18-ot3-04-02","title":"Abstract OT3-04-02: Neoadjuvant Her2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Pertuzumab; Regimen; Lapatinib; Taxane; Blockade; Metastatic breast cancer; Neoadjuvant therapy; Cancer; Immunotherapy; Receptor","score_opus":0.17144214421042142,"score_gpt":0.5137250226387211,"score_spread":0.3422828784282997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944776474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743469,0.0044082976,0.0010145878,0.001636483,0.0005602905,0.0103065865,0.0034656061,0.00026320812,0.003998078],"genre_scores_gemma":[0.9710307,0.0025759568,0.0026074785,0.0026028526,0.00068465783,0.010397909,0.0036335094,0.00004752166,0.0064193658],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994937,0.00025977902,0.000030528154,0.000079715755,0.00004078637,0.00009551515],"domain_scores_gemma":[0.9994248,0.00009689537,0.00010671662,0.00005732009,0.00003854481,0.0002755986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018835076,0.0016137663,0.0019292231,0.00029905385,0.00047093618,0.0012049307,0.0008202994,0.0017250321,0.0073074293],"category_scores_gemma":[0.0007389164,0.00055313885,0.0014557164,0.00040405412,0.0013602911,0.0011323511,0.0003781612,0.0027429902,0.0014122826],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9618412,0.013314636,0.0009071255,0.00041033793,0.00042338326,0.000057389472,0.000034414723,0.00023773419,0.0044009173,0.00013375201,0.0018316759,0.016407486],"study_design_scores_gemma":[0.9085146,0.08803991,0.0012153261,0.00003105466,0.0002210858,0.000044612218,0.000013710161,0.00028636423,0.0004723379,0.00014589416,0.0010064186,0.00000868036],"about_ca_topic_score_codex":0.0007055202,"about_ca_topic_score_gemma":0.0013273978,"teacher_disagreement_score":0.0073074293,"about_ca_system_score_codex":0.00086944865,"about_ca_system_score_gemma":0.0013714391,"threshold_uncertainty_score":0.024445832},"labels":[],"label_agreement":null},{"id":"W2944967705","doi":"10.1097/pai.0000000000000773","title":"Chromogenic and Silver in Situ Hybridization for Identification of HER 2 Overexpression in Breast Cancer Patients: A Systematic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Confidence interval; Medicine; Meta-analysis; Concordance; Oncology; Breast cancer; Internal medicine; Cancer; In situ hybridization; Biology; Genetics","score_opus":0.03241972078852673,"score_gpt":0.3696589229634074,"score_spread":0.3372392021748807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944967705","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030339158,0.9952454,0.00039798455,0.00016561158,0.00009672095,0.0002496169,0.0006024703,0.000015841688,0.0001924401],"genre_scores_gemma":[0.103527255,0.89034384,0.0025128748,0.0008548444,0.00025826885,0.0013863248,0.0008817396,0.000023968989,0.00021080936],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98648584,0.0065800403,0.003853537,0.0012709508,0.0014841647,0.00032539768],"domain_scores_gemma":[0.9540814,0.036287617,0.0061114356,0.00087878696,0.0023910222,0.00024970828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018132528,0.0022346538,0.01565984,0.009073373,0.00058916135,0.0026831706,0.0019439574,0.0016913419,0.0034659903],"category_scores_gemma":[0.05180466,0.001230288,0.024173234,0.010542493,0.0009145191,0.0016144648,0.0011655305,0.0009827071,0.00030532535],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091863354,0.000015304324,0.005295511,0.73836464,0.23847023,0.00012162989,0.000095050775,0.00036893904,0.00021629423,0.00013820457,0.0008369359,0.015158638],"study_design_scores_gemma":[0.0005195489,0.00024167883,0.008053011,0.13585974,0.8514925,0.00023071934,0.000073693474,0.00021572762,0.0001808595,0.000265411,0.0028296686,0.000037489735],"about_ca_topic_score_codex":0.006476762,"about_ca_topic_score_gemma":0.016096983,"teacher_disagreement_score":0.018132528,"about_ca_system_score_codex":0.0027899607,"about_ca_system_score_gemma":0.004119598,"threshold_uncertainty_score":0.09589511},"labels":[],"label_agreement":null},{"id":"W2945268366","doi":"10.1093/annonc/mdz100.045","title":"Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 for HER2-positive breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Pertuzumab; Metastatic breast cancer; Oncology; Clinical endpoint; Breast cancer; Taxane; Population; Antibody-drug conjugate; Phases of clinical research; Cancer; Clinical trial; Immunology; Antibody","score_opus":0.12893878878310253,"score_gpt":0.5177291619702629,"score_spread":0.38879037318716037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945268366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909161,0.0023702225,0.00049169554,0.0007428716,0.00025095564,0.0010851566,0.0013329209,0.000118794065,0.0026913765],"genre_scores_gemma":[0.9868989,0.00248811,0.0012098755,0.0009029975,0.00020111968,0.00114934,0.0022519063,0.000063793945,0.0048338464],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99968445,0.00013831751,0.000011860991,0.00006010322,0.000021283673,0.00008393479],"domain_scores_gemma":[0.9994349,0.00010719179,0.00008647918,0.000052550105,0.000026558004,0.00029223348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011468049,0.0013453894,0.0019180138,0.00041234307,0.0004177243,0.0013164957,0.0011610874,0.0013169785,0.0046134987],"category_scores_gemma":[0.0008126368,0.00066644565,0.0011937249,0.00042334225,0.0010028888,0.0009218604,0.00031092545,0.0032893894,0.0013903447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8017761,0.056460235,0.003615913,0.0005418167,0.0015897579,0.00023054212,0.00025860252,0.0049804156,0.039844844,0.0006515512,0.0045318017,0.08551843],"study_design_scores_gemma":[0.6277555,0.3514642,0.007980622,0.000043163436,0.0006819718,0.00027285438,0.000100479716,0.002408547,0.0048358114,0.00039563558,0.0040221736,0.000039017643],"about_ca_topic_score_codex":0.0028592532,"about_ca_topic_score_gemma":0.006085878,"teacher_disagreement_score":0.0046134987,"about_ca_system_score_codex":0.0014570742,"about_ca_system_score_gemma":0.0017833886,"threshold_uncertainty_score":0.015433669},"labels":[],"label_agreement":null},{"id":"W2947440045","doi":"10.1200/jco.2019.37.15_suppl.554","title":"Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Exome sequencing; Internal medicine; Cancer; Digital polymerase chain reaction; Copy number analysis; Exome; Chemotherapy; Population; Cohort; Mutation; Copy-number variation; Genetics; Gene; Genome; Biology; Polymerase chain reaction","score_opus":0.046394274262798976,"score_gpt":0.45771201654683535,"score_spread":0.4113177422840364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947440045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99919206,0.000098945704,0.000042479016,0.000027025446,0.0000016314555,0.000003887315,0.00044296545,0.0000020824725,0.00018893045],"genre_scores_gemma":[0.99837863,0.00010029553,0.00012246454,0.000052568164,0.0000037499779,0.000009626905,0.0009623826,0.0000031449379,0.0003670035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999386,0.0000103118355,0.0000031244542,0.000021201293,0.000008472971,0.000018268118],"domain_scores_gemma":[0.99988663,0.00002745037,0.000040517825,0.0000049980686,0.000012288231,0.000028048351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008224855,0.000091835245,0.00015641935,0.0002615514,0.00018853841,0.00018901918,0.00007484166,0.0002204205,0.0011226343],"category_scores_gemma":[0.00039457073,0.00007327308,0.00014276744,0.00034788664,0.000079463745,0.00008123143,0.00014468831,0.00013014495,0.00018784076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011863967,0.0000804288,0.9529995,0.000041365714,0.000051664854,0.0017666211,0.0005554856,0.00018677032,0.03184044,0.00005968986,0.00057738007,0.010654211],"study_design_scores_gemma":[0.0000044539,0.00013729534,0.99789494,0.0000023176976,0.00001328699,0.00086876587,0.0001411522,0.000098119905,0.0004137512,0.00002028197,0.00040382106,0.0000017868034],"about_ca_topic_score_codex":0.0040188674,"about_ca_topic_score_gemma":0.0032789302,"teacher_disagreement_score":0.0040188674,"about_ca_system_score_codex":0.00018924172,"about_ca_system_score_gemma":0.00012600163,"threshold_uncertainty_score":0.007990956},"labels":[],"label_agreement":null},{"id":"W2947469974","doi":"10.1200/jco.2019.37.15_suppl.500","title":"Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Internal medicine; Oncology; Trastuzumab emtansine; Taxane; Docetaxel; Breast cancer; Regimen; Chemotherapy; Carboplatin; Cancer; Cisplatin","score_opus":0.17629281528993362,"score_gpt":0.5137821301172162,"score_spread":0.33748931482728256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947469974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950688,0.002874717,0.00016693243,0.00019505326,0.00004805362,0.00031470618,0.0004077091,0.000015589603,0.00090847444],"genre_scores_gemma":[0.9950342,0.0017480812,0.0005006816,0.00029930996,0.000085090134,0.00031125834,0.00088293536,0.000008732669,0.0011296669],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99946564,0.00030285187,0.00003985925,0.00007128022,0.00005360401,0.00006670993],"domain_scores_gemma":[0.9991326,0.00022860031,0.00028574385,0.00006832738,0.000040708423,0.00024404912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013970141,0.00065395044,0.0010336338,0.00021865008,0.00022117965,0.00062708376,0.00063864555,0.0006749868,0.0017929809],"category_scores_gemma":[0.0010530184,0.0002925422,0.0011127663,0.0002858325,0.00048687105,0.0005988634,0.00027785343,0.0015098692,0.00027786032],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9131187,0.011827884,0.0076047215,0.00054718344,0.0019866037,0.000059484264,0.00011419229,0.0016010613,0.0076441607,0.0001029116,0.0012984327,0.054094724],"study_design_scores_gemma":[0.4510457,0.4870785,0.043915965,0.00013622594,0.0052540596,0.0003292261,0.00014704638,0.0017489855,0.006612164,0.00023986318,0.0034371533,0.000055097287],"about_ca_topic_score_codex":0.0011566939,"about_ca_topic_score_gemma":0.0055540134,"teacher_disagreement_score":0.0017929809,"about_ca_system_score_codex":0.0011407781,"about_ca_system_score_gemma":0.0010409807,"threshold_uncertainty_score":0.008276939},"labels":[],"label_agreement":null},{"id":"W2948116664","doi":"10.1177/1078155219850299","title":"Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario","year":2019,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Ontario Institute for Cancer Research; Public Health Ontario; Institute for Clinical Evaluative Sciences; Alberta Bone and Joint Health Institute; University of Calgary; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre; Hospital for Sick Children; Cancer Care Ontario; McMaster University; St. Joseph’s Healthcare Hamilton; Canadian Centre for Applied Research in Cancer Control","funders":"Ontario Institute for Cancer Research; Ontario Ministry of Health and Long-Term Care","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Epidermal growth factor receptor; Immunohistochemistry; Gynecology","score_opus":0.31022023476033067,"score_gpt":0.5294626497073359,"score_spread":0.21924241494700525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948116664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947465,0.00045283925,0.00009396967,0.00064840744,0.000011909523,0.0000449246,0.0017091767,0.000007284979,0.0022849303],"genre_scores_gemma":[0.99838614,0.00027794953,0.00009139547,0.00009249169,0.0000069544294,0.000020129892,0.0005974783,0.0000028599366,0.0005246481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837,0.00015198051,0.0001410911,0.00019683522,0.0006410908,0.00049906166],"domain_scores_gemma":[0.99425405,0.00041269083,0.0026679586,0.00014833579,0.0015444214,0.0009726036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007034678,0.00017843592,0.00024936348,0.0007291753,0.0013658922,0.00081469887,0.00082165207,0.0002783195,0.0016357594],"category_scores_gemma":[0.0051832474,0.00031642092,0.0004069748,0.0023576904,0.00055479154,0.00031822425,0.0008325331,0.00032943903,0.00010461259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004103654,0.000018133604,0.99557143,0.00002431476,0.000022877726,0.000086497465,0.0005608186,0.00008165832,0.000104332685,0.000051997587,0.0006443905,0.0027924601],"study_design_scores_gemma":[0.000007107385,0.000013978617,0.9987417,0.000014850716,0.00000920257,0.00003795755,0.00031836098,0.00014390849,0.00002521253,0.000009937236,0.0006738657,0.0000038652793],"about_ca_topic_score_codex":0.9832722,"about_ca_topic_score_gemma":0.9862109,"teacher_disagreement_score":0.9832722,"about_ca_system_score_codex":0.021844374,"about_ca_system_score_gemma":0.030315818,"threshold_uncertainty_score":0.15849274},"labels":[],"label_agreement":null},{"id":"W2948405934","doi":"10.1200/jco.19.00882","title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Pertuzumab; Medicine; Trastuzumab emtansine; Internal medicine; Hazard ratio; Trastuzumab; Oncology; Breast cancer; Docetaxel; Adverse effect; Cancer; Surgery; Confidence interval","score_opus":0.1404453096150034,"score_gpt":0.5111550693327782,"score_spread":0.3707097597177748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948405934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405515,0.003564417,0.00020818062,0.00018670714,0.00004056974,0.00028914044,0.0007729915,0.000013982498,0.00086880685],"genre_scores_gemma":[0.9931398,0.0022343865,0.00038494542,0.00039901116,0.00009314045,0.0003541187,0.0025332246,0.000009348596,0.000852122],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99920756,0.00046353554,0.000050002764,0.000078172256,0.000116838004,0.00008385299],"domain_scores_gemma":[0.99888164,0.00021820718,0.00039886043,0.000118045915,0.00006957082,0.00031365696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002409769,0.00057890144,0.0011840177,0.00019472306,0.00025997072,0.00072284567,0.00043300446,0.0006046284,0.0008020871],"category_scores_gemma":[0.0012149509,0.00022281817,0.0014762804,0.00028498736,0.0004054499,0.0005106172,0.00036544347,0.001105325,0.00016948492],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78944194,0.015189835,0.071544625,0.0010005442,0.006278976,0.00024710144,0.00027759493,0.0044721663,0.01048358,0.00024457503,0.004728026,0.096091054],"study_design_scores_gemma":[0.33931106,0.3024053,0.32970127,0.00024840402,0.0090170335,0.0008636037,0.00029279335,0.003599746,0.0054085716,0.00043614558,0.008601124,0.00011496852],"about_ca_topic_score_codex":0.0011380657,"about_ca_topic_score_gemma":0.0035286292,"teacher_disagreement_score":0.002409769,"about_ca_system_score_codex":0.0006713197,"about_ca_system_score_gemma":0.00078685576,"threshold_uncertainty_score":0.012744248},"labels":[],"label_agreement":null},{"id":"W2948726637","doi":"10.1016/s0140-6736(19)30650-6","title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research; University of Warwick; Cancer Research UK; University of Cambridge; Department of Health and Social Care","keywords":"Medicine; Trastuzumab; Breast cancer; Clinical endpoint; Internal medicine; Intention-to-treat analysis; Surgery; Randomized controlled trial; Clinical trial; Chemotherapy; Adjuvant; Cancer; Oncology","score_opus":0.05371163214208088,"score_gpt":0.3732203289132454,"score_spread":0.31950869677116456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948726637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877743,0.0049848654,0.0005601247,0.000715517,0.00038900186,0.0030882224,0.0006676619,0.000058834936,0.0017614613],"genre_scores_gemma":[0.98358387,0.0029889722,0.001552822,0.0013963294,0.0005551768,0.005448194,0.0008209709,0.000033647862,0.0036200937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99814856,0.0013286098,0.00009070165,0.00017826224,0.000086142725,0.00016779648],"domain_scores_gemma":[0.9974833,0.0010685426,0.0006819596,0.00020045867,0.00009801025,0.0004677502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004834649,0.001482618,0.0022170204,0.00041072047,0.00033348758,0.00087895355,0.0007725456,0.0020752125,0.007191629],"category_scores_gemma":[0.0041647726,0.00047528153,0.0026193634,0.00036022498,0.0011957985,0.0011399199,0.00043970565,0.0022497014,0.00086042087],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98739153,0.002852875,0.00028936614,0.00030166638,0.00044777343,0.000022664453,0.00004061605,0.00019407866,0.00088103145,0.000042921074,0.0002544478,0.0072810953],"study_design_scores_gemma":[0.9508998,0.046781246,0.0012414589,0.000036860976,0.0003186125,0.000024285417,0.000010892426,0.00018009763,0.00015137937,0.00011591351,0.00022994012,0.000009598333],"about_ca_topic_score_codex":0.00048685903,"about_ca_topic_score_gemma":0.0009970089,"teacher_disagreement_score":0.007191629,"about_ca_system_score_codex":0.00069142453,"about_ca_system_score_gemma":0.0009132443,"threshold_uncertainty_score":0.025568366},"labels":[],"label_agreement":null},{"id":"W2949261725","doi":"10.1089/bio.2019.0039","title":"The Importance of Human Tissue Bioresources in Advancing Biomedical Research","year":2019,"lang":"en","type":"article","venue":"Biopreservation and Biobanking","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Personalized medicine; Precision medicine; Medicine; Biotechnology; Business; Computational biology; Bioinformatics; Pathology; Biology","score_opus":0.08483540331221695,"score_gpt":0.4416111439184968,"score_spread":0.35677574060627987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949261725","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03961085,0.24126393,0.5634807,0.040189363,0.010249616,0.0022121,0.004061305,0.001741055,0.09719105],"genre_scores_gemma":[0.22684784,0.1952194,0.52094704,0.01614383,0.005398644,0.002675093,0.005551161,0.0009181004,0.026298812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916899,0.004659387,0.00057903666,0.00064780295,0.002202365,0.00022137731],"domain_scores_gemma":[0.9855515,0.0052600848,0.0015710205,0.003378734,0.003333354,0.00090532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019830393,0.0006360354,0.0008316245,0.002806078,0.0008148452,0.0050021326,0.00136757,0.001902408,0.0095515195],"category_scores_gemma":[0.014847062,0.00047655177,0.0007420368,0.0023573863,0.0027601295,0.003308115,0.003167558,0.00284828,0.0061283545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010857309,0.0004304918,0.008029763,0.0037736055,0.00013324738,0.0013975055,0.0013719794,0.0024578176,0.17615773,0.10599169,0.028128948,0.6710415],"study_design_scores_gemma":[0.00009227758,0.0008085595,0.005788771,0.0018125656,0.00009528545,0.0031482233,0.0010002566,0.0008639605,0.0723595,0.038874824,0.87505263,0.00010308691],"about_ca_topic_score_codex":0.0009888004,"about_ca_topic_score_gemma":0.0014437209,"teacher_disagreement_score":0.019830393,"about_ca_system_score_codex":0.0011612655,"about_ca_system_score_gemma":0.0026538556,"threshold_uncertainty_score":0.10487437},"labels":[],"label_agreement":null},{"id":"W2949384952","doi":"10.1158/0008-5472.can-19-0989","title":"A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy","year":2019,"lang":"en","type":"review","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Tribute; Cancer; Cancer therapy; Medicine; Art; Internal medicine; Art history","score_opus":0.522667861932053,"score_gpt":0.6135850359263461,"score_spread":0.09091717399429311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949384952","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00077811454,0.062969364,0.0019841918,0.73002046,0.18618247,0.000040119678,0.00006409095,0.0001834641,0.017777728],"genre_scores_gemma":[0.02929777,0.09914511,0.0061083077,0.49080446,0.1654268,0.00012190417,0.00014321119,0.0004891378,0.2084633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99432856,0.0014650094,0.00023240385,0.0008123741,0.00267669,0.0004849393],"domain_scores_gemma":[0.98815304,0.002503964,0.0004014881,0.00040450023,0.003436044,0.0051009883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006026577,0.00081561034,0.0010078552,0.0013087551,0.0029444431,0.0065747336,0.0015370694,0.0045130583,0.010759187],"category_scores_gemma":[0.014182788,0.000375698,0.0006342899,0.00059261563,0.003996594,0.0036471684,0.002135956,0.015097636,0.0059504174],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023575529,0.000022151808,0.00013801298,0.00006153204,0.0000082171755,0.00024349695,0.00016894437,0.000028010652,0.0002748092,0.0065163537,0.9699775,0.02253733],"study_design_scores_gemma":[0.000012271917,0.0000327009,0.00012846205,0.0001853438,0.0000061248643,0.0010352529,0.0001750703,0.00005757052,0.00029399252,0.003332851,0.9947239,0.000016593312],"about_ca_topic_score_codex":0.002865323,"about_ca_topic_score_gemma":0.004788861,"teacher_disagreement_score":0.010759187,"about_ca_system_score_codex":0.0032499463,"about_ca_system_score_gemma":0.0058700475,"threshold_uncertainty_score":0.03599304},"labels":[],"label_agreement":null},{"id":"W2952744834","doi":"","title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update","year":2018,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Clinical Oncology; Guideline; Medicine; Human Epidermal Growth Factor Receptor 2; Breast cancer; Oncology; Internal medicine; Clinical Practice; Cancer; Gynecology; Pathology; Family medicine","score_opus":0.22644169620457952,"score_gpt":0.548833630365114,"score_spread":0.32239193416053447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952744834","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008475681,0.45889485,0.011836587,0.2915009,0.029084418,0.0029289115,0.032298345,0.0020526205,0.16292761],"genre_scores_gemma":[0.048129976,0.621957,0.044085376,0.18424895,0.017354438,0.0025922584,0.05367147,0.00048586493,0.02747472],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99650913,0.0011378975,0.0007022823,0.00017064794,0.0012854259,0.00019449077],"domain_scores_gemma":[0.9893415,0.00230733,0.001249403,0.0002502104,0.0062966747,0.00055486406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034696485,0.0008307105,0.0010000198,0.00274086,0.0004988059,0.0013356666,0.002032684,0.0027179695,0.005538444],"category_scores_gemma":[0.015285038,0.000339466,0.0012115003,0.0027919302,0.0005135782,0.0013266033,0.0013594637,0.0030764313,0.005095062],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038768583,0.000053873024,0.0017452087,0.0011902129,0.000052822856,0.00011869921,0.000037569065,0.00019068104,0.00029550667,0.00060156867,0.8419444,0.1537307],"study_design_scores_gemma":[0.00017514644,0.00010916207,0.011839762,0.010126337,0.00031603908,0.0018314067,0.000163013,0.0005060221,0.0006271446,0.0020013305,0.97225225,0.00005244026],"about_ca_topic_score_codex":0.013038427,"about_ca_topic_score_gemma":0.03030092,"teacher_disagreement_score":0.013038427,"about_ca_system_score_codex":0.0014454825,"about_ca_system_score_gemma":0.0039944877,"threshold_uncertainty_score":0.02592504},"labels":[],"label_agreement":null},{"id":"W2953389360","doi":"10.1016/j.pneurobio.2019.101643","title":"Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair","year":2019,"lang":"en","type":"review","venue":"Progress in Neurobiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Multiple Sclerosis Society of Canada","keywords":"Neuregulin; ErbB; Neuroscience; Neuregulin 1; Biology; Nervous system; Receptor tyrosine kinase; Remyelination; Central nervous system; Signal transduction; Myelin; Cell biology","score_opus":0.10506675705289172,"score_gpt":0.44379408326948694,"score_spread":0.33872732621659524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953389360","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013204236,0.99830073,0.000112569534,0.00040758186,0.00023390644,0.000001941719,0.000021556105,0.000007429065,0.00078238675],"genre_scores_gemma":[0.00074585865,0.99814546,0.00011988302,0.00022174766,0.00019785133,0.000002888218,0.000023804156,7.833844e-7,0.0005418357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999162,0.000012147953,0.000009503219,0.000017384371,0.00003114245,0.000013560554],"domain_scores_gemma":[0.99986446,0.000052517174,0.000024304582,0.0000034957882,0.00003361557,0.000021551792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042486115,0.0007639265,0.0009389723,0.0012423748,0.00017012625,0.00096533867,0.0005886104,0.0009030255,0.0032717227],"category_scores_gemma":[0.00042881485,0.00015219011,0.00022928187,0.0015038284,0.00041674665,0.0011547914,0.00062497903,0.0014056908,0.0015237043],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013108998,0.000048986803,0.00027428404,0.009106073,0.00008050712,0.0002593345,0.00004055571,0.00043602294,0.0033848458,0.006450678,0.040956482,0.9388311],"study_design_scores_gemma":[0.000027234611,0.00009466497,0.0009237149,0.0019045918,0.00013223694,0.0008066148,0.00007201965,0.00016644351,0.0006593593,0.002991331,0.99220544,0.000016247539],"about_ca_topic_score_codex":0.0007572659,"about_ca_topic_score_gemma":0.0021692014,"teacher_disagreement_score":0.0032717227,"about_ca_system_score_codex":0.0006252862,"about_ca_system_score_gemma":0.0009930619,"threshold_uncertainty_score":0.010945022},"labels":[],"label_agreement":null},{"id":"W2954367118","doi":"10.1158/1538-7445.am2019-218","title":"Abstract 218: AVID100 is an anti-EGFR ADC that promotes DM1-meditated cytotoxicity on cancer cells but not on normal cells","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Cytotoxicity; Cancer research; Epidermal growth factor receptor; EGFR inhibitors; Cytotoxic T cell; Antibody-drug conjugate; Cancer cell; Chemistry; Antibody; Cancer; In vivo; Cell culture; In vitro; Biology; Receptor; Monoclonal antibody; Immunology; Medicine; Internal medicine; Biochemistry","score_opus":0.1687449514968752,"score_gpt":0.4478875337279058,"score_spread":0.2791425822310306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954367118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844155,0.0020812098,0.0046016388,0.0002467622,0.00008269362,0.00005688916,0.00043839624,0.00022679142,0.007850056],"genre_scores_gemma":[0.9895012,0.00072566175,0.0018420871,0.00010465995,0.000012475185,0.000024264447,0.00067372905,0.000023959905,0.007091923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999138,0.000009464522,0.0000051297643,0.000016760763,0.00003356268,0.00002126662],"domain_scores_gemma":[0.99995553,0.000010410764,0.000007208946,0.000006918068,0.00001052565,0.0000095017895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007439799,0.00030519586,0.00023237932,0.00016143493,0.00009405428,0.00024402846,0.00024030628,0.00042344615,0.003239635],"category_scores_gemma":[0.00008803589,0.00011142112,0.00016902045,0.00014735447,0.00013670941,0.00015633795,0.00013583867,0.0005419243,0.00078023365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020933665,0.0000843545,0.00013578462,0.000060884664,0.000006409257,0.000092303475,0.000009973282,0.00020383531,0.99325126,0.00012956846,0.00029344053,0.005522916],"study_design_scores_gemma":[0.00003247182,0.00037873306,0.000754811,0.0000032380576,0.0000084957555,0.00021138575,0.0000036952033,0.0010009792,0.9950631,0.000020213827,0.002520803,0.0000019787472],"about_ca_topic_score_codex":0.0005386583,"about_ca_topic_score_gemma":0.000567254,"teacher_disagreement_score":0.003239635,"about_ca_system_score_codex":0.00033240393,"about_ca_system_score_gemma":0.00018262083,"threshold_uncertainty_score":0.010837674},"labels":[],"label_agreement":null},{"id":"W2963723783","doi":"10.1136/esmoopen-2019-000532","title":"A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Carboplatin; Paclitaxel; Lung cancer; Medicine; Oncology; Internal medicine; Cancer research; Chemotherapy; Cisplatin","score_opus":0.02520585020919555,"score_gpt":0.3661034264544797,"score_spread":0.34089757624528416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963723783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950295,0.0018210639,0.0003695657,0.00017592908,0.000060827708,0.0015010152,0.00026897455,0.000053048392,0.0007201159],"genre_scores_gemma":[0.99346393,0.0014331092,0.0011047679,0.00040387365,0.00010331433,0.0011406554,0.0010054107,0.000021065922,0.0013239186],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996824,0.00015962693,0.000016150725,0.000052394367,0.000025451243,0.00006383655],"domain_scores_gemma":[0.99965477,0.000046006546,0.00006758378,0.000029713463,0.000021476351,0.00018044494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010306337,0.0010105617,0.001894337,0.0003669259,0.0003484089,0.00080783566,0.0007081429,0.00094330235,0.0024540701],"category_scores_gemma":[0.0005484262,0.00044770062,0.0010040494,0.00035621863,0.00078266533,0.00052675966,0.0002232509,0.001869268,0.0005330505],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62860847,0.096536905,0.013417447,0.0014092491,0.0018047844,0.00054505095,0.00044331938,0.0030477673,0.12971486,0.00020588996,0.0023499853,0.1219164],"study_design_scores_gemma":[0.43999928,0.5283896,0.01685028,0.000041815714,0.00069355074,0.000529649,0.000080178776,0.0013013604,0.009919502,0.000094276395,0.0020756205,0.000024796263],"about_ca_topic_score_codex":0.0007724506,"about_ca_topic_score_gemma":0.0025941422,"teacher_disagreement_score":0.0024540701,"about_ca_system_score_codex":0.0008067556,"about_ca_system_score_gemma":0.0012583121,"threshold_uncertainty_score":0.008209705},"labels":[],"label_agreement":null},{"id":"W2966607539","doi":"10.14740/cr888","title":"Trastuzumab-Induced Cardiomyopathy and Intermittent Left Bundle Branch Block","year":2019,"lang":"en","type":"article","venue":"Cardiology Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Asymptomatic; Cardiology; Internal medicine; Left bundle branch block; Cardiomyopathy; Breast cancer; Bundle branch block; Heart failure; Cancer; Electrocardiography","score_opus":0.09741754072748693,"score_gpt":0.4148566247322922,"score_spread":0.31743908400480525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966607539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836257,0.00480152,0.0011582985,0.0020257805,0.00020967308,0.000059625887,0.00014477552,0.00007730924,0.007897268],"genre_scores_gemma":[0.9974819,0.0006689684,0.000150833,0.00047081045,0.00026202286,0.000005926417,0.000057242378,0.000006104788,0.00089627627],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997843,0.000023901088,0.000019960184,0.000054948152,0.000029415667,0.00008754001],"domain_scores_gemma":[0.9991542,0.00028758912,0.00024560592,0.000045179422,0.00004725394,0.00022007577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016218617,0.0005301034,0.0005036528,0.00064346084,0.0006171006,0.00049004366,0.0003937696,0.0013983226,0.001359087],"category_scores_gemma":[0.001504948,0.000239116,0.00040883155,0.00047179346,0.00043226997,0.0005265438,0.00036884082,0.0013702334,0.0003478152],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004735829,0.00003121898,0.019563332,0.000021118722,0.000007476731,0.9766802,0.00011098901,0.00006200795,0.0012589182,0.00012994022,0.00022141004,0.0018659786],"study_design_scores_gemma":[0.00001557467,0.00014737654,0.023341408,0.000015470912,0.000013023404,0.9749361,0.000064331754,0.00020268973,0.0004906217,0.00011024065,0.0006566972,0.000006337362],"about_ca_topic_score_codex":0.0008591768,"about_ca_topic_score_gemma":0.0009145217,"teacher_disagreement_score":0.0013983226,"about_ca_system_score_codex":0.0004787669,"about_ca_system_score_gemma":0.00027502727,"threshold_uncertainty_score":0.0045465827},"labels":[],"label_agreement":null},{"id":"W2968994994","doi":"10.1016/j.scr.2019.101538","title":"Prolactin hormone exerts anti-tumorigenic effects in HER-2 overexpressing breast cancer cells through regulation of stemness","year":2019,"lang":"en","type":"article","venue":"Stem Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Iran Nanotechnology Initiative Council; Consejo Nacional de Ciencia y Tecnología","keywords":"Biology; Prolactin; Hormone; Cancer research; Breast cancer; Cancer; Mammary gland; Internal medicine; Endocrinology; Genetics","score_opus":0.050077471872063586,"score_gpt":0.38531601513218466,"score_spread":0.3352385432601211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968994994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179804,0.0026137307,0.0017578361,0.00012041797,0.000018757144,0.00001754585,0.002043075,0.00021157687,0.001418999],"genre_scores_gemma":[0.9959835,0.00084592885,0.0008539497,0.00004401642,0.000005464962,0.000016647662,0.0016502303,0.0000110038,0.0005893273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992573,0.000011231678,0.0000062551035,0.000010638595,0.000030200881,0.000016042703],"domain_scores_gemma":[0.99991846,0.000019884032,0.000025812269,0.000008560689,0.000011259201,0.000015998692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010204302,0.0001673268,0.00018184361,0.00020963508,0.000084023835,0.00032814223,0.000085395186,0.00010721279,0.0009037494],"category_scores_gemma":[0.0001282358,0.00005980392,0.00022237754,0.00019815509,0.000082939834,0.00007634926,0.00012691772,0.00021423044,0.0002129515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003882665,0.000043040945,0.0043047634,0.00011777545,0.000024218012,0.00011932489,0.00002467133,0.00047122984,0.987229,0.000065777356,0.0002822009,0.00692969],"study_design_scores_gemma":[0.00008447035,0.0009866054,0.054462787,0.0000160263,0.00009141797,0.00052836334,0.00009920981,0.0038658706,0.9301396,0.0001144831,0.009594749,0.000016422116],"about_ca_topic_score_codex":0.0010429035,"about_ca_topic_score_gemma":0.0018028548,"teacher_disagreement_score":0.0010429035,"about_ca_system_score_codex":0.00019409876,"about_ca_system_score_gemma":0.00022464628,"threshold_uncertainty_score":0.003023386},"labels":[],"label_agreement":null},{"id":"W2969017474","doi":"10.1634/theoncologist.2019-0321","title":"A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Durvalumab; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Chemotherapy; Gastroenterology; Clinical trial; Nivolumab; Immunotherapy","score_opus":0.05384371908796651,"score_gpt":0.4257430872117402,"score_spread":0.37189936812377367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969017474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930012,0.0013261326,0.00021876284,0.00032866918,0.00009312079,0.0018930334,0.00069934106,0.00007715643,0.0023625172],"genre_scores_gemma":[0.9927255,0.0009440473,0.0008011548,0.00048733692,0.00012481312,0.0010920385,0.0016541248,0.000014729815,0.0021561845],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997125,0.00013072373,0.000013704348,0.000039212,0.000029543156,0.00007419488],"domain_scores_gemma":[0.9997254,0.00003217906,0.000035153716,0.00001902772,0.0000152092325,0.00017291865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008162417,0.0008008121,0.001364538,0.0002594752,0.0003059466,0.0005612214,0.00072026014,0.00060577545,0.002754938],"category_scores_gemma":[0.00039064055,0.00030094013,0.00046909117,0.00028551603,0.00048096429,0.0003045445,0.00025286232,0.0015493975,0.00057638285],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7198088,0.057478484,0.008352256,0.00073393213,0.00082188466,0.0005907738,0.00019426124,0.002560682,0.054408886,0.0004236566,0.0093792025,0.14524716],"study_design_scores_gemma":[0.63400954,0.3416829,0.0129252,0.000040004707,0.00029719603,0.00041247162,0.00003777202,0.0017519199,0.0046107885,0.0001666297,0.0040401085,0.000025503532],"about_ca_topic_score_codex":0.0020373943,"about_ca_topic_score_gemma":0.0063188476,"teacher_disagreement_score":0.002754938,"about_ca_system_score_codex":0.00088261854,"about_ca_system_score_gemma":0.0012960302,"threshold_uncertainty_score":0.00921613},"labels":[],"label_agreement":null},{"id":"W2969950347","doi":"10.1007/s10549-019-05398-3","title":"Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Georgetown University; GlaxoSmithKline; Breast Cancer Research Foundation","keywords":"Trastuzumab; Lapatinib; Medicine; Oncology; Internal medicine; Breast cancer; Chemotherapy; Estrogen receptor; Proportional hazards model; Neoadjuvant therapy; Cancer","score_opus":0.05395772915114432,"score_gpt":0.38805740147013806,"score_spread":0.33409967231899373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969950347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99910563,0.00044725265,0.00006421958,0.000061518236,0.000010991685,0.000074552234,0.000064965985,0.0000037887983,0.00016712092],"genre_scores_gemma":[0.99903286,0.00017350694,0.00014649035,0.000084072446,0.0000309516,0.00011976187,0.00021537596,0.0000014762787,0.00019560425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99920076,0.0005044064,0.0000397547,0.0000805898,0.000090250614,0.00008421128],"domain_scores_gemma":[0.9990669,0.0002648464,0.00026776982,0.00006582252,0.000036056448,0.0002986522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020161825,0.0004938083,0.0008300182,0.00025027836,0.00023022118,0.00046463494,0.00027209832,0.00046934455,0.001067376],"category_scores_gemma":[0.0013937007,0.0002994704,0.00078140106,0.00018733082,0.00049768004,0.00033610823,0.00027543138,0.0009542824,0.00011973905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88608307,0.0053853933,0.0627656,0.00022054127,0.0018475224,0.000070770104,0.00007896919,0.0015272995,0.006797959,0.000100880105,0.0006669978,0.03445495],"study_design_scores_gemma":[0.34545764,0.29688758,0.33739042,0.00010202503,0.0029308444,0.00051401433,0.0001333452,0.007446837,0.006579668,0.0006851665,0.0018176051,0.000054842363],"about_ca_topic_score_codex":0.00051027176,"about_ca_topic_score_gemma":0.0015897395,"teacher_disagreement_score":0.0020161825,"about_ca_system_score_codex":0.000673677,"about_ca_system_score_gemma":0.0010295827,"threshold_uncertainty_score":0.0106627345},"labels":[],"label_agreement":null},{"id":"W2978627448","doi":"10.1093/annonc/mdz268.096","title":"Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; University of British Columbia","funders":"","keywords":"Afatinib; Medicine; Oncology; Cancer research; Computational biology; Internal medicine; Cancer; Gefitinib","score_opus":0.1542739538545159,"score_gpt":0.4589318350192664,"score_spread":0.30465788116475045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978627448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5317135,0.3565318,0.016163561,0.030250862,0.0016593557,0.00026578875,0.0014435773,0.000820024,0.061151505],"genre_scores_gemma":[0.9120441,0.07012764,0.0049439506,0.0023711107,0.00036961108,0.00007766577,0.00074884266,0.000054337626,0.009262612],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998591,0.0000208183,0.000010311074,0.00002977872,0.00002953092,0.000050350674],"domain_scores_gemma":[0.9999186,0.000018148685,0.000019068166,0.0000064200985,0.000013625429,0.000024129582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003959783,0.00038417525,0.0009133753,0.00032466173,0.00024034984,0.0011902852,0.0005063518,0.00081995357,0.0029973767],"category_scores_gemma":[0.00025227715,0.00012702147,0.0005027477,0.0004519392,0.00031216847,0.00080987933,0.00044308687,0.0014063631,0.00095867435],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041978178,0.00068777095,0.0047737584,0.0010813462,0.0003181833,0.004132181,0.00022071927,0.00360708,0.16018394,0.01024346,0.02674335,0.78381044],"study_design_scores_gemma":[0.0059158513,0.012148718,0.020707035,0.0006055535,0.0013013668,0.07176425,0.00070933875,0.013047216,0.1389567,0.021178376,0.7133743,0.00029128476],"about_ca_topic_score_codex":0.00047735695,"about_ca_topic_score_gemma":0.0022739344,"teacher_disagreement_score":0.0029973767,"about_ca_system_score_codex":0.00073229015,"about_ca_system_score_gemma":0.00043102913,"threshold_uncertainty_score":0.01002717},"labels":[],"label_agreement":null},{"id":"W2978854127","doi":"10.1093/annonc/mdz394.008","title":"Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Veliparib; Medicine; Carboplatin; Paclitaxel; Oncology; Metastatic breast cancer; PARP inhibitor; Internal medicine; Breast cancer; Cancer; Chemotherapy; Cisplatin; Poly ADP ribose polymerase","score_opus":0.09477682576886066,"score_gpt":0.47934025473107505,"score_spread":0.3845634289622144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978854127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99004024,0.0024727432,0.00074686116,0.000606484,0.00021253625,0.002300012,0.0011024827,0.00016407073,0.002354711],"genre_scores_gemma":[0.9869898,0.0025121078,0.0018662001,0.0008158094,0.00016719865,0.0023937738,0.002128772,0.00008545577,0.0030408916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99950635,0.00021437078,0.000020445135,0.00008633983,0.000036062953,0.0001363219],"domain_scores_gemma":[0.99926656,0.00010673748,0.00009499215,0.00007917311,0.000036478043,0.00041613393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016889955,0.0013803862,0.002866889,0.0006222649,0.00066980417,0.001844107,0.0017651132,0.0015275148,0.0036206187],"category_scores_gemma":[0.00082608836,0.0007896334,0.0016125407,0.0007361956,0.0013938871,0.0010974804,0.00048966013,0.005141623,0.0012538389],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72874856,0.118108936,0.0036855105,0.0007119046,0.0021635357,0.00030719693,0.00040570632,0.006370673,0.03594006,0.0006277901,0.0052359616,0.09769425],"study_design_scores_gemma":[0.6339006,0.34843707,0.0064990474,0.000044697637,0.0006098493,0.00030614348,0.00012811004,0.0024496876,0.0038815727,0.00041124318,0.0032960065,0.000036080826],"about_ca_topic_score_codex":0.0032223586,"about_ca_topic_score_gemma":0.005775234,"teacher_disagreement_score":0.0036206187,"about_ca_system_score_codex":0.001555253,"about_ca_system_score_gemma":0.0025604775,"threshold_uncertainty_score":0.0121122},"labels":[],"label_agreement":null},{"id":"W2978938554","doi":"10.21873/anticanres.13727","title":"Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients","year":2019,"lang":"en","type":"article","venue":"Anticancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Internal medicine; Oncology; Pathological; Cohort; Human Epidermal Growth Factor Receptor 2; Cancer; HER2 negative; Gastroenterology; Pathology","score_opus":0.3407760826680046,"score_gpt":0.5048778119201074,"score_spread":0.1641017292521028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978938554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99932134,0.000083222294,0.000086418906,0.000017668493,0.000005850684,0.000037873782,0.00011562716,0.0000035348953,0.00032844348],"genre_scores_gemma":[0.99932754,0.000034269582,0.00019408211,0.00003720812,0.000011700988,0.00003791659,0.00020909627,0.0000012994825,0.00014698843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956423,0.00015736991,0.000031065938,0.00011076063,0.00007102539,0.00006549228],"domain_scores_gemma":[0.9988397,0.00032372924,0.00022300101,0.00009190812,0.0002652545,0.00025637168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073989056,0.0003246252,0.0002700599,0.00033380726,0.0003776192,0.0005067258,0.00017243193,0.00034684746,0.0010956116],"category_scores_gemma":[0.0021316917,0.00014734913,0.00017559718,0.0003195324,0.00022487924,0.00028114356,0.0002718841,0.00042829275,0.00034531215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049437927,0.000968655,0.979155,0.00002908632,0.00004848994,0.00046102732,0.00043180794,0.00011053644,0.005916268,0.000041047322,0.0002099198,0.0076844343],"study_design_scores_gemma":[0.00039615802,0.014631613,0.97523403,0.000015326312,0.00010242571,0.0021778336,0.0005261707,0.00081221526,0.004489677,0.000070159505,0.0015293519,0.0000150442565],"about_ca_topic_score_codex":0.0009427305,"about_ca_topic_score_gemma":0.0006258964,"teacher_disagreement_score":0.0010956116,"about_ca_system_score_codex":0.00038322582,"about_ca_system_score_gemma":0.00030404344,"threshold_uncertainty_score":0.0039129257},"labels":[],"label_agreement":null},{"id":"W2979515484","doi":"10.1634/theoncologist.2019-0446","title":"De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Hazard ratio; Internal medicine; Breast cancer; Pertuzumab; Clinical endpoint; Oncology; Proportional hazards model; Metastasis; Trastuzumab; Confidence interval; Cancer; Chemotherapy; Cancer registry; Progression-free survival; Clinical trial","score_opus":0.05891216506106133,"score_gpt":0.37614151386067546,"score_spread":0.3172293487996141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979515484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98892117,0.00038696633,0.00012700904,0.000110069566,0.000004537922,0.000030549512,0.0095565235,0.0000075094035,0.0008557492],"genre_scores_gemma":[0.9822,0.00032370753,0.00021951976,0.000107094624,0.00002308315,0.00010628765,0.016741883,0.000007563648,0.00027084464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991198,0.00020424575,0.00016392836,0.00024029244,0.00019100885,0.00008073019],"domain_scores_gemma":[0.996768,0.00063988025,0.0019790719,0.00019817273,0.00022637345,0.00018862655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013258713,0.00012934265,0.00033104976,0.0007798608,0.00023785833,0.00040398573,0.00033516987,0.0002389255,0.002147414],"category_scores_gemma":[0.0028667415,0.00013872724,0.00032910376,0.0014173142,0.00018082402,0.00047659993,0.0004749317,0.00032489334,0.000335167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043851617,0.00004113399,0.9960748,0.000031392057,0.00007211155,0.000055267014,0.000051297982,0.00007580194,0.00015079817,0.00004630724,0.0011083699,0.001854338],"study_design_scores_gemma":[0.000096683354,0.0001983006,0.99707067,0.00002534329,0.00010089468,0.00046764922,0.00012186981,0.0002718561,0.00014648371,0.000043235348,0.0014493108,0.0000076971655],"about_ca_topic_score_codex":0.0023752,"about_ca_topic_score_gemma":0.0047841296,"teacher_disagreement_score":0.0023752,"about_ca_system_score_codex":0.00036450164,"about_ca_system_score_gemma":0.00053783844,"threshold_uncertainty_score":0.00718379},"labels":[],"label_agreement":null},{"id":"W2981000307","doi":"10.1200/jgo.2019.5.suppl.110","title":"Afatinib as a novel potential treatment option for <i>NRG1</i> fusion-positive tumors.","year":2019,"lang":"en","type":"article","venue":"Journal of Global Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; University of British Columbia","funders":"","keywords":"Afatinib; Medicine; Oncology; KRAS; Internal medicine; Adenocarcinoma; Lung cancer; Epidermal growth factor receptor; Colorectal cancer; Cancer; Erlotinib","score_opus":0.02958158023751304,"score_gpt":0.4123533889199466,"score_spread":0.38277180868243355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981000307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8204191,0.11303521,0.0056290017,0.01291392,0.0004769235,0.00016262523,0.00096392754,0.0004247401,0.0459747],"genre_scores_gemma":[0.9803683,0.011664571,0.0018369382,0.0011927483,0.00017386035,0.000032535474,0.000709336,0.000016557886,0.004005114],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992573,0.000011899729,0.000010150246,0.000015090428,0.000015212715,0.000021864233],"domain_scores_gemma":[0.99993145,0.0000139481945,0.000019180816,0.0000055785144,0.000005553163,0.000024195198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001289171,0.00025651243,0.0002864567,0.00020134098,0.00024680095,0.0004441468,0.0002684447,0.0007041956,0.0025614493],"category_scores_gemma":[0.00016264085,0.000071944596,0.00031288358,0.0001956443,0.00023063907,0.00040191357,0.0001615472,0.000448546,0.0009090053],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005230834,0.0007065098,0.05129291,0.0016235622,0.00023994817,0.082058795,0.0003302363,0.0020138351,0.21926275,0.0040526297,0.025901783,0.60728616],"study_design_scores_gemma":[0.0014035463,0.006238671,0.05716774,0.00019023832,0.0002837753,0.5839066,0.000309545,0.0033035676,0.0704928,0.0027567353,0.27387884,0.00006801948],"about_ca_topic_score_codex":0.00025903474,"about_ca_topic_score_gemma":0.0011373649,"teacher_disagreement_score":0.0025614493,"about_ca_system_score_codex":0.0004372973,"about_ca_system_score_gemma":0.00017033855,"threshold_uncertainty_score":0.008568883},"labels":[],"label_agreement":null},{"id":"W2982402876","doi":"10.21873/anticanres.11701","title":"Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Anticancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Fondation du cancer du sein du Québec; Université Laval","keywords":"Concordance; Immunohistochemistry; Tissue microarray; Fluorescence in situ hybridization; Breast cancer; Pathology; In situ hybridization; Medicine; Cancer; Biology; Oncology; Internal medicine; Gene expression; Gene","score_opus":0.08115000927052714,"score_gpt":0.486531928542941,"score_spread":0.40538191927241385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982402876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550325,0.00074830954,0.0024172403,0.000059676746,0.000018387787,0.000031652457,0.00023575615,0.000028641163,0.0009570533],"genre_scores_gemma":[0.9983677,0.00010877393,0.0009907861,0.000019705385,0.0000083676105,0.00002552543,0.00025151335,0.000007414961,0.00022029338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940129,0.0023201038,0.0007823584,0.0012043848,0.0014104769,0.00026989085],"domain_scores_gemma":[0.9937524,0.0031377373,0.0010362882,0.00073331984,0.0012131588,0.00012701873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004676539,0.00025496678,0.0004397478,0.0012651923,0.00040849947,0.0005717319,0.0005263185,0.0004379454,0.0011104199],"category_scores_gemma":[0.011355267,0.00029859715,0.00020933946,0.0007878588,0.00038188812,0.00042320546,0.0006189623,0.0002995458,0.0004078211],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004867387,0.00002966934,0.9692515,0.00008482978,0.000141775,0.0004232123,0.00031098086,0.00046745501,0.019337721,0.000055476063,0.0002381714,0.009172649],"study_design_scores_gemma":[0.000012287684,0.00019402488,0.97730404,0.000016192402,0.000088589186,0.003631223,0.00024847203,0.0030229574,0.014472446,0.00010903163,0.000888084,0.000012628611],"about_ca_topic_score_codex":0.0015815467,"about_ca_topic_score_gemma":0.0019617018,"teacher_disagreement_score":0.004676539,"about_ca_system_score_codex":0.00042338198,"about_ca_system_score_gemma":0.00024807843,"threshold_uncertainty_score":0.024732172},"labels":[],"label_agreement":null},{"id":"W2982411421","doi":"10.1158/1541-7786.mcr-19-0582","title":"Antibody–Drug Conjugates: A Comprehensive Review","year":2019,"lang":"en","type":"review","venue":"Molecular Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":770,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Natural Science Foundation of Jiangsu Province; National Natural Science Foundation of China","keywords":"Antibody-drug conjugate; Drug; Payload (computing); Monoclonal antibody; Cytotoxic T cell; Immunotherapy; Computational biology; Cancer immunotherapy; Cancer research; Medicine; Pharmacology; Cancer; Antibody; Chemistry; Biology; Computer science; Immunology; In vitro; Biochemistry; Internal medicine","score_opus":0.354517806902707,"score_gpt":0.6034749384917816,"score_spread":0.24895713158907457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982411421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018887543,0.9968437,0.00019593505,0.00019269806,0.0002850868,0.000012505859,0.000046758065,0.0000151165705,0.002219347],"genre_scores_gemma":[0.0006997648,0.99746025,0.00030027702,0.00017239446,0.0001347413,0.000012830323,0.00006675817,0.000002467212,0.0011504479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998254,0.000026980597,0.00002445564,0.000030720792,0.00007384211,0.000018603132],"domain_scores_gemma":[0.99979144,0.00009473979,0.00003212011,0.0000076090973,0.00005580396,0.00001837836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044940604,0.0009840383,0.001089662,0.0023575467,0.0002492551,0.0008873161,0.00069195253,0.0008566852,0.0073326007],"category_scores_gemma":[0.00057317887,0.00031961742,0.0005239042,0.0023526978,0.00024937204,0.0011552525,0.0005728389,0.0013452715,0.003735789],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005759953,0.00011265756,0.00010404217,0.02235985,0.000075222524,0.00015551667,0.00004800753,0.00042701306,0.0025013476,0.0037176947,0.043522447,0.92691875],"study_design_scores_gemma":[0.000009473484,0.00006661639,0.00019857353,0.0020053745,0.00005495084,0.00047267022,0.00001592671,0.000055518947,0.00040447424,0.00061982364,0.9960872,0.000009440728],"about_ca_topic_score_codex":0.0007810925,"about_ca_topic_score_gemma":0.0015157502,"teacher_disagreement_score":0.0073326007,"about_ca_system_score_codex":0.00049256673,"about_ca_system_score_gemma":0.0010294062,"threshold_uncertainty_score":0.024529994},"labels":[],"label_agreement":null},{"id":"W2984163037","doi":"10.1182/blood-2019-123449","title":"Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Jewish General Hospital; Spinal Cord Injury BC","funders":"","keywords":"Bendamustine; Rituximab; Medicine; Internal medicine; Refractory (planetary science); Phases of clinical research; Oncology; Diffuse large B-cell lymphoma; Lymphoma; Clinical trial","score_opus":0.014116232482786045,"score_gpt":0.3040344386412057,"score_spread":0.2899182061584197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984163037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9116653,0.07202483,0.0013998783,0.002204362,0.00077199953,0.002726776,0.004683841,0.00012921267,0.004393855],"genre_scores_gemma":[0.96220964,0.022541234,0.0024542226,0.0027497131,0.0005604733,0.0017471391,0.005860206,0.000043038002,0.0018343629],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99877816,0.00065250543,0.00014135489,0.0001597506,0.00017496015,0.00009334713],"domain_scores_gemma":[0.9984176,0.00048953865,0.0005272245,0.00012050647,0.00018603381,0.00025906164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003491858,0.0006769565,0.0019969987,0.0004168661,0.00018286983,0.0015261074,0.0006063302,0.0006042289,0.0024717576],"category_scores_gemma":[0.0028126691,0.000432589,0.002051047,0.00060214027,0.0004021253,0.0008449378,0.00037327004,0.0018862311,0.00039714455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76306295,0.004057496,0.01172189,0.004760729,0.015055893,0.00016340998,0.00021587074,0.0014094677,0.007566933,0.0003775672,0.0055844705,0.18602334],"study_design_scores_gemma":[0.84008664,0.083052695,0.037035383,0.00081230735,0.02165622,0.0004983553,0.0001451254,0.0011744519,0.0014510915,0.0006569814,0.013365449,0.00006533223],"about_ca_topic_score_codex":0.0007452634,"about_ca_topic_score_gemma":0.002150849,"teacher_disagreement_score":0.003491858,"about_ca_system_score_codex":0.00079587434,"about_ca_system_score_gemma":0.00087854284,"threshold_uncertainty_score":0.01846695},"labels":[],"label_agreement":null},{"id":"W2990808969","doi":"","title":"Stromal mast cells as a favorable prognostic marker in early breast cancer","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Tissue microarray; Oncology; Stromal cell; Internal medicine; Lymph node; Immunohistochemistry; Antibody; Adjuvant; Mast cell; Pathology; Cohort; Cancer; Immunology","score_opus":0.07651018433685033,"score_gpt":0.4339942106875084,"score_spread":0.357484026350658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990808969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994462,0.00022243486,0.00008550549,0.000026645603,0.0000035495837,0.0000021151131,0.000044131004,0.0000036687372,0.00016577807],"genre_scores_gemma":[0.99957174,0.00007159671,0.000117677264,0.000008166411,0.000010788209,0.0000027340384,0.000070938055,7.563857e-7,0.0001454848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998698,0.00004457915,0.000008953592,0.000016391214,0.000028678287,0.000031514606],"domain_scores_gemma":[0.99957293,0.00013278658,0.0001336259,0.000023242746,0.000048888694,0.00008861739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003177471,0.00014749898,0.00019627021,0.0005051233,0.00020739072,0.0002954184,0.000116357114,0.00022135433,0.0010193042],"category_scores_gemma":[0.000979901,0.0001370702,0.00010682143,0.0003258618,0.00014331765,0.0001417421,0.00016160327,0.00021677976,0.00023181368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007795754,0.000037888465,0.98276156,0.000014454014,0.000019388739,0.00085425813,0.000049829003,0.00012005842,0.008644993,0.000022309789,0.00020096531,0.006494879],"study_design_scores_gemma":[0.000019691965,0.0002359317,0.9923454,0.0000060769034,0.00003562953,0.004108799,0.00008191553,0.0007886107,0.0017203015,0.000070073555,0.00058314746,0.000004431975],"about_ca_topic_score_codex":0.00053110655,"about_ca_topic_score_gemma":0.0010327764,"teacher_disagreement_score":0.0010193042,"about_ca_system_score_codex":0.000109473614,"about_ca_system_score_gemma":0.000107736174,"threshold_uncertainty_score":0.0034099221},"labels":[],"label_agreement":null},{"id":"W2991090638","doi":"10.1093/annonc/mdz420.002","title":"NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Afatinib; Series (stratigraphy); Oncology; Cancer research; Internal medicine; Cancer","score_opus":0.10946429398928428,"score_gpt":0.4602900680415992,"score_spread":0.35082577405231496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991090638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611597,0.008411621,0.0053193183,0.003235587,0.00046076166,0.00021529742,0.0005913927,0.00023530351,0.020370975],"genre_scores_gemma":[0.9935749,0.0021520804,0.0012746017,0.0007313299,0.00048495867,0.000017700013,0.0001854331,0.00005009471,0.0015288263],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994603,0.000059106365,0.000073948235,0.00014362458,0.00009356558,0.00016944557],"domain_scores_gemma":[0.9982944,0.00056744553,0.00031815135,0.000250609,0.00009984532,0.00046958105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030073445,0.0017859235,0.001060147,0.0013814548,0.0018741454,0.0020344772,0.001042895,0.0052239574,0.0025483682],"category_scores_gemma":[0.0022933641,0.0007805348,0.0015534844,0.0009916017,0.0016852772,0.0017315461,0.0011132561,0.0032276348,0.0016217444],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043104617,0.000032790358,0.0029686363,0.00003093599,0.000014112186,0.9935782,0.00008085855,0.000106114385,0.0009806076,0.0001416655,0.0002840253,0.0017388648],"study_design_scores_gemma":[0.000005997809,0.000028492634,0.0014344633,0.0000054383345,0.000014591901,0.99736017,0.00005152785,0.00017706375,0.0003910703,0.00009511132,0.00042985112,0.0000062419585],"about_ca_topic_score_codex":0.0013309283,"about_ca_topic_score_gemma":0.0023852068,"teacher_disagreement_score":0.0052239574,"about_ca_system_score_codex":0.0012451593,"about_ca_system_score_gemma":0.0006832148,"threshold_uncertainty_score":0.009034276},"labels":[],"label_agreement":null},{"id":"W2994601580","doi":"10.1186/s13058-019-1240-y","title":"Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer","year":2020,"lang":"en","type":"erratum","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Trastuzumab; Neratinib; Medicine; Surgical oncology; Paclitaxel; Oncology; Breast cancer; Internal medicine; Chemotherapy; Neoadjuvant therapy; Cancer","score_opus":0.043530157859972565,"score_gpt":0.42125467691721774,"score_spread":0.3777245190572452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994601580","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000069836606,0.0005916776,0.00032420858,0.098672114,0.8966225,0.000030161154,0.0015868384,0.0001885227,0.0019141894],"genre_scores_gemma":[0.0058835843,0.0050171358,0.0031399997,0.28992224,0.5602903,0.00032267632,0.0029691078,0.0012551191,0.13119987],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937395,0.0014154715,0.0011585952,0.00077496446,0.0023134623,0.000598034],"domain_scores_gemma":[0.9580014,0.015115479,0.0023228645,0.0017334864,0.01993715,0.0028896306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008065309,0.0024312807,0.002637963,0.0029669674,0.00304677,0.004909157,0.003664053,0.008227109,0.054544307],"category_scores_gemma":[0.08606606,0.00142507,0.0022845077,0.0027038597,0.0018911185,0.001849563,0.0014181195,0.017895676,0.036402613],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003413182,0.000003711157,0.000025384894,0.000045754554,0.0000071949307,0.00005801424,0.000006404933,0.000016123868,0.00001026019,0.00018128267,0.9980172,0.0015945727],"study_design_scores_gemma":[0.00026098837,0.00004380031,0.00075973716,0.00065948744,0.00008131198,0.00038055933,0.00004735094,0.0002829864,0.00022961499,0.0014984543,0.9957082,0.000047474015],"about_ca_topic_score_codex":0.023566348,"about_ca_topic_score_gemma":0.03109824,"teacher_disagreement_score":0.054544307,"about_ca_system_score_codex":0.0058494336,"about_ca_system_score_gemma":0.010047056,"threshold_uncertainty_score":0.18246883},"labels":[],"label_agreement":null},{"id":"W2994917610","doi":"10.1200/jco.19.01455","title":"NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":420,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute; American Society of Clinical Oncology; Amgen; Pfizer; Eli Lilly and Company; Genentech","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Docetaxel; Chemotherapy; Immunohistochemistry; Adjuvant; Cancer; Confidence interval","score_opus":0.11634704752836855,"score_gpt":0.5119909698977256,"score_spread":0.3956439223693571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994917610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870744,0.0030798642,0.0005204659,0.00084868533,0.0004446816,0.0043494287,0.001134002,0.00008327032,0.002465311],"genre_scores_gemma":[0.9860771,0.002099636,0.0012836551,0.0012825892,0.00038705047,0.004271238,0.0013489369,0.00001991139,0.0032297347],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991725,0.0005549965,0.00003383696,0.00009166595,0.00005168424,0.000095327145],"domain_scores_gemma":[0.9991811,0.00019954186,0.00019271806,0.000059992864,0.000041920648,0.0003246795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018946264,0.0013997516,0.0021155374,0.0004554611,0.0003371761,0.00075574004,0.0007198509,0.0012518448,0.004480266],"category_scores_gemma":[0.001522979,0.0005431481,0.001367611,0.00041807888,0.0011945775,0.0006450173,0.00037382075,0.0024199756,0.0006681312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98484933,0.0034584715,0.0007574642,0.00016790611,0.00040460183,0.000020969088,0.000024280254,0.00034387072,0.001535653,0.000108945096,0.0005663671,0.0077621313],"study_design_scores_gemma":[0.9445882,0.05200861,0.0016665871,0.000021096776,0.0003297252,0.00002384469,0.00001177551,0.00037601168,0.00029756062,0.00016649936,0.0005027129,0.0000073950578],"about_ca_topic_score_codex":0.0019110705,"about_ca_topic_score_gemma":0.0042614182,"teacher_disagreement_score":0.004480266,"about_ca_system_score_codex":0.0010367833,"about_ca_system_score_gemma":0.0015950098,"threshold_uncertainty_score":0.014988005},"labels":[],"label_agreement":null},{"id":"W2995808512","doi":"10.1056/nejmoa1914609","title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1313,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Seattle Genetics","keywords":"Capecitabine; Trastuzumab; Metastatic breast cancer; Oncology; Medicine; Internal medicine; Breast cancer; Cancer; Colorectal cancer","score_opus":0.03135860786207033,"score_gpt":0.37047147226077715,"score_spread":0.3391128643987068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995808512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97288233,0.021102397,0.00043671922,0.00076912116,0.00021120618,0.00095704163,0.00015652267,0.00003194705,0.0034527162],"genre_scores_gemma":[0.9924465,0.0050689974,0.00047049325,0.00036823424,0.00016611902,0.0005445176,0.00017383606,0.0000021660157,0.0007592456],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996208,0.00019320153,0.00003446153,0.000048341488,0.000059707607,0.000043531225],"domain_scores_gemma":[0.9997553,0.000074665346,0.00006965219,0.000011166415,0.000010858807,0.00007844071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007405127,0.00028547682,0.00069805904,0.00029867774,0.00016261899,0.00024104565,0.00022306452,0.00041367402,0.0023660283],"category_scores_gemma":[0.0011620269,0.00010251429,0.00033659226,0.000267299,0.00027233138,0.00016081915,0.0001744282,0.0005163798,0.0001970014],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35387537,0.007371324,0.0171454,0.0027092125,0.0015632306,0.00075965514,0.00012944006,0.004554329,0.01566115,0.0013442402,0.00544341,0.58944315],"study_design_scores_gemma":[0.5757533,0.27081895,0.095662,0.0007289834,0.0025570744,0.0035999627,0.0001253536,0.005217191,0.0062834183,0.0022938447,0.036889974,0.000069887195],"about_ca_topic_score_codex":0.0005207922,"about_ca_topic_score_gemma":0.0016668196,"teacher_disagreement_score":0.0023660283,"about_ca_system_score_codex":0.0004570871,"about_ca_system_score_gemma":0.0005949184,"threshold_uncertainty_score":0.007915199},"labels":[],"label_agreement":null},{"id":"W2998482686","doi":"10.1158/1541-7786.mcr-19-0856","title":"Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Vetenskapsrådet; Cancerfonden","keywords":"Internalization; Cancer research; Trastuzumab; Cytotoxicity; Endocytosis; Trastuzumab emtansine; Phosphorylation; Biology; Flow cytometry; Breast cancer; Pharmacology; Chemistry; Cancer; In vitro; Cell biology; Cell; Molecular biology; Biochemistry","score_opus":0.10406138963881843,"score_gpt":0.4044872859441323,"score_spread":0.30042589630531386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998482686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986407,0.0005121079,0.00033461355,0.00003061979,0.000004714961,0.000005102466,0.000089189656,0.000010876959,0.0003720466],"genre_scores_gemma":[0.99853945,0.00022084625,0.00027897142,0.000020996014,0.0000019712713,0.000007353816,0.00013007617,0.0000035698342,0.000796801],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995065,0.000009233969,0.000003447071,0.00000937805,0.000009700937,0.000017681677],"domain_scores_gemma":[0.9999728,0.0000056512486,0.000007765615,0.0000020460714,0.0000034658349,0.000008267527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054828066,0.0000870471,0.000117934826,0.000059009846,0.000072224095,0.00014416306,0.000065569846,0.00008878301,0.0011508486],"category_scores_gemma":[0.00006969635,0.000054392127,0.00007810231,0.00005396738,0.000080624086,0.000092637834,0.0000927792,0.00016482796,0.00011367123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032757528,0.000031336353,0.00042859625,0.000018067052,0.0000036530873,0.000021132682,0.000008790656,0.00004639479,0.9980028,0.000029737157,0.00003346976,0.0010484199],"study_design_scores_gemma":[0.000018393286,0.00044554268,0.015794016,0.0000028421066,0.00001095493,0.00015969707,0.000025777561,0.001242084,0.9810807,0.000019028112,0.0011989772,0.0000019067229],"about_ca_topic_score_codex":0.001057558,"about_ca_topic_score_gemma":0.001275048,"teacher_disagreement_score":0.0011508486,"about_ca_system_score_codex":0.00019814623,"about_ca_system_score_gemma":0.00011624067,"threshold_uncertainty_score":0.0038499832},"labels":[],"label_agreement":null},{"id":"W2998888159","doi":"10.1002/jcla.23187","title":"Genetic variation in NRG 1 gene and risk of post‐traumatic stress disorders in patients with hepatocellular carcinoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Laboratory Analysis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Genotype; Internal medicine; Hepatocellular carcinoma; Cognition; Medicine; Neuregulin 1; Clinical psychology; Gastroenterology; Montreal Cognitive Assessment; Oncology; Psychiatry; Gene; Cognitive impairment; Biology; Genetics; Receptor","score_opus":0.028810753936203637,"score_gpt":0.33848294256660566,"score_spread":0.309672188630402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998888159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993229,0.0002975547,0.00007439073,0.000040469116,0.0000064792525,0.0000030628216,0.00007673737,0.0000020058085,0.00017647297],"genre_scores_gemma":[0.9997582,0.000053124553,0.000043081724,0.0000111241325,0.000004343972,0.000002099282,0.000049743347,6.888097e-7,0.00007765167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998641,0.00003306963,0.000016944929,0.000040358413,0.000025847914,0.000019620034],"domain_scores_gemma":[0.9997731,0.000035642286,0.000112874455,0.000016385673,0.000020324018,0.000041643718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020568866,0.00019286197,0.00018064617,0.00029215615,0.00021632365,0.00019052647,0.00013870688,0.00023766926,0.0014186038],"category_scores_gemma":[0.00070450664,0.00009678277,0.00031517688,0.0004349424,0.00013739053,0.00010423003,0.00013847178,0.0002233252,0.00011699506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026963325,0.000024355953,0.99588096,0.00001526956,0.00011395105,0.0002257574,0.000066557186,0.00006254337,0.0017354328,0.00002764865,0.00007060269,0.0015072182],"study_design_scores_gemma":[0.000008428794,0.000075979704,0.9987117,0.000005654714,0.000048233822,0.00053309894,0.00007341556,0.00020935439,0.00017117997,0.00003951365,0.000120261444,0.0000030813771],"about_ca_topic_score_codex":0.0019686823,"about_ca_topic_score_gemma":0.0020101566,"teacher_disagreement_score":0.0019686823,"about_ca_system_score_codex":0.00013678792,"about_ca_system_score_gemma":0.00009673572,"threshold_uncertainty_score":0.004745662},"labels":[],"label_agreement":null},{"id":"W2999581422","doi":"10.1016/s0923-7534(20)34201-0","title":"Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Docetaxel; Trastuzumab; Metastatic breast cancer; Bevacizumab; Oncology; Internal medicine; HER2 negative; Breast cancer; Phases of clinical research; Chemotherapy; Cancer","score_opus":0.22965652475487,"score_gpt":0.5029663557028642,"score_spread":0.2733098309479942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999581422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9291426,0.016132753,0.0020571554,0.008789229,0.0011719223,0.002001568,0.019755932,0.00061025104,0.020338528],"genre_scores_gemma":[0.93747735,0.004311252,0.0057120495,0.008514685,0.0006822832,0.0016462151,0.02508288,0.00013485143,0.016438564],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994361,0.00033984854,0.000016337435,0.000066497654,0.000054153803,0.00008699429],"domain_scores_gemma":[0.9993325,0.00014110084,0.00012382676,0.000048028025,0.000051585455,0.00030300245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021614055,0.00076877995,0.0011381448,0.00026046342,0.0002775971,0.00087014935,0.0005130226,0.0009682651,0.005463872],"category_scores_gemma":[0.0020622744,0.000252966,0.0007229173,0.00029994102,0.00033694587,0.00075773144,0.00041330233,0.0017702391,0.0015415899],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5542651,0.010258148,0.008896512,0.0010020327,0.0027536263,0.0002307379,0.00017246467,0.0037165238,0.018810058,0.0014011207,0.056727514,0.3417661],"study_design_scores_gemma":[0.6412076,0.18770035,0.078487016,0.00028851928,0.004174375,0.00078742136,0.00014756332,0.003195261,0.008656899,0.0045757564,0.07067103,0.00010823188],"about_ca_topic_score_codex":0.0009843793,"about_ca_topic_score_gemma":0.0037286973,"teacher_disagreement_score":0.005463872,"about_ca_system_score_codex":0.0007046638,"about_ca_system_score_gemma":0.0010042159,"threshold_uncertainty_score":0.01827848},"labels":[],"label_agreement":null},{"id":"W2999743029","doi":"10.1002/ijc.32859","title":"Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University; Israel Cancer Research Fund; Breast Cancer Research Foundation","keywords":"Trastuzumab; Breast cancer; Stroma; Oncology; Medicine; Internal medicine; Mammary gland; Cancer; Cancer research; Immunohistochemistry","score_opus":0.025397180332142045,"score_gpt":0.38695985745350214,"score_spread":0.3615626771213601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999743029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993444,0.00045668395,0.000038387865,0.000021761909,0.0000014912652,0.000002419796,0.00002460549,0.0000011537503,0.00010901583],"genre_scores_gemma":[0.99971515,0.00009105147,0.00005031669,0.00001752834,0.0000067582287,0.000002269382,0.00005797157,5.073527e-7,0.000058404912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982315,0.000078767625,0.000012543538,0.00002273441,0.000036109694,0.000026685817],"domain_scores_gemma":[0.99942553,0.00022174299,0.0002150773,0.000028493998,0.000030720985,0.00007842051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005213614,0.00014139032,0.0002643888,0.00022097034,0.00010042065,0.00026931966,0.00011547087,0.00015037615,0.0004447086],"category_scores_gemma":[0.00091140147,0.000090663445,0.00020022143,0.00024020321,0.0001182358,0.00012416118,0.00014968333,0.00023594835,0.00005762955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025084228,0.00010450585,0.9769636,0.00002785219,0.00011318737,0.00025831923,0.000037361453,0.00034290258,0.0057793753,0.000028328353,0.000071701324,0.013764365],"study_design_scores_gemma":[0.000111027504,0.0009792413,0.9955576,0.0000070053657,0.00009800694,0.00076563406,0.00003131065,0.001052815,0.0009438949,0.000078991485,0.0003699657,0.000004443659],"about_ca_topic_score_codex":0.0003938644,"about_ca_topic_score_gemma":0.0008703861,"teacher_disagreement_score":0.0005213614,"about_ca_system_score_codex":0.00015959052,"about_ca_system_score_gemma":0.00013845171,"threshold_uncertainty_score":0.0027572513},"labels":[],"label_agreement":null},{"id":"W2999808793","doi":"10.1016/s0923-7534(20)32799-x","title":"Meta-Analysis of HER3 Expression and Prognosis in Solid Tumors","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Expression (computer science); Solid tumor; Internal medicine; Cancer research; Pathology; Cancer; Programming language","score_opus":0.5046343515644572,"score_gpt":0.5479802251370528,"score_spread":0.04334587357259556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999808793","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43945125,0.5371856,0.011635092,0.00121433,0.0025376359,0.00017944597,0.0056486665,0.00052639295,0.0016215943],"genre_scores_gemma":[0.9820842,0.012953567,0.0016433479,0.0005076104,0.00046311304,0.00011056345,0.001316795,0.00012612758,0.0007947302],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98410636,0.008814235,0.002062062,0.003273694,0.0010369188,0.00070679636],"domain_scores_gemma":[0.97878736,0.01387602,0.001974763,0.0036838483,0.0009921989,0.0006856705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016885245,0.0031158822,0.011689743,0.002888666,0.0010518358,0.0029931946,0.0027385668,0.002457895,0.003017638],"category_scores_gemma":[0.020843547,0.0021260048,0.044041473,0.0042821066,0.00078873103,0.0017481421,0.0019762472,0.0025504925,0.0005158106],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008139606,0.000021853042,0.062117912,0.0030032177,0.92208195,0.00013555496,0.00003901005,0.0009189281,0.0006014509,0.00007233473,0.00045403882,0.0024142202],"study_design_scores_gemma":[0.0011750411,0.00056537526,0.04010551,0.00024658281,0.95448446,0.00020202885,0.000060414353,0.0014989483,0.00027477,0.00040240702,0.00094313803,0.000041269243],"about_ca_topic_score_codex":0.0073540956,"about_ca_topic_score_gemma":0.012585767,"teacher_disagreement_score":0.016885245,"about_ca_system_score_codex":0.0013450749,"about_ca_system_score_gemma":0.0014745375,"threshold_uncertainty_score":0.089298785},"labels":[],"label_agreement":null},{"id":"W3002686079","doi":"10.1080/07357907.2020.1720223","title":"Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry","year":2020,"lang":"en","type":"article","venue":"Cancer Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Essar Steel Algoma (Canada); Sault Area Hospital; NOSM University","funders":"","keywords":"Chromosome 17 (human); Breast cancer; Internal medicine; Biology; Immunohistochemistry; Chromosome; Medicine; Fluorescence in situ hybridization; Cancer; Pathology; Genetics; Gene","score_opus":0.026211123835748643,"score_gpt":0.3091500376235991,"score_spread":0.28293891378785047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002686079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99922395,0.0004184075,0.00009893169,0.000010162885,0.0000029049284,0.0000070781716,0.000043717093,0.0000014399336,0.00019342049],"genre_scores_gemma":[0.9996681,0.0001465705,0.00007393928,0.000007029528,0.000005123283,0.0000047183757,0.00005861531,7.652427e-7,0.000035167293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994779,0.00011011191,0.00007337651,0.000103167964,0.00014894079,0.000086531494],"domain_scores_gemma":[0.99823296,0.0005710388,0.0008350022,0.00006367327,0.00016743371,0.0001298858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000716557,0.0001820695,0.0002819905,0.0011683818,0.00023133788,0.00034325564,0.00023215188,0.00024511485,0.0015647471],"category_scores_gemma":[0.00227731,0.00020143317,0.00017710464,0.0007949489,0.00031147996,0.00030679334,0.00031919233,0.00018554374,0.0002470406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015723199,0.00000869362,0.99636227,0.000013937483,0.000013141115,0.0010773685,0.00004388747,0.000010782508,0.0008678006,0.0000064929773,0.000029864448,0.0014085739],"study_design_scores_gemma":[0.000010087634,0.00021953182,0.9864624,0.000015088553,0.000060576625,0.011864784,0.00023360373,0.00013152396,0.0006013787,0.000022434888,0.00037459595,0.000003923814],"about_ca_topic_score_codex":0.0005223908,"about_ca_topic_score_gemma":0.0005592422,"teacher_disagreement_score":0.0015647471,"about_ca_system_score_codex":0.00015854443,"about_ca_system_score_gemma":0.00017239181,"threshold_uncertainty_score":0.005234599},"labels":[],"label_agreement":null},{"id":"W3003660073","doi":"10.1016/j.amjcard.2020.01.029","title":"Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer","year":2020,"lang":"en","type":"article","venue":"The American Journal of Cardiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; Women's College Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Cardiotoxicity; Medicine; Metastatic breast cancer; Breast cancer; Internal medicine; Oncology; Cardiology; Cancer; Chemotherapy","score_opus":0.011490205173424318,"score_gpt":0.3000320926430055,"score_spread":0.2885418874695812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003660073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571806,0.0023263153,0.000036490423,0.00034227752,0.00002512393,0.000006185003,0.00014401431,0.0000035043752,0.001397966],"genre_scores_gemma":[0.9987447,0.0006728112,0.00002623357,0.00016278026,0.00008945578,0.0000041509434,0.0001434417,0.0000012014493,0.00015522707],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972624,0.00008438938,0.000034638222,0.000036193247,0.000051319992,0.000067155954],"domain_scores_gemma":[0.9991812,0.00024346146,0.00030109388,0.000031080493,0.000043018277,0.00020015558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029714656,0.00017757641,0.00032420675,0.0003659984,0.00024816574,0.00053199474,0.00018458453,0.00051255024,0.0015886341],"category_scores_gemma":[0.0025259303,0.00014300096,0.00037345014,0.0006012336,0.00016506875,0.00033475374,0.0002683894,0.0007318004,0.00013267643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007181357,0.00010677616,0.99183816,0.000027522914,0.000106652,0.0015453105,0.000045408826,0.00010973736,0.00036491404,0.000052253028,0.00028731057,0.0047978344],"study_design_scores_gemma":[0.000054573757,0.00028123218,0.9965115,0.000018162069,0.00008802169,0.0020620802,0.00014842568,0.00030370947,0.000067169894,0.000087026085,0.0003727185,0.0000053195363],"about_ca_topic_score_codex":0.0016462478,"about_ca_topic_score_gemma":0.0031349638,"teacher_disagreement_score":0.0016462478,"about_ca_system_score_codex":0.00038428456,"about_ca_system_score_gemma":0.00038626202,"threshold_uncertainty_score":0.005314529},"labels":[],"label_agreement":null},{"id":"W3005632677","doi":"10.1158/1538-7445.sabcs19-p3-08-52","title":"Abstract P3-08-52: Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trastuzumab emtansine; Medicine; Metastatic breast cancer; Toxicity; Trastuzumab; Internal medicine; Oncology; Cancer; Antibody-drug conjugate; Breast cancer; Antibody; Immunology; Monoclonal antibody","score_opus":0.13632153337005212,"score_gpt":0.44626065717162655,"score_spread":0.3099391238015744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005632677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973345,0.0003062084,0.00014806596,0.000025602378,0.0000028695256,0.000033291795,0.0013476141,0.000010755505,0.0007912753],"genre_scores_gemma":[0.998256,0.00006410429,0.00014522597,0.000016880947,0.0000073939937,0.000020071777,0.0012423121,0.0000024316482,0.00024545254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977,0.00006243787,0.00004403136,0.00005323437,0.000043910884,0.00002652615],"domain_scores_gemma":[0.99890995,0.00030937683,0.00045519968,0.00007412542,0.0001356566,0.000115667324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052443735,0.00015449148,0.00028209484,0.00051017036,0.00017938115,0.00035218234,0.0002741769,0.00025377987,0.003299341],"category_scores_gemma":[0.0012289304,0.00010355004,0.00018562248,0.0006984323,0.00012657001,0.00022770501,0.00022350202,0.00018676723,0.00059210917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006702396,0.000039139366,0.99430615,0.00002759377,0.000019635328,0.00016837895,0.000016516684,0.000052068674,0.0011963157,0.000006478911,0.00018889298,0.0033086073],"study_design_scores_gemma":[0.00003105516,0.00026631562,0.9969015,0.000005266988,0.00002716186,0.001168543,0.000029895946,0.00025071608,0.0008484226,0.000012278121,0.00045701052,0.0000017751173],"about_ca_topic_score_codex":0.0006706163,"about_ca_topic_score_gemma":0.0008647487,"teacher_disagreement_score":0.003299341,"about_ca_system_score_codex":0.0002285812,"about_ca_system_score_gemma":0.00017117528,"threshold_uncertainty_score":0.011037469},"labels":[],"label_agreement":null},{"id":"W3005905875","doi":"10.1158/1538-7445.sabcs19-p6-13-02","title":"Abstract P6-13-02: Subcutaneous trastuzumab for the treatment of HER2+ breast cancer in Canada: A cost-minimization study","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Roche (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Metastatic breast cancer; Internal medicine; Health care; Clinical trial; Cancer; Drug; Intensive care medicine; Pharmacology","score_opus":0.16501558405181768,"score_gpt":0.4549794697304116,"score_spread":0.2899638856785939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005905875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753949,0.00183194,0.0011025651,0.0016922079,0.00002896755,0.0015284996,0.0117870765,0.000043787484,0.006590068],"genre_scores_gemma":[0.9918652,0.00085350336,0.0012348765,0.00030724215,0.000014078549,0.00028464454,0.003569284,0.000013392642,0.0018576377],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99916446,0.00025521513,0.00003508999,0.00008924281,0.0002195841,0.00023634557],"domain_scores_gemma":[0.997976,0.00045953185,0.00023764359,0.00006192106,0.0008142026,0.00045063338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016639449,0.0011154684,0.0009973045,0.0010556836,0.0012068886,0.0012324126,0.0015379317,0.0009359524,0.0036149703],"category_scores_gemma":[0.004279657,0.00046467216,0.002037245,0.0021357893,0.00049744034,0.00039625718,0.0006625285,0.0009932824,0.00018930036],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028436987,0.012325529,0.37893987,0.0041036652,0.0061019897,0.0020665524,0.000846392,0.40986246,0.0029517761,0.009001533,0.038806465,0.10655682],"study_design_scores_gemma":[0.014768766,0.0063368753,0.5074471,0.00084090827,0.004451076,0.0006058198,0.0026712033,0.44107452,0.0015608848,0.0018206541,0.018106373,0.00031589594],"about_ca_topic_score_codex":0.9831402,"about_ca_topic_score_gemma":0.97443175,"teacher_disagreement_score":0.06972632,"about_ca_system_score_codex":0.06972632,"about_ca_system_score_gemma":0.053488366,"threshold_uncertainty_score":0.5059022},"labels":[],"label_agreement":null},{"id":"W3006656146","doi":"10.1186/s13058-020-1252-7","title":"HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates","year":2020,"lang":"en","type":"review","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Instituto de Salud Carlos III; CRIS Cancer Foundation","keywords":"Trastuzumab; Trastuzumab emtansine; Antibody-drug conjugate; Medicine; Breast cancer; Surgical oncology; Drug resistance; Drug development; Drug; Cancer; Computational biology; Oncology; Pharmacology; Internal medicine; Antibody; Monoclonal antibody; Immunology; Biology","score_opus":0.1406654208036132,"score_gpt":0.5094523079334535,"score_spread":0.3687868871298403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006656146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015889929,0.9988555,0.00006307907,0.00017687354,0.000055059223,0.0000031412021,0.00001114876,0.0000026702826,0.00067364983],"genre_scores_gemma":[0.0014245483,0.9978683,0.000079126214,0.00013467924,0.00005353253,0.000004784612,0.000018223116,7.241431e-7,0.00041611318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998129,0.00004945053,0.000024915898,0.000032625296,0.00005977036,0.000020428559],"domain_scores_gemma":[0.99977297,0.000117958276,0.000043766067,0.000006042998,0.000047724676,0.000011608516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005675293,0.00046466835,0.00093269773,0.0017612049,0.00014177049,0.0007488564,0.00050687144,0.00079602725,0.0030411182],"category_scores_gemma":[0.00056305673,0.00019044802,0.00043996162,0.0015288128,0.00028922566,0.0006821137,0.00041650163,0.0008259593,0.0011170305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010614897,0.00005300759,0.0002608259,0.031558428,0.00016814527,0.0003122142,0.000068898895,0.00058921595,0.003331236,0.00698636,0.018017273,0.9385482],"study_design_scores_gemma":[0.0000243381,0.00016001743,0.0010019597,0.006680585,0.00028009817,0.002331257,0.00006985799,0.00014228499,0.0016022573,0.002264648,0.9854226,0.000020133015],"about_ca_topic_score_codex":0.00082289113,"about_ca_topic_score_gemma":0.0013997422,"teacher_disagreement_score":0.0030411182,"about_ca_system_score_codex":0.0005697409,"about_ca_system_score_gemma":0.000790963,"threshold_uncertainty_score":0.010173559},"labels":[],"label_agreement":null},{"id":"W3007877035","doi":"10.1016/j.ygyno.2020.01.037","title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"ImmunoGen","keywords":"Medicine; Bevacizumab; Ovarian cancer; Adverse effect; Internal medicine; Gastroenterology; Combination therapy; Oncology; Pharmacology; Cancer; Chemotherapy","score_opus":0.029979538483348143,"score_gpt":0.36143151902576276,"score_spread":0.3314519805424146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007877035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913257,0.003077624,0.0006102113,0.00043169974,0.0001863755,0.0011888222,0.0006130959,0.000111266236,0.0024551798],"genre_scores_gemma":[0.9920738,0.0021115546,0.0008669432,0.00042578374,0.0000814772,0.0007059513,0.0011914633,0.000030085448,0.0025130191],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971527,0.000119628436,0.00001534388,0.00005111799,0.000024722747,0.00007393629],"domain_scores_gemma":[0.9995844,0.000058600956,0.000057063324,0.000035755318,0.000026906342,0.00023721484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009295431,0.0009699816,0.0020388558,0.0004160566,0.0003423486,0.0011603428,0.0006737675,0.001094921,0.0025525095],"category_scores_gemma":[0.0007653273,0.0007039124,0.0010596374,0.00045580795,0.00075990445,0.00078980764,0.000254185,0.0026748397,0.00076910306],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69492096,0.068188116,0.005626908,0.0012731216,0.0022401246,0.00039389246,0.0005621834,0.0052335053,0.07128881,0.0006605132,0.004504569,0.1451072],"study_design_scores_gemma":[0.42571467,0.5462694,0.0113574155,0.000053580105,0.0007793649,0.00043155556,0.00014971355,0.0026315295,0.007063926,0.00025600064,0.0052457484,0.00004714393],"about_ca_topic_score_codex":0.0021547999,"about_ca_topic_score_gemma":0.004988204,"teacher_disagreement_score":0.0025525095,"about_ca_system_score_codex":0.000952611,"about_ca_system_score_gemma":0.0013484611,"threshold_uncertainty_score":0.008539021},"labels":[],"label_agreement":null},{"id":"W3008959887","doi":"10.1096/fj.201902649r","title":"Substrate‐selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains","year":2020,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute of General Medical Sciences; National Institutes of Health","keywords":"Ectodomain; Disintegrin; Metalloproteinase; Epidermal growth factor; Cell biology; Transmembrane domain; Epidermal growth factor receptor; Mutant; Transmembrane protein; Biology; Chemistry; Receptor; Biochemistry; Matrix metalloproteinase; Gene","score_opus":0.029448935846276243,"score_gpt":0.2900757147255682,"score_spread":0.260626778879292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008959887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99824476,0.00027889147,0.00081622734,0.00003484899,0.000013209233,0.00000504166,0.00011447593,0.000021203505,0.0004714002],"genre_scores_gemma":[0.9973424,0.00013897684,0.0006987245,0.00003096796,0.000010200956,0.000014046141,0.0003745664,0.00002394918,0.0013662423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998331,0.000028210217,0.000024483832,0.000030303296,0.00004507253,0.00003884169],"domain_scores_gemma":[0.99979585,0.00002768675,0.00007561507,0.000029821482,0.000012379765,0.000058686568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014454641,0.0003191905,0.00023725787,0.00015786588,0.0001410854,0.00033373473,0.00026743335,0.00023857219,0.0013914726],"category_scores_gemma":[0.00014715789,0.00015971671,0.0002854311,0.00010370834,0.00023794998,0.00015568013,0.000313357,0.00056675903,0.00062145677],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101431324,0.000014359647,0.0006315592,0.000011161206,0.000004056958,0.00019539728,0.000008847498,0.00002876728,0.9985879,0.00007818213,0.000025767009,0.00031261763],"study_design_scores_gemma":[0.00003354025,0.00012245755,0.018399026,0.000005144378,0.000019395397,0.003001378,0.000058161088,0.001146652,0.9747121,0.00006939866,0.002426006,0.000006721459],"about_ca_topic_score_codex":0.00018024356,"about_ca_topic_score_gemma":0.00019086957,"teacher_disagreement_score":0.0013914726,"about_ca_system_score_codex":0.0001878241,"about_ca_system_score_gemma":0.00010121174,"threshold_uncertainty_score":0.004654944},"labels":[],"label_agreement":null},{"id":"W3009135015","doi":"10.1158/1535-7163.targ-19-b001","title":"Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Capecitabine; Medicine; Trastuzumab; Internal medicine; Oncology; Cancer; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Metastatic breast cancer; Paclitaxel; Breast cancer; Phases of clinical research; Colorectal cancer","score_opus":0.0167205724280495,"score_gpt":0.3281169170133715,"score_spread":0.31139634458532195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009135015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935343,0.0029109113,0.00041856442,0.0001912459,0.00004009183,0.00033492595,0.0004554365,0.000069764865,0.0020447231],"genre_scores_gemma":[0.995784,0.0012009263,0.0005054859,0.00017308757,0.000042452546,0.00017857175,0.00088190136,0.000012153744,0.0012213113],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998702,0.000054982338,0.000011967248,0.000023016293,0.000020702075,0.000019197594],"domain_scores_gemma":[0.9998461,0.000029245899,0.000037497583,0.000010167884,0.000011457786,0.00006544356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003948518,0.00050189137,0.0006261417,0.0002645542,0.00014924721,0.00037535772,0.00031142653,0.00034525484,0.0028633384],"category_scores_gemma":[0.0005260775,0.00017588372,0.00043381326,0.00020242395,0.00025155852,0.0003782394,0.00020451432,0.0009513507,0.00054652285],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33644953,0.015450634,0.016387325,0.0012743573,0.0014898675,0.0007034811,0.0002753226,0.0031863824,0.1617514,0.00035590152,0.0064853993,0.45619047],"study_design_scores_gemma":[0.1955151,0.6337738,0.09171682,0.00017510036,0.0018779284,0.0019539318,0.00015717135,0.005778693,0.052056,0.00028689206,0.016647717,0.00006091095],"about_ca_topic_score_codex":0.00056516466,"about_ca_topic_score_gemma":0.0015591714,"teacher_disagreement_score":0.0028633384,"about_ca_system_score_codex":0.00048001943,"about_ca_system_score_gemma":0.00055216695,"threshold_uncertainty_score":0.009578824},"labels":[],"label_agreement":null},{"id":"W3010753547","doi":"10.1177/1078155220910252","title":"Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report","year":2020,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Trastuzumab emtansine; Trastuzumab; Nodular regenerative hyperplasia; Internal medicine; Breast cancer; Oncology; Cirrhosis; Surgery; Gastroenterology; Cancer; Portal hypertension","score_opus":0.10711538175138427,"score_gpt":0.4658162816026355,"score_spread":0.3587008998512512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010753547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615892,0.016068364,0.00502873,0.005122546,0.0005485983,0.00019267257,0.00019833758,0.00024605435,0.01100557],"genre_scores_gemma":[0.9938362,0.0016275718,0.0006586617,0.0009878069,0.0006629555,0.000028034892,0.00011743499,0.000024337609,0.0020568776],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9991559,0.00014066829,0.000098366705,0.00019741122,0.0001597781,0.0002479466],"domain_scores_gemma":[0.9970228,0.0009970013,0.00076225144,0.00037441516,0.00018994397,0.0006535873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006001659,0.0011552991,0.0011015041,0.0014394377,0.0015831951,0.0015959532,0.0010199444,0.004642463,0.0018262689],"category_scores_gemma":[0.0033252824,0.0006081559,0.001388799,0.0008195723,0.0012581587,0.0016234244,0.0011965972,0.0029196064,0.000874754],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059667636,0.00004622218,0.0048680156,0.000026906522,0.000014234521,0.9922909,0.00010664178,0.000064984975,0.0006055703,0.00013875576,0.00021181509,0.0015663209],"study_design_scores_gemma":[0.000018178062,0.000091251786,0.0022423714,0.000010053153,0.000015619053,0.9959965,0.00005209262,0.00027128754,0.00054753973,0.00010341838,0.0006448685,0.000006829071],"about_ca_topic_score_codex":0.00095373846,"about_ca_topic_score_gemma":0.00087835867,"teacher_disagreement_score":0.004642463,"about_ca_system_score_codex":0.0012608003,"about_ca_system_score_gemma":0.00081707555,"threshold_uncertainty_score":0.009147823},"labels":[],"label_agreement":null},{"id":"W3010907432","doi":"10.1200/jco.2013.31.15_suppl.518","title":"A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care South East; McGill University; Royal Victoria Hospital; Queen's University; Cancer Care Ontario; Interior Health; BC Cancer Agency","funders":"","keywords":"Lapatinib; Medicine; Internal medicine; Metastatic breast cancer; Tyrosine-kinase inhibitor; Oncology; Pharmacokinetics; Phases of clinical research; Regimen; Breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Pharmacology; Gastroenterology; Toxicity; Trastuzumab","score_opus":0.10205888868964136,"score_gpt":0.4980479330769425,"score_spread":0.39598904438730115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010907432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928417,0.0012321041,0.0004997735,0.00037558406,0.00008423212,0.0025255133,0.00095040526,0.000062893865,0.0014277529],"genre_scores_gemma":[0.9865826,0.0020257889,0.0016598989,0.0007248131,0.00015311659,0.0033069449,0.00246558,0.000041107345,0.0030400443],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995427,0.00021786113,0.000023073844,0.00006958235,0.00004513449,0.0001016119],"domain_scores_gemma":[0.9991239,0.00015260802,0.0001392142,0.000071330775,0.000053154683,0.00045986343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013807254,0.001639204,0.0017094779,0.0005839755,0.0005847892,0.0009949906,0.001269766,0.0014215473,0.0037582584],"category_scores_gemma":[0.0009019356,0.0008751979,0.0010735901,0.0005810795,0.0010372453,0.00091706443,0.00036851902,0.0033584773,0.00083966594],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5696777,0.24215323,0.008056464,0.0011245719,0.0011349136,0.00076272554,0.0005518801,0.0037554505,0.08809324,0.00034979082,0.004883855,0.07945615],"study_design_scores_gemma":[0.3071429,0.6724972,0.009917256,0.00004125404,0.00034209198,0.000488624,0.00007965745,0.0008355282,0.0061181094,0.00013707927,0.002372097,0.000028116126],"about_ca_topic_score_codex":0.0017438692,"about_ca_topic_score_gemma":0.0035676805,"teacher_disagreement_score":0.0037582584,"about_ca_system_score_codex":0.0010521024,"about_ca_system_score_gemma":0.001993127,"threshold_uncertainty_score":0.012572587},"labels":[],"label_agreement":null},{"id":"W3012129470","doi":"10.1158/1538-7445.sabcs19-ot1-07-01","title":"Abstract OT1-07-01: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Trastuzumab; Trastuzumab emtansine; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Lapatinib; Antibody-drug conjugate; Phases of clinical research; Cancer; Breast cancer; Antibody; Clinical trial; Immunology; Monoclonal antibody","score_opus":0.08177458749404355,"score_gpt":0.4152758576420249,"score_spread":0.33350127014798137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012129470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884296,0.0022570882,0.00034223605,0.00095347763,0.00053856947,0.0016307305,0.001970926,0.00013629513,0.003327753],"genre_scores_gemma":[0.98737514,0.0016028291,0.0008261944,0.0011654058,0.00038228388,0.0013829233,0.0019554454,0.000029423067,0.0052803773],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99965346,0.00015793095,0.000020497288,0.00006626014,0.000024897676,0.000076963304],"domain_scores_gemma":[0.9994254,0.0001479941,0.00010748692,0.000032353983,0.000025826077,0.00026100784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010287086,0.0013262768,0.0016387485,0.0003301886,0.0002829687,0.00091406435,0.00061039365,0.0013831905,0.010028756],"category_scores_gemma":[0.0007788297,0.0004853142,0.0012956045,0.00032752776,0.00084089895,0.00075530336,0.00024085058,0.0030179366,0.0013071551],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96778095,0.007537182,0.00049683556,0.00023611018,0.00043337882,0.000033202676,0.000028953209,0.00029495035,0.005299877,0.00013919173,0.0015501956,0.016169222],"study_design_scores_gemma":[0.8639338,0.13048163,0.0021927014,0.000029518756,0.000476181,0.00005171679,0.00002020727,0.0006332532,0.001052809,0.00015371495,0.00096071075,0.0000136779945],"about_ca_topic_score_codex":0.001217887,"about_ca_topic_score_gemma":0.0029966303,"teacher_disagreement_score":0.010028756,"about_ca_system_score_codex":0.00093120284,"about_ca_system_score_gemma":0.0011635802,"threshold_uncertainty_score":0.033549488},"labels":[],"label_agreement":null},{"id":"W3012233653","doi":"10.1200/jco.2012.30.15_suppl.634","title":"Evaluation of Ile655Val HER2 polymorphism associated with cardiac toxicity following the administration of trastuzumab in women with breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Centre hospitalier universitaire de Québec","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Metastatic breast cancer; Population; Internal medicine; Oncology; Toxicity; Genotyping; Genotype; Cancer; Gastroenterology; Biology; Genetics","score_opus":0.18276055988397144,"score_gpt":0.5201602895009736,"score_spread":0.33739972961700215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012233653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992962,0.0002914821,0.000051412673,0.000033890177,0.000005009051,0.000007939674,0.000051767103,0.0000014520062,0.0002608942],"genre_scores_gemma":[0.99961734,0.000067872286,0.000064770116,0.000031273925,0.000006014801,0.0000051974544,0.00006298965,9.4567764e-7,0.00014360646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997489,0.00008893603,0.000026238318,0.000046472593,0.000056470773,0.00003295526],"domain_scores_gemma":[0.9995382,0.00013604428,0.00019787041,0.000017321972,0.00003648083,0.000074041716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039434287,0.0001864004,0.00022060111,0.00035576866,0.0002379924,0.0001948568,0.00012756392,0.0003465997,0.00071883836],"category_scores_gemma":[0.001234428,0.00014073458,0.00024698148,0.00048246927,0.00014798967,0.000093175346,0.000118684264,0.00025167008,0.00016556293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004691111,0.00007558607,0.9931037,0.000017956243,0.00003514398,0.0009927659,0.00012882012,0.000043258227,0.0020153555,0.000011103679,0.00006173669,0.0030455042],"study_design_scores_gemma":[0.000018248784,0.00077168224,0.9955071,0.000006171462,0.000050481023,0.0025738287,0.00010235367,0.00018280199,0.00045388422,0.000026339292,0.00030372848,0.0000033880349],"about_ca_topic_score_codex":0.0012121149,"about_ca_topic_score_gemma":0.0012512858,"teacher_disagreement_score":0.0012121149,"about_ca_system_score_codex":0.00020738995,"about_ca_system_score_gemma":0.00014708929,"threshold_uncertainty_score":0.0024101138},"labels":[],"label_agreement":null},{"id":"W3013826160","doi":"10.1101/2020.03.24.006379","title":"Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lapatinib; Cancer research; Trastuzumab; Breast cancer; Pertuzumab; Gene silencing; Cancer; Medicine; Downregulation and upregulation; Receptor tyrosine kinase; Tyrosine kinase; Biology; Internal medicine; Receptor; Gene","score_opus":0.021497249528566527,"score_gpt":0.28597440801122803,"score_spread":0.2644771584826615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013826160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929595,0.0033794567,0.0017622459,0.00014088699,0.000035884626,0.00002301488,0.0003154944,0.000055046687,0.0013285034],"genre_scores_gemma":[0.99767643,0.00058313244,0.0002718926,0.0000716223,0.000005975397,0.000012906193,0.00020997293,0.0000031119914,0.0011649383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990165,0.000014091668,0.000007488512,0.000017946508,0.000035441317,0.000023330571],"domain_scores_gemma":[0.9999299,0.000009555924,0.000025098358,0.000006241127,0.000017420542,0.000011775485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012092204,0.00011565436,0.0001707005,0.00016907234,0.00010907078,0.00018557807,0.00007706765,0.00016218214,0.0012491846],"category_scores_gemma":[0.000122008336,0.000086640895,0.00019357626,0.00013728904,0.00009497474,0.00014920296,0.00013721836,0.0003495742,0.00018996993],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001347439,0.000046768342,0.0040824027,0.000059147966,0.000018836474,0.00013673665,0.000023002027,0.0001357603,0.99119425,0.00011346423,0.00014130039,0.0039137527],"study_design_scores_gemma":[0.00002408451,0.0006331131,0.10144582,0.000014883188,0.00006717473,0.001522119,0.00011756791,0.002757345,0.88694173,0.00018178996,0.0062846243,0.000009745369],"about_ca_topic_score_codex":0.00027311168,"about_ca_topic_score_gemma":0.00053787767,"teacher_disagreement_score":0.0012491846,"about_ca_system_score_codex":0.00020173147,"about_ca_system_score_gemma":0.000093345465,"threshold_uncertainty_score":0.0041789412},"labels":[],"label_agreement":null},{"id":"W3014809226","doi":"10.1007/s10549-020-05614-5","title":"Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes","year":2020,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Institute for Clinical Evaluative Sciences; Sunnybrook Hospital; Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; Ontario Institute for Cancer Research; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research","keywords":"Pertuzumab; Medicine; Trastuzumab; Cohort; Internal medicine; Metastatic breast cancer; Population; Breast cancer; Trastuzumab emtansine; Oncology; Randomized controlled trial; Cohort study; Cancer","score_opus":0.23654628794184537,"score_gpt":0.5262910221048149,"score_spread":0.28974473416296953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014809226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969586,0.0007926444,0.00018037991,0.00011674325,0.00003094654,0.000036189627,0.0011322624,0.0000060676275,0.00074628013],"genre_scores_gemma":[0.9977418,0.00018518347,0.000051179406,0.00007864737,0.000035907153,0.000041675834,0.0016928132,0.0000041604176,0.00016848945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970203,0.0010719916,0.00039770262,0.0006674429,0.00036718132,0.00047540088],"domain_scores_gemma":[0.99396604,0.0019978262,0.0024906588,0.00043757237,0.00048891595,0.0006190452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029912982,0.0003841789,0.0010656391,0.0010327888,0.0004352885,0.0015029896,0.0006861777,0.0009373445,0.0025247026],"category_scores_gemma":[0.011598542,0.0002293081,0.0020776037,0.0013033802,0.00038546728,0.0012065547,0.0009833932,0.000976643,0.0002670942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021587798,0.0002829415,0.96676075,0.000108619744,0.0038567884,0.00021119977,0.00011946601,0.0003687745,0.00060450786,0.00019963698,0.00073900324,0.0051604905],"study_design_scores_gemma":[0.0008939622,0.0035363587,0.9918934,0.000027420409,0.0012626031,0.0003664841,0.0003305009,0.00070232135,0.00014274806,0.00027056911,0.00055042445,0.000023165645],"about_ca_topic_score_codex":0.002395705,"about_ca_topic_score_gemma":0.002015841,"teacher_disagreement_score":0.0029912982,"about_ca_system_score_codex":0.0007554153,"about_ca_system_score_gemma":0.0006691569,"threshold_uncertainty_score":0.015819728},"labels":[],"label_agreement":null},{"id":"W3018446798","doi":"10.1007/s00432-020-03220-y","title":"Afatinib is active in osteosarcoma in osteosarcoma cell lines","year":2020,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Afatinib; Osteosarcoma; Cancer research; Viability assay; Medicine; ErbB; Cell culture; Motility; Oncology; Internal medicine; Biology; Cancer; Cell biology; Gefitinib","score_opus":0.34528108718722733,"score_gpt":0.6026386473651789,"score_spread":0.2573575601779516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018446798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986108,0.0038295474,0.0010425089,0.00045972713,0.00015477581,0.000074687036,0.0035279004,0.00013654814,0.0046662805],"genre_scores_gemma":[0.984153,0.0019833564,0.0011729283,0.00011457579,0.000028689876,0.00007282575,0.006627825,0.00002143126,0.0058252625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916804,0.00011659985,0.00016144793,0.000104597704,0.00029528656,0.00015411024],"domain_scores_gemma":[0.99967384,0.000085511674,0.00004576678,0.000058719153,0.0000837242,0.000052448857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039930557,0.00035567334,0.0009393705,0.00065176433,0.0005455872,0.00074744015,0.0003192578,0.00060964737,0.0036186306],"category_scores_gemma":[0.00053066376,0.00024951476,0.00061933935,0.000943173,0.00029008643,0.00046257558,0.00021161906,0.00080723426,0.0009683528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015312389,0.00065258326,0.0026653912,0.00037306876,0.00008945695,0.00057915197,0.00021241214,0.00059087493,0.9799492,0.00050158484,0.0016229888,0.011232016],"study_design_scores_gemma":[0.00032947725,0.0036007145,0.019443253,0.000023486316,0.0001278839,0.0019686588,0.00048670924,0.0016636545,0.95430434,0.00022352752,0.017801056,0.000027368167],"about_ca_topic_score_codex":0.0038055535,"about_ca_topic_score_gemma":0.0054009412,"teacher_disagreement_score":0.0038055535,"about_ca_system_score_codex":0.00045543918,"about_ca_system_score_gemma":0.0007353584,"threshold_uncertainty_score":0.012105525},"labels":[],"label_agreement":null},{"id":"W3020654673","doi":"10.1093/jnci/djaa054","title":"Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Queen's University; McMaster University; Ottawa Hospital; University of Ottawa","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Trastuzumab; Hazard ratio; Internal medicine; Breast cancer; Cardiotoxicity; Discontinuation; Population; Confidence interval; Retrospective cohort study; Cancer; Oncology; Surgery; Chemotherapy","score_opus":0.09539194288725586,"score_gpt":0.39898250008616615,"score_spread":0.30359055719891026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020654673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941035,0.0009583535,0.00009231574,0.00041501815,0.000013787911,0.000070873335,0.002805217,0.000008338087,0.0015327602],"genre_scores_gemma":[0.99795145,0.0004684408,0.000069826136,0.00015020935,0.000007948091,0.000019828987,0.0008365926,0.000004239139,0.00049144216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840933,0.00013327535,0.000111073394,0.00028761654,0.0005338208,0.0005250097],"domain_scores_gemma":[0.996684,0.00020346217,0.00097216264,0.00013787765,0.0012054959,0.00079704024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008729908,0.00048104546,0.0006502387,0.00083603215,0.0024531588,0.0012111951,0.0014812117,0.00058753765,0.0015350488],"category_scores_gemma":[0.0025060615,0.00048139706,0.0008297146,0.0039337236,0.0010206996,0.00038800933,0.000818731,0.00074405485,0.00016654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106855994,0.000025656054,0.9974753,0.000027898777,0.000069271024,0.00009015459,0.0002965905,0.000060042963,0.0001123204,0.000037121696,0.0004944768,0.0012043148],"study_design_scores_gemma":[0.000023814579,0.00003528439,0.9986149,0.000022227283,0.00004805702,0.00006741016,0.00045833003,0.00016320238,0.000022956443,0.00001645212,0.0005187241,0.000008593188],"about_ca_topic_score_codex":0.9906708,"about_ca_topic_score_gemma":0.9929166,"teacher_disagreement_score":0.03503859,"about_ca_system_score_codex":0.03503859,"about_ca_system_score_gemma":0.038109038,"threshold_uncertainty_score":0.25422394},"labels":[],"label_agreement":null},{"id":"W3020879346","doi":"10.1016/j.humpath.2009.10.006","title":"HER-2 amplification is highly homogenous in gastric cancer","year":2009,"lang":"en","type":"letter","venue":"Human Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Cancer; Medicine; Pathology; Internal medicine","score_opus":0.08778048155360492,"score_gpt":0.3900565801647532,"score_spread":0.3022760986111483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020879346","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5047724,0.0128910085,0.0032602304,0.40715048,0.009670638,0.00013933051,0.0006051159,0.00046135634,0.06104939],"genre_scores_gemma":[0.9034667,0.004238084,0.0017795707,0.06721121,0.015185821,0.00005338139,0.0002561938,0.000107159845,0.007701875],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9992644,0.0002263214,0.00009830902,0.00010709483,0.00017420082,0.00012969442],"domain_scores_gemma":[0.99794465,0.0012646826,0.00016416803,0.0001592659,0.00025320516,0.00021411771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010020359,0.00033795336,0.0007659895,0.0009321243,0.00064727577,0.0010532726,0.00061204046,0.0048856162,0.0017693993],"category_scores_gemma":[0.0065609543,0.00048028646,0.00034218986,0.0007154295,0.0010131125,0.00078626245,0.0004890274,0.002203693,0.0011513211],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015708406,0.00013025496,0.10742869,0.000415504,0.00014303403,0.5687815,0.0012524223,0.00043687157,0.058851603,0.0033285648,0.19340827,0.064252354],"study_design_scores_gemma":[0.00024263296,0.0006001393,0.15479286,0.00017490418,0.00028570846,0.6788752,0.0014238744,0.00278242,0.015974069,0.0052123684,0.13955308,0.00008271949],"about_ca_topic_score_codex":0.0010923814,"about_ca_topic_score_gemma":0.002223149,"teacher_disagreement_score":0.0048856162,"about_ca_system_score_codex":0.0009966637,"about_ca_system_score_gemma":0.00030010432,"threshold_uncertainty_score":0.0072313547},"labels":[],"label_agreement":null},{"id":"W3021570777","doi":"10.1158/1078-0432.ccr-20-0152","title":"NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Breast cancer; Oncology; Trastuzumab; Medicine; Internal medicine; Estrogen receptor; Proportional hazards model; Cancer; Biology; Cancer research","score_opus":0.49011177305954695,"score_gpt":0.5634234850545039,"score_spread":0.07331171199495695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021570777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758923,0.0011554526,0.00024201557,0.0003202744,0.000026397931,0.00010045008,0.00031686327,0.00001528802,0.00023398125],"genre_scores_gemma":[0.99773455,0.00028839058,0.00046618909,0.00019625628,0.000033248787,0.00022566394,0.00076705177,0.0000039732477,0.00028462405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99908733,0.00065247586,0.0000410458,0.00010537761,0.00007007983,0.000043679363],"domain_scores_gemma":[0.99914575,0.00032977448,0.00027429443,0.000056470566,0.000038517883,0.00015521004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018546105,0.00048157948,0.00083346147,0.00016744649,0.0002190457,0.0005561875,0.0001907395,0.00039013964,0.0011494927],"category_scores_gemma":[0.0021283347,0.00017927361,0.00057783915,0.00025714491,0.0004579142,0.00030474167,0.00021025103,0.0007492422,0.00012384534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7970182,0.002884837,0.09987196,0.00084376585,0.0037504302,0.0001869394,0.00013376135,0.007490312,0.020391576,0.00023597012,0.0017329552,0.06545946],"study_design_scores_gemma":[0.26111844,0.14829127,0.5060814,0.00035471914,0.007327765,0.0014854902,0.0004041454,0.043063108,0.018209662,0.0034873483,0.010044909,0.00013182047],"about_ca_topic_score_codex":0.00034798717,"about_ca_topic_score_gemma":0.00073511736,"teacher_disagreement_score":0.0018546105,"about_ca_system_score_codex":0.0004548372,"about_ca_system_score_gemma":0.0009842119,"threshold_uncertainty_score":0.009808242},"labels":[],"label_agreement":null},{"id":"W3023558472","doi":"10.1093/annonc/mdw364.65","title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Population; Cohort; Adverse effect; Breast cancer; Internal medicine; Confidence interval; Surgery; Cancer","score_opus":0.056440000735117485,"score_gpt":0.40708711098821365,"score_spread":0.35064711025309614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023558472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967096,0.0013457708,0.00038037918,0.00013660076,0.0001308187,0.00034080812,0.00041207235,0.000028283004,0.00051569426],"genre_scores_gemma":[0.9966834,0.00059449725,0.00040329038,0.00017457205,0.00021085341,0.00030046038,0.0007091338,0.000019948155,0.0009037563],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946062,0.0036274125,0.00026864887,0.0006041454,0.0003546668,0.0005389313],"domain_scores_gemma":[0.99421704,0.0026845082,0.00095193693,0.0011058253,0.00027031696,0.0007703431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006823477,0.0020379364,0.0041968795,0.000514042,0.00040529203,0.0015370687,0.0015113228,0.0024438624,0.0035211926],"category_scores_gemma":[0.0070908535,0.0012084743,0.0044504264,0.0006091749,0.0024362344,0.0020723704,0.00083535135,0.0035617442,0.0007865559],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9892292,0.0021683476,0.0012281913,0.0000905314,0.0008878049,0.000017327096,0.00003801718,0.00024702994,0.0011310675,0.00003775026,0.00009576769,0.0048290873],"study_design_scores_gemma":[0.8110058,0.16865541,0.01486686,0.00003127904,0.0028992046,0.000053558357,0.000052992367,0.0007332435,0.0009833873,0.00026241073,0.00040380095,0.00005197375],"about_ca_topic_score_codex":0.0011381014,"about_ca_topic_score_gemma":0.0012728095,"teacher_disagreement_score":0.006823477,"about_ca_system_score_codex":0.0013566694,"about_ca_system_score_gemma":0.0014741183,"threshold_uncertainty_score":0.03608644},"labels":[],"label_agreement":null},{"id":"W3027663151","doi":"10.1016/j.annonc.2020.05.012","title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Sunnybrook Hospital","funders":"National Cancer Institute; National Institutes of Health; Puma Biotechnology; American Society of Clinical Oncology","keywords":"Medicine; Neratinib; Tolerability; Oncology; Breast cancer; Internal medicine; Stage (stratigraphy); Metastatic breast cancer; Cancer; Trastuzumab; Adverse effect","score_opus":0.07013071804840221,"score_gpt":0.40395035431116005,"score_spread":0.33381963626275785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027663151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875174,0.00568116,0.00040135285,0.0006185179,0.00023139993,0.00074251276,0.0006926669,0.000089635614,0.0040253773],"genre_scores_gemma":[0.9946532,0.0011935056,0.00033536198,0.0006564704,0.00018625199,0.00034005078,0.0008663401,0.000010344269,0.0017584536],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99962866,0.00014393523,0.000036803147,0.0001017207,0.000036522422,0.000052402636],"domain_scores_gemma":[0.999566,0.00007599989,0.00013403659,0.000050236886,0.000045866047,0.00012777426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011547293,0.00065263116,0.001019432,0.00015540842,0.00014725838,0.00068518013,0.00047732986,0.00057398225,0.0033667167],"category_scores_gemma":[0.0009587872,0.00015684382,0.0008936516,0.00017217857,0.0003350865,0.0004985936,0.00019864732,0.0012643846,0.00042496604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86988086,0.010280767,0.004785136,0.0011387882,0.0020166512,0.00025282172,0.00008508863,0.0008735714,0.011458939,0.00034488647,0.005063871,0.09381871],"study_design_scores_gemma":[0.8637822,0.106991135,0.019986521,0.00005798318,0.0011620632,0.00039950208,0.000034357894,0.0009385981,0.0018686905,0.00026844308,0.00448168,0.000028811482],"about_ca_topic_score_codex":0.00036536265,"about_ca_topic_score_gemma":0.0008819443,"teacher_disagreement_score":0.0033667167,"about_ca_system_score_codex":0.00044136186,"about_ca_system_score_gemma":0.00038962488,"threshold_uncertainty_score":0.0112627745},"labels":[],"label_agreement":null},{"id":"W3032274390","doi":"10.1200/jco.2020.38.15_suppl.e13079","title":"A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Infectious Diseases Centre","funders":"","keywords":"Medicine; Eribulin; Cyclophosphamide; Internal medicine; Docetaxel; Breast cancer; Toxicity; Metastatic breast cancer; Cancer; Gastroenterology; Oncology; Surgery; Chemotherapy","score_opus":0.11389035408599417,"score_gpt":0.517889981634441,"score_spread":0.4039996275484468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032274390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98776627,0.0018206304,0.0005737859,0.00049370225,0.00011625838,0.006158347,0.00068374665,0.0000772524,0.0023099966],"genre_scores_gemma":[0.98283434,0.002130297,0.0026715742,0.0013750127,0.00023960356,0.0063604503,0.0015145245,0.000031307034,0.002842801],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993913,0.0003227462,0.000028928918,0.00008869817,0.00004769145,0.00012066931],"domain_scores_gemma":[0.99921,0.000111309295,0.00011148011,0.00006181945,0.000051786046,0.0004534838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019789257,0.0016793822,0.0022039916,0.0005980933,0.0004643343,0.0010484987,0.000972891,0.0014902303,0.003915521],"category_scores_gemma":[0.00093517196,0.0007758238,0.0010209267,0.00075393385,0.0011333223,0.00094376085,0.00049397186,0.0033134758,0.001147041],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6332655,0.20638935,0.008787258,0.0010852467,0.0012388811,0.00057442643,0.00047001956,0.0034969302,0.047249153,0.00041903416,0.0037824158,0.093241885],"study_design_scores_gemma":[0.457944,0.52723414,0.007098445,0.00003636883,0.00035541577,0.00029179826,0.00006421674,0.0007860141,0.0027841781,0.00016006482,0.0032255969,0.000019733563],"about_ca_topic_score_codex":0.0009700661,"about_ca_topic_score_gemma":0.002220185,"teacher_disagreement_score":0.003915521,"about_ca_system_score_codex":0.0010585417,"about_ca_system_score_gemma":0.0019452976,"threshold_uncertainty_score":0.013098717},"labels":[],"label_agreement":null},{"id":"W3032425473","doi":"10.1186/s12964-020-00575-0","title":"CAMKK2-CAMK4 signaling regulates transferrin trafficking, turnover, and iron homeostasis","year":2020,"lang":"en","type":"article","venue":"Cell Communication and Signaling","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Boniface Hospital","funders":"School of Medicine, Indiana University","keywords":"Cell biology; Transferrin receptor; HEK 293 cells; Biology; Receptor; Downregulation and upregulation; Ferroportin; Chemistry; Biochemistry; Metabolism; Gene; Iron homeostasis","score_opus":0.0528266430946191,"score_gpt":0.3033934389698981,"score_spread":0.250566795875279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032425473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9539371,0.014018134,0.011541202,0.0010968304,0.00048019,0.00012318799,0.004296681,0.00066021347,0.013846431],"genre_scores_gemma":[0.9830183,0.0031920972,0.0028608958,0.00019926469,0.00003866272,0.00013915972,0.001831113,0.000048430833,0.008672177],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998061,0.000015222518,0.000014448309,0.000049100014,0.0000467358,0.00006845181],"domain_scores_gemma":[0.99989796,0.000007432576,0.000025540236,0.000008240861,0.000022221506,0.000038709743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013135393,0.00038915992,0.00027757065,0.00034521733,0.00040440628,0.00048836914,0.00048632495,0.0005844223,0.0032336016],"category_scores_gemma":[0.0001731572,0.00018256686,0.00040096926,0.00024198147,0.0002858712,0.0003388092,0.00031872586,0.0007377171,0.00080241077],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003898765,0.000033096963,0.0012627038,0.0002590024,0.000019051826,0.00017136493,0.00003763239,0.00023310118,0.99200374,0.00070519437,0.001043297,0.0038419045],"study_design_scores_gemma":[0.00016719075,0.00022627895,0.04746357,0.000082645376,0.00014371348,0.0009995147,0.0002587215,0.012584028,0.9106821,0.000885733,0.026455702,0.000050766954],"about_ca_topic_score_codex":0.0026776397,"about_ca_topic_score_gemma":0.0026505599,"teacher_disagreement_score":0.0032336016,"about_ca_system_score_codex":0.0008901335,"about_ca_system_score_gemma":0.00058911584,"threshold_uncertainty_score":0.010817528},"labels":[],"label_agreement":null},{"id":"W3034998325","doi":"10.1158/1535-7163.mct-19-0993","title":"Patient Selection Strategies to Maximize Therapeutic Index of Antibody–Drug Conjugates: Prior Approaches and Future Directions","year":2020,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Clinical trial; Selection (genetic algorithm); Antibody-drug conjugate; Drug development; Medicine; Biomarker; Drug; Expression (computer science); Computational biology; Computer science; Pharmacology; Antibody; Machine learning; Internal medicine; Monoclonal antibody; Biology; Immunology","score_opus":0.0828555232670809,"score_gpt":0.3865256745269056,"score_spread":0.3036701512598247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034998325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000320053,0.99588364,0.0010892261,0.001316497,0.00015386946,0.000052241434,0.000016678092,0.000009278835,0.0011585715],"genre_scores_gemma":[0.003211505,0.99244213,0.0024014509,0.0011032865,0.00024283346,0.00010846046,0.000029943109,0.0000052551013,0.00045506688],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990466,0.00044797518,0.00013800008,0.00010902679,0.00019805055,0.000060263395],"domain_scores_gemma":[0.99718744,0.0020219549,0.00024845722,0.00006944249,0.00039056447,0.00008215227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005266952,0.0008287517,0.0018674085,0.0013789613,0.0002002432,0.0015511645,0.0010053086,0.0013122257,0.0034802577],"category_scores_gemma":[0.0045528277,0.0003029757,0.0010522573,0.0014171947,0.0007326073,0.0017233619,0.0006920208,0.0029675472,0.0009873756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020571638,0.0001720796,0.00016983818,0.020260384,0.00015451339,0.00009111222,0.0000721052,0.00086339004,0.0009827445,0.011146782,0.0072713955,0.95861],"study_design_scores_gemma":[0.0004783546,0.0014514289,0.0016422144,0.029376697,0.00094987074,0.0013149416,0.00016265931,0.0012502264,0.002114254,0.015019245,0.94615424,0.00008587851],"about_ca_topic_score_codex":0.0006184042,"about_ca_topic_score_gemma":0.0013030358,"teacher_disagreement_score":0.005266952,"about_ca_system_score_codex":0.001067559,"about_ca_system_score_gemma":0.0020712456,"threshold_uncertainty_score":0.027854621},"labels":[],"label_agreement":null},{"id":"W3036172594","doi":"10.1016/bs.acr.2020.04.004","title":"In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches","year":2020,"lang":"en","type":"review","venue":"Advances in cancer research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Breast cancer; In vivo; Cancer research; Epidermal growth factor receptor; Medicine; Metastasis; Cancer; Human Epidermal Growth Factor Receptor 2; Oncology; Biology; Internal medicine; Genetics","score_opus":0.3671908909486335,"score_gpt":0.5569368107235614,"score_spread":0.18974591977492788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036172594","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007678932,0.9956872,0.0015108916,0.00031870126,0.0001584415,0.000009899242,0.00003740227,0.000019382478,0.00149032],"genre_scores_gemma":[0.005774085,0.99196786,0.00083011296,0.0001835555,0.00007752568,0.000016004125,0.00007233882,0.000004059588,0.0010743905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989486,0.000024476916,0.000006046369,0.000015809199,0.00004229502,0.000016443135],"domain_scores_gemma":[0.99991107,0.000039211332,0.000016352746,0.0000041442026,0.000020534953,0.000008751334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050360884,0.0008392132,0.00091418286,0.0007112642,0.000094796495,0.00066442485,0.00080670527,0.0008330501,0.0015947487],"category_scores_gemma":[0.00035564147,0.0002223606,0.0005234408,0.0006282608,0.0002577662,0.0006318249,0.0003450599,0.0013526871,0.0007080292],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028289747,0.0002679536,0.00023174372,0.014736318,0.00014538904,0.0003518219,0.000057299414,0.0054348726,0.03727522,0.013255117,0.030752573,0.8972088],"study_design_scores_gemma":[0.00009535545,0.00042087687,0.0008259054,0.0024668071,0.00035619954,0.001768217,0.000060381586,0.0032354181,0.02142072,0.0057008406,0.9636041,0.000045129495],"about_ca_topic_score_codex":0.0010612397,"about_ca_topic_score_gemma":0.0014437978,"teacher_disagreement_score":0.0015947487,"about_ca_system_score_codex":0.00061922753,"about_ca_system_score_gemma":0.0005430736,"threshold_uncertainty_score":0.0053349733},"labels":[],"label_agreement":null},{"id":"W3036364287","doi":"10.1074/jbc.ra119.010925","title":"The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration","year":2020,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Turun Yliopistollinen Keskussairaala; Academy of Finland","keywords":"Guanine nucleotide exchange factor; ERBB4; ERBB3; Receptor tyrosine kinase; Epidermal growth factor receptor; Cell biology; Cancer research; Biology; ErbB; Signal transduction; Epidermal growth factor; Tyrosine phosphorylation; Tyrosine kinase; Receptor; Biochemistry","score_opus":0.12745283606116675,"score_gpt":0.3662935132493659,"score_spread":0.23884067718819912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036364287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909368,0.003721224,0.0020576103,0.00017031691,0.000033682973,0.000021645705,0.00027701326,0.0001288874,0.0026528996],"genre_scores_gemma":[0.9963242,0.0007884597,0.00082348165,0.000034812732,0.0000043407013,0.000012196726,0.00027349294,0.0000101256355,0.0017288387],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990976,0.00001426959,0.0000043998116,0.000014448788,0.000022126944,0.000034896326],"domain_scores_gemma":[0.99996626,0.0000034653062,0.000008989118,0.000004068265,0.0000060140833,0.000011349826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007284315,0.0002841368,0.00012433853,0.00021165518,0.0003114972,0.00027669582,0.00013167899,0.00030778325,0.0010640703],"category_scores_gemma":[0.000078503144,0.000086003274,0.0003371096,0.00014996677,0.00013331027,0.0001298087,0.00023249477,0.00031481413,0.00048056166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012640814,0.000020215986,0.00076222525,0.00003551696,0.0000099697545,0.00014196883,0.000018210576,0.00010933903,0.9958748,0.00035052546,0.00015274191,0.0023981063],"study_design_scores_gemma":[0.000033632783,0.00014048895,0.026863158,0.000014710727,0.000030012947,0.0010598231,0.00007193389,0.003614376,0.95726883,0.00034024,0.010550518,0.000012217798],"about_ca_topic_score_codex":0.0018986758,"about_ca_topic_score_gemma":0.0015733001,"teacher_disagreement_score":0.0018986758,"about_ca_system_score_codex":0.00049956265,"about_ca_system_score_gemma":0.00024035649,"threshold_uncertainty_score":0.0037751794},"labels":[],"label_agreement":null},{"id":"W3037008990","doi":"10.1371/journal.pone.0234991","title":"Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines","year":2020,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval; Centre hospitalier de l'Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Trastuzumab; Medicine; Breast cancer; Immunohistochemistry; Oncology; Cancer research; Internal medicine; Biomarker; Cancer; Cell growth; Biology; Genetics","score_opus":0.06255074206964746,"score_gpt":0.314305918201733,"score_spread":0.25175517613208553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037008990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904446,0.004042705,0.000700995,0.00011404817,0.00006480532,0.000044445886,0.0016008166,0.000059309776,0.0029282395],"genre_scores_gemma":[0.98364913,0.004485302,0.00157991,0.00018502788,0.000030951003,0.0001648688,0.0051405313,0.000024550802,0.0047397143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996892,0.00006141767,0.000046561912,0.000042247626,0.00011495196,0.00004554903],"domain_scores_gemma":[0.99986863,0.000039297156,0.000020201951,0.00002154808,0.00003246537,0.000017932536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017694767,0.00023656241,0.00044573206,0.0002483397,0.00021073391,0.0003411384,0.00015254185,0.00019256798,0.0019268611],"category_scores_gemma":[0.00017835818,0.00013795962,0.00025594322,0.00048532858,0.000104179555,0.00014772292,0.00015269319,0.00042743093,0.0006442027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010733175,0.00047142408,0.005093022,0.0001696858,0.00006026314,0.00020208923,0.000115828385,0.0003245979,0.9812677,0.0001096821,0.0009353405,0.010177071],"study_design_scores_gemma":[0.000121948906,0.0025329397,0.049190994,0.00001929455,0.000080230064,0.0007658946,0.00011808979,0.0014393143,0.93798816,0.00007789702,0.0076514487,0.000013752185],"about_ca_topic_score_codex":0.0013024645,"about_ca_topic_score_gemma":0.0016411226,"teacher_disagreement_score":0.0019268611,"about_ca_system_score_codex":0.0002260976,"about_ca_system_score_gemma":0.00017457879,"threshold_uncertainty_score":0.006446004},"labels":[],"label_agreement":null},{"id":"W3037873371","doi":"10.1001/jamaoncol.2020.1796","title":"Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer","year":2020,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Capecitabine; Medicine; Metastatic breast cancer; Trastuzumab emtansine; Internal medicine; Trastuzumab; Oncology; Phases of clinical research; Breast cancer; Cancer; Gastroenterology; Chemotherapy","score_opus":0.019962352137295275,"score_gpt":0.31567226766944956,"score_spread":0.2957099155321543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037873371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974673,0.0015455897,0.00010913905,0.000097502634,0.000040689858,0.00018787243,0.000109390174,0.000013507876,0.0004290382],"genre_scores_gemma":[0.99829525,0.00062720047,0.00021688007,0.00013724895,0.00007783981,0.00018464145,0.00018268898,0.0000032158887,0.0002750163],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99952674,0.000247284,0.000037998867,0.00006873872,0.00005443398,0.00006474623],"domain_scores_gemma":[0.9989699,0.00029984344,0.0003127411,0.000053749427,0.00003636886,0.00032749772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012955071,0.0005581771,0.0016195886,0.00034044767,0.00021131983,0.0005506491,0.0004056225,0.0006480254,0.0015355459],"category_scores_gemma":[0.0017932891,0.0002713408,0.0010072696,0.00032306142,0.00042106202,0.00062167214,0.00020778779,0.0015561677,0.00021850878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8626672,0.017240405,0.013063305,0.00032305138,0.0014838761,0.00017675677,0.00012127999,0.0025751705,0.01642412,0.00013241539,0.0008328988,0.084959485],"study_design_scores_gemma":[0.2707265,0.67493224,0.044022806,0.000059455397,0.0013520699,0.00030146097,0.000045437602,0.0032603336,0.003761797,0.00021342133,0.0012942802,0.00003017211],"about_ca_topic_score_codex":0.00043277213,"about_ca_topic_score_gemma":0.0013413662,"teacher_disagreement_score":0.0016195886,"about_ca_system_score_codex":0.0008383968,"about_ca_system_score_gemma":0.0008041001,"threshold_uncertainty_score":0.006851375},"labels":[],"label_agreement":null},{"id":"W3041329672","doi":"10.1007/s10637-020-00958-7","title":"Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Moiety; EGFR inhibitors; Quinazoline; Gefitinib; Chemistry; Transfection; Small molecule; Potency; Mechanism of action; Epidermal growth factor receptor; Penetration (warfare); Biophysics; Biochemistry; Phosphorylation; In vitro; Receptor; Biology; Stereochemistry","score_opus":0.0797261951099458,"score_gpt":0.30861932225513944,"score_spread":0.22889312714519364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041329672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546233,0.01246914,0.015496961,0.0010477422,0.0001079792,0.000060753475,0.0015700853,0.0005331213,0.014090989],"genre_scores_gemma":[0.9924845,0.0020205274,0.0024134822,0.000080496255,0.000010309988,0.000012371124,0.0004254702,0.00002386041,0.0025290723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999299,0.000010533072,0.0000031785032,0.00001774146,0.000016513017,0.00002204352],"domain_scores_gemma":[0.9999716,0.000006208167,0.0000073214087,0.0000036513684,0.000005406191,0.0000058896476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014351336,0.000208578,0.00021045702,0.000197242,0.0001853314,0.00040744356,0.00039805312,0.00031631324,0.001079304],"category_scores_gemma":[0.000077093304,0.00012845034,0.00024688215,0.00012868215,0.00025476582,0.00037460917,0.000101444704,0.0005316528,0.0004925442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006778726,0.00009231027,0.00017818538,0.00008131907,0.000011569554,0.000098997356,0.000023900608,0.000500155,0.9886501,0.002009526,0.00052844075,0.0071477313],"study_design_scores_gemma":[0.00006614993,0.00033793796,0.0016379114,0.0000036409049,0.000018656932,0.00038327053,0.000026374451,0.003008615,0.989739,0.00024036356,0.004530311,0.000007759008],"about_ca_topic_score_codex":0.0016659676,"about_ca_topic_score_gemma":0.0011803213,"teacher_disagreement_score":0.0016659676,"about_ca_system_score_codex":0.00059958873,"about_ca_system_score_gemma":0.00033707023,"threshold_uncertainty_score":0.004350364},"labels":[],"label_agreement":null},{"id":"W3042132061","doi":"10.1016/s1470-2045(20)30326-0","title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McMaster University; Juravinski Cancer Centre","funders":"Merck Sharp and Dohme; MacroGenics","keywords":"Pembrolizumab; Gastro-; Medicine; Internal medicine; Adenocarcinoma; Gastroenterology; Oncology; Cancer; Immunotherapy; Reflux; Disease","score_opus":0.07346060626970793,"score_gpt":0.3594422757535952,"score_spread":0.28598166948388726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042132061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027586,0.004914972,0.00023586465,0.0008851266,0.0003563998,0.0006295767,0.00056432304,0.00009554336,0.0020424274],"genre_scores_gemma":[0.98648584,0.003587814,0.0008177532,0.0016200009,0.00026916768,0.00079503725,0.0017979636,0.000027563214,0.004598836],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99973303,0.0001061108,0.00001067898,0.000058669673,0.000021092199,0.0000703932],"domain_scores_gemma":[0.99971527,0.000044146676,0.00004917015,0.000020298457,0.0000151194145,0.00015595632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011647413,0.0016150352,0.0017974329,0.00028314194,0.00028587258,0.0010157063,0.0006852716,0.0012637934,0.0038694956],"category_scores_gemma":[0.0007114025,0.00050185714,0.0017187881,0.00029396918,0.00064851384,0.001096272,0.00034213768,0.0031836305,0.00090978947],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8558791,0.013802646,0.0033224712,0.0014249599,0.00340712,0.00024761521,0.00022133601,0.0027958169,0.012740227,0.0003528631,0.006214049,0.099591784],"study_design_scores_gemma":[0.86365664,0.118499,0.010378219,0.0000739282,0.00091119745,0.00022506493,0.00007641975,0.0015026102,0.0011115584,0.0003129165,0.0032178522,0.00003458768],"about_ca_topic_score_codex":0.0013434873,"about_ca_topic_score_gemma":0.005053739,"teacher_disagreement_score":0.0038694956,"about_ca_system_score_codex":0.0009783286,"about_ca_system_score_gemma":0.00083606923,"threshold_uncertainty_score":0.012944758},"labels":[],"label_agreement":null},{"id":"W3044214090","doi":"10.1016/j.clon.2020.07.006","title":"Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK","year":2020,"lang":"en","type":"editorial","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Daiichi Sankyo Company; National Institute on Handicapped Research; Merck Sharp and Dohme; Health Technology Assessment Programme; Eisai; AstraZeneca France; Daiichi-Sankyo; National Institute for Health and Care Research; Puma Biotechnology; Les Laboratories Pierre Fabre; Genomic Health; Elsevier Foundation; Sanofi; Novartis; Celgene; Roche; Oncolytics Biotech; Cancer Research UK; Intas Pharmaceuticals; Department for Culture, Heritage and the Gaeltacht, Ireland; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Neratinib; Breast cancer; Internal medicine; Adjuvant therapy; Adjuvant; Cancer; Surgery; Oncology","score_opus":0.12727869513434384,"score_gpt":0.5247389173070323,"score_spread":0.3974602221726884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044214090","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000066369306,0.019253852,0.00014513862,0.077966034,0.90076447,0.00002574985,0.000072371535,0.000039115195,0.0016668257],"genre_scores_gemma":[0.0009542009,0.015184188,0.00013125775,0.035650622,0.9423421,0.000033211123,0.000028920771,0.000033984306,0.005641483],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99204636,0.0021200234,0.0013390402,0.00071488926,0.0032151141,0.00056451577],"domain_scores_gemma":[0.9531182,0.027872778,0.0029583918,0.00057963445,0.010354261,0.005116727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0147927515,0.0029564223,0.003905209,0.002495716,0.0016761043,0.007766252,0.003366032,0.020134808,0.011935743],"category_scores_gemma":[0.05008215,0.0012324713,0.0028726987,0.0014484319,0.002442809,0.004930313,0.0015783934,0.025400367,0.00609141],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019509453,0.000018558572,0.000031574677,0.0007288976,0.000057403326,0.0001032399,0.00002172038,0.00008215937,0.00008159778,0.0007299117,0.98391104,0.014038872],"study_design_scores_gemma":[0.00040482837,0.0001730982,0.00063810975,0.0017823485,0.0002765421,0.0002501072,0.00008439592,0.00028491343,0.00018497586,0.00201505,0.99385464,0.000051111012],"about_ca_topic_score_codex":0.004467625,"about_ca_topic_score_gemma":0.010475713,"teacher_disagreement_score":0.020134808,"about_ca_system_score_codex":0.0072474466,"about_ca_system_score_gemma":0.0058054347,"threshold_uncertainty_score":0.07823253},"labels":[],"label_agreement":null},{"id":"W3044478606","doi":"10.1016/s2055-6640(20)31142-0","title":"Selection of the R263K and H51Y resistance substitutions for DTG causes diminished integration and explains the lack of clinically significant drug resistance to this compound","year":2016,"lang":"en","type":"article","venue":"Journal of Virus Eradication","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Drug; Selection (genetic algorithm); Drug resistance; Resistance (ecology); Pharmacology; Computational biology; Medicine; Biology; Computer science; Genetics; Artificial intelligence; Ecology","score_opus":0.09224462931416175,"score_gpt":0.4000524584154449,"score_spread":0.3078078291012831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044478606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756707,0.000566671,0.0037559583,0.00055738416,0.000120540244,0.00007231921,0.000952044,0.00017556174,0.006232318],"genre_scores_gemma":[0.9943427,0.00027334524,0.0025672019,0.0001451237,0.000012395775,0.000021772947,0.00051382126,0.00010386351,0.0020197616],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997863,0.00005584925,0.000026998305,0.000046188896,0.000045795725,0.000038785238],"domain_scores_gemma":[0.9998599,0.00003121083,0.000041199244,0.000028681012,0.00000818028,0.000030705334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018728421,0.00038460415,0.00038993344,0.00024100911,0.0002437859,0.00028409535,0.00034334764,0.00041947272,0.0041434565],"category_scores_gemma":[0.00023095969,0.00015890812,0.0003231332,0.0002196294,0.0004624698,0.00019057115,0.00024626852,0.00076518505,0.0012129257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001844104,0.000057370085,0.0007811135,0.00002257876,0.000013144366,0.0003190495,0.000018853392,0.00029087267,0.99299884,0.0005260091,0.0003132789,0.0044745198],"study_design_scores_gemma":[0.00010187916,0.00054468185,0.005490065,0.000014830816,0.000029562581,0.0022191282,0.00005303816,0.0023978895,0.97951025,0.00022800913,0.009384752,0.000025926774],"about_ca_topic_score_codex":0.0016111509,"about_ca_topic_score_gemma":0.0014646609,"teacher_disagreement_score":0.0041434565,"about_ca_system_score_codex":0.00038242113,"about_ca_system_score_gemma":0.00033906687,"threshold_uncertainty_score":0.013861239},"labels":[],"label_agreement":null},{"id":"W3046257387","doi":"10.1016/j.clon.2020.07.013","title":"Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Queen's University","keywords":"Medicine; Trastuzumab; Internal medicine; Cancer; Population; Cohort; Clinical trial; Oncology; Gastroenterology; Breast cancer","score_opus":0.07581011858358351,"score_gpt":0.48774804402756294,"score_spread":0.41193792544397945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046257387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993136,0.00028110138,0.000023889676,0.000060482886,0.0000042173697,0.000006595198,0.000088381734,0.000001858447,0.00022004769],"genre_scores_gemma":[0.99960667,0.00010674479,0.000025475978,0.000060740313,0.000012760475,0.0000053528624,0.00011608605,0.0000012115984,0.00006490262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980001,0.00082443975,0.00021519311,0.0004699194,0.00028271336,0.00020761695],"domain_scores_gemma":[0.9966453,0.001147649,0.0012502918,0.00020082694,0.00025126652,0.0005046228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009888433,0.00035166903,0.00077646645,0.00065101444,0.0005472682,0.0013188287,0.00043357056,0.0012014168,0.0011897853],"category_scores_gemma":[0.0072769565,0.00040084965,0.0007137536,0.0014023775,0.00060455553,0.0011231995,0.00063047657,0.0009633046,0.00022987419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007551527,0.0003118502,0.9965442,0.000015693118,0.00019124386,0.00009817248,0.00015568238,0.000052405012,0.0001633608,0.000014109918,0.000077317774,0.001620784],"study_design_scores_gemma":[0.000096184034,0.0010288702,0.9975497,0.000006510816,0.00013153032,0.00028465115,0.0003732481,0.00031617185,0.000038161706,0.00003201327,0.00013274548,0.000010191912],"about_ca_topic_score_codex":0.0041807746,"about_ca_topic_score_gemma":0.0048121815,"teacher_disagreement_score":0.0041807746,"about_ca_system_score_codex":0.0006534393,"about_ca_system_score_gemma":0.0005063499,"threshold_uncertainty_score":0.008312881},"labels":[],"label_agreement":null},{"id":"W3052318948","doi":"10.1016/j.ijpharm.2020.119786","title":"The pharmaceutical stability of trastuzumab after short-term storage at room temperature assessed by analytical techniques and tumour imaging by microSPECT/CT","year":2020,"lang":"en","type":"article","venue":"International Journal of Pharmaceutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Canadian Cancer Society; University Health Network","keywords":"Trastuzumab; Biodistribution; Chemistry; High-performance liquid chromatography; Chromatography; Medicine; Cancer; Breast cancer; Biochemistry; In vitro; Internal medicine","score_opus":0.04466126435502655,"score_gpt":0.42241515929937823,"score_spread":0.3777538949443517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3052318948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97260904,0.0075384835,0.014685914,0.0003171758,0.00018189623,0.00010120478,0.0013423141,0.00022184543,0.0030021784],"genre_scores_gemma":[0.9877764,0.0014959449,0.005044384,0.00009592773,0.000040418738,0.000106701045,0.0010926394,0.00011474063,0.004233007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995828,0.00007254171,0.00003437547,0.00011442001,0.000120318255,0.000075570555],"domain_scores_gemma":[0.99941385,0.00012446613,0.00013237819,0.00009428515,0.0001921219,0.000042924763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008700826,0.00044852207,0.0002719212,0.00033589537,0.0006023105,0.00065865123,0.0003921008,0.00056700973,0.0027537541],"category_scores_gemma":[0.0017542755,0.00018354307,0.0003656043,0.0004603309,0.0005974438,0.00071581954,0.00035746186,0.0008146061,0.0008743498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010343444,0.000036927457,0.0011650971,0.000074748976,0.00003884989,0.00010868644,0.0001858343,0.00020190138,0.9896864,0.00018723377,0.00022005741,0.007059875],"study_design_scores_gemma":[0.00001872327,0.0004031098,0.008755087,0.000012747842,0.00006160943,0.00027795575,0.00007692047,0.0013046591,0.9857599,0.00009651209,0.0032013098,0.00003155079],"about_ca_topic_score_codex":0.0023799594,"about_ca_topic_score_gemma":0.0020108281,"teacher_disagreement_score":0.0027537541,"about_ca_system_score_codex":0.0005967433,"about_ca_system_score_gemma":0.00051740976,"threshold_uncertainty_score":0.0092122555},"labels":[],"label_agreement":null},{"id":"W30545388","doi":"10.1186/s13058-018-1080-1","title":"統合教育現場における聴覚障害児の「当事者性」の涵養 : ろう者モデルの提示をめぐる関係者の語りの分析(IV-1部会 【テーマ部会】ニューカマーと近接領域,研究発表IV,一般研究報告)","year":2009,"lang":"ja","type":"article","venue":"日本教育社会学会大会発表要旨集録","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine, Dalhousie University; Canadian Institutes of Health Research; Breast Cancer Society of Canada; Beatrice Hunter Cancer Research Institute","keywords":"Computer science","score_opus":0.06410206263565742,"score_gpt":0.41650894046566245,"score_spread":0.352406877830005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W30545388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978496,0.004889016,0.005919912,0.00047661367,0.00010869185,0.000037424736,0.00021906536,0.000059129627,0.0097941775],"genre_scores_gemma":[0.99020654,0.0012200195,0.0038783157,0.00007914696,0.00002951037,0.000020059788,0.00021566695,0.000011192928,0.00433956],"study_design_codex":"bench_or_experimental","study_design_gemma":"qualitative","domain_scores_codex":[0.99983966,0.000025498275,0.00001390085,0.000030263696,0.000033546366,0.000057097168],"domain_scores_gemma":[0.9998697,0.00003745958,0.00002757209,0.00001979452,0.000021914107,0.000023536139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004001212,0.00021167495,0.00011937958,0.00016400818,0.00030702303,0.00034097163,0.00023751432,0.00035890285,0.0041524167],"category_scores_gemma":[0.00023730338,0.0001353742,0.0003207542,0.00009403276,0.000552466,0.00039128086,0.00014221187,0.0008687273,0.0007432208],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072759273,0.00014375833,0.0013914063,0.00014251463,0.000028948276,0.00017857314,0.00011786822,0.00023155034,0.9840412,0.0015960099,0.00028945034,0.011111178],"study_design_scores_gemma":[0.00004031226,0.00030039708,0.0031536636,0.000011006905,0.00003261997,0.0004556224,0.00007824967,0.0004617365,0.99013805,0.00043387405,0.0048856563,0.000008862703],"about_ca_topic_score_codex":0.001044487,"about_ca_topic_score_gemma":0.0012765876,"teacher_disagreement_score":0.0041524167,"about_ca_system_score_codex":0.0004894938,"about_ca_system_score_gemma":0.00032603333,"threshold_uncertainty_score":0.01389122},"labels":[],"label_agreement":null},{"id":"W3080952862","doi":"10.1634/theoncologist.2020-0379","title":"Therapeutic Potential of Afatinib in<i>NRG1</i>Fusion-Driven Solid Tumors: A Case Series","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; William Osler Health System; University of Toronto","funders":"National Cancer Institute","keywords":"Afatinib; Series (stratigraphy); Fusion; Computer science; Computational biology; Cancer research; Medicine; Biology; Internal medicine; Cancer","score_opus":0.08401261259245403,"score_gpt":0.391276329499115,"score_spread":0.307263716906661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080952862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97208834,0.007123539,0.005068329,0.002285829,0.0003395794,0.00019572479,0.00029043283,0.00026554248,0.012342843],"genre_scores_gemma":[0.99497116,0.0015745746,0.0014165232,0.00043109225,0.0003891566,0.000025212552,0.00010285862,0.00003035364,0.001059088],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9993268,0.00007409867,0.00010040457,0.00013179945,0.00012862397,0.00023819525],"domain_scores_gemma":[0.99848855,0.0003885397,0.00034184597,0.00018584859,0.00008194845,0.0005133353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036020952,0.0016354113,0.0010040168,0.0015341495,0.0020234885,0.0016076495,0.0010550839,0.0047837123,0.0017002124],"category_scores_gemma":[0.0019296306,0.00064287236,0.0016496732,0.0010866642,0.0014248997,0.001416251,0.001023663,0.002337232,0.0013262755],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033001466,0.0000494644,0.0037024028,0.000040138144,0.000017302906,0.99222916,0.00012118658,0.00015830011,0.0010745414,0.00013024543,0.00023479643,0.0022094673],"study_design_scores_gemma":[0.000008761923,0.00005858166,0.001462119,0.000007805832,0.000012354961,0.99693847,0.000042689764,0.00024987658,0.000568986,0.000060217608,0.00058378465,0.000006323363],"about_ca_topic_score_codex":0.0010583557,"about_ca_topic_score_gemma":0.0014780014,"teacher_disagreement_score":0.0047837123,"about_ca_system_score_codex":0.00115046,"about_ca_system_score_gemma":0.00060141593,"threshold_uncertainty_score":0.008347213},"labels":[],"label_agreement":null},{"id":"W3081708016","doi":"10.1101/2020.08.28.273029","title":"Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; National Institutes of Health; University of Toronto","keywords":"Biology; Transcriptome; Cancer research; Breast cancer; Population; Cancer; Genetics; Medicine; Gene; Gene expression","score_opus":0.030010849726923413,"score_gpt":0.28534996269393487,"score_spread":0.25533911296701145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081708016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968533,0.00083411415,0.00062574825,0.000045827896,0.0000059815115,0.00001437875,0.00040468556,0.000021922111,0.001194175],"genre_scores_gemma":[0.99642026,0.00039907882,0.00033715463,0.000036940713,0.000005787517,0.000025678704,0.00040632172,0.000009759606,0.0023589772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994767,0.0000051153793,0.0000033035121,0.000014035581,0.0000138171235,0.000015981437],"domain_scores_gemma":[0.99986994,0.000016815808,0.000041636038,0.000010659257,0.000018972483,0.00004206236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007232107,0.00009532851,0.0001180819,0.00038050176,0.00018786083,0.00036907734,0.00010656881,0.00028285917,0.00193628],"category_scores_gemma":[0.00013381714,0.00008835792,0.00011496757,0.00014650782,0.0001064176,0.00023512887,0.00039143921,0.00033260428,0.00043949235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025133597,0.00003693101,0.018790701,0.000033474855,0.0000077971,0.00027195006,0.00013879892,0.00011539891,0.9715971,0.00050117157,0.00014952227,0.00810585],"study_design_scores_gemma":[0.000024832123,0.0012749014,0.71140796,0.000036516907,0.000042465763,0.0047070202,0.0010092896,0.0029189312,0.26223782,0.001287441,0.015021172,0.00003167456],"about_ca_topic_score_codex":0.0003453166,"about_ca_topic_score_gemma":0.00032638505,"teacher_disagreement_score":0.00193628,"about_ca_system_score_codex":0.0001989343,"about_ca_system_score_gemma":0.00012550782,"threshold_uncertainty_score":0.006477535},"labels":[],"label_agreement":null},{"id":"W3081807968","doi":"10.3310/hta24400","title":"Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT","year":2020,"lang":"en","type":"article","venue":"Health Technology Assessment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"National Institute for Health and Care Research; Cancer Research UK; Eli Lilly and Company; AstraZeneca; National Cancer Research Institute; Daiichi Sankyo Europe; Health Technology Assessment Programme; Genentech; Servier; Pfizer; Eisai; Cancer Research Institute","keywords":"Trastuzumab; Medicine; Breast cancer; Clinical endpoint; Internal medicine; Randomized controlled trial; Oncology; Metastatic breast cancer; Adjuvant; Cancer; Surgery","score_opus":0.025793146387843965,"score_gpt":0.37273332795000214,"score_spread":0.34694018156215817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081807968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8230324,0.08577117,0.008677415,0.0074097747,0.0071342126,0.050580073,0.0024782098,0.00028828534,0.014628399],"genre_scores_gemma":[0.94213724,0.008227028,0.0070716063,0.004770793,0.0014514237,0.030315101,0.0005567493,0.00004655571,0.0054236],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97270274,0.02191415,0.0022793554,0.0013619164,0.00090676703,0.0008350877],"domain_scores_gemma":[0.98324424,0.010031752,0.003562363,0.0015710464,0.0008064319,0.0007842062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02226211,0.0022681842,0.0043263,0.0008317953,0.0006517295,0.0021207964,0.0011557477,0.0047358656,0.0109954225],"category_scores_gemma":[0.032766655,0.00087270007,0.007907086,0.00083414663,0.002036961,0.0029164974,0.0014585139,0.0038623947,0.0011304531],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9521069,0.002797769,0.0011043192,0.009258199,0.009905307,0.00015217291,0.00033853293,0.00038338703,0.0008428242,0.001008426,0.0010805767,0.021021653],"study_design_scores_gemma":[0.9582463,0.027437048,0.0013153311,0.0012474338,0.0065138396,0.000073885705,0.00010494026,0.00032232038,0.00027276576,0.0018476315,0.0025827927,0.000035754456],"about_ca_topic_score_codex":0.0010021061,"about_ca_topic_score_gemma":0.0015918525,"teacher_disagreement_score":0.02226211,"about_ca_system_score_codex":0.0015639577,"about_ca_system_score_gemma":0.0021474867,"threshold_uncertainty_score":0.11773473},"labels":[],"label_agreement":null},{"id":"W3083872932","doi":"10.1002/cncr.33149","title":"Higher serum PD‐L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Hazard ratio; Oncology; Proportional hazards model; Biomarker; Population; Cancer; Breast cancer; Gastroenterology; Confidence interval","score_opus":0.24914493463437037,"score_gpt":0.4245487594532483,"score_spread":0.17540382481887795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083872932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868227,0.0070470874,0.00018559211,0.00082801236,0.00006525909,0.00035423745,0.0008533684,0.000034078475,0.001950126],"genre_scores_gemma":[0.99647254,0.00076851354,0.00034388446,0.0005138799,0.00009301226,0.0002914068,0.0010602992,0.000009709576,0.00044674744],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99862814,0.0008962261,0.000060837247,0.00013224625,0.00014436674,0.00013813342],"domain_scores_gemma":[0.9976676,0.0007968718,0.00076777785,0.00012617411,0.00016379362,0.00047772905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003100077,0.0005337129,0.0014266465,0.00020788904,0.00033285073,0.00096505356,0.00053895696,0.0005932989,0.0016808027],"category_scores_gemma":[0.0039238804,0.00017958996,0.0011576936,0.00040787124,0.00032760898,0.00032545417,0.00022127078,0.001345399,0.00019614655],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.760868,0.0015114249,0.13961133,0.0010236951,0.0044485508,0.00019595989,0.00019868794,0.0023617288,0.0060925037,0.00043062668,0.009313485,0.073944055],"study_design_scores_gemma":[0.30933896,0.08849786,0.5680384,0.00048733442,0.008898512,0.0007908751,0.00016152904,0.00863713,0.0022703835,0.0011208088,0.011629974,0.00012821087],"about_ca_topic_score_codex":0.005822565,"about_ca_topic_score_gemma":0.024245609,"teacher_disagreement_score":0.005822565,"about_ca_system_score_codex":0.0017535074,"about_ca_system_score_gemma":0.002979847,"threshold_uncertainty_score":0.016394973},"labels":[],"label_agreement":null},{"id":"W3083874242","doi":"10.3389/fgene.2020.01016","title":"Pathway-Based Drug Response Prediction Using Similarity Identification in Gene Expression","year":2020,"lang":"en","type":"article","venue":"Frontiers in Genetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Princess Margaret Cancer Centre; Institute of Cancer Research; Ontario Institute for Cancer Research; University of Toronto","funders":"Ontario Institute for Cancer Research; Canadian Institutes of Health Research; Government of Ontario; Cancer Research Society; Genome Canada","keywords":"Lapatinib; Trastuzumab; Medicine; Breast cancer; Oncology; Logistic regression; Concordance; Univariate; Internal medicine; Cancer; Computational biology; Machine learning; Biology; Multivariate statistics; Computer science","score_opus":0.059988346184270326,"score_gpt":0.3287130958285926,"score_spread":0.26872474964432225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083874242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8777356,0.00065602915,0.11779219,0.00018505509,0.000012979296,0.00013986393,0.0014414821,0.0006493422,0.001387466],"genre_scores_gemma":[0.97771114,0.00012157614,0.020829666,0.000019601195,0.000008520475,0.00004296051,0.00097125256,0.000009142635,0.00028625823],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9995259,0.00016721706,0.000041605203,0.0001203106,0.0001010681,0.000044009274],"domain_scores_gemma":[0.99926096,0.00040246942,0.000176372,0.00003706483,0.00007907457,0.000043921227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007862426,0.0004084169,0.00052417,0.0021292889,0.00016600364,0.00051679637,0.00021223717,0.0003158118,0.0010145019],"category_scores_gemma":[0.001864596,0.00010027595,0.0005786739,0.0012617842,0.00023596229,0.0003476683,0.00036321487,0.00036020455,0.00034851072],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002769183,0.0011989448,0.34276336,0.00044673213,0.0006521522,0.00037283765,0.0001727392,0.15633312,0.13363321,0.0017507818,0.0009823437,0.3589247],"study_design_scores_gemma":[0.000049264647,0.0006168341,0.11997635,0.000017826826,0.00010131796,0.00040743657,0.00007036768,0.8527152,0.022124397,0.0031504787,0.00073446264,0.00003603557],"about_ca_topic_score_codex":0.0018036016,"about_ca_topic_score_gemma":0.0019287007,"teacher_disagreement_score":0.0021292889,"about_ca_system_score_codex":0.00045559916,"about_ca_system_score_gemma":0.0005273369,"threshold_uncertainty_score":0.004158139},"labels":[],"label_agreement":null},{"id":"W3084151679","doi":"10.1101/2020.09.09.290122","title":"Structural and dynamic characterization of the C-terminal tail of ErbB2: disordered but not random","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"French Infrastructure for Integrated Structural Biology; Centre National de la Recherche Scientifique; Université Paris-Sud; Agence Nationale de la Recherche","keywords":"Small-angle X-ray scattering; Protein kinase domain; Receptor tyrosine kinase; Signal transducing adaptor protein; Biophysics; Signal transduction; Protein tertiary structure; Intrinsically disordered proteins; Tyrosine kinase; Tyrosine; Protein structure; Biology; Chemistry; Cell biology; Biochemistry; Mutant; Physics; Scattering","score_opus":0.02044600539116284,"score_gpt":0.2665999173037357,"score_spread":0.24615391191257288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084151679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560744,0.0005432263,0.0024238012,0.00006266665,0.000010924333,0.0000065231557,0.00049042626,0.000040259478,0.0008147532],"genre_scores_gemma":[0.9971431,0.00017369611,0.001033785,0.0000345099,0.000005400671,0.000006186711,0.00089596416,0.000015291886,0.0006921824],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999535,0.0000041249587,0.0000029813996,0.0000115472285,0.00001574131,0.000012133494],"domain_scores_gemma":[0.99983954,0.00002584501,0.000041291783,0.000016191449,0.000039850474,0.00003737958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009328709,0.00016206435,0.00009023495,0.0001744021,0.00018633215,0.0001649215,0.00018055335,0.00014863156,0.0011054692],"category_scores_gemma":[0.00018173821,0.000101131096,0.00010982294,0.00018595978,0.00015857133,0.0001970976,0.00013451926,0.00026494672,0.0001751106],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011752985,0.0000217139,0.0019112171,0.000044463195,0.000013087548,0.00016342277,0.00003418556,0.0007853102,0.995665,0.00016796534,0.00018352696,0.0008925784],"study_design_scores_gemma":[0.000037734553,0.0003346323,0.07948597,0.00002837985,0.00005741691,0.0015833684,0.00033889132,0.051255804,0.8570915,0.00048070282,0.009260198,0.000045407913],"about_ca_topic_score_codex":0.0013285398,"about_ca_topic_score_gemma":0.0011437752,"teacher_disagreement_score":0.0013285398,"about_ca_system_score_codex":0.00019514591,"about_ca_system_score_gemma":0.00010865129,"threshold_uncertainty_score":0.0036981106},"labels":[],"label_agreement":null},{"id":"W3084860251","doi":"10.1017/s1460396920000746","title":"A review of clinical and emerging biomarkers for breast cancers: towards precision medicine for patients","year":2020,"lang":"en","type":"review","venue":"Journal of Radiotherapy in Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Guelph; Grand River Hospital; University of Waterloo","funders":"","keywords":"Medicine; Breast cancer; Malignancy; Disease; Precision medicine; Oncology; Cancer; Internal medicine; Intensive care medicine; Pathology","score_opus":0.154204515137662,"score_gpt":0.5709382007861928,"score_spread":0.41673368564853086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084860251","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010167214,0.99514425,0.00089554815,0.002889912,0.00045180248,0.000009754547,0.00003286996,0.000019531293,0.00045474808],"genre_scores_gemma":[0.0015926653,0.9921875,0.002110626,0.0025838704,0.0010698239,0.00003504736,0.000080630416,0.0000072081793,0.00033258827],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99667156,0.0013711166,0.000515627,0.0003673034,0.00095241686,0.00012194506],"domain_scores_gemma":[0.9900502,0.0062941522,0.0008451416,0.00028557103,0.002270722,0.00025417848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064418637,0.001225421,0.0025340952,0.0055076075,0.0005192628,0.0029196162,0.0015888314,0.0027907367,0.0020654937],"category_scores_gemma":[0.008616037,0.000627525,0.0016072026,0.004195168,0.0015476774,0.0037571178,0.0013754469,0.003971619,0.0011884844],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014322884,0.00007888318,0.0010731494,0.02659856,0.0003437943,0.00036788962,0.00022767864,0.00057707157,0.0019128849,0.0140998205,0.062304243,0.8922728],"study_design_scores_gemma":[0.000024342433,0.00021153239,0.0014690429,0.015195462,0.00034764453,0.001522628,0.00017650779,0.0004348135,0.0009949303,0.009101249,0.97045195,0.000069936825],"about_ca_topic_score_codex":0.0013010107,"about_ca_topic_score_gemma":0.0014136886,"teacher_disagreement_score":0.0064418637,"about_ca_system_score_codex":0.0018597479,"about_ca_system_score_gemma":0.0030205445,"threshold_uncertainty_score":0.034068227},"labels":[],"label_agreement":null},{"id":"W3087853974","doi":"10.1016/j.annonc.2020.08.454","title":"352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Pertuzumab; Hazard ratio; Trastuzumab; Internal medicine; Taxane; Breast cancer; Oncology; Clinical endpoint; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Placebo; Cancer; Clinical trial; Confidence interval; Pathology; Signal transduction","score_opus":0.06491574675293652,"score_gpt":0.4117682651337963,"score_spread":0.34685251838085973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087853974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240124,0.0022552053,0.000411471,0.0004317825,0.00012047615,0.00079071283,0.0011792546,0.00016748486,0.0022424767],"genre_scores_gemma":[0.9886502,0.0018040217,0.0011469444,0.00077157083,0.00015454051,0.0009901507,0.0033812763,0.00005871976,0.003042545],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99965394,0.00014273227,0.000016009979,0.000062286636,0.00002929859,0.00009581906],"domain_scores_gemma":[0.99960285,0.000050597428,0.000042781492,0.000032732896,0.000018193618,0.0002528774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001218751,0.0013942403,0.0015507407,0.00048380613,0.00033540544,0.0013158902,0.00091137236,0.0010768027,0.0044059004],"category_scores_gemma":[0.00061184156,0.000566839,0.0011944097,0.00048323534,0.0009610031,0.0010240766,0.0003783552,0.004132476,0.0013255203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.782895,0.039901156,0.0058079693,0.0005263933,0.001587146,0.0002405771,0.00026339793,0.002323951,0.04732001,0.0004112067,0.0041796565,0.11454355],"study_design_scores_gemma":[0.61902463,0.35180557,0.015847541,0.00003750136,0.00082712754,0.00039050548,0.00007847219,0.0015547285,0.0055979807,0.00019584091,0.0045931637,0.00004692228],"about_ca_topic_score_codex":0.0014326404,"about_ca_topic_score_gemma":0.0025436468,"teacher_disagreement_score":0.0044059004,"about_ca_system_score_codex":0.0008124936,"about_ca_system_score_gemma":0.0011593826,"threshold_uncertainty_score":0.014739156},"labels":[],"label_agreement":null},{"id":"W3087905898","doi":"10.1016/j.annonc.2020.08.2239","title":"LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Puma Biotechnology; Syndax Pharmaceuticals; F. Hoffmann-La Roche; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Taxane; Internal medicine; Clinical endpoint; Anthracycline; Cyclophosphamide; Breast cancer; Oncology; Triple-negative breast cancer; Chemotherapy; Phases of clinical research; Placebo; Neoadjuvant therapy; Doxorubicin; Gastroenterology; Surgery; Cancer; Randomized controlled trial; Pathology; Immunotherapy; Pembrolizumab","score_opus":0.16364009510904998,"score_gpt":0.48364156771962136,"score_spread":0.3200014726105714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087905898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97999144,0.0065226983,0.0010331525,0.0016678189,0.00037300942,0.0015032968,0.0042660404,0.0002574284,0.0043852776],"genre_scores_gemma":[0.9646435,0.0066611096,0.0036093334,0.0029038936,0.00032495311,0.0021022228,0.012851059,0.00017377826,0.006730116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995098,0.00022225859,0.0000232781,0.00007571422,0.000049503527,0.00011950135],"domain_scores_gemma":[0.99906534,0.00017739742,0.00013451945,0.00008642446,0.000056076584,0.00048029752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019678972,0.0013008763,0.0018819638,0.00034864797,0.00041490226,0.0013768473,0.0011901163,0.0011695932,0.004324676],"category_scores_gemma":[0.001031171,0.0005437163,0.001719685,0.0004952904,0.0009297521,0.00084702036,0.0004720656,0.00423741,0.0013722086],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5478737,0.0904021,0.012855537,0.0015196238,0.0033000729,0.000297845,0.0003550378,0.004279985,0.060934324,0.0005104124,0.015777454,0.26189396],"study_design_scores_gemma":[0.39852443,0.54305696,0.032875285,0.00014623685,0.002542264,0.00069931993,0.00018564123,0.0020756312,0.007339687,0.00046508113,0.012003784,0.00008567038],"about_ca_topic_score_codex":0.0018677694,"about_ca_topic_score_gemma":0.008204713,"teacher_disagreement_score":0.004324676,"about_ca_system_score_codex":0.0010627806,"about_ca_system_score_gemma":0.0017381409,"threshold_uncertainty_score":0.014467478},"labels":[],"label_agreement":null},{"id":"W3088305507","doi":"10.1016/j.annonc.2020.08.343","title":"221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Society for Medical Oncology; Pfizer Japan; Meso Scale Diagnostics; Novartis; AstraZeneca","keywords":"Medicine; Trastuzumab; Internal medicine; Breast cancer; Lapatinib; Clinical endpoint; Anthracycline; Oncology; Median follow-up; Cancer; Gastroenterology; Surgery; Chemotherapy; Randomized controlled trial","score_opus":0.1255883365181992,"score_gpt":0.45173019833508016,"score_spread":0.326141861816881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088305507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584633,0.0005918974,0.000050499573,0.00025236208,0.00006317005,0.00000973757,0.0017930069,0.000004133079,0.0013888787],"genre_scores_gemma":[0.99600214,0.00027099557,0.000018372142,0.0001940858,0.000073300005,0.000012958533,0.0022626545,0.0000022602248,0.0011633326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997837,0.000024910609,0.000016177923,0.00004765751,0.000021518506,0.000105944775],"domain_scores_gemma":[0.99939406,0.000066096734,0.00019108878,0.000032419834,0.00006405814,0.00025219918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029004776,0.00020057532,0.00029477722,0.0003016102,0.0004740671,0.0008977067,0.0003058002,0.0005243434,0.003109548],"category_scores_gemma":[0.0011069161,0.00014794084,0.0007590645,0.00053261983,0.00019131544,0.00083185476,0.0006118177,0.0010409664,0.00044498357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034412025,0.00030972835,0.9849321,0.00005629823,0.00030371183,0.00021456831,0.000120061544,0.00018857232,0.00041748834,0.00010171356,0.0015136555,0.008400781],"study_design_scores_gemma":[0.000100536585,0.0009875544,0.99650204,0.000027640683,0.00024405113,0.00018753426,0.0003590766,0.00028323606,0.00007530302,0.00017174434,0.0010466102,0.000014679463],"about_ca_topic_score_codex":0.0046603666,"about_ca_topic_score_gemma":0.008411196,"teacher_disagreement_score":0.0046603666,"about_ca_system_score_codex":0.00053094485,"about_ca_system_score_gemma":0.00046307585,"threshold_uncertainty_score":0.010402441},"labels":[],"label_agreement":null},{"id":"W3090447719","doi":"10.1016/j.cjca.2020.07.126","title":"CHALLENGES IN USING A DEEP LEARNING NETWORK TO PREDICT TRASTUZUMAB INDUCED CARDIOTOXICITY","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Asymptomatic; Internal medicine; Breast cancer; Oncology; Monoclonal antibody; Cardiology; Cancer; Antibody; Chemotherapy; Immunology","score_opus":0.1800084144554361,"score_gpt":0.3507374176590548,"score_spread":0.1707290032036187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090447719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50147235,0.012359221,0.4468335,0.020763407,0.0009526673,0.00021293656,0.0038280326,0.0022943632,0.011283586],"genre_scores_gemma":[0.9526291,0.001997375,0.03952981,0.0010542303,0.00023469613,0.00007299505,0.0009977969,0.00005482207,0.0034291274],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996289,0.00013316965,0.000035194866,0.00008267912,0.00007171411,0.000048397837],"domain_scores_gemma":[0.99746954,0.0016124168,0.00015463286,0.00011221054,0.00053641817,0.00011482466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019145018,0.0008418907,0.0007699479,0.00050763146,0.00024142838,0.0013862844,0.0009247873,0.0010971993,0.0014443892],"category_scores_gemma":[0.0055857785,0.00034071927,0.00039137097,0.0003044066,0.00022798439,0.0011617823,0.0006310032,0.0017388982,0.0007034202],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047554623,0.00050908484,0.051652044,0.0003093938,0.0003471796,0.00035450465,0.00005111989,0.5262696,0.0072167064,0.0029367893,0.012934357,0.39694363],"study_design_scores_gemma":[0.000011410443,0.00006748775,0.002235415,0.000038854912,0.000028426592,0.00005964072,0.000025055584,0.9911209,0.0016299316,0.0036691916,0.001104778,0.000008962996],"about_ca_topic_score_codex":0.010708407,"about_ca_topic_score_gemma":0.015765786,"teacher_disagreement_score":0.010708407,"about_ca_system_score_codex":0.0006181912,"about_ca_system_score_gemma":0.0011385232,"threshold_uncertainty_score":0.02129215},"labels":[],"label_agreement":null},{"id":"W3090684381","doi":"10.1007/s40265-020-01411-y","title":"Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars","year":2020,"lang":"en","type":"review","venue":"Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Pertuzumab; Lapatinib; Medicine; Biosimilar; Neratinib; Trastuzumab emtansine; Metastatic breast cancer; Breast cancer; Oncology; Targeted therapy; Internal medicine; Cancer; Pharmacology","score_opus":0.05352402178422109,"score_gpt":0.3772090738336325,"score_spread":0.3236850520494114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090684381","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000093506904,0.9984402,0.0001613694,0.00047281204,0.00021908201,0.000004492862,0.000021934364,0.0000064307033,0.00058023166],"genre_scores_gemma":[0.00068738905,0.99789447,0.00022871564,0.0005907047,0.00020353781,0.0000060190646,0.000037899572,0.000002217382,0.00034901052],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999627,0.000091751914,0.000045395373,0.000057871894,0.0001376309,0.000040280174],"domain_scores_gemma":[0.9992055,0.00050847256,0.00009408622,0.000014406645,0.00013183185,0.00004569049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014065123,0.0007728872,0.0016520701,0.0015023198,0.00013733644,0.0011584713,0.00081901613,0.0013842653,0.00467519],"category_scores_gemma":[0.0016249995,0.00022063832,0.00092742953,0.0014577488,0.0004167004,0.0016388858,0.0007108465,0.0025699192,0.001461389],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019109267,0.00006713384,0.00008934835,0.017691648,0.00013892811,0.0001240615,0.000032346805,0.00044208602,0.0015791885,0.005763621,0.027137661,0.94674283],"study_design_scores_gemma":[0.000114023795,0.00022037009,0.0005154674,0.006248644,0.00028744806,0.00066033617,0.000039462997,0.00020892335,0.0005005923,0.0033293872,0.98785317,0.00002226939],"about_ca_topic_score_codex":0.00085345993,"about_ca_topic_score_gemma":0.0019195927,"teacher_disagreement_score":0.00467519,"about_ca_system_score_codex":0.0007067514,"about_ca_system_score_gemma":0.0011150201,"threshold_uncertainty_score":0.01564002},"labels":[],"label_agreement":null},{"id":"W3092280067","doi":"10.1016/j.clbc.2020.09.014","title":"Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly Japan; Chugai Pharmaceutical; PharmaMar; AstraZeneca Australia; Kyowa Hakko Kirin; Astellas Pharma; Eisai; GlaxoSmithKline Australia; Puma Biotechnology; Genentech; Seattle Genetics; Genomic Health; AbbVie; Mount Sylvia Diatomite; Roche; Daiichi-Sankyo; Teva Pharmaceutical Industries; Pfizer Australia; Celgene; Novartis; Merck; GlaxoSmithKline; British Microcirculation Society; Amgen; Ontario Brain Institute; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company","keywords":"Neratinib; Medicine; Breast cancer; Oncology; Hormone receptor; Internal medicine; Stage (stratigraphy); Gynecology; Cancer; Trastuzumab","score_opus":0.12503202366143637,"score_gpt":0.45440523439789093,"score_spread":0.32937321073645454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092280067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94881636,0.020604918,0.0022333937,0.0034278254,0.0007281826,0.0011167198,0.010142043,0.00030081795,0.012629738],"genre_scores_gemma":[0.96435267,0.006381806,0.0018446653,0.002844501,0.000250645,0.00070781895,0.01616977,0.00013202963,0.007316187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993179,0.00030959942,0.00004464318,0.00008942633,0.00008325598,0.00015513068],"domain_scores_gemma":[0.99919707,0.00024825564,0.00011561057,0.00009314445,0.00008594398,0.00025994325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034017474,0.0013385842,0.0026010035,0.00023454202,0.0002965805,0.0014473654,0.00060939207,0.0007644151,0.003748509],"category_scores_gemma":[0.0022131116,0.00022859866,0.0024360733,0.00030164787,0.00051910395,0.001290692,0.00047481107,0.0029007695,0.0009488712],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6076659,0.006986404,0.009828628,0.0033369246,0.0080605885,0.0006703092,0.00036038097,0.014921799,0.02341738,0.001957823,0.037959125,0.28483468],"study_design_scores_gemma":[0.72891045,0.13559486,0.054770987,0.00053514686,0.008507668,0.002195588,0.00030859988,0.006823496,0.011216153,0.00632052,0.04458794,0.00022858431],"about_ca_topic_score_codex":0.00039384188,"about_ca_topic_score_gemma":0.0016143357,"teacher_disagreement_score":0.003748509,"about_ca_system_score_codex":0.0008249446,"about_ca_system_score_gemma":0.00071843667,"threshold_uncertainty_score":0.01799035},"labels":[],"label_agreement":null},{"id":"W3092474336","doi":"10.3390/cancers12102929","title":"Drug Resistance and Novel Therapies in Cancers","year":2020,"lang":"en","type":"editorial","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Drug resistance; Medicine; Drug; Pharmacology; Intensive care medicine; Bioinformatics; Biology; Microbiology","score_opus":0.02930812947669069,"score_gpt":0.3517981079342054,"score_spread":0.3224899784575147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092474336","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002497965,0.019994583,0.00011845548,0.05591892,0.9200529,0.00002058051,0.000047617676,0.00006530251,0.0037567748],"genre_scores_gemma":[0.00032448524,0.009629894,0.000090463276,0.042027242,0.9336322,0.000029283043,0.00003252981,0.00003617981,0.014197792],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937691,0.0016607102,0.0005219697,0.00055534596,0.0030358953,0.00045687],"domain_scores_gemma":[0.98054403,0.0091232415,0.0013183143,0.0005121857,0.0050598225,0.0034424202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009252347,0.00447072,0.004618408,0.0035767728,0.0036037245,0.0085381605,0.0040812283,0.025336374,0.02823116],"category_scores_gemma":[0.022530299,0.0016408158,0.00313211,0.0015142073,0.0029083746,0.0064730565,0.002776587,0.024326771,0.018489936],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027824526,0.000006210315,0.0000080380405,0.00012381755,0.000010363914,0.00003503627,0.0000037071675,0.000015581938,0.00002721177,0.00022721665,0.9948567,0.0046582744],"study_design_scores_gemma":[0.00011012714,0.000034243767,0.00011417094,0.00042687004,0.00005632194,0.0001427405,0.000016534383,0.00015365196,0.00004939947,0.0012414437,0.99764,0.000014524899],"about_ca_topic_score_codex":0.0032172913,"about_ca_topic_score_gemma":0.011201134,"teacher_disagreement_score":0.02823116,"about_ca_system_score_codex":0.0055959662,"about_ca_system_score_gemma":0.0037825152,"threshold_uncertainty_score":0.094442666},"labels":[],"label_agreement":null},{"id":"W3093476204","doi":"10.1016/j.ctrv.2020.102113","title":"National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study","year":2020,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Food and drug administration; Metastatic breast cancer; Cancer; Breast cancer; Drug; Cancer drugs; Oncology; Drug approval; Drug administration; Internal medicine; Intensive care medicine; Pharmacology","score_opus":0.2736387104802975,"score_gpt":0.5247481558783833,"score_spread":0.25110944539808583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093476204","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071746664,0.9904525,0.000368444,0.002809653,0.00046260323,0.00026104302,0.0026297553,0.000026794456,0.0022716664],"genre_scores_gemma":[0.0048663034,0.98778594,0.0019152972,0.0028147248,0.0001338021,0.0002830746,0.0014168166,0.00001437097,0.0007695877],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963068,0.0011295864,0.0009953479,0.00030237297,0.0011444417,0.00012137619],"domain_scores_gemma":[0.99077564,0.0046684747,0.0022336082,0.00018276337,0.0018939114,0.00024564247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009292885,0.000709261,0.0030351575,0.0033381952,0.00033221036,0.0015020267,0.0019327613,0.0014496462,0.00582151],"category_scores_gemma":[0.015385077,0.0005881831,0.0039220224,0.00396448,0.00033590078,0.0015115818,0.000663494,0.0017672763,0.0009984605],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090788834,0.0001681436,0.0049060397,0.1993446,0.006826169,0.00008399417,0.00013625191,0.0005097982,0.00052202115,0.0023766146,0.1508569,0.6333615],"study_design_scores_gemma":[0.0011448611,0.0004167242,0.03291266,0.2819427,0.02519646,0.00038497138,0.00027045494,0.00033614424,0.00053107354,0.0013779625,0.6553824,0.00010355546],"about_ca_topic_score_codex":0.014760422,"about_ca_topic_score_gemma":0.05258242,"teacher_disagreement_score":0.014760422,"about_ca_system_score_codex":0.002746495,"about_ca_system_score_gemma":0.007002084,"threshold_uncertainty_score":0.049146056},"labels":[],"label_agreement":null},{"id":"W3093752709","doi":"10.1016/j.breast.2020.10.003","title":"Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Toronto; Mount Sinai Hospital; Western University","funders":"Janssen Canada; Novartis; Bayer","keywords":"Trastuzumab; Medicine; Breast cancer; Meta-analysis; Internal medicine; Adjuvant; Oncology; Adjuvant therapy; Randomized controlled trial; Subgroup analysis; Cancer; Surgery","score_opus":0.10818742444388223,"score_gpt":0.39569247456465007,"score_spread":0.2875050501207678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093752709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031489255,0.99537694,0.00030523373,0.00023216683,0.00013277875,0.00016445645,0.00039862577,0.00001246962,0.0002283404],"genre_scores_gemma":[0.16291095,0.83149457,0.0015281086,0.0015709435,0.00030197747,0.00082322356,0.000955425,0.000031317475,0.00038346843],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99100083,0.0041712937,0.002640206,0.0009799238,0.0009407617,0.0002669824],"domain_scores_gemma":[0.9817514,0.013286166,0.0030465776,0.00056063145,0.0011336851,0.00022154255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013268175,0.0022644503,0.018432308,0.004469256,0.0004981438,0.0030811366,0.0019402391,0.002066359,0.00346476],"category_scores_gemma":[0.030328687,0.0015044198,0.03830362,0.005044823,0.0006783268,0.002083512,0.0012786685,0.0019794474,0.00033919894],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023617374,0.000022814811,0.0033511273,0.36054552,0.62054133,0.000104924504,0.00006953126,0.0004807747,0.00015779119,0.00017005547,0.00071429164,0.011480015],"study_design_scores_gemma":[0.00073999335,0.0001726622,0.0034093787,0.02681491,0.96637636,0.00010153472,0.000036957943,0.00013635057,0.00007818709,0.00027042945,0.001841485,0.00002168636],"about_ca_topic_score_codex":0.0069973217,"about_ca_topic_score_gemma":0.015944414,"teacher_disagreement_score":0.018432308,"about_ca_system_score_codex":0.0028571372,"about_ca_system_score_gemma":0.0030094534,"threshold_uncertainty_score":0.07016963},"labels":[],"label_agreement":null},{"id":"W3093782821","doi":"10.1007/s10549-020-05976-w","title":"A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer","year":2020,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Lumpectomy; Breast cancer; Trastuzumab; Stage (stratigraphy); Population; Internal medicine; Cancer; Oncology; Cancer registry; Health care; Gynecology; Mastectomy; Environmental health","score_opus":0.10140654018881648,"score_gpt":0.41887150982277555,"score_spread":0.3174649696339591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093782821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279636,0.00046611897,0.00006569941,0.00017854368,0.0000047467747,0.000030284751,0.005529478,0.000004013878,0.00092477596],"genre_scores_gemma":[0.9971143,0.00016405224,0.00007113695,0.00004200532,0.000004971251,0.000017815728,0.0024043266,0.0000015609578,0.00017969584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991592,0.00010278228,0.000071896204,0.0001264282,0.00031934446,0.00022034126],"domain_scores_gemma":[0.99867475,0.000111178175,0.0006549633,0.000047396992,0.00033308237,0.0001785652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005641505,0.0002808507,0.0003101962,0.0012334161,0.00086784706,0.0006757569,0.0006189514,0.00031226283,0.001650347],"category_scores_gemma":[0.002460403,0.00021983305,0.00073825265,0.0034710949,0.0003830719,0.00035461565,0.0005254884,0.00027590815,0.000103712795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008333839,0.000016080916,0.9971258,0.000037909584,0.00011359764,0.000028726363,0.00014459692,0.00016796715,0.0000678307,0.000035982997,0.00058095943,0.0015974243],"study_design_scores_gemma":[0.000008826164,0.000013956637,0.99933237,0.00001034145,0.000024216288,0.000023711784,0.00012278475,0.00016052056,0.000009805253,0.000008757854,0.00028183416,0.0000027549506],"about_ca_topic_score_codex":0.938063,"about_ca_topic_score_gemma":0.95561135,"teacher_disagreement_score":0.98303086,"about_ca_system_score_codex":0.016969131,"about_ca_system_score_gemma":0.009797786,"threshold_uncertainty_score":0.12460339},"labels":[],"label_agreement":null},{"id":"W3095550184","doi":"10.1038/s41598-020-75279-z","title":"Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Insulin-like growth factor; Drug; Conjugate; Pharmacology; Cancer; Growth factor; Medicine; Cancer research; Receptor; Oncology; Internal medicine","score_opus":0.15934996027989135,"score_gpt":0.4128545193625031,"score_spread":0.25350455908261177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095550184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927229,0.0011855223,0.0037640466,0.000115193005,0.00007321317,0.00045991174,0.00045575228,0.00012406822,0.0010992438],"genre_scores_gemma":[0.98942685,0.0013489022,0.00600162,0.00005024414,0.000020233128,0.00042052034,0.00070041016,0.0000394662,0.001991801],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979776,0.00004790808,0.000014400537,0.00003171938,0.000058262583,0.000049916154],"domain_scores_gemma":[0.9998282,0.000026804402,0.000044420784,0.00002358648,0.00003067512,0.00004631041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000610352,0.00066159054,0.000542249,0.0003358046,0.00019572918,0.00038745304,0.0005430024,0.00052305625,0.0010514295],"category_scores_gemma":[0.00027653464,0.0002672111,0.0002992598,0.00030128832,0.00024114127,0.00031173605,0.0001464694,0.0010098866,0.00032816318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001125044,0.001535286,0.0002398993,0.00009582697,0.00002450548,0.00005874563,0.000034639965,0.0012678418,0.99018526,0.00009228131,0.00016565171,0.005174958],"study_design_scores_gemma":[0.00023119952,0.01345182,0.0010418227,0.0000062802806,0.00006173809,0.00012670418,0.000014252451,0.0029028011,0.9803611,0.000018955747,0.0017756843,0.0000077458135],"about_ca_topic_score_codex":0.0014195004,"about_ca_topic_score_gemma":0.0014008972,"teacher_disagreement_score":0.0014195004,"about_ca_system_score_codex":0.0005882927,"about_ca_system_score_gemma":0.0005139516,"threshold_uncertainty_score":0.004268408},"labels":[],"label_agreement":null},{"id":"W3095704533","doi":"10.1182/blood-2020-137078","title":"Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Bendamustine; Rituximab; Medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; Phases of clinical research; Lymphoma; Internal medicine; Oncology; Chemotherapy; Materials science","score_opus":0.032755742784233016,"score_gpt":0.3085714796981534,"score_spread":0.27581573691392036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095704533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722692,0.017272605,0.0012267276,0.001155961,0.0003222709,0.0029102024,0.0023316683,0.00012478206,0.0023865753],"genre_scores_gemma":[0.9784631,0.008411984,0.0029289683,0.0020097685,0.00051281526,0.0023765543,0.004148066,0.000044967783,0.0011037625],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99804556,0.0012239158,0.00018370962,0.00020886428,0.00020025573,0.00013765777],"domain_scores_gemma":[0.99724233,0.0008487696,0.00085369765,0.00024863324,0.00026401275,0.0005425509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051808828,0.00083031005,0.002035494,0.00042083568,0.00020795011,0.0013911049,0.00090041274,0.0008452144,0.0024121578],"category_scores_gemma":[0.0032631473,0.00048808297,0.0018818267,0.00068498944,0.00062589464,0.0010108786,0.0004583118,0.0023351682,0.00032448288],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8356913,0.010089722,0.007603527,0.0021756764,0.0061721103,0.0001781307,0.00018567973,0.0011442337,0.012556862,0.00029009598,0.002874763,0.12103794],"study_design_scores_gemma":[0.8421325,0.12648736,0.01574693,0.00022683947,0.0065680603,0.00033559342,0.000064624466,0.0007400958,0.0017332999,0.0002690812,0.005656193,0.000039558356],"about_ca_topic_score_codex":0.00071149645,"about_ca_topic_score_gemma":0.0021768038,"teacher_disagreement_score":0.0051808828,"about_ca_system_score_codex":0.0008643603,"about_ca_system_score_gemma":0.0013363824,"threshold_uncertainty_score":0.02739942},"labels":[],"label_agreement":null},{"id":"W3096107020","doi":"10.1182/blood-2020-142859","title":"A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Adverse effect; Population; Internal medicine; Gastroenterology; Phases of clinical research; Pharmacodynamics; Refractory (planetary science); Antibody-drug conjugate; Diffuse large B-cell lymphoma; Toxicity; Pharmacology; Lymphoma; Urology; Antibody; Immunology; Monoclonal antibody","score_opus":0.02164718382084827,"score_gpt":0.31118856560637054,"score_spread":0.28954138178552224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096107020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964813,0.00044415466,0.00067295454,0.00012120912,0.00001937686,0.00096833217,0.0003931146,0.00009272648,0.0008068231],"genre_scores_gemma":[0.9949674,0.00043020703,0.001402098,0.00028755894,0.000048857954,0.00090055243,0.0008779977,0.000032053656,0.001053233],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996495,0.00018138203,0.000014026073,0.00005744753,0.000041907595,0.000055587734],"domain_scores_gemma":[0.9994499,0.00009622051,0.00011248416,0.0000743811,0.000041554533,0.00022543146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011534068,0.00091797224,0.0011347871,0.00031443138,0.0002709086,0.00073440385,0.00061483664,0.0006298363,0.0019604026],"category_scores_gemma":[0.0007365335,0.00041612345,0.0007307495,0.00029881162,0.0007059631,0.0006119454,0.0002344014,0.0023895632,0.00062096363],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30483225,0.14705251,0.020594053,0.0008338356,0.001275206,0.0007290847,0.0010046235,0.00784827,0.31040853,0.00047833906,0.005075494,0.19986781],"study_design_scores_gemma":[0.1855212,0.756666,0.025219876,0.000027074346,0.0005376226,0.0008142539,0.00011609586,0.0031363405,0.023823233,0.00027458367,0.0038143226,0.000049422542],"about_ca_topic_score_codex":0.00045083315,"about_ca_topic_score_gemma":0.0010326013,"teacher_disagreement_score":0.0019604026,"about_ca_system_score_codex":0.0006553377,"about_ca_system_score_gemma":0.0008869751,"threshold_uncertainty_score":0.00655818},"labels":[],"label_agreement":null},{"id":"W3101556373","doi":"10.3390/ijms21228732","title":"Role of iRhoms 1 and 2 in Endochondral Ossification","year":2020,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; National Institutes of Health; Deutsche Forschungsgemeinschaft","keywords":"Endochondral ossification; Cell biology; Chemistry; Cartilage; Chondrocyte; Ossification; Transforming growth factor; Bone growth; Intramembranous ossification; Internal medicine; Endocrinology; Biology; Anatomy; Medicine","score_opus":0.04461041628779224,"score_gpt":0.3859035092801751,"score_spread":0.34129309299238286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101556373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071306,0.003802221,0.0012563356,0.00016819083,0.00003796239,0.000021962314,0.00040042066,0.00010293486,0.0034970609],"genre_scores_gemma":[0.99004084,0.0014624047,0.0015137434,0.00009949919,0.00002762956,0.000031074323,0.0005595797,0.000028103472,0.0062371837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979955,0.000015386762,0.000017393966,0.000060806753,0.000051243107,0.00005558198],"domain_scores_gemma":[0.99973327,0.000017043985,0.00011826944,0.000020880574,0.000013625944,0.00009700119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017571828,0.00037583787,0.0003009134,0.00046917904,0.00028852004,0.00044554466,0.0003638562,0.0005847505,0.002086421],"category_scores_gemma":[0.00013014408,0.00022923072,0.00026935842,0.00012268031,0.00032827054,0.00030494397,0.0003971393,0.0006099726,0.00063755905],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023228569,0.000034575314,0.001255302,0.00007195065,0.0000055130213,0.00037948196,0.000025230549,0.000059059654,0.994942,0.00037437188,0.000074357544,0.0025460308],"study_design_scores_gemma":[0.00008824752,0.00048661555,0.07634946,0.00005257117,0.000048820362,0.002915663,0.00019744491,0.00073602924,0.90794843,0.0002962606,0.010851127,0.00002940901],"about_ca_topic_score_codex":0.00023621845,"about_ca_topic_score_gemma":0.00039493333,"teacher_disagreement_score":0.002086421,"about_ca_system_score_codex":0.00022182504,"about_ca_system_score_gemma":0.0002177619,"threshold_uncertainty_score":0.006979823},"labels":[],"label_agreement":null},{"id":"W310270586","doi":"","title":"[Prognostic role of human epidermal growth factor receptor 2 in resectable gastric cancer: a meta-analysis].","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Cochrane Library; Internal medicine; Oncology; Cancer; MEDLINE; Web of science; Gastroenterology","score_opus":0.21101581042050882,"score_gpt":0.37390667580121845,"score_spread":0.16289086538070963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W310270586","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022751303,0.97101676,0.002113079,0.0007386295,0.0008703834,0.00048634293,0.001486768,0.00009691625,0.00043980937],"genre_scores_gemma":[0.64865935,0.33688068,0.0054321773,0.0023162905,0.0010431665,0.0019220356,0.002164121,0.00010009208,0.00148215],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9941497,0.003313661,0.0010272078,0.00074921816,0.00050355104,0.00025668603],"domain_scores_gemma":[0.9943141,0.00345711,0.0011914301,0.00036985756,0.00047594207,0.00019157695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011425807,0.0028838234,0.011339519,0.005069372,0.0005144361,0.002450763,0.0016679538,0.0027244682,0.003925256],"category_scores_gemma":[0.019027717,0.0013993925,0.049255755,0.0043669157,0.00035749766,0.0011815964,0.0011682293,0.0017022727,0.00046865788],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054528755,0.000020201196,0.00768754,0.05639216,0.9235171,0.00013445911,0.000029291046,0.00053245376,0.00035049857,0.00006695458,0.0007397248,0.0050767115],"study_design_scores_gemma":[0.0013402062,0.00025428605,0.00422866,0.0026205417,0.99024826,0.00009430378,0.000016017375,0.00022992755,0.00010156471,0.00011776298,0.00073153095,0.00001678075],"about_ca_topic_score_codex":0.005406531,"about_ca_topic_score_gemma":0.009721941,"teacher_disagreement_score":0.011425807,"about_ca_system_score_codex":0.0013155858,"about_ca_system_score_gemma":0.0018004195,"threshold_uncertainty_score":0.060426176},"labels":[],"label_agreement":null},{"id":"W3105819471","doi":"10.1021/acs.jpclett.0c02327","title":"Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor","year":2020,"lang":"en","type":"article","venue":"The Journal of Physical Chemistry Letters","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Canadian Institute for Advanced Research; Richard and Susan Smith Family Foundation; National Cancer Institute; Arnold and Mabel Beckman Foundation; Alfred P. Sloan Foundation","keywords":"Autophosphorylation; Phosphorylation; Epidermal growth factor receptor; Biophysics; Tyrosine; Epidermal growth factor; Chemistry; Docking (animal); Tyrosine phosphorylation; Receptor tyrosine kinase; Cell biology; Tyrosine kinase; Protein kinase domain; Signal transduction; Receptor; Biochemistry; Biology; Protein kinase A; Mutant","score_opus":0.021964697882905435,"score_gpt":0.28512667786527696,"score_spread":0.2631619799823715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105819471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863964,0.000057895068,0.0007120326,0.000029048375,0.000004930814,0.0000036867805,0.00003297912,0.000019121175,0.00050066627],"genre_scores_gemma":[0.9992435,0.00006470374,0.0004612787,0.0000121725425,0.0000012953793,0.000004517172,0.000077668854,0.000007892676,0.00012701645],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996436,0.0000039176175,0.0000015414365,0.000008514517,0.0000073331857,0.000014293169],"domain_scores_gemma":[0.9999368,0.000022242852,0.000012324551,0.0000060823477,0.000006047615,0.000016486048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009684527,0.00016944323,0.00016369336,0.00012254562,0.00036361642,0.00028507024,0.0003246246,0.00020814908,0.0010367003],"category_scores_gemma":[0.0002191044,0.00016365123,0.00018486493,0.000098903234,0.00051655923,0.00050443714,0.00017663311,0.00040715662,0.000069969115],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014294831,0.00060777547,0.010765817,0.00028650174,0.00016323755,0.0010822046,0.00060249213,0.5959579,0.36413714,0.015158731,0.00144552,0.008363243],"study_design_scores_gemma":[0.00019527134,0.0003425413,0.009649514,0.000013326542,0.000040196188,0.000072355,0.00025393243,0.9469761,0.03898432,0.002754525,0.0006665121,0.000051344137],"about_ca_topic_score_codex":0.003341595,"about_ca_topic_score_gemma":0.0036467162,"teacher_disagreement_score":0.003341595,"about_ca_system_score_codex":0.0005046812,"about_ca_system_score_gemma":0.00035738997,"threshold_uncertainty_score":0.006644249},"labels":[],"label_agreement":null},{"id":"W3107784614","doi":"10.1021/acs.bioconjchem.0c00563","title":"Rapid, High-Yielding Solid-Phase Synthesis of Cathepsin-B Cleavable Linkers for Targeted Cancer Therapeutics","year":2020,"lang":"en","type":"article","venue":"Bioconjugate Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Linker; Chemistry; Combinatorial chemistry; Solid-phase synthesis; Conjugate; Protecting group; Peptide synthesis; Peptide; Biochemistry; Organic chemistry","score_opus":0.09069001897675098,"score_gpt":0.39973601750512205,"score_spread":0.30904599852837106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107784614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68964314,0.0114381295,0.28036273,0.00039608608,0.00015371568,0.0009679436,0.0019263494,0.0015259066,0.01358602],"genre_scores_gemma":[0.86917853,0.005726097,0.11779541,0.00013351349,0.000028818278,0.0003750225,0.0011773758,0.0001694216,0.005415773],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997707,0.00003891282,0.000022845843,0.000036859947,0.00009273512,0.000037947153],"domain_scores_gemma":[0.99987745,0.000032298896,0.000039878865,0.000013455582,0.00001708345,0.000019750585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040874156,0.00049025746,0.000283869,0.00028710635,0.00016419627,0.00026939,0.00031228308,0.00036462204,0.00154658],"category_scores_gemma":[0.00034531445,0.00022855811,0.00022613727,0.0003221667,0.00017721156,0.00036885694,0.00029830294,0.00054813066,0.0010112696],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048866015,0.000044296274,0.000047466117,0.00012971585,0.000008628294,0.000090081994,0.000029648296,0.00070541253,0.9906792,0.0007172514,0.00018658001,0.007312818],"study_design_scores_gemma":[0.000026103966,0.00021671299,0.0001483559,0.000006807497,0.000006455186,0.00015827428,0.0000074259774,0.0010305899,0.99173707,0.00011071477,0.006542122,0.0000092674345],"about_ca_topic_score_codex":0.00019268774,"about_ca_topic_score_gemma":0.0008031612,"teacher_disagreement_score":0.00154658,"about_ca_system_score_codex":0.00030274183,"about_ca_system_score_gemma":0.00044130255,"threshold_uncertainty_score":0.005173862},"labels":[],"label_agreement":null},{"id":"W3111242120","doi":"10.1101/2020.12.08.417006","title":"A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Extracellular; Transmembrane protein; Epidermal growth factor; Receptor tyrosine kinase; Epidermal growth factor receptor; Cell biology; Tyrosine kinase; Transforming growth factor; Ligand (biochemistry); Chemistry; Transmembrane domain; Intracellular; Receptor; Signal transduction; Biophysics; Growth factor receptor; Biology; Biochemistry","score_opus":0.04844546252924644,"score_gpt":0.28581171924563425,"score_spread":0.2373662567163878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111242120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95262086,0.0013064982,0.037469625,0.0012874859,0.00013173914,0.00004714847,0.00016789157,0.0003608876,0.00660795],"genre_scores_gemma":[0.9929467,0.00030834664,0.004447634,0.00017723735,0.000020827089,0.000023823919,0.0000695445,0.000017007575,0.001988952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989355,0.000016518936,0.000005472454,0.000025346299,0.000033527864,0.00002560282],"domain_scores_gemma":[0.9999416,0.0000089033665,0.000013527045,0.000009783472,0.0000073143,0.000018984485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017712626,0.00019790565,0.00019443234,0.00012099551,0.00021793744,0.00038356302,0.0003387858,0.0004543036,0.0020159818],"category_scores_gemma":[0.0001704219,0.00016472144,0.00022114824,0.000085309075,0.00034346236,0.000436141,0.00033789972,0.00058892975,0.0005954493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080528065,0.00003633553,0.0003062536,0.00003398958,0.0000066252737,0.00019840655,0.000019402656,0.00030440983,0.99209964,0.004467578,0.00024868746,0.0021981508],"study_design_scores_gemma":[0.00008972787,0.00017774271,0.0040333113,0.000013702439,0.00001184107,0.00071229594,0.00005633892,0.009148063,0.9777581,0.00323986,0.0047453893,0.000013576603],"about_ca_topic_score_codex":0.00008211939,"about_ca_topic_score_gemma":0.00008379276,"teacher_disagreement_score":0.0020159818,"about_ca_system_score_codex":0.00026729185,"about_ca_system_score_gemma":0.00012585813,"threshold_uncertainty_score":0.0067441463},"labels":[],"label_agreement":null},{"id":"W3112085252","doi":"10.1186/s13046-020-01797-3","title":"Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study","year":2020,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Pertuzumab; Trastuzumab; Trastuzumab emtansine; Medicine; Taxane; Oncology; Internal medicine; Breast cancer; Cancer; Pharmacology; Cancer research","score_opus":0.1485700922824443,"score_gpt":0.5444483581006178,"score_spread":0.3958782658181734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112085252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992157,0.00038464088,0.00007061962,0.000035752357,0.000003834072,0.000016591926,0.00004462172,0.000002884366,0.00022537069],"genre_scores_gemma":[0.99855417,0.000480256,0.00015147399,0.00006384093,0.000023449016,0.000021682621,0.00019748662,0.0000030016115,0.0005045687],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998529,0.000058239577,0.000010762774,0.000023344213,0.000028578504,0.000026145522],"domain_scores_gemma":[0.9998154,0.000051111558,0.000034967154,0.000029861225,0.000013895012,0.000054818956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005094111,0.00023910572,0.0005691675,0.00019558758,0.0001117935,0.0003092908,0.0002019834,0.000270174,0.0013670543],"category_scores_gemma":[0.00030392114,0.00011279835,0.0003581632,0.00016997075,0.00023362761,0.00024207884,0.00019181079,0.0007374078,0.00018127389],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1181017,0.030063527,0.08244282,0.00057826156,0.0010921472,0.0016501998,0.0005417866,0.0020992907,0.6523697,0.00047232938,0.0013340645,0.1092542],"study_design_scores_gemma":[0.011459307,0.41513127,0.28682303,0.000034056662,0.0016979175,0.006344167,0.00029101124,0.0059063546,0.25766778,0.00038612552,0.01420689,0.000052195894],"about_ca_topic_score_codex":0.00020578381,"about_ca_topic_score_gemma":0.00032362,"teacher_disagreement_score":0.0013670543,"about_ca_system_score_codex":0.00026218232,"about_ca_system_score_gemma":0.00020852512,"threshold_uncertainty_score":0.0045732856},"labels":[],"label_agreement":null},{"id":"W3114182039","doi":"10.1111/cge.13900","title":"Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review","year":2020,"lang":"en","type":"review","venue":"Clinical Genetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Women's College Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Subtyping; Breast cancer; Computational biology; Cancer; Biology; Genetics; Oncology; Medicine; Bioinformatics; Computer science; Programming language","score_opus":0.4118269879179667,"score_gpt":0.5911137378199902,"score_spread":0.17928674990202353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114182039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038870527,0.99934715,0.00004980034,0.0001828658,0.00010052255,0.0000029182268,0.000012120032,0.0000029223766,0.00026282325],"genre_scores_gemma":[0.00027488323,0.9993111,0.00009497184,0.00012202699,0.000081218146,0.0000035313246,0.000018277491,8.012988e-7,0.00009317356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971145,0.000068639136,0.000058574264,0.000046741985,0.000091957816,0.000022637289],"domain_scores_gemma":[0.99877805,0.00079545454,0.00012633251,0.00002450198,0.00021917245,0.00005650144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011938796,0.0008347088,0.0016042825,0.0038587565,0.00023527708,0.0010433646,0.0009920236,0.0008860108,0.0031058576],"category_scores_gemma":[0.0022858875,0.0003014406,0.0007917688,0.0042367163,0.00050447416,0.0014369307,0.00071031286,0.001512764,0.0010850292],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008583172,0.000044261455,0.00023654461,0.043687172,0.00018132699,0.00012776296,0.00006818678,0.00032546077,0.00055629987,0.0029993288,0.029674662,0.9220132],"study_design_scores_gemma":[0.000028551527,0.00013148854,0.0016851011,0.03147931,0.00057599135,0.0014448892,0.000094594,0.00012646047,0.00023179766,0.0025954375,0.96157545,0.000030936342],"about_ca_topic_score_codex":0.0015903157,"about_ca_topic_score_gemma":0.0030182851,"teacher_disagreement_score":0.0038587565,"about_ca_system_score_codex":0.00089454785,"about_ca_system_score_gemma":0.0019246725,"threshold_uncertainty_score":0.010390103},"labels":[],"label_agreement":null},{"id":"W3115087778","doi":"10.3390/cancers13010044","title":"HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Leids Universitair Medisch Centrum; National Institute for Health and Care Research; Universiteit Leiden; Cancer Research UK","keywords":"Oncology; Medicine; Internal medicine; Endometrial cancer; Bioinformatics; Gynecology; Cancer; Biology","score_opus":0.10741671877125591,"score_gpt":0.40010839891139355,"score_spread":0.29269168014013763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115087778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990748,0.0005527877,0.000071930386,0.00002339029,0.000003194326,0.000008954584,0.00006904764,9.8026e-7,0.00019483964],"genre_scores_gemma":[0.9994148,0.00013943866,0.000089738634,0.000024381316,0.000011965038,0.000014338572,0.0002113617,8.543677e-7,0.000093209004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968445,0.0001418716,0.00003319601,0.00004170715,0.000058132773,0.000040545576],"domain_scores_gemma":[0.99956876,0.00012884935,0.00013596244,0.000057323912,0.000031409327,0.000077590914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012115631,0.000112326925,0.00027671162,0.00023202752,0.00012021852,0.00035936644,0.00015529034,0.00021210994,0.00055153185],"category_scores_gemma":[0.0011607623,0.000089934976,0.0003263583,0.0003491264,0.0001847636,0.00026979562,0.00028437638,0.00029908694,0.00007678369],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054984097,0.00022678799,0.9735584,0.00005692297,0.00023507873,0.00018053943,0.000030323961,0.00021112672,0.003199773,0.000048719965,0.000115152725,0.016638733],"study_design_scores_gemma":[0.00039870606,0.0026654946,0.9926682,0.0000134655465,0.00021824946,0.0010164372,0.00005468739,0.0007595587,0.0013242353,0.00008985978,0.0007857441,0.0000053591166],"about_ca_topic_score_codex":0.0002538723,"about_ca_topic_score_gemma":0.00072561053,"teacher_disagreement_score":0.0012115631,"about_ca_system_score_codex":0.00015600525,"about_ca_system_score_gemma":0.00019023566,"threshold_uncertainty_score":0.0064074397},"labels":[],"label_agreement":null},{"id":"W3115666250","doi":"10.1016/j.ejca.2020.11.023","title":"Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Charles-Le Moyne","funders":"","keywords":"Pertuzumab; Medicine; Rash; Internal medicine; Hazard ratio; Metastatic breast cancer; Cohort; Proportional hazards model; Breast cancer; Oncology; Cohort study; Cancer; Confidence interval","score_opus":0.03363012525165893,"score_gpt":0.3112171129630532,"score_spread":0.2775869877113943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115666250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975005,0.0013765949,0.00007292914,0.00010962494,0.000015688534,0.000025362726,0.0006305355,0.00000570924,0.0002629868],"genre_scores_gemma":[0.99783105,0.00041259718,0.00010924082,0.00011276441,0.0000756928,0.000034171404,0.001169999,0.0000048840725,0.00024972227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884415,0.0006036181,0.00009027694,0.00020286912,0.00010433251,0.0001547391],"domain_scores_gemma":[0.99699175,0.0011734583,0.0008621067,0.00036566297,0.00012962832,0.000477247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00245526,0.000816125,0.0014811673,0.00028076052,0.00037625016,0.0014410727,0.0006013531,0.000841444,0.0017482318],"category_scores_gemma":[0.003641972,0.00035440593,0.0026654266,0.00066920184,0.00047729025,0.00076874916,0.0007575618,0.0015455523,0.00021693711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28025952,0.0016959005,0.65710443,0.0010169479,0.026355436,0.00084283267,0.00025383433,0.0023705757,0.0058396235,0.0002354877,0.0022131498,0.02181229],"study_design_scores_gemma":[0.01957788,0.018200519,0.9403896,0.000109895474,0.014958453,0.0010833595,0.0002578143,0.0020783113,0.00077123946,0.000500862,0.0019692185,0.00010283791],"about_ca_topic_score_codex":0.00081112934,"about_ca_topic_score_gemma":0.0016954255,"teacher_disagreement_score":0.00245526,"about_ca_system_score_codex":0.00041190404,"about_ca_system_score_gemma":0.00049247686,"threshold_uncertainty_score":0.012984812},"labels":[],"label_agreement":null},{"id":"W3116148769","doi":"10.3747/co.27.6517","title":"Economic Evaluation of Adjuvant Trastuzumab Emtansine in Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease after Neoadjuvant Taxane and Trastuzumab–Based Treatment in Canada","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Roche (Canada); Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Trastuzumab emtansine; Medicine; Hazard ratio; Oncology; Internal medicine; Breast cancer; Taxane; Confidence interval; Clinical trial; Cancer","score_opus":0.055360135410148364,"score_gpt":0.3608170115498937,"score_spread":0.30545687613974537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116148769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753465,0.0051266607,0.0018613745,0.0031120414,0.000048615817,0.0010236442,0.0040195645,0.00001991319,0.00944174],"genre_scores_gemma":[0.9965772,0.0009454565,0.000823178,0.0001516431,0.000007228059,0.000097610355,0.0008604818,0.0000045006177,0.0005327289],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9976585,0.0012114488,0.00008890569,0.00011975347,0.00040652996,0.0005148601],"domain_scores_gemma":[0.99579716,0.0019261622,0.000526862,0.00009065001,0.0008890139,0.00077017536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003970921,0.0007487376,0.00081737497,0.0009794832,0.0010283774,0.0017306001,0.0012460544,0.00066649547,0.0025133756],"category_scores_gemma":[0.013402076,0.00039999787,0.002174123,0.0017225738,0.000681944,0.0005439229,0.0010890424,0.0009927707,0.00008662891],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031466495,0.0018880464,0.19737144,0.0023310604,0.0049954974,0.0012268412,0.0005463584,0.66159374,0.0011953054,0.01569133,0.008508985,0.07318486],"study_design_scores_gemma":[0.006283677,0.0050536646,0.19490252,0.0010792147,0.0035936364,0.0007830658,0.0017626074,0.76939905,0.0010327434,0.005491482,0.010352511,0.00026585924],"about_ca_topic_score_codex":0.9161705,"about_ca_topic_score_gemma":0.91543573,"teacher_disagreement_score":0.09053784,"about_ca_system_score_codex":0.09053784,"about_ca_system_score_gemma":0.054727584,"threshold_uncertainty_score":0.65690106},"labels":[],"label_agreement":null},{"id":"W3120020809","doi":"10.1007/s10549-020-06048-9","title":"HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"In situ hybridization; In situ; Fluorescence in situ hybridization; Breast cancer; Degradation (telecommunications); Fluorescence; Medicine; Retrospective cohort study; Biology; Pathology; Internal medicine; Chemistry; Genetics; Cancer; Computer science; Telecommunications; Chromosome; Optics; Physics; Gene expression","score_opus":0.07400740665816091,"score_gpt":0.40829915614598367,"score_spread":0.33429174948782275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120020809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99838257,0.000429079,0.0003689834,0.000015113277,0.000005133518,0.000009738472,0.00018870953,0.0000046770465,0.00059604796],"genre_scores_gemma":[0.9984085,0.0002907897,0.00009218738,0.000029648754,0.000009656784,0.0000100001635,0.000460784,0.0000069452335,0.0006915248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993069,0.00011900221,0.000083247614,0.00021613596,0.00010488296,0.00016984681],"domain_scores_gemma":[0.9983423,0.0003226178,0.0004207408,0.00028085013,0.0003949077,0.00023867491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095731264,0.0004796798,0.00050363864,0.0013824281,0.0009520289,0.0008751075,0.00037071639,0.00070072315,0.0017369541],"category_scores_gemma":[0.0013852636,0.00056287966,0.0007850762,0.0012558952,0.0006970074,0.0006547655,0.00048906513,0.00056432013,0.0008772279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005364506,0.00014817563,0.98928773,0.000017397168,0.00006632496,0.0028083138,0.00037904014,0.00007256665,0.002414364,0.00004121644,0.000114505405,0.0041139037],"study_design_scores_gemma":[0.000017012992,0.0009643821,0.9844061,0.000010836982,0.00021467575,0.009845487,0.0009665408,0.00020707652,0.001487812,0.000053209147,0.0018034884,0.000023366754],"about_ca_topic_score_codex":0.00435221,"about_ca_topic_score_gemma":0.002972359,"teacher_disagreement_score":0.00435221,"about_ca_system_score_codex":0.00054994866,"about_ca_system_score_gemma":0.00050774496,"threshold_uncertainty_score":0.00865376},"labels":[],"label_agreement":null},{"id":"W3125841806","doi":"10.1007/s11307-020-01571-z","title":"Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [99mTc]-(I)-Tricarbonyl Complex","year":2021,"lang":"en","type":"article","venue":"Molecular Imaging and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Government of Ontario; Genentech; University of Toronto; Canadian Cancer Society; Terry Fox Foundation","keywords":"Pertuzumab; Biodistribution; Chemistry; Molecular biology; Peptide; Biochemistry; Cancer; Medicine; Metastatic breast cancer; In vitro; Biology; Breast cancer; Internal medicine","score_opus":0.01644187833566498,"score_gpt":0.30140612448920623,"score_spread":0.28496424615354127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125841806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98522633,0.0017064475,0.006938281,0.00032006373,0.00005363779,0.000071508424,0.00039287106,0.00021032312,0.0050805407],"genre_scores_gemma":[0.981858,0.001112448,0.009343239,0.00017503825,0.000023927298,0.000087038396,0.00048807843,0.00007706632,0.006835212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984896,0.000021922244,0.000007678183,0.000041307452,0.000027040222,0.000053071795],"domain_scores_gemma":[0.9998833,0.000023377583,0.00003599081,0.000011467865,0.000012779574,0.000033146363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032668488,0.0006278394,0.00031058415,0.00042845734,0.00018987124,0.00031184396,0.00039032134,0.0008119862,0.0013706785],"category_scores_gemma":[0.0001266649,0.00032616733,0.0003356436,0.00023547099,0.00028483034,0.00042191704,0.00021007509,0.00083093933,0.00030138946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005899755,0.000057003737,0.00013073572,0.00004523081,0.000012813267,0.000120463155,0.000024416622,0.0002851397,0.9975241,0.00017969837,0.000080915874,0.0009495415],"study_design_scores_gemma":[0.000075098505,0.0005089679,0.0014321333,0.000007526187,0.00005292045,0.0006389979,0.000021086587,0.003434397,0.99276227,0.00005666479,0.0010026359,0.0000073358888],"about_ca_topic_score_codex":0.0015976698,"about_ca_topic_score_gemma":0.0009625806,"teacher_disagreement_score":0.0015976698,"about_ca_system_score_codex":0.00033710833,"about_ca_system_score_gemma":0.0003256683,"threshold_uncertainty_score":0.0045853257},"labels":[],"label_agreement":null},{"id":"W3127832917","doi":"10.1007/s00428-021-03034-4","title":"Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry","year":2021,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Guideline; Medicine; Immunohistochemistry; Breast cancer; Fluorescence in situ hybridization; Pathology; Internal medicine; Cancer; Fish <Actinopterygii>; Staining; Oncology; Biology","score_opus":0.06921580976706479,"score_gpt":0.4775608253405975,"score_spread":0.40834501557353275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127832917","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22162546,0.29011846,0.0540956,0.17710905,0.009526908,0.0026480316,0.01365339,0.002578128,0.22864497],"genre_scores_gemma":[0.6120057,0.15041463,0.13572152,0.04710544,0.00679096,0.0018161881,0.02225971,0.0009086949,0.02297717],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980945,0.00047072262,0.00046160127,0.000099834,0.0007068891,0.00016644751],"domain_scores_gemma":[0.9952247,0.0008767549,0.00048366483,0.00023185654,0.0029605113,0.0002224089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004683943,0.0006874088,0.000857069,0.00307755,0.0006793779,0.001463273,0.001358601,0.0012756755,0.0013411478],"category_scores_gemma":[0.008517736,0.0003533798,0.00071573874,0.0014051268,0.0006033087,0.0012333549,0.0008722666,0.0014690169,0.0010153146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031568512,0.00013536798,0.18930562,0.0016556861,0.00021753176,0.004791008,0.0006139761,0.0013049262,0.008924294,0.002517933,0.3709222,0.41929576],"study_design_scores_gemma":[0.000061033945,0.00025974787,0.23590352,0.006080569,0.00055620685,0.022821141,0.0018641003,0.004366511,0.008069953,0.004086663,0.7158098,0.000120798126],"about_ca_topic_score_codex":0.0063891527,"about_ca_topic_score_gemma":0.0152265765,"teacher_disagreement_score":0.0063891527,"about_ca_system_score_codex":0.0009898437,"about_ca_system_score_gemma":0.0015575641,"threshold_uncertainty_score":0.024771333},"labels":[],"label_agreement":null},{"id":"W3128947316","doi":"10.26443/mjm.v4i1.673","title":"HER2/neu Oncogene and Sensitivity to the DNA-Interactive Drug Doxorubicin","year":2020,"lang":"en","type":"article","venue":"McGill Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University","funders":"McGill University","keywords":"Doxorubicin; Oncogene; Cell culture; IC50; Sulforhodamine B; Molecular biology; Cancer research; Cell; Medicine; Drug resistance; Cancer; In vitro; Chemistry; Biology; Internal medicine; Cytotoxicity; Cell cycle; Chemotherapy; Biochemistry; Genetics","score_opus":0.06253521179347514,"score_gpt":0.37345508086361673,"score_spread":0.3109198690701416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128947316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987765,0.00058803544,0.00013708771,0.000017950502,0.0000027306676,0.0000050556637,0.000104782914,0.000007324335,0.0003604891],"genre_scores_gemma":[0.99901676,0.00019762314,0.00012119036,0.000016729555,0.0000020437003,0.0000058212327,0.00020134206,0.0000013470533,0.000437216],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998423,0.000034432167,0.000021700364,0.00003083173,0.000044649398,0.000026049178],"domain_scores_gemma":[0.99966264,0.000101102276,0.00011076319,0.000029715087,0.000045587578,0.000050186187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019152788,0.00013802989,0.00015813134,0.00040590717,0.000075621545,0.00023916295,0.00007003781,0.00018734798,0.0012953689],"category_scores_gemma":[0.00047561282,0.00017518493,0.000119851786,0.00023872007,0.000119764736,0.00015050784,0.00014466098,0.00025285725,0.00019331637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044390289,0.00008866059,0.06840049,0.000039752755,0.000049205413,0.00019067987,0.00006432013,0.00021192826,0.9271981,0.00004974775,0.00009351591,0.0031697287],"study_design_scores_gemma":[0.000013222264,0.0009180023,0.65126616,0.0000069471685,0.000051130937,0.001760494,0.0001294202,0.0013912932,0.34317955,0.000048472713,0.001224879,0.000010421319],"about_ca_topic_score_codex":0.0008554852,"about_ca_topic_score_gemma":0.0011315014,"teacher_disagreement_score":0.0012953689,"about_ca_system_score_codex":0.00021976138,"about_ca_system_score_gemma":0.000112163056,"threshold_uncertainty_score":0.004333377},"labels":[],"label_agreement":null},{"id":"W3130005770","doi":"10.1007/s10549-021-06109-7","title":"The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; National Institute for Health and Care Research; Pfizer","keywords":"Trastuzumab; Medicine; Enzalutamide; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Response Evaluation Criteria in Solid Tumors; Regimen; Adverse effect; Androgen receptor; Cancer; Clinical endpoint; Progressive disease; Phases of clinical research; Prostate cancer; Clinical trial; Chemotherapy","score_opus":0.027840409809214116,"score_gpt":0.35712052906739994,"score_spread":0.32928011925818584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130005770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971795,0.0018450352,0.000119755816,0.00007321043,0.000010652384,0.00010279662,0.000073109535,0.00001716129,0.00057879626],"genre_scores_gemma":[0.9986449,0.00047526567,0.00019434872,0.00008871827,0.000024871937,0.00006505187,0.0001807543,0.0000029990972,0.00032303797],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99978167,0.000098958786,0.000021156868,0.000031789277,0.00003928594,0.000027026903],"domain_scores_gemma":[0.99977857,0.000042693144,0.00008336891,0.000010958945,0.000012319169,0.00007211373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005477953,0.00043467732,0.0006825412,0.00017197529,0.00015531997,0.00041216976,0.0002497242,0.000270944,0.0008873335],"category_scores_gemma":[0.0006698511,0.00017646089,0.00038142514,0.00018057314,0.00028751668,0.00026743565,0.00018737209,0.0006589376,0.0001864363],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37910008,0.027474025,0.08519543,0.00088402245,0.001507783,0.00078510965,0.00037379033,0.0045598517,0.08368606,0.00014957125,0.002472648,0.4138116],"study_design_scores_gemma":[0.16717264,0.5177001,0.27949372,0.00013110063,0.0011353602,0.0023654117,0.0001228973,0.0052018617,0.016957242,0.00025518468,0.0094170775,0.00004735709],"about_ca_topic_score_codex":0.00048946805,"about_ca_topic_score_gemma":0.0014560645,"teacher_disagreement_score":0.0008873335,"about_ca_system_score_codex":0.00057081436,"about_ca_system_score_gemma":0.0005604973,"threshold_uncertainty_score":0.0041416287},"labels":[],"label_agreement":null},{"id":"W3132376902","doi":"10.1038/s41523-021-00220-0","title":"Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"npj Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario; University of Toronto","funders":"University of Toronto","keywords":"Trastuzumab; Medicine; Internal medicine; Oncology; Incidence (geometry); Breast cancer; Meta-analysis; Randomized controlled trial; Targeted therapy; Observational study; Metastatic breast cancer; Surgery; Cancer","score_opus":0.16813124575614494,"score_gpt":0.43838207818789926,"score_spread":0.2702508324317543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132376902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006757427,0.9912185,0.0005157977,0.00016215837,0.00011259344,0.00021530631,0.0007377808,0.000021576356,0.00025889516],"genre_scores_gemma":[0.21458127,0.7796007,0.0020960823,0.0009639961,0.00024952425,0.00094161666,0.0011865703,0.000037634643,0.00034258634],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9912156,0.0038192736,0.0029206702,0.0009901642,0.00080581167,0.00024845495],"domain_scores_gemma":[0.9762966,0.017791316,0.0037123451,0.00064090954,0.0013256103,0.0002332113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012737372,0.0021496376,0.016801165,0.005001606,0.00046321805,0.0029849738,0.00180335,0.0016998452,0.0027306862],"category_scores_gemma":[0.028412197,0.0012356355,0.03240258,0.00674314,0.00065745565,0.0013910912,0.0012343158,0.0015469467,0.0002567079],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018870601,0.000020240856,0.0050938968,0.34794468,0.6350767,0.00009996112,0.00005651505,0.00048315804,0.00017378801,0.00011476765,0.0005232217,0.008526055],"study_design_scores_gemma":[0.0004329757,0.00012358437,0.0034733454,0.017999351,0.9764534,0.00007909331,0.000025495392,0.00014692644,0.00009472904,0.00014210942,0.0010114091,0.000017589598],"about_ca_topic_score_codex":0.005292463,"about_ca_topic_score_gemma":0.010850828,"teacher_disagreement_score":0.016801165,"about_ca_system_score_codex":0.0020832582,"about_ca_system_score_gemma":0.0026771151,"threshold_uncertainty_score":0.06736249},"labels":[],"label_agreement":null},{"id":"W3134342541","doi":"10.1007/s10549-021-06103-z","title":"Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Taxane; Pertuzumab; Breast cancer; Cancer registry; Trastuzumab; Oncology; Cancer; Odds ratio; Chemotherapy","score_opus":0.04727928516653658,"score_gpt":0.3718786086865928,"score_spread":0.3245993235200562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134342541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224573,0.00027231316,0.00007741372,0.00010457049,0.00000905694,0.0000100675725,0.0062084314,0.0000120148125,0.0010602981],"genre_scores_gemma":[0.9934095,0.00017094622,0.00005380324,0.00007434944,0.000015899566,0.000018381517,0.0056899996,0.0000065296385,0.0005606645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995995,0.00006806139,0.00004694993,0.00012560906,0.00005982021,0.000100109806],"domain_scores_gemma":[0.99914086,0.0001647028,0.00038070168,0.00006725502,0.00008957887,0.00015698149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036904955,0.00014622312,0.00045433693,0.00082090584,0.0003023651,0.00043117587,0.00028087053,0.0003405704,0.0030683898],"category_scores_gemma":[0.0016656606,0.00019886185,0.000470151,0.0016929576,0.00013036554,0.00058004557,0.00028230873,0.00041950832,0.00031989577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023506439,0.00004888146,0.9976024,0.000009133021,0.000049929535,0.00007372186,0.000030029874,0.000074482174,0.0001399298,0.00003442804,0.0007226324,0.0009794247],"study_design_scores_gemma":[0.000024216295,0.00008625858,0.99880767,0.0000064392566,0.000029152068,0.00018570243,0.00014053979,0.00024791193,0.00005000063,0.00002691237,0.00039037823,0.000004837373],"about_ca_topic_score_codex":0.0102327205,"about_ca_topic_score_gemma":0.013730938,"teacher_disagreement_score":0.0102327205,"about_ca_system_score_codex":0.00044071424,"about_ca_system_score_gemma":0.0005802277,"threshold_uncertainty_score":0.020346284},"labels":[],"label_agreement":null},{"id":"W3134813321","doi":"10.1186/s12885-021-08003-3","title":"Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"review","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"Western Economic Diversification Canada","keywords":"Nimotuzumab; Medicine; Pharmacokinetics; Monoclonal antibody; Toxicity; Pharmacology; Epidermal growth factor receptor; Antibody; Oncology; Internal medicine; Cancer; Immunology","score_opus":0.3541460664967972,"score_gpt":0.5736643055672753,"score_spread":0.21951823907047813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134813321","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98218334,0.005993148,0.0061926437,0.00021464066,0.0001223884,0.0015065757,0.00044209266,0.0001505666,0.0031946006],"genre_scores_gemma":[0.98825175,0.0019350871,0.0041141724,0.00027594954,0.000083742656,0.000732048,0.00079201814,0.00005488632,0.003760321],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99955887,0.00013432417,0.00002477219,0.00006806141,0.00016106348,0.00005288318],"domain_scores_gemma":[0.9994777,0.000114459704,0.00013017951,0.00003920234,0.0001447715,0.00009364487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011861094,0.000492233,0.00065132877,0.00020758915,0.00019513065,0.000566191,0.0003812296,0.0004682562,0.0026011372],"category_scores_gemma":[0.0016265792,0.00018271437,0.00039984784,0.00021548296,0.00037387296,0.00034896604,0.00018712749,0.0008848609,0.0008285527],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031284492,0.013402015,0.005769679,0.0010793158,0.00027471376,0.0008579293,0.00044109763,0.004125399,0.7867823,0.00056832784,0.003612172,0.1518025],"study_design_scores_gemma":[0.0028087143,0.3360949,0.03306955,0.00011475203,0.00065476645,0.002066039,0.00019132043,0.0073743504,0.5746137,0.00040985827,0.04253022,0.00007174263],"about_ca_topic_score_codex":0.0003486727,"about_ca_topic_score_gemma":0.00040383055,"teacher_disagreement_score":0.0026011372,"about_ca_system_score_codex":0.00043113905,"about_ca_system_score_gemma":0.0005585899,"threshold_uncertainty_score":0.008701682},"labels":[],"label_agreement":null},{"id":"W3134994882","doi":"10.1111/hae.14292","title":"Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study","year":2021,"lang":"en","type":"article","venue":"Haemophilia","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University; University of Waterloo","funders":"","keywords":"Vial; Dosing; Medicine; Pharmacokinetics; Regimen; Nuclear medicine; Pharmacology; Surgery; Chromatography; Chemistry","score_opus":0.07041949286454836,"score_gpt":0.429097122988103,"score_spread":0.35867763012355464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134994882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833213,0.00033612762,0.010760465,0.00038464004,0.000027457114,0.000110015055,0.00059240236,0.000046719622,0.0044209003],"genre_scores_gemma":[0.9941048,0.00018119406,0.0042647687,0.00008387645,0.0000069283524,0.000073568335,0.00027953007,0.000010260028,0.0009951807],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99955994,0.00023811021,0.000016502592,0.000047365862,0.00005962346,0.00007860463],"domain_scores_gemma":[0.99437296,0.004493772,0.00043816102,0.000108688684,0.00044114,0.0001453259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012715529,0.000615998,0.0007105536,0.0003892651,0.00028952223,0.0008218286,0.00083358644,0.0013041272,0.0023807837],"category_scores_gemma":[0.005114287,0.00035068474,0.0012411523,0.0004318447,0.0003523469,0.00052925874,0.00047663966,0.0010933226,0.00016378252],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002737423,0.00017826569,0.005293858,0.000044801178,0.000052067662,0.00012734036,0.000024344161,0.99056727,0.00052587024,0.00055786985,0.00037432805,0.001980266],"study_design_scores_gemma":[0.00013682533,0.00038314957,0.0024482608,0.000016785265,0.000075803044,0.000063089254,0.000038937098,0.9953734,0.000554675,0.00046104423,0.00043516664,0.000012924172],"about_ca_topic_score_codex":0.018895388,"about_ca_topic_score_gemma":0.008933584,"teacher_disagreement_score":0.018895388,"about_ca_system_score_codex":0.0015923247,"about_ca_system_score_gemma":0.0014106829,"threshold_uncertainty_score":0.037570834},"labels":[],"label_agreement":null},{"id":"W3136212749","doi":"10.1016/j.ejca.2021.01.053","title":"Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Cancer Society; National Institutes of Health; Novartis Pharmaceuticals Corporation; GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Internal medicine; Hazard ratio; Breast cancer; Chemotherapy; Oncology; Gastroenterology; Confidence interval; Cancer","score_opus":0.11838979315974739,"score_gpt":0.41610397808041366,"score_spread":0.29771418492066626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136212749","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17847575,0.22192495,0.01369385,0.0691021,0.025098262,0.004473381,0.3540731,0.003156952,0.13000175],"genre_scores_gemma":[0.3927609,0.04922669,0.022848831,0.082087025,0.012347942,0.006059743,0.38219032,0.0015444779,0.05093403],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971847,0.001326696,0.000229788,0.0002767715,0.0006188604,0.0003632116],"domain_scores_gemma":[0.9948807,0.001811052,0.0010198735,0.0005896527,0.00091423834,0.0007845479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007919611,0.001466529,0.0028856504,0.00069479394,0.00044897763,0.0029015848,0.0012380724,0.0014690602,0.018308774],"category_scores_gemma":[0.009887285,0.00050741696,0.0033475747,0.0012680141,0.0003794511,0.0022074454,0.0011222023,0.003988666,0.0048105377],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13565747,0.0011395451,0.009225604,0.004597808,0.006940954,0.00023166835,0.00012297719,0.0024226701,0.0034469226,0.0014629589,0.5387243,0.29602712],"study_design_scores_gemma":[0.20368241,0.018973663,0.09566194,0.0024952197,0.023103837,0.0013158969,0.00017346756,0.0019202107,0.0031321074,0.010343,0.6388884,0.00030980166],"about_ca_topic_score_codex":0.0019795,"about_ca_topic_score_gemma":0.006527306,"teacher_disagreement_score":0.018308774,"about_ca_system_score_codex":0.0013028168,"about_ca_system_score_gemma":0.0017608393,"threshold_uncertainty_score":0.061249018},"labels":[],"label_agreement":null},{"id":"W3137776366","doi":"10.1007/s10549-021-06164-0","title":"Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Saint John Regional Hospital; Nova Scotia Health Authority; Dalhousie University","funders":"Canadian Institutes of Health Research; Beatrice Hunter Cancer Research Institute","keywords":"Trastuzumab; Anoikis; Medicine; Breast cancer; Oncology; Cancer; Immunohistochemistry; Internal medicine; Epidermal growth factor receptor; Apoptosis; Cancer research; Cancer cell; Biology","score_opus":0.03670378781311591,"score_gpt":0.34039308619681263,"score_spread":0.30368929838369674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137776366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99869823,0.00046339713,0.00008542945,0.000054661232,0.0000053722792,0.0000052320397,0.00012302754,0.000007614889,0.0005570171],"genre_scores_gemma":[0.9993086,0.00009210117,0.000049649047,0.00002084666,0.000013590391,0.0000058225883,0.00015322938,0.0000020648845,0.00035413087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998362,0.000039245544,0.000014230545,0.000024961524,0.000035281784,0.00005007709],"domain_scores_gemma":[0.9993019,0.00017144227,0.00032119898,0.000044939166,0.000057794565,0.0001027699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026456127,0.00016155165,0.0003569994,0.00044800373,0.0002000869,0.00078019017,0.0001700711,0.000313398,0.0019918724],"category_scores_gemma":[0.001189391,0.0001742249,0.00016022129,0.00040993796,0.00017220501,0.0003432985,0.00018319165,0.0006023679,0.00031247965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004457109,0.00032821152,0.9407183,0.000031693467,0.00016969218,0.00045690048,0.00014673441,0.00032557137,0.0414016,0.00019482338,0.00033544688,0.01143399],"study_design_scores_gemma":[0.000029955354,0.0004776571,0.99222696,0.000003978729,0.00008116256,0.00073013466,0.00015698445,0.0006027427,0.0049438123,0.0001556737,0.0005846062,0.0000064292394],"about_ca_topic_score_codex":0.00034145615,"about_ca_topic_score_gemma":0.00037045,"teacher_disagreement_score":0.0019918724,"about_ca_system_score_codex":0.0002118401,"about_ca_system_score_gemma":0.00016618482,"threshold_uncertainty_score":0.0066634417},"labels":[],"label_agreement":null},{"id":"W3139363653","doi":"10.11159/nddte19.102","title":"Half-Chain Trastuzumab Nanoconjugates Enhance Antitumor Activityin HER2+ breast cancer","year":2019,"lang":"en","type":"article","venue":"Proceedings of the World Congress on Recent Advances in Nanotechnology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Breast cancer; Cancer research; Cancer; Oncology; Medicine; Internal medicine","score_opus":0.010128694441214435,"score_gpt":0.32333386655248897,"score_spread":0.3132051721112745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139363653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928207,0.0023129836,0.0024078118,0.00009938246,0.000039613205,0.000024996318,0.00006549769,0.000111487716,0.0021174555],"genre_scores_gemma":[0.9946504,0.00088662986,0.0019382573,0.000111157504,0.000015010128,0.000018771896,0.00008553407,0.000015886335,0.0022783638],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999281,0.000007871367,0.0000036493439,0.000014715457,0.000028467926,0.00001714737],"domain_scores_gemma":[0.999972,0.0000042368833,0.000008010175,0.0000022351605,0.000006636889,0.000006929162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007883743,0.00029865323,0.00022808004,0.00012543939,0.00006443766,0.00016544109,0.00012928162,0.00023902983,0.00077501684],"category_scores_gemma":[0.000079915364,0.0000784325,0.00013999123,0.00010183278,0.00011093779,0.00019285188,0.00016555171,0.0002672124,0.00017897079],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001439503,0.0000399996,0.00008523951,0.000050949486,0.000006767413,0.00004397192,0.000016819331,0.00020193121,0.9942595,0.00011498772,0.00013942763,0.004896509],"study_design_scores_gemma":[0.00002900941,0.00058531726,0.0012994515,0.000005986287,0.00002250432,0.00014086437,0.000008881608,0.0024673487,0.99270636,0.0000413842,0.0026875697,0.0000054356733],"about_ca_topic_score_codex":0.00047317325,"about_ca_topic_score_gemma":0.00073626294,"teacher_disagreement_score":0.00077501684,"about_ca_system_score_codex":0.0002982222,"about_ca_system_score_gemma":0.00010190155,"threshold_uncertainty_score":0.0025926828},"labels":[],"label_agreement":null},{"id":"W3148173154","doi":"10.3390/cancers13071688","title":"Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Oncology; Prostate; Medicine; Internal medicine; Cancer","score_opus":0.037529794219627356,"score_gpt":0.400819810740704,"score_spread":0.3632900165210766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148173154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675,0.0011601462,0.0013637182,0.00006684246,0.000006296025,0.000006680266,0.00021027769,0.00001889129,0.00041720978],"genre_scores_gemma":[0.9992349,0.00013799964,0.00045270438,0.0000064091414,0.000005716506,0.0000032335738,0.00009529337,0.0000011689335,0.000062641644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981874,0.00008004966,0.000010256894,0.000030268835,0.000037277172,0.000023403867],"domain_scores_gemma":[0.99929,0.0003823727,0.00016279567,0.000025514606,0.000050125782,0.0000891556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008130837,0.00031481532,0.00020713106,0.00055851904,0.00011864681,0.0002984028,0.00015558055,0.00017234348,0.00088107755],"category_scores_gemma":[0.0013068134,0.00007654565,0.00030485733,0.00037963112,0.0001516693,0.000135372,0.00017488484,0.00035574017,0.00011449975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006214838,0.000030349158,0.98543835,0.000024709507,0.0000969291,0.00004808953,0.000018369938,0.0022897206,0.0028530268,0.000036378653,0.00012833673,0.0084143225],"study_design_scores_gemma":[0.00001649225,0.00020744975,0.9801702,0.000014562953,0.0002207891,0.00036738362,0.000058681315,0.01575426,0.0024488622,0.00033569045,0.00039679895,0.000008825401],"about_ca_topic_score_codex":0.0009492244,"about_ca_topic_score_gemma":0.0014705587,"teacher_disagreement_score":0.0009492244,"about_ca_system_score_codex":0.00019549287,"about_ca_system_score_gemma":0.0002312155,"threshold_uncertainty_score":0.004300058},"labels":[],"label_agreement":null},{"id":"W3148214373","doi":"10.3390/cancers13071726","title":"Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"","keywords":"Ductal carcinoma; In situ; Biomarker; Oncology; Medicine; Breast cancer; Pathology; Transcriptome; Cancer research; Downregulation and upregulation; Internal medicine; Biology; Cancer; Gene expression; Chemistry; Gene","score_opus":0.052245894604464174,"score_gpt":0.361034075551956,"score_spread":0.30878818094749183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148214373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9489922,0.038887404,0.0020741664,0.004370295,0.00034454215,0.000038234295,0.0012498819,0.000096884316,0.003946409],"genre_scores_gemma":[0.9932941,0.0037636077,0.0008991627,0.00021408855,0.0003119804,0.00001485862,0.00071289926,0.000006755583,0.00078260206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996966,0.00007298899,0.000028671651,0.00006466249,0.00007815363,0.000058908507],"domain_scores_gemma":[0.99901474,0.00024553537,0.00030693968,0.00007888865,0.00018138895,0.00017249871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001300654,0.00048031803,0.0007417851,0.0013081906,0.000264529,0.00096238306,0.00046951819,0.0009307997,0.0019977011],"category_scores_gemma":[0.0019404487,0.00018301724,0.00027849682,0.0012542981,0.0004523189,0.000623134,0.0002495614,0.00074221566,0.0010850845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017454136,0.000107570784,0.8960448,0.00019943726,0.00015852331,0.00047943456,0.00006167999,0.00026804733,0.018901853,0.0001957677,0.0018623773,0.07997519],"study_design_scores_gemma":[0.00010421582,0.001044772,0.9483831,0.00021516973,0.00059210596,0.005142219,0.0004550059,0.0055390275,0.018637935,0.0015293255,0.018296588,0.000060497132],"about_ca_topic_score_codex":0.00063341664,"about_ca_topic_score_gemma":0.00068633753,"teacher_disagreement_score":0.0019977011,"about_ca_system_score_codex":0.00032913042,"about_ca_system_score_gemma":0.00022971864,"threshold_uncertainty_score":0.006878555},"labels":[],"label_agreement":null},{"id":"W3149083586","doi":"10.1111/his.14381","title":"Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer","year":2021,"lang":"en","type":"article","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Leids Universitair Medisch Centrum; Unicancer; KWF Kankerbestrijding; Universiteit Leiden","keywords":"Immunohistochemistry; Medicine; Confidence interval; Kappa; Concordance; Human Epidermal Growth Factor Receptor 2; Cancer; Gold standard (test); Internal medicine; Pathology; Gynecology; Breast cancer; Oncology; Mathematics","score_opus":0.10201119053040816,"score_gpt":0.3671584360928934,"score_spread":0.26514724556248526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149083586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9272498,0.001342344,0.06694874,0.00020233687,0.000067195266,0.00038651229,0.0002874054,0.0008007846,0.0027148982],"genre_scores_gemma":[0.9528264,0.00012356431,0.04617516,0.00005961383,0.00001715366,0.00010554733,0.00038838584,0.00003266107,0.0002715654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552923,0.0020722612,0.000566138,0.0008767472,0.0007640677,0.00019163026],"domain_scores_gemma":[0.9919961,0.003750901,0.0009471041,0.0004810709,0.0024830806,0.0003417003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009654863,0.0007411195,0.0007430203,0.0019000381,0.00046144065,0.0012550792,0.0007682512,0.0008582833,0.00083250104],"category_scores_gemma":[0.019808482,0.00029127506,0.0006343534,0.0006123955,0.00029423978,0.0007575261,0.0010281507,0.0004354583,0.00037181037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034115491,0.0002399868,0.7695719,0.00027078722,0.0005488367,0.00018814803,0.0003997568,0.018031424,0.015555908,0.00034996748,0.002176921,0.1892548],"study_design_scores_gemma":[0.0004555774,0.0015616664,0.46944913,0.00016896818,0.00075886457,0.0023238491,0.00038344477,0.49464422,0.025767472,0.0012497358,0.0031124337,0.00012463097],"about_ca_topic_score_codex":0.001529511,"about_ca_topic_score_gemma":0.0016373683,"teacher_disagreement_score":0.009654863,"about_ca_system_score_codex":0.00063302676,"about_ca_system_score_gemma":0.00085672515,"threshold_uncertainty_score":0.05106044},"labels":[],"label_agreement":null},{"id":"W3149876840","doi":"10.1093/jnci/djp403","title":"Response: Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy","year":2009,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University; University of Toronto; University of Calgary; University of British Columbia; Sunnybrook Health Science Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Topoisomerase; Breast cancer; Adjuvant; Oncology; Medicine; Internal medicine; Adjuvant chemotherapy; Chemotherapy; Alpha (finance); Cancer; Pharmacology; Biology; DNA; Surgery; Genetics","score_opus":0.05730616838911928,"score_gpt":0.42148059456968884,"score_spread":0.36417442618056955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149876840","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039123872,0.0010449024,0.0001272141,0.9427075,0.054089833,0.00006306623,0.0003704619,0.000111551635,0.0010942868],"genre_scores_gemma":[0.0021149977,0.00090015476,0.00024835885,0.9422425,0.050124653,0.00010092986,0.00017575876,0.000048491744,0.004044175],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99729234,0.0007321281,0.0005105668,0.00047554876,0.00063334854,0.00035604168],"domain_scores_gemma":[0.98696774,0.0056203012,0.00061558594,0.0005065205,0.0047561037,0.0015337686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042459476,0.0014659453,0.0028269042,0.0012973815,0.002073872,0.002706072,0.004556929,0.03474358,0.0114619285],"category_scores_gemma":[0.029062144,0.0006802178,0.0027083664,0.0010030417,0.0018826661,0.0030655,0.001581174,0.034740414,0.015104333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001301323,0.000033019507,0.0007135421,0.000117638774,0.000025925168,0.0007612985,0.00004769719,0.000050140203,0.0001340289,0.0003388247,0.99292964,0.0047181672],"study_design_scores_gemma":[0.00040051606,0.00028973652,0.0055921082,0.001004658,0.00016139804,0.004739278,0.000793332,0.00073756155,0.000755469,0.006463518,0.9788224,0.00024001865],"about_ca_topic_score_codex":0.004608159,"about_ca_topic_score_gemma":0.0045855395,"teacher_disagreement_score":0.03474358,"about_ca_system_score_codex":0.0044396417,"about_ca_system_score_gemma":0.0034633132,"threshold_uncertainty_score":0.038344026},"labels":[],"label_agreement":null},{"id":"W3154532546","doi":"10.1002/ijc.33597","title":"Systemic toxicities of trastuzumab‐emtansine predict tumor response in <scp>HER2</scp>+ metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"National Institute of General Medical Sciences; Agencia de Innovación y Desarrollo de Andalucía","keywords":"Trastuzumab emtansine; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Trastuzumab; Breast cancer; Toxicity; Cancer; Clinical endpoint; Biomarker; Clinical trial; Gastroenterology; Biology","score_opus":0.029030348334815867,"score_gpt":0.3842017598161571,"score_spread":0.35517141148134124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154532546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996086,0.00014764183,0.00006640233,0.000011246399,9.0839944e-7,0.0000029574799,0.00004118099,0.0000014246685,0.00011966039],"genre_scores_gemma":[0.9997348,0.000054793898,0.00004623852,0.000009478264,0.0000029754253,0.0000018286869,0.00008584537,6.672122e-7,0.00006337548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976844,0.00008388646,0.00002255931,0.000035762656,0.000055527427,0.00003381313],"domain_scores_gemma":[0.9991379,0.00022851107,0.00042324778,0.000039078837,0.0000791174,0.000092103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005381361,0.00016388843,0.00020659319,0.00025219948,0.00013863771,0.0002958186,0.00012819802,0.00016753896,0.0005498873],"category_scores_gemma":[0.0013774597,0.00011686628,0.00030127453,0.00038237174,0.00015307892,0.00014727791,0.00019646906,0.00032217315,0.000080316764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038013922,0.000026212725,0.99524236,0.000008034219,0.00003858827,0.00004673899,0.000015469652,0.00014805819,0.00065451016,0.000005034883,0.00003924985,0.0033957164],"study_design_scores_gemma":[0.000014730362,0.00020048188,0.9983479,0.000002384667,0.000046693454,0.000270279,0.000025975218,0.00060945534,0.00036041654,0.00001675037,0.00010312132,0.0000019255478],"about_ca_topic_score_codex":0.0029615036,"about_ca_topic_score_gemma":0.006009132,"teacher_disagreement_score":0.0029615036,"about_ca_system_score_codex":0.00031714304,"about_ca_system_score_gemma":0.00027837392,"threshold_uncertainty_score":0.0058885813},"labels":[],"label_agreement":null},{"id":"W3156985612","doi":"10.1056/nejmoa2028485","title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1543,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Vinorelbine; Metastatic breast cancer; Oncology; Breast cancer; Chemotherapy; Eribulin; Gemcitabine; Cancer; Gastroenterology; Surgery; Confidence interval","score_opus":0.051532004151187895,"score_gpt":0.38854795709070733,"score_spread":0.3370159529395194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156985612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922156,0.006568769,0.00008331595,0.00014300032,0.000033144686,0.0001439134,0.00004911232,0.000010260961,0.00075281574],"genre_scores_gemma":[0.9967205,0.0025226849,0.00017588571,0.00009586846,0.00003623264,0.00008534991,0.00009470784,0.000001593701,0.00026726123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99985576,0.00006631629,0.000013083744,0.000018371322,0.000026674092,0.00001977345],"domain_scores_gemma":[0.9997497,0.00007832888,0.00006845062,0.000008213357,0.000015171155,0.00008023054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005771544,0.00027017065,0.00076104834,0.00016964483,0.0001244486,0.00028754654,0.00022403049,0.00026992892,0.0013649897],"category_scores_gemma":[0.00062534993,0.000102592145,0.0003163184,0.00018887506,0.0002640497,0.00016292086,0.00015485828,0.0004387301,0.00012326216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6007553,0.0054489975,0.034101665,0.003073925,0.0015156912,0.0008189066,0.00027868003,0.004273102,0.040793218,0.0006077912,0.002142829,0.3061898],"study_design_scores_gemma":[0.31845117,0.52226925,0.10891644,0.00060943654,0.0033937935,0.005014874,0.00031035708,0.0065390356,0.019452773,0.0012246831,0.013771732,0.000046496516],"about_ca_topic_score_codex":0.0007456594,"about_ca_topic_score_gemma":0.0021754028,"teacher_disagreement_score":0.0013649897,"about_ca_system_score_codex":0.00045720977,"about_ca_system_score_gemma":0.0005924434,"threshold_uncertainty_score":0.004566312},"labels":[],"label_agreement":null},{"id":"W3157870687","doi":"10.3390/curroncol28030150","title":"HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pathology; HER2 negative; Invasive lobular carcinoma; Invasive ductal carcinoma; Breast cancer; Internal medicine; Cancer","score_opus":0.22356879943461647,"score_gpt":0.5105782300579937,"score_spread":0.28700943062337725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157870687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99946135,0.00022040115,0.0000612752,0.000008475795,0.0000019340168,0.0000057014336,0.00004753622,0.0000019751865,0.00019152001],"genre_scores_gemma":[0.99960417,0.00006753983,0.00011398429,0.000010380471,0.0000054839606,0.000007195131,0.00013101833,9.780184e-7,0.000059322763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99960595,0.00009451764,0.00007265057,0.00008384995,0.000067504225,0.00007555918],"domain_scores_gemma":[0.99895275,0.00034545286,0.00028260134,0.000078429766,0.00012150824,0.00021933102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085654395,0.00016195698,0.0002049471,0.0014835253,0.00023859742,0.00043756355,0.00023761512,0.0002734126,0.0009803589],"category_scores_gemma":[0.0016964105,0.00015480809,0.00015043882,0.0006467378,0.0003171512,0.00053557224,0.0004699832,0.00013434634,0.00014663332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021012737,0.000021471104,0.9951526,0.000012412024,0.000017158594,0.00053792197,0.00007208609,0.000028278575,0.0013510195,0.000015747788,0.00005327642,0.0025279056],"study_design_scores_gemma":[0.000011416803,0.000115896655,0.9955224,0.0000035541132,0.00001652549,0.0032108417,0.00037398824,0.00018723129,0.0002984754,0.000027539501,0.00022811495,0.000004101521],"about_ca_topic_score_codex":0.0013759584,"about_ca_topic_score_gemma":0.003096504,"teacher_disagreement_score":0.0014835253,"about_ca_system_score_codex":0.00035325097,"about_ca_system_score_gemma":0.00024777683,"threshold_uncertainty_score":0.0045298934},"labels":[],"label_agreement":null},{"id":"W3164370300","doi":"10.1038/s41388-021-01841-2","title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","year":2021,"lang":"en","type":"review","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Receptor tyrosine kinase; Biology; Receptor Protein-Tyrosine Kinases; Cancer research; Tyrosine kinase; Cancer; Signal transduction; Receptor; Kinase; Targeted therapy; Bioinformatics; Computational biology; Cell biology; Genetics","score_opus":0.25863309324506767,"score_gpt":0.42782301358025915,"score_spread":0.16918992033519148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164370300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041789135,0.99887735,0.00006075495,0.00021186823,0.00020171888,0.000002680156,0.000015125151,0.0000056337963,0.0005829886],"genre_scores_gemma":[0.00025921967,0.99880373,0.00008328587,0.00018329087,0.00025848008,0.0000039224483,0.000019825113,7.531021e-7,0.00038739733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975306,0.000043482047,0.000025617368,0.00003295402,0.000111722955,0.00003322708],"domain_scores_gemma":[0.99968636,0.0001555337,0.000042501815,0.000008945482,0.00007167925,0.000034973746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074475113,0.0014279418,0.0018107195,0.0022262046,0.00024224877,0.0015025989,0.0010326422,0.0014576794,0.0046686754],"category_scores_gemma":[0.0008485019,0.00032002965,0.000543146,0.0028958127,0.00060194236,0.0017339942,0.0009189983,0.002642496,0.002556457],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015496305,0.00009083046,0.000113567214,0.012612149,0.0000875008,0.00012967741,0.000043490712,0.00056973187,0.0014994225,0.0039840625,0.06913297,0.9115816],"study_design_scores_gemma":[0.000049740054,0.00011069359,0.0005199489,0.002679682,0.00015096206,0.00066191866,0.000045711473,0.00011785923,0.00023573432,0.002288658,0.9931183,0.000020837344],"about_ca_topic_score_codex":0.0010279915,"about_ca_topic_score_gemma":0.002429966,"teacher_disagreement_score":0.0046686754,"about_ca_system_score_codex":0.0008222136,"about_ca_system_score_gemma":0.0013264499,"threshold_uncertainty_score":0.015618324},"labels":[],"label_agreement":null},{"id":"W3166496575","doi":"10.1200/jco.2021.39.15_suppl.3015","title":"A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AbbVie","keywords":"Medicine; Nausea; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Taxane; Vomiting; Diarrhea; Tolerability; Chills; Surgery; Cancer; Breast cancer","score_opus":0.13510556123169,"score_gpt":0.5069815495929816,"score_spread":0.37187598836129154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166496575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949868,0.0011990726,0.0004609619,0.00014980354,0.000067901834,0.0013063438,0.00080431986,0.000066006505,0.0009590056],"genre_scores_gemma":[0.99076253,0.0014697129,0.0014296158,0.00031784162,0.00016102286,0.0010745453,0.0019406263,0.00003977136,0.0028043103],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988954,0.00053268083,0.000059587965,0.00017031073,0.00011769098,0.00022432658],"domain_scores_gemma":[0.99873275,0.00022320436,0.00023789683,0.00022869742,0.00008749899,0.00048998423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023148276,0.0016900059,0.0021992307,0.0009073417,0.000722679,0.0015414555,0.0011917952,0.0014542851,0.0037851664],"category_scores_gemma":[0.0011931605,0.0010044418,0.0018660936,0.0006782677,0.0018271018,0.0012752285,0.00043844205,0.003681943,0.0013435532],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48621055,0.33386832,0.008633246,0.0007089865,0.0015680734,0.00058901956,0.00061768346,0.0029255163,0.09007102,0.00031599888,0.0034189594,0.07107266],"study_design_scores_gemma":[0.121651575,0.8371886,0.019749688,0.000028395862,0.00067020155,0.00060894474,0.00014698748,0.0016460947,0.014680964,0.0001633558,0.003400753,0.00006438848],"about_ca_topic_score_codex":0.0017507651,"about_ca_topic_score_gemma":0.0029977432,"teacher_disagreement_score":0.0037851664,"about_ca_system_score_codex":0.0018397018,"about_ca_system_score_gemma":0.0012556596,"threshold_uncertainty_score":0.013347983},"labels":[],"label_agreement":null},{"id":"W3167002996","doi":"","title":"モノクローナル抗体Trastuzumab(Herceptin)をめぐって 2 乳癌におけるHER2(c-erbB-2)のamplification & overexpression","year":2000,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; ErbB; Cancer research; Virology; Biology; Medicine; Internal medicine; Receptor; Cancer; Breast cancer","score_opus":0.07202902031683282,"score_gpt":0.4115252189068889,"score_spread":0.3394961985900561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167002996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8912781,0.017053224,0.008161174,0.00205889,0.0007526507,0.00041195806,0.0010522617,0.00044898363,0.078782745],"genre_scores_gemma":[0.9150568,0.010024536,0.0071511203,0.0008955707,0.0002783916,0.00026888546,0.0013367642,0.000040752187,0.064947106],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999897,0.0000093096205,0.000005334469,0.000016693992,0.00004284672,0.000028834207],"domain_scores_gemma":[0.9999386,0.000014111851,0.000008442336,0.000006734619,0.000014498814,0.000017496483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025263458,0.0002490577,0.00016261899,0.00019012106,0.00022409542,0.0002564354,0.000116214964,0.00019252485,0.0047221794],"category_scores_gemma":[0.00019761529,0.0001269113,0.00015671524,0.00012741135,0.00017469835,0.00017829766,0.00014808663,0.00039673308,0.0019454142],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012843459,0.00035377176,0.0034316052,0.00021000228,0.000043295648,0.00051371136,0.00012204165,0.0003372774,0.8337231,0.0023782232,0.0055336524,0.15206885],"study_design_scores_gemma":[0.0005507437,0.0028454317,0.0326645,0.000042685137,0.00014449687,0.0040270146,0.00011999267,0.0007895739,0.8048617,0.0010959649,0.15281534,0.000042454423],"about_ca_topic_score_codex":0.0006897877,"about_ca_topic_score_gemma":0.0014483187,"teacher_disagreement_score":0.0047221794,"about_ca_system_score_codex":0.00029298099,"about_ca_system_score_gemma":0.0002865452,"threshold_uncertainty_score":0.015797257},"labels":[],"label_agreement":null},{"id":"W3168005110","doi":"10.1055/s-0041-1730167","title":"IMpassion031: Efficacy, safety and patient (pts)-reported outcomes/quality of life (QoL) - Results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemo in early stage triple-negative breast cancer (eTNBC)","year":2021,"lang":"en","type":"article","venue":"Senologie - Zeitschrift für Mammadiagnostik und -therapie","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Atezolizumab; Placebo; Oncology; Medicine; Paclitaxel; Breast cancer; Internal medicine; Doxorubicin; Cyclophosphamide; Quality of life (healthcare); Stage (stratigraphy); Triple-negative breast cancer; Chemotherapy; Cancer; Pembrolizumab; Immunotherapy; Nursing","score_opus":0.0626525346854209,"score_gpt":0.39185394507235083,"score_spread":0.32920141038692996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168005110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97727305,0.011188051,0.0006725957,0.0010118363,0.00013329662,0.0026067519,0.0042316825,0.00008737706,0.0027952834],"genre_scores_gemma":[0.9866333,0.0027553444,0.0013111284,0.0012069388,0.0003656053,0.0023635675,0.004002825,0.000030362467,0.0013309427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984465,0.00095669343,0.000106646025,0.00020107732,0.00011977037,0.00016940177],"domain_scores_gemma":[0.99774456,0.0007245473,0.0006531244,0.00016939086,0.00012789,0.0005805121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035026446,0.0012491869,0.0016986527,0.00042801094,0.000322375,0.00086399337,0.001270617,0.0017282474,0.0066074566],"category_scores_gemma":[0.001999807,0.00037691696,0.0032786748,0.0006373525,0.0011517083,0.00082987617,0.00074938894,0.002711543,0.0007651009],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9224701,0.015226056,0.007274994,0.0013834022,0.0027401396,0.000110512534,0.000086271866,0.0005574768,0.010210144,0.00010736165,0.0011519816,0.03868165],"study_design_scores_gemma":[0.62236595,0.34044036,0.027378837,0.00013386415,0.0035819907,0.0002616304,0.000044935274,0.00038312966,0.0031482433,0.00020299718,0.002017203,0.00004092652],"about_ca_topic_score_codex":0.00049986824,"about_ca_topic_score_gemma":0.0010349128,"teacher_disagreement_score":0.0066074566,"about_ca_system_score_codex":0.00066373846,"about_ca_system_score_gemma":0.0011216946,"threshold_uncertainty_score":0.022104084},"labels":[],"label_agreement":null},{"id":"W3168045009","doi":"10.3390/cancers13122922","title":"Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Breast Cancer Society of Canada; Dalhousie Medical Research Foundation","keywords":"PI3K/AKT/mTOR pathway; Breast cancer; Medicine; Glycolysis; Cancer research; Cancer; Internal medicine; Discovery and development of mTOR inhibitors; Protein kinase B; Oncology; Signal transduction; Biology; Metabolism; Biochemistry","score_opus":0.05457637850732933,"score_gpt":0.4224668694947123,"score_spread":0.36789049098738297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168045009","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011422238,0.9989103,0.000046344026,0.0001652634,0.00012543822,0.000003466622,0.000013662905,0.0000052852465,0.00061603455],"genre_scores_gemma":[0.00052634894,0.9987746,0.00006470589,0.00012737779,0.000077471545,0.000003978368,0.000023191491,8.53516e-7,0.00040157247],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998827,0.000021055519,0.000016777176,0.000017758905,0.000046004043,0.000015667023],"domain_scores_gemma":[0.9998784,0.00005024501,0.000021503742,0.000003298637,0.000033484026,0.000013125383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034248212,0.00060180953,0.000986691,0.0016627414,0.00018646687,0.00070819724,0.00058549555,0.00072545424,0.0032314444],"category_scores_gemma":[0.00042790693,0.00021159585,0.0005412517,0.001307416,0.00021294237,0.00082638045,0.0005099059,0.0014486947,0.0016031602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011331049,0.00008558492,0.00014160623,0.021863192,0.000121302335,0.00019792424,0.000045602785,0.00037247268,0.0020430286,0.0028895787,0.035064925,0.9370615],"study_design_scores_gemma":[0.000027717751,0.00016933531,0.0007788585,0.004441721,0.00016593865,0.0012192456,0.00003843897,0.0001241333,0.00061875954,0.0015710045,0.9908292,0.000015700443],"about_ca_topic_score_codex":0.0007865825,"about_ca_topic_score_gemma":0.0018068581,"teacher_disagreement_score":0.0032314444,"about_ca_system_score_codex":0.00046788072,"about_ca_system_score_gemma":0.0007203021,"threshold_uncertainty_score":0.010810256},"labels":[],"label_agreement":null},{"id":"W3168166940","doi":"10.1200/jco.2021.39.15_suppl.524","title":"The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Trastuzumab; Breast cancer; Stage (stratigraphy); Oncology; Receiver operating characteristic; Confidence interval; Cancer; Adjuvant therapy","score_opus":0.07048322028907646,"score_gpt":0.4645412224529246,"score_spread":0.3940580021638482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168166940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957955,0.0008152332,0.00083934184,0.00007325601,0.000016349473,0.000032543354,0.0016954766,0.000015083921,0.00071726326],"genre_scores_gemma":[0.9973232,0.00013017136,0.00048281805,0.000031994678,0.000025143992,0.00002699013,0.0018478229,0.0000036384972,0.00012824824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993831,0.00030217427,0.000065339555,0.00012707866,0.00008327857,0.000039037386],"domain_scores_gemma":[0.99683595,0.0015109205,0.0010818449,0.00024028015,0.00019187263,0.00013907196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022113717,0.0002664954,0.00046203902,0.00035899886,0.000110572895,0.00060705416,0.00024414365,0.00030780674,0.001217988],"category_scores_gemma":[0.004637818,0.00013993759,0.00044058397,0.0004766047,0.00018291952,0.00049696566,0.000487587,0.00034274784,0.00033819408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066700424,0.00007501075,0.97558004,0.000107111846,0.00024953534,0.00004648187,0.000027924907,0.0012463139,0.0005957424,0.00006898975,0.00066080544,0.014671988],"study_design_scores_gemma":[0.0004537398,0.0037391933,0.98034036,0.000037910708,0.0006535772,0.00086433854,0.00006733405,0.009749912,0.0015196301,0.00046533483,0.0020887482,0.000019996562],"about_ca_topic_score_codex":0.0002870746,"about_ca_topic_score_gemma":0.00035777705,"teacher_disagreement_score":0.0022113717,"about_ca_system_score_codex":0.00019919623,"about_ca_system_score_gemma":0.00017714991,"threshold_uncertainty_score":0.011695027},"labels":[],"label_agreement":null},{"id":"W3173791032","doi":"10.1096/fasebj.2019.33.1_supplement.250.6","title":"Association between genome‐wide DNA methylation pattern and response to trastuzumab in HER2‐positive breast cancer patients","year":2019,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé","keywords":"Breast cancer; Trastuzumab; DNA methylation; Epigenetics; Methylation; Oncology; Cancer; Medicine; Internal medicine; Cancer research; Bioinformatics; Biology; Gene; Genetics; Gene expression","score_opus":0.01880126149840886,"score_gpt":0.32115654239431973,"score_spread":0.30235528089591085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173791032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990663,0.00038611895,0.00006114541,0.000032984088,0.000002426359,0.0000026080531,0.00024719434,0.000003099681,0.00019819086],"genre_scores_gemma":[0.99951935,0.00007053916,0.00004304416,0.000012870918,0.0000038482394,0.0000039305105,0.00022101954,9.3666006e-7,0.00012446776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998338,0.000037231937,0.000015529227,0.000056279005,0.000027016302,0.000030078854],"domain_scores_gemma":[0.99977344,0.000058862934,0.000087402004,0.000014287415,0.000024286566,0.000041721523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023031933,0.00011795451,0.00021563914,0.00038470206,0.00012267435,0.00020072455,0.00015248629,0.00027797557,0.0013823141],"category_scores_gemma":[0.000640966,0.00008921507,0.00021035972,0.00039879148,0.00010279662,0.00010954128,0.00016430981,0.00021102687,0.00011330048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044005914,0.000019835445,0.993196,0.000011853732,0.00009898692,0.00008169705,0.000026326908,0.000084570354,0.0036873121,0.000012584463,0.00009481389,0.0022460145],"study_design_scores_gemma":[0.000005877666,0.000053111453,0.9990952,0.0000016919445,0.000033799413,0.00017094545,0.000026047794,0.00021400873,0.00026198206,0.00001307328,0.00012270447,0.0000015113949],"about_ca_topic_score_codex":0.0014748584,"about_ca_topic_score_gemma":0.0017434842,"teacher_disagreement_score":0.0014748584,"about_ca_system_score_codex":0.00013221636,"about_ca_system_score_gemma":0.000087280496,"threshold_uncertainty_score":0.004624307},"labels":[],"label_agreement":null},{"id":"W3175466915","doi":"10.1096/fasebj.27.1_supplement.1087.12","title":"Association of HER2 Ile655Val and Ala1170Pro polymorphisms with breast cancer prognosis factors","year":2013,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Breast cancer; Oncology; Medicine; Internal medicine; Genotyping; Lymphovascular invasion; Carcinogenesis; CA15-3; Cancer; Genotype; Metastasis; Biology; Gene; Genetics","score_opus":0.022679191979553343,"score_gpt":0.29491062935611845,"score_spread":0.2722314373765651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175466915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994168,0.00022054359,0.000116813106,0.000025259524,0.0000046480714,0.000001451337,0.000043234664,0.0000021767771,0.00016907694],"genre_scores_gemma":[0.9997002,0.00004192299,0.00005432642,0.000008257851,0.0000047964368,0.000001322194,0.000043622043,0.0000012561475,0.00014429174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999765,0.000071990646,0.000030375124,0.000044578,0.000043590102,0.000044417295],"domain_scores_gemma":[0.9993237,0.0002409207,0.00024457372,0.00004379666,0.000041778392,0.00010520229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003435398,0.00023540904,0.00023029497,0.00035575626,0.00016280609,0.00023202042,0.00010050687,0.00027734338,0.0016592417],"category_scores_gemma":[0.00091604266,0.00011098943,0.00022066926,0.00037054816,0.00014789148,0.00011051587,0.00010852176,0.00029569818,0.00017096373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019479102,0.00012934074,0.9749486,0.00002042087,0.00019151068,0.00064007647,0.00008895361,0.00021042624,0.014760193,0.000080378915,0.00013893424,0.0068433397],"study_design_scores_gemma":[0.000029442732,0.0002519381,0.99506664,0.0000058286028,0.00010789114,0.0013325305,0.000055789857,0.0006401449,0.0020690486,0.00012720516,0.00030774597,0.000005824707],"about_ca_topic_score_codex":0.0007847549,"about_ca_topic_score_gemma":0.0010114425,"teacher_disagreement_score":0.0016592417,"about_ca_system_score_codex":0.00010673997,"about_ca_system_score_gemma":0.00010764242,"threshold_uncertainty_score":0.005550742},"labels":[],"label_agreement":null},{"id":"W3178119289","doi":"10.3390/cancers13143540","title":"Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Action (physics); Cancer; Internal medicine; Bioinformatics; Biology","score_opus":0.3822447179344954,"score_gpt":0.5475082367344839,"score_spread":0.16526351879998852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178119289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000067512185,0.99741924,0.00007322559,0.0013435493,0.0004352592,0.0000015401122,0.00000958248,0.0000044561907,0.0006456357],"genre_scores_gemma":[0.00066235225,0.99713373,0.00011047014,0.0009895002,0.0006199671,0.0000034990678,0.00001612815,0.0000018359095,0.0004625695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999676,0.00008832487,0.00004148794,0.00004808657,0.00011400933,0.000032121672],"domain_scores_gemma":[0.99939096,0.00033063337,0.00005104393,0.000017827308,0.00015992334,0.000049645092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011413394,0.00070588343,0.0013462354,0.0017630148,0.0003436938,0.0015233343,0.0007996888,0.0015027648,0.0031708176],"category_scores_gemma":[0.0014801768,0.00022257207,0.0004609432,0.0015702957,0.0008180821,0.0025447358,0.000813329,0.0026643884,0.0016680826],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014625739,0.00007397628,0.00022603951,0.014152506,0.00010304555,0.00037924398,0.00016412794,0.0003723138,0.0018231587,0.01651903,0.08219533,0.883845],"study_design_scores_gemma":[0.000016874783,0.000058893274,0.00029350724,0.0037221059,0.000065574124,0.0009043078,0.00007313077,0.0000669665,0.0002099561,0.0055698557,0.9890047,0.000014222274],"about_ca_topic_score_codex":0.00082789373,"about_ca_topic_score_gemma":0.0013095745,"teacher_disagreement_score":0.0031708176,"about_ca_system_score_codex":0.0010967583,"about_ca_system_score_gemma":0.0016316832,"threshold_uncertainty_score":0.010607421},"labels":[],"label_agreement":null},{"id":"W3179982079","doi":"10.1016/j.cjco.2021.06.019","title":"Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis","year":2021,"lang":"en","type":"review","venue":"CJC Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Population Health Research Institute; McMaster University; Hamilton Health Sciences; Impact","funders":"","keywords":"Pertuzumab; Medicine; Internal medicine; Trastuzumab; Relative risk; Placebo; Breast cancer; Meta-analysis; Asymptomatic; Oncology; Adverse effect; Randomized controlled trial; Cardiotoxicity; Cancer; Confidence interval; Chemotherapy; Pathology","score_opus":0.1463421792317762,"score_gpt":0.46422019880430915,"score_spread":0.3178780195725329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179982079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044986107,0.99418193,0.00029484316,0.00012233309,0.000084478816,0.00021181477,0.0003918708,0.000014008254,0.00020012874],"genre_scores_gemma":[0.16664256,0.82892334,0.001440452,0.0008491646,0.00024230403,0.00090123893,0.00068237307,0.000022622286,0.00029600735],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9924395,0.003589499,0.0021258562,0.00076315453,0.00084347284,0.00023851538],"domain_scores_gemma":[0.98409384,0.011446156,0.0027918173,0.00037541272,0.0011025842,0.00019011479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009733204,0.0021577065,0.015019275,0.0055178525,0.0004760555,0.0023515094,0.0017323517,0.0017156557,0.0029751798],"category_scores_gemma":[0.022283806,0.0011684985,0.027258549,0.0065049664,0.00057830004,0.0011920382,0.0011257988,0.0013444882,0.00022603986],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015481593,0.000025749214,0.0039529298,0.44018102,0.54188496,0.00015265531,0.00006898698,0.00057857385,0.00018065378,0.000111489746,0.000639394,0.010675367],"study_design_scores_gemma":[0.0006193019,0.00020111553,0.0041753477,0.02992985,0.96282035,0.0001411515,0.000035502962,0.00022196125,0.000101475416,0.00017279421,0.0015587071,0.000022418062],"about_ca_topic_score_codex":0.005745508,"about_ca_topic_score_gemma":0.012666762,"teacher_disagreement_score":0.015019275,"about_ca_system_score_codex":0.002161425,"about_ca_system_score_gemma":0.0025322565,"threshold_uncertainty_score":0.05147469},"labels":[],"label_agreement":null},{"id":"W3180426532","doi":"10.1001/jamaoncol.2021.2140","title":"Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of <i>ERBB2</i>-Positive Metastatic Breast Cancer","year":2021,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Cancer; Internal medicine; Intensive care medicine","score_opus":0.08597336018157553,"score_gpt":0.4605725266895825,"score_spread":0.37459916650800695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180426532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926358,0.0013137768,0.00026301033,0.0014476589,0.00001192153,0.00006650855,0.0023626988,0.000011369476,0.0018872498],"genre_scores_gemma":[0.9983354,0.00049609755,0.00017776078,0.00012384675,0.000009857396,0.0000335205,0.0006577884,0.0000032304472,0.00016244623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762267,0.0004971306,0.00034744944,0.00047996177,0.00069735956,0.00035533062],"domain_scores_gemma":[0.98497355,0.0014723289,0.010812809,0.00033457825,0.0014060274,0.0010006786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014010979,0.00012041861,0.0002261101,0.0007689738,0.00042359333,0.000739814,0.0005608957,0.00037835032,0.0014755721],"category_scores_gemma":[0.012523272,0.00016315529,0.0002746544,0.0020327189,0.00044236518,0.00047912338,0.00061464065,0.00040581624,0.0001385752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048681883,0.000020550118,0.9945891,0.000037069218,0.00003696275,0.000031035943,0.00028368647,0.00008024662,0.000051722844,0.00007010986,0.0005941032,0.0041566817],"study_design_scores_gemma":[0.000011052748,0.00003604176,0.99814487,0.000049300943,0.000016243373,0.00008244866,0.0005128,0.00035876504,0.000032459295,0.00005582566,0.0006950141,0.0000052272862],"about_ca_topic_score_codex":0.19025925,"about_ca_topic_score_gemma":0.29259068,"teacher_disagreement_score":0.19025925,"about_ca_system_score_codex":0.004582474,"about_ca_system_score_gemma":0.005929026,"threshold_uncertainty_score":0.37830365},"labels":[],"label_agreement":null},{"id":"W3186846250","doi":"10.1111/cas.15086","title":"TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Science","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Theratechnologies (Canada)","funders":"Québec Consortium for Drug Discovery","keywords":"Docetaxel; Cancer research; Triple-negative breast cancer; In vivo; Breast cancer; Gene silencing; Medicine; Cancer; Internalization; Apoptosis; Receptor; Internal medicine; Biology","score_opus":0.07158712367629191,"score_gpt":0.4232752614865087,"score_spread":0.3516881378102168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186846250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796504,0.009461502,0.0053873723,0.0002490249,0.00011630317,0.00026498298,0.00039469515,0.00014289934,0.004332795],"genre_scores_gemma":[0.988865,0.004369727,0.0031976204,0.000111673275,0.00002270096,0.000072958144,0.0004946496,0.000016420992,0.0028491954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999678,0.000005038451,0.000002639883,0.0000073034507,0.000009787125,0.0000074361437],"domain_scores_gemma":[0.9999877,0.0000010323437,0.0000029909766,8.197629e-7,0.0000019215977,0.000005536163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000061350736,0.0003675349,0.0002086299,0.00018295094,0.000102857906,0.00017132159,0.0001664738,0.00024933045,0.00046443037],"category_scores_gemma":[0.00003650561,0.00011083217,0.00015695198,0.00011995675,0.0000978048,0.00015644441,0.00012345036,0.0003266568,0.00018871123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045531444,0.00015747188,0.0002694791,0.00016703797,0.00002549505,0.00030815037,0.00003516448,0.00045379176,0.97533834,0.00025390144,0.00054887345,0.021986954],"study_design_scores_gemma":[0.00077714655,0.0056560426,0.0042650285,0.000017406333,0.00012410022,0.0029912249,0.000028889066,0.0030439026,0.95583516,0.00007342198,0.027148936,0.000038814396],"about_ca_topic_score_codex":0.00064397464,"about_ca_topic_score_gemma":0.0012240438,"teacher_disagreement_score":0.00064397464,"about_ca_system_score_codex":0.00026753254,"about_ca_system_score_gemma":0.00020430148,"threshold_uncertainty_score":0.0019410849},"labels":[],"label_agreement":null},{"id":"W3194861850","doi":"10.3390/jpm11080808","title":"Breast Cancer Treatments: Updates and New Challenges","year":2021,"lang":"en","type":"review","venue":"Journal of Personalized Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":473,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Breast cancer; Estrogen receptor; Cancer; Immunotherapy; Oncology; Targeted therapy; Radiation therapy; Triple-negative breast cancer; Internal medicine; Epidermal growth factor receptor; Bioinformatics; Cancer research; Biology","score_opus":0.26747323684843194,"score_gpt":0.49935521943700617,"score_spread":0.23188198258857423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194861850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000090673595,0.9961379,0.00012988914,0.0015520653,0.00068909925,0.0000051724974,0.000024887107,0.000012998547,0.0013571894],"genre_scores_gemma":[0.0004926458,0.9970772,0.00020881671,0.00080158544,0.0006450325,0.000005681588,0.000049168146,0.0000029185624,0.0007169909],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99958736,0.0000893425,0.00005593071,0.00005330196,0.00017819874,0.000035984143],"domain_scores_gemma":[0.9991173,0.00042871063,0.00007536828,0.000026054382,0.00029000212,0.00006253818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010072495,0.00070952735,0.0012338537,0.0016789576,0.0003542222,0.001380055,0.0008758769,0.0013125533,0.006738023],"category_scores_gemma":[0.0016498584,0.00026966678,0.00065123505,0.0015064463,0.0005084201,0.0019716234,0.00078438973,0.002912551,0.0026964175],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054105632,0.00006184092,0.00010908885,0.010862977,0.000056990415,0.00011232854,0.000057052403,0.00023254447,0.00068645645,0.0050823055,0.07118059,0.91150373],"study_design_scores_gemma":[0.000010718023,0.000053945107,0.00022566048,0.0028826972,0.00005132557,0.0005359337,0.000042597894,0.00006378019,0.000116044794,0.0018854946,0.99412245,0.00000943474],"about_ca_topic_score_codex":0.0010249023,"about_ca_topic_score_gemma":0.0023407561,"teacher_disagreement_score":0.006738023,"about_ca_system_score_codex":0.00084520277,"about_ca_system_score_gemma":0.001504763,"threshold_uncertainty_score":0.022540987},"labels":[],"label_agreement":null},{"id":"W3195543529","doi":"10.3390/life11090868","title":"Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Life","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Alberta","funders":"Canadian Institutes of Health Research; Women and Children's Health Research Institute; Children's Health Research Institute","keywords":"Lapatinib; Gene silencing; Cancer research; Trastuzumab; Breast cancer; Epigenetics; Epithelial–mesenchymal transition; Cancer; Biology; Chromatin; Gene; Metastasis; Genetics","score_opus":0.021159398207756013,"score_gpt":0.3219307502491696,"score_spread":0.3007713520414136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195543529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972736,0.0010892915,0.00081988506,0.000039859468,0.000008948128,0.000007323818,0.0001493608,0.000028995393,0.000582785],"genre_scores_gemma":[0.99884206,0.0002708846,0.00016287065,0.000026831161,0.0000021122323,0.0000051130723,0.00017287102,0.0000028560244,0.00051444344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999275,0.000010939712,0.0000059447843,0.00001408561,0.000023855524,0.00001764559],"domain_scores_gemma":[0.9999616,0.0000070958035,0.000015105512,0.000004468862,0.0000056738013,0.0000059477034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095940246,0.00008065993,0.00013495544,0.00012298155,0.00008186497,0.00022220715,0.00006762119,0.000116600364,0.00077881524],"category_scores_gemma":[0.000114825365,0.00006212593,0.00012512472,0.00013467482,0.00009253119,0.00008728157,0.00010549756,0.00018465318,0.0001328419],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013051828,0.000026060352,0.002844484,0.000027360102,0.000014742084,0.00009437637,0.00002676967,0.00015512458,0.99296886,0.000091837566,0.00005649661,0.0035632204],"study_design_scores_gemma":[0.000017979244,0.00039759645,0.09733739,0.000009331513,0.000054804143,0.00075272424,0.00009669839,0.0030638275,0.8948038,0.0001377119,0.0033207855,0.0000072669527],"about_ca_topic_score_codex":0.0003233554,"about_ca_topic_score_gemma":0.00069859676,"teacher_disagreement_score":0.00077881524,"about_ca_system_score_codex":0.0001574753,"about_ca_system_score_gemma":0.0000757946,"threshold_uncertainty_score":0.0026054382},"labels":[],"label_agreement":null},{"id":"W3197219028","doi":"10.3390/ijms22179569","title":"Quantitative Analysis of the Potency of Equimolar Two-Drug Combinations and Combi-Molecules Involving Kinase Inhibitors In Vitro: The Concept of Balanced Targeting","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Potency; Kinase; IC50; Pharmacology; In vitro; Drug; Chemistry; Small molecule; Combinatorial chemistry; Biochemistry; Medicine","score_opus":0.024508568542378976,"score_gpt":0.3675815611742724,"score_spread":0.3430729926318934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197219028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82110643,0.013938991,0.1548653,0.00027895535,0.0002721942,0.0005968109,0.0018712011,0.0003756763,0.006694424],"genre_scores_gemma":[0.95361024,0.0031834084,0.039145254,0.0001472151,0.000072742885,0.00071307854,0.001313595,0.000055489214,0.0017589867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972434,0.00088454894,0.00033663603,0.00036972607,0.0009465028,0.00021910213],"domain_scores_gemma":[0.9971301,0.0015888946,0.0004157661,0.00032481525,0.0004127549,0.00012772156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026557066,0.001009108,0.0012604821,0.0014292499,0.0002771528,0.0006320329,0.00056067493,0.0006814818,0.00088218646],"category_scores_gemma":[0.0022042906,0.00037917827,0.00074273784,0.0015811424,0.0007641988,0.00087717146,0.00058959844,0.0014688511,0.00037048812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005587442,0.00038474248,0.0019926352,0.0003596905,0.00012485488,0.000045632776,0.00013820744,0.0051596356,0.9694119,0.0005100192,0.00016396098,0.021150025],"study_design_scores_gemma":[0.000028651126,0.0020717185,0.0035620388,0.00001330579,0.00008687535,0.000099636134,0.00006543009,0.0115126,0.98095185,0.00027629736,0.0013011774,0.00003039287],"about_ca_topic_score_codex":0.00039556724,"about_ca_topic_score_gemma":0.00035472692,"teacher_disagreement_score":0.0026557066,"about_ca_system_score_codex":0.00042755276,"about_ca_system_score_gemma":0.00033964452,"threshold_uncertainty_score":0.014044881},"labels":[],"label_agreement":null},{"id":"W3197623252","doi":"10.1503/jpn.200166","title":"Neurobiological substrates of major psychiatry disorders: transdiagnostic associations between white matter abnormalities, neuregulin 1 and clinical manifestation","year":2021,"lang":"en","type":"article","venue":"Journal of Psychiatry and Neuroscience","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"National Science Fund for Distinguished Young Scholars; National Key Research and Development Program of China","keywords":"Neuregulin 1; White matter; Neuregulin; Psychology; Psychiatry; Neuroscience; Medicine; Clinical psychology; Internal medicine; Magnetic resonance imaging","score_opus":0.04579744722907405,"score_gpt":0.3689059528014966,"score_spread":0.32310850557242254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197623252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991892,0.0002911642,0.00006723039,0.000044698176,0.0000023719865,0.00000720773,0.00007507942,0.0000022696422,0.00032072907],"genre_scores_gemma":[0.999542,0.00013149234,0.00012360787,0.00001842914,0.0000027975445,0.0000036921745,0.00010573669,8.397141e-7,0.00007143921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999912,0.000016475535,0.000012191588,0.000028257033,0.000016363776,0.000014790011],"domain_scores_gemma":[0.99953055,0.000039387214,0.000306489,0.000020729118,0.000042046035,0.000060840383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024092181,0.0003244102,0.00018126593,0.0006169072,0.0002764648,0.00029211355,0.00020540193,0.00022103419,0.001478996],"category_scores_gemma":[0.00069807365,0.00012896801,0.0001591066,0.00039793568,0.00031548113,0.00015732732,0.00035946222,0.00024065892,0.000114247385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024852893,0.000031281284,0.9887582,0.000029485196,0.000079119876,0.00074487046,0.00011747795,0.000040182746,0.0072972495,0.000054667813,0.000070359,0.0025284544],"study_design_scores_gemma":[0.0000035895455,0.00003430243,0.99838793,0.0000049289506,0.000018636681,0.0011016956,0.000075821765,0.00004604018,0.00024368867,0.00004622249,0.00003603184,0.0000011507218],"about_ca_topic_score_codex":0.002466034,"about_ca_topic_score_gemma":0.00477309,"teacher_disagreement_score":0.002466034,"about_ca_system_score_codex":0.000300848,"about_ca_system_score_gemma":0.00020853862,"threshold_uncertainty_score":0.004947722},"labels":[],"label_agreement":null},{"id":"W3198257986","doi":"10.21203/rs.3.rs-841103/v1","title":"Definitive Results of a Phase III Adjuvant Trial Comparing Six Cycles of FEC-100 to Four Cycles of AC in Women with Operable Node-negative Breast Cancer: The NSABP B-36 Trial (NRG Oncology)","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"National Institutes of Health","keywords":"Breast cancer; Medicine; Adjuvant; Oncology; Internal medicine; Node (physics); Gynecology; Cancer; Physics","score_opus":0.18937807339919693,"score_gpt":0.49025522985159664,"score_spread":0.3008771564523997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198257986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854961,0.006132008,0.0006004522,0.0010803245,0.00039765416,0.0025951078,0.0013496362,0.00007791128,0.002270787],"genre_scores_gemma":[0.9867203,0.0024685853,0.0014730036,0.00095350924,0.00036133948,0.0018489106,0.0020948974,0.000018841656,0.004060424],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99924195,0.00055065536,0.00004121849,0.00006953554,0.00004202896,0.000054593023],"domain_scores_gemma":[0.9981186,0.00082373794,0.00037976346,0.00016909502,0.000090690795,0.0004181244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003387313,0.0011392344,0.0015682994,0.000343106,0.0003057961,0.00064613525,0.0005866228,0.0016227482,0.0064750533],"category_scores_gemma":[0.0026426858,0.00036195133,0.0015686756,0.00032408713,0.00084919826,0.0005395763,0.0002468805,0.0022778485,0.000742458],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9663703,0.0072037396,0.0013272614,0.0005680986,0.0009800995,0.00004801911,0.000049246344,0.00048352228,0.0037372827,0.000081626175,0.00093234645,0.018218488],"study_design_scores_gemma":[0.84988356,0.1418852,0.0045655877,0.000049939867,0.00080001575,0.000066140834,0.000016963706,0.0002995602,0.00097262603,0.00011864954,0.0013296574,0.000012192717],"about_ca_topic_score_codex":0.00048516417,"about_ca_topic_score_gemma":0.0012805333,"teacher_disagreement_score":0.0064750533,"about_ca_system_score_codex":0.0005083518,"about_ca_system_score_gemma":0.0007327407,"threshold_uncertainty_score":0.021661222},"labels":[],"label_agreement":null},{"id":"W3199342822","doi":"10.30683/1929-2279.2019.08.01","title":"HER2 Expression Discordance between Ductal Carcinoma In situ and Invasive Breast Carcinoma. How to Analyze Oncotype DX","year":2019,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Ductal carcinoma; Breast cancer; Oncology; Progesterone receptor; Stage (stratigraphy); Hormone receptor; Internal medicine; Invasive ductal carcinoma; Medicine; Breast carcinoma; In situ hybridization; Pathology; Cancer; Cancer research; Biology; Gene expression; Gene; Estrogen receptor","score_opus":0.05139895220199545,"score_gpt":0.4067404122457482,"score_spread":0.3553414600437527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199342822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95816106,0.012333009,0.0065256953,0.00195546,0.0003778539,0.00006668793,0.00024873667,0.00020198074,0.020129584],"genre_scores_gemma":[0.99031806,0.0028221947,0.0039702933,0.0004957869,0.00028932487,0.000016614043,0.00020101933,0.000037247475,0.0018493459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954575,0.00011675055,0.00006433199,0.00006408179,0.00014457246,0.00006448973],"domain_scores_gemma":[0.9989396,0.00040083754,0.00022307054,0.00008543289,0.00024167614,0.000109554356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012131117,0.00027850267,0.00036214426,0.0014123134,0.00017231193,0.00085018325,0.00030997684,0.00047272304,0.001574032],"category_scores_gemma":[0.0026895558,0.00020283606,0.00025123468,0.000491938,0.00043170498,0.0006278468,0.00030351317,0.0004013467,0.00065041997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000837663,0.00007016469,0.70658594,0.00029046953,0.00010473719,0.0448798,0.00055532245,0.00022822838,0.093938574,0.0012369925,0.0045926967,0.14667936],"study_design_scores_gemma":[0.00003824907,0.00019499651,0.7801651,0.00014423009,0.00021744223,0.17262839,0.0018363554,0.0019366133,0.026045913,0.0020002967,0.014748578,0.000043918397],"about_ca_topic_score_codex":0.0010731539,"about_ca_topic_score_gemma":0.0014223407,"teacher_disagreement_score":0.001574032,"about_ca_system_score_codex":0.00024648372,"about_ca_system_score_gemma":0.00013397279,"threshold_uncertainty_score":0.006415665},"labels":[],"label_agreement":null},{"id":"W3200858465","doi":"10.1002/pbc.29316","title":"Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma","year":2021,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute for Health and Care Research; Brain Tumour Charity; Boehringer Ingelheim","keywords":"ErbB; Medulloblastoma; Ependymoma; Neuroblastoma; Epidermal growth factor receptor; Rhabdomyosarcoma; Medicine; Cancer research; Glioma; EGFR inhibitors; Pathology; Oncology; Internal medicine; Sarcoma; Biology; Receptor; Cell culture","score_opus":0.025577329739935158,"score_gpt":0.30539863850700044,"score_spread":0.2798213087670653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200858465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939075,0.0034781012,0.00086053624,0.000021841577,0.000002856768,0.000023479879,0.0011828295,0.000021199443,0.00050168764],"genre_scores_gemma":[0.9930676,0.0019328858,0.001976143,0.000019789764,0.000004659065,0.000030996147,0.002793699,0.000008774288,0.0001653564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997787,0.00003282012,0.000031609194,0.00005097086,0.00006681883,0.000039077095],"domain_scores_gemma":[0.9997358,0.000066986126,0.00007999303,0.000023946197,0.000055753724,0.00003749906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046065115,0.00020963629,0.00024605214,0.001475697,0.00017084673,0.0001698604,0.00019865416,0.00011211986,0.00052930566],"category_scores_gemma":[0.00038858585,0.000111027744,0.00024365204,0.00089568604,0.00013637767,0.00014389717,0.0003350686,0.00013212107,0.00021517047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006389053,0.000027206153,0.842117,0.00031063455,0.00012049913,0.002369233,0.00019225849,0.00058578356,0.11977275,0.00013487927,0.0004231345,0.03330767],"study_design_scores_gemma":[0.000008862679,0.00016655643,0.96222264,0.000024361065,0.00013925816,0.009659286,0.00018889054,0.00047110431,0.022897014,0.00008541411,0.0041305264,0.000006003312],"about_ca_topic_score_codex":0.0010442407,"about_ca_topic_score_gemma":0.002179683,"teacher_disagreement_score":0.001475697,"about_ca_system_score_codex":0.00022268477,"about_ca_system_score_gemma":0.00045247973,"threshold_uncertainty_score":0.0024362206},"labels":[],"label_agreement":null},{"id":"W3202236569","doi":"10.1158/1078-0432.ccr-21-1181","title":"Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Università degli Studi di Milano; Bristol-Myers Squibb","keywords":"Nivolumab; Maximum tolerated dose; Clinical trial; Solid tumor; Immunotherapy; Phases of clinical research; Cytotoxic T cell","score_opus":0.14198669748668777,"score_gpt":0.559179952943152,"score_spread":0.41719325545646424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202236569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99297464,0.0030938569,0.00027545006,0.00024848388,0.00013600197,0.0010853031,0.0004182389,0.000072999675,0.0016950796],"genre_scores_gemma":[0.99246335,0.0019858105,0.0008082107,0.00044677095,0.00018828253,0.00080193684,0.001131231,0.000018953742,0.0021555428],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997793,0.00010442322,0.000014533033,0.000039635604,0.000021632672,0.000040469375],"domain_scores_gemma":[0.99970704,0.000037207268,0.00007223295,0.000022224554,0.000018054998,0.00014319224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010101704,0.0013750317,0.0014339548,0.00026672368,0.0002889272,0.0007238994,0.00056622154,0.00083363295,0.0026111954],"category_scores_gemma":[0.00041297838,0.00048794132,0.0009551448,0.000305681,0.000655057,0.0005277565,0.00021998337,0.001989847,0.00084917725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7404884,0.040198006,0.0066493833,0.0013245075,0.0012033458,0.0002649024,0.00021761357,0.002360571,0.094733275,0.00024553228,0.0037154881,0.10859907],"study_design_scores_gemma":[0.5006267,0.47466275,0.013566478,0.000046033492,0.00048541994,0.00029082192,0.00004615156,0.0011586219,0.0062866644,0.000115341005,0.0026907804,0.00002421015],"about_ca_topic_score_codex":0.0006010876,"about_ca_topic_score_gemma":0.0019004723,"teacher_disagreement_score":0.0026111954,"about_ca_system_score_codex":0.0006629005,"about_ca_system_score_gemma":0.00097554235,"threshold_uncertainty_score":0.008735299},"labels":[],"label_agreement":null},{"id":"W3203662700","doi":"10.1186/s12967-021-03081-0","title":"Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma","year":2021,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Immunohistochemistry; Proportional hazards model; Medicine; Oncology; Cancer; Internal medicine; Epidermal growth factor receptor; Laryngeal Neoplasm; Survival analysis; Pathology; Cancer research","score_opus":0.014668160104112695,"score_gpt":0.28565917043076733,"score_spread":0.2709910103266546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203662700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984036,0.00068408763,0.00033076343,0.00007696647,0.000010088951,0.000007447808,0.00012522176,0.000015185574,0.00034656771],"genre_scores_gemma":[0.9995646,0.00008037088,0.00012114388,0.000011456166,0.0000070620326,0.0000023292023,0.00011033769,0.0000020362565,0.00010068047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99984014,0.000046329646,0.000017513723,0.000033002052,0.00003363942,0.000029394763],"domain_scores_gemma":[0.9992379,0.00030790723,0.00018366652,0.000052905893,0.00009330882,0.00012431991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078879524,0.0002826408,0.00034023405,0.00028828386,0.00028574778,0.00044124472,0.00020584071,0.00030729332,0.0017579952],"category_scores_gemma":[0.0022043095,0.00009190244,0.0004799661,0.0002888462,0.00019335472,0.0003225481,0.0002697681,0.00040834644,0.00026586655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017269463,0.00005582684,0.97635925,0.000027200047,0.000086877604,0.000115737144,0.000058064685,0.00065587385,0.0025624107,0.000022457605,0.0002516175,0.01807781],"study_design_scores_gemma":[0.0000409248,0.000514791,0.9925972,0.000013629564,0.00018942663,0.0006027561,0.00009346452,0.0039003761,0.001144906,0.00020178038,0.0006913764,0.000009238527],"about_ca_topic_score_codex":0.001153376,"about_ca_topic_score_gemma":0.002661452,"teacher_disagreement_score":0.0017579952,"about_ca_system_score_codex":0.00030417278,"about_ca_system_score_gemma":0.00033858235,"threshold_uncertainty_score":0.0058811307},"labels":[],"label_agreement":null},{"id":"W3204588330","doi":"10.1016/j.annonc.2021.08.1489","title":"1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Princess Margaret Cancer Centre","funders":"Astellas Pharma; Natera; Pharmacyclics; MacroGenics; BeiGene; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb; Incyte; Amgen","keywords":"Medicine; Internal medicine; Hypokalemia; Oxaliplatin; Gastroenterology; Vomiting; Nausea; Capecitabine; Adverse effect; Cancer; Colorectal cancer","score_opus":0.16177578153297198,"score_gpt":0.4767629339354125,"score_spread":0.3149871524024406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204588330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881457,0.0013489698,0.00047172504,0.0006390168,0.00021153074,0.0022715398,0.0036231729,0.00011199782,0.003176266],"genre_scores_gemma":[0.97190386,0.0025712529,0.002109113,0.0013407795,0.00019490503,0.002807204,0.008488619,0.00008244814,0.010501882],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970967,0.00010596886,0.000011806059,0.00004944675,0.000027421522,0.00009573178],"domain_scores_gemma":[0.9995484,0.000046170157,0.00006009664,0.000044917855,0.00003189524,0.00026850612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009278578,0.0012739641,0.002164359,0.00047401784,0.0003528099,0.0010708214,0.00081260625,0.0009691825,0.0076688644],"category_scores_gemma":[0.0006342315,0.0005518137,0.0014086559,0.00043070343,0.000747225,0.0006762974,0.00040163758,0.0033029967,0.0016282566],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78654486,0.047043297,0.0057714423,0.00086269,0.001189982,0.00018303223,0.00020614658,0.0023353442,0.039104566,0.00053193996,0.007148477,0.109078236],"study_design_scores_gemma":[0.59590673,0.37968352,0.01223464,0.000043857428,0.00063272036,0.00025280748,0.000075395066,0.0009464531,0.0047226334,0.0003580961,0.005114399,0.000028733231],"about_ca_topic_score_codex":0.0024718374,"about_ca_topic_score_gemma":0.006101386,"teacher_disagreement_score":0.0076688644,"about_ca_system_score_codex":0.0012177838,"about_ca_system_score_gemma":0.002040436,"threshold_uncertainty_score":0.025654852},"labels":[],"label_agreement":null},{"id":"W3204658474","doi":"10.1016/j.annonc.2021.08.1962","title":"1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Refractory (planetary science); Oncology; Lung cancer; Cancer; non-small cell lung cancer (NSCLC); Antibody-drug conjugate; Antibody; Breast cancer; Monoclonal antibody; Immunology","score_opus":0.09043951009908645,"score_gpt":0.4486056378400373,"score_spread":0.35816612774095086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204658474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996053,0.0014052088,0.00011771758,0.00024116907,0.000059577793,0.00026239743,0.0005614209,0.00003576596,0.0012636614],"genre_scores_gemma":[0.9938212,0.0013500873,0.0003475919,0.00036312928,0.00007014123,0.00021252142,0.0017654387,0.000011966324,0.0020578895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998211,0.000077592005,0.000008409856,0.000031933043,0.00001566498,0.000045336776],"domain_scores_gemma":[0.99983084,0.000030391615,0.000025943911,0.000010238859,0.000010792817,0.00009163008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046865724,0.00068188173,0.0009756316,0.00018340645,0.00017873239,0.0005965178,0.00034681192,0.00051024504,0.002631211],"category_scores_gemma":[0.00044206736,0.0002856015,0.00056575134,0.00025691555,0.0003081306,0.00038980017,0.00023004149,0.0011172311,0.00052887143],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6575473,0.021435915,0.03752525,0.0005863907,0.0017842453,0.00029935077,0.0002160633,0.003106125,0.051159658,0.00024450733,0.0062264306,0.21986893],"study_design_scores_gemma":[0.5103267,0.37258178,0.09879279,0.00006331595,0.0011848097,0.00054637925,0.00011492887,0.0025409933,0.0064907484,0.00018210967,0.0071368893,0.00003858909],"about_ca_topic_score_codex":0.0014067013,"about_ca_topic_score_gemma":0.004333849,"teacher_disagreement_score":0.002631211,"about_ca_system_score_codex":0.0006476964,"about_ca_system_score_gemma":0.00074103934,"threshold_uncertainty_score":0.008802295},"labels":[],"label_agreement":null},{"id":"W3207977249","doi":"10.2217/fon-2021-0753","title":"Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Placebo; Randomized controlled trial; Cancer; Pathology","score_opus":0.015681021701659328,"score_gpt":0.3375341293603767,"score_spread":0.3218531076587174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207977249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98099774,0.0053177197,0.0006964489,0.001141022,0.00045443178,0.005021019,0.0011081197,0.00010998728,0.0051534963],"genre_scores_gemma":[0.98132277,0.0030207857,0.0017930382,0.001512677,0.0003882935,0.0050666593,0.0015802033,0.000022947308,0.005292627],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994861,0.00027851356,0.000035032495,0.0000807883,0.00004076378,0.00007885875],"domain_scores_gemma":[0.9994746,0.00009315504,0.00013239356,0.00004040726,0.000031016472,0.00022851636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018592956,0.0010808097,0.001151024,0.00050397887,0.00036631394,0.0008323697,0.0008815226,0.0012408338,0.0055025327],"category_scores_gemma":[0.00081904733,0.00037378547,0.0010714531,0.00050593837,0.00085225434,0.0009195173,0.00050558976,0.0022100327,0.00083664106],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8872203,0.029017057,0.0018582803,0.001077197,0.0006962161,0.000066256966,0.0000799788,0.0009536023,0.010286498,0.0006932502,0.0020212748,0.06603006],"study_design_scores_gemma":[0.72667587,0.26506588,0.0024952646,0.000061701816,0.00029292057,0.00010248219,0.00004017603,0.00046490593,0.0013467235,0.000276603,0.0031567807,0.00002076975],"about_ca_topic_score_codex":0.00072692934,"about_ca_topic_score_gemma":0.0033943825,"teacher_disagreement_score":0.0055025327,"about_ca_system_score_codex":0.0007919699,"about_ca_system_score_gemma":0.001483269,"threshold_uncertainty_score":0.018407762},"labels":[],"label_agreement":null},{"id":"W3209164903","doi":"10.1093/ajcp/aqab191.053","title":"HER2 testing in metastatic breast cancer – is reflex in situ hybridization necessary in cases that are equivocal by immunohistochemistry?","year":2021,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Immunohistochemistry; Pathology; Metastatic breast cancer; Metastasis; In situ hybridization; Breast cancer; Incidence (geometry); Cancer; Oncology; Internal medicine; Biology","score_opus":0.155043225926168,"score_gpt":0.5059862879618359,"score_spread":0.35094306203566783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209164903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97175115,0.014451726,0.0023737801,0.002539169,0.00022216696,0.00004262767,0.00019772514,0.00008025386,0.008341422],"genre_scores_gemma":[0.9954151,0.0024179383,0.0013530969,0.0003209383,0.00016752632,0.0000063360667,0.00009205486,0.00001583285,0.00021114071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839336,0.00053794775,0.0003163795,0.00016517457,0.00041437097,0.00017278577],"domain_scores_gemma":[0.99507153,0.0017009894,0.001620154,0.00026070085,0.000977453,0.00036925048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032410105,0.00028451416,0.0004393847,0.0014907363,0.00041530922,0.0009019137,0.00076725875,0.0008036371,0.0017957713],"category_scores_gemma":[0.010670768,0.00027226986,0.00028572817,0.001042237,0.0011405591,0.00096469466,0.0003527085,0.00045255912,0.00090327463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022727589,0.000037880218,0.9284812,0.00022439723,0.000036620208,0.027318886,0.00020005334,0.00011930906,0.0036864756,0.00015398844,0.002009778,0.03750411],"study_design_scores_gemma":[0.000030726686,0.0005274211,0.68416333,0.00090229866,0.00014281967,0.28774434,0.0033784902,0.0016966752,0.009635889,0.0008885683,0.010843627,0.00004574876],"about_ca_topic_score_codex":0.0013359885,"about_ca_topic_score_gemma":0.002242613,"teacher_disagreement_score":0.0032410105,"about_ca_system_score_codex":0.00037521246,"about_ca_system_score_gemma":0.00049544836,"threshold_uncertainty_score":0.017140329},"labels":[],"label_agreement":null},{"id":"W3214083702","doi":"10.1158/0008-5472.can-21-3360","title":"HER3 Is an Actionable Target in Advanced Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute; Wellcome Trust Centre for Mitochondrial Research; Daiichi Sankyo Company; Imperial Experimental Cancer Medicine Centre; Stand Up To Cancer; National Institute for Health and Care Research; Prostate Cancer UK; Mark Foundation For Cancer Research; National Institutes of Health; Prostate Cancer Foundation; Cancer Research UK; Academy of Medical Sciences; Wellcome Trust; Chordoma Foundation","keywords":"Prostate cancer; Prostate; Cancer; PCA3; ErbB; Antibody; Immunotherapy","score_opus":0.15372566243138425,"score_gpt":0.5247178831692222,"score_spread":0.37099222073783794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214083702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95883906,0.024962699,0.00539983,0.0006932941,0.00008528756,0.000074085765,0.0009194891,0.0003770665,0.008649134],"genre_scores_gemma":[0.9941658,0.0026290677,0.000945106,0.00013397342,0.000017084785,0.000012797108,0.00027555018,0.000012888613,0.0018076703],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999037,0.000015342239,0.000004157758,0.000013704458,0.000032341817,0.000030775922],"domain_scores_gemma":[0.99996495,0.000004900818,0.000009273098,0.0000033882288,0.000005475606,0.000012002683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014491018,0.00020755947,0.0002089074,0.00014427815,0.00012917994,0.00020780599,0.00012759822,0.00020333294,0.0020204547],"category_scores_gemma":[0.0000614382,0.00005566483,0.00016862735,0.00019946496,0.00016350274,0.00009840108,0.00018300187,0.0003771853,0.0004516074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038253222,0.00004648824,0.0012486302,0.00014383548,0.000012819353,0.00021591027,0.000015695176,0.00027575815,0.98522675,0.00037407468,0.00046125255,0.011596325],"study_design_scores_gemma":[0.00008314075,0.0011972439,0.022609083,0.000030692634,0.00006473693,0.00371326,0.000046218127,0.0014324285,0.941126,0.0004748134,0.029207798,0.000014601546],"about_ca_topic_score_codex":0.0008734159,"about_ca_topic_score_gemma":0.0010759014,"teacher_disagreement_score":0.0020204547,"about_ca_system_score_codex":0.00040112392,"about_ca_system_score_gemma":0.00025451457,"threshold_uncertainty_score":0.0067590475},"labels":[],"label_agreement":null},{"id":"W3217635890","doi":"10.7554/elife.73218","title":"A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor","year":2021,"lang":"en","type":"article","venue":"eLife","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of General Medical Sciences; National Cancer Institute; Canada Excellence Research Chairs, Government of Canada; VGH and UBC Hospital Foundation","keywords":"Extracellular; Epidermal growth factor; Transmembrane protein; Epidermal growth factor receptor; Tyrosine kinase; Receptor tyrosine kinase; Transmembrane domain; Intracellular; Receptor","score_opus":0.061377380090935844,"score_gpt":0.33700611762329374,"score_spread":0.2756287375323579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217635890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93272275,0.0022873094,0.05504195,0.0016277663,0.00016602653,0.00006561233,0.00019346044,0.0004908109,0.0074044433],"genre_scores_gemma":[0.99073845,0.0007299677,0.0061872443,0.00022675282,0.000018366183,0.000041519572,0.000085857275,0.000021876562,0.0019499104],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998331,0.000019037285,0.000006733985,0.00005042457,0.00004085189,0.000049819664],"domain_scores_gemma":[0.9999269,0.000009993428,0.000016177491,0.000012797645,0.000008272841,0.000025893456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022079679,0.00023329484,0.00025929938,0.00012203348,0.00028657963,0.00051672105,0.00055871473,0.000595152,0.0010992504],"category_scores_gemma":[0.00021193022,0.00023521474,0.00030416175,0.000095390256,0.0004923079,0.0007776857,0.0004970697,0.00093590457,0.00049517164],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010390652,0.000038464925,0.00038280268,0.000054726956,0.000011343804,0.00031541282,0.00004630155,0.0005212244,0.98697275,0.007909082,0.00022888437,0.00341522],"study_design_scores_gemma":[0.00010840222,0.00022983225,0.0039155968,0.000018227483,0.0000183271,0.0009314396,0.0001262719,0.008717465,0.97440445,0.0044188728,0.0070852484,0.000025899959],"about_ca_topic_score_codex":0.000136075,"about_ca_topic_score_gemma":0.00016375846,"teacher_disagreement_score":0.0010992504,"about_ca_system_score_codex":0.00032919002,"about_ca_system_score_gemma":0.00018418227,"threshold_uncertainty_score":0.0036773682},"labels":[],"label_agreement":null},{"id":"W3217700626","doi":"10.1002/1878-0261.13141","title":"The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial","year":2021,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"Associazione Italiana per la Ricerca sul Cancro; International Breast Cancer Research Foundation; F. Hoffmann-La Roche; Breast Cancer Research Foundation","keywords":"Oncology; Breast cancer; Medicine; Internal medicine; Neoadjuvant therapy; Bioinformatics; Gynecology; Cancer; Biology","score_opus":0.02953605829063439,"score_gpt":0.37249265669463144,"score_spread":0.34295659840399706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217700626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998575,0.00030417263,0.00035442496,0.00008503989,0.0000085778365,0.000026068465,0.00032252527,0.0000071815625,0.0003169798],"genre_scores_gemma":[0.99699926,0.00012317213,0.00069493044,0.000078864905,0.000019606125,0.000034323588,0.0016780455,0.000007229486,0.00036448214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991105,0.00060568564,0.00003636829,0.00008694306,0.000109463224,0.000051058283],"domain_scores_gemma":[0.9985971,0.0008983649,0.00016223425,0.00012954664,0.00007513045,0.00013768433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00418586,0.00042173447,0.00060681003,0.00024730194,0.00012075195,0.00045246634,0.00024069635,0.00027726675,0.00072988303],"category_scores_gemma":[0.0030778267,0.00011299244,0.00054006255,0.00018971146,0.00021246194,0.00025674904,0.0003291941,0.00047162734,0.00018480237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065760784,0.0018214853,0.80485487,0.0001526021,0.0019422321,0.00018594631,0.00017059651,0.0133578,0.015245218,0.00019500635,0.0021593338,0.094154075],"study_design_scores_gemma":[0.005525481,0.034135904,0.8366431,0.000053285807,0.0028287466,0.0007599294,0.0002799789,0.10549074,0.008193532,0.000937849,0.0050762193,0.000075221746],"about_ca_topic_score_codex":0.0004256317,"about_ca_topic_score_gemma":0.00081554934,"teacher_disagreement_score":0.00418586,"about_ca_system_score_codex":0.00021989802,"about_ca_system_score_gemma":0.00034820882,"threshold_uncertainty_score":0.022137165},"labels":[],"label_agreement":null},{"id":"W4200093061","doi":"10.1002/cam4.4449","title":"What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"National Center for Advancing Translational Sciences; Ministero della Salute","keywords":"microRNA; Breast cancer; Cancer; Oncology; Exploratory research; Exploratory analysis; Medicine; Internal medicine; Biology; Genetics; Computer science; Gene; Data science","score_opus":0.030898679600262283,"score_gpt":0.37358260290346085,"score_spread":0.3426839233031986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200093061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574846,0.0017035634,0.00027198638,0.0005469981,0.000020465232,0.000022428823,0.0008274231,0.000004310673,0.00085444626],"genre_scores_gemma":[0.9984372,0.00023669284,0.00015901326,0.0001894715,0.00003842514,0.000023013445,0.00065483403,0.0000060235566,0.00025531749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993766,0.0002950326,0.000039377694,0.00013102024,0.0000809993,0.000076924014],"domain_scores_gemma":[0.9980463,0.0009909712,0.0004806322,0.00015093331,0.000117482545,0.00021372373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023975072,0.00020517154,0.00041172447,0.00021621436,0.00020983486,0.00072445214,0.00027473713,0.00034558217,0.0014042458],"category_scores_gemma":[0.0036344652,0.00013914854,0.0009148825,0.00030729128,0.0002206015,0.0006493581,0.0004248919,0.0005446086,0.00027084872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0098045105,0.00014298945,0.9690018,0.00016971334,0.0008373707,0.00025718004,0.00035770467,0.00045496805,0.0015547127,0.00031021272,0.0011869654,0.015921852],"study_design_scores_gemma":[0.00018699786,0.0021161635,0.98535144,0.00005089384,0.0014599961,0.0006099394,0.0006502432,0.0023130197,0.00075268996,0.0011499561,0.0053359256,0.000022784196],"about_ca_topic_score_codex":0.00025228606,"about_ca_topic_score_gemma":0.00058929896,"teacher_disagreement_score":0.0023975072,"about_ca_system_score_codex":0.00018635757,"about_ca_system_score_gemma":0.0003011097,"threshold_uncertainty_score":0.012679398},"labels":[],"label_agreement":null},{"id":"W4200320387","doi":"10.1158/1535-7163.targ-21-p196","title":"Abstract P196: Novel hydrophilic drug linkers enable exatecan-based antibody-drug conjugates with promising physiochemical properties and in vivo activity","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Profound Medical (Canada)","funders":"","keywords":"In vivo; Conjugate; Linker; Pharmacokinetics; Chemistry; Camptothecin; Drug; Potency; Pharmacology; Combinatorial chemistry; Pharmacodynamics; In vitro; Biochemistry; Medicine; Biology","score_opus":0.04894244771709914,"score_gpt":0.32794026793012554,"score_spread":0.2789978202130264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200320387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810827,0.0014474707,0.012115325,0.00018744593,0.00004948072,0.00010527507,0.0004950057,0.00015694318,0.004360383],"genre_scores_gemma":[0.98606306,0.0006034195,0.0072316974,0.000101684396,0.000016097709,0.000048957336,0.00048752705,0.000038011978,0.0054095984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993956,0.0000076181614,0.0000050657522,0.00001327424,0.000020936634,0.00001350607],"domain_scores_gemma":[0.9999435,0.0000058063297,0.000024872665,0.0000038423937,0.000008821704,0.000013131846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092107475,0.00035665274,0.00011516332,0.000104159495,0.000071614675,0.0001842325,0.0001593284,0.00023933084,0.0020823346],"category_scores_gemma":[0.00009250498,0.00008671107,0.000108059656,0.00011655867,0.00015936318,0.00025121603,0.00018003881,0.00034909215,0.00035065215],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006374103,0.000023675202,0.000048305195,0.00002772913,0.0000025382187,0.000052689487,0.000004894869,0.00015874532,0.9975356,0.00019075707,0.000068341564,0.0018230085],"study_design_scores_gemma":[0.00002375044,0.00023056792,0.00047705512,0.000002180626,0.0000052127484,0.00013846265,0.0000027304657,0.0004430046,0.9955408,0.000024044362,0.003108627,0.0000034993768],"about_ca_topic_score_codex":0.00024719234,"about_ca_topic_score_gemma":0.00032117587,"teacher_disagreement_score":0.0020823346,"about_ca_system_score_codex":0.00022570064,"about_ca_system_score_gemma":0.00016006693,"threshold_uncertainty_score":0.0069661736},"labels":[],"label_agreement":null},{"id":"W4200511560","doi":"10.1038/s41416-021-01676-4","title":"No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Princess Margaret Cancer Centre; University of Alberta; St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Trastuzumab; Oncology; Hazard ratio; Breast cancer; Taxane; Proportional hazards model; Radiation therapy; Lapatinib; Chemotherapy; Cancer; Surgery; Confidence interval","score_opus":0.07852426429881962,"score_gpt":0.4304724511525911,"score_spread":0.3519481868537715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200511560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931162,0.0033290817,0.00011571228,0.00017258518,0.000024582656,0.000014787842,0.00025968734,0.000008654115,0.0029586488],"genre_scores_gemma":[0.99882025,0.00021887715,0.000039778806,0.0000798369,0.000016222417,0.000006138754,0.00027260854,0.0000037056236,0.0005426339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994066,0.00024104891,0.00004985215,0.0000655316,0.00009796874,0.00013907615],"domain_scores_gemma":[0.99684876,0.0019227114,0.000459751,0.0001883605,0.00016738438,0.00041297384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019889902,0.0001185501,0.00062708405,0.0004571808,0.0002036348,0.00052921334,0.0002358487,0.0005792351,0.0030034976],"category_scores_gemma":[0.003001699,0.00007114439,0.00041980293,0.00026122047,0.00043760528,0.0005326348,0.00029174448,0.00060171087,0.0003522522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10459138,0.0006825905,0.74306697,0.00061636575,0.00059261126,0.0042273114,0.00077969674,0.0007973293,0.03748728,0.00039809872,0.0009971008,0.105763294],"study_design_scores_gemma":[0.00025916632,0.012469595,0.9753847,0.00006677247,0.00041419282,0.004713814,0.0006087558,0.00044738606,0.0022269303,0.0004541164,0.0029316563,0.00002301656],"about_ca_topic_score_codex":0.00069587975,"about_ca_topic_score_gemma":0.0014760013,"teacher_disagreement_score":0.0030034976,"about_ca_system_score_codex":0.0002922598,"about_ca_system_score_gemma":0.00018445766,"threshold_uncertainty_score":0.0105189085},"labels":[],"label_agreement":null},{"id":"W4200592628","doi":"10.1158/1535-7163.targ-21-p062","title":"Abstract P062: The CL2A-SN38 linker-payload system conjugated to trastuzumab results in improved cellular cytotoxicity over time relative to T-DM1","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Linker; Cytotoxicity; Chemistry; Conjugate; Trastuzumab; Conjugated system; Antibody-drug conjugate; Internalization; Prodrug; Endosome; Cancer cell; Biophysics; Combinatorial chemistry; Biochemistry; Monoclonal antibody; Cancer; In vitro; Antibody; Biology; Intracellular; Cell","score_opus":0.03613944612334209,"score_gpt":0.33726379957734026,"score_spread":0.3011243534539982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200592628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961689,0.00039743102,0.001328598,0.000052802887,0.000020374458,0.000017218055,0.0002621703,0.000094278126,0.0016581768],"genre_scores_gemma":[0.99362355,0.0001721825,0.0012654113,0.000026621277,0.0000049441956,0.000015047736,0.00049767544,0.000027469889,0.004367107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987566,0.00001421323,0.000008763283,0.00003272329,0.000037312766,0.00003129179],"domain_scores_gemma":[0.99993217,0.00000898038,0.000018572056,0.000006047875,0.00001657702,0.000017647963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010790335,0.00027825584,0.00014624208,0.000120699464,0.00008514312,0.00019411262,0.00018986111,0.00026040978,0.0029360696],"category_scores_gemma":[0.0001084022,0.00007338677,0.00012083224,0.00013084638,0.00011699998,0.00019866001,0.00009651394,0.00029231273,0.0005259191],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026278157,0.000036146925,0.000061001454,0.000017675975,0.0000028122151,0.000029565634,0.000007878633,0.00006863526,0.9984106,0.00003121309,0.000091526534,0.0009800484],"study_design_scores_gemma":[0.000011002611,0.00031552574,0.000433773,0.0000012810902,0.000002216381,0.000039069295,0.0000037068546,0.00045988764,0.9981816,0.0000053675953,0.00054506183,0.0000015625212],"about_ca_topic_score_codex":0.000908778,"about_ca_topic_score_gemma":0.0006369317,"teacher_disagreement_score":0.0029360696,"about_ca_system_score_codex":0.0003289996,"about_ca_system_score_gemma":0.00017371301,"threshold_uncertainty_score":0.00982213},"labels":[],"label_agreement":null},{"id":"W4205118191","doi":"10.51731/cjht.2022.240","title":"Tucatinib (Tukysa)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Capecitabine; Trastuzumab; Pertuzumab; Medicine; Trastuzumab emtansine; Oncology; Internal medicine; Breast cancer; Cancer; Political science; Colorectal cancer","score_opus":0.08428908766939776,"score_gpt":0.38703315185344067,"score_spread":0.3027440641840429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205118191","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03997964,0.8129088,0.0012466299,0.0043040817,0.0010238682,0.00042212434,0.0046999785,0.0005599967,0.13485484],"genre_scores_gemma":[0.4584352,0.4497861,0.002591441,0.0043941285,0.00047808816,0.00033077347,0.009457692,0.000044244465,0.074482344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998548,0.00002365965,0.000013453276,0.000022711682,0.000055967823,0.000029335208],"domain_scores_gemma":[0.99990535,0.000014124038,0.00002637105,0.0000041372527,0.000028210397,0.000021806085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023661858,0.00028229124,0.00034036167,0.0010731202,0.00033225596,0.0007511549,0.00028997142,0.00039381275,0.010325639],"category_scores_gemma":[0.00039178308,0.00007769139,0.00045976893,0.0008721323,0.00016962687,0.0003393945,0.00029980863,0.00070835353,0.0021417057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090238114,0.00013780399,0.0011302701,0.0038786214,0.00019340994,0.00029279603,0.000042830332,0.00053733645,0.008050029,0.0031841553,0.07317497,0.90847534],"study_design_scores_gemma":[0.0007473258,0.0009992182,0.008519319,0.0021345492,0.00040317274,0.0026851755,0.000060320428,0.0005212216,0.0074878503,0.00062738213,0.9757816,0.000032848984],"about_ca_topic_score_codex":0.013146488,"about_ca_topic_score_gemma":0.046071492,"teacher_disagreement_score":0.013146488,"about_ca_system_score_codex":0.0016327656,"about_ca_system_score_gemma":0.0015905814,"threshold_uncertainty_score":0.03454268},"labels":[],"label_agreement":null},{"id":"W4205404910","doi":"10.1038/s41598-022-05209-8","title":"Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Saskatchewan Cancer Agency","keywords":"Trastuzumab; Medicine; Breast cancer; Hazard ratio; Internal medicine; Oncology; Adjuvant; Cohort; Proportional hazards model; Population; Gynecology; Concordance; Cancer; Confidence interval","score_opus":0.01860266590587352,"score_gpt":0.33582704513284545,"score_spread":0.31722437922697194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205404910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989115,0.0002409711,0.00004531808,0.000043511995,0.000007506238,0.000022918824,0.00048275504,0.0000018905364,0.00024364494],"genre_scores_gemma":[0.9988273,0.00021383018,0.000048501046,0.00006869226,0.000012623775,0.000021646354,0.00057751033,0.0000021136418,0.00022779652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993437,0.0001770545,0.000064169,0.0001635364,0.00012345165,0.00012803232],"domain_scores_gemma":[0.9987859,0.00017427257,0.0003405833,0.00020885801,0.00022034907,0.00027003582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013266797,0.00038251063,0.0005277663,0.00054771255,0.000549608,0.00073769357,0.00052410504,0.00049951836,0.00085488183],"category_scores_gemma":[0.0020408256,0.0004203141,0.00084078603,0.0012097268,0.00034551448,0.0004562037,0.00048119447,0.00071963825,0.00031447635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009273428,0.00011805249,0.99663734,0.000010871467,0.00027368826,0.000118700606,0.00008064012,0.000058267316,0.00031390338,0.000016826018,0.00018769373,0.0012566089],"study_design_scores_gemma":[0.00018638311,0.0003928079,0.99788934,0.000009373438,0.00020646793,0.00021393951,0.00018927254,0.0003555151,0.00007917476,0.000030125871,0.00043556732,0.000012013222],"about_ca_topic_score_codex":0.03962869,"about_ca_topic_score_gemma":0.05030622,"teacher_disagreement_score":0.03962869,"about_ca_system_score_codex":0.0014080784,"about_ca_system_score_gemma":0.0013975757,"threshold_uncertainty_score":0.07879603},"labels":[],"label_agreement":null},{"id":"W4205813526","doi":"10.1177/17588359211066677","title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Calgary; Université Laval; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University; University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche; AstraZeneca; Mylan; Pfizer","keywords":"Medicine; Trastuzumab; Neratinib; Oncology; Capecitabine; Internal medicine; Breast cancer; Hazard ratio; Clinical trial; Metastatic breast cancer; Cancer; Progression-free survival; Overall survival; Confidence interval; Colorectal cancer","score_opus":0.053771382150858645,"score_gpt":0.4747381370782596,"score_spread":0.420966754927401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205813526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010896066,0.97703254,0.00044622575,0.020209381,0.00035764577,0.000014224883,0.000055144184,0.000021951435,0.0007733474],"genre_scores_gemma":[0.014968885,0.96735895,0.0019171038,0.013226364,0.0017175075,0.000054740227,0.00012798015,0.000024147233,0.00060421566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622786,0.0019695582,0.0006444554,0.00033847665,0.00063766015,0.00018201637],"domain_scores_gemma":[0.981898,0.011724895,0.0027113433,0.0003950382,0.002646659,0.0006240165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014168776,0.000688975,0.0025176888,0.0025786834,0.0004301481,0.0040520183,0.0017936083,0.0026822865,0.006343753],"category_scores_gemma":[0.012340876,0.00034813565,0.0016182399,0.0034938413,0.0016057267,0.008631899,0.0011839139,0.0027783662,0.0013182886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001253961,0.00018761016,0.0022968522,0.031811018,0.00040778035,0.0002449536,0.00031341147,0.0007006039,0.0017743459,0.010604444,0.026498498,0.9239065],"study_design_scores_gemma":[0.0008238081,0.0023841234,0.0093479715,0.10770367,0.002546017,0.0021481721,0.0021741989,0.0021002595,0.001109591,0.037616733,0.831893,0.00015241852],"about_ca_topic_score_codex":0.0018466436,"about_ca_topic_score_gemma":0.004933643,"teacher_disagreement_score":0.014168776,"about_ca_system_score_codex":0.0027017079,"about_ca_system_score_gemma":0.00548165,"threshold_uncertainty_score":0.074932516},"labels":[],"label_agreement":null},{"id":"W4210879173","doi":"10.1007/s10549-021-06449-4","title":"Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial","year":2022,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Vinorelbine; Medicine; Afatinib; Lapatinib; Internal medicine; Oncology; Trastuzumab; Breast cancer; Metastatic breast cancer; Clinical endpoint; Rash; Cancer; Chemotherapy; Clinical trial; Gefitinib; Epidermal growth factor receptor","score_opus":0.07544896408578985,"score_gpt":0.4259875661619342,"score_spread":0.3505386020761443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210879173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684405,0.0013302385,0.00011132629,0.00021123118,0.000048708196,0.00053082046,0.00025256965,0.000016883874,0.0006542239],"genre_scores_gemma":[0.9967481,0.00080815115,0.00032874165,0.00029763437,0.000137082,0.0004552026,0.00049833406,0.0000046608648,0.00072212995],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957854,0.00021112755,0.00003689372,0.000073659445,0.00003099022,0.00006870977],"domain_scores_gemma":[0.99949074,0.00008903737,0.00009614748,0.000033868688,0.00002566877,0.00026454698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012417838,0.0010978434,0.0014848243,0.00028427038,0.00033112644,0.0006972147,0.00052346074,0.00097277004,0.0025314519],"category_scores_gemma":[0.0007825676,0.00045718515,0.0010513974,0.00029758373,0.000655034,0.00078040647,0.00026773848,0.0016740407,0.00049435766],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8261135,0.05409622,0.019793456,0.00057741656,0.0016484777,0.00026140801,0.0002856419,0.0015050828,0.023770612,0.00017184822,0.002322488,0.06945379],"study_design_scores_gemma":[0.63248396,0.33440152,0.026736973,0.000030098114,0.00054765504,0.00027622358,0.000070576774,0.0011183147,0.0023395536,0.00012353317,0.0018416039,0.000030032737],"about_ca_topic_score_codex":0.00045070358,"about_ca_topic_score_gemma":0.0013337902,"teacher_disagreement_score":0.0025314519,"about_ca_system_score_codex":0.0006288991,"about_ca_system_score_gemma":0.0007737598,"threshold_uncertainty_score":0.008468509},"labels":[],"label_agreement":null},{"id":"W4211157853","doi":"10.3389/fonc.2021.667397","title":"Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches","year":2022,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; University of Toronto","keywords":"Medicine; Minimal residual disease; Disease; Breast cancer; Clinical trial; Oncology; Bone marrow; Internal medicine; Cancer; Stage (stratigraphy); Bioinformatics","score_opus":0.1652289853562642,"score_gpt":0.4071593561355931,"score_spread":0.2419303707793289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211157853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005771448,0.99565804,0.0008974844,0.0017147496,0.00031234225,0.00002861277,0.00002595558,0.000023587343,0.000762055],"genre_scores_gemma":[0.0054641645,0.99069303,0.0014487752,0.0012966564,0.0003913691,0.00007851403,0.00006259792,0.0000080078735,0.00055693823],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994956,0.00018693916,0.00006952428,0.00006373205,0.00011199947,0.00007211004],"domain_scores_gemma":[0.9989046,0.00064845965,0.00012646859,0.000031850508,0.00021978696,0.00006877329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022039874,0.00057546014,0.002058678,0.00095767895,0.000263276,0.001678205,0.0011800516,0.0013965021,0.0026609164],"category_scores_gemma":[0.0021374475,0.00031345265,0.0010584157,0.0005789221,0.0007564299,0.0019214939,0.00077496073,0.0037299464,0.00090101437],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040234457,0.000306025,0.00036715998,0.021291576,0.00023830638,0.00034074552,0.00021784774,0.001318028,0.0059944256,0.012517617,0.023973208,0.93303275],"study_design_scores_gemma":[0.00033857662,0.0019956438,0.0013887772,0.012146827,0.0005059289,0.0013017954,0.0003359235,0.0012559077,0.0023223278,0.011412015,0.9669231,0.000073279894],"about_ca_topic_score_codex":0.0005294088,"about_ca_topic_score_gemma":0.0014215438,"teacher_disagreement_score":0.0026609164,"about_ca_system_score_codex":0.0006110313,"about_ca_system_score_gemma":0.0011499149,"threshold_uncertainty_score":0.011655927},"labels":[],"label_agreement":null},{"id":"W4212796650","doi":"10.5306/wjco.v13.i2.135","title":"Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas","year":2022,"lang":"en","type":"article","venue":"World Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital","funders":"","keywords":"Breast cancer; Medicine; Receptor tyrosine kinase; Cancer research; Tyrosine kinase; Cancer; Oncology; Internal medicine; Bioinformatics; Receptor; Biology","score_opus":0.0986459385811777,"score_gpt":0.43283005071646263,"score_spread":0.3341841121352849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212796650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791685,0.01633358,0.0003685732,0.00019074274,0.000026164882,0.000021255879,0.00060305046,0.0000174943,0.0032706636],"genre_scores_gemma":[0.99495053,0.0031301053,0.0002711301,0.000028741682,0.00001583476,0.00000942705,0.00044744572,0.000003522413,0.0011432674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999892,0.000012887509,0.000010404445,0.000017716118,0.00004173515,0.000025269988],"domain_scores_gemma":[0.999821,0.000032809054,0.00005324323,0.000010219503,0.00003971937,0.000043016193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023090267,0.00015570744,0.00014714456,0.0005154656,0.00014752064,0.00019191214,0.00019387733,0.00017762384,0.0017992955],"category_scores_gemma":[0.00029304103,0.000064822554,0.00018528898,0.00039884375,0.00015454511,0.00016535088,0.00017850586,0.00021562557,0.0003421667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004513925,0.00018570408,0.6240803,0.0010744004,0.00018328958,0.008459482,0.0006832803,0.0006512402,0.24590474,0.0012566547,0.0036441786,0.10936275],"study_design_scores_gemma":[0.00006511704,0.00034299627,0.93577564,0.00007467187,0.00011744699,0.022700172,0.0006966419,0.00072418054,0.022955107,0.0009662834,0.015566747,0.000014984363],"about_ca_topic_score_codex":0.0015218402,"about_ca_topic_score_gemma":0.0022629534,"teacher_disagreement_score":0.0017992955,"about_ca_system_score_codex":0.00030960707,"about_ca_system_score_gemma":0.0002897343,"threshold_uncertainty_score":0.0060192347},"labels":[],"label_agreement":null},{"id":"W4212829434","doi":"10.1093/jnci/djv244","title":"Response","year":2015,"lang":"en","type":"letter","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Computer science","score_opus":0.23137384200923772,"score_gpt":0.46457669080654057,"score_spread":0.23320284879730285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212829434","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025245053,0.0004143374,0.000060540526,0.9706762,0.023790209,0.00002431098,0.000118291726,0.00005008152,0.0046135406],"genre_scores_gemma":[0.0010360513,0.00015514728,0.00005412676,0.9803018,0.006698881,0.000036947415,0.000036859816,0.000014650109,0.011665553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957932,0.00078475993,0.000347866,0.0007108645,0.0012613107,0.0011021052],"domain_scores_gemma":[0.9924616,0.0022671926,0.00063480437,0.0002537103,0.0019018514,0.0024807563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003659483,0.0011041604,0.0017473724,0.0011192978,0.006918569,0.005932231,0.0028858026,0.07954501,0.019957218],"category_scores_gemma":[0.031236479,0.0010854609,0.0017723715,0.0006663758,0.0030027025,0.003229972,0.003508053,0.045688875,0.013432217],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024872445,0.00001872721,0.00037353864,0.000019456995,0.000007702024,0.0003809282,0.00005467642,0.000028023549,0.000044720815,0.0009367228,0.99616927,0.001941366],"study_design_scores_gemma":[0.0000932625,0.0000607302,0.0015534926,0.00027961345,0.000028769518,0.00063346117,0.00056616275,0.0002855136,0.00015107884,0.003919046,0.99235314,0.00007567725],"about_ca_topic_score_codex":0.01974972,"about_ca_topic_score_gemma":0.03435068,"teacher_disagreement_score":0.07954501,"about_ca_system_score_codex":0.006787485,"about_ca_system_score_gemma":0.009509025,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4212868198","doi":"10.1007/978-3-662-46875-3_1933","title":"Epidermal Growth Factor-like Ligands","year":2014,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Factor (programming language); Epidermal growth factor; Computer science; Medicine; Internal medicine; Programming language; Receptor","score_opus":0.0645098071193837,"score_gpt":0.3399901661483824,"score_spread":0.2754803590289987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212868198","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008446913,0.090929955,0.007129027,0.003235247,0.004246988,0.000037676964,0.00031072527,0.0002470686,0.89301854],"genre_scores_gemma":[0.00337538,0.040314563,0.0024581377,0.0015072221,0.0005361989,0.00003550454,0.00017845357,0.00006894705,0.9515256],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990857,0.000012510619,0.0000029080722,0.000012106573,0.000054816013,0.0000091577485],"domain_scores_gemma":[0.99996483,0.000015113775,0.0000024869148,0.0000032067264,0.000008513604,0.0000059324216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014668156,0.00062129804,0.0002939084,0.000664088,0.00032459333,0.0012496766,0.00049560564,0.0005507901,0.047162145],"category_scores_gemma":[0.0002484266,0.00015750562,0.00018045507,0.00070352305,0.00036529178,0.0012502958,0.00075400993,0.0014134027,0.02102001],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024397732,0.000052071628,0.00003222937,0.00032972137,0.0000060876073,0.00011135152,0.000105163206,0.000436334,0.0028526697,0.09794566,0.4194877,0.47861657],"study_design_scores_gemma":[0.000001574589,0.000003449839,0.00002087481,0.00005155953,0.0000010859915,0.00008236071,0.000010547792,0.000040438525,0.0003003192,0.0055113477,0.9939746,0.0000017995101],"about_ca_topic_score_codex":0.0005707371,"about_ca_topic_score_gemma":0.001787046,"teacher_disagreement_score":0.047162145,"about_ca_system_score_codex":0.0007360444,"about_ca_system_score_gemma":0.00043446998,"threshold_uncertainty_score":0.15777308},"labels":[],"label_agreement":null},{"id":"W4214522566","doi":"10.1016/j.clbc.2022.02.008","title":"Characteristics, Clinical Differences and Outcomes of Breast Cancer Patients with Negative or Low HER2 Expression","year":2022,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital; Algoma University","funders":"","keywords":"Medicine; Breast cancer; Immunohistochemistry; Internal medicine; Oncology; Trastuzumab; Cancer; Stage (stratigraphy)","score_opus":0.067916034245382,"score_gpt":0.43671123553147156,"score_spread":0.36879520128608956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214522566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985447,0.00019751018,0.00005287665,0.000048342437,0.000009673274,0.0000055206506,0.0004562817,0.0000024619526,0.00068273896],"genre_scores_gemma":[0.99907744,0.000056624875,0.00001672137,0.000025616935,0.000014799739,0.000007807391,0.0005404974,0.0000015571907,0.00025889935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99960357,0.000052288604,0.000050103554,0.00009479356,0.00004732115,0.00015204093],"domain_scores_gemma":[0.99919015,0.00015748334,0.0002850086,0.00003906877,0.00007912992,0.00024916758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003269319,0.00020636422,0.00037879334,0.00074983796,0.00040631407,0.0006506345,0.00027679236,0.00050964765,0.0030339991],"category_scores_gemma":[0.0017100949,0.00014389114,0.00046097662,0.0010933721,0.00031946113,0.0006067508,0.00048640234,0.00055772485,0.00040848833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062459405,0.00006399833,0.99715817,0.00000873575,0.000047316986,0.00012539649,0.00007041924,0.000065587956,0.00036247255,0.000057219877,0.00013464889,0.0012814016],"study_design_scores_gemma":[0.00001979787,0.00018968736,0.99845517,0.000002869111,0.00002304232,0.0003678404,0.00037042165,0.00019124018,0.000044575423,0.000098853685,0.0002307272,0.000005921596],"about_ca_topic_score_codex":0.0024550252,"about_ca_topic_score_gemma":0.0021189284,"teacher_disagreement_score":0.0030339991,"about_ca_system_score_codex":0.00042908124,"about_ca_system_score_gemma":0.0003946439,"threshold_uncertainty_score":0.010149717},"labels":[],"label_agreement":null},{"id":"W4214616073","doi":"10.1001/jamaoncol.2021.8049","title":"Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer","year":2022,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Canadian Centre for Applied Research in Cancer Control; Public Health Ontario; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Pertuzumab; Medicine; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Cost effectiveness; Population; Chemotherapy; Cancer; Environmental health","score_opus":0.048287472551245374,"score_gpt":0.3967369460307583,"score_spread":0.34844947347951294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214616073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.937216,0.04643984,0.0014274972,0.0021118922,0.00009480048,0.0011326342,0.004695158,0.000033256492,0.0068488675],"genre_scores_gemma":[0.9955825,0.0025181016,0.00056185125,0.00010283283,0.000024946328,0.00010601032,0.0008734174,0.000002687467,0.00022770444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99638915,0.0020109643,0.00027448862,0.00020227865,0.0007594795,0.00036361805],"domain_scores_gemma":[0.9963643,0.0018100496,0.0009223043,0.00009713713,0.0005055652,0.00030077118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043104803,0.00076653715,0.001345032,0.001636141,0.00024638762,0.0013794322,0.000754685,0.0005338742,0.001856391],"category_scores_gemma":[0.0162096,0.00034063144,0.0038308653,0.0018985984,0.00044556765,0.00065411505,0.00069204386,0.00079332985,0.00007155372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.077892505,0.0021121036,0.40639678,0.012418874,0.045691215,0.0009752339,0.0004163165,0.2325848,0.0014067697,0.008257371,0.0062738154,0.20557429],"study_design_scores_gemma":[0.01752712,0.016250782,0.64529836,0.005247679,0.04506221,0.0015805331,0.00082177966,0.24406424,0.0013239582,0.0063952287,0.016188316,0.00023982918],"about_ca_topic_score_codex":0.17997992,"about_ca_topic_score_gemma":0.16609678,"teacher_disagreement_score":0.17997992,"about_ca_system_score_codex":0.022128168,"about_ca_system_score_gemma":0.00961209,"threshold_uncertainty_score":0.35786462},"labels":[],"label_agreement":null},{"id":"W4214692750","doi":"10.3390/curroncol13050019","title":"Receptor Tyrosine Kinases: Role in Cancer Progression","year":2006,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Receptor tyrosine kinase; Medicine; Tyrosine kinase; Kinase; Cancer research; Receptor; Receptor Protein-Tyrosine Kinases; Cancer; Protein-Serine-Threonine Kinases; Bioinformatics; Computational biology; Cell biology; Biology; Internal medicine; Protein kinase A","score_opus":0.13165655459075395,"score_gpt":0.5191632641784624,"score_spread":0.3875067095877084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214692750","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07706859,0.8659711,0.006439315,0.010360303,0.001378328,0.000053361753,0.0006314313,0.00027898222,0.037818592],"genre_scores_gemma":[0.41991818,0.54274434,0.003448968,0.0010557027,0.0009851382,0.000037889185,0.0004751863,0.000023362649,0.031311143],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99991655,0.000011145446,0.0000046321857,0.00001452756,0.000033263463,0.000019843266],"domain_scores_gemma":[0.9999498,0.0000056236895,0.000013087109,0.0000028056236,0.000012212891,0.000016464723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023747786,0.00035323514,0.00030303377,0.00028749584,0.00027068556,0.0009450277,0.0002465723,0.00039184882,0.0029459668],"category_scores_gemma":[0.00020900262,0.00009318982,0.00011353451,0.00032128062,0.00033102828,0.00063862116,0.00028810115,0.0007645321,0.0012530426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001155564,0.00016565203,0.002728312,0.0019450691,0.00006263849,0.0014285403,0.00029545146,0.002890022,0.24196012,0.07716997,0.048217878,0.6219807],"study_design_scores_gemma":[0.00011849236,0.00053090765,0.010191065,0.0002784081,0.000097762124,0.005648851,0.00027264666,0.0018775681,0.08382273,0.020169668,0.8769353,0.000056554483],"about_ca_topic_score_codex":0.0006483164,"about_ca_topic_score_gemma":0.00073403755,"teacher_disagreement_score":0.0029459668,"about_ca_system_score_codex":0.00064773246,"about_ca_system_score_gemma":0.00043721896,"threshold_uncertainty_score":0.009855211},"labels":[],"label_agreement":null},{"id":"W4220811973","doi":"10.1158/1538-7445.sabcs21-p2-13-07","title":"Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Jewish General Hospital; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pertuzumab; Vinorelbine; Capecitabine; Trastuzumab; Internal medicine; Tolerability; Oncology; Breast cancer; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Toxicity; Phases of clinical research; Chemotherapy; Adverse effect; Cisplatin","score_opus":0.08425191162979943,"score_gpt":0.4665428208257864,"score_spread":0.38229090919598696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220811973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876695,0.004346473,0.0006858727,0.00039396496,0.00007905575,0.0019652327,0.0022102373,0.00012225399,0.0025273762],"genre_scores_gemma":[0.98317575,0.0038069522,0.0019164367,0.0006274822,0.000103925864,0.0012671296,0.0048915297,0.00004105989,0.0041696373],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99975544,0.00009325999,0.000019807077,0.000043210643,0.000038740272,0.000049618226],"domain_scores_gemma":[0.99977976,0.000025926904,0.00005200493,0.000015994396,0.000022942686,0.00010350783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083057355,0.0007592512,0.0010917641,0.0003735203,0.00031258393,0.0006170457,0.0006579561,0.0007136165,0.0047742818],"category_scores_gemma":[0.00035311445,0.00032462986,0.00074614596,0.00039381447,0.00051571353,0.00048401745,0.00025963582,0.001839432,0.0009962949],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41491508,0.06752972,0.0110103255,0.0023887905,0.0026230828,0.00062741176,0.000294421,0.0028177476,0.26518816,0.000404849,0.013096541,0.21910383],"study_design_scores_gemma":[0.31402203,0.5971872,0.033589263,0.00012722398,0.0019804894,0.0009885962,0.00009775256,0.0016822075,0.03691047,0.0001814275,0.013191617,0.000041648695],"about_ca_topic_score_codex":0.0016951375,"about_ca_topic_score_gemma":0.00459659,"teacher_disagreement_score":0.0047742818,"about_ca_system_score_codex":0.0007581724,"about_ca_system_score_gemma":0.0013904261,"threshold_uncertainty_score":0.015971541},"labels":[],"label_agreement":null},{"id":"W4220980555","doi":"10.3390/curroncol29010026","title":"Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Neoadjuvant therapy; Cancer; Immune system; Immunology","score_opus":0.07569433129261209,"score_gpt":0.44758842209662436,"score_spread":0.37189409080401226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220980555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585706,0.00079714187,0.0015528466,0.00014018461,0.000016296499,0.000017629322,0.0009820706,0.000035312234,0.00060137577],"genre_scores_gemma":[0.99686974,0.00017604898,0.0011913793,0.000033932498,0.000016635358,0.000017984159,0.0014772367,0.0000071730874,0.00020984677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997484,0.00006543185,0.000021091033,0.000061172395,0.00006654324,0.00003740656],"domain_scores_gemma":[0.9993432,0.00020018613,0.00022673591,0.000044553544,0.00008009068,0.0001053214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000805416,0.00044794695,0.00038429795,0.0011297168,0.0001877165,0.0005796261,0.00023231396,0.00028600125,0.0015638398],"category_scores_gemma":[0.0015842038,0.000095136085,0.00064428215,0.0010555569,0.00023498677,0.00018408027,0.00053623447,0.00043767746,0.00018904982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006382907,0.000053150936,0.9785432,0.000068708076,0.000432052,0.0000799222,0.000026520565,0.0025367185,0.0030724152,0.00009630928,0.0005779522,0.013874649],"study_design_scores_gemma":[0.00004385029,0.00024276979,0.98547506,0.000020205971,0.00049797335,0.00032786597,0.000052483727,0.01037778,0.001276462,0.00059115747,0.0010795738,0.0000146650655],"about_ca_topic_score_codex":0.0007606543,"about_ca_topic_score_gemma":0.0012992376,"teacher_disagreement_score":0.0015638398,"about_ca_system_score_codex":0.00024448024,"about_ca_system_score_gemma":0.00036030004,"threshold_uncertainty_score":0.005231619},"labels":[],"label_agreement":null},{"id":"W4221069651","doi":"10.3390/curroncol29030154","title":"Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis—The Adjuvant Role of Lifestyle Changes","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Breast cancer; Internal medicine; Docetaxel; Cancer; Oncology; Gastroenterology; Surgery","score_opus":0.05094887773735504,"score_gpt":0.41298838487317246,"score_spread":0.36203950713581745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221069651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97595906,0.015978929,0.0017448738,0.0024993815,0.00017312016,0.000060530452,0.000047275367,0.00006595769,0.0034708537],"genre_scores_gemma":[0.99267066,0.004838598,0.00077157264,0.00074428634,0.00024394426,0.000020908232,0.00007729273,0.0000047681365,0.0006281632],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99997437,0.000006077595,0.0000028700972,0.000003994529,0.0000031449724,0.000009573517],"domain_scores_gemma":[0.99993074,0.000009776986,0.000015949743,0.0000022429217,0.000004188284,0.000037047535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060238697,0.00021634428,0.00025979057,0.0001839557,0.00026008376,0.00018592183,0.00013149492,0.00041601158,0.000538072],"category_scores_gemma":[0.00029718736,0.000055162658,0.00023958358,0.00010018324,0.00010717334,0.00019112545,0.00013861894,0.00043415907,0.00015235259],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016496669,0.0011666619,0.23109965,0.0007803295,0.0001476326,0.47541758,0.0005638192,0.0006935002,0.0416169,0.0004947101,0.0044335197,0.24193606],"study_design_scores_gemma":[0.00037816112,0.0057021556,0.17669182,0.00030092843,0.00021897772,0.7885868,0.0008159,0.0024195053,0.008462926,0.00076758116,0.015604486,0.00005074493],"about_ca_topic_score_codex":0.00022379246,"about_ca_topic_score_gemma":0.0006010417,"teacher_disagreement_score":0.000538072,"about_ca_system_score_codex":0.00012255298,"about_ca_system_score_gemma":0.00019783984,"threshold_uncertainty_score":0.0018000603},"labels":[],"label_agreement":null},{"id":"W4221092886","doi":"10.1016/j.esmoop.2022.100419","title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Genentech; Novartis Farmacéutica; Servier; Oncolytics Biotech; Else Kröner-Fresenius-Stiftung; Cancer Research UK; AstraZeneca España; Tessa Therapeutics; Eli Lilly and Company; Boehringer Ingelheim España; Novartis; Celgene; Roche España; F. Hoffmann-La Roche; Roche; NordForsk; Ernst Schering Foundation; GlaxoSmithKline España; Wilhelm Sander-Stiftung; Amgen; Pfizer; Bristol-Myers Squibb; Sanofi; MedImmune; Merck","keywords":"Medicine; Atezolizumab; Internal medicine; Clinical endpoint; Interim analysis; Hazard ratio; Lung cancer; Oncology; Surgery; Cancer; Confidence interval; Clinical trial; Gastroenterology; Pembrolizumab; Immunotherapy","score_opus":0.09255978133815697,"score_gpt":0.4642404448781073,"score_spread":0.37168066353995033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221092886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843768,0.0014219799,0.0012090103,0.0004930421,0.00019294048,0.0075632394,0.0031815986,0.0001768402,0.0013845933],"genre_scores_gemma":[0.9728319,0.0016865691,0.004357608,0.0011656403,0.00028890514,0.009970355,0.0060681524,0.00007651866,0.003554436],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99916923,0.0004059634,0.000047709826,0.0001447808,0.000100083606,0.00013220691],"domain_scores_gemma":[0.9986351,0.00014868894,0.00029442293,0.00019606396,0.00013602809,0.0005896384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004442608,0.0022578365,0.002399682,0.0007324486,0.0005882764,0.0013718898,0.00095865387,0.0011790331,0.0046042674],"category_scores_gemma":[0.0016407132,0.0009857345,0.001605842,0.00073700247,0.00076353276,0.0011631188,0.00093632337,0.0028071175,0.0010513234],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79953635,0.0919429,0.014953288,0.00065680896,0.002367343,0.00021194683,0.00022639756,0.002714255,0.02107468,0.00051256834,0.008422599,0.05738096],"study_design_scores_gemma":[0.74862546,0.22968838,0.013591251,0.000028048722,0.0006431444,0.00027328226,0.00005894223,0.0013427612,0.0018572927,0.0003876566,0.0034568363,0.00004690477],"about_ca_topic_score_codex":0.0011386772,"about_ca_topic_score_gemma":0.0018463361,"teacher_disagreement_score":0.0046042674,"about_ca_system_score_codex":0.0011456426,"about_ca_system_score_gemma":0.0026343814,"threshold_uncertainty_score":0.023495018},"labels":[],"label_agreement":null},{"id":"W4221120760","doi":"10.1158/1538-7445.sabcs21-p2-03-04","title":"Abstract P2-03-04: Characteristics and clinical differences of breast cancer patients with negative or low HER2 expression","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Algoma University; Sault Area Hospital","funders":"","keywords":"Medicine; Breast cancer; Immunohistochemistry; Internal medicine; Oncology; Cancer; Trastuzumab; Stage (stratigraphy); Biology","score_opus":0.13593175903646715,"score_gpt":0.479460287434435,"score_spread":0.3435285283979678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221120760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993642,0.000052513333,0.000033035863,0.00001831535,0.000002817587,0.00000560568,0.00020444306,0.0000017735998,0.0003174255],"genre_scores_gemma":[0.99950624,0.000017879904,0.000024190214,0.000013160247,0.0000074060645,0.000007705812,0.00028834448,0.0000012688915,0.0001338426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997693,0.000041542768,0.000030760904,0.00006072378,0.000038130293,0.000059639133],"domain_scores_gemma":[0.99869907,0.000286938,0.00047305238,0.000040246854,0.00010933439,0.00039142615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000292972,0.00020459585,0.0002526806,0.00084679964,0.00040264064,0.0004946711,0.00030573548,0.00046336398,0.0044687404],"category_scores_gemma":[0.0014633483,0.00016991468,0.00022669467,0.00082367094,0.00037334475,0.00042028184,0.0003133863,0.00037041184,0.00072651176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014100898,0.000023975514,0.9989838,0.0000027506087,0.000008349738,0.00011745963,0.000017219381,0.000017231276,0.00021315755,0.00000622986,0.0000583001,0.00041040475],"study_design_scores_gemma":[0.000014418445,0.00018024698,0.998007,0.000002549929,0.000010424283,0.0012610431,0.00014387452,0.00011846267,0.00008649435,0.000020985059,0.00015116997,0.0000033624158],"about_ca_topic_score_codex":0.0009965298,"about_ca_topic_score_gemma":0.00084426306,"teacher_disagreement_score":0.0044687404,"about_ca_system_score_codex":0.00024095671,"about_ca_system_score_gemma":0.00021682565,"threshold_uncertainty_score":0.014949441},"labels":[],"label_agreement":null},{"id":"W4223510214","doi":"10.1101/2022.04.11.487842","title":"The ADAM17 sheddase complex regulator iTAP modulates inflammation, epithelial repair, and tumor growth","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação para a Ciência e a Tecnologia; Queen's University; Queen's University Belfast","keywords":"Cell biology; Biology; Cytokine; Cancer research; Cell; Immunology; Biochemistry","score_opus":0.023913963058486018,"score_gpt":0.27124518293336775,"score_spread":0.2473312198748817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223510214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240416,0.0039083934,0.0020906788,0.00015928657,0.000035115005,0.000020339507,0.0003847322,0.000087214445,0.0009101163],"genre_scores_gemma":[0.9952657,0.0017585241,0.0011052949,0.00005305714,0.000022025248,0.000024520401,0.00029964896,0.00002899472,0.0014421477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998766,0.000020834355,0.000011869699,0.000025744568,0.0000285824,0.000036276033],"domain_scores_gemma":[0.9998468,0.000010144472,0.000057767433,0.000011930264,0.0000146378,0.000058611422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013343489,0.00046438014,0.00030887767,0.00030032187,0.00014907327,0.00039282723,0.0001706014,0.00024352431,0.0012464675],"category_scores_gemma":[0.00011518209,0.00012285744,0.000301832,0.00014919144,0.00032785925,0.0002595529,0.0002388535,0.0007063628,0.0003078622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041486853,0.000034911332,0.00066105294,0.000059865997,0.00001206836,0.0001812378,0.000011867091,0.000056299377,0.9968124,0.00009637747,0.00006047384,0.0015985549],"study_design_scores_gemma":[0.00003955024,0.0006526002,0.016048621,0.000016544578,0.00007081428,0.00074322347,0.00006288066,0.0007393882,0.9787007,0.00014412469,0.0027757005,0.0000058778114],"about_ca_topic_score_codex":0.00020528857,"about_ca_topic_score_gemma":0.0002455387,"teacher_disagreement_score":0.0012464675,"about_ca_system_score_codex":0.00027733203,"about_ca_system_score_gemma":0.00016653539,"threshold_uncertainty_score":0.0041698813},"labels":[],"label_agreement":null},{"id":"W4224091336","doi":"10.3390/curroncol29040222","title":"Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital; University of British Columbia; University of Alberta; Fluidigm (Canada); Memorial University of Newfoundland; McGill University; Jewish General Hospital","funders":"AstraZeneca Canada","keywords":"Medicine; Pertuzumab; Trastuzumab; Context (archaeology); Oncology; Taxane; Trastuzumab emtansine; Capecitabine; Metastatic breast cancer; Internal medicine; Clinical trial; Breast cancer; Regimen; Intensive care medicine; Cancer","score_opus":0.30072225588401286,"score_gpt":0.5542062625307176,"score_spread":0.25348400664670473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224091336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037739792,0.99753296,0.000044867447,0.00094976457,0.00029120516,0.0000036376075,0.000016037344,0.000004463619,0.0011193517],"genre_scores_gemma":[0.0002466731,0.99867624,0.000106537474,0.00037201427,0.00011005517,0.0000020904927,0.000015303249,9.770322e-7,0.000470032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999624,0.00005547902,0.00003754711,0.000034205394,0.00019356621,0.00005520379],"domain_scores_gemma":[0.99906844,0.00024230509,0.00006939098,0.000013628536,0.00051596056,0.00009029755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011280328,0.00076035754,0.0011536309,0.0033244686,0.0005270035,0.0012517578,0.0009382442,0.0012407942,0.005360954],"category_scores_gemma":[0.0012889771,0.00021313148,0.0007082671,0.003632383,0.0006303249,0.001239453,0.0006752541,0.0025138084,0.0015869167],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009131439,0.000052515614,0.00014434986,0.022908421,0.000098420685,0.00018263183,0.00011551436,0.00034635657,0.0011221637,0.00669403,0.09683799,0.8714063],"study_design_scores_gemma":[0.000014439834,0.000034601326,0.00043431108,0.005495975,0.00007980805,0.0003034847,0.00004981275,0.000040788993,0.00009891721,0.0008115671,0.99262625,0.000010121975],"about_ca_topic_score_codex":0.06032084,"about_ca_topic_score_gemma":0.16135915,"teacher_disagreement_score":0.93967915,"about_ca_system_score_codex":0.0041448795,"about_ca_system_score_gemma":0.0092150755,"threshold_uncertainty_score":0.119939506},"labels":[],"label_agreement":null},{"id":"W4224238498","doi":"10.1016/j.anndiagpath.2022.151953","title":"HER2 testing in metastatic breast cancer – Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?","year":2022,"lang":"en","type":"article","venue":"Annals of Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Immunohistochemistry; Context (archaeology); Breast cancer; Pathology; Metastasis; Biopsy; Cancer; Metastatic breast cancer; Oncology; Internal medicine; Biology","score_opus":0.2816990791093923,"score_gpt":0.4717600769175204,"score_spread":0.19006099780812813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224238498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86306673,0.040747423,0.006406641,0.040100228,0.0025987187,0.000100350335,0.0007316059,0.0004139043,0.045834523],"genre_scores_gemma":[0.98199534,0.0072492287,0.0037988694,0.0038374008,0.0018658796,0.000024583498,0.0003860708,0.00007166767,0.0007710029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783164,0.00064633985,0.0004900036,0.00027269372,0.00045622597,0.00030317673],"domain_scores_gemma":[0.9923968,0.003985596,0.0009592864,0.0005525676,0.00125521,0.0008505682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004610113,0.00051263475,0.000846932,0.0014591898,0.0005154504,0.0015384584,0.0014442502,0.0021292078,0.003265032],"category_scores_gemma":[0.018203659,0.0004495031,0.0006708436,0.0011534826,0.001679798,0.002358166,0.00056955655,0.0015129736,0.0017401478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020746002,0.00023029713,0.7774246,0.00056144304,0.00015170581,0.018542178,0.0005695309,0.0008895285,0.009520521,0.0013243486,0.013547769,0.1751635],"study_design_scores_gemma":[0.00025267148,0.0022170036,0.7708502,0.0023535867,0.0006250412,0.14085506,0.006115126,0.0067517264,0.01286171,0.012545826,0.044375323,0.00019674661],"about_ca_topic_score_codex":0.0014467184,"about_ca_topic_score_gemma":0.0027129347,"teacher_disagreement_score":0.004610113,"about_ca_system_score_codex":0.00053151575,"about_ca_system_score_gemma":0.00087886484,"threshold_uncertainty_score":0.024380863},"labels":[],"label_agreement":null},{"id":"W4224299878","doi":"10.32388/sgz7ro","title":"Review of: \"Blocking Gi/o-coupled signaling eradicates cancer stem cells and sensitizes breast tumors to HER2-targeted therapies to inhibit tumor relapse\"","year":2022,"lang":"en","type":"peer-review","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Blocking (statistics); Cancer research; Breast cancer; Cancer; Medicine; Oncology; Internal medicine; Computer science","score_opus":0.0409102015812574,"score_gpt":0.3492797994662499,"score_spread":0.30836959788499246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224299878","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049921963,0.38287443,0.0017311779,0.17466106,0.39887053,0.00036306572,0.0011005045,0.00033472615,0.039565302],"genre_scores_gemma":[0.0031751252,0.604694,0.0019388524,0.085520275,0.18172228,0.00021374393,0.0016331399,0.00020157557,0.12090104],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778676,0.0003749049,0.0002675785,0.0001810475,0.0012450531,0.0001446795],"domain_scores_gemma":[0.9863805,0.0023444458,0.00076557917,0.00026977883,0.009143326,0.0010963315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042582066,0.00080829766,0.001211535,0.0034219755,0.00096832734,0.0025154324,0.001752602,0.0028286763,0.025123615],"category_scores_gemma":[0.013092653,0.00034213768,0.0008397627,0.0023723599,0.0010442875,0.0024973336,0.0014680519,0.002425423,0.01693894],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022890152,0.000012373184,0.000032725246,0.0011651099,0.000011034069,0.000029589784,0.000012670399,0.000016557102,0.00020070325,0.0004824017,0.9388661,0.05914792],"study_design_scores_gemma":[0.0000109208695,0.000016584063,0.00021400537,0.00062861654,0.000016832986,0.000094766816,0.000016506303,0.000019915396,0.00012551906,0.0002541042,0.99859554,0.0000066045277],"about_ca_topic_score_codex":0.0026344338,"about_ca_topic_score_gemma":0.009323208,"teacher_disagreement_score":0.025123615,"about_ca_system_score_codex":0.0016703256,"about_ca_system_score_gemma":0.0071163564,"threshold_uncertainty_score":0.0840469},"labels":[],"label_agreement":null},{"id":"W4224311311","doi":"10.2217/fon-2022-0045","title":"A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i> -mutated breast cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Trastuzumab; Medicine; Fulvestrant; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; Estrogen receptor","score_opus":0.03373686270539864,"score_gpt":0.405549785522902,"score_spread":0.37181292281750333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224311311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97421706,0.004542431,0.0012919854,0.0012911268,0.0006172962,0.007855824,0.002457338,0.00021965143,0.007507359],"genre_scores_gemma":[0.9589289,0.004435697,0.005068134,0.0030871828,0.0005878846,0.010988533,0.0049588084,0.00004946613,0.011895297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99957985,0.0002538618,0.00001811641,0.000043907723,0.000039678827,0.00006463651],"domain_scores_gemma":[0.99934953,0.00017377992,0.00012784042,0.000048522477,0.000034432695,0.0002659331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019955349,0.0011230321,0.0015271032,0.00037617196,0.00031594193,0.00079605303,0.0007182765,0.0010614586,0.0060000084],"category_scores_gemma":[0.0010549629,0.00034031758,0.0011725494,0.0002917328,0.00060306414,0.0005150963,0.00031181183,0.0023764477,0.0011551348],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89625365,0.027240101,0.0015269023,0.00065126363,0.00062144245,0.00009664636,0.00006168643,0.0012479536,0.0069609014,0.00048932823,0.0036971448,0.061152924],"study_design_scores_gemma":[0.87539643,0.119376145,0.0017565406,0.00003639279,0.00017854745,0.00006161508,0.000018752511,0.00059154007,0.0006940167,0.00018909821,0.0016911427,0.000009646808],"about_ca_topic_score_codex":0.0005890423,"about_ca_topic_score_gemma":0.0014603136,"teacher_disagreement_score":0.0060000084,"about_ca_system_score_codex":0.0005228945,"about_ca_system_score_gemma":0.0014182586,"threshold_uncertainty_score":0.020072043},"labels":[],"label_agreement":null},{"id":"W4224313646","doi":"10.3390/curroncol29040208","title":"Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Human Epidermal Growth Factor Receptor 2; Metastatic breast cancer; Oncology; Breast cancer; Lapatinib; Cancer; Systemic therapy; Antibody-drug conjugate; Internal medicine; Hormone receptor; Disease; Antibody; Immunology; Monoclonal antibody","score_opus":0.427164784705476,"score_gpt":0.5917821791165028,"score_spread":0.1646173944110268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224313646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007366538,0.9986518,0.00006688453,0.00022009836,0.00017715752,0.0000043424766,0.000012344933,0.000005699614,0.0007880664],"genre_scores_gemma":[0.00025160454,0.99908984,0.00011611614,0.00012377508,0.00011535104,0.000003189604,0.000016217544,8.396177e-7,0.00028309145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998615,0.000023910548,0.000022423485,0.000022406446,0.00005665769,0.000013138536],"domain_scores_gemma":[0.9997656,0.00010218454,0.000039168703,0.000004804671,0.00006308472,0.000025188796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038879688,0.00070294476,0.00092805986,0.0023289998,0.000265067,0.0008025981,0.000676185,0.00073075126,0.003920566],"category_scores_gemma":[0.0005828989,0.00017626314,0.0004532596,0.0021859778,0.0002826742,0.0010420643,0.00047963747,0.0014420329,0.0019507757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040577517,0.00006118865,0.00011311625,0.018200155,0.000051351763,0.00018895736,0.00005945393,0.00024938208,0.00079682155,0.0016463529,0.033816975,0.94477576],"study_design_scores_gemma":[0.000012639255,0.00010474728,0.00069298496,0.00702611,0.00010082973,0.0015236216,0.000075571435,0.00006873021,0.00018548893,0.00095380226,0.98924047,0.000015079732],"about_ca_topic_score_codex":0.0012943897,"about_ca_topic_score_gemma":0.003141226,"teacher_disagreement_score":0.003920566,"about_ca_system_score_codex":0.00050426816,"about_ca_system_score_gemma":0.0009405491,"threshold_uncertainty_score":0.013115585},"labels":[],"label_agreement":null},{"id":"W4225002517","doi":"10.51731/cjht.2022.320","title":"Pertuzumab (Perjeta)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Reimbursement; Trastuzumab; Medicine; Breast cancer; Oncology; Family medicine; Internal medicine; Cancer; Political science; Health care","score_opus":0.0735274290851781,"score_gpt":0.364587629344771,"score_spread":0.2910602002595929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225002517","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011256107,0.835979,0.0023727485,0.004621663,0.0016848877,0.00024037703,0.0017309226,0.0008068606,0.14130744],"genre_scores_gemma":[0.16698417,0.638497,0.0052680443,0.01060354,0.0013571222,0.00031144053,0.0049018185,0.00014420523,0.1719327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99956614,0.00006267915,0.000037741338,0.00006833117,0.00021465427,0.000050484716],"domain_scores_gemma":[0.9997011,0.00004767885,0.000079091675,0.000013833425,0.00011378203,0.00004440446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005293165,0.0004346067,0.00039136066,0.0015864869,0.00028686092,0.001094287,0.0005883519,0.00065088633,0.0144335],"category_scores_gemma":[0.0008950381,0.00015107852,0.00046273504,0.00090586673,0.00028715288,0.0006509806,0.00044554682,0.00081893575,0.0056219418],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004036564,0.00008924887,0.0003711647,0.0030673759,0.00010425964,0.0002098256,0.000036830188,0.00015415794,0.005199847,0.002772613,0.087132394,0.90045863],"study_design_scores_gemma":[0.00015928494,0.0004237463,0.0019854216,0.00091166276,0.00014054634,0.0016662913,0.000019346246,0.000100443176,0.00554112,0.0004433323,0.98859286,0.000015909418],"about_ca_topic_score_codex":0.006446367,"about_ca_topic_score_gemma":0.012347232,"teacher_disagreement_score":0.0144335,"about_ca_system_score_codex":0.0013150991,"about_ca_system_score_gemma":0.0015639726,"threshold_uncertainty_score":0.04828489},"labels":[],"label_agreement":null},{"id":"W4229028760","doi":"10.1016/j.jmoldx.2022.04.002","title":"Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Ontario Institute for Cancer Research","funders":"Cancer Research UK; BioTheranostics; Government of Ontario; Breast Cancer Society of Canada; Ontario Institute for Cancer Research","keywords":"Immunohistochemistry; Breast cancer; Epidermal growth factor receptor; Tyrosine kinase; Cancer research; Receptor tyrosine kinase; Human Epidermal Growth Factor Receptor 2; Receptor; Internal medicine; Biology; Oncology; Medicine; Cancer","score_opus":0.02415254706952066,"score_gpt":0.3498008022656732,"score_spread":0.3256482551961526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229028760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241525,0.0007216631,0.00093097764,0.00021638644,0.00006603663,0.000028141763,0.00009737195,0.00004412719,0.0054801297],"genre_scores_gemma":[0.9988656,0.0001216414,0.0005122286,0.000074351236,0.000024635956,0.000013356427,0.00008625807,0.000009827339,0.00029206174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984919,0.00040557855,0.00023795289,0.00021948191,0.00034348416,0.00030162508],"domain_scores_gemma":[0.9958371,0.0022679619,0.00040709053,0.0003341647,0.0008659906,0.00028773042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032869221,0.00034766583,0.00023998092,0.0026459617,0.00050037977,0.0010494291,0.00060891197,0.0008434742,0.0023133073],"category_scores_gemma":[0.006047356,0.00030452386,0.00026048702,0.00054320245,0.00093037856,0.00051765546,0.00045684495,0.0006404876,0.00070426235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002343146,0.00012804371,0.75570524,0.00014215788,0.00008925603,0.012062239,0.0011098308,0.00027465183,0.2123409,0.0006991833,0.0008403016,0.014264944],"study_design_scores_gemma":[0.000083710394,0.0005328373,0.78675556,0.00011353516,0.00030567806,0.050832685,0.0030575665,0.0061969305,0.14443448,0.0014588697,0.0061878264,0.000040311694],"about_ca_topic_score_codex":0.0010475352,"about_ca_topic_score_gemma":0.0015792421,"teacher_disagreement_score":0.0032869221,"about_ca_system_score_codex":0.00059649505,"about_ca_system_score_gemma":0.00029518304,"threshold_uncertainty_score":0.017383158},"labels":[],"label_agreement":null},{"id":"W4229046548","doi":"10.1055/s-0042-1746156","title":"Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB)","year":2022,"lang":"de","type":"article","venue":"Geburtshilfe und Frauenheilkunde","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Gynecology","score_opus":0.044023793344331874,"score_gpt":0.34594898073692804,"score_spread":0.30192518739259616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229046548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887341,0.00810615,0.00021977417,0.00020524982,0.0003978659,0.00037660604,0.0005058917,0.000048040027,0.0014062724],"genre_scores_gemma":[0.9931867,0.0027702001,0.0004468651,0.00019285675,0.00018406098,0.0007175748,0.00064180826,0.000014430925,0.0018454927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999624,0.000118159456,0.000047349342,0.00007258747,0.000041798517,0.00009612114],"domain_scores_gemma":[0.9995921,0.00013007368,0.00009228858,0.000039246854,0.00003628827,0.00011000126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008255191,0.0007349489,0.0019844254,0.00032256808,0.00020686955,0.00088983966,0.000376378,0.0006897223,0.003890485],"category_scores_gemma":[0.0012595934,0.00027558347,0.0011888698,0.00037526846,0.00040890017,0.00079431967,0.00021783939,0.0020841407,0.0005940656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88194466,0.0113663785,0.00088785647,0.0008118061,0.0012628731,0.00006070425,0.00010214396,0.0010385723,0.027664369,0.0001531927,0.0010259975,0.07368148],"study_design_scores_gemma":[0.3709265,0.57340777,0.01587321,0.00019049333,0.004793544,0.00017941877,0.00014125003,0.0026224551,0.026294153,0.0003541532,0.005138268,0.000078785],"about_ca_topic_score_codex":0.00065101567,"about_ca_topic_score_gemma":0.0010655533,"teacher_disagreement_score":0.003890485,"about_ca_system_score_codex":0.00042895487,"about_ca_system_score_gemma":0.0006204199,"threshold_uncertainty_score":0.013014972},"labels":[],"label_agreement":null},{"id":"W4230568286","doi":"10.1200/edbk_175630","title":"Optimal Management of Early and Advanced HER2 Breast Cancer","year":2017,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Disease; Breast cancer; Oncology; Internal medicine; Intensive care medicine; Adjuvant chemotherapy; Cancer; Chemotherapy; Adjuvant","score_opus":0.26462721998985017,"score_gpt":0.6238183746282034,"score_spread":0.35919115463835327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230568286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014412185,0.9953969,0.0002191909,0.0011890531,0.0006006933,0.0000059528415,0.000026776715,0.000012793835,0.002404598],"genre_scores_gemma":[0.0007193049,0.99692863,0.00032311323,0.0005676274,0.000508249,0.0000062281056,0.000041864012,0.0000021233068,0.00090294436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983215,0.000034029086,0.000017098078,0.000017889743,0.00008383662,0.0000150758115],"domain_scores_gemma":[0.99988496,0.000041852036,0.00002018064,0.0000031762665,0.000035909,0.000013954119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035113134,0.00053763523,0.00072000694,0.001272656,0.00021545809,0.0006724297,0.0007121636,0.00081200554,0.0027824116],"category_scores_gemma":[0.0006884683,0.00013567026,0.00032427817,0.0009042818,0.00026429127,0.0010637069,0.00055972266,0.0016175675,0.0018956846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025624264,0.00004917295,0.00014082853,0.007994607,0.00003579087,0.00022798008,0.000052714244,0.00021389354,0.00084749155,0.0027478437,0.10735001,0.8803141],"study_design_scores_gemma":[0.000011240963,0.00005304377,0.0008027359,0.0051671565,0.000033186123,0.0020699673,0.00006049838,0.00008743704,0.00024913176,0.0019435671,0.9895084,0.000013547286],"about_ca_topic_score_codex":0.00076775794,"about_ca_topic_score_gemma":0.0019737845,"teacher_disagreement_score":0.0027824116,"about_ca_system_score_codex":0.00044623943,"about_ca_system_score_gemma":0.00072138914,"threshold_uncertainty_score":0.0093081},"labels":[],"label_agreement":null},{"id":"W4230918009","doi":"10.1200/jco.2004.22.90140.581","title":"Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Gefitinib; Medicine; Breast cancer; Pharmacokinetics; Lung cancer; Adenocarcinoma; Cancer; Internal medicine; Colorectal cancer; Oncology; Urology; Epidermal growth factor receptor","score_opus":0.14831609006630797,"score_gpt":0.48750950387369624,"score_spread":0.33919341380738827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230918009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99698764,0.00040509013,0.00022173455,0.00012290833,0.000011266752,0.0005443426,0.00065701536,0.000033565906,0.0010163516],"genre_scores_gemma":[0.99308103,0.00039453706,0.0010417899,0.00044792,0.00009765048,0.00089426857,0.002942452,0.000022051454,0.00107836],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9988599,0.0005101299,0.000056992714,0.00021395119,0.00022783132,0.00013126509],"domain_scores_gemma":[0.99857795,0.0003256075,0.00024640758,0.00012987766,0.00022353294,0.00049663044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016956062,0.00091058644,0.0010757452,0.00041137566,0.00061393686,0.00047990368,0.00036893328,0.00087855,0.0021265633],"category_scores_gemma":[0.0015827992,0.0003689746,0.0005760635,0.00055510254,0.00058826664,0.00044592816,0.00032594876,0.0013684,0.0009544497],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36046913,0.051692434,0.2933843,0.00069972407,0.0010816372,0.0027068963,0.0021063818,0.0010982117,0.15048008,0.00009415876,0.005654298,0.13053271],"study_design_scores_gemma":[0.05505019,0.30802226,0.611243,0.000027472792,0.0007362868,0.0027203308,0.00033104856,0.00085001707,0.013788987,0.00008382433,0.007063757,0.000082861254],"about_ca_topic_score_codex":0.0018822075,"about_ca_topic_score_gemma":0.002818178,"teacher_disagreement_score":0.0021265633,"about_ca_system_score_codex":0.0007614314,"about_ca_system_score_gemma":0.001141905,"threshold_uncertainty_score":0.00896734},"labels":[],"label_agreement":null},{"id":"W4232358903","doi":"10.1158/1538-7445.am2019-1556","title":"Abstract 1556: Preclinical development of antibody drug conjugates targetting EGFRvIII","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Antibody; Antibody-drug conjugate; Cancer research; In vivo; Epidermal growth factor receptor; Conjugate; Cancer; Chemistry; Monoclonal antibody; Molecular biology; Medicine; Biology; Immunology; Internal medicine; Genetics","score_opus":0.1575404227938784,"score_gpt":0.5331337627656179,"score_spread":0.3755933399717395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232358903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965357,0.0063894363,0.008019447,0.00034750756,0.00030225125,0.0013978583,0.0021360558,0.00041596525,0.015634509],"genre_scores_gemma":[0.96813834,0.004816231,0.0058232113,0.00016273244,0.00006440868,0.0006502227,0.0031938904,0.000048976555,0.017102072],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999082,0.000018857434,0.000006935437,0.000013582681,0.000026071722,0.000026334961],"domain_scores_gemma":[0.9999423,0.000007970511,0.000009982323,0.000004880396,0.0000132328805,0.000021569858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030171924,0.00045696012,0.00033933562,0.00034644463,0.0001437947,0.00024828454,0.00037406475,0.0003440049,0.0037630713],"category_scores_gemma":[0.00016402695,0.00018427729,0.00025179295,0.00018492769,0.000107462125,0.00019130576,0.0001310238,0.0006228405,0.0009910983],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023892575,0.0029796897,0.00044578093,0.00028275012,0.000055634602,0.0001657292,0.00006713668,0.0018896445,0.9507623,0.0005750329,0.0029421905,0.037444897],"study_design_scores_gemma":[0.0012509925,0.04494337,0.0031751406,0.00004068734,0.00009090854,0.0005209951,0.000026723492,0.0023477888,0.91970426,0.00011483908,0.027767455,0.000016797394],"about_ca_topic_score_codex":0.00075039506,"about_ca_topic_score_gemma":0.00080300664,"teacher_disagreement_score":0.0037630713,"about_ca_system_score_codex":0.00027631776,"about_ca_system_score_gemma":0.00038897668,"threshold_uncertainty_score":0.012588739},"labels":[],"label_agreement":null},{"id":"W4233227002","doi":"10.12688/f1000research.9417.1","title":"Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning","year":2016,"lang":"en","type":"preprint","venue":"F1000Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Windsor","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Biology; Cancer","score_opus":0.04348960773477192,"score_gpt":0.37474096455814815,"score_spread":0.33125135682337625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233227002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974137,0.00013119708,0.0007709454,0.00008143229,0.0000050917706,0.000029454988,0.0011186278,0.000021235268,0.00042830405],"genre_scores_gemma":[0.99453014,0.000066305656,0.0021746524,0.000052559702,0.000009610835,0.00003715688,0.0027831276,0.000008586849,0.000337915],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996953,0.00012811158,0.00002344512,0.00006997177,0.000048810543,0.000034268563],"domain_scores_gemma":[0.9992083,0.00014287846,0.00028032972,0.000153497,0.00012488518,0.00009026748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009435716,0.0003323507,0.00029884579,0.00072270207,0.00031231256,0.00052633055,0.00030542727,0.00031936157,0.0004229586],"category_scores_gemma":[0.0021107171,0.0001304384,0.00024774467,0.0006576148,0.00013948198,0.00020885262,0.0005895661,0.0003313121,0.0001879445],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029617062,0.00004463936,0.9894275,0.000008536097,0.000053234682,0.000041979136,0.00005636103,0.0008780034,0.0007403154,0.000063107094,0.00058188406,0.0078082564],"study_design_scores_gemma":[0.000044499393,0.000286193,0.98148245,0.000011557217,0.00009255871,0.0003786982,0.00017969123,0.0141538335,0.0011319941,0.00016176428,0.0020643908,0.000012379459],"about_ca_topic_score_codex":0.014167909,"about_ca_topic_score_gemma":0.021519927,"teacher_disagreement_score":0.014167909,"about_ca_system_score_codex":0.0005991734,"about_ca_system_score_gemma":0.00063448393,"threshold_uncertainty_score":0.028170884},"labels":[],"label_agreement":null},{"id":"W4234549590","doi":"10.1016/s0021-9258(19)61439-0","title":"Superagonistic Activation of ErbB-1 by EGF-related Growth Factors with Enhanced Association and Dissociation Rate Constants","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Biotechnology Research Institute","funders":"Stichting de Drie Lichten","keywords":"ErbB; Chemistry; Dissociation (chemistry); Dissociation rate; Biochemistry; Receptor; Physical chemistry","score_opus":0.01755594530503023,"score_gpt":0.28725033365545005,"score_spread":0.2696943883504198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234549590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963438,0.00039860414,0.00252825,0.000030850715,0.000010259802,0.000010670033,0.00008756075,0.000025191197,0.0005648152],"genre_scores_gemma":[0.99483067,0.00035685758,0.003414114,0.000028002123,0.000003338714,0.000026885422,0.00031965665,0.000025533427,0.0009949866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998223,0.000025282476,0.00001466817,0.000045284112,0.000052259562,0.000040325333],"domain_scores_gemma":[0.9998362,0.000035654393,0.000048794285,0.00002311626,0.000015151977,0.000041164254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016189538,0.0003367683,0.0002437724,0.00010622356,0.00009884601,0.00036768662,0.00034751257,0.00019179123,0.0010786919],"category_scores_gemma":[0.0002016707,0.00016163517,0.0003071021,0.00015460997,0.00014992444,0.00023464087,0.0002474017,0.0006682882,0.00026950304],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024999186,0.00003073728,0.00018935798,0.000019402869,0.0000058637343,0.000019713552,0.000012529237,0.000187848,0.9982901,0.00015981437,0.000023334836,0.00081122987],"study_design_scores_gemma":[0.0000149697835,0.00013571404,0.001615278,0.0000027655315,0.000012988087,0.0002555987,0.00002391038,0.00363519,0.992663,0.00007223566,0.001558728,0.000009535039],"about_ca_topic_score_codex":0.00043030025,"about_ca_topic_score_gemma":0.0003009602,"teacher_disagreement_score":0.0010786919,"about_ca_system_score_codex":0.000534619,"about_ca_system_score_gemma":0.00016151067,"threshold_uncertainty_score":0.0038790107},"labels":[],"label_agreement":null},{"id":"W4234834979","doi":"10.3390/curroncol16050001","title":"Erratum","year":2009,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Oncology; Medical physics; Bioinformatics; Internal medicine; Cancer; Biology","score_opus":0.22260729816970312,"score_gpt":0.5184633407299551,"score_spread":0.295856042560252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234834979","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002674578,0.0013757331,0.0013341897,0.09143376,0.86474925,0.00012819532,0.005059123,0.0010781952,0.034574084],"genre_scores_gemma":[0.005104431,0.004576154,0.00456513,0.17215535,0.089497305,0.00032403943,0.009624652,0.0026264135,0.71152645],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99532783,0.0006063541,0.0007594353,0.0005025934,0.0025499384,0.00025382696],"domain_scores_gemma":[0.97340834,0.0049426844,0.0014061026,0.0015122383,0.017871121,0.0008596365],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003106974,0.0012370723,0.0010559959,0.002499475,0.0033693449,0.0033774597,0.0018773655,0.0040776655,0.19228616],"category_scores_gemma":[0.048850443,0.0006509213,0.001100223,0.0017052134,0.0010841226,0.0019495098,0.001693392,0.0065079336,0.17236249],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011385736,0.000003039622,0.000027171965,0.00002883726,0.0000013402204,0.000046158955,0.000008690564,0.000008795606,0.000020369114,0.00025885558,0.9955657,0.004019611],"study_design_scores_gemma":[0.0000085169095,0.000009468915,0.00014428399,0.00012237424,0.0000047513495,0.00017015797,0.00003725156,0.00002691145,0.00011181922,0.00035617658,0.9989993,0.0000089675705],"about_ca_topic_score_codex":0.0120288925,"about_ca_topic_score_gemma":0.016334925,"teacher_disagreement_score":0.80771387,"about_ca_system_score_codex":0.0028605193,"about_ca_system_score_gemma":0.00438981,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4235487124","doi":"10.3410/f.1032827.554251","title":"Faculty Opinions recommendation of An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.","year":2007,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Allosteric regulation; Epidermal growth factor receptor; Mechanism (biology); Domain (mathematical analysis); Chemistry; Factor (programming language); Epidermal growth factor; Cell biology; Cancer research; Computational biology; Receptor; Computer science; Biology; Biochemistry; Mathematics; Physics","score_opus":0.06663620951716587,"score_gpt":0.4145805635379009,"score_spread":0.34794435402073504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235487124","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038073532,0.0001239039,0.000194997,0.00026710084,0.00006919632,0.0000282751,0.99626285,0.00068889296,0.0019839625],"genre_scores_gemma":[0.00082714186,0.000093470066,0.00058022246,0.00012949784,0.000011473469,0.000040240597,0.99685967,0.0000599015,0.0013982988],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986493,0.00019657264,0.00013288014,0.00037056432,0.00047726012,0.00017350899],"domain_scores_gemma":[0.997358,0.0006329585,0.00032435887,0.00061581854,0.00075895607,0.0003098888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012594056,0.0021165966,0.0013678272,0.0023320187,0.000653359,0.0023719685,0.0028239004,0.0031068912,0.061226983],"category_scores_gemma":[0.0061953617,0.0006727791,0.0017055016,0.003547661,0.00029229713,0.0014193916,0.001089637,0.0019206136,0.06538005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001169479,0.000034188823,0.0008155458,0.00043793273,0.00003644344,0.000016117176,0.0000047110316,0.00028047652,0.00020168259,0.00026218317,0.99496067,0.0028329962],"study_design_scores_gemma":[0.0005924408,0.000038016155,0.0064974837,0.00018029984,0.00010149927,0.00008243102,0.000027072627,0.0025685108,0.0018465045,0.001117536,0.98691094,0.00003725228],"about_ca_topic_score_codex":0.026577046,"about_ca_topic_score_gemma":0.066628136,"teacher_disagreement_score":0.061226983,"about_ca_system_score_codex":0.0018239209,"about_ca_system_score_gemma":0.003918438,"threshold_uncertainty_score":0.20482463},"labels":[],"label_agreement":null},{"id":"W4235681351","doi":"10.1200/jco.2004.22.14_suppl.2622","title":"ARH460–16-2: a therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Immunohistochemistry; CD44; Medicine; Breast cancer; Monoclonal antibody; Cancer; Epitope; Antigen; Cancer research; HER2/neu; Antibody; Pathology; Internal medicine; Immunology; Biology; Cell","score_opus":0.18380388789095847,"score_gpt":0.5762637421299914,"score_spread":0.39245985423903296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235681351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781095,0.011381375,0.0027773713,0.00035276622,0.0001128891,0.00013516392,0.00029004668,0.00016588828,0.0066750734],"genre_scores_gemma":[0.98491687,0.0044009,0.0046675517,0.00020663186,0.00009985052,0.00007494552,0.00075145235,0.00001667925,0.0048651826],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998404,0.00003256132,0.000012275668,0.000027583721,0.00004811297,0.00003901408],"domain_scores_gemma":[0.9999298,0.000009226461,0.000014810557,0.000007002754,0.0000116737665,0.000027532098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003762146,0.00031553317,0.00021159889,0.0004840661,0.00015471631,0.00023272833,0.00027612815,0.0004643155,0.0027901146],"category_scores_gemma":[0.00013277263,0.00013140166,0.00015290198,0.00024421138,0.00014565868,0.00018092888,0.00017411415,0.00038039952,0.001051726],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088543375,0.0005268649,0.004311257,0.00017100066,0.000032249704,0.00035273583,0.000025245943,0.00034343763,0.9570103,0.00018693566,0.0013831967,0.034771256],"study_design_scores_gemma":[0.0006248417,0.0072559505,0.053743478,0.000058083482,0.0001385412,0.013273499,0.00003704662,0.0046758223,0.8821608,0.00019721365,0.037809372,0.000025386169],"about_ca_topic_score_codex":0.00021463465,"about_ca_topic_score_gemma":0.0003606509,"teacher_disagreement_score":0.0027901146,"about_ca_system_score_codex":0.00026280398,"about_ca_system_score_gemma":0.00019371622,"threshold_uncertainty_score":0.009333909},"labels":[],"label_agreement":null},{"id":"W4235748407","doi":"10.1097/pai.0000000000000163","title":"Standardization of Positive Controls in Diagnostic Immunohistochemistry","year":2014,"lang":"en","type":"review","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Standardization; Immunohistochemistry; Harmonization; Medicine; Computer science; Pathology; Medical physics","score_opus":0.014024258154765623,"score_gpt":0.3609952550895327,"score_spread":0.3469709969347671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235748407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0080801705,0.6799536,0.26111075,0.007692122,0.008326409,0.0033564772,0.00090664654,0.00086154125,0.029712357],"genre_scores_gemma":[0.08589345,0.43566447,0.4469181,0.0073755295,0.0041296203,0.0064726486,0.0043946463,0.0006691095,0.008482446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.91804385,0.037433363,0.0118768625,0.007103299,0.02411845,0.0014241154],"domain_scores_gemma":[0.92984885,0.03782349,0.00630405,0.005760769,0.019563839,0.00069898384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08689834,0.0019482574,0.0031171932,0.008053134,0.0010366756,0.004606812,0.0060306033,0.0040936605,0.0023432025],"category_scores_gemma":[0.05501488,0.0011824516,0.0018626526,0.004413569,0.007888654,0.0031911554,0.0029831864,0.004478033,0.0022132862],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036784605,0.00023783154,0.0053938795,0.030545153,0.0003998468,0.0012563465,0.0014286267,0.0015737592,0.030910457,0.05487408,0.029532835,0.84347934],"study_design_scores_gemma":[0.000098907425,0.00051040825,0.008070603,0.014752042,0.0005329698,0.0059796185,0.00083421235,0.0014615722,0.053212367,0.022263814,0.892083,0.00020048332],"about_ca_topic_score_codex":0.0016044582,"about_ca_topic_score_gemma":0.0014954717,"teacher_disagreement_score":0.08689834,"about_ca_system_score_codex":0.002434199,"about_ca_system_score_gemma":0.005844508,"threshold_uncertainty_score":0.45956784},"labels":[],"label_agreement":null},{"id":"W4235904818","doi":"10.1007/s40278-015-3201-2","title":"Trastuzumab emtansine: lower AE-related costs in Canada","year":2015,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab emtansine; Medicine; Trastuzumab; Internal medicine; Breast cancer; Cancer","score_opus":0.04215747184043541,"score_gpt":0.32872668504274083,"score_spread":0.28656921320230544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235904818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8497525,0.020468438,0.00069270254,0.050678633,0.0006547302,0.0003265097,0.011556344,0.00016360015,0.06570654],"genre_scores_gemma":[0.96364206,0.0074362285,0.0007724954,0.005464182,0.00018597086,0.000047934256,0.0022652908,0.00005725354,0.02012861],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936444,0.00007957845,0.000042611326,0.000063236344,0.0002214699,0.00022866797],"domain_scores_gemma":[0.99763584,0.00016190181,0.0003532063,0.000029939147,0.0007842994,0.0010347881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050743,0.00016968735,0.00027969797,0.00054761366,0.00089230726,0.0011451172,0.00066059316,0.00061983307,0.007882835],"category_scores_gemma":[0.0034740071,0.00014456143,0.00050692965,0.0013140904,0.00027580874,0.00036766418,0.0003467959,0.0009903857,0.00026639938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007907057,0.00108763,0.40994105,0.001038782,0.00068060035,0.0016671857,0.0007519971,0.004989601,0.004451932,0.007558636,0.14298852,0.41693702],"study_design_scores_gemma":[0.0019555509,0.0008951951,0.8598273,0.00045632623,0.0005406768,0.0009735274,0.0010458449,0.0036108424,0.0012440744,0.00065705925,0.12872896,0.00006465012],"about_ca_topic_score_codex":0.9781423,"about_ca_topic_score_gemma":0.9900761,"teacher_disagreement_score":0.053051125,"about_ca_system_score_codex":0.053051125,"about_ca_system_score_gemma":0.05632387,"threshold_uncertainty_score":0.3849147},"labels":[],"label_agreement":null},{"id":"W4236472457","doi":"10.5858/133.4.597","title":"Practice Evolution: Decentralized Computer-Assisted Immunohistochemical Image Analysis","year":2009,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Computer science; Pathology; Medicine","score_opus":0.015740116940510303,"score_gpt":0.3631940186392202,"score_spread":0.3474539016987099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236472457","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112157,0.0073926537,0.73044205,0.08048118,0.0015275403,0.0024232136,0.00049047946,0.012328025,0.052757863],"genre_scores_gemma":[0.4595455,0.003040221,0.51036054,0.012928646,0.00197652,0.0016257759,0.0008497527,0.0015089248,0.008164167],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.97168994,0.011678094,0.0017361422,0.0061606644,0.0075027887,0.0012323478],"domain_scores_gemma":[0.9320373,0.022757735,0.005799255,0.014866834,0.01798152,0.0065573566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04387588,0.000630278,0.00053107366,0.0048676687,0.0017001914,0.0064167376,0.005347718,0.0026161117,0.008303126],"category_scores_gemma":[0.049832094,0.0009843075,0.0008187996,0.0038401135,0.0034555132,0.0055647506,0.0073234513,0.003193544,0.0034231318],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029135004,0.0006499246,0.029709274,0.00042462794,0.000106184525,0.00040074522,0.003008744,0.005266682,0.0031461094,0.015942726,0.03591776,0.90513605],"study_design_scores_gemma":[0.0009863556,0.0021655583,0.093318745,0.0026371246,0.0002482995,0.0063478434,0.008688621,0.13981064,0.010811351,0.14962016,0.58480984,0.0005554497],"about_ca_topic_score_codex":0.006158304,"about_ca_topic_score_gemma":0.009342773,"teacher_disagreement_score":0.04387588,"about_ca_system_score_codex":0.0069371406,"about_ca_system_score_gemma":0.013069204,"threshold_uncertainty_score":0.23204064},"labels":[],"label_agreement":null},{"id":"W4236939410","doi":"10.1007/978-3-662-46875-3_1932","title":"Epidermal Growth Factor Receptor","year":2014,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Epidermal growth factor receptor; Factor (programming language); Biology; Receptor; Computer science; Genetics; Programming language","score_opus":0.07684365104587398,"score_gpt":0.34825861066300934,"score_spread":0.27141495961713535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236939410","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006482708,0.040259037,0.0067132255,0.0024795057,0.0030799294,0.00006348823,0.00053362286,0.00041672454,0.94580615],"genre_scores_gemma":[0.0017647984,0.015587583,0.0019293878,0.001123649,0.00027940242,0.000030271845,0.00028084448,0.000053804913,0.97895026],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9998739,0.000012927035,0.0000043070413,0.000023119424,0.000071745155,0.0000140392585],"domain_scores_gemma":[0.9999523,0.000013458874,0.0000036757478,0.0000062271165,0.000015252241,0.000009051419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016280501,0.00071603793,0.0003770174,0.0007940835,0.00042266233,0.0012883211,0.0005947185,0.0006782063,0.10002744],"category_scores_gemma":[0.00033995794,0.0001912815,0.00024348902,0.0007156882,0.00037317947,0.0012689704,0.0010244026,0.001472017,0.068760626],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021875334,0.000043976455,0.00005122819,0.00021736765,0.000005398336,0.000116738855,0.00007290367,0.00021295703,0.001981063,0.03770268,0.4899407,0.46963307],"study_design_scores_gemma":[0.0000015025116,0.0000049195505,0.00003954884,0.000050181567,0.0000013922491,0.00015033502,0.000009679962,0.00002939844,0.0002526658,0.0027597877,0.9966987,0.0000019450215],"about_ca_topic_score_codex":0.0010669099,"about_ca_topic_score_gemma":0.0030006191,"teacher_disagreement_score":0.10002744,"about_ca_system_score_codex":0.0006752146,"about_ca_system_score_gemma":0.0006901063,"threshold_uncertainty_score":0.33462512},"labels":[],"label_agreement":null},{"id":"W4237424163","doi":"10.1007/978-3-642-27841-9_1933-2","title":"Epidermal Growth Factor-like Ligands","year":2014,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Factor (programming language); Epidermal growth factor; Chemistry; Computer science; Programming language; Biochemistry","score_opus":0.0645098071193837,"score_gpt":0.3399901661483824,"score_spread":0.2754803590289987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237424163","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008446913,0.090929955,0.007129027,0.003235247,0.004246988,0.000037676964,0.00031072527,0.0002470686,0.89301854],"genre_scores_gemma":[0.00337538,0.040314563,0.0024581377,0.0015072221,0.0005361989,0.00003550454,0.00017845357,0.00006894705,0.9515256],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990857,0.000012510619,0.0000029080722,0.000012106573,0.000054816013,0.0000091577485],"domain_scores_gemma":[0.99996483,0.000015113775,0.0000024869148,0.0000032067264,0.000008513604,0.0000059324216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014668156,0.00062129804,0.0002939084,0.000664088,0.00032459333,0.0012496766,0.00049560564,0.0005507901,0.047162145],"category_scores_gemma":[0.0002484266,0.00015750562,0.00018045507,0.00070352305,0.00036529178,0.0012502958,0.00075400993,0.0014134027,0.02102001],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024397732,0.000052071628,0.00003222937,0.00032972137,0.0000060876073,0.00011135152,0.000105163206,0.000436334,0.0028526697,0.09794566,0.4194877,0.47861657],"study_design_scores_gemma":[0.000001574589,0.000003449839,0.00002087481,0.00005155953,0.0000010859915,0.00008236071,0.000010547792,0.000040438525,0.0003003192,0.0055113477,0.9939746,0.0000017995101],"about_ca_topic_score_codex":0.0005707371,"about_ca_topic_score_gemma":0.001787046,"teacher_disagreement_score":0.047162145,"about_ca_system_score_codex":0.0007360444,"about_ca_system_score_gemma":0.00043446998,"threshold_uncertainty_score":0.15777308},"labels":[],"label_agreement":null},{"id":"W4238539811","doi":"10.1007/978-3-540-47648-1_1933","title":"Epidermal Growth Factor-like Ligands","year":2008,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Factor (programming language); Computer science; Programming language","score_opus":0.08436577679503883,"score_gpt":0.3410091998712522,"score_spread":0.2566434230762134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238539811","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010441946,0.079279624,0.008298609,0.002486638,0.003215815,0.000044829863,0.00029412552,0.00028838654,0.90504783],"genre_scores_gemma":[0.0034942105,0.031235768,0.0028248997,0.0012502762,0.000321671,0.000036308666,0.00015354664,0.000056537527,0.9606268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99993527,0.000008065301,0.000002071692,0.000009036034,0.000038811773,0.0000066897114],"domain_scores_gemma":[0.99997365,0.000011574407,0.0000018712989,0.0000027304493,0.000006336816,0.0000038721632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001170204,0.0005837103,0.0002993311,0.00051009236,0.00028161838,0.001001572,0.0004931911,0.0005029145,0.040320687],"category_scores_gemma":[0.00017422841,0.00015300348,0.00016312682,0.0005555067,0.0002782797,0.0010350266,0.0005657773,0.0013024502,0.019984834],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025677258,0.00005901617,0.00003545168,0.00034758347,0.000006322034,0.0001660783,0.000118591124,0.00048369516,0.004694619,0.09156409,0.3871267,0.5153721],"study_design_scores_gemma":[0.000001770071,0.000004295134,0.000023430282,0.000042298372,0.0000013685146,0.00012616644,0.000010151571,0.000046544897,0.00047996407,0.0045062127,0.994756,0.0000017622925],"about_ca_topic_score_codex":0.00046235384,"about_ca_topic_score_gemma":0.0015168295,"teacher_disagreement_score":0.040320687,"about_ca_system_score_codex":0.00056582876,"about_ca_system_score_gemma":0.0003461772,"threshold_uncertainty_score":0.13488615},"labels":[],"label_agreement":null},{"id":"W4239258335","doi":"10.1200/jco.2012.30.18_suppl.lba506","title":"Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Neoadjuvant therapy; Exact test; Clinical endpoint; Gastroenterology; Oncology; Cancer; Gynecology; Clinical trial","score_opus":0.45636250260094796,"score_gpt":0.651772909540381,"score_spread":0.19541040693943307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239258335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7260644,0.0065093916,0.0065979594,0.0054641156,0.000655788,0.16520312,0.03286803,0.0009319734,0.055705115],"genre_scores_gemma":[0.7356173,0.004384983,0.014392716,0.0047228164,0.00026796936,0.17902654,0.027708564,0.00016746488,0.03371156],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99881136,0.00083262095,0.00006653085,0.000068322224,0.00009132895,0.00012978591],"domain_scores_gemma":[0.99877995,0.00017757014,0.0002763361,0.000103827544,0.0001234472,0.0005388652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002607553,0.0009325298,0.0011091643,0.0004168925,0.0005728656,0.00065872475,0.001229057,0.0014139937,0.017002134],"category_scores_gemma":[0.0018486645,0.0004319985,0.00064574124,0.00054653344,0.0005424918,0.00048169654,0.0005137946,0.0020757192,0.0039838552],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8155512,0.01981887,0.0040872903,0.0016074851,0.00036242514,0.00020537866,0.00013739822,0.0016916646,0.020139355,0.0008282717,0.024773559,0.11079698],"study_design_scores_gemma":[0.74547327,0.18804425,0.014883772,0.00032864412,0.00036621702,0.0004142159,0.0000767656,0.0018975539,0.004936295,0.0008103908,0.042725943,0.00004273973],"about_ca_topic_score_codex":0.0015036487,"about_ca_topic_score_gemma":0.005504717,"teacher_disagreement_score":0.017002134,"about_ca_system_score_codex":0.0011802933,"about_ca_system_score_gemma":0.004269645,"threshold_uncertainty_score":0.056877792},"labels":[],"label_agreement":null},{"id":"W4243113348","doi":"10.1200/jco.2017.35.15_suppl.502","title":"Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Tolerability; Clinical endpoint; Gastroenterology; Surgery; Breast cancer; Clinical trial; Cancer; Adverse effect","score_opus":0.3334326856360255,"score_gpt":0.5070968932165508,"score_spread":0.1736642075805253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243113348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.696305,0.07815811,0.007267543,0.008088035,0.002397999,0.0054683965,0.17707302,0.00057247723,0.024669489],"genre_scores_gemma":[0.7892092,0.012364005,0.007662375,0.007999647,0.0014539821,0.005555147,0.16490105,0.00020774019,0.010646908],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99705744,0.0019889977,0.00016746939,0.00019910786,0.0004286317,0.0001584486],"domain_scores_gemma":[0.99266195,0.0032493682,0.0024391897,0.0004853577,0.00047388056,0.0006901895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009069399,0.0009544348,0.001702113,0.0005248457,0.0002715968,0.0012632206,0.00095056416,0.0012760297,0.005319623],"category_scores_gemma":[0.009211085,0.00042451397,0.0027815346,0.000835841,0.00028684697,0.0011307122,0.0007883861,0.0025325397,0.00087327784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7212682,0.0026929877,0.02536936,0.005305886,0.018355966,0.00030008185,0.00026759665,0.0047877687,0.005194574,0.0008145985,0.10792541,0.107717656],"study_design_scores_gemma":[0.58081067,0.0743104,0.20546782,0.0014442594,0.039662633,0.0015722279,0.00016012393,0.0031337086,0.0039579486,0.0018496641,0.08737302,0.000257547],"about_ca_topic_score_codex":0.0011631653,"about_ca_topic_score_gemma":0.0041179117,"teacher_disagreement_score":0.009069399,"about_ca_system_score_codex":0.0008227504,"about_ca_system_score_gemma":0.0011668024,"threshold_uncertainty_score":0.047964156},"labels":[],"label_agreement":null},{"id":"W4243385540","doi":"10.1200/jco.2012.30.18_suppl.lba1","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab emtansine; Lapatinib; Capecitabine; Taxane; Trastuzumab; Metastatic breast cancer; Internal medicine; Interim analysis; Adverse effect; Gastroenterology; Refractory (planetary science); Tolerability; Breast cancer; Oncology; Cancer; Clinical trial","score_opus":0.12002997400766796,"score_gpt":0.48375085071599894,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243385540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9409077,0.008539661,0.0018794754,0.0012525015,0.00035958766,0.01829277,0.015099361,0.0003121144,0.013356832],"genre_scores_gemma":[0.9553478,0.0045419773,0.0034465753,0.002576885,0.000512219,0.009025063,0.016003473,0.00011512839,0.008430752],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991667,0.00051800715,0.000044346627,0.00009004397,0.000062722436,0.00011812996],"domain_scores_gemma":[0.9983596,0.00042612493,0.00038034632,0.00012399418,0.00010174737,0.0006081297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003831368,0.002148993,0.0020916357,0.000575636,0.0004916352,0.0009026311,0.0015626767,0.0014115268,0.010385942],"category_scores_gemma":[0.0019536465,0.0006918665,0.0019098042,0.0005364822,0.00079643464,0.000663147,0.0004298765,0.0034900052,0.0018291883],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86449206,0.04524702,0.0051764552,0.0017459387,0.0023992283,0.00027610577,0.0001688216,0.0022985907,0.019560901,0.00018927491,0.009979621,0.04846607],"study_design_scores_gemma":[0.675148,0.2915781,0.01980693,0.000115371244,0.0019708232,0.00032506458,0.000043776836,0.0006358343,0.004492328,0.000106892956,0.0057471474,0.000029806837],"about_ca_topic_score_codex":0.0008727534,"about_ca_topic_score_gemma":0.0026915467,"teacher_disagreement_score":0.010385942,"about_ca_system_score_codex":0.0011255163,"about_ca_system_score_gemma":0.0014268558,"threshold_uncertainty_score":0.034744382},"labels":[],"label_agreement":null},{"id":"W4243460686","doi":"10.1186/s13058-019-1196-y","title":"NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Trastuzumab; Medicine; Neratinib; Oncology; Internal medicine; Breast cancer; Cyclophosphamide; Chemotherapy; Gastroenterology; Cancer","score_opus":0.03781533341049981,"score_gpt":0.4208535751548812,"score_spread":0.3830382417443814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243460686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99606687,0.0013402418,0.00025864254,0.00022935885,0.00013748472,0.0009257943,0.0003605327,0.0000354356,0.00064558943],"genre_scores_gemma":[0.9889972,0.001771989,0.0020020222,0.000784456,0.00018863076,0.0024114212,0.0016813414,0.0000232075,0.0021397069],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99953234,0.00028065473,0.000022807613,0.000055393153,0.00005504753,0.00005386243],"domain_scores_gemma":[0.9995364,0.000096698095,0.00008854378,0.000040299423,0.00003877014,0.00019942825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016930939,0.00093250145,0.0016941718,0.00024954995,0.00023099977,0.0005898454,0.00049647305,0.0007018366,0.0023330783],"category_scores_gemma":[0.00087760703,0.00039666137,0.00093569333,0.00022644106,0.0007661081,0.00052057777,0.00025063608,0.0018062021,0.00039635107],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9248214,0.01716193,0.0026749822,0.00044666682,0.0011028111,0.0000553683,0.000058558093,0.0012642898,0.015269903,0.00015960287,0.0011737851,0.03581081],"study_design_scores_gemma":[0.71423376,0.27108708,0.007930962,0.000042310567,0.0006305834,0.00014720706,0.00003750847,0.001698852,0.0027280487,0.00019369,0.0012414408,0.00002848893],"about_ca_topic_score_codex":0.00093520933,"about_ca_topic_score_gemma":0.0030333486,"teacher_disagreement_score":0.0023330783,"about_ca_system_score_codex":0.0007494986,"about_ca_system_score_gemma":0.0012036815,"threshold_uncertainty_score":0.008954048},"labels":[],"label_agreement":null},{"id":"W4243654865","doi":"10.1093/jnci/djx242","title":"Response","year":2017,"lang":"en","type":"letter","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Computer science","score_opus":0.20334903797934395,"score_gpt":0.473213058432316,"score_spread":0.26986402045297203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243654865","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002366138,0.00043942116,0.000053924385,0.96873593,0.025441596,0.000022068833,0.000117566546,0.000048159432,0.0049047675],"genre_scores_gemma":[0.0010644122,0.00019959119,0.000052072977,0.97799474,0.007913009,0.00003772037,0.00004280752,0.000018349583,0.0126773305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609923,0.000747509,0.00030664983,0.0006186167,0.0011955121,0.0010324984],"domain_scores_gemma":[0.99236506,0.0022959965,0.00057490147,0.00024992795,0.0021304935,0.0023835776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032893426,0.0010500432,0.0016211702,0.0010806132,0.006724368,0.005822932,0.0026713246,0.07176472,0.020565644],"category_scores_gemma":[0.029545864,0.00095777423,0.001526795,0.0006652187,0.0031096262,0.0031293419,0.003355036,0.04565846,0.014923184],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020127494,0.000014941746,0.00030659157,0.00001693367,0.000005654785,0.00033420272,0.000047313584,0.00002260948,0.00003705531,0.0008218627,0.99665964,0.0017132045],"study_design_scores_gemma":[0.00007526243,0.000044780943,0.0011456414,0.00024589835,0.000022020722,0.00054452743,0.00059384864,0.0002209027,0.00013460105,0.003504937,0.9934047,0.00006286373],"about_ca_topic_score_codex":0.018049283,"about_ca_topic_score_gemma":0.029873956,"teacher_disagreement_score":0.07176472,"about_ca_system_score_codex":0.0064670704,"about_ca_system_score_gemma":0.009504266,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4244123106","doi":"10.1097/01.pas.0000169497.11907.3a","title":"Description of a Novel System for Grading of Endometrial Carcinoma and Comparison With Existing Grading Systems","year":2005,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Grading (engineering); Medicine; Carcinoma; General surgery; Radiology; Oncology; Pathology; Biology","score_opus":0.14336739730510878,"score_gpt":0.37683670121627433,"score_spread":0.23346930391116555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244123106","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08205991,0.005379289,0.87092686,0.003628908,0.0033241096,0.004282138,0.0060419654,0.006381493,0.017975422],"genre_scores_gemma":[0.075207196,0.0012792862,0.9127215,0.00027351614,0.0006231283,0.0018219869,0.0042497776,0.0003614528,0.003462087],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99595815,0.0009106893,0.0008516508,0.00044977755,0.0016364697,0.00019328833],"domain_scores_gemma":[0.99013525,0.0018032723,0.0007338643,0.0009964729,0.0059639425,0.00036722748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008170939,0.001045611,0.0011824697,0.007873953,0.0010270732,0.0025993215,0.0017854985,0.0011888682,0.0052466206],"category_scores_gemma":[0.01530325,0.0005024203,0.0013035721,0.0034573541,0.00049323885,0.0025690529,0.0017195031,0.0016953512,0.0032950006],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006755738,0.0004702233,0.072688915,0.00075582066,0.00034853903,0.0005193137,0.00033659872,0.0029341814,0.025256632,0.00645102,0.03447701,0.85508615],"study_design_scores_gemma":[0.001330864,0.006224641,0.32411712,0.0012211589,0.0024951715,0.02755719,0.0013064578,0.21695063,0.076199904,0.03643613,0.30494082,0.0012199291],"about_ca_topic_score_codex":0.0037668291,"about_ca_topic_score_gemma":0.0064430027,"teacher_disagreement_score":0.008170939,"about_ca_system_score_codex":0.0015049005,"about_ca_system_score_gemma":0.0029792208,"threshold_uncertainty_score":0.043212533},"labels":[],"label_agreement":null},{"id":"W4245612590","doi":"10.1111/j.1471-0528.2007.01357.x","title":"What’s new in the other journals?","year":2007,"lang":"en","type":"article","venue":"BJOG An International Journal of Obstetrics & Gynaecology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.09633261367511584,"score_gpt":0.4452345611641628,"score_spread":0.348901947489047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245612590","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024780704,0.09141139,0.00043005936,0.19683576,0.6736426,0.00003638134,0.0004792585,0.00035986953,0.036557015],"genre_scores_gemma":[0.002889517,0.104735844,0.0007516335,0.14782833,0.6471203,0.00005880392,0.0007851724,0.0003021557,0.095528185],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99545926,0.0007630692,0.0004935883,0.00049793633,0.0023446537,0.0004415375],"domain_scores_gemma":[0.96688986,0.0054171016,0.0025266234,0.0017966112,0.014730477,0.00863927],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040122364,0.0013282134,0.0018955644,0.0054770582,0.0020482526,0.01177635,0.00309882,0.007713594,0.16692743],"category_scores_gemma":[0.032463633,0.00049743155,0.0013897496,0.0039664274,0.0026561816,0.008659858,0.0023697545,0.008034807,0.10205582],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034238292,0.000033506873,0.00017471431,0.00067239726,0.000013981149,0.000114833354,0.000046126293,0.000025152993,0.00007305986,0.000946136,0.9371462,0.060719654],"study_design_scores_gemma":[0.0000074588966,0.000014131152,0.00021416532,0.00075598084,0.000007492569,0.00029177472,0.00012169546,0.000016651707,0.000032029493,0.0007637138,0.9977621,0.000012823317],"about_ca_topic_score_codex":0.0016486038,"about_ca_topic_score_gemma":0.003156007,"teacher_disagreement_score":0.83307254,"about_ca_system_score_codex":0.0024521332,"about_ca_system_score_gemma":0.0059567303,"threshold_uncertainty_score":0.5584279},"labels":[],"label_agreement":null},{"id":"W4247991125","doi":"10.1200/edbk_159161","title":"A Value-Based Approach to Treatment of HER2-Positive Breast Cancer: Examining the Evidence","year":2016,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Breast cancer; Medicine; Value (mathematics); Oncology; Cancer; Family medicine; Intensive care medicine; Internal medicine; Computer science","score_opus":0.3712633474379659,"score_gpt":0.5953295001663849,"score_spread":0.22406615272841895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247991125","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026547235,0.9983039,0.00004623147,0.0010496217,0.000203325,0.0000045013144,0.0000065058534,0.0000015709294,0.0003578003],"genre_scores_gemma":[0.00041188326,0.9985446,0.00015000624,0.000632994,0.00015536154,0.0000050702233,0.0000066823254,6.663034e-7,0.00009274036],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9979436,0.0007893761,0.00029696868,0.00012160193,0.00078311353,0.00006535018],"domain_scores_gemma":[0.99218434,0.005931918,0.0007863436,0.00008560996,0.0008590557,0.00015281972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004242876,0.00092568557,0.0023807113,0.0045491788,0.00039021883,0.0021371911,0.0013457823,0.0018366877,0.0033943516],"category_scores_gemma":[0.012220414,0.00040977562,0.0013524154,0.006691757,0.0010075681,0.0029685278,0.0010850959,0.0030912873,0.0008190298],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008754181,0.000043778193,0.00023127873,0.11047261,0.00091891625,0.00013010061,0.00013807861,0.0004673955,0.00025505378,0.0098975245,0.062590405,0.8147673],"study_design_scores_gemma":[0.000096566495,0.0001474505,0.0014502482,0.23041214,0.001521379,0.00076585007,0.0003154646,0.00028965846,0.00015748112,0.015102964,0.7496941,0.000046730584],"about_ca_topic_score_codex":0.0033741198,"about_ca_topic_score_gemma":0.00785094,"teacher_disagreement_score":0.0045491788,"about_ca_system_score_codex":0.002458633,"about_ca_system_score_gemma":0.00444338,"threshold_uncertainty_score":0.022438765},"labels":[],"label_agreement":null},{"id":"W4248017765","doi":"10.1177/117955490800200202","title":"Biological Markers Predictive of Invasive Recurrence in DCIS","year":2008,"lang":"en","type":"article","venue":"Clinical medicine Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Hazard ratio; Univariate analysis; Breast cancer; Oncology; Internal medicine; Immunohistochemistry; Multivariate analysis; Ductal carcinoma; Pathology; Confidence interval; Proportional hazards model; Cancer","score_opus":0.3741225147348614,"score_gpt":0.5492625681031179,"score_spread":0.1751400533682565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248017765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992612,0.00041564822,0.000049247275,0.000020271309,0.0000027469182,0.0000024168594,0.00003145109,0.0000016846318,0.0002153541],"genre_scores_gemma":[0.9996792,0.000089973124,0.00003898072,0.0000070646142,0.000007653574,0.000002259994,0.00009807521,6.18575e-7,0.00007627623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998795,0.000028216367,0.000015256686,0.00001497467,0.000030515454,0.000031581887],"domain_scores_gemma":[0.99915326,0.0002455181,0.00030152104,0.000041541727,0.00009724363,0.00016104589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030042467,0.0001426866,0.000244931,0.0004385206,0.00018847227,0.0002704663,0.000117095966,0.00022707367,0.00051628903],"category_scores_gemma":[0.001383873,0.00011721997,0.00021246639,0.0004259272,0.00016204952,0.00018444342,0.00016323417,0.00036204158,0.000117527656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018285858,0.000021288011,0.9954744,0.0000067353394,0.000013661003,0.000261609,0.00003229342,0.00006326352,0.0010005782,0.0000074135523,0.000041750794,0.002894079],"study_design_scores_gemma":[0.000006172581,0.00015436823,0.9977902,0.00000330293,0.00002780907,0.0012512353,0.00006011487,0.00020320177,0.00029459968,0.000021646183,0.00018508545,0.00000232876],"about_ca_topic_score_codex":0.00068022433,"about_ca_topic_score_gemma":0.0012155528,"teacher_disagreement_score":0.00068022433,"about_ca_system_score_codex":0.00013568021,"about_ca_system_score_gemma":0.00012687947,"threshold_uncertainty_score":0.0017271638},"labels":[],"label_agreement":null},{"id":"W4249293748","doi":"10.5858/2008-132-61-htiaps","title":"HER2 Testing in a Population-Based Study of Patients With Metastatic Breast Cancer Treated With Trastuzumab","year":2008,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Lunenfeld-Tanenbaum Research Institute; University of Toronto; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Concordance; Medicine; Immunohistochemistry; Breast cancer; Oncology; Internal medicine; Context (archaeology); Metastatic breast cancer; Fish <Actinopterygii>; Cancer; Population; Fluorescence in situ hybridization; Pathology; Biology","score_opus":0.03244274009161618,"score_gpt":0.32535604436669985,"score_spread":0.29291330427508366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249293748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99955684,0.000049696297,0.000033784927,0.000032198135,0.0000016558214,0.000007887754,0.00008273271,0.0000021730684,0.00023299996],"genre_scores_gemma":[0.99975353,0.000025227124,0.000029030733,0.000030392861,0.000003311961,0.000004502519,0.00009443104,9.803452e-7,0.0000585219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933076,0.00014428864,0.000034053468,0.00014028937,0.00020700904,0.00014355639],"domain_scores_gemma":[0.9989134,0.0001960012,0.00024609859,0.00005802986,0.00027640993,0.00031008004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004936544,0.00024689038,0.00039534652,0.00068700605,0.001235066,0.00071281777,0.0004478989,0.0004592479,0.00097524637],"category_scores_gemma":[0.0026312084,0.0003500114,0.0002348526,0.0010630606,0.00072815694,0.00028843977,0.0003339747,0.00067247014,0.00018795345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049467937,0.000024604095,0.9991304,0.0000020775558,0.000009803432,0.00012801454,0.00008523459,0.00001898139,0.00013488611,0.0000044232343,0.000053317443,0.00035875334],"study_design_scores_gemma":[0.0000139509175,0.00012757312,0.9983437,0.000003285361,0.000015861104,0.0007254976,0.00034117178,0.00019697087,0.00006808014,0.000009992326,0.00014935147,0.0000044852018],"about_ca_topic_score_codex":0.30656767,"about_ca_topic_score_gemma":0.26965058,"teacher_disagreement_score":0.30656767,"about_ca_system_score_codex":0.0026414844,"about_ca_system_score_gemma":0.0022563084,"threshold_uncertainty_score":0.60956645},"labels":[],"label_agreement":null},{"id":"W4250006491","doi":"10.5858/2008-132-1635-coqiwc","title":"Comparison of Quantitative Immunofluorescence With Conventional Methods for HER2/neu Testing With Respect to Response to Trastuzumab Therapy in Metastatic Breast Cancer","year":2008,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"National Center for Research Resources; National Institute of General Medical Sciences; National Cancer Institute","keywords":"Immunohistochemistry; Tissue microarray; Trastuzumab; Breast cancer; Medicine; Internal medicine; Cancer; Fish <Actinopterygii>; Context (archaeology); Oncology; Pathology; Biology","score_opus":0.13129772062697326,"score_gpt":0.4896196454963863,"score_spread":0.35832192486941306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250006491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96070343,0.00311669,0.03234298,0.00017815386,0.00011130693,0.00017851577,0.0004998216,0.00023007927,0.0026390334],"genre_scores_gemma":[0.98220325,0.00034758585,0.016127804,0.00009849326,0.000045908182,0.00020272782,0.00038838678,0.000027176337,0.0005587729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951592,0.002619052,0.00029051027,0.0006723178,0.0011296741,0.00012925366],"domain_scores_gemma":[0.99278885,0.00451358,0.0010022579,0.000446593,0.001032015,0.00021667877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069188303,0.0004887976,0.0003270535,0.0018280664,0.00020118555,0.00053113943,0.00053689216,0.000772843,0.0014060216],"category_scores_gemma":[0.0077920044,0.0002472138,0.00040674364,0.00059483387,0.0006021931,0.00070142106,0.00038950916,0.0005565072,0.00042919844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014182696,0.0009139835,0.51561517,0.00059895474,0.0011517586,0.00025974828,0.00032094214,0.0034901623,0.38685292,0.0005253809,0.0011447883,0.074943416],"study_design_scores_gemma":[0.0003516902,0.010501043,0.7721198,0.00005084492,0.0004003655,0.0027267039,0.0003394891,0.033277623,0.17676993,0.000882599,0.0024501528,0.00012986577],"about_ca_topic_score_codex":0.00035795174,"about_ca_topic_score_gemma":0.00055152667,"teacher_disagreement_score":0.0069188303,"about_ca_system_score_codex":0.0005896742,"about_ca_system_score_gemma":0.00015127932,"threshold_uncertainty_score":0.036590695},"labels":[],"label_agreement":null},{"id":"W4251289754","doi":"10.1007/978-3-642-16483-5_1933","title":"Epidermal Growth Factor–Like Ligands","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Factor (programming language); Computer science; Programming language","score_opus":0.11157145975790331,"score_gpt":0.34298060869531616,"score_spread":0.23140914893741285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251289754","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00088039547,0.103939295,0.008041874,0.0030153445,0.0041504484,0.00004371934,0.0003091935,0.00025158457,0.8793681],"genre_scores_gemma":[0.0031966607,0.04437055,0.0027844594,0.0015064155,0.000494583,0.000039976174,0.00017692916,0.00006256871,0.94736797],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999162,0.00001179371,0.000003102028,0.000011362209,0.000049076018,0.000008469615],"domain_scores_gemma":[0.9999664,0.00001527053,0.000002305545,0.000003365568,0.000007777231,0.00000493406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014597554,0.00067373895,0.00032630013,0.000645733,0.00032101516,0.0011542125,0.00049626624,0.00057933526,0.0422863],"category_scores_gemma":[0.00022194501,0.00017117822,0.00018743733,0.00071485934,0.0003441259,0.0012747524,0.0006597812,0.0014587381,0.02084725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026271517,0.00005921089,0.000032865933,0.00038136408,0.0000065906115,0.00014321585,0.00011446182,0.00046392353,0.003627465,0.09241651,0.38360015,0.519128],"study_design_scores_gemma":[0.0000016122731,0.000003837013,0.000021509813,0.000047899703,0.0000012487527,0.00010593217,0.0000092610535,0.000040764146,0.0003357977,0.0045967936,0.99483347,0.0000018932651],"about_ca_topic_score_codex":0.0005311721,"about_ca_topic_score_gemma":0.001807522,"teacher_disagreement_score":0.0422863,"about_ca_system_score_codex":0.00067768426,"about_ca_system_score_gemma":0.00040570876,"threshold_uncertainty_score":0.14146179},"labels":[],"label_agreement":null},{"id":"W4251422122","doi":"10.1159/000423687","title":"Tyrosine Protein Kinases in T Lymphocytes","year":2015,"lang":"en","type":"book-chapter","venue":"Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital; McGill University Health Centre","funders":"","keywords":"Tyrosine kinase; Protein tyrosine phosphatase; Cell biology; Receptor tyrosine kinase; Kinase; Biology; Signal transduction","score_opus":0.03309474698557992,"score_gpt":0.3030187165639056,"score_spread":0.2699239695783257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251422122","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030128073,0.42371264,0.0060282038,0.009304678,0.014031949,0.000047166337,0.00016518752,0.00020885182,0.54348844],"genre_scores_gemma":[0.01564216,0.14710179,0.0025829596,0.003839399,0.003364567,0.00004623419,0.00012818884,0.000060893035,0.8272337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999925,0.000011483622,0.0000029158236,0.000012241997,0.000037833106,0.000010583164],"domain_scores_gemma":[0.9999715,0.000011241333,0.0000024660794,0.000002574513,0.000006746868,0.0000053871986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001526814,0.0005720625,0.00027351506,0.0004171072,0.00029944812,0.001046174,0.00044602592,0.00064533274,0.01827777],"category_scores_gemma":[0.00016806248,0.00019367355,0.00020573947,0.00039456922,0.00045155807,0.0012767543,0.0006877119,0.0016115368,0.008301803],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007935778,0.0000694552,0.00009490341,0.00089892425,0.000016805096,0.000286625,0.00039779904,0.0007318839,0.022138128,0.14944765,0.37064016,0.45519835],"study_design_scores_gemma":[0.000006098334,0.000014299243,0.00007588924,0.00008605448,0.0000038603594,0.00014006585,0.00003115528,0.00008337131,0.0013497198,0.013874781,0.9843322,0.000002504647],"about_ca_topic_score_codex":0.0004911698,"about_ca_topic_score_gemma":0.0012868788,"teacher_disagreement_score":0.01827777,"about_ca_system_score_codex":0.0008507322,"about_ca_system_score_gemma":0.00042006955,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4252392529","doi":"10.5858/2010-0038-oa.1","title":"Immunohistochemical Expression of Neurotrophic Tyrosine Kinase Receptors 1 and 2 in Lung Carcinoma: Potential Discriminators Between Squamous and Nonsquamous Subtypes","year":2011,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immunohistochemistry; Tissue microarray; Adenocarcinoma; Pathology; Lung cancer; Carcinoma; Immunostaining; Medicine; Receptor tyrosine kinase; Cancer; Cancer research; Internal medicine; Receptor","score_opus":0.02190539495490347,"score_gpt":0.2921123080271221,"score_spread":0.27020691307221867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252392529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976388,0.0010620164,0.0005577621,0.000021455618,0.0000075036983,0.000018147637,0.00014621703,0.00000934885,0.0005387443],"genre_scores_gemma":[0.998563,0.00022401316,0.0008198986,0.0000150416045,0.00000980351,0.00001724285,0.00018366064,0.000002132507,0.00016518342],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996213,0.00011918289,0.000055975564,0.000063950734,0.00008677572,0.00005276351],"domain_scores_gemma":[0.9994407,0.00019036466,0.00015312388,0.000044410936,0.00008691268,0.00008455627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010911636,0.00015055506,0.0002313522,0.0009958636,0.00015829293,0.0003055385,0.00023619324,0.0002211653,0.0014241474],"category_scores_gemma":[0.0012011703,0.000113518276,0.00012593532,0.000401831,0.00021288128,0.00025413145,0.0001714332,0.00014103108,0.00028752876],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007665357,0.000050454662,0.9151526,0.00006068028,0.000070202776,0.00037821947,0.000060908253,0.00010522115,0.072160766,0.000036746093,0.00021859937,0.01093901],"study_design_scores_gemma":[0.000019479432,0.0001638034,0.98519343,0.000010989549,0.00005119433,0.002255046,0.00015227425,0.0006905245,0.010998819,0.00006730362,0.00039191233,0.0000051880966],"about_ca_topic_score_codex":0.0005078178,"about_ca_topic_score_gemma":0.0016394946,"teacher_disagreement_score":0.0014241474,"about_ca_system_score_codex":0.00018785991,"about_ca_system_score_gemma":0.00012950493,"threshold_uncertainty_score":0.005770743},"labels":[],"label_agreement":null},{"id":"W4253408104","doi":"10.1200/jco.2012.30.27_suppl.98","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab emtansine; Lapatinib; Capecitabine; Taxane; Trastuzumab; Metastatic breast cancer; Internal medicine; Interim analysis; Adverse effect; Refractory (planetary science); Gastroenterology; Pertuzumab; Breast cancer; Cancer; Oncology; Clinical trial","score_opus":0.12002997400766796,"score_gpt":0.48375085071599894,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253408104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94200337,0.008439748,0.0016675428,0.0012336788,0.00037585522,0.016385306,0.0148908375,0.0002913489,0.0147122545],"genre_scores_gemma":[0.95579875,0.0047626337,0.0031470114,0.0024951634,0.0004822717,0.007967799,0.01662811,0.00010519561,0.008613113],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99925476,0.00044218957,0.000045298737,0.00008476811,0.00006257129,0.00011046782],"domain_scores_gemma":[0.9984971,0.00038755048,0.0003306194,0.00010959725,0.00010035373,0.00057471317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036921038,0.0018766266,0.0021864844,0.0005137106,0.00047931026,0.000932851,0.0014302819,0.001226719,0.011292833],"category_scores_gemma":[0.0019534754,0.0006227321,0.0018823856,0.00050873857,0.0006833614,0.00065964984,0.00040381806,0.0034657726,0.0020383825],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8594188,0.0443111,0.0052541676,0.0018891926,0.002587134,0.00027418928,0.0001736729,0.0018862823,0.020038506,0.00017655092,0.00987339,0.05411703],"study_design_scores_gemma":[0.6839676,0.28121307,0.02144762,0.00012870335,0.0020188966,0.00035942512,0.000048585458,0.0005773423,0.0042112987,0.00011144616,0.0058878884,0.00002812018],"about_ca_topic_score_codex":0.0007546275,"about_ca_topic_score_gemma":0.002457196,"teacher_disagreement_score":0.011292833,"about_ca_system_score_codex":0.0010256915,"about_ca_system_score_gemma":0.0013063612,"threshold_uncertainty_score":0.037778318},"labels":[],"label_agreement":null},{"id":"W4254075956","doi":"10.3410/f.717999671.793528402","title":"Faculty Opinions recommendation of Wnt stabilization of β-catenin reveals principles for morphogen receptor-scaffold assemblies.","year":2017,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Morphogen; Scaffold; Wnt signaling pathway; Computational biology; Cell biology; World Wide Web; Biology; Computer science; Engineering; Genetics; Signal transduction; Biomedical engineering","score_opus":0.11208554817992725,"score_gpt":0.44306380982439864,"score_spread":0.3309782616444714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254075956","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038202174,0.0003442461,0.00011262003,0.00017469135,0.000048421847,0.000014541342,0.997336,0.0004129035,0.0011746055],"genre_scores_gemma":[0.000865098,0.00021023976,0.00029889215,0.000102340695,0.00001222761,0.00003706867,0.9975286,0.000058220285,0.0008872176],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998536,0.00022941444,0.00017324412,0.0004077569,0.00043879676,0.00021490372],"domain_scores_gemma":[0.99710745,0.00072468974,0.00048617958,0.00058603805,0.0007342135,0.00036150854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001380291,0.0021330623,0.0015811062,0.0030069978,0.0007320543,0.002835005,0.0027153804,0.0028118733,0.041836493],"category_scores_gemma":[0.007989378,0.00064345467,0.0019877288,0.0048110355,0.0004042627,0.0013753657,0.001838716,0.0016416095,0.06612694],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022287834,0.00003381914,0.0030582652,0.0015674751,0.00011678207,0.000040378087,0.000021802463,0.0003480321,0.00041565203,0.000447259,0.9890876,0.004640045],"study_design_scores_gemma":[0.0004470923,0.00003785598,0.00925327,0.00059027126,0.00017992208,0.00013504656,0.000064591884,0.00089052814,0.0014441451,0.0013842152,0.98553467,0.00003839013],"about_ca_topic_score_codex":0.024305843,"about_ca_topic_score_gemma":0.06410305,"teacher_disagreement_score":0.041836493,"about_ca_system_score_codex":0.0017418517,"about_ca_system_score_gemma":0.004015494,"threshold_uncertainty_score":0.13995701},"labels":[],"label_agreement":null},{"id":"W4281640394","doi":"10.1056/nejmoa2203690","title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2548,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; First Hospital of Jilin University; West China Hospital, Sichuan University; University of California, San Francisco; Kyungpook National University; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Peking Union Medical College; Cleveland Clinic; Samsung; Universitat de Barcelona; Seoul National University Hospital; College of Medicine, Seoul National University; Memorial Sloan-Kettering Cancer Center; Yonsei University; Chinese Academy of Medical Sciences; Tel Aviv University; Seoul National University; Jilin University; Liaoning Cancer Hospital and Institute; Sichuan University; Sun Yat-sen University; Queen Mary University of London; Cleveland Clinic Foundation; University of Ulsan; Institute of Genetics; AstraZeneca; Cancer Research Institute","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.0217942489314834,"score_gpt":0.3451216111915363,"score_spread":0.3233273622600529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281640394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674773,0.0024516233,0.00007839432,0.00011662798,0.000025487465,0.000055810877,0.000037048976,0.0000062468894,0.0004808939],"genre_scores_gemma":[0.9975859,0.0014589567,0.0002088814,0.00015802887,0.000045976965,0.00007262112,0.0001374746,0.0000018726578,0.00033030694],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99972814,0.0001587381,0.000013240574,0.000029727522,0.000034366698,0.000035872774],"domain_scores_gemma":[0.99969685,0.00010640498,0.00006995906,0.000013448251,0.00000935901,0.00010393069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074769196,0.00021475583,0.0005839727,0.00018904477,0.00016381251,0.0002663486,0.00020457535,0.00021007047,0.00075991056],"category_scores_gemma":[0.0008621488,0.00009203891,0.00023007987,0.00022815922,0.00024115024,0.00017286783,0.00016659907,0.00042074465,0.00010331441],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40236747,0.013837343,0.10594736,0.0008019426,0.0015152001,0.0012981879,0.00037743303,0.01110436,0.029608747,0.0006578915,0.0043533538,0.4281307],"study_design_scores_gemma":[0.20668736,0.42923763,0.31386787,0.00029014418,0.0014175151,0.0030245008,0.00018017506,0.011585729,0.012678964,0.0015051642,0.019474708,0.00005035645],"about_ca_topic_score_codex":0.00059617567,"about_ca_topic_score_gemma":0.001715716,"teacher_disagreement_score":0.00075991056,"about_ca_system_score_codex":0.0005760767,"about_ca_system_score_gemma":0.00046823703,"threshold_uncertainty_score":0.0041797757},"labels":[],"label_agreement":null},{"id":"W4281722441","doi":"10.1007/s11523-022-00884-z","title":"A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Neratinib; Cancer; Epidermal growth factor receptor; Breast cancer; Clinical trial; Erlotinib; Phases of clinical research; Trastuzumab","score_opus":0.06037269198487216,"score_gpt":0.3976504848924063,"score_spread":0.3372777929075341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281722441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98597217,0.0030882051,0.0007900615,0.002469093,0.00035089476,0.0010157006,0.0027660364,0.00016217482,0.0033856463],"genre_scores_gemma":[0.98523986,0.00261724,0.0015126528,0.0020542943,0.00017159533,0.001187861,0.003737564,0.000076326796,0.0034026057],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964106,0.0001265681,0.00001679827,0.00007114495,0.000030297013,0.00011408856],"domain_scores_gemma":[0.9994307,0.00009215496,0.0000985929,0.00004626071,0.000037064547,0.00029518257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012647845,0.0019988234,0.0025688868,0.0003875295,0.00045412043,0.0013693712,0.00077179243,0.0016952334,0.0049867798],"category_scores_gemma":[0.0011600124,0.00049130537,0.0020624353,0.00051772554,0.0008146584,0.0015303188,0.00055183686,0.0035595787,0.0011255875],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8093213,0.011441811,0.00713887,0.0010612359,0.0043111467,0.00065211905,0.00032972672,0.00516824,0.028857647,0.0015599709,0.016345073,0.11381294],"study_design_scores_gemma":[0.88449013,0.09604952,0.00793211,0.000049121696,0.00089857244,0.00065807963,0.000119220844,0.0014982321,0.0017496241,0.0013893266,0.0050863433,0.00007971885],"about_ca_topic_score_codex":0.0011625837,"about_ca_topic_score_gemma":0.0037641241,"teacher_disagreement_score":0.0049867798,"about_ca_system_score_codex":0.0010632601,"about_ca_system_score_gemma":0.0013020724,"threshold_uncertainty_score":0.016682506},"labels":[],"label_agreement":null},{"id":"W4281746025","doi":"10.3390/curroncol29060329","title":"Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Oncology; Anthracycline; Internal medicine; Adjuvant therapy; Stage (stratigraphy); Targeted therapy; Neoadjuvant therapy; Systemic therapy; Clinical trial; Disease; Trastuzumab; Cancer","score_opus":0.14555198247840234,"score_gpt":0.4902207322631705,"score_spread":0.34466874978476814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281746025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013693334,0.5867799,0.0018258614,0.38736483,0.004901429,0.00006546682,0.00029626666,0.00008328774,0.017313572],"genre_scores_gemma":[0.02611314,0.89510775,0.005364434,0.06279526,0.0050066537,0.00006855211,0.00029696088,0.00007642226,0.005170861],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99668056,0.00082196534,0.0002329065,0.0003369963,0.001446764,0.00048075605],"domain_scores_gemma":[0.9777281,0.004107788,0.00087910466,0.00040582567,0.012521005,0.0043582944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0101735275,0.00061812927,0.0012013196,0.0017924919,0.0019108197,0.0036666393,0.0024206247,0.0029926808,0.0074584186],"category_scores_gemma":[0.016692074,0.00027084842,0.000872183,0.0029695965,0.0032367874,0.0025758052,0.0023491313,0.007060181,0.0009415156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003553476,0.00011719048,0.002403358,0.0045714453,0.00012498726,0.0005278057,0.0010060047,0.0011229604,0.0011930253,0.04928284,0.28987446,0.6494206],"study_design_scores_gemma":[0.00012824195,0.00015281717,0.0035102142,0.005375893,0.0001413615,0.00048751928,0.00065245316,0.00047805012,0.00026991242,0.009952808,0.97877467,0.00007607438],"about_ca_topic_score_codex":0.6510064,"about_ca_topic_score_gemma":0.7311511,"teacher_disagreement_score":0.3489936,"about_ca_system_score_codex":0.04471968,"about_ca_system_score_gemma":0.10478241,"threshold_uncertainty_score":0.7020978},"labels":[],"label_agreement":null},{"id":"W4281764145","doi":"10.1200/jco.2022.40.16_suppl.tps9137","title":"Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Trastuzumab; KRAS; Metastatic breast cancer; Phases of clinical research; Cancer; Lung cancer; Clinical trial; Breast cancer; Colorectal cancer","score_opus":0.24050476738856874,"score_gpt":0.5669676579238045,"score_spread":0.3264628905352358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281764145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986259,0.002552294,0.0008448393,0.0006632223,0.00037631477,0.0051944735,0.0017760405,0.00014961873,0.0021841351],"genre_scores_gemma":[0.9843965,0.0019407728,0.0020650912,0.0015402772,0.00029687185,0.0042167148,0.0024502336,0.000045195404,0.0030482076],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994615,0.00027479773,0.000020021562,0.00010416776,0.000040961906,0.00009862198],"domain_scores_gemma":[0.99898213,0.0001886553,0.00021540014,0.00008181072,0.00006730054,0.0004646639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002034603,0.0015600355,0.0019485349,0.00035166985,0.0004706523,0.0015490723,0.0010684122,0.0016951995,0.0048446027],"category_scores_gemma":[0.0014051087,0.00071203976,0.0013968586,0.00048345694,0.0012391018,0.0013601752,0.00040244014,0.003477064,0.0011113151],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9278293,0.032736123,0.0025614873,0.0003567049,0.0009223914,0.00009364698,0.00014092735,0.0009196545,0.008076136,0.00018134198,0.0020414812,0.024140893],"study_design_scores_gemma":[0.85300153,0.14041771,0.0035332784,0.00001940402,0.0002590961,0.00007706467,0.00004176477,0.0007134591,0.0006806995,0.00017030352,0.0010691307,0.00001654606],"about_ca_topic_score_codex":0.0015435655,"about_ca_topic_score_gemma":0.004916047,"teacher_disagreement_score":0.0048446027,"about_ca_system_score_codex":0.0014466005,"about_ca_system_score_gemma":0.0019222777,"threshold_uncertainty_score":0.016206801},"labels":[],"label_agreement":null},{"id":"W4281936531","doi":"10.1200/jco.2022.40.16_suppl.105","title":"Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Cancer; Phases of clinical research; Internal medicine; Oncology; Population; Response Evaluation Criteria in Solid Tumors; Antibody; Stage (stratigraphy); Clinical trial; Cancer research; Immunology","score_opus":0.15167348230874803,"score_gpt":0.5658398469977208,"score_spread":0.41416636468897283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281936531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949567,0.0016514745,0.00031165077,0.0001231709,0.000030144602,0.0002489044,0.0005329731,0.000044585133,0.0021003864],"genre_scores_gemma":[0.99759835,0.00044574245,0.00023600708,0.00011381004,0.000024485786,0.000074275886,0.00074637175,0.0000071976206,0.0007537364],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99981993,0.000059475675,0.000012672754,0.00003258737,0.000031530828,0.000043783737],"domain_scores_gemma":[0.99976104,0.000045262597,0.00005640601,0.000015051353,0.000016964963,0.00010536935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066416775,0.00028645233,0.00053197064,0.00020770518,0.00017622969,0.00050508115,0.00026642758,0.00044968264,0.0018049353],"category_scores_gemma":[0.00048809528,0.00013565629,0.0005849428,0.00020788607,0.00033311994,0.00041393534,0.00015972067,0.000841616,0.00031548954],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4705608,0.02512817,0.03244833,0.0007099426,0.0009156091,0.0005108821,0.0002900787,0.0070304065,0.11274123,0.00057948474,0.0067849136,0.34230018],"study_design_scores_gemma":[0.09195457,0.6885251,0.1708006,0.00008010256,0.0012052443,0.0013937885,0.00010740407,0.0069408794,0.027183397,0.00041775312,0.011347885,0.000043339995],"about_ca_topic_score_codex":0.0014333636,"about_ca_topic_score_gemma":0.002479262,"teacher_disagreement_score":0.0018049353,"about_ca_system_score_codex":0.000987758,"about_ca_system_score_gemma":0.0007097434,"threshold_uncertainty_score":0.0071666837},"labels":[],"label_agreement":null},{"id":"W4282940254","doi":"10.1158/1538-7445.am2022-819","title":"Abstract 819: ERBB4 mediates IL10-induced growth of EGFR-independent colon tumors","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"ERBB4; Downregulation and upregulation; ErbB; Cancer research; Colorectal cancer; ERBB3; Biology; Medicine; Receptor; Cancer; Internal medicine; Epidermal growth factor receptor; Receptor tyrosine kinase; Gene; Genetics","score_opus":0.14543979386801828,"score_gpt":0.46036240678029816,"score_spread":0.31492261291227985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282940254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884504,0.000936566,0.0031324483,0.00027179622,0.00007604296,0.0000914385,0.0028545675,0.00021856025,0.0039680894],"genre_scores_gemma":[0.9815539,0.0006375636,0.0023023176,0.00015101826,0.00002193991,0.0001577438,0.0035032004,0.00008797047,0.0115843285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997029,0.00004361596,0.000025701045,0.000048949267,0.00007501207,0.00010378443],"domain_scores_gemma":[0.9997911,0.000026955086,0.00005135774,0.000031141222,0.000019026356,0.000080437254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015989668,0.00058584666,0.00026492475,0.00031661225,0.00015910628,0.0002566477,0.00030482595,0.00042400375,0.0040613506],"category_scores_gemma":[0.000113503025,0.00020079078,0.0004063017,0.0001434548,0.0002396334,0.0001605919,0.00026382602,0.0010973974,0.0020419552],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001291955,0.000066405155,0.0000886227,0.00002230435,0.0000024027368,0.000040998126,0.000004863346,0.000035717618,0.9991229,0.000035456156,0.00006321407,0.0003878296],"study_design_scores_gemma":[0.00004497794,0.00051336427,0.005292633,0.000006655355,0.000008081114,0.00023408592,0.000029864173,0.0009169407,0.9908138,0.000034933375,0.0021001755,0.0000045128468],"about_ca_topic_score_codex":0.0012450757,"about_ca_topic_score_gemma":0.001483264,"teacher_disagreement_score":0.0040613506,"about_ca_system_score_codex":0.00046871285,"about_ca_system_score_gemma":0.00028052425,"threshold_uncertainty_score":0.013586521},"labels":[],"label_agreement":null},{"id":"W4282968322","doi":"10.3390/curroncol29060337","title":"A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Biosimilar; Stage (stratigraphy); Chemotherapy; Regimen; Cancer","score_opus":0.4092377757126683,"score_gpt":0.5581179420768986,"score_spread":0.1488801663642303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282968322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009466233,0.9984896,0.000032435313,0.0002264418,0.00007053103,0.000009238414,0.000036075842,0.0000016237869,0.00018737484],"genre_scores_gemma":[0.005509814,0.9936326,0.0001540689,0.00042240592,0.00011703453,0.000017514783,0.00006201044,0.0000022087604,0.0000823601],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764025,0.00076804974,0.0008428051,0.00017466334,0.0005042732,0.000069933485],"domain_scores_gemma":[0.9897996,0.0068828203,0.0018354678,0.00009300513,0.0012354671,0.00015357384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003950479,0.00042989783,0.0021895305,0.0046187704,0.00021270291,0.0013833756,0.0006471413,0.0006611865,0.0010481607],"category_scores_gemma":[0.009228181,0.0003529273,0.0018089897,0.0058218334,0.00034563837,0.0008855551,0.00040222515,0.0006517246,0.00015947872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013497485,0.00010778685,0.003845501,0.30948445,0.0036198664,0.00026812917,0.00039588092,0.000366429,0.0015629346,0.0013753915,0.015504517,0.6621194],"study_design_scores_gemma":[0.0004512978,0.0026184819,0.051713828,0.42977956,0.020189399,0.0029552467,0.00080058776,0.00046218597,0.0011244516,0.0010381503,0.4887695,0.00009738229],"about_ca_topic_score_codex":0.0043230373,"about_ca_topic_score_gemma":0.01037233,"teacher_disagreement_score":0.0046187704,"about_ca_system_score_codex":0.0020315768,"about_ca_system_score_gemma":0.0041304226,"threshold_uncertainty_score":0.020892382},"labels":[],"label_agreement":null},{"id":"W4284959551","doi":"10.1371/journal.pone.0271090","title":"Reduced CREB3L1 expression in triple negative and luminal a breast cancer cells contributes to enhanced cell migration, anchorage-independent growth and metastasis","year":2022,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Canadian Institutes of Health Research; Saskatchewan Cancer Agency; University of Saskatchewan","keywords":"Breast cancer; Metastasis; Cancer research; Cancer; Medicine; Triple-negative breast cancer; Cell; Internal medicine; Biology; Biochemistry","score_opus":0.03333294983593834,"score_gpt":0.29248249797600695,"score_spread":0.25914954814006863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284959551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745935,0.0006153856,0.000597905,0.00006388294,0.000011849724,0.000009620115,0.0003539068,0.000042228956,0.00084573164],"genre_scores_gemma":[0.9966582,0.00032382386,0.00038555908,0.00003078911,0.000004102995,0.000016478838,0.0005997682,0.0000115900875,0.0019696802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999131,0.0000067350634,0.000005464801,0.000015509973,0.000031027863,0.00002819491],"domain_scores_gemma":[0.9999392,0.000005617969,0.000013701914,0.0000068293557,0.000006105685,0.00002859564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076434706,0.00021845086,0.00020077813,0.00024862352,0.00016680635,0.00022626949,0.00012222563,0.00019615251,0.0015644446],"category_scores_gemma":[0.00006965011,0.00013121935,0.0002039776,0.00016051214,0.0002175158,0.00009429504,0.00015146812,0.00041202107,0.0004743648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007730679,0.000017616418,0.00032622798,0.000013422918,0.0000020945654,0.000030763098,0.0000085943875,0.000012873141,0.99886477,0.000025403762,0.00004266006,0.0005782509],"study_design_scores_gemma":[0.000034482684,0.0005385164,0.044350635,0.0000069910793,0.000027159136,0.0012593183,0.00012717638,0.0012151613,0.9484193,0.00007367469,0.003937812,0.0000098426935],"about_ca_topic_score_codex":0.0019548964,"about_ca_topic_score_gemma":0.002182838,"teacher_disagreement_score":0.0019548964,"about_ca_system_score_codex":0.0002633121,"about_ca_system_score_gemma":0.0002588328,"threshold_uncertainty_score":0.005233586},"labels":[],"label_agreement":null},{"id":"W4285196366","doi":"10.1007/978-1-0716-2376-3_11","title":"Flow Cytometry Analysis to Detect Lapatinib-Induced Modulation of Constitutive and IFN-γ-Induced HLA Class I Expression in HER2-Positive Breast Cancer Cells","year":2022,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Lapatinib; Flow cytometry; Downregulation and upregulation; Cancer research; Immune system; Cancer; Human leukocyte antigen; Biology; Cancer cell; Immunology; Breast cancer; Trastuzumab; Antigen; Genetics; Gene","score_opus":0.0402782762195107,"score_gpt":0.45619999057676763,"score_spread":0.41592171435725694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285196366","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94915724,0.0009228279,0.038158696,0.00037936855,0.00025101815,0.00037192076,0.0026309576,0.0005141278,0.007613861],"genre_scores_gemma":[0.95023996,0.0012956671,0.034317642,0.0004932339,0.00012579415,0.0017428242,0.003131055,0.00009398662,0.008559906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99951994,0.00006654745,0.000048456477,0.00011897129,0.00009956458,0.0001464067],"domain_scores_gemma":[0.99985385,0.00004873976,0.000021179107,0.00001940306,0.000035886587,0.000020937812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027668342,0.0005379192,0.00054025743,0.0004592593,0.00048422205,0.0005093516,0.00037534517,0.00045492762,0.006233651],"category_scores_gemma":[0.00015395238,0.00016242651,0.0004132062,0.00074430235,0.00027620108,0.0002687128,0.00019371972,0.0015122751,0.0007834522],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016422519,0.000108478336,0.00027670758,0.000050471604,0.000009247712,0.00003160373,0.00005840794,0.00006443349,0.9973168,0.0002510869,0.000097815544,0.0015707838],"study_design_scores_gemma":[0.00010624536,0.00040822968,0.01085957,0.000013946596,0.0000367185,0.00022384698,0.000117950185,0.005921473,0.9794805,0.00030653176,0.0025068035,0.000018210254],"about_ca_topic_score_codex":0.0006626924,"about_ca_topic_score_gemma":0.0006764302,"teacher_disagreement_score":0.006233651,"about_ca_system_score_codex":0.00041445933,"about_ca_system_score_gemma":0.00022978433,"threshold_uncertainty_score":0.020853698},"labels":[],"label_agreement":null},{"id":"W4285285895","doi":"10.1007/978-1-0716-2376-3_14","title":"Western Blot Analysis of Lapatinib-Mediated Inhibition of the Epidermal Growth Factor Receptor 2 (HER2) Pathway in Breast Cancer Cells","year":2022,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Lapatinib; Western blot; Phosphorylation; Blot; Epidermal growth factor receptor; Molecular biology; Signal transduction; Receptor tyrosine kinase; Tyrosine-kinase inhibitor; Chemistry; Cancer research; Cancer; Tyrosine phosphorylation; Biology; Breast cancer; Receptor; Cell biology; Biochemistry; Trastuzumab","score_opus":0.040004353161672446,"score_gpt":0.41591909066818633,"score_spread":0.3759147375065139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285285895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87613785,0.015977146,0.042769905,0.0031386171,0.0024464529,0.0006521812,0.02379656,0.0017250759,0.033356085],"genre_scores_gemma":[0.8292588,0.01729911,0.061770905,0.0013046437,0.00044878168,0.0019569283,0.043799944,0.00025538265,0.043905407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906105,0.000095039206,0.000105520645,0.0002127936,0.00024853263,0.0002770399],"domain_scores_gemma":[0.99980193,0.000046524812,0.000028417548,0.000024152692,0.00006287554,0.000036057005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051371846,0.0012620079,0.0010212983,0.00093055144,0.00094455655,0.00067627325,0.0009698305,0.0007518847,0.006538658],"category_scores_gemma":[0.00017943914,0.0004794997,0.0016487915,0.0018457589,0.00043574107,0.000576409,0.00031204408,0.0032362123,0.0015140986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004410844,0.00033593233,0.0002505214,0.00033548125,0.00010124171,0.00016336115,0.00012681806,0.00014354658,0.9942567,0.0006375834,0.0012322948,0.0019755217],"study_design_scores_gemma":[0.0002957931,0.00088806386,0.025056105,0.000074030766,0.00026991745,0.0011239987,0.00042771193,0.009216565,0.94446737,0.00045818294,0.01765753,0.000064881395],"about_ca_topic_score_codex":0.0030062518,"about_ca_topic_score_gemma":0.003963876,"teacher_disagreement_score":0.006538658,"about_ca_system_score_codex":0.00091877294,"about_ca_system_score_gemma":0.00058998034,"threshold_uncertainty_score":0.02187401},"labels":[],"label_agreement":null},{"id":"W4285992942","doi":"10.1038/s41523-022-00452-8","title":"PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer","year":2022,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"Novartis Pharma; National Cancer Institute; National Institutes of Health; Amis de l'Institut Bordet; Ministero della Salute; Associazione Italiana per la Ricerca sul Cancro; National Institute for Health and Care Research; American Society of Clinical Oncology; GlaxoSmithKline","keywords":"Lapatinib; Trastuzumab; Medicine; Internal medicine; Breast cancer; Oncology; Stage (stratigraphy); Chemotherapy; Population; Cancer","score_opus":0.019051291407503723,"score_gpt":0.31597203856608413,"score_spread":0.2969207471585804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285992942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994764,0.0013710038,0.0018546681,0.00015956425,0.000036215835,0.000012138285,0.0010992329,0.00002793173,0.00067521574],"genre_scores_gemma":[0.9981096,0.00018289434,0.00038380708,0.000070519985,0.000040617557,0.0000065994377,0.001042114,0.000009278499,0.00015466836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984397,0.0008754856,0.0001307952,0.00023920639,0.00021279839,0.00010193338],"domain_scores_gemma":[0.9906911,0.006447029,0.001486225,0.00068371784,0.00044922243,0.00024255467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004635173,0.0005782471,0.00069951813,0.0006885002,0.00018903828,0.000872188,0.0002936437,0.00032492678,0.0008574671],"category_scores_gemma":[0.009474663,0.00016151067,0.0007750644,0.0005732586,0.0002177563,0.0005709227,0.0006579897,0.0005926814,0.00029777584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006505619,0.000015114795,0.9886645,0.000045031844,0.00018405427,0.00003154123,0.00003937709,0.0012457364,0.00027254352,0.000039461145,0.00029631046,0.008515711],"study_design_scores_gemma":[0.000034864282,0.00045259413,0.98242754,0.000046986126,0.00040792,0.0005466502,0.00011081157,0.012472314,0.0010167537,0.0005349419,0.0019290566,0.000019614135],"about_ca_topic_score_codex":0.0012488122,"about_ca_topic_score_gemma":0.0023026492,"teacher_disagreement_score":0.004635173,"about_ca_system_score_codex":0.0002276579,"about_ca_system_score_gemma":0.00033385563,"threshold_uncertainty_score":0.024513423},"labels":[],"label_agreement":null},{"id":"W4288431972","doi":"10.1021/acsomega.2c03407","title":"Toward the Development of GE11-Based Radioligands for Imaging of Epidermal Growth Factor Receptor-Positive Tumors","year":2022,"lang":"en","type":"article","venue":"ACS Omega","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Bundesministerium für Bildung und Forschung","keywords":"Epidermal growth factor receptor; Chemistry; Cancer research; In vivo; Peptide; Positron emission tomography; Ligand (biochemistry); Rational design; Biophysics; Receptor; Computational biology; Medicine; Nuclear medicine; Biochemistry; Nanotechnology; Materials science; Biology","score_opus":0.05339359974201312,"score_gpt":0.3354542421718758,"score_spread":0.2820606424298627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288431972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8272962,0.0052056056,0.1575239,0.00042849762,0.000059577782,0.00057152956,0.0006016517,0.00061640545,0.007696703],"genre_scores_gemma":[0.76740927,0.006552527,0.20925683,0.00038006448,0.00002994235,0.00033450936,0.0014152603,0.00017042171,0.014451305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989533,0.000028482391,0.00000717392,0.00002472194,0.000024076659,0.000020185755],"domain_scores_gemma":[0.99993455,0.000016446014,0.000014982067,0.0000053635113,0.000016140908,0.00001249573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030138888,0.0006323559,0.00023046364,0.00018656239,0.00010909398,0.00035030168,0.00041335612,0.0005805256,0.0013305437],"category_scores_gemma":[0.00018661468,0.0002240482,0.00019880309,0.00016923461,0.00017065136,0.0003160956,0.00028848456,0.00047381522,0.0008616093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004304783,0.000012853515,0.000043135526,0.00004789859,0.0000046318573,0.000055080807,0.000013379862,0.00024356158,0.99680185,0.00017157005,0.00009003755,0.002472985],"study_design_scores_gemma":[0.000009130151,0.00021503832,0.00033215547,0.000005667559,0.000010119581,0.00019447874,0.000012507294,0.0023469166,0.99236876,0.000026568341,0.004470355,0.000008323648],"about_ca_topic_score_codex":0.00048255935,"about_ca_topic_score_gemma":0.0007778514,"teacher_disagreement_score":0.0013305437,"about_ca_system_score_codex":0.0002697362,"about_ca_system_score_gemma":0.00018306068,"threshold_uncertainty_score":0.0044511557},"labels":[],"label_agreement":null},{"id":"W4288749431","doi":"10.1186/s13550-022-00915-w","title":"Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases","year":2022,"lang":"en","type":"article","venue":"EJNMMI Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atuka (Canada); University Health Network; McGill University; Montreal Neurological Institute and Hospital; University of Alberta","funders":"University of Alberta; Weston Brain Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Medicine; In vivo; Kinase; Peripheral; Tropomyosin; Receptor; Internal medicine; Cell biology; Actin; Genetics; Biology","score_opus":0.14741915073502457,"score_gpt":0.4392329236631014,"score_spread":0.29181377292807686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288749431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9102903,0.0046026013,0.07525491,0.00022816309,0.00008372281,0.00023888038,0.001315832,0.00035958647,0.0076259756],"genre_scores_gemma":[0.94599503,0.002415695,0.041803747,0.000115482464,0.000036726844,0.00021303263,0.0014626719,0.00010992061,0.007847608],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975365,0.0000637828,0.00001107335,0.00008345131,0.000042243824,0.000045841854],"domain_scores_gemma":[0.99975437,0.000083386934,0.000051150906,0.00003576079,0.000046828944,0.000028515717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046034297,0.00060471916,0.00042909806,0.00015834847,0.00023519994,0.00036218864,0.00055938214,0.00047483123,0.0022021437],"category_scores_gemma":[0.00037152617,0.00031615858,0.00029485926,0.00017937792,0.0002126577,0.000247136,0.00020115524,0.00055791944,0.0008491797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001554913,0.000030029023,0.00012026315,0.0000590857,0.000005564572,0.000052221574,0.000017600114,0.00018291672,0.9981584,0.0001287784,0.00009700849,0.0009925372],"study_design_scores_gemma":[0.000021270364,0.00035966586,0.00070566154,0.000007487149,0.000012185083,0.00029905717,0.000014091146,0.00167815,0.99441576,0.00002165768,0.0024594776,0.000005567735],"about_ca_topic_score_codex":0.0019705729,"about_ca_topic_score_gemma":0.0018034229,"teacher_disagreement_score":0.0022021437,"about_ca_system_score_codex":0.0003984586,"about_ca_system_score_gemma":0.0003358286,"threshold_uncertainty_score":0.0073669553},"labels":[],"label_agreement":null},{"id":"W4290993146","doi":"10.1016/j.esmoop.2022.100553","title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Lilly Deutschland; Merck Sharp and Dohme; Eisai; Clovis Oncology; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Daiichi-Sankyo; Teva Pharmaceutical Industries; Novartis; Merck; Sanofi-Aventis Deutschland; Pfizer; Queen Mary University of London; Bristol-Myers Squibb; AstraZeneca; Gilead Sciences","keywords":"Medicine; Breast cancer; Trastuzumab; Internal medicine; Pneumonitis; Nausea; Context (archaeology); Neutropenia; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Lung","score_opus":0.33804201657331107,"score_gpt":0.5932876732972931,"score_spread":0.2552456567239821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290993146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071933903,0.9142903,0.0043794075,0.046397205,0.0013754203,0.00018928296,0.00016578834,0.000104232044,0.02590496],"genre_scores_gemma":[0.066703185,0.8932126,0.014688657,0.017982272,0.0028744834,0.00030935626,0.00044228378,0.000041970878,0.0037452376],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796754,0.0010593124,0.00034694685,0.00012299829,0.00041524868,0.000088074004],"domain_scores_gemma":[0.9969318,0.0010505859,0.0008287897,0.000060293056,0.0009252839,0.00020312282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031100488,0.00025402437,0.00047672875,0.0006965223,0.00026125633,0.0010624931,0.00060977496,0.00076323014,0.0023712555],"category_scores_gemma":[0.0081213815,0.00011348223,0.00046039827,0.00074767304,0.00030463247,0.0009322824,0.000637471,0.0009692222,0.00069040037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014585751,0.00006094637,0.0026923853,0.006677965,0.00010997163,0.00033280972,0.00029036237,0.00065166195,0.00073909276,0.0033325166,0.0659524,0.9190141],"study_design_scores_gemma":[0.0002295354,0.0003588948,0.008650057,0.019836694,0.0003286974,0.0030311884,0.0005091101,0.00070570124,0.0011229883,0.004495641,0.9606938,0.00003771808],"about_ca_topic_score_codex":0.0011877278,"about_ca_topic_score_gemma":0.0032429718,"teacher_disagreement_score":0.0031100488,"about_ca_system_score_codex":0.0012817206,"about_ca_system_score_gemma":0.0025813153,"threshold_uncertainty_score":0.016447723},"labels":[],"label_agreement":null},{"id":"W4292121937","doi":"10.1007/s00432-022-04189-6","title":"Triple negative breast cancer: approved treatment options and their mechanisms of action","year":2022,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Triple-negative breast cancer; Epirubicin; Olaparib; Breast cancer; Oncology; Docetaxel; Paclitaxel; Internal medicine; Adverse effect; Cancer; Pharmacology","score_opus":0.3171317950564267,"score_gpt":0.5861197862775303,"score_spread":0.26898799122110356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292121937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000950569,0.9907755,0.00031464413,0.0022230549,0.00044918657,0.0000201317,0.00015230497,0.00002216376,0.005092405],"genre_scores_gemma":[0.008695972,0.9854731,0.00075117504,0.0019584813,0.00052871474,0.00004490031,0.00030257303,0.000007444626,0.002237781],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996735,0.00008323661,0.00004046517,0.0000457641,0.00012341751,0.00003359826],"domain_scores_gemma":[0.9996623,0.00008963468,0.00007320159,0.000010634484,0.00013486065,0.000029336496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007495625,0.0003995674,0.000594306,0.0008703554,0.0002737509,0.0009323179,0.0006285306,0.00071156287,0.0067395163],"category_scores_gemma":[0.0008954045,0.00015427067,0.00047040675,0.00076167454,0.0003369396,0.00092926977,0.0004612149,0.0013861913,0.0015503494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032228112,0.000112467904,0.00054902385,0.01320484,0.00011488198,0.00039158147,0.00010642694,0.00035556243,0.004557273,0.009384982,0.059013333,0.9118873],"study_design_scores_gemma":[0.000074709555,0.00033581923,0.0009535263,0.004622443,0.00018972305,0.0013637885,0.000085452426,0.00013740575,0.0012509188,0.0029068,0.9880586,0.000020952004],"about_ca_topic_score_codex":0.0006564936,"about_ca_topic_score_gemma":0.0018670461,"teacher_disagreement_score":0.0067395163,"about_ca_system_score_codex":0.00065524277,"about_ca_system_score_gemma":0.000958527,"threshold_uncertainty_score":0.022545993},"labels":[],"label_agreement":null},{"id":"W4292265152","doi":"10.3390/curroncol29080458","title":"Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Breast cancer; Trastuzumab; Internal medicine; Chemotherapy; Neoadjuvant therapy; Capecitabine; Disease; Stage (stratigraphy); Cancer; Taxane; Colorectal cancer","score_opus":0.24325960886720419,"score_gpt":0.5219915138139263,"score_spread":0.27873190494672206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292265152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034118347,0.9480276,0.004090732,0.004786803,0.00049663516,0.0002153715,0.00008763766,0.00007210865,0.008104761],"genre_scores_gemma":[0.2205546,0.7593696,0.009769122,0.004266489,0.0015609142,0.00040817753,0.000600809,0.000027186868,0.0034431103],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982435,0.000068430796,0.00002883522,0.000015544654,0.000042323267,0.00002060656],"domain_scores_gemma":[0.9997255,0.00011182434,0.00009335667,0.000005430508,0.000033978275,0.000029945915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047329566,0.00025953408,0.00057072705,0.00043128047,0.00020346945,0.0004732226,0.00037679158,0.00033471675,0.0008714138],"category_scores_gemma":[0.000928679,0.0000667204,0.0004906317,0.00023865452,0.0001602708,0.0004245597,0.00032440803,0.00066925323,0.00028634886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061502686,0.00026240118,0.009139249,0.005128779,0.00016458101,0.0018999173,0.0002536081,0.00079986296,0.0045493534,0.0009850998,0.010388304,0.9658138],"study_design_scores_gemma":[0.00074826163,0.0071848296,0.08204359,0.023848327,0.0022592517,0.03683689,0.0017269708,0.0032061758,0.01039624,0.007640199,0.8239727,0.00013657354],"about_ca_topic_score_codex":0.00033189918,"about_ca_topic_score_gemma":0.0016708354,"teacher_disagreement_score":0.0008714138,"about_ca_system_score_codex":0.0003539039,"about_ca_system_score_gemma":0.0005179205,"threshold_uncertainty_score":0.0029152036},"labels":[],"label_agreement":null},{"id":"W4292634632","doi":"10.47102/annals-acadmedsg.v44n10p360","title":"Singapore Cancer Network (SCAN) Guidelines for Adjuvant Trastuzumab Use in Early Stage HER2 Positive Breast Cancer","year":2015,"lang":"en","type":"article","venue":"Annals of the Academy of Medicine Singapore","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"NIH Clinical Center; National University Cancer Institute, Singapore; University of Toronto; National Cancer Centre of Singapore","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Cancer; Stage (stratigraphy); Adjuvant; Workgroup","score_opus":0.4128579596647815,"score_gpt":0.5084332479875551,"score_spread":0.09557528832277357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292634632","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08773069,0.09885749,0.042208552,0.35511717,0.009437091,0.017787766,0.033319302,0.0015701561,0.35397178],"genre_scores_gemma":[0.40053383,0.09665194,0.28312755,0.06681075,0.002519158,0.017971592,0.068900846,0.0005848803,0.06289956],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9825623,0.008730354,0.00473167,0.00032313683,0.0033029246,0.00034956454],"domain_scores_gemma":[0.95776033,0.005956952,0.0060017174,0.0010240133,0.027668979,0.0015880084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014690521,0.00042086295,0.0005566011,0.0030002866,0.00072138576,0.0013927374,0.0016293483,0.0012077114,0.0034994076],"category_scores_gemma":[0.03145972,0.00026278844,0.0011042246,0.0032869284,0.0007629865,0.0008820402,0.0014577084,0.001862969,0.0013818791],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029308986,0.00023133359,0.05340821,0.0042319833,0.00020526434,0.0006714818,0.0012359136,0.0020061373,0.001621111,0.0062988326,0.6278332,0.30196345],"study_design_scores_gemma":[0.00029007078,0.00042711388,0.05505596,0.008024546,0.00024928374,0.0014146651,0.0010217075,0.0016799549,0.0015646272,0.0030605677,0.92712474,0.00008684837],"about_ca_topic_score_codex":0.029753704,"about_ca_topic_score_gemma":0.06735304,"teacher_disagreement_score":0.029753704,"about_ca_system_score_codex":0.004881612,"about_ca_system_score_gemma":0.020672794,"threshold_uncertainty_score":0.07769179},"labels":[],"label_agreement":null},{"id":"W4293029338","doi":"10.3390/curroncol29090476","title":"Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China; China Medical Board","keywords":"Capecitabine; Lapatinib; Medicine; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; China; Cancer; Trastuzumab; Colorectal cancer","score_opus":0.16749156255611966,"score_gpt":0.4809945161196087,"score_spread":0.313502953563489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293029338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97749627,0.004739718,0.006042896,0.0020129916,0.00007253736,0.0005319604,0.0037596,0.000043556025,0.005300599],"genre_scores_gemma":[0.9963446,0.0007921253,0.00093204767,0.00010029147,0.000017182638,0.0001542487,0.00094744563,0.000007110363,0.0007049132],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99763644,0.0014158818,0.000071553004,0.0002033069,0.00016935523,0.0005034777],"domain_scores_gemma":[0.99542,0.00327681,0.0005013538,0.00009034482,0.0002866269,0.00042495894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005705907,0.0018392754,0.0021593003,0.0025377981,0.00055020873,0.0017660663,0.0018263428,0.0017986593,0.0049745576],"category_scores_gemma":[0.008848836,0.0007089785,0.0044313977,0.0014805525,0.000796254,0.0016838898,0.0014264141,0.0015911441,0.00015402287],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002794338,0.00031436558,0.012416835,0.0005170335,0.00083533145,0.0006076244,0.000062621366,0.9693034,0.00037113627,0.004879288,0.0012934777,0.0066043874],"study_design_scores_gemma":[0.0007867128,0.001501868,0.01178279,0.00017627278,0.0012431002,0.00027089252,0.0002156868,0.97878647,0.0002907012,0.0038846552,0.0009839205,0.00007708944],"about_ca_topic_score_codex":0.040476937,"about_ca_topic_score_gemma":0.016962063,"teacher_disagreement_score":0.040476937,"about_ca_system_score_codex":0.009240793,"about_ca_system_score_gemma":0.0045701903,"threshold_uncertainty_score":0.08048272},"labels":[],"label_agreement":null},{"id":"W4293395719","doi":"10.1158/0008-5472.18.65.1","title":"The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sylvester Comprehensive Cancer Center, University of Miami Health Systems; U.S. Department of Defense","keywords":"Tamoxifen; Lapatinib; Estrogen receptor; Antiestrogen; Cancer research; Breast cancer; Cyclin D1; Cancer; Medicine; Biology; Internal medicine; Endocrinology; Pharmacology; Cell cycle; Trastuzumab","score_opus":0.03860283302467069,"score_gpt":0.3709254548999244,"score_spread":0.3323226218752537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293395719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107915,0.0039512822,0.00166235,0.00013980905,0.0000587833,0.000060595867,0.00037585397,0.000137385,0.0025347231],"genre_scores_gemma":[0.9925648,0.002031742,0.0017738568,0.000067817025,0.000015409843,0.00006527413,0.000855244,0.000014128426,0.002611792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989426,0.000016247683,0.000013458298,0.000015270041,0.00003003452,0.000030668638],"domain_scores_gemma":[0.9999685,0.0000032193564,0.0000069223684,0.000003928026,0.000003455836,0.000013948046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012916369,0.00044222354,0.00041720222,0.00032089918,0.000123438,0.00020774815,0.00023052386,0.00022485114,0.0010927905],"category_scores_gemma":[0.000058500926,0.00014028602,0.00025867342,0.00017967902,0.000101254605,0.0001491482,0.00017999728,0.00046659267,0.0003896711],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002894201,0.00017351194,0.000330421,0.00006114028,0.00001460754,0.00007964225,0.000005951538,0.00011629538,0.9924976,0.000092304974,0.000176896,0.0061622807],"study_design_scores_gemma":[0.00015666184,0.0011678917,0.0045825234,0.000007168511,0.00003316656,0.00086766796,0.000012079218,0.0018678835,0.9867526,0.000031066273,0.00451572,0.0000054855527],"about_ca_topic_score_codex":0.0003857726,"about_ca_topic_score_gemma":0.0010039728,"teacher_disagreement_score":0.0010927905,"about_ca_system_score_codex":0.00022082943,"about_ca_system_score_gemma":0.00019782115,"threshold_uncertainty_score":0.0036557317},"labels":[],"label_agreement":null},{"id":"W4294992606","doi":"10.1139/bcb-2022-0099","title":"HER2 induces cell scattering and invasion through ∆Np63α and E-cadherin","year":2022,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cell migration; Metastasis; Cancer research; Cell growth; Transfection; Cell; Biology; Downregulation and upregulation; Cancer; Cell culture; Genetics; Gene","score_opus":0.040440815122009116,"score_gpt":0.31292957342054534,"score_spread":0.27248875829853625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294992606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952508,0.0010055262,0.0012447054,0.00009009176,0.000021970522,0.00001626525,0.00007971685,0.0000395698,0.0022513987],"genre_scores_gemma":[0.99391806,0.0007322847,0.00079284335,0.0000635255,0.000006294215,0.000022352224,0.00025568568,0.000007488343,0.004201453],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998814,0.000018020162,0.0000070271135,0.000012339063,0.000049244958,0.000032038257],"domain_scores_gemma":[0.99995935,0.000007593505,0.000008990418,0.0000056863346,0.0000054238476,0.000012993329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008346101,0.0002563271,0.00013783116,0.00015361073,0.00011517451,0.0001480495,0.00009965065,0.00014753977,0.0010125755],"category_scores_gemma":[0.00006335843,0.00010537088,0.00023691905,0.00009976217,0.00013641694,0.00012325864,0.00015411733,0.0003996007,0.00020922413],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004892216,0.00003318242,0.00009106853,0.000014377782,0.0000019931394,0.000042612395,0.000007121762,0.000025540325,0.99899215,0.000056016892,0.000028672604,0.00065832975],"study_design_scores_gemma":[0.000014186519,0.00027037953,0.005813356,0.000004101356,0.000005425047,0.00020404221,0.000029553037,0.0010677592,0.99051535,0.00005346293,0.002019885,0.0000025877737],"about_ca_topic_score_codex":0.00090704864,"about_ca_topic_score_gemma":0.0015611323,"teacher_disagreement_score":0.0010125755,"about_ca_system_score_codex":0.00017257387,"about_ca_system_score_gemma":0.00016233826,"threshold_uncertainty_score":0.0033873916},"labels":[],"label_agreement":null},{"id":"W4295679167","doi":"10.1007/s00280-022-04471-x","title":"Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Dosing; Pharmacokinetics; Medicine; Population; Body surface area; Cancer; Internal medicine; Pharmacology; Oncology","score_opus":0.035151670659454175,"score_gpt":0.43091332078514066,"score_spread":0.3957616501256865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295679167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700016,0.0009852501,0.0007184296,0.00012316096,0.000015681204,0.000029110248,0.0002420605,0.00005265237,0.000833513],"genre_scores_gemma":[0.99834573,0.0003435867,0.00031800117,0.00012062529,0.00002608558,0.000025676483,0.0003818107,0.000018831954,0.0004196479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995902,0.0001518753,0.000020687676,0.000097507036,0.00007707779,0.00006257697],"domain_scores_gemma":[0.9995883,0.00013079029,0.000112697315,0.000052045623,0.000033748503,0.000082414015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006204803,0.00030666438,0.0009031111,0.00022077658,0.00019082044,0.0006917155,0.00019141487,0.0004088152,0.000932548],"category_scores_gemma":[0.0019722474,0.0003701139,0.00045112378,0.00028991752,0.00022421873,0.0006796437,0.00023279978,0.0012523493,0.00019883418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17894642,0.0027500812,0.577362,0.00023064298,0.0039861933,0.0007055852,0.00086501974,0.010884364,0.06167889,0.0009229794,0.004190916,0.15747693],"study_design_scores_gemma":[0.0046695704,0.029445373,0.93688345,0.000026435106,0.001623983,0.0015101234,0.0002782188,0.012135785,0.0055778073,0.0008566604,0.0069007827,0.000091831025],"about_ca_topic_score_codex":0.0010600307,"about_ca_topic_score_gemma":0.0013031699,"teacher_disagreement_score":0.0010600307,"about_ca_system_score_codex":0.00056461495,"about_ca_system_score_gemma":0.0005033008,"threshold_uncertainty_score":0.0040966272},"labels":[],"label_agreement":null},{"id":"W4295837361","doi":"10.1016/j.annonc.2022.07.1858","title":"274TiP Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Drug; Cancer; Gynecology; Pharmacology","score_opus":0.06520598839853473,"score_gpt":0.41253695573535093,"score_spread":0.34733096733681623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871116,0.002397383,0.0003534065,0.001094416,0.0002929541,0.000073353236,0.0005785208,0.00003301821,0.008065186],"genre_scores_gemma":[0.99589086,0.0007470608,0.00030221735,0.00031653835,0.000076009645,0.000038460235,0.00040292897,0.0000098225655,0.0022159743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996835,0.00015594704,0.000015955016,0.00004780727,0.0000281322,0.00006872578],"domain_scores_gemma":[0.9995678,0.00021819389,0.00006423863,0.000021579759,0.000014264805,0.00011392951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005618524,0.00025552945,0.00048210332,0.00019092509,0.00013113266,0.00058184454,0.00027339984,0.00042865568,0.009429504],"category_scores_gemma":[0.0012460722,0.00011326288,0.0005925462,0.00021202641,0.00030439033,0.00044390257,0.00019191268,0.001174617,0.0005530695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69136554,0.0044491263,0.0148337055,0.00035882293,0.0011685845,0.00019656136,0.0001093648,0.0041010454,0.008160435,0.0019901309,0.0073650344,0.2659016],"study_design_scores_gemma":[0.23239282,0.47779512,0.12535794,0.0007040048,0.00791218,0.00218222,0.0011612657,0.043558896,0.028893594,0.008097349,0.07177225,0.00017237183],"about_ca_topic_score_codex":0.0011729666,"about_ca_topic_score_gemma":0.0034653728,"teacher_disagreement_score":0.009429504,"about_ca_system_score_codex":0.00074031233,"about_ca_system_score_gemma":0.0006975769,"threshold_uncertainty_score":0.031544864},"labels":[],"label_agreement":null},{"id":"W4295872731","doi":"10.5858/arpa.2022-0031-ra","title":"A Consortium for Analytic Standardization in Immunohistochemistry","year":2022,"lang":"en","type":"review","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health Quality Council; Saskatchewan Health Authority","funders":"National Cancer Institute; National Institutes of Health","keywords":"Standardization; Immunohistochemistry; Pathology; Medicine; Computer science","score_opus":0.06853813911439628,"score_gpt":0.44192988354096086,"score_spread":0.3733917444265646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295872731","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0081027765,0.015882995,0.23734936,0.54734004,0.05418375,0.01395444,0.003459234,0.0040354505,0.11569192],"genre_scores_gemma":[0.06975704,0.013461949,0.5838725,0.124878846,0.020908447,0.014423162,0.022948584,0.0045831096,0.1451664],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.7880331,0.083865404,0.018668909,0.012044143,0.08650363,0.010884753],"domain_scores_gemma":[0.47989073,0.043582648,0.024494404,0.067016825,0.31909025,0.06592522],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.30926806,0.0020789327,0.0018155859,0.008136183,0.007243379,0.021853728,0.0101581635,0.009687452,0.015320166],"category_scores_gemma":[0.15966162,0.0014953163,0.0030987924,0.0073161367,0.0087147085,0.010261181,0.020429837,0.01631947,0.010799772],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036744835,0.00050334376,0.004769744,0.00096336636,0.00014611305,0.00052494934,0.0014865879,0.001107847,0.0047830907,0.1104166,0.619415,0.2555159],"study_design_scores_gemma":[0.000085191394,0.00013143524,0.002124925,0.001109888,0.00004587293,0.0003141514,0.00049817946,0.00097103976,0.0021512692,0.014413177,0.9780797,0.00007512187],"about_ca_topic_score_codex":0.011162299,"about_ca_topic_score_gemma":0.00905457,"teacher_disagreement_score":0.30926806,"about_ca_system_score_codex":0.012123709,"about_ca_system_score_gemma":0.17290966,"threshold_uncertainty_score":0.85179543},"labels":[],"label_agreement":null},{"id":"W4296246565","doi":"10.3390/pharmaceutics14091917","title":"Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates","year":2022,"lang":"en","type":"article","venue":"Pharmaceutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Nimotuzumab; Monoclonal antibody; Epitope; Epidermal growth factor receptor; Biodistribution; Conjugate; Chemistry; Antibody; Cancer research; Antibody-drug conjugate; Pharmacology; Immunohistochemistry; Molecular biology; Receptor; Medicine; In vitro; Immunology; Biochemistry; Biology","score_opus":0.11598252000600795,"score_gpt":0.42953738690281595,"score_spread":0.313554866896808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296246565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95732397,0.0047069974,0.034580056,0.00014041172,0.00004229818,0.00013520375,0.0002597877,0.00026446927,0.0025467353],"genre_scores_gemma":[0.97015107,0.0017179535,0.024598075,0.00007766419,0.000016729908,0.0001312833,0.00033154013,0.000037380254,0.0029382212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977237,0.000036963327,0.000010305363,0.00007393479,0.00006932336,0.000037179834],"domain_scores_gemma":[0.9999548,0.0000075811267,0.000015761489,0.0000058686583,0.000006625904,0.000009276028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022238411,0.00035367857,0.00053600146,0.00022355445,0.00009025681,0.00035390205,0.000380978,0.0004524381,0.0004970384],"category_scores_gemma":[0.00012453563,0.00019958177,0.00028913686,0.00022777972,0.0001509816,0.00026739892,0.00025892732,0.00037280557,0.0001789312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011365383,0.000028576616,0.00018000277,0.000033083703,0.000008937392,0.00004321212,0.000009241617,0.0002145461,0.9965778,0.000054848868,0.000052302978,0.0026837569],"study_design_scores_gemma":[0.000022488191,0.0003001226,0.0014643831,0.000002078048,0.000020788797,0.00025812446,0.0000063888856,0.0028076565,0.9933524,0.000019095254,0.0017417895,0.000004646081],"about_ca_topic_score_codex":0.00069414603,"about_ca_topic_score_gemma":0.0011601417,"teacher_disagreement_score":0.00069414603,"about_ca_system_score_codex":0.00050468196,"about_ca_system_score_gemma":0.00018358245,"threshold_uncertainty_score":0.0036617517},"labels":[],"label_agreement":null},{"id":"W4299117194","doi":"","title":"Trastuzumab (T) and everolimus (E) pharmacokinetics (PK) in HER2 positive (+) primary breast cancer (BC) patients (pts): Unicancer RADHER trial results","year":2013,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Trastuzumab; Everolimus; Medicine; Breast cancer; Pharmacokinetics; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.02166874102913106,"score_gpt":0.3020995897932127,"score_spread":0.28043084876408164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299117194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858575,0.005979766,0.00035903996,0.0011379523,0.00009074368,0.0002044219,0.002354553,0.00009147895,0.0039245263],"genre_scores_gemma":[0.9871952,0.0033447456,0.0007399162,0.00063093443,0.0001549655,0.00031287837,0.0029779156,0.0000551723,0.0045883427],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999678,0.000206552,0.000013644098,0.000042828553,0.000020781405,0.000038316946],"domain_scores_gemma":[0.999587,0.00012790311,0.00008505125,0.000049680406,0.000023242408,0.00012712376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010261446,0.0004898228,0.0013457001,0.000116248535,0.00012378738,0.0006161128,0.00028511861,0.00045932847,0.0038630299],"category_scores_gemma":[0.0015057764,0.0001706245,0.00075007416,0.00024933854,0.0002734577,0.00055030966,0.0002843791,0.0011121321,0.00050670205],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81476456,0.0030823683,0.0070863846,0.0008220624,0.0017627181,0.0002079441,0.00013389772,0.003907042,0.008057626,0.00041556967,0.011348936,0.14841095],"study_design_scores_gemma":[0.7432438,0.1425305,0.061419886,0.00028039239,0.0076440214,0.0011382169,0.0001511891,0.0047562853,0.007403567,0.0021554085,0.0291825,0.00009420674],"about_ca_topic_score_codex":0.0005860237,"about_ca_topic_score_gemma":0.0013605328,"teacher_disagreement_score":0.0038630299,"about_ca_system_score_codex":0.0005607396,"about_ca_system_score_gemma":0.0006365269,"threshold_uncertainty_score":0.012923121},"labels":[],"label_agreement":null},{"id":"W4300137879","doi":"","title":"Activation of P38MAP kinase in estrogen-positive invasive breast cancers: Relation with HER2 and downstream signaling phosphorylated proteins expression","year":2013,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Phosphorylation; Cancer research; Kinase; Estrogen; Downstream (manufacturing); Protein kinase A; Signal transduction; Cell biology; Chemistry; Biology; Internal medicine; Medicine","score_opus":0.015341786391121565,"score_gpt":0.2559631362785085,"score_spread":0.2406213498873869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300137879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965172,0.0018399865,0.00035208644,0.00008547153,0.000012630108,0.0000065271174,0.00023781274,0.000014386148,0.0009339835],"genre_scores_gemma":[0.99635637,0.001003894,0.00022676171,0.000018301856,0.000026393811,0.000015102208,0.00028057952,0.0000043758805,0.002068346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999101,0.000011927583,0.00000549758,0.000019643518,0.000023095801,0.000029719522],"domain_scores_gemma":[0.99988043,0.000021841546,0.000034660057,0.000008005874,0.000019257312,0.000035667472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016552978,0.00020799293,0.00020720217,0.00047267732,0.00021972344,0.0004372904,0.00013167321,0.00026203564,0.003593324],"category_scores_gemma":[0.00028991228,0.00014073217,0.0001888783,0.0004046564,0.00023556665,0.0002688781,0.00021980223,0.00040979026,0.0005358513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010452354,0.0008028866,0.13761851,0.0004975438,0.00012887685,0.002416553,0.00059238647,0.0003644492,0.81572914,0.0005882991,0.0010670199,0.02974196],"study_design_scores_gemma":[0.00010016397,0.0010283382,0.7926586,0.000022338221,0.00012226249,0.004974106,0.00076643453,0.0010600677,0.19501226,0.0009842749,0.0032522294,0.000018814688],"about_ca_topic_score_codex":0.0002563452,"about_ca_topic_score_gemma":0.00020239055,"teacher_disagreement_score":0.003593324,"about_ca_system_score_codex":0.00019931402,"about_ca_system_score_gemma":0.0001922132,"threshold_uncertainty_score":0.012020886},"labels":[],"label_agreement":null},{"id":"W4304127970","doi":"10.1016/j.jaad.2022.10.005","title":"Prognostic factors for the development of acneiform eruptions in patients on epidermal growth factor receptor inhibitors","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Dermatology; Epidermal growth factor receptor; Receptor; Internal medicine","score_opus":0.0506189236224899,"score_gpt":0.3628806373907033,"score_spread":0.31226171376821343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304127970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970396,0.00094151584,0.00009136461,0.0001247436,0.0000340899,0.000007939375,0.00026640407,0.00000959928,0.0014846709],"genre_scores_gemma":[0.99937785,0.00015112171,0.00003652705,0.00002249467,0.000051276576,0.0000034648197,0.00017488579,0.00000216438,0.00018018947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996451,0.00007903182,0.000035655066,0.000060941613,0.00007211868,0.00010721393],"domain_scores_gemma":[0.9972691,0.0007162138,0.0010900592,0.00012124955,0.00017463331,0.00062872935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045096746,0.0003609572,0.00050789356,0.00085276004,0.00058346614,0.00093079795,0.0003645296,0.00085887156,0.0031251544],"category_scores_gemma":[0.002803304,0.0002877185,0.0007048294,0.001316166,0.00038715027,0.00071072794,0.00035279008,0.0012644822,0.00038215765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003321293,0.000034622033,0.9979267,0.0000048484058,0.000037379905,0.00015831235,0.000012010406,0.000057655783,0.00021333527,0.0000162408,0.000100495374,0.0011062396],"study_design_scores_gemma":[0.000019785477,0.0001346252,0.9980311,0.0000054914162,0.00006687662,0.0008919077,0.00008581504,0.0003933505,0.00008246119,0.000044636956,0.00023782538,0.000006067879],"about_ca_topic_score_codex":0.0014206655,"about_ca_topic_score_gemma":0.0016630184,"teacher_disagreement_score":0.0031251544,"about_ca_system_score_codex":0.00026620235,"about_ca_system_score_gemma":0.00041128095,"threshold_uncertainty_score":0.010454714},"labels":[],"label_agreement":null},{"id":"W4306155108","doi":"10.1016/j.ccell.2022.09.016","title":"The therapeutic window of antibody drug conjugates: A dogma in need of revision","year":2022,"lang":"en","type":"article","venue":"Cancer Cell","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Drug; Therapeutic window; Conjugate; Maximum tolerated dose; Pharmacology; Antibody; Medicine; Antibody-drug conjugate; Computational biology; Pharmacokinetics; Immunology; Monoclonal antibody; Biology","score_opus":0.026803969198095252,"score_gpt":0.3725866003387929,"score_spread":0.3457826311406976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306155108","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032328109,0.23915601,0.007957627,0.7010403,0.042321824,0.000048092636,0.00016181251,0.00024434197,0.0058371956],"genre_scores_gemma":[0.09319964,0.22142622,0.023212822,0.4600172,0.18965258,0.00039718498,0.00020785171,0.00032700755,0.011559548],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99133646,0.0025646533,0.0016482392,0.0010511163,0.0028503595,0.0005490912],"domain_scores_gemma":[0.94344604,0.0358649,0.002225735,0.0034267653,0.012793236,0.0022433673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.043878745,0.0009622515,0.0037219299,0.001286012,0.0025470522,0.007524224,0.0054446016,0.016507596,0.004396229],"category_scores_gemma":[0.04220421,0.0005626981,0.0013425132,0.00078712346,0.019039247,0.02165792,0.0032896444,0.026482306,0.0020465485],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009117721,0.0003725643,0.0010527673,0.004321403,0.00027837727,0.0015367311,0.0018839065,0.0014342534,0.007073564,0.3590166,0.34427828,0.27783978],"study_design_scores_gemma":[0.00016079868,0.00034593215,0.0005013906,0.0013871975,0.00011822476,0.0012043834,0.0009951883,0.0011956964,0.0013625291,0.24587041,0.74669033,0.00016791942],"about_ca_topic_score_codex":0.002022316,"about_ca_topic_score_gemma":0.0023880906,"teacher_disagreement_score":0.043878745,"about_ca_system_score_codex":0.0042839916,"about_ca_system_score_gemma":0.007228584,"threshold_uncertainty_score":0.23205578},"labels":[],"label_agreement":null},{"id":"W4306739715","doi":"10.1016/j.breast.2022.10.007","title":"Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer","year":2022,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Genentech; PharmaMar; G1 Therapeutics; MacroGenics; Pfizer; Incyte; NuCana; Seagen; Relay Therapeutics; Plexxikon; Ontario Brain Institute; Syndax Pharmaceuticals; Regeneron Pharmaceuticals; Amgen; Radius Health; Gilead Sciences; Merck; Mersana Therapeutics; Novartis; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Roche; Astellas Pharma US","keywords":"Medicine; Metastatic breast cancer; Antibody-drug conjugate; Drug; Cancer; Antibody; Breast cancer; Oncology; Conjugate; Drug development; Cancer research; Internal medicine; Pharmacology; Immunology; Monoclonal antibody","score_opus":0.05927251587468007,"score_gpt":0.42484980232567876,"score_spread":0.3655772864509987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306739715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6910909,0.23811089,0.02640375,0.0042301673,0.00077842124,0.0019550861,0.0015847969,0.0010956706,0.03475032],"genre_scores_gemma":[0.8755597,0.09617613,0.014127999,0.0016048313,0.00026271658,0.00063909177,0.0021558108,0.00008758259,0.00938612],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998466,0.00004304499,0.0000073694205,0.000022266693,0.000045683148,0.000035076697],"domain_scores_gemma":[0.99983,0.000026508014,0.000026468128,0.0000078053845,0.00004034641,0.00006876942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092874584,0.00040584354,0.00041608795,0.00038151606,0.00013638273,0.0005634024,0.0003281041,0.0006336247,0.002194352],"category_scores_gemma":[0.0005622419,0.00019320947,0.00023824032,0.00039462018,0.000251719,0.00042500877,0.0003144311,0.0009133875,0.0008060725],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030093323,0.0026289236,0.0022302312,0.0010041167,0.000092433496,0.0008567265,0.00037103813,0.0027151362,0.2729343,0.003298296,0.0107472185,0.70011234],"study_design_scores_gemma":[0.013097428,0.07298602,0.023070585,0.00056810013,0.00029975772,0.00986474,0.0001821946,0.00895739,0.29663777,0.0020190228,0.57220465,0.00011228571],"about_ca_topic_score_codex":0.00072932395,"about_ca_topic_score_gemma":0.0012133468,"teacher_disagreement_score":0.002194352,"about_ca_system_score_codex":0.0004312106,"about_ca_system_score_gemma":0.00054885313,"threshold_uncertainty_score":0.007340789},"labels":[],"label_agreement":null},{"id":"W4308016405","doi":"10.1186/s12885-022-10206-1","title":"Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients","year":2022,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Roche Canada","keywords":"Surgical oncology; Medicine; Internal medicine; Cancer; Oncology; Association (psychology); General surgery","score_opus":0.06354620483384012,"score_gpt":0.3958588212015545,"score_spread":0.3323126163677144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308016405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992742,0.0002463639,0.000025822146,0.00001732336,0.000002969517,0.0000043644036,0.00026802366,0.000001265237,0.0001595753],"genre_scores_gemma":[0.99945146,0.00011562975,0.000034537148,0.000011068611,0.000006396802,0.000005881399,0.00031417457,5.314057e-7,0.000060299604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997422,0.00005485474,0.000035348585,0.00006647534,0.000050620652,0.000050397055],"domain_scores_gemma":[0.999353,0.00012136985,0.0003101872,0.000025930942,0.000088124645,0.000101309604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004022478,0.00012646626,0.00020101432,0.00094781816,0.00021604479,0.00035982375,0.00018995581,0.00017118329,0.0013246969],"category_scores_gemma":[0.00091141666,0.00012156241,0.00014016514,0.0006667029,0.00013405035,0.00022937173,0.00022957039,0.00017363303,0.0001184909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001860706,0.0000056620092,0.99933857,0.0000040662308,0.0000057014126,0.000052268515,0.000020765672,0.000008536133,0.000072079725,0.0000023929138,0.000023012723,0.00044842606],"study_design_scores_gemma":[0.0000019277186,0.000031191597,0.99912184,0.0000042000293,0.0000070660303,0.00042853865,0.00019227303,0.00004475778,0.00004153345,0.00000427363,0.00012112395,0.0000013317219],"about_ca_topic_score_codex":0.0040322538,"about_ca_topic_score_gemma":0.004583786,"teacher_disagreement_score":0.0040322538,"about_ca_system_score_codex":0.0003392392,"about_ca_system_score_gemma":0.00023672392,"threshold_uncertainty_score":0.00801754},"labels":[],"label_agreement":null},{"id":"W4308254239","doi":"10.1200/jco.21.02937","title":"Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"MacroGenics; University of Washington","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Internal medicine; Overall survival; Randomized controlled trial; Cancer","score_opus":0.1259646493750785,"score_gpt":0.49088681888886,"score_spread":0.3649221695137815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308254239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98732436,0.005288199,0.00048658083,0.00073121313,0.00029291218,0.0017535739,0.0006957762,0.000069753514,0.0033575618],"genre_scores_gemma":[0.989176,0.0024766957,0.0015091345,0.0014312073,0.0003518554,0.0019331193,0.0012707933,0.000014986953,0.00183629],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993299,0.00043601665,0.000048996284,0.00007569914,0.000048343925,0.00006107312],"domain_scores_gemma":[0.9993243,0.00018995696,0.00022106242,0.00004583738,0.000047904126,0.00017094423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027224491,0.00050430035,0.0010504003,0.00018361992,0.00020954777,0.00062517537,0.00028115883,0.00067835243,0.0023472358],"category_scores_gemma":[0.0015968211,0.00026127425,0.0018844042,0.00013359773,0.00037099922,0.00038525235,0.0002843612,0.0013111669,0.00033800246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91935444,0.0057825814,0.0044557196,0.0013103471,0.0030003171,0.00008053345,0.00018000924,0.0008830229,0.0063767866,0.00030527852,0.0029662605,0.055304732],"study_design_scores_gemma":[0.6558301,0.30775973,0.024122156,0.0002531706,0.0028080747,0.0002341338,0.0000525151,0.0016785075,0.0018721919,0.0003365972,0.0050104195,0.00004234962],"about_ca_topic_score_codex":0.0005151955,"about_ca_topic_score_gemma":0.002257857,"teacher_disagreement_score":0.0027224491,"about_ca_system_score_codex":0.00050981186,"about_ca_system_score_gemma":0.00078865775,"threshold_uncertainty_score":0.0143978},"labels":[],"label_agreement":null},{"id":"W4309412600","doi":"10.1016/s1470-2045(22)00621-0","title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Trastuzumab; Adverse effect; Bispecific antibody; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research; Cancer; Monoclonal antibody; Antibody; Breast cancer; Immunology","score_opus":0.2538568129815828,"score_gpt":0.5097609920992456,"score_spread":0.25590417911766283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309412600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806637,0.009637418,0.0011195455,0.0010757409,0.00023911383,0.0013540605,0.001484361,0.00016968086,0.004256353],"genre_scores_gemma":[0.9705173,0.012767815,0.0034198433,0.0018778822,0.00012892672,0.0011823222,0.0030845483,0.00009019991,0.0069312253],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972004,0.000097770375,0.000011069263,0.000038591217,0.00004499649,0.00008745253],"domain_scores_gemma":[0.99977905,0.000036841175,0.000048644448,0.000022566908,0.00001657908,0.00009637969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013287865,0.0011082048,0.0015031542,0.0004513504,0.00028286374,0.00093304255,0.00077071873,0.0008464645,0.0027225346],"category_scores_gemma":[0.0005228534,0.0005115482,0.0011655039,0.00047317432,0.0006548289,0.00085570005,0.00028956888,0.0032978612,0.0006489129],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34653217,0.05756346,0.0073034316,0.002536609,0.003319026,0.0004017234,0.0006457659,0.010982722,0.11058601,0.0018805867,0.01842643,0.43982205],"study_design_scores_gemma":[0.65752846,0.277361,0.02091561,0.00014483921,0.0019954385,0.0008720714,0.0001584245,0.0041914596,0.014883153,0.00087340345,0.02096942,0.00010679906],"about_ca_topic_score_codex":0.0020169772,"about_ca_topic_score_gemma":0.0071771224,"teacher_disagreement_score":0.0027225346,"about_ca_system_score_codex":0.0010539668,"about_ca_system_score_gemma":0.001147301,"threshold_uncertainty_score":0.009107769},"labels":[],"label_agreement":null},{"id":"W4311302338","doi":"10.1016/j.breast.2022.12.003","title":"Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer","year":2022,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; McGill University Health Centre","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Loperamide; Diarrhea; Internal medicine; Incidence (geometry); Discontinuation; Gastroenterology; Tolerability; Oncology; Breast cancer; Adverse effect; Cancer; Trastuzumab","score_opus":0.02128492988764032,"score_gpt":0.31009708585149054,"score_spread":0.28881215596385024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311302338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95681643,0.014918544,0.0023681375,0.0020982753,0.0007017392,0.010323791,0.004900684,0.0002128494,0.0076595615],"genre_scores_gemma":[0.9822165,0.0023306378,0.002019002,0.0015590499,0.00039890996,0.0045388904,0.00389962,0.000027077205,0.0030103738],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984871,0.00084950746,0.00015220579,0.00023777845,0.00013072832,0.00014266605],"domain_scores_gemma":[0.99821067,0.0005877791,0.0004377937,0.00020116809,0.00024101157,0.00032166843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037348699,0.0012939108,0.0018444406,0.000281087,0.0002578596,0.0010550397,0.0008655289,0.0011147493,0.004549842],"category_scores_gemma":[0.0037998452,0.00026313544,0.0024389904,0.00023062983,0.00049277925,0.00062356296,0.00032434217,0.001806649,0.00046776189],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9252587,0.0057753953,0.0024631852,0.0010820738,0.0034096774,0.00007156679,0.000067732624,0.0006144312,0.0034922305,0.00021910113,0.0037862097,0.05375974],"study_design_scores_gemma":[0.9068494,0.0788233,0.008154871,0.00010748395,0.0017482502,0.00006250916,0.000017237677,0.00039457003,0.0010975477,0.00021145791,0.0025162562,0.000017067294],"about_ca_topic_score_codex":0.0006711934,"about_ca_topic_score_gemma":0.0013433383,"teacher_disagreement_score":0.004549842,"about_ca_system_score_codex":0.00052515464,"about_ca_system_score_gemma":0.0010501471,"threshold_uncertainty_score":0.019752145},"labels":[],"label_agreement":null},{"id":"W4311497732","doi":"10.1016/j.jval.2022.09.242","title":"CO166 Clinical Outcomes of Patients With Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Cancer Treated With Non-Tropomyosin Recepter Kinase Inhibitors: A Systematic Literature Review","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Trk receptor; Medicine; Fusion gene; Tropomyosin receptor kinase B; Tropomyosin receptor kinase C; Tyrosine kinase; Oncology; Receptor tyrosine kinase; Clinical trial; Internal medicine; Kinase; Tropomyosin receptor kinase A; Neurotrophin; Bioinformatics; Cancer research; Gene; Receptor; Biology; Neurotrophic factors; Genetics; Platelet-derived growth factor receptor","score_opus":0.050287907902456706,"score_gpt":0.3700510836361082,"score_spread":0.31976317573365154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311497732","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0090909265,0.98857516,0.00008631711,0.00018949158,0.00008385095,0.00008317938,0.001581462,0.0000037569102,0.0003058617],"genre_scores_gemma":[0.19633998,0.7992868,0.0005986669,0.0014084197,0.00018953723,0.00035819664,0.0015698241,0.000008685939,0.00023989749],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9961747,0.00082473335,0.0018423563,0.00054940867,0.000442373,0.00016647135],"domain_scores_gemma":[0.9912169,0.0051099476,0.0027993196,0.000128389,0.0006046305,0.00014082402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027959782,0.00075158133,0.0056345006,0.004102097,0.00035172905,0.0016675418,0.0009319445,0.001282805,0.0030072809],"category_scores_gemma":[0.0122024985,0.0005890493,0.009679541,0.0065628286,0.0005247006,0.0012020796,0.0009640565,0.0009365969,0.00020101298],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024660088,0.000075505064,0.044033058,0.7581347,0.14674757,0.00024542885,0.0002994938,0.00027059834,0.00047149736,0.00028248416,0.002646488,0.044327192],"study_design_scores_gemma":[0.0017947069,0.00076354446,0.09408394,0.27472368,0.6087099,0.0008766206,0.0007524104,0.00024870387,0.00029715343,0.0005255001,0.017070852,0.00015292618],"about_ca_topic_score_codex":0.006603743,"about_ca_topic_score_gemma":0.02265018,"teacher_disagreement_score":0.006603743,"about_ca_system_score_codex":0.0015673065,"about_ca_system_score_gemma":0.0029124233,"threshold_uncertainty_score":0.01478672},"labels":[],"label_agreement":null},{"id":"W4311621345","doi":"10.3390/curroncol29120778","title":"Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network; Ottawa Hospital; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Breast cancer; Neoadjuvant therapy; Oncology; Internal medicine; Adverse effect; Chemotherapy; Stage (stratigraphy); Guideline; Cancer; Pathology","score_opus":0.12635178229933344,"score_gpt":0.46221414231616426,"score_spread":0.3358623600168308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311621345","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009749567,0.024500921,0.0006950774,0.94141257,0.0014981376,0.00003681905,0.0005898103,0.00003196019,0.02148523],"genre_scores_gemma":[0.4343403,0.09833804,0.0051798266,0.43701255,0.0064004976,0.00011955914,0.0012239375,0.00022456043,0.017160688],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955325,0.0006290836,0.00037815038,0.00042977082,0.0018087904,0.0012217396],"domain_scores_gemma":[0.9828896,0.0032442496,0.0014276884,0.0003180437,0.007601967,0.0045184097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035275598,0.00030512863,0.0005511259,0.0012986048,0.005633229,0.0038698192,0.0019321543,0.0038223441,0.0077839238],"category_scores_gemma":[0.021456914,0.00029413853,0.00049402035,0.0022784101,0.0042516203,0.0026891246,0.0019312624,0.0067508575,0.0006686199],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002967126,0.000094868505,0.050327428,0.0011064899,0.00015558013,0.008869956,0.0043130647,0.0011667006,0.0013054458,0.078458965,0.6226355,0.23126924],"study_design_scores_gemma":[0.00015643152,0.000101694415,0.05671996,0.004609393,0.00021859563,0.008190023,0.012498105,0.002119437,0.00087494345,0.048503816,0.8656504,0.0003572352],"about_ca_topic_score_codex":0.961845,"about_ca_topic_score_gemma":0.9779926,"teacher_disagreement_score":0.059216864,"about_ca_system_score_codex":0.059216864,"about_ca_system_score_gemma":0.1378714,"threshold_uncertainty_score":0.42965043},"labels":[],"label_agreement":null},{"id":"W4312069235","doi":"10.21203/rs.3.rs-2322502/v1","title":"Development of DHES0815A; a novel HER2-directed antibody-drug conjugate comprised of a reduced potency mono-alkylating agent linked to a domain I binding HER2 antibody","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"Genentech; MacroGenics; Pfizer","keywords":"Conjugate; Potency; Antibody; Chemistry; Antibody-drug conjugate; Pharmacology; Drug; Medicine; Biochemistry; Monoclonal antibody; Immunology; In vitro; Mathematics","score_opus":0.12340316379014168,"score_gpt":0.4697713062184486,"score_spread":0.34636814242830694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312069235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635492,0.0025241543,0.024867237,0.0004535834,0.00018994759,0.0007538482,0.0009163423,0.00030182162,0.0064439205],"genre_scores_gemma":[0.9795187,0.0011171026,0.0117125185,0.00009547889,0.000014767799,0.00010702034,0.0010209105,0.000026845333,0.0063867457],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987876,0.000019042476,0.000009777559,0.000031519514,0.000036984045,0.000023895642],"domain_scores_gemma":[0.99994147,0.000005335988,0.000012169899,0.000007875197,0.000012261606,0.000020915939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003019592,0.00039168017,0.000310106,0.00018848071,0.00010182443,0.00033254625,0.0004252278,0.00040089685,0.0010701439],"category_scores_gemma":[0.00016876793,0.00022532372,0.00025806474,0.000114288574,0.00016650934,0.00026014354,0.0002157825,0.0005369436,0.00058866205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030742242,0.00030739483,0.00028725126,0.00007682702,0.000033168762,0.000120441386,0.00002836123,0.0009222285,0.97832495,0.00062244636,0.00042179634,0.01854781],"study_design_scores_gemma":[0.000109723755,0.0011745837,0.00041330306,0.0000031867105,0.000024092491,0.00026103327,0.0000045316824,0.0012770497,0.98947996,0.000027948923,0.007219381,0.0000052525097],"about_ca_topic_score_codex":0.0006743209,"about_ca_topic_score_gemma":0.00085634,"teacher_disagreement_score":0.0010701439,"about_ca_system_score_codex":0.00039249466,"about_ca_system_score_gemma":0.0003731754,"threshold_uncertainty_score":0.0035799742},"labels":[],"label_agreement":null},{"id":"W4312194612","doi":"10.3390/cells11244093","title":"A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells","year":2022,"lang":"en","type":"article","venue":"Cells","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Inhibitory postsynaptic potential; Mechanism (biology); Breast cancer; Cancer; Cancer research; Medicine; Pharmacology; Internal medicine","score_opus":0.03168771625906569,"score_gpt":0.303700326435653,"score_spread":0.2720126101765873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312194612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9269195,0.042433247,0.0149728665,0.0018902455,0.00045834226,0.00028113413,0.00095042173,0.0004340286,0.0116601065],"genre_scores_gemma":[0.9834198,0.00809693,0.0016896748,0.0003220839,0.00006894112,0.00012733144,0.00042512928,0.000012340134,0.005837868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998838,0.000011533833,0.000007990266,0.000022785323,0.000038032424,0.000035943223],"domain_scores_gemma":[0.99996746,0.000004571776,0.000008226601,0.0000049334117,0.0000069063894,0.000007949312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012320235,0.00050863286,0.00043145343,0.0002663877,0.00025020418,0.0005324046,0.00036103206,0.00048084097,0.0013337516],"category_scores_gemma":[0.00009362262,0.00014724772,0.00042854392,0.00021495599,0.00020614298,0.0003632883,0.00024536037,0.00066295103,0.0004508544],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002801513,0.00018357532,0.0006558937,0.00032088888,0.000039908784,0.0011385682,0.000059770708,0.00029293462,0.98301214,0.0031606029,0.00054612296,0.010309308],"study_design_scores_gemma":[0.00033285792,0.0006577348,0.01556879,0.00004197602,0.00009772534,0.0042190785,0.00007018541,0.0044779354,0.9535655,0.0013870107,0.019555468,0.000025793584],"about_ca_topic_score_codex":0.0005127836,"about_ca_topic_score_gemma":0.00056627335,"teacher_disagreement_score":0.0013337516,"about_ca_system_score_codex":0.0006156907,"about_ca_system_score_gemma":0.00023118505,"threshold_uncertainty_score":0.0044671297},"labels":[],"label_agreement":null},{"id":"W4316511360","doi":"10.1101/2023.01.13.523972","title":"Death by a Thousand Cuts – Combining Kinase Inhibitors for Selective Target Inhibition and Rational Polypharmacology","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of North Carolina at Chapel Hill; Genentech; Ontario Genomics; National Institutes of Health; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; Deutschen Konsortium für Translationale Krebsforschung; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; McGill University; Memorial Sloan-Kettering Cancer Center; Pfizer; Genome Canada; Damon Runyon Cancer Research Foundation","keywords":"Pharmacology; Computational biology; Biology","score_opus":0.03258838149492683,"score_gpt":0.31382389745023226,"score_spread":0.28123551595530544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316511360","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32691643,0.0025053548,0.6572932,0.0006499926,0.00011077862,0.00024576113,0.00040239553,0.0018074199,0.010068685],"genre_scores_gemma":[0.694233,0.000993898,0.29937327,0.00027432578,0.000031556865,0.000253374,0.00042600065,0.00024452744,0.0041700774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99953854,0.00007862109,0.000025913976,0.0000880805,0.00021546565,0.000053532563],"domain_scores_gemma":[0.9998448,0.000045388635,0.000040305746,0.00002090875,0.00002736613,0.000021173302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007138444,0.0007550267,0.0007197751,0.0005503986,0.00020415583,0.0008002643,0.00061941193,0.00043574668,0.0019005854],"category_scores_gemma":[0.000495862,0.00031520842,0.0005303877,0.00041582246,0.0003833402,0.000561498,0.0006692165,0.00091264286,0.0005485174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037891607,0.00038570986,0.0011425874,0.00037654466,0.00015571075,0.00013209884,0.000043209915,0.28173712,0.5535295,0.01779886,0.0026961886,0.14162359],"study_design_scores_gemma":[0.000092880466,0.00053834997,0.00048326713,0.000015122377,0.00004559304,0.00015919576,0.000013952474,0.68718165,0.29938558,0.0045799827,0.0074660606,0.000038486705],"about_ca_topic_score_codex":0.00071953604,"about_ca_topic_score_gemma":0.0011415461,"teacher_disagreement_score":0.0019005854,"about_ca_system_score_codex":0.0007795165,"about_ca_system_score_gemma":0.00045267236,"threshold_uncertainty_score":0.006358087},"labels":[],"label_agreement":null},{"id":"W4317934829","doi":"10.51731/cjht.2023.551","title":"Trastuzumab Deruxtecan (Enhertu)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Reimbursement; Medicine; Regimen; Adjuvant; Oncology; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Metastatic breast cancer; Cancer; Health care","score_opus":0.10286531305846934,"score_gpt":0.398326580389078,"score_spread":0.2954612673306086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317934829","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016183332,0.747167,0.0015477058,0.008441798,0.0015340731,0.0003091224,0.0030221855,0.00021549076,0.22157937],"genre_scores_gemma":[0.20513052,0.5653984,0.004420662,0.008187304,0.00068714964,0.00021609858,0.0047614696,0.00005083552,0.21114756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999653,0.000071878516,0.000026601116,0.000036016954,0.00017072914,0.000041750605],"domain_scores_gemma":[0.99972576,0.000054327604,0.00005138863,0.000008711993,0.00012702383,0.000032726683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006169733,0.00021860925,0.00024161696,0.00080988865,0.00020520734,0.0006623139,0.00032411463,0.00031566314,0.010699157],"category_scores_gemma":[0.00076663535,0.00006474984,0.0003032572,0.0005941234,0.0002311033,0.00032253642,0.00025479402,0.00043187372,0.0015065561],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039087638,0.000044232936,0.00096400926,0.0025044794,0.00009532553,0.00015509661,0.00003710672,0.0003244801,0.0031156072,0.0052278657,0.08635024,0.90079063],"study_design_scores_gemma":[0.00015785317,0.00024119964,0.0041625435,0.001324285,0.00009870542,0.00040641893,0.000031017866,0.0001548474,0.003952825,0.00040743125,0.98905116,0.000011724337],"about_ca_topic_score_codex":0.037437502,"about_ca_topic_score_gemma":0.118663855,"teacher_disagreement_score":0.037437502,"about_ca_system_score_codex":0.0032830548,"about_ca_system_score_gemma":0.0028770566,"threshold_uncertainty_score":0.07443917},"labels":[],"label_agreement":null},{"id":"W4318696356","doi":"10.26508/lsa.202201644","title":"The ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth","year":2023,"lang":"en","type":"article","venue":"Life Science Alliance","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund; Fundação para a Ciência e a Tecnologia; Queen's University; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; “la Caixa” Foundation; Queen's University Belfast; Worldwide Cancer Research","keywords":"Cell biology; Cancer research; Biology","score_opus":0.060158230119526986,"score_gpt":0.36024009416225755,"score_spread":0.3000818640427306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318696356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885627,0.005206726,0.0026338713,0.000359975,0.000047364847,0.000026361477,0.0003365794,0.00012818351,0.0026981656],"genre_scores_gemma":[0.9937627,0.001977608,0.0011663666,0.00006537323,0.000018194429,0.000017566277,0.0002625391,0.000019751991,0.0027099124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999137,0.000014326589,0.0000063004927,0.000015881456,0.000022190365,0.000027581822],"domain_scores_gemma":[0.9999403,0.000003888245,0.000021088445,0.000005079582,0.000007013962,0.000022579225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011093747,0.00031908066,0.00020446615,0.00024451848,0.00013970387,0.0002960951,0.00014737934,0.00020771251,0.0012823512],"category_scores_gemma":[0.00008428425,0.000078462646,0.00018838799,0.00009738276,0.00024497233,0.00021563545,0.00015673916,0.0005140045,0.00025614045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029300884,0.000041252773,0.0005350103,0.000047358328,0.000008915243,0.00015676634,0.000013477377,0.000089157584,0.99426454,0.00027996587,0.00016568425,0.0041049896],"study_design_scores_gemma":[0.00006191601,0.0006061422,0.014820726,0.000018258526,0.000048695765,0.0009702535,0.00005528609,0.0009589635,0.9735065,0.00021371873,0.008733169,0.0000062368695],"about_ca_topic_score_codex":0.00028547086,"about_ca_topic_score_gemma":0.00046665495,"teacher_disagreement_score":0.0012823512,"about_ca_system_score_codex":0.0002883262,"about_ca_system_score_gemma":0.00018470107,"threshold_uncertainty_score":0.004289925},"labels":[],"label_agreement":null},{"id":"W4318926335","doi":"10.1158/1078-0432.ccr-22-1989","title":"Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Adjuvant; Biomarker; Internal medicine; Adjuvant therapy; Neoadjuvant therapy; Cancer; Biology","score_opus":0.5670680553339,"score_gpt":0.6237006534623429,"score_spread":0.0566325981284429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318926335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963414,0.0015875493,0.00016563956,0.00014327733,0.000020353631,0.00013742915,0.0011402244,0.00000951672,0.00045451443],"genre_scores_gemma":[0.9933914,0.00065719703,0.00045449543,0.00030570396,0.000033285545,0.00025083555,0.003983785,0.000008896191,0.0009144901],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986833,0.0008406936,0.00006707348,0.00017446768,0.00015690451,0.00007767529],"domain_scores_gemma":[0.9979253,0.0007263502,0.0005751821,0.00023652456,0.00012263666,0.00041400455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004258445,0.00048392423,0.0012782898,0.00018005684,0.00020893708,0.00079091213,0.0005887645,0.00061253615,0.0012037944],"category_scores_gemma":[0.002733581,0.00026219332,0.0010347768,0.00032515766,0.00040343078,0.00045261453,0.00037445652,0.0007907452,0.0002666507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7464586,0.004594681,0.17348345,0.00074267737,0.014008242,0.0001474014,0.00025722294,0.0016272774,0.013775885,0.00015377277,0.0022982378,0.04245256],"study_design_scores_gemma":[0.16419001,0.13707791,0.67501265,0.00011193087,0.009579664,0.00044955517,0.00015745303,0.0014379941,0.0050426093,0.0002285416,0.0066398717,0.00007179573],"about_ca_topic_score_codex":0.0011476055,"about_ca_topic_score_gemma":0.002675836,"teacher_disagreement_score":0.004258445,"about_ca_system_score_codex":0.0006178716,"about_ca_system_score_gemma":0.0007196969,"threshold_uncertainty_score":0.022521019},"labels":[],"label_agreement":null},{"id":"W4319164392","doi":"10.1016/j.trecan.2023.01.003","title":"Antibody–drug conjugates: in search of partners of choice","year":2023,"lang":"en","type":"review","venue":"Trends in cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Toronto; Conquer Cancer Foundation","keywords":"Drug; Antibody-drug conjugate; Computational biology; Pharmacology; Medicine; Antibody; Cancer research; Monoclonal antibody; Immunology; Biology","score_opus":0.36880977156407213,"score_gpt":0.6077878399316997,"score_spread":0.23897806836762758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319164392","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003710022,0.99347734,0.0012898212,0.00069120055,0.00038377004,0.00001890478,0.000043824213,0.00003257739,0.0036914814],"genre_scores_gemma":[0.0022053695,0.99256694,0.0010225055,0.00067160936,0.00021253293,0.000022989154,0.000076279444,0.000007054221,0.0032146822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997485,0.000051997056,0.00001949553,0.000049716404,0.00010035789,0.000029828574],"domain_scores_gemma":[0.99979347,0.00008163188,0.000032476495,0.000009937811,0.000053428845,0.000029197265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007929882,0.0009480078,0.0012149145,0.0014626343,0.00022745482,0.0014129477,0.0008601651,0.0011940991,0.00597681],"category_scores_gemma":[0.00057037926,0.00039604664,0.00037845585,0.0016351389,0.00056675845,0.0028863885,0.0010365862,0.0027967282,0.0046424563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009403377,0.0001072976,0.00011209884,0.011543938,0.00008347639,0.00025228542,0.00008054849,0.0007415979,0.0097085275,0.030710323,0.038494054,0.90807176],"study_design_scores_gemma":[0.000015685077,0.000064147476,0.0000755633,0.0008796572,0.00002844782,0.00038502822,0.000026594997,0.00011817355,0.0011341961,0.0026074261,0.9946554,0.000009741241],"about_ca_topic_score_codex":0.0004977894,"about_ca_topic_score_gemma":0.0010337383,"teacher_disagreement_score":0.00597681,"about_ca_system_score_codex":0.00069997297,"about_ca_system_score_gemma":0.0007957352,"threshold_uncertainty_score":0.019994378},"labels":[],"label_agreement":null},{"id":"W4319922981","doi":"10.1016/j.ejca.2023.02.002","title":"Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Chugai Pharmaceutical; PharmaMar; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Astellas Pharma; Eisai; Genomic Health; Fondation ARC pour la Recherche sur le Cancer; Seagen; Genentech; Veracyte; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Medpace; Puma Biotechnology; Regeneron Pharmaceuticals; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Kræftens Bekæmpelse; European Commission; Exelixis; Amgen; Pfizer; Celgene","keywords":"Neratinib; Trastuzumab; Medicine; Placebo; Oncology; Breast cancer; Internal medicine; Pertuzumab; Adjuvant; Adjuvant therapy; Double blind; Cancer; Alternative medicine; Pathology","score_opus":0.0521616362129542,"score_gpt":0.38182823190836057,"score_spread":0.32966659569540635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319922981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845841,0.007760743,0.00077817467,0.00074885157,0.0009077694,0.002007054,0.0010882065,0.00019179807,0.0019334559],"genre_scores_gemma":[0.98346704,0.0044804895,0.0011256427,0.0011352549,0.0005200044,0.002880502,0.0015112656,0.00004630547,0.0048334887],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99936384,0.00031806022,0.000039638522,0.00012648065,0.00003691089,0.00011498262],"domain_scores_gemma":[0.99932885,0.00019679159,0.00014031853,0.00007303426,0.000036920508,0.00022404968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020067005,0.0021075846,0.0043355078,0.00040785235,0.00041509356,0.0012303811,0.0010999722,0.0020983557,0.0063042003],"category_scores_gemma":[0.0016453454,0.0005984075,0.0027058881,0.00044236184,0.0014322503,0.0016851352,0.0005364924,0.0036842104,0.0011143087],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9878109,0.0017296233,0.00021439206,0.00051978737,0.0006728717,0.000025813566,0.0000278704,0.00026586858,0.0011733206,0.00007592726,0.00046753927,0.007016036],"study_design_scores_gemma":[0.97150606,0.026591593,0.0007179138,0.000024910367,0.00033163955,0.000025241407,0.000013619718,0.00018594292,0.00016949876,0.000119445416,0.0003025584,0.000011485096],"about_ca_topic_score_codex":0.0006946847,"about_ca_topic_score_gemma":0.0014693401,"teacher_disagreement_score":0.0063042003,"about_ca_system_score_codex":0.0006701819,"about_ca_system_score_gemma":0.00075070665,"threshold_uncertainty_score":0.021089673},"labels":[],"label_agreement":null},{"id":"W4322760569","doi":"10.1158/1538-7445.sabcs22-p2-01-06","title":"Abstract P2-01-06: Real-world outcome and cost analysis of the addition of pertuzumab to neoadjuvant therapy in localized HER2 positive breast cancer: a single center experience","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Pertuzumab; Medicine; Breast cancer; Neoadjuvant therapy; Trastuzumab; Oncology; Internal medicine; Clinical endpoint; Cancer; Perioperative; Exact test; Clinical trial; Surgery","score_opus":0.15228257007957094,"score_gpt":0.48874254072948536,"score_spread":0.3364599706499144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322760569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984124,0.00016327559,0.0001496693,0.000085875916,0.000007286543,0.00008138481,0.00079939194,0.0000049086425,0.00029584797],"genre_scores_gemma":[0.99784875,0.00013827713,0.00031821866,0.000076878234,0.000029554913,0.00008722518,0.001334264,0.000006294453,0.00016061199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885297,0.00050051545,0.00013825309,0.00015672298,0.00015858264,0.00019299294],"domain_scores_gemma":[0.9947344,0.0014040254,0.0018031413,0.0002528252,0.00063781213,0.0011678039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002193549,0.000591394,0.0007579709,0.0010016222,0.00049440033,0.0013794886,0.00065662403,0.00067423034,0.0025038894],"category_scores_gemma":[0.0048907218,0.00037444188,0.0016789385,0.0013397748,0.00046298624,0.0007345974,0.00094874925,0.00084388297,0.0004623814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019857237,0.0066089914,0.9259415,0.00046240143,0.0017502033,0.0025846835,0.0005872477,0.008698801,0.0011006522,0.0002978464,0.0041200956,0.027990304],"study_design_scores_gemma":[0.0024314518,0.030557605,0.9425651,0.00020500833,0.0012381119,0.0030681652,0.0020714933,0.013913431,0.0012564332,0.00024839694,0.0022838674,0.0001609322],"about_ca_topic_score_codex":0.0054391334,"about_ca_topic_score_gemma":0.004307653,"teacher_disagreement_score":0.0054391334,"about_ca_system_score_codex":0.003174517,"about_ca_system_score_gemma":0.0013447284,"threshold_uncertainty_score":0.023032844},"labels":[],"label_agreement":null},{"id":"W4322769277","doi":"10.1158/1538-7445.sabcs22-p5-07-08","title":"Abstract P5-07-08: Evaluating the risk of cardiotoxicity associated with concurrent trastuzumab emtansine (TDM1) and radiation therapy in patients with early-stage HER2 positive breast cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Cardiotoxicity; Internal medicine; Oncology; Breast cancer; Trastuzumab; Ejection fraction; Trastuzumab emtansine; Radiation therapy; Adjuvant therapy; Cardiology; Heart failure; Cancer; Chemotherapy","score_opus":0.0851732530163475,"score_gpt":0.44099505400862105,"score_spread":0.35582180099227356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322769277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98659617,0.009686925,0.0005232344,0.00025006325,0.00006297627,0.00053165667,0.0011742936,0.000019304096,0.0011553946],"genre_scores_gemma":[0.99701285,0.00093455415,0.00044138476,0.00018485043,0.00015634195,0.00021634095,0.0007572784,0.0000053849235,0.00029104002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997288,0.001551744,0.0003236017,0.00035253994,0.00037687787,0.00010720969],"domain_scores_gemma":[0.99255824,0.003166017,0.002616443,0.00027869517,0.000508636,0.00087194226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050687343,0.0006401788,0.0014440756,0.0006184802,0.00024119852,0.0008946003,0.00064927945,0.00089997274,0.0027151804],"category_scores_gemma":[0.0073411656,0.00034468292,0.0029983388,0.0008055366,0.0003465193,0.00069449213,0.00046318845,0.001123906,0.00034582295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43996486,0.004007197,0.4478096,0.0024716377,0.022963505,0.00041902348,0.00014010252,0.0020941584,0.0045668446,0.00012142323,0.0017090833,0.07373263],"study_design_scores_gemma":[0.033477746,0.23628111,0.695428,0.00032735855,0.022209523,0.0010967407,0.00013832912,0.00401986,0.0028532834,0.00028926326,0.0037928433,0.00008590279],"about_ca_topic_score_codex":0.0005705571,"about_ca_topic_score_gemma":0.0010237738,"teacher_disagreement_score":0.0050687343,"about_ca_system_score_codex":0.0008947768,"about_ca_system_score_gemma":0.00079493795,"threshold_uncertainty_score":0.026806355},"labels":[],"label_agreement":null},{"id":"W4324132274","doi":"10.1016/s0960-9776(23)00123-6","title":"P004 Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Trastuzumab; Open label; Oncology; Adjuvant; Breast cancer; Internal medicine; Adjuvant therapy; Clinical trial; Cancer","score_opus":0.04864517656838026,"score_gpt":0.3922865478377956,"score_spread":0.34364137126941535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324132274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925598,0.0013386604,0.0002928442,0.0006034385,0.0001286343,0.0011832262,0.00089007645,0.00007802943,0.0029254274],"genre_scores_gemma":[0.9881919,0.0012347198,0.0012029441,0.00077326345,0.0002316293,0.0012662733,0.0018471952,0.000017893251,0.0052341213],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99974793,0.00014262255,0.000010150475,0.000027546708,0.000027112937,0.000044670356],"domain_scores_gemma":[0.99968696,0.000077878845,0.000071988055,0.000022825638,0.000019044199,0.000121299425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010687979,0.0006426261,0.00065883744,0.00025667023,0.0002091348,0.0007008594,0.0004635171,0.0007518066,0.0063281907],"category_scores_gemma":[0.00092445605,0.00015394269,0.0005608981,0.0002879666,0.00037766653,0.00059668015,0.00019526243,0.0014788356,0.0007386369],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73904455,0.034499176,0.0070524383,0.0007529947,0.0010636005,0.0002530233,0.000133678,0.0019470307,0.014655279,0.00044514137,0.0056913765,0.19446176],"study_design_scores_gemma":[0.67193,0.30221668,0.016357854,0.00005481068,0.00037926005,0.00023922062,0.00005949064,0.001571832,0.0024170268,0.00040171333,0.0043488415,0.000023293538],"about_ca_topic_score_codex":0.0004737789,"about_ca_topic_score_gemma":0.0014768718,"teacher_disagreement_score":0.0063281907,"about_ca_system_score_codex":0.0005416196,"about_ca_system_score_gemma":0.00092154474,"threshold_uncertainty_score":0.0211699},"labels":[],"label_agreement":null},{"id":"W4353015178","doi":"10.1007/s10549-023-06881-8","title":"Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; NSABP Foundation; GlaxoSmithKline; U.S. Department of Health and Human Services","keywords":"Medicine; Lapatinib; Breast cancer; Trastuzumab; Internal medicine; Neoadjuvant therapy; Randomized controlled trial; Gastroenterology; Surgery; Confidence interval; Cohort; Cancer","score_opus":0.16420894382315235,"score_gpt":0.45441019810179134,"score_spread":0.29020125427863896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353015178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943275,0.0032118224,0.00011513506,0.0002440584,0.00008318754,0.000019492256,0.0006512782,0.00000745924,0.0013400306],"genre_scores_gemma":[0.9962525,0.0009916114,0.000056927925,0.00020005844,0.0000580163,0.000040977455,0.001386151,0.0000039584042,0.0010097845],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996226,0.00008659702,0.000031548065,0.000055905643,0.000052311792,0.00015100931],"domain_scores_gemma":[0.9990596,0.00023841106,0.00023465128,0.00007682425,0.00006113456,0.0003294933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079054816,0.00022098908,0.00076663936,0.00019165249,0.00028839768,0.00070367265,0.00025032513,0.0004748276,0.002172822],"category_scores_gemma":[0.0013609799,0.00010216084,0.0012583145,0.00031355934,0.00041948853,0.00078898884,0.00036283972,0.0011571028,0.00039914975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44808632,0.010637964,0.19200583,0.0007624497,0.0038339826,0.0010056375,0.00052777503,0.005217837,0.011957174,0.0008929068,0.005448242,0.31962383],"study_design_scores_gemma":[0.007670097,0.19077526,0.7729618,0.0004920734,0.004629403,0.0015516633,0.0011378851,0.0033220297,0.004984247,0.0022306307,0.010109425,0.00013549427],"about_ca_topic_score_codex":0.0010283255,"about_ca_topic_score_gemma":0.0024643126,"teacher_disagreement_score":0.002172822,"about_ca_system_score_codex":0.00067631254,"about_ca_system_score_gemma":0.0005614908,"threshold_uncertainty_score":0.007268846},"labels":[],"label_agreement":null},{"id":"W4361190864","doi":"10.1158/1078-0432.ccr-22-2535","title":"A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Saskatchewan Cancer Agency; Centre hospitalier de l'Université Laval; Saskatoon Medical Imaging; University of Saskatchewan; Centre hospitalier universitaire de Québec; Royal University Hospital","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research; Saskatchewan Health Research Foundation; National Cancer Institute; Genome Canada","keywords":"Bispecific antibody; EPH receptor A2; Cancer; Medicine; Antibody; Cancer therapy; Epidermal growth factor receptor; Cancer research; Antibody therapy; Oncology; Internal medicine; Immunology; Monoclonal antibody; Receptor","score_opus":0.700667143084389,"score_gpt":0.6785639125598978,"score_spread":0.022103230524491257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361190864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.672837,0.0044504665,0.31074274,0.00054286723,0.00012337502,0.00085460074,0.00076100504,0.0010067852,0.008681134],"genre_scores_gemma":[0.85425246,0.0022220064,0.13605052,0.0003065807,0.000034479413,0.0004973682,0.00082977477,0.00012511773,0.0056816596],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933124,0.00012822148,0.00004588992,0.00014623968,0.00025887325,0.00008964902],"domain_scores_gemma":[0.9997956,0.000023837665,0.00006294161,0.00004041076,0.00004845685,0.000028742254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087339187,0.0007546476,0.0004381124,0.0006466296,0.00023726285,0.00046989674,0.0003886946,0.00040693022,0.0011105653],"category_scores_gemma":[0.00037348806,0.00027902942,0.00028959016,0.0003248695,0.00028167103,0.00035464982,0.0006511506,0.00060983683,0.00061232934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008291185,0.00006493721,0.0004889579,0.000047163914,0.000015003799,0.000053215357,0.000020841879,0.00087069796,0.98622197,0.00075366604,0.00020721786,0.011173333],"study_design_scores_gemma":[0.0000124872695,0.00026198642,0.0006275115,0.0000056278145,0.000022923903,0.00020487324,0.0000069229704,0.0037004382,0.9899866,0.00013996668,0.005021495,0.000009245424],"about_ca_topic_score_codex":0.00021113615,"about_ca_topic_score_gemma":0.0006117113,"teacher_disagreement_score":0.0011105653,"about_ca_system_score_codex":0.00042466493,"about_ca_system_score_gemma":0.00045871915,"threshold_uncertainty_score":0.0046189427},"labels":[],"label_agreement":null},{"id":"W4361249370","doi":"10.1158/0008-5472.22367729","title":"Supplementary Figure 5 from Distinct ErbB-2–Coupled Signaling Pathways Promote Mammary Tumors with Unique Pathologic and Transcriptional Profiles","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"ErbB; Cancer research; Signal transduction; Biology; Mammary tumor; Cell biology; Computational biology; Genetics; Cancer; Breast cancer","score_opus":0.07118641295120709,"score_gpt":0.3134633758700232,"score_spread":0.24227696291881612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361249370","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018840715,0.0019847192,0.020641245,0.0054581785,0.018363155,0.00027328343,0.85539174,0.013981415,0.06506553],"genre_scores_gemma":[0.07931402,0.0027555171,0.055437148,0.002631957,0.0039265216,0.00052648253,0.7325384,0.0055941143,0.117275774],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940336,0.000030526735,0.000032972788,0.00010771214,0.00029662382,0.00012879523],"domain_scores_gemma":[0.9986298,0.00055170315,0.00011047498,0.0001864302,0.00024315521,0.00027838084],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000327728,0.0016350214,0.0009689323,0.0017880796,0.0006723185,0.0010985715,0.00092902285,0.0011043382,0.5857953],"category_scores_gemma":[0.0017999387,0.0006356491,0.0013490784,0.0012472995,0.0003414112,0.0007932002,0.000463058,0.001453635,0.102876596],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068926794,0.00015661833,0.0008571904,0.00096077245,0.00009989153,0.00041602182,0.00003055187,0.0008719746,0.03651919,0.0055510746,0.9370644,0.016782925],"study_design_scores_gemma":[0.0010124579,0.0004338837,0.023621732,0.00029107358,0.00012684282,0.00260688,0.00013874807,0.0074640196,0.09341298,0.013442213,0.85731184,0.00013737586],"about_ca_topic_score_codex":0.0036008062,"about_ca_topic_score_gemma":0.0061773527,"teacher_disagreement_score":0.41420472,"about_ca_system_score_codex":0.001262517,"about_ca_system_score_gemma":0.001214151,"threshold_uncertainty_score":0.59081274},"labels":[],"label_agreement":null},{"id":"W4361822765","doi":"10.1158/0008-5472.c.6500066.v1","title":"Data from β&lt;sub&gt;1&lt;/sub&gt;-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of California, Los Angeles; Alberta Cancer Foundation; Cancer Research Institute","keywords":"Trastuzumab; Cancer research; Protein kinase B; Breast cancer; Integrin; Epidermal growth factor receptor; Metastatic breast cancer; PI3K/AKT/mTOR pathway; Growth factor receptor; Cancer; Medicine; Internal medicine; Biology; Receptor; Signal transduction; Cell biology","score_opus":0.08616599863725775,"score_gpt":0.3870258860101897,"score_spread":0.30085988737293196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361822765","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97613245,0.0034828791,0.0022232798,0.0010725082,0.00031688155,0.00012029577,0.0069253566,0.000175045,0.009551234],"genre_scores_gemma":[0.9731923,0.0020429664,0.0017410906,0.00048555995,0.00004273317,0.00018337177,0.012585055,0.00006670655,0.009660167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996406,0.000061155704,0.000046125384,0.000044302717,0.00012882752,0.00007905521],"domain_scores_gemma":[0.9998394,0.00004235112,0.000017232387,0.00003316502,0.000026342592,0.000041378895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047992,0.0003112324,0.00046594976,0.00026461022,0.00023138552,0.00044116125,0.00026932402,0.00041161085,0.0034976052],"category_scores_gemma":[0.0002801856,0.00014980325,0.00039638547,0.00026201067,0.00019703936,0.00018747128,0.00012179051,0.0010793858,0.0009892436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013788753,0.00042262446,0.0005375945,0.00010705694,0.000035435318,0.00010475065,0.000035854522,0.0002766505,0.98892224,0.00028666185,0.0019078758,0.0059844344],"study_design_scores_gemma":[0.00030611563,0.0019965293,0.014384178,0.000009804559,0.00007457618,0.0007085061,0.00005966197,0.0016135907,0.955748,0.00015311629,0.024931353,0.000014568126],"about_ca_topic_score_codex":0.0015384064,"about_ca_topic_score_gemma":0.001678244,"teacher_disagreement_score":0.0034976052,"about_ca_system_score_codex":0.00035821085,"about_ca_system_score_gemma":0.00036415152,"threshold_uncertainty_score":0.01170063},"labels":[],"label_agreement":null},{"id":"W4361954460","doi":"10.1158/1078-0432.c.6533189.v1","title":"Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; Breast cancer; Oncology; Biomarker; Medicine; Internal medicine; Adjuvant; Cancer; Biology; Genetics","score_opus":0.3330609675641214,"score_gpt":0.48522905722732396,"score_spread":0.15216808966320255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361954460","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623985,0.00494024,0.00069758866,0.0005163444,0.00008782506,0.00041333973,0.02838423,0.000034268014,0.0025276532],"genre_scores_gemma":[0.9514693,0.0011232744,0.00073163724,0.0007840478,0.00006334996,0.0007755152,0.043040443,0.000033085977,0.0019792977],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99745315,0.001494362,0.0002255151,0.00030370578,0.00039842035,0.00012471016],"domain_scores_gemma":[0.99523807,0.0019409797,0.0013116528,0.00065411173,0.00035136178,0.00050365814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047339085,0.00047646114,0.001501825,0.00031034852,0.00026987097,0.0009044171,0.00065245235,0.0006643583,0.0018356529],"category_scores_gemma":[0.005313178,0.00032178394,0.0014861744,0.00081903365,0.0002523604,0.0006046831,0.00048606284,0.0009250239,0.0004360774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5497224,0.0026024855,0.30981877,0.0024786007,0.035394344,0.00029063947,0.00036186332,0.0038377973,0.010399638,0.0004179768,0.022143058,0.06253243],"study_design_scores_gemma":[0.075518705,0.030006194,0.84907645,0.00022777481,0.01583411,0.00047197158,0.00015329896,0.0014372107,0.0042993324,0.00034036004,0.022534708,0.00009976571],"about_ca_topic_score_codex":0.0017523392,"about_ca_topic_score_gemma":0.004514957,"teacher_disagreement_score":0.0047339085,"about_ca_system_score_codex":0.0005801376,"about_ca_system_score_gemma":0.0007573774,"threshold_uncertainty_score":0.02503556},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"dataset","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"dataset","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4361954621","doi":"10.1158/1078-0432.c.6533189","title":"Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; Breast cancer; Oncology; Medicine; Biomarker; Internal medicine; Cancer; Biology; Genetics","score_opus":0.3330609675641214,"score_gpt":0.48522905722732396,"score_spread":0.15216808966320255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361954621","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96616256,0.004519332,0.000681719,0.0004912064,0.00008432018,0.00045640868,0.025317995,0.000033805893,0.0022525548],"genre_scores_gemma":[0.95360625,0.0011663759,0.0007977192,0.000807586,0.00006807742,0.00091164967,0.04072515,0.000034260058,0.0018829595],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99725693,0.0016682863,0.00022801496,0.0003128692,0.0004035775,0.00013036285],"domain_scores_gemma":[0.99466395,0.0022393654,0.0014093819,0.0007412163,0.0003745445,0.0005715565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052081402,0.00050882006,0.0016414392,0.0003126385,0.0002871351,0.0009308236,0.00069329515,0.00072483165,0.0018282466],"category_scores_gemma":[0.005792231,0.00034673605,0.0015609702,0.000827609,0.00028582162,0.0006255714,0.0004945233,0.0009709067,0.000441957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6316779,0.0027215413,0.24472544,0.002227908,0.031751454,0.00025968754,0.00033550395,0.0033945115,0.01010486,0.00034551564,0.017975137,0.05448049],"study_design_scores_gemma":[0.09948495,0.038434587,0.8174699,0.00022647501,0.016742082,0.00045148734,0.00015916085,0.0014509121,0.004574153,0.00033385522,0.02056394,0.00010856621],"about_ca_topic_score_codex":0.0017741153,"about_ca_topic_score_gemma":0.004350021,"teacher_disagreement_score":0.0052081402,"about_ca_system_score_codex":0.0005918141,"about_ca_system_score_gemma":0.00082644034,"threshold_uncertainty_score":0.027543604},"labels":[],"label_agreement":null},{"id":"W4362536143","doi":"10.1158/1538-7445.am2023-2641","title":"Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Antibody-drug conjugate; Camptothecin; Antibody; Cytotoxicity; Humanized antibody; DU145; Cancer research; Conjugate; Chemistry; Cell culture; Monoclonal antibody; Molecular biology; Cancer cell; Cancer; Biology; Medicine; Immunology; In vitro; Biochemistry; Internal medicine","score_opus":0.127248917654099,"score_gpt":0.4785073000761052,"score_spread":0.35125838242200624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362536143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984885,0.0028573903,0.0072548343,0.00019436164,0.00004442256,0.00012472477,0.0005491662,0.00011907859,0.003971214],"genre_scores_gemma":[0.9845412,0.0015654995,0.006696136,0.00006465139,0.00001572907,0.00004257474,0.0010142367,0.000017201684,0.006042749],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999373,0.0000068886907,0.00000421939,0.000014953659,0.000025561516,0.0000111354775],"domain_scores_gemma":[0.99996364,0.0000032167998,0.00001629067,0.0000017745551,0.000007765737,0.0000072535754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085040316,0.00043689064,0.00012252833,0.00018254945,0.000091325855,0.00014044195,0.00022715617,0.00025923783,0.0013175061],"category_scores_gemma":[0.000080955826,0.00010158332,0.000133511,0.00013595333,0.00009232846,0.00019605286,0.00011562469,0.00025019248,0.0004702624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073431474,0.000031294207,0.0001753489,0.00004647742,0.000005499566,0.000052072497,0.0000067546994,0.00015007,0.9962586,0.00009718205,0.00011641521,0.0029868549],"study_design_scores_gemma":[0.000018244498,0.00035959264,0.00077778636,0.0000029774294,0.000010156695,0.0002509465,0.000004167154,0.0005919528,0.9949839,0.000009916705,0.0029875145,0.000002729191],"about_ca_topic_score_codex":0.00050499884,"about_ca_topic_score_gemma":0.0005535537,"teacher_disagreement_score":0.0013175061,"about_ca_system_score_codex":0.0003866603,"about_ca_system_score_gemma":0.00019506054,"threshold_uncertainty_score":0.0044074655},"labels":[],"label_agreement":null},{"id":"W4365509978","doi":"10.1158/1078-0432.c.6533189.v2","title":"Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; Breast cancer; Oncology; Medicine; Biomarker; Internal medicine; Adjuvant; Cancer; Biology; Genetics","score_opus":0.3330609675641214,"score_gpt":0.48522905722732396,"score_spread":0.15216808966320255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365509978","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96616256,0.004519332,0.000681719,0.0004912064,0.00008432018,0.00045640868,0.025317995,0.000033805893,0.0022525548],"genre_scores_gemma":[0.95360625,0.0011663759,0.0007977192,0.000807586,0.00006807742,0.00091164967,0.04072515,0.000034260058,0.0018829595],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99725693,0.0016682863,0.00022801496,0.0003128692,0.0004035775,0.00013036285],"domain_scores_gemma":[0.99466395,0.0022393654,0.0014093819,0.0007412163,0.0003745445,0.0005715565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052081402,0.00050882006,0.0016414392,0.0003126385,0.0002871351,0.0009308236,0.00069329515,0.00072483165,0.0018282466],"category_scores_gemma":[0.005792231,0.00034673605,0.0015609702,0.000827609,0.00028582162,0.0006255714,0.0004945233,0.0009709067,0.000441957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6316779,0.0027215413,0.24472544,0.002227908,0.031751454,0.00025968754,0.00033550395,0.0033945115,0.01010486,0.00034551564,0.017975137,0.05448049],"study_design_scores_gemma":[0.09948495,0.038434587,0.8174699,0.00022647501,0.016742082,0.00045148734,0.00015916085,0.0014509121,0.004574153,0.00033385522,0.02056394,0.00010856621],"about_ca_topic_score_codex":0.0017741153,"about_ca_topic_score_gemma":0.004350021,"teacher_disagreement_score":0.0052081402,"about_ca_system_score_codex":0.0005918141,"about_ca_system_score_gemma":0.00082644034,"threshold_uncertainty_score":0.027543604},"labels":[],"label_agreement":null},{"id":"W4365512223","doi":"10.1158/1538-7445.am2023-ct229","title":"Abstract CT229: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Cohort; Internal medicine; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; ErbB; Adenocarcinoma; Cancer research; Phases of clinical research; Chemotherapy","score_opus":0.076277487442443,"score_gpt":0.4803886962775271,"score_spread":0.4041112088350841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925634,0.0014219676,0.00032122573,0.0002595965,0.000047588474,0.0012303587,0.0018614325,0.0000989804,0.0021953702],"genre_scores_gemma":[0.9888848,0.0011790016,0.000956862,0.0005944273,0.00004862893,0.0007606572,0.0045136055,0.000021148224,0.0030408504],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99980384,0.000070213406,0.000014168254,0.000035190253,0.00003405549,0.00004245034],"domain_scores_gemma":[0.99966264,0.00003508041,0.000058562913,0.000021068761,0.000039791936,0.00018292807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007040295,0.0009712244,0.00083953637,0.00025148154,0.00025663743,0.0007529021,0.00055134186,0.0006689994,0.003161358],"category_scores_gemma":[0.00045965737,0.0002959255,0.0007751365,0.00027179625,0.00036746694,0.00037289516,0.00029430375,0.0016975761,0.00065906136],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4182633,0.054973666,0.049884222,0.0019059019,0.003112611,0.0018564053,0.000824154,0.0062849377,0.229625,0.00061325415,0.023019165,0.20963748],"study_design_scores_gemma":[0.32860222,0.5245363,0.105471954,0.00016085531,0.0013945056,0.002566397,0.00019623706,0.0041703614,0.018577669,0.0002277139,0.014002024,0.00009378403],"about_ca_topic_score_codex":0.0019032104,"about_ca_topic_score_gemma":0.007200285,"teacher_disagreement_score":0.003161358,"about_ca_system_score_codex":0.0007296956,"about_ca_system_score_gemma":0.0011926607,"threshold_uncertainty_score":0.010575831},"labels":[],"label_agreement":null},{"id":"W4366427874","doi":"10.3389/fimmu.2023.1181014","title":"Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa","funders":"Health Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Mitacs; University of Ottawa; Ovarian Cancer Canada; Terry Fox Research Institute; Australian Government; Natural Sciences and Engineering Research Council of Canada; Ottawa Hospital Research Institute","keywords":"Oncolytic virus; Immune system; Trastuzumab emtansine; Trastuzumab; Immunotherapy; Cancer research; Medicine; Vesicular stomatitis virus; Cancer; Immunology; Breast cancer; Antibody; Virus; Internal medicine","score_opus":0.09414800290936359,"score_gpt":0.39520593003516635,"score_spread":0.30105792712580276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366427874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95062256,0.0043161716,0.018847896,0.0010420327,0.0007680965,0.0016944172,0.011314993,0.0008223566,0.010571616],"genre_scores_gemma":[0.9330979,0.0041146576,0.017545192,0.00048797287,0.00009751401,0.0026109882,0.00987579,0.00021074136,0.03195928],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99943095,0.000074609095,0.0000662356,0.00015768963,0.00016025158,0.0001102264],"domain_scores_gemma":[0.9997274,0.000037127214,0.000071910676,0.000049046354,0.000040321236,0.000074265794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064293423,0.0013563973,0.00057688635,0.001119624,0.00037116103,0.0004988344,0.0005988762,0.0012497398,0.005758756],"category_scores_gemma":[0.00014274797,0.00045070978,0.0006437694,0.0005453063,0.00042977656,0.0005198816,0.00026534742,0.0022109372,0.002015695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008327189,0.000735289,0.00028214706,0.00011363388,0.000026073976,0.00015475621,0.000049860133,0.00026320198,0.9948191,0.000572984,0.0005771044,0.0015730889],"study_design_scores_gemma":[0.00030255105,0.004802694,0.002248881,0.000037854803,0.00009448483,0.0012344059,0.00007355328,0.0015467015,0.9739612,0.000228605,0.015448757,0.000020301402],"about_ca_topic_score_codex":0.00078252814,"about_ca_topic_score_gemma":0.0010639137,"teacher_disagreement_score":0.005758756,"about_ca_system_score_codex":0.0006873675,"about_ca_system_score_gemma":0.0004683859,"threshold_uncertainty_score":0.019264996},"labels":[],"label_agreement":null},{"id":"W4366485651","doi":"10.1055/s-0043-1766335","title":"Untersuchung von monomeren Radioliganden ausgehend von publizierten EGFR-spezifischen Peptiden hinsichtlich ihrer Eignung für die Theranostik maligner Transformationen","year":2023,"lang":"de","type":"article","venue":"Nuklearmedizin - NuclearMedicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Epidermal growth factor receptor; Receptor; Biochemistry","score_opus":0.04559089352838608,"score_gpt":0.34648343989692104,"score_spread":0.30089254636853496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366485651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98524123,0.0048844703,0.0061617014,0.00013084241,0.00006576697,0.00009033832,0.00026909844,0.00007220065,0.0030842123],"genre_scores_gemma":[0.97733897,0.0040229964,0.010579048,0.0003081758,0.000049577604,0.00018325906,0.0011566506,0.00008834641,0.006272907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99950993,0.0001658919,0.000026608575,0.0001288623,0.000069237314,0.00009948214],"domain_scores_gemma":[0.9994848,0.00024654082,0.00007917786,0.00003532971,0.00009701,0.000057064764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007252303,0.00052901666,0.0003106496,0.00033306598,0.00023938745,0.00045530137,0.0003613938,0.00062900875,0.0026563723],"category_scores_gemma":[0.00091449125,0.00028024544,0.0002469193,0.00036836622,0.00028965587,0.0003349389,0.00021476892,0.0005456952,0.00060162606],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009951872,0.00010315129,0.00032822703,0.0001850776,0.00003624219,0.00008313217,0.00010035862,0.0005801444,0.99407804,0.00011770679,0.0001470241,0.0032457376],"study_design_scores_gemma":[0.00007609593,0.0031964064,0.0015702242,0.00002657434,0.00008907747,0.0002241138,0.00012456051,0.0013215729,0.98932475,0.00006861987,0.0039576567,0.000020392865],"about_ca_topic_score_codex":0.0009492818,"about_ca_topic_score_gemma":0.0010574955,"teacher_disagreement_score":0.0026563723,"about_ca_system_score_codex":0.00032888702,"about_ca_system_score_gemma":0.00032662597,"threshold_uncertainty_score":0.0088864565},"labels":[],"label_agreement":null},{"id":"W4366496702","doi":"10.1016/j.ejca.2023.04.007","title":"Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Afatinib; Refractory (planetary science); Medicine; Oncology; Internal medicine; Pediatrics; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.04850224767936248,"score_gpt":0.3747968129093108,"score_spread":0.32629456522994826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366496702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923422,0.00478234,0.0004951472,0.00031815446,0.00003938258,0.0005549522,0.0005083568,0.000041590625,0.0009178867],"genre_scores_gemma":[0.9903234,0.0042194054,0.0022691577,0.00039311333,0.000063587984,0.00054326054,0.0015039394,0.000029460929,0.0006545602],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99944013,0.00028849288,0.000053836717,0.00007179157,0.00007620339,0.00006945628],"domain_scores_gemma":[0.9991628,0.0001475366,0.00024407395,0.0000897018,0.000104310966,0.000251639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016435408,0.0007120907,0.0017464361,0.0001373041,0.0002386245,0.0006216437,0.0005476382,0.0006101397,0.0013788036],"category_scores_gemma":[0.0012397742,0.00020460617,0.0009778314,0.00038807903,0.0005180044,0.00054839137,0.0002801148,0.002389983,0.0003895322],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30716208,0.024984578,0.052903093,0.0033092382,0.0032962142,0.0036782587,0.0017668131,0.008443337,0.13925995,0.0007502846,0.012373001,0.44207317],"study_design_scores_gemma":[0.28857428,0.51736945,0.12255541,0.0003253091,0.0018209673,0.0109206475,0.0003713553,0.0034001465,0.026608756,0.00045559276,0.027503852,0.00009420536],"about_ca_topic_score_codex":0.0011747825,"about_ca_topic_score_gemma":0.0020836915,"teacher_disagreement_score":0.0017464361,"about_ca_system_score_codex":0.0009491578,"about_ca_system_score_gemma":0.0012771033,"threshold_uncertainty_score":0.0086919665},"labels":[],"label_agreement":null},{"id":"W4366597244","doi":"10.3390/curroncol30040330","title":"‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Trastuzumab; Lung cancer; Cancer; Drug; Oncology; Targeted therapy; Cancer research; Internal medicine; Breast cancer; Pharmacology","score_opus":0.16381891991469927,"score_gpt":0.5315866527994902,"score_spread":0.367767732884791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366597244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013573855,0.99776185,0.00009841437,0.0008355817,0.00043543027,0.000006991024,0.000027140071,0.000007971796,0.0006908057],"genre_scores_gemma":[0.00054655643,0.99784505,0.00017843745,0.0006886847,0.00039529224,0.000008864708,0.00003516511,0.0000020901057,0.00029975353],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99970585,0.00007563956,0.000055153625,0.000048612783,0.000085371896,0.000029326418],"domain_scores_gemma":[0.9993005,0.0004000719,0.00008527065,0.000013635095,0.00016631711,0.00003420515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010722276,0.00059012434,0.001015822,0.0016326475,0.00022088502,0.0011215776,0.0007309912,0.0010364318,0.0037951407],"category_scores_gemma":[0.0015470779,0.00019728582,0.0007432703,0.0018196226,0.00040748747,0.0017713711,0.00061828544,0.001706606,0.001148284],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010044267,0.000056105473,0.00020843727,0.020294623,0.00012006438,0.00009238232,0.00006799597,0.00029531203,0.00088333426,0.002896977,0.06024443,0.91473997],"study_design_scores_gemma":[0.000022775943,0.00014639134,0.0007240821,0.0062896954,0.00019180447,0.00067247404,0.000045794128,0.000089834895,0.0002911789,0.0012708813,0.99023694,0.000018202292],"about_ca_topic_score_codex":0.0009054599,"about_ca_topic_score_gemma":0.0016237745,"teacher_disagreement_score":0.0037951407,"about_ca_system_score_codex":0.00081190345,"about_ca_system_score_gemma":0.0011642128,"threshold_uncertainty_score":0.012696028},"labels":[],"label_agreement":null},{"id":"W4366815856","doi":"10.1038/s41416-023-02272-4","title":"Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"CIHR Skin Research Training Centre; Canadian Institutes of Health Research; Government of Canada","keywords":"Medicine; Breast cancer; Drug; Oncology; Cancer; Internal medicine; Pharmacology","score_opus":0.022176495954511766,"score_gpt":0.37173380882424717,"score_spread":0.3495573128697354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366815856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7521339,0.13822274,0.031440802,0.0037845534,0.0018466898,0.0004029575,0.0010801293,0.0010701197,0.07001818],"genre_scores_gemma":[0.92300844,0.036414683,0.007195687,0.0010354291,0.00019890601,0.00018983112,0.00054323045,0.00011050703,0.03130324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998723,0.000039390536,0.000005044932,0.00002076175,0.00002943734,0.00003305698],"domain_scores_gemma":[0.99995923,0.000008173318,0.000009466649,0.0000043677287,0.0000074367604,0.000011469108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002382251,0.0003551155,0.000291621,0.00032915082,0.00015450857,0.00046941437,0.00033772225,0.0004957263,0.0038643104],"category_scores_gemma":[0.00014700193,0.00015313528,0.00018056385,0.0002527623,0.00020028789,0.00037922256,0.0004123757,0.00064038043,0.0014880834],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015199501,0.00034813612,0.00023565348,0.00065122196,0.00006995562,0.00037339545,0.00009117417,0.0026757987,0.8624045,0.0067771054,0.005559423,0.11929356],"study_design_scores_gemma":[0.00034292488,0.0030907895,0.0016925358,0.00007167157,0.00010679878,0.0012236936,0.000051772236,0.0036093437,0.8445436,0.0014473381,0.14377353,0.00004596417],"about_ca_topic_score_codex":0.00027947727,"about_ca_topic_score_gemma":0.00034273902,"teacher_disagreement_score":0.0038643104,"about_ca_system_score_codex":0.00042512832,"about_ca_system_score_gemma":0.00014357605,"threshold_uncertainty_score":0.012927413},"labels":[],"label_agreement":null},{"id":"W4366982735","doi":"10.3233/bd-220052","title":"Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials","year":2023,"lang":"en","type":"review","venue":"Breast Disease","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Trastuzumab emtansine; Internal medicine; Trastuzumab; Breast cancer; Randomized controlled trial; Oncology; Chemotherapy; Meta-analysis; Cancer; Gastroenterology","score_opus":0.2870142338148702,"score_gpt":0.5635373667569885,"score_spread":0.27652313294211833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366982735","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004200256,0.994351,0.00040079927,0.00015547048,0.00010102485,0.0001769364,0.00040552995,0.000017922783,0.00019091944],"genre_scores_gemma":[0.16825514,0.8257782,0.0023440854,0.0009858976,0.00028444506,0.0010005211,0.0009876933,0.000041581927,0.00032236121],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9882288,0.00591951,0.0034544696,0.0010707735,0.0010413172,0.00028514763],"domain_scores_gemma":[0.9775695,0.016878331,0.003235694,0.00069162156,0.0013807799,0.0002439563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015311874,0.0027038597,0.020298738,0.0058409325,0.00062447326,0.0033266796,0.0017556922,0.0021266474,0.0028773958],"category_scores_gemma":[0.032902684,0.0014791857,0.041860394,0.0067577707,0.00074988365,0.0017053434,0.0014208299,0.0018800345,0.00028500555],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024148969,0.000023594384,0.002693524,0.36359805,0.61976,0.00009031275,0.00006818971,0.00054611656,0.00024389465,0.00012339756,0.00051072787,0.009927342],"study_design_scores_gemma":[0.0005057276,0.00014622057,0.002209431,0.019181825,0.976301,0.00006481022,0.000026811222,0.00015215152,0.000107482745,0.00015333887,0.0011337044,0.000017522614],"about_ca_topic_score_codex":0.005718962,"about_ca_topic_score_gemma":0.012195068,"teacher_disagreement_score":0.020298738,"about_ca_system_score_codex":0.0024677624,"about_ca_system_score_gemma":0.002873752,"threshold_uncertainty_score":0.08097792},"labels":[],"label_agreement":null},{"id":"W4376645278","doi":"10.3390/curroncol30050381","title":"Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network; Ottawa Hospital; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Pertuzumab; Medicine; Breast cancer; Dilemma; Cancer; Internal medicine; Trastuzumab; Epistemology","score_opus":0.12050075996441456,"score_gpt":0.48514988563745276,"score_spread":0.3646491256730382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376645278","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000065508226,0.00067494775,0.00010549645,0.9737215,0.024098365,0.000034011096,0.00022579152,0.00006174704,0.0010126055],"genre_scores_gemma":[0.00033604415,0.00034033804,0.00009094074,0.9901452,0.0062045096,0.000062550534,0.00004854578,0.00002696548,0.0027450037],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9846518,0.0033620016,0.0019338528,0.0019115224,0.006315765,0.0018251573],"domain_scores_gemma":[0.94448245,0.022286978,0.003947534,0.0011597106,0.023732917,0.0043902905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018884758,0.001374542,0.002342895,0.00181649,0.0062528597,0.0048233797,0.00530733,0.053704716,0.016585905],"category_scores_gemma":[0.11032495,0.0015751723,0.0032381462,0.0017184272,0.0056843837,0.0044412944,0.003921199,0.05958111,0.02009247],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013259693,0.0000022957643,0.000054470034,0.000028802244,0.0000040765194,0.00006257606,0.000040543095,0.0000073581477,0.000028403907,0.00022743517,0.9989753,0.00055568176],"study_design_scores_gemma":[0.00007708112,0.000032112213,0.0009312329,0.0004461785,0.000037416667,0.00033855034,0.00032648677,0.000100675206,0.00024989172,0.0013513702,0.99602866,0.00008024736],"about_ca_topic_score_codex":0.044604596,"about_ca_topic_score_gemma":0.057979286,"teacher_disagreement_score":0.98711634,"about_ca_system_score_codex":0.012883677,"about_ca_system_score_gemma":0.020740204,"threshold_uncertainty_score":0.099873364},"labels":[],"label_agreement":null},{"id":"W4376956449","doi":"10.3390/curroncol30050380","title":"The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Medicine; Breast cancer; Dilemma; Cancer; Family medicine; Trastuzumab; Oncology; Internal medicine","score_opus":0.12885039517155653,"score_gpt":0.49870845031395566,"score_spread":0.3698580551423991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376956449","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005924811,0.0013141615,0.00006948546,0.95961404,0.036319636,0.000057235295,0.00041363642,0.00004301862,0.0021096019],"genre_scores_gemma":[0.0004449753,0.00065877615,0.000103359955,0.9831125,0.008543408,0.00012272343,0.00009488516,0.000029160465,0.006890171],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97141415,0.0051366067,0.0026329213,0.0027666849,0.013376299,0.0046734116],"domain_scores_gemma":[0.9168194,0.023355937,0.0039754324,0.0017055926,0.045911327,0.008232324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026277168,0.00168499,0.0035299873,0.002410419,0.014374085,0.008947971,0.00855674,0.083243005,0.019959347],"category_scores_gemma":[0.13313496,0.0019999375,0.0050769965,0.0028973196,0.0077396166,0.004222259,0.0050358935,0.06903548,0.015188564],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011544864,0.0000016628243,0.000028926352,0.000031224838,0.0000036006757,0.00004172997,0.000031679254,0.0000057454517,0.000012811604,0.00025850665,0.99908733,0.0004851724],"study_design_scores_gemma":[0.00006929236,0.00001841378,0.00057674124,0.00057733804,0.00003956633,0.000098803204,0.0002222078,0.0000592325,0.00011149477,0.00074821047,0.99741626,0.000062341926],"about_ca_topic_score_codex":0.34629926,"about_ca_topic_score_gemma":0.53001434,"teacher_disagreement_score":0.9572931,"about_ca_system_score_codex":0.04270693,"about_ca_system_score_gemma":0.09124267,"threshold_uncertainty_score":0.68856716},"labels":[],"label_agreement":null},{"id":"W4379282852","doi":"10.1200/jco.2023.41.16_suppl.tps3153","title":"TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Prostate cancer; Internal medicine; Oncology; Cancer; Combination therapy; Bevacizumab; Cancer research; Immunotherapy; Chemotherapy","score_opus":0.139887455660775,"score_gpt":0.5423854401283179,"score_spread":0.4024979844675429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889314,0.0016207942,0.00058453064,0.00055415323,0.00008501704,0.0029170052,0.003144175,0.00019111822,0.0019716513],"genre_scores_gemma":[0.97859985,0.0018884359,0.0023520722,0.0012043267,0.0001761839,0.00424908,0.0074111,0.00009222106,0.0040268195],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995189,0.00023351474,0.00001757196,0.00007803198,0.000047854406,0.00010419749],"domain_scores_gemma":[0.9993382,0.00007179081,0.00014660333,0.00005455404,0.00004367542,0.00034508263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017886559,0.0021817954,0.0013645614,0.0006406564,0.0004332743,0.0012227364,0.0012191741,0.0015934447,0.00498655],"category_scores_gemma":[0.00087874214,0.0007785974,0.0013428995,0.0006343062,0.00094027485,0.0010931039,0.00049585867,0.0028731918,0.0015093704],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68639886,0.112920664,0.013708201,0.0009368524,0.0017001798,0.0005156496,0.000626141,0.0041671116,0.068406366,0.0005597857,0.011179445,0.09888077],"study_design_scores_gemma":[0.5409942,0.4330057,0.014394171,0.000041121668,0.00048210143,0.0006726654,0.00011046093,0.0014392717,0.004368498,0.00027380453,0.0041756677,0.000042288008],"about_ca_topic_score_codex":0.0018879987,"about_ca_topic_score_gemma":0.004570238,"teacher_disagreement_score":0.00498655,"about_ca_system_score_codex":0.0014747476,"about_ca_system_score_gemma":0.0019191342,"threshold_uncertainty_score":0.016681671},"labels":[],"label_agreement":null},{"id":"W4379285655","doi":"10.1200/jco.2023.41.16_suppl.e13113","title":"Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Trastuzumab emtansine; Internal medicine; Trastuzumab; Oncology; Breast cancer; Cancer; Metastatic breast cancer; Meta-analysis; Randomized controlled trial; Antibody-drug conjugate; Antibody; Monoclonal antibody; Immunology","score_opus":0.6540924356858592,"score_gpt":0.6992106650388575,"score_spread":0.04511822935299836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050690915,0.9917019,0.00091312244,0.0002690952,0.00018835979,0.00067049224,0.00087947637,0.000030130323,0.00027828987],"genre_scores_gemma":[0.22840826,0.757869,0.0055444995,0.0013026245,0.00036805004,0.0042569228,0.0017068848,0.00004915521,0.00049463904],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98026603,0.011865642,0.0045208293,0.0014096771,0.0015299369,0.00040790168],"domain_scores_gemma":[0.972472,0.020736061,0.0042698546,0.00081148563,0.0014542774,0.00025623664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022061117,0.002651604,0.019304583,0.0062712515,0.0005446086,0.0026706515,0.0018941883,0.0022858798,0.0043278225],"category_scores_gemma":[0.04305994,0.0014719295,0.037845254,0.007483127,0.0007598468,0.0018955988,0.0013842171,0.0017588431,0.00036018275],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028632793,0.000030835905,0.0029047574,0.40905973,0.5750346,0.00007358206,0.000055484365,0.0005276502,0.000173091,0.00015168358,0.00060830434,0.008516922],"study_design_scores_gemma":[0.0012703101,0.00027722,0.0027195574,0.026470419,0.96701884,0.000062066625,0.000037015827,0.00023987502,0.000110830864,0.00021938024,0.0015537144,0.000020784104],"about_ca_topic_score_codex":0.0044620144,"about_ca_topic_score_gemma":0.008906033,"teacher_disagreement_score":0.022061117,"about_ca_system_score_codex":0.002421454,"about_ca_system_score_gemma":0.003325055,"threshold_uncertainty_score":0.1166718},"labels":[],"label_agreement":null},{"id":"W4379383902","doi":"10.1177/17588359231175440","title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Ottawa Hospital; Sinai Health System; University of Toronto; University of Alberta; University of Calgary","funders":"National Cancer Institute; Mylan; AstraZeneca Canada; Seagen; Gilead Sciences; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Clinical trial; Biomarker; Disease; Hormone receptor; Pertuzumab; Cancer; Population; Human Epidermal Growth Factor Receptor 2","score_opus":0.13996570816914805,"score_gpt":0.5367814479793399,"score_spread":0.39681573981019186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379383902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007934044,0.9985709,0.00007308522,0.0007483986,0.00010294624,0.0000032904081,0.0000083360965,0.0000036965885,0.00040989253],"genre_scores_gemma":[0.0005527016,0.9985531,0.00013019612,0.00045493033,0.00012788175,0.0000049054916,0.000012988253,0.0000012367473,0.0001621278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997204,0.00009167896,0.000041144653,0.000041285955,0.00007972099,0.000025751177],"domain_scores_gemma":[0.9993255,0.00041999,0.00006687,0.000013756044,0.00013710644,0.000036830148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001705392,0.0005937441,0.0017626692,0.001528291,0.00021235539,0.0013434163,0.0010343317,0.00112377,0.0023730814],"category_scores_gemma":[0.0012561932,0.00021026045,0.00060368725,0.001461899,0.0005734015,0.0017778947,0.0006777017,0.0030594263,0.0012275225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012825192,0.00007214268,0.00012709074,0.01661779,0.00011543747,0.00014463798,0.00006019813,0.00040800517,0.00081138697,0.007723448,0.019536987,0.9542545],"study_design_scores_gemma":[0.000078102494,0.00026729386,0.0005799297,0.011058766,0.00021365042,0.0010673972,0.0001049815,0.00021759456,0.00030807088,0.004879908,0.98120236,0.00002186737],"about_ca_topic_score_codex":0.0008113477,"about_ca_topic_score_gemma":0.0025364899,"teacher_disagreement_score":0.0023730814,"about_ca_system_score_codex":0.0007323913,"about_ca_system_score_gemma":0.0012678113,"threshold_uncertainty_score":0.009019077},"labels":[],"label_agreement":null},{"id":"W4379984937","doi":"10.1158/1538-7445.am2023-1837","title":"Abstract 1837: E7386, a selective inhibitor of the interaction between β-catenin and CREB-binding protein (CBP), enhances antitumor activity in combination with lenvatinib (LEN), and LEN + anti-PD-1 antibody in a preclinical tumor model","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Cancer research; Population; Medicine; Chemistry; Pharmacology","score_opus":0.16830660519183713,"score_gpt":0.49233501208204594,"score_spread":0.32402840689020884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379984937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957326,0.00083844434,0.00067152065,0.00011673531,0.00004857748,0.00010141134,0.00038911917,0.00010807172,0.0019935474],"genre_scores_gemma":[0.9955888,0.0005096793,0.00096992176,0.00005929213,0.000020406138,0.00007200449,0.00047707447,0.00001142469,0.0022914286],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983513,0.000029151515,0.000011018146,0.000019113217,0.00004483302,0.00006075095],"domain_scores_gemma":[0.9999471,0.0000060660805,0.000011677185,0.0000045845977,0.0000042530073,0.000026269387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012971256,0.00047368702,0.00059596234,0.0003911063,0.00015873804,0.00018745323,0.00023246907,0.0003297721,0.0021714845],"category_scores_gemma":[0.000058344933,0.00012636428,0.00025473474,0.00029128173,0.00027029277,0.00023227165,0.00012508476,0.00091713906,0.0003900104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005588776,0.0030925951,0.0005148042,0.00013079801,0.000050871124,0.00010438246,0.000021533288,0.0006122746,0.97644216,0.00017813213,0.0005417649,0.012721888],"study_design_scores_gemma":[0.0011268139,0.01667723,0.004696731,0.000007588967,0.00009122673,0.00027061696,0.000029952324,0.0019512454,0.9720172,0.000049366743,0.0030712453,0.000010719667],"about_ca_topic_score_codex":0.00087542227,"about_ca_topic_score_gemma":0.0015838622,"teacher_disagreement_score":0.0021714845,"about_ca_system_score_codex":0.00025712873,"about_ca_system_score_gemma":0.00041204898,"threshold_uncertainty_score":0.0072643757},"labels":[],"label_agreement":null},{"id":"W4380086049","doi":"10.1158/1538-7445.am2023-1538","title":"Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Tolerability; Medicine; Drug; Antibody-drug conjugate; Therapeutic index; Pharmacology; Payload (computing); Linker; Cancer research; Antibody; Monoclonal antibody; Adverse effect; Immunology; Computer science","score_opus":0.22548872914863063,"score_gpt":0.4925144957504283,"score_spread":0.26702576660179766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380086049","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071743014,0.92132473,0.0023908988,0.062455,0.0024783306,0.000060027356,0.0011865288,0.000049387192,0.0028807558],"genre_scores_gemma":[0.13912216,0.79303974,0.004360595,0.046721265,0.012683806,0.0001803242,0.0017750664,0.0001348607,0.0019822323],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99407685,0.0032864981,0.0007581539,0.00062568556,0.0011162914,0.00013652621],"domain_scores_gemma":[0.9434697,0.043309156,0.0046267654,0.002324191,0.0055663064,0.0007038862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020744842,0.00059494446,0.0021890095,0.0019171742,0.00023823508,0.003132107,0.0012979142,0.0018372438,0.010145949],"category_scores_gemma":[0.035295743,0.00024164439,0.0015106271,0.0027435368,0.0015448953,0.0033154213,0.001230874,0.0032086219,0.001809552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027072432,0.00009777467,0.0065633045,0.04344093,0.0071652485,0.00028460007,0.00031490944,0.0017962774,0.0024200145,0.01727658,0.07148758,0.84644544],"study_design_scores_gemma":[0.0010114091,0.0021660503,0.029339496,0.10713367,0.017241282,0.00092337345,0.0009723152,0.0035842983,0.0031142468,0.07388609,0.7604383,0.0001893876],"about_ca_topic_score_codex":0.0022140867,"about_ca_topic_score_gemma":0.0023559895,"teacher_disagreement_score":0.020744842,"about_ca_system_score_codex":0.0013221873,"about_ca_system_score_gemma":0.002925235,"threshold_uncertainty_score":0.109710515},"labels":[],"label_agreement":null},{"id":"W4380303043","doi":"10.1021/acs.jmedchem.3c00760","title":"Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads","year":2023,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Linker; Conjugate; Chemistry; In vivo; In vitro; Cytotoxicity; Peptide; Combinatorial chemistry; Antibody-drug conjugate; Intercalation (chemistry); Conjugated system; Drug; Payload (computing); Antibody; Stereochemistry; Biochemistry; Pharmacology; Monoclonal antibody; Immunology; Biology; Organic chemistry","score_opus":0.03054896719663998,"score_gpt":0.3614380745643872,"score_spread":0.33088910736774724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380303043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966947,0.0016737407,0.00091773004,0.000020071215,0.0000048457923,0.00003351818,0.0000820126,0.000015249671,0.0005581671],"genre_scores_gemma":[0.99776614,0.0006521315,0.0010648964,0.000016316066,0.0000033499582,0.000014710368,0.00014601245,0.000003113254,0.0003333212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998735,0.000040783663,0.000012832328,0.000019172629,0.000030245363,0.000023312057],"domain_scores_gemma":[0.9997565,0.00010381386,0.000052761236,0.000015877264,0.000029020133,0.000042071388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000290777,0.00020966827,0.00018570392,0.00016557302,0.00005255932,0.00018151378,0.000144507,0.00025478672,0.00077234826],"category_scores_gemma":[0.00041614525,0.00010666021,0.00011767702,0.00017104346,0.00013409549,0.0002028047,0.00007909307,0.00024460288,0.00012105875],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004941442,0.00013635473,0.0005470106,0.000046650573,0.000009311199,0.000048818285,0.00002076604,0.0012936256,0.99327713,0.000065229964,0.000017167285,0.004043702],"study_design_scores_gemma":[0.00004306854,0.0027843085,0.0026523373,0.0000031521593,0.00002044245,0.00016817483,0.000008168418,0.0028745446,0.99056387,0.000027591637,0.00084962137,0.0000046747537],"about_ca_topic_score_codex":0.00025961277,"about_ca_topic_score_gemma":0.0003315984,"teacher_disagreement_score":0.00077234826,"about_ca_system_score_codex":0.00021667665,"about_ca_system_score_gemma":0.00012526654,"threshold_uncertainty_score":0.0025838017},"labels":[],"label_agreement":null},{"id":"W4380323763","doi":"10.1186/s13058-023-01649-w","title":"XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Medicine; Everolimus; Internal medicine; Breast cancer; Hazard ratio; Tolerability; Placebo; Oncology; Metastatic breast cancer; Clinical endpoint; Aromatase inhibitor; Cancer; Clinical trial; Adverse effect; Confidence interval; Aromatase; Pathology","score_opus":0.054923355716337066,"score_gpt":0.3966304399903068,"score_spread":0.34170708427396973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380323763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976705,0.004239185,0.0011010241,0.00082415174,0.00094876246,0.01178998,0.0014952001,0.00023460585,0.0026619867],"genre_scores_gemma":[0.9732572,0.002641281,0.0022796392,0.0011779831,0.0006782345,0.012299063,0.0014742023,0.000043685766,0.0061486987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99919325,0.00046193757,0.00004315917,0.00013467966,0.000043019285,0.00012406551],"domain_scores_gemma":[0.99904484,0.00028130278,0.00022324834,0.00006861234,0.00005199357,0.0003298626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021388107,0.0022187382,0.0030841525,0.0005911055,0.00047516465,0.001150261,0.0011398407,0.002287531,0.008758067],"category_scores_gemma":[0.0019546538,0.0010533505,0.0017046178,0.0004223885,0.001784084,0.0012769605,0.0005691609,0.003015395,0.001315513],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98302865,0.0067646634,0.00015693433,0.00034045707,0.00022554898,0.00002396604,0.00003662186,0.00024091652,0.0026750476,0.00008693043,0.00035203135,0.0060681873],"study_design_scores_gemma":[0.9310283,0.06760209,0.00039770146,0.000013281827,0.00009127879,0.000020861062,0.000008908998,0.00019900687,0.00027423454,0.00007366921,0.00028249965,0.000008219072],"about_ca_topic_score_codex":0.0006585289,"about_ca_topic_score_gemma":0.0015215724,"teacher_disagreement_score":0.008758067,"about_ca_system_score_codex":0.0008751192,"about_ca_system_score_gemma":0.0013722876,"threshold_uncertainty_score":0.029298663},"labels":[],"label_agreement":null},{"id":"W4383162923","doi":"10.1016/j.esmoop.2023.101592","title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Ipsen; Astellas Pharma; Eisai; Seagen; Gilead Sciences; Servier; Instituto de Salud Carlos III; Amgen; Pfizer; Celgene; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Breast cancer; Confidence interval; Meta-analysis; Odds ratio; Hormone receptor; Cancer","score_opus":0.26727533271768683,"score_gpt":0.5170282764841014,"score_spread":0.2497529437664146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383162923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009311161,0.9883016,0.00046040738,0.0001916976,0.00010222546,0.00024142493,0.0011024873,0.000025770589,0.00026326592],"genre_scores_gemma":[0.29308087,0.7004636,0.0018791526,0.00081039727,0.0002364026,0.0012209009,0.0017643445,0.00003859284,0.0005057782],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945971,0.0022998422,0.0015015567,0.0007504655,0.0005842043,0.00026685087],"domain_scores_gemma":[0.9868239,0.0095635755,0.002099769,0.00043222326,0.0008762803,0.00020427015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008326847,0.0020168964,0.014791771,0.005482685,0.00063869724,0.0025644505,0.0016864785,0.001738294,0.0039456524],"category_scores_gemma":[0.01953911,0.0011272497,0.028020596,0.0081417225,0.0006055543,0.0013032375,0.001308777,0.0012330002,0.00033930907],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018708911,0.000026532409,0.00997222,0.39530012,0.5817328,0.00015114878,0.00009094429,0.00053371646,0.00023132426,0.000112105285,0.0009347931,0.009043368],"study_design_scores_gemma":[0.00036118203,0.00012651095,0.007192816,0.022041067,0.9683915,0.00010508811,0.00004187985,0.0001748327,0.00008063973,0.0001261873,0.0013365698,0.00002179906],"about_ca_topic_score_codex":0.007495915,"about_ca_topic_score_gemma":0.01873692,"teacher_disagreement_score":0.014791771,"about_ca_system_score_codex":0.0018755766,"about_ca_system_score_gemma":0.0027249309,"threshold_uncertainty_score":0.044037104},"labels":[],"label_agreement":null},{"id":"W4383553191","doi":"10.3390/curroncol30070474","title":"Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Trastuzumab emtansine; Breast cancer; Trastuzumab; Cancer; Antibody-drug conjugate; Metastatic breast cancer; Clinical trial; Drug; Oncology; Internal medicine; Pharmacology; Immunology; Antibody; Monoclonal antibody","score_opus":0.29384681142776564,"score_gpt":0.5896260345667751,"score_spread":0.29577922313900945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383553191","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008185639,0.9979663,0.0000921223,0.0003619497,0.00032293887,0.0000054747875,0.000014001841,0.000006241001,0.0011491773],"genre_scores_gemma":[0.000362743,0.99844956,0.00011752475,0.0002637029,0.00016400425,0.000005224924,0.000020449967,0.0000014163514,0.0006153997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998271,0.000035712503,0.000020900507,0.000027425083,0.000068796704,0.000020160829],"domain_scores_gemma":[0.9997311,0.00012348668,0.000033360182,0.0000081307435,0.0000777559,0.000026138001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004945905,0.0007768647,0.001009687,0.0020767942,0.00026587973,0.0010513188,0.0006574083,0.0011584918,0.00500701],"category_scores_gemma":[0.00068829936,0.00028020242,0.00049658236,0.0022620363,0.0003881856,0.0015951215,0.00062378834,0.001725579,0.0026386168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058459595,0.00007707297,0.000120045144,0.017733954,0.00006654239,0.00016177706,0.000075550684,0.00039034124,0.0014388674,0.006134532,0.058944467,0.9147984],"study_design_scores_gemma":[0.000009128501,0.00006087394,0.00025060802,0.0032076526,0.000047857113,0.0006259148,0.000034223638,0.000062873354,0.00020378348,0.0013489133,0.9941386,0.000009515505],"about_ca_topic_score_codex":0.0009955913,"about_ca_topic_score_gemma":0.0018136529,"teacher_disagreement_score":0.00500701,"about_ca_system_score_codex":0.00067564676,"about_ca_system_score_gemma":0.0011636313,"threshold_uncertainty_score":0.016750097},"labels":[],"label_agreement":null},{"id":"W4384009290","doi":"10.1055/s-0043-1769867","title":"TROP-2 expression in vulval carcinoma – as a possible target for the treatment approach with antibody drug conjugates (ADC)","year":2023,"lang":"en","type":"article","venue":"Geburtshilfe und Frauenheilkunde","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Antibody; Antibody-drug conjugate; Cancer research; Cervical carcinoma; Antigen; Medicine; Drug; Carcinoma; Cancer; Pathology; Immunology; Internal medicine; Cervical cancer; Monoclonal antibody; Pharmacology","score_opus":0.04100265128176192,"score_gpt":0.36674009025587423,"score_spread":0.32573743897411234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384009290","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41769555,0.5287941,0.0112427585,0.01789934,0.0017323918,0.00036539818,0.0006509108,0.0001968382,0.021422634],"genre_scores_gemma":[0.8791166,0.10428992,0.0052858046,0.0022331935,0.0011299996,0.00021291882,0.0004063586,0.000032891185,0.007292334],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999889,0.00003725324,0.00000707684,0.000021383865,0.00001747537,0.000027739918],"domain_scores_gemma":[0.99991775,0.000029474017,0.000016245927,0.000008081891,0.000016247692,0.000012223533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041304887,0.00019730163,0.00038857938,0.00020583738,0.00017294862,0.0006025588,0.00036148183,0.0008804703,0.002745428],"category_scores_gemma":[0.000325909,0.00008695717,0.00032516045,0.00017210405,0.0003206316,0.00047445408,0.00021082436,0.00056746195,0.00058990053],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045317016,0.0008410134,0.009985658,0.005852116,0.00015786341,0.0041681533,0.0003065687,0.002857837,0.5508933,0.013506871,0.015854869,0.391044],"study_design_scores_gemma":[0.00064594747,0.0068400935,0.010911682,0.000730577,0.0005198076,0.019595124,0.00045716297,0.005637379,0.626199,0.005164301,0.32323626,0.00006269643],"about_ca_topic_score_codex":0.00034059767,"about_ca_topic_score_gemma":0.000353304,"teacher_disagreement_score":0.002745428,"about_ca_system_score_codex":0.0004917678,"about_ca_system_score_gemma":0.00029661926,"threshold_uncertainty_score":0.0091843605},"labels":[],"label_agreement":null},{"id":"W4384076785","doi":"10.20960/revcancer.00025","title":"Beyond the first line of HER2+ metastatic breast cancer","year":2023,"lang":"es","type":"article","venue":"Revisiones en Cáncer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Metastatic breast cancer; Breast cancer; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.052102977007611,"score_gpt":0.41777546711219415,"score_spread":0.36567249010458314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384076785","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019086031,0.6023055,0.008273096,0.20352323,0.022819275,0.000074260315,0.0005096811,0.00037628654,0.14303267],"genre_scores_gemma":[0.2748795,0.502694,0.0081599485,0.09328253,0.03609868,0.00012676216,0.00064131076,0.00020668178,0.083910644],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914074,0.00030376794,0.00006779853,0.00012746095,0.0002118164,0.00014843671],"domain_scores_gemma":[0.9980902,0.0006674394,0.00024337103,0.0001811772,0.0004970814,0.00032071865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020579267,0.00039718582,0.0006309881,0.0009025219,0.0004488683,0.0019459605,0.00068554917,0.001488449,0.008320632],"category_scores_gemma":[0.003656294,0.00014783916,0.00067840447,0.0004225097,0.0012406205,0.0019640557,0.0014752061,0.003415977,0.0020595146],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004539335,0.00019070304,0.0026211082,0.0024322604,0.00009802257,0.0017216406,0.00045703194,0.00083562644,0.0057035964,0.116712935,0.17883822,0.6899349],"study_design_scores_gemma":[0.00005579075,0.00031420766,0.0029593802,0.0016793491,0.000060875926,0.0038674625,0.00018273364,0.00038496775,0.0017034891,0.02743698,0.9613202,0.000034474273],"about_ca_topic_score_codex":0.0019335569,"about_ca_topic_score_gemma":0.004788059,"teacher_disagreement_score":0.008320632,"about_ca_system_score_codex":0.002442908,"about_ca_system_score_gemma":0.0024760657,"threshold_uncertainty_score":0.02783525},"labels":[],"label_agreement":null},{"id":"W4385173573","doi":"10.1016/j.esmoop.2023.101613","title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Internal medicine; Breast cancer; Incidence (geometry); Asymptomatic; Cardiotoxicity; Oncology; Gastroenterology; Lung cancer; Cancer; Chemotherapy","score_opus":0.15007037871251086,"score_gpt":0.4438841884306995,"score_spread":0.2938138097181886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385173573","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007767315,0.9901793,0.00038098375,0.0001500979,0.00010148338,0.0003246406,0.0007812643,0.000022586268,0.00029238852],"genre_scores_gemma":[0.22138938,0.7729459,0.0017066543,0.00092122075,0.00020847215,0.0012412403,0.0011429287,0.000034661694,0.0004095123],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.994327,0.0021169935,0.0020679813,0.0006226832,0.0006694782,0.000195971],"domain_scores_gemma":[0.9887045,0.0072939135,0.0024491516,0.0003562234,0.0010340887,0.00016208665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008566621,0.0018700832,0.014405876,0.0056152577,0.000484226,0.0023490062,0.0015605318,0.001414552,0.0027261842],"category_scores_gemma":[0.018446138,0.0011360347,0.030185707,0.0063816747,0.0005824152,0.0011813798,0.0011713359,0.0010960381,0.00022339997],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018625895,0.000032231375,0.0053225127,0.47103998,0.5096733,0.00013830158,0.0000766872,0.0004311221,0.00027823538,0.000105128325,0.0006645509,0.010375403],"study_design_scores_gemma":[0.0005322311,0.00019083217,0.005084621,0.029902676,0.9621166,0.00012122907,0.000035950805,0.00015723721,0.0001230723,0.00013014355,0.0015822195,0.000023185192],"about_ca_topic_score_codex":0.0060102977,"about_ca_topic_score_gemma":0.015298199,"teacher_disagreement_score":0.014405876,"about_ca_system_score_codex":0.0022270244,"about_ca_system_score_gemma":0.0027445024,"threshold_uncertainty_score":0.045305133},"labels":[],"label_agreement":null},{"id":"W4385547758","doi":"10.1158/2767-9764.c.6773851","title":"Data from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sanofi","keywords":"Pharmacokinetics; Medicine; Dosing; Internal medicine; Chemistry; Gastroenterology; Animal science; Biology","score_opus":0.1697949845590386,"score_gpt":0.4671297690045865,"score_spread":0.29733478444554795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385547758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98315835,0.00538828,0.0011559267,0.00045649975,0.00011199935,0.00078519806,0.0046988763,0.00009851488,0.004146196],"genre_scores_gemma":[0.98584807,0.0024661622,0.000946381,0.00064736436,0.00011302651,0.00077105686,0.007301,0.000044409462,0.0018625024],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991491,0.00042998214,0.00008049638,0.000120027835,0.00013160308,0.00008874579],"domain_scores_gemma":[0.9984944,0.00042801493,0.00039259912,0.00025941856,0.0001195073,0.0003061526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019076169,0.0007917544,0.0017259177,0.00036013382,0.00036905307,0.00092033856,0.0005464908,0.00079038506,0.0033083512],"category_scores_gemma":[0.0014128179,0.00030342434,0.0020595305,0.0006390836,0.0005608955,0.00087879825,0.00027167733,0.0024757772,0.0007706265],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63311034,0.024270713,0.026130622,0.00178445,0.0036601448,0.00056425756,0.00038851483,0.007320495,0.08290059,0.0005939672,0.009517285,0.20975868],"study_design_scores_gemma":[0.20503685,0.6454704,0.083747886,0.00021544502,0.0032277224,0.0016681344,0.00020472391,0.0033399584,0.028872259,0.00040271087,0.027714444,0.00009953382],"about_ca_topic_score_codex":0.0009808826,"about_ca_topic_score_gemma":0.001582357,"teacher_disagreement_score":0.0033083512,"about_ca_system_score_codex":0.0008211092,"about_ca_system_score_gemma":0.00090514374,"threshold_uncertainty_score":0.011067569},"labels":[],"label_agreement":null},{"id":"W4385651875","doi":"10.1016/j.esmoop.2023.101615","title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"AstraZeneca","keywords":"Concordance; Medicine; Immunohistochemistry; Internal medicine; Trastuzumab; Oncology; Breast cancer; Cancer","score_opus":0.09067429760705649,"score_gpt":0.4811611636940519,"score_spread":0.3904868660869954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385651875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721939,0.0024577954,0.002606301,0.00007809494,0.000044164983,0.0018897995,0.01597334,0.000057559384,0.004699086],"genre_scores_gemma":[0.9814641,0.0006068788,0.0015658514,0.00036806072,0.00005794012,0.0015527179,0.013203848,0.00004052386,0.0011401359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988643,0.00021096261,0.00018491379,0.0004349179,0.00018010101,0.00012477004],"domain_scores_gemma":[0.9977724,0.00030419495,0.00078315404,0.0004601186,0.00040795983,0.0002721442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018906668,0.00048393253,0.0005287719,0.0016681476,0.0009004325,0.00064447103,0.0005043124,0.0004001109,0.0056672553],"category_scores_gemma":[0.0021809973,0.0007065164,0.0005612719,0.0022730485,0.00051648245,0.00082384085,0.00079527317,0.00052254874,0.0016836261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004209678,0.0001100688,0.9943861,0.000146377,0.00010012277,0.00019530367,0.00014161393,0.000042709802,0.00031586934,0.00009572441,0.000945241,0.0030998744],"study_design_scores_gemma":[0.0002255825,0.0012348141,0.9845803,0.0001334106,0.0002863135,0.0027217711,0.0006562747,0.00028859708,0.00035882383,0.00024696247,0.009241537,0.00002567916],"about_ca_topic_score_codex":0.004360256,"about_ca_topic_score_gemma":0.0053086616,"teacher_disagreement_score":0.0056672553,"about_ca_system_score_codex":0.0008103494,"about_ca_system_score_gemma":0.0011504912,"threshold_uncertainty_score":0.018958926},"labels":[],"label_agreement":null},{"id":"W4386688264","doi":"10.51731/cjht.2023.734","title":"Trastuzumab Deruxtecan (Enhertu)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Reimbursement; Metastatic breast cancer; Oncology; Chemotherapy; Breast cancer; Internal medicine; Disease; Adjuvant; Cancer; Intensive care medicine; Health care","score_opus":0.10286531305846934,"score_gpt":0.398326580389078,"score_spread":0.2954612673306086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386688264","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014070055,0.60926634,0.0016729643,0.014491741,0.0023067826,0.00033879385,0.004393535,0.0003163357,0.3531434],"genre_scores_gemma":[0.18546133,0.48526156,0.005414978,0.015264137,0.0010306305,0.00023575904,0.006763228,0.00006955956,0.3004988],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996227,0.00007800184,0.000029756464,0.000035594403,0.00019123023,0.0000425755],"domain_scores_gemma":[0.9996043,0.00007998831,0.00007232664,0.000011996775,0.00018251156,0.00004887093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072561885,0.00020975225,0.00021923815,0.0007593105,0.00019858975,0.00068379194,0.0003525598,0.0003697271,0.014469038],"category_scores_gemma":[0.0010672042,0.00006995764,0.00029350937,0.0005208009,0.00025328892,0.00035087453,0.0002666029,0.0004580703,0.0020968085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000357525,0.000037598806,0.0008889298,0.0020559023,0.00007427438,0.00012529375,0.00003231553,0.0001920481,0.0023811895,0.0050862916,0.14629428,0.84247434],"study_design_scores_gemma":[0.00012730937,0.00018796723,0.0034399442,0.0010357946,0.000066835084,0.0002918772,0.000022662682,0.00010005062,0.0024055745,0.00035544016,0.99195766,0.000008904403],"about_ca_topic_score_codex":0.03482638,"about_ca_topic_score_gemma":0.11139958,"teacher_disagreement_score":0.03482638,"about_ca_system_score_codex":0.0027950597,"about_ca_system_score_gemma":0.0028400293,"threshold_uncertainty_score":0.069247305},"labels":[],"label_agreement":null},{"id":"W4386779326","doi":"10.3390/curroncol30090615","title":"Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"California State University, Fresno","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Lapatinib; Metastatic breast cancer; Internal medicine; Meta-analysis; Cancer","score_opus":0.3205140542993283,"score_gpt":0.5329883481369438,"score_spread":0.21247429383761557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386779326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08755665,0.87707496,0.025102405,0.0019820416,0.000614267,0.00085536623,0.004440346,0.0003250407,0.0020489183],"genre_scores_gemma":[0.8797824,0.103342436,0.010234214,0.0013601412,0.00035962902,0.0009827394,0.0030777063,0.0000846368,0.0007762167],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98465097,0.01233468,0.0010064446,0.0011470737,0.00062340667,0.00023749203],"domain_scores_gemma":[0.9779177,0.018924668,0.0014521417,0.0007996238,0.00063320243,0.00027265673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027195415,0.0027646956,0.010361989,0.0048774052,0.00038798695,0.0023653079,0.0019544864,0.0015201103,0.0031814172],"category_scores_gemma":[0.029040355,0.0013122244,0.040857356,0.0039333557,0.00042707782,0.0014306892,0.0012576154,0.0023537804,0.00028667774],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065359166,0.000064455184,0.009700701,0.021395016,0.9352721,0.00010849489,0.000038246966,0.013127057,0.0003110612,0.0003758234,0.0006834476,0.012387623],"study_design_scores_gemma":[0.001212619,0.0004398333,0.0039984137,0.0013496191,0.9815338,0.00007441451,0.000020120728,0.008886745,0.00012943536,0.0011996836,0.0011274361,0.000027851815],"about_ca_topic_score_codex":0.0073273587,"about_ca_topic_score_gemma":0.008161242,"teacher_disagreement_score":0.027195415,"about_ca_system_score_codex":0.0018403193,"about_ca_system_score_gemma":0.0016684819,"threshold_uncertainty_score":0.14382482},"labels":[],"label_agreement":null},{"id":"W4387338086","doi":"10.1016/j.cjca.2023.06.322","title":"INTERRUPTIONS IN TRASTUZUMAB THERAPY FOR BREAST CANCER ARE ASSOCIATED WITH ADVERSE CARDIOVASCULAR AND ONCOLOGIC OUTCOMES","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Internal medicine; Adjuvant; Oncology; Limiting; Cancer; Adjuvant therapy; Adverse effect","score_opus":0.07536772514643893,"score_gpt":0.35635336037631493,"score_spread":0.280985635229876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387338086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97100824,0.020726597,0.00022401562,0.0016454295,0.00017852758,0.000019653351,0.00073186465,0.00002654821,0.005439148],"genre_scores_gemma":[0.99627304,0.0018859459,0.00011145879,0.00045095934,0.00022297382,0.000010662176,0.000572384,0.0000089824,0.0004636611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988285,0.00022720036,0.00014727077,0.00019221693,0.0003381752,0.00026666044],"domain_scores_gemma":[0.9886761,0.0026316373,0.00643275,0.00039299647,0.0005608152,0.0013057629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010462572,0.00018363394,0.00044824363,0.00032274466,0.00039702476,0.00061750866,0.00043258528,0.00061486766,0.0024368314],"category_scores_gemma":[0.0082666045,0.00018374216,0.00058963295,0.000991238,0.00018348549,0.0004434657,0.00035479825,0.002341405,0.00021002782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033414,0.00029930915,0.95728487,0.00014007922,0.0006959355,0.00036078895,0.00016285731,0.00024330319,0.00076491095,0.00018609784,0.001810899,0.034709483],"study_design_scores_gemma":[0.00003801449,0.00017485613,0.99768865,0.000043726584,0.00020008296,0.00023649643,0.00005499716,0.00015031238,0.000053460197,0.00011921855,0.0012339826,0.00000630701],"about_ca_topic_score_codex":0.00928911,"about_ca_topic_score_gemma":0.011546295,"teacher_disagreement_score":0.00928911,"about_ca_system_score_codex":0.0007115524,"about_ca_system_score_gemma":0.00082283857,"threshold_uncertainty_score":0.018470109},"labels":[],"label_agreement":null},{"id":"W4387809682","doi":"10.1016/j.annonc.2023.10.011","title":"LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Seagen; Genentech; Hope Foundation; AstraZeneca; Breast Cancer Research Foundation; Pfizer; Bristol-Myers Squibb; Merck","keywords":"Medicine; Pembrolizumab; Oncology; Stage (stratigraphy); Adjuvant; Chemotherapy; Breast cancer; Adjuvant chemotherapy; Internal medicine; Gynecology; Cancer; Immunotherapy","score_opus":0.12724318332632856,"score_gpt":0.4865900282985598,"score_spread":0.35934684497223124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763084,0.00523868,0.0008103252,0.0014160896,0.0007800115,0.0036991972,0.0033114483,0.0003859349,0.008049897],"genre_scores_gemma":[0.9639707,0.005274617,0.00299988,0.0022585145,0.0004592662,0.0047677835,0.005995344,0.000090129135,0.014183632],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99971133,0.000115456925,0.000011432307,0.00004689065,0.000022982194,0.00009188365],"domain_scores_gemma":[0.99956876,0.000059115824,0.000058080554,0.000031142317,0.000018033299,0.00026492588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013191439,0.0018143696,0.001812494,0.0005115011,0.00053015846,0.0013462136,0.0013145768,0.0014748155,0.007256688],"category_scores_gemma":[0.0007223399,0.000666259,0.0014737681,0.00039937318,0.0009996693,0.0008201001,0.0003605038,0.0043396163,0.0021108536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78781414,0.06674572,0.0016713113,0.0011715881,0.0015018797,0.00014034648,0.00017887547,0.0022462679,0.039003126,0.0006798208,0.008736713,0.09011019],"study_design_scores_gemma":[0.72974175,0.2569591,0.0040975437,0.000055423134,0.0006368796,0.00013272667,0.00005391338,0.0008580588,0.0030614086,0.00024650525,0.0041207056,0.000035929537],"about_ca_topic_score_codex":0.0023196794,"about_ca_topic_score_gemma":0.006996404,"teacher_disagreement_score":0.007256688,"about_ca_system_score_codex":0.0011309653,"about_ca_system_score_gemma":0.0022319697,"threshold_uncertainty_score":0.024276018},"labels":[],"label_agreement":null},{"id":"W4387810529","doi":"10.1016/j.annonc.2023.09.2538","title":"1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Internal medicine; Oncology; Pemetrexed; Carboplatin; Chemotherapy; Combination therapy; Phases of clinical research; non-small cell lung cancer (NSCLC); Lung cancer; Cisplatin","score_opus":0.08150752208758626,"score_gpt":0.4458721133865545,"score_spread":0.36436459129896825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995352,0.0009814594,0.00019804225,0.00029487867,0.00011966135,0.00089527434,0.00086183375,0.000047661226,0.0012492387],"genre_scores_gemma":[0.9906583,0.0012105163,0.00081717916,0.00060972956,0.00020455486,0.0010860182,0.0027140898,0.00002685444,0.0026727945],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995944,0.00019316365,0.000016996495,0.00006026413,0.000023705565,0.00011139534],"domain_scores_gemma":[0.9993979,0.00009467432,0.00007142127,0.000045395314,0.00002695178,0.0003638057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014197107,0.0011040658,0.0018427926,0.00042122242,0.00037224626,0.0010900155,0.0009135986,0.0011183125,0.0044738133],"category_scores_gemma":[0.00069849525,0.00048450351,0.0012210923,0.00044147254,0.0009816305,0.0006787792,0.00037081286,0.0023564883,0.00090885634],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8757684,0.044602916,0.0069484487,0.00023985446,0.0009849927,0.00012057431,0.00014015465,0.0012679616,0.0192228,0.00022276721,0.0020602422,0.048420846],"study_design_scores_gemma":[0.569793,0.4115562,0.01314931,0.000020445243,0.00052901835,0.00011924643,0.00005489394,0.00078395667,0.0021397383,0.000094614144,0.001740291,0.000019278408],"about_ca_topic_score_codex":0.0022720678,"about_ca_topic_score_gemma":0.005618275,"teacher_disagreement_score":0.0044738133,"about_ca_system_score_codex":0.0009474714,"about_ca_system_score_gemma":0.0018551516,"threshold_uncertainty_score":0.014966369},"labels":[],"label_agreement":null},{"id":"W4387811438","doi":"10.1016/j.annonc.2023.09.1878","title":"692P First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Aptitude Health; Centre Léon Bérard; PharmaMar; Basilea Pharmaceutica; Eisai; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Memorial Sloan-Kettering Cancer Center; Genentech; Institut Gustave-Roussy; Daiichi Sankyo Europe; Servier; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; Pfizer; Incyte; Boston Pharmaceuticals; F. Hoffmann-La Roche; Seagen; Agios Pharmaceuticals; Roche; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neutropenia; Folate receptor; Anemia; Internal medicine; Regimen; Adverse effect; Toxicity; Gastroenterology; Conjugate; Pharmacology; Cancer; Cancer cell","score_opus":0.09242421790982693,"score_gpt":0.432836990109584,"score_spread":0.3404127721997571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691546,0.00039736775,0.00046529912,0.000072815776,0.00004773404,0.00037673814,0.00045173863,0.000038895316,0.0012339881],"genre_scores_gemma":[0.9937103,0.00040969223,0.0003015723,0.00018515228,0.000056378074,0.0002756815,0.0007057079,0.000027355161,0.0043281512],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997509,0.000067163564,0.000005765883,0.00006300948,0.000021192967,0.00009192462],"domain_scores_gemma":[0.99967647,0.00006556575,0.000032802778,0.000042136235,0.000036283578,0.00014685058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073268905,0.0011074523,0.001553946,0.0003436779,0.0007061192,0.00079311035,0.00038304084,0.0011419735,0.0028167218],"category_scores_gemma":[0.00046605305,0.0004647237,0.00077904266,0.00027072063,0.001087302,0.0007616048,0.00024606177,0.0023315006,0.0008898205],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6603631,0.14645387,0.014493338,0.0003080813,0.0007220697,0.0015543961,0.00064822246,0.0015315838,0.12113252,0.00025360307,0.0022795822,0.05025976],"study_design_scores_gemma":[0.016912775,0.92123395,0.023400223,0.000013319383,0.000659278,0.00050485774,0.00032150123,0.0013871883,0.03155986,0.0001431354,0.003810369,0.000053666052],"about_ca_topic_score_codex":0.004882319,"about_ca_topic_score_gemma":0.0033800064,"teacher_disagreement_score":0.004882319,"about_ca_system_score_codex":0.00075802754,"about_ca_system_score_gemma":0.0010162212,"threshold_uncertainty_score":0.009707749},"labels":[],"label_agreement":null},{"id":"W4387836897","doi":"10.1016/j.annonc.2023.09.563","title":"386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"AstraZeneca","keywords":"Medicine; Trastuzumab; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Cancer","score_opus":0.215818782700106,"score_gpt":0.5112288047317133,"score_spread":0.29541002203160727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387836897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935,0.004094827,0.00018162148,0.00085787865,0.00015108215,0.0002774052,0.00076127745,0.000070675174,0.0042551183],"genre_scores_gemma":[0.98799616,0.0033724527,0.0006177602,0.0009134145,0.00022539918,0.0004117814,0.0014261518,0.000031338033,0.0050054924],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997533,0.00011365565,0.000006874627,0.00003777102,0.000018354802,0.00007000186],"domain_scores_gemma":[0.9996704,0.00010455434,0.000046866913,0.000023365163,0.000013024318,0.00014193388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081526226,0.00085630734,0.0013940086,0.00022438641,0.0002689499,0.0010186416,0.0005837025,0.0008186778,0.004109857],"category_scores_gemma":[0.0008392068,0.0002463594,0.00088506035,0.00023783793,0.00055196916,0.0006973762,0.00035321698,0.00267691,0.0009626156],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8427806,0.009022256,0.003446808,0.00047473877,0.0012213498,0.00011034298,0.0001459727,0.0022128301,0.005553698,0.00036099108,0.0042940974,0.13037628],"study_design_scores_gemma":[0.7553111,0.20254846,0.0244793,0.00022852418,0.0021599845,0.00033750516,0.00020818756,0.0039052577,0.0028111849,0.001050918,0.0068909023,0.00006868919],"about_ca_topic_score_codex":0.0012912276,"about_ca_topic_score_gemma":0.0043379683,"teacher_disagreement_score":0.004109857,"about_ca_system_score_codex":0.0009050515,"about_ca_system_score_gemma":0.000795233,"threshold_uncertainty_score":0.013748825},"labels":[],"label_agreement":null},{"id":"W4387836902","doi":"10.1016/j.annonc.2023.09.556","title":"379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Santé Montérégie; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; London Health Sciences Centre; Western University","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Internal medicine; Tolerability; Oncology; Adverse effect; Gastroenterology","score_opus":0.1913055246931296,"score_gpt":0.5132972358923467,"score_spread":0.32199171119921705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387836902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7358133,0.21234399,0.0012782895,0.0037215017,0.0012509928,0.00094152015,0.014904009,0.0003314649,0.029414915],"genre_scores_gemma":[0.8738632,0.08833038,0.0027453692,0.004233164,0.00036969857,0.00048175585,0.02072161,0.000071682596,0.009183093],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997811,0.000079667756,0.000022302447,0.000029439652,0.000048623813,0.000038951686],"domain_scores_gemma":[0.99977356,0.000065485,0.00006835779,0.000018722301,0.000026444255,0.000047346355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073433836,0.00039963558,0.00092201197,0.00039045923,0.00011337591,0.0006710965,0.0003902103,0.00027997358,0.0044566654],"category_scores_gemma":[0.0005699022,0.00016702806,0.0007300865,0.00055283366,0.00015812847,0.0003615287,0.0001766001,0.00074215914,0.0007467801],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071564585,0.0018494148,0.01712115,0.002724715,0.0030650443,0.00024139693,0.000090190544,0.002182532,0.021110453,0.00050601596,0.022725297,0.8568192],"study_design_scores_gemma":[0.18667607,0.09707684,0.27506652,0.0030030394,0.018173229,0.0034645922,0.00031386083,0.004696446,0.017116237,0.0019230249,0.39231545,0.00017480926],"about_ca_topic_score_codex":0.0022256095,"about_ca_topic_score_gemma":0.013480718,"teacher_disagreement_score":0.0044566654,"about_ca_system_score_codex":0.00092916796,"about_ca_system_score_gemma":0.0008211722,"threshold_uncertainty_score":0.014909029},"labels":[],"label_agreement":null},{"id":"W4387865238","doi":"10.1200/jco.23.02005","title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":931,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Oncology; Genentech; Menarini Group; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; Jounce Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; AstraZeneca; Novocure; Eisai Canada; Cholangiocarcinoma Foundation; F. Hoffmann-La Roche; Taiho Pharmaceutical; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Mersana Therapeutics; Karyopharm Therapeutics; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Trastuzumab; Immunohistochemistry; Clinical endpoint; Gastroenterology; Oncology; Surgery; Cancer; Breast cancer; Clinical trial","score_opus":0.16127771494674698,"score_gpt":0.5034432526818972,"score_spread":0.3421655377351502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387865238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957266,0.002362277,0.00014470845,0.00019977041,0.000028273358,0.00020616372,0.0004508233,0.000020836356,0.0008605513],"genre_scores_gemma":[0.9960141,0.00095126237,0.00024474977,0.00028612374,0.00006782632,0.00016505257,0.0016075049,0.000007601097,0.0006558032],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996344,0.00019182866,0.00002615789,0.00004969072,0.000046905334,0.000050930656],"domain_scores_gemma":[0.9993641,0.00015429918,0.0001861008,0.000034196306,0.00004058596,0.00022074298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017537269,0.0007219521,0.0010481082,0.00019233824,0.00020825467,0.0007142502,0.00030115191,0.00047245095,0.0013316086],"category_scores_gemma":[0.0009854683,0.00019859581,0.0008045186,0.000229382,0.00040406373,0.00043213894,0.00020870869,0.0012436487,0.00026278544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72069913,0.01691626,0.06368087,0.00087151286,0.003111296,0.00043518812,0.00034706958,0.0042938767,0.018730089,0.00022792266,0.0071411557,0.16354558],"study_design_scores_gemma":[0.5305281,0.2918528,0.15543966,0.00015330737,0.0020707888,0.0013278932,0.00013913686,0.0043009426,0.006132687,0.00037583188,0.0076286322,0.000050177052],"about_ca_topic_score_codex":0.00056992174,"about_ca_topic_score_gemma":0.0014122629,"teacher_disagreement_score":0.0017537269,"about_ca_system_score_codex":0.00079332606,"about_ca_system_score_gemma":0.0006857576,"threshold_uncertainty_score":0.009274721},"labels":[],"label_agreement":null},{"id":"W4387934295","doi":"10.1016/j.jcjd.2023.10.325","title":"INTERRUPTIONS IN TRASTUZUMAB THERAPY FOR BREAST CANCER ARE ASSOCIATED WITH ADVERSE CARDIOVASCULAR AND ONCOLOGIC OUTCOMES","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Medicine; Trastuzumab; Adverse effect; Breast cancer; Oncology; Internal medicine; Cancer; Intensive care medicine","score_opus":0.05743949454727167,"score_gpt":0.33392838100517425,"score_spread":0.2764888864579026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387934295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717149,0.020141575,0.00020196167,0.001483116,0.00018747822,0.000017545872,0.0008800921,0.00002763477,0.005345759],"genre_scores_gemma":[0.99605066,0.0020119746,0.000113709575,0.00040239876,0.00018189532,0.000009615235,0.0006553445,0.000009167908,0.00056517345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988691,0.00022122549,0.00014376828,0.0001815307,0.00030931373,0.00027501074],"domain_scores_gemma":[0.98963404,0.0022543196,0.0059653763,0.00036877237,0.00049997406,0.0012775798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010485431,0.0001963331,0.0004405964,0.000357744,0.00041035473,0.00070268754,0.00046300484,0.00061610335,0.0027436842],"category_scores_gemma":[0.0072527803,0.00021448632,0.0006848932,0.0011142355,0.00018158286,0.00043724937,0.0003891629,0.002440657,0.00021685439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029609136,0.00025195198,0.96671695,0.00011626207,0.00063584204,0.00027178566,0.00012419873,0.00019892173,0.0005142914,0.00014413462,0.0013895698,0.026675181],"study_design_scores_gemma":[0.00003300272,0.00013921961,0.9979857,0.00004139911,0.000200331,0.00018562768,0.000054492884,0.00013772739,0.000044613396,0.00009991082,0.0010720866,0.0000060078874],"about_ca_topic_score_codex":0.012887032,"about_ca_topic_score_gemma":0.015257023,"teacher_disagreement_score":0.012887032,"about_ca_system_score_codex":0.00075541856,"about_ca_system_score_gemma":0.0008452052,"threshold_uncertainty_score":0.025624037},"labels":[],"label_agreement":null},{"id":"W4388495210","doi":"10.1136/ijgc-2023-igcs.288","title":"EP206/#943  The spectrum of HER2 expression in endometrial carcinoma","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Immunohistochemistry; Medicine; Internal medicine; Oncology; Serous carcinoma; Serous fluid; Endometrial cancer; Trastuzumab; Carcinoma; Cancer; Breast cancer; Ovarian cancer","score_opus":0.08222163464780835,"score_gpt":0.4235963263892816,"score_spread":0.3413746917414732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388495210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046046,0.0005466699,0.00020223066,0.00011745708,0.000009425452,0.000012631029,0.0007004642,0.000020449597,0.0079302285],"genre_scores_gemma":[0.9970331,0.0003103393,0.00039917807,0.00008442524,0.00000992704,0.000010809708,0.00058564544,0.000012943302,0.0015536074],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99984753,0.00002261413,0.000015418274,0.000016741982,0.000050388284,0.00004728578],"domain_scores_gemma":[0.99986434,0.000042484462,0.000022322669,0.000010374274,0.00003244635,0.000028094146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031928578,0.0002087672,0.0001890109,0.0012322348,0.0002794658,0.0003433231,0.00020252628,0.00032386722,0.0040218784],"category_scores_gemma":[0.00060046796,0.000104278144,0.00017613394,0.00067830103,0.00019965487,0.00019976836,0.00033884987,0.00017871942,0.0009573026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043563903,0.00023348394,0.290398,0.00016749371,0.00007615692,0.03065675,0.00039378912,0.0004246432,0.6036414,0.0012391462,0.0027895123,0.06562333],"study_design_scores_gemma":[0.000071274764,0.00064126065,0.8682155,0.000063863175,0.00009430205,0.060442563,0.00079640845,0.0010757997,0.05857172,0.0010019368,0.009003687,0.000021625092],"about_ca_topic_score_codex":0.00084642536,"about_ca_topic_score_gemma":0.0008642389,"teacher_disagreement_score":0.0040218784,"about_ca_system_score_codex":0.00020648722,"about_ca_system_score_gemma":0.00012052671,"threshold_uncertainty_score":0.013454556},"labels":[],"label_agreement":null},{"id":"W4388498898","doi":"10.1007/s11912-023-01469-3","title":"Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan","year":2023,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences North","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Cancer; Lung cancer; Vinorelbine; Clinical trial; Chemotherapy; Immunotherapy; Antibody-drug conjugate; Biomarker; Internal medicine; Antibody; Immunology; Monoclonal antibody","score_opus":0.8062497559473588,"score_gpt":0.575193570234524,"score_spread":0.23105618571283482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388498898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003173813,0.9952011,0.0005075803,0.0020664155,0.0002819987,0.0000049972145,0.000019076359,0.00001340162,0.0015880434],"genre_scores_gemma":[0.0030235683,0.9926663,0.0009856068,0.0017849366,0.00063978025,0.000009019259,0.00005444385,0.0000062767326,0.0008300924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995771,0.00012418102,0.00004940833,0.00006588917,0.00013788203,0.000045512916],"domain_scores_gemma":[0.998858,0.000700883,0.00009993151,0.000038980725,0.00024456842,0.000057678495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002008468,0.00047724933,0.0011827552,0.0012928144,0.00015104382,0.0016910173,0.0009134641,0.0009082123,0.0034331162],"category_scores_gemma":[0.0020313438,0.00019034217,0.00070663117,0.0007633007,0.00056569366,0.0017872611,0.00073027785,0.0024418125,0.0013026784],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008767224,0.00003666561,0.00040588633,0.004360985,0.00008033496,0.00019473469,0.000035121462,0.0002987289,0.0010909218,0.0056689302,0.016352097,0.9713879],"study_design_scores_gemma":[0.000048501934,0.00015818226,0.0012809202,0.005131488,0.00021006128,0.0020796233,0.00008946038,0.00030711698,0.00089801144,0.0043293694,0.9854431,0.00002413854],"about_ca_topic_score_codex":0.0009887853,"about_ca_topic_score_gemma":0.0025148895,"teacher_disagreement_score":0.0034331162,"about_ca_system_score_codex":0.00076203933,"about_ca_system_score_gemma":0.0014617675,"threshold_uncertainty_score":0.011484921},"labels":[],"label_agreement":null},{"id":"W4388796117","doi":"10.1080/14712598.2023.2285996","title":"The endosomal-lysosomal system in ADC design and cancer therapy","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Endosome; Rab; Transferrin receptor; Epidermal growth factor receptor; Computational biology; Cancer; Cancer research; Medicine; GTPase; Biology; Transferrin; Cell biology; Biochemistry; Internal medicine; Intracellular","score_opus":0.4938790619789927,"score_gpt":0.5135073950707947,"score_spread":0.019628333091802008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388796117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010781318,0.9947613,0.00034858595,0.0019963006,0.00076985464,0.0000071907302,0.000020202377,0.000009190806,0.001979501],"genre_scores_gemma":[0.0012870444,0.99570787,0.00029903225,0.0009779596,0.0005139529,0.000010602402,0.000026258469,0.0000030505576,0.0011742339],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99950695,0.00012586481,0.000041897703,0.00007650544,0.00020172345,0.000046992973],"domain_scores_gemma":[0.9995098,0.00023613186,0.000061418126,0.000016226064,0.00014724312,0.000029198058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011750897,0.0007023441,0.0010454108,0.0012229605,0.00028491914,0.0015213615,0.0008994203,0.002103591,0.005660096],"category_scores_gemma":[0.0011778033,0.00022809439,0.0005087613,0.0011595374,0.00092764344,0.0023128781,0.0009137178,0.0026244386,0.0032725967],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103767365,0.000047196256,0.00010738381,0.02490544,0.00008404925,0.00023391609,0.00016947597,0.0008185789,0.0034475818,0.0392736,0.081755675,0.84905326],"study_design_scores_gemma":[0.000009154524,0.000047932346,0.00010877183,0.0029902686,0.00002662809,0.00040886473,0.00004881121,0.00010361685,0.00056920666,0.00432577,0.9913504,0.000010619434],"about_ca_topic_score_codex":0.0010880459,"about_ca_topic_score_gemma":0.0016456282,"teacher_disagreement_score":0.005660096,"about_ca_system_score_codex":0.0012172096,"about_ca_system_score_gemma":0.0013639221,"threshold_uncertainty_score":0.018934906},"labels":[],"label_agreement":null},{"id":"W4389020371","doi":"10.1096/fasebj.31.1_supplement.775.2","title":"Targeting Cancer Progression Genes Upregulated in CREB3L1‐Deficient Breast Cancer Cells","year":2017,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research; Saskatchewan Health Research Foundation","keywords":"Breast cancer; Cancer research; Downregulation and upregulation; Microarray analysis techniques; Cancer; Metastasis; Carcinogenesis; Gene; Cancer cell; Biology; Gene expression; Medicine; Internal medicine; Genetics","score_opus":0.04526489795576984,"score_gpt":0.3945698354451919,"score_spread":0.3493049374894221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389020371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98917794,0.0014079721,0.0050785267,0.00021690811,0.000080312435,0.00015408572,0.0023798866,0.0002158106,0.0012886266],"genre_scores_gemma":[0.9806896,0.0010464308,0.010639492,0.00021701158,0.00002192057,0.00042549853,0.0028073664,0.00005583048,0.004096743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997656,0.000012133759,0.000015359998,0.000059837224,0.00008401136,0.00006302153],"domain_scores_gemma":[0.99983037,0.000026533216,0.000060699178,0.000018934388,0.000025745341,0.00003768211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016054153,0.00045001885,0.00047187533,0.0004056921,0.00027158254,0.00026717366,0.0002892844,0.00025657576,0.0018227961],"category_scores_gemma":[0.00012597964,0.0001794763,0.00036377195,0.00027659925,0.00030793238,0.00013496548,0.00028400734,0.000579099,0.00043526464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006794563,0.000022825296,0.00026125956,0.000032318974,0.00000352061,0.000015873395,0.0000069085318,0.000037805396,0.9988201,0.00002306332,0.00005842189,0.0006497874],"study_design_scores_gemma":[0.000023645844,0.000326593,0.007234407,0.000005290612,0.00002506774,0.00014508421,0.000029800036,0.0007386818,0.98860383,0.000027581484,0.0028331089,0.0000068179115],"about_ca_topic_score_codex":0.00096675655,"about_ca_topic_score_gemma":0.002274589,"teacher_disagreement_score":0.0018227961,"about_ca_system_score_codex":0.0004880648,"about_ca_system_score_gemma":0.00041345877,"threshold_uncertainty_score":0.006097853},"labels":[],"label_agreement":null},{"id":"W4389203459","doi":"10.3390/curroncol30120743","title":"Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab emtansine; Trastuzumab; Breast cancer; Antibody-drug conjugate; Adverse effect; Clinical trial; Pertuzumab; Oncology; Cancer; Metastatic breast cancer; Human Epidermal Growth Factor Receptor 2; Internal medicine; Immunology; Antibody; Monoclonal antibody","score_opus":0.23401407147636205,"score_gpt":0.49557800240253663,"score_spread":0.2615639309261746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389203459","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003599624,0.9778977,0.0034664767,0.0077590058,0.0009414601,0.000030882155,0.00009143782,0.00008290511,0.00613042],"genre_scores_gemma":[0.022962332,0.961771,0.0037630904,0.0046587302,0.0010229725,0.000054268166,0.00024186735,0.000033343727,0.0054925336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946636,0.00018137976,0.000034819932,0.00007487926,0.00016385359,0.000078807425],"domain_scores_gemma":[0.9991208,0.00040111082,0.00007590043,0.000032394437,0.00024554177,0.00012428126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021106708,0.00053598767,0.000791645,0.0007703791,0.0003083795,0.0017132888,0.00080209045,0.0017477643,0.0064267507],"category_scores_gemma":[0.0023655791,0.00030093463,0.00062235835,0.0008053063,0.0007940832,0.0032328488,0.00091471267,0.0027905458,0.0021772222],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004192292,0.0002640184,0.00084114866,0.005272287,0.00007958509,0.00056415534,0.00036122382,0.0021628405,0.013845137,0.034903824,0.04374727,0.89753944],"study_design_scores_gemma":[0.00009055202,0.0009636249,0.00060694234,0.0017718283,0.000092096154,0.0013380776,0.0002169754,0.0012895932,0.0073776525,0.017308285,0.9688928,0.000051482533],"about_ca_topic_score_codex":0.0007101338,"about_ca_topic_score_gemma":0.0019025583,"teacher_disagreement_score":0.0064267507,"about_ca_system_score_codex":0.00083017047,"about_ca_system_score_gemma":0.0012627189,"threshold_uncertainty_score":0.021499634},"labels":[],"label_agreement":null},{"id":"W4389227449","doi":"10.1158/1535-7163.targ-23-ia003","title":"Abstract IA003: Refining our understanding of ADCs: Drug development insights from 40 years of data","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Magic bullet; Medicine; Drug; Linker; Pharmacology; Computational biology; Computer science; Bioinformatics; Biology","score_opus":0.2877227097958665,"score_gpt":0.4243710880456244,"score_spread":0.1366483782497579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227449","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01250753,0.8545232,0.016849706,0.07858441,0.002810938,0.00012276355,0.0020208783,0.00032023457,0.032260347],"genre_scores_gemma":[0.08564906,0.85528797,0.017204748,0.022896925,0.0040264945,0.0001416474,0.0031175094,0.00019016875,0.011485505],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99805284,0.0006056518,0.00016059031,0.0001827802,0.000822447,0.0001756632],"domain_scores_gemma":[0.99177074,0.0033394075,0.0006733333,0.00071704737,0.0028268453,0.0006727351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065076477,0.0008008437,0.001138089,0.0024911596,0.00055821944,0.0050129117,0.0014616874,0.002049567,0.008643974],"category_scores_gemma":[0.010176361,0.00037762584,0.0010338781,0.002971469,0.0018541771,0.007465143,0.0020267882,0.00666031,0.003425581],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067164935,0.00036725122,0.0041713975,0.006299055,0.0002340751,0.0005370458,0.00072416436,0.0035325466,0.010672027,0.08066203,0.117420234,0.77470845],"study_design_scores_gemma":[0.00006208137,0.00058865757,0.0023167483,0.0045427913,0.0001787772,0.0006471637,0.00039661012,0.0030533443,0.0068691275,0.059356194,0.9218984,0.00009007941],"about_ca_topic_score_codex":0.002444626,"about_ca_topic_score_gemma":0.0026938207,"teacher_disagreement_score":0.008643974,"about_ca_system_score_codex":0.0029934424,"about_ca_system_score_gemma":0.0043501197,"threshold_uncertainty_score":0.03441614},"labels":[],"label_agreement":null},{"id":"W4389306890","doi":"10.1097/coc.0000000000001068","title":"Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2–Positive Metastatic Breast Cancer in Manitoba","year":2023,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"George & Fay Yee Centre for Healthcare Innovation; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Univariate analysis; Odds ratio; Cohort; Proportional hazards model; Oncology; Breast cancer; Cancer; Survival analysis; Multivariate analysis","score_opus":0.09528721805467023,"score_gpt":0.48239477823000837,"score_spread":0.38710756017533815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389306890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99839336,0.0006930404,0.000041581567,0.000110019384,0.0000048065353,0.000007916826,0.0004097321,0.000003354472,0.00033626705],"genre_scores_gemma":[0.99858415,0.00062253553,0.000046702276,0.00005265074,0.0000057028706,0.000008540782,0.00042111377,0.0000013066525,0.00025723834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998702,0.000023165334,0.000009347492,0.000027682207,0.00002629787,0.000043349915],"domain_scores_gemma":[0.9995989,0.000040185427,0.00013117991,0.00001736661,0.00009157171,0.00012081519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003265052,0.0002300544,0.0001784851,0.00061063014,0.0006939751,0.000457244,0.00039070967,0.00019418889,0.0008436815],"category_scores_gemma":[0.0006433704,0.00020122719,0.00021668679,0.0008570371,0.0002706623,0.00020324241,0.00056254823,0.0003982742,0.00016330798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067866706,0.000017349957,0.99811006,0.000009248819,0.000029580646,0.00013148566,0.00012733166,0.000038983428,0.00025926577,0.000009257389,0.00012216158,0.0010774422],"study_design_scores_gemma":[0.000010865004,0.00006952538,0.9985796,0.000023094386,0.000046681715,0.00023418138,0.00042803696,0.00013053314,0.00007349313,0.000015007123,0.0003848235,0.0000040520217],"about_ca_topic_score_codex":0.30623877,"about_ca_topic_score_gemma":0.49715844,"teacher_disagreement_score":0.6937612,"about_ca_system_score_codex":0.002470963,"about_ca_system_score_gemma":0.0022922975,"threshold_uncertainty_score":0.6089125},"labels":[],"label_agreement":null},{"id":"W4389516076","doi":"10.1096/fj.202301209r","title":"Different <scp>EGF</scp> ‐induced receptor dimer conformations for signaling and internalization","year":2023,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Région Occitanie Pyrénées-Méditerranée; Laboratoire d'Excellence MAbImprove; Centre National de la Recherche Scientifique; Ligue Contre le Cancer; Institute of Genetics; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"Internalization; Erlotinib; Chemistry; Dimer; Epidermal growth factor receptor; Signal transduction; Tyrosine kinase; Epidermal growth factor; Cell biology; Receptor; Gefitinib; Cancer research; Biochemistry; Biology","score_opus":0.08137704500790463,"score_gpt":0.3611804125892828,"score_spread":0.27980336758137814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389516076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98685735,0.0012919343,0.0054525137,0.00031371348,0.000055713524,0.000055285123,0.0004110076,0.00010293182,0.0054595983],"genre_scores_gemma":[0.9951326,0.000604287,0.0020891102,0.0001243082,0.0000060525654,0.000047419882,0.00044330533,0.00003391889,0.0015190848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997373,0.0000583384,0.000023618863,0.00004975967,0.000069491376,0.000061445404],"domain_scores_gemma":[0.9998771,0.000035130593,0.000024764673,0.000020080937,0.000016218362,0.000026648318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028000987,0.00028665506,0.0002379325,0.00012532652,0.00022118766,0.0005377203,0.0002430182,0.00043250073,0.002378117],"category_scores_gemma":[0.00033507688,0.00013961237,0.00031905543,0.00012944851,0.00027519805,0.00043220425,0.00018574482,0.00084428437,0.000491934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020378546,0.000054325195,0.00015485744,0.00007471475,0.000012807078,0.00010834045,0.00002413523,0.00016876357,0.996335,0.0008637374,0.00021767287,0.0017817244],"study_design_scores_gemma":[0.00002139975,0.00010301192,0.0023970597,0.000008791801,0.0000089893465,0.00033248818,0.000034404584,0.001694424,0.9937125,0.00014227336,0.0015368448,0.000007758869],"about_ca_topic_score_codex":0.00026162647,"about_ca_topic_score_gemma":0.00038859842,"teacher_disagreement_score":0.002378117,"about_ca_system_score_codex":0.00043666083,"about_ca_system_score_gemma":0.00023652676,"threshold_uncertainty_score":0.007955551},"labels":[],"label_agreement":null},{"id":"W4389555553","doi":"10.30683/1929-2279.2023.12.9","title":"A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting","year":2023,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab emtansine; Trastuzumab; Medicine; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Cancer; Disease; Population; Human Epidermal Growth Factor Receptor 2; Lapatinib","score_opus":0.08048723051552804,"score_gpt":0.4850504688383424,"score_spread":0.4045632383228144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389555553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8664491,0.031333175,0.015381041,0.028035259,0.0031056071,0.00073083706,0.001181202,0.00091131736,0.052872397],"genre_scores_gemma":[0.9801805,0.0039495016,0.0029358643,0.005121804,0.0021683618,0.00007238088,0.00022716098,0.000084707564,0.0052597458],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9986754,0.00018294218,0.00010417232,0.0003583744,0.00017056738,0.00050842605],"domain_scores_gemma":[0.9976883,0.000561233,0.0005270984,0.0002490003,0.00017198552,0.0008023407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005243651,0.0024388232,0.0019881707,0.0030010783,0.0032682307,0.0024799174,0.0022184849,0.008990092,0.0032016705],"category_scores_gemma":[0.0036050363,0.0011527785,0.0024345117,0.0025106093,0.00200877,0.0032170163,0.0023847418,0.008412059,0.0014825495],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024280214,0.000027435453,0.0010340749,0.000022433436,0.00000753219,0.9970433,0.00013172811,0.00007326335,0.00025824065,0.00021670706,0.0003677819,0.00079328386],"study_design_scores_gemma":[0.000008866615,0.000043014807,0.00086123607,0.000017353368,0.000012114558,0.9976714,0.000093233655,0.00019850979,0.0001852838,0.0001651767,0.0007347672,0.000008932919],"about_ca_topic_score_codex":0.004580947,"about_ca_topic_score_gemma":0.005298845,"teacher_disagreement_score":0.008990092,"about_ca_system_score_codex":0.0029394357,"about_ca_system_score_gemma":0.0015515116,"threshold_uncertainty_score":0.021327198},"labels":[],"label_agreement":null},{"id":"W4389684245","doi":"10.3389/jpps.2023.12078","title":"Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada","year":2023,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Ottawa Hospital; Health Sciences Centre; Jewish General Hospital; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Centre hospitalier universitaire de Québec; Aegera Therapeutics (Canada); Moncton Hospital; Innovation and Economic Development Trois Rivières; Horizon Health Network; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Dr. Georges-L.-Dumont University Hospital Centre; IGNIS Innovation (Canada)","funders":"Université de Montréal; Jewish General Hospital","keywords":"Lapatinib; Metastatic breast cancer; Trastuzumab; Medicine; Cohort; Neratinib; Real world evidence; Breast cancer; Retrospective cohort study; Cancer; Oncology; Internal medicine","score_opus":0.22791909789375314,"score_gpt":0.529580517470613,"score_spread":0.3016614195768598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389684245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95465285,0.004023432,0.00052100176,0.0011022877,0.00002425263,0.0001574884,0.03607237,0.000040450996,0.0034058818],"genre_scores_gemma":[0.98888075,0.0017971452,0.0004593731,0.0003323191,0.000010528752,0.00004075578,0.008079791,0.000021669211,0.00037774752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631625,0.00029954044,0.00046769308,0.0006085182,0.0015078756,0.0008000934],"domain_scores_gemma":[0.9889621,0.0008946839,0.0035123709,0.00053546735,0.004729302,0.0013660834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014647509,0.00035015654,0.00071748154,0.0031979822,0.001815706,0.0019817576,0.0012384439,0.0004318484,0.0014956674],"category_scores_gemma":[0.0067187618,0.00042432034,0.000716112,0.011463117,0.0008817637,0.0004244458,0.0011141155,0.00077372324,0.00019438971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010464023,0.000015885727,0.99171984,0.00012414846,0.00013632193,0.00015167877,0.0005824826,0.00020057507,0.00014868929,0.00015961818,0.002072269,0.004583774],"study_design_scores_gemma":[0.000009536987,0.000023655695,0.9930229,0.00013721905,0.000079524354,0.00030771812,0.0016991032,0.0005053721,0.00015825778,0.000035129695,0.0039942735,0.000027301172],"about_ca_topic_score_codex":0.98587495,"about_ca_topic_score_gemma":0.99018574,"teacher_disagreement_score":0.03512579,"about_ca_system_score_codex":0.03512579,"about_ca_system_score_gemma":0.054624803,"threshold_uncertainty_score":0.25485665},"labels":[],"label_agreement":null},{"id":"W4389858628","doi":"10.1093/ajcp/aqad167","title":"<i>HER2/ERBB2</i> copy number analysis by targeted next-generation sequencing in breast cancer","year":2023,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Gilead Sciences; Eisai; National Comprehensive Cancer Network; Daiichi Sankyo Europe; Sanofi; Pfizer; Genentech; Dana-Farber/Harvard Cancer Center; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Breast cancer; Fluorescence in situ hybridization; Oncology; Immunohistochemistry; Internal medicine; Medicine; Fish <Actinopterygii>; Clinical Oncology; Copy-number variation; Cancer; Pathology; Biology; Genetics; Gene; Genome","score_opus":0.15449250155855102,"score_gpt":0.4836317958463231,"score_spread":0.3291392942877721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389858628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795008,0.003196326,0.013381912,0.00024476458,0.000020017389,0.000086453976,0.0009842349,0.00019471541,0.002390912],"genre_scores_gemma":[0.9855268,0.0008300546,0.012028124,0.00016009755,0.000025989384,0.00007214917,0.00086418015,0.000018961182,0.00047373946],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996038,0.00011160172,0.000031628206,0.00008519296,0.00013678515,0.00003100599],"domain_scores_gemma":[0.9996196,0.00014864061,0.00010071972,0.000031336807,0.00007610544,0.00002357288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011110626,0.0002600964,0.00024806283,0.0008236734,0.00014686337,0.0004265338,0.0002876568,0.00029899197,0.00076457317],"category_scores_gemma":[0.0016895923,0.00009744174,0.00019179488,0.00037184157,0.00020353096,0.00017055373,0.0002534817,0.00018992755,0.0002090078],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013059606,0.00017216099,0.58172464,0.00044651542,0.00028579478,0.0012338131,0.00018926265,0.008386825,0.27143776,0.00057963707,0.0028141472,0.13142338],"study_design_scores_gemma":[0.00009732145,0.0007241741,0.7906115,0.00010869859,0.0003194753,0.010233077,0.00016639555,0.039320543,0.15077896,0.0013155573,0.006279277,0.000044912467],"about_ca_topic_score_codex":0.0011542827,"about_ca_topic_score_gemma":0.0017032112,"teacher_disagreement_score":0.0011542827,"about_ca_system_score_codex":0.0003712359,"about_ca_system_score_gemma":0.000351203,"threshold_uncertainty_score":0.005875945},"labels":[],"label_agreement":null},{"id":"W4389924284","doi":"10.3390/curroncol30120763","title":"Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Stage (stratigraphy); Hormonal therapy; Adjuvant therapy; Internal medicine; Cancer; Oncology; Family medicine","score_opus":0.08536906940342316,"score_gpt":0.45939691896454926,"score_spread":0.3740278495611261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389924284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.574746,0.10609099,0.0006863222,0.29076257,0.0006910224,0.000037354268,0.0004429668,0.00001831687,0.026524417],"genre_scores_gemma":[0.9363312,0.034459006,0.00085373555,0.02553159,0.0011085848,0.000015116474,0.00013214386,0.000007315414,0.0015612327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988832,0.00056136743,0.00006395168,0.000072812705,0.00023963214,0.00017907354],"domain_scores_gemma":[0.98983103,0.0038418928,0.0028070947,0.00009458543,0.0011755568,0.0022497238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021254616,0.0000898669,0.0002246557,0.00024348135,0.00074478483,0.0010804016,0.0003295794,0.00072376,0.0030081188],"category_scores_gemma":[0.011021703,0.000072887415,0.0002343109,0.00048855843,0.0005961143,0.00089460664,0.00027522165,0.0012018913,0.0001687924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017165081,0.0010451846,0.48063415,0.0027028811,0.0003756021,0.0012929555,0.0113447225,0.00067241094,0.0024093674,0.005190452,0.075504616,0.41711113],"study_design_scores_gemma":[0.0003506421,0.00343134,0.75940895,0.0030989419,0.0006040079,0.004260381,0.034879442,0.0005820288,0.001067741,0.0033324787,0.18887271,0.000111334135],"about_ca_topic_score_codex":0.05839591,"about_ca_topic_score_gemma":0.22109239,"teacher_disagreement_score":0.05839591,"about_ca_system_score_codex":0.003201106,"about_ca_system_score_gemma":0.005698189,"threshold_uncertainty_score":0.11611205},"labels":[],"label_agreement":null},{"id":"W4390233924","doi":"10.1016/j.jtho.2023.12.019","title":"Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Brigham and Women's Hospital","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.1175471607756235,"score_gpt":0.4995437960313276,"score_spread":0.3819966352557041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390233924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98644626,0.0062769363,0.0007566985,0.0005186581,0.000027011021,0.000023647648,0.00019364357,0.000021641588,0.005735405],"genre_scores_gemma":[0.99859387,0.00076529174,0.00013634001,0.000052932635,0.0000200146,0.0000070113947,0.00006929085,0.0000028845702,0.0003523178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954337,0.000115234594,0.000050444432,0.00007523148,0.00012914625,0.00008652288],"domain_scores_gemma":[0.99942976,0.00018112335,0.00018958679,0.00003399039,0.00010884499,0.000056639008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009757153,0.00017507155,0.00025514868,0.00073200057,0.0002439654,0.0010756381,0.00024380915,0.00046298694,0.0015717406],"category_scores_gemma":[0.0022086126,0.00019410356,0.00014944287,0.00048419877,0.0002788199,0.0006557648,0.00031936765,0.00044524498,0.00023643342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002177485,0.00027837936,0.81133646,0.0001913892,0.00010944817,0.0007049923,0.00015123075,0.0006434755,0.090863734,0.000850518,0.0006222294,0.092070654],"study_design_scores_gemma":[0.000029354545,0.0010345189,0.9628228,0.000051937015,0.00023519597,0.0051159537,0.0006597574,0.0029703968,0.020442368,0.0007559588,0.0058647403,0.000017084367],"about_ca_topic_score_codex":0.0006892134,"about_ca_topic_score_gemma":0.0012995753,"teacher_disagreement_score":0.0015717406,"about_ca_system_score_codex":0.00048426545,"about_ca_system_score_gemma":0.00028888835,"threshold_uncertainty_score":0.0052580237},"labels":[],"label_agreement":null},{"id":"W4391229921","doi":"10.3390/cancers16030518","title":"Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Calgary","funders":"AstraZeneca Canada","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.06547864330049104,"score_gpt":0.41366605153146385,"score_spread":0.34818740823097283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391229921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781823,0.00088023505,0.000024386047,0.00010266763,0.0000032637943,0.00000604908,0.00075080123,0.0000016376711,0.00041269622],"genre_scores_gemma":[0.99899596,0.00025689325,0.000022052145,0.00005126138,0.0000036569772,0.000002613541,0.0005835742,5.688725e-7,0.00008347288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958605,0.00007739641,0.000038704202,0.00008375006,0.0001116961,0.000102428814],"domain_scores_gemma":[0.998993,0.00016345891,0.00047988136,0.000057979047,0.00015883463,0.00014681989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005460945,0.00013046304,0.00021463505,0.0005689903,0.00038265032,0.0006009509,0.00036959932,0.0002586061,0.00070729817],"category_scores_gemma":[0.0017344564,0.00012866719,0.00031356025,0.0015830126,0.0002585992,0.00017503316,0.00023060146,0.00034174044,0.00006662643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049282942,0.000009815689,0.99862766,0.0000068168083,0.000048399692,0.000016190217,0.000025548907,0.00003234555,0.00003532046,0.000006937218,0.00008119976,0.0010604903],"study_design_scores_gemma":[0.000006431812,0.000025398336,0.9995709,0.0000072766484,0.000039523966,0.00004524704,0.00009748971,0.00006304893,0.000012324554,0.000010403782,0.00012031349,0.0000015756498],"about_ca_topic_score_codex":0.40883473,"about_ca_topic_score_gemma":0.58977234,"teacher_disagreement_score":0.40883473,"about_ca_system_score_codex":0.002121322,"about_ca_system_score_gemma":0.0022908812,"threshold_uncertainty_score":0.8129101},"labels":[],"label_agreement":null},{"id":"W4391430175","doi":"10.1172/jci176454","title":"HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Genentech; Astellas Pharma; Eisai; Knight Cancer Institute, Oregon Health and Science University; G1 Therapeutics; MacroGenics; Puma Biotechnology; Incyte; National Cancer Institute; Natera; Genomic Health; Daiichi Sankyo Europe; Sanofi; Oregon Health and Science University; Gilead Sciences; University of Texas Southwestern Medical Center; Amgen; Pfizer; Susan G. Komen for the Cure; AstraZeneca; Eli Lilly and Company","keywords":"Breast cancer; Trastuzumab; Medicine; Pertuzumab; Lapatinib; Oncology; Internal medicine; KRAS; Neoadjuvant therapy; ErbB; Cancer research; Cancer; Colorectal cancer","score_opus":0.25934820909865275,"score_gpt":0.5403783004386817,"score_spread":0.281030091340029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391430175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915029,0.00096050854,0.00031973148,0.00042277513,0.000042263826,0.0010235121,0.0029757663,0.000049694914,0.0027027756],"genre_scores_gemma":[0.99045277,0.00022111168,0.000543353,0.0005233995,0.000059753955,0.0016193817,0.00484488,0.000022773607,0.001712582],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9990545,0.00049546495,0.000053843,0.00012967546,0.00011227314,0.0001542127],"domain_scores_gemma":[0.9994381,0.0001376197,0.00016359943,0.000050061833,0.000045731864,0.00016492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026062885,0.0005544574,0.001166079,0.00034750364,0.00038825924,0.0007145175,0.00037349906,0.0008721731,0.003401125],"category_scores_gemma":[0.0013205569,0.00021528188,0.00047060364,0.00055022206,0.000446675,0.0006065394,0.0003683722,0.0011247381,0.000549804],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7685505,0.009054597,0.09110963,0.00057275075,0.0019332311,0.00045519407,0.0002282747,0.0036699546,0.04309681,0.000596424,0.01039567,0.07033695],"study_design_scores_gemma":[0.27401087,0.19862853,0.48586595,0.00009437916,0.002406679,0.0011192192,0.00027843713,0.005907751,0.011126013,0.0023850983,0.01804962,0.00012744644],"about_ca_topic_score_codex":0.00058082974,"about_ca_topic_score_gemma":0.0022406091,"teacher_disagreement_score":0.003401125,"about_ca_system_score_codex":0.00078950933,"about_ca_system_score_gemma":0.0009821553,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4391486548","doi":"10.1158/1078-0432.ccr-23-3414","title":"Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Magic bullet; Drug; Conjugate; Missile; Medicine; Antibody-drug conjugate; Virology; Antibody; Pharmacology; Immunology; Biology; Engineering; Monoclonal antibody; Bioinformatics","score_opus":0.39801736688730605,"score_gpt":0.6481958773268562,"score_spread":0.2501785104395502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391486548","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057365973,0.5916317,0.24474809,0.03706823,0.005596474,0.0002495432,0.00025889976,0.0014953869,0.06158569],"genre_scores_gemma":[0.411248,0.33969364,0.14296283,0.016051812,0.0030781403,0.0002683427,0.00026018836,0.0003761974,0.08606086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961406,0.00008000137,0.000015338786,0.00007100509,0.00018779421,0.000031773645],"domain_scores_gemma":[0.99972636,0.00012626748,0.00004147005,0.000016659973,0.00005239427,0.000036789483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008333494,0.0005660771,0.00042527082,0.0007636699,0.00033005455,0.0012701923,0.00047115053,0.001447519,0.003159115],"category_scores_gemma":[0.0006043196,0.00035468533,0.00023226193,0.00037556925,0.0012985176,0.0025524707,0.0011197692,0.002413542,0.0021366675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004582062,0.00023538312,0.0005040667,0.0014480286,0.000053480504,0.0007859592,0.00036392553,0.0013323902,0.2826147,0.121519774,0.041027397,0.5496567],"study_design_scores_gemma":[0.00009916612,0.001311438,0.0004644052,0.00019645663,0.00003454314,0.0024909293,0.00012621097,0.0042935433,0.34480283,0.03273367,0.61337113,0.0000757337],"about_ca_topic_score_codex":0.0002209714,"about_ca_topic_score_gemma":0.00043478777,"teacher_disagreement_score":0.003159115,"about_ca_system_score_codex":0.0007432944,"about_ca_system_score_gemma":0.0002558571,"threshold_uncertainty_score":0.010568261},"labels":[],"label_agreement":null},{"id":"W4391532335","doi":"10.26226/morressier.5c8f909bb5d368000a26b3a0","title":"1357 - Short Link N Acts as a Disease Modifying Osteoarthritis Drug","year":2019,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Link (geometry); Osteoarthritis; Drug; Disease; Medicine; Internal medicine; Pharmacology; Computer science; Alternative medicine; Computer network; Pathology","score_opus":0.06437922146239913,"score_gpt":0.3887170902338482,"score_spread":0.3243378687714491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391532335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8645317,0.09707493,0.0033743852,0.00095347624,0.0010149211,0.00041006776,0.0016030935,0.00043376608,0.030603645],"genre_scores_gemma":[0.94826436,0.026288312,0.0024457173,0.0007644398,0.00022617754,0.00017208386,0.0017729691,0.000022976856,0.020042904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993587,0.0000145226595,0.0000072437856,0.000010356946,0.000020259398,0.000011774366],"domain_scores_gemma":[0.9999502,0.0000075198636,0.000013992235,0.0000041118387,0.000008663238,0.000015530606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012468534,0.00035365447,0.00031679342,0.00032080436,0.00015583681,0.0002230037,0.00024143643,0.00038972942,0.0052412353],"category_scores_gemma":[0.00010491038,0.00007422898,0.00023465429,0.00018096993,0.00016528249,0.00016619862,0.00017806268,0.0004979325,0.0011792846],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032939161,0.0014652652,0.0011604485,0.0012191804,0.00013365422,0.00042096275,0.000053310192,0.00030106862,0.89195925,0.00091101375,0.0032156343,0.09586636],"study_design_scores_gemma":[0.0035485527,0.051511068,0.024034133,0.00033087333,0.0005351266,0.0041214055,0.0001397643,0.0021288132,0.66159916,0.00070736586,0.2512693,0.00007439835],"about_ca_topic_score_codex":0.0004012314,"about_ca_topic_score_gemma":0.0008019002,"teacher_disagreement_score":0.0052412353,"about_ca_system_score_codex":0.00010844625,"about_ca_system_score_gemma":0.0002106614,"threshold_uncertainty_score":0.01753372},"labels":[],"label_agreement":null},{"id":"W4391805157","doi":"10.1158/1535-7163.mct-23-0822","title":"Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Camptothecin; Drug; Conjugate; Pharmacology; Payload (computing); Antibody; Chemistry; Medicine; Immunology; Biochemistry; Computer science","score_opus":0.12025473286422184,"score_gpt":0.44940770754084514,"score_spread":0.3291529746766233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391805157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98835003,0.001392121,0.007722209,0.00009140724,0.000016858114,0.00042522384,0.00029041406,0.000044096898,0.0016675892],"genre_scores_gemma":[0.98794496,0.0011345681,0.008630668,0.000035531328,0.000008207376,0.00010598494,0.00046974747,0.000009643556,0.0016606518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999143,0.000015579728,0.000007439363,0.000018621311,0.000026601472,0.000017532453],"domain_scores_gemma":[0.99994695,0.0000061074097,0.000016555683,0.000004471328,0.000011466998,0.000014423648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016654968,0.00030459353,0.00017858265,0.00017956598,0.00014067462,0.000184706,0.00022769698,0.00026502958,0.000528358],"category_scores_gemma":[0.00014847404,0.00010786056,0.00013168815,0.00012755686,0.00013869285,0.00019066149,0.00013376305,0.00027448896,0.00020437884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017827336,0.00014192387,0.00029519,0.00006415332,0.000008379128,0.00008426829,0.00002538633,0.0020199122,0.9886827,0.00032284923,0.00008323413,0.008093662],"study_design_scores_gemma":[0.00008204547,0.0019724504,0.0012156387,0.000004853675,0.000014483627,0.00019925846,0.000008327541,0.0018921323,0.9904715,0.00003240411,0.0041007698,0.000006117998],"about_ca_topic_score_codex":0.0004413884,"about_ca_topic_score_gemma":0.00062690116,"teacher_disagreement_score":0.000528358,"about_ca_system_score_codex":0.00043825922,"about_ca_system_score_gemma":0.00025220524,"threshold_uncertainty_score":0.0031797886},"labels":[],"label_agreement":null},{"id":"W4391839227","doi":"10.21203/rs.3.rs-3950210/v1","title":"Local Delivery of Accutox® Synergises With Immune-checkpoint Inhibitors at Disrupting Tumor Growth","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Defence Research and Development Canada; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"","keywords":"Immune system; Cancer research; Immune checkpoint; Medicine; Immunotherapy; Immunology","score_opus":0.06336038282571765,"score_gpt":0.4122147257744266,"score_spread":0.34885434294870893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391839227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817092,0.0056559728,0.003953291,0.00030912666,0.00017882725,0.00012838797,0.0016731762,0.00045536456,0.0059366245],"genre_scores_gemma":[0.98214287,0.0029847596,0.0038603307,0.00018699963,0.00004572696,0.00011383768,0.0015912564,0.00006754167,0.009006518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993074,0.000007709431,0.0000064124174,0.000016187078,0.000022010685,0.000016922626],"domain_scores_gemma":[0.9999418,0.000010297657,0.000019304667,0.0000053421204,0.000010288382,0.000012962679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010023877,0.00027599366,0.00020191581,0.0001753706,0.00008458054,0.00019229735,0.00018335416,0.00028490665,0.0036267997],"category_scores_gemma":[0.00007878302,0.00007299926,0.00019568384,0.00010595032,0.000115972194,0.0001421361,0.00012448315,0.000327803,0.0006506829],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040544558,0.00006298602,0.0001273122,0.0001438807,0.000008778814,0.00004937129,0.000009699983,0.00020814138,0.99423945,0.00012025936,0.0006308906,0.0039938153],"study_design_scores_gemma":[0.00002891959,0.00066969136,0.0010642313,0.000010537562,0.000017661761,0.00010251389,0.000008563759,0.00058839563,0.99192977,0.000021026754,0.0055541,0.000004612934],"about_ca_topic_score_codex":0.0003985646,"about_ca_topic_score_gemma":0.0005988014,"teacher_disagreement_score":0.0036267997,"about_ca_system_score_codex":0.0002316776,"about_ca_system_score_gemma":0.0001764254,"threshold_uncertainty_score":0.0121328235},"labels":[],"label_agreement":null},{"id":"W4391962054","doi":"10.1007/s00259-024-06648-3","title":"Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"Institute of Cancer Research","keywords":"Trastuzumab; Internalization; Flow cytometry; Monoclonal antibody; Immunoconjugate; Chemistry; In vitro; Medicine; Breast cancer; Pharmacology; Cancer research; Cancer; Antibody; Receptor; Internal medicine; Immunology; Biochemistry","score_opus":0.011050268542110267,"score_gpt":0.3207989335418847,"score_spread":0.30974866499977444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391962054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98707795,0.007061472,0.0009082167,0.00023100729,0.00015783809,0.00004149323,0.00006036959,0.00012274052,0.004339011],"genre_scores_gemma":[0.9962136,0.0016229186,0.00041270367,0.00006434835,0.000024740406,0.000019761299,0.00006369366,0.00001769605,0.0015605737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998759,0.00003861259,0.000004590278,0.00001829452,0.000017114618,0.000045405595],"domain_scores_gemma":[0.9999505,0.000012841324,0.000008737352,0.0000068666714,0.0000083938985,0.0000127053545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002042822,0.0003100667,0.00051011494,0.00023040871,0.00027286285,0.00040463245,0.000294696,0.0004540356,0.0013005739],"category_scores_gemma":[0.0002131455,0.00013338974,0.00020850403,0.00019171387,0.00023485038,0.00026781278,0.00023842664,0.0003979042,0.00022208282],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017094119,0.0020908879,0.0014549663,0.00067633315,0.00028497085,0.00056608074,0.00024530626,0.0039562,0.8586067,0.0014154929,0.0027710753,0.11083792],"study_design_scores_gemma":[0.001978425,0.018863708,0.00577747,0.00007553696,0.0007536291,0.0010684646,0.00015931095,0.011177201,0.93556166,0.00033178198,0.024199609,0.0000532446],"about_ca_topic_score_codex":0.0021145924,"about_ca_topic_score_gemma":0.0018099283,"teacher_disagreement_score":0.0021145924,"about_ca_system_score_codex":0.00028908395,"about_ca_system_score_gemma":0.00047208564,"threshold_uncertainty_score":0.004350841},"labels":[],"label_agreement":null},{"id":"W4392210732","doi":"10.2196/54178","title":"Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes","year":2024,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Universität Zürich; Swiss Tumor Institute","keywords":"Biosimilar; Trastuzumab; Medicine; Observational study; Breast cancer; Clinical trial; Human Epidermal Growth Factor Receptor 2; Oncology; Internal medicine; Cancer","score_opus":0.1278437417289211,"score_gpt":0.4706072347069483,"score_spread":0.3427634929780272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392210732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940838,0.0005795906,0.0003969893,0.00006936739,0.000021091795,0.00022536548,0.0039343685,0.000008706882,0.0006807584],"genre_scores_gemma":[0.9917494,0.00022549547,0.00035282475,0.00009131604,0.00003012016,0.00032396155,0.0070966776,0.000007724896,0.00012251783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895076,0.00537861,0.0016952533,0.0016126384,0.0014049185,0.00040102616],"domain_scores_gemma":[0.9600063,0.008312151,0.024399199,0.003066091,0.002895485,0.0013207287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0106226355,0.00047771516,0.00068870885,0.0014402425,0.00035916883,0.001384794,0.0008112519,0.00085009536,0.001363702],"category_scores_gemma":[0.023317907,0.00031190197,0.0014648484,0.002200379,0.0005293115,0.0011959791,0.0014682044,0.0011187734,0.0003561859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005455305,0.00042158543,0.9881467,0.00017969254,0.0013133073,0.00003371754,0.0002475237,0.00014929348,0.00019073652,0.0000842615,0.00047566518,0.0033020969],"study_design_scores_gemma":[0.0006752502,0.0021863286,0.99391913,0.000069090114,0.0005906269,0.0002132469,0.0003416561,0.00061013055,0.00020989956,0.00006504791,0.0010910855,0.000028489483],"about_ca_topic_score_codex":0.0014620883,"about_ca_topic_score_gemma":0.0015762495,"teacher_disagreement_score":0.0106226355,"about_ca_system_score_codex":0.00070271565,"about_ca_system_score_gemma":0.00066611514,"threshold_uncertainty_score":0.05617851},"labels":[],"label_agreement":null},{"id":"W4392433377","doi":"10.1016/j.jddst.2024.105519","title":"Intratumoral implantable drug delivery system for targeted localized chemotherapy in breast cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Drug Delivery Science and Technology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Drug delivery; Breast cancer; Drug; Medicine; Chemotherapy; Targeted drug delivery; Oncology; Internal medicine; Pharmacology; Cancer; Nanotechnology; Materials science","score_opus":0.011216440701605738,"score_gpt":0.30694541351492505,"score_spread":0.29572897281331934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392433377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92455167,0.013931497,0.05458345,0.0005112741,0.0006753241,0.00013940487,0.00041519103,0.0007713679,0.0044208304],"genre_scores_gemma":[0.978437,0.002799854,0.012957468,0.0001756297,0.000056141693,0.00009219656,0.00015268667,0.00005629943,0.005272757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999006,0.000010432752,0.000004984962,0.000033045115,0.000028655604,0.000022342818],"domain_scores_gemma":[0.99992704,0.000016142543,0.000023149776,0.000007607335,0.0000148158,0.000011342834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014133667,0.00030812944,0.0003383605,0.00030374678,0.00017575713,0.00039328847,0.0004029217,0.00042870673,0.00087399036],"category_scores_gemma":[0.00016715615,0.00018641657,0.00023373435,0.0002232539,0.00014701637,0.00042505254,0.00019597642,0.00036398927,0.0003240031],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023820756,0.000116482355,0.000233795,0.00015347412,0.000013249949,0.00011636644,0.000037629645,0.00045126662,0.9795376,0.00023953272,0.0002876265,0.01857482],"study_design_scores_gemma":[0.000099925455,0.0023780656,0.0033648913,0.000023834291,0.0001398774,0.00051788194,0.000065648426,0.010575607,0.9697198,0.000111151756,0.012964452,0.000038825812],"about_ca_topic_score_codex":0.0005109018,"about_ca_topic_score_gemma":0.0008539435,"teacher_disagreement_score":0.00087399036,"about_ca_system_score_codex":0.00030727632,"about_ca_system_score_gemma":0.0003533535,"threshold_uncertainty_score":0.0029237866},"labels":[],"label_agreement":null},{"id":"W4392631941","doi":"10.1136/ijgc-2024-esgo.130","title":"85 Lymphovascular invasion in cervical squamous cell carcinoma is associated with mitogen-activated protein kinase (MAP kinase) pathway alterations","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lymphovascular invasion; Medicine; Pathology; MAPK/ERK pathway; Protein kinase A; Internal medicine; Oncology; Cancer; Cancer research; Kinase; Metastasis; Biology; Genetics","score_opus":0.03779154242643258,"score_gpt":0.325780249370875,"score_spread":0.28798870694444245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392631941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976956,0.00046089874,0.00028653682,0.00002462898,0.000005226827,0.0000080110785,0.00013893012,0.000014573886,0.001365581],"genre_scores_gemma":[0.99931324,0.00012207625,0.00009643681,0.000006542997,0.0000041643407,0.0000035541684,0.00010914892,0.000001846016,0.000342945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998925,0.000015678805,0.000010528018,0.000019579282,0.00003091118,0.000030842453],"domain_scores_gemma":[0.99970907,0.00007209703,0.00010281364,0.000019424204,0.000034039276,0.000062395724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018635544,0.00014178846,0.00012845437,0.00086795294,0.00022532737,0.00033113244,0.00013905475,0.00020899826,0.002537343],"category_scores_gemma":[0.0005415306,0.00015336543,0.00018495643,0.000720947,0.00021988,0.00016962687,0.00022799526,0.00016242373,0.00028632948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010096437,0.000072547344,0.8876879,0.00010774982,0.000062571096,0.0052463687,0.00018767438,0.00014509808,0.09420154,0.00019784384,0.00030644436,0.010774556],"study_design_scores_gemma":[0.0000072013286,0.000055727134,0.9900767,0.0000057869597,0.000042503907,0.0042218254,0.00012267203,0.0003531459,0.0043349154,0.00012961484,0.0006455414,0.000004408831],"about_ca_topic_score_codex":0.0015339924,"about_ca_topic_score_gemma":0.0018754766,"teacher_disagreement_score":0.002537343,"about_ca_system_score_codex":0.00018802963,"about_ca_system_score_gemma":0.00021399524,"threshold_uncertainty_score":0.008488238},"labels":[],"label_agreement":null},{"id":"W4393041772","doi":"10.3390/curroncol31030124","title":"Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; Health Sciences Centre; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"Cancer Care Ontario","keywords":"Medicine; Trastuzumab; Internal medicine; Biosimilar; Breast cancer; Oncology; Hazard ratio; Discontinuation; Retrospective cohort study; Proportional hazards model; Adjuvant; Population; Cancer; Confidence interval","score_opus":0.2116304947401476,"score_gpt":0.5426354668958013,"score_spread":0.3310049721556537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393041772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917561,0.0062735737,0.00014537037,0.00012471322,0.000024064162,0.000074736396,0.0003789937,0.0000031067875,0.001219435],"genre_scores_gemma":[0.9983429,0.0009204411,0.00009082535,0.00006379547,0.000031205527,0.000020028338,0.0004157566,0.000001226296,0.00011379553],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959894,0.0017554655,0.0003185421,0.0003511418,0.00141536,0.00017004051],"domain_scores_gemma":[0.99114263,0.002275557,0.004928957,0.00037871883,0.0008571551,0.00041683315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051337774,0.00018541499,0.00042235004,0.00042664446,0.00015832597,0.0008322813,0.00030624424,0.00036107353,0.0011111822],"category_scores_gemma":[0.012464864,0.00012234374,0.0009631541,0.0005430311,0.0007655125,0.00038625248,0.00030527616,0.000498988,0.00009865231],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29520714,0.002935464,0.47471786,0.0026459922,0.011515684,0.0003026578,0.00067211606,0.005049298,0.010807633,0.001145015,0.0018835701,0.1931176],"study_design_scores_gemma":[0.017575463,0.10672636,0.85377556,0.0004200484,0.0049539753,0.00075028517,0.0002318311,0.0030574144,0.0038533425,0.0005118013,0.00807983,0.00006399326],"about_ca_topic_score_codex":0.0061898152,"about_ca_topic_score_gemma":0.00707032,"teacher_disagreement_score":0.0061898152,"about_ca_system_score_codex":0.0034097848,"about_ca_system_score_gemma":0.0015685786,"threshold_uncertainty_score":0.027150333},"labels":[],"label_agreement":null},{"id":"W4393042534","doi":"10.14740/wjon1769","title":"The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Erlotinib; Dasatinib; Afatinib; Medicine; Cancer research; Lapatinib; Tyrosine kinase; Growth inhibition; Trastuzumab; Epidermal growth factor receptor; Hepatocyte Growth Factor Receptor; Growth factor receptor; Pharmacology; Cancer; Hepatocyte growth factor; Cell growth; Imatinib; Internal medicine; Biology; Receptor; C-Met; Breast cancer; Myeloid leukemia","score_opus":0.04696844984805061,"score_gpt":0.40109314676017704,"score_spread":0.35412469691212645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393042534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989776,0.0041597364,0.00071543426,0.00014570242,0.000075831296,0.00006641138,0.00040185478,0.00009862349,0.0045604887],"genre_scores_gemma":[0.9957769,0.0011878926,0.0010622316,0.00005670454,0.000014157936,0.000051482664,0.00047695145,0.000010117352,0.0013635708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978775,0.000032720694,0.000024772215,0.000030080737,0.000068075824,0.0000566513],"domain_scores_gemma":[0.99992204,0.000016718084,0.000012119281,0.000012274752,0.000010414268,0.000026453934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001660141,0.0004115881,0.0005678329,0.00032343867,0.00018041911,0.0002644909,0.00019121585,0.00021119656,0.0018456638],"category_scores_gemma":[0.00013433417,0.00016367853,0.00044541963,0.0002964499,0.0001825054,0.00016059788,0.0003147484,0.0004534921,0.0005381664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012769083,0.0005251339,0.0011627568,0.00023123971,0.000079070924,0.00014364587,0.000049283757,0.0005319193,0.9754716,0.0001353164,0.0008392233,0.019553825],"study_design_scores_gemma":[0.00021574883,0.004023136,0.010526196,0.000012158687,0.00010260023,0.0011814983,0.000052337593,0.0015161235,0.9730232,0.000056919842,0.009276853,0.000013232373],"about_ca_topic_score_codex":0.0005017995,"about_ca_topic_score_gemma":0.0012834918,"teacher_disagreement_score":0.0018456638,"about_ca_system_score_codex":0.0002555409,"about_ca_system_score_gemma":0.00031377946,"threshold_uncertainty_score":0.006174326},"labels":[],"label_agreement":null},{"id":"W4393073328","doi":"10.1158/1538-7445.am2024-6599","title":"Abstract 6599: 3D genomic analysis reveals novel enhancer hijacking mechanisms caused by complex structural alterations that drive oncogene overexpression","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Enhancer; Oncogene; Biology; Cancer research; Cell biology; Cancer; Genetics; Computational biology; Gene; Gene expression","score_opus":0.18460482854299134,"score_gpt":0.48257775260103336,"score_spread":0.297972924058042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393073328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80051637,0.0013686679,0.17293847,0.0004755534,0.00018836107,0.00010146763,0.01252789,0.0049969945,0.0068862564],"genre_scores_gemma":[0.8877491,0.0011780728,0.09097136,0.00037166607,0.000033486285,0.00018851158,0.012032866,0.0016893452,0.005785732],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975103,0.000015986694,0.000011790233,0.00006415721,0.000108243265,0.000048762595],"domain_scores_gemma":[0.9997882,0.0000557875,0.000048605296,0.000037219805,0.000032717995,0.000037331924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030395738,0.00043318424,0.0004015773,0.00069476414,0.0003265771,0.00071567664,0.00038262882,0.0005567969,0.0040485635],"category_scores_gemma":[0.00025588172,0.00038307442,0.00060092314,0.0004116283,0.00031508706,0.0002945491,0.0005746281,0.0010607282,0.0013426611],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044382545,0.000018414965,0.0009762055,0.00007598728,0.000018774552,0.00015736479,0.000038512884,0.0014295389,0.9926484,0.0004670473,0.0004922062,0.0036330537],"study_design_scores_gemma":[0.000025966192,0.00010764576,0.027320473,0.000028500826,0.000056695528,0.0007463309,0.00014404321,0.039349567,0.9140869,0.00082859525,0.017236741,0.00006870052],"about_ca_topic_score_codex":0.0019804377,"about_ca_topic_score_gemma":0.003182157,"teacher_disagreement_score":0.0040485635,"about_ca_system_score_codex":0.000508336,"about_ca_system_score_gemma":0.00028283327,"threshold_uncertainty_score":0.013543785},"labels":[],"label_agreement":null},{"id":"W4393075724","doi":"10.1158/1538-7445.am2024-6909","title":"Abstract 6909: KRASG12C inhibitor resistance in patient-derived non-small cell lung cancer models","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Cancer; Lung cancer; Internal medicine; Oncology","score_opus":0.09395832323132718,"score_gpt":0.4287630284169272,"score_spread":0.3348047051856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393075724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838213,0.0006885693,0.0055379346,0.00023580302,0.000052274416,0.00036008755,0.0059795156,0.00031045775,0.0030140933],"genre_scores_gemma":[0.97821075,0.0007015671,0.00616782,0.00012214147,0.000010380094,0.0004123134,0.007536995,0.00004755044,0.0067905122],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99964297,0.00006309119,0.00004617831,0.000072374554,0.0001225794,0.00005266863],"domain_scores_gemma":[0.9997148,0.000055529265,0.000052794418,0.00006245395,0.000039037688,0.00007530482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004809464,0.0004807759,0.00048052412,0.0004906434,0.00026762567,0.00050650653,0.0006108126,0.00057175447,0.0033178176],"category_scores_gemma":[0.00019270262,0.00020097083,0.00049841637,0.00037611692,0.00027815215,0.00028517624,0.00032844648,0.001398354,0.0010400425],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010205677,0.0010651207,0.0034481962,0.00013948063,0.000037345704,0.0003458272,0.00011845801,0.0015836114,0.9851265,0.00040900378,0.0011706906,0.005535275],"study_design_scores_gemma":[0.00020625102,0.008514811,0.018929385,0.000021697686,0.000065364446,0.001945908,0.00015385091,0.0072841463,0.9533292,0.00016827972,0.009359266,0.000021804808],"about_ca_topic_score_codex":0.0026302377,"about_ca_topic_score_gemma":0.0032940675,"teacher_disagreement_score":0.0033178176,"about_ca_system_score_codex":0.00061665295,"about_ca_system_score_gemma":0.0004846906,"threshold_uncertainty_score":0.01109916},"labels":[],"label_agreement":null},{"id":"W4393078914","doi":"10.1016/j.ejca.2024.113608","title":"Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Stage (stratigraphy); Breast cancer; Oncology; Placebo; Chemotherapy; Internal medicine; Adjuvant; Adjuvant chemotherapy; Cancer; Immunotherapy; Pathology","score_opus":0.04050519310740351,"score_gpt":0.3783540340905074,"score_spread":0.33784884098310386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393078914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98338,0.009269721,0.00053459825,0.0007282545,0.00046230052,0.0010307388,0.0012757431,0.000092791444,0.003225724],"genre_scores_gemma":[0.9871501,0.0047683236,0.0011379338,0.001037009,0.00030295787,0.000905202,0.0015360707,0.000027960657,0.0031346288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99959356,0.00021278522,0.000020947402,0.000065979046,0.000026403564,0.00008021486],"domain_scores_gemma":[0.9995571,0.0001365064,0.000086095235,0.000043414526,0.000017636901,0.00015924248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013969949,0.0010162615,0.0021053124,0.0002805264,0.0003178986,0.00074589107,0.0006075259,0.0008739296,0.003949496],"category_scores_gemma":[0.00082974415,0.00036618212,0.0015939813,0.00029903048,0.00068954355,0.0009127776,0.00025055485,0.002282842,0.00086725474],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9361245,0.011750648,0.00075829215,0.0005788851,0.0011685078,0.000036902446,0.00004002576,0.00067368563,0.0073379693,0.00010289318,0.0013179819,0.040109705],"study_design_scores_gemma":[0.6919343,0.2920278,0.00922662,0.00009487067,0.0016749137,0.000115479896,0.00005450573,0.0004988856,0.0017681345,0.0002995615,0.0022745957,0.000030261363],"about_ca_topic_score_codex":0.00105959,"about_ca_topic_score_gemma":0.004410218,"teacher_disagreement_score":0.003949496,"about_ca_system_score_codex":0.00075228105,"about_ca_system_score_gemma":0.0010829448,"threshold_uncertainty_score":0.013212383},"labels":[],"label_agreement":null},{"id":"W4393085303","doi":"10.1158/1538-7445.am2024-6996","title":"Abstract 6996: A role for the cell adhesion molecule NCAM1 in regulating activity of the receptor tyrosine kinase RET in cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Saskatchewan; Queen's University","funders":"","keywords":"Receptor tyrosine kinase; Cancer; Tyrosine kinase; Cancer research; Cell adhesion molecule; ROR1; Neural cell adhesion molecule; Cell biology; Chemistry; Cell adhesion; Receptor; Biology; Kinase; Cell; Signal transduction; Biochemistry; Platelet-derived growth factor receptor; Genetics","score_opus":0.11762551135676212,"score_gpt":0.46308895044232273,"score_spread":0.3454634390855606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393085303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751329,0.009950229,0.0042997804,0.0010282402,0.00019953278,0.000060025377,0.0018202309,0.00021183632,0.00729728],"genre_scores_gemma":[0.982479,0.002365959,0.0027501178,0.0002543563,0.000053582207,0.00005424956,0.0013755764,0.000033089935,0.010634112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989235,0.00000964152,0.000010021006,0.000021778806,0.00004541604,0.000020768424],"domain_scores_gemma":[0.999899,0.00001427785,0.00002709775,0.0000094055995,0.00001662225,0.000033700162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009291484,0.0003684203,0.00019159821,0.00030615844,0.0002695611,0.00029537446,0.00036084317,0.00044227226,0.002702375],"category_scores_gemma":[0.00013150218,0.0001049394,0.00018975433,0.00020994394,0.00020524257,0.00020146812,0.0002762024,0.0004965007,0.0009343561],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005468707,0.000008842524,0.00018342023,0.000027246582,0.0000029260307,0.0001294215,0.0000056017657,0.00003034513,0.99754214,0.000113946764,0.00008349047,0.0018178652],"study_design_scores_gemma":[0.000031873988,0.00026915426,0.023822023,0.000017942513,0.00002878043,0.001341512,0.000040946456,0.0010229656,0.9633461,0.00018413636,0.009885428,0.000008944292],"about_ca_topic_score_codex":0.0009963181,"about_ca_topic_score_gemma":0.0010249399,"teacher_disagreement_score":0.002702375,"about_ca_system_score_codex":0.0004210478,"about_ca_system_score_gemma":0.00019415317,"threshold_uncertainty_score":0.009040356},"labels":[],"label_agreement":null},{"id":"W4393085675","doi":"10.1158/1538-7445.am2024-1862","title":"Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Antibody-drug conjugate; Medicine; Drug; Conjugate; Antibody; Pharmacology; Cancer research; Immunology; Monoclonal antibody","score_opus":0.1774213273968225,"score_gpt":0.5574039194081839,"score_spread":0.3799825920113614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393085675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814523,0.002595853,0.0076845204,0.00019063597,0.000054521424,0.00023402825,0.0008667238,0.00018692271,0.006734523],"genre_scores_gemma":[0.980706,0.0016129486,0.0064596534,0.00007913857,0.000023318986,0.000078236575,0.0016176138,0.00004587883,0.009377333],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998883,0.000015080224,0.000007862216,0.00002025347,0.000043706128,0.000024754961],"domain_scores_gemma":[0.99993587,0.000005524726,0.00002381549,0.0000043522546,0.000016986225,0.000013468282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019358954,0.00052085525,0.00019082353,0.00026322302,0.00010932496,0.00021711693,0.00023670701,0.00030113297,0.0025927408],"category_scores_gemma":[0.00011952322,0.00014655519,0.00018019098,0.0002081977,0.000110181885,0.00026891247,0.00014452367,0.00040668415,0.0007875474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023950169,0.00009274173,0.00021020105,0.00005296292,0.000008958597,0.000042494044,0.000012295959,0.00024816062,0.9940538,0.0001388511,0.00026262752,0.004637339],"study_design_scores_gemma":[0.000056510635,0.0012188581,0.001042479,0.0000042078505,0.000018162968,0.00022152171,0.000005402286,0.0007938742,0.99195546,0.00001474334,0.004665257,0.0000034927248],"about_ca_topic_score_codex":0.00061611517,"about_ca_topic_score_gemma":0.00064416986,"teacher_disagreement_score":0.0025927408,"about_ca_system_score_codex":0.00044178934,"about_ca_system_score_gemma":0.00030238414,"threshold_uncertainty_score":0.008673608},"labels":[],"label_agreement":null},{"id":"W4393088686","doi":"10.1158/1538-7445.am2024-684","title":"Abstract 684: DT-9045, a novel PAR2 inhibitor with best-in-class properties that reduces resistance to both EGFR-targeting therapies and immunotherapy in oncology models","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada); Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Internal medicine; Cancer; Cancer research","score_opus":0.1920960856307969,"score_gpt":0.44219075160412197,"score_spread":0.2500946659733251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393088686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635579,0.0151821915,0.0060735047,0.00060848764,0.00031935482,0.0002967197,0.0023426872,0.00063118903,0.010987951],"genre_scores_gemma":[0.9815291,0.004602247,0.003004683,0.00039806476,0.000059184655,0.000104858336,0.002375017,0.000047856433,0.007879038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993,0.0000108907525,0.0000060087573,0.000016450364,0.000014729623,0.000021874857],"domain_scores_gemma":[0.99997294,0.0000018280832,0.0000072624957,0.0000022199417,0.0000033533865,0.0000124307635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000099487144,0.00049265503,0.00039060737,0.00023105022,0.00009993041,0.00024173957,0.00025414792,0.00031037073,0.002841149],"category_scores_gemma":[0.000060380284,0.00015041788,0.00028859984,0.00016759905,0.00010408541,0.00022557523,0.00014716433,0.0006457372,0.000867699],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025408107,0.0008142283,0.00041399125,0.00033978862,0.00009293956,0.0001908466,0.000024118059,0.00057891675,0.95847285,0.0004972119,0.003083707,0.03295067],"study_design_scores_gemma":[0.0021714175,0.010962019,0.0069408133,0.000027172919,0.000246814,0.0020548375,0.000021141068,0.0027866268,0.94217986,0.00013419967,0.032445457,0.000029716235],"about_ca_topic_score_codex":0.00045101493,"about_ca_topic_score_gemma":0.00051575387,"teacher_disagreement_score":0.002841149,"about_ca_system_score_codex":0.00021479576,"about_ca_system_score_gemma":0.00017506853,"threshold_uncertainty_score":0.009504557},"labels":[],"label_agreement":null},{"id":"W4393090873","doi":"10.1158/1538-7445.am2024-3127","title":"Abstract 3127: Development of three-dimensional cancer cell line spheroid models for the <i>in vitro</i> functional characterization of cytotoxic antibody-drug conjugates","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Spheroid; In vitro; Antibody-drug conjugate; Cytotoxic T cell; Cancer; Drug; Conjugate; Cell culture; Cancer cell lines; Cancer research; Antibody; Chemistry; Medicine; Biology; Cancer cell; Immunology; Pharmacology; Monoclonal antibody; Internal medicine; Biochemistry; Genetics; Mathematics","score_opus":0.12110038014965273,"score_gpt":0.4125313699256697,"score_spread":0.29143098977601695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393090873","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88568616,0.0030728742,0.08947868,0.00029588796,0.00016119922,0.00059799856,0.009255286,0.000971531,0.010480425],"genre_scores_gemma":[0.90244925,0.0020136354,0.07839814,0.0001042764,0.000015555499,0.00072102656,0.0073026717,0.0001646603,0.008830643],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997887,0.000026594631,0.000028124428,0.000050873416,0.000079308054,0.000026411915],"domain_scores_gemma":[0.9998049,0.000045898363,0.000042432534,0.000032235253,0.000048338912,0.000026114143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034483298,0.00047993887,0.00034792678,0.0002928366,0.00020650635,0.00028087082,0.0002479538,0.00044627112,0.0012625206],"category_scores_gemma":[0.00013205722,0.00021220985,0.00031947304,0.00036307276,0.00018683812,0.00025000554,0.00016203808,0.000437792,0.0008423666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042032272,0.000027949693,0.00017761085,0.00005395553,0.0000045157326,0.00006422893,0.00003377842,0.0005266106,0.9977731,0.00015903742,0.00019921431,0.00093800144],"study_design_scores_gemma":[0.0000093050385,0.00014095774,0.0018962423,0.0000054993684,0.000009927433,0.00011974171,0.000014067336,0.0041473727,0.99042624,0.000032714775,0.0031917286,0.000006155994],"about_ca_topic_score_codex":0.0031832778,"about_ca_topic_score_gemma":0.0039212084,"teacher_disagreement_score":0.0031832778,"about_ca_system_score_codex":0.00051345606,"about_ca_system_score_gemma":0.00037858103,"threshold_uncertainty_score":0.006329477},"labels":[],"label_agreement":null},{"id":"W4393093045","doi":"10.1158/1538-7445.am2024-1030","title":"Abstract 1030: Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: First phase of a large-scale, multicenter global ring study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Concordance; Breast cancer; Cancer; Destiny (ISS module); Medicine; Immunohistochemistry; Oncology; Internal medicine","score_opus":0.2276398584926865,"score_gpt":0.5914306417682521,"score_spread":0.3637907832755656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393093045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960495,0.00092899625,0.0024089334,0.000116633186,0.00006147667,0.0004481705,0.0022929462,0.00008038121,0.0040574893],"genre_scores_gemma":[0.9957086,0.000047111957,0.0013844064,0.000121984405,0.000018919196,0.00020337067,0.0019832093,0.000022343043,0.00051019783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9809739,0.01213889,0.0013035785,0.0024586965,0.0027552538,0.00036971495],"domain_scores_gemma":[0.97098696,0.013746388,0.0054498394,0.0032594407,0.0054375874,0.0011196728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023940587,0.00042980726,0.00044295448,0.0008899019,0.00039331752,0.0010325083,0.0011394271,0.00079206005,0.0021164624],"category_scores_gemma":[0.02291149,0.0003278902,0.00049654284,0.0006919832,0.0008703931,0.00063535717,0.0010471516,0.0006779956,0.0012696155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014687151,0.00060030614,0.9563846,0.00019831474,0.0009057401,0.00006630009,0.0005344213,0.0007426374,0.0067725163,0.00022047172,0.0034055114,0.0154821295],"study_design_scores_gemma":[0.00094150746,0.0051374943,0.97721696,0.00004419868,0.00039112833,0.00038564327,0.00020791992,0.0036562027,0.007889866,0.00015108172,0.0039450307,0.00003297177],"about_ca_topic_score_codex":0.0018459572,"about_ca_topic_score_gemma":0.0022369886,"teacher_disagreement_score":0.023940587,"about_ca_system_score_codex":0.0007666105,"about_ca_system_score_gemma":0.00047984443,"threshold_uncertainty_score":0.12661147},"labels":[],"label_agreement":null},{"id":"W4393166040","doi":"","title":"Amplification of cycline D1, c-myc and EGFR oncogenes in tumour samples of breast cancer patients","year":2013,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Biological Sciences","funders":"","keywords":"Breast cancer; Oncology; Cancer research; Gene duplication; Medicine; Internal medicine; Cancer; Biology; Gene; Genetics","score_opus":0.31373332295768513,"score_gpt":0.5966062829018832,"score_spread":0.2828729599441981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393166040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991941,0.00027380485,0.00008355197,0.000007726133,0.0000034214477,0.0000057257707,0.00019787945,0.000004367126,0.00022940959],"genre_scores_gemma":[0.99897516,0.00013454708,0.00014751282,0.000008324755,0.0000037521288,0.000014140103,0.0004461327,0.000002039081,0.0002683388],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998635,0.000014682615,0.00001831835,0.000038936592,0.000037086116,0.000027462069],"domain_scores_gemma":[0.99978966,0.00006309455,0.000059806258,0.000013582316,0.000038771166,0.00003511519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013968548,0.00013692546,0.00018016864,0.0006856717,0.0002332846,0.0002440545,0.00012136354,0.00024264543,0.0011989413],"category_scores_gemma":[0.0005340243,0.00011965903,0.00013661312,0.00046405883,0.00019356831,0.00009394949,0.00018237792,0.00018340224,0.00025236158],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014294299,0.0001283129,0.9387305,0.000105823965,0.00005679641,0.001969193,0.00041307954,0.000138132,0.04964386,0.000038159753,0.00019380379,0.007152935],"study_design_scores_gemma":[0.00001958159,0.00043475776,0.97900224,0.000007034155,0.000054738837,0.008193871,0.0002568766,0.0002474166,0.010878808,0.000023786166,0.0008755333,0.000005413453],"about_ca_topic_score_codex":0.00081939704,"about_ca_topic_score_gemma":0.00081927644,"teacher_disagreement_score":0.0011989413,"about_ca_system_score_codex":0.0001831747,"about_ca_system_score_gemma":0.00012959153,"threshold_uncertainty_score":0.004010856},"labels":[],"label_agreement":null},{"id":"W4393317592","doi":"10.21203/rs.3.rs-4165568/v1","title":"Backbone and methyl side-chain resonance assignments of the single chain Fab fragment of trastuzumab","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Canada","funders":"","keywords":"Trastuzumab; Fragment (logic); Chain (unit); Side chain; Chemistry; Resonance (particle physics); Stereochemistry; Computer science; Physics; Medicine; Algorithm; Internal medicine; Organic chemistry; Cancer; Polymer","score_opus":0.11143938424696605,"score_gpt":0.4332458645943632,"score_spread":0.3218064803473972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393317592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792205,0.0009082614,0.012107613,0.00021451504,0.000047652804,0.000014732165,0.00077039126,0.00013181877,0.0065844585],"genre_scores_gemma":[0.9829654,0.0007428601,0.00865177,0.00009673898,0.000018011922,0.000019307927,0.0020290718,0.00006317846,0.00541371],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999254,0.0000090181065,0.0000018739569,0.000016934287,0.000021944545,0.000024840592],"domain_scores_gemma":[0.9998882,0.000018810628,0.000025220346,0.000014737058,0.00003012901,0.000022799899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015529124,0.00021408833,0.00013434685,0.00026768027,0.00018152346,0.000088932225,0.00036847315,0.00023709168,0.0033277378],"category_scores_gemma":[0.0002042787,0.00009199293,0.00014338573,0.00024109735,0.00015227344,0.00014935227,0.00014560217,0.00040670703,0.00044299607],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017833649,0.000012352411,0.00025292998,0.00003057881,0.0000059851877,0.00008300222,0.000027491931,0.00023395366,0.995852,0.00019364244,0.00019956534,0.0029302193],"study_design_scores_gemma":[0.000024374933,0.00016550423,0.005216312,0.000010179392,0.000015727524,0.00026738795,0.000035798123,0.0020588927,0.9886218,0.00015383966,0.003420342,0.000009941255],"about_ca_topic_score_codex":0.0010528935,"about_ca_topic_score_gemma":0.00084103964,"teacher_disagreement_score":0.0033277378,"about_ca_system_score_codex":0.00020364199,"about_ca_system_score_gemma":0.0002016011,"threshold_uncertainty_score":0.0111323595},"labels":[],"label_agreement":null},{"id":"W4393989206","doi":"10.1158/1538-7445.am2024-ct265","title":"Abstract CT265: Trastuzumab emtansine in patients (pts) with <i>HER2</i> mutation-positive <i>(HER2</i>mut<i>)</i> tumors: TAPISTRY study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Trastuzumab; Trastuzumab emtansine; Medicine; Mutation; Internal medicine; Oncology; Cancer; Cancer research; Breast cancer; Biology; Genetics; Gene","score_opus":0.048789231404111184,"score_gpt":0.4222173071015696,"score_spread":0.37342807569745845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393989206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890593,0.0016855539,0.0002894704,0.00045701495,0.00006931505,0.00068137975,0.0040137772,0.000054364205,0.0036896828],"genre_scores_gemma":[0.9900157,0.00092274183,0.00036358825,0.00058773084,0.00013066958,0.0003813706,0.0053786235,0.000017524579,0.002202059],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976546,0.00010512952,0.000016740738,0.000047670233,0.00003350749,0.0000315191],"domain_scores_gemma":[0.99958736,0.000052980904,0.00011408286,0.000025760202,0.00003742465,0.0001824279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008792668,0.0006966136,0.000700599,0.00020593162,0.00024478298,0.00069735624,0.00033931766,0.0005044436,0.0037568125],"category_scores_gemma":[0.00061160896,0.00022390643,0.0008279707,0.00033209985,0.00034145828,0.00052619085,0.00032324443,0.0015350993,0.0008190149],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80848724,0.013268395,0.049506906,0.00091168773,0.0018247637,0.00047866502,0.00019870853,0.0025495226,0.03408365,0.0003946893,0.016520878,0.071775004],"study_design_scores_gemma":[0.44902882,0.37753266,0.1391313,0.0002027361,0.0030117715,0.0011019696,0.00016092011,0.002459576,0.010140763,0.00040634474,0.016749857,0.0000733242],"about_ca_topic_score_codex":0.0008999003,"about_ca_topic_score_gemma":0.0024210797,"teacher_disagreement_score":0.0037568125,"about_ca_system_score_codex":0.0007134254,"about_ca_system_score_gemma":0.00092914817,"threshold_uncertainty_score":0.012567818},"labels":[],"label_agreement":null},{"id":"W4393994610","doi":"10.1038/s41388-024-03023-2","title":"Correction: E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer","year":2024,"lang":"en","type":"erratum","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"National Cancer Institute; Johns Hopkins University","keywords":"Biology; Cadherin; MAPK/ERK pathway; Breast cancer; Cancer research; Carcinogenesis; Cancer; Internal medicine; Oncology; Bioinformatics; Cell biology; Signal transduction; Genetics; Cell","score_opus":0.06554297268671097,"score_gpt":0.3582832299099896,"score_spread":0.2927402572232787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393994610","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022268554,0.00064535334,0.00070566253,0.036668357,0.95921767,0.000014705139,0.00067590666,0.00030357204,0.0015460153],"genre_scores_gemma":[0.030123448,0.01031762,0.011309109,0.11133077,0.45524457,0.00029108246,0.0035104805,0.0027445972,0.37512833],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697435,0.0003900439,0.00047841162,0.00040561278,0.0014329817,0.0003186495],"domain_scores_gemma":[0.98179376,0.0041388287,0.0010421483,0.001250516,0.01044785,0.0013269517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032902386,0.002283406,0.0018091188,0.0029630302,0.0025937215,0.0028197675,0.0034215497,0.0075123194,0.04483794],"category_scores_gemma":[0.03732712,0.0011131819,0.0018621278,0.0016514922,0.002022831,0.0017930107,0.0017228904,0.0116427345,0.02312791],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067138986,0.000010403207,0.0000770902,0.00014368622,0.000024867097,0.0007368165,0.000024080811,0.000058076246,0.0001927969,0.00072022196,0.9931466,0.0047982386],"study_design_scores_gemma":[0.00011474728,0.00003623129,0.0010125712,0.0002693188,0.00012333419,0.0022012554,0.000094476614,0.0004600446,0.0016315979,0.0016862254,0.99230725,0.00006291639],"about_ca_topic_score_codex":0.011807661,"about_ca_topic_score_gemma":0.01354198,"teacher_disagreement_score":0.04483794,"about_ca_system_score_codex":0.0034907728,"about_ca_system_score_gemma":0.0038556326,"threshold_uncertainty_score":0.14999789},"labels":[],"label_agreement":null},{"id":"W4394071983","doi":"10.6084/m9.figshare.13154069","title":"Metadata record for the manuscript: Glembatumumab vedotin for patients with metastatic, gpNMB over-expressing, triplenegative breast cancer (“METRIC”): A Randomized Multicenter Study","year":2021,"lang":"en","type":"dataset","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metadata; Oncology; Medicine; Internal medicine; Metric (unit); Breast cancer; Randomized controlled trial; Metastatic breast cancer; World Wide Web; Cancer; Computer science; Engineering","score_opus":0.079194503838024,"score_gpt":0.38363819325446313,"score_spread":0.3044436894164391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394071983","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059915625,0.00089644967,0.001263259,0.0082055135,0.0020340201,0.004639886,0.9543428,0.0017618648,0.026257025],"genre_scores_gemma":[0.010561346,0.0036335352,0.012339896,0.013239912,0.003261615,0.020769767,0.84906286,0.0032696563,0.083861366],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907816,0.002141424,0.0037427554,0.0006812331,0.0022076333,0.00044529373],"domain_scores_gemma":[0.90394443,0.037089556,0.015880352,0.01205243,0.026085138,0.004948074],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010386682,0.0010386731,0.0026249604,0.0035198007,0.0017036751,0.007416786,0.0024446188,0.0037953425,0.7142374],"category_scores_gemma":[0.099529244,0.0013211248,0.0026988701,0.0061626513,0.00094115053,0.0055512437,0.002484918,0.0027237844,0.317589],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012429602,0.00006853498,0.00067308336,0.0064422,0.00009612897,0.000038138915,0.000041092862,0.000086660795,0.0003307828,0.0013111234,0.9669999,0.022669412],"study_design_scores_gemma":[0.006844192,0.0005665923,0.004899608,0.006740824,0.00031089524,0.00025784792,0.00018599402,0.0002610907,0.0012222957,0.0040310607,0.9745499,0.00012967225],"about_ca_topic_score_codex":0.003895396,"about_ca_topic_score_gemma":0.008825275,"teacher_disagreement_score":0.7142374,"about_ca_system_score_codex":0.0027519346,"about_ca_system_score_gemma":0.011269245,"threshold_uncertainty_score":0.40760565},"labels":[],"label_agreement":null},{"id":"W4394724801","doi":"10.1186/s40959-024-00223-3","title":"Cancer therapy related cardiac dysfunction as a result of Panitumumab","year":2024,"lang":"en","type":"article","venue":"Cardio-Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"Fondation Leducq","keywords":"Panitumumab; Medicine; Ejection fraction; Cardiology; Internal medicine; Heart failure; Colorectal cancer; Radiology; Oncology; Cancer; Cetuximab","score_opus":0.051955655534409256,"score_gpt":0.4218888970599156,"score_spread":0.36993324152550633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394724801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97029704,0.007428596,0.0026213261,0.0016482379,0.0002572187,0.00009359737,0.00010979878,0.00015200267,0.017392093],"genre_scores_gemma":[0.99745303,0.00073637156,0.00016600551,0.00053881126,0.00017343079,0.000008530197,0.000064010295,0.0000073837773,0.0008524074],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9997658,0.000047291836,0.00001805871,0.000046383142,0.000042415337,0.000079992235],"domain_scores_gemma":[0.99906725,0.0002906521,0.0002732101,0.000077346944,0.000069173795,0.0002224133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030219337,0.0004859901,0.00040450133,0.00040933795,0.0005323637,0.00038943638,0.00029293823,0.0009219767,0.001478706],"category_scores_gemma":[0.0014076112,0.00014863723,0.0004561267,0.00032270805,0.00041327078,0.00029876546,0.0003360145,0.0013747521,0.0003708035],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040477695,0.000113576796,0.11187418,0.00008968365,0.000058045884,0.86309654,0.00030915227,0.00024697123,0.006679712,0.00051283743,0.0013918276,0.0152228],"study_design_scores_gemma":[0.00006501068,0.00061826943,0.12566212,0.000082507344,0.00009088349,0.8626797,0.00017235114,0.0012294425,0.0035607212,0.00045095704,0.005370174,0.000017863471],"about_ca_topic_score_codex":0.0006390267,"about_ca_topic_score_gemma":0.00096588884,"teacher_disagreement_score":0.001478706,"about_ca_system_score_codex":0.00041116864,"about_ca_system_score_gemma":0.0002493466,"threshold_uncertainty_score":0.0049467683},"labels":[],"label_agreement":null},{"id":"W4395464611","doi":"10.51731/cjht.2024.875","title":"Sacituzumab Govitecan (Trodelvy)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Immunohistochemistry; Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Metastatic breast cancer; Internal medicine; Family medicine; Cancer; Breast cancer; Political science","score_opus":0.060535617426535994,"score_gpt":0.3863126043444558,"score_spread":0.3257769869179198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395464611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028330877,0.8634068,0.0012022963,0.004078837,0.0006952055,0.0003009349,0.0016640051,0.00019463961,0.10012646],"genre_scores_gemma":[0.27790472,0.6577558,0.0033809138,0.004107879,0.00049508555,0.000189664,0.0030177818,0.00004355143,0.053104624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996183,0.000073104195,0.000024966606,0.000032252483,0.00021519802,0.000036140536],"domain_scores_gemma":[0.99972147,0.000055516182,0.00006702204,0.000007897295,0.00011905703,0.000029025372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000586769,0.00020374746,0.00026484442,0.0010419452,0.0001728629,0.00068874453,0.00027967637,0.00032317356,0.0048493315],"category_scores_gemma":[0.0007088154,0.00006565288,0.00034063938,0.000786415,0.0002216067,0.00024629247,0.00016775573,0.00043138186,0.0010346337],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045899116,0.0000574652,0.0011162513,0.0029858495,0.0001533034,0.00016959482,0.00003822853,0.00033656464,0.0059303483,0.002569692,0.03938471,0.94679904],"study_design_scores_gemma":[0.0003489646,0.00084548915,0.006953319,0.0022808188,0.00029882873,0.0015114058,0.00006640255,0.0002676855,0.005416973,0.0004964178,0.98149544,0.000018296943],"about_ca_topic_score_codex":0.016675342,"about_ca_topic_score_gemma":0.08659583,"teacher_disagreement_score":0.016675342,"about_ca_system_score_codex":0.0020408293,"about_ca_system_score_gemma":0.002143241,"threshold_uncertainty_score":0.033156574},"labels":[],"label_agreement":null},{"id":"W4395467322","doi":"10.1007/s10549-024-07302-0","title":"Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey","year":2024,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Pertuzumab; Trastuzumab; Internal medicine; myalgia; Clinical trial; Cancer; Adverse effect; Oncology; Physical therapy","score_opus":0.07811656565937058,"score_gpt":0.42488924505717257,"score_spread":0.346772679397802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395467322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817135,0.0031678837,0.00024402043,0.009182877,0.00006604035,0.000018592611,0.0020828487,0.00000737185,0.003516913],"genre_scores_gemma":[0.9929403,0.001997718,0.00013230686,0.0035202533,0.00012458026,0.000025028672,0.00077463704,0.0000037047716,0.0004814946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907446,0.00041068572,0.00011791904,0.00008419172,0.00012638688,0.00018640829],"domain_scores_gemma":[0.9937575,0.0016835515,0.0028929918,0.00012285914,0.00051173096,0.0010313381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019748388,0.00011810601,0.0002900795,0.0004196699,0.00040483812,0.0007474355,0.00022189382,0.00065843825,0.003861118],"category_scores_gemma":[0.005197737,0.00010314283,0.00042852454,0.0013075449,0.00019161026,0.0010350425,0.00032075174,0.00072292663,0.0002986322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022923668,0.000101930986,0.98650867,0.000061837476,0.000048524664,0.00007007077,0.00038709174,0.00006905874,0.0002511629,0.00009128011,0.0011341878,0.011046849],"study_design_scores_gemma":[0.000018138135,0.00026428193,0.9949582,0.000036579466,0.000039108152,0.0001678517,0.0013765814,0.000059260627,0.00006215467,0.000054182805,0.0029545831,0.000009057342],"about_ca_topic_score_codex":0.00681075,"about_ca_topic_score_gemma":0.009622826,"teacher_disagreement_score":0.00681075,"about_ca_system_score_codex":0.0005428052,"about_ca_system_score_gemma":0.00074891705,"threshold_uncertainty_score":0.013542235},"labels":[],"label_agreement":null},{"id":"W4396228518","doi":"10.1111/febs.17143","title":"Can the <scp>HB‐EGF</scp>/<scp>EGFR</scp> pathway restore injured neurons?","year":2024,"lang":"en","type":"article","venue":"FEBS Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; Calouste Gulbenkian Foundation","keywords":"Cell biology; Chemistry; Neuroscience; Biology","score_opus":0.0475490130170152,"score_gpt":0.34178681163406627,"score_spread":0.29423779861705107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396228518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8951028,0.055894192,0.009811078,0.018774785,0.0027214843,0.00030823416,0.00090802554,0.00068733783,0.015792053],"genre_scores_gemma":[0.93064255,0.048053876,0.004512005,0.0034341242,0.00032135204,0.00017249493,0.0008819367,0.00008173431,0.011899851],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998858,0.000014513984,0.0000090453805,0.000014010388,0.000028709175,0.000047873527],"domain_scores_gemma":[0.9999286,0.000010332927,0.0000150332735,0.0000093648305,0.000014821023,0.00002194064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003174882,0.0003995026,0.00050030893,0.00023170783,0.00022556428,0.00052798394,0.00038557054,0.001058576,0.0024032795],"category_scores_gemma":[0.00022596293,0.00010014753,0.00048035194,0.000110044646,0.0004307936,0.00067013846,0.00022661623,0.0013394181,0.0007634058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032996042,0.0013636152,0.00065994344,0.0011751724,0.00020655534,0.0009966693,0.00009495626,0.0005866869,0.8684575,0.0043919706,0.009009603,0.10975779],"study_design_scores_gemma":[0.0012390413,0.0107805785,0.010426741,0.0003341375,0.00057369063,0.003999314,0.00051173446,0.003122921,0.8467558,0.0055003576,0.1166653,0.00009049791],"about_ca_topic_score_codex":0.0006652137,"about_ca_topic_score_gemma":0.0015050777,"teacher_disagreement_score":0.0024032795,"about_ca_system_score_codex":0.0002770313,"about_ca_system_score_gemma":0.000468162,"threshold_uncertainty_score":0.008039832},"labels":[],"label_agreement":null},{"id":"W4396586818","doi":"10.1158/1538-7445.sabcs23-ps17-07","title":"Abstract PS17-07: Interim analysis of giredestrant + inavolisib in MORPHEUS Breast Cancer: a Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Breast cancer; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Cancer; Estrogen receptor; Interim analysis; HER2 negative; Interim; Clinical trial","score_opus":0.09188087022298844,"score_gpt":0.48113297864485843,"score_spread":0.38925210842186997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396586818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969556,0.0024470706,0.0010974956,0.00066634786,0.00036844664,0.0051983465,0.0065052505,0.00024006257,0.0037814323],"genre_scores_gemma":[0.9664075,0.0020868753,0.003016462,0.0013236783,0.0002725161,0.008389525,0.010216524,0.000104838604,0.008182203],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993191,0.00030259296,0.000034674867,0.000091093556,0.00006592043,0.00018665301],"domain_scores_gemma":[0.9989473,0.00015146975,0.00018530805,0.00012596746,0.00008216143,0.0005078174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002432119,0.0019150858,0.0034187282,0.0006549494,0.0004921913,0.0013883256,0.0009939764,0.0011975311,0.0077746785],"category_scores_gemma":[0.0013716808,0.00065045344,0.0027870585,0.00054484204,0.0010170988,0.0010797261,0.00048145602,0.0042401315,0.0018489336],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91937023,0.02457713,0.003077807,0.00043620833,0.001599333,0.00012632289,0.000088013665,0.0023340916,0.013415587,0.00021694216,0.0034742935,0.031284004],"study_design_scores_gemma":[0.426511,0.5515053,0.010281224,0.000048766567,0.0014442417,0.00021382507,0.000086320906,0.0013881252,0.0035416675,0.00048807962,0.0044411663,0.000050374794],"about_ca_topic_score_codex":0.0009791781,"about_ca_topic_score_gemma":0.0020404418,"teacher_disagreement_score":0.0077746785,"about_ca_system_score_codex":0.000996761,"about_ca_system_score_gemma":0.0019116929,"threshold_uncertainty_score":0.026008904},"labels":[],"label_agreement":null},{"id":"W4396587235","doi":"10.1158/1538-7445.sabcs23-ps16-03","title":"Abstract PS16-03: Intratumoral dosing of INT230-6 in Early-Stage Breast Cancer Patients Induces Tumor Cell Necrosis and Immunomodulatory Effects: A Phase II Randomized Window-Of-Opportunity Study – the INVINCIBLE Trial","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Ontario Institute for Cancer Research; Institute of Cancer Research; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Randomized controlled trial; Stage (stratigraphy); Dosing; Cancer; Necrosis; Window of opportunity; Oncology; Internal medicine; Therapeutic window; Pathology; Pharmacology; Biology","score_opus":0.08482277067803398,"score_gpt":0.436833172211823,"score_spread":0.35201040153378904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396587235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164057,0.0022135312,0.00048624916,0.0005061901,0.00015784604,0.0019093371,0.0009881536,0.00010795695,0.0019902135],"genre_scores_gemma":[0.98808515,0.0017321506,0.0013578353,0.00069742557,0.00019458745,0.0022015325,0.0012484211,0.000035519904,0.0044472646],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997131,0.00013226132,0.0000150683245,0.000052444862,0.0000310979,0.000056026267],"domain_scores_gemma":[0.999553,0.000072557545,0.000114452065,0.00004564226,0.000026470841,0.00018782375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00115538,0.001325855,0.0012546015,0.00029171194,0.000257986,0.0008837491,0.00068201136,0.0011585386,0.0054336493],"category_scores_gemma":[0.00060967734,0.00037012168,0.0011160094,0.0003047841,0.00081921445,0.0008269429,0.0002573225,0.0033453782,0.0009507544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8282757,0.046857726,0.0016534583,0.00089257635,0.000756228,0.00012804674,0.00012640214,0.001138653,0.04829849,0.00037975193,0.0031217248,0.06837128],"study_design_scores_gemma":[0.59675807,0.38921672,0.0033295802,0.000044752513,0.00033693458,0.00014925773,0.000044412634,0.000678607,0.0066104243,0.0003759171,0.0024295105,0.000025724414],"about_ca_topic_score_codex":0.0005207215,"about_ca_topic_score_gemma":0.001221606,"teacher_disagreement_score":0.0054336493,"about_ca_system_score_codex":0.0007593901,"about_ca_system_score_gemma":0.0013089279,"threshold_uncertainty_score":0.01817739},"labels":[],"label_agreement":null},{"id":"W4396588255","doi":"10.1158/1538-7445.sabcs23-gs01-10","title":"Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Trastuzumab emtansine; Medicine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Trastuzumab; Cancer; Double blind; Randomized controlled trial; Pathology; Alternative medicine","score_opus":0.1888228164544587,"score_gpt":0.5289525704182272,"score_spread":0.3401297539637685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396588255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647401,0.0036172643,0.0010520255,0.0014683427,0.001163784,0.017481182,0.0044592875,0.00060231565,0.0054156994],"genre_scores_gemma":[0.96524954,0.0020213614,0.0018556362,0.0028108633,0.0007297273,0.014591026,0.0033901446,0.00007544395,0.009276239],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99930084,0.00033681688,0.00003491821,0.000137618,0.000053797907,0.00013595077],"domain_scores_gemma":[0.9991505,0.00013638572,0.00013908005,0.000058758418,0.00005653092,0.00045867125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022550733,0.0023603893,0.0031178112,0.000573257,0.0006881177,0.0015617098,0.0013170142,0.002205198,0.013230745],"category_scores_gemma":[0.0013178876,0.0010780278,0.0015587163,0.0005542519,0.0017234546,0.0012476922,0.0004629629,0.0042877905,0.0025429162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9793762,0.008771973,0.0002852231,0.00031671862,0.00040973106,0.000037169517,0.0000282289,0.00026219734,0.0028176429,0.00009300717,0.0014712027,0.006130754],"study_design_scores_gemma":[0.96778685,0.030745843,0.00053622643,0.000010576007,0.00008979761,0.000017536197,0.0000066217303,0.00019666419,0.00016544417,0.00006689292,0.0003699086,0.000007594183],"about_ca_topic_score_codex":0.0013890887,"about_ca_topic_score_gemma":0.0047064465,"teacher_disagreement_score":0.013230745,"about_ca_system_score_codex":0.001116946,"about_ca_system_score_gemma":0.0023840782,"threshold_uncertainty_score":0.044261217},"labels":[],"label_agreement":null},{"id":"W4396591228","doi":"10.1158/1538-7445.sabcs23-po1-04-07","title":"Abstract PO1-04-07: Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical breast cancer models","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Antibody-drug conjugate; Cancer; Oncology; Stage (stratigraphy); Breast cancer; Drug; Internal medicine; Conjugate; Pharmacology; Antibody; Monoclonal antibody; Immunology; Biology","score_opus":0.1508340742934629,"score_gpt":0.5248850737820561,"score_spread":0.37405099948859316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396591228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216074,0.0013905461,0.0012058896,0.00016534881,0.000038857866,0.0000865826,0.0008150405,0.00013116919,0.0040057236],"genre_scores_gemma":[0.992446,0.00063787174,0.0008972018,0.00005245456,0.000010174057,0.000054790606,0.0017077302,0.000019491343,0.004174278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999923,0.000013329697,0.000004580371,0.000012758015,0.000019330852,0.000027095712],"domain_scores_gemma":[0.9999614,0.0000058761393,0.0000071918075,0.000003535227,0.000005279956,0.000016771346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110843685,0.0003279227,0.0002684616,0.00019573684,0.00010242157,0.0002659758,0.00021064273,0.00024976418,0.0023818507],"category_scores_gemma":[0.000076272845,0.00008891077,0.0001391626,0.00014967761,0.00011578943,0.00018272779,0.00009054395,0.0006472681,0.00045269934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025301517,0.0013782773,0.00046261068,0.00009945316,0.000024224368,0.00009811673,0.000019936877,0.0007041163,0.9749341,0.00019404247,0.0013265095,0.018228509],"study_design_scores_gemma":[0.00044460234,0.009241559,0.0037529282,0.0000062444524,0.00003596287,0.0004212888,0.000013972678,0.0019214295,0.9776898,0.00003763381,0.006428671,0.0000058569976],"about_ca_topic_score_codex":0.0009109679,"about_ca_topic_score_gemma":0.0009365376,"teacher_disagreement_score":0.0023818507,"about_ca_system_score_codex":0.00034096153,"about_ca_system_score_gemma":0.0002811642,"threshold_uncertainty_score":0.007968128},"labels":[],"label_agreement":null},{"id":"W4396716435","doi":"10.14740/wjon1829","title":"Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Taxane; Internal medicine; Metastatic breast cancer; Oncology; Clinical trial; Breast cancer; Cancer; Gynecology","score_opus":0.05443212531543985,"score_gpt":0.45939366738275805,"score_spread":0.4049615420673182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396716435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936848,0.005362063,0.00010702752,0.00012475345,0.000009767179,0.000048868227,0.000043734322,0.000013007359,0.0006058742],"genre_scores_gemma":[0.99933076,0.00038163093,0.00013055785,0.000025536436,0.000011787457,0.000015818341,0.00005333871,9.733299e-7,0.00004955913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802643,0.0011702622,0.00017086879,0.00018033064,0.00031486835,0.00013713598],"domain_scores_gemma":[0.99623054,0.0009079626,0.0016145221,0.00019308396,0.0005238245,0.0005299661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003235322,0.00019843644,0.00075993815,0.00044833866,0.00023438397,0.00054461876,0.0003890321,0.0003833437,0.0005716093],"category_scores_gemma":[0.008328982,0.00009312231,0.00032091816,0.00031987138,0.00027413902,0.00036230483,0.00057164714,0.00033774186,0.00009815077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014606882,0.0025334018,0.64597756,0.00063655386,0.00043686517,0.00040729807,0.0008555807,0.0018240015,0.0043790964,0.000094112045,0.0006820507,0.3275666],"study_design_scores_gemma":[0.00068953563,0.03285111,0.95720196,0.00014060872,0.00033756942,0.0013742655,0.00033939176,0.001982676,0.0023149147,0.000073066745,0.0026736152,0.000021354963],"about_ca_topic_score_codex":0.0018078533,"about_ca_topic_score_gemma":0.0019063769,"teacher_disagreement_score":0.003235322,"about_ca_system_score_codex":0.000935803,"about_ca_system_score_gemma":0.0007182926,"threshold_uncertainty_score":0.017110229},"labels":[],"label_agreement":null},{"id":"W4396904404","doi":"10.1101/2024.05.10.593500","title":"G6b-B antibody-based cis-acting platelet receptor inhibitors (CAPRIs) as a new family of anti-thrombotic therapeutics","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Institut National de la Santé et de la Recherche Médicale; Etablissement Français du Sang; Agence Nationale de la Recherche","keywords":"Antibody; Platelet; Pharmacology; Chemistry; Receptor; Medicine; Immunology; Biochemistry","score_opus":0.04383900418984382,"score_gpt":0.32598727391547655,"score_spread":0.2821482697256327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396904404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6693258,0.24723159,0.05603357,0.0016523219,0.0006519961,0.00047008545,0.00076933595,0.0010043309,0.022860974],"genre_scores_gemma":[0.9105909,0.06296571,0.017196467,0.00089223345,0.00015912806,0.0001798966,0.00081223017,0.00003922315,0.007164202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999118,0.00001466681,0.0000038421326,0.000018120769,0.000033183678,0.0000184457],"domain_scores_gemma":[0.9999678,0.000004534405,0.0000093583585,0.0000026557104,0.000006326448,0.000009264276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013482194,0.00042252944,0.00025279095,0.00024868303,0.0000799968,0.0003303281,0.00032933665,0.00042065,0.00074954645],"category_scores_gemma":[0.00007324227,0.00009689433,0.00022140521,0.00015512845,0.00016016142,0.0001993452,0.0001746269,0.0008721839,0.00031675052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029762875,0.00019368218,0.00028405758,0.00036683382,0.000043821772,0.00025064216,0.000042053292,0.00085035054,0.9246615,0.0024294958,0.0014635891,0.06911634],"study_design_scores_gemma":[0.0001696636,0.0039370228,0.0022672333,0.000051929514,0.00012703327,0.0026191748,0.000027350374,0.0037812057,0.89739865,0.00041964362,0.089173995,0.000027163604],"about_ca_topic_score_codex":0.00024767665,"about_ca_topic_score_gemma":0.0004445204,"teacher_disagreement_score":0.00074954645,"about_ca_system_score_codex":0.00024786187,"about_ca_system_score_gemma":0.00015626,"threshold_uncertainty_score":0.0025075078},"labels":[],"label_agreement":null},{"id":"W4397007360","doi":"10.1016/j.esmoop.2024.103115","title":"127P Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Pertuzumab; Atezolizumab; Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Immunotherapy","score_opus":0.051704810733827496,"score_gpt":0.41411049754855733,"score_spread":0.36240568681472984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963206,0.0084641185,0.0013546542,0.0008848775,0.00026968675,0.0023470623,0.00957617,0.00022001202,0.013677381],"genre_scores_gemma":[0.96968675,0.0056273416,0.0016594683,0.0009843499,0.00018222225,0.0024789919,0.008573693,0.000042927153,0.010764338],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998505,0.000082971725,0.0000094566785,0.000017538925,0.000020267988,0.000019261071],"domain_scores_gemma":[0.9998586,0.000045321874,0.000030783754,0.000009442697,0.00000935698,0.000046446723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045091286,0.00041155316,0.000733898,0.00015144054,0.0001139006,0.00032478588,0.00030647556,0.00041044634,0.010210336],"category_scores_gemma":[0.0003813759,0.00014993588,0.00057662494,0.00020376805,0.00019501962,0.00021683164,0.00018718709,0.0009035846,0.0012353725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64979345,0.0070468844,0.003575217,0.0023047172,0.0013993268,0.00017686577,0.00006365079,0.0012129721,0.026670594,0.00039175255,0.02230427,0.28506026],"study_design_scores_gemma":[0.6977673,0.24910502,0.024606667,0.00023673581,0.0013376811,0.0006786904,0.00004215656,0.0014963811,0.0070100976,0.00039439887,0.017302727,0.000022183041],"about_ca_topic_score_codex":0.00032651672,"about_ca_topic_score_gemma":0.0009686651,"teacher_disagreement_score":0.010210336,"about_ca_system_score_codex":0.0003007964,"about_ca_system_score_gemma":0.00037590953,"threshold_uncertainty_score":0.034156978},"labels":[],"label_agreement":null},{"id":"W4399122010","doi":"10.1200/jco.2024.42.16_suppl.1005","title":"Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Oncology; Triple-negative breast cancer; Internal medicine; Triple negative; Cancer; Gynecology","score_opus":0.1377817727281921,"score_gpt":0.5451264201042444,"score_spread":0.4073446473760523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963671,0.0010968893,0.00012282666,0.0001282709,0.00003692124,0.00052828586,0.00065448176,0.000019440342,0.0010458473],"genre_scores_gemma":[0.99265224,0.00075476593,0.0006504848,0.00033183678,0.00004214649,0.000779305,0.002672092,0.000011448363,0.0021057266],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997942,0.00007361571,0.000012419158,0.00003925995,0.000023816705,0.000056702687],"domain_scores_gemma":[0.9996873,0.00003642348,0.000042836717,0.000024919944,0.000024246823,0.00018443118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008678516,0.0005330647,0.00068434025,0.00020970605,0.00028136853,0.0005690622,0.00029844744,0.0004936344,0.0033303371],"category_scores_gemma":[0.00044575648,0.00022403816,0.00042324016,0.00021798107,0.0003017632,0.0004684158,0.00034545784,0.0012278255,0.00052690884],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64733964,0.061313227,0.044762105,0.0009247497,0.0011378555,0.0004553432,0.0004932589,0.00207674,0.070285976,0.00064578466,0.008622177,0.1619432],"study_design_scores_gemma":[0.2292559,0.6178894,0.10570366,0.00014460513,0.0011694226,0.0017419229,0.0003784897,0.0032045452,0.014582498,0.0009042908,0.024975672,0.000049547478],"about_ca_topic_score_codex":0.0010068297,"about_ca_topic_score_gemma":0.003999332,"teacher_disagreement_score":0.0033303371,"about_ca_system_score_codex":0.0007586448,"about_ca_system_score_gemma":0.0011401197,"threshold_uncertainty_score":0.011141121},"labels":[],"label_agreement":null},{"id":"W4399122099","doi":"10.1200/jco.2024.42.16_suppl.1007","title":"Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Medicine; Pertuzumab; Trastuzumab; Eribulin; Taxane; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Paclitaxel; Anthracycline; Cancer","score_opus":0.11762713107934504,"score_gpt":0.5248258775869272,"score_spread":0.4071987465075822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98968375,0.00395958,0.00046266228,0.0006062454,0.0003753783,0.0027150533,0.0006917462,0.00006503378,0.0014405422],"genre_scores_gemma":[0.986754,0.0032532318,0.001768571,0.0011512236,0.0004939932,0.0027479816,0.001557889,0.000027867567,0.002245248],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989617,0.0006992232,0.000058646776,0.00010690955,0.000058182617,0.00011537838],"domain_scores_gemma":[0.998968,0.00021196649,0.00024075962,0.000097990574,0.000050100884,0.0004311199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003399726,0.001600616,0.0025818876,0.00060032867,0.0004057099,0.0009956155,0.0010687434,0.0016272956,0.004082777],"category_scores_gemma":[0.0016272715,0.0007677191,0.0020320166,0.00057949685,0.0014833439,0.0012978233,0.00046887124,0.0032166357,0.00068071263],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95731735,0.017209342,0.0007386457,0.00036865493,0.000942781,0.00004112919,0.000048494952,0.00035529016,0.004750836,0.00009133556,0.000896152,0.017240029],"study_design_scores_gemma":[0.88696873,0.109578244,0.0015361006,0.00002155013,0.00046055144,0.000037814152,0.000013651474,0.00026358647,0.00049352145,0.00007622993,0.0005388946,0.000010963149],"about_ca_topic_score_codex":0.0006453638,"about_ca_topic_score_gemma":0.002365657,"teacher_disagreement_score":0.004082777,"about_ca_system_score_codex":0.0009084421,"about_ca_system_score_gemma":0.0013285327,"threshold_uncertainty_score":0.017979681},"labels":[],"label_agreement":null},{"id":"W4399322695","doi":"10.1200/jco.2024.42.16_suppl.596","title":"Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Oncology; Breast cancer; Chemotherapy; Internal medicine; Doxorubicin; Cancer","score_opus":0.036807645094533374,"score_gpt":0.4450239036082301,"score_spread":0.4082162585136967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399322695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934344,0.0017595572,0.000381708,0.00024094278,0.00015709264,0.0030824845,0.00026486375,0.000039708517,0.0006392586],"genre_scores_gemma":[0.98765624,0.002298081,0.0016301323,0.0006564727,0.00031290692,0.005270484,0.000807843,0.0000127198655,0.0013550968],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995584,0.00022891267,0.00003129165,0.000070890645,0.000039754595,0.00007071265],"domain_scores_gemma":[0.9994931,0.00007957155,0.00010614827,0.000044526583,0.000029894816,0.0002466699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015493407,0.0014047794,0.002780079,0.00051555136,0.00031955526,0.00067677617,0.00068612926,0.00095891475,0.0027237698],"category_scores_gemma":[0.0007573539,0.00078435795,0.0012447424,0.0004976065,0.0010699318,0.0008812979,0.00040784557,0.0018588816,0.00043527296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90539306,0.04936939,0.0032157,0.00063507364,0.00083884265,0.00007459756,0.000095574935,0.00074265467,0.011151722,0.0001173581,0.0006190501,0.027747018],"study_design_scores_gemma":[0.72472054,0.26963532,0.003151627,0.000020708057,0.00040070334,0.000039861843,0.000020169988,0.00046141856,0.00085659855,0.00005370211,0.00062749896,0.000011863592],"about_ca_topic_score_codex":0.000530874,"about_ca_topic_score_gemma":0.0014319316,"teacher_disagreement_score":0.002780079,"about_ca_system_score_codex":0.0007567104,"about_ca_system_score_gemma":0.0015787324,"threshold_uncertainty_score":0.009111941},"labels":[],"label_agreement":null},{"id":"W4399504365","doi":"10.1158/1538-8514.synthleth24-a013","title":"Abstract A013: NF1 loss is syntetic lethal with Trastuzumab emtansine","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In vivo; Microtubule; Microtubule polymerization; In vitro; Cancer research; Tubulin; Chemistry; Biophysics; Cell biology; Biology; Biochemistry","score_opus":0.046124812847405355,"score_gpt":0.3743399704367299,"score_spread":0.3282151575893245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843443,0.0010016754,0.0031152694,0.00051912863,0.00014779798,0.00007587288,0.0039829453,0.00029261105,0.006520305],"genre_scores_gemma":[0.9872062,0.00033580998,0.0010663412,0.0001575467,0.00001742788,0.00007113983,0.0020926215,0.00008283257,0.008969967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998179,0.00002478662,0.000025172489,0.00003799928,0.000050578354,0.000043689048],"domain_scores_gemma":[0.9998574,0.000032560132,0.00003733501,0.000016290978,0.000009240233,0.000047072168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119245,0.00035888952,0.00026807282,0.00027671453,0.00023368467,0.00025077208,0.00022544601,0.0004874109,0.008564122],"category_scores_gemma":[0.00013435415,0.00008823667,0.00029429872,0.00015310285,0.0002857306,0.00016483739,0.00016376596,0.0010674288,0.0013804934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035446306,0.00012411104,0.0002249582,0.000026646449,0.000009982636,0.00025777522,0.000012332707,0.0000904311,0.99557376,0.00024655164,0.00042204215,0.0026569106],"study_design_scores_gemma":[0.00008303962,0.00080736534,0.0051814676,0.000016020851,0.0000176011,0.0020041084,0.000048989266,0.0014466562,0.98083305,0.00015472871,0.009397413,0.000009593293],"about_ca_topic_score_codex":0.0009794403,"about_ca_topic_score_gemma":0.00080303726,"teacher_disagreement_score":0.008564122,"about_ca_system_score_codex":0.00041525188,"about_ca_system_score_gemma":0.00021612203,"threshold_uncertainty_score":0.028649807},"labels":[],"label_agreement":null},{"id":"W4399803891","doi":"10.1016/j.ijbiomac.2024.133247","title":"HER-2 positive gastric cancer: Current targeted treatments","year":2024,"lang":"en","type":"review","venue":"International Journal of Biological Macromolecules","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Trastuzumab; Drug resistance; Cancer; Cancer research; Metastasis; Medicine; Drug; Pharmacology; Biology; Internal medicine; Breast cancer","score_opus":0.1302679898086728,"score_gpt":0.4882950427009865,"score_spread":0.35802705289231374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399803891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010008154,0.9991763,0.000058465914,0.00020044953,0.00012487164,0.000002954828,0.000013873793,0.0000050562794,0.00031787745],"genre_scores_gemma":[0.000729397,0.99837816,0.00010190308,0.0002690584,0.00014673358,0.0000048972383,0.000024319585,9.866156e-7,0.00034454602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985313,0.000028007826,0.000020479632,0.000030349194,0.000044748824,0.000023297958],"domain_scores_gemma":[0.999788,0.00009303418,0.00004620532,0.000006285035,0.000041030344,0.000025423218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005228479,0.0010362304,0.0018186892,0.0017778719,0.00016237232,0.0010393223,0.0007110792,0.00095037854,0.0041386466],"category_scores_gemma":[0.0005713489,0.00029395183,0.0006063444,0.0017028847,0.0003796769,0.0012150876,0.00075938326,0.0016647221,0.0013694572],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019557576,0.0000859848,0.00015130518,0.018089104,0.00013858972,0.00012832398,0.000032425993,0.00041342407,0.0015367426,0.0015671456,0.035053805,0.94260746],"study_design_scores_gemma":[0.00011376024,0.0003255131,0.0009974886,0.0061805327,0.00057432643,0.0010199999,0.00007537975,0.00024092691,0.0007138755,0.0016566665,0.98807037,0.000031067415],"about_ca_topic_score_codex":0.00067161536,"about_ca_topic_score_gemma":0.0022710238,"teacher_disagreement_score":0.0041386466,"about_ca_system_score_codex":0.00062694156,"about_ca_system_score_gemma":0.0007832093,"threshold_uncertainty_score":0.013845146},"labels":[],"label_agreement":null},{"id":"W4399828028","doi":"10.32920/26052757.v1","title":"The Regulation of Epidermal Growth Factor Receptor Signaling","year":2024,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Epidermal growth factor receptor; Factor (programming language); Epidermal growth factor; Cell biology; Receptor; Biology; Computer science; Genetics","score_opus":0.08166949638005443,"score_gpt":0.3859924481226286,"score_spread":0.3043229517425742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399828028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7261174,0.11746826,0.026261633,0.0056638042,0.001546857,0.00013611402,0.0023961002,0.0009344885,0.119475424],"genre_scores_gemma":[0.92059994,0.032934185,0.004158913,0.0007018521,0.00017452927,0.00004603027,0.0012121471,0.00008649223,0.0400859],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99983644,0.000017077911,0.0000058456326,0.00003481097,0.00006418736,0.000041514308],"domain_scores_gemma":[0.9999573,0.000004962462,0.000009241553,0.0000052394253,0.000009611997,0.000013522472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013958881,0.00025352085,0.00013219366,0.00022902276,0.00019643627,0.00097677,0.00017271691,0.00030893332,0.0021990603],"category_scores_gemma":[0.0001432036,0.00011264164,0.000199303,0.00018120579,0.00019485512,0.0003221864,0.00029759394,0.0006665152,0.0015897759],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017469516,0.00005359247,0.00096786063,0.0002694666,0.000031686024,0.0004359458,0.000058930695,0.00033821212,0.92382866,0.009157886,0.0049815765,0.059701417],"study_design_scores_gemma":[0.00003614242,0.00011485313,0.015053133,0.000064849955,0.000030965115,0.0012843065,0.00009937275,0.002135263,0.82780874,0.0032645806,0.15008757,0.000020227902],"about_ca_topic_score_codex":0.00047654266,"about_ca_topic_score_gemma":0.00042496686,"teacher_disagreement_score":0.0021990603,"about_ca_system_score_codex":0.0005423271,"about_ca_system_score_gemma":0.00021035552,"threshold_uncertainty_score":0.007356584},"labels":[],"label_agreement":null},{"id":"W4399828159","doi":"10.32920/26052757","title":"The Regulation of Epidermal Growth Factor Receptor Signaling","year":2024,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Epidermal growth factor receptor; Cell biology; Epidermal growth factor; Factor (programming language); Receptor; Biology; Computer science; Genetics","score_opus":0.08166949638005443,"score_gpt":0.3859924481226286,"score_spread":0.3043229517425742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399828159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7261174,0.11746826,0.026261633,0.0056638042,0.001546857,0.00013611402,0.0023961002,0.0009344885,0.119475424],"genre_scores_gemma":[0.92059994,0.032934185,0.004158913,0.0007018521,0.00017452927,0.00004603027,0.0012121471,0.00008649223,0.0400859],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983644,0.000017077911,0.0000058456326,0.00003481097,0.00006418736,0.000041514308],"domain_scores_gemma":[0.9999573,0.000004962462,0.000009241553,0.0000052394253,0.000009611997,0.000013522472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013958881,0.00025352085,0.00013219366,0.00022902276,0.00019643627,0.00097677,0.00017271691,0.00030893332,0.0021990603],"category_scores_gemma":[0.0001432036,0.00011264164,0.000199303,0.00018120579,0.00019485512,0.0003221864,0.00029759394,0.0006665152,0.0015897759],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017469516,0.00005359247,0.00096786063,0.0002694666,0.000031686024,0.0004359458,0.000058930695,0.00033821212,0.92382866,0.009157886,0.0049815765,0.059701417],"study_design_scores_gemma":[0.00003614242,0.00011485313,0.015053133,0.000064849955,0.000030965115,0.0012843065,0.00009937275,0.002135263,0.82780874,0.0032645806,0.15008757,0.000020227902],"about_ca_topic_score_codex":0.00047654266,"about_ca_topic_score_gemma":0.00042496686,"teacher_disagreement_score":0.0021990603,"about_ca_system_score_codex":0.0005423271,"about_ca_system_score_gemma":0.00021035552,"threshold_uncertainty_score":0.007356584},"labels":[],"label_agreement":null},{"id":"W4399901966","doi":"10.1158/1535-7163.mct-23-0393","title":"Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McGill University","funders":"Institute of Cancer Research","keywords":"Metastasis; Colorectal cancer; Claudin; Cancer; Cancer research; Monoclonal antibody; Antibody; In vivo; Antibody-drug conjugate; Medicine; Liver cancer; Immunology; Biology; Internal medicine; Tight junction","score_opus":0.06740540409596586,"score_gpt":0.41211183557284087,"score_spread":0.344706431476875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399901966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9564878,0.024139617,0.0141962655,0.0003924985,0.00009655443,0.0002568614,0.00019776006,0.00017589815,0.004056825],"genre_scores_gemma":[0.9859409,0.005940089,0.005430934,0.00007559858,0.000020674008,0.000063567575,0.00014183634,0.000012035811,0.0023743694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999232,0.000021887605,0.000003817064,0.000012389386,0.000022719347,0.000015890122],"domain_scores_gemma":[0.9999701,0.000005259307,0.000009305977,0.0000023721293,0.0000054718917,0.0000074969566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015705169,0.00028208355,0.0002230337,0.00028822038,0.000107942775,0.00020545482,0.00016307643,0.00023340898,0.0007398845],"category_scores_gemma":[0.00008790302,0.000105526335,0.00012554743,0.0001729379,0.0001137044,0.00016734673,0.00013851456,0.00035307705,0.00015325828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016713717,0.00011515336,0.00020501974,0.00013686348,0.000018398709,0.00012323182,0.000021614609,0.00055501034,0.98092455,0.00042073816,0.00031231888,0.016999958],"study_design_scores_gemma":[0.0001608489,0.0020165672,0.0021829114,0.00001336566,0.000042781372,0.0010672683,0.000012035365,0.0037907618,0.97252524,0.000086791915,0.018088434,0.000012999899],"about_ca_topic_score_codex":0.00046101725,"about_ca_topic_score_gemma":0.00092029606,"teacher_disagreement_score":0.0007398845,"about_ca_system_score_codex":0.0004013431,"about_ca_system_score_gemma":0.00020363112,"threshold_uncertainty_score":0.002911985},"labels":[],"label_agreement":null},{"id":"W4399984692","doi":"10.3389/fonc.2024.1395970","title":"Germline rare variants in HER2-positive breast cancer predisposition: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Germline; Meta-analysis; Breast cancer; Medicine; Oncology; Cancer; Genetic testing; Germline mutation; Bioinformatics; Internal medicine; Genetics; Gene; Biology; Mutation","score_opus":0.08222996412548599,"score_gpt":0.45784727354163207,"score_spread":0.3756173094161461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399984692","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042817155,0.9933082,0.0006149515,0.00021569623,0.00011044309,0.00023548612,0.0009977946,0.000021964368,0.0002136669],"genre_scores_gemma":[0.18113337,0.81151783,0.0029246346,0.0008947103,0.00029907198,0.0013978569,0.0014785969,0.000036544876,0.00031735256],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9911488,0.003988762,0.0025793312,0.0010712554,0.00086144067,0.00035032965],"domain_scores_gemma":[0.97929114,0.016212158,0.0024113036,0.0005648561,0.0013142263,0.00020626986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011968826,0.0020230948,0.013776505,0.0076121096,0.0005780044,0.0026502197,0.0020782938,0.0017637947,0.0041537797],"category_scores_gemma":[0.028045442,0.0010365221,0.027758371,0.009799434,0.0006207843,0.00139828,0.0013091804,0.0012575927,0.00030186682],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009414266,0.00002548584,0.009149245,0.5152777,0.4590522,0.00025255393,0.000112996946,0.00070219877,0.00023595446,0.00023899927,0.001041564,0.012969786],"study_design_scores_gemma":[0.00031469046,0.0001427388,0.0076783793,0.04713088,0.9410199,0.00018998429,0.00007034347,0.00026017896,0.00010713974,0.00034680023,0.0027072371,0.000031849086],"about_ca_topic_score_codex":0.0077296034,"about_ca_topic_score_gemma":0.017570231,"teacher_disagreement_score":0.013776505,"about_ca_system_score_codex":0.0019895032,"about_ca_system_score_gemma":0.003952187,"threshold_uncertainty_score":0.06329793},"labels":[],"label_agreement":null},{"id":"W4400350261","doi":"10.3390/biomedicines12071491","title":"Antibody-Drug Conjugates to Promote Immune Surveillance: Lessons Learned from Breast Cancer","year":2024,"lang":"en","type":"review","venue":"Biomedicines","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Pembrolizumab; Atezolizumab; Immunotherapy; Trastuzumab; Immune system; Oncology; Breast cancer; Cancer; Cancer immunotherapy; Antibody-drug conjugate; Immunology; Chimeric antigen receptor; Cancer research; Antibody; Internal medicine; Monoclonal antibody","score_opus":0.14175747946290512,"score_gpt":0.49666867723443187,"score_spread":0.35491119777152674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400350261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011955931,0.99885845,0.00011389546,0.00020533626,0.00012784111,0.0000027627664,0.000009288419,0.0000037153586,0.00055911596],"genre_scores_gemma":[0.0008235235,0.9983546,0.00017836026,0.00021596724,0.00009378404,0.0000042905676,0.00001672255,0.0000011051144,0.00031155837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998441,0.000032552904,0.000021789241,0.000027266153,0.000057234152,0.000017071414],"domain_scores_gemma":[0.9997601,0.0001341222,0.000021467187,0.0000071383242,0.0000575594,0.000019639576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069234375,0.0006240832,0.0010057023,0.0018432235,0.0001962659,0.0008554746,0.00049999094,0.00091177115,0.002160439],"category_scores_gemma":[0.00071357907,0.00023609686,0.00044871983,0.001683272,0.00039572816,0.0013324254,0.0005795043,0.0017006439,0.00095986394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008605789,0.0000921326,0.00013389907,0.02353277,0.00011308568,0.00026035306,0.00009453791,0.00047424465,0.0030300699,0.007894111,0.020879004,0.9434096],"study_design_scores_gemma":[0.000030117271,0.00013796105,0.0005081776,0.003474748,0.00010313745,0.0009110741,0.00005134556,0.0001233745,0.00082062616,0.002373088,0.99144816,0.000018156466],"about_ca_topic_score_codex":0.0008007525,"about_ca_topic_score_gemma":0.0014647355,"teacher_disagreement_score":0.002160439,"about_ca_system_score_codex":0.00052194786,"about_ca_system_score_gemma":0.0008912312,"threshold_uncertainty_score":0.007227361},"labels":[],"label_agreement":null},{"id":"W4400382953","doi":"10.14740/wjon1853","title":"Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Yunnan Provincial Science and Technology Department; Kunming Medical University","keywords":"Medicine; Triple-negative breast cancer; Conjugate; Antibody-drug conjugate; Drug; Breast cancer; Antibody; Drug development; Oncology; Cancer; Monoclonal antibody; Immunology; Internal medicine; Pharmacology","score_opus":0.20008682607938005,"score_gpt":0.4285066110945388,"score_spread":0.22841978501515875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400382953","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075223073,0.9608081,0.006687133,0.019205147,0.000809514,0.00003786187,0.00009426466,0.00007628684,0.0047593685],"genre_scores_gemma":[0.03314526,0.942596,0.013597329,0.0055963555,0.0011772997,0.00007193302,0.00024332399,0.00004165912,0.0035308162],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988172,0.00034798362,0.00011925557,0.00018090793,0.00038063567,0.00015393629],"domain_scores_gemma":[0.9982065,0.00079450745,0.00019822078,0.00006300629,0.0005118057,0.00022597252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042702206,0.0005562418,0.0010179407,0.00079871167,0.0005078928,0.002345114,0.00097464543,0.0019548917,0.0040730555],"category_scores_gemma":[0.0026764951,0.00036177246,0.00073767145,0.00081529375,0.0011037766,0.005967936,0.0014100189,0.0032486366,0.0016722971],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003300381,0.000270319,0.0018885335,0.010339436,0.00009273687,0.00112666,0.00082863716,0.0023444637,0.02230583,0.02982682,0.034033034,0.89661336],"study_design_scores_gemma":[0.00007655676,0.0013192439,0.0013109552,0.0026016652,0.00016030885,0.0042550885,0.0019366292,0.002875604,0.013661913,0.029806346,0.94186556,0.00013009473],"about_ca_topic_score_codex":0.0006068396,"about_ca_topic_score_gemma":0.0015015648,"teacher_disagreement_score":0.0042702206,"about_ca_system_score_codex":0.00065629627,"about_ca_system_score_gemma":0.002079094,"threshold_uncertainty_score":0.022583365},"labels":[],"label_agreement":null},{"id":"W4400810123","doi":"10.1002/1878-0261.13698","title":"<i>ERBB2</i> mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high ( <scp>MSI</scp> ‐H) molecular subtype","year":2024,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Fonds de Recherche du Québec - Santé; Cycle for Survival; Ovarian Cancer Research Alliance; Breast Cancer Research Foundation","keywords":"Microsatellite instability; Biology; Cancer research; Mutation; Molecular biology; Wild type; Genetics; Microsatellite; Gene; Allele; Mutant","score_opus":0.015298773788025227,"score_gpt":0.29417872628802716,"score_spread":0.2788799525000019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400810123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996481,0.0000932585,0.000058713835,0.000007345948,6.345712e-7,0.0000038570543,0.000038345337,0.00000343957,0.0001464583],"genre_scores_gemma":[0.99969757,0.000049724677,0.0000934197,0.0000076476,0.000005257302,0.0000022402912,0.00009270976,0.0000015272271,0.000049901588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998826,0.000020910338,0.000016836366,0.000026037387,0.00002091327,0.00003279221],"domain_scores_gemma":[0.9997868,0.000031068797,0.00010111309,0.000021618109,0.000015533415,0.00004399793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017402916,0.00020238534,0.00024031433,0.0006286252,0.00021316177,0.00033488273,0.00013930493,0.0002797852,0.00067424605],"category_scores_gemma":[0.0004652082,0.00014443659,0.000133754,0.00034216687,0.00022687153,0.00014994702,0.00024540222,0.00013462166,0.0001663819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031475027,0.00002732206,0.9711793,0.000012889323,0.00002942842,0.0012656843,0.000099586585,0.00008504828,0.021175371,0.000061061015,0.00011488819,0.005634692],"study_design_scores_gemma":[0.000011987834,0.00015182604,0.9863724,0.0000045161455,0.000029224086,0.010289135,0.00021675174,0.00045926293,0.0019581553,0.00009493768,0.00040728037,0.0000045094876],"about_ca_topic_score_codex":0.0007865502,"about_ca_topic_score_gemma":0.0010302485,"teacher_disagreement_score":0.0007865502,"about_ca_system_score_codex":0.00010984368,"about_ca_system_score_gemma":0.0001308384,"threshold_uncertainty_score":0.002255559},"labels":[],"label_agreement":null},{"id":"W4400915869","doi":"10.17504/protocols.io.rm7vzj6rrlx1/v1","title":"Immunohistochemistry of free floating slices v1","year":2024,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Canadian Sleep & Circadian Network","funders":"","keywords":"Immunohistochemistry; Computer science; Chemistry; Pathology; Medicine","score_opus":0.04930180660465027,"score_gpt":0.4138150619434787,"score_spread":0.36451325533882845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400915869","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08600994,0.017010944,0.6721957,0.0016186971,0.0044971313,0.0057211565,0.07686086,0.021043396,0.11504224],"genre_scores_gemma":[0.10395824,0.014531425,0.5727365,0.0012488788,0.0007957275,0.011299569,0.106616855,0.010168051,0.17864478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877614,0.00011866743,0.00012156231,0.00041127965,0.00032165885,0.00025062572],"domain_scores_gemma":[0.9990295,0.00016937238,0.00005815023,0.00033689052,0.00026399904,0.00014213662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015467538,0.0023902468,0.0012569514,0.0021344116,0.0016408508,0.0013709795,0.0019820349,0.001970239,0.06812566],"category_scores_gemma":[0.001143462,0.0016728592,0.0016368484,0.0010638204,0.0008078569,0.0011451332,0.00094343,0.0036745581,0.037934378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006591144,0.00018508967,0.00060261384,0.0018361954,0.00015797805,0.00088342954,0.00033824402,0.0005988727,0.931542,0.0130296545,0.024578486,0.025588347],"study_design_scores_gemma":[0.0003597799,0.000619859,0.0060039936,0.00078281417,0.00034137457,0.004128096,0.00019400379,0.004237507,0.5612892,0.008942742,0.41293934,0.00016129867],"about_ca_topic_score_codex":0.002133369,"about_ca_topic_score_gemma":0.004306622,"teacher_disagreement_score":0.06812566,"about_ca_system_score_codex":0.0007709567,"about_ca_system_score_gemma":0.0013895949,"threshold_uncertainty_score":0.22790307},"labels":[],"label_agreement":null},{"id":"W4401831557","doi":"10.37349/etat.2024.00265","title":"Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort","year":2024,"lang":"en","type":"article","venue":"Exploration of Targeted Anti-tumor Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Immunohistochemistry; Biomarker; Breast cancer; Internal medicine; Interquartile range; Oncology; Cancer; Prospective cohort study; Trastuzumab; Pathology; Biology","score_opus":0.052198028531590335,"score_gpt":0.3792982925428761,"score_spread":0.3271002640112858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401831557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99904937,0.00005732386,0.00009992569,0.000011527989,0.000002673469,0.000017131208,0.0004903932,0.0000036032905,0.00026803312],"genre_scores_gemma":[0.99872595,0.000037075803,0.000096562486,0.000015272606,0.000004247388,0.000019218207,0.00095925777,0.0000038352273,0.00013860276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916816,0.000104726874,0.000089017114,0.00030287835,0.00019072846,0.00014453371],"domain_scores_gemma":[0.998164,0.00023893653,0.0006298238,0.00027803428,0.00037641687,0.00031289554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011143278,0.00027711954,0.00030967378,0.0008854977,0.000663195,0.0007197278,0.0004635323,0.0002854891,0.0021748596],"category_scores_gemma":[0.0021696659,0.00028834102,0.0003546794,0.00090676144,0.00035842144,0.00045602067,0.00055923156,0.00037217065,0.00058282167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011501226,0.000016852866,0.99877244,0.0000035654373,0.000017952825,0.00007819674,0.000042741303,0.000014763072,0.00034075123,0.0000054287057,0.00006836976,0.000523875],"study_design_scores_gemma":[0.000008434804,0.00016512882,0.9983663,0.0000029908551,0.000020992753,0.000624735,0.00018213522,0.000110862245,0.0002229774,0.0000083755185,0.00028363176,0.000003487429],"about_ca_topic_score_codex":0.009060096,"about_ca_topic_score_gemma":0.011693891,"teacher_disagreement_score":0.009060096,"about_ca_system_score_codex":0.00067935034,"about_ca_system_score_gemma":0.000674195,"threshold_uncertainty_score":0.01801467},"labels":[],"label_agreement":null},{"id":"W4401994840","doi":"10.3390/cells13171452","title":"A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Cells","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Environmental Health Sciences","keywords":"Trastuzumab; ADAM10; Cancer research; Signal transduction; Cell growth; Cell biology; Breast cancer; Biology; Cancer; Medicine; Metalloproteinase; Matrix metalloproteinase; Biochemistry; Internal medicine; Disintegrin","score_opus":0.08228409039915346,"score_gpt":0.3902386193413681,"score_spread":0.30795452894221464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401994840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.930006,0.05082369,0.0052730697,0.0017035431,0.00013065236,0.00010834333,0.00039070632,0.00023578084,0.0113282725],"genre_scores_gemma":[0.9869511,0.008953933,0.0006562609,0.00026884172,0.00003473343,0.00002352958,0.00018479089,0.0000056491567,0.002921134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998996,0.000012478657,0.0000067714636,0.000015642148,0.000033113414,0.00003226279],"domain_scores_gemma":[0.9999733,0.0000032266012,0.00000893208,0.0000030041635,0.0000046698947,0.000006871819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095593234,0.00026250022,0.0001739706,0.00019499005,0.00015152995,0.000350225,0.00020310118,0.00027395115,0.0009355975],"category_scores_gemma":[0.000092561015,0.00007884225,0.00018126974,0.00017220911,0.00019843152,0.00025098186,0.00019858882,0.00044428083,0.0002857197],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036974496,0.0001604353,0.0060940767,0.00041865322,0.00006548019,0.0066916514,0.00012720097,0.0010811263,0.91599,0.0049229604,0.0031588557,0.060919847],"study_design_scores_gemma":[0.00016721751,0.00106784,0.08409376,0.00007867191,0.0001522736,0.03474053,0.00027641986,0.009435734,0.79853237,0.005736892,0.06566627,0.00005198329],"about_ca_topic_score_codex":0.00058590784,"about_ca_topic_score_gemma":0.00063822843,"teacher_disagreement_score":0.0009355975,"about_ca_system_score_codex":0.0005252295,"about_ca_system_score_gemma":0.00024700502,"threshold_uncertainty_score":0.0038108826},"labels":[],"label_agreement":null},{"id":"W4402250142","doi":"10.7759/cureus.68576","title":"Long-Term Survival in Human Epidermal Growth Factor Receptor 2-Positive Bone-Only Metastatic Breast Cancer: Trastuzumab, Denosumab, and Potential Synergistic Effects","year":2024,"lang":"en","type":"article","venue":"Cureus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor; Western University","funders":"","keywords":"Medicine; Trastuzumab; Denosumab; Metastatic breast cancer; Oncology; Human Epidermal Growth Factor Receptor 2; Breast cancer; Internal medicine; Cancer; Cancer research; Osteoporosis","score_opus":0.024915133658435045,"score_gpt":0.3520927106908752,"score_spread":0.32717757703244016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402250142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99058986,0.007039794,0.0006414281,0.00031149114,0.000024002331,0.000007719191,0.00002236346,0.000013112678,0.0013503095],"genre_scores_gemma":[0.9981451,0.001267539,0.00016223353,0.0000832697,0.000045305213,0.0000034996453,0.000026676724,0.0000026785744,0.00026371903],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9999126,0.000014281707,0.0000110403425,0.000012898437,0.000014119372,0.00003509909],"domain_scores_gemma":[0.999744,0.000062698906,0.00009981033,0.000015615895,0.0000138283085,0.00006415186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001343202,0.00023630247,0.00029636399,0.00028492158,0.0005097035,0.00032657993,0.00018357528,0.00063035905,0.0005777004],"category_scores_gemma":[0.00061073666,0.00009408039,0.00036305236,0.00027500186,0.00030044417,0.00020649195,0.0003335305,0.0004257009,0.00012152345],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005906586,0.00016828664,0.19070055,0.00026510147,0.00010323323,0.7393962,0.00066438515,0.00061682955,0.017908538,0.0007612147,0.0007793676,0.048045702],"study_design_scores_gemma":[0.000027777673,0.00040620592,0.0589849,0.000042740154,0.00009643746,0.93304145,0.0002261491,0.00052218913,0.0033314172,0.00039921247,0.002906599,0.00001501437],"about_ca_topic_score_codex":0.00049277337,"about_ca_topic_score_gemma":0.0012162565,"teacher_disagreement_score":0.00063035905,"about_ca_system_score_codex":0.00028172528,"about_ca_system_score_gemma":0.00021556391,"threshold_uncertainty_score":0.002044022},"labels":[],"label_agreement":null},{"id":"W4402267218","doi":"10.1158/1538-7445.pediatric24-b002","title":"Abstract B002: A novel NTRK2-activating internal tandem duplication characterizes a new mechanism of receptor tyrosine kinase activation","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tyrosine kinase; Receptor tyrosine kinase; Chemistry; Mechanism (biology); Cell biology; Cancer research; Receptor; Biochemistry; Biology; Philosophy","score_opus":0.16115813381259803,"score_gpt":0.4563875239758575,"score_spread":0.2952293901632595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415624,0.0003566286,0.0013909981,0.00026141066,0.000028424947,0.000023675579,0.0006165496,0.000072869116,0.003093003],"genre_scores_gemma":[0.99679023,0.00017182285,0.0008437615,0.00008795232,0.000015144966,0.000009322689,0.0005578982,0.000017537131,0.001506351],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998902,0.000008080318,0.000011733854,0.00003823403,0.000029118444,0.000022664884],"domain_scores_gemma":[0.99991834,0.000018891862,0.000023776063,0.0000072026314,0.000006921763,0.000024965908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000744153,0.00038968577,0.00022100785,0.00033664808,0.00018394341,0.000339127,0.00027701943,0.00059222657,0.0028762359],"category_scores_gemma":[0.00017033661,0.00013488482,0.00023675893,0.00022425786,0.00044383085,0.0001529743,0.00024048965,0.0005514735,0.0008149228],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039497786,0.000068719455,0.012193047,0.000070910035,0.000029812772,0.05620609,0.00014972681,0.00027571715,0.9237502,0.0009895342,0.00094508723,0.0049260445],"study_design_scores_gemma":[0.00014799564,0.0009312106,0.11731352,0.000036036105,0.00012378725,0.44587567,0.0004019445,0.0040871715,0.41020694,0.0010138853,0.019820536,0.000041299914],"about_ca_topic_score_codex":0.0012892282,"about_ca_topic_score_gemma":0.001225331,"teacher_disagreement_score":0.0028762359,"about_ca_system_score_codex":0.00036200878,"about_ca_system_score_gemma":0.0001722615,"threshold_uncertainty_score":0.009621918},"labels":[],"label_agreement":null},{"id":"W4402472398","doi":"10.1200/jco.24.00920","title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center; AstraZeneca","keywords":"Medicine; Vinorelbine; Internal medicine; Metastatic breast cancer; Oncology; Chemotherapy; Eribulin; Gemcitabine; Breast cancer; Cancer","score_opus":0.12024444603652502,"score_gpt":0.47170743713032226,"score_spread":0.35146299109379725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402472398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98984396,0.0056596156,0.00031247898,0.00038057315,0.00028317785,0.0012168809,0.0007805016,0.000056238678,0.0014665044],"genre_scores_gemma":[0.99124324,0.003506246,0.0006528082,0.00062947936,0.00030078544,0.00094239006,0.00072065624,0.00001719922,0.0019873236],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993499,0.000428322,0.000026603198,0.000072714436,0.000038919337,0.00008353113],"domain_scores_gemma":[0.99918693,0.00026065207,0.00018770574,0.00005148476,0.000033548262,0.0002796354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019456919,0.0013079385,0.002406295,0.00044124955,0.00021433832,0.0008159928,0.0007072466,0.00088323944,0.0035992994],"category_scores_gemma":[0.0010614864,0.00044312302,0.001759456,0.00039426523,0.0008851683,0.0006125184,0.00032393239,0.0022279073,0.0004620421],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9571681,0.008680682,0.001137959,0.0004894191,0.00067338534,0.000035628123,0.00005157608,0.00062060275,0.0039763865,0.00007190356,0.0007016002,0.026392723],"study_design_scores_gemma":[0.69266194,0.29669693,0.0060150875,0.000060732644,0.0009742727,0.0000866417,0.000042868833,0.0007880835,0.001364567,0.0001560662,0.0011335699,0.00001918733],"about_ca_topic_score_codex":0.001269078,"about_ca_topic_score_gemma":0.0048357463,"teacher_disagreement_score":0.0035992994,"about_ca_system_score_codex":0.00088921154,"about_ca_system_score_gemma":0.0008146181,"threshold_uncertainty_score":0.012040794},"labels":[],"label_agreement":null},{"id":"W4402561305","doi":"10.1016/j.annonc.2024.08.384","title":"437TiP An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Antibody-drug conjugate; Open label; Conjugate; Trastuzumab; Drug; Oncology; Pharmacology; Phases of clinical research; Internal medicine; Antibody; Clinical trial; Monoclonal antibody; Adverse effect; Cancer; Immunology; Breast cancer","score_opus":0.14514835074140064,"score_gpt":0.5117613860980696,"score_spread":0.366613035356669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988257,0.002107293,0.0011513508,0.0004426623,0.00017443678,0.0022820025,0.0017655838,0.00016076321,0.0036588563],"genre_scores_gemma":[0.9823506,0.0015850129,0.0028258336,0.0014902633,0.00026013821,0.0021703031,0.0048289276,0.00007444511,0.0044146623],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99963105,0.00016412708,0.0000142172075,0.00006631663,0.000037487767,0.00008677145],"domain_scores_gemma":[0.99941504,0.000090890724,0.000082964936,0.000050015868,0.00004195862,0.0003192289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010575912,0.0009990922,0.0016395809,0.00033079545,0.00037182524,0.0009014746,0.00066864083,0.0009870962,0.0056597693],"category_scores_gemma":[0.0005902059,0.00040719117,0.00083485595,0.00036074492,0.0008037745,0.0006564817,0.00026729162,0.003275259,0.0015207909],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6333577,0.089362524,0.008659073,0.00073547906,0.0012432446,0.00030288158,0.00024819854,0.002269148,0.091962785,0.00056250417,0.0074034436,0.16389303],"study_design_scores_gemma":[0.3354689,0.63773715,0.011698368,0.00003288206,0.0004432602,0.00030942247,0.000056310913,0.0017339996,0.0075822254,0.00021601438,0.0046893214,0.000032300202],"about_ca_topic_score_codex":0.00111833,"about_ca_topic_score_gemma":0.0020622488,"teacher_disagreement_score":0.0056597693,"about_ca_system_score_codex":0.000747584,"about_ca_system_score_gemma":0.0016686773,"threshold_uncertainty_score":0.018933773},"labels":[],"label_agreement":null},{"id":"W4402826410","doi":"10.1007/s12032-024-02504-4","title":"Personalized treatment approach for HER2-positive metastatic breast cancer","year":2024,"lang":"en","type":"review","venue":"Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Science and Engineering Research Board","keywords":"Hematology; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Medicine; Cancer; Trastuzumab","score_opus":0.20989891219432807,"score_gpt":0.5502231872662202,"score_spread":0.3403242750718921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402826410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007809635,0.99892116,0.00010793363,0.00026087565,0.0001342614,0.00000396668,0.000017533823,0.000005448114,0.00047082524],"genre_scores_gemma":[0.00084997027,0.99803597,0.00019648432,0.00039925674,0.00013759069,0.000006033218,0.000040305833,0.000001353732,0.00033300425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998448,0.000038558734,0.000019641186,0.000030365358,0.00004838927,0.00001820932],"domain_scores_gemma":[0.99979824,0.00012094304,0.000029467685,0.0000051933753,0.000033915672,0.000012230677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047122219,0.0006946043,0.0014297285,0.001281073,0.00018348114,0.00081705215,0.0008334844,0.0007992789,0.0039976626],"category_scores_gemma":[0.00077047304,0.0001969973,0.0007817757,0.0009789505,0.00023826826,0.00075736037,0.0005646621,0.0018406949,0.0010136714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000853888,0.00006830856,0.00014687849,0.015491108,0.00022394268,0.00011151486,0.000025916768,0.00046992555,0.0007634311,0.0021636891,0.02876415,0.9516857],"study_design_scores_gemma":[0.000121427904,0.00021191545,0.0014495015,0.010677228,0.0008529034,0.0012397505,0.000049013466,0.00035806667,0.000483729,0.0033325201,0.98119223,0.00003166359],"about_ca_topic_score_codex":0.00085982593,"about_ca_topic_score_gemma":0.0026831555,"teacher_disagreement_score":0.0039976626,"about_ca_system_score_codex":0.0005258319,"about_ca_system_score_gemma":0.0006503906,"threshold_uncertainty_score":0.013373494},"labels":[],"label_agreement":null},{"id":"W4402922378","doi":"10.3390/curroncol31090422","title":"Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University of British Columbia; University of Calgary; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Saskatchewan Health Research Foundation; Gilead Sciences","keywords":"Medicine; Triple-negative breast cancer; Metastatic breast cancer; Neutropenia; Adverse effect; Irinotecan; Internal medicine; Oncology; Breast cancer; Anemia; Tolerability; Febrile neutropenia; Cancer; Toxicity","score_opus":0.44193512524009676,"score_gpt":0.5652496553908358,"score_spread":0.12331453015073907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402922378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027876257,0.9594755,0.0010065467,0.015841737,0.0011589199,0.00035003625,0.0013749651,0.000094505594,0.020419046],"genre_scores_gemma":[0.0029989707,0.9745686,0.0052293423,0.0082651805,0.00036996795,0.00031176078,0.0016813462,0.000027008538,0.006547934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969849,0.000685031,0.00063813495,0.00016126517,0.0013294397,0.00020127432],"domain_scores_gemma":[0.99340326,0.0015890576,0.0009777141,0.00010601449,0.003648129,0.00027580507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005715392,0.0009902753,0.0018937205,0.004593968,0.00083780976,0.0016678396,0.003141602,0.0031495958,0.0106346905],"category_scores_gemma":[0.009589392,0.0005184403,0.0028903713,0.003969675,0.0007002402,0.0011593413,0.0009260821,0.0026661528,0.0030986036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015130191,0.000057316603,0.00031982356,0.041139815,0.00027054045,0.0002941504,0.00020981344,0.00044111602,0.0007623593,0.004665966,0.25493082,0.69675696],"study_design_scores_gemma":[0.00009816503,0.000044013752,0.0008713856,0.032672364,0.0005507513,0.0002943408,0.00007678075,0.00007077558,0.00021521583,0.0014109085,0.9636686,0.000026749336],"about_ca_topic_score_codex":0.0974252,"about_ca_topic_score_gemma":0.18132435,"teacher_disagreement_score":0.9025748,"about_ca_system_score_codex":0.0058881454,"about_ca_system_score_gemma":0.023045776,"threshold_uncertainty_score":0.19371623},"labels":[],"label_agreement":null},{"id":"W4403173283","doi":"10.1200/jco.23.02768","title":"Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Trastuzumab; Immunohistochemistry; Oncology; Internal medicine; Lapatinib; Human Epidermal Growth Factor Receptor 2; Cohort; Stage (stratigraphy); Proportional hazards model; Cancer; Endometrial cancer; Breast cancer; Pathology; Biology","score_opus":0.30072103029406194,"score_gpt":0.566065639248905,"score_spread":0.265344608954843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403173283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993218,0.00015503724,0.00004174434,0.000009411706,0.0000014654794,0.00000701836,0.000117312964,0.0000012638574,0.00034494718],"genre_scores_gemma":[0.99958974,0.000042379448,0.000046084435,0.000010067998,0.0000031722295,0.0000055857204,0.00021407608,0.0000010667021,0.00008777257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99980956,0.00003173812,0.000028769473,0.000051328236,0.00004073305,0.00003785862],"domain_scores_gemma":[0.9993082,0.00015781543,0.00022817371,0.00006321826,0.000086985645,0.00015565155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032734484,0.00019180695,0.00020192814,0.0008266852,0.00030052123,0.00038949485,0.00023658878,0.00035021064,0.0015135984],"category_scores_gemma":[0.0015062985,0.00015556838,0.00014701861,0.0004975871,0.000297605,0.00024117071,0.0002787864,0.00017614788,0.00022937283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009716608,0.000012490638,0.9979766,0.0000055579635,0.000011374049,0.00033799701,0.000020920537,0.000019040303,0.0009008604,0.0000084769035,0.000040248895,0.0005692674],"study_design_scores_gemma":[0.000007963564,0.00007814434,0.99542636,0.000004517498,0.000013534147,0.0038138484,0.000117736905,0.0000924206,0.00019052972,0.000016578542,0.00023662606,0.0000017535622],"about_ca_topic_score_codex":0.0015042559,"about_ca_topic_score_gemma":0.0022760862,"teacher_disagreement_score":0.0015135984,"about_ca_system_score_codex":0.00023461225,"about_ca_system_score_gemma":0.00019341668,"threshold_uncertainty_score":0.005063474},"labels":[],"label_agreement":null},{"id":"W4403284224","doi":"10.17615/hpyc-bg25","title":"Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)","year":2024,"lang":"en","type":"article","venue":"UNC Libraries","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Aptitude Health; Oncolytics Biotech; Seagen; Puma Biotechnology; Daiichi-Sankyo; Genentech; Veracyte; Pfizer; Incyte; Queen Mary University of London; Clovis Oncology; Astellas Pharma; Eisai; Jazz Pharmaceuticals; Natera; Baxalta; Amgen; Ariad Pharmaceuticals; Servier; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Les Laboratories Pierre Fabre","keywords":"Breast cancer; Stage (stratigraphy); Oncology; Internal medicine; Medicine; Gynecology; Cancer; Biology","score_opus":0.026881259007008367,"score_gpt":0.3289802243166732,"score_spread":0.3020989653096648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403284224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6589692,0.0043065134,0.00025743988,0.0006879715,0.00004226534,0.000026035716,0.33442467,0.000088190565,0.0011976201],"genre_scores_gemma":[0.5024622,0.0020252306,0.00075617887,0.00042269,0.000059072587,0.00012339478,0.49307695,0.00007174924,0.0010024876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993135,0.00014322285,0.0000693429,0.00025337527,0.00011357002,0.00010704495],"domain_scores_gemma":[0.9988329,0.000412102,0.00024943575,0.00017760987,0.0001742251,0.00015372437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007034068,0.0006252406,0.0013346246,0.0014285519,0.0005847638,0.0011350721,0.0008571853,0.0008421262,0.0032897072],"category_scores_gemma":[0.0034823255,0.0003313617,0.0011325178,0.0034527916,0.00025471507,0.00043434429,0.0014128557,0.000572724,0.0013014704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041671726,0.00017897582,0.8738123,0.0012058234,0.004418741,0.00076030096,0.0005108705,0.00240213,0.0028560543,0.00032832692,0.08418749,0.025171803],"study_design_scores_gemma":[0.0003520282,0.00011538383,0.9763556,0.00024739502,0.0015730544,0.0010833847,0.00040805136,0.0013294215,0.0005073447,0.00038950442,0.017589858,0.000048919297],"about_ca_topic_score_codex":0.022262929,"about_ca_topic_score_gemma":0.036706686,"teacher_disagreement_score":0.022262929,"about_ca_system_score_codex":0.00057753385,"about_ca_system_score_gemma":0.0011194785,"threshold_uncertainty_score":0.0442667},"labels":[],"label_agreement":null},{"id":"W4403410103","doi":"10.1016/j.jtho.2024.09.436","title":"P2.10A.01 Phase 2 Study of Disitamab Vedotin in Patients with HER2-Expressing Non-Small Cell Lung Cancer (DV-005; Trial in Progress)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Phases of clinical research; Clinical trial","score_opus":0.03779296339728983,"score_gpt":0.4926715589626017,"score_spread":0.45487859556531185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538587,0.006659393,0.0016628474,0.0052900445,0.0011472207,0.003527749,0.011721023,0.00064351654,0.015489482],"genre_scores_gemma":[0.938899,0.0057747536,0.003529048,0.0054519754,0.0005818999,0.0046147075,0.015012306,0.00020271628,0.02593362],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99960345,0.0001486504,0.000008693458,0.000058271762,0.00003196728,0.00014906179],"domain_scores_gemma":[0.9994624,0.000081235245,0.00007470692,0.000034062246,0.000028048833,0.00031963794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015438263,0.002473464,0.0019681484,0.00041479472,0.00039686903,0.002094857,0.0012980656,0.0017784669,0.008741719],"category_scores_gemma":[0.0007963637,0.00076364406,0.0018059674,0.0003820183,0.0011356241,0.001091438,0.000429453,0.0052390527,0.0024452424],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6879129,0.032353725,0.0059263823,0.0016796548,0.0028239829,0.00053763686,0.00044418988,0.0062229703,0.043537058,0.0031159616,0.047826696,0.1676189],"study_design_scores_gemma":[0.84024054,0.13617742,0.0074230446,0.00008294429,0.00055131724,0.00036250212,0.00008933145,0.0019293864,0.002456136,0.00088398583,0.009758241,0.000045131652],"about_ca_topic_score_codex":0.0030950382,"about_ca_topic_score_gemma":0.009554281,"teacher_disagreement_score":0.008741719,"about_ca_system_score_codex":0.0016587608,"about_ca_system_score_gemma":0.0020845404,"threshold_uncertainty_score":0.029243946},"labels":[],"label_agreement":null},{"id":"W4403419652","doi":"10.1016/j.jtho.2024.09.543","title":"P3.02G.02 Integrin-Linked Kinase Facilitates Drug Tolerant Persister Cell Survival and EMT in Response to EGFR Targeted Therapy","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation","funders":"","keywords":"Medicine; Drug; Cancer research; Pharmacology; Multidrug tolerance; Oncology; Biology; Genetics; Bacteria","score_opus":0.05558787460023284,"score_gpt":0.4507780967487866,"score_spread":0.39519022214855376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99736303,0.00021015415,0.0005616384,0.00021197415,0.000034302142,0.00001370232,0.00012682301,0.000035435045,0.0014427961],"genre_scores_gemma":[0.9980332,0.00008492035,0.00021819053,0.000065874796,0.000006455112,0.0000149461075,0.00011637549,0.00000807307,0.001451993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999856,0.000022003122,0.000007578498,0.000018874767,0.000026997404,0.00006845247],"domain_scores_gemma":[0.999946,0.000006992123,0.000015406698,0.0000067299625,0.0000056372855,0.000019328916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012476384,0.00016010707,0.00016467023,0.00009328033,0.00019448111,0.0003808126,0.0001852231,0.00044145886,0.0030553218],"category_scores_gemma":[0.00014528207,0.00008063501,0.00016130692,0.00009435729,0.0002011539,0.00020523592,0.00014811757,0.00084180216,0.0005724492],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004874551,0.00015381494,0.0004952726,0.000017315982,0.000008619891,0.0002210982,0.000019348056,0.0000921185,0.99530375,0.00040490302,0.00035028736,0.002446039],"study_design_scores_gemma":[0.00027891935,0.002060259,0.03259177,0.00001371277,0.000055651348,0.002978453,0.0002275078,0.007230538,0.9450424,0.00062123634,0.008882203,0.000017320386],"about_ca_topic_score_codex":0.0006048797,"about_ca_topic_score_gemma":0.0008020722,"teacher_disagreement_score":0.0030553218,"about_ca_system_score_codex":0.00022056345,"about_ca_system_score_gemma":0.00022111619,"threshold_uncertainty_score":0.010221124},"labels":[],"label_agreement":null},{"id":"W4403455062","doi":"10.1016/j.esmoop.2024.103938","title":"Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"National Cancer Institute; ECOG-ACRIN Cancer Research Group; National Institutes of Health; Meso Scale Diagnostics; Gilead Sciences; American College of Radiology Imaging Network; Roche; Canadian Cancer Society; GlaxoSmithKline; AstraZeneca; Novartis; Pfizer","keywords":"Lapatinib; Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Cancer","score_opus":0.07178304164162665,"score_gpt":0.3880955706819111,"score_spread":0.31631252904028445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403455062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531259,0.01379975,0.003345478,0.0027586643,0.0006331605,0.004959562,0.010919505,0.00024550266,0.0102124335],"genre_scores_gemma":[0.9619801,0.0023202451,0.0033303972,0.002265318,0.00064593053,0.0040920596,0.020364456,0.00008764985,0.0049137953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975617,0.0017101637,0.00009452291,0.00023155233,0.0001857827,0.00021630486],"domain_scores_gemma":[0.99816966,0.00045228258,0.00052936474,0.00016210297,0.00021678807,0.00046971944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00748097,0.0012050265,0.0017555327,0.0003437975,0.0002678222,0.0011953436,0.00080562284,0.0010424758,0.003250104],"category_scores_gemma":[0.0033919928,0.00035409204,0.0029463363,0.00034553258,0.00055276626,0.0009807873,0.00061295525,0.0019890345,0.0005979773],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94179475,0.0022494313,0.009075922,0.00090208935,0.0058262516,0.00012561062,0.00008524389,0.0029905248,0.004992655,0.0005153738,0.0072236205,0.024218475],"study_design_scores_gemma":[0.76016515,0.17138584,0.03998489,0.00020152504,0.008989507,0.00031316897,0.000071559305,0.0032797516,0.0023558226,0.00095619546,0.012211169,0.000085411746],"about_ca_topic_score_codex":0.00048753447,"about_ca_topic_score_gemma":0.0014154009,"teacher_disagreement_score":0.00748097,"about_ca_system_score_codex":0.0007330197,"about_ca_system_score_gemma":0.0011946714,"threshold_uncertainty_score":0.039563596},"labels":[],"label_agreement":null},{"id":"W4403602928","doi":"10.26685/urncst.606","title":"Mouse Models of HER2+ Human Breast Cancer: A Literature Review","year":2024,"lang":"en","type":"review","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Breast cancer; Human breast; Oncology; Internal medicine; Biology; Cancer; Medicine","score_opus":0.178777673544888,"score_gpt":0.5535555379536692,"score_spread":0.3747778644087812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403602928","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043099764,0.9979925,0.00019182652,0.00035910239,0.0001405667,0.000042970907,0.00022857587,0.000013363192,0.00060009654],"genre_scores_gemma":[0.0016520645,0.99720424,0.00037560868,0.00027656532,0.000067591674,0.000047158253,0.00020995161,0.0000040202467,0.00016271806],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9988827,0.00021334524,0.00043452377,0.000108762804,0.00030656916,0.000054103482],"domain_scores_gemma":[0.994779,0.0034215979,0.0008082764,0.00010187695,0.00078431814,0.00010496362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024946337,0.0010252798,0.0024239284,0.01014153,0.0004148912,0.0014617229,0.0014019381,0.0013137194,0.0042257328],"category_scores_gemma":[0.0051637855,0.00045252027,0.0025482096,0.008140772,0.00048007225,0.0017929955,0.0007051875,0.00095895625,0.0011059701],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030941245,0.00012175122,0.001356998,0.44050866,0.0010364855,0.0007081566,0.00030203705,0.00034300596,0.0027461394,0.001976556,0.025641149,0.5249496],"study_design_scores_gemma":[0.00009543011,0.00048345,0.0061828634,0.35509312,0.010082716,0.0048871865,0.0004936192,0.00025860922,0.0024585547,0.0020959137,0.6177766,0.00009204543],"about_ca_topic_score_codex":0.0024578387,"about_ca_topic_score_gemma":0.004427783,"teacher_disagreement_score":0.01014153,"about_ca_system_score_codex":0.0009986422,"about_ca_system_score_gemma":0.003587698,"threshold_uncertainty_score":0.014136493},"labels":[],"label_agreement":null},{"id":"W4403604899","doi":"10.58931/cot.2024.1222","title":"From Intractable to Treatable: Milestones and Horizons in the Management of HER2+ Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Breast cancer; Medicine; New horizons; Cancer; General surgery; Internal medicine; Engineering","score_opus":0.027025459900487908,"score_gpt":0.37526584115896766,"score_spread":0.3482403812584798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403604899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022108273,0.603322,0.00383108,0.35812303,0.014849792,0.000051591425,0.00015625625,0.00016385435,0.017291676],"genre_scores_gemma":[0.030154219,0.8076773,0.00628631,0.12096973,0.022923864,0.00009977695,0.0003751682,0.00011426695,0.011399328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876547,0.0004205368,0.00010118306,0.00013698816,0.0004263774,0.00014940857],"domain_scores_gemma":[0.99773335,0.00060382,0.00021732123,0.00008070972,0.0005413886,0.0008234185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027966565,0.00068262126,0.00074890204,0.0008527137,0.000928487,0.002999823,0.0012584818,0.0025580893,0.009611985],"category_scores_gemma":[0.0054417495,0.00018617924,0.0005763768,0.0005739527,0.002124764,0.0060003526,0.0029903175,0.009983575,0.003194473],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022013535,0.00022492264,0.00079553545,0.002293408,0.000037106733,0.00067919557,0.0005252545,0.00044043554,0.0010943883,0.030386198,0.41821232,0.5450911],"study_design_scores_gemma":[0.00004620308,0.000221848,0.0008529457,0.0040495335,0.00002879403,0.0016674054,0.0006265174,0.0002673133,0.0002695237,0.024245277,0.9676916,0.000032970922],"about_ca_topic_score_codex":0.0014282593,"about_ca_topic_score_gemma":0.004843989,"teacher_disagreement_score":0.009611985,"about_ca_system_score_codex":0.0020639345,"about_ca_system_score_gemma":0.003302099,"threshold_uncertainty_score":0.032155335},"labels":[],"label_agreement":null},{"id":"W4403665847","doi":"10.1200/jco.24.00529","title":"Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Medac","keywords":"Medicine; Metastatic breast cancer; Trastuzumab; Internal medicine; Trastuzumab emtansine; Oncology; Hazard ratio; Breast cancer; Clinical endpoint; Pertuzumab; Lapatinib; Cancer; Progression-free survival; Clinical trial; Surgery; Chemotherapy; Confidence interval","score_opus":0.2651344660519626,"score_gpt":0.5945402876781979,"score_spread":0.3294058216262353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403665847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388266,0.0018455351,0.0003145065,0.00023476439,0.00013994591,0.0022627695,0.0003610222,0.000055415625,0.0009034003],"genre_scores_gemma":[0.99098575,0.0020849758,0.0010161573,0.0004854121,0.00024846653,0.002923111,0.00077015214,0.000014100072,0.0014719561],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995678,0.00023685036,0.000021151776,0.00007181772,0.000027104588,0.00007523705],"domain_scores_gemma":[0.9995602,0.00011053595,0.00008098482,0.000025755277,0.0000231355,0.0001994328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016790472,0.0014263978,0.0019993419,0.00039413106,0.00032461312,0.0008963469,0.00065165694,0.0009777988,0.0026882053],"category_scores_gemma":[0.0010608197,0.00041870825,0.000914479,0.00033618417,0.0009823233,0.00084298203,0.0004039707,0.0017962527,0.00044463927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9628787,0.010970462,0.0009412209,0.00034752465,0.0002918306,0.000049780705,0.0000828895,0.00044114006,0.0041170805,0.00013144984,0.0006491083,0.019098895],"study_design_scores_gemma":[0.8958091,0.10092938,0.0013813281,0.000022992457,0.00019989924,0.00003823339,0.000021428097,0.00057365076,0.00047570062,0.000100332734,0.00043783055,0.000010067582],"about_ca_topic_score_codex":0.00068172376,"about_ca_topic_score_gemma":0.0016324866,"teacher_disagreement_score":0.0026882053,"about_ca_system_score_codex":0.0007084737,"about_ca_system_score_gemma":0.0011568189,"threshold_uncertainty_score":0.00899291},"labels":[],"label_agreement":null},{"id":"W4403694618","doi":"10.1158/2159-8290.cd-24-0708","title":"The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development","year":2024,"lang":"en","type":"review","venue":"Cancer Discovery","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Drug development; Clinical trial; Medicine; Identification (biology); Modalities; Computational biology; Drug; Drug discovery; Bioinformatics; Pharmacology; Biology; Internal medicine","score_opus":0.2113580981287041,"score_gpt":0.491369090281659,"score_spread":0.2800109921529549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403694618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025675603,0.9954209,0.00029482457,0.0023999012,0.0005214288,0.0000028235784,0.000011138867,0.000009237281,0.0010829603],"genre_scores_gemma":[0.0019677223,0.9946966,0.00042096552,0.0015914171,0.00047640223,0.0000066987322,0.00002140079,0.0000046220302,0.00081417285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99933016,0.00017018185,0.000076323806,0.00008847453,0.00025707722,0.00007777937],"domain_scores_gemma":[0.9987935,0.00069747824,0.00007734293,0.00004791038,0.00026061255,0.00012313284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024496093,0.00072816975,0.0011698384,0.0014456373,0.0004673619,0.0017100784,0.0007610353,0.0018007469,0.0027235989],"category_scores_gemma":[0.0024592327,0.000296375,0.00059476757,0.0013753198,0.001403018,0.004445513,0.0012657902,0.0047071683,0.0012816814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015591046,0.00013480218,0.0002767708,0.011443274,0.0000929653,0.00037495542,0.00051395746,0.00075800024,0.002881703,0.03345232,0.053952664,0.89596266],"study_design_scores_gemma":[0.000014776193,0.00012728154,0.0002794641,0.0024460708,0.000036669564,0.000671839,0.00017039497,0.00010542626,0.00050541054,0.0077189156,0.9879045,0.00001932004],"about_ca_topic_score_codex":0.0011201623,"about_ca_topic_score_gemma":0.0021993783,"teacher_disagreement_score":0.0027235989,"about_ca_system_score_codex":0.0011341058,"about_ca_system_score_gemma":0.001999549,"threshold_uncertainty_score":0.01295495},"labels":[],"label_agreement":null},{"id":"W4403732678","doi":"10.3390/curroncol31110484","title":"Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"St Joseph's Health Care; Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre; McGill University Health Centre; Sunnybrook Health Science Centre; Saskatchewan Cancer Agency; Mount Sinai Hospital; Dr. H. Bliss Murphy Cancer Centre; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Genentech; Astellas Pharma; Seagen; Ipsen; BeiGene; McGill University; Helsinn; Eisai; Purdue University; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene; Myriad Genetics; AstraZeneca; Eli Lilly and Company; University of Toronto; Genomic Health; GlaxoSmithKline","keywords":"Medicine; Breast cancer; Excellence; Metastatic breast cancer; Cancer; Family medicine; Oncology; Systemic therapy; Clinical trial; Internal medicine","score_opus":0.124020790390795,"score_gpt":0.48708459200591114,"score_spread":0.36306380161511614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403732678","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022194278,0.025646035,0.02271064,0.7984004,0.011562855,0.010304451,0.0066057094,0.0009619829,0.12158854],"genre_scores_gemma":[0.05850867,0.065617405,0.52388644,0.22237507,0.0027895875,0.027150469,0.019929746,0.0008173591,0.07892523],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.92557037,0.03348545,0.00784061,0.0016933263,0.026431052,0.004979232],"domain_scores_gemma":[0.77503645,0.033124585,0.008111981,0.0032440869,0.1625291,0.017953737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.074347876,0.0016420253,0.002036361,0.0077148974,0.007800628,0.006509467,0.009169792,0.014757552,0.020215789],"category_scores_gemma":[0.18009762,0.0014106097,0.0058349296,0.007028981,0.0043561733,0.004677509,0.0066714333,0.012471715,0.008765037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044801403,0.000103884246,0.0008687042,0.0025171763,0.000049834132,0.00025323214,0.0017073482,0.00059377356,0.00019954631,0.005483428,0.8993418,0.088836506],"study_design_scores_gemma":[0.0002613917,0.000057893776,0.0035705732,0.015163892,0.00012658304,0.0003382334,0.002654308,0.0007310211,0.00025515276,0.009165649,0.9674604,0.00021494462],"about_ca_topic_score_codex":0.64250576,"about_ca_topic_score_gemma":0.7496973,"teacher_disagreement_score":0.35749424,"about_ca_system_score_codex":0.060778867,"about_ca_system_score_gemma":0.35379982,"threshold_uncertainty_score":0.7191992},"labels":[],"label_agreement":null},{"id":"W4403789396","doi":"10.1016/j.ygyno.2024.10.013","title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"ImmunoGen","keywords":"Medicine; Tolerability; Ovarian cancer; Oncology; Folate receptor; Internal medicine; Gynecology; Cancer; Adverse effect; Cancer cell","score_opus":0.05559084458819756,"score_gpt":0.40697704372038457,"score_spread":0.351386199132187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403789396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9565769,0.031388283,0.0032399343,0.00076768413,0.00008937644,0.00043680752,0.0015121492,0.00020873341,0.005780083],"genre_scores_gemma":[0.99017125,0.0051110582,0.0011291261,0.0005431465,0.00013022035,0.00013209453,0.001352123,0.000036401627,0.001394597],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990983,0.00037404933,0.00011367981,0.00009262574,0.00024369887,0.00007768964],"domain_scores_gemma":[0.9984658,0.00045911415,0.0005947649,0.00009887586,0.00026312185,0.00011836396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023415512,0.00039428798,0.0013776283,0.0003431521,0.00019815075,0.00089154707,0.00035216135,0.0005149895,0.001416048],"category_scores_gemma":[0.0018129738,0.00018361467,0.0014947867,0.0003782032,0.00025612043,0.00044608547,0.00014754006,0.0010427446,0.00037619402],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10271582,0.00297123,0.052474994,0.0030112609,0.0056945346,0.0005884553,0.00036861555,0.007289198,0.09166726,0.0005301257,0.0042137387,0.7284748],"study_design_scores_gemma":[0.023909852,0.3448259,0.48553592,0.00088195,0.01520536,0.0047803703,0.00045392403,0.014661067,0.05945813,0.0010303727,0.0490261,0.00023107092],"about_ca_topic_score_codex":0.0004932015,"about_ca_topic_score_gemma":0.0011470136,"teacher_disagreement_score":0.0023415512,"about_ca_system_score_codex":0.0007835089,"about_ca_system_score_gemma":0.000753154,"threshold_uncertainty_score":0.012383461},"labels":[],"label_agreement":null},{"id":"W4404321660","doi":"10.3390/curroncol31110522","title":"Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Antibody; Drug; Antibody-drug conjugate; Conjugate; Bioinformatics; Computational biology; Immunology; Pharmacology; Monoclonal antibody; Biology","score_opus":0.39152912207707863,"score_gpt":0.5939985891599726,"score_spread":0.20246946708289398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404321660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009125747,0.9985037,0.00009574751,0.0003082096,0.00020705124,0.0000029490088,0.000012418549,0.0000069272273,0.0007717471],"genre_scores_gemma":[0.00050415535,0.9984445,0.000140992,0.0002656279,0.00017622807,0.0000030729707,0.00002219602,0.0000016186007,0.00044166652],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982834,0.00003463555,0.000023095497,0.00002707894,0.00006793448,0.00001886404],"domain_scores_gemma":[0.9997261,0.0001354462,0.000030091565,0.000008642352,0.00007591238,0.000023776978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051987194,0.00060391973,0.0009754155,0.0022306894,0.00022921564,0.0009029825,0.0005228108,0.00093396136,0.0035405753],"category_scores_gemma":[0.00063978933,0.00023578641,0.000511835,0.0023168041,0.00045537882,0.0017621549,0.00060204935,0.001932511,0.0017944571],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006695141,0.000059228503,0.00012242365,0.017119486,0.000053777374,0.0001846072,0.000084615465,0.00026122452,0.002071674,0.0056513646,0.033015333,0.9413092],"study_design_scores_gemma":[0.00001089276,0.00007071306,0.00033910316,0.0020565167,0.00004490601,0.0007063852,0.00004118992,0.00004683057,0.00024163083,0.001324413,0.99510807,0.000009382492],"about_ca_topic_score_codex":0.000884796,"about_ca_topic_score_gemma":0.0020200778,"teacher_disagreement_score":0.0035405753,"about_ca_system_score_codex":0.0006953494,"about_ca_system_score_gemma":0.0010140496,"threshold_uncertainty_score":0.011844397},"labels":[],"label_agreement":null},{"id":"W4404367648","doi":"10.1016/j.ctrv.2024.102853","title":"Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer","year":2024,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Foundation; Spinal Cord Injury BC; BC Cancer Agency","funders":"Seagen; Pfizer","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Metastatic breast cancer; Breast cancer; Oncology; Cancer; Internal medicine; Epidermal growth factor receptor; Lapatinib; Cancer research; Trastuzumab","score_opus":0.3394679420235394,"score_gpt":0.5386860887968553,"score_spread":0.1992181467733159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404367648","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025380247,0.08506217,0.034606203,0.8138598,0.02355869,0.0015456631,0.0008481093,0.00070342224,0.037277956],"genre_scores_gemma":[0.0558421,0.16187839,0.22493038,0.501186,0.023056487,0.0051640044,0.0038935477,0.0006142126,0.023434995],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9620283,0.022467291,0.0074254107,0.0011525181,0.0050741755,0.0018523136],"domain_scores_gemma":[0.90919274,0.041382592,0.006516665,0.001844361,0.033930037,0.0071335514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.040988106,0.0014091537,0.0019093641,0.0026848733,0.0025405504,0.0037399943,0.0058254553,0.018267276,0.007065966],"category_scores_gemma":[0.09948337,0.00082159176,0.004160758,0.0017993049,0.0025109572,0.0056614815,0.004468174,0.016010882,0.0052782563],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114478076,0.00013714959,0.0010834056,0.004771849,0.00012209719,0.0013699912,0.0016786843,0.0019957535,0.0008435608,0.010128664,0.7423956,0.23535882],"study_design_scores_gemma":[0.00012838707,0.00008779719,0.00096815533,0.015556832,0.0001846462,0.001299445,0.0017380132,0.0008127238,0.0004432466,0.016681936,0.96197116,0.00012754451],"about_ca_topic_score_codex":0.0055735838,"about_ca_topic_score_gemma":0.01237237,"teacher_disagreement_score":0.040988106,"about_ca_system_score_codex":0.0046041366,"about_ca_system_score_gemma":0.016727895,"threshold_uncertainty_score":0.21676838},"labels":[],"label_agreement":null},{"id":"W4405050108","doi":"10.1182/blood-2024-198536","title":"Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Myeloid leukemia; Calicheamicin; Leukemia; Internal medicine; Oncology; CD33; Biology","score_opus":0.024610560995963298,"score_gpt":0.3166875365898274,"score_spread":0.2920769755938641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825484,0.0009158709,0.00026272106,0.00006556654,0.000009525325,0.000043263215,0.00005600096,0.000006279204,0.00038589365],"genre_scores_gemma":[0.99834883,0.0007727703,0.00038554575,0.0000868907,0.000037145666,0.000025125866,0.0001904536,0.000005211826,0.00014804164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99965477,0.00009563856,0.000052618947,0.0000671297,0.000051794617,0.00007790337],"domain_scores_gemma":[0.9994998,0.00007766625,0.00010067827,0.00003002857,0.000031918335,0.0002598998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005507806,0.0002715994,0.0003479981,0.00034178852,0.00042596724,0.00045946793,0.0002210521,0.00024229867,0.00072043284],"category_scores_gemma":[0.0011177479,0.00012882998,0.0003102607,0.0003793701,0.00022092274,0.00026199265,0.0005304721,0.00029460216,0.00021157043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003089665,0.0023684348,0.8708687,0.0001543153,0.00018264278,0.0084238,0.00085781957,0.00033917426,0.004528445,0.00019496346,0.0014004329,0.10759159],"study_design_scores_gemma":[0.0010329514,0.0149968695,0.9262498,0.00012695491,0.00042958735,0.04173778,0.001647621,0.0015986729,0.003574607,0.00026088336,0.008288007,0.00005624539],"about_ca_topic_score_codex":0.0009391606,"about_ca_topic_score_gemma":0.0017877725,"teacher_disagreement_score":0.0009391606,"about_ca_system_score_codex":0.000450436,"about_ca_system_score_gemma":0.0004930729,"threshold_uncertainty_score":0.0032681227},"labels":[],"label_agreement":null},{"id":"W4405182393","doi":"10.1158/1538-8514.cancerchem24-ia023","title":"Abstract IA023: Dual-drug ADC platform for effective and safe cancer treatment","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Antibody-drug conjugate; Tolerability; Drug; Cancer; Pharmacology; Cancer research; Drug resistance; Internal medicine; Antibody; Immunology; Biology; Adverse effect; Monoclonal antibody","score_opus":0.05581262807661499,"score_gpt":0.4060311569159849,"score_spread":0.35021852883936994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6783262,0.047802005,0.16376016,0.0041540978,0.0014361333,0.0014254024,0.005415901,0.0056125,0.092067614],"genre_scores_gemma":[0.9290577,0.006837671,0.037316695,0.00067023496,0.00010745595,0.00031281204,0.0015918253,0.00012213209,0.02398348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990404,0.0000093580475,0.000005949131,0.000020043823,0.000034812198,0.000025764039],"domain_scores_gemma":[0.99995196,0.0000029827117,0.0000100588695,0.0000041803796,0.000016248156,0.000014639981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018342621,0.00040429353,0.0003635296,0.00033302404,0.00018966026,0.0005720153,0.000367455,0.0005509678,0.0046757734],"category_scores_gemma":[0.00012655626,0.00017990221,0.00019686398,0.00024522355,0.00014243294,0.00042024397,0.00038100177,0.0006756773,0.0017292448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030778087,0.00012886194,0.00020887694,0.0002143305,0.00001732208,0.00016992232,0.000028367638,0.0011265503,0.9322333,0.0019577192,0.00714618,0.05646075],"study_design_scores_gemma":[0.00014691973,0.0009169165,0.0010449116,0.000026069976,0.000046373414,0.0006447863,0.000018056457,0.010399363,0.9173247,0.00034726702,0.06905288,0.000031711654],"about_ca_topic_score_codex":0.0009255744,"about_ca_topic_score_gemma":0.0011387961,"teacher_disagreement_score":0.0046757734,"about_ca_system_score_codex":0.0006016748,"about_ca_system_score_gemma":0.00056705024,"threshold_uncertainty_score":0.015642047},"labels":[],"label_agreement":null},{"id":"W4405368113","doi":"10.1158/1078-0432.ccr-24-1779","title":"Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody–Drug Radioconjugate","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Canadian Nuclear Laboratories; University of Saskatchewan; Saskatoon Medical Imaging; Université Laval; Centre hospitalier de l'Université Laval; Hôtel-Dieu de Québec","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Biodistribution; Medicine; Pharmacology; Cancer; Internal medicine; Breast cancer; Chemistry; In vitro","score_opus":0.32613720757807146,"score_gpt":0.588059894922568,"score_spread":0.2619226873444966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405368113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953811,0.001178725,0.0012573437,0.00007838583,0.000026810301,0.000063456195,0.00023250637,0.00010317172,0.0016783765],"genre_scores_gemma":[0.9973826,0.0004118193,0.0004316535,0.000035464072,0.000007770002,0.000023228402,0.0003406287,0.000013133938,0.0013537203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993,0.0000073932456,0.0000049477485,0.000013440079,0.00002120552,0.000022972275],"domain_scores_gemma":[0.999943,0.0000065830714,0.000013740831,0.000012736036,0.0000043954833,0.000019542664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014025431,0.00021193386,0.00030636837,0.00012165518,0.00012755019,0.00021404709,0.00018967726,0.00018970149,0.00071843906],"category_scores_gemma":[0.00008090852,0.00008793563,0.00015696096,0.00010567456,0.00011005903,0.00015929664,0.000101743,0.000461853,0.00017433676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010280163,0.00055786804,0.0008854835,0.000081664504,0.000042232212,0.00015907292,0.000051834468,0.0007588865,0.9813968,0.00016434015,0.0005575006,0.014316325],"study_design_scores_gemma":[0.000655998,0.011426812,0.0136370845,0.000010891823,0.00009926338,0.001335536,0.0000469129,0.0030330683,0.9607827,0.00008730347,0.008872894,0.000011421957],"about_ca_topic_score_codex":0.00068900426,"about_ca_topic_score_gemma":0.0010077299,"teacher_disagreement_score":0.00071843906,"about_ca_system_score_codex":0.00028913165,"about_ca_system_score_gemma":0.00017489537,"threshold_uncertainty_score":0.002403438},"labels":[],"label_agreement":null},{"id":"W4405602713","doi":"10.26434/chemrxiv-2024-v1sc1","title":"Large library docking and biophysical analysis of small molecule TMPRSS2 inhibitors","year":2024,"lang":"en","type":"preprint","venue":"ChemRxiv","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of British Columbia; University of Toronto","funders":"Canadian Institutes of Health Research; Genentech; Mitacs; Killam Trusts; Wellcome Trust; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; American Foundation for Pharmaceutical Education; Merck KGaA; National Institutes of Health; Ontario Genomics; Genome Canada; Bayer; Natural Sciences and Engineering Research Council of Canada; Canadian Light Source; Pfizer; National Institute of Health Sciences","keywords":"Docking (animal); Computational biology; TMPRSS2; Small molecule; Chemistry; Biology; Medicine; Biochemistry; Coronavirus disease 2019 (COVID-19); Internal medicine","score_opus":0.03558635022213707,"score_gpt":0.33518207523741295,"score_spread":0.29959572501527587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405602713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971592,0.00041809885,0.02235614,0.00016234272,0.000016816468,0.000059321348,0.0011067514,0.0005324069,0.0037561695],"genre_scores_gemma":[0.9831777,0.0005100694,0.011794137,0.000041042826,0.0000035121307,0.00007484693,0.0018693702,0.00008896104,0.00244032],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998004,0.000024005367,0.000011099221,0.00003166636,0.000098487995,0.000034426655],"domain_scores_gemma":[0.9998853,0.00004767022,0.000015238483,0.000012933028,0.000021268288,0.000017638622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020710696,0.0005020397,0.00063306233,0.0004491463,0.0002812878,0.00054897217,0.0004884318,0.0002471365,0.0017015646],"category_scores_gemma":[0.0004919591,0.00018183581,0.00032517037,0.000563743,0.00018398972,0.00024337761,0.0002708549,0.00044543744,0.00044433548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094249623,0.0008723888,0.0027890136,0.00015061024,0.000112869755,0.00027057074,0.00007937192,0.25997823,0.70752513,0.0030132867,0.0013727966,0.02289328],"study_design_scores_gemma":[0.00009761564,0.0006243157,0.0018301974,0.0000032698715,0.000028196646,0.00008054323,0.000045870405,0.42278543,0.5725633,0.000409857,0.0015061061,0.000025244473],"about_ca_topic_score_codex":0.0025522984,"about_ca_topic_score_gemma":0.002788954,"teacher_disagreement_score":0.0025522984,"about_ca_system_score_codex":0.00072631304,"about_ca_system_score_gemma":0.00040016658,"threshold_uncertainty_score":0.005692303},"labels":[],"label_agreement":null},{"id":"W4405732807","doi":"10.3390/curroncol32010001","title":"The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Cancer; Internal medicine; Metastatic breast cancer","score_opus":0.12324691670883109,"score_gpt":0.47708145774799177,"score_spread":0.3538345410391607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405732807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994573,0.00023142004,0.000034174256,0.000021259324,0.0000015135455,0.000007840966,0.00004884399,0.000001262224,0.00019633453],"genre_scores_gemma":[0.9997429,0.000071729126,0.00003596072,0.000014622424,0.0000065110075,0.000004531781,0.0000935096,9.59559e-7,0.000029173216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993261,0.00020142515,0.00009569615,0.00014445292,0.000119059434,0.00011337677],"domain_scores_gemma":[0.99779165,0.00033439058,0.0012154505,0.00006762117,0.00013759716,0.00045315243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005681964,0.00017883739,0.00041663466,0.00040992486,0.0003588281,0.00073101866,0.0002471063,0.00034291224,0.0009860552],"category_scores_gemma":[0.0020310024,0.00016320338,0.00028771796,0.0005179198,0.00037522553,0.0002996469,0.0004524366,0.00033941306,0.00015388618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012472474,0.00012208942,0.9892461,0.000035714613,0.0001005337,0.001697233,0.00022520189,0.00030872438,0.0011603483,0.000022823131,0.00013316216,0.005700831],"study_design_scores_gemma":[0.00012284616,0.0026021756,0.98667437,0.000017832172,0.000125109,0.008081466,0.00050052244,0.0005336475,0.0006636323,0.0000337309,0.00062643155,0.000018219776],"about_ca_topic_score_codex":0.001150985,"about_ca_topic_score_gemma":0.0014403914,"teacher_disagreement_score":0.001150985,"about_ca_system_score_codex":0.0008501253,"about_ca_system_score_gemma":0.00042583505,"threshold_uncertainty_score":0.006168127},"labels":[],"label_agreement":null},{"id":"W4405987481","doi":"10.1101/2024.12.31.630944","title":"Structural conservation and divergence across the Receptor Tyrosine Kinase superfamily","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Haifa; Azrieli Foundation; Israel Science Foundation; International Development Research Centre; Council for Higher Education; United States-Israel Binational Science Foundation; National Science Foundation","keywords":"SUPERFAMILY; Tyrosine kinase; Receptor tyrosine kinase; Divergence (linguistics); ROR1; Platelet-derived growth factor receptor; Receptor; Cell biology; Biology; Kinase; Genetics","score_opus":0.03422649518746598,"score_gpt":0.3054845277984733,"score_spread":0.27125803261100734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405987481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927886,0.0012352866,0.0035603626,0.000049160277,0.000009587476,0.000008627917,0.0012391367,0.00012861489,0.0009805528],"genre_scores_gemma":[0.9931206,0.0003473687,0.0033091593,0.000042349257,0.0000072043977,0.000008638584,0.0028701124,0.00005653958,0.00023801283],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9996051,0.00008159276,0.000037633046,0.00011180192,0.000106910484,0.00005699065],"domain_scores_gemma":[0.9995326,0.00013504882,0.00012260913,0.00006403507,0.00007483311,0.00007087847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065182743,0.0002617485,0.00052153564,0.0013135505,0.00042152728,0.00063450093,0.00033024623,0.00029974262,0.0016455388],"category_scores_gemma":[0.00091042556,0.00014021687,0.0004581375,0.0010569994,0.000295328,0.00045938842,0.0005076017,0.00048071952,0.00066729187],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022717896,0.00020597961,0.16836451,0.0009969157,0.00076883956,0.0015298049,0.0011165757,0.012735155,0.73992246,0.0028580574,0.0028103052,0.0664197],"study_design_scores_gemma":[0.00013818794,0.00074353546,0.755883,0.0002486337,0.00080548844,0.007342593,0.0013086536,0.0567309,0.12945406,0.0055234237,0.041693438,0.00012810533],"about_ca_topic_score_codex":0.0005465137,"about_ca_topic_score_gemma":0.00061613944,"teacher_disagreement_score":0.0016455388,"about_ca_system_score_codex":0.00029533586,"about_ca_system_score_gemma":0.00026709496,"threshold_uncertainty_score":0.0055048466},"labels":[],"label_agreement":null},{"id":"W4406206869","doi":"10.2139/ssrn.5087372","title":"New Standards in Her2-Low Testing: The Casi-01 Comparative Methods Study","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"","keywords":"Computer science","score_opus":0.14338908652328425,"score_gpt":0.5266827475577621,"score_spread":0.3832936610344779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406206869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7827269,0.026509402,0.10418661,0.0062889666,0.0024365059,0.005548697,0.0087808,0.00030161985,0.06322046],"genre_scores_gemma":[0.9470622,0.0014648233,0.034781083,0.002411266,0.00035252413,0.0054957652,0.0032418412,0.0004818259,0.0047087437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.7834858,0.17806333,0.008659751,0.01069254,0.016976248,0.0021224099],"domain_scores_gemma":[0.6613371,0.24735397,0.017004434,0.04985746,0.020384079,0.00406294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1398285,0.0010007814,0.0014900537,0.0030192495,0.0025678682,0.003989297,0.0043611955,0.0028745062,0.011074166],"category_scores_gemma":[0.31152466,0.0010403953,0.002346069,0.0034581297,0.0032265948,0.0028823854,0.004804597,0.0029753295,0.0015620169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053768676,0.002467386,0.57018393,0.0037720632,0.014621519,0.0005109367,0.014051996,0.0014088136,0.0027335838,0.099212624,0.031055655,0.20621286],"study_design_scores_gemma":[0.011512028,0.0189684,0.7267643,0.004092441,0.01800943,0.004178133,0.010236959,0.008928821,0.0074410182,0.06709419,0.12212621,0.0006481033],"about_ca_topic_score_codex":0.009371739,"about_ca_topic_score_gemma":0.009667919,"teacher_disagreement_score":0.1398285,"about_ca_system_score_codex":0.004602583,"about_ca_system_score_gemma":0.0048430352,"threshold_uncertainty_score":0.73949265},"labels":[],"label_agreement":null},{"id":"W4406536614","doi":"10.1038/s41591-024-03462-0","title":"Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"FUJIFILM Toyama Chemical; Bayer Yakuhin; MSD K.K.; Chugai Pharmaceutical; Eli Lilly Japan; Sierra Oncology; Sirtex Medical; Ono Pharmaceutical; Astellas Pharma; Swedish Orphan Biovitrum; Celgene; Yakult Honsha; Amgen; Coherus Biosciences; FibroGen; Puma Biotechnology; Seagen; Relay Therapeutics; Daiichi Sankyo Europe; European Society for Medical Oncology; Agios Pharmaceuticals; Veracyte; Foundation Medicine; GlaxoSmithKline; Advanced Accelerator Applications; BeiGene; PharmaMar; Array BioPharma; Nihon Medi-Physics; Clovis Oncology; Genentech; AstraZeneca; Novocure; Natera; Regeneron Pharmaceuticals; G1 Therapeutics; Lantheus Medical Imaging; Merck KGaA; Gilead Sciences; Taiho Pharmaceutical; Sumitomo Dainippon Pharma Oncology; Ipsen; Pancreatic Cancer Action Network; Mirati Therapeutics; Handok; F. Hoffmann-La Roche; Eisai; National Cancer Institute; Fondazione Beretta; Incyte; Servier; Halozyme; Exelixis; Apollomics; Sanofi; Miyarisan Pharmaceutical; Aptitude Health; Eli Lilly and Company; Bristol-Myers Squibb; Yuhan; Spectrum Pharmaceuticals; Pfizer","keywords":"Trastuzumab; Oncology; Metastatic breast cancer; Breast cancer; Medicine; Internal medicine; Clinical trial; Cancer; Cancer research","score_opus":0.025803389683979588,"score_gpt":0.4717154380101767,"score_spread":0.4459120483261971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406536614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98452073,0.0052859914,0.00052401307,0.0013170477,0.00026749691,0.0018895838,0.0026067975,0.00013734335,0.0034509765],"genre_scores_gemma":[0.9767606,0.005660911,0.0016265258,0.002082801,0.00033444507,0.0025156054,0.0067969747,0.000052516483,0.0041695945],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996244,0.00015350616,0.000018532251,0.00006628596,0.00004204192,0.000095116564],"domain_scores_gemma":[0.9995592,0.00005810399,0.00009611464,0.000031230647,0.000034056644,0.00022114434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015518767,0.001602835,0.00174912,0.00041713798,0.00027777685,0.0013557825,0.0007357558,0.0013483745,0.0044027604],"category_scores_gemma":[0.0010099732,0.0004231264,0.0011006262,0.00059619325,0.0005245646,0.0012377152,0.000537729,0.0024752473,0.00076794747],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81700146,0.016974492,0.0041121664,0.0013060381,0.0019952136,0.00037958543,0.00022021579,0.003369539,0.019779542,0.0012561269,0.012467778,0.12113779],"study_design_scores_gemma":[0.8911733,0.09216549,0.0069974167,0.00009358548,0.00059580774,0.0004457868,0.00006257068,0.0019699268,0.001278794,0.0005758164,0.0046083783,0.000033228916],"about_ca_topic_score_codex":0.0010361642,"about_ca_topic_score_gemma":0.002592684,"teacher_disagreement_score":0.0044027604,"about_ca_system_score_codex":0.0012516774,"about_ca_system_score_gemma":0.0013103418,"threshold_uncertainty_score":0.014728665},"labels":[],"label_agreement":null},{"id":"W4406584190","doi":"10.1016/j.ypat.2014.01.032","title":"10.1016/j.ypat.2014.01.032","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Fish <Actinopterygii>; Breast cancer; Cancer; Oncology; Internal medicine; Gynecology; Fishery; Biology","score_opus":0.017112444629831615,"score_gpt":0.2692044084067701,"score_spread":0.2520919637769385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584190","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058577145,0.017324625,0.0042987415,0.015133879,0.0042204875,0.00013474979,0.005311822,0.002728119,0.94498986],"genre_scores_gemma":[0.011595928,0.004514964,0.0020940588,0.0023741077,0.00084724504,0.00007579313,0.0025215766,0.00035698357,0.9756193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997478,0.000021851527,0.000018468478,0.00006960579,0.00007622823,0.00006603518],"domain_scores_gemma":[0.9991048,0.0001410956,0.0001014722,0.00005821915,0.00014257198,0.0004518083],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006381691,0.0011786805,0.00062120927,0.0014981177,0.00094520696,0.0031308804,0.0011434244,0.0035407853,0.9089867],"category_scores_gemma":[0.0013729008,0.0004752716,0.0007867598,0.0007945532,0.00094820245,0.0020753734,0.0014169755,0.0018525303,0.8782619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034735788,0.00023840726,0.0041577276,0.00041783397,0.000040214803,0.0005040035,0.00008598399,0.00029368058,0.0011980698,0.005441946,0.36385462,0.62342024],"study_design_scores_gemma":[0.00007587388,0.000106471234,0.0037748734,0.00058128446,0.000041122643,0.0027163709,0.0001550618,0.00023897977,0.0006072232,0.0048024757,0.9868774,0.000022861608],"about_ca_topic_score_codex":0.0018989561,"about_ca_topic_score_gemma":0.0018614685,"teacher_disagreement_score":0.09101331,"about_ca_system_score_codex":0.0008600013,"about_ca_system_score_gemma":0.001339614,"threshold_uncertainty_score":0.1298194},"labels":[],"label_agreement":null},{"id":"W4406588304","doi":"10.1016/s1541-9800(08)70524-6","title":"10.1016/s1541-9800(08)70524-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.01764804893609909,"score_gpt":0.26796130889026404,"score_spread":0.2503132599541649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406588304","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050802255,0.00059185683,0.000593567,0.0005474464,0.0003751459,0.00011946598,0.00082746346,0.00080327346,0.99563366],"genre_scores_gemma":[0.0005068982,0.00019856147,0.00030705298,0.0002204046,0.000074318945,0.000052660485,0.00041445927,0.000111782785,0.9981139],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99947816,0.00003289824,0.00004207676,0.00016903525,0.00014831008,0.00012948226],"domain_scores_gemma":[0.99807703,0.00044144187,0.00012627538,0.00017809994,0.00035081012,0.0008263836],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008613006,0.0025582816,0.0015725992,0.0022808893,0.0019455345,0.0029893408,0.0028334283,0.0051408233,0.98764646],"category_scores_gemma":[0.0013424577,0.00077650533,0.0014343468,0.0016749119,0.0012869426,0.0038397522,0.0028336747,0.0025783228,0.9910601],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004363017,0.00027542302,0.0007420712,0.000519553,0.00003137181,0.00023903028,0.000070647715,0.0003568339,0.002244327,0.003754168,0.32316753,0.6681627],"study_design_scores_gemma":[0.00008093013,0.00014358191,0.00095526857,0.00026277915,0.000013534602,0.00038493943,0.0000849934,0.00017835943,0.0004968704,0.000536993,0.9968401,0.000021703196],"about_ca_topic_score_codex":0.003184958,"about_ca_topic_score_gemma":0.0028215647,"teacher_disagreement_score":0.0123535395,"about_ca_system_score_codex":0.0009276934,"about_ca_system_score_gemma":0.0011925498,"threshold_uncertainty_score":0.017620742},"labels":[],"label_agreement":null},{"id":"W4406606700","doi":"10.1016/j.tranon.2025.102284","title":"Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan","year":2025,"lang":"en","type":"article","venue":"Translational Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Syöpäjärjestöt; Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; Biocenter Finland; Helsingin Yliopisto","keywords":"Trastuzumab; Trastuzumab emtansine; Medicine; Oncology; Internal medicine; Breast cancer; Cancer","score_opus":0.04665332703341679,"score_gpt":0.4109207860228478,"score_spread":0.364267458989431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406606700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529344,0.0014983136,0.00073635095,0.00012922005,0.000047005626,0.0001895711,0.0006482052,0.00008673472,0.001371262],"genre_scores_gemma":[0.9911849,0.001695604,0.0018188773,0.000061617706,0.000022231568,0.00029896098,0.0013971727,0.000026002594,0.003494653],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975747,0.00005107527,0.000018677985,0.000037176233,0.000056656336,0.000078982914],"domain_scores_gemma":[0.9998375,0.000029010393,0.00004004236,0.000023325027,0.000019344874,0.00005072595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045775555,0.0008242045,0.0006364644,0.00053152436,0.00022271812,0.00033672032,0.0005188756,0.00042199428,0.0013988388],"category_scores_gemma":[0.00018274922,0.0002734436,0.00036364433,0.0003916208,0.00025469734,0.0003713525,0.00014427953,0.0012223952,0.00029270875],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004744962,0.004405798,0.0008101559,0.00020972152,0.00007285884,0.00017476277,0.00011349927,0.0016357313,0.97790456,0.0003258028,0.00071812054,0.008884085],"study_design_scores_gemma":[0.0011628845,0.04403166,0.0067125587,0.000017460829,0.0001362368,0.0006552442,0.000075014876,0.004330076,0.93726236,0.00009036965,0.0055102534,0.00001585874],"about_ca_topic_score_codex":0.002551212,"about_ca_topic_score_gemma":0.003999277,"teacher_disagreement_score":0.002551212,"about_ca_system_score_codex":0.0008455278,"about_ca_system_score_gemma":0.0005863053,"threshold_uncertainty_score":0.006134689},"labels":[],"label_agreement":null},{"id":"W4406690075","doi":"10.1159/000543554","title":"Trop2 Expression in Correlation to the Molecular Subtype in Vulvar Squamous Cell Carcinomas","year":2025,"lang":"en","type":"article","venue":"Pathobiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"Universität Leipzig","keywords":"Immunohistochemistry; Medicine; Targeted therapy; Monoclonal antibody; Cancer; Cancer research; Vulvar cancer; Immunotherapy; Oncology; Antibody; Pathology; Internal medicine; Immunology","score_opus":0.017315386114867506,"score_gpt":0.3228786584515315,"score_spread":0.305563272336664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406690075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99870217,0.00047979268,0.000118277785,0.000010647691,0.0000027347382,0.000006623665,0.00008079495,0.0000040526656,0.00059492525],"genre_scores_gemma":[0.9994475,0.00015354915,0.00009861674,0.0000047377903,0.0000060900543,0.0000074364007,0.00011641523,0.0000015138426,0.00016402152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999803,0.000035112782,0.000028157145,0.00004104885,0.000051878287,0.00004085954],"domain_scores_gemma":[0.9994854,0.00011203571,0.00018675227,0.00003672464,0.000098186356,0.0000810129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036897705,0.00015755415,0.00017051407,0.00082645443,0.0001978736,0.00042295476,0.00022463,0.00030855802,0.0025220178],"category_scores_gemma":[0.0007652179,0.00013616949,0.00014714821,0.00043398363,0.0002488908,0.00023810974,0.00026870306,0.00018744107,0.00041642817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024991872,0.000014434111,0.9878368,0.000021736882,0.000017330929,0.00037027363,0.00006136963,0.00004936722,0.009022509,0.000019610032,0.000060548315,0.0022760883],"study_design_scores_gemma":[0.000005382559,0.000097879456,0.9925156,0.000012107686,0.00002837758,0.004058258,0.00027988682,0.0002931947,0.0022992836,0.000042443673,0.00036397213,0.0000035567316],"about_ca_topic_score_codex":0.0006219406,"about_ca_topic_score_gemma":0.0008968329,"teacher_disagreement_score":0.0025220178,"about_ca_system_score_codex":0.00016127493,"about_ca_system_score_gemma":0.00010939316,"threshold_uncertainty_score":0.008436978},"labels":[],"label_agreement":null},{"id":"W4406869258","doi":"10.1200/jco.2025.43.4_suppl.tps847","title":"A phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Antibody-drug conjugate; Antibody; Conjugate; Cancer research; Monoclonal antibody; Internal medicine; Immunology","score_opus":0.07766651630289706,"score_gpt":0.5127989989166067,"score_spread":0.4351324826137097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803366,0.0023468577,0.0013614589,0.0009503305,0.00015893292,0.0061601335,0.003861722,0.00032720165,0.0044967732],"genre_scores_gemma":[0.9705391,0.0024230024,0.0040960857,0.0026388161,0.00013092901,0.005783957,0.008784703,0.00010663412,0.00549675],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995827,0.00016895962,0.000014742182,0.00008328861,0.000051737225,0.0000985607],"domain_scores_gemma":[0.9994511,0.000061631836,0.00012300856,0.00005024309,0.000043808424,0.00027026923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015478316,0.0018052927,0.0013685295,0.0005684334,0.0003309128,0.0008651344,0.0008634573,0.0011239969,0.0056028054],"category_scores_gemma":[0.0008132256,0.0007506082,0.0011015324,0.0005101952,0.0009044015,0.0011281493,0.0004811211,0.0040942463,0.0014225906],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42807057,0.17436665,0.015084833,0.0020039033,0.0024292946,0.000560539,0.00093623705,0.007974699,0.099811025,0.00089815096,0.031941574,0.23592256],"study_design_scores_gemma":[0.48324448,0.4752251,0.020157441,0.0000739257,0.0007738018,0.00067328836,0.00013000623,0.0020719804,0.0063085402,0.0006282163,0.010657519,0.000055673147],"about_ca_topic_score_codex":0.0009623203,"about_ca_topic_score_gemma":0.0031846808,"teacher_disagreement_score":0.0056028054,"about_ca_system_score_codex":0.0012049864,"about_ca_system_score_gemma":0.0018132319,"threshold_uncertainty_score":0.018743277},"labels":[],"label_agreement":null},{"id":"W4407162975","doi":"10.1056/nejmoa2405008","title":"Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Cancer; Fusion; Oncology; Internal medicine; Mathematics; Philosophy","score_opus":0.026742302585877658,"score_gpt":0.3892594150297424,"score_spread":0.3625171124438647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407162975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98260444,0.013129113,0.00026727482,0.00037142343,0.00005135353,0.00009664049,0.00020650169,0.000053003125,0.0032202331],"genre_scores_gemma":[0.99688065,0.0021660065,0.00017793971,0.00014708369,0.000034638524,0.000022150522,0.00027085826,0.0000055659193,0.00029503345],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99991477,0.00003361909,0.0000061592636,0.000012709845,0.000012957607,0.000019726736],"domain_scores_gemma":[0.9998667,0.000036447676,0.000040056322,0.000008770228,0.000008877198,0.00003916277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005132936,0.0001814143,0.0004469325,0.000109909786,0.00012781938,0.0002774074,0.00016407511,0.00021875916,0.0013982514],"category_scores_gemma":[0.00040868018,0.00004775828,0.00025984977,0.00013372111,0.00023092423,0.00022691503,0.00010277025,0.0003969188,0.00017261057],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14585546,0.005346592,0.02823488,0.0018825926,0.0010565268,0.0006295278,0.00020505494,0.006360332,0.122557096,0.0009849294,0.011884612,0.6750024],"study_design_scores_gemma":[0.10060813,0.45953393,0.25517756,0.0007788698,0.0025810648,0.008153053,0.0003614138,0.011752247,0.10596029,0.0017226383,0.05327244,0.0000984433],"about_ca_topic_score_codex":0.00055900717,"about_ca_topic_score_gemma":0.0018712431,"teacher_disagreement_score":0.0013982514,"about_ca_system_score_codex":0.0005355158,"about_ca_system_score_gemma":0.00032572856,"threshold_uncertainty_score":0.0046776533},"labels":[],"label_agreement":null},{"id":"W4407230737","doi":"10.1177/17588359251316176","title":"TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Astellas Pharma; Daiichi-Sankyo; Natera; Puma Biotechnology; Syndax Pharmaceuticals; Chugai Pharmaceutical; Nihon Medi-Physics; Eisai; Jazz Pharmaceuticals; Incyte; Taiho Pharmaceutical; Spectrum Pharmaceuticals; Boston Scientific Corporation; Gilead Sciences; Exelixis; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Pembrolizumab; Internal medicine; Breast cancer; Chemotherapy; Clinical endpoint; Oncology; Adjuvant; Triple-negative breast cancer; Cancer; Clinical trial; Immunotherapy","score_opus":0.01792386089167593,"score_gpt":0.41262272750791656,"score_spread":0.39469886661624065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407230737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98050135,0.0022071819,0.00086140836,0.0007501349,0.00054243597,0.0106489,0.0020681184,0.00016887598,0.0022515005],"genre_scores_gemma":[0.96203494,0.0031118705,0.0039121467,0.0020719746,0.00072097307,0.017754855,0.0031144433,0.00006685443,0.0072119487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990232,0.0005882219,0.000039102983,0.00012361773,0.000062452906,0.00016350923],"domain_scores_gemma":[0.99853957,0.00029620808,0.00033033467,0.00012095309,0.000083032144,0.0006298178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032059574,0.0027150668,0.002935334,0.0006019558,0.0005003187,0.0012169239,0.0015349106,0.0018941965,0.008653352],"category_scores_gemma":[0.0019848591,0.0009459492,0.0018089957,0.000597922,0.0017542295,0.0013826657,0.0005527668,0.0034959237,0.0014400271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9586334,0.023194656,0.0007720438,0.00037235353,0.000396912,0.00003002264,0.000051222414,0.000404527,0.0035515586,0.00012330923,0.0008793705,0.011590712],"study_design_scores_gemma":[0.85796285,0.13939649,0.0009706487,0.000015726586,0.00020429977,0.00002913325,0.000020164565,0.00027846335,0.00043864868,0.000082409824,0.00058977003,0.000011327111],"about_ca_topic_score_codex":0.0013166824,"about_ca_topic_score_gemma":0.0029353525,"teacher_disagreement_score":0.008653352,"about_ca_system_score_codex":0.0013272017,"about_ca_system_score_gemma":0.0023144996,"threshold_uncertainty_score":0.028948307},"labels":[],"label_agreement":null},{"id":"W4408080074","doi":"10.1016/j.breast.2025.104432","title":"A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)","year":2025,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Association of Schools and Colleges of Optometry; Breakthrough Cancer Research; Translational Breast Cancer Research Consortium; Susan G. Komen; AbbVie; Breast Cancer Research Foundation; National Cancer Institute; Conquer Cancer Foundation; Sidney Kimmel Comprehensive Cancer Center; Genentech; Susan G. Komen for the Cure","keywords":"Medicine; Pertuzumab; Trastuzumab; Breast cancer; Oncology; Biomarker; Internal medicine; Neoadjuvant therapy; Cancer","score_opus":0.015187110065405239,"score_gpt":0.34014640719778816,"score_spread":0.3249592971323829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408080074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991091,0.00017929076,0.000267172,0.00004912346,0.000003817042,0.000016641732,0.00019600407,0.00000970901,0.00016913179],"genre_scores_gemma":[0.998483,0.00004005926,0.00070254947,0.00002277092,0.000007115037,0.000017113922,0.00059881917,0.0000028450609,0.0001256878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996853,0.00008709029,0.00003116,0.00007233581,0.00008610127,0.000038158956],"domain_scores_gemma":[0.99898785,0.0002446401,0.00029604134,0.000056191824,0.00016885214,0.0002463231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013854066,0.0005954817,0.0005763439,0.0006212095,0.00019123209,0.000707313,0.00054923183,0.0004744529,0.00081002444],"category_scores_gemma":[0.0027522172,0.00020302819,0.0004470143,0.0005147814,0.00022396875,0.00025305478,0.00043555687,0.0005664326,0.0003908676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002907478,0.00014967748,0.9828765,0.000025777723,0.00009561332,0.00013548593,0.00003240768,0.0011918038,0.003532773,0.000014950862,0.00021927054,0.008818289],"study_design_scores_gemma":[0.00027526342,0.0024444663,0.9658925,0.000017405679,0.0001688147,0.001953954,0.000095597126,0.023237366,0.0051606675,0.00008936571,0.0006435884,0.000021204609],"about_ca_topic_score_codex":0.0015952574,"about_ca_topic_score_gemma":0.002766668,"teacher_disagreement_score":0.0015952574,"about_ca_system_score_codex":0.00050439895,"about_ca_system_score_gemma":0.00036361226,"threshold_uncertainty_score":0.0073268414},"labels":[],"label_agreement":null},{"id":"W4408245897","doi":"10.1200/po-24-00641","title":"Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Oncology; Internal medicine; Metastatic breast cancer; Subgroup analysis; Population; Cancer; Cohort; Brain metastasis; Gynecology; Metastasis; Meta-analysis; Confidence interval","score_opus":0.01767704248195932,"score_gpt":0.36299924804994055,"score_spread":0.3453222055679812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408245897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987991,0.00020479174,0.000054067907,0.000018163062,0.000005819786,0.0000128400125,0.00069260824,0.0000023020038,0.00021023567],"genre_scores_gemma":[0.99905926,0.00011190232,0.000058750138,0.000023523655,0.000008262133,0.000015024516,0.0006329106,0.0000021106675,0.00008821829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949217,0.000080182865,0.00006307915,0.00018969196,0.00008653091,0.00008836272],"domain_scores_gemma":[0.99872845,0.00016004503,0.0005414016,0.0001890978,0.00014881448,0.00023222057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000642944,0.00027719905,0.00053950766,0.000703198,0.0005604919,0.0006612398,0.00044878208,0.00040694012,0.0011304191],"category_scores_gemma":[0.0015729241,0.00043609884,0.00055487297,0.0011977957,0.00024878167,0.0005194638,0.0004173104,0.00066809845,0.00021506014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012655556,0.00002121503,0.99924755,0.000004963169,0.00006510734,0.00005077828,0.000032262727,0.000017728458,0.00011952971,0.0000071309914,0.000056515815,0.00025075406],"study_design_scores_gemma":[0.000018484,0.0001451095,0.9989718,0.00000556035,0.00005985236,0.000301214,0.00013077022,0.00013635831,0.000040699466,0.000015313357,0.00017030588,0.0000045210973],"about_ca_topic_score_codex":0.011850547,"about_ca_topic_score_gemma":0.011507265,"teacher_disagreement_score":0.011850547,"about_ca_system_score_codex":0.0003939872,"about_ca_system_score_gemma":0.00046667145,"threshold_uncertainty_score":0.023563087},"labels":[],"label_agreement":null},{"id":"W4408284710","doi":"10.5858/arpa.2024-0305-oa","title":"Breast Cancer Biopsies With Group 2 and Group 4 Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization Results Should Have Repeated Testing on Excision","year":2025,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Breast cancer; Immunohistochemistry; Fluorescence in situ hybridization; Human Epidermal Growth Factor Receptor 2; Medicine; Context (archaeology); Group A; Group B; Internal medicine; In situ hybridization; Pathology; Fish <Actinopterygii>; Oncology; Clinical Oncology; Cancer; Biology","score_opus":0.039494407735406745,"score_gpt":0.34618099218674514,"score_spread":0.3066865844513384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408284710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98480123,0.002588786,0.0023029782,0.00058301305,0.00015941542,0.00055035175,0.001409858,0.000090319845,0.007514003],"genre_scores_gemma":[0.98855907,0.0010372153,0.0059479983,0.00083323277,0.00012691336,0.0001872866,0.0016601674,0.000019882775,0.0016281197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989975,0.00018333553,0.00026988288,0.00013129743,0.00030901676,0.00010901],"domain_scores_gemma":[0.99745744,0.00038544586,0.0013107148,0.00022239868,0.00044706088,0.00017689486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014750403,0.00035766658,0.0002657606,0.000992311,0.00044591798,0.00049722247,0.0004502465,0.00064383505,0.002214622],"category_scores_gemma":[0.0022696306,0.00021138614,0.0003216177,0.000678962,0.000377115,0.0005418277,0.00035701794,0.0002569851,0.0007059325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031890365,0.000088980305,0.9604749,0.00020308697,0.000050631515,0.00822896,0.00015961942,0.0000755215,0.013485756,0.00008798694,0.0024053145,0.014420242],"study_design_scores_gemma":[0.00003473499,0.00055340125,0.9301899,0.00017976413,0.00007333411,0.04451031,0.0010072738,0.00020497486,0.010185287,0.0001778456,0.0128600225,0.000023109604],"about_ca_topic_score_codex":0.0016405743,"about_ca_topic_score_gemma":0.004773038,"teacher_disagreement_score":0.002214622,"about_ca_system_score_codex":0.00036464882,"about_ca_system_score_gemma":0.0006303293,"threshold_uncertainty_score":0.0078008175},"labels":[],"label_agreement":null},{"id":"W4408796472","doi":"10.1016/j.labinv.2024.102474","title":"250 Development and Clinical Performance of an LLM-Generated Application for Assessment of HER2 in Situ Hybridization in Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital","funders":"","keywords":"In situ; In situ hybridization; Breast cancer; Medicine; Cancer; Oncology; Internal medicine; Medical physics; Cancer research; Biology; Chemistry; Genetics; Gene; Gene expression","score_opus":0.046106559356971964,"score_gpt":0.4193930743033043,"score_spread":0.37328651494633236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408796472","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33910304,0.002144072,0.631934,0.0010993625,0.00034215918,0.0016488935,0.0020369499,0.013168426,0.008523162],"genre_scores_gemma":[0.50898445,0.00078929064,0.47686207,0.00093410636,0.000093172726,0.0014525157,0.0024400689,0.0006973262,0.0077470196],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984377,0.00053157675,0.00008610025,0.00032241456,0.00054934964,0.00007294408],"domain_scores_gemma":[0.9989348,0.00040244168,0.00008494908,0.00014526183,0.00036227264,0.00007030099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003299876,0.00058148557,0.0003581108,0.0011965933,0.00031320142,0.0007648315,0.00074377377,0.00096229184,0.0036069825],"category_scores_gemma":[0.0031324064,0.00045745456,0.00038498914,0.00047282624,0.000395532,0.00027810282,0.0007387249,0.0005090985,0.0020471779],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075579557,0.0002901852,0.01438983,0.00021156693,0.00007119139,0.00027661744,0.00020916371,0.0020766458,0.8817346,0.0006399354,0.0022559853,0.0970885],"study_design_scores_gemma":[0.00011806748,0.001153213,0.016294423,0.00005648448,0.00016085593,0.0012340228,0.00011015001,0.05274904,0.90298986,0.0005219781,0.024546653,0.00006526931],"about_ca_topic_score_codex":0.00061764783,"about_ca_topic_score_gemma":0.0013590648,"teacher_disagreement_score":0.0036069825,"about_ca_system_score_codex":0.0004651541,"about_ca_system_score_gemma":0.0005427925,"threshold_uncertainty_score":0.017451644},"labels":[],"label_agreement":null},{"id":"W4409127671","doi":"10.1200/po-24-00546","title":"Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Translational Breast Cancer Research Consortium; Breakthrough Cancer Research; American Society of Clinical Oncology; Genentech; Breast Cancer Research Foundation","keywords":"Breast cancer; Trastuzumab; Pertuzumab; Immunohistochemistry; Immune system; Medicine; Oncology; Estrogen receptor; Stromal cell; Antibody; Internal medicine; Pathology; Cancer; Cancer research; Biology; Immunology","score_opus":0.015748799155744012,"score_gpt":0.36758629728602243,"score_spread":0.3518374981302784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409127671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863654,0.00028160727,0.0004897023,0.000018163535,0.0000026932107,0.000007572468,0.0002479156,0.000017682438,0.00029808257],"genre_scores_gemma":[0.9985215,0.000117663425,0.0007463435,0.000021659982,0.000004674923,0.00001169977,0.00026041912,0.0000026419361,0.00031335946],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99985135,0.00002081748,0.000012706784,0.000038578844,0.000050463444,0.000026046035],"domain_scores_gemma":[0.9998629,0.00002573361,0.000059669233,0.000010511434,0.000021126627,0.000020055237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019170347,0.0001743798,0.000188549,0.00044852015,0.00010617687,0.0003325491,0.000087038796,0.00015189232,0.0007304863],"category_scores_gemma":[0.00035384603,0.000085329986,0.000111679066,0.00040058015,0.000103503146,0.00016452867,0.0001263627,0.00014569187,0.00015387298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010387843,0.00009898234,0.12556563,0.00005547468,0.000064910986,0.00012733023,0.000053802014,0.00041961294,0.8610126,0.000057478446,0.00016576343,0.011339619],"study_design_scores_gemma":[0.000025776722,0.00054002565,0.7758692,0.0000061043706,0.00007306919,0.0012684452,0.00017907955,0.0059400476,0.21489891,0.00013696437,0.0010498995,0.00001253868],"about_ca_topic_score_codex":0.0002671726,"about_ca_topic_score_gemma":0.00042997077,"teacher_disagreement_score":0.0007304863,"about_ca_system_score_codex":0.00015734711,"about_ca_system_score_gemma":0.00006919847,"threshold_uncertainty_score":0.0024437308},"labels":[],"label_agreement":null},{"id":"W4409528322","doi":"10.1177/17588359251327992","title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Chugai Pharmaceutical; Samsung; Aptitude Health; Astellas Pharma; Eisai; Relay Therapeutics; Seagen; Silverback Therapeutics; Daewoong Pharmaceutical Company; AstraZeneca España; Puma Biotechnology; Genentech; Veracyte; Mersana Therapeutics; Menarini Silicon Biosystems; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; HCA Healthcare; Les Laboratories Pierre Fabre; G1 Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Durvalumab; Gemcitabine; Clinical endpoint; Internal medicine; Oncology; Carboplatin; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Cisplatin","score_opus":0.031952928587810535,"score_gpt":0.43753937024167455,"score_spread":0.40558644165386404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409528322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98633844,0.001975231,0.00062456616,0.0008303358,0.0005906888,0.005968989,0.0014489007,0.00012469091,0.0020982358],"genre_scores_gemma":[0.97835714,0.002138917,0.0021738042,0.0020075203,0.000572711,0.0076914662,0.002015121,0.000039325547,0.0050039757],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99926585,0.00038219214,0.000030170648,0.000112520946,0.00004952799,0.00015975744],"domain_scores_gemma":[0.9986972,0.00025571007,0.00025382175,0.00008439728,0.00006237206,0.00064650085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024283782,0.0022357726,0.0028928844,0.0004834323,0.00049514906,0.0013355954,0.0014305551,0.0018483417,0.0068590306],"category_scores_gemma":[0.0016073541,0.00093423814,0.00170538,0.00046658202,0.0015617656,0.0012707714,0.00050723803,0.0036401127,0.0014835474],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9613875,0.021625068,0.00067595846,0.00026697156,0.00041288702,0.000033745488,0.000051522213,0.0003909007,0.0036360004,0.00012087628,0.00079558394,0.010602876],"study_design_scores_gemma":[0.87358546,0.12359892,0.001022499,0.000013964654,0.00022659793,0.000031482945,0.000022688388,0.00039224644,0.00045290092,0.000097000295,0.0005443131,0.000011916724],"about_ca_topic_score_codex":0.0013314392,"about_ca_topic_score_gemma":0.0032278248,"teacher_disagreement_score":0.0068590306,"about_ca_system_score_codex":0.0012582624,"about_ca_system_score_gemma":0.0019769159,"threshold_uncertainty_score":0.022945762},"labels":[],"label_agreement":null},{"id":"W4409625684","doi":"10.1158/1538-7445.am2025-1704","title":"Abstract 1704: Overcoming resistance in HER2-positive gastric and breast cancers: Efficacy of disitamab vedotin in preclinical models resistant to trastuzumab emtansine and trastuzumab deruxtecan","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Trastuzumab; Medicine; Trastuzumab emtansine; Internal medicine; Oncology; Breast cancer; Cancer","score_opus":0.08495907479758326,"score_gpt":0.45098030383120075,"score_spread":0.3660212290336175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409625684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948965,0.002137375,0.0006149033,0.00013440088,0.00004128533,0.00007967258,0.00034817212,0.00005674184,0.0016910551],"genre_scores_gemma":[0.99067044,0.0017508112,0.002485299,0.00007340094,0.000024483654,0.00010420027,0.0010955669,0.000019535713,0.003776384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998957,0.00002112013,0.000008867285,0.000014914612,0.000029351631,0.000030129751],"domain_scores_gemma":[0.9999366,0.000010950312,0.000012798732,0.0000056355125,0.000010988202,0.00002305295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021087904,0.0005343497,0.00043510494,0.0003783164,0.00014307298,0.000248711,0.000318234,0.00032749033,0.001842292],"category_scores_gemma":[0.000117718875,0.0001248806,0.00022530783,0.00022421917,0.00016449855,0.00027245007,0.00013025657,0.00068099523,0.0002653641],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020689096,0.0013354712,0.00080434553,0.00021156234,0.000040827705,0.000101606245,0.000039961506,0.00072680984,0.9806621,0.00020639462,0.00060808397,0.013193896],"study_design_scores_gemma":[0.0005381667,0.014342514,0.0048810164,0.000014336529,0.00007750033,0.00052832894,0.000028620836,0.0019196275,0.9720053,0.000048438927,0.005606243,0.0000099685685],"about_ca_topic_score_codex":0.0014000155,"about_ca_topic_score_gemma":0.002014182,"teacher_disagreement_score":0.001842292,"about_ca_system_score_codex":0.00048956956,"about_ca_system_score_gemma":0.0004133222,"threshold_uncertainty_score":0.0061630607},"labels":[],"label_agreement":null},{"id":"W4409626158","doi":"10.1158/1538-7445.am2025-2874","title":"Abstract 2874: ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Conjugate; Antibody-drug conjugate; Topoisomerase; Drug; Antibody; Medicine; Pharmacology; Biology; Monoclonal antibody; Immunology; DNA; Genetics; Mathematics","score_opus":0.08370463835081471,"score_gpt":0.47499742427321706,"score_spread":0.39129278592240235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409626158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627314,0.0052930554,0.01744174,0.0003270303,0.00010606822,0.00021748639,0.00072116486,0.00029706457,0.012864953],"genre_scores_gemma":[0.97677475,0.001829594,0.0069117597,0.00010710309,0.00001946694,0.00007632125,0.0011351187,0.00003631919,0.013109613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994147,0.000010155325,0.0000047839885,0.000012561148,0.000021569222,0.000009491856],"domain_scores_gemma":[0.99997795,0.0000020958225,0.000007014962,0.0000015254908,0.0000054180036,0.0000060446923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008945198,0.00039911663,0.00016323138,0.00016391421,0.00007516889,0.0001575151,0.00021574814,0.00034918252,0.0022643446],"category_scores_gemma":[0.00007751593,0.00009986049,0.000120047385,0.0001043857,0.00010177928,0.00022699356,0.00018850065,0.00026634478,0.0011582645],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012270192,0.000038249065,0.000089988025,0.00007968476,0.000008015123,0.00008088876,0.0000071023737,0.00017564645,0.9940328,0.00024154082,0.0002935866,0.004829854],"study_design_scores_gemma":[0.000047195943,0.0005299015,0.00052079326,0.000004960497,0.000009594767,0.0004836809,0.000004734125,0.00086643646,0.9902102,0.000035696106,0.0072827,0.000004123416],"about_ca_topic_score_codex":0.00024744842,"about_ca_topic_score_gemma":0.00019099445,"teacher_disagreement_score":0.0022643446,"about_ca_system_score_codex":0.0002375988,"about_ca_system_score_gemma":0.0001485896,"threshold_uncertainty_score":0.007575035},"labels":[],"label_agreement":null},{"id":"W4409627141","doi":"10.1158/1538-7445.am2025-1694","title":"Abstract 1694: Combination of inhibitors of RAD51 and FLT-3 and other tyrosine kinase inhibitors synergistically inhibits proliferation of cultured human leukemia cell lines","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Tyrosine kinase; Cancer research; Leukemia; Cell growth; Cell culture; Chemistry; Tyrosine-kinase inhibitor; Pharmacology; Biology; Cancer; Medicine; Biochemistry; Immunology; Internal medicine; Signal transduction; Genetics","score_opus":0.052923884148162306,"score_gpt":0.41336898773774405,"score_spread":0.36044510358958176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409627141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94028753,0.022930374,0.0029540749,0.0010228418,0.0010599748,0.00047323204,0.0050898516,0.00091080513,0.025271352],"genre_scores_gemma":[0.9741654,0.0061457967,0.0034188624,0.0003040058,0.00013655887,0.00029071912,0.005052281,0.000052437073,0.010433889],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979335,0.000046570407,0.00002725011,0.000028382365,0.000054671877,0.000049693885],"domain_scores_gemma":[0.99992216,0.000017831988,0.000011906656,0.000010136436,0.000010780757,0.000027192815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021917294,0.0007737045,0.000715137,0.0006484483,0.00023060894,0.00041552723,0.00035920375,0.00040647291,0.007125678],"category_scores_gemma":[0.00015100824,0.0002296538,0.0005784555,0.00040010692,0.0001616233,0.000228935,0.00035142855,0.0007637529,0.0021020912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029460466,0.0016246389,0.00051191833,0.0005045088,0.00012989508,0.00031063778,0.000070291266,0.0009194862,0.9521391,0.00038235093,0.0060563404,0.034404982],"study_design_scores_gemma":[0.000786842,0.008448381,0.0057929996,0.00004456858,0.00017186759,0.0007998148,0.000048427664,0.002018572,0.956571,0.00010573863,0.025184914,0.000027019838],"about_ca_topic_score_codex":0.0012959951,"about_ca_topic_score_gemma":0.0021372621,"teacher_disagreement_score":0.007125678,"about_ca_system_score_codex":0.00032055945,"about_ca_system_score_gemma":0.0006103119,"threshold_uncertainty_score":0.023837745},"labels":[],"label_agreement":null},{"id":"W4409628417","doi":"10.1158/1538-7445.am2025-1565","title":"Abstract 1565: Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Conjugate; Antibody; Tyrosine kinase; Drug; Pharmacology; Tyrosine; Medicine; Biology; Immunology; Biochemistry; Signal transduction","score_opus":0.12732124567528805,"score_gpt":0.46816191315220906,"score_spread":0.340840667476921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409628417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96335787,0.0029740594,0.02770393,0.00014379746,0.00005405256,0.000632425,0.00044543148,0.00014679381,0.0045416723],"genre_scores_gemma":[0.96021026,0.0018727788,0.032410808,0.00009623883,0.000016206728,0.0002826853,0.0008488517,0.000029335457,0.004232738],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987686,0.0000180461,0.000014589766,0.000023437615,0.00004646804,0.000020635825],"domain_scores_gemma":[0.99992824,0.000005705876,0.00002146748,0.000005362864,0.000017552587,0.0000217138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022503024,0.00035276168,0.0002549583,0.00025841754,0.00011774718,0.00027445075,0.00036500202,0.00029695427,0.0009942448],"category_scores_gemma":[0.00014190722,0.00016783028,0.00019105383,0.0001794684,0.00012757171,0.0002105116,0.00021481072,0.00029824578,0.0005756085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014425845,0.00016920525,0.00024643412,0.00010812489,0.000016595126,0.0000762969,0.000017554696,0.0016707819,0.9857277,0.00034448708,0.00015089895,0.011327563],"study_design_scores_gemma":[0.00011442443,0.0016139694,0.0009171169,0.0000076287283,0.000025967636,0.00020516512,0.000006913277,0.003142522,0.98822623,0.00003948483,0.0056930697,0.000007514081],"about_ca_topic_score_codex":0.00028311223,"about_ca_topic_score_gemma":0.00047375154,"teacher_disagreement_score":0.0009942448,"about_ca_system_score_codex":0.000403536,"about_ca_system_score_gemma":0.000313539,"threshold_uncertainty_score":0.0033260584},"labels":[],"label_agreement":null},{"id":"W4409630451","doi":"10.1158/1538-7445.am2025-5533","title":"Abstract 5533: Drug tolerance mechanisms in patient-derived xenograft models with <i>epidermal growth factor receptor</i> mutated tumors treated with tyrosine kinase inhibitors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tyrosine kinase; Epidermal growth factor receptor; Cancer research; Receptor tyrosine kinase; Drug; Lapatinib; Tyrosine-kinase inhibitor; Medicine; Pharmacology; Biology; Receptor; Cancer; Internal medicine; Trastuzumab","score_opus":0.040799973165433046,"score_gpt":0.3462554423397977,"score_spread":0.30545546917436467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409630451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586546,0.00034854846,0.0016764529,0.000054229935,0.00002632022,0.00008310448,0.00085973163,0.000050557213,0.0010355084],"genre_scores_gemma":[0.99291843,0.00031219298,0.00218246,0.000050015893,0.000008445206,0.00011469997,0.002559687,0.000030900268,0.0018232195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997271,0.000059664886,0.00002819964,0.00006403245,0.00006268936,0.000058274305],"domain_scores_gemma":[0.9997241,0.00006699256,0.00004714158,0.00006410533,0.000036069436,0.00006148498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037557085,0.00040141845,0.0004157965,0.00026183284,0.00021659402,0.00040110614,0.00025914417,0.000355189,0.0021687371],"category_scores_gemma":[0.00019469578,0.00013866072,0.00044046578,0.00028731773,0.0002582609,0.0003196007,0.00019373746,0.0010084847,0.0006084278],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013074977,0.00073717633,0.0031852156,0.00006100729,0.000030982043,0.00027426134,0.00013902149,0.0005304487,0.99026525,0.00020092848,0.00040807648,0.002860185],"study_design_scores_gemma":[0.00019559852,0.012522001,0.030165115,0.000014554254,0.00007924585,0.0024130528,0.00024029516,0.0038919412,0.94638157,0.00009368921,0.0039851572,0.00001774219],"about_ca_topic_score_codex":0.0011926322,"about_ca_topic_score_gemma":0.000903746,"teacher_disagreement_score":0.0021687371,"about_ca_system_score_codex":0.00034176293,"about_ca_system_score_gemma":0.00024404521,"threshold_uncertainty_score":0.0072551966},"labels":[],"label_agreement":null},{"id":"W4409631957","doi":"10.1158/1538-7445.am2025-6748","title":"Abstract 6748: Comparison of activities and identification of predictive genomic biomarkers of response to trastuzumab and the trastuzumab deruxtecan ADC using the OncoPanel® platform","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Cancer; Breast cancer","score_opus":0.1297112918120443,"score_gpt":0.4849850739072937,"score_spread":0.3552737820952494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409631957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958905,0.0017052402,0.00089586974,0.000025283762,0.000022731927,0.000039565602,0.00032193444,0.000036514775,0.0010624613],"genre_scores_gemma":[0.99552035,0.0006024673,0.0013753255,0.000040000934,0.000014045893,0.000055739867,0.0012548913,0.000012191756,0.0011250634],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9996686,0.000078280405,0.000018898494,0.000061682185,0.00012237357,0.000050107294],"domain_scores_gemma":[0.9997956,0.00007994573,0.000035216584,0.000014265608,0.00004329843,0.000031826366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000421675,0.00031142504,0.00041396715,0.0006663711,0.00006970732,0.0005024296,0.00016514196,0.0002814697,0.0014289648],"category_scores_gemma":[0.000581093,0.00013227688,0.00028020938,0.00039465821,0.00014310805,0.00021946152,0.00018111442,0.00030754157,0.0003724695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018505251,0.0011967844,0.020422373,0.00023516365,0.00021327664,0.00020611481,0.00012506671,0.003212705,0.86854964,0.00023154891,0.00071118795,0.086390816],"study_design_scores_gemma":[0.0010695875,0.018259384,0.077791676,0.00003030089,0.00041255905,0.00093745097,0.00010959566,0.025316995,0.8702876,0.0001917045,0.005535752,0.000057352896],"about_ca_topic_score_codex":0.00082948763,"about_ca_topic_score_gemma":0.00046671394,"teacher_disagreement_score":0.0014289648,"about_ca_system_score_codex":0.0002778746,"about_ca_system_score_gemma":0.00019642616,"threshold_uncertainty_score":0.004780352},"labels":[],"label_agreement":null},{"id":"W4409644074","doi":"10.1158/1538-7445.am2025-5215","title":"Abstract 5215: IL-17RA expression by NSCLC is vital for restraining homeostatic tumor cell proliferation and baseline cytokine production","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Homeostasis; Cytokine; Cell growth; Baseline (sea); Cancer research; Immunology; Medicine; Biology; Internal medicine; Genetics","score_opus":0.0761928336317277,"score_gpt":0.44039412346696183,"score_spread":0.36420128983523414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409644074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96998525,0.008746503,0.0057115383,0.000731758,0.00034347855,0.00010138035,0.0061470475,0.00045007403,0.0077829813],"genre_scores_gemma":[0.97195286,0.004178387,0.0032411248,0.00025130453,0.00008183725,0.00017455399,0.0059783063,0.00013107111,0.014010595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977475,0.000024608058,0.000028201737,0.000050090635,0.000078729936,0.000043483156],"domain_scores_gemma":[0.9998925,0.00001325392,0.00003206832,0.000013373487,0.000022763148,0.000025999481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001286104,0.00040613883,0.00037384068,0.00021914557,0.00023588356,0.00042856453,0.0002348918,0.00034862038,0.0070422734],"category_scores_gemma":[0.00010021191,0.00015778822,0.0004030314,0.00022349988,0.00025347178,0.0002151682,0.0002045194,0.0007787491,0.0027248492],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015439835,0.000024301242,0.00055767916,0.000109175475,0.00000847382,0.00009222001,0.000010930095,0.000036492384,0.99654776,0.0000786852,0.00029431732,0.002085545],"study_design_scores_gemma":[0.000031635376,0.0002599984,0.00814367,0.000023620792,0.000034132907,0.0006774648,0.000049009654,0.00038047953,0.9785275,0.000070081274,0.01179793,0.000004498758],"about_ca_topic_score_codex":0.00049930677,"about_ca_topic_score_gemma":0.00052396045,"teacher_disagreement_score":0.0070422734,"about_ca_system_score_codex":0.00032404577,"about_ca_system_score_gemma":0.0004196357,"threshold_uncertainty_score":0.023558676},"labels":[],"label_agreement":null},{"id":"W4409689959","doi":"10.1158/1538-7445.am2025-1230","title":"Abstract 1230: High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Antibody-drug conjugate; Characterization (materials science); Cytotoxic T cell; Selection (genetic algorithm); High-throughput screening; Drug; Computational biology; Spheroid; Antibody; Chemistry; Biology; Pharmacology; Immunology; In vitro; Bioinformatics; Materials science; Nanotechnology; Monoclonal antibody; Computer science; Biochemistry","score_opus":0.06537420895556471,"score_gpt":0.4193367668752878,"score_spread":0.3539625579197231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409689959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65062743,0.0014871852,0.32340157,0.0002280194,0.000109085675,0.0010050585,0.009094281,0.003996953,0.010050447],"genre_scores_gemma":[0.6820072,0.0017312403,0.28026432,0.00023325895,0.000028470768,0.002196077,0.014295867,0.0007702852,0.018473344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994216,0.00009358301,0.000040040515,0.000116339834,0.0002905786,0.000037850208],"domain_scores_gemma":[0.9997278,0.00007697174,0.000041711148,0.000037830698,0.00009308999,0.000022626953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072300306,0.0007022032,0.0005334378,0.0005641701,0.00031960767,0.00046979237,0.00026024922,0.00038229153,0.0024139348],"category_scores_gemma":[0.0003499625,0.0002227126,0.0003222764,0.0006557307,0.00030607407,0.00025227692,0.00020751692,0.0005675593,0.0013955049],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003550823,0.000017879041,0.0001213781,0.000029409466,0.0000028003421,0.00001768327,0.000014195417,0.00023129005,0.9975051,0.00008070356,0.00016680836,0.0017770928],"study_design_scores_gemma":[0.0000074823497,0.00012512563,0.0010838382,0.0000032377093,0.0000067510227,0.000033676242,0.00000752543,0.0030682767,0.993331,0.000032241256,0.0022949737,0.000005951516],"about_ca_topic_score_codex":0.0013883184,"about_ca_topic_score_gemma":0.0024392167,"teacher_disagreement_score":0.0024139348,"about_ca_system_score_codex":0.00060312764,"about_ca_system_score_gemma":0.0005663478,"threshold_uncertainty_score":0.008075416},"labels":[],"label_agreement":null},{"id":"W4409708840","doi":"10.21203/rs.3.rs-6256038/v1","title":"A Machine Learning Platform for Interconnecting Antibody-Drug Conjugate Cytotoxic Design with Tumor Cell Biology","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research; Alliance de recherche numérique du Canada","keywords":"Cytotoxic T cell; Conjugate; Antibody-drug conjugate; Drug; Antibody; Computer science; Tumor cells; Computational biology; Cancer research; Biology; Immunology; Pharmacology; Monoclonal antibody; Mathematics; In vitro; Genetics","score_opus":0.12356467777840584,"score_gpt":0.4607400425210185,"score_spread":0.33717536474261267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409708840","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013969384,0.00015552556,0.9777468,0.00024139485,0.000095636955,0.00005904768,0.0001827185,0.003911876,0.0036375397],"genre_scores_gemma":[0.2551081,0.0004119639,0.7339935,0.00028002326,0.00008530442,0.0002985717,0.0006981843,0.00049487385,0.0086295735],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9997669,0.00005868263,0.000013716469,0.000052562453,0.00008586106,0.000022355856],"domain_scores_gemma":[0.9996045,0.00018807937,0.00004244718,0.00007651379,0.00006465168,0.000023742456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005706341,0.00066973653,0.00053243735,0.00035061286,0.0003021052,0.00078353356,0.00087422645,0.0007939643,0.005864527],"category_scores_gemma":[0.0013224165,0.00035930306,0.0006925087,0.0003829585,0.00030777595,0.000676505,0.00078509934,0.0011636968,0.001657759],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025891446,0.00033466725,0.00093925564,0.0002457372,0.0001420667,0.0002283198,0.000059547456,0.59385616,0.08431863,0.03724798,0.0070957933,0.27527288],"study_design_scores_gemma":[0.000014465626,0.000049904913,0.00007845755,0.000006196783,0.00001139516,0.000022902585,0.000003541548,0.9688051,0.013920224,0.013272527,0.0038091647,0.0000061202973],"about_ca_topic_score_codex":0.0006353832,"about_ca_topic_score_gemma":0.00085851067,"teacher_disagreement_score":0.005864527,"about_ca_system_score_codex":0.00043223926,"about_ca_system_score_gemma":0.0006039836,"threshold_uncertainty_score":0.01961881},"labels":[],"label_agreement":null},{"id":"W4409713352","doi":"10.1002/ijc.35448","title":"Real‐world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan‐Canadian population‐based cohort study","year":2025,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre; McGill University; Simon Fraser University; Hospital for Sick Children; University of Saskatchewan; University of New Brunswick; Dalhousie University; Newfoundland and Labrador Centre for Applied Health Research; OmniActive Health Technologies (Canada); University of Manitoba; Government of Manitoba; Centre for Addiction and Mental Health; University of Calgary; Health Sciences Centre; CancerCare Manitoba; Saskatchewan Cancer Agency; Canadian Centre for Applied Research in Cancer Control; University of Toronto; Public Health Ontario","funders":"Canadian Institutes of Health Research","keywords":"Pertuzumab; Medicine; Internal medicine; Propensity score matching; Febrile neutropenia; Metastatic breast cancer; Trastuzumab; Population; Breast cancer; Incidence (geometry); Cumulative incidence; Cohort; Cancer; Chemotherapy; Oncology; Surgery; Neutropenia","score_opus":0.020757184820117788,"score_gpt":0.4055644816163519,"score_spread":0.3848072967962341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409713352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726972,0.015911458,0.00035686788,0.00056619674,0.000044074466,0.0002603062,0.0087730205,0.000016330976,0.0013745631],"genre_scores_gemma":[0.99377406,0.0022615364,0.00041168337,0.00024286227,0.000032808115,0.00007909995,0.003027348,0.0000056502986,0.00016503951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99599624,0.001206192,0.00040615306,0.00063659326,0.0012549805,0.00049982703],"domain_scores_gemma":[0.9907101,0.0016375915,0.003068997,0.0007218137,0.002994078,0.0008673469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052152225,0.00070137053,0.0012665946,0.0011981666,0.001162391,0.0013165722,0.0014130016,0.0008497657,0.001327215],"category_scores_gemma":[0.011537657,0.00041858034,0.0029335038,0.0041934177,0.000750702,0.0003515886,0.00065383175,0.0008976874,0.0001087982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078037847,0.00022489305,0.9469468,0.0014778851,0.021497807,0.00020620269,0.00044363303,0.0013683782,0.00035576583,0.0004271071,0.0025193181,0.016728388],"study_design_scores_gemma":[0.0019444823,0.00086973695,0.9796069,0.00030079743,0.010780418,0.00023155214,0.00029723297,0.0018157404,0.00013663362,0.00017868204,0.0037470816,0.000090867135],"about_ca_topic_score_codex":0.8905742,"about_ca_topic_score_gemma":0.8966865,"teacher_disagreement_score":0.10942578,"about_ca_system_score_codex":0.017748764,"about_ca_system_score_gemma":0.01758913,"threshold_uncertainty_score":0.2201404},"labels":[],"label_agreement":null},{"id":"W4409822066","doi":"10.1158/1538-7445.am2025-ct195","title":"Abstract CT195: A phase 1 dose escalation/expansion study of GSK5764227, a B7-homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Antibody-drug conjugate; Conjugate; Standard of care; Medicine; Antibody; Drug; Cancer research; Solid tumor; Cancer; Oncology; Pharmacology; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.022690009711956734,"score_gpt":0.4296070132920876,"score_spread":0.4069170035801309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409822066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98540145,0.0025079744,0.001004358,0.00074166124,0.00016629622,0.00367768,0.0029895834,0.00023649776,0.003274425],"genre_scores_gemma":[0.9812462,0.00217057,0.0024771318,0.0014365499,0.00014253684,0.0025443078,0.0057042725,0.000061460116,0.004216849],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996611,0.00013186153,0.00001626144,0.00006998445,0.00005283273,0.000068017565],"domain_scores_gemma":[0.99955195,0.000042749136,0.00008079323,0.00002881626,0.000032760647,0.00026289237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012419577,0.0021104116,0.0014978488,0.00067239546,0.00037487494,0.0010208577,0.0012489905,0.0010508333,0.0056827865],"category_scores_gemma":[0.00062954077,0.00054675207,0.0012771484,0.0006440719,0.0010254078,0.000976535,0.00043801154,0.004588716,0.0013717723],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5014784,0.15775928,0.011187525,0.0019682513,0.0021826343,0.0007159834,0.00066701235,0.0067385235,0.14596194,0.00093979714,0.018619336,0.15178132],"study_design_scores_gemma":[0.4344176,0.5346953,0.013501542,0.00006199723,0.0005673156,0.00042319464,0.00011051042,0.0017161717,0.008371818,0.00021538604,0.0058719045,0.00004722414],"about_ca_topic_score_codex":0.0017506351,"about_ca_topic_score_gemma":0.0048680804,"teacher_disagreement_score":0.0056827865,"about_ca_system_score_codex":0.0016976342,"about_ca_system_score_gemma":0.0021329212,"threshold_uncertainty_score":0.019010842},"labels":[],"label_agreement":null},{"id":"W4410512952","doi":"10.3899/jrheum.2025-0390.pv254","title":"REAL-WORLD ASSESSMENT OF PATTERNS OF PAIN TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: A PATHWAY VISUALIZATION STUDY USING EHR","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Systemic lupus; Lupus erythematosus; Visualization; Systemic disease; Dermatology; Internal medicine; Immunopathology; Immunology; Data mining; Disease","score_opus":0.04728678434799391,"score_gpt":0.41783211113072416,"score_spread":0.3705453267827302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410512952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926226,0.00018360697,0.0012224892,0.00024818958,0.0000046713976,0.000056127894,0.0051700273,0.00006851966,0.00042384918],"genre_scores_gemma":[0.99163896,0.00019333935,0.0044193356,0.000029070832,0.0000047065837,0.000057649468,0.0035370078,0.000008561983,0.00011140993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828917,0.0008022705,0.00032327263,0.00026860117,0.00017715718,0.00013952464],"domain_scores_gemma":[0.9908504,0.00490296,0.0024076798,0.0005431144,0.0009166746,0.00037901552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031883067,0.00022857726,0.00021652054,0.004077522,0.00028198218,0.0015710179,0.00031562342,0.00043865337,0.0011926378],"category_scores_gemma":[0.01351205,0.00017650919,0.0005094636,0.004203407,0.00023675148,0.0021435062,0.0014118946,0.00039957993,0.00022049679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000153578,0.00008325306,0.97884333,0.00016889279,0.00007875231,0.0001225489,0.002707874,0.0006685818,0.00026440262,0.00034082372,0.0007596857,0.015808405],"study_design_scores_gemma":[0.000027336966,0.0002636396,0.9579105,0.0003323904,0.00011947289,0.0005967243,0.015722137,0.018425716,0.0008277229,0.0008565727,0.0048634894,0.00005423876],"about_ca_topic_score_codex":0.0102514075,"about_ca_topic_score_gemma":0.013539426,"teacher_disagreement_score":0.0102514075,"about_ca_system_score_codex":0.0009794622,"about_ca_system_score_gemma":0.001004815,"threshold_uncertainty_score":0.020383477},"labels":[],"label_agreement":null},{"id":"W4410708732","doi":"10.1038/s41523-025-00759-2","title":"Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis","year":2025,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Single Center; Breast cancer; Medicine; Oncology; Internal medicine; Center (category theory); Cancer","score_opus":0.024748921851020744,"score_gpt":0.37959586164959996,"score_spread":0.35484693979857923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410708732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995566,0.00009230554,0.000043805823,0.00001181281,0.000001151803,0.0000040263067,0.0001620708,0.0000013570741,0.00012681934],"genre_scores_gemma":[0.9995752,0.000034713143,0.00003494945,0.000012927032,0.0000042686024,0.0000054039347,0.00028789145,0.0000016677886,0.000043020384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995371,0.00012382258,0.000060498838,0.00013449597,0.000071581664,0.00007247616],"domain_scores_gemma":[0.9987864,0.0002370802,0.0005599612,0.000090986316,0.00011286127,0.00021269757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046865674,0.00016863763,0.00042114832,0.00062110095,0.0003714005,0.00043503483,0.00026973672,0.0003101338,0.000996115],"category_scores_gemma":[0.0014702253,0.00024300916,0.00039265145,0.0010038414,0.0002389159,0.0003414822,0.00027146397,0.0002906606,0.00019751827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018504549,0.000028224504,0.9987809,0.0000034694044,0.00004466508,0.000060558723,0.000021997203,0.000052651623,0.00018858454,0.0000052040073,0.000043595355,0.0005851277],"study_design_scores_gemma":[0.000016836833,0.00019287928,0.99880564,0.0000025233471,0.00004008933,0.00040241747,0.00010817216,0.00020650975,0.00010610349,0.000011576543,0.000102562146,0.000004769148],"about_ca_topic_score_codex":0.003216339,"about_ca_topic_score_gemma":0.0038485737,"teacher_disagreement_score":0.003216339,"about_ca_system_score_codex":0.00042993407,"about_ca_system_score_gemma":0.00033649214,"threshold_uncertainty_score":0.0063952208},"labels":[],"label_agreement":null},{"id":"W4410803503","doi":"10.1200/jco.2025.43.16_suppl.1037","title":"Characterization of the immune microenvironment and spatial phenotypes across HER2 subtypes in advanced or metastatic breast cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Immune system; Tumor microenvironment; Phenotype; Cancer; Cancer research; Oncology; Internal medicine; Immunology; Biology; Genetics; Gene","score_opus":0.07010473532947813,"score_gpt":0.4910602070998903,"score_spread":0.42095547177041215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965687,0.0009772134,0.0013716578,0.000015710666,0.000002629625,0.000022826249,0.00029765946,0.00002172192,0.00072189013],"genre_scores_gemma":[0.9971807,0.00016998142,0.0017886256,0.000014395178,0.0000040956043,0.00003654225,0.0004982718,0.000008723559,0.00029876226],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998704,0.000017881197,0.000010501453,0.000036606234,0.00003485717,0.00002977582],"domain_scores_gemma":[0.99985707,0.00002537004,0.000037508435,0.000016095204,0.000039512364,0.00002436181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024995048,0.00011340165,0.00020294882,0.00079641724,0.00022369048,0.00032597303,0.00017062986,0.00021047608,0.0010794012],"category_scores_gemma":[0.0002573139,0.00011071576,0.0001488013,0.0005725916,0.00014611523,0.00018903145,0.00023780006,0.00016844575,0.00030030124],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012457151,0.00007940434,0.3638423,0.00029684408,0.00006380488,0.00054877764,0.000338389,0.0007398129,0.605571,0.00016812785,0.0003189797,0.026786946],"study_design_scores_gemma":[0.000020823587,0.00030380182,0.94129145,0.000014399393,0.00006307958,0.002890362,0.0005421331,0.0029003823,0.049402744,0.00011674097,0.0024453886,0.0000087173385],"about_ca_topic_score_codex":0.0011216374,"about_ca_topic_score_gemma":0.0021427576,"teacher_disagreement_score":0.0011216374,"about_ca_system_score_codex":0.00020967367,"about_ca_system_score_gemma":0.0001376973,"threshold_uncertainty_score":0.0036109686},"labels":[],"label_agreement":null},{"id":"W4410803724","doi":"10.1200/jco.2025.43.16_suppl.1062","title":"Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech","keywords":"Medicine; Pharmacokinetics; Paclitaxel; Pharmacology; Internal medicine; Oncology; Chemotherapy","score_opus":0.08265775153649609,"score_gpt":0.5225800354404776,"score_spread":0.4399222839039815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857449,0.0017465797,0.0009765922,0.00040760374,0.00014298661,0.005485962,0.0018611534,0.00018709895,0.0034471557],"genre_scores_gemma":[0.9811779,0.0018791709,0.0020803679,0.0008537471,0.00016511559,0.0053935274,0.004652656,0.00007696198,0.0037205028],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996388,0.00014513203,0.000018744913,0.000067788875,0.000031828506,0.00009772525],"domain_scores_gemma":[0.9993057,0.000075655014,0.0001281182,0.00007151897,0.0000398387,0.00037926374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010604125,0.0015625033,0.0025241277,0.0005760586,0.00044329072,0.0014641358,0.0012161661,0.0012895879,0.004074265],"category_scores_gemma":[0.00071192917,0.0008553092,0.0013872128,0.0007219986,0.0008501027,0.0008938527,0.00041942034,0.0040003485,0.0016224997],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7008697,0.13818654,0.0069051413,0.00082711043,0.0014749424,0.00030668697,0.00038528934,0.003884757,0.05943025,0.00036305623,0.0052454923,0.082121156],"study_design_scores_gemma":[0.46544823,0.51210517,0.010334094,0.000042786753,0.00064214785,0.00035504415,0.00009262595,0.0016077982,0.005499194,0.00024191503,0.0035964733,0.00003449629],"about_ca_topic_score_codex":0.0016457707,"about_ca_topic_score_gemma":0.0036579254,"teacher_disagreement_score":0.004074265,"about_ca_system_score_codex":0.0012162582,"about_ca_system_score_gemma":0.0022877827,"threshold_uncertainty_score":0.013629794},"labels":[],"label_agreement":null},{"id":"W4410804527","doi":"10.1200/jco.2025.43.16_suppl.e13135","title":"Phase 1 study of the anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) + paclitaxel for previously untreated advanced triple negative breast cancer (TNBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Monoclonal antibody; Pembrolizumab; Triple-negative breast cancer; Antibody; Trastuzumab; Paclitaxel; Breast cancer; Cancer research; Virology; Cancer; Immunology; Immunotherapy; Immune system; Internal medicine","score_opus":0.11285010697904874,"score_gpt":0.5465878771365084,"score_spread":0.4337377701574596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98179126,0.0017680391,0.0008918417,0.0005879179,0.00017388436,0.009015756,0.0023980725,0.00015833921,0.003214874],"genre_scores_gemma":[0.9715316,0.0022619576,0.0031126684,0.0016137187,0.00019923014,0.009653127,0.003935752,0.0000684516,0.007623519],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972063,0.0001281559,0.000008248001,0.00005456019,0.000030232231,0.000058136484],"domain_scores_gemma":[0.99962497,0.000054395114,0.000092845126,0.000027050282,0.000034034656,0.00016659992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011527939,0.001744164,0.001375659,0.00039093598,0.00041220355,0.00074623304,0.0010336225,0.0012870131,0.0067336136],"category_scores_gemma":[0.00070682884,0.00080043625,0.0008984884,0.00031880033,0.0005712588,0.000671705,0.00031558008,0.0029463323,0.0013944422],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66899747,0.16735347,0.0072010295,0.0014009633,0.0014144013,0.00038847883,0.00040798436,0.004025287,0.06422511,0.0004686414,0.009655337,0.074461885],"study_design_scores_gemma":[0.47815877,0.4995361,0.010926132,0.000046937268,0.00054803235,0.00029561055,0.00007161134,0.0011294775,0.004023928,0.0002556745,0.004982871,0.000024901274],"about_ca_topic_score_codex":0.0016086961,"about_ca_topic_score_gemma":0.0049170502,"teacher_disagreement_score":0.0067336136,"about_ca_system_score_codex":0.0011372811,"about_ca_system_score_gemma":0.0021818671,"threshold_uncertainty_score":0.022526205},"labels":[],"label_agreement":null},{"id":"W4410812638","doi":"10.1200/jco.2025.43.16_suppl.e15024","title":"Pharmacologic and pharmacometric studies of factors affecting the pharmacokinetics and pharmacodynamics of antibody drug conjugate anetumab ravtansine in patients with solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Antibody-drug conjugate; Pharmacology; Drug; Conjugate; Antibody; Monoclonal antibody; Immunology","score_opus":0.11965148810061271,"score_gpt":0.5611931399788107,"score_spread":0.441541651878198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968078,0.0014502367,0.0007772732,0.000050575905,0.00001038942,0.000071698276,0.00021495797,0.000016118664,0.0006010018],"genre_scores_gemma":[0.99872017,0.000220385,0.00045103952,0.000060406517,0.00001455275,0.000040497624,0.000314713,0.0000038007893,0.00017437099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932826,0.00034852975,0.000045410983,0.000113707276,0.000110613524,0.000053422067],"domain_scores_gemma":[0.99851125,0.0006367071,0.000498422,0.0001107641,0.000109886096,0.00013300935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012821954,0.00023222117,0.00045830873,0.00028885668,0.00013989075,0.00039946265,0.00020858854,0.0003573755,0.0010170992],"category_scores_gemma":[0.0028761046,0.00017946995,0.00043722586,0.0003874113,0.00026988593,0.00033095127,0.00015417936,0.00055872294,0.0002918691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07222093,0.0061424063,0.5663715,0.0005974021,0.0017634375,0.0008373137,0.00035687417,0.008652959,0.21927345,0.00049729727,0.0015594655,0.12172696],"study_design_scores_gemma":[0.0022385207,0.070252724,0.8444345,0.000020692212,0.00079666305,0.0029327043,0.00016133803,0.013733043,0.06042547,0.00025331278,0.0047062575,0.000044780558],"about_ca_topic_score_codex":0.00034926954,"about_ca_topic_score_gemma":0.0002862282,"teacher_disagreement_score":0.0012821954,"about_ca_system_score_codex":0.00046162764,"about_ca_system_score_gemma":0.00031104672,"threshold_uncertainty_score":0.006780982},"labels":[],"label_agreement":null},{"id":"W4410872809","doi":"10.3389/fonc.2025.1564888","title":"Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting","year":2025,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northern College","funders":"Chinese Society of Clinical Oncology; National Natural Science Foundation of China; Shanghai Municipal Health Commission","keywords":"Metastatic breast cancer; Medicine; Oncology; Breast cancer; Internal medicine; First line; Second line; Cancer; Line (geometry)","score_opus":0.012006504483170009,"score_gpt":0.33463157575941616,"score_spread":0.3226250712762461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410872809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972953,0.0017464018,0.00008399877,0.000034517932,0.0000056651847,0.00003983001,0.00027573647,0.00000389423,0.0005144861],"genre_scores_gemma":[0.9988883,0.00038184336,0.000081927246,0.000051971743,0.000016807408,0.000027792932,0.00045926048,0.0000011824038,0.00009102259],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971634,0.000112867296,0.000031940966,0.00005638961,0.00004730077,0.000035183813],"domain_scores_gemma":[0.99925166,0.00017124637,0.00039744427,0.000036189867,0.000039710685,0.00010373423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066170184,0.000118785705,0.00039122693,0.00018312476,0.00011056678,0.00034175464,0.00012812762,0.00017928077,0.000714109],"category_scores_gemma":[0.0011187707,0.000057895388,0.00028469675,0.0002526606,0.00011804948,0.00025667757,0.00012239975,0.0003385846,0.000111617104],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05452755,0.002238455,0.78960097,0.00045593723,0.0006910557,0.0005447544,0.000106384,0.0020446358,0.012635837,0.0001589683,0.0009666848,0.13602877],"study_design_scores_gemma":[0.0038181215,0.058815036,0.9189713,0.00010648851,0.0005957884,0.0033339683,0.00011382202,0.00239618,0.006625508,0.00020190168,0.0050003394,0.000021584787],"about_ca_topic_score_codex":0.00018058313,"about_ca_topic_score_gemma":0.00032584346,"teacher_disagreement_score":0.000714109,"about_ca_system_score_codex":0.00035167238,"about_ca_system_score_gemma":0.00022075638,"threshold_uncertainty_score":0.0034994483},"labels":[],"label_agreement":null},{"id":"W4410952304","doi":"10.1016/s1470-2045(25)00287-6","title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Jazz Pharmaceuticals","keywords":"Oxaliplatin; Medicine; Capecitabine; Regimen; Internal medicine; Tolerability; Chemotherapy; Gastroenterology; Dosing; Oncology; Adenocarcinoma; Adverse effect; Cancer; Colorectal cancer","score_opus":0.04556820725942549,"score_gpt":0.3980022265406252,"score_spread":0.3524340192811997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410952304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880052,0.007970619,0.00029375,0.00052912073,0.000259607,0.0007457594,0.00092438044,0.000060447164,0.0012111319],"genre_scores_gemma":[0.9853897,0.0071869814,0.0011297121,0.0009956533,0.00023399707,0.000682368,0.0017536832,0.000037656275,0.0025902994],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995709,0.00022223679,0.000021690377,0.00006662902,0.0000382009,0.000080238446],"domain_scores_gemma":[0.9993974,0.00012776173,0.00016254555,0.000050816467,0.000035675508,0.00022595188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016558092,0.001362673,0.0031128828,0.00048370034,0.00030299192,0.0011591895,0.0008026505,0.0010545091,0.0028889054],"category_scores_gemma":[0.0011777562,0.0006814081,0.0023465212,0.00055439933,0.00073593116,0.0010194499,0.00033366823,0.0028720691,0.000652768],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8922676,0.014198796,0.004135979,0.0017408438,0.004135097,0.00009852435,0.00017607,0.0018128221,0.009438254,0.00012835792,0.0021943203,0.06967343],"study_design_scores_gemma":[0.8242712,0.15219952,0.017215025,0.000084872336,0.0024995187,0.00013594961,0.00008446425,0.00081506785,0.0007835426,0.00016130289,0.0017078747,0.000041682008],"about_ca_topic_score_codex":0.0015994285,"about_ca_topic_score_gemma":0.00604533,"teacher_disagreement_score":0.0031128828,"about_ca_system_score_codex":0.0009210615,"about_ca_system_score_gemma":0.0009534614,"threshold_uncertainty_score":0.009664416},"labels":[],"label_agreement":null},{"id":"W4410954716","doi":"10.1016/j.critrevonc.2025.104787","title":"Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North; NOSM University; Lakeshore General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Trastuzumab; Meta-analysis; Oncology; Adverse effect; Medicine; Systematic review; Internal medicine; MEDLINE; Cancer; Chemistry; Breast cancer","score_opus":0.1405847298912986,"score_gpt":0.5463202509195888,"score_spread":0.4057355210282902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410954716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004917357,0.99395907,0.00028748898,0.00012468845,0.00012167871,0.00010922126,0.0003217225,0.000014584697,0.00014417949],"genre_scores_gemma":[0.18405399,0.81163114,0.0014439711,0.0012246353,0.0002473764,0.00037932585,0.0005288223,0.000030432246,0.00046024495],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945181,0.002278204,0.001663845,0.00066506374,0.00063604757,0.00023881692],"domain_scores_gemma":[0.98957354,0.0070653707,0.0022522425,0.00034735719,0.000612571,0.00014886611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008377141,0.0022957386,0.012329247,0.0030852626,0.0003910532,0.002279876,0.0014742911,0.0019201245,0.0039028747],"category_scores_gemma":[0.019206582,0.0013355261,0.02720997,0.004005799,0.00063525845,0.0013990226,0.0015287355,0.001890852,0.00029020317],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003034468,0.00002828691,0.0041239155,0.31561178,0.66327,0.00013794824,0.00007507136,0.00042370462,0.00028237334,0.00010811832,0.0007611453,0.012143169],"study_design_scores_gemma":[0.00077182887,0.00015599477,0.0034834538,0.013541357,0.9802571,0.000077128214,0.000037462778,0.000108261745,0.00008419212,0.0001258221,0.0013337157,0.000023736226],"about_ca_topic_score_codex":0.00595042,"about_ca_topic_score_gemma":0.017878018,"teacher_disagreement_score":0.012329247,"about_ca_system_score_codex":0.0021046584,"about_ca_system_score_gemma":0.0023342462,"threshold_uncertainty_score":0.04430306},"labels":[],"label_agreement":null},{"id":"W4411197152","doi":"10.1055/a-2549-4288","title":"HER2-positives Mammakarzinom: Ansprechen auf die neoadjuvante Chemotherapie","year":2025,"lang":"de","type":"article","venue":"Geburtshilfe und Frauenheilkunde","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology","score_opus":0.027008713538358663,"score_gpt":0.3631233033884621,"score_spread":0.33611458985010345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411197152","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29031026,0.39245993,0.02532739,0.084762745,0.0054472904,0.00036489245,0.0017011513,0.0009909151,0.19863546],"genre_scores_gemma":[0.7872066,0.13630515,0.011517168,0.009233583,0.0044610747,0.00011340897,0.0017480877,0.00012602578,0.049288895],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99977857,0.000055943485,0.000018320427,0.000026484719,0.00008130993,0.00003933377],"domain_scores_gemma":[0.9996885,0.00014632447,0.00003930338,0.000023664017,0.00004711532,0.00005507793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005701953,0.00038223324,0.00039953177,0.00053074904,0.00040317993,0.0006464943,0.0002148228,0.0006351964,0.006568219],"category_scores_gemma":[0.0013384605,0.00017134789,0.00018273458,0.00036551003,0.00039689837,0.00045401652,0.00046742804,0.00086303777,0.00420127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017127418,0.0002747672,0.033438656,0.0012755733,0.00008959869,0.042642295,0.0006506243,0.0012688306,0.061419547,0.004926535,0.0988172,0.7534836],"study_design_scores_gemma":[0.00013415479,0.0012580515,0.072753906,0.0015430149,0.00021978703,0.14955208,0.0014156555,0.0021532506,0.06812442,0.009519403,0.6932389,0.00008747329],"about_ca_topic_score_codex":0.00090766686,"about_ca_topic_score_gemma":0.001788798,"teacher_disagreement_score":0.006568219,"about_ca_system_score_codex":0.00036385673,"about_ca_system_score_gemma":0.00045577798,"threshold_uncertainty_score":0.021972895},"labels":[],"label_agreement":null},{"id":"W4411289858","doi":"10.1158/1557-3265.sabcs24-p3-07-03","title":"Abstract P3-07-03: Real-world comparison of safety and effectiveness of dose dense (2-weekly) versus weekly paclitaxel given with trastuzumab as neoadjuvant treatment in HER2-positive early stage breast cancer","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Oncology; Breast cancer; Stage (stratigraphy); Internal medicine; Cancer","score_opus":0.14634287494718778,"score_gpt":0.5437414468488628,"score_spread":0.39739857190167505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411289858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986979,0.0002886847,0.00010568005,0.000022579556,0.000005836715,0.00016340688,0.0004242375,0.000009586771,0.0002820721],"genre_scores_gemma":[0.9989737,0.00008514852,0.00021976633,0.000028001397,0.000016273894,0.00011560611,0.00047959053,0.0000028979098,0.00007889646],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9985715,0.00096669496,0.00009956473,0.00013442717,0.00016195928,0.00006579414],"domain_scores_gemma":[0.9948179,0.002161908,0.001968619,0.0003137181,0.00031431016,0.00042361923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002448592,0.00024578438,0.00059366314,0.0003544933,0.00019552828,0.0005071928,0.0003999351,0.00048423756,0.0020066442],"category_scores_gemma":[0.004164138,0.00015975647,0.000779401,0.00073767983,0.00042409168,0.0003679261,0.00022642832,0.00054789876,0.00022064065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8018403,0.012755166,0.09974101,0.00070021866,0.0015857393,0.00014761802,0.00016398758,0.0055271173,0.007046012,0.000102657505,0.0010986332,0.06929151],"study_design_scores_gemma":[0.08391773,0.44863287,0.4493471,0.00008463461,0.0016752644,0.00045112465,0.00014853355,0.0065203365,0.007027845,0.00015613089,0.0019772402,0.00006125478],"about_ca_topic_score_codex":0.0029184143,"about_ca_topic_score_gemma":0.0029068857,"teacher_disagreement_score":0.0029184143,"about_ca_system_score_codex":0.0016670759,"about_ca_system_score_gemma":0.0011378634,"threshold_uncertainty_score":0.012949526},"labels":[],"label_agreement":null},{"id":"W4411290570","doi":"10.1158/1557-3265.sabcs24-p2-11-15","title":"Abstract P2-11-15: Axillary Pathologic Complete Response in Triple-Negative Breast Cancer Patients with Mammary Pathologic Complete Response: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Complete response; Triple-negative breast cancer; Cancer; Triple negative; Pathology; Oncology; Internal medicine; Chemotherapy","score_opus":0.3170601579605599,"score_gpt":0.5545073676760174,"score_spread":0.23744720971545746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411290570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042503476,0.9886678,0.0005090004,0.00059073634,0.00020135858,0.0025017622,0.0026382161,0.000030461979,0.0006102406],"genre_scores_gemma":[0.08598828,0.8989304,0.0022272172,0.0018805388,0.00024608837,0.008246794,0.0018945237,0.000027149314,0.000559006],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9848363,0.004845153,0.006527771,0.0010860636,0.0023537518,0.00035096277],"domain_scores_gemma":[0.9616194,0.024599878,0.009629366,0.00070664665,0.003069416,0.00037531042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012826816,0.0016069165,0.011540529,0.00967461,0.00072486926,0.003202363,0.0024340923,0.002070539,0.006461202],"category_scores_gemma":[0.04799955,0.0009403313,0.00954256,0.011002098,0.0013411383,0.002917181,0.0018166977,0.0010056798,0.0003777407],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015523437,0.0000063801904,0.0007970114,0.98449004,0.007955029,0.000045183147,0.00011217213,0.000043166063,0.00009406529,0.00008482973,0.0005754641,0.0056415363],"study_design_scores_gemma":[0.0004676298,0.00016886217,0.0054773004,0.8831085,0.10348354,0.00026563925,0.00025321913,0.000111699774,0.00015998211,0.00029564786,0.0061713546,0.00003653099],"about_ca_topic_score_codex":0.007406582,"about_ca_topic_score_gemma":0.018222768,"teacher_disagreement_score":0.012826816,"about_ca_system_score_codex":0.0044071916,"about_ca_system_score_gemma":0.010854304,"threshold_uncertainty_score":0.06783551},"labels":[],"label_agreement":null},{"id":"W4411290861","doi":"10.1158/1557-3265.sabcs24-p4-08-02","title":"Abstract P4-08-02: Identifying unique transcriptomes associated with HER2+ breast cancer recurrence at the single-cell level","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Transcriptome; Cancer; Oncology; Internal medicine; Computational biology; Biology; Genetics; Gene; Gene expression","score_opus":0.45902800883359274,"score_gpt":0.5609312424808137,"score_spread":0.10190323364722098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411290861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8931328,0.004961829,0.04328061,0.0012813475,0.00058133213,0.00028991004,0.047377937,0.0021027105,0.0069915275],"genre_scores_gemma":[0.87205017,0.0025234963,0.046188597,0.0014181962,0.00019913964,0.0006325652,0.06365849,0.0006514498,0.012677862],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999671,0.000022012755,0.00002132038,0.00010656734,0.000119426964,0.000059702463],"domain_scores_gemma":[0.99966645,0.00008696855,0.000056462777,0.000034983193,0.00011897443,0.000036142446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041976254,0.00031889547,0.00048193053,0.00060165697,0.00047063705,0.0008189584,0.00031345803,0.0005509707,0.003881175],"category_scores_gemma":[0.0005835079,0.00020192582,0.00053668267,0.00056806725,0.00023971176,0.00029337424,0.00048357423,0.0008592764,0.0018035544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028694206,0.00004668284,0.010563471,0.00035123195,0.00005427087,0.000347723,0.00014680621,0.00045703663,0.9699275,0.00018118123,0.0036138147,0.01402337],"study_design_scores_gemma":[0.000036515077,0.00046868646,0.18097736,0.00009182104,0.0002032935,0.0022181894,0.0005675454,0.00946589,0.76315755,0.00073757244,0.041992337,0.00008323313],"about_ca_topic_score_codex":0.0012120301,"about_ca_topic_score_gemma":0.0018508515,"teacher_disagreement_score":0.003881175,"about_ca_system_score_codex":0.0003207172,"about_ca_system_score_gemma":0.0004929082,"threshold_uncertainty_score":0.012983859},"labels":[],"label_agreement":null},{"id":"W4411306607","doi":"10.14740/wjon2552","title":"Co-expression of HER2/EGFRvIII/CD44 and Claudin 18.2/CD109 as Novel Prognostic Indicators in Stomach Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Stomach; Claudin; CD44; Adenocarcinoma; Internal medicine; Oncology; Cancer research; Gastroenterology; Cancer; Tight junction; Biochemistry; Cell","score_opus":0.03872907709233955,"score_gpt":0.4218318991536418,"score_spread":0.3831028220613022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411306607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99930906,0.0004199695,0.00006590626,0.000010456204,0.0000019400393,0.0000025315821,0.000033218155,0.0000026322002,0.00015429348],"genre_scores_gemma":[0.9995976,0.0000922509,0.00017094353,0.0000040926852,0.000005211423,0.0000041518147,0.00007608279,7.221897e-7,0.00004901567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997981,0.000041805324,0.000023713788,0.000035892393,0.00004879164,0.000051758194],"domain_scores_gemma":[0.999448,0.00011479452,0.00022923342,0.000027239137,0.00007173498,0.00010900613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042811214,0.00021946194,0.00027202725,0.0009784461,0.00029561136,0.0004275267,0.00023963455,0.00034926608,0.0008451641],"category_scores_gemma":[0.0007847804,0.00014633595,0.00019254924,0.00074913976,0.00024534634,0.00026090062,0.0004063232,0.00028514036,0.00017448625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026000565,0.000013287865,0.99435824,0.000013186495,0.000015093901,0.00016041506,0.000026043685,0.00004114621,0.0031787155,0.000008705141,0.000031204265,0.0018939009],"study_design_scores_gemma":[0.000019051604,0.00022314265,0.9936207,0.0000076085753,0.000083710824,0.0023706397,0.00019033633,0.0006809001,0.002302815,0.00004281953,0.00045392543,0.0000043640116],"about_ca_topic_score_codex":0.00055298995,"about_ca_topic_score_gemma":0.000951809,"teacher_disagreement_score":0.0009784461,"about_ca_system_score_codex":0.00026856555,"about_ca_system_score_gemma":0.00017453535,"threshold_uncertainty_score":0.0028273463},"labels":[],"label_agreement":null},{"id":"W4411421224","doi":"10.1016/j.ard.2025.05.967","title":"POS0585 SEX DIFFERENCES IN THE SAFETY PROFILE OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS: RESULTS FROM THE JAK-POT INTERNATIONAL COLLABORATION","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Janus kinase; Rheumatoid arthritis; Janus kinase inhibitor; Tofacitinib; Dermatology; Janus; Internal medicine; Receptor","score_opus":0.03913187294183144,"score_gpt":0.34826958363718125,"score_spread":0.3091377106953498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411421224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90311944,0.03919606,0.00072717696,0.001815786,0.00021589258,0.00021748255,0.038559902,0.0000387538,0.016109481],"genre_scores_gemma":[0.9822792,0.005024807,0.00024497154,0.00095526926,0.00017045398,0.000092251576,0.010381783,0.000024418467,0.00082685106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936801,0.0021157707,0.0012613491,0.00082473643,0.0015999686,0.0005180352],"domain_scores_gemma":[0.97159594,0.008341661,0.01302285,0.0024141518,0.0032764864,0.0013488726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008714823,0.00029057666,0.0007449097,0.0006542606,0.00038330493,0.0014015958,0.00043727085,0.0007624443,0.0034154248],"category_scores_gemma":[0.022692936,0.00015274722,0.0021057292,0.0021306998,0.0002851458,0.0004898945,0.00077456754,0.0006574857,0.0005255272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027069377,0.00016705101,0.8925002,0.0012247732,0.007258995,0.0001697092,0.0003502269,0.0005233232,0.00033701782,0.00050309126,0.0073175402,0.06257862],"study_design_scores_gemma":[0.0019027471,0.00171685,0.97953314,0.00066240004,0.0038574515,0.0004034457,0.00028049064,0.00027320324,0.00019309837,0.00037758326,0.010747682,0.000052014115],"about_ca_topic_score_codex":0.0067497003,"about_ca_topic_score_gemma":0.0087996265,"teacher_disagreement_score":0.008714823,"about_ca_system_score_codex":0.0007038205,"about_ca_system_score_gemma":0.0015572883,"threshold_uncertainty_score":0.046088934},"labels":[],"label_agreement":null},{"id":"W4411561109","doi":"10.1007/s10549-025-07749-9","title":"Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole","year":2025,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Essar Steel Algoma (Canada); North York General Hospital; London Health Sciences Centre; Queen's University; McMaster University; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; AstraZeneca; Government of Ontario; Strong; Pfizer","keywords":"Anastrozole; Exemestane; Medicine; Oncology; Breast cancer; Internal medicine; Adjuvant; Clinical trial; Cancer; Gynecology; Aromatase inhibitor; Tamoxifen","score_opus":0.09989953334003839,"score_gpt":0.47022284479665905,"score_spread":0.3703233114566207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411561109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85801345,0.01582163,0.051333256,0.0061980993,0.0021860348,0.012134972,0.023598248,0.0019632357,0.028751107],"genre_scores_gemma":[0.952359,0.0006582635,0.021055985,0.0012278744,0.00029220237,0.0046857684,0.0039424268,0.00023789893,0.015540524],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9746448,0.01916677,0.00076861,0.0015953216,0.0028709725,0.0009535067],"domain_scores_gemma":[0.98848057,0.0046897326,0.0018949063,0.0029040354,0.0013711766,0.00065958325],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019425133,0.0010428916,0.0019671968,0.00049707154,0.00066081766,0.0011547771,0.0019175741,0.0007196626,0.0061230073],"category_scores_gemma":[0.029127534,0.00038481908,0.0020796044,0.0009917289,0.0007862183,0.00059980305,0.0007139804,0.0022753216,0.00035370252],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64515746,0.0012238126,0.041375723,0.0010684147,0.02659986,0.00009507838,0.0003488509,0.009049191,0.0065492666,0.0080171535,0.039974403,0.22054079],"study_design_scores_gemma":[0.21063362,0.043596677,0.51689005,0.00037657763,0.024570618,0.00023272907,0.0003973269,0.07822509,0.01440841,0.012583543,0.09764611,0.00043923117],"about_ca_topic_score_codex":0.13719715,"about_ca_topic_score_gemma":0.2017567,"teacher_disagreement_score":0.98057485,"about_ca_system_score_codex":0.0054329126,"about_ca_system_score_gemma":0.012567462,"threshold_uncertainty_score":0.2727971},"labels":[],"label_agreement":null},{"id":"W4411770375","doi":"10.14740/jmc5136","title":"Long Durable Response With Trastuzumab Deruxtecan Monotherapy in a Triple-Negative Metastatic Breast Cancer Patient With Human Epidermal Growth Factor Receptor 2 Mutation: A Long-Term Follow-Up and Literature Review","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Human Epidermal Growth Factor Receptor 2; Oncology; Triple-negative breast cancer; Breast cancer; Internal medicine; Cancer; Cancer research","score_opus":0.03018995388442816,"score_gpt":0.3777845148453995,"score_spread":0.3475945609609713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411770375","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009932224,0.98723155,0.00028599225,0.0005646092,0.00014179086,0.00005238128,0.000273376,0.000007670779,0.0015104446],"genre_scores_gemma":[0.048328016,0.9475496,0.00065548165,0.0012975183,0.00045725136,0.00006213789,0.00091975805,0.0000109510365,0.00071926543],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99948967,0.00006275132,0.0002321373,0.00007991623,0.00010917755,0.000026367077],"domain_scores_gemma":[0.99854004,0.0006419128,0.00044104937,0.000052633302,0.0002711948,0.000053274453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009137266,0.000405608,0.0018036154,0.001953771,0.0003603347,0.0012203122,0.0007785733,0.0007056843,0.0014868489],"category_scores_gemma":[0.0017404817,0.00025390595,0.0013991626,0.0028616386,0.00043427624,0.0016327688,0.0004064421,0.0007539636,0.00048293167],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010405473,0.0003250213,0.019958816,0.065869294,0.0026547308,0.02376946,0.0008398945,0.0007938724,0.0050826734,0.0012207627,0.01804001,0.86040485],"study_design_scores_gemma":[0.00036210637,0.0024141024,0.08972097,0.06011805,0.022534873,0.27409428,0.0025131328,0.0010990027,0.007719891,0.0022618833,0.5367907,0.00037086412],"about_ca_topic_score_codex":0.00077316863,"about_ca_topic_score_gemma":0.0015799558,"teacher_disagreement_score":0.001953771,"about_ca_system_score_codex":0.0006587257,"about_ca_system_score_gemma":0.0012103162,"threshold_uncertainty_score":0.004973948},"labels":[],"label_agreement":null},{"id":"W4412072814","doi":"10.1080/14796694.2025.2529151","title":"Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Cancer; Trastuzumab","score_opus":0.029248126771143183,"score_gpt":0.4596720816154097,"score_spread":0.4304239548442665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412072814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007567636,0.9991007,0.000039251994,0.00017664199,0.00008800926,0.000002891288,0.000008981869,0.0000034170487,0.00050450856],"genre_scores_gemma":[0.00039692223,0.9991142,0.000059945552,0.00011815293,0.00005721523,0.000002965753,0.000015007255,8.035536e-7,0.00023471109],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980277,0.000044857785,0.000026175649,0.000027222599,0.00007797907,0.000021000375],"domain_scores_gemma":[0.99973124,0.00013269595,0.00003964697,0.000006893376,0.00006675776,0.000022720402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061586354,0.00059148984,0.0011445447,0.0022476525,0.00023031802,0.0010485217,0.00071607204,0.00076924753,0.003995681],"category_scores_gemma":[0.0007245367,0.00019511,0.00068350666,0.002078545,0.0003273898,0.0010894269,0.00062215904,0.001959164,0.0016184958],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087658904,0.00005380408,0.000098493656,0.021529678,0.00011223083,0.00010832918,0.00006431918,0.00032171715,0.0008634742,0.0029382922,0.028921815,0.94490016],"study_design_scores_gemma":[0.000034187913,0.00011274434,0.0006702723,0.008858546,0.00018333612,0.0008944608,0.0000547214,0.000112540554,0.0002437962,0.0017861753,0.9870344,0.000014691591],"about_ca_topic_score_codex":0.0011937938,"about_ca_topic_score_gemma":0.0029922202,"teacher_disagreement_score":0.003995681,"about_ca_system_score_codex":0.00062381476,"about_ca_system_score_gemma":0.00087981287,"threshold_uncertainty_score":0.013366878},"labels":[],"label_agreement":null},{"id":"W4412163726","doi":"10.1158/1557-3265.aimachine-b043","title":"Abstract B043: Cellular localization as a prognostic indicator in invasive breast cancer","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Cancer; Breast cancer; Medicine; Oncology; Pathology; Internal medicine","score_opus":0.1948853610627769,"score_gpt":0.5672121022401246,"score_spread":0.37232674117734776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412163726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683507,0.00091883476,0.0074485373,0.000768096,0.00008762278,0.000040911335,0.019142533,0.0007087729,0.0025339604],"genre_scores_gemma":[0.98321885,0.00014517482,0.002763854,0.000050811595,0.000042394957,0.00002808969,0.011953538,0.000049545535,0.00174768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976295,0.00004740531,0.000019103147,0.00007376915,0.00005960924,0.000037243433],"domain_scores_gemma":[0.99838686,0.0007354358,0.00023562308,0.00012773104,0.00033711942,0.00017713956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000919664,0.0004602706,0.00037839738,0.0011568746,0.0002515681,0.00071321026,0.0005582753,0.0005970018,0.0067107915],"category_scores_gemma":[0.0032065574,0.00016509347,0.0005908588,0.0010483654,0.00025783895,0.00031861497,0.00049788976,0.0006775106,0.0016650289],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014919634,0.00014383555,0.92770034,0.0001593875,0.00025854498,0.00016834194,0.000057850826,0.017843965,0.004656995,0.00015976721,0.008767473,0.038591523],"study_design_scores_gemma":[0.00007449457,0.00036094664,0.86971813,0.00006137395,0.0002571883,0.0006424361,0.00013981912,0.11756047,0.0051055388,0.0009043726,0.0051251105,0.000050011615],"about_ca_topic_score_codex":0.022666676,"about_ca_topic_score_gemma":0.022036286,"teacher_disagreement_score":0.022666676,"about_ca_system_score_codex":0.00082228414,"about_ca_system_score_gemma":0.000775248,"threshold_uncertainty_score":0.045069456},"labels":[],"label_agreement":null},{"id":"W4412662543","doi":"10.14740/wjon2583","title":"Clinical Utility of Targeted Next-Generation Sequencing for Determining Human Epidermal Growth Factor Receptor 2 Status and Optimizing Targeted Therapy in Breast Cancer","year":2025,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Targeted therapy; Breast cancer; Epidermal growth factor receptor; Oncology; Cancer; DNA sequencing; Cancer research; Internal medicine; Gene; Genetics; Biology","score_opus":0.20033985539002883,"score_gpt":0.46555932314368786,"score_spread":0.265219467753659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412662543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97732055,0.00995587,0.008443412,0.00042998814,0.000038884682,0.00008397562,0.00023027748,0.00012171245,0.0033752378],"genre_scores_gemma":[0.99164987,0.0013661886,0.0063564614,0.00014907224,0.000022891554,0.00002576979,0.00016103646,0.0000070447995,0.00026159073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999559,0.00017224261,0.000025223251,0.000077082295,0.00013393688,0.00003247191],"domain_scores_gemma":[0.99929845,0.0003667149,0.00011664989,0.000041486786,0.00012964838,0.000047141828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018171195,0.00025284785,0.0002746374,0.0006275979,0.00013208606,0.00047663832,0.00019425353,0.00037368658,0.0007337578],"category_scores_gemma":[0.0024319259,0.00009073626,0.00013580175,0.0002818795,0.00029279082,0.0002951912,0.0001962193,0.0002657659,0.0001520642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040553566,0.00031395623,0.46995255,0.00031443595,0.00018695834,0.0006858004,0.00019255577,0.005998386,0.20624274,0.00045199782,0.0015213739,0.31008393],"study_design_scores_gemma":[0.00018350277,0.0043532625,0.7430493,0.00018086194,0.0004745059,0.008833185,0.0003724111,0.052249976,0.17902535,0.0024461604,0.008777849,0.000053572214],"about_ca_topic_score_codex":0.00058276695,"about_ca_topic_score_gemma":0.00095698936,"teacher_disagreement_score":0.0018171195,"about_ca_system_score_codex":0.00042776988,"about_ca_system_score_gemma":0.0003018323,"threshold_uncertainty_score":0.009609997},"labels":[],"label_agreement":null},{"id":"W4412956201","doi":"10.1158/1535-7163.mct-24-1176","title":"Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjugate","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FSD Pharma (Canada)","funders":"National Applied Research Laboratories","keywords":"Pharmacology; Medicine; Pharmacokinetics; In vivo; Toxicity; Pharmacodynamics; Drug; Antibody; Cancer research; Cell culture; Immunology; Internal medicine; Biology","score_opus":0.03920731020912873,"score_gpt":0.42594948924018755,"score_spread":0.38674217903105884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412956201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931861,0.0013667662,0.0025671704,0.00010783903,0.000029240267,0.00019846193,0.000722889,0.000066102744,0.0017555285],"genre_scores_gemma":[0.9937309,0.0010884253,0.0014041287,0.00008622952,0.000021770615,0.00016017418,0.0014018869,0.000027374417,0.0020791763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998652,0.00003049724,0.000009080164,0.00002223269,0.00003944672,0.00003358301],"domain_scores_gemma":[0.9998673,0.000017859737,0.000041553933,0.00001445898,0.000026365724,0.00003245691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030955335,0.0004653202,0.00037755875,0.00023262405,0.00014899795,0.00030762778,0.00024648418,0.00028844937,0.0012683613],"category_scores_gemma":[0.00028779038,0.00019174058,0.00026312415,0.00027556246,0.0002261252,0.00033236717,0.0001363449,0.0008669111,0.000331075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009629121,0.0038530568,0.0028097536,0.00022308121,0.00011093745,0.00026126366,0.00010499242,0.0042262077,0.94238013,0.00030529412,0.001175728,0.034920402],"study_design_scores_gemma":[0.0011995398,0.06580321,0.015400669,0.000022930599,0.0003083799,0.0012362454,0.00008243172,0.011208057,0.88895833,0.00020054389,0.015534275,0.00004543438],"about_ca_topic_score_codex":0.00078931556,"about_ca_topic_score_gemma":0.00075557333,"teacher_disagreement_score":0.0012683613,"about_ca_system_score_codex":0.0004010738,"about_ca_system_score_gemma":0.00047620686,"threshold_uncertainty_score":0.004243076},"labels":[],"label_agreement":null},{"id":"W4412974237","doi":"10.1158/2767-9764.crc-25-0019","title":"Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Alberta; Spinal Cord Injury BC; Ontario Institute for Cancer Research; Jewish General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Merck Canada; National Cancer Institute; Incyte; Memorial Sloan-Kettering Cancer Center; BeiGene; AstraZeneca; Celgene; Gilead Sciences","keywords":"Medicine; Internal medicine; Discontinuation; Nausea; Adverse effect; Oncology; Breast cancer; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Clinical endpoint; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial","score_opus":0.3892141963931314,"score_gpt":0.6154104701398585,"score_spread":0.22619627374672713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412974237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917304,0.0009569377,0.00070530566,0.00022978359,0.00006895072,0.004751284,0.0007115693,0.000050613988,0.0007951934],"genre_scores_gemma":[0.9910124,0.00048053407,0.0015643549,0.00040997512,0.0000785013,0.0045966846,0.0005944744,0.000014843205,0.001248284],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991272,0.0005497854,0.000042153908,0.00011061775,0.00008266718,0.00008762384],"domain_scores_gemma":[0.9990337,0.00021603957,0.00027387214,0.00007723172,0.000115058254,0.00028408266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031533495,0.00091274455,0.00088701054,0.00019532183,0.00031938654,0.00046854332,0.00044357477,0.00087268103,0.0036758294],"category_scores_gemma":[0.001651894,0.00037902413,0.0007677872,0.00018463082,0.00049414235,0.0005790808,0.00026300503,0.0015194591,0.00063608115],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8069577,0.051229853,0.02228033,0.00096908485,0.0014834346,0.0001807352,0.00038820275,0.0007665917,0.049918678,0.0002489433,0.0023280662,0.063248366],"study_design_scores_gemma":[0.47143468,0.4957244,0.023654077,0.000044909928,0.0005032258,0.00020383336,0.000070872295,0.00073630444,0.004237337,0.00021495386,0.0031574513,0.00001798618],"about_ca_topic_score_codex":0.00051668775,"about_ca_topic_score_gemma":0.0014816928,"teacher_disagreement_score":0.0036758294,"about_ca_system_score_codex":0.00052010093,"about_ca_system_score_gemma":0.001440089,"threshold_uncertainty_score":0.016676724},"labels":[],"label_agreement":null},{"id":"W4413314398","doi":"10.7759/cureus.90253","title":"Exploring Human Epidermal Growth Factor Receptor 2 (HER2)-Low Early Breast Cancer in a Moroccan Population: Clinical Characteristics and Survival Outcomes","year":2025,"lang":"en","type":"article","venue":"Cureus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Breast cancer; Oncology; Epidermal growth factor receptor; Internal medicine; Population; Epidermal growth factor; Cancer; Gynecology; Receptor; Environmental health","score_opus":0.19132457683614965,"score_gpt":0.44721974159378153,"score_spread":0.25589516475763185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413314398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99962866,0.00013630115,0.000021454276,0.000025625519,0.0000016916906,0.0000029582554,0.00008282628,5.589494e-7,0.000099965604],"genre_scores_gemma":[0.9997402,0.00005581382,0.000020245121,0.000017026408,0.000004945262,0.0000034829486,0.000102460246,3.750702e-7,0.000055372395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968874,0.000073803014,0.000028021843,0.000070321315,0.000043625576,0.000095565774],"domain_scores_gemma":[0.9995086,0.000085708656,0.00021063395,0.000036780977,0.000074884854,0.000083444545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064929406,0.0002353655,0.00024202044,0.0010423145,0.00051833753,0.00041159277,0.00028669467,0.00026579632,0.001082411],"category_scores_gemma":[0.001083452,0.00013499857,0.00021399384,0.0007323711,0.00028626723,0.000285805,0.0005075841,0.00021544207,0.00017498125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003301559,0.000014316112,0.998689,0.0000065062654,0.000008277751,0.00011840816,0.00009926857,0.000015718002,0.00020813846,0.000008702477,0.000032255364,0.0007664464],"study_design_scores_gemma":[0.0000021811386,0.00005415559,0.9989793,0.000004626687,0.000008900737,0.00028408074,0.00034594457,0.00007739916,0.00005662358,0.000012576892,0.00017209626,0.0000021210253],"about_ca_topic_score_codex":0.009458709,"about_ca_topic_score_gemma":0.010561331,"teacher_disagreement_score":0.009458709,"about_ca_system_score_codex":0.0006017662,"about_ca_system_score_gemma":0.0003473796,"threshold_uncertainty_score":0.018807352},"labels":[],"label_agreement":null},{"id":"W4413372506","doi":"10.1016/j.ijgc.2025.102117","title":"Safety of antibody-drug conjugates in gynecologic cancers: current evidence and management approaches","year":2025,"lang":"en","type":"review","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Instituto de Salud Carlos III; Eisai; Seagen; Gilead Sciences; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Medicine; Antibody-drug conjugate; Gynecologic cancer; Drug; Antibody; Gynecology; Oncology; Pharmacology; Monoclonal antibody; Internal medicine; Ovarian cancer; Immunology; Cancer","score_opus":0.21986321063698808,"score_gpt":0.5025747878709089,"score_spread":0.2827115772339208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413372506","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012526936,0.99957794,0.000039256476,0.00007464091,0.000028170329,0.0000046093182,0.000020260337,0.0000016904099,0.00012808848],"genre_scores_gemma":[0.0016476685,0.9979335,0.00012707393,0.00013297208,0.000045095745,0.000006292347,0.00002644926,6.5377066e-7,0.000080281454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993755,0.0001740973,0.00015168203,0.00008269104,0.00018352791,0.000032514035],"domain_scores_gemma":[0.99775034,0.0016183975,0.00040389426,0.000025330062,0.00016620758,0.00003589801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016803585,0.0007089184,0.0033841787,0.0015456798,0.00015408544,0.0011542509,0.0010264805,0.0013577207,0.0044002403],"category_scores_gemma":[0.0035026977,0.0003030615,0.002271013,0.0015538166,0.00036614863,0.00086570624,0.0004970571,0.0012225437,0.0005557887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006738021,0.00009137697,0.00055435917,0.1369066,0.0018257331,0.00012683171,0.0000421342,0.0005419364,0.0010223299,0.0011626938,0.0072381296,0.84981406],"study_design_scores_gemma":[0.0011932832,0.0022065847,0.009516618,0.15791954,0.024158318,0.0028509113,0.00033303045,0.0007589365,0.002579839,0.0049222535,0.7934292,0.0001314762],"about_ca_topic_score_codex":0.0013173493,"about_ca_topic_score_gemma":0.0026353148,"teacher_disagreement_score":0.0044002403,"about_ca_system_score_codex":0.0005468214,"about_ca_system_score_gemma":0.0012985207,"threshold_uncertainty_score":0.014720321},"labels":[],"label_agreement":null},{"id":"W4413417222","doi":"10.58931/cot.2025.2235","title":"Antibody-Drug Conjugates in Breast Cancer: Current Landscape and Future Targets","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Mount Sinai Hospital","funders":"University of Toronto; University of Ottawa","keywords":"Antibody-drug conjugate; Breast cancer; Antibody; Drug; Conjugate; Medicine; Cancer; Cancer drugs; Current (fluid); Immunology; Cancer research; Pharmacology; Monoclonal antibody; Internal medicine; Engineering","score_opus":0.011839490796647313,"score_gpt":0.3703987486551005,"score_spread":0.35855925785845316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413417222","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038074984,0.989813,0.00027791827,0.006648741,0.0004922732,0.000007770282,0.000021934055,0.00001826592,0.0023393894],"genre_scores_gemma":[0.0035998176,0.99099475,0.00063872273,0.0022511887,0.00084633846,0.000011779732,0.00004708326,0.0000072836365,0.0016029887],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993368,0.0001782897,0.000049906514,0.00006435204,0.00025340606,0.000117230724],"domain_scores_gemma":[0.9987074,0.0004325153,0.00009902135,0.000028237127,0.0005137383,0.00021900191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002907534,0.0005077832,0.0008079858,0.0013785424,0.0005729625,0.0018792821,0.00074459426,0.0014613096,0.0055319765],"category_scores_gemma":[0.0019331567,0.00022959556,0.0003598872,0.0020644758,0.0014047681,0.002904983,0.0009150229,0.002215328,0.0017366251],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001806344,0.00009793032,0.0004889214,0.0036381192,0.000027068156,0.00031200275,0.00015031177,0.00063599437,0.002021023,0.014176556,0.088123724,0.8901476],"study_design_scores_gemma":[0.000040129944,0.00022801978,0.00068937324,0.0013608556,0.000033870856,0.0007415557,0.00014771863,0.00024050064,0.00058708875,0.0044605127,0.9914487,0.00002169097],"about_ca_topic_score_codex":0.010145557,"about_ca_topic_score_gemma":0.036094464,"teacher_disagreement_score":0.010145557,"about_ca_system_score_codex":0.003563772,"about_ca_system_score_gemma":0.0046583726,"threshold_uncertainty_score":0.02585715},"labels":[],"label_agreement":null},{"id":"W4413835243","doi":"10.62110/sciencein.cbl.2025.v12.1271","title":"Synthesis and in-vitro anti-EGFR screening of new 1,2,3-triazole-benzimidazole hybrids and insilico studies","year":2025,"lang":"en","type":"article","venue":"Chemical Biology Letters","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of Manitoba","funders":"","keywords":"Benzimidazole; Triazole; In vitro; Chemistry; Pharmacology; Medicine; Biochemistry; Organic chemistry","score_opus":0.05006576369567979,"score_gpt":0.3667755083768124,"score_spread":0.3167097446811326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413835243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96354145,0.008155619,0.011570455,0.00037187256,0.00008018446,0.00030695132,0.0013978443,0.00035810127,0.014217604],"genre_scores_gemma":[0.9814811,0.0036728168,0.0073598227,0.00010026501,0.00001544633,0.00014938232,0.0009981846,0.000019427585,0.006203529],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992967,0.000008688436,0.00000429932,0.000012675548,0.000023367567,0.000021325246],"domain_scores_gemma":[0.99996006,0.0000047906697,0.000011373908,0.0000035450403,0.000012973551,0.000007306571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009917977,0.00030937543,0.0002497492,0.00021828533,0.00019439342,0.00018638547,0.00036298574,0.00031294592,0.0022018377],"category_scores_gemma":[0.00011017264,0.00013790057,0.00023306049,0.0003171485,0.00012070441,0.00019018416,0.00016029786,0.0003288569,0.0005511795],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099634584,0.0001229102,0.00016320066,0.00038268708,0.000016544875,0.00034482626,0.00006840363,0.00076605735,0.9905138,0.0005131291,0.00046444344,0.006544283],"study_design_scores_gemma":[0.000037601032,0.0014652739,0.0016947241,0.000017071363,0.000045491783,0.00050783716,0.000043362263,0.0011441018,0.9852905,0.000084929314,0.009647976,0.000021213304],"about_ca_topic_score_codex":0.0007116799,"about_ca_topic_score_gemma":0.002228308,"teacher_disagreement_score":0.0022018377,"about_ca_system_score_codex":0.00027722842,"about_ca_system_score_gemma":0.00015586044,"threshold_uncertainty_score":0.007365823},"labels":[],"label_agreement":null},{"id":"W4414145653","doi":"10.1101/2025.09.04.674072","title":"APOE+ Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo; Canadian Institutes of Health Research; Susan G. Komen","keywords":"Breast cancer; Estrogen; Cancer; Hormone; Human breast; Inflammation; Immune system; Mammary gland","score_opus":0.006999774018335251,"score_gpt":0.2476053088905238,"score_spread":0.24060553487218853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414145653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99864465,0.00017409778,0.00052603567,0.000039221657,0.0000041728645,0.000006191615,0.00008945049,0.000014121062,0.000501987],"genre_scores_gemma":[0.9976646,0.00009669316,0.0005927975,0.00005724959,0.000008330882,0.00001812633,0.00017117523,0.0000066454686,0.0013843578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991226,0.000013992666,0.0000070920305,0.000024179371,0.000013523952,0.00002904534],"domain_scores_gemma":[0.9999517,0.0000056767653,0.000011573601,0.0000043829054,0.000008058376,0.000018519482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015856589,0.00012847372,0.00009865908,0.00030274992,0.00012399364,0.00026248873,0.00009592726,0.00015615602,0.0014351474],"category_scores_gemma":[0.00010455973,0.00008700801,0.00008215143,0.000109412664,0.00016567978,0.00013612211,0.00019929445,0.00023971385,0.00022994631],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079072034,0.000073863004,0.015036702,0.000035832316,0.00001030179,0.00020769851,0.000059954516,0.000069802685,0.9806598,0.00017627513,0.00010942886,0.0027695512],"study_design_scores_gemma":[0.00014668897,0.00090450706,0.2605204,0.0000164254,0.00007820725,0.0035635377,0.0008970603,0.0037513953,0.7252704,0.0007205828,0.004116064,0.000014668666],"about_ca_topic_score_codex":0.0003170883,"about_ca_topic_score_gemma":0.00044913645,"teacher_disagreement_score":0.0014351474,"about_ca_system_score_codex":0.00014351925,"about_ca_system_score_gemma":0.00009869485,"threshold_uncertainty_score":0.0048010945},"labels":[],"label_agreement":null},{"id":"W4414163609","doi":"10.1016/j.ebiom.2025.105919","title":"New standards in HER2-low testing: the CASI-01 comparative methods study","year":2025,"lang":"en","type":"article","venue":"EBioMedicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Saskatchewan Health Authority","funders":"National Cancer Institute; National Institutes of Health","keywords":"Work (physics); MEDLINE; Cancer; Public health; Health policy","score_opus":0.1858812564281991,"score_gpt":0.5752051402724534,"score_spread":0.3893238838442543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414163609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63333416,0.030491807,0.20042087,0.0060755266,0.0020352695,0.0114314975,0.0079768505,0.0011456485,0.10708836],"genre_scores_gemma":[0.83691597,0.0027813476,0.13229468,0.0037141722,0.00054465304,0.0089167645,0.007911301,0.00053199613,0.006389182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8476372,0.09252676,0.0061140526,0.014286037,0.037854504,0.0015814989],"domain_scores_gemma":[0.87075263,0.061777137,0.012127504,0.020575497,0.032343987,0.0024232096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13886608,0.0013478512,0.00076019444,0.003472401,0.0015741144,0.004332016,0.0036069003,0.0023913363,0.0032508376],"category_scores_gemma":[0.12604775,0.0006840566,0.0017552,0.0029842346,0.0026052524,0.0013902646,0.0035002953,0.002572332,0.0010711954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022308253,0.0027674495,0.5398623,0.0022780446,0.004031258,0.00044076447,0.005228284,0.0057815337,0.020552317,0.044248987,0.031262457,0.32123843],"study_design_scores_gemma":[0.0027295675,0.02794097,0.60987574,0.0022574463,0.0037309157,0.005555704,0.002290157,0.022857368,0.06284163,0.010800545,0.24865687,0.00046312524],"about_ca_topic_score_codex":0.008581046,"about_ca_topic_score_gemma":0.007478467,"teacher_disagreement_score":0.13886608,"about_ca_system_score_codex":0.0067913923,"about_ca_system_score_gemma":0.0062859096,"threshold_uncertainty_score":0.7344028},"labels":[],"label_agreement":null},{"id":"W4414167666","doi":"10.31557/apjcp.2025.26.9.3175","title":"Effect of HER3 Overexpression on Survival Outcomes in Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Asian Pacific Journal of Cancer Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pancreatic cancer; Biomarker; Overall survival; Cancer; Survival analysis","score_opus":0.029516183761866845,"score_gpt":0.41493590106367617,"score_spread":0.38541971730180935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414167666","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009012265,0.9885002,0.0004808416,0.00022425911,0.000102869424,0.00024188649,0.0011609423,0.000019289368,0.0002574679],"genre_scores_gemma":[0.28988117,0.7032613,0.002181009,0.0008250886,0.000261286,0.0013721085,0.0017678416,0.00003273926,0.0004173943],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9923707,0.0035067978,0.0021697672,0.0008356705,0.0008239969,0.0002930999],"domain_scores_gemma":[0.9799151,0.0152433505,0.0027417983,0.0005682636,0.0012963904,0.00023512071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010946621,0.0019363011,0.013108442,0.005892761,0.00066729763,0.002476021,0.0017892248,0.001746245,0.0031838226],"category_scores_gemma":[0.024361117,0.000980266,0.02950201,0.007953961,0.0005642177,0.0013254156,0.0012492166,0.0012907007,0.0002430555],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018165059,0.00002546724,0.011807958,0.3956211,0.5794182,0.00018155413,0.00010218722,0.00066347927,0.00023195472,0.00012416174,0.0007313398,0.009276133],"study_design_scores_gemma":[0.00031540403,0.00015568222,0.007919927,0.025549771,0.96381706,0.00012869465,0.000051720042,0.00022442306,0.00010725261,0.00015825561,0.0015488699,0.000022895538],"about_ca_topic_score_codex":0.0068100276,"about_ca_topic_score_gemma":0.016392196,"teacher_disagreement_score":0.013108442,"about_ca_system_score_codex":0.0022248833,"about_ca_system_score_gemma":0.0031592336,"threshold_uncertainty_score":0.057891905},"labels":[],"label_agreement":null},{"id":"W4414309670","doi":"10.1200/jco-25-01235","title":"Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Missile; Conjugate; Pandemic; Key (lock); Cancer","score_opus":0.3070645395625706,"score_gpt":0.579066841590274,"score_spread":0.27200230202770337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414309670","genre_codex":"methods","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1228392,0.1261904,0.5523219,0.06932757,0.0039052211,0.0002819132,0.00031079852,0.00089376693,0.12392926],"genre_scores_gemma":[0.82393265,0.05542564,0.08915728,0.009421938,0.0015227176,0.0003114733,0.00012634408,0.00018511062,0.01991688],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986204,0.00064905395,0.000037336144,0.00016642344,0.00037095105,0.00015584465],"domain_scores_gemma":[0.998211,0.0010970884,0.00016224547,0.00023844448,0.000175907,0.000115339404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026316326,0.00061949523,0.0012770486,0.00057607866,0.0010933606,0.0041035875,0.0016632179,0.0028831542,0.0046950374],"category_scores_gemma":[0.0042445045,0.00051253755,0.000641738,0.00033778275,0.0042531975,0.008094404,0.003088441,0.0044566565,0.0013444814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033907016,0.00016681399,0.0013314171,0.0011786902,0.00011844201,0.0012128027,0.00071291253,0.02778391,0.04349197,0.77804,0.010969616,0.13465428],"study_design_scores_gemma":[0.0001007218,0.0012112723,0.0008189995,0.0004470421,0.00010155806,0.0032462163,0.00087393064,0.07329371,0.03110486,0.6799313,0.20872013,0.00015030966],"about_ca_topic_score_codex":0.000560939,"about_ca_topic_score_gemma":0.0010357862,"teacher_disagreement_score":0.0046950374,"about_ca_system_score_codex":0.0013871065,"about_ca_system_score_gemma":0.0011321385,"threshold_uncertainty_score":0.01570642},"labels":[],"label_agreement":null},{"id":"W4414404323","doi":"10.1136/bmjopen-2025-100889","title":"Canadian real-world hybrid longitudinal cohort study of treatment discontinuations and modifications for patients with HER2+ and HER2-low metastatic breast cancer on trastuzumab deruxtecan enrolled in a patient support programme: the HER-TEMPO study protocol","year":2025,"lang":"en","type":"article","venue":"BMJ Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Toronto; EVERSANA (Canada); Mount Sinai Hospital","funders":"Daiichi Sankyo Europe; AstraZeneca Canada; AstraZeneca","keywords":"Metastatic breast cancer; Trastuzumab; Breast cancer; Cohort study; Cohort; Epidemiology; Chemotherapy","score_opus":0.07744423486717573,"score_gpt":0.4562676566616243,"score_spread":0.37882342179444856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414404323","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70210224,0.005066557,0.0021907175,0.0030844745,0.00029101394,0.027341643,0.24790956,0.000089062814,0.01192471],"genre_scores_gemma":[0.8708274,0.0022228288,0.0047749532,0.0021215235,0.00015759023,0.020148544,0.09551763,0.00004299194,0.0041866335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596775,0.0009765817,0.00042360462,0.00082818524,0.00092596933,0.0008779225],"domain_scores_gemma":[0.9912431,0.0005379181,0.0019540878,0.0009931065,0.0036651518,0.0016065703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005263556,0.0014812413,0.0011381129,0.0011400736,0.0034881746,0.0019161152,0.003278251,0.0017756739,0.00556312],"category_scores_gemma":[0.008759632,0.001012769,0.0022555324,0.0044459286,0.001145915,0.0007975568,0.0018870932,0.002352512,0.0010242625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021033296,0.0011968508,0.91213936,0.0017168787,0.0041311006,0.00032944774,0.001791126,0.0012444959,0.0003791441,0.0020130028,0.039711364,0.014314011],"study_design_scores_gemma":[0.0076220795,0.0015399115,0.9534754,0.000805716,0.001863021,0.00021863681,0.0014184124,0.0015866464,0.00016925098,0.0005310679,0.03052846,0.00024147748],"about_ca_topic_score_codex":0.8740165,"about_ca_topic_score_gemma":0.93093985,"teacher_disagreement_score":0.12598348,"about_ca_system_score_codex":0.02623154,"about_ca_system_score_gemma":0.054274384,"threshold_uncertainty_score":0.2534508},"labels":[],"label_agreement":null},{"id":"W4414891572","doi":"10.5858/arpa.2025-0074-oa","title":"Clinicopathologic Features and Genomic Profile of Human Epidermal Growth Factor Receptor 2–Low and Human Epidermal Growth Factor Receptor 2–Ultralow Invasive Breast Carcinomas","year":2025,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health; Sunnybrook Health Science Centre; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Immunohistochemistry; Epidermal growth factor receptor; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Receptor; Hormone; Epidermal growth factor; Breast cancer","score_opus":0.027701960705590223,"score_gpt":0.33101573002568474,"score_spread":0.3033137693200945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414891572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99918705,0.00016421464,0.00021824642,0.0000133612475,0.000004274492,0.000016323103,0.00010587711,0.000004513054,0.00028608335],"genre_scores_gemma":[0.9994598,0.000044610104,0.00016857898,0.00001093953,0.000012403441,0.000017585977,0.00019139901,0.0000024256647,0.00009233023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925,0.00016033872,0.0001406735,0.00017935607,0.00014359778,0.00012603555],"domain_scores_gemma":[0.9975464,0.0006579473,0.0009114824,0.00023167115,0.0002458481,0.0004066882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010842574,0.00033615693,0.00031840877,0.0012124365,0.00053604663,0.0005732447,0.00032510152,0.0004279418,0.0018304922],"category_scores_gemma":[0.002686816,0.00032958228,0.00023017378,0.0006159798,0.0006145601,0.00043967506,0.00050991395,0.0002975471,0.0005767945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019044914,0.000025209329,0.99617034,0.000009195498,0.000016824355,0.00065718987,0.00005935325,0.00003506203,0.0014362042,0.000019163183,0.00007113599,0.0013099356],"study_design_scores_gemma":[0.000015864827,0.00014620222,0.9896484,0.000005700819,0.000023784401,0.008906176,0.00031638495,0.00016897164,0.00045092695,0.000054539327,0.00025382102,0.000009283359],"about_ca_topic_score_codex":0.0007036599,"about_ca_topic_score_gemma":0.0012675106,"teacher_disagreement_score":0.0018304922,"about_ca_system_score_codex":0.0003029994,"about_ca_system_score_gemma":0.0002687141,"threshold_uncertainty_score":0.0061236024},"labels":[],"label_agreement":null},{"id":"W4415301317","doi":"10.3390/curroncol32100575","title":"Trastuzumab Deruxtecan-Associated Interstitial Lung Disease: Real-World Insights from a Tertiary Care Center","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Interstitial lung disease; Common Terminology Criteria for Adverse Events; Logistic regression; Lung cancer; Adverse effect; Univariate analysis; Tertiary care; Retrospective cohort study","score_opus":0.05646300562863377,"score_gpt":0.45100709929598465,"score_spread":0.3945440936673509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415301317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973775,0.00058095943,0.00012297493,0.00047495298,0.0000071265167,0.000039917944,0.0005999177,0.0000065410504,0.00079003547],"genre_scores_gemma":[0.99826556,0.0004991403,0.00019878054,0.0003771219,0.00004313111,0.00001739818,0.00051016756,0.000003678882,0.00008503883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982943,0.00047541494,0.00023689966,0.00029655502,0.00035404295,0.00034270625],"domain_scores_gemma":[0.9946925,0.0010752562,0.0024271691,0.0002283277,0.00058913033,0.0009877279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012649845,0.00031983416,0.00038090118,0.001228755,0.0009929158,0.0013869089,0.0006543747,0.0005397718,0.0018778034],"category_scores_gemma":[0.0034162058,0.00035003872,0.00031814724,0.0020667897,0.00051628257,0.00083007314,0.0015067369,0.0006826294,0.00028812754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000993758,0.00014210172,0.9924446,0.000047454258,0.00003826918,0.0020312218,0.000706828,0.00007600965,0.00025779463,0.00004359517,0.00071753317,0.0033952976],"study_design_scores_gemma":[0.00005531903,0.00037829464,0.98844993,0.00011151894,0.000061155195,0.00521892,0.0033277692,0.0006506173,0.00025040365,0.00006915353,0.0014028641,0.000023860333],"about_ca_topic_score_codex":0.012742398,"about_ca_topic_score_gemma":0.02282565,"teacher_disagreement_score":0.012742398,"about_ca_system_score_codex":0.002263678,"about_ca_system_score_gemma":0.002200691,"threshold_uncertainty_score":0.025336444},"labels":[],"label_agreement":null},{"id":"W4415306169","doi":"10.1016/j.ctarc.2025.101021","title":"Retrospective database analysis to assess treatment patterns, clinical outcomes, and healthcare resource utilization in metastatic or recurrent HER2-positive breast cancer in Alberta","year":2025,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Alberta Cancer Foundation; University of Calgary; Foothills Medical Centre","funders":"AstraZeneca","keywords":"Metastatic breast cancer; Breast cancer; Recurrent breast cancer; Health care; Medical diagnosis; Retrospective cohort study; Cancer treatment","score_opus":0.37454311074845226,"score_gpt":0.5960753306706257,"score_spread":0.22153221992217342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415306169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626164,0.0013456692,0.00039853086,0.00017873311,0.000014534718,0.00026096817,0.032895833,0.00003439457,0.002254892],"genre_scores_gemma":[0.9806333,0.0006313243,0.0006286736,0.00013863291,0.000011601581,0.00012833266,0.017367018,0.000008480859,0.00045261753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796677,0.0002120412,0.00023771574,0.00034469832,0.0007866495,0.00045226264],"domain_scores_gemma":[0.99494725,0.0004533366,0.0016085458,0.00037633316,0.0020454987,0.0005690257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016843644,0.00043365135,0.0005650814,0.0040598135,0.0014503483,0.001290018,0.001615949,0.00040211843,0.0014308977],"category_scores_gemma":[0.004384834,0.00043268673,0.000726046,0.011968365,0.00043833716,0.00028576658,0.0008848298,0.0004585224,0.00020942473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091651746,0.000020392486,0.99699235,0.000042596137,0.000096098585,0.000062913576,0.00009602694,0.00015128481,0.00005899006,0.000051729883,0.00086941454,0.001466586],"study_design_scores_gemma":[0.000019661153,0.000028931598,0.9975327,0.000039115675,0.00007908059,0.00013000552,0.00041828986,0.000558803,0.000051694875,0.000018927954,0.0011144927,0.000008187854],"about_ca_topic_score_codex":0.9723188,"about_ca_topic_score_gemma":0.9720625,"teacher_disagreement_score":0.027681172,"about_ca_system_score_codex":0.021349067,"about_ca_system_score_gemma":0.023970935,"threshold_uncertainty_score":0.15489906},"labels":[],"label_agreement":null},{"id":"W4415321954","doi":"10.1016/j.annonc.2025.10.013","title":"Antibody–drug conjugates in combination therapy: defining the next chapter","year":2025,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Conjugate; Cancer","score_opus":0.1082992593934442,"score_gpt":0.4806774783455847,"score_spread":0.3723782189521405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415321954","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059955393,0.04762555,0.00039697866,0.03649575,0.9136094,0.000032762608,0.000026399413,0.000041120962,0.0017121003],"genre_scores_gemma":[0.0005766387,0.03119753,0.00035274806,0.03234354,0.9288558,0.00003678461,0.000017863831,0.000032215517,0.0065868837],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926634,0.0019398357,0.0009904339,0.0006509771,0.0033926747,0.00036273044],"domain_scores_gemma":[0.98059195,0.010103408,0.0011855441,0.00033459804,0.0054664416,0.0023181338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013334981,0.0030243506,0.0036579536,0.002572375,0.0020923316,0.0074376073,0.0034370194,0.01790349,0.006050389],"category_scores_gemma":[0.018244607,0.0013007338,0.0028816727,0.0014521609,0.0028211398,0.0064437203,0.0018084896,0.026442051,0.004842773],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010011846,0.00003833618,0.000030881227,0.00071634835,0.00005642259,0.00014084067,0.000021566446,0.00008011241,0.00021622101,0.0013964487,0.9723121,0.02489062],"study_design_scores_gemma":[0.00010480657,0.0000917289,0.00012892166,0.00053639465,0.0000893521,0.00028376223,0.000030777275,0.00023312635,0.00018930674,0.0015602988,0.9967284,0.000023101047],"about_ca_topic_score_codex":0.0011219537,"about_ca_topic_score_gemma":0.0045117135,"teacher_disagreement_score":0.01790349,"about_ca_system_score_codex":0.0033594319,"about_ca_system_score_gemma":0.003260907,"threshold_uncertainty_score":0.070522904},"labels":[],"label_agreement":null},{"id":"W4415390112","doi":"10.1016/j.annonc.2025.10.019","title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Daiichi Sankyo Europe; Allergan; Genentech; Servier; Astellas Pharma; Seagen; Eisai; Jazz Pharmaceuticals; Taiho Pharmaceutical; Gilead Sciences; Relay Therapeutics; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Les Laboratories Pierre Fabre; Nipro","keywords":"Pertuzumab; Trastuzumab; Neoadjuvant therapy; Breast cancer; Clinical trial; Chemotherapy","score_opus":0.08287070357006318,"score_gpt":0.4633421922553893,"score_spread":0.3804714886853261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415390112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817109,0.0049667386,0.0005754453,0.0009251812,0.00042929035,0.0065047713,0.0015931228,0.000093178496,0.003201281],"genre_scores_gemma":[0.9759916,0.0040403544,0.0018606989,0.0015454758,0.0005079751,0.00808583,0.0028033236,0.000034915865,0.005129902],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990758,0.0005624028,0.00005152845,0.00011739407,0.00007200279,0.000120799414],"domain_scores_gemma":[0.99883455,0.00024073296,0.00027992946,0.00008808195,0.000063098625,0.0004936242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029639797,0.0013965653,0.001798024,0.00033599976,0.00034651646,0.0011408025,0.0006735473,0.0012840042,0.0053754584],"category_scores_gemma":[0.0014773083,0.000562075,0.0011307601,0.00040542518,0.0013401003,0.0008674113,0.0005242187,0.0026396434,0.0011645516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96420383,0.01041343,0.0009870244,0.00051259797,0.00037853347,0.00003804104,0.000064006985,0.0005059302,0.0036020486,0.00014285112,0.0014596641,0.017692039],"study_design_scores_gemma":[0.9237497,0.07322795,0.0012025351,0.000036384463,0.000131908,0.00004643757,0.000011940095,0.00013271645,0.0003728829,0.00007288786,0.0010073116,0.000007314499],"about_ca_topic_score_codex":0.0006643093,"about_ca_topic_score_gemma":0.0020949915,"teacher_disagreement_score":0.0053754584,"about_ca_system_score_codex":0.0012208074,"about_ca_system_score_gemma":0.0018618106,"threshold_uncertainty_score":0.017982662},"labels":[],"label_agreement":null},{"id":"W4415755512","doi":"10.1016/j.atherosclerosis.2025.120567","title":"Loss of ADAM17 in smooth muscle cells enhances their transformation to macrophage-like cells leading to more severe atherosclerosis in mice","year":2025,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta; Canada Research Chairs; Heart and Stroke Foundation of Canada","keywords":"Smooth muscle; Transformation (genetics); Regulator; Function (biology); Vascular smooth muscle; Loss function","score_opus":0.026766718112091595,"score_gpt":0.3158507381304776,"score_spread":0.289084020018386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415755512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936737,0.00081477995,0.002528939,0.00031900214,0.00011631809,0.000056710756,0.00086504716,0.00022465181,0.0014008331],"genre_scores_gemma":[0.9852364,0.0010565994,0.0025760895,0.00019823838,0.00006529613,0.000094995885,0.0009859478,0.00013935301,0.009647162],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99931645,0.00013173865,0.00008538691,0.00011070583,0.00013442949,0.00022132267],"domain_scores_gemma":[0.9991768,0.00008358949,0.00026498493,0.000094420415,0.0000392891,0.00034085504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043228458,0.0009884683,0.0006057708,0.0011929747,0.00036545206,0.0007208274,0.00035808672,0.0010338741,0.002959228],"category_scores_gemma":[0.0002642731,0.0006062571,0.0010460848,0.00034089718,0.0005772793,0.00047693303,0.00046266906,0.0028292132,0.0012184189],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059162406,0.00017575483,0.00025772568,0.000031535037,0.000016373819,0.00023453127,0.000038411108,0.00010015928,0.9975426,0.0002673585,0.000077752426,0.0006661502],"study_design_scores_gemma":[0.00011119939,0.0009782856,0.0045844885,0.000016446615,0.000058276288,0.00070148264,0.00012187894,0.0013272448,0.988896,0.00017184638,0.0030176481,0.000015273281],"about_ca_topic_score_codex":0.0008214633,"about_ca_topic_score_gemma":0.0013270917,"teacher_disagreement_score":0.002959228,"about_ca_system_score_codex":0.00040005578,"about_ca_system_score_gemma":0.00035485576,"threshold_uncertainty_score":0.009899557},"labels":[],"label_agreement":null},{"id":"W4415820113","doi":"10.3390/curroncol32110606","title":"Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministero della Salute","keywords":"Trastuzumab; Liver injury; Breast cancer; Refractory (planetary science); Transaminase; Liver function; Liver function tests; Lung; Lung cancer","score_opus":0.09664931523836957,"score_gpt":0.4844381077683479,"score_spread":0.38778879252997833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415820113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95985836,0.013236521,0.006810462,0.0053593395,0.0005402697,0.00032612882,0.00032558703,0.00033364884,0.013209642],"genre_scores_gemma":[0.99047905,0.003493983,0.00131113,0.001361606,0.0015695486,0.000038590977,0.00014179811,0.000033309374,0.0015709893],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.998923,0.00017828574,0.00013402294,0.00022702714,0.00015669661,0.0003809219],"domain_scores_gemma":[0.99749786,0.00081477547,0.0006082849,0.00028246976,0.00015098337,0.0006456481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006096695,0.0024771353,0.0016772065,0.0033385155,0.002777798,0.0025866122,0.0013075406,0.005529031,0.0026392494],"category_scores_gemma":[0.0034168132,0.0015396938,0.0017471578,0.0021142995,0.0018604305,0.0029273832,0.002419667,0.004057971,0.0012752521],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021698617,0.00003827363,0.0044012954,0.000023528975,0.000012302504,0.9940897,0.000117127674,0.000053179185,0.00023408685,0.000095045485,0.00021664552,0.00069715915],"study_design_scores_gemma":[0.0000069208318,0.000029540612,0.0015601319,0.0000089406385,0.000013229269,0.9976712,0.000060415507,0.0001427387,0.00015755976,0.00006808614,0.0002741669,0.000007066964],"about_ca_topic_score_codex":0.002669482,"about_ca_topic_score_gemma":0.0024975603,"teacher_disagreement_score":0.005529031,"about_ca_system_score_codex":0.0016650987,"about_ca_system_score_gemma":0.0010726874,"threshold_uncertainty_score":0.012081206},"labels":[],"label_agreement":null},{"id":"W4415937477","doi":"10.1200/oa-25-00053","title":"Enfortumab Vedotin in Patients With Previously Treated Advanced Breast Cancer in the Phase II EV-202 Study","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Rash; Maculopapular rash; Breast cancer; Adverse effect; Regimen; Clinical endpoint; Phases of clinical research; Toxicity; Metastatic breast cancer","score_opus":0.01476243486084391,"score_gpt":0.4208429098651232,"score_spread":0.4060804750042793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415937477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912305,0.0041857553,0.00032600528,0.00021087419,0.00007640169,0.0008293017,0.0005314999,0.000045929955,0.0025636677],"genre_scores_gemma":[0.99299777,0.0021804518,0.00066119677,0.00051971525,0.00008206105,0.0006009647,0.0010967263,0.000011054012,0.0018499562],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998603,0.00007332503,0.0000069350117,0.000016523065,0.000017637709,0.000025253867],"domain_scores_gemma":[0.99984086,0.000031190302,0.00003670842,0.000013079508,0.0000116236615,0.00006642746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080212794,0.000369341,0.000541891,0.00011415329,0.00012002391,0.00044367058,0.00031606606,0.000384035,0.0016232436],"category_scores_gemma":[0.00040475803,0.00016124846,0.0004132517,0.00013783878,0.00019999724,0.00030363153,0.00015629068,0.0008944925,0.0002904387],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4684055,0.048885062,0.0383078,0.0020364823,0.0017074826,0.0005379529,0.00026526648,0.005429692,0.064522415,0.001121843,0.008867134,0.35991338],"study_design_scores_gemma":[0.44729373,0.4704777,0.04061016,0.00023809526,0.000968362,0.0009838564,0.00018889958,0.004874329,0.010595837,0.0007364893,0.022992188,0.000040368082],"about_ca_topic_score_codex":0.00036481014,"about_ca_topic_score_gemma":0.0014114194,"teacher_disagreement_score":0.0016232436,"about_ca_system_score_codex":0.00033790953,"about_ca_system_score_gemma":0.00055401237,"threshold_uncertainty_score":0.005430281},"labels":[],"label_agreement":null},{"id":"W4415939974","doi":"10.1016/j.annonc.2025.08.720","title":"291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Trastuzumab; Paclitaxel; Breast cancer; Chemotherapy","score_opus":0.06240779686711495,"score_gpt":0.42127854042782764,"score_spread":0.3588707435607127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055696,0.0022597427,0.00018626473,0.0007303807,0.0006199967,0.0002750678,0.0007218645,0.00003834008,0.0046114046],"genre_scores_gemma":[0.9900147,0.0023103966,0.00061457034,0.000632126,0.00030219473,0.00027625708,0.0014651314,0.0000234558,0.0043611103],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99979967,0.00006131535,0.0000139692775,0.00003630376,0.000018072642,0.000070690476],"domain_scores_gemma":[0.9996793,0.00008866283,0.00003570389,0.000029630884,0.0000113970955,0.00015522778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051764457,0.00060151704,0.0012910961,0.00029614734,0.00021297201,0.0008772602,0.0004714057,0.0007424838,0.008541778],"category_scores_gemma":[0.00062644907,0.00025765292,0.0010068292,0.00023971518,0.00062541227,0.00080772914,0.00036250902,0.0014854656,0.0008791416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8796234,0.016660815,0.0028852671,0.0005330391,0.00067205203,0.0001336606,0.00010292128,0.0014209335,0.014932476,0.0006964119,0.0035849358,0.07875403],"study_design_scores_gemma":[0.3157194,0.6234735,0.026211502,0.00028792754,0.0022514053,0.0006444884,0.00033523465,0.0034900357,0.011900309,0.0012178257,0.014380401,0.00008799464],"about_ca_topic_score_codex":0.0013438815,"about_ca_topic_score_gemma":0.0046202373,"teacher_disagreement_score":0.008541778,"about_ca_system_score_codex":0.00064712716,"about_ca_system_score_gemma":0.001138585,"threshold_uncertainty_score":0.028575122},"labels":[],"label_agreement":null},{"id":"W4415940538","doi":"10.1016/j.annonc.2025.08.978","title":"555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); McGill University Health Centre; Santé Montérégie","funders":"AstraZeneca","keywords":"Durvalumab; Begonia; Breast cancer; Cancer","score_opus":0.18474838880903363,"score_gpt":0.5169851682150306,"score_spread":0.33223677940599694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97957736,0.008438461,0.00040487503,0.00051481964,0.000160045,0.0005412569,0.002713812,0.00011332981,0.0075359666],"genre_scores_gemma":[0.979267,0.0057822717,0.00110015,0.0011039606,0.00007432085,0.0003055792,0.0069118296,0.00003555481,0.0054193037],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99982834,0.00006684363,0.000008895722,0.00002856072,0.000016974811,0.00005030622],"domain_scores_gemma":[0.9998834,0.000020534544,0.000017365228,0.0000126248715,0.000005674711,0.000060270744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006145255,0.0005174268,0.0007952562,0.00027382295,0.00016790231,0.00053317397,0.0004020385,0.00030223627,0.0035656132],"category_scores_gemma":[0.00025351482,0.00017746065,0.00053525605,0.00031703632,0.00027477014,0.00029166133,0.00023311896,0.00090279104,0.0007768698],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39463145,0.016167004,0.022115812,0.0014679111,0.0029458795,0.00030711453,0.00022116305,0.0041589066,0.06037987,0.0010578302,0.014454779,0.48209238],"study_design_scores_gemma":[0.4423746,0.3435446,0.1344369,0.00038810575,0.004288594,0.0012199992,0.00023557435,0.0034641125,0.013712974,0.0009551731,0.05530552,0.00007375155],"about_ca_topic_score_codex":0.0025167167,"about_ca_topic_score_gemma":0.010743679,"teacher_disagreement_score":0.0035656132,"about_ca_system_score_codex":0.0008515964,"about_ca_system_score_gemma":0.0008076887,"threshold_uncertainty_score":0.011928141},"labels":[],"label_agreement":null},{"id":"W4415940769","doi":"10.1016/j.annonc.2025.08.2572","title":"1948P Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"AbbVie","keywords":"Phases of clinical research; Conjugate; Wild type; Overall survival; Adverse effect; Clinical trial","score_opus":0.09948266861913178,"score_gpt":0.44885699711055543,"score_spread":0.34937432849142364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961027,0.0012468399,0.000116212985,0.00034507556,0.000083725354,0.00007654956,0.00066806155,0.000013057998,0.0013477891],"genre_scores_gemma":[0.99662375,0.00047770637,0.000105282896,0.0003635249,0.00007314688,0.00008365339,0.0012635658,0.0000051475245,0.0010042032],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997749,0.00009450559,0.000012724123,0.000041894946,0.000021293965,0.000054685832],"domain_scores_gemma":[0.9997627,0.000055286262,0.00005277802,0.000017285742,0.000014294268,0.0000976198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060535176,0.00034031205,0.0008691218,0.00011222179,0.00017901551,0.000655721,0.0002561141,0.0005096571,0.0019519504],"category_scores_gemma":[0.00062462833,0.00014784325,0.0010367271,0.00023288548,0.00030246083,0.00059373135,0.00029173892,0.001325651,0.00036389715],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7749258,0.0041902894,0.08365557,0.000481779,0.0034875267,0.00034684612,0.00016181704,0.0034913567,0.010991003,0.00062512996,0.005698005,0.11194477],"study_design_scores_gemma":[0.36035427,0.26541162,0.345326,0.00017809683,0.0055586756,0.0007256824,0.00029160548,0.0045191175,0.003326281,0.0018182897,0.01238762,0.00010269678],"about_ca_topic_score_codex":0.0007320236,"about_ca_topic_score_gemma":0.0021949983,"teacher_disagreement_score":0.0019519504,"about_ca_system_score_codex":0.00071945554,"about_ca_system_score_gemma":0.0004535751,"threshold_uncertainty_score":0.006529987},"labels":[],"label_agreement":null},{"id":"W4415940977","doi":"10.1016/j.annonc.2025.08.2574","title":"1950P Ocular surface disorders in patients with c-Met protein–overexpressing NSCLC treated with telisotuzumab vedotin in the LUMINOSITY study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"AbbVie","keywords":"Antibody-drug conjugate; Phases of clinical research; Conjugate; Adverse effect; Clinical trial; Brentuximab vedotin","score_opus":0.04071054316473132,"score_gpt":0.38936537763969814,"score_spread":0.3486548344749668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984616,0.00041023715,0.000047116187,0.000074665935,0.000011123859,0.000020475192,0.00019991073,0.0000027126166,0.0007722038],"genre_scores_gemma":[0.9991135,0.00013998651,0.000028979739,0.00007154915,0.000020951902,0.00001180557,0.0003205418,0.0000012969832,0.00029136936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997919,0.000043297197,0.000017929895,0.00005238441,0.000042416283,0.000052154217],"domain_scores_gemma":[0.999731,0.000045233704,0.00008620495,0.000015642463,0.000029973366,0.0000919184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029800335,0.000360539,0.00044632368,0.0003880284,0.00039614274,0.00066611834,0.00027370208,0.00046962203,0.0013840187],"category_scores_gemma":[0.00052106206,0.00022505254,0.00081432593,0.0005660313,0.00027734076,0.000570794,0.00027216552,0.00064826605,0.00019412946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00916764,0.00048683133,0.9759731,0.000045957277,0.00050214614,0.0016602722,0.000081774946,0.000108674525,0.0034059118,0.00011253924,0.000522833,0.0079323],"study_design_scores_gemma":[0.0008875731,0.0022558186,0.9930159,0.000012911698,0.00041372774,0.00155006,0.00016478391,0.00034664627,0.00030373386,0.00007262966,0.000961822,0.000014339212],"about_ca_topic_score_codex":0.0030560554,"about_ca_topic_score_gemma":0.0038856375,"teacher_disagreement_score":0.0030560554,"about_ca_system_score_codex":0.0006349942,"about_ca_system_score_gemma":0.00040833128,"threshold_uncertainty_score":0.0060765147},"labels":[],"label_agreement":null},{"id":"W4415941146","doi":"10.1016/j.annonc.2025.08.690","title":"262eP Comprehensive HER2 isoform expression analysis reveals subgroup-specific profiles and implications for ADC resistance","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Gene isoform; Expression (computer science); Gene expression; Focus (optics)","score_opus":0.16175002698525984,"score_gpt":0.48723935820992287,"score_spread":0.32548933122466306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937797,0.00048339367,0.0008457145,0.00011509743,0.000009919042,0.000017002956,0.001710654,0.000050204333,0.0029882358],"genre_scores_gemma":[0.99278426,0.00032343692,0.0009253734,0.000100806814,0.000014726037,0.000019507508,0.0032923052,0.00003945574,0.0025001375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998318,0.000015532645,0.000014324569,0.000044413064,0.000040072082,0.000053860276],"domain_scores_gemma":[0.99986327,0.00002143115,0.000026424139,0.00003209621,0.00003430091,0.000022449392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031814846,0.00028681196,0.00032552925,0.0007136773,0.00026323355,0.00076554326,0.0002149031,0.0003155118,0.003155699],"category_scores_gemma":[0.0003751749,0.00013019063,0.00031257974,0.00064082036,0.00019301615,0.00030866248,0.00034081738,0.00038744602,0.00093904644],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022523953,0.00014470037,0.1919943,0.00010993808,0.00022176442,0.0017317005,0.00020066832,0.0007590852,0.7488724,0.00059681624,0.0021964132,0.050919794],"study_design_scores_gemma":[0.00007996285,0.0006251779,0.8455432,0.00003445784,0.00040363497,0.007528123,0.00054847886,0.0035585982,0.12276523,0.0013128264,0.017565165,0.000035244684],"about_ca_topic_score_codex":0.0008515372,"about_ca_topic_score_gemma":0.0013776309,"teacher_disagreement_score":0.003155699,"about_ca_system_score_codex":0.00026214484,"about_ca_system_score_gemma":0.00015413188,"threshold_uncertainty_score":0.010556877},"labels":[],"label_agreement":null},{"id":"W4415941485","doi":"10.1016/j.annonc.2025.08.1705","title":"1065MO First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Ovarian cancer; Conjugate; Folate receptor; Phases of clinical research; Topoisomerase; Chemotherapy","score_opus":0.05104004993616807,"score_gpt":0.4325312644285181,"score_spread":0.38149121449235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657553,0.0014030697,0.00018592626,0.00012674861,0.00005025472,0.00022276219,0.00032210982,0.000034889694,0.0010787167],"genre_scores_gemma":[0.997488,0.000549448,0.00017662397,0.00016682838,0.00004791945,0.000082544386,0.00048024562,0.000009870977,0.0009985095],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999584,0.0001687883,0.000020054404,0.00008403223,0.000033682893,0.00010945288],"domain_scores_gemma":[0.99963284,0.00007112123,0.000047693968,0.000047607806,0.00001936184,0.00018145912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007908511,0.0008172842,0.0020052735,0.00042688407,0.0005010685,0.00089083595,0.00041825007,0.0009917709,0.0019642015],"category_scores_gemma":[0.0007322542,0.00041868992,0.0013242761,0.00037482262,0.0006867432,0.0005587086,0.0002574955,0.0020192051,0.0005634922],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6703487,0.052766994,0.06571107,0.0004843298,0.0023744183,0.001939521,0.00076207257,0.0031636655,0.060147382,0.0003687561,0.0022360526,0.13969706],"study_design_scores_gemma":[0.06532418,0.8332872,0.07771052,0.000035914363,0.0014800449,0.0011529471,0.00018973982,0.002200782,0.012413655,0.00013865969,0.005998754,0.00006756896],"about_ca_topic_score_codex":0.0021439174,"about_ca_topic_score_gemma":0.002692476,"teacher_disagreement_score":0.0021439174,"about_ca_system_score_codex":0.0008387032,"about_ca_system_score_gemma":0.0007392009,"threshold_uncertainty_score":0.0065709352},"labels":[],"label_agreement":null},{"id":"W4415941514","doi":"10.1016/j.annonc.2025.08.3571","title":"2959eP EGFR-targeted monoclonal antibodies administered to patients with colon cancer can increase the risk of bone fracture","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Monoclonal antibody; Colorectal cancer; Monoclonal; Risk factor; Antibody; Pathologic fracture; Cancer","score_opus":0.050522614143201895,"score_gpt":0.4299389961492394,"score_spread":0.3794163820060375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97033453,0.015066265,0.0006829287,0.0018065317,0.0002399261,0.0000509638,0.00045823352,0.00005087969,0.011309839],"genre_scores_gemma":[0.9943159,0.002305431,0.0003726315,0.00069407246,0.00012228297,0.000010114597,0.00021324617,0.000005581711,0.0019606277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996927,0.00010075899,0.000015077677,0.000026487798,0.00011922392,0.00004575477],"domain_scores_gemma":[0.99941945,0.00023398371,0.00019328037,0.000025295001,0.00005126194,0.00007678907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002904526,0.0001576099,0.0003038945,0.00026388513,0.00023648821,0.000322234,0.00014967775,0.0005225188,0.003871373],"category_scores_gemma":[0.0012638723,0.00015282909,0.0006445146,0.00035018043,0.00013017052,0.00010120132,0.0001338825,0.0007759087,0.00030070552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014159458,0.0020383135,0.77520025,0.0003613233,0.0014868448,0.0019977666,0.00007860924,0.0004251878,0.02045011,0.00039319394,0.005954198,0.17745465],"study_design_scores_gemma":[0.0005050775,0.005612074,0.98065805,0.00011655489,0.00068410666,0.0030921667,0.00009217973,0.00058553764,0.0021229817,0.00037326422,0.006142199,0.000015717196],"about_ca_topic_score_codex":0.001832363,"about_ca_topic_score_gemma":0.0044579245,"teacher_disagreement_score":0.003871373,"about_ca_system_score_codex":0.00022763466,"about_ca_system_score_gemma":0.00039611838,"threshold_uncertainty_score":0.012951076},"labels":[],"label_agreement":null},{"id":"W4415942079","doi":"10.1016/j.annonc.2025.08.2701","title":"2080eTiP A phase I/IIa, open-label, dose-finding study of the safety, pharmacokinetics, and preliminary efficacy of iza-bren (BL-B01D1) combinations in patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Lung cancer; Conjugate; Solid tumor; Phases of clinical research; Monoclonal antibody; Response Evaluation Criteria in Solid Tumors; Antibody; Cancer","score_opus":0.1152148650888674,"score_gpt":0.5120847254551094,"score_spread":0.396869860366242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895778,0.0019079802,0.0012354765,0.0005606595,0.00011859912,0.0013561823,0.0018278421,0.00033708118,0.0030784986],"genre_scores_gemma":[0.9843448,0.001664191,0.0030592713,0.00076334545,0.00015059128,0.0011799188,0.004516718,0.00011187643,0.004209358],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99960583,0.00019113364,0.000012990705,0.00006112891,0.000039648497,0.000089314],"domain_scores_gemma":[0.9994734,0.00011391919,0.000078493176,0.000055466007,0.000031480547,0.0002472977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001409861,0.0015296428,0.0019363066,0.00075342605,0.00049318076,0.0011076723,0.0010140892,0.0012286454,0.003480271],"category_scores_gemma":[0.0008203283,0.0007064588,0.0011441337,0.0006145144,0.0010033739,0.0008809197,0.0002940289,0.0043350155,0.0011804028],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6275006,0.07761142,0.006466414,0.0006493936,0.0013177936,0.0007206231,0.00040257524,0.005529585,0.13063373,0.0010006017,0.009973416,0.13819386],"study_design_scores_gemma":[0.38767093,0.5736921,0.012758472,0.00003881183,0.0005484896,0.0008033295,0.00010682751,0.0037879727,0.013505869,0.00050978747,0.0065097655,0.00006773011],"about_ca_topic_score_codex":0.0016187284,"about_ca_topic_score_gemma":0.0033125721,"teacher_disagreement_score":0.003480271,"about_ca_system_score_codex":0.0010744225,"about_ca_system_score_gemma":0.0016290225,"threshold_uncertainty_score":0.0116426945},"labels":[],"label_agreement":null},{"id":"W4415942575","doi":"10.1016/j.annonc.2025.08.1043","title":"621TiP BNT323-03: A phase I/II trial of BNT323/DB-1303 (HER2 ADC) with BNT327 (PD-L1 x VEGF-A) in patients (pts) with advanced breast cancer (BC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Tolerability; Breast cancer; Limiting; Phases of clinical research; Cancer; Topoisomerase; Clinical trial","score_opus":0.07087206971817465,"score_gpt":0.4770906131229302,"score_spread":0.40621854340475555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97843826,0.0046179043,0.0007737835,0.0016285249,0.00031945613,0.0028678018,0.003382738,0.00043376148,0.0075378385],"genre_scores_gemma":[0.96739936,0.004619653,0.002635394,0.0022974766,0.00018939184,0.0026566463,0.008925504,0.000097640375,0.011178895],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997967,0.00006402665,0.000009903273,0.00003456681,0.000022011343,0.00007275714],"domain_scores_gemma":[0.9997223,0.000020951236,0.000029429051,0.000014989233,0.000014272236,0.00019803544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008835404,0.0012590477,0.0013058996,0.000320638,0.00032478524,0.0010052128,0.00088873506,0.00109974,0.006706785],"category_scores_gemma":[0.00044037827,0.00043518626,0.00086064026,0.00042101645,0.0006763938,0.0006074593,0.00039049904,0.0033731947,0.0019817038],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51188946,0.04435636,0.00766212,0.0013140684,0.0016912571,0.0005304339,0.00032146618,0.0042537306,0.0955747,0.0010387969,0.02287716,0.30849046],"study_design_scores_gemma":[0.6519003,0.30870795,0.013609064,0.000085749845,0.0006691494,0.0006955558,0.00008422099,0.0023495639,0.0074127372,0.0005572864,0.0138781285,0.000050207556],"about_ca_topic_score_codex":0.0029203158,"about_ca_topic_score_gemma":0.006948314,"teacher_disagreement_score":0.006706785,"about_ca_system_score_codex":0.0010572709,"about_ca_system_score_gemma":0.0017362839,"threshold_uncertainty_score":0.02243638},"labels":[],"label_agreement":null},{"id":"W4416018995","doi":"10.1016/j.ijgc.2025.102238","title":"FIRST-LINE LENVATINIB + PEMBROLIZUMAB VERSUS CHEMOTHERAPY FOR ADVANCED OR RECURRENT ENDOMETRIAL CANCER: ADDITIONAL 1-YEAR FOLLOW-UP RESULTS FROM ENGOT-EN9/LEAP-001","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Pembrolizumab; Lenvatinib; Chemotherapy; MEDLINE; Compassionate Use","score_opus":0.09522776136698008,"score_gpt":0.43349187069703443,"score_spread":0.33826410933005435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416018995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914795,0.0033119514,0.00023613108,0.00028544816,0.0001294837,0.00023953847,0.0030280487,0.00003506476,0.0012547865],"genre_scores_gemma":[0.9848016,0.0021315797,0.00054199476,0.0008964051,0.00019261093,0.00032559544,0.008458015,0.000024740568,0.0026273695],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9987662,0.00044990037,0.000077172175,0.0002768274,0.00011740315,0.00031255058],"domain_scores_gemma":[0.99836844,0.0003824039,0.00039223954,0.00025385464,0.00009129219,0.0005117593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027478351,0.0009789892,0.0023508978,0.00044422812,0.000468665,0.0011995638,0.00078321964,0.0012680576,0.003222472],"category_scores_gemma":[0.0018656257,0.00039075248,0.0037584386,0.0005340407,0.0004740913,0.0014426799,0.00048237471,0.0027644525,0.00075094955],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8460257,0.017464587,0.039246373,0.0005431566,0.0086574,0.0002817198,0.0001646352,0.0024687382,0.0057295943,0.000121044104,0.0028981655,0.0763988],"study_design_scores_gemma":[0.19307686,0.34044346,0.43698427,0.00023284885,0.01532985,0.0006549636,0.0003312326,0.0031654201,0.0029791067,0.0005202931,0.0061658835,0.00011578106],"about_ca_topic_score_codex":0.0027719238,"about_ca_topic_score_gemma":0.005582757,"teacher_disagreement_score":0.003222472,"about_ca_system_score_codex":0.0012544928,"about_ca_system_score_gemma":0.0010234397,"threshold_uncertainty_score":0.014532089},"labels":[],"label_agreement":null},{"id":"W4416019198","doi":"10.1016/j.ijgc.2025.102156","title":"PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Bevacizumab; Pembrolizumab; Chemotherapy; Cervical cancer; Monoclonal","score_opus":0.103389803524005,"score_gpt":0.4244518838935613,"score_spread":0.3210620803695563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416019198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990449,0.0035584872,0.00017039615,0.00020340896,0.00013292619,0.0003322313,0.0037038105,0.000021263364,0.0014284297],"genre_scores_gemma":[0.9926886,0.0015680705,0.000264776,0.0004084584,0.00008102458,0.000528647,0.00254283,0.0000078514895,0.0019097726],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993987,0.00016580813,0.000045807228,0.0001746756,0.000076407334,0.00013867192],"domain_scores_gemma":[0.9991037,0.00024472587,0.00032562768,0.00006803529,0.00008826606,0.00016963035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015847839,0.00041117985,0.0008431994,0.00031279708,0.0004303989,0.0007460724,0.0005750749,0.0010022698,0.003999353],"category_scores_gemma":[0.0027172626,0.00034534224,0.0022992974,0.0005216597,0.00025266182,0.0010054389,0.00052644446,0.001670037,0.0005713266],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68562496,0.009927021,0.19533609,0.0023970995,0.0148642985,0.00014284742,0.00049098587,0.0005320275,0.003870514,0.00019156269,0.006284409,0.08033826],"study_design_scores_gemma":[0.10725711,0.0930458,0.76310253,0.00093198015,0.025668243,0.00018004769,0.00089115533,0.0007603706,0.0014253238,0.0004671661,0.006175338,0.00009499263],"about_ca_topic_score_codex":0.006225147,"about_ca_topic_score_gemma":0.010389652,"teacher_disagreement_score":0.006225147,"about_ca_system_score_codex":0.000528629,"about_ca_system_score_gemma":0.001037472,"threshold_uncertainty_score":0.013379157},"labels":[],"label_agreement":null},{"id":"W4416019222","doi":"10.1016/j.ijgc.2025.102160","title":"POST-(NEO)ADJUVANT THERAPY OUTCOMES WITH LENVATINIB PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER: RESULTS FROM STUDY 309/KEYNOTE-775 AND ENGOT-EN9/LEAP-001","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Lenvatinib; MEDLINE; Compassionate Use; Nivolumab","score_opus":0.09727618982288361,"score_gpt":0.4481342611936658,"score_spread":0.3508580713707822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416019222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99230736,0.004210456,0.000095340736,0.00029179943,0.00009705182,0.00007736022,0.0021101898,0.0000064034416,0.00080401223],"genre_scores_gemma":[0.99579453,0.0011077648,0.0001156268,0.00026708248,0.00007498007,0.00014064864,0.0016979993,0.000003747141,0.00079763326],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993191,0.00022855251,0.00007764111,0.00015430857,0.000067673674,0.00015273655],"domain_scores_gemma":[0.9988136,0.00026067646,0.00044673684,0.00008456601,0.00013241117,0.00026199938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001309244,0.00034079773,0.00067057513,0.00018673306,0.000280707,0.00053948164,0.00047689688,0.0006583658,0.002291628],"category_scores_gemma":[0.0030731673,0.00020860664,0.0023834738,0.000400881,0.0001768257,0.00069434685,0.00053078774,0.0012685504,0.00029431892],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15168013,0.003515329,0.76991487,0.0017596693,0.012372376,0.00017621455,0.00038033986,0.00037332883,0.0017971271,0.00020126792,0.003460528,0.05436888],"study_design_scores_gemma":[0.007041603,0.014552077,0.9645264,0.00029246914,0.00973247,0.0001038282,0.0003723138,0.00029845696,0.00048131475,0.00023885233,0.00232636,0.00003378155],"about_ca_topic_score_codex":0.0047064666,"about_ca_topic_score_gemma":0.008070443,"teacher_disagreement_score":0.0047064666,"about_ca_system_score_codex":0.00046116894,"about_ca_system_score_gemma":0.0008078988,"threshold_uncertainty_score":0.009358168},"labels":[],"label_agreement":null},{"id":"W4416019250","doi":"10.1016/j.ijgc.2025.102732","title":"PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDY","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Pembrolizumab; Bevacizumab; Placebo; Paclitaxel; Phases of clinical research; Monoclonal; Ovarian cancer","score_opus":0.07765121716790024,"score_gpt":0.45433611366968646,"score_spread":0.3766848965017862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416019250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839951,0.010325754,0.00038712143,0.00075038045,0.0003454518,0.0006514207,0.00094103214,0.0000791467,0.0025245233],"genre_scores_gemma":[0.9890814,0.0047825715,0.00066012423,0.0009856748,0.00025011122,0.0005632901,0.0010686101,0.00002561378,0.002582706],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99967206,0.0001550191,0.000019791096,0.000059343143,0.000028212371,0.000065583714],"domain_scores_gemma":[0.99951077,0.00014886657,0.00012134654,0.00003402496,0.000020462392,0.00016449986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012018186,0.00089978287,0.0018958594,0.0003316509,0.00025841137,0.0008862486,0.00057847204,0.0009181411,0.0034282792],"category_scores_gemma":[0.0012449377,0.00037854566,0.0018779517,0.00039768577,0.0004859181,0.0010036181,0.00027564022,0.0027139322,0.00067235634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9194792,0.0057845907,0.0012006451,0.00087754,0.0022757528,0.000050842853,0.00006940148,0.0009663919,0.004320254,0.00013883122,0.0014113671,0.06342519],"study_design_scores_gemma":[0.8415374,0.13914663,0.011643734,0.00014296749,0.002789578,0.00010521082,0.00007940465,0.00096162956,0.0009755968,0.00037183234,0.0022181505,0.000027983013],"about_ca_topic_score_codex":0.0014670052,"about_ca_topic_score_gemma":0.0037265914,"teacher_disagreement_score":0.0034282792,"about_ca_system_score_codex":0.00078521157,"about_ca_system_score_gemma":0.0007336029,"threshold_uncertainty_score":0.011468768},"labels":[],"label_agreement":null},{"id":"W4416019293","doi":"10.1016/j.ijgc.2025.102245","title":"PEMBROLIZUMAB PLUS ADJUVANT CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK ENDOMETRIAL CANCER: HEALTH-RELATED QUALITY OF LIFE (HRQOL) FROM THE PHASE 3 ENGOT-EN11/GOG-3053/KEYNOTE-B21 STUDY","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Pembrolizumab; Radiation therapy; Quality of life (healthcare); Chemotherapy; Adjuvant; Phases of clinical research","score_opus":0.08763137003118326,"score_gpt":0.4690589906847477,"score_spread":0.38142762065356445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416019293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884828,0.00803076,0.0002650617,0.0003283862,0.00012536986,0.00036599016,0.0014137103,0.000013239757,0.0009746176],"genre_scores_gemma":[0.99223137,0.0033829578,0.00038885893,0.0007406348,0.000119520766,0.00036932545,0.002100374,0.000008699753,0.0006582431],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999332,0.00033901393,0.00004891016,0.000095719166,0.00006146596,0.0001228175],"domain_scores_gemma":[0.9993443,0.00019166475,0.00018389095,0.000052814026,0.000034031367,0.00019319156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021587743,0.00077202596,0.0015471927,0.00030414,0.0002716618,0.0007775412,0.00043847234,0.0007891441,0.0017227723],"category_scores_gemma":[0.001370364,0.00035293086,0.0029925716,0.0004510427,0.000420481,0.0008938122,0.00042112003,0.0018397998,0.00026652793],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8749394,0.007798494,0.026082104,0.0015483212,0.011323705,0.00011239307,0.0001362706,0.0020354725,0.004562646,0.00013823397,0.002006678,0.06931629],"study_design_scores_gemma":[0.51275843,0.21714555,0.23765634,0.00049695704,0.02135162,0.00026487268,0.00025757708,0.001774776,0.0014962604,0.00042150944,0.0062918453,0.000084308],"about_ca_topic_score_codex":0.0020947242,"about_ca_topic_score_gemma":0.006146536,"teacher_disagreement_score":0.0021587743,"about_ca_system_score_codex":0.00078474334,"about_ca_system_score_gemma":0.0008146957,"threshold_uncertainty_score":0.0114168525},"labels":[],"label_agreement":null},{"id":"W4416088438","doi":"10.1136/jitc-2025-sitc2025.0057","title":"57 High-throughput quantitative characterization of cytotoxic antibody-drug conjugates using spheroid models reveals important considerations in potential molecular mechanisms of ADC resistance","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Cytotoxic T cell; Conjugate; Spheroid; Cytotoxicity; Cell culture","score_opus":0.026555963767107112,"score_gpt":0.3195329329115008,"score_spread":0.2929769691443937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416088438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8529826,0.0016354833,0.13370538,0.00052604877,0.00009293361,0.0003301441,0.0032415108,0.0010592758,0.006426598],"genre_scores_gemma":[0.9362757,0.0012629658,0.05043783,0.00014265963,0.000011832579,0.0002492381,0.0023210032,0.00016757425,0.009131235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996915,0.000040929313,0.000021762908,0.00005816485,0.00014597827,0.000041693645],"domain_scores_gemma":[0.9998129,0.00008219577,0.000020033953,0.000030942752,0.00004390297,0.000010099878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004206927,0.00030562154,0.0006980757,0.0002645204,0.00029566773,0.00090726954,0.00028385792,0.00041353563,0.0016520686],"category_scores_gemma":[0.00037975307,0.00020116274,0.00030567776,0.00038341986,0.00026065225,0.00037671422,0.00016245981,0.00060568965,0.0006937142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006213253,0.00004291376,0.0005371036,0.000043483764,0.000008947327,0.00002874145,0.000039090643,0.0007922865,0.99369365,0.0005191476,0.00033337838,0.0038990008],"study_design_scores_gemma":[0.0000045576394,0.00006139162,0.0016001995,0.000002419524,0.00000823736,0.000030202129,0.000028234183,0.006830738,0.98990273,0.00010281761,0.0014228811,0.000005505863],"about_ca_topic_score_codex":0.0032339706,"about_ca_topic_score_gemma":0.0054835454,"teacher_disagreement_score":0.0032339706,"about_ca_system_score_codex":0.00072853937,"about_ca_system_score_gemma":0.00039956433,"threshold_uncertainty_score":0.0064302683},"labels":[],"label_agreement":null},{"id":"W4416138490","doi":"10.25259/ijmr_2009_2024","title":"Challenges &amp; recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement","year":2025,"lang":"en","type":"review","venue":"The Indian Journal of Medical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"AstraZeneca","keywords":"Metastatic breast cancer; Trastuzumab; Breast cancer; Human Epidermal Growth Factor Receptor 2; Immunohistochemistry; Cancer; Clinical trial; CA15-3; Statement (logic)","score_opus":0.3880157786016005,"score_gpt":0.5899644220023963,"score_spread":0.20194864340079577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416138490","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028044762,0.028815608,0.0027228992,0.9357697,0.021710431,0.00043724471,0.0007945573,0.00022340092,0.009245742],"genre_scores_gemma":[0.0077347113,0.06838346,0.038912274,0.8154516,0.043476813,0.0022560162,0.002712648,0.00023375834,0.020838713],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98438394,0.0075398996,0.002508672,0.00089499075,0.0034845974,0.0011878817],"domain_scores_gemma":[0.9180152,0.020919297,0.0048154406,0.0016992191,0.048292056,0.0062588234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023479313,0.00088598003,0.002227158,0.001695817,0.0021164264,0.0050351867,0.0066806385,0.017818395,0.011959098],"category_scores_gemma":[0.05382215,0.00073055003,0.004026134,0.0014227823,0.0027559118,0.0048970846,0.003366176,0.016020576,0.015886437],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004456442,0.000038274968,0.00029862905,0.001680231,0.000038272774,0.00023683938,0.00014692667,0.000120110926,0.00027974098,0.0018639255,0.9188504,0.076402225],"study_design_scores_gemma":[0.00008036099,0.000059819995,0.0007344381,0.0046929508,0.00008880123,0.00035254826,0.0004319458,0.00020183859,0.00017733208,0.006911818,0.98621535,0.000052854935],"about_ca_topic_score_codex":0.007160104,"about_ca_topic_score_gemma":0.0123446435,"teacher_disagreement_score":0.023479313,"about_ca_system_score_codex":0.0038887593,"about_ca_system_score_gemma":0.014399095,"threshold_uncertainty_score":0.12417197},"labels":[],"label_agreement":null},{"id":"W4416254472","doi":"10.17615/4s15-x497","title":"HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1","year":2025,"lang":"","type":"article","venue":"UNC Libraries","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Society for Medical Oncology; Sociedad Española de Oncología Médica; Banco Bilbao Vizcaya Argentaria; Astellas Pharma; Università degli Studi di Padova; Fundación BBVA; Seagen; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Trastuzumab; Breast cancer; Immunohistochemistry; Trastuzumab emtansine; Messenger RNA; Overall survival; Antibody; Cancer","score_opus":0.014004692194790924,"score_gpt":0.31111052610432377,"score_spread":0.2971058339095328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416254472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997242,0.00010573338,0.000020803802,0.00000882965,0.0000012165636,0.0000017238316,0.000018784007,9.96924e-7,0.000117782234],"genre_scores_gemma":[0.9997141,0.00006195902,0.000029686391,0.000009382682,0.0000026005766,0.0000027943545,0.000056261102,5.2319973e-7,0.00012278259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999312,0.0000222843,0.0000052216355,0.000012302147,0.000011997816,0.000016903407],"domain_scores_gemma":[0.9998493,0.000045297988,0.00005269317,0.000007686529,0.00001272274,0.00003225483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022673272,0.000103090126,0.00014388825,0.00028573172,0.00009992717,0.00021064632,0.00007253068,0.00014528928,0.0006869039],"category_scores_gemma":[0.0004573026,0.00008273824,0.00013506023,0.00020763864,0.00016721146,0.00012107006,0.00013043803,0.00022287511,0.00007435097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073371297,0.0002624826,0.9216627,0.000035680285,0.000066892,0.00080553564,0.00018108924,0.00033335754,0.05286699,0.000035187368,0.00017536846,0.016237581],"study_design_scores_gemma":[0.000055722394,0.0018409904,0.9918031,0.0000044615617,0.00004368561,0.00089911494,0.00013177792,0.0004948862,0.0043168464,0.000035900615,0.00037069857,0.0000028930556],"about_ca_topic_score_codex":0.00074992364,"about_ca_topic_score_gemma":0.00091879786,"teacher_disagreement_score":0.00074992364,"about_ca_system_score_codex":0.00018460829,"about_ca_system_score_gemma":0.00009421918,"threshold_uncertainty_score":0.0022979379},"labels":[],"label_agreement":null},{"id":"W4416391581","doi":"10.1016/j.annonc.2025.09.031","title":"LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Astellas Pharma; Eisai; Jazz Pharmaceuticals; Chugai Pharmaceutical; Seagen; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; G1 Therapeutics; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Metastatic breast cancer; Chemotherapy; Immunotherapy; Breast cancer; Cancer; Chemotherapy regimen","score_opus":0.08251542603776353,"score_gpt":0.4295659143172496,"score_spread":0.3470504882794861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985529,0.0075084413,0.00023804978,0.0010499813,0.00034984277,0.00045520483,0.0012680154,0.00008295439,0.0035184813],"genre_scores_gemma":[0.98670304,0.0042724703,0.00051601307,0.0010656604,0.00023210958,0.00049799157,0.001928454,0.000028194068,0.0047561866],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999684,0.00016825006,0.000011848063,0.000047987218,0.00002109056,0.00006688659],"domain_scores_gemma":[0.9995561,0.00013292878,0.00009707848,0.000030158551,0.000016509912,0.00016708726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000909493,0.0009805892,0.0017490917,0.0002754768,0.00021367332,0.0010183249,0.0006009472,0.0009478845,0.0055919504],"category_scores_gemma":[0.0010469945,0.00032459333,0.0015288854,0.0003484936,0.00062273245,0.00076243887,0.0003195181,0.002665296,0.0008699877],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9243913,0.004000614,0.0016760142,0.00082197646,0.0017407965,0.000073174044,0.00008720167,0.0014449757,0.005478746,0.0003037884,0.0028401061,0.057141345],"study_design_scores_gemma":[0.84366816,0.13685383,0.009893414,0.00014182225,0.0019387966,0.000228613,0.0000952254,0.0014339497,0.0014054129,0.00074628677,0.003559739,0.00003475991],"about_ca_topic_score_codex":0.0011749382,"about_ca_topic_score_gemma":0.0041604815,"teacher_disagreement_score":0.0055919504,"about_ca_system_score_codex":0.0009781235,"about_ca_system_score_gemma":0.00069079455,"threshold_uncertainty_score":0.018706977},"labels":[],"label_agreement":null},{"id":"W4416391787","doi":"10.1016/j.annonc.2025.09.028","title":"LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Taxane; Trastuzumab; Breast cancer; Chemotherapy","score_opus":0.147782217334356,"score_gpt":0.4590405512808375,"score_spread":0.3112583339464815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711454,0.0010401681,0.00008826962,0.00024519267,0.00004341256,0.000049231076,0.00050493266,0.000008950414,0.00090524467],"genre_scores_gemma":[0.9978515,0.00027234002,0.00013748369,0.00014223381,0.00006792578,0.00004058239,0.0005991043,0.0000037628104,0.0008851051],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993586,0.00026895534,0.00003441164,0.000120676756,0.000041639596,0.00017567862],"domain_scores_gemma":[0.9992113,0.00036660754,0.00012248779,0.000041630123,0.000026024,0.00023200295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011430085,0.0004186939,0.00086214393,0.00027458897,0.00020980087,0.00076193834,0.0004116838,0.0006217915,0.005168403],"category_scores_gemma":[0.0017167168,0.00017252484,0.0017179555,0.00034579623,0.00030916257,0.0009453047,0.0003762962,0.0012549387,0.00039277237],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7954261,0.0029016829,0.12269168,0.00032056903,0.0032289184,0.0002400057,0.00022853637,0.0012227684,0.007950069,0.00036884233,0.0019950557,0.063425735],"study_design_scores_gemma":[0.09323566,0.23610593,0.6323299,0.00015950893,0.01049519,0.0008250789,0.00094879273,0.006426515,0.0060394956,0.0017627552,0.011579382,0.00009184109],"about_ca_topic_score_codex":0.0011852515,"about_ca_topic_score_gemma":0.0036505368,"teacher_disagreement_score":0.005168403,"about_ca_system_score_codex":0.00067863823,"about_ca_system_score_gemma":0.0007678633,"threshold_uncertainty_score":0.017290056},"labels":[],"label_agreement":null},{"id":"W4416410316","doi":"10.1016/j.annonc.2025.11.005","title":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Alberta","funders":"Seagen; Gilead Sciences; Roche; Novartis; Daiichi-Sankyo; Pfizer; Bristol-Myers Squibb","keywords":"Metastatic breast cancer; Trastuzumab emtansine; Trastuzumab; Phases of clinical research; Randomized controlled trial; Clinical endpoint","score_opus":0.033511208488277475,"score_gpt":0.4264416677257516,"score_spread":0.3929304592374741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416410316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986453,0.0061271745,0.00043973388,0.0010969652,0.00040751335,0.00092947995,0.0015202023,0.000113423244,0.002912532],"genre_scores_gemma":[0.9904799,0.0023471185,0.0005180908,0.00083871186,0.00027182593,0.000705712,0.0020550694,0.000032461452,0.002751082],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991841,0.0004653881,0.00003097743,0.00012133973,0.000047891648,0.00015037296],"domain_scores_gemma":[0.9992762,0.00017608966,0.00016341796,0.000059580565,0.000032238433,0.00029235685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021577936,0.0014068305,0.0025285352,0.00035265792,0.00034436386,0.001401144,0.00081837486,0.001151614,0.0058536334],"category_scores_gemma":[0.0015696065,0.00064238237,0.002099776,0.0004808916,0.00085257686,0.0014172184,0.00045988354,0.0034247446,0.00087863917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96047145,0.0042944876,0.0023338294,0.00034617167,0.0019348008,0.00003926208,0.000053941254,0.0011138363,0.002055117,0.00015182066,0.0022070403,0.024998277],"study_design_scores_gemma":[0.92636895,0.05958117,0.0084108105,0.000045585486,0.0015277092,0.00010443074,0.00005857302,0.001126511,0.0006127051,0.0003305198,0.0018098706,0.00002318125],"about_ca_topic_score_codex":0.0016207016,"about_ca_topic_score_gemma":0.0067713894,"teacher_disagreement_score":0.0058536334,"about_ca_system_score_codex":0.0012737153,"about_ca_system_score_gemma":0.0014101838,"threshold_uncertainty_score":0.019582331},"labels":[],"label_agreement":null},{"id":"W4416592902","doi":"10.3390/curroncol32120658","title":"Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Sequencing, and Safety","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Taxane; Pathological; Blockade; Breast cancer; Neoadjuvant therapy; Prospective cohort study","score_opus":0.09665490570086571,"score_gpt":0.4812934815231594,"score_spread":0.3846385758222937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416592902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783474,0.00090755883,0.0002711291,0.000036252153,0.000004712778,0.00002700691,0.00025874627,0.0000070153983,0.00065277185],"genre_scores_gemma":[0.9988906,0.00026661373,0.0001992323,0.00004535008,0.000012386322,0.000023928917,0.00046978667,0.000003613312,0.0000886342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993475,0.00026102632,0.00009468166,0.000090859976,0.00014939303,0.000056540877],"domain_scores_gemma":[0.9967033,0.0006484493,0.0019836864,0.00017879234,0.00024901982,0.00023675275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001740214,0.00014368999,0.00030799667,0.00020561689,0.00010319468,0.00036980727,0.00014495246,0.00013702916,0.0007414102],"category_scores_gemma":[0.0020363815,0.00006799396,0.00029779517,0.00036879122,0.00028515558,0.000316117,0.0002461643,0.00027140445,0.00015119353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015203955,0.00044604027,0.87245846,0.00042795448,0.00031784992,0.0004609188,0.00026861025,0.0016240984,0.007941157,0.000075872806,0.000762206,0.1000128],"study_design_scores_gemma":[0.00061841274,0.016688501,0.9609095,0.00007915977,0.0005078747,0.002828937,0.00030200573,0.0017610734,0.011747416,0.00013756515,0.004397916,0.000021668833],"about_ca_topic_score_codex":0.0003486777,"about_ca_topic_score_gemma":0.0005062377,"teacher_disagreement_score":0.001740214,"about_ca_system_score_codex":0.0004945276,"about_ca_system_score_gemma":0.0003320777,"threshold_uncertainty_score":0.009203255},"labels":[],"label_agreement":null},{"id":"W4416738297","doi":"10.3390/curroncol32110603","title":"Predictors of Pathologic Complete Response and Its Prognostic Value in Early Breast Cancer: A Real-World Cohort Study","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Complete response; Surrogate endpoint; Clinical endpoint; Cohort; Cohort study; Value (mathematics); Disease; Event (particle physics)","score_opus":0.12626779724652026,"score_gpt":0.471336344793251,"score_spread":0.3450685475467307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416738297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99959105,0.000095633106,0.0000626519,0.000014076332,0.0000022460122,0.0000069860425,0.00016759949,0.0000012202531,0.00005846124],"genre_scores_gemma":[0.9994497,0.000060275175,0.00006945502,0.000012292213,0.000006432044,0.000010205833,0.00035362953,0.0000015193795,0.000036589296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946016,0.00016973489,0.000058381323,0.00013171224,0.00009513704,0.00008490367],"domain_scores_gemma":[0.9979965,0.00043039105,0.00082818663,0.00029596992,0.00017920267,0.00026974693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012578988,0.0002484079,0.00037864238,0.0006142357,0.00032497046,0.0005652493,0.00038817152,0.00032243374,0.0010060008],"category_scores_gemma":[0.0023778656,0.00029413938,0.0004533912,0.00085683295,0.00032359286,0.00046411483,0.00044560415,0.0005199017,0.00018010338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018823407,0.000037896807,0.9985985,0.000006282061,0.000059502916,0.00007431108,0.00003967145,0.00005093244,0.00011688221,0.0000069840594,0.000081923405,0.00073896674],"study_design_scores_gemma":[0.000029346134,0.00013396917,0.9984555,0.000005094873,0.000051731597,0.00045940376,0.0001300516,0.00043369783,0.000059083282,0.000018190245,0.00021743227,0.00000636419],"about_ca_topic_score_codex":0.0022791645,"about_ca_topic_score_gemma":0.0036776073,"teacher_disagreement_score":0.0022791645,"about_ca_system_score_codex":0.00038355828,"about_ca_system_score_gemma":0.00038496382,"threshold_uncertainty_score":0.0066524744},"labels":[],"label_agreement":null},{"id":"W4417048935","doi":"10.1021/acsomega.5c08654","title":"Multiscale Computational Studies of PEG Chain Length Effects on HER2 mAb Fc Structure and Binding Energetics","year":2025,"lang":"en","type":"article","venue":"ACS Omega","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"PEGylation; Molecular dynamics; PEG ratio; Polyethylene glycol; Steric effects; Hydrogen bond; Monoclonal antibody; Dihedral angle; Tripeptide","score_opus":0.02737456954147662,"score_gpt":0.375535016196717,"score_spread":0.3481604466552404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417048935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880654,0.00016388315,0.0067015397,0.00046725295,0.000027400501,0.00003262718,0.0006100166,0.00015704271,0.0037747587],"genre_scores_gemma":[0.99392056,0.00008256329,0.0049224873,0.00008342586,0.000011660408,0.00006960527,0.0005238015,0.000049173726,0.00033685644],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99986744,0.00003668049,0.0000059796057,0.000019995628,0.000031045744,0.00003886481],"domain_scores_gemma":[0.99936587,0.00040868504,0.000048020058,0.000042604683,0.00007249582,0.000062276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054958364,0.00057393353,0.00082416873,0.0004942229,0.0006165633,0.00062451937,0.00092950626,0.0009220559,0.0014397167],"category_scores_gemma":[0.0019796658,0.0003948407,0.00081618526,0.0004912789,0.00061785546,0.00050024386,0.00050625385,0.0007824453,0.00012516338],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009147136,0.00007196574,0.0028203337,0.00004335446,0.000047204838,0.00007699987,0.00004271896,0.9914893,0.0018075224,0.0017513955,0.00035786297,0.0013999164],"study_design_scores_gemma":[0.000014729345,0.000017165896,0.00062016735,0.0000025080262,0.000005831569,0.000004913606,0.000013012989,0.99867415,0.00022478952,0.0003303108,0.00008878884,0.0000036298725],"about_ca_topic_score_codex":0.01823988,"about_ca_topic_score_gemma":0.010867848,"teacher_disagreement_score":0.01823988,"about_ca_system_score_codex":0.0012970422,"about_ca_system_score_gemma":0.0012172769,"threshold_uncertainty_score":0.03626746},"labels":[],"label_agreement":null},{"id":"W4417156739","doi":"10.1038/s41416-025-03287-9","title":"Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer","year":2025,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Natural Science Foundation of Heilongjiang Province; National Natural Science Foundation of China; Harbin Medical University","keywords":"Breast cancer; Endocrine system; Mammary gland; Oestrogen receptor; Key (lock); Cancer","score_opus":0.013944085488671354,"score_gpt":0.3942441363294163,"score_spread":0.3803000508407449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417156739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971487,0.00046960785,0.0009011262,0.00002257732,0.0000028749153,0.000007281014,0.0009480795,0.000031396008,0.0004683033],"genre_scores_gemma":[0.99738103,0.00016727949,0.00070198235,0.000019815878,0.000002859688,0.0000139749045,0.0012157564,0.0000070750084,0.00049019075],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999249,0.000007804814,0.00000479253,0.000022515938,0.000019600508,0.000020472236],"domain_scores_gemma":[0.99993634,0.000007952924,0.000028540606,0.0000056083813,0.000011753279,0.000009785268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008491179,0.000121480705,0.00015493849,0.00030616077,0.00009478646,0.00023377869,0.0000923865,0.00015330286,0.0009392339],"category_scores_gemma":[0.00014074895,0.00008153783,0.00015278654,0.0003527808,0.00009695236,0.00011778299,0.00014398171,0.00016473055,0.00017447428],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011399629,0.00006400494,0.07401281,0.00012763766,0.00006086282,0.00014402403,0.00009159912,0.0011801835,0.90813357,0.000107225525,0.0002555458,0.014682496],"study_design_scores_gemma":[0.000013739572,0.00035833206,0.8620417,0.000008020743,0.00006544608,0.00078949897,0.00028762984,0.004281787,0.12970792,0.00018966732,0.002240634,0.00001566831],"about_ca_topic_score_codex":0.0005140873,"about_ca_topic_score_gemma":0.0009001451,"teacher_disagreement_score":0.0009392339,"about_ca_system_score_codex":0.00015531597,"about_ca_system_score_gemma":0.0000898921,"threshold_uncertainty_score":0.0031419992},"labels":[],"label_agreement":null},{"id":"W4417198347","doi":"10.1200/jco-25-02600","title":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Ottawa Hospital","funders":"","keywords":"Pertuzumab; Trastuzumab; Metastatic breast cancer; Placebo; Maintenance therapy; Phases of clinical research; Chemotherapy; Clinical trial","score_opus":0.1733979768876252,"score_gpt":0.5582290306535705,"score_spread":0.38483105376594534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417198347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881391,0.005475481,0.00048335997,0.0004396954,0.00032177533,0.002174758,0.0008172432,0.0001721886,0.0019763703],"genre_scores_gemma":[0.9916539,0.0024280543,0.0007368864,0.00046954333,0.00028336686,0.0017252435,0.0007115121,0.000015593785,0.0019759634],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994911,0.00027658744,0.000027809918,0.000074954136,0.00004866435,0.00008098324],"domain_scores_gemma":[0.99944896,0.000100057885,0.00012502764,0.000028627095,0.000027678463,0.00026972327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017105354,0.0013400684,0.0023500992,0.00062148523,0.0003697928,0.001076048,0.001082459,0.0013679535,0.0041198577],"category_scores_gemma":[0.0010996535,0.0005422904,0.0012250429,0.000455401,0.001006368,0.00091500586,0.00034906002,0.0023409685,0.0008139334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9384821,0.017761804,0.0008484661,0.0006443182,0.00079983874,0.000051702697,0.00006742595,0.00055180164,0.0066348184,0.00014264508,0.001027725,0.032987442],"study_design_scores_gemma":[0.76480937,0.22909272,0.0027962436,0.000035884706,0.0004570357,0.00007389211,0.000029050238,0.00073209795,0.0010655416,0.00010914111,0.0007807492,0.000018321807],"about_ca_topic_score_codex":0.0009777881,"about_ca_topic_score_gemma":0.0028818634,"teacher_disagreement_score":0.0041198577,"about_ca_system_score_codex":0.0008245053,"about_ca_system_score_gemma":0.0012211052,"threshold_uncertainty_score":0.013782263},"labels":[],"label_agreement":null},{"id":"W4417479984","doi":"10.1016/j.jval.2025.09.192","title":"CO90 Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario","funders":"","keywords":"Lung cancer; Toxicity; Systematic review; Cytotoxic T cell; Conjugate; Cancer; Clinical trial","score_opus":0.0194310146393124,"score_gpt":0.3837935148397427,"score_spread":0.3643625002004303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417479984","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037575776,0.9948225,0.00010920621,0.00018960866,0.00006393311,0.00012916693,0.000660627,0.00000543103,0.00026190435],"genre_scores_gemma":[0.07459219,0.9227201,0.00067364634,0.00096832594,0.000089868,0.00023970721,0.0005256369,0.0000066265675,0.00018395612],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962155,0.0010450452,0.0016696551,0.0004633249,0.00047327447,0.00013325393],"domain_scores_gemma":[0.9872328,0.00855403,0.0029131211,0.00021840783,0.00093456963,0.00014712711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005951278,0.0006978961,0.0051671206,0.004997877,0.00030174194,0.0017403167,0.00093906705,0.0012780572,0.0031144088],"category_scores_gemma":[0.018639578,0.00060647243,0.009335917,0.0047332905,0.0006962413,0.00123314,0.0010748007,0.00096172676,0.00022501672],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001275941,0.000035079745,0.004018631,0.8806115,0.05474732,0.000087901455,0.00019331784,0.00019028116,0.00053004036,0.00024790305,0.0012278325,0.05683427],"study_design_scores_gemma":[0.0011343049,0.0010107375,0.018392194,0.45129067,0.50351405,0.00043538137,0.00038158134,0.00017561983,0.0005271301,0.00046329226,0.022596763,0.00007823874],"about_ca_topic_score_codex":0.0071412474,"about_ca_topic_score_gemma":0.02139855,"teacher_disagreement_score":0.0071412474,"about_ca_system_score_codex":0.0019440803,"about_ca_system_score_gemma":0.003976823,"threshold_uncertainty_score":0.031473696},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4417480012","doi":"10.1016/j.jval.2025.09.317","title":"CO216 Safety and Efficacy of Antibody Drug Conjugate (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Triple-Negative Breast Cancer (TNBC): Systematic Literature Review (SLR)","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario","funders":"","keywords":"Breast cancer; Antibody-drug conjugate; Systematic review; Drug; Conjugate","score_opus":0.021433026575349914,"score_gpt":0.40031154003912167,"score_spread":0.37887851346377177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417480012","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005031554,0.9930361,0.00012420563,0.0002493123,0.000085229105,0.00017855852,0.00096844515,0.0000061242763,0.0003205119],"genre_scores_gemma":[0.092324845,0.90401626,0.0007919148,0.0013170723,0.000119487035,0.00033074,0.0008138275,0.000008503884,0.00027740852],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99585706,0.001280594,0.0017021399,0.00049942225,0.0005033623,0.00015745636],"domain_scores_gemma":[0.98508227,0.00949558,0.003694421,0.00027845692,0.0012748572,0.00017453198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006192089,0.00069222064,0.0051531973,0.004315997,0.00030537805,0.0019041743,0.000904901,0.0014523427,0.0038652322],"category_scores_gemma":[0.023362415,0.00064853084,0.009991467,0.0045203865,0.0006996188,0.0011785002,0.0012001462,0.0010725427,0.00030592002],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017063428,0.000036949015,0.0041842014,0.8822287,0.06761738,0.00008261035,0.0001773064,0.00016423796,0.0005207626,0.00019986606,0.0013093512,0.041772287],"study_design_scores_gemma":[0.0016155061,0.001093276,0.018518522,0.42182967,0.5340155,0.00037122032,0.00034089372,0.00017674743,0.0004772174,0.00045133953,0.02103304,0.000077050456],"about_ca_topic_score_codex":0.007972906,"about_ca_topic_score_gemma":0.024977045,"teacher_disagreement_score":0.007972906,"about_ca_system_score_codex":0.0018202671,"about_ca_system_score_gemma":0.0043916483,"threshold_uncertainty_score":0.03274727},"labels":[],"label_agreement":null},{"id":"W4417481095","doi":"10.1016/j.jval.2025.09.1774","title":"HSD114 Treatment Characteristics of Breast Cancer Patients per HER2/HR Status in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada","funders":"","keywords":"Breast cancer; Cancer; MEDLINE; Real world evidence","score_opus":0.08004581664081484,"score_gpt":0.41839420921166537,"score_spread":0.33834839257085053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417481095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83414406,0.0015752421,0.00030302117,0.0002052954,0.00004201585,0.0000498727,0.16129826,0.000038637332,0.0023435454],"genre_scores_gemma":[0.9277097,0.0007139381,0.00016234303,0.0001961247,0.00003528967,0.00006933376,0.069257274,0.000019548299,0.0018364865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908805,0.0001724898,0.00017963766,0.000247761,0.00015785878,0.00015428553],"domain_scores_gemma":[0.997903,0.0005674078,0.00092760666,0.00016863756,0.00023468,0.0001986108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050488353,0.00026987973,0.0006335537,0.0016818463,0.00023018343,0.0006118282,0.00043486053,0.00048215917,0.004129189],"category_scores_gemma":[0.002676751,0.00034158767,0.0015144229,0.0044947853,0.00013826898,0.00048008756,0.00035386847,0.00062991015,0.0005762994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008984374,0.000084193256,0.988246,0.00008861595,0.0007170342,0.000047924863,0.000032268617,0.00040597425,0.00015688711,0.000075724114,0.0054903673,0.0037566326],"study_design_scores_gemma":[0.00008525229,0.000098946555,0.99705315,0.000029998919,0.00026756726,0.00012783223,0.00010957599,0.00043501996,0.00009772005,0.00003774143,0.0016473449,0.000009727211],"about_ca_topic_score_codex":0.02721817,"about_ca_topic_score_gemma":0.02941788,"teacher_disagreement_score":0.02721817,"about_ca_system_score_codex":0.0005882325,"about_ca_system_score_gemma":0.0007068517,"threshold_uncertainty_score":0.054119468},"labels":[],"label_agreement":null},{"id":"W57864847","doi":"10.1007/978-1-59745-169-7_3","title":"Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy","year":2007,"lang":"en","type":"book-chapter","venue":"Humana Press eBooks","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Cancer Research Society","keywords":"Targeted therapy; Tyrosine kinase; Profiling (computer programming); Kinase; Proteomics; Cancer therapy; Computational biology; Cancer research; Bioinformatics; Medicine; Biology; Cancer; Gene; Signal transduction; Internal medicine; Biochemistry; Computer science","score_opus":0.3107914055341564,"score_gpt":0.4579386004752196,"score_spread":0.1471471949410632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W57864847","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036166634,0.4889754,0.20821685,0.008449638,0.0041295,0.00033420877,0.0021114268,0.0016084923,0.25000784],"genre_scores_gemma":[0.10626907,0.43994623,0.189263,0.005197887,0.001507157,0.00052382844,0.0015638905,0.00046978722,0.255259],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983,0.00003237915,0.000007770232,0.000029244704,0.00009332628,0.0000072868897],"domain_scores_gemma":[0.9999254,0.0000352001,0.0000053240788,0.000005641073,0.000020976306,0.0000074263316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048748127,0.00069248595,0.0006047468,0.00095555984,0.00017895235,0.0010616517,0.00042488807,0.000554416,0.0030550838],"category_scores_gemma":[0.00026663952,0.00023668716,0.00029215726,0.00081979804,0.00037780264,0.00094088376,0.00043892986,0.0009955819,0.0031027838],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020459772,0.0001856088,0.0009144615,0.0015707322,0.00004541301,0.0005009555,0.00026898173,0.0021979294,0.3396487,0.04709737,0.048868332,0.558497],"study_design_scores_gemma":[0.000027492064,0.0002597779,0.0047161886,0.00052746467,0.000058498023,0.0026429798,0.0001993955,0.0049900864,0.1684188,0.033743948,0.7843482,0.00006718264],"about_ca_topic_score_codex":0.00017013418,"about_ca_topic_score_gemma":0.00045367627,"teacher_disagreement_score":0.0030550838,"about_ca_system_score_codex":0.0005143932,"about_ca_system_score_gemma":0.00025335824,"threshold_uncertainty_score":0.010220289},"labels":[],"label_agreement":null},{"id":"W593708258","doi":"10.1200/jco.2005.23.16_suppl.500","title":"Clinical and molecular predictors of sustained response to trastuzumab in metastatic breast cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; PTEN; Tissue microarray; Immunohistochemistry; Metastatic breast cancer; Hormonal therapy","score_opus":0.12459404427531262,"score_gpt":0.563880348099123,"score_spread":0.4392863038238104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W593708258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990287,0.00036779235,0.00006185399,0.000070311224,0.0000032589958,0.000006894157,0.00018080013,0.0000033243198,0.0002771062],"genre_scores_gemma":[0.999474,0.00008145068,0.00006108728,0.000013492162,0.000009475863,0.0000066283665,0.00029901843,9.933418e-7,0.000053831303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997421,0.00007573983,0.000040437662,0.000029388684,0.00006761838,0.000044837954],"domain_scores_gemma":[0.99755883,0.0007998447,0.0009393185,0.00005873692,0.0002770584,0.00036616033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006860995,0.000120099365,0.00016950237,0.000571609,0.00017005115,0.00031669013,0.00020942732,0.00026897888,0.0012038059],"category_scores_gemma":[0.0032940705,0.00008027112,0.00015440342,0.0006438607,0.00014822719,0.00021204744,0.00021452621,0.000323455,0.00019282704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002082498,0.000023028462,0.9968503,0.000005988623,0.000009905269,0.000057583045,0.00000901768,0.00006604731,0.00024074143,0.0000061100172,0.00011683336,0.002406105],"study_design_scores_gemma":[0.000011410431,0.00015782844,0.99833137,0.0000047275053,0.000017025555,0.00049556076,0.000042654974,0.0004453737,0.00019189842,0.00003454707,0.00026606707,0.0000015898319],"about_ca_topic_score_codex":0.0011437022,"about_ca_topic_score_gemma":0.0016457301,"teacher_disagreement_score":0.0012038059,"about_ca_system_score_codex":0.00024961255,"about_ca_system_score_gemma":0.00020198245,"threshold_uncertainty_score":0.004027128},"labels":[],"label_agreement":null},{"id":"W6902013696","doi":"10.6084/m9.figshare.14211591.v1","title":"Additional file 9 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Table (database); Listing (finance); Clinical trial; Subpoena; Data file","score_opus":0.14997297660444242,"score_gpt":0.4332336874999872,"score_spread":0.2832607108955448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902013696","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021535864,0.000053320862,0.00023028543,0.00022113365,0.000031645213,0.00040031137,0.99551743,0.00034022442,0.0029903138],"genre_scores_gemma":[0.014804089,0.0005090234,0.004730722,0.0020709303,0.0003153171,0.0073901564,0.9293659,0.0010550369,0.03975879],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830747,0.00034137987,0.00046421995,0.00025372248,0.00043749472,0.00019573775],"domain_scores_gemma":[0.9582701,0.027531808,0.004820074,0.0024065333,0.0057341526,0.0012375066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037274146,0.00087593414,0.001629837,0.0020100772,0.000763241,0.0016824614,0.0012521723,0.0013249044,0.8918072],"category_scores_gemma":[0.038250953,0.00059255405,0.0010024342,0.0032666388,0.00025343263,0.0018108444,0.00089909934,0.0010096635,0.20594613],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016526164,0.00020249843,0.0014582995,0.0038954054,0.00006878751,0.000056836485,0.00003247854,0.00027804024,0.00014454173,0.00061049586,0.9738748,0.017725091],"study_design_scores_gemma":[0.013616203,0.00095454266,0.019819273,0.005028288,0.00029056557,0.00035111659,0.00015090941,0.0009494381,0.0009993751,0.0068996027,0.95083773,0.00010300338],"about_ca_topic_score_codex":0.0033060957,"about_ca_topic_score_gemma":0.0068806,"teacher_disagreement_score":0.8918072,"about_ca_system_score_codex":0.0015628091,"about_ca_system_score_gemma":0.0024881517,"threshold_uncertainty_score":0.15432382},"labels":[],"label_agreement":null},{"id":"W6902023125","doi":"10.6084/m9.figshare.14211570","title":"Additional file 2 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Schematic; Clinical trial; Event (particle physics); Troubleshooting; Table (database)","score_opus":0.14765557452903916,"score_gpt":0.43310266191126606,"score_spread":0.2854470873822269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902023125","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030553006,0.00012302035,0.00038388206,0.00018585085,0.0000481188,0.0005409582,0.9970591,0.00017670012,0.0011767433],"genre_scores_gemma":[0.03386789,0.000978242,0.012634179,0.002641922,0.0005647986,0.027988238,0.88677156,0.0010466927,0.03350645],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980044,0.0004851982,0.00060110545,0.00035433206,0.00035912445,0.00019577559],"domain_scores_gemma":[0.9421915,0.046068806,0.004315242,0.0024078188,0.004316765,0.00069989334],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042629726,0.001233694,0.0024452808,0.0025479815,0.00081760983,0.0017690548,0.0015263327,0.0017075455,0.86390704],"category_scores_gemma":[0.055411298,0.00090017094,0.002214833,0.0042816205,0.00035095162,0.002339804,0.00087848934,0.0010560015,0.08492368],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003873662,0.00023601258,0.0037666883,0.05062779,0.0007273409,0.00015819875,0.00010318122,0.0011597507,0.00029128022,0.0022918216,0.9158166,0.020947618],"study_design_scores_gemma":[0.05511486,0.002023052,0.034511957,0.022914255,0.003244834,0.0010943933,0.00035119854,0.003627522,0.0015837483,0.022616755,0.85263896,0.00027849653],"about_ca_topic_score_codex":0.003381094,"about_ca_topic_score_gemma":0.007761304,"teacher_disagreement_score":0.86390704,"about_ca_system_score_codex":0.0013013671,"about_ca_system_score_gemma":0.0031800943,"threshold_uncertainty_score":0.19412011},"labels":[],"label_agreement":null},{"id":"W6902125348","doi":"10.6084/m9.figshare.14211591","title":"Additional file 9 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Table (database); Listing (finance); Clinical trial; Subpoena; Data file","score_opus":0.14997297660444242,"score_gpt":0.4332336874999872,"score_spread":0.2832607108955448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902125348","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021535864,0.000053320862,0.00023028543,0.00022113365,0.000031645213,0.00040031137,0.99551743,0.00034022442,0.0029903138],"genre_scores_gemma":[0.014804089,0.0005090234,0.004730722,0.0020709303,0.0003153171,0.0073901564,0.9293659,0.0010550369,0.03975879],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830747,0.00034137987,0.00046421995,0.00025372248,0.00043749472,0.00019573775],"domain_scores_gemma":[0.9582701,0.027531808,0.004820074,0.0024065333,0.0057341526,0.0012375066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037274146,0.00087593414,0.001629837,0.0020100772,0.000763241,0.0016824614,0.0012521723,0.0013249044,0.8918072],"category_scores_gemma":[0.038250953,0.00059255405,0.0010024342,0.0032666388,0.00025343263,0.0018108444,0.00089909934,0.0010096635,0.20594613],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016526164,0.00020249843,0.0014582995,0.0038954054,0.00006878751,0.000056836485,0.00003247854,0.00027804024,0.00014454173,0.00061049586,0.9738748,0.017725091],"study_design_scores_gemma":[0.013616203,0.00095454266,0.019819273,0.005028288,0.00029056557,0.00035111659,0.00015090941,0.0009494381,0.0009993751,0.0068996027,0.95083773,0.00010300338],"about_ca_topic_score_codex":0.0033060957,"about_ca_topic_score_gemma":0.0068806,"teacher_disagreement_score":0.8918072,"about_ca_system_score_codex":0.0015628091,"about_ca_system_score_gemma":0.0024881517,"threshold_uncertainty_score":0.15432382},"labels":[],"label_agreement":null},{"id":"W6920486473","doi":"10.6084/m9.figshare.14211567.v1","title":"Additional file 1 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Listing (finance); Table (database); Clinical trial; Data collection; Subpoena","score_opus":0.1531541678876461,"score_gpt":0.43397828516669323,"score_spread":0.2808241172790471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920486473","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039470088,0.00008550594,0.00035401667,0.00024898496,0.000030966898,0.0006383462,0.99535745,0.00024367947,0.0026463545],"genre_scores_gemma":[0.026798619,0.00083066156,0.008000834,0.0027301346,0.00038336852,0.015713215,0.90443546,0.00089224987,0.04021553],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987067,0.00029697418,0.00032544057,0.0002195149,0.00029995345,0.00015137928],"domain_scores_gemma":[0.96392936,0.024919575,0.0041511054,0.0018019916,0.0042662024,0.0009317159],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032748843,0.00078553264,0.0014065893,0.0015854654,0.00069991255,0.0013007666,0.0010450364,0.0010903059,0.8639889],"category_scores_gemma":[0.034110337,0.0005118745,0.00091074395,0.0029157707,0.00023802872,0.0015516896,0.0006567051,0.00097259635,0.13117458],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026430553,0.0003094095,0.0022457198,0.0056855436,0.00010943077,0.0000736969,0.000046197893,0.00044099806,0.00019070382,0.00090325053,0.96288544,0.024466539],"study_design_scores_gemma":[0.019841837,0.0016924454,0.025449518,0.0053336862,0.0004817488,0.0006487846,0.00017225463,0.0014310252,0.0014365974,0.008796915,0.9345971,0.00011803644],"about_ca_topic_score_codex":0.0026211368,"about_ca_topic_score_gemma":0.0058065224,"teacher_disagreement_score":0.8639889,"about_ca_system_score_codex":0.0013630424,"about_ca_system_score_gemma":0.0028063275,"threshold_uncertainty_score":0.19400328},"labels":[],"label_agreement":null},{"id":"W6920583159","doi":"10.6084/m9.figshare.14211588","title":"Additional file 8 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Listing (finance); Table (database); Key (lock); Subpoena; Data file","score_opus":0.1500435749855026,"score_gpt":0.43330015212976836,"score_spread":0.2832565771442658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920583159","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037570653,0.00009966745,0.00035294998,0.0003221422,0.00005030729,0.000663942,0.99360365,0.00045001725,0.0040815985],"genre_scores_gemma":[0.020790117,0.00081022293,0.007123053,0.0029302035,0.00043985396,0.011344029,0.8999792,0.0013015304,0.055281844],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984937,0.00031960383,0.00040101146,0.0002164417,0.00038935273,0.00017989962],"domain_scores_gemma":[0.9660294,0.022564165,0.003820062,0.0018764177,0.0047473437,0.00096265867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035879845,0.0008318405,0.0015850253,0.001645455,0.00071530946,0.0016070909,0.0011525941,0.0012976459,0.8854429],"category_scores_gemma":[0.034795564,0.00056488655,0.0010972604,0.0026816195,0.00023648278,0.001615628,0.0007823093,0.0009915852,0.19277227],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00259811,0.00026910537,0.0016019967,0.0048409873,0.000088778266,0.00006661079,0.000036882648,0.00027926706,0.00018974108,0.0006318424,0.96623933,0.023157375],"study_design_scores_gemma":[0.015041584,0.0011753378,0.018864544,0.0048710774,0.00034927827,0.00043333243,0.00014023064,0.0008861953,0.0012419056,0.006030681,0.9508655,0.00010034944],"about_ca_topic_score_codex":0.002521952,"about_ca_topic_score_gemma":0.005911108,"teacher_disagreement_score":0.8854429,"about_ca_system_score_codex":0.0014036976,"about_ca_system_score_gemma":0.002335426,"threshold_uncertainty_score":0.16340178},"labels":[],"label_agreement":null},{"id":"W6920611533","doi":"10.6084/m9.figshare.14211570.v1","title":"Additional file 2 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Schematic; Clinical trial; Event (particle physics); Troubleshooting; Table (database)","score_opus":0.14765557452903916,"score_gpt":0.43310266191126606,"score_spread":0.2854470873822269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920611533","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030553006,0.00012302035,0.00038388206,0.00018585085,0.0000481188,0.0005409582,0.9970591,0.00017670012,0.0011767433],"genre_scores_gemma":[0.03386789,0.000978242,0.012634179,0.002641922,0.0005647986,0.027988238,0.88677156,0.0010466927,0.03350645],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980044,0.0004851982,0.00060110545,0.00035433206,0.00035912445,0.00019577559],"domain_scores_gemma":[0.9421915,0.046068806,0.004315242,0.0024078188,0.004316765,0.00069989334],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042629726,0.001233694,0.0024452808,0.0025479815,0.00081760983,0.0017690548,0.0015263327,0.0017075455,0.86390704],"category_scores_gemma":[0.055411298,0.00090017094,0.002214833,0.0042816205,0.00035095162,0.002339804,0.00087848934,0.0010560015,0.08492368],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003873662,0.00023601258,0.0037666883,0.05062779,0.0007273409,0.00015819875,0.00010318122,0.0011597507,0.00029128022,0.0022918216,0.9158166,0.020947618],"study_design_scores_gemma":[0.05511486,0.002023052,0.034511957,0.022914255,0.003244834,0.0010943933,0.00035119854,0.003627522,0.0015837483,0.022616755,0.85263896,0.00027849653],"about_ca_topic_score_codex":0.003381094,"about_ca_topic_score_gemma":0.007761304,"teacher_disagreement_score":0.86390704,"about_ca_system_score_codex":0.0013013671,"about_ca_system_score_gemma":0.0031800943,"threshold_uncertainty_score":0.19412011},"labels":[],"label_agreement":null},{"id":"W6921037962","doi":"10.6084/m9.figshare.23505264","title":"Additional file 1 of XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Everolimus; Metastatic breast cancer; Breast cancer; Phases of clinical research; Placebo; Clinical trial","score_opus":0.040559955304512625,"score_gpt":0.35173738428798557,"score_spread":0.31117742898347295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921037962","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013580674,0.00031292424,0.00088250655,0.00067187904,0.00016407625,0.003931831,0.9872241,0.0005595893,0.004895024],"genre_scores_gemma":[0.06839785,0.0019400528,0.019124592,0.00491424,0.0010144542,0.08591985,0.7555018,0.001109183,0.062078044],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990338,0.000397147,0.00015705588,0.00015737778,0.0001349495,0.00011965558],"domain_scores_gemma":[0.9832565,0.012277256,0.0018801048,0.0007321156,0.0011882305,0.0006658437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002975986,0.0013248009,0.0018937232,0.00073387387,0.0006838881,0.0011464336,0.0013268106,0.001405646,0.8384896],"category_scores_gemma":[0.020567067,0.00077953987,0.0011255827,0.0013273685,0.00034637825,0.0010590855,0.0005559519,0.0012796975,0.06224516],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035004754,0.0011646756,0.0011638134,0.018399248,0.0005595024,0.00012770896,0.00006630384,0.001244551,0.0004715888,0.0023407529,0.9013454,0.03811171],"study_design_scores_gemma":[0.46007824,0.008371575,0.017744849,0.0053318194,0.0017898778,0.0006211064,0.00010044897,0.0026927495,0.0015948268,0.014303512,0.48719865,0.00017231375],"about_ca_topic_score_codex":0.0017837886,"about_ca_topic_score_gemma":0.0041722846,"teacher_disagreement_score":0.8384896,"about_ca_system_score_codex":0.0010745227,"about_ca_system_score_gemma":0.002174751,"threshold_uncertainty_score":0.23037499},"labels":[],"label_agreement":null},{"id":"W6921278677","doi":"10.6084/m9.figshare.26710013","title":"Additional file 1 of NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Neratinib; Metastatic breast cancer; Breast cancer; Trastuzumab emtansine; Clinical trial; Phases of clinical research; Cancer","score_opus":0.08063681552332634,"score_gpt":0.41486271223250426,"score_spread":0.3342258967091779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921278677","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024499692,0.00006124332,0.00022805383,0.00021396865,0.000024032433,0.00041115613,0.99659866,0.00011778488,0.0021000039],"genre_scores_gemma":[0.021465477,0.000574195,0.004695066,0.0020451338,0.0002949072,0.01680627,0.9272901,0.0006366855,0.026192214],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984964,0.00040627815,0.00034413114,0.00029917102,0.00026695622,0.00018709061],"domain_scores_gemma":[0.9676404,0.023999844,0.0031905342,0.0016677084,0.002618031,0.00088353496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027970686,0.0010414416,0.0015764746,0.0016348487,0.0009641929,0.0017286679,0.0016486872,0.0013022448,0.8378676],"category_scores_gemma":[0.04451309,0.000699007,0.0014504222,0.0037015774,0.00030961298,0.0017593004,0.00087667396,0.0010927505,0.10643999],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025330205,0.00017021642,0.0024779348,0.0060709007,0.00019403282,0.00008436399,0.000053662257,0.00069110614,0.00008879565,0.0012720628,0.97420156,0.012162325],"study_design_scores_gemma":[0.063676946,0.0016194372,0.038122267,0.010482986,0.0013879748,0.0010060706,0.00029522914,0.0025686477,0.0011011055,0.021459442,0.85807735,0.00020262097],"about_ca_topic_score_codex":0.0060726046,"about_ca_topic_score_gemma":0.010720659,"teacher_disagreement_score":0.8378676,"about_ca_system_score_codex":0.0015464651,"about_ca_system_score_gemma":0.0031701878,"threshold_uncertainty_score":0.23126209},"labels":[],"label_agreement":null},{"id":"W6925137650","doi":"10.1594/pangaea.325075","title":"Water temperature real-time profiles from cruise 5188600 (DCQC)","year":2005,"lang":"en","type":"dataset","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cruise; Temperature measurement; Sea surface temperature; Ectotherm","score_opus":0.047459931808038855,"score_gpt":0.3465715143368315,"score_spread":0.2991115825287926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6925137650","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013147065,0.0000188649,0.000022692911,0.000026133608,0.000008080988,0.000003978628,0.99939907,0.000154191,0.00023566635],"genre_scores_gemma":[0.00042012386,0.00001816794,0.00011151767,0.0000120134855,0.0000025772852,0.00002142138,0.99900156,0.000031985714,0.0003806437],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99944156,0.00005686082,0.000057473328,0.0001558714,0.00017906073,0.000109236345],"domain_scores_gemma":[0.9984036,0.00017461902,0.00016612728,0.0003321223,0.0007418829,0.00018169268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006710792,0.0019100223,0.0012799735,0.0021429516,0.000610904,0.0011439552,0.002884856,0.0018469426,0.02812771],"category_scores_gemma":[0.0032190813,0.0007811423,0.0012584009,0.0064355135,0.00030447045,0.0007886735,0.0010923872,0.0013502191,0.04256001],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062405226,0.000013164042,0.0013909145,0.00026885406,0.000037930033,0.0000148625695,0.000015909014,0.0007039793,0.00009935285,0.00012841467,0.99589086,0.0013733465],"study_design_scores_gemma":[0.0005130204,0.00002571065,0.029410776,0.00026704386,0.00006402759,0.000044911685,0.00011560623,0.0017584198,0.00075506576,0.0006421754,0.9663336,0.00006950156],"about_ca_topic_score_codex":0.32079503,"about_ca_topic_score_gemma":0.40894362,"teacher_disagreement_score":0.32079503,"about_ca_system_score_codex":0.0025906737,"about_ca_system_score_gemma":0.0036173812,"threshold_uncertainty_score":0.6378556},"labels":[],"label_agreement":null},{"id":"W6927256940","doi":"10.25549/webster-c100-10089","title":"Toward Community-Oriented Policing, 1987-01","year":2021,"lang":"en","type":"dataset","venue":"University of Southern California Digital Library","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Commission; Newspaper; Economic Justice; Variety (cybernetics); Criminal justice; Government (linguistics)","score_opus":0.026216559793152655,"score_gpt":0.23964924562996395,"score_spread":0.2134326858368113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6927256940","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004140066,0.00007544161,0.00004857531,0.00022641671,0.00002890692,0.000014713454,0.99845517,0.000115339346,0.0006213662],"genre_scores_gemma":[0.00044532618,0.00006253036,0.00022718761,0.000051812553,0.000009439546,0.00006472111,0.998382,0.000030077714,0.00072700693],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779946,0.00043092208,0.00028662433,0.00039574434,0.0007745694,0.00031262173],"domain_scores_gemma":[0.9945911,0.00071170664,0.00069024204,0.0008988239,0.0024629664,0.0006451729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031322918,0.0015889459,0.0010398434,0.0039579067,0.0011256867,0.0045207343,0.0026688068,0.0015803628,0.019829722],"category_scores_gemma":[0.011864731,0.0011922852,0.00086811546,0.010403821,0.00043819216,0.0014853432,0.0024188487,0.0025065562,0.048897058],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026106114,0.000021234628,0.0029748667,0.000115380724,0.0000098873725,0.000008445713,0.00002439196,0.00018621159,0.000012181956,0.00022462026,0.99456835,0.001828342],"study_design_scores_gemma":[0.00043726002,0.000034041263,0.05533131,0.00041292523,0.000034824538,0.000049836777,0.00036878636,0.0013372566,0.00031913046,0.0007902104,0.94084764,0.000036783833],"about_ca_topic_score_codex":0.20358217,"about_ca_topic_score_gemma":0.29943988,"teacher_disagreement_score":0.20358217,"about_ca_system_score_codex":0.00390945,"about_ca_system_score_gemma":0.0058892095,"threshold_uncertainty_score":0.4047944},"labels":[],"label_agreement":null},{"id":"W6929426964","doi":"10.5061/dryad.44jk0","title":"Data from: Acute, delayed and chronic remote ischemic conditioning is associated with downregulation of mTOR and enhanced autophagy signaling","year":2014,"lang":"en","type":"dataset","venue":"Data Archiving and Networked Services (DANS)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Autophagy; Cardioprotection; PI3K/AKT/mTOR pathway; Ischemia; AMPK; Ischemic preconditioning; Signal transduction; Downregulation and upregulation","score_opus":0.029391244070330582,"score_gpt":0.32030643246463,"score_spread":0.2909151883942994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929426964","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6429855,0.009677656,0.012871131,0.006148272,0.004799215,0.002186588,0.26312286,0.003700364,0.054508287],"genre_scores_gemma":[0.6516185,0.0073677837,0.0128604425,0.0034142314,0.0008694403,0.0045174006,0.2087662,0.0005191571,0.110066846],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988707,0.000076608776,0.00019296176,0.0001641213,0.00051700743,0.00017857077],"domain_scores_gemma":[0.99912256,0.00012350405,0.00018202652,0.00012260408,0.00025982253,0.00018952563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011057811,0.0008383492,0.0012262978,0.000881253,0.0005550152,0.00080842245,0.00070989464,0.00079610385,0.07044665],"category_scores_gemma":[0.0009105999,0.00019948665,0.0007339015,0.00085541065,0.0006590893,0.00048197602,0.000672656,0.0016157188,0.013735252],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06503634,0.005403704,0.01709283,0.005533094,0.0009929888,0.001304147,0.0003966885,0.0006244391,0.694793,0.0011870204,0.08892484,0.1187109],"study_design_scores_gemma":[0.004925675,0.012563216,0.33962667,0.00087021844,0.0010451385,0.0034702457,0.00048854324,0.0013805429,0.37254193,0.0012277807,0.26167354,0.00018657622],"about_ca_topic_score_codex":0.00090589095,"about_ca_topic_score_gemma":0.0012860041,"teacher_disagreement_score":0.07044665,"about_ca_system_score_codex":0.00033064128,"about_ca_system_score_gemma":0.0011492261,"threshold_uncertainty_score":0.23566747},"labels":[],"label_agreement":null},{"id":"W6929572632","doi":"10.5061/dryad.ksn02v785","title":"Data from: Palaeobiology and taphonomy of the rangeomorph (Culmofrons plumosa)","year":2023,"lang":"en","type":"dataset","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Taphonomy; Paleobiology; Paleoecology; Clade; Phylogenetic tree; Lineage (genetic); Tree of life (biology)","score_opus":0.28176754424813694,"score_gpt":0.4568649326875173,"score_spread":0.17509738843938039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929572632","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018946012,0.0004938574,0.000063289925,0.00010772245,0.000018454552,0.00001059301,0.9965209,0.00008189084,0.0008086627],"genre_scores_gemma":[0.0051705022,0.00034935772,0.00034688355,0.00008848972,0.000010975225,0.00009475327,0.99291503,0.000033681372,0.000990317],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99938667,0.00008161003,0.000089448855,0.00021014761,0.00011064521,0.000121430676],"domain_scores_gemma":[0.9983606,0.00050281594,0.00038498978,0.00021170895,0.00036393135,0.00017597899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072565104,0.0009843811,0.0011448598,0.002882761,0.00070537534,0.0013008472,0.0014814896,0.0011638076,0.024882918],"category_scores_gemma":[0.0040969127,0.00028788316,0.0007209288,0.004996523,0.0003838099,0.00066438364,0.0016155951,0.0010904061,0.019059656],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048213213,0.000045389865,0.02520074,0.0068148794,0.0003098086,0.00027274233,0.00027207055,0.0006233972,0.0011341117,0.00080356817,0.9508027,0.013238407],"study_design_scores_gemma":[0.0003219148,0.000037122354,0.08000186,0.0014211392,0.00026456185,0.000497193,0.00048704736,0.0003546024,0.0009120994,0.00076086464,0.91488767,0.000053903103],"about_ca_topic_score_codex":0.037578,"about_ca_topic_score_gemma":0.08746581,"teacher_disagreement_score":0.037578,"about_ca_system_score_codex":0.0010368031,"about_ca_system_score_gemma":0.0017198274,"threshold_uncertainty_score":0.08324164},"labels":[],"label_agreement":null},{"id":"W6930097254","doi":"10.5281/zenodo.11031626","title":"Canadian University of Nigeria, Abuja 2024/2025 Admission form is on sale Now☎07066280862} Dr ANITA {O7066280862} For Admission help NOW!!!","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hospital admission; Work (physics); Government (linguistics); Public health","score_opus":0.03782249664164417,"score_gpt":0.29061488684134423,"score_spread":0.25279239019970007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930097254","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015861422,0.001009663,0.00023012719,0.0036244544,0.0025422482,0.00017540343,0.0026382084,0.00061638054,0.98757744],"genre_scores_gemma":[0.0011487075,0.00023300869,0.00014883828,0.00024296428,0.00006179553,0.0000145034455,0.00031883793,0.00007884293,0.99775237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99948174,0.000044159013,0.000023217275,0.0000769812,0.0001950181,0.00017889484],"domain_scores_gemma":[0.9979235,0.000113814356,0.000059458896,0.000085086496,0.00075956277,0.001058493],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005644371,0.0009262868,0.00054037303,0.0014161175,0.003430564,0.003273468,0.00083426625,0.0019404616,0.8245067],"category_scores_gemma":[0.0020744188,0.00042092218,0.00057132903,0.00088566815,0.0006700123,0.0008306844,0.0019972126,0.001760024,0.6416899],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012298783,0.000089680645,0.0005240891,0.0000982363,0.0000040282216,0.00024601913,0.000054198852,0.00006884295,0.0003395273,0.0017652155,0.9211768,0.07551019],"study_design_scores_gemma":[0.000022674758,0.000030051038,0.0011592188,0.00012300414,0.000003146978,0.00016573245,0.00020317723,0.000064517364,0.00025862327,0.0004322668,0.99752885,0.000008688621],"about_ca_topic_score_codex":0.045525704,"about_ca_topic_score_gemma":0.14718409,"teacher_disagreement_score":0.1754933,"about_ca_system_score_codex":0.0028669024,"about_ca_system_score_gemma":0.008217069,"threshold_uncertainty_score":0.2503199},"labels":[],"label_agreement":null},{"id":"W6930217236","doi":"10.5281/zenodo.12732406","title":"Binding Lost Love Spells Specialist in USA UK Canada +27787407632South Africa UAE Indonesia Singapore Turkey Luxembourg Finland Norway German Spain Sweden Malta Brunei Japan Ireland Iceland Australia Qatar Croatia Austria Denmark Netherlands Romania Oman","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spell; German; Wife; North west; Quarter (Canadian coin); Scots; Kingdom","score_opus":0.04770322174299311,"score_gpt":0.29405115386045017,"score_spread":0.24634793211745706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930217236","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001279148,0.0007955439,0.00016350945,0.0039737555,0.0020904434,0.00007996151,0.0015828696,0.00043483134,0.98959994],"genre_scores_gemma":[0.0011769529,0.0001648096,0.00005263016,0.00041863555,0.00006638777,0.000013017378,0.00019018266,0.0000919345,0.9978255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99945325,0.000047702775,0.000017996445,0.00008646576,0.00018713957,0.00020744608],"domain_scores_gemma":[0.99709845,0.00011403716,0.000088975845,0.00008479988,0.0008976024,0.0017160695],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00048536004,0.00064292876,0.00050904875,0.00072655396,0.0032088996,0.003154642,0.0006095306,0.0011631969,0.8597017],"category_scores_gemma":[0.0013933331,0.00025210404,0.00024120082,0.0007247722,0.0005152173,0.0017428044,0.0025944468,0.001178937,0.6685661],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013416805,0.000015255051,0.00030153387,0.000046897763,7.962559e-7,0.000071157745,0.00007471797,0.000014781445,0.00014022103,0.00043934086,0.96737456,0.031507302],"study_design_scores_gemma":[0.0000043243344,0.000009429158,0.0010601954,0.000038132013,0.0000010254469,0.00005734817,0.00034876933,0.000014723959,0.00005137334,0.00005903755,0.99835277,0.0000028460847],"about_ca_topic_score_codex":0.020232016,"about_ca_topic_score_gemma":0.10014964,"teacher_disagreement_score":0.1402983,"about_ca_system_score_codex":0.0018128839,"about_ca_system_score_gemma":0.00680244,"threshold_uncertainty_score":0.20011854},"labels":[],"label_agreement":null},{"id":"W6930334914","doi":"10.5281/zenodo.11789149","title":"Iso 17556 pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Work (physics); Nucleofection; Limiting; Point (geometry)","score_opus":0.04781651636468972,"score_gpt":0.31114694003018595,"score_spread":0.26333042366549625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930334914","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003679503,0.0013503043,0.007012774,0.0006962986,0.0029470965,0.00045591642,0.009036763,0.0057800566,0.97235286],"genre_scores_gemma":[0.0020632858,0.0017811462,0.0038901635,0.0005796252,0.00047216043,0.00023872199,0.009984223,0.0027984213,0.9781924],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961825,0.0001932139,0.00025443066,0.00031065408,0.002803099,0.00025613265],"domain_scores_gemma":[0.99317026,0.00036429922,0.00020076061,0.0006888216,0.0051964894,0.00037936293],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024729136,0.002381272,0.0014567211,0.0065850727,0.0018813539,0.009186604,0.0044453186,0.0034192412,0.72753173],"category_scores_gemma":[0.0079875635,0.0012776618,0.0014052136,0.0052173184,0.0012755753,0.00691661,0.0032094684,0.0025366964,0.75923276],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008488647,0.000058365327,0.0000752788,0.00060931034,0.000006367487,0.00009554943,0.00006064139,0.00026585918,0.002315419,0.006889477,0.8319678,0.15757114],"study_design_scores_gemma":[0.000007162554,0.000016996753,0.0001228242,0.00009072567,0.0000032828013,0.00005761372,0.00002639273,0.000047077603,0.0006850456,0.0006405314,0.99829394,0.000008365787],"about_ca_topic_score_codex":0.006898244,"about_ca_topic_score_gemma":0.0062297205,"teacher_disagreement_score":0.72753173,"about_ca_system_score_codex":0.0025318796,"about_ca_system_score_gemma":0.0042117024,"threshold_uncertainty_score":0.3886429},"labels":[],"label_agreement":null},{"id":"W6930357843","doi":"10.5281/zenodo.12043003","title":"giochi di investigazione per bambini pdf","year":2024,"lang":"it","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Roller coaster; Girl; Child health; Fantasy","score_opus":0.051503107063154814,"score_gpt":0.29596890428221656,"score_spread":0.24446579721906175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930357843","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004197698,0.041552823,0.0037625572,0.010543495,0.013734468,0.0006015457,0.0048509743,0.0041335016,0.916623],"genre_scores_gemma":[0.012820252,0.017374963,0.0034723058,0.0022549757,0.0028975978,0.00019279947,0.0027030485,0.0016045714,0.9566795],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990729,0.0001040662,0.000032667405,0.0001433753,0.00050034304,0.0001466013],"domain_scores_gemma":[0.9977877,0.00029304434,0.00008125776,0.00021414857,0.00086738117,0.00075647474],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015822945,0.0012974221,0.0010584253,0.0026180486,0.0012922573,0.004188622,0.0011048181,0.0018821949,0.4624452],"category_scores_gemma":[0.0025831368,0.000465972,0.0006252942,0.0019291431,0.00075864693,0.0028421867,0.0023212978,0.002450721,0.3177147],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031450661,0.00009864222,0.00025300015,0.000714553,0.000010715617,0.00024126,0.00017787615,0.00007281833,0.008230496,0.0032940262,0.790401,0.19619113],"study_design_scores_gemma":[0.000019991761,0.00005520024,0.0006290037,0.00017621055,0.0000066819143,0.00026151113,0.00006183017,0.000030739327,0.001653711,0.00042468423,0.99667275,0.000007768925],"about_ca_topic_score_codex":0.0024122703,"about_ca_topic_score_gemma":0.004440371,"teacher_disagreement_score":0.5375548,"about_ca_system_score_codex":0.0019086093,"about_ca_system_score_gemma":0.0014073659,"threshold_uncertainty_score":0.76675665},"labels":[],"label_agreement":null},{"id":"W6930545875","doi":"10.5281/zenodo.12501376","title":"slow carb list pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Taste; Cruciferous vegetables; Bitter taste; Feeding behavior; JAMS; Food supply; Food intake; Food products","score_opus":0.043613550974797174,"score_gpt":0.304145419622963,"score_spread":0.2605318686481658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930545875","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035783782,0.000557039,0.0019019663,0.0008461592,0.002868023,0.00032199218,0.007329294,0.008790939,0.9770269],"genre_scores_gemma":[0.0012108042,0.00038478375,0.00079488155,0.000553863,0.0003507344,0.00009114487,0.003080991,0.0035839549,0.98994887],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993831,0.000031975324,0.000028984186,0.00009316668,0.00037395602,0.00008888034],"domain_scores_gemma":[0.9962645,0.0004170181,0.00009188482,0.0003712672,0.002082358,0.0007728116],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005424339,0.0015455082,0.001336518,0.0024816864,0.0021978773,0.006900622,0.002687133,0.0021234744,0.9539051],"category_scores_gemma":[0.004665034,0.0010825363,0.0010921208,0.0020680253,0.00064415694,0.0068936166,0.003143846,0.0027950332,0.9189697],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004073988,0.000030800384,0.000033771135,0.00020627439,0.0000018805262,0.000037486836,0.000024025576,0.000034817098,0.0005591337,0.0009000415,0.96617305,0.03195788],"study_design_scores_gemma":[0.00002029123,0.000023213193,0.00017281892,0.000060740113,0.0000031783595,0.000065193286,0.000051552906,0.000052142394,0.0005744855,0.00052540377,0.99843913,0.000011890176],"about_ca_topic_score_codex":0.0034051957,"about_ca_topic_score_gemma":0.0070437468,"teacher_disagreement_score":0.046094894,"about_ca_system_score_codex":0.0014684191,"about_ca_system_score_gemma":0.0016734359,"threshold_uncertainty_score":0.06574869},"labels":[],"label_agreement":null},{"id":"W6930549519","doi":"10.5281/zenodo.13620871","title":"Fig. 1 in New evidence on brain-endocranial cavity relationships in ornithischian dinosaurs","year":2005,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Holotype; Indeterminate; Theropoda; Taxonomy (biology); Fossil Record","score_opus":0.10814675137179994,"score_gpt":0.33357886766103384,"score_spread":0.2254321162892339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930549519","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25039563,0.014041702,0.008933311,0.0010591353,0.0011574391,0.00016293091,0.025195561,0.001400464,0.6976539],"genre_scores_gemma":[0.8044394,0.009117256,0.028205222,0.00047963098,0.00043277358,0.00010211486,0.019545004,0.00026867655,0.13740994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99994254,0.0000067273663,0.0000034162183,0.000023920857,0.000013021468,0.000010299521],"domain_scores_gemma":[0.99985826,0.000038687722,0.000024571444,0.000031406053,0.000031690728,0.0000153211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010247295,0.000273182,0.00011926149,0.0013354607,0.0007489053,0.00056618237,0.00037902215,0.00033747184,0.06604842],"category_scores_gemma":[0.0002716649,0.000107810374,0.0001318505,0.0014213563,0.0007422185,0.000513049,0.0005269083,0.00029683084,0.007385427],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010633089,0.000062477746,0.100052334,0.0018589892,0.00008047819,0.003715368,0.0038851907,0.0007641947,0.055593576,0.020545917,0.13027129,0.6821068],"study_design_scores_gemma":[0.000022957693,0.000060651768,0.3208037,0.00019124836,0.000042122538,0.0036635422,0.00090980466,0.00021579317,0.0035578336,0.0016335305,0.6688833,0.000015485068],"about_ca_topic_score_codex":0.014236853,"about_ca_topic_score_gemma":0.06854156,"teacher_disagreement_score":0.06604842,"about_ca_system_score_codex":0.00034153461,"about_ca_system_score_gemma":0.00018730207,"threshold_uncertainty_score":0.22095394},"labels":[],"label_agreement":null},{"id":"W6930604239","doi":"10.5281/zenodo.14920013","title":"Diplocardia verrucosa Ude 1895","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dorsum; Groove (engineering); Adult male; Apex (geometry); Sucker","score_opus":0.03872318634108398,"score_gpt":0.31411062854216404,"score_spread":0.2753874422010801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930604239","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5066209,0.018926295,0.008661625,0.00059712055,0.0016599207,0.00052758557,0.003023331,0.00038797836,0.45959526],"genre_scores_gemma":[0.9783226,0.0017826161,0.0022270882,0.0002823528,0.00012130635,0.000067142675,0.0012053172,0.00001434695,0.015977127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998191,0.000023741777,0.000017451166,0.00006479185,0.000046282217,0.000028712846],"domain_scores_gemma":[0.9998945,0.000026293445,0.000039709674,0.000009899068,0.000016742817,0.000012975398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105860636,0.00042722357,0.00029079005,0.0009866707,0.0010758124,0.00047986754,0.0003596941,0.0004410162,0.009080106],"category_scores_gemma":[0.0004837077,0.00018944447,0.0000989255,0.00049270503,0.00047385952,0.0008187266,0.0005775402,0.0003532269,0.0020389452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007117586,0.00017721654,0.07868995,0.0011094884,0.000088079214,0.012789932,0.003615043,0.0017889745,0.03931854,0.012374564,0.05005663,0.7992798],"study_design_scores_gemma":[0.00009102625,0.0006106568,0.27566007,0.0010377524,0.00010766395,0.023201313,0.0028663278,0.0015426864,0.006944724,0.0017872074,0.6861006,0.000049946633],"about_ca_topic_score_codex":0.0058828834,"about_ca_topic_score_gemma":0.008199977,"teacher_disagreement_score":0.009080106,"about_ca_system_score_codex":0.00046866457,"about_ca_system_score_gemma":0.00014608374,"threshold_uncertainty_score":0.030376017},"labels":[],"label_agreement":null},{"id":"W6931022459","doi":"10.5281/zenodo.16566502","title":"CITAC NEWS 2025","year":2025,"lang":"en","type":"report","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Traceability; Comparability; Key (lock); Standardization; Consistency (knowledge bases)","score_opus":0.11269136907180899,"score_gpt":0.3648266176713024,"score_spread":0.25213524859949343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931022459","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005727192,0.003655717,0.00076552393,0.0144775305,0.028770613,0.00045231177,0.03779754,0.0026132935,0.9108948],"genre_scores_gemma":[0.0013934947,0.0014754607,0.000783057,0.0045634797,0.0014180737,0.00023220468,0.030710647,0.0006431243,0.95878047],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99570495,0.0002531728,0.00012904906,0.00027702973,0.0031431736,0.00049261376],"domain_scores_gemma":[0.9956162,0.00035962235,0.00020574825,0.0002609209,0.0026797066,0.0008777884],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002747686,0.0016113067,0.0007110389,0.0032823575,0.0022059944,0.009189624,0.0022950624,0.0055593597,0.379663],"category_scores_gemma":[0.006479819,0.00057514757,0.0010484228,0.0032911208,0.0005174061,0.0021654498,0.0018600993,0.0034951349,0.39941084],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001395435,0.000009744753,0.000024197474,0.000034770932,8.965716e-7,0.000019107561,0.0000046206883,0.000012546423,0.000048708254,0.00058227417,0.9938911,0.005358105],"study_design_scores_gemma":[0.000005897969,0.000008357599,0.00014883207,0.000030906303,0.0000010661723,0.000017757257,0.000013621547,0.000018279814,0.00006999448,0.00016112023,0.99952114,0.000003088693],"about_ca_topic_score_codex":0.030880077,"about_ca_topic_score_gemma":0.044176243,"teacher_disagreement_score":0.620337,"about_ca_system_score_codex":0.0037241455,"about_ca_system_score_gemma":0.010967225,"threshold_uncertainty_score":0.8848355},"labels":[],"label_agreement":null},{"id":"W6931161418","doi":"10.5281/zenodo.3866890","title":"Ommatoiulus imminutus","year":2017,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Research (Canada)","funders":"","keywords":"Schizophyllum commune; Distribution (mathematics); Process (computing); Identification (biology)","score_opus":0.07695822765553972,"score_gpt":0.3297608615452099,"score_spread":0.25280263388967017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931161418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59511423,0.007858437,0.0036265326,0.0006838276,0.0004954595,0.00026778335,0.007967815,0.00053568085,0.38345024],"genre_scores_gemma":[0.96703637,0.0013002784,0.002888798,0.0003241803,0.00012405853,0.00010780354,0.0034448595,0.000029678476,0.024743987],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998853,0.000009125559,0.00001401848,0.000037835496,0.000029645755,0.000023917913],"domain_scores_gemma":[0.9997974,0.000029224011,0.000087927714,0.000017137758,0.000032581476,0.00003572851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007661254,0.00042198523,0.00019714987,0.0010100213,0.0010606586,0.00025543055,0.0003518597,0.00051746034,0.011460135],"category_scores_gemma":[0.00029192757,0.00013759479,0.00020250387,0.0006247349,0.000361461,0.0005700891,0.00095192145,0.00035219005,0.0037966392],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012440311,0.00020747758,0.046646956,0.00125005,0.00007426016,0.0033526309,0.0013741145,0.00075244263,0.30300474,0.00294689,0.0099006,0.6292458],"study_design_scores_gemma":[0.00007086969,0.0007404685,0.75997514,0.00044775987,0.00009024014,0.0041957963,0.0012338747,0.0005593986,0.019076303,0.0011454474,0.21242355,0.000041000665],"about_ca_topic_score_codex":0.006788376,"about_ca_topic_score_gemma":0.009432533,"teacher_disagreement_score":0.011460135,"about_ca_system_score_codex":0.0004649096,"about_ca_system_score_gemma":0.00027737883,"threshold_uncertainty_score":0.038337946},"labels":[],"label_agreement":null},{"id":"W6931360755","doi":"10.5281/zenodo.5555408","title":"stfxecutables/error-consistency: v0.3.2-alpha","year":2021,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Francis Xavier University","funders":"","keywords":"Process (computing); Identification (biology); Product (mathematics); Work (physics)","score_opus":0.07234457896070746,"score_gpt":0.3187038909340337,"score_spread":0.24635931197332622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931360755","genre_codex":"software","genre_gemma":"software","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"software","genre_consensus":"software","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00063229474,0.0003881008,0.074527636,0.00053148007,0.0008949934,0.00026590217,0.03754505,0.8705201,0.014694426],"genre_scores_gemma":[0.012914328,0.0005328718,0.040868595,0.0008216227,0.0004258805,0.0005986135,0.13536891,0.7625234,0.0459457],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98359007,0.0028501304,0.0018547858,0.0030451135,0.006737196,0.0019225576],"domain_scores_gemma":[0.969015,0.007990332,0.001410153,0.013461107,0.0066445316,0.0014788703],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014262406,0.006630853,0.0037804204,0.0043765567,0.0022989812,0.010144126,0.0152841555,0.006238116,0.41743705],"category_scores_gemma":[0.058932085,0.006399314,0.0050837183,0.0033961122,0.003240083,0.011990686,0.009547555,0.008776607,0.45192897],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010392737,0.000074705815,0.0010300254,0.0011557319,0.00010936688,0.00014769679,0.00018234325,0.0021102855,0.0022513499,0.008626225,0.94550925,0.03776374],"study_design_scores_gemma":[0.00053935836,0.00012410626,0.00066587003,0.0005673191,0.00008167055,0.00040644352,0.00006498441,0.01462622,0.020048091,0.019236643,0.9433758,0.00026352616],"about_ca_topic_score_codex":0.007127554,"about_ca_topic_score_gemma":0.004179699,"teacher_disagreement_score":0.41743705,"about_ca_system_score_codex":0.002813635,"about_ca_system_score_gemma":0.00488608,"threshold_uncertainty_score":0.8309553},"labels":[],"label_agreement":null},{"id":"W6931538674","doi":"10.5281/zenodo.8249834","title":"Nobel Prize and Europe(s). Prix Nobel : un esprit européen ?","year":2019,"lang":"fr","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"General interest; Czech; Twenty-First Century","score_opus":0.0357360313191603,"score_gpt":0.28054597017727323,"score_spread":0.24480993885811292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931538674","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059609255,0.078713305,0.00077529706,0.33105886,0.2407286,0.000058939844,0.0010453148,0.00018822352,0.34147057],"genre_scores_gemma":[0.053026922,0.031401776,0.0009332294,0.048785444,0.020464158,0.00009770664,0.0010299103,0.00039357116,0.8438672],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.997632,0.00035589084,0.00011148381,0.00032669937,0.000715846,0.0008580548],"domain_scores_gemma":[0.9957967,0.0002396847,0.00021558099,0.0001432591,0.0006690216,0.0029357627],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.004214079,0.0010036544,0.0011312665,0.0010966434,0.0043031927,0.016450373,0.00092982996,0.0051407106,0.08306262],"category_scores_gemma":[0.00562412,0.00035450462,0.0006972197,0.0013357768,0.0020666646,0.0068493607,0.0063328184,0.007813996,0.04197871],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009143873,0.000028870409,0.00035084755,0.000087854634,0.000010944038,0.00005644993,0.00015306214,0.000047656893,0.00012947866,0.033142302,0.93241775,0.0334834],"study_design_scores_gemma":[0.000013044547,0.0000260801,0.0007998184,0.0001374028,0.000004665913,0.000054114676,0.000270861,0.000020510957,0.00005694832,0.004998648,0.99360484,0.000013039883],"about_ca_topic_score_codex":0.003149642,"about_ca_topic_score_gemma":0.0048538507,"teacher_disagreement_score":0.9956968,"about_ca_system_score_codex":0.0024032255,"about_ca_system_score_gemma":0.006366653,"threshold_uncertainty_score":0.27787215},"labels":[],"label_agreement":null},{"id":"W6939471573","doi":"10.6084/m9.figshare.14211579.v1","title":"Additional file 5 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Toxicity; Alkaline phosphatase; Alanine aminotransferase; Glutamate dehydrogenase; Alanine; Aspartate Aminotransferases","score_opus":0.15003309822266772,"score_gpt":0.4333167021039686,"score_spread":0.2832836038813009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939471573","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008947707,0.000111898466,0.00063100323,0.00033873942,0.000048522757,0.0009583609,0.9926456,0.00042569207,0.0039453395],"genre_scores_gemma":[0.040782843,0.0008366595,0.010706035,0.0032395334,0.00036432274,0.015882498,0.8854438,0.0009860735,0.04175819],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988751,0.00022277636,0.00029124037,0.00019076746,0.00029879366,0.000121359364],"domain_scores_gemma":[0.9751981,0.016628187,0.0027393133,0.0014315943,0.0034555688,0.00054732134],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031636758,0.0007332884,0.0014008485,0.0011280215,0.00066276314,0.0012210226,0.0010049888,0.0010999568,0.8367113],"category_scores_gemma":[0.028828822,0.00044721528,0.0009330222,0.0018213304,0.00020357948,0.0012508145,0.0006010317,0.0008861746,0.10908152],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004401576,0.0005720904,0.0028145635,0.0054393513,0.00012998372,0.00010746082,0.000059744707,0.00048947573,0.0002669174,0.00085064664,0.94960743,0.035260767],"study_design_scores_gemma":[0.020428669,0.002303682,0.027697796,0.0052317725,0.00052480685,0.00078947627,0.00019674815,0.0019274369,0.0021838327,0.007993097,0.9305939,0.00012868343],"about_ca_topic_score_codex":0.0026141973,"about_ca_topic_score_gemma":0.005526329,"teacher_disagreement_score":0.8367113,"about_ca_system_score_codex":0.0013312198,"about_ca_system_score_gemma":0.0019985447,"threshold_uncertainty_score":0.23291147},"labels":[],"label_agreement":null},{"id":"W6939613204","doi":"10.6084/m9.figshare.25143611","title":"Additional file 1 of Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; Jewish General Hospital","funders":"","keywords":"Immunofluorescence; Antibody; Staining; Monoclonal antibody","score_opus":0.06469028045558681,"score_gpt":0.4069933686294916,"score_spread":0.34230308817390476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939613204","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000631486,0.000069788,0.0029339031,0.00012292796,0.00004953115,0.0001106467,0.9916162,0.0024913468,0.0019742271],"genre_scores_gemma":[0.017127832,0.0003715973,0.021139486,0.00063871825,0.000097211254,0.0021150163,0.9421932,0.004067683,0.012249259],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994832,0.00006390886,0.000061717226,0.000122018675,0.00019109853,0.00007803694],"domain_scores_gemma":[0.99226624,0.005541443,0.00044274036,0.00065165374,0.0008293149,0.00026862664],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013690015,0.0012212755,0.0011333843,0.0016758274,0.0006182766,0.0013410322,0.00192563,0.0013297139,0.8180737],"category_scores_gemma":[0.0076742806,0.0008328474,0.0007091593,0.0018098784,0.00025521268,0.0010891965,0.00082244474,0.001060303,0.16754536],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009140005,0.0003489796,0.0018931316,0.0032037748,0.00007370453,0.00021474178,0.000063153064,0.0020691666,0.0049500912,0.0013904717,0.9576613,0.027217494],"study_design_scores_gemma":[0.003461629,0.0006798161,0.018414842,0.0017877442,0.00023725277,0.0014850262,0.00023177007,0.011868405,0.0386693,0.012215348,0.9106369,0.00031193517],"about_ca_topic_score_codex":0.0031918655,"about_ca_topic_score_gemma":0.0069872737,"teacher_disagreement_score":0.8180737,"about_ca_system_score_codex":0.0009823963,"about_ca_system_score_gemma":0.0010895053,"threshold_uncertainty_score":0.2594958},"labels":[],"label_agreement":null},{"id":"W6943188177","doi":"10.15468/dl.qxbq9d","title":"Occurrence Download","year":2022,"lang":"en","type":"dataset","venue":"Global Biodiversity Information Facility","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Download; Matching (statistics); Range (aeronautics); Task (project management); Reference data","score_opus":0.03529397703872908,"score_gpt":0.2980316917159591,"score_spread":0.26273771467723006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6943188177","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004927289,0.00003444838,0.000048198224,0.000044338096,0.000013042464,0.000005868717,0.99879164,0.00039863397,0.0006145224],"genre_scores_gemma":[0.00016128612,0.000035340436,0.00018927823,0.00004852498,0.000003271729,0.00003677597,0.99899334,0.00012008079,0.00041213265],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999006,0.00014846411,0.00012552335,0.00034612013,0.00021846444,0.00015553164],"domain_scores_gemma":[0.99780077,0.00064803753,0.00020163624,0.0005634506,0.0005168025,0.00026927903],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010303898,0.0020305465,0.0015998184,0.0043606553,0.000999068,0.0025195288,0.0029558446,0.002166737,0.13017625],"category_scores_gemma":[0.0056500845,0.0008859788,0.0012502719,0.008248193,0.00046594915,0.0020480335,0.0023128903,0.0021188206,0.18571153],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032896085,0.0000128378215,0.00041468057,0.0004918148,0.000016746295,0.000016820499,0.00002187157,0.00014504041,0.00010996873,0.0003720063,0.99705374,0.0013115436],"study_design_scores_gemma":[0.000093124356,0.000009611339,0.0019506093,0.0001870138,0.000016670581,0.000049300357,0.00007029449,0.0002081377,0.00020968854,0.0008470111,0.9963404,0.00001816905],"about_ca_topic_score_codex":0.020434324,"about_ca_topic_score_gemma":0.036758244,"teacher_disagreement_score":0.86982375,"about_ca_system_score_codex":0.0016628591,"about_ca_system_score_gemma":0.0023320685,"threshold_uncertainty_score":0.43548292},"labels":[],"label_agreement":null},{"id":"W6958178961","doi":"10.6084/m9.figshare.14211585","title":"Additional file 7 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Table (database); Key (lock); File system; Data file; Data collection","score_opus":0.15007368053587383,"score_gpt":0.4332643322469285,"score_spread":0.2831906517110547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958178961","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002969772,0.00016270186,0.0003012552,0.00032931,0.000046885176,0.00096650113,0.9939983,0.00031269083,0.00358537],"genre_scores_gemma":[0.023923304,0.0014790753,0.008090682,0.0036484224,0.0005321696,0.021076964,0.88089955,0.001124518,0.05922526],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837565,0.00039382942,0.00046569764,0.0002225011,0.00038224587,0.00016004099],"domain_scores_gemma":[0.9685273,0.021172926,0.003571049,0.0015202134,0.004533393,0.00067493645],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037082215,0.0009475337,0.0018939159,0.0016720687,0.00066783366,0.0015276764,0.0013612275,0.0015421257,0.88012695],"category_scores_gemma":[0.03204598,0.00055975973,0.0013880373,0.0027411452,0.00027073795,0.0017152997,0.00076019706,0.0010327671,0.15634337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034471718,0.00028677215,0.0011104444,0.011778346,0.00014431696,0.000070176015,0.00004200632,0.00030141667,0.00018085854,0.00095116167,0.9554193,0.026267985],"study_design_scores_gemma":[0.02422552,0.0014140141,0.015336688,0.008532986,0.00062380807,0.00047712124,0.00015375312,0.0009865282,0.0011346953,0.008381314,0.9386166,0.00011689761],"about_ca_topic_score_codex":0.0032797235,"about_ca_topic_score_gemma":0.0067782756,"teacher_disagreement_score":0.88012695,"about_ca_system_score_codex":0.0016064369,"about_ca_system_score_gemma":0.002763447,"threshold_uncertainty_score":0.17098427},"labels":[],"label_agreement":null},{"id":"W6958297444","doi":"10.60692/q4x54-j6955","title":"Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Downregulation and upregulation; Monoclonal antibody; Antibody; Polyclonal antibodies; Epitope; Receptor; Cytotoxicity","score_opus":0.057490557917117824,"score_gpt":0.3086334556016433,"score_spread":0.25114289768452547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958297444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199647,0.0022066776,0.002945034,0.000048826994,0.000034483608,0.000033974575,0.00013047791,0.00012714085,0.0024768389],"genre_scores_gemma":[0.9948561,0.0008938005,0.0016644455,0.00004631587,0.000021944974,0.000043011438,0.00034466968,0.000023605979,0.002106063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974686,0.000039879054,0.0000198586,0.000054450953,0.000059541355,0.000079258694],"domain_scores_gemma":[0.9998938,0.00003182084,0.000020336323,0.000015490603,0.000016107588,0.000022420467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020490937,0.00046602485,0.000436727,0.00021589179,0.00008099165,0.00027272658,0.00015021279,0.00024118769,0.0016093863],"category_scores_gemma":[0.00012689762,0.00014179441,0.00030018104,0.00017850094,0.000119173375,0.00020553241,0.00017347647,0.0006328932,0.00037053193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078153964,0.000068000096,0.00007569706,0.000031819527,0.0000053344197,0.00001140504,0.000004356767,0.00004384951,0.9979406,0.000049864935,0.00003817801,0.0016526436],"study_design_scores_gemma":[0.000014972965,0.0007167181,0.0016691526,0.000003059089,0.000020008334,0.00012876329,0.000003844334,0.0006325944,0.99530005,0.000017005535,0.0014916824,0.0000020208877],"about_ca_topic_score_codex":0.00023837802,"about_ca_topic_score_gemma":0.00044731158,"teacher_disagreement_score":0.0016093863,"about_ca_system_score_codex":0.00021387225,"about_ca_system_score_gemma":0.00019236721,"threshold_uncertainty_score":0.0053839087},"labels":[],"label_agreement":null},{"id":"W6958436557","doi":"10.6084/m9.figshare.21550986.v1","title":"Additional file 2 of The impact of facility-based transitional care programs on function and discharge destination for older adults with cognitive impairment: a systematic review","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"","keywords":"Transitional care; Cognition; Function (biology); Older people; MEDLINE; Aged care","score_opus":0.03563368801682821,"score_gpt":0.32996245237872124,"score_spread":0.29432876436189304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958436557","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018266201,0.00053510204,0.00006367864,0.00010943818,0.000020300366,0.0004360039,0.99808204,0.000045070985,0.0005257709],"genre_scores_gemma":[0.014967698,0.004571255,0.004040922,0.001382508,0.00013261693,0.033312622,0.93146056,0.00026692398,0.0098648695],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981111,0.000359462,0.00077441096,0.00026976562,0.0003062158,0.00017888001],"domain_scores_gemma":[0.98076814,0.012870761,0.0030809508,0.0005100235,0.0024571437,0.00031300102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003370054,0.0013260545,0.003100273,0.004976208,0.0005818703,0.0017847993,0.0015734244,0.0013439116,0.4773836],"category_scores_gemma":[0.034764685,0.00087470555,0.004510587,0.008635613,0.00029039386,0.0018677225,0.001488707,0.0009869899,0.015746212],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013246499,0.000062888714,0.0036403947,0.5036095,0.0028083774,0.00008039554,0.0002100591,0.000654717,0.00023545658,0.0022648044,0.47617757,0.008931216],"study_design_scores_gemma":[0.033685986,0.00075118785,0.070148386,0.27628627,0.017338937,0.00046235643,0.0006824621,0.0017318222,0.00075556146,0.0059937346,0.5918931,0.0002702385],"about_ca_topic_score_codex":0.021261781,"about_ca_topic_score_gemma":0.042921837,"teacher_disagreement_score":0.4773836,"about_ca_system_score_codex":0.0027812743,"about_ca_system_score_gemma":0.006203811,"threshold_uncertainty_score":0.7454488},"labels":[],"label_agreement":null},{"id":"W6958634373","doi":"10.6084/m9.figshare.c.3723055_d2.v1","title":"Additional file 2: of The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","year":2017,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cohort; Expression (computer science); Scale (ratio); Cohort study; Clinical significance","score_opus":0.16666382388697107,"score_gpt":0.3897621831193099,"score_spread":0.2230983592323388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958634373","genre_codex":"dataset","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001261573,0.0005687369,0.00081386033,0.00026167647,0.00007428491,0.00044970805,0.99589634,0.00021945736,0.0004543879],"genre_scores_gemma":[0.14263426,0.0041033486,0.03640655,0.0036838294,0.0007888639,0.05751686,0.7284301,0.0019445261,0.024491727],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996636,0.00095748325,0.0010282147,0.0006168188,0.00045618106,0.0003053835],"domain_scores_gemma":[0.88073105,0.10470612,0.0064179483,0.0029171866,0.0045273923,0.0007003585],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0070975507,0.0019738672,0.0042080944,0.00662293,0.0009358698,0.002286711,0.0024749672,0.0016185474,0.6553905],"category_scores_gemma":[0.095300555,0.0013826796,0.008139377,0.009006982,0.00047918825,0.0038583751,0.0014090757,0.0014920102,0.021239853],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006515812,0.00031231157,0.023030741,0.44184226,0.020174455,0.0005351657,0.00052931946,0.00401965,0.00086712476,0.0029329949,0.47560588,0.023634288],"study_design_scores_gemma":[0.108850464,0.0028190257,0.1752897,0.12942234,0.1001064,0.0029460657,0.0019489769,0.015088039,0.0038778353,0.030440595,0.4279504,0.0012601061],"about_ca_topic_score_codex":0.0072823935,"about_ca_topic_score_gemma":0.015350826,"teacher_disagreement_score":0.6553905,"about_ca_system_score_codex":0.0017221434,"about_ca_system_score_gemma":0.003560382,"threshold_uncertainty_score":0.4915436},"labels":[],"label_agreement":null},{"id":"W6961280585","doi":"10.1371/journal.pone.0305485.t003","title":"Percent distribution of homeless individuals by episodes of homelessness, according to selected characteristics, Nipissing District, Ontario 2021.","year":2024,"lang":"en","type":"dataset","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Distribution (mathematics); Population; Statistical analysis","score_opus":0.03287647388166012,"score_gpt":0.3255246239496338,"score_spread":0.2926481500679736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6961280585","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002696279,0.000080648875,0.000018082263,0.00009257425,0.000012860956,0.0000090496405,0.99890006,0.000034026816,0.0005831081],"genre_scores_gemma":[0.0039287866,0.00021651875,0.00019548213,0.00011603691,0.000016433507,0.00010848194,0.9923395,0.000042726206,0.003036134],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9992079,0.000047613397,0.00010015117,0.00017209067,0.0002436266,0.0002285916],"domain_scores_gemma":[0.99601495,0.00033001587,0.00049308443,0.00027849126,0.0023279858,0.0005553968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006892292,0.0010170107,0.0014797358,0.0026641835,0.0012914448,0.0015288624,0.0028734857,0.0011077584,0.042559445],"category_scores_gemma":[0.006673263,0.0008460407,0.0014359328,0.0077495105,0.0003895563,0.00070347084,0.0012362741,0.001210027,0.014382281],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006427602,0.000008302311,0.0074054166,0.0005336448,0.00005357817,0.000016449801,0.00004243231,0.00016031221,0.000033454486,0.0002419516,0.9897804,0.0016597419],"study_design_scores_gemma":[0.0011685526,0.000032170225,0.25935578,0.0018789861,0.00029793073,0.0001476757,0.00058790547,0.0013482224,0.00027067633,0.000750168,0.73406875,0.00009318481],"about_ca_topic_score_codex":0.9527647,"about_ca_topic_score_gemma":0.97632354,"teacher_disagreement_score":0.04723531,"about_ca_system_score_codex":0.010609019,"about_ca_system_score_gemma":0.018699,"threshold_uncertainty_score":0.14237553},"labels":[],"label_agreement":null},{"id":"W6968976635","doi":"10.5281/zenodo.7224378","title":"FIGURES 4–10. Hydrocanthus debilis Sharp, 1882, instar I in Description and chaetotaxic analysis of the larval instars of Hydrocanthus debilis Sharp, 1882 (Coleoptera: Noteridae)","year":2022,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University","funders":"","keywords":"Instar; Dorsum; Seta; Larva; Predation","score_opus":0.03312751978464471,"score_gpt":0.26400192217898477,"score_spread":0.23087440239434007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968976635","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47947094,0.00811709,0.010781387,0.00085075013,0.0014392977,0.0013415025,0.075127795,0.00238675,0.4204844],"genre_scores_gemma":[0.882981,0.0021139605,0.012370668,0.0003484419,0.00016100616,0.0003810414,0.031640768,0.00027041923,0.069732696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999571,0.0000031352276,0.000003424132,0.000014308259,0.000015590738,0.0000064535134],"domain_scores_gemma":[0.99993634,0.000011033416,0.000022203867,0.0000062127688,0.000013702189,0.000010486714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003630536,0.00041325387,0.0001265326,0.0014605925,0.00031753938,0.00014760901,0.00025728054,0.00024664073,0.037081648],"category_scores_gemma":[0.00014671487,0.00017457978,0.00023344325,0.0006972944,0.00026504474,0.00023154,0.00024248958,0.00044715748,0.008090832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012512176,0.00013808158,0.05113141,0.0020224906,0.00012374141,0.0028500946,0.00158067,0.0017032654,0.296269,0.003722492,0.15377156,0.48543602],"study_design_scores_gemma":[0.000063366744,0.00030836192,0.6021294,0.0002595597,0.00010046926,0.0068919878,0.001058265,0.00055582984,0.0186946,0.0007224707,0.36916837,0.000047299636],"about_ca_topic_score_codex":0.004595992,"about_ca_topic_score_gemma":0.011421467,"teacher_disagreement_score":0.037081648,"about_ca_system_score_codex":0.00036353947,"about_ca_system_score_gemma":0.00015910932,"threshold_uncertainty_score":0.1240505},"labels":[],"label_agreement":null},{"id":"W6969419833","doi":"10.5281/zenodo.7246421","title":"Strange Quark as a probe for new physics in the Higgs sector","year":2022,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Higgs boson; Physics beyond the Standard Model; Top quark; Standard Model (mathematical formulation); Quark; Presentation (obstetrics)","score_opus":0.12336085945589462,"score_gpt":0.33110626193960085,"score_spread":0.20774540248370624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6969419833","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27819625,0.02800233,0.014515371,0.2716036,0.076383635,0.0006433139,0.005864883,0.0011495993,0.3236411],"genre_scores_gemma":[0.72276634,0.0060280915,0.0051122685,0.02558013,0.023739194,0.00033168102,0.0029491168,0.0003295556,0.21316372],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99957925,0.00011053552,0.000012349481,0.00008977909,0.00009284088,0.00011521258],"domain_scores_gemma":[0.99935704,0.00016809384,0.000041040206,0.0000315705,0.00009213041,0.00031024142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015389235,0.00069430843,0.00039792276,0.0007432523,0.0014213177,0.002226104,0.00046433008,0.0020001268,0.01783896],"category_scores_gemma":[0.0011974638,0.00020487013,0.00046924816,0.00040011836,0.0006051161,0.00057302974,0.0010379857,0.0015943788,0.0026623113],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015550418,0.0011343494,0.00851474,0.0009880333,0.00027980903,0.010839068,0.0004979781,0.0007513271,0.09534322,0.11708271,0.6489703,0.10004802],"study_design_scores_gemma":[0.0024329128,0.003154926,0.016481087,0.00020329007,0.00025758633,0.009465206,0.00072815554,0.0049283314,0.10500262,0.06878212,0.7884011,0.00016267224],"about_ca_topic_score_codex":0.00045804385,"about_ca_topic_score_gemma":0.0010306087,"teacher_disagreement_score":0.01783896,"about_ca_system_score_codex":0.0018239052,"about_ca_system_score_gemma":0.00092698436,"threshold_uncertainty_score":0.059677243},"labels":[],"label_agreement":null},{"id":"W6976743783","doi":"10.6084/m9.figshare.25143611.v1","title":"Additional file 1 of Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; Jewish General Hospital","funders":"","keywords":"Immunofluorescence; Antibody; Staining; Monoclonal antibody","score_opus":0.05643962261975415,"score_gpt":0.36165966343586975,"score_spread":0.3052200408161156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976743783","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00056929834,0.000070854716,0.0029816928,0.00012191298,0.000049743052,0.00010820924,0.9911911,0.0028470228,0.0020600685],"genre_scores_gemma":[0.014509378,0.00035019877,0.019886086,0.000601748,0.000092356764,0.0020391867,0.94632393,0.0043862476,0.011810786],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994318,0.00006952369,0.00006658488,0.00013379486,0.00021002766,0.000088275345],"domain_scores_gemma":[0.99212646,0.005593408,0.0004414956,0.00071190816,0.0008357007,0.00029103257],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014372524,0.0012855815,0.0012206364,0.0018087924,0.0006514259,0.0013954452,0.0021027245,0.0013875067,0.8254591],"category_scores_gemma":[0.007794678,0.00092569616,0.0007623546,0.0019208237,0.00026428018,0.0011571037,0.0008554649,0.0011289642,0.19201551],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008141122,0.00031025812,0.0015972784,0.002863933,0.00006960018,0.00018340528,0.000056077573,0.0018031311,0.00468173,0.0012421738,0.9615265,0.024851903],"study_design_scores_gemma":[0.0033698536,0.0006428476,0.017116003,0.0016536332,0.00023209598,0.0013777203,0.00020396318,0.010896082,0.03916743,0.011581399,0.9134527,0.00030628665],"about_ca_topic_score_codex":0.003041595,"about_ca_topic_score_gemma":0.006986731,"teacher_disagreement_score":0.8254591,"about_ca_system_score_codex":0.0010613999,"about_ca_system_score_gemma":0.0011323036,"threshold_uncertainty_score":0.24896133},"labels":[],"label_agreement":null},{"id":"W6976866888","doi":"10.6084/m9.figshare.14211585.v1","title":"Additional file 7 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Table (database); Key (lock); File system; Data file; Data collection","score_opus":0.15007368053587383,"score_gpt":0.4332643322469285,"score_spread":0.2831906517110547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976866888","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002969772,0.00016270186,0.0003012552,0.00032931,0.000046885176,0.00096650113,0.9939983,0.00031269083,0.00358537],"genre_scores_gemma":[0.023923304,0.0014790753,0.008090682,0.0036484224,0.0005321696,0.021076964,0.88089955,0.001124518,0.05922526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837565,0.00039382942,0.00046569764,0.0002225011,0.00038224587,0.00016004099],"domain_scores_gemma":[0.9685273,0.021172926,0.003571049,0.0015202134,0.004533393,0.00067493645],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037082215,0.0009475337,0.0018939159,0.0016720687,0.00066783366,0.0015276764,0.0013612275,0.0015421257,0.88012695],"category_scores_gemma":[0.03204598,0.00055975973,0.0013880373,0.0027411452,0.00027073795,0.0017152997,0.00076019706,0.0010327671,0.15634337],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034471718,0.00028677215,0.0011104444,0.011778346,0.00014431696,0.000070176015,0.00004200632,0.00030141667,0.00018085854,0.00095116167,0.9554193,0.026267985],"study_design_scores_gemma":[0.02422552,0.0014140141,0.015336688,0.008532986,0.00062380807,0.00047712124,0.00015375312,0.0009865282,0.0011346953,0.008381314,0.9386166,0.00011689761],"about_ca_topic_score_codex":0.0032797235,"about_ca_topic_score_gemma":0.0067782756,"teacher_disagreement_score":0.88012695,"about_ca_system_score_codex":0.0016064369,"about_ca_system_score_gemma":0.002763447,"threshold_uncertainty_score":0.17098427},"labels":[],"label_agreement":null},{"id":"W6976952699","doi":"10.6084/m9.figshare.23505264.v1","title":"Additional file 1 of XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Everolimus; Metastatic breast cancer; Breast cancer; Phases of clinical research; Placebo; Clinical trial","score_opus":0.03896974722991319,"score_gpt":0.32600910823917123,"score_spread":0.28703936100925803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976952699","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009094284,0.00024434904,0.0006777206,0.00052213325,0.00012329686,0.0026194523,0.9905199,0.00047614684,0.0039075236],"genre_scores_gemma":[0.052318335,0.0016643167,0.01471692,0.0042100255,0.0008391392,0.0601458,0.8119047,0.0011686465,0.05303211],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891055,0.00042768932,0.00018239967,0.0001823075,0.00016229943,0.00013467034],"domain_scores_gemma":[0.980493,0.014554996,0.0019823893,0.0008621218,0.0013638648,0.00074359775],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031099927,0.00134544,0.0020072125,0.00083672797,0.00071267487,0.001282959,0.001436746,0.0014687693,0.86265606],"category_scores_gemma":[0.02237315,0.0008390525,0.001243776,0.0015516246,0.00035925957,0.0012014289,0.00061218254,0.0012742722,0.08161492],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023390211,0.0009073491,0.0011189306,0.015415456,0.00048146734,0.00011111366,0.000056368117,0.0011446567,0.00039068953,0.002004867,0.9237036,0.03127513],"study_design_scores_gemma":[0.3905739,0.0075135604,0.019292032,0.0056732967,0.001811586,0.0006818189,0.00011215866,0.002708351,0.0016978874,0.01598481,0.5537583,0.00019226872],"about_ca_topic_score_codex":0.0019034096,"about_ca_topic_score_gemma":0.0044688657,"teacher_disagreement_score":0.86265606,"about_ca_system_score_codex":0.0011215151,"about_ca_system_score_gemma":0.0022014722,"threshold_uncertainty_score":0.1959045},"labels":[],"label_agreement":null},{"id":"W6977638607","doi":"10.6084/m9.figshare.c.3723055_d2","title":"Additional file 2: of The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","year":2017,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cohort; Expression (computer science); Scale (ratio); Cohort study; Clinical significance","score_opus":0.16666382388697107,"score_gpt":0.3897621831193099,"score_spread":0.2230983592323388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977638607","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001261573,0.0005687369,0.00081386033,0.00026167647,0.00007428491,0.00044970805,0.99589634,0.00021945736,0.0004543879],"genre_scores_gemma":[0.14263426,0.0041033486,0.03640655,0.0036838294,0.0007888639,0.05751686,0.7284301,0.0019445261,0.024491727],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996636,0.00095748325,0.0010282147,0.0006168188,0.00045618106,0.0003053835],"domain_scores_gemma":[0.88073105,0.10470612,0.0064179483,0.0029171866,0.0045273923,0.0007003585],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0070975507,0.0019738672,0.0042080944,0.00662293,0.0009358698,0.002286711,0.0024749672,0.0016185474,0.6553905],"category_scores_gemma":[0.095300555,0.0013826796,0.008139377,0.009006982,0.00047918825,0.0038583751,0.0014090757,0.0014920102,0.021239853],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006515812,0.00031231157,0.023030741,0.44184226,0.020174455,0.0005351657,0.00052931946,0.00401965,0.00086712476,0.0029329949,0.47560588,0.023634288],"study_design_scores_gemma":[0.108850464,0.0028190257,0.1752897,0.12942234,0.1001064,0.0029460657,0.0019489769,0.015088039,0.0038778353,0.030440595,0.4279504,0.0012601061],"about_ca_topic_score_codex":0.0072823935,"about_ca_topic_score_gemma":0.015350826,"teacher_disagreement_score":0.6553905,"about_ca_system_score_codex":0.0017221434,"about_ca_system_score_gemma":0.003560382,"threshold_uncertainty_score":0.4915436},"labels":[],"label_agreement":null},{"id":"W6979865066","doi":"","title":"Amélioration de la résistance à la fissuration des bétons projetés : composition des mélanges et mise en place = Improving the cracking resistance of shotcrete : mix designs and placement","year":2021,"lang":"fr","type":"other","venue":"Corpus Université Laval (Université Laval)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Université Laval","keywords":"Construction industry; Impact resistance; Steel frame","score_opus":0.022353169429925327,"score_gpt":0.2759333595517896,"score_spread":0.2535801901218643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6979865066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91629225,0.0013031218,0.06390158,0.00014239748,0.00009334719,0.00011185543,0.0001233868,0.0005239128,0.017508091],"genre_scores_gemma":[0.9403557,0.00042675453,0.036563642,0.00004070398,0.000010841892,0.000056631543,0.00011011834,0.00013390611,0.022301603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99951553,0.000033787615,0.000018538753,0.00006818521,0.00031369086,0.000050196035],"domain_scores_gemma":[0.9996476,0.00005139613,0.000078111356,0.000033916906,0.00014363356,0.00004545999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004037097,0.00050779484,0.00033983222,0.00089052704,0.00041028863,0.0009837131,0.0005716153,0.0007019222,0.005214466],"category_scores_gemma":[0.0006358366,0.00046022714,0.0002707604,0.0004528711,0.00032354012,0.00075038656,0.00065145537,0.0005072083,0.0009669818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004165228,0.00022664228,0.004210594,0.00037592358,0.000032282314,0.00021730638,0.00026775117,0.018434634,0.85860056,0.0025931566,0.0006669734,0.11395782],"study_design_scores_gemma":[0.000092163704,0.0037242624,0.027241599,0.000156273,0.00014318866,0.0008945025,0.0006887294,0.10371788,0.8270569,0.0023615395,0.033814535,0.0001084897],"about_ca_topic_score_codex":0.0020192398,"about_ca_topic_score_gemma":0.0072455397,"teacher_disagreement_score":0.005214466,"about_ca_system_score_codex":0.00045718276,"about_ca_system_score_gemma":0.00058803766,"threshold_uncertainty_score":0.017444074},"labels":[],"label_agreement":null},{"id":"W6982897497","doi":"","title":"La partecipazione digitale alla governance urbana attraverso i mapping collaborativi: approcci metodologici ed esempi","year":2023,"lang":"it","type":"article","venue":"Aisberg (University of Bergamo)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute on Governance","funders":"","keywords":"Corporate governance; Context (archaeology); Field (mathematics); Perspective (graphical); Work (physics)","score_opus":0.06905225047434815,"score_gpt":0.29495766296551534,"score_spread":0.2259054124911672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6982897497","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046495777,0.023888532,0.42801222,0.089485414,0.002051269,0.00082240143,0.0018753588,0.0005421489,0.40682682],"genre_scores_gemma":[0.765476,0.01934826,0.15579356,0.00449674,0.0010746211,0.0015748009,0.00144041,0.00021955221,0.050576065],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9914522,0.0049770256,0.00029729083,0.001347264,0.001477832,0.00044837507],"domain_scores_gemma":[0.9904827,0.0052814395,0.0005956399,0.0016186293,0.0015369684,0.0004845544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00691145,0.0010496101,0.00076922774,0.0034967728,0.002785075,0.016805498,0.0024303647,0.0033798667,0.014846978],"category_scores_gemma":[0.009934458,0.00060199,0.0010538453,0.00613989,0.008170112,0.014655934,0.008095231,0.0032605163,0.001853773],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005228055,0.000072485156,0.006836715,0.00086126337,0.000051591105,0.00017304909,0.007745023,0.0017959841,0.0005032861,0.86181605,0.011114937,0.10897733],"study_design_scores_gemma":[0.000029461444,0.00006999178,0.0060448307,0.0016261584,0.00007914983,0.000527192,0.020161191,0.0064806314,0.0011043107,0.5535635,0.41024247,0.000071063085],"about_ca_topic_score_codex":0.0071702288,"about_ca_topic_score_gemma":0.010165972,"teacher_disagreement_score":0.016805498,"about_ca_system_score_codex":0.006568219,"about_ca_system_score_gemma":0.005817088,"threshold_uncertainty_score":0.049668074},"labels":[],"label_agreement":null},{"id":"W6986370126","doi":"","title":"Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations","year":2014,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Trastuzumab; Breast cancer; Metastatic breast cancer; Disease; Clinical trial; Neratinib; Monoclonal antibody","score_opus":0.31423442667542384,"score_gpt":0.6089967220706151,"score_spread":0.2947622953951912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6986370126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043244488,0.9279764,0.0008493678,0.055178624,0.0008671565,0.00008787964,0.00009328618,0.000015714892,0.010607145],"genre_scores_gemma":[0.045193307,0.9329007,0.0021051897,0.011609139,0.0036008528,0.00020000798,0.00016000286,0.000013485927,0.00421736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998406,0.00084757566,0.00015225845,0.0000724552,0.00043034717,0.00009139755],"domain_scores_gemma":[0.99576133,0.0027368853,0.0005745871,0.000049285947,0.0005791489,0.00029874616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046524177,0.0002703624,0.0007069262,0.00075738644,0.00020763488,0.0020109573,0.00067985005,0.001982601,0.0056051253],"category_scores_gemma":[0.008292356,0.00011403133,0.00047124064,0.00090123847,0.00050321204,0.0013039948,0.000556219,0.0015948473,0.00088132307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010336456,0.00013962702,0.00086180685,0.0037511322,0.00013054447,0.00079725275,0.00005836161,0.0012179943,0.0013788099,0.011329366,0.04983031,0.92947114],"study_design_scores_gemma":[0.0016267187,0.0027102116,0.0075106635,0.015875021,0.00050685083,0.006727067,0.00029614326,0.002880969,0.0020403361,0.022995833,0.93675154,0.00007867906],"about_ca_topic_score_codex":0.00073397317,"about_ca_topic_score_gemma":0.002158686,"teacher_disagreement_score":0.0056051253,"about_ca_system_score_codex":0.0013865815,"about_ca_system_score_gemma":0.0024258,"threshold_uncertainty_score":0.024604619},"labels":[],"label_agreement":null},{"id":"W6995824537","doi":"","title":"Profile of census tracts in Halifax, 2006 Census : map volume","year":2008,"lang":"en","type":"other","venue":"Bulletin of Miscellaneous Information (Royal Gardens Kew)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Census; Volume (thermodynamics); Field (mathematics); Population; Data collection","score_opus":0.013963267162930835,"score_gpt":0.24095674044900572,"score_spread":0.2269934732860749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995824537","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013499869,0.00039599388,0.00021302495,0.00023049992,0.000047757072,0.00012513959,0.9659864,0.0003306148,0.019170748],"genre_scores_gemma":[0.058600593,0.0017497848,0.0027580194,0.00030758322,0.000038745256,0.0009082294,0.82435906,0.00018740549,0.11109059],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975485,0.000022513568,0.00003504686,0.000050494677,0.00008678401,0.00005038448],"domain_scores_gemma":[0.9989372,0.000085927204,0.0001801851,0.000043580854,0.0006298447,0.00012327559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000167069,0.0006986141,0.00040545952,0.004448597,0.0006933695,0.0006854917,0.0007166611,0.00028624188,0.03980389],"category_scores_gemma":[0.001675455,0.0003993564,0.00026856043,0.0075582503,0.00019548504,0.00047297747,0.0005384773,0.0004207691,0.018795393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012517053,0.000030583575,0.04644974,0.00066524214,0.00002771578,0.00013071092,0.00059351843,0.00087853597,0.00048791544,0.0005856097,0.9213651,0.028660145],"study_design_scores_gemma":[0.00003689281,0.000028741957,0.5368221,0.00026696414,0.000016383312,0.00027405334,0.0010529823,0.0008503872,0.00033193408,0.00015333,0.46013767,0.000028605342],"about_ca_topic_score_codex":0.6144695,"about_ca_topic_score_gemma":0.6764747,"teacher_disagreement_score":0.38553047,"about_ca_system_score_codex":0.0030025127,"about_ca_system_score_gemma":0.0063566878,"threshold_uncertainty_score":0.77560186},"labels":[],"label_agreement":null},{"id":"W6998611194","doi":"","title":"Assessing the role of ADAM10 in Trastuzumab treatment and resistance","year":2012,"lang":"en","type":"dissertation","venue":"Oxford University Research Archive (ORA) (University of Oxford)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"University of Oxford","keywords":"ADAM10; Trastuzumab; Monoclonal antibody; Downregulation and upregulation; Gene knockdown; Cell; Extracellular; Cancer","score_opus":0.04010930535740649,"score_gpt":0.33180867554647137,"score_spread":0.2916993701890649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6998611194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969114,0.007047961,0.00085166993,0.00021472928,0.000042961914,0.000052883122,0.0002248934,0.000025898542,0.0018479248],"genre_scores_gemma":[0.9926133,0.003276223,0.0008574938,0.00007444375,0.00003157008,0.000041727068,0.0002741974,0.0000085982965,0.0028223856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999627,0.00008594964,0.00003231459,0.000045381865,0.00015223457,0.000057021145],"domain_scores_gemma":[0.99954957,0.00011362101,0.0001538715,0.000018202643,0.00010088647,0.000063782005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072998006,0.00017866354,0.00034174306,0.0004660642,0.00010853584,0.00074913085,0.000186818,0.00029768815,0.001300049],"category_scores_gemma":[0.00083068793,0.00015817568,0.00026542458,0.00023833325,0.00014706502,0.00026150426,0.00016697153,0.00053212076,0.0003657795],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007856598,0.0008765266,0.3192559,0.0006655807,0.00031692677,0.002245041,0.000713912,0.0013277641,0.5086478,0.00059668755,0.0024661352,0.15503109],"study_design_scores_gemma":[0.00013253493,0.0072071613,0.5422945,0.0001583542,0.00045960615,0.004966133,0.00070476125,0.0051350207,0.41871834,0.0004755699,0.019710207,0.00003781538],"about_ca_topic_score_codex":0.0003479744,"about_ca_topic_score_gemma":0.0004003202,"teacher_disagreement_score":0.001300049,"about_ca_system_score_codex":0.00041290303,"about_ca_system_score_gemma":0.00022206228,"threshold_uncertainty_score":0.004349053},"labels":[],"label_agreement":null},{"id":"W6998839979","doi":"","title":"Bank of Canada unveils 3 digital currency proposals from universities","year":2021,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Currency; Payment; Digital currency; Government (linguistics)","score_opus":0.01835721845225615,"score_gpt":0.27997114587339555,"score_spread":0.2616139274211394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6998839979","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03935585,0.0041830707,0.0038696933,0.24325834,0.013218606,0.0006411085,0.0023756933,0.001530092,0.6915674],"genre_scores_gemma":[0.16879559,0.0018889423,0.0033138033,0.1020537,0.0020282138,0.00028281857,0.00089298794,0.0004812303,0.72026265],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98351514,0.0011505759,0.00046365228,0.0008211194,0.009835244,0.0042141727],"domain_scores_gemma":[0.97759706,0.0055165137,0.0004969426,0.001647797,0.010014593,0.0047270856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0109896315,0.0007922046,0.0008176811,0.0029423526,0.013287979,0.019339904,0.0029801189,0.023380421,0.03236359],"category_scores_gemma":[0.04006157,0.0009783393,0.0012856061,0.0027382337,0.0042079384,0.003538251,0.0045764507,0.0096858,0.0049109],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017309109,0.000095392636,0.0022650415,0.000081869024,0.000025638952,0.0005949516,0.0005784844,0.00072191824,0.0007056663,0.2641775,0.7011284,0.029452045],"study_design_scores_gemma":[0.00012548285,0.00005099478,0.0027948446,0.000108197746,0.000036648566,0.00007312681,0.0006352062,0.0007582506,0.00086553284,0.010917653,0.98352414,0.000109877714],"about_ca_topic_score_codex":0.7040811,"about_ca_topic_score_gemma":0.80593336,"teacher_disagreement_score":0.9616526,"about_ca_system_score_codex":0.038347427,"about_ca_system_score_gemma":0.111421935,"threshold_uncertainty_score":0.5953232},"labels":[],"label_agreement":null},{"id":"W7000248523","doi":"","title":"ES1, a new lung carcinoma antibody - an immunohistochemical study.","year":2006,"lang":"en","type":"article","venue":"NPARC","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Antibody; Carcinoma; Lung cancer; Lung","score_opus":0.025273962201421446,"score_gpt":0.3831008264392179,"score_spread":0.3578268642377964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000248523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7511749,0.054216813,0.010277383,0.009812277,0.004711667,0.00065246987,0.0028738244,0.0006488371,0.16563174],"genre_scores_gemma":[0.8242931,0.01517896,0.0115145175,0.0017828081,0.0018191659,0.00027557154,0.0071358248,0.00014858031,0.13785154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999584,0.000044310094,0.000052423642,0.000100558354,0.00011520917,0.000103427075],"domain_scores_gemma":[0.9995474,0.00013644899,0.000028549373,0.00004353949,0.0001414817,0.00010256268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008478925,0.00040201723,0.00028786997,0.002073199,0.0005741576,0.0005062883,0.0008022204,0.0013761898,0.02585785],"category_scores_gemma":[0.00062837155,0.00030709713,0.00044280142,0.0005890718,0.00046223815,0.0009649327,0.00029997563,0.00080799154,0.003915811],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002993572,0.001230854,0.027647367,0.0012390651,0.00039369895,0.054072604,0.00029897643,0.00046408235,0.7264852,0.0041489042,0.0463641,0.13466166],"study_design_scores_gemma":[0.00095849275,0.0034626503,0.11938511,0.00028691767,0.0008799886,0.17251478,0.0006308611,0.003455286,0.31921408,0.0022139088,0.37689075,0.000107178545],"about_ca_topic_score_codex":0.0009692573,"about_ca_topic_score_gemma":0.0017068865,"teacher_disagreement_score":0.02585785,"about_ca_system_score_codex":0.00054618536,"about_ca_system_score_gemma":0.00032234492,"threshold_uncertainty_score":0.08650309},"labels":[],"label_agreement":null},{"id":"W7009165784","doi":"","title":"Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer","year":2024,"lang":"en","type":"dissertation","venue":"University Library (University of Saskatchewan)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Atomic Energy of Canada Limited","keywords":"Trastuzumab; Breast cancer; Cancer; Disease; Epidermal growth factor receptor; Acquired resistance; Colorectal cancer; Metastatic breast cancer","score_opus":0.02319679075002021,"score_gpt":0.26628122636418283,"score_spread":0.24308443561416263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7009165784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52516615,0.40067646,0.017688258,0.00416349,0.0018180166,0.0014049435,0.0026658664,0.0008681871,0.04554866],"genre_scores_gemma":[0.8010982,0.16221689,0.0090548005,0.0039089383,0.0002967157,0.0008179901,0.0031957997,0.000052231302,0.019358397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998826,0.00001725879,0.000007360716,0.000023178658,0.000039132028,0.000030448542],"domain_scores_gemma":[0.9999542,0.000004071826,0.000009108016,0.0000024409705,0.000013356887,0.00001685679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027385977,0.00043055194,0.00068464584,0.000516994,0.00021702297,0.0006054663,0.00043215827,0.0005192071,0.0026153205],"category_scores_gemma":[0.00020443107,0.00018047176,0.0006008493,0.0002911243,0.0001813638,0.00045093417,0.00039761848,0.0011613751,0.000750442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012658418,0.00248543,0.0013387593,0.005250127,0.0003809161,0.0013046135,0.00028116445,0.0068127317,0.5485431,0.0068481322,0.021510128,0.40397915],"study_design_scores_gemma":[0.002809706,0.023133062,0.010990331,0.001274971,0.0010576893,0.004705937,0.0003635251,0.016113339,0.34605545,0.0038205471,0.58942205,0.0002533476],"about_ca_topic_score_codex":0.00047790282,"about_ca_topic_score_gemma":0.0011943687,"teacher_disagreement_score":0.0026153205,"about_ca_system_score_codex":0.00029119453,"about_ca_system_score_gemma":0.0003204064,"threshold_uncertainty_score":0.008749187},"labels":[],"label_agreement":null},{"id":"W7011675343","doi":"","title":"Novel mass spectrometry methods for characterizing antibodies and antibody-drug conjugates","year":2014,"lang":"en","type":"article","venue":"NPARC","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Glycosylation; Monoclonal antibody; Conjugate; Glycan; Antibody; Mass spectrometry; Sialic acid","score_opus":0.045948215495613974,"score_gpt":0.4220269215621523,"score_spread":0.37607870606653837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7011675343","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041784395,0.032086555,0.90509397,0.0016812272,0.0012474378,0.0006405312,0.001525404,0.0027447063,0.013195822],"genre_scores_gemma":[0.10325379,0.025997873,0.8524372,0.00202132,0.000622847,0.0010701835,0.0014479451,0.00026365457,0.012885159],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978157,0.00030313808,0.0001683678,0.0005880247,0.0010190421,0.00010577174],"domain_scores_gemma":[0.99916005,0.00022397297,0.00018740502,0.000091923925,0.00027035162,0.000066324326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022076976,0.0017432933,0.0009630531,0.003504053,0.0008486842,0.0011202673,0.0015030296,0.0020711904,0.0031641857],"category_scores_gemma":[0.0015053564,0.0007984682,0.0008843573,0.0015323544,0.0009211979,0.0020439005,0.0011924561,0.0025918593,0.0026560805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098137774,0.000119816345,0.0006483493,0.00064237806,0.00008084489,0.00020850678,0.000070716465,0.0003588522,0.9311636,0.0053049847,0.0022443435,0.059059467],"study_design_scores_gemma":[0.00005367947,0.00037113545,0.0028393716,0.00013443903,0.00010152193,0.0021566271,0.00007002551,0.011710862,0.91651684,0.003874482,0.062076185,0.00009486458],"about_ca_topic_score_codex":0.0006468617,"about_ca_topic_score_gemma":0.0014123484,"teacher_disagreement_score":0.003504053,"about_ca_system_score_codex":0.0008651529,"about_ca_system_score_gemma":0.0008136042,"threshold_uncertainty_score":0.011675537},"labels":[],"label_agreement":null},{"id":"W7019702876","doi":"","title":"Germline rare variants in HER2-positive breast cancer predisposition : a systematic review and meta-analysis","year":2024,"lang":"en","type":"article","venue":"Lume (Universidade Federal do Rio Grande do Sul)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Germline; Genetic testing; Breast cancer; Germline mutation; Cancer; Genetic association; Gene; Genetic variants; Phenotype; Genome-wide association study","score_opus":0.025101461603355094,"score_gpt":0.32037356921882987,"score_spread":0.2952721076154748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7019702876","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005081519,0.992554,0.00060789345,0.00021990968,0.00011526856,0.00023561498,0.0009300313,0.000022582772,0.00023319399],"genre_scores_gemma":[0.19646028,0.79652786,0.0027182156,0.0008947172,0.00029270066,0.0013458837,0.0013945868,0.000036818754,0.00032896447],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99164855,0.0037514446,0.0024401434,0.0010182941,0.0008115421,0.0003299479],"domain_scores_gemma":[0.9798852,0.015671972,0.0023752807,0.00058033934,0.0012766266,0.00021065414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01168473,0.0019617586,0.013677888,0.006770197,0.00060393725,0.0026286968,0.0021012533,0.0017492315,0.0039624413],"category_scores_gemma":[0.027870353,0.0010765074,0.027239716,0.009490101,0.0005944201,0.0014183336,0.0013225349,0.0012435077,0.0003026766],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010603218,0.000024694235,0.009919949,0.493203,0.48101056,0.00027101237,0.00011809183,0.0006655202,0.00024846304,0.00022263071,0.001019162,0.0122366175],"study_design_scores_gemma":[0.00031045298,0.00013569246,0.007512834,0.04208912,0.9467588,0.00018056105,0.000067061526,0.00024946194,0.00010074359,0.00029406024,0.0022712976,0.000029946837],"about_ca_topic_score_codex":0.007223806,"about_ca_topic_score_gemma":0.016962133,"teacher_disagreement_score":0.013677888,"about_ca_system_score_codex":0.001899446,"about_ca_system_score_gemma":0.0038364544,"threshold_uncertainty_score":0.061795473},"labels":[],"label_agreement":null},{"id":"W7027053911","doi":"","title":"Bioanalytical investigation of type I and type II epidermal growth factor (EGFR)-DNA targeting combi-molecules in «in vitro» and «in vivo» tumour models","year":2011,"lang":"en","type":"other","venue":"Library and Archives Canada (Government of Canada)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"In vivo; In vitro; Potency; Epidermal growth factor receptor; Epidermal growth factor; Receptor; Ex vivo; Cell culture; DNA damage","score_opus":0.014952255332175944,"score_gpt":0.203483757017773,"score_spread":0.18853150168559704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7027053911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807741,0.0032992645,0.012898623,0.00011671885,0.00003474624,0.000084568885,0.0003371851,0.00008503146,0.0023698066],"genre_scores_gemma":[0.9738098,0.003958712,0.016758101,0.00007796868,0.000015754275,0.00010331586,0.00044620788,0.00002810762,0.004801918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999859,0.000024903458,0.0000060675707,0.000029031136,0.00006201607,0.000018966413],"domain_scores_gemma":[0.999908,0.000019309371,0.000038222566,0.000007731918,0.00001789627,0.000008876108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023848782,0.0002876793,0.00013955754,0.00012683024,0.00009008011,0.00025845968,0.00014920808,0.00030772487,0.0006006028],"category_scores_gemma":[0.00017835155,0.00014830397,0.00019820347,0.00012679808,0.00013698057,0.00019410727,0.00008843724,0.00035531886,0.00020624009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006294217,0.000023448103,0.00010557591,0.000033494485,0.000004293452,0.000015898437,0.00000972705,0.000105343985,0.9982449,0.00005342643,0.000031017098,0.0013098961],"study_design_scores_gemma":[0.000004229606,0.0003482481,0.00064476643,0.000002080467,0.000008983638,0.000063344196,0.000008683201,0.00071572047,0.9971413,0.000012534169,0.001046912,0.0000030455767],"about_ca_topic_score_codex":0.00037062095,"about_ca_topic_score_gemma":0.000542904,"teacher_disagreement_score":0.0006006028,"about_ca_system_score_codex":0.00020957395,"about_ca_system_score_gemma":0.00013577353,"threshold_uncertainty_score":0.002009213},"labels":[],"label_agreement":null},{"id":"W7034491428","doi":"","title":"The thorny issue of tight labour marketsWhat’s the significance of the ongoing recruitment and skills issues faced by Cumbrian businesses?","year":2024,"lang":"en","type":"other","venue":"Insight (University of Cumbria)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Quarter (Canadian coin); Job loss; Affect (linguistics); Unemployment","score_opus":0.027155722814496793,"score_gpt":0.2997644452977361,"score_spread":0.2726087224832393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7034491428","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016446487,0.008281601,0.00013438679,0.9783303,0.0019167071,0.000007442285,0.00003922282,0.000014558619,0.009631034],"genre_scores_gemma":[0.1003235,0.05949889,0.0013453015,0.74728185,0.015300973,0.00011523924,0.00017379128,0.0001450067,0.07581538],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932162,0.0028121616,0.00024490745,0.00046243775,0.0016920401,0.001572277],"domain_scores_gemma":[0.9831535,0.0077083716,0.0014360573,0.0005267904,0.002057624,0.005117715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00960072,0.00039956282,0.00057056337,0.0009329581,0.0053004315,0.0077426936,0.0014353667,0.0067779254,0.03303499],"category_scores_gemma":[0.020943493,0.0003336765,0.00036175264,0.0011191501,0.007719564,0.010894586,0.0043646777,0.008385686,0.0063275006],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047905305,0.000052761006,0.002960621,0.00052285485,0.000011349376,0.00041781238,0.0056790523,0.000082954546,0.0005076365,0.038701594,0.81297493,0.13804056],"study_design_scores_gemma":[0.000021011923,0.0000810481,0.009176936,0.0010785235,0.0000073275028,0.00062194886,0.018789291,0.00010724725,0.00025151472,0.022882774,0.946936,0.000046347028],"about_ca_topic_score_codex":0.03280821,"about_ca_topic_score_gemma":0.07237182,"teacher_disagreement_score":0.03303499,"about_ca_system_score_codex":0.006765299,"about_ca_system_score_gemma":0.012138098,"threshold_uncertainty_score":0.11051303},"labels":[],"label_agreement":null},{"id":"W7066617335","doi":"","title":"Latent multi-state models for non-equidistant longitudinal observations with finite and infinite mixture model-based clustering","year":2019,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cluster analysis; Markov chain Monte Carlo; Bayesian probability; Inference; Covariate; Markov chain; Bayesian inference; Trajectory; Statistical inference; Markov process","score_opus":0.09429552422286308,"score_gpt":0.3250005111047202,"score_spread":0.23070498688185714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7066617335","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008517298,0.0015868467,0.98526704,0.0010493649,0.00021748747,0.00012622996,0.0011403579,0.00061954756,0.0014758398],"genre_scores_gemma":[0.5095998,0.0059612603,0.43020698,0.001322798,0.0013594653,0.0024861784,0.010179736,0.001124913,0.037758883],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9944266,0.0028038549,0.0003075046,0.0015033996,0.00045539124,0.00050320086],"domain_scores_gemma":[0.9738506,0.019905828,0.002134265,0.0017010205,0.0017791511,0.00062917144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012295376,0.0024047683,0.003815538,0.0037812681,0.0017361095,0.003966789,0.0077829957,0.0040250253,0.009439726],"category_scores_gemma":[0.030035831,0.0022571792,0.0051063406,0.003661946,0.0037351397,0.00504377,0.004256585,0.0066689025,0.002914942],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025422528,0.000164404,0.005645778,0.00044951492,0.0005893941,0.00035134616,0.00080315256,0.5997965,0.0004884394,0.35235488,0.0073352926,0.03176706],"study_design_scores_gemma":[0.00002222683,0.000019748923,0.00064664,0.0000655074,0.00006204743,0.00003887668,0.00005089859,0.9047432,0.00006797772,0.092132315,0.002109192,0.000041397114],"about_ca_topic_score_codex":0.041889183,"about_ca_topic_score_gemma":0.03921713,"teacher_disagreement_score":0.041889183,"about_ca_system_score_codex":0.0042905337,"about_ca_system_score_gemma":0.0034772425,"threshold_uncertainty_score":0.083290756},"labels":[],"label_agreement":null},{"id":"W7086310305","doi":"10.17613/9wev-gj66","title":"How to be an ally with Kashmir: War stories from the kitchen","year":2019,"lang":"en","type":"article","venue":"Humanities Commons CORE (Modern Language Association / Columbia University)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Narrative; Face (sociological concept); Government (linguistics); Clothing","score_opus":0.04281105910540114,"score_gpt":0.2546347322204122,"score_spread":0.21182367311501107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7086310305","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13032536,0.025995404,0.0023463352,0.7391206,0.00935528,0.000047199657,0.00015193633,0.00015260084,0.09250525],"genre_scores_gemma":[0.78427243,0.0107238935,0.0014231184,0.14774412,0.0012355862,0.00007828988,0.00007744968,0.00029006915,0.05415498],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.99391985,0.003993937,0.0000834032,0.00022056476,0.0005049746,0.0012772647],"domain_scores_gemma":[0.9929178,0.0030327463,0.0004925709,0.0002437217,0.00074732624,0.002565898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076798303,0.0010035875,0.0007641048,0.000659388,0.038626663,0.008276708,0.0017393851,0.0057602986,0.01141099],"category_scores_gemma":[0.014905809,0.00054874306,0.0004853876,0.00068620086,0.01908379,0.012078881,0.008794591,0.02061665,0.0029497072],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002696905,0.00011094739,0.0021801703,0.00022915941,0.0000624976,0.0031674162,0.5008194,0.00018023812,0.0009935795,0.06315365,0.39146706,0.03736617],"study_design_scores_gemma":[0.000012121882,0.00008564808,0.0015073266,0.0003004216,0.000017831648,0.0014724382,0.5787944,0.00011413489,0.0004867701,0.008464299,0.4086648,0.000079770616],"about_ca_topic_score_codex":0.0177591,"about_ca_topic_score_gemma":0.047242317,"teacher_disagreement_score":0.038626663,"about_ca_system_score_codex":0.0066491235,"about_ca_system_score_gemma":0.0056823874,"threshold_uncertainty_score":0.048242986},"labels":[],"label_agreement":null},{"id":"W7104928747","doi":"10.71781/28716","title":"Identification de nouvelles cibles thérapeutiques impliquées dans la formation de métastases dans le cancer du sein","year":2025,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Breast cancer; Medical screening; Hair dyes","score_opus":0.0575694255113575,"score_gpt":0.4316993397871998,"score_spread":0.3741299142758423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104928747","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37328473,0.55847913,0.028518792,0.008773373,0.0006770463,0.00050189253,0.0008442901,0.0002949551,0.028625859],"genre_scores_gemma":[0.768641,0.19638368,0.016967503,0.0019087257,0.00036437946,0.00044217845,0.0013877412,0.000057362424,0.013847475],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897313,0.0002733819,0.00005704007,0.00022800975,0.00032149962,0.00014692481],"domain_scores_gemma":[0.9988433,0.00046984327,0.00020690334,0.0000905984,0.00026581332,0.0001235283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011885127,0.000630646,0.0010119597,0.0011186785,0.0007056039,0.0029235666,0.00067927554,0.0014352655,0.0033351553],"category_scores_gemma":[0.0018488412,0.00049203157,0.0009080401,0.0008316395,0.0010782629,0.0012045996,0.0005952005,0.001945115,0.00086396787],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014653445,0.00073222205,0.033915848,0.0063854125,0.0003000746,0.0014528586,0.0007994766,0.0030823643,0.44779825,0.014364487,0.005059813,0.48464388],"study_design_scores_gemma":[0.0004067062,0.004600598,0.10601444,0.0028664016,0.0010932892,0.011768015,0.0026664576,0.013025946,0.4770833,0.008762777,0.37145787,0.0002542691],"about_ca_topic_score_codex":0.002755098,"about_ca_topic_score_gemma":0.003464645,"teacher_disagreement_score":0.0033351553,"about_ca_system_score_codex":0.001488568,"about_ca_system_score_gemma":0.0016255148,"threshold_uncertainty_score":0.011157155},"labels":[],"label_agreement":null},{"id":"W7106485843","doi":"10.21203/rs.3.rs-8020339/v1","title":"Translational and Real-World Evidence of Trastuzumab Biosimilar CT-P6 Plus Pertuzumab in Neoadjuvant HER2-Positive Early Breast Cancer","year":2025,"lang":"","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Pertuzumab; Trastuzumab; Biosimilar; Breast cancer; Clinical endpoint; Neoadjuvant therapy; Adverse effect; Clinical trial; Biomarker","score_opus":0.10511809782627815,"score_gpt":0.47284473067639543,"score_spread":0.3677266328501173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7106485843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7542976,0.17002591,0.0023073326,0.036479708,0.0020735438,0.00058838347,0.0060875453,0.00008718451,0.02805272],"genre_scores_gemma":[0.968334,0.023107156,0.0010690594,0.0034064131,0.0010490629,0.00012437282,0.001937997,0.00003969235,0.00093228696],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9909615,0.0065024323,0.0007970389,0.0005216561,0.0008435442,0.00037378143],"domain_scores_gemma":[0.9340291,0.0454285,0.010902476,0.0030707973,0.004606798,0.0019623528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012715015,0.00039253128,0.0010729869,0.00045967093,0.00035417275,0.00254374,0.0006844925,0.0014155816,0.011625479],"category_scores_gemma":[0.057713162,0.00024830987,0.0016125368,0.00113421,0.0017627337,0.0013057832,0.0008889185,0.0023060774,0.0014154696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45161644,0.0045016725,0.03129289,0.031188035,0.014103422,0.00087607873,0.0013740105,0.0032894823,0.012019095,0.008614245,0.01914812,0.42197654],"study_design_scores_gemma":[0.108408675,0.18369627,0.25637418,0.033681028,0.0691507,0.004064371,0.0051477854,0.0043347026,0.018672265,0.027642611,0.2883938,0.000433732],"about_ca_topic_score_codex":0.0010895764,"about_ca_topic_score_gemma":0.0009213853,"teacher_disagreement_score":0.012715015,"about_ca_system_score_codex":0.0016072661,"about_ca_system_score_gemma":0.0023292701,"threshold_uncertainty_score":0.06724423},"labels":[],"label_agreement":null},{"id":"W7108248980","doi":"","title":"Risk Signals of Antibody-Drug Conjugates in Bladder Cancer: A Real-World FAERS Study","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacovigilance; Adverse Event Reporting System; Adverse effect; Odds ratio; Quarter (Canadian coin); Traditional Chinese medicine; Bladder cancer; Cancer","score_opus":0.24354764448475896,"score_gpt":0.6435171973427783,"score_spread":0.3999695528580194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108248980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98337287,0.009345948,0.0015768324,0.0002871243,0.00005499192,0.00019340124,0.0036126801,0.000033301363,0.0015229482],"genre_scores_gemma":[0.9964373,0.00081610103,0.00052341906,0.00013990838,0.000053013824,0.000099948644,0.0016150819,0.000008028048,0.00030726657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701786,0.0009900833,0.00054565904,0.0007190497,0.00048626872,0.00024109324],"domain_scores_gemma":[0.9946707,0.0010787088,0.0029175917,0.00064320996,0.00051913474,0.00017065472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034615726,0.00048241863,0.0007168459,0.0011563407,0.0004455031,0.0012814703,0.00049807585,0.00082004495,0.0021193386],"category_scores_gemma":[0.0047861845,0.0004675118,0.0020937438,0.0019453892,0.0002891016,0.0008834553,0.00075896975,0.000923397,0.0003160627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033776087,0.00015557387,0.98321366,0.0003821502,0.001903377,0.00024678625,0.00015787315,0.00031038528,0.0005324415,0.00022370633,0.00077330525,0.008723055],"study_design_scores_gemma":[0.00031641618,0.0009804434,0.9866023,0.0001341061,0.0030774798,0.0014081985,0.00034324484,0.0022272025,0.0007919693,0.00040384693,0.0036575927,0.00005729445],"about_ca_topic_score_codex":0.0014062404,"about_ca_topic_score_gemma":0.0015556879,"teacher_disagreement_score":0.0034615726,"about_ca_system_score_codex":0.0006962111,"about_ca_system_score_gemma":0.00059298147,"threshold_uncertainty_score":0.018306732},"labels":[],"label_agreement":null},{"id":"W7115819241","doi":"","title":"ECONOMIC EVALUATION OF HER2 TARGETED BREAST CANCER THERAPY","year":2014,"lang":"en","type":"dissertation","venue":"MacSphere (McMaster University)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Economic evaluation; Breast cancer; Cost-effectiveness analysis; Cost–benefit analysis; Cohort; Cost effectiveness; Clinical trial; Cancer","score_opus":0.03405525428188679,"score_gpt":0.3169055184233334,"score_spread":0.28285026414144665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115819241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35426965,0.1367452,0.2234791,0.035033662,0.0017635279,0.011255619,0.011065967,0.0002935619,0.22609363],"genre_scores_gemma":[0.9535353,0.016544472,0.022141768,0.0007559514,0.0001754057,0.0020688935,0.0010430567,0.00004123772,0.0036938386],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.96284413,0.032906376,0.0007276732,0.00048693147,0.002310863,0.00072400895],"domain_scores_gemma":[0.9457425,0.047957562,0.002184031,0.00067148067,0.002652677,0.0007917312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027084494,0.0012949822,0.0018921439,0.0021816615,0.00047611585,0.0033993623,0.0012232023,0.0014781323,0.0059181736],"category_scores_gemma":[0.0852901,0.00049538084,0.0019380382,0.0024394058,0.0010376178,0.0018470997,0.0015531346,0.0018625079,0.00024495643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046302485,0.00064000057,0.01020984,0.0063056643,0.0031192137,0.00021944681,0.00026097024,0.6699009,0.00023458242,0.09972167,0.009680703,0.19507676],"study_design_scores_gemma":[0.0019811091,0.0033729814,0.010336419,0.0073689413,0.0032189144,0.0003327447,0.0008110482,0.78922033,0.0007031214,0.14886253,0.03362829,0.00016355392],"about_ca_topic_score_codex":0.015830021,"about_ca_topic_score_gemma":0.008485166,"teacher_disagreement_score":0.027084494,"about_ca_system_score_codex":0.01407163,"about_ca_system_score_gemma":0.010803054,"threshold_uncertainty_score":0.14323825},"labels":[],"label_agreement":null},{"id":"W7116050106","doi":"10.3390/curroncol33010002","title":"Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Cancer; Safety profile; Systemic therapy; First line; Adverse effect; Clinical trial","score_opus":0.09372716798261112,"score_gpt":0.47894800412537286,"score_spread":0.38522083614276176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116050106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977335,0.0016973302,0.0001346857,0.000026833455,0.000008857193,0.000039092036,0.000080339196,0.000006789848,0.00027262763],"genre_scores_gemma":[0.9992422,0.00029646512,0.00014979299,0.000034048797,0.000016964083,0.000023383815,0.00014120601,0.0000011897578,0.00009484889],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99947745,0.00028702337,0.0000476931,0.000069994225,0.00008615539,0.00003173445],"domain_scores_gemma":[0.99930465,0.00016434629,0.0003426728,0.00005055287,0.000041779032,0.000095960306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011605263,0.000246844,0.00048754076,0.00016386983,0.00013257565,0.00036206242,0.00022075196,0.00028734212,0.0005109145],"category_scores_gemma":[0.0011847035,0.000101431455,0.00031730725,0.00015958307,0.0002623924,0.00036082664,0.00015706036,0.000504618,0.00011995332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31628504,0.013969966,0.291603,0.0011735313,0.0022947986,0.0008953284,0.00044128043,0.007514068,0.08903087,0.00017786086,0.0010625628,0.27555174],"study_design_scores_gemma":[0.02228799,0.40940058,0.51334375,0.000064998945,0.0015805095,0.0033065472,0.0002480814,0.0071459026,0.03318101,0.00010759749,0.009258627,0.00007437965],"about_ca_topic_score_codex":0.00021738374,"about_ca_topic_score_gemma":0.00040147814,"teacher_disagreement_score":0.0011605263,"about_ca_system_score_codex":0.00038978015,"about_ca_system_score_gemma":0.00015475716,"threshold_uncertainty_score":0.00613755},"labels":[],"label_agreement":null},{"id":"W7116663774","doi":"10.1200/po-25-00221","title":"CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( <i>NRG1</i> ) Fusions","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"National Cancer Institute","keywords":"Monoclonal antibody; Solid tumor; Phase (matter); Cancer; Antibody; Tumor cells","score_opus":0.026661932388642968,"score_gpt":0.42918210070895435,"score_spread":0.4025201683203114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116663774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375737,0.0011770446,0.000551423,0.00016408398,0.000054002543,0.0018527755,0.0007132028,0.000058779646,0.0016713197],"genre_scores_gemma":[0.9925034,0.0010605678,0.0012867547,0.00042453693,0.00007181599,0.0012499713,0.0015205195,0.000014000802,0.0018684686],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99938715,0.00027607486,0.000037577505,0.00009483723,0.00011545779,0.000088989524],"domain_scores_gemma":[0.99918085,0.0001394333,0.0001745664,0.00007112732,0.000070829476,0.0003630554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020529893,0.0012669723,0.0012452684,0.0003911734,0.0003576705,0.0008678499,0.000757211,0.00091871474,0.0020343987],"category_scores_gemma":[0.0010108385,0.00040466178,0.0011562229,0.00026947018,0.0009614203,0.0005346279,0.000424705,0.0017340818,0.00045261774],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6949934,0.055436943,0.020204684,0.002033502,0.0022903262,0.00065140275,0.0006287477,0.005681086,0.11403399,0.00087868574,0.004549049,0.09861832],"study_design_scores_gemma":[0.4598805,0.4861862,0.03326177,0.000071192495,0.0014282455,0.0006844116,0.000095439136,0.002887442,0.010389828,0.00022400699,0.004811038,0.00007992846],"about_ca_topic_score_codex":0.0010693321,"about_ca_topic_score_gemma":0.003459915,"teacher_disagreement_score":0.0020529893,"about_ca_system_score_codex":0.0006516665,"about_ca_system_score_gemma":0.0015380394,"threshold_uncertainty_score":0.010857403},"labels":[],"label_agreement":null},{"id":"W7116938074","doi":"10.1016/j.annonc.2025.10.727","title":"1016P Patient (pt) characteristics, HER2 testing, and treatment (Tx) patterns in advanced HER2 (ERBB2)-mutant (HER2m) NSCLC in real-world clinical practice","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"AstraZeneca","keywords":"Clinical Practice; Mutation; Chemotherapy; Clinical trial; MEDLINE","score_opus":0.20592206771403104,"score_gpt":0.5385735729854448,"score_spread":0.3326515052714138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116938074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397296,0.0006434488,0.00016275016,0.0005767546,0.000019063775,0.000014466155,0.0007342941,0.000012115373,0.0038640557],"genre_scores_gemma":[0.9986628,0.00027415558,0.00019612383,0.00018562593,0.000031047784,0.000009084567,0.0002643969,0.000004672376,0.0003719935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996494,0.000086937296,0.000060756527,0.00007718725,0.00006329468,0.000062363804],"domain_scores_gemma":[0.99878234,0.0003314413,0.0004481801,0.00004833361,0.00008386752,0.00030592564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039399584,0.00013086485,0.00022581106,0.00079832016,0.00045172792,0.0006614557,0.00020456346,0.0004709923,0.005907349],"category_scores_gemma":[0.0023855418,0.00018305877,0.00019781492,0.0013558819,0.0002822541,0.00057588017,0.00036460743,0.0004305657,0.00075312884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012501667,0.000049827508,0.9926335,0.000017326722,0.000016383989,0.000803675,0.000058677233,0.000060181454,0.00018195545,0.000047253772,0.0005695988,0.005436408],"study_design_scores_gemma":[0.000020982116,0.00016549797,0.98892385,0.00003674961,0.00003725855,0.0072709015,0.0006972062,0.00056040764,0.00014691701,0.00026681213,0.0018644341,0.000009002049],"about_ca_topic_score_codex":0.0017408933,"about_ca_topic_score_gemma":0.003184861,"teacher_disagreement_score":0.005907349,"about_ca_system_score_codex":0.0003200239,"about_ca_system_score_gemma":0.00043159717,"threshold_uncertainty_score":0.019762099},"labels":[],"label_agreement":null},{"id":"W7116952014","doi":"10.1016/j.annonc.2025.10.923","title":"88MO Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of Asian patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): A DESTINY-Breast09 analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Taxane; Trastuzumab; Breast cancer; Chemotherapy","score_opus":0.06237122466736459,"score_gpt":0.4233950909921288,"score_spread":0.3610238663247642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116952014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978471,0.00090545806,0.000058082125,0.00011194928,0.000025300214,0.00004883925,0.00021470302,0.0000061694955,0.0007824907],"genre_scores_gemma":[0.99775034,0.0006602822,0.00012609472,0.00014488354,0.00005463941,0.000035910747,0.0003757305,0.0000045920015,0.0008476187],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996032,0.00017998947,0.00002472778,0.000054244738,0.000034448367,0.0001033351],"domain_scores_gemma":[0.9994272,0.00020285248,0.00012253155,0.00003419543,0.000021831105,0.00019149683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011911818,0.00038705784,0.00091849675,0.00027792124,0.00013587209,0.000577142,0.00037390148,0.00044511762,0.0030271213],"category_scores_gemma":[0.00081243704,0.00016607791,0.0014044704,0.00032840794,0.00033853907,0.00060191564,0.00026337866,0.00089844124,0.00027165326],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80983233,0.007361781,0.05181066,0.00039412873,0.0037517126,0.0002431229,0.00023883193,0.0023235884,0.016141145,0.00039831162,0.0015595304,0.10594483],"study_design_scores_gemma":[0.10896805,0.5249136,0.3357332,0.00013169785,0.0095548155,0.0008496522,0.00049439823,0.0049610636,0.0061816317,0.000667634,0.0074752467,0.00006902885],"about_ca_topic_score_codex":0.0011072662,"about_ca_topic_score_gemma":0.0037954308,"teacher_disagreement_score":0.0030271213,"about_ca_system_score_codex":0.0006680934,"about_ca_system_score_gemma":0.0006177185,"threshold_uncertainty_score":0.01012671},"labels":[],"label_agreement":null},{"id":"W7116955310","doi":"10.1016/j.annonc.2025.12.017","title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Memorial Sloan-Kettering Cancer Center; Daiichi Sankyo Europe; AstraZeneca","keywords":"Clinical endpoint; Chemotherapy; Overall survival; Phases of clinical research; Chemotherapy regimen; Hormone therapy; Hormone","score_opus":0.09547552410677164,"score_gpt":0.4617903217570697,"score_spread":0.36631479765029806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116955310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958199,0.001986998,0.0001657546,0.00017083494,0.0000572548,0.00047224763,0.0005403086,0.000018911824,0.00076775724],"genre_scores_gemma":[0.9954587,0.001209729,0.00037360005,0.00028900002,0.000105829065,0.00051689753,0.0010603581,0.000010852522,0.00097501697],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99891305,0.00078520464,0.000049983548,0.00009880042,0.00006445358,0.000088479785],"domain_scores_gemma":[0.9989736,0.0002660948,0.0003028226,0.00008822688,0.000050823357,0.00031844524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003063398,0.000975493,0.0015792075,0.0004015463,0.00021084445,0.00074530137,0.00061390037,0.0006798769,0.0018109934],"category_scores_gemma":[0.0013645465,0.0003438419,0.0015860837,0.00037726315,0.000610407,0.0005557595,0.00033290722,0.0016248905,0.00028014233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93314266,0.010378593,0.012206547,0.0004734814,0.00237503,0.00006341845,0.000113506205,0.0014812099,0.006865637,0.00009040007,0.0010864082,0.03172309],"study_design_scores_gemma":[0.4891805,0.44646603,0.05320553,0.000070873364,0.0031162212,0.00023729476,0.00008773638,0.001854832,0.0030359162,0.00020624314,0.0025062403,0.000032597007],"about_ca_topic_score_codex":0.0007837482,"about_ca_topic_score_gemma":0.0030462039,"teacher_disagreement_score":0.003063398,"about_ca_system_score_codex":0.00090770493,"about_ca_system_score_gemma":0.0008643582,"threshold_uncertainty_score":0.01620096},"labels":[],"label_agreement":null},{"id":"W7116977830","doi":"10.1016/j.annonc.2025.10.1101","title":"664TiP BEHOLD-2: A phase I/II randomised study evaluating GSK5733584, a B7-H4-targeted antibody-drug conjugate, in combination with anti-cancer agents in patients with advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Abbotsford Veterinary Clinic; McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Phases of clinical research; Phase (matter); Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Cancer","score_opus":0.09961585291141915,"score_gpt":0.517144164483099,"score_spread":0.4175283115716798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116977830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844236,0.0047942735,0.0007276839,0.000928212,0.00046980698,0.002963109,0.0018579791,0.00018326772,0.0036521687],"genre_scores_gemma":[0.9762324,0.004839639,0.001756743,0.001724008,0.00044790452,0.002807709,0.00316906,0.00006201931,0.008960522],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995757,0.00021141124,0.000016200845,0.000063751984,0.00003236863,0.00010060097],"domain_scores_gemma":[0.9995184,0.000097652824,0.00006646692,0.00003176903,0.000024371357,0.0002612772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015004935,0.0017239504,0.0024387608,0.00056482543,0.00030248592,0.0010997311,0.0007218541,0.0014981078,0.008248388],"category_scores_gemma":[0.0009242623,0.00075759104,0.0017609358,0.0004734085,0.0011372286,0.000982982,0.00040434676,0.0035595412,0.001538062],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93925124,0.0093245525,0.0012159594,0.0008144778,0.0012110525,0.00009453574,0.000074646545,0.00083323533,0.010105796,0.0002699184,0.0019928217,0.034811646],"study_design_scores_gemma":[0.90161085,0.09409031,0.0017952048,0.000023157552,0.00036257046,0.000046225992,0.000022674953,0.0002979076,0.0005283198,0.0001401588,0.0010673472,0.000015408978],"about_ca_topic_score_codex":0.0016695252,"about_ca_topic_score_gemma":0.0037682569,"teacher_disagreement_score":0.008248388,"about_ca_system_score_codex":0.0008366825,"about_ca_system_score_gemma":0.0010828922,"threshold_uncertainty_score":0.027593613},"labels":[],"label_agreement":null},{"id":"W7117293899","doi":"10.3390/biomedicines14010049","title":"HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision Management","year":2025,"lang":"en","type":"article","venue":"Biomedicines","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; Queen's University","funders":"","keywords":"Liquid biopsy; Breast cancer; Biopsy; Histopathology; Narrative review; Standardization; Precision medicine; Targeted therapy; Cancer","score_opus":0.020049636351909483,"score_gpt":0.39522193475878387,"score_spread":0.3751722984068744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117293899","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020907645,0.9159468,0.020619499,0.054953158,0.0012307097,0.00004382714,0.000120326586,0.0001278939,0.004867118],"genre_scores_gemma":[0.055676937,0.8859599,0.036384877,0.016533576,0.0036845016,0.00012952129,0.00021095763,0.00005986682,0.0013598326],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9935268,0.002896527,0.00060334813,0.00061355834,0.0021214297,0.0002383508],"domain_scores_gemma":[0.9763564,0.01630368,0.0023363263,0.0009008827,0.0036688787,0.00043387729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01521374,0.000842511,0.0015606477,0.003768114,0.0008240168,0.006976711,0.0017177222,0.0027425534,0.0018402971],"category_scores_gemma":[0.019401332,0.0004230066,0.0010966846,0.0022750932,0.004411638,0.0069990912,0.00382288,0.0043061827,0.0010069491],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014465713,0.00008753448,0.0049322136,0.026029028,0.00041069827,0.00073105964,0.0014059024,0.0020195034,0.004970712,0.106217355,0.040234998,0.8128163],"study_design_scores_gemma":[0.00003402927,0.00029690922,0.0037901208,0.039040137,0.0007343292,0.0028060914,0.0032393895,0.002589697,0.00655528,0.1771828,0.76355654,0.000174644],"about_ca_topic_score_codex":0.0014456799,"about_ca_topic_score_gemma":0.0015480142,"teacher_disagreement_score":0.01521374,"about_ca_system_score_codex":0.003219231,"about_ca_system_score_gemma":0.006694014,"threshold_uncertainty_score":0.08045894},"labels":[],"label_agreement":null},{"id":"W7123335096","doi":"10.1093/cvr/cvaf256","title":"Temporal inhibition of ADAM17 in fibroblasts reduces stiffness and promotes vascularization following myocardial infarction","year":2025,"lang":"en","type":"article","venue":"Cardiovascular Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Alberta","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Downregulation and upregulation; Myocardial infarction; Compliance (psychology); Limiting; Heart failure; Homeostasis; Stiffness","score_opus":0.04768868621588366,"score_gpt":0.3771006596338615,"score_spread":0.32941197341797784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7123335096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935715,0.0021442208,0.0023022236,0.000109659726,0.00007165207,0.000046074932,0.00043481612,0.00012453669,0.0011952461],"genre_scores_gemma":[0.9935428,0.0014663863,0.0012971029,0.00006198426,0.000022246828,0.000112288566,0.00053209165,0.000023482704,0.0029415637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998115,0.000028301953,0.00002612236,0.000036377598,0.00003879191,0.000059053087],"domain_scores_gemma":[0.99986386,0.000014174254,0.00004699747,0.000015171439,0.000011977939,0.00004784719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021058327,0.00038569095,0.00032016638,0.000227631,0.00017253356,0.00029708224,0.00016415055,0.00021277349,0.0018196478],"category_scores_gemma":[0.00012253733,0.0001639805,0.00031794407,0.000119375254,0.00025412827,0.00018079953,0.00021030197,0.0006053624,0.000493573],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005284454,0.000103197526,0.00031562903,0.00006719304,0.000008359395,0.000082167324,0.000030480936,0.000049102266,0.99692327,0.000072434996,0.00008271697,0.0017370638],"study_design_scores_gemma":[0.00007618666,0.0013572562,0.01009619,0.000016658503,0.00005035857,0.00041119443,0.00008729456,0.000809364,0.9836908,0.000058985843,0.0033380317,0.000007731948],"about_ca_topic_score_codex":0.0003642411,"about_ca_topic_score_gemma":0.0006828842,"teacher_disagreement_score":0.0018196478,"about_ca_system_score_codex":0.00017932439,"about_ca_system_score_gemma":0.00018889505,"threshold_uncertainty_score":0.006087303},"labels":[],"label_agreement":null},{"id":"W7132891896","doi":"","title":"Comparison of HER2/neu Status Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry","year":2001,"lang":"","type":"article","venue":"TSpace","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Immunohistochemistry; Polymerase chain reaction; Real-time polymerase chain reaction; Reverse transcription polymerase chain reaction; Antibody","score_opus":0.07489093250805003,"score_gpt":0.5009703699068477,"score_spread":0.4260794373987977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132891896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9290177,0.0036139858,0.048321754,0.00022832645,0.0004381533,0.0003747277,0.0022315108,0.00059512514,0.015178688],"genre_scores_gemma":[0.919757,0.0018901177,0.05562914,0.0002353437,0.00012838085,0.0009911488,0.0049011027,0.0002335472,0.016234132],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986135,0.0004359318,0.00016520768,0.00023185463,0.00033206478,0.00022150789],"domain_scores_gemma":[0.9978816,0.0010072711,0.00015582473,0.00030908163,0.00052313576,0.00012303614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019967612,0.0005384096,0.0006028799,0.0017689544,0.00047330718,0.0008585505,0.0004891141,0.0005748809,0.00520917],"category_scores_gemma":[0.0018192086,0.00050863746,0.00050838955,0.00094716327,0.00058632373,0.0006147086,0.00040256084,0.00076981506,0.0014023728],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025172576,0.00035624742,0.006893794,0.00015582604,0.000079352525,0.00020894448,0.00021532108,0.0001324724,0.97748655,0.0005374586,0.00023239234,0.011184317],"study_design_scores_gemma":[0.00019904313,0.0021815428,0.07997399,0.000028283703,0.00016117266,0.002222691,0.0003775574,0.0036400228,0.9043073,0.0007560191,0.0061134268,0.000038963557],"about_ca_topic_score_codex":0.0010980614,"about_ca_topic_score_gemma":0.0016736622,"teacher_disagreement_score":0.00520917,"about_ca_system_score_codex":0.0003656897,"about_ca_system_score_gemma":0.00034187126,"threshold_uncertainty_score":0.017426431},"labels":[],"label_agreement":null},{"id":"W7136033153","doi":"10.6084/m9.figshare.4776154.v1","title":"Additional file 2: of The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","year":2017,"lang":"","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cohort; Expression (computer science); Scale (ratio); Cohort study; Clinical significance","score_opus":0.17285375311511028,"score_gpt":0.3902435760244508,"score_spread":0.21738982290934053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7136033153","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012227896,0.0006052999,0.00083930086,0.00026922752,0.00007916791,0.00046845735,0.99582005,0.0002271148,0.00046859612],"genre_scores_gemma":[0.1430417,0.004207163,0.038018588,0.0038230943,0.0008237763,0.058272056,0.7244737,0.0020673997,0.025272578],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964005,0.001039784,0.0011010696,0.000653838,0.00048308357,0.00032170513],"domain_scores_gemma":[0.8729653,0.1118289,0.006570028,0.003115694,0.0047936933,0.0007263167],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007434634,0.0020177518,0.0043352856,0.006909339,0.0009548727,0.0023429038,0.0025836774,0.0016672552,0.6586997],"category_scores_gemma":[0.099350475,0.0014430253,0.0087840855,0.009357676,0.0004936711,0.0039353603,0.0014560437,0.0015307786,0.021979619],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063779964,0.00030309887,0.021911688,0.4500107,0.020978268,0.00052561826,0.00052291807,0.003943374,0.000860713,0.002857305,0.46840614,0.023302136],"study_design_scores_gemma":[0.10676561,0.0027730886,0.16965556,0.1330443,0.1039561,0.0028964465,0.001903295,0.014713371,0.003843449,0.029871508,0.429303,0.0012742614],"about_ca_topic_score_codex":0.0072838697,"about_ca_topic_score_gemma":0.0153911095,"teacher_disagreement_score":0.6586997,"about_ca_system_score_codex":0.0017861938,"about_ca_system_score_gemma":0.0035929112,"threshold_uncertainty_score":0.48682344},"labels":[],"label_agreement":null},{"id":"W7136061490","doi":"10.6084/m9.figshare.4776154","title":"Additional file 2: of The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","year":2017,"lang":"","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cohort; Expression (computer science); Scale (ratio); Cohort study; Clinical significance","score_opus":0.17285375311511028,"score_gpt":0.3902435760244508,"score_spread":0.21738982290934053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7136061490","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012227896,0.0006052999,0.00083930086,0.00026922752,0.00007916791,0.00046845735,0.99582005,0.0002271148,0.00046859612],"genre_scores_gemma":[0.1430417,0.004207163,0.038018588,0.0038230943,0.0008237763,0.058272056,0.7244737,0.0020673997,0.025272578],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964005,0.001039784,0.0011010696,0.000653838,0.00048308357,0.00032170513],"domain_scores_gemma":[0.8729653,0.1118289,0.006570028,0.003115694,0.0047936933,0.0007263167],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007434634,0.0020177518,0.0043352856,0.006909339,0.0009548727,0.0023429038,0.0025836774,0.0016672552,0.6586997],"category_scores_gemma":[0.099350475,0.0014430253,0.0087840855,0.009357676,0.0004936711,0.0039353603,0.0014560437,0.0015307786,0.021979619],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063779964,0.00030309887,0.021911688,0.4500107,0.020978268,0.00052561826,0.00052291807,0.003943374,0.000860713,0.002857305,0.46840614,0.023302136],"study_design_scores_gemma":[0.10676561,0.0027730886,0.16965556,0.1330443,0.1039561,0.0028964465,0.001903295,0.014713371,0.003843449,0.029871508,0.429303,0.0012742614],"about_ca_topic_score_codex":0.0072838697,"about_ca_topic_score_gemma":0.0153911095,"teacher_disagreement_score":0.6586997,"about_ca_system_score_codex":0.0017861938,"about_ca_system_score_gemma":0.0035929112,"threshold_uncertainty_score":0.48682344},"labels":[],"label_agreement":null},{"id":"W7161972053","doi":"10.82308/47405","title":"Regulation of the MAFF transcription factor function in breast cancer cells","year":2023,"lang":"en","type":"dissertation","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Trastuzumab; Inflammatory breast cancer; Metastasis; Transcription factor","score_opus":0.043248764312501645,"score_gpt":0.35626865920340833,"score_spread":0.3130198948909067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7161972053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519018,0.027223054,0.0063301083,0.00068696716,0.00024780963,0.00006321058,0.002580953,0.0001737634,0.010792298],"genre_scores_gemma":[0.97516257,0.0047250623,0.0033198947,0.00033033328,0.000042480788,0.000107205684,0.004242603,0.000027735674,0.012042107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99957246,0.000059585265,0.000027934617,0.00007323663,0.00017750628,0.00008928751],"domain_scores_gemma":[0.99985445,0.000043332042,0.000015243462,0.00002101721,0.000048767128,0.00001718679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022777906,0.00022350266,0.0002837432,0.00044535976,0.0003274978,0.00066596724,0.00018782589,0.00032742473,0.0020956167],"category_scores_gemma":[0.00033709468,0.00012356248,0.00040497433,0.0005423961,0.0002491646,0.00022500535,0.00021940481,0.0004163885,0.0011129179],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000180899,0.000029336792,0.0016783032,0.00008452054,0.000011162294,0.00009674215,0.00009217749,0.00006780687,0.99105316,0.00029651696,0.0002933029,0.0061161383],"study_design_scores_gemma":[0.000026159189,0.00042389406,0.05253874,0.000039784816,0.000029393228,0.0007799052,0.0003999891,0.0024301077,0.9101176,0.00021101354,0.0329805,0.00002286664],"about_ca_topic_score_codex":0.0060426025,"about_ca_topic_score_gemma":0.006952718,"teacher_disagreement_score":0.0060426025,"about_ca_system_score_codex":0.0007904469,"about_ca_system_score_gemma":0.00035097788,"threshold_uncertainty_score":0.012014866},"labels":[],"label_agreement":null},{"id":"W846849520","doi":"10.71781/30168","title":"Growth factor activation of ErbB2/ErbB3 signaling pathways regulate the activity of Estrogen Receptors (ER)","year":2010,"lang":"en","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Université de Montréal; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Estrogen receptor; Signal transduction; Cell biology; Receptor; ERBB3; Cancer research; Chemistry; Biology; Internal medicine; Medicine; Cancer; Receptor tyrosine kinase; Breast cancer","score_opus":0.01479742512499417,"score_gpt":0.22475192343784642,"score_spread":0.20995449831285223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W846849520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9105065,0.0576796,0.009346726,0.0008074832,0.0003191531,0.00008186663,0.0018199172,0.00023105765,0.019207716],"genre_scores_gemma":[0.9552096,0.022249728,0.0021735637,0.00022961468,0.000044495264,0.000059333153,0.0013897175,0.000030120931,0.0186137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997857,0.000023777762,0.0000121828425,0.00004387093,0.00007334502,0.00006116849],"domain_scores_gemma":[0.99991405,0.000014378964,0.000023106466,0.000010853935,0.000024747527,0.000012847005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018955613,0.00044241876,0.00028919973,0.00025665652,0.0003051673,0.00056629116,0.00019272503,0.00032716015,0.0051470823],"category_scores_gemma":[0.00020010713,0.0001626773,0.0005176421,0.0003557037,0.00022417065,0.000369395,0.000384024,0.0006422125,0.0012123493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048822764,0.00006897544,0.0035237276,0.0004988623,0.00003836141,0.0002719654,0.00010233378,0.00040773695,0.96718293,0.0014371158,0.00066332624,0.02531635],"study_design_scores_gemma":[0.00007143973,0.0005549342,0.063006364,0.00010451974,0.0001051489,0.0012554677,0.0004688978,0.0020275512,0.85418886,0.001320043,0.07685853,0.000038055103],"about_ca_topic_score_codex":0.0016134467,"about_ca_topic_score_gemma":0.0020450805,"teacher_disagreement_score":0.0051470823,"about_ca_system_score_codex":0.0006025987,"about_ca_system_score_gemma":0.00040478408,"threshold_uncertainty_score":0.01721865},"labels":[],"label_agreement":null},{"id":"W97040042","doi":"10.1096/fasebj.20.5.lb72-c","title":"Acquired Capabilities of Cancer Cells Intersect at ADAM17 (TACE)","year":2006,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Autocrine signalling; Gene silencing; Epidermal growth factor receptor; Cancer research; Cancer cell; Cancer; Biology; Epidermal growth factor; Cell biology; Receptor","score_opus":0.03001105445655388,"score_gpt":0.32970453021344037,"score_spread":0.2996934757568865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W97040042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920678,0.0020869519,0.0025420277,0.00012419261,0.000021623735,0.000018803446,0.00027902384,0.00009435964,0.00276511],"genre_scores_gemma":[0.9953929,0.000551102,0.0009022566,0.00003074468,0.000004767998,0.00001564482,0.00031176364,0.000011265318,0.0027796126],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998123,0.000029013785,0.00001729948,0.000023089444,0.00006690034,0.000051464052],"domain_scores_gemma":[0.9998822,0.00001936948,0.000023565675,0.000031215874,0.000016024389,0.000027579694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011881935,0.00028800202,0.0003112155,0.00018567631,0.00019878184,0.000556298,0.00013001806,0.00026268826,0.0019468414],"category_scores_gemma":[0.00012242964,0.00012539967,0.0003006777,0.00012988831,0.0002559642,0.00027292478,0.00036803732,0.00065106153,0.00066909567],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006023738,0.000015787551,0.0003467572,0.000028484257,0.0000057594657,0.00017021669,0.000027509072,0.000053314554,0.99714404,0.00033131253,0.000047681144,0.0017689106],"study_design_scores_gemma":[0.000011245531,0.00022223883,0.0033171931,0.0000031736026,0.000014362856,0.0016102021,0.000046392175,0.00049297017,0.9891139,0.000112785725,0.0050517833,0.000003767776],"about_ca_topic_score_codex":0.00034992516,"about_ca_topic_score_gemma":0.000489015,"teacher_disagreement_score":0.0019468414,"about_ca_system_score_codex":0.00024502256,"about_ca_system_score_gemma":0.0002243877,"threshold_uncertainty_score":0.0065128207},"labels":[],"label_agreement":null}]}